<SEC-DOCUMENT>0001558370-22-004211.txt : 20220324
<SEC-HEADER>0001558370-22-004211.hdr.sgml : 20220324
<ACCEPTANCE-DATETIME>20220324073228
ACCESSION NUMBER:		0001558370-22-004211
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220324
DATE AS OF CHANGE:		20220324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HOOKIPA Pharma Inc.
		CENTRAL INDEX KEY:			0001760542
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815395687
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38869
		FILM NUMBER:		22764702

	BUSINESS ADDRESS:	
		STREET 1:		430 EAST 29TH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		0114318906360

	MAIL ADDRESS:	
		STREET 1:		430 EAST 29TH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>hook-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/24/2022 11:19:32 AM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 9ba43cdd-f785-48e2-b68e-a0b302f83616 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:hook="http://www.hookipapharma.com/20211231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" xs:nil="true" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_gvgzIMj6nUeUWxe0_y-Jwg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" xs:nil="true" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_zCSNkhGMCk6qJSihJFzovQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_GjhzT8Q77EKyUG4HLJai2Q">2.30</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_WAlIWKg3_kGPFwdfEOmjyg">1.69</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" sign="-" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_PQ_AJu4vDU-8R34Q01Wvxg">2.41</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_gFfph1YY2UKzJMfVCi4-aw">http://www.hookipapharma.com/20211231#AccruedExpensesAndOtherCurrentLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_tvmVHvIJdU2wwY7HpN_TxA">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Y2uUY9PnaEu425eLIIFSWQ">32833590</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_9GsyheM0nk2Vq9EwIxi8jw">26039108</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_xeQBGPQR4ESWq7MOG3v3-w">17859935</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_6-gyEFXupUu6flBiLprClQ">3819732</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_SpzvgrlBO0K58lHSEpRDng">3819732</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:DocumentFiscalPeriodFocus" id="Tc_bFSzj01QKUScEVMlQ6O1Cw_4_1">FY</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_M4QO-ITDuk6l7x8QEJvWqQ">25948712</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_ei_Ikp7_JkWHvn3i30w8hQ">27383483</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA" decimals="-5" name="hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" id="Hidden_l0XBTDSRf02Br1mMnKhitQ">300000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw" decimals="-5" name="hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" id="Hidden_0ppv5nVtqUW_59qTfEqsxA">100000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" id="Hidden_Ig22UHVZRkKGX2x0KG_1_A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_ilfqJ_zyb0aZGfg-9XrTsA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Hidden_yp-p9Vk_-kOWrEU_xREtbA">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_oRmXSROYc0OcSjQ6MQGWpg">http://www.hookipapharma.com/20211231#AccruedExpensesAndOtherCurrentLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_qGfyuLYvk0GVroGAArA9Ww">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_0vCtFWOMdU6TUe8bLbDs8w">27383483</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_lsKpVaKZlU2VrubLnN7E_w">3819732</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_qvPF7Qsm3kquM23a168syQ">1697</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_xm72ylqy7EWXDfD5Rmo5kg">2.30</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_ix31qi0nv0-3tRNXPNStAg">1.69</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" sign="-" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_6TH1JwQjZkq-oybyyIOUrA">2.41</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityCentralIndexKey" id="Narr_rDrX29g05UuEen2MIS8mCg">0001760542</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:DocumentFiscalYearFocus" id="Narr_NIqVUY_kOkqGL6eJubJxDQ">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:AmendmentFlag" id="Narr_N18IXFMr2kCzIoRm46dp7Q">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="hook-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:RedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_1-rISPKNH0inC5yV4XqosA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_iaIK2Z0eQUemaaWm5dk9Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SY6vqrZCAUCbmXcKYv08WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_GPWyabmAdEKvKH-pRh2Odg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_CHI8dxT2OkidwL8Mu4XUrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_11_2020_To_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_KcIuT04yhEWxmnluDeFr0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-11</xbrli:startDate><xbrli:endDate>2020-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_C7sFin4R1EaaFWUj-j20vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rb58nqtF00-ccIOKSQPjSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember__-4lq1gvk0iz6FWV-SY_DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TievCB1XuUO1RkPCD7kOtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-23</xbrli:startDate><xbrli:endDate>2019-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_NFEgg-7L7kKUdGMo__0AuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-23</xbrli:startDate><xbrli:endDate>2019-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mxgxUBrs5EahlanRFV9dLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lmHisS_hEGTk6TeU1vfOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3N0JhOmgVUmYfBmky7vmOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OfuYA2C3xke_bo6pMP4VvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_f2ZtYakwfEGzUa_ReenKsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7wWUwYMC0EOxNoennfjkiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_N55shTLEaEarslhWegOJbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7enHd9VRCkazAjqXa7n2IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8U9btLCFf0-_E1ZmkdKY9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VASM6wKbREa6i5X-hf4OnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fJMSYe6Db0aF4O1Ae_jMRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n6WF9srQk0-nfgx2hH6GHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bza-EjmjGkyDiE1cBzmY_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JCLAhxpWfUK_BCMc8Crq6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F487s_zlB0qFdik4pgQi0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_KY00BOBu8Uie8DRIDNVBvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_trtcRd5UvE-g8RW5tXD87Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Kwh0f-7tfEWtcfjIz3sd0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_go0VxtWuoEOC8lkT9c9QBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LULifWjM2k2MitqBT78QxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vo3P-fAsj0qkzNtmN_hjhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mMp048LvZEKwM3usixUYtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_n0YxpBmAWUqt8sgKu-qHDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_P9-ctvWwd0qVNZJLztP7lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fDr8f-o960agj3wW41LU3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bmkwQPPsg0m3l7ZM8QwDVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_YG3CoyW76UCnds2S4wKCbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_yBu7KRZGvUyBIFDw4F8mQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9-wYstNW-kqgqsk59PAAeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_2dw45hjqck2FIlWYMhpGDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_beVG5N6ZTEC9isTgGKHBeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2022_To_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b78AfSk_ikSR3aA4hEpw6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_9n3p1gHKx0CGfWWuBr4x9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hook:ExercisePriceRangingTo0.09EuroPerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_mveODV43Qk2j2ktXiQesTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_twPgggzgsEqZUfvcKLhARA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hook:ExercisePriceRangingTo0.09EuroPerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo2.93DollarsPerShareMember__xThJ8xgwECdT4PnUdSrEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hook:ExercisePriceRangingTo2.93DollarsPerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UzL7A7Iha0WXUjRxbCPtMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yxPIhqNASUaCbZD8h1tf_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hpzhb_Bppk67Nw3sDM-ihg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_Y24Eexf4xkCs_eHMPufkaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_NvEZsiucNEarngOHkIEwqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Qyh0v6uhbEG1Th-ftOQ75Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tspqlK_mSEuko-7EX1OHCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_4UVSVApoFESt0pKFq_aAcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_fmE0VmQhIk2B4XyRkIcu2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-DFpbMUslEae1ED399zLwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_22rnLqSJCUSZdw6cMXG4eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FgZEcu-x6ESzKZv_nwLtiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_M7e0-G2Jc0mMZbDTVrVaQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_WVL2EC15ZUqXg0iRX6l96w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_pZ8SP9MhHUePH3GzlSb8nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_mXlTlYVhXE--Iu97sO2IOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4BwGZSWxKES82uxhJw-yBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__YrrPJBfXEKiNjwR_7k7OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_RnEWI9I70EeTbY-Xi8vklA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_qytkKxk8CEm7bN6P8U8VzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NyQzVSOZCUW4XmIPhFet_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_ANXP3tESvE-8MHgi_Ck3uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oM1lWRGbvEiE-FT3XrMDcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_zjRiqY7na0mdESnAmAgN5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_h3bbPTbCck67We_5POyRoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kZ2Gy961l0-3UxadFPp3yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_p1qmf6wjLk6uR_JhX4mV2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_03RMuix68kaDY62cZtc7HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j9QTccxA8kSS8q3279Cm-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_7otYFkeHoUKeaKz76AWKEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mmAIdyTOBEGGYm394Dfgdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_B5fIRUIsikiF5KXD5x6cHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Ft-tF1iTN0Gyv_gaYiFXZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_11_2020_To_12_11_2020_lwzbDOodv0Si697Xzru_Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-11</xbrli:startDate><xbrli:endDate>2020-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember__DCiYylTbUSqoGmdQ3GRYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_DDij82CjqUCydxqkEFWIhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IzO1tarH8EWCgudDOfIH8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0EmWweoQGke319p9rpY0xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6lqA7X0UVkCwZjjrPXO1kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wlEd_mxNOkeq4y6xJ7gacw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_gHDM5dWWTEuXar6FbiCeBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_G_2_M_kOZUillKcUGB9iFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AT_VDTF1Hi9ZEmGsqw3fw3zPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_g5-9_PFDAkeum_3TPJDJ1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AT_bcqjl_Vcukegg0RdiMWQ4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rtH4Ec9QWkKmuKYhDdJTqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MoCC3vP5_Uyo7dm3xckcaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3xEUlzHOy06ZPsj-DQ1mAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_lfUPt9xHTECs1PBzglCNhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_Ayr8wO2i8EqBHFydPDrBIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_8aWV_Z5u30CrNnuDLkmpsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_76blQDrh8EykPQMtShDiPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_y8byg_XyWUKkNI6G_f1TrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_yxLDZPy_JkCTBy3vQ0rANw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_hounmkd6wkGAMVpwq87DJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_tyTRnlIXPUi1yW0nB28asw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_VGIrjRmoLU2n3YXR5TnwLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_kFwGKKMO6U2oE6qi3AFdmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_r8XLGskgdEyxWiQ5NQyIKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OLb_2bn0qEy2UW_m4JwHoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHJvZ8_EJ0OzSnSQBM0_6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ld1bC-KnG0yjbLLvZcbh9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U3zEzG1qXkK9lJ83V5wUyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0cA_3wN87kC_T3pK3UXc2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DNp-TcR4d0uu2uDNfHmJLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Hi8vNfG0OketOKVTNEWdKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3LNaEjX6U06CsywOTygF8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8ArpbU0oC0yIg8CJBYRJmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Tblo1dfAsE-WhYeQhF--_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_5rBz_7VLf0GCJz8u9a-5hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_g4i69HykyUOop1GtYNoS3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_wAHzp7MTe0eWsXdFl7PgAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_TFoTZQzTG0eYRQ27zNvfiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-23</xbrli:startDate><xbrli:endDate>2019-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7Bp0zhTgI06LSu47f4p2jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_MW8Mqd0iIEG_9OzHPNz_yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_Xf3pHxRC4UOPsU0Tyuw4UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7WLlmoedJEi4B7q-431RSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_2rHrjRN4ikCe0MkQAF8I5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:RedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_ioF2r0Uas0uFcTusXG0EVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:RedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_UozogPZl3kqm-mLqR-1Ajw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_1_2019_XDfkQ2lQ5UGH271C7716Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rLd-8jjIakKEuR52k7XE-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_tBzOSNE1VEeWs3G7uVNFMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GB1HtsQo9UWwp1QaQ-17vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_lRtNrbT0JEmwrX6k2vVYAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_YCN1Wdur2kOhWvhtqG7FTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_gifEUz7mSku6eu-AYJEHoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_paPyAdbqWE-j29GBmOS_lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2022_To_2_1_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_zDBbt61-QkWRp1SuDXvEgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2019_To_11_30_2019_1iZi9iUIoEu0KQgEUiQByw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ilxWs-hFzUu1oK7UGRu04Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_FbkMEjEJl0WQtmJecOY1vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_12_31_2026_Z5BVccme10iEHOgWw4JA2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_HNQ1RpgYeke7cwk7fsoeRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9NpKAk2xnE-XmHW-HPDY4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsTwoMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4hozc3IA_UemHLG5L4Tssg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:MilestonePaymentsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsOneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_X8z0GhjTXEaCy2ODr2m1sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:MilestonePaymentsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_kRKK4hhFqUmimB34ezmG7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_2Vq0EfxlZkK7tBpSzeg_iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Sx4TWQDqgU-t8yTvWjEuDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_1YzcX0Wm8UuRD0c642O46A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Program_p93h6a_140eCP-r_hTy6gg"><xbrli:measure>hook:Program</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA"><xbrli:measure>hook:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_t09LAWcUrk2_inHGi-A6Ng"><xbrli:measure>hook:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q"><xbrli:measure>hook:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_590Vq7m6Nk2ruyUEdyuF7Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b3078964_0917_4e1c_aa1b_fd49ba07e250"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:DocumentType" id="Narr_w7QHGDGu_UmVYz8JC1y1Jw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:DocumentAnnualReport" id="Narr_VWPC3f7maU2x3T5JJR0_6A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:normal;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;font-weight:normal;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:DocumentPeriodEndDate" id="Narr_Y43p7SMldkyGCJYoIF0SJw"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:CurrentFiscalYearEndDate" id="Narr_GS6L7-CsBkKhL44CCPgsKQ"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:DocumentTransitionReport" id="Narr_e7sV4mAB-kKfYYHo4AR8dw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:normal;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;font-weight:normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityFileNumber" id="Narr_bAxI-O_jDEu64elICaGpnA"><b style="font-size:8pt;font-weight:bold;">001-38869</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityRegistrantName" id="Narr_sjd4NmsKRUqTYNUhBBMRwA"><b style="font-weight:bold;">HOOKIPA PHARMA&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_bf00e41e_95ca_4e7e_b718_b937c7f2934c"></a><a id="Tc_pw7wBXCpukSXwSDCqrYaig_2_0"></a><a id="Tc_Nue6PpTwGkW8BHwEmnhJ7w_2_1"></a><a id="Tc__fcFSZrog06_MWQB5lbN4g_4_0"></a><a id="Tc_ZxVTkWYqKUesFPieDupJoA_5_0"></a><a id="Tc_6wf22XlPbE6PAeD1dEMU8w_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:2.35pt;padding-right:2.35pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityIncorporationStateCountryCode" id="Tc_ti4TJIzaF0isRIFbl3OZKw_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityTaxIdentificationNumber" id="Tc_vafhyZ-K6UucDn0PRLj3Ew_1_1"><b style="font-size:8pt;font-weight:bold;">81-5395687</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityAddressAddressLine1" id="Narr_9Pvo966ryEebhnrX_t1TOw"><b style="font-size:8pt;font-weight:bold;">350 Fifth Avenue, 72nd Floor, Suite&#160;7240</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityAddressCityOrTown" id="Narr__VeSy4HbsUuHW-2sIxuLDw"><b style="font-size:8pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityAddressStateOrProvince" id="Narr_vyKFdOwPF0K_JS_qu3UeLg"><b style="font-size:8pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityAddressPostalZipCode" id="Tc_tEGE8o2HtUuXo0sfkNqiuA_4_1"><b style="font-size:8pt;font-weight:bold;">10118</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#39;s telephone number, including area code: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:CountryRegion" id="Narr_GGtvWN2RZEyenFyJ1bNz-g"><b style="font-size:8pt;font-weight:bold;">+43</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:CityAreaCode" id="Narr_6Hynt1qiY0GdjFP7da8iag"><b style="font-size:8pt;font-weight:bold;">1</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:LocalPhoneNumber" id="Narr_9fvXT5lPO06okvRmG4kX_A"><b style="font-size:8pt;font-weight:bold;">890 63 60</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_ac58c657_2a31_444a_a1f6_763af3bcc52a"></a><a id="Tc_CCiP6ftPOkyGZjf350m6mw_1_2"></a><a id="Tc_o4R8Fy3DeUyoNLRfb2i_2A_2_0"></a><a id="Tc_xmCm4oFoWEysvm1O8D3MgA_2_1"></a><a id="Tc_CAM1Tj7TGEmKphrRmnKufA_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</b></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">On Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:Security12bTitle" id="Tc_3TwWFk2bN0ejhJJCismJqw_3_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, $0.0001 Par Value per Share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:TradingSymbol" id="Tc_ZbAjs1wW-UatAYDbHSMoIA_3_1"><b style="font-size:8pt;font-weight:bold;">HOOK</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:SecurityExchangeName" id="Tc_mSg7lKxiXUmZsdP9Vr_few_3_2"><b style="font-size:8pt;font-weight:bold;">The Nasdaq Global Select Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Securities registered pursuant to Section 12(g) of the Act:  None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_pQTbw0K1eUqIpdvVPPDd0w"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityVoluntaryFilers" id="Narr_2_32KWVS20SQflAWV_oCrA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;white-space:pre-wrap;">Indicate by check mark whether the registrant:  (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityCurrentReportingStatus" id="Narr_3Gg5anRwQ0y8CORJ3YEtXg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityInteractiveDataCurrent" id="Narr_K_NrxIoyOUqJcQhplesi_A"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Large accelerated filer&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Accelerated filer&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityFilerCategory" id="Narr_InOgc55q0EGs6vXVA1pEfQ"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;&#160;</span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntitySmallBusiness" id="Narr_WlQhpwbA80SLIKBoaGFMCA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;&#160;</span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityEmergingGrowthCompany" id="Narr_UihmZO1jgEWyl7yT0OfELA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityExTransitionPeriod" id="Narr_wIbfQFpU60CtkbMPckYyMQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:IcfrAuditorAttestationFlag" id="Narr_IfEW-8zq60-3rRZu6i3_Jg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:EntityShellCompany" id="Narr_pHsy58WfZUyB_sROCgXnGQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Based on the closing price as reported on the Nasdaq Global Select Market, the aggregate market value of the Registrant&#39;s Common Stock held by non-affiliates on June&#160;30,&#160;2021 (the last business day of the Registrant&#39;s most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_2Vq0EfxlZkK7tBpSzeg_iQ" decimals="-5" name="dei:EntityPublicFloat" id="Narr_hW8wKVXPokS3ig98nVOIEw">237.9</ix:nonFraction>&#160;million. Shares of Common Stock held by each executive officer and director and by each shareholder affiliated with a director or an executive officer have been excluded from this calculation because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The number of outstanding shares of the Registrant&#39;s Common Stock as of March&#160;14,&#160;2022 was <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_1YzcX0Wm8UuRD0c642O46A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_YaxxYAwl5ESXcBCjXFw4bA">50,868,668</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Sx4TWQDqgU-t8yTvWjEuDw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_MXgx3FqyTke-xFXYZ51lUQ">3,819,732</ix:nonFraction> shares of Class&#160;A common stock outstanding, each $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;text-align:center;margin:0pt;">Documents Incorporated by Reference</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If the Registrant&#8217;s Definitive Proxy Statement relating to the 2022 Annual General Meeting of Shareholders (the &#8220;Proxy Statement&#8221;) is filed with the Commission within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, then portions of the Proxy Statement will be incorporated by reference into Part III of this Annual Report on Form 10-K. If the Proxy Statement is not filed within such 120-day period, then the Registrant will file an amendment to this Annual Report within such 120-day period that will contain the information required to be included or incorporated by reference into Part III of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e450b3f1_efb2_4838_a983_14c11ce54b33"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">PART I</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Business_108848"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Business_108848"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">5</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#RiskFactors_480000"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#RiskFactors_480000"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">67</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#UnresolvedStaffComments_377193"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#UnresolvedStaffComments_377193"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">119</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Properties_188239"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Properties_188239"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">119</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;">PART II</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#LegalProceedings_351583"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#LegalProceedings_351583"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">119</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><a href="#MineSafetyDisclosures_997431"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#MineSafetyDisclosures_997431"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">119</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#MarketforRegistrantsCommon_947933"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#MarketforRegistrantsCommon_947933"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#39;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">120</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SelectedFinancialData_379980"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SelectedFinancialData_379980"><span style="font-style:normal;font-weight:normal;">Selected Financial Data</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">120</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ManagementsDiscussionandAnalysis_660301"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ManagementsDiscussionandAnalysis_660301"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">120</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#FinancialStatementsandSupplementaryData_"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#FinancialStatementsandSupplementaryData_"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">138</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ChangesinandDisagreements_29131"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ChangesinandDisagreements_29131"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">139</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ControlsandProcedures_489690"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ControlsandProcedures_489690"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">139</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#OtherInformation_174221"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#OtherInformation_174221"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">140</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9CDisclosureregardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9CDisclosureregardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">140</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">PART III</p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#DirectorsExecutiveOfficersandCorporateGo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#DirectorsExecutiveOfficersandCorporateGo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers, and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">141</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ExecutiveCompensation_255286"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ExecutiveCompensation_255286"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">141</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SecurityOwnershipofCertainBeneficial_240"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SecurityOwnershipofCertainBeneficial_240"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">141</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#CertainRelationshipsandRelatedTransactio"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#CertainRelationshipsandRelatedTransactio"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">141</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#PrincipalAccountantsFeesandServices_2130"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#PrincipalAccountantsFeesandServices_2130"><span style="font-style:normal;font-weight:normal;">Principal Accountant&#8217;s Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">141</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;">PART IV</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Exhibits_364151"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Exhibits_364151"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">142</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item16Form10KSummary_412517"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item16Form10KSummary_412517"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">146</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:94.24%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><a href="#SIGNATURES_467"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">147</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0410beb3_fb6d_4fff_9ad8_6920ea128cc2"></a><a id="FORWARDLOOKINGSTATEMENTS_927471"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, including &#8220;Business&#8221; in Part I Item I and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II Item 7, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These statements may be identified by such forward-looking terminology as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success, cost and timing of our product development activities and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application and Biological Licensing Application filings for our current and future product candidates, and final U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authority approval of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our manufacturing, commercialization and marketing capabilities and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of and our ability to maintain our collaboration with Gilead Sciences,</span><span style="font-family:'Times';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inc., or Gilead, and establish or maintain future collaborations or strategic relationships or obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance and clinical utility of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering our non-replicating and replicating technologies and the product candidates based on these technologies, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future agreements with third parties in connection with the commercialization of our product candidates and any other approved product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of the ongoing coronavirus pandemic on business and operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive companies, technologies and our industry and the success of competing therapies that are or may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our estimates of our annual total addressable market, future revenue, expenses, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations about market trends;</span><span style="font-family:'Times';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of our forward-looking statements are as of the date of this Annual Report on Form&#160;10-K only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Annual Report on Form&#160;10-K or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report on Form&#160;10-K, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Annual Report on Form&#160;10-K that modify or impact any of the forward-looking statements contained in this Annual Report on Form&#160;10-K will be deemed to modify or supersede such statements in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><a id="_1a9be8ca_61be_474f_8919_cf92334fe623"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Note Regarding Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This 10-K report includes trademarks and trade names that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this 10-K report appear without the &#174; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, trade names and service marks appearing in 10-K report are the property of their respective owners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated or the context otherwise requires, all references in this 10-K report to &#8220;HOOKIPA Pharma&#8221;, &#8220;HOOKIPA&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;ours&#8221;, &#8220;us&#8221; or similar terms refer to HOOKIPA Pharma Inc. and our consolidated subsidiaries.</p><a id="_5f2a2b37_885d_4387_8495_fc62685983e9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Summary Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business is subject to numerous risks and uncertainties, including those described in Item 1A &#8220;Risk Factors&#8221;. These risk factors include, but are not limited to the following:</p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical-stage biopharmaceutical company with no approved products and a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional financing and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA, the EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential or result in significant negative consequence.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are fully dependent on our collaboration with Gilead for the development of our hepatitis B virus programs, rely on funding from Gilead for development of our human immunodeficiency virus, and may depend on Gilead or additional third parties for the development and commercialization of our other programs and future product candidates. Our current and future collaborators may control aspects of our clinical trials, which could result in delays or other obstacles in the commercialization of the product candidates we develop. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ongoing effect of the COVID-19 pandemic has adversely impacted, and we expect it will continue to adversely impact our business, including our clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, and, if we fail to comply with our obligations under these arrangements or resolve related disputes, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in licenses.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_74cb9756_6f58_4c53_a1bb_8deaf11f5f5e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I</p><a id="Business_108848"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1.&#160;&#160;Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify a T cell and immune response to disease. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. We believe that our technologies can meaningfully leverage the human </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">immune system for prophylactic and therapeutic purposes by inducing CD8+ T cell response levels previously not achieved by other immunotherapy approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and next-generation antigens. Our lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase 1/2 clinical trial. Our non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is a potential first-in-class compound in a Phase 2 clinical trial for patients awaiting kidney transplantation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As announced in November 2021, based on the strength of our HB-200 data in HPV16+ cancers, we have prioritized our oncology portfolio and we plan to continue developing infectious disease therapies in partnership with other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our differentiated platform is based on engineered arenaviruses that are designed to activate the natural immune defense mechanism to trigger potent and target-specific T cell and B cell immunity. Arenaviruses have been used for decades as a preclinical tool to study CD8+&#160;T&#160;cell responses. Our cofounder, Rolf Zinkernagel, was awarded a Nobel Prize in Physiology or Medicine for his arenavirus-based work on how CD8+&#160;T&#160;cells recognize virus-infected cells. We believe that arenaviruses have several key advantages which give them the characteristics of an optimal immunotherapy, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to induce a robust CD8+&#160;T&#160;cell response by directly targeting and activating antigen-presenting cells (APCs), such as dendritic cells, which are the most efficient antigen presenting cells of the body;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to induce a robust antibody response to disease specific target antigens;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced neutralization of vector specific antibodies, which facilitates potential for repeat administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">do not require an adjuvant to stimulate the immune system; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have been observed to be well tolerated in our preclinical studies and clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe we are the first to reengineer arenaviruses for therapeutic purposes. Our systemic and reproduceable approach features two technologies capable of delivering disease-specific antigens for the prevention and treatment of disease. Our non-replicating technology is designed to induce a strong immune response for prophylactic and therapeutic use against infectious disease. Our replicating technology is engineered to produce an even more powerful immune response, which we are currently exploring in oncology indications. In preclinical studies, our replicating technology was able to reprogram the immune system such that more than half of the body&#8217;s CD8+&#160;T&#160;cells focused on a specific cancer self-antigen target without observed serious adverse events. We have designed our platform to be modular in nature in order to allow substitution of antigens to target a broad range of infectious diseases and cancers. We have a robust intellectual property portfolio for our suite of arenaviruses with exclusive rights in issued patents and patent applications related to our non-replicating technology and exclusive and joint rights in issued patents and patent applications for our replicating technology. We believe the breadth and depth of our intellectual property portfolio is a strategic asset that has the potential to provide us with a significant competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe that our arenavirus platform approach gives us a unique and powerful way to tap into the biology of the immune system and reprogram it by instructing APCs, such as dendritic cells, to express antigens that direct the immune system to the desired targets. Our product candidates are designed to deliver full length proteins to activate T&#160;cells and B&#160;cells to produce a robust immune response through natural means, avoiding the use of artificial <i style="font-style:italic;">ex&#160;vivo</i> constructs such as CAR-T&#160;cells and related approaches that bypass the immune system&#8217;s normal control mechanisms. Although these latter approaches have shown clinical efficacy, they have the potential to cause life threatening side effects, including cytokine release syndrome. In addition, we believe that our immunotherapy approach is simpler, more </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">straightforward and cost effective to manufacture and administer than CAR-T&#160;cells or other patient derived cellular approaches.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Oncology Pipeline Highlights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The HB-200 program is our first program in oncology and the first clinical exploration of our replicating technology. The HB-200 program is therapeutic agents for people with cancers caused by the Human Papillomavirus (HPV), specifically Human Papillomavirus type 16 (HPV16+).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HPV is estimated to cause about 5% of the worldwide burden of cancer. This includes approximately 99% of cases in cervical, up to 60% of head and neck, 70% of vaginal and 88% of anal cancers. Prevalence and recent studies have shown that approximately 70% of cancers of the tonsil and tongue base and the majority of cervical and anal cancers may be linked to HPV. It is estimated that the yearly incidence of metastatic head and neck cancers in Spain, France, Germany, Italy, Japan, the United Kingdom and the United States will be 44,000 by 2030. Tumors caused by HPV are referred to as HPV-positive tumors (HPV+) and can be characterized by their expression of proteins from the HPV genome, particularly the viral E6 and E7 proteins. These two proteins are expressed in tumors but are absent in normal cells, which makes them ideal target candidates for immunotherapy; however, to date, there are no therapeutically approved agents directed against these targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HPV16+ cancers include cancers of the head, neck, anus, vagina, cervix and penis. Based on a market research study we commissioned from an independent third party, we believe that in developed countries, approximately 70,000 patients annually are newly diagnosed with HPV16+ head and neck cancer. Each year, approximately 30,000 of these patients present with metastatic disease and an additional 10,000 patients progress to the recurrent and metastatic stages of the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The HB-200 program encompasses our arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by HPV16+. These arenaviral-based immunotherapies include</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">HB-201 single vector therapy</b>: sequential injections of HB-201 (E7E6 fusion protein derived from HPV16 encoded in a Lymphocytic Choriomeningitis Virus (LCMV) vector);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">HB-201/HB-202 two vector therapy</b>: alternating sequential injections of HB-201 and HB-202 (the same E7E6 fusion protein encoded in a Pichinde Virus (PICV) vector).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preclinical studies, HB-201, as a monotherapy, was observed to suppress tumor growth and eliminated up to 40% of HPV+ tumors. HB-201 generated a strong and durable T&#160;cell response with successfully treated animals demonstrating resistance to a tumor rechallenge. Based on these preliminary results, we believe that treating patients with HB-201 has the potential to both control metastatic disease and prevent relapse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, we opened the HB-200 Phase 1/2 trial (NCT04180215), investigating both Phase 1 dose optimization and Phase 2 dose expansion in a single trial. During the initial 10 months of the trial, the HB-201 single vector therapy was studied through escalating doses. Starting in October 2020, enrollment into the HB-201/HB-202 alternating sequential two vector therapy began, representing a parallel dose escalation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first-in-human trial, the Phase 1 arm of the trial was designed to investigate multiple questions for HB-200 program, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Route of administration: intravenous (IV) vs. intratumoral (IT)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dose optimization</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dosing schedule: every two weeks (Q2W) or every three weeks (Q3W)</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2021, interim Phase&#160;1 data on HB-201 single vector therapy and HB-201/HB-202 two vector therapy for advanced/metastatic HPV16+ cancers showed promising anti-tumor activity and favorable tolerability. The interim data was derived from 62 patients who received either HB-201 single vector therapy or HB-201/HB-202 two vector therapy for advanced/metastatic HPV16+ cancers. Data demonstrated responses and stable disease in head and neck cancer patients who failed prior standard of care therapy, platinum therapy, PD(L)1 inhibitor, or both. We believe that these early-stage data establish proof of concept for our replicating single-vector immunotherapy in oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the interim Phase 1 data released in November 2021 enabled decisions on Phase 2 clinical plans for target tumor type as well as recommended schedule and route of administration for HB-200:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IV administration was observed to be superior to IT administration; therefore, the IT route has been discontinued and IV only will be used in Phase 2;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The initial Q3W dosing schedule was observed to be superior to Q2W; therefore, the Q2W regimen arm has been discontinued and the Q3W dosing will be used in Phase 2;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The majority of data accrued to date has been from HNSCC patients; therefore, the Phase 2 target tumor type will be HNSCC.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In coordination with the November 2021 update, the Recommended Phase 2 Dose (RP2D) for HB-201 single vector therapy was determined. In January 2022, we dosed the first patient with a combination of HB-201 and pembrolizumab for the treatment of first line advanced/metastatic HPV16+ HNSCC in the Phase 2 expansion portion of the ongoing Phase 1/2 trial (NCT04180215). The Phase 2 portion of the trial is also open for enrollment of patients with second line advanced/metastatic HPV16+ HNSCC for treatment with a combination of HB-201 and pembrolizumab. Similarly, for the alternating sequential two vector HB-201/HB-202 therapy, a recommended Phase 2 Dose will be determined. Thereafter, enrollment of patients with first line or second line advanced/metastatic HPV16+ HNSCC will begin, using a combination treatment of HB-201/HB-202 and pembrolizumab. Enrollment of those patients will also proceed in the unrandomized Phase 2 dose expansion part of the ongoing Phase 1/2 trial (NCT04180215).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Infectious Disease Pipeline Highlights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate in infectious diseases, HB-101, is a potential first-in-class vaccine for the prevention of CMV disease. CMV is a type of herpes virus that infects the majority of people over the course of their lifetime. The U.S. Centers for Disease Control and Prevention estimates that more than half of adults have been infected with CMV by age 40. The majority of CMV infections are not serious, and the virus can lay dormant in the body for years. However, CMV infection poses a considerable risk to infants in utero, as well as immune-compromised individuals, such as solid organ transplant recipients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In a CMV-negative patient receiving an organ or stem cells from a CMV-positive donor, the spread of the virus through the bloodstream, known as viremia, can cause end-organ damage, such as hepatitis, pneumonitis, gastroenteritis and retinitis, and can result in transplant rejection and patient death. In this high-risk patient group, approximately 80% of kidney transplant recipients develop active CMV infections. CMV progression in the transplant setting varies according to the type of transplant, the immunosuppressive drugs used and the presence of any other comorbidity risk factors. Symptomatic CMV infections develop in patients in between 8% and 32% of kidney transplants, 22% and 29% of liver transplants, 9% and 23% of heart transplants and 50% and 75% of lung transplants. Based on a market research study we commissioned from an independent third party and reviewed by management, we believe that approximately 110,000 patients are added to the solid organ transplant waiting list annually in developed countries, with kidney transplantation representing approximately 60% of cases. Furthermore, more than 20,000 allogeneic cell transplants, in which cell and tissue donors are matched with transplant recipients, are carried out annually worldwide. In this group, the incidence of CMV infection is approximately 30% as a result of the donor being CMV positive. Current therapies to prevent the transmission of CMV during organ transplants utilize antiviral prophylactic and therapeutic strategies. However, these therapies are only partially protective in preventing viral disease while also being hampered by toxicity and resistance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-101 uses our proprietary non-replicating technology and two antigens to stimulate both arms of the adaptive immune system: phosphoprotein 65 (pp65), to induce CMV-specific T cells and glycoprotein B (gB fusion protein) to elicit CMV-neutralizing antibodies. In our Phase&#160;1 clinical trial, reviewed in the April&#160;2020 issue of <i style="font-style:italic;">The Journal of Infectious Diseases, </i>HB-101 was well-tolerated and elicited strong CMV-specific immune responses in all 42 of the treatment arm volunteers. Importantly, we observed robust CD8+ and CD4+ T cell responses, as well as CMV-neutralizing antibody responses, without meaningful vector-neutralizing antibody responses. These responses increased in a statistically significant manner upon repeat administration. We believe these results demonstrate the differentiating features of our arenavirus platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We reported interim safety, immunogenicity and efficacy data for HB-101 in evaluable patients in November&#160;2021. The interim Phase 2 data were released for patients who received two- or three-doses of HB-101 prior to a kidney organ transplantation. These interim results showed a reduction in CMV viremia, reduction in antiviral use, and no CMV disease in these CMV-negative kidney transplant recipients as compared to placebo. Strong CMV-neutralizing antibody responses and a favorable tolerability profile were also observed. We concluded enrollment of this trial in June 2021 and anticipate the final data read-out in 2023. We plan to explore partnership opportunities for further development of HB-101 in order to focus on advancing our oncology portfolio.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To expand our infectious disease portfolio, we entered into a collaboration and licensing agreement, the Collaboration Agreement, with Gilead in June&#160;2018, to research arenavirus functional cures for HIV and chronic Hepatitis B infections. We received a one-time upfront payment of $10.0&#160;million upon entering into the Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2022, we signed an amended and restated collaboration agreement, the Restated Collaboration Agreement, which revised the terms only for the HIV program, whereby we will take on development responsibilities for the HIV program candidate through a Phase 1b clinical trial and Gilead will provide funding through a combination of an initiation payment of $15.0 million, a milestone payment of $5.0 and equity contributions of up to $35.0 million, pursuant to a Stock Purchase Agreement entered into by us and Gilead in February 2022. Pursuant to the Restated Collaboration Agreement, Gilead will retain an exclusive right, the Option, to take back the rights for the HIV program, including further development and commercialization in return for an option exercise payment of $10.0 million. Pursuant to the Restated Collaboration Agreement, we are eligible for up to $140.0 million in developmental milestone payments for the HBV program and $50.0 million in commercialization milestone payments. If Gilead exercises the Option, we are eligible for up to a further $167.5 million in developmental milestone payments for the HIV program, inclusive of the $10.0 million Option exercise payment, and $65.0 million in commercialization milestone payments for the HIV program. Upon the commercialization of an approved product, we are eligible to receive tiered royalties of a high single-digit to mid-teens percentage on the worldwide net sales of each HBV product, and royalties of a mid-single-digit to 10% of worldwide net sales of each HIV product. Through to December 31, 2021, we have received from Gilead the non-refundable upfront payment of $10.0&#8239;million and $12.2&#8239;million in milestone payments for the achievement of pre-clinical research milestones. In addition, we have recognized $35.6&#160;million of cost reimbursements for research and development services performed under the Restated Collaboration Agreement. In the first quarter of 2022, we received an additional milestone payment of $4.0 million and a payment of $15.0 million upon execution of the Restated Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are led by a team of highly experienced executives, clinicians, and scientists with focused and translational expertise in oncology, immunology, vaccinology, clinical development, and commercialization. Our Chief Executive Officer, Joern Aldag, was previously the Chief Executive Officer of uniQure, a company that under his leadership pioneered the approval of the first gene therapy product. Igor Matushansky, M.D., Ph.D., our Chief Medical Officer and Global Head of Research and Development was previously Global Head of Translational Development for Oncology at Daiichi Sankyo. The fundamental discoveries underlying our arenavirus platform originated with our co-founders, Nobel laureate Rolf Zinkernagel, M.D., and Daniel Pinschewer, M.D., an internationally recognized arenavirus expert who serves as Scientific Advisor to our Chief Executive Officer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:258pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are leveraging our modular arenavirus platform to develop the following product candidates for multiple cancers and infectious diseases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k001.jpg" alt="Graphic" style="display:inline-block;height:257.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:457.56pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also pursuing the development of &#8220;off-the-shelf&#8221; cancer therapies by identifying the next generation cancer testis antigens, which are tumor associated antigens that are generally not expressed in normal tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Immune System Function: Antigen Presentation by Dendritic and Other Antigen Presenting Cells</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The immune system is designed to protect the human body from infections and cancers. Infections can be generally defined as the proliferation of foreign microorganisms such as bacteria, viruses, and parasites in a patient&#8217;s body resulting in clinical manifestations of disease. Cancer can be generally defined as the uncontrolled proliferation of native cells resulting in disease. In both cases, the immune system recognizes and destroys microorganisms, infected cells and cancers by targeting specific proteins, or antigens, as well as their immunogenic sub-parts, which are referred to as epitopes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The innate immune system is the body&#8217;s first line of defense and enables a rapid, short-lived and nonspecific response. In contrast, the adaptive immune system utilizes highly specialized immune cells called lymphocytes that have been selected to recognize specific foreign antigens. Although it takes longer to mobilize, the adaptive immune system is capable of providing long-term, more effective immunity against specific pathogens by being able to recall prior antigen exposure and mounting a very powerful and specific response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In order for the adaptive immune system to function effectively, the innate immune system must first present disease specific antigens to a subset of lymphocytes called T&#160;cells in order to &#8220;instruct&#8221; the T&#160;cells as to which antigen they must recognize. The T&#160;cell population consists of CD8+ T&#160;cells, those that kill virus infected and cancer cells by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">releasing cytotoxic proteins, and CD4+ T&#160;cells that help or stimulate additional parts of the immune system such as B&#160;cells that produce antibodies. Antigen presentation to T cells is mediated by APCs, such as dendritic cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Immunotherapy and Current Limitations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical application of immunotherapy in the context of managing infectious diseases and cancers is distinctly different. The approach taken for infectious diseases is commonly that of &#8220;vaccination&#8221;, whereby the aim is to prevent onset of disease by administering a derivative of the disease-causing agent to a healthy individual. In contrast, for cancer, the approach is typically one of therapeutic intervention in patients with active disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Infectious disease and cancer immunotherapies represent areas of medicine with high potential for prophylactic and therapeutic benefit and have generated significant interest and investment from leading biopharmaceutical companies. Data from ongoing industry and academic research have demonstrated the potential clinical benefit for patients in a range of infectious disease and cancer settings. Several immunotherapy products have been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other foreign regulatory agencies. However, despite ongoing development efforts and successes, we believe that the current immunotherapies are limited by several factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Lack of Robust CD8+ T&#160;Cell Response.</i> APCs, like Dendritic cells, are the most efficient antigen presenting cells of the body and the natural mechanism by which to induce a robust CD8+ T&#160;cell response to fight the disease. However, we do not believe there are any existing immunotherapies that have the ability to independently and directly deliver full length proteins to target and activate dendritic cells to present antigens directly to CD8+ T&#160;cells. This limitation prevents them from inducing a robust and durable CD8+ T&#160;cell response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Presence of Virus Neutralizing Antibodies and Pre-Existing Immunity.</i> Nearly all viral vectors used to deliver antigens elicit neutralizing antibodies against both the desired target and the vectors themselves. In some cases, these circulating antibodies can be present before treatment is commenced owing to prior virus exposure. The presence of pre-existing vector neutralizing antibodies can reduce or eliminate the viral vector&#8217;s ability to elicit CD8+ T&#160;cell and antibody responses to the desired antigen. For example, a significant proportion of the global population carries adenovirus 5 neutralizing antibodies from natural infection which can affect vector immunogenicity. Even in the absence of pre-existing immunity, if virus neutralizing antibodies are induced in response to immunization, such as is the case with recombinant adenovirus or poxvirus based vaccines, repeat doses administered to the patient may also be rendered ineffective or impractical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Safety and Toxicity Concerns.</i> Some immunotherapies, such as engineered T&#160;cells (CAR-T and TCR-T), use artificial constructs that bypass normal control mechanisms of the immune system. As a result, these approaches have the risk of causing life threatening immune reactions, including cytokine release syndrome, and can have various other toxicity concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Clinical Application.</i> Two common limiting factors of many immunotherapies are the inability to deliver full length proteins directly to antigen presenting cells and the inability to be administered systemically. The former limitation restricts these therapies to being patient specific as they can only deliver smaller proteins such as neoantigens and it furthermore prevents an &#8220;off-the-shelf&#8221; approach. The latter restricts their application only to tumors that are amenable to intratumoral administration, as is the case for oncolytic viruses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Handling and Manufacturing.</i> <i style="font-style:italic;">Ex vivo</i> approaches, such as CAR-T, require CD8+ T lymphocytes to be isolated from cancer patients, manipulated, substantially expanded and delivered back into the patient. This represents a costly, time consuming and substantially more complex approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unlike with cancer treatment, immunotherapies in the context of infectious diseases, commonly stimulate an antibody response that is dependent on the presence of CD4+ T cells. We believe that a vaccine approach that can generate the combination of CD8+ T cells with an antibody response offers a solution to optimally mobilize the immune response and potentially overcome many of the limitations that exist with current approaches.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Technology Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proprietary platform is based on engineering arenaviruses to carry and deliver virus specific or tumor specific genes to APCs, such as dendritic cells, which are natural activators of CD8+ T&#160;cells. Arenaviruses have been used for decades to stimulate potent CD8+ T&#160;cells responses in preclinical research. Our cofounder, Rolf Zinkernagel, was awarded a Nobel Prize in Physiology or Medicine for his arenavirus based work on how CD8+ T cells recognize virus infected cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Arenaviruses have several important advantages, which we believe represent the optimal characteristics for an antigen specific immunotherapy. Specifically, they:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the ability to induce a robust CD8+ T&#160;cell response by directly targeting and activating APCs, such as dendritic cells, which are the most efficient antigen presenting cells of the body;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the ability to induce a robust antibody response to disease specific target antigens;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are not efficiently neutralized by vector specific antibodies, which may facilitate repeat administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">do not require an adjuvant to stimulate the immune system; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have been observed to be well tolerated in preclinical studies and clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The arenavirus family is comprised of over 30 currently known species, many of which we believe have potential prophylactic and therapeutic applications. We believe we are the first to reengineer arenaviruses for the prevention and treatment of disease. We have created two types of viral technologies capable of delivering disease specific antigens: a replication defective vector, and a replication competent but attenuated vector.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our non-replicating and replicating technologies utilize both LCMV and PICV, two of over 30 species of arenaviruses, as a backbone of the product candidates we are developing. LCMV is principally carried and secreted by wild mice, with human infection being secondary to such exposure and uncommon. Approximately 2% to 5% of individuals in industrialized countries have circulating antibodies against LCMV, which indicates prior exposure in these individuals. Individuals infected with LCMV typically remain asymptomatic or may present with a nonspecific and self-resolving flu-like illness. PICV is principally carried and secreted by Colombian rice rats (<i style="font-style:italic;">oryzomys albigularis</i>) and is a nonpathogenic virus that does not cause disease in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Non-Replicating Technology Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proprietary non-replicating technology disables arenavirus replication by substituting one of its four structural genes with the gene for a desired antigen. The modified, non-replicating arenavirus is able to directly infect individual APCs, such as dendritic cells and deliver proteins that serve as antigens to activate the immune system but is not able to replicate and infect additional cells in the body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Advantages of Non-Replicating Technology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the preclinical and clinical data that we have generated to date, we believe our non-replicating technology supports the benefits of our arenavirus platform approach. Specifically, in preclinical studies and clinical trials this technology has demonstrated that it is well tolerated and has the following additional benefits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Robust CD8+ T&#160;Cell Response as Well as Pathogen Neutralization Response.</i> Our non-replicating technology is designed to induce a robust CD8+ T cell and pathogen neutralizing response to fight disease. We believe our technology results in a prophylactic and immuno-therapeutic and prophylactic approach with potential for greater potency than existing prophylactic treatments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Immunological Memory and Protection Against Challenge.</i> Our non-replicating technology has shown the ability to trigger a robust and long term CD8+ T&#160;cell response of at least 12&#160;months in humans. Furthermore, in various animal models non-replicating vector immunization resulted in protection against infectious challenge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Reduced Neutralization of Vector Specific Antibodies.</i> The reduced neutralization of vector specific antibodies facilitates repeat administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Replicating Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proprietary replicating technology was designed to provide the beneficial properties of our non-replicating technology but to induce an even more robust immune response. Unlike naturally occurring arenaviruses which have two genomic segments, our replicating constructs were engineered to have three segments in order to allow for the introduction of genomic space in which to insert additional target antigens of choice. As a result of the larger genome the virus&#8217; ability to replicate is reduced (attenuated).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Advantages of our Replicating Technology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on our preclinical data, we believe our replicating technology shows all of the benefits of the non-replicating technology and the following additional benefits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Quantitatively: Even More Robust CD8+ T&#160;Cell Response.</i> In animal studies, our replicating technology has shown to induce a CD8+ T&#160;cell response that directs more than 50% of a body&#8217;s T&#160;cells, which is approximately ten times greater than the response induced by our non-replicating technology, to focus on a single target of choice. We believe our technology results in an immunotherapeutic approach with potential for greater potency than existing therapeutic treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Qualitatively: Immunological Memory and Protection Against Challenge.</i> Our replicating technology has shown the ability to trigger a long term CD8+ T&#160;cell response. Furthermore, in various animal models replicating immunization resulted in complete tumor remission after a single treatment and protection against a cancer re-challenge months after primary treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The additional benefits noted above are attributable to our technology&#8217;s ability to replicate. This allows it to infect not only APCs, such as dendritic cells, but also lymphoid stromal cells, which are immune support cells found in lymph nodes and the spleen. Infection of lymphoid stromal cells results in the release of a signaling protein which further drives the proliferation and differentiation of CD8+ T&#160;cells. This mechanism has the potential to generate ten-fold more antigen specific CD8+ T&#160;cells as compared to viral delivery systems that are unable to trigger this pathway. Furthermore, we believe our replicating technologies may also be synergistic with other approved immuno-oncology agents and currently are conducting a clinical trial of our replicating technology in combination with checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To demonstrate the superior properties of our approach, we performed a head-to-head comparison in mice of our replicating LCMV and PICV E7 constructs versus modified vaccinia virus Ankara (MVA), and adenovirus 5 (Adeno5), each expressing E7 antigens for their ability to induce E7 specific CD8+ T&#160;cells. As shown below, our replicating constructs were superior to MVA and Adeno5, despite being dosed at concentrations 1,000 times lower than </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:318.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the latter two vectors. Furthermore, sequential dosing of replicating PICV vector followed by administration of replicating (LCMV) vector resulted in over 50% of CD8+ T cells being targeted against E7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k002.jpg" alt="Graphic" style="display:inline-block;height:317.29pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:395.79pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In additional preclinical models, including a mouse melanoma model and a cancer testis self-antigen cancer model, we again demonstrated the ability of sequential administration of replicating PICV and LCMV constructs to direct up to 50% of a body&#8217;s T&#160;cells to focus on a single target of choice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Non-Replicating Preclinical Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our preclinical data support the development of our non-replicating technology for prophylactic and therapeutic uses for infectious disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HIV Model</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A third-party preclinical study was conducted in a monkey model of HIV infection using simian immunodeficiency virus (SIV). Ten monkeys were treated with an adenoviral vector carrying the SIV Env protein. The expression of the SIV Env protein is meant to prime the animal&#8217;s immune system to detect and attack SIV. From earlier work, this initial adenoviral-prophylactic immunization on its own was shown not to prevent SIV infection. Monkeys were then boosted eight weeks later with our non-replicating LCMV vector encoding SIV Env. The ten monkeys were also treated with vectors encoding no relevant genes, identified as the null group below. Starting at week six, both groups were challenged with weekly SIV injections for 12&#160;weeks. The dosing regimen of the study is shown in Figure&#160;1 below. As depicted in the Figure&#160;2 below, the non-replicating (LCMV)-Env vaccination resulted in over 70% of monkeys being SIV free at the end of the study, as compared to less than 20% in the null group.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:285pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20211231x10k003.jpg" alt="Graphic" style="display:inline-block;height:285pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:453.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Figure: Flatz, L. et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates; https://pubmed.ncbi.nlm.nih.gov/22593152/<span style="font-size:10pt;"> </span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:12pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:8pt;">*</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:8pt;font-weight:bold;">A p-value of 0.05 or less represents statistical significance, meaning that there is a less than 1in20 likelihood that the observed results occurred by chance. A p-value of 0.01 or less means that there is a less than 1in100 likelihood that the observed results occurred by chance.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Hepatitis B Virus Model</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the HIV model, we explored the ability of our non-replicating vectors to induce immune responses against hepatitis B core, HBc, and hepatitis B surface, HBs, antigens. In our study, we observed that a non-replicating (LCMV) vector expressing both HBc and HBs was able to generate significant CD8+ T&#160;cell responses against both proteins. These data indicate that a single dose of a non-replicating LCMV vector expressing Hepatitis&#160;B Virus antigens elicits robust cellular immunity against both encoded proteins delivered in a single vector. We believe that non-replicating vector based immunotherapy may form an important cornerstone of a potential cure for the estimated 350&#160;million people worldwide who are persistently infected with Hepatitis&#160;B Virus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that the combination of our HIV and Hepatitis&#160;B Virus preclinical and subsequent non-replicating vector clinical data facilitated our Gilead collaboration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Replicating Vector Preclinical Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have conducted several preclinical studies assessing the efficacy of our replicating technology, for both LCMV and PICV constructs, carrying the HPV specific E7E6 fusion protein through intravenous (IV) and intratumoral (IT) administration. Mice treated with the replicating vectors showed no evidence of toxicity. In a mouse model of HPV-induced cancer (TC1), we observed that a single intravenous administration of replicating LCMV significantly suppressed and delayed tumor growth while a single IT administration of replicating LCMV eliminated the tumor in approximately half of the mice (top left panel). IV administration of replicating PICV eliminated the tumor in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:192.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approximately half of the mice, by the same definition, while IT administration of replicating PICV significantly suppressed and delayed tumor growth (bottom left panel). These mice had complete remission without recurrence for at least six months, which represents over 25% of a mouse&#8217;s lifetime (right panel). In contrast, replicating vectors carrying non-tumor specific antigens, such as GFP, demonstrated no anti-tumor activity. In these studies, we also observed resistance to a tumor re-challenge after six months (right panel).<span style="font-size:12pt;"> </span><span style="font-size:12pt;"><br /></span><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20211231x10k005.jpg" alt="Graphic" style="display:inline-block;height:192.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:347.66pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have also performed &#8220;tracking&#8221; experiments wherein we observed that while our intravenous replicating vectors travel to APCs, such as dendritic cells, the reprogrammed antigen CD8+ T cells travel to tumors. We illustrated this in an EG7-OVA model, which analyzed subcutaneous tumors for the presence of antigen specific CD8+T&#160;cells. In mice injected with a replicating vector, histopathology showed clear evidence of strong CD8+ T cell infiltration, as shown by the brown staining in the pictures below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k006.jpg" alt="Graphic" style="display:inline-block;height:135.4pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:479.68pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We observed similar results in a more aggressive B16F10 melanoma mouse model. In this experiment B16F10 malignant cells were introduced into the tail vein of mice, resulting in lung metastases within three weeks. Ten days after the introduction of B16F10, a replicating vector expressing Trp2, a melanoma antigen, was introduced intravenously </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:148.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">leading to a significant delay in disease progression. Similarly, in subcutaneously growing B16F10 tumors treated intravenously, histopathology showed clear evidence of strong CD8+ T&#160;cell infiltration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k007.jpg" alt="Graphic" style="display:inline-block;height:126.73pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:434.8pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When we combined the above two experiments, by initially introducing B16F10 malignant cells subcutaneously, and then intravenously, we achieved both a localized subcutaneous tumor and metastatic lung lesions. Subsequent administration of our intratumoral replicating vector demonstrated both a localized response, through subcutaneous tumor shrinkage, and systemic response, through clearance of lung metastases. The long-term survivor mice were then rechallenged with B16F10 several months after remission with no observed subsequent tumor regrowth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k008.jpg" alt="Graphic" style="display:inline-block;height:147.98pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:459.92pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Advantages of sequential administration of replicating PICV and replicating LCMV</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have observed increased antitumor activity and survival of animals that received sequential administration of replicating PICV and replicating LCMV in a preclinical mastocytoma model. In this model, tumor cells expressed a cancer testis self-antigen known as P1A. In the absence of treatment, tumors grew rapidly and most of the mice died by day 25. When given a first dose with a replicating LCMV P1A vector, followed by a second dose with the same vector, there was a delay in tumor growth of approximately ten days and an increase in survival rates, with some mice surviving to almost 100&#160;days (left panel below). In contrast, mice that were treated first with replicating PICV P1A followed by a second dose with a different arenavirus, replicating LCMV P1A, had an average tumor growth delay of approximately 25&#160;days and in 18% of the mice the tumors were eliminated, and they survived beyond the 160&#160;days of the study. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:135.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, and as seen in our other studies, mice with eliminated tumors demonstrated resistance to a tumor rechallenge (right panel below). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k009.jpg" alt="Graphic" style="display:inline-block;height:134.33pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:477.76pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Figure: Bonilla, W. et al. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T&#160;cell attack. journal.ppat. 100209. Cell Reports Medicine</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HB-200 Program for the Treatment of HPV16+ Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently developing two immunotherapeutics targeting HPV16+ cancers, referred to as our HB-200 program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-201 is a replicating LCMV-based product candidate expressing the E7E6 fusion protein specific to HPV16+ cells and being developed for the treatment of HPV16+ cancers, including head and neck squamous cell carcinoma (HNSCC) cervical and anal cancer. HB-201 is being evaluated as both monotherapy and in combination with a checkpoint inhibitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-202 is a replicating PICV-based product candidate expressing the same E7E6 fusion protein as HB-201. HB-202 is being evaluated as an alternating vector therapy with HB-201, so called &#8220;HB-201/HB-202 therapy&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The &#8220;HB-200 program&#8221; encompasses our arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by HPV16+. These two arenaviral-based immunotherapy regimens include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:32.2pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">HB-201 single vector therapy</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: sequential injections of HB-201 (E7E6 fusion protein derived from HPV16 encoded in a Lymphocytic Choriomeningitis Virus (LCMV) vector);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:32.2pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">HB-201/HB-202 two vector therapy</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: alternating sequential injections of HB-201 and HB-202 (the same E7E6 fusion protein encoded in a Pichinde Virus (PICV) vector).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preclinical studies, HB-201, as a monotherapy, was observed to suppress tumor growth and eliminated up to 40% of HPV+ tumors. HB-201 generated a strong and durable T cell response with successfully treated animals demonstrating resistance to a tumor rechallenge. Based on these preliminary results, we believe that treating patients with HB-201 has the potential to both control metastatic disease and prevent relapse. Additionally, our preclinical data support the concept that the alternating vector therapy of two different replicating constructs based on different arenaviruses, but carrying the same tumor antigen, results in an exponentially more robust immune response with potential improvements in antitumor activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, we opened the HB-200 Phase 1/2 trial (NCT04180215), investigating both Phase 1 dose optimization and Phase 2 dose expansion in a single trial. During the initial 10 months of the trial, the HB-201 single vector therapy was studied through escalating doses. Starting in October 2020, enrollment into the HB-201/HB-202 alternating sequential two vector therapy began, representing a parallel dose escalation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, interim Phase 1 data on HB-201 for the treatment of advanced HPV16+ cancers continued to show promising anti-tumor activity and favorable tolerability as a monotherapy. The interim data was derived from 62 patients who received either HB-201 single vector therapy or HB-201/HB-202 two vector therapy for advanced/metastatic HPV16+ cancers. Data demonstrated responses and stable disease in head and neck cancer patients who failed prior standard of care therapy, platinum therapy, PD(L)1 inhibitor, or both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In coordination with the November 2021 update, the Recommended Phase 2 Dose (RP2D) for HB-201 single vector therapy was determined. In January 2022, we dosed the first patient with a combination of HB-201 and pembrolizumab for the treatment of first line advanced/metastatic HPV16+ HNSCC in the Phase 2 expansion portion of the ongoing Phase 1/2 trial (NCT04180215).  The Phase 2 portion of the trial is also open for enrollment of patients with second line advanced/metastatic HPV16+ HNSCC for treatment with a combination of HB-201 and pembrolizumab. Similarly, for the alternating sequential two vector HB-201/HB-202 therapy, a recommended Phase 2 Dose will be determined. Thereafter, enrollment of patients with first line or second line advanced/metastatic HPV16+ HNSCC will begin, using a combination treatment of HB-201/HB-202 and pembrolizumab. Enrollment of those patients will also proceed in the unrandomized Phase 2 dose expansion part of the ongoing Phase 1/2 trial (NCT04180215).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The first data from Phase 2 arms with combination therapy of HB-200 and pembrolizumab in first line and second line advanced/metastatic HPV16+ HNSCC are anticipated in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HPV-Positive Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HPV is estimated to cause about 5% of cancers worldwide, including approximately 99% of cervical cancers, up to 60% of HNSCC, 70% of vaginal cancers and 88% of anal cancers, the majority of which are caused by the HPV serotype&#160;16. While most infections with HPV are cleared from the body with no lasting consequences, in some cases, HPV DNA becomes integrated into chromosomal DNA. When host cells take up this DNA, they express the HPV E6 and E7 proteins. The expression of these proteins can lead to alterations in cell cycle control, which in turn predisposes these cells to become cancerous.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While the rates of HNSCC from causes such as smoking and alcohol are decreasing, the rates of HPV16+ HNSCC are increasing. HNSCC is the sixth most common form of cancer. Each year, HNSCC is diagnosed in more than 600,000 people worldwide, with 65,000 new cases and more than 14,500 deaths occurring in the United States alone. HNSCC includes tumors of the oral cavity, oropharynx, larynx and hypopharynx. The current standard of care for HNSCC is the same regardless of HPV status. Treatment typically involves immunotherapy, chemotherapy, radiation and surgery, the precise regimen varying based on the Stage of cancer and responses to prior therapies. These treatments are associated with acute and long-term effects including mucositis, swallowing dysfunction, dry mouth, and dental problems. The overall survival time for patients with advanced metastatic HNSCC progressing on platinum and checkpoint-based therapies is less than six months. While there is no T&#160;cell therapy approved for HNSCC, retrospective analyses have shown that patients&#8217; outcomes are improved for those with high levels of CD8+ T&#160;cells in tumors as compared to patients with low levels. In many cases, the survival rate of patients with higher levels is more than double that of patients with lower levels of CD8+ T&#160;cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that HB-200 has potential to provide beneficial treatment to persons with HPV16+ HNSCC, in the post-standard of care therapy OR in combination with pembrolizumab in earlier line (e.g., first-line or second-line) therapy. Proof of concept in either HPV16+ HNSCC or HPV16+ non-HNSCC could support the potential of our product candidates to be effective for all HPV16+ cancers, regardless of the cancer&#8217;s tissue of origin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Our Solution HB-200 Programs: HB-201 and HB-202</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Both HB-201 (LCMV) and HB-202 (PICV) are replicating based product candidates expressing a non-oncogenic but highly antigenic E7E6 fusion protein from HPV16. In animal models, HB-201 was observed to be highly immunogenic, resulting in a robust CD8+ T&#160;cell response. Based on the levels of antigen-specific CD8+ T&#160;cells induced by HB-201 in preclinical models, notably when compared to therapeutic levels induced by other published approaches including adoptive cell therapies, as observed in separately designed and conducted third-party clinical trials, we believe that HB-201 single vector therapy has the potential to provide therapeutic benefit to patients across the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">broader HPV16+ cancer setting. We have observed strong immunogenicity and robust antitumor activity in mouse models for HB-201 alone as well as for the sequential administration of HB-201 and HB-202.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Relevance of E6 and E7 as Tumor Antigens</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Integration of HPV viral sequences into the genome of a cell can result in the introduction of E6 and E7 oncoproteins. They are present in cells that become cancerous and play a critical role in interfering with cellular processes and interrupting normal tumor suppressor functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Profiling of immune cells isolated from patients with HPV16+ tumors has identified E6 and E7 specific T&#160;cells, indicating that the E6 and E7 proteins are immunogenic, meaning that they trigger antigen specific CD8+ T&#160;cell responses. Because both E6 and E7 are highly expressed in tumor cells and are absent in normal cells, they are ideal candidates for use as targets of tumor directed active immunization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">HB-201 Preclinical Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ability of HB-201 to suppress tumor growth was tested in a TC1 mouse model of a transplantable HPV16+ E6/E7 expressing tumor. HB-201 was administered either intravenously or intratumorally to animals when tumor volume was approximately 100mm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>. In both cases, as depicted in the figures below, single doses of HB-201 led to suppression of tumor growth in a statistically significant manner (p &lt;&#160;0.05) in all treated mice, and intratumoral administrations resulted in an approximately 40% long term survival rate. When these long-term survivor mice were rechallenged with the same tumor six months later, no new tumor growth was detected. We believe that these results demonstrate the potential for HB-201 to be active both in treating primary tumors and also controlling metastatic and recurring disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Furthermore, we have observed that the dose of HB-201 strongly correlated with both immunogenicity, as depicted in the left side of the figure below, and antitumor activity, as depicted in the right side of the figure below. We believe that this indicates that antitumor activity is directly linked to immunogenicity. Specifically, low doses of HB-201 containing as few as 100 replication competent vector (RCV) particles per dose suppressed tumor growth by more than 50% as compared to untreated tumors. Dosing with the highest three doses of HB-201, ranging from 10,000 to 1,000,000 RCV particles per dose, led to greater suppression of tumor growth. These data suggest that the maximal effective dose </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:294pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">was already achieved at the lower of those three doses, or 10,000 RCV particles per dose. All doses of HB-201 were well tolerated in this model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k010.jpg" alt="Graphic" style="display:inline-block;height:293.6pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:432.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">HB-202 Preclinical Studies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-202, like HB-201, is directed against HPV16+ E6/E7 tumors. In a mouse model of HPV16+ E6/E7 tumors, single doses of HB-202 were shown to be similarly effective as single doses of HB-201 when administered both intravenously and intratumorally. Also, as in HB-201, long term survivor mice were uniformly resistant to re-challenge at six months. The results of our preclinical studies of HB-202 are depicted below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k011.jpg" alt="Graphic" style="display:inline-block;height:179.55pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:392.65pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:178.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Figure: Bonilla, W. et al. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack. journal.ppat. 100209. Cell Reports Medicine</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k012.jpg" alt="Chart, box and whisker chart&#10;&#10;Description automatically generated" style="display:inline-block;height:177.91pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:358.49pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we have observed that if HB-202 and HB-201 are administered sequentially, activity levels, which tend to indicate effectiveness, are significantly superior to those observed after repeated administration of either one alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">HB-200 Clinical Trial (NCT04180215)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our oncology product candidates, HB-201 and HB-202, are in an ongoing Phase&#160;1/2 clinical trial (NCT04180215) for the treatment of HPV16+ cancers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2019, we opened the HB-200 Phase 1/2 trial (NCT04180215), investigating both Phase 1 dose optimization and Phase 2 dose expansion in a single trial.  During the initial 10 months of the trial, the HB-201 single vector therapy was studied through escalating doses. Starting in October 2020, enrollment into the HB-201/HB-202 alternating sequential two vector therapy began, representing a parallel dose escalation. The primary endpoint of the Phase 1 part of the Phase 1/2 trial is a recommended Phase 2 dose based on safety and tolerability. Secondary endpoints include anti-tumor activity as defined by RECIST 1.1, immunogenicity, safety, and tolerability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first-in-human trial, the Phase 1 arm of the trial opened to investigate multiple questions for HB-200 program:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Route of administration: intravenous (IV) vs. intratumoral (IT)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dose optimization</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dosing schedule: every two weeks (Q2W) or every three weeks (Q3W)</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:212.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k013.jpg" alt="Graphic" style="display:inline-block;height:212.2pt;width:242.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, interim Phase 1 data on HB-201 single vector therapy and HB-201/HB-202 two vector therapy for advanced/metastatic HPV16+ cancers showed promising anti-tumor activity and favorable tolerability. The interim data was derived from 62 patients who received either HB-201 single vector therapy or HB-201/HB-202 two vector therapy for advanced/metastatic HPV16+ cancers. Data demonstrated responses and stable disease in head and neck cancer patients who failed prior standard of care therapy, platinum therapy, PD(L)1 inhibitor, or both. We believe that these early-stage data establish proof of concept for our replicating single-vector immunotherapy in oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the interim Phase 1 data released in November 2021 enabled decisions on Phase 2 clinical plans for target tumor type as well as recommended schedule and route of administration for HB-200:</p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IV administration was observed to be superior to IT administration; therefore, the IT route has been discontinued and IV only will be used in Phase 2;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The initial Q3W dosing schedule was observed to be superior to Q2W; therefore, the Q2W regimen arm has been discontinued and the Q3W dosing will be used in Phase 2;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The majority of data accrued to date has been from HNSCC patients; therefore, the Phase 2 target tumor type will be HNSCC.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patient Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the November 2021 data release, a total of 62 patients with advanced HPV16+ tumors had been enrolled and treated with HB-200 therapy. Forty patients with HNSCC tumors were treated intravenously every three weeks, including 20 patients who received single vector HB-201 and 20 patients who received alternating two-vector HB-202/HB-201. Twenty-eight of these 40 patients (14 who received single vector HB-201 and 14 who received alternating two-vector HB-202/HB-201) were evaluable (they had at least one scan). An additional 22 patients were dosed in cohorts dedicated to exploring other schedules and/or non-head and neck squamous cell carcinoma subtypes. Participants had received a median of three prior therapies (ranging from zero to eleven), and 87% had previously received a checkpoint inhibitor regimen.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:261.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k014.jpg" alt="Graphic" style="display:inline-block;height:260.38pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:462.7pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical Biomarker Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The November 2021 data release included clinical biomarker data on 20 patients treated with the Q3W IV regimens (including 10 patients who received HB-201 and 10 who received alternating two-vector HB-201/HB-202).  These data demonstrated that HB-200, either as a single or alternating two-vector, rapidly induced high levels of activated, tumor-specific CD8+ T cells. As depicted in the figures below, the clinical data showed remarkable similarity to the preclinical mouse models in terms of expansion of E7E6 specific CD8+ T cells.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k015.jpg" alt="Graphic" style="display:inline-block;height:204.49pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:452.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Important clinical biomarker findings in the November 2021 data update included:</p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">More than 90% of patients showed an increase in tumor-specific CD8+ T cells within 2 weeks of the initial HB-200 dose (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Figure A</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">);</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:243.72pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">More than 50% of patients had tumor antigen-specific CD8+ T cell levels that exceeded the single-digit percentage threshold of the circulating T cell pool, which is generally considered a strong indicator of response (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Figure B</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50% of patients with paired biopsies (3 of 6 patients) showed elevated tumor infiltrating lymphocytes (TILs), or an increase in CD8+ T cells in their tumors (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Figure C</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">).</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure A:</i> Fast induction of active tumor-specific T cell responses in nearly all patients (ELISpot: HPV16+ E6/E7 specific responses). Direct measurement without prior in vitro expansion of cells; data from HB-201 and HB-201/HB-202 combined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k016.jpg" alt="Graphic" style="display:inline-block;height:243.72pt;width:283pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Figure B:</i> More than 50% of patients achieved greater than single digit percentage increases of tumor specific systemic CD8+ T cells (HPV16+ E6/E7 specific CD8+ responses). Direct measurement without prior <i style="font-style:italic;">in vitro</i> expansion of cells; majority of patients show peak responses within two to three weeks post the first administration of study drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:261.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k017.jpg" alt="Graphic" style="display:inline-block;height:261.35pt;width:285pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure C</i>: Three of six of biopsied patients show TILs (i.e. CD8+ T cells infiltrating tumors)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k018.jpg" alt="Graphic" style="display:inline-block;height:193.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:438.99pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical Safety Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-200 continued to demonstrate a favorable tolerability profile in heavily pre-treated patients with HPV16+ cancers, highlighting its potential in combination with checkpoint inhibitors and other agents. As of the November 2021 data release, safety was evaluated across all 62 patients who received any regimen of HB-200, inclusive of all doses, frequencies and routes of administration. As shown below, treatment-related adverse events were reported in 66% of the patients, with 8% experiencing treatment-related adverse events rated grade 3 or higher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:202.62pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k019.jpg" alt="Graphic" style="display:inline-block;height:189.15pt;width:269.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical Efficacy Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Efficacy was considered for the 40 patients who received the intended Phase 2 dose frequency (initial Q3W, moving to Q6W) and route of administration (IV) for treatment of HPV16+ advanced/metastatic HNSCC.  As shown below, the efficacy was evaluated separately for the single vector therapy of HB-201 (20 patients) and for the alternating two vector therapy HB-201/HB-202 (also 20 patients). Combined, the regimens demonstrated tumor shrinkage in 53% of patients (15 of 28 evaluable patients) and an ongoing median progression-free survival (mPFS) of 3.45 months, which compares favorably with published, historical mPFS of 2.0 months for nivolumab in line 2+ HNSCC patients (Ferris et al, NEJM 2016; 375: 1856-1867).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-201 Single Vector Therapy Efficacy Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For HB-201, the interim efficacy results released in November 2021 were based on 14 evaluable patients (who had at least one scan) and a median time on treatment of 107 days. As shown below, treatment was ongoing for six of the 14 evaluable patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k020.jpg" alt="Graphic" style="display:inline-block;height:202.62pt;width:316.8pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As shown below, the interim data for the HB-201 treated patients included one confirmed PR (41% tumor shrinkage), one unconfirmed PR (60% tumor shrinkage), a disease control rate of 71% (10 of 14 evaluable patients) and tumor shrinkage in 50% of patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k021.jpg" alt="Graphic" style="display:inline-block;height:236.84pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:300.6pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-201/HB-202 Alternating Two Vector Therapy Efficacy Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For HB-201/HB-202, the interim efficacy results released in November 2021 were based 14 evaluable patients (who had at least one scan) and a median time on treatment of 75 days. As shown below, treatment was ongoing for seven of the 14 evaluable patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k022.jpg" alt="Graphic" style="display:inline-block;height:218.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:397pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:258.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As shown below, the interim data for the HB-201 treated patients included one confirmed PR (31% tumor shrinkage), one near PR (29% tumor shrinkage), a disease control rate of 78% (11 of 14 evaluable patients) and tumor shrinkage in 57% of patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k023.jpg" alt="Graphic" style="display:inline-block;height:257.93pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:343pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the November 2021 update, the Recommended Phase 2 Dose for HB-201 single vector therapy was determined. In January 2022, we dosed the first patient with a combination of HB-201 and pembrolizumab for the treatment of first line advanced/metastatic HPV16+ HNSCC in the Phase 2 expansion portion of the ongoing Phase 1/2 trial (NCT04180215). The Phase 2 portion of the trial is also open for enrollment of patients with second line advanced/metastatic HPV16+ HNSCC for treatment with a combination of HB-201 and pembrolizumab. Similarly, for the alternating sequential two vector HB-201/HB-202 therapy, a Recommended Phase 2 Dose will be determined. Thereafter, enrollment of patients with first line or second line advanced/metastatic HPV16+ HNSCC will begin, using a combination treatment of HB-201/HB-202 and pembrolizumab. Enrollment of those patients will also proceed in the unrandomized Phase 2 dose expansion part of the ongoing Phase 1/2 trial (NCT04180215). The initial data from the combination with pembrolizumab treatment groups of patients with first line or second line advanced/metastatic HPV16+ HNSCC is anticipated in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has granted Fast Track Designation to single-vector HB-201 and alternating two-vector HB-201/HB-202, both in combination with pembrolizumab, for the treatment of first-line advanced/metastatic HPV16+ HNSCC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the ongoing nonrandomized Phase 1/2 clinical trial (NCT04180215), in September 2021 we announced a clinical collaboration with Merck &amp; Co., Inc, Kenilworth, NJ, USA, to study HB-200 in combination with pembrolizumab in a randomized Phase 2 trial of patients with first-line advanced/metastatic HPV16+ HNSCC. We anticipate starting this Phase 2 clinical trial in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HB-300 Program for Prostate Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Targeting Self Antigens</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our viral vectors may be appropriate for any antigen where a T&#160;cell response may be therapeutically meaningful. We have shown in multiple preclinical models that replicating product candidates are active in generating robust immune responses to tumor self-antigens and that this response results in decreased tumor growth and an increase in survival rates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-200 program targets viral antigens associated with tumors induced by HPV16. In these programs, the viral, or non-self nature of the antigens, makes them a natural target for an immunotherapy approach. In addition, we are pursuing the development of product candidates based on our arenavirus platform to target self-antigens, nonviral antigenic proteins that are highly overexpressed in solid tumors or only minimally expressed in normal cells. Because self-antigens are found in certain normal cells as well as tumor cells, the immune system does not typically recognize them as foreign proteins and does not respond to them. This protection of self-antigens from immune system attack is known as immune tolerance. The results obtained by earlier-generation marketed products such as sipuleucel-T, developed as PROVENGE by Dendreon Pharmaceuticals,&#160;Inc. and currently marketed by Sanpower Group&#160;Co.,&#160;Ltd., have proven that it is possible to overcome immune tolerance and activate the immune system to produce an antitumor response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Our Solution: HB-300 for Prostate Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are developing our most advanced self-antigen candidate in this area, HB-300, based on our replicating technology in metastatic, hormone resistant prostate cancer. Prostate cancer provides a unique treatment opportunity for immunotherapy because prostate cancer cells express a number of tumor-specific antigens that serve as potential targets. HB-300 targets three of these antigens: prostatic acid phosphatase (PAP), prostate specific antigen (PSA), and prostate specific membrane antigen (PSMA).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Direct evidence for the ability to induce a therapeutically relevant immune response to one of these antigens, PAP, comes from PROVENGE. To create PROVENGE, a personalized treatment, clinicians remove dendritic cells from the body, load them with PAP and then reintroduce them to the patient. The use of PROVENGE has been shown to increase survival in patients with metastatic, hormone resistant prostate cancer. Other companies are developing dendritic cell therapies similar to PROVENGE by using other tumor antigens. All of these dendritic cell therapies require complex, patient-specific therapeutic manufacturing processes involving isolating cells from patients, loading them <i style="font-style:italic;">ex vivo</i> with tumor antigens and then readministering the cells to patients.</p><a id="_Hlk63672829"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our replicating technology has been engineered to contain two additional genes compared to the natural form of the arenavirus. This allows us to express multiple antigens in one construct. In HB-300, we are including the coding sequences for PAP, PSA and PSMA antigens in our vectors. Since it is a replicating-based product candidate, we can deliver HB-300 by simple infusion- and it can target APCs, such as dendritic cells, in the body, without the need for cellular isolation or <i style="font-style:italic;">ex vivo</i> processing. We have shown in preclinical experiments that replicating vectors can lead to robust CD8+ T&#160;cell responses to the encoded antigens. We intend to maximize these CD8+ T&#160;cell responses using a combination of replicating vectors based on both LCMV and PICV in a sequential dosing regimen and are planning to file an IND for HB-300 in the second half of 2022. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:274.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k024.jpg" alt="Graphic" style="display:inline-block;height:274.4pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:445.6pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the future, we intend to develop further product candidates against other self-antigens with the aim of eventually establishing a franchise of dendritic cell-targeting agents that take advantage of the ability of arenaviruses to stimulate CD8+ T&#160;cell responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HB-700 for Targeting Mutated KRAS in Pancreatic Cancer, Colorectal Cancer and Lung Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-700 is based on our replicating arenavirus platform and was designed for treatment of cancers encoding mutated KRAS. KRAS, as an immunotherapy target, is relevant in many cancers. Many modern, targeted cancer therapies are specific to a cancer type or even sub-groups within those cancer types. The fact that KRAS mutations are present in many different cancers offers the potential for a new therapy to add benefit to the treatment of many patients suffering from myriad cancer types.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Specifically, KRAS is a key regulator of cell proliferation and survival. It is one of the most frequently mutated proto-oncogenes with respective mutations found in approximately 30% of all human cancers. KRAS mutations are most frequently found in pancreatic cancer (85% to 90%), colorectal cancer (approximately 40%) and lung cancer (approximately 32%). However, the spectrum of mutations is limited and focused on amino acid position 12 (G12D, G12V, G12R, and G12C) and position 13 (G13D), rendering these mutations an attractive target for immunotherapy. We plan to develop our KRAS targeted therapy for patients suffering from pancreatic adenocarcinoma (PAAD), colorectal cancer (CRC) and lung adenocarcinoma (LUAD).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">An early proof of concept for targeting KRAS mutations via CD8+ T cells was reported by Tran et al in 2016. Tran targeted a KRAS mutation on position 12 (G12D) in a patient with metastatic CRC by tumor infiltrating lymphocyte (TILs); Tran demonstrated objective regression of all seven lung metastatic lesions from underlying CRC after the infusion of KRAS G12D-directed tumor infiltrating lymphocytes. More recently, small molecule inhibitors targeting mutated KRAS were developed and have showed promising results in clinical trials. However, those targeted therapies are limited to a single, specific KRAS mutation (KRAS G12C), which is frequently found in LUAD (approximately 50% of the late-stage cancers). However, KRAS G12C is underrepresented in PAAD and CRC when compared to other KRAS mutations such as G12D, G12V, G12R and G13D, which are much more frequently found </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(greater than 60% and greater than 90% in advanced CRC or PAAD, respectively). Hence, we believe that there is an urgent medical need to develop effective therapies for those patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pancreatic cancer is considered one of the most lethal malignancies. Overall, approximately 500,000 new cases of pancreatic cancer per year are recorded globally. Incidence, prevalence and mortality for pancreatic cancer has increased by more than 50% during the last 25 years. Pancreatic cancer accounts for 1.8% of all cancers but causes 4.6% of all cancer deaths and pancreatic cancer deaths are expected to double by the year 2060. The high mortality rate can be explained in part as pancreatic cancer typically remains silent, not causing signs or symptoms for a long time. When patients become symptomatic, the cancer has usually reached an advanced and incurable stage. According to the American Cancer Society, the overall 5-year survival rate for pancreatic cancer is approximately 9%. 97% of patients with metastatic cancer (i.e., stage IV) are expected to die within 5 years after diagnosis. Additional effective therapies are therefore urgently needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Colorectal cancer is the third most diagnosed malignancy worldwide and the second leading cause of cancer death. The incidence of colorectal cancer was estimated at 1.9 million cases in 2020, causing 0.9 million deaths worldwide. The incidence is higher in highly developed countries and it is increasing in middle- and low-income countries due to westernization. The death rate from colorectal cancer in 2018 was 55%. The 5-year survival rate of patients with localized stage colorectal cancer is 90%. About 38% of patients are diagnosed at this early stage. If the cancer has spread to surrounding tissues or organs and/or the regional lymph nodes, the 5-year survival rate is 72%. If the cancer has metastasized to distant parts of the body, the 5-year survival rate is 14%. The advancements made in understanding colorectal cancer pathophysiology have led to increased treatment options, including endoscopic and surgical excision, radiotherapy, immunotherapy, palliative chemotherapy, targeted therapy, and extensive surgery and local ablative therapies for metastases. These treatments have prolonged overall survival and screening through endoscopy also greatly enhanced the early detection, leading to good prospects of a cure. Although the prospect for colorectal cancer therapy is generally good, the increasing number of cases and rising incidence among younger generations still poses a heavy financial burden and a public health challenge.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths annually. Approximately 85% of lung cancer patients suffer from a subgroup called non-small cell lung cancer (NSCLC), of which LUAD and lung squamous cell carcinoma (LUSC) are the most common subtypes. LUAD represents approximately 40% of NSCLC and is the most common primary lung cancer diagnosed in the United States. Despite new treatments, the 5-year survival rate is only 12% to 15%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our replicating technology has been engineered to encode fragments encoding multiple KRAS mutations found in Pancreatic, CRC and LUAD. Analogous to our other immuno-oncology candidate therapies, we can deliver HB-700 by simple infusion; HB-700 is designed to target APCs, such as dendritic cells, in the body, without the need for cellular isolation or <i style="font-style:italic;">ex vivo</i> processing. Since induction of KRAS mutation-specific CD8+ T cells is the mode of action of this investigational therapy, and administration of alternating LCMV (HB-201)- and PICV (HB-202)- based vectors have been shown to induce unprecedented tumor antigen-specific CD8+ T cell levels in the context of our HB-200 program, we also intend to maximize HB-700 induced CD8+ T cell responses of by using replicating vectors based on both LCMV and PICV in a sequential dosing regimen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Next Generation Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A critical advantage of our technology is that it is designed to deliver full length proteins directly to APCs, such as dendritic cells, for endogenous expression and direct presentation to CD8+ T cells. Having APCs, such as dendritic cells, express full-length proteins and present all fragments (epitopes) overcomes the major difficulty of attempting to predict which part of the protein, or epitope, will be presented by the patient&#8217;s individual major histocompatibility complex (MHC) class&#160;I alleles. This presentation is important in immunotherapy because T cells will only recognize and respond to the antigen when it is bound to the individual&#8217;s MHC class&#160;I molecules, of which several hundred different versions exist in the population. While this approach overcomes the major issue faced by neoepitope based personalized antigen approaches, it also has limitations in that the repertoire of known tumor associated proteins that could be used for targets is limited. The best example of full-length proteins that are, to a degree, cancer specific and immunogenic include the cancer testis antigens, examples of which include NYESO1, MAGE and CAGE. These cancer testis antigens </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">have been known for decades, and many of them are currently being pursued by other companies. For many tumor types the cancer testis type of antigens remains unknown. Furthermore, most of the known tumor associated antigens are not commonly expressed or are not sufficiently specific to tumor tissue, making them suboptimal targets for clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2018, we entered into a research collaboration and license agreement with DarwinHealth, a New York City based bioinformatics company pioneering novel bioinformatic approaches, with the intent to identify the next generation of &#8220;cancer testis antigens.&#8221; Our goal is to find novel immunogenic full-length transcripts that are specific for, and highly represented in specific tumor types, allowing for an &#8220;off-the-shelf&#8221; approach for many cancer types. During the initial collaboration period, we intend to develop and validate the bioinformatics approach and resulting proprietary algorithms. We will start out by identifying &#8220;off-the-shelf&#8221; next generation cancer-testis type antigens in mouse tumors and will assess the antitumor efficacy of our technology when targeting these same antigens in tumor bearing animals. Mice will thereby serve as a testing ground to validate and optimize our new proprietary bioinformatics algorithms. In parallel we will apply the same validated algorithms to human samples and will prepare the next generation of cancer testis antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HB-101, a Prophylactic Vaccine for Cytomegalovirus (CMV)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-101 is a vector candidate based on our non-replicating technology that delivers two clinically validated antigens: pp65, to induce CMV-specific CD8+ T cells, and gB, to elicit CMV-neutralizing antibodies. CMV infections present a serious risk for patients with suppressed immune systems, such as solid organ and stem cell transplant recipients. In our Phase 1 clinical trial, HB-101 was well tolerated and elicited strong and durable CMV-specific immune responses in all 42 volunteers in the treatment arm. Importantly, we observed robust CD8+ and CD4+ T cell responses as well as CMV-neutralizing antibody responses. As anticipated, the LCMV vector did not elicit clinically meaningful vector-neutralizing antibodies, as only one volunteer developed a transient neutralizing antibody response against the vector after three administrations. Furthermore, upon repeat administration, the pp65 CD8+ T cell levels achieved by the non-replicating vector increased in a statistically significant manner. The Phase 1 clinical findings were published in the April 2020 issue of The Journal of Infectious Diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2018, we commenced a randomized, double-blinded Phase 2 clinical trial for HB-101 in CMV-negative patients awaiting kidney transplantation from living CMV-positive donors. Based on HB-101&#8217;s tolerability profile observed in the target patient population, and to gain further insights to inform a Phase 3 trial design, we added a new cohort of CMV-positive recipients awaiting kidney transplantation from CMV-positive or CMV-negative donors to the trial in early 2020 and amended the investigational new drug (IND) application accordingly in January 2020. The goal of our Phase 2 trial is to assess safety, immunogenicity and efficacy of HB-101 in individuals receiving a kidney transplant from live donors to measure the decrease of post-transplant viremia. In November 2020, we reported initial positive interim safety, immunogenicity and efficacy data in which we observed a pre-transplant three-dose vaccination schedule was able to reduce incidence of CMV viremia, reduce antiviral use and prevent CMV disease. In November 2021, we reported additional strong immunogenicity and reduced incidence of CMV viremia in people who received three doses of HB-101, consistent with results previously reported in November 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Phase 2 HB-101 clinical trial concluded recruitment in June 2021 with 80 patients dosed. Given the challenges of enrollment of voluntary, live donor kidney transplantation during the on-going COVID-19 pandemic, the total number of patients enrolled in the trial was smaller than the originally planned 150 patients. Patients continue on-trial to progress through transplantation and a 12-month follow-up period. We expect the last patient to complete follow-up in the second half of 2022 and a final data read-out in 2023. As announced in November 2021, based on the strength of our HB-200 data in HPV16+ cancers, we have prioritized our oncology portfolio and we plan to continue developing infectious disease therapies in partnership with other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cytomegalovirus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cytomegalovirus is a virus that is commonly transmitted in childhood and early adulthood. Approximately 60% of the U.S. population has been exposed, and as such, is latently infected. Worldwide data indicate that while half the people in industrialized countries have been exposed, up to 99% of people in developing countries, including China and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">India, have been exposed. Infections result in lifelong latent persistence of the virus with few symptoms, if any. However, in immunosuppressed patients, such as transplant recipients, primary CMV infection or reactivation generally causes significant morbidity, mortality and graft rejection. There are two scenarios in which CMV infections are relevant in the transplant setting. In one case, the recipient could be CMV negative, or previously uninfected, and the donor CMV positive. In this case, introduction of CMV into the immunocompromised recipient can lead to rapid virus spread and development of serious complications. In the other case, the recipient is already CMV positive, but the immunosuppressive treatments required as part of the transplant procedure can lead to reactivation of latent virus. Based on a market research study we commissioned from an independent third party, we believe that approximately 110,000 patients are added to the solid organ transplant waiting list annually in developed countries, with kidney transplantation representing approximately 60% of cases. Furthermore, more than 20,000 allogeneic cell transplants, in which cell and tissue donors are matched with transplant recipients, are carried out annually worldwide. In this group, the incidence of CMV infection is approximately 30% as a result of the donor being CMV positive. Current therapies to prevent the transmission of CMV during organ transplants utilize antiviral prophylactic and therapeutic strategies. However, these therapies are only partially protective in preventing viral disease while also being hampered by toxicity and resistance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are currently two standards of care to deal with CMV during solid organ transplant: prophylactic and preemptive. In prophylactic therapy, patients are given antiviral drugs for several months after transplant. Antivirals can reduce the rate of CMV viremia from approximately 70% to 36% in kidney transplant patients over a 12-month period. Of the 36% that present with viremia, most of these cases emerge once antiviral treatment has been stopped. In preemptive therapy, patients are intensively monitored posttransplant for CMV reactivation using laboratory diagnostics, and short term antiviral treatment is given only to those with significant viral loads, or CMV viremia, before symptoms and overt CMV disease occur. In preemptive therapy, most infections occur within a year following a transplant. However, the antiviral drugs used to treat CMV have the potential to induce significant toxicities, including bone marrow toxicity for ganciclovir, valganciclovir and cidofovir, and renal toxicity for foscarnet and cidofovir. In addition, CMV drug resistance mutations arise during this antiviral therapy. Despite the use of prophylactic and preemptive therapy using small molecule antivirals, many transplant patients develop serious symptomatic complications from CMV, highlighting the need for new treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cytomegalovirus in Kidney Transplant Patients</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2018, approximately 92,000 of the approximately 141,000 solid organ transplants performed worldwide were kidney transplants, an increase of 8.2% compared to 2015. Approximately 80% of high-risk kidney transplant recipients develop active CMV infections. High-risk recipients are defined as CMV negative patients receiving kidney transplants from CMV positive donors. In most solid organ transplant patients, complications from CMV develop between 30 and 90 days after transplantation and rarely after 180 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Solution, HB-101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-101 is a non-replicating based product candidate designed to stimulate the immune system against CMV and to protect against future CMV infection or reactivation from latency. HB-101 is comprised of two non-replicating LCMV based vectors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one vector expresses the gene encoding the CMV 65 kD pp65 protein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">another vector expresses the gene encoding the CMV gB protein.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We, and third parties, have shown that pp65 is immunogenic. Adoptive T cell transfer approaches performed by third parties, in which CD8+ T cells directed against pp65 are isolated from exposed individuals and transferred to patients with active CMV viremia, have also demonstrated the therapeutic efficacy of pp65. However, no vaccine approach to date has been successful in achieving CD8+ T cell levels sufficiently high enough to be protective. gB has been shown in previous third-party clinical trials to be immunogenic and protective by inducing antibody responses but not CD8+ T cells. However, response rates were limited, immunity was transient and protection was incomplete. In our preclinical data, using pp65 and gB as targets, we have observed robust immunogenicity, activity and durability thereby potentially overcoming the limitations of current approaches.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:165.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-101 Preclinical Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preclinical studies, we have observed that HB-101 has the ability to improve the survival rates in animal models in a statistically significant manner. In our study, nonpregnant female guinea pigs were administered three doses of HB-101 at 30-day intervals. Thirty days after the last vaccination, females were allowed to mate. Following conception, the pregnant females were infected with CMV during the gestation period, putting the guinea pig pups at risk of severe viral infection, low birth weight and potential mortality. As depicted below, guinea pig pups born to CMV infected females that had received a guinea pig equivalent of HB-101 (gpHB101) had a statistically significant (p&lt;0.0001) lower mortality rate at birth compared to those born to females who had only received a non-replicating vector carrying an irrelevant antigen, labeled as GFP in the figure below. CMV positive pups born to mothers that received gpHB101 vaccination also gained weight more rapidly and had improved survival rates as compared to those born to mothers vaccinated with placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k025.jpg" alt="Graphic" style="display:inline-block;height:165.15pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:314.45pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-101 Phase 1 Clinical Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We conducted a placebo controlled, randomized doubleblinded dose escalating Phase 1 clinical trial of HB-101 to assess its safety and immunogenicity. In this trial (NCT02798692), 54 healthy volunteers aged 18 to 45 were administered three consecutive doses of either HB-101 or placebo by intramuscular injection at month zero, one and three, then monitored for one year after the initial dose. The volunteers were randomized into three cohorts of 18 volunteers, with 14 volunteers receiving the study drug and four receiving placebo in each cohort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We observed that HB-101 was well tolerated with no dose limiting toxicities and no serious adverse events. Symptoms by volunteers were of mild to moderate intensity and 93.5% of reported symptoms were of short duration (18 days). The maximum duration of any symptom was 10 days. Pain at the injection site was the predominant solicited local adverse event. Malaise, fatigue and generalized myalgia were the most common solicited general symptoms. The percentage of subjects reporting unsolicited causally related adverse events of mild to moderate intensity was similar for placebo and the vaccine groups. Upper respiratory tract infections were the predominant adverse event, occurring at rates in the low dose group that were twice as high as those seen in all three other groups (placebo, middle and high dose). The percentage of volunteers reporting related adverse events of mild to moderate intensity was similar for placebo and vaccine groups. None of the adverse events appeared to be treatment related.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, HB-101 elicited a strong, dose dependent, and durable response as measured by the frequency of pp65 specific interferon gamma (IFN&#947;) producing CD8+ T cells. Each administration of HB-101, as depicted by the black arrows in the figure below, resulted in an increase in IFN&#947; producing CD8+ T cells, demonstrating the potential and rationale for repeat administrations of HB-101. Importantly, the frequencies of IFN&#947; producing CD8+ T cells induced by the highest dose of HB-101 after the third administration in healthy volunteers were in the range of, or higher than, the therapeutic levels reported in human adoptive T cell therapy clinical trials which were separately designed and conducted by third parties for patients with active CMV viremia. These frequencies were observed to be therapeutic in patients experiencing active CMV infection following stem cell as well as organ transplantation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:243pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k026.jpg" alt="Graphic" style="display:inline-block;height:205pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:319.7pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similarly, HB-101 administration also resulted in a strong neutralizing antibody response to the CMV antigen gB that increased with each additional dose, as depicted by the black arrows in the figures below, which was sustained over the 12-month follow up period. All volunteers receiving the highest or middle doses of HB-101, and 92% of the volunteers receiving the lowest dose, developed CMV neutralizing antibodies. The levels of antibodies generated in the highest dose after three doses were comparable to therapeutic levels reported with other CMV vaccine product candidates in development that have demonstrated clinical efficacy in separately designed and conducted, published third-party clinical trials. As anticipated, the LCMV vector did not elicit clinically meaningful vector neutralizing antibodies, as only one volunteer developed a transient neutralizing antibody response against the vector after three administrations. We believe that a fourth administration of the vaccine in all 42 of these volunteers could have resulted in an additional antibody response, if desired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k027.jpg" alt="Graphic" style="display:inline-block;height:242.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:485.3pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:180.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-101 Phase 2 (H100-001) Clinical Development Plan and Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2018, we initiated a randomized, multi-center double blind Phase 2 trial (NCT03629080) of HB-101 to assess the safety, reactogenicity, immunogenicity and efficacy of HB-101 in CMV-negative patients receiving a kidney transplant from living CMV-positive donors. Based on HB-101&#8217;s observed tolerability profile in the target patient through August 24, 2020 cut off date, and to gain further insights that will inform a potential Phase 3 trial design, we added a new cohort of CMV-positive recipients awaiting kidney transplantation from CMV-positive or CMV-negative donors to the trial in early 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We enrolled&#8239;patients in three treatment arms:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Arm 1 (CMV-negative, pre-emptive antivirals): CMV-negative patients were randomized 2:1 to either receive two to three administrations of HB-101 or placebo prior to transplant and then treated with standard preemptive antiviral therapy post-transplant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Arm 2 (CMV-negative, prophylactic antivirals): CMV-negative patients were randomized 2:1 to either receive two to three administrations of HB-101 or placebo before transplant and will then receive three to six months of antiviral prophylaxis therapy post-transplant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Arm 3 (CMV-positive, prophylactic antivirals): CMV-positive patients received two to three administrations of HB-101 before transplant and will then receive up to six months of antiviral prophylaxis therapy post-transplant.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patients are monitored for twelve months post-transplant to assess safety and T cell and antibody responses to pp65, gB and the LCMV vector, as well as CMV viremia and the need for use of antivirals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trial design is depicted in the figure below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20211231x10k028.jpg" alt="Graphic" style="display:inline-block;height:180.5pt;width:457.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, we reported initial interim safety and immunogenicity data (containing both CMV specific antibody and CMV specific CD8+ T cell responses) from the ongoing Phase 2 trial. HB-101 was observed to be well tolerated with fewer adverse events in patients with end-stage kidney disease than in the previous healthy volunteer trial. Patients who received three doses of HB-101 showed comparable immunogenicity to healthy volunteers in the Phase 1 clinical trial of HB-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Safety and tolerability data was reported in June 2020, which evaluated 51 CMV-negative patients prior to kidney transplantation. Of the 51 patients, eight patients (16%) across the combined, blinded HB-101 and placebo </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">groups showed adverse events related to the administration. Most of these adverse events were of mild intensity, indicating that HB-101 was generally well tolerated in this patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CMV-neutralizing antibody titers on the day of transplantation were evaluated in all of the 30 CMV-negative patients who had been transplanted by the cutoff date and had valid results. Nineteen of the 30 patients received HB-101 and eleven received placebo. All five patients who received three doses of HB-101 mounted CMV-neutralizing antibodies. Three of the fourteen patients (21%) who received only two doses of HB-101 also mounted CMV-neutralizing antibodies. The antibody response of the kidney transplant recipients who completed the three-dose regimen was comparable to the antibody response observed in the Phase 1 trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cellular immune (CD8+ T cell) responses to CMV on the day of transplantation were evaluated in 25 CMV-negative patients who had been transplanted in time for this interim analysis. Technically valid results from T cell assays on the day of transplantation were available for seven recipients (as a consequence of sample logistics and assay performance). Two of the seven patients received placebo and five received HB-101. All three patients (100%) who received three doses of HB-101 and one of the two patients who received only two doses (50%) mounted a CMV-specific cellular immune response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, we reported an additional interim data update on the ongoing Phase 2 trial, encompassing safety, immunogenicity, and preliminary efficacy data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Safety and tolerability were evaluated in 80 participants who were dosed in the trial by the cut-off date. HB-101 was generally well tolerated with a low incidence of side effects, which were mostly mild to moderate. Specifically, 21.3% of participants across the combined HB-101 and placebo groups showed side effects related to vaccine administration. Five cases of human leukocyte antigen (HLA)-sensitization have been reported, two as serious adverse events. HLA-sensitization is a known complication of dialysis patients waiting for kidney transplantation, affecting an estimated 4% of this patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The interim immunogenicity analysis included CMV-neutralizing antibody data assessed from 33 patients, a subset of the 52 included in the efficacy analysis. 21 participants were vaccinated with HB-101 and 12 received placebo. In line with the previous interim data, all of the participants who received three doses of HB-101 mounted CMV-neutralizing antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preliminary efficacy analysis included data from 52 participants as of the cut-off date; 9 were vaccinated with three doses of HB-101 pre-transplant, 25 were vaccinated with two doses and 18 received placebo. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compared to placebo, participants vaccinated with three HB-101 doses had:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A 41% reduction in CMV viremia (presence of CMV DNA in the blood);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A 41% reduction in the use of antiviral therapy; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No CMV disease (compared to 2 out of 14 cases in the placebo group)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Response to a two-dose schedule did not show an improvement compared to placebo, which is consistent with the low levels of CMV-neutralizing antibody in the two-dose cohort as well as with the T cell data reported in June 2020 for the two-dose group. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enrollment of this trial concluded in June 2021. Dosed patients will continue on-study to progress through transplantation and a 12-month follow-up period. We expect the last patient to complete follow-up by the second half of 2022 and a final data read-out in 2023. We will explore partnership opportunities for further development of HB-101 in order to focus on advancing our oncology portfolio.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends, in part, on our ability to obtain and maintain intellectual property protection for our product candidates, technology and knowhow, to defend and enforce our intellectual property rights, in particular, our patent rights, to preserve the confidentiality of our knowhow and trade secrets, and to operate without infringing the proprietary rights of others. We seek to protect our product candidates and technologies by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. We also rely on trade secrets, knowhow, continuing technological innovation and in-licensing of third-party intellectual property to develop and maintain our proprietary position. We, or our collaborators and licensors, file patent applications directed to our key product candidates in an effort to establish intellectual property positions to protect our product candidates as well as uses of our product candidates for the prevention and/or treatment of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 24, 2022, we are the owner or exclusive licensee to nine issued U.S. patents and ten pending U.S. patent applications, two pending international Patent Cooperation Treaty (PCT) applications, five pending U.S. provisional patent applications, and 105 issued foreign patents and approximately 78 foreign patent applications. These patents and patent applications are related to our technologies concerned with the arenavirus-based immunization systems, non-replicating and replicating, our product candidates and various development programs, which are directed to the use of these immunization systems for the treatment and/or prevention of various infectious diseases or cancer, and certain clinical uses of our current or future product candidates in oncology. The issued patents and pending patent applications contain claims directed to various aspects of our work, including compositions of matter, methods of treatment and prevention, methods of producing certain compositions, and use of our product candidates in combination with certain other therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Non-Replicating Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our patent portfolio related to our non-replicating technology includes a patent family exclusively licensed to us from the University of Zurich. This patent family includes four patents granted in the United States and patents granted in Europe (validated in Austria, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Poland, Spain, Sweden, Switzerland and the United Kingdom), Canada, China, India, Hong Kong and Japan. This patent family also includes pending applications in the United States, Europe, China, Hong Kong and India. The granted patents and pending applications related to our non-replicating technology are expected to expire no earlier than 2028, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Our non-replicating technology is being employed or may be employed in one or more of the product candidates or programs described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Replicating Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are the owner or exclusive licensee to proprietary patent positions related to our replicating technology. Our patent portfolio related to our replicating technology includes a patent family exclusively licensed from the University of Geneva. This patent family includes a patent granted in the United States and patents granted in Europe (validated in Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland/LI, The Netherlands, Turkey and the United Kingdom), Hong Kong and Japan. The European patent in this family (European Patent No. 3218504) was opposed by a third party in April 2021. This patent family also includes pending applications in the United States, Europe, Canada, Australia, Japan, India, China and Hong Kong. The second patent family in our replicating platform portfolio is jointly owned by us and the University of Basel. The rights of the University of Basel under this patent family are exclusively licensed to us. This second patent family includes pending applications in various countries, including in the United States, Europe, Eurasia, Hong Kong, Korea, China, Canada, Australia, New Zealand, Mexico, Japan, Brazil, Singapore, India, and Israel. The granted United States patent from the first patent family is expected to expire in April&#160;2037 due to patent term adjustment. The granted patents in Europe, Hong Kong and Japan, and the pending applications related to our replicating technology are expected to expire between 2035 and 2037, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">governmental fees. Our replicating technology is being employed or may be employed in one or more of the product candidates or programs described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Split Vector Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have an exclusive license from the University of Basel to proprietary patent positions related to a novel molecular strategy to vectorize arenavirus genomes, which we refer to as the Split Vector Technology. Our patent portfolio related to the Split Vector Technology includes an international PCT application exclusively licensed from the University of Basel as well as a pending U.S. provisional patent application jointly owned by us and the University of Basel. The rights of the University of Basel under this patent family are exclusively licensed to us. Applications claiming priority to the respective PCT application are expected to expire in November&#160;2040, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The Split Vector technology is currently not employed in any of our clinical stage product candidates or late-stage preclinical programs.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Oncology Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the application of our non-replicating and replicating technologies in oncology, we own three patent families. Each of these patent families include pending applications in the United States, Europe, Australia, Canada, China, Hong&#160;Kong, India and Japan. These patent families relate to potential clinical uses of our product candidates, such as combination treatments and modes of administration. The pending applications are expected to expire between 2036 and 2038, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-101 (Cytomegalovirus)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-101 product candidate relies on our non-replicating technology. In addition to the non- replicating patent portfolio, we own one patent family that more specifically relates to our HB-101 product candidate. This patent family includes one patent granted in the United States with claims directed to pharmaceutical compositions. This patent family also includes granted patents in Europe (validated in Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland/LI, The Netherlands, Turkey and the United Kingdom), Australia, Hong&#176;Kong and Japan, as well as pending applications in the United States, Europe, Australia, Canada, China, India and Japan. Excluding the non- replicating patent portfolio, the granted patent and pending applications specifically related to our HB-101 product candidate are expected to expire in 2034, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Hepatitis B Virus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Hepatitis&#160;B Virus program, codeveloped with Gilead, is in the preclinical phase and is being built on either our non-replicating or replicating technologies. In addition to the non-replicating and replicating patent portfolios, we own one patent family that relates to the use of our platform technologies for prevention and treatment of Hepatitis&#160;B Virus. This patent family includes patents granted in the United States and Japan. This patent family also includes pending applications in the United States, Europe, Australia, Brazil, Canada, China, India, Israel, Japan, Hong&#160;Kong, Korea, Mexico, New Zealand and Singapore. Excluding the non-replicating and replicating patent portfolios, the granted patents and pending applications related to the Hepatitis&#160;B Virus program are expected to expire in 2036, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HIV</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our HIV program, codeveloped with Gilead, is in preclinical phase and is being built on either our non-replicating or replicating technologies. We announced an amended agreement wherein we will assume development </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">responsibilities through the end of Phase 1b. We currently do not own any patents or patent applications that more specifically relate to an HIV program outside of the non-replicating and replicating patent portfolios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-201 (HPV16+)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-201 product candidate relies on our replicating technology and, depending on its clinical implementation, may relate to one or more applications in our oncology patent portfolio. In addition to the replicating and oncology patent portfolios, we own two patent families that relate more specifically to our HB-201 product candidate. The first patent family includes one patent granted in the United States and one patent granted in Australia with claims directed to compositions of matter. This patent family also includes pending applications in the United States, Europe, Australia, Canada, China, India, Japan and Hong&#160;Kong. The second patent family currently includes a pending international Patent Cooperation Treaty (PCT) application relating to HB-201 treatment regimens. Excluding the replicating and oncology patent portfolios, the granted patents and pending applications specifically related to our HB-201 product candidate are expected to expire in 2036 and 2041, respectively, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-202 (HPV)</p><a id="_Hlk63673176"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-202 product candidate relies on our replicating technology and, depending on its clinical implementation, may relate to one or more applications in our oncology patent portfolio. In addition to the replicating and oncology patent portfolios, we own two patent families that relate more specifically to our HB-202 product candidate. The first patent family includes one patent granted in the United States and one patent granted in Australia with claims directed to compositions of matter. This patent family also includes pending applications in the United States, Europe, Australia, Canada, China, India, Japan and Hong&#160;Kong. The second patent family currently includes a pending international Patent Cooperation Treaty (PCT) application relating to HB-202 treatment regimens. Excluding the replicating and oncology patent portfolios, the granted patents and pending applications specifically related to our HB-202 product candidate are expected to expire in 2036 and 2041, respectively, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-300</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-300 product candidate relies on our replicating technology and, depending on its clinical implementation, may relate to one or more applications in our oncology patent portfolio. In addition to the replicating and oncology patent portfolios, we currently own one pending U.S. provisional patent application that more specifically relates to our HB-<span style="white-space:pre-wrap;">300 product candidate. This provisional patent application is not eligible to become an issued patent until, among other things, we file a nonprovisional patent application within 12 months of the filing of our provisional patent application.  If we do not timely file any nonprovisional patent applications, we may lose our priority date with respect to our provisional patent application and possibly any patent protection on the inventions disclosed in our provisional patent application. Subject to the timely filing of a non-provisional patent application, any patent claiming priority to this pending provisional patent application specifically related to our HB-300 product candidate is expected to expire in 2042, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-700</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Our HB-700 product candidate relies on our replicating technology and, depending on its clinical implementation, may relate to one or more applications in our oncology patent portfolio. In addition to the replicating and oncology patent portfolios, we currently own two pending U.S. provisional patent applications that more specifically relate to our HB-700 product candidate. These provisional patent applications are not eligible to become issued patents until, among other things, we file at least one nonprovisional patent application within 12 months of the filing of our provisional patent applications.  If we do not timely file any nonprovisional patent applications, we may lose our priority date with respect to our provisional patent applications and possibly any patent protection on the inventions disclosed in </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">our provisional patent applications. Subject to the timely filing of at least one non-provisional patent application, any patent claiming priority to these pending provisional patent applications specifically related to our HB-700 product candidate is expected to expire in 2042, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The actual term of any patent that may issue from the above described patent applications claiming one of our product candidates could be longer than described above due to patent term adjustment or patent term extension, if available, or shorter if we are required to file terminal disclaimers. The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20&#160;years from the earliest claimed filing date of a non-provisional patent application in the applicable country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to maintain and solidify our proprietary position for our product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims once granted. We do not know whether any of our patent applications will result in the issuance of any patents, or what the scope of the claims in any future issued patents may be. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated, narrowed, rendered unenforceable or circumvented, which could limit our ability to stop competitors from marketing identical or substantially similar products or could reduce the length of term of patent protection that we may have for our products. With respect to patents and patent applications licensed to us, our licensors may have the right to terminate our licenses if we fail to comply with our obligations under the applicable license agreement. In addition, the claims granted in any of our issued patents may not provide us with advantages against competitors with similar products or technology. Furthermore, our competitors may independently develop technologies that are similar or identical to technology developed by us but that do not infringe our patents or other intellectual property. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, by the time that any of our product candidates or those developed by our collaborators can be commercialized, our key patent may have expired or may only continue to remain in force for a short period following commercialization, thereby reducing the usefulness of the patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and other contractors. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants or contractors use technology or know-how owned by others in their work for us, disputes may arise as to the rights in related inventions. For this and more comprehensive risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gilead Collaboration Agreement and Stock Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;4,&#160;2018, we entered into a Research Collaboration and License Agreement, Collaboration Agreement, with Gilead to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating our replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis&#160;B Virus or HIV, which we refer to, collectively, as the Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Collaboration Agreement, we granted Gilead an exclusive (even as to us and our affiliates), worldwide, royalty bearing license to our knowhow and our owned and in-licensed patent rights (including those patent rights in-licensed from the University of Geneva, the University of Basel, and the University of Zurich) that are necessary or reasonably useful for researching, developing, manufacturing or commercializing products that contain a vaccine that uses our replicating or non-replicating technology platforms for expressing one or more HIV or Hepatitis B Virus antigens, which foregoing knowhow and patent rights we refer to as the Licensed Technology (and each such product a Licensed Product), for the purpose of researching, developing, manufacturing and commercializing Licensed Products for uses in the Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the Collaboration Agreement, we will own all new intellectual property conceived or created out of the activities conducted under the Collaboration Agreement that specifically relate to the replicating and non-replicating </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technology platforms. Gilead will own all other intellectual property rights conceived or created out of the activities conducted under the Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 15, 2022, we entered into the Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic. Specifically, we assumed responsibility for advancing the HIV program through to the end of a Phase 1b clinical program, and Gilead retains an exclusive right, the Option, for further development thereafter. Pursuant to the Option, Gilead has the exclusive right to take back the development rights for such HIV program candidates and to further research, develop, and commercialize such candidates in accordance with the terms and conditions of the Restated Collaboration Agreement. Gilead may exercise the Option at any time, but no later than 60 days after the receipt of a data package containing pre-clinical, clinical, chemistry and manufacturing control, regulatory and other data specified by the Restated Collaboration Agreement in return for an option exercise fee of $10.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the Option is not exercised by Gilead during the term of the Option, or if Gilead provides written notice to us of its intention to not exercise the Option, then the terms of the Restated Collaboration Agreement will be deemed terminated with respect to the HIV Development Plan and HIV Licensed Products (each as defined in the Restated Collaboration Agreement), and the Field and rights granted under the Restated Collaboration Agreement will be limited to the HBV indication. Furthermore, if the Option expires or is terminated, the non-competition and right of first negotiations terms contained in the Restated Collaboration Agreement and summarized below will not be applicable to the development for HIV indications. In the event the Option is not exercised, we and Gilead will work in good faith to enter into a license agreement pursuant to which Gilead will grant us a milestone and/or royalty-bearing license under certain Gilead owned intellectual property necessary or reasonably useful to allow us to research, develop, manufacture and commercialize HIV product candidates as of the date on which the Option is declined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial support from Gilead to us includes a $15.0 million non-refundable initiation fee and $35.0 million equity commitment pursuant to a Stock Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development of the programs governed by the Collaboration Agreement is overseen by a six member joint steering committee (JSC), comprised of three representatives from each of us and Gilead. The JSC will oversee the activities carried out pursuant to the Collaboration Agreement, including settling disputes arising under the Restated Collaboration Agreement, and approving a Licensed Product as being ready for development. Similarly, the Collaboration Agreement establishes a four member joint development committee (JDC) to oversee HIV development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Research on Hepatitis&#160;B Virus and HIV products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the original Collaboration Agreement, we are responsible for manufacturing and supplying to Gilead Lymphocytic Choriomeningitis Virus and Pichinde Virus based vectors expressing one or more Hepatitis B Virus antigens to the extent necessary for both us and Gilead to carry out our respective research activities under the research plans. These research plans are largely completed and both programs have advanced to development stage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Development and Commercialization of products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Restated Collaboration Agreement, Gilead is solely responsible for conducting the development activities, including all regulatory filings, at its expense for any product arising from the Restated Collaboration Agreement designated for development by Gilead and approved by the JSC with respect to the HBV product candidates and we are responsible for conducting development activities for the HIV product candidates through the end of a Phase 1b study. If Gilead exercises the Option for the HIV product candidates, Gilead will be solely responsible for further (post Phase 1b) development activities of the HIV product candidates. Gilead is also solely responsible, at its expense, for the manufacture and commercialization of any HBV Licensed Product developed and commercialized under the Restated Collaboration Agreement, and if the Option is exercised, it will responsible, at its expense, for the manufacture and commercialization of any HIV Licensed Product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Non-Compete</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not, directly or indirectly, conduct, participate in or fund any research, development, manufacture, or commercialization of, or with respect to products utilizing arenavirus based vectors for the treatment, cure, diagnosis, or prevention of Hepatitis&#160;B Virus or HIV, except for the activities we are expressly permitted to perform under the Restated Collaboration Agreement. If the Option expires or is terminated, the non-competition terms contained in the Restated Collaboration Agreement shall not be applicable to the development for HIV indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Right of First Negotiation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Collaboration Agreement, in the event we offer a license or other rights to the Licensed Technology to a third party to research, develop, manufacture or commercialize a Licensed Product outside of the Field before June&#160;4,&#160;2028, we are required to offer Gilead a right of first negotiation for the same rights to the Licensed Technology in such field offered to the third party. If the Option expires or is terminated, the right of first negotiations terms contained in the Restated Collaboration Agreement will not be applicable to the development for HIV indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Financial Terms</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the Collaboration Agreement, Gilead paid us a one-time upfront fee of $10.0&#160;million and through to December&#160;31,&#160;2021, we received $12.2&#160;million in milestone payments for the achievement of pre-clinical research milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the Restated Collaboration Agreement, we became entitled to a program initiation fee of $15.0 million. In addition, we are eligible for up to $140.0 million in developmental milestone payments for the HBV program and $50.0 million in commercialization milestone payments for the HBV program. If Gilead exercises the Option, we are eligible for up to a further $167.5 million in developmental milestone payments for the HIV program, inclusive of the $10.0 million program completion fee payable upon Option exercise, and $65.0 million in commercialization milestone payments for the HIV program. Upon the commercialization of a Licensed Product, if ever, we are eligible to receive tiered royalties of a high single-digit to mid-teens percentage on the worldwide net sales of each HBV Licensed Product, and royalties of a mid-single-digit to 10% of worldwide net sales of each HIV Licensed Product, if the Option is exercised. The royalty payments are subject to reduction under specified conditions set forth in the Collaboration Agreement. In addition, Gilead is obligated to pay us for all out-of-pocket costs actually incurred by us in connection with the HBV program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, Gilead is obligated to pay us for all out-of-pocket costs actually incurred by us in connection with the Hepatitis&#160;B Virus programs, including CMO related costs, to the extent contemplated under the research plans and research budget. In December&#160;2019, Gilead agreed to expand the reimbursement for our resources allocated to the collaboration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Termination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Either party may terminate for the uncured breach of the other party and upon the other party filing for bankruptcy, reorganization, liquidation, or receivership proceedings. On a program-by-program basis, at any time after the expiration or termination of the collaboration term for such program, Gilead may terminate the Restated Collaboration Agreement with respect to such program or on a product by product or a country-by-country basis upon prior written notice. If the Restated Collaboration Agreement is not otherwise terminated prior to the expiration of the last to expire royalty term, upon such expiration the license granted to Gilead will continue in effect, but will be fully paid-up, royalty free, perpetual, and irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supply Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December&#160;2020, we entered into a Clinical Supply Agreement with Gilead. Under the terms of the Clinical Supply Agreement, we will provide Gilead with drug product for use in proof-of-concept clinical trials associated with the Licensed Products designated under the Collaboration Agreement. We will receive reimbursement at an agreed cost </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in accordance with the terms of the Restated Collaboration Agreement. Clinical supply of a potential Phase&#160;3 clinical trial will be regulated in a separate supply agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Restated Collaboration Agreement, on February 15, 2022, the Effective Date, we entered into a Stock Purchase Agreement, the Stock Purchase Agreement, with Gilead. Pursuant to, and subject to the terms and conditions of, the Stock Purchase Agreement, Gilead will be required, at our option, to purchase up to $35,000,000 of our common stock, the proceeds of which we intend to use to fund additional research and development activities of our HIV program. On the Effective Date, Gilead purchased an initial amount of 1,666,666 unregistered shares of our common stock in exchange for approximately $5.0 million at a purchase price per share equal to $3.00. Pursuant to the terms of the Stock Purchase Agreement, we may require Gilead to purchase the balance of the $30.0 million of common stock in two subsequent purchases. The purchase price per share of the first subsequent purchase shall be equal to (a) the VWAP Purchase Price (as defined in the Stock Purchase Agreement), calculated at the date we exercise our right to require Gilead to purchase shares, plus (b) a premium of 30% on the VWAP Purchase Price, and the purchase price per share of the second subsequent purchase shall be equal to the VWAP Purchase Price, calculated at the date we exercise our right to require Gilead to purchase shares. Our ability to sell shares of our common stock to Gilead are subject to specified limitations, including compliance with Nasdaq Rule 5635(d) and continued compliance with the Nasdaq listing rules. The Stock Purchase Agreement also prohibits Gilead from purchasing shares of our common stock if such purchase would result in Gilead being a beneficial owner of more than 19.9% of the total number of our then-issued and outstanding shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Stock Purchase Agreement may be terminated: (1) by Gilead (a) any time an Event of Default (as defined in the Stock Purchase Agreement) exists or (b) if we suspend, terminate or otherwise cease to perform our obligations under the HIV Development Plan; (2) automatically if Gilead exercises its Option pursuant to the Restated Collaboration Agreement; (3) by us for any reason; (4) automatically on the date that we sell and Gilead purchases the full $35.0&#160;million of common stock; or (5) automatically on December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Stock Purchase Agreement, we and Gilead agreed to enter into a registration rights agreement within two months following the Effective Date, obligating us to file a registration statement on Form S-3 to register for resale the initial 1,666,666 shares of common stock issued to Gilead within six months of the issuance on the Effective Date and thereafter, within four months of any additional purchases of common stock by Gilead.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">University of Geneva License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, we entered into an Exclusive License Agreement with the University of Geneva, the Geneva Agreement. Pursuant to the Geneva Agreement, the University of Geneva granted us a worldwide, exclusive license to use the University of Geneva&#8217;s technology titled &#8220;method for vaccine delivery&#8221; and the patent rights in the subject matter of U.S. Provisional Patent Application No.&#160;62/079,493 and PCT Patent Application No.&#160;PCT/EP2015/076458, each titled &#8220;Tri-Segmented Arenaviruses as Vaccine Vectors,&#8221; including any patents that claim priority thereto, the Geneva Licensed Patent Rights, to make, have made, to use and have used, to sell and have sold, to commercialize and have commercialized products, the manufacture, use, or sale of which would infringe a claim of the Geneva Licensed Patent Rights, each a Geneva Licensed Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Geneva Agreement, we are obligated to use reasonable efforts to develop and make commercially available Geneva Licensed Products. We were also required to provide proof to the University of Geneva that we have filed an IND or an equivalent application for a Geneva Licensed Product within seven years of the effective date of the Geneva Agreement. In June&#160;2019 we informed the University of Geneva about the filing of an IND for a Geneva Licensed Product. The University of Geneva can terminate the Geneva Agreement if we stop the development and/or exploitation of the technology licensed by the University of Geneva to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Starting with the third anniversary of the effective date of the Geneva Agreement, we are required to pay the University of Geneva a nominal annual fee, which is deductible from any milestone payments, royalties or sublicense payments payable by us to the University of Geneva during the same fiscal year. We are required to pay the University of Geneva, subject to the achievement by us of specified development and regulatory milestones, payments aggregating up to CHF&#160;290,000 per Geneva Licensed Product. While the Geneva Agreement remains in effect, we are required to pay the University of Geneva low single digit royalties on aggregate net sales of Geneva Licensed Products sold by us. We must also pay the University of Geneva percentages ranging from the low single digits to 10%, decreasing as a Geneva Licensed Product proceeds through development stages, of any consideration we receive from sublicensees, depending on the timing of such sublicense. We are also responsible for the prosecution and maintenance of the Geneva Licensed Patents Rights, including the costs related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Geneva Agreement remains in effect until the expiration of the last to expire of the Geneva Licensed Patent Rights. Following the expiry of the Geneva Agreement due to the last to expire of the Geneva Licensed Patent Rights, we will have a fully paid-up, royalty-free right to use, sell and commercialize Geneva Licensed Products. We or the University of Geneva may terminate the Geneva Agreement for the other party&#8217;s breach that remains uncured after 60&#160;days&#8217; notice. We may terminate the Geneva Agreement for convenience upon prior notice. The University of Geneva may terminate the Geneva Agreement if we cease to carry on our business or become insolvent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">University of Basel License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2017, we entered into an Exclusive License Agreement with the University of Basel, the Basel Agreement. Pursuant to the Basel Agreement, the University of Basel granted us a worldwide, exclusive license under the University of Basel&#8217;s share in U.S. Provisional Patent Application No.&#160;62/338,400, titled &#8220;Tri-segmented Pichinde viruses as vaccine vectors,&#8221; including any patents that claim priority thereto, the Basel Licensed Patent Rights to use the technology titled &#8220;tri-segmented Pichinde viruses as vaccine vectors&#8221; as covered by the Basel Licensed Patent Rights, to make and have made, to use and have used, to sell and have sold, to commercialize and have commercialized products, the manufacture, use, sale, or importation of which would infringe a claim of the Basel Licensed Patent Rights, each a Basel Licensed Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Basel Agreement, we are obligated to use reasonable efforts to develop and make commercially available Basel Licensed Products. Beginning on February&#160;28,&#160;2018, and for as long as we have not effected a first commercial use of a Basel Licensed Product, we are required to provide the University of Basel with an annual report detailing our efforts to develop Basel Licensed Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are required to pay the University of Basel, subject to the achievement of specified development and regulatory milestones, payments aggregating up to CHF&#160;265,000 per Basel Licensed Product. While the Basel Agreement remains in effect, we are required to pay the University of Basel low single digit royalties on net sales of Basel Licensed Products. We must also pay the University of Basel a low to high single digit percentage, decreasing as a Basel Licensed Product proceeds through development stages, of any consideration we receive from sublicensees, depending on the timing of such sublicense. We are also responsible for the prosecution and maintenance of the Basel Licensed Patent Rights, and the costs related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Basel Agreement remains in effect until the expiration of the last to expire of the Basel Licensed Patent Rights. Following the expiry of the Basel Agreement due to the last to expire of the Basel Licensed Patent Rights, we will have a fully paid-up, royalty-free right to use, sell and commercialize Basel Licensed Products. We or the University of Basel may terminate the agreement for the other party&#8217;s breach that remains uncured after 60&#160;days&#8217; notice. We may terminate the Basel Agreement for convenience upon prior notice. The University of Basel may terminate the Basel Agreement if we cease to pay for the costs associated with prosecution and maintenance of the Basel Licensed Patent Rights.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">University of Basel Split License Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2020, we entered into an Exclusive License Agreement with the University of Basel, the Basel Split Agreement. Pursuant to the Basel Split Agreement, the University of Basel granted us a worldwide, exclusive license under a currently pending international Patent Cooperation Treaty (PCT) application related to a novel molecular strategy to vectorize arenavirus genomes (Split Vector Technology as described in the Intellectual Property Section), including any patents and patent applications that claim priority thereto, the Basel Licensed Split Patent Rights, to make or to have made, to develop or have developed, to use, have used, sell, have sold, market, have marketed, offer for sale, distribute, have distributed, import or have imported products, the manufacture, use, sale, or importation of which would infringe a claim of the Basel Licensed Split Patent Rights, each a Basel Licensed Split Product. Pursuant to the Basel Split Agreement, the University of Basel further granted us a worldwide, exclusive license under the University of Basel&#8217;s share in a currently pending U.S. provisional patent application related to certain improvements of the Split Vector Technology, including any patents and patent applications that claim priority thereto, such patents and patent applications are further included in the Basel Licensed Split Patent Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Basel Split Agreement, we are obligated to use commercially reasonable efforts to develop and manufacture Basel Licensed Split Products and make commercially available Basel Licensed Split Products in the United States and at least three major European countries. In addition, we have to reach certain pre-clinical and clinical development milestones within specified time periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have the right to request postponement of pre-defined pre-clinical or clinical development milestones against payment of rescheduling fees in the range of CHF&#160;100,000 to CHF&#160;1,000,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to perform any of our diligence obligations specified in the Basel Split Agreement, after having exercised all available postponement options, the University of Basel can demand a written development and marketing plan. If we fail to agree with the University of Basel on any amendments to our development and marketing plans based on the procedure specified in the Basel Split Agreement upon such demand for amendments from the University of Basel, the University of Basel has the right to send us a notice of its intention to terminate the Basel Split Agreement. If we are not in agreement, we may request that the matter is assessed by an independent expert arbitrator. If such an expert arbitrator determines that we fail to meet our diligence obligations, the University of Basel may terminate the Basel Split Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beginning on January&#160;1,&#160;2021, and ending on the date of the first commercial sale of a Basel Licensed Split Products, we are required to provide the University of Basel with an annual report detailing our efforts to develop Basel Licensed Split Products and to obtain governmental approvals necessary for marketing the same. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We paid the University of Basel a nominal amount upon entering into the agreement and are required to pay a non-material annual maintenance fee, which is deductible from any milestone payments, royalties or sublicense payments payable by us to the University of Basel during the same year. We are required to pay the University of Basel, subject to the achievement of specified development and regulatory milestones, payments aggregating up to CHF&#160;1,700,000 per Basel Licensed Split Product. While the Basel Split Agreement remains in effect, we are required to pay the University of Basel low single digit royalties on net sales of Basel Licensed Split Products. We must also pay the University of Basel a low double digit to low single digit percentage, decreasing as a Basel Licensed Split Product proceeds through development stages, of any consideration we receive from sublicensees, depending on the timing of such sublicense. We are also responsible for the prosecution and maintenance of the Basel Licensed Split Patent Rights, and the costs related thereto. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Unless earlier terminated, the Basel Split Agreement remains in effect until the expiration of the last to expire of the Basel Licensed Split Patent Rights. Following the expiry of the Basel Split Agreement due to the last to expire of the Basel Licensed Split Patent Rights, we will have a fully paid up, royalty free right to use, sell and commercialize Basel Licensed Split Products. We or the University of Basel may terminate the agreement for the other party&#8217;s breach that remains uncured after 60&#160;days&#8217; notice. We may terminate the Basel Agreement for convenience upon prior notice. The University of Basel may terminate the Basel Split Agreement if we file&#160;a petition for bankruptcy or insolvency or both, or reorganization relating to bankruptcy or insolvency, or in the event of an adjudication that we have become </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">bankrupt or insolvent or both. The University of Basel may further terminate the Basel Split Agreement if we oppose or dispute the validity of any of the Basel Licensed Split Patent Rights or assist a third party to do the same. If we fail to perform any of our diligence obligations specified in the Basel Split Agreement, after having exercised all available postponement options, and if we fail to agree with the University of Basel on any amendments to our development and marketing plans based on the procedure specified in the Basel Split Agreement upon such demand for amendments from the University of Basel, the University of Basel may terminate the Basel Split Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">University of Zurich License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2011, we entered into a License Agreement with the University of Zurich, the Zurich Agreement. Pursuant to the Zurich Agreement, the University of Zurich granted us a worldwide, exclusive license to PCT Patent Application No. PCT/EP/08/010994, titled &#8220;Propagation deficient arenavirus vectors,&#8221; the Zurich Licensed Patent Rights, to make and have made, use, sell, offer for sale, and import products that fall within the scope of the Zurich Licensed Patent Rights, each a Zurich Licensed Product and to practice the Zurich Licensed Patent Rights and methods that fall within the scope of the Zurich Licensed Patent Rights, each a Zurich Licensed Method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Zurich Agreement, we are obligated to diligently proceed with the development, manufacture, and sale of, and the obtaining of government approvals for the manufacture, use and sale of, suitable Zurich Licensed Products in the United States, Japan and certain European countries. If we fail to use commercially reasonable efforts to do the foregoing, the University of Zurich can demand a written development and marketing plan. Failure of the parties to agree on a development and marketing plan entitles the University of Zurich to terminate the Zurich Agreement. Beginning on January&#160;1,&#160;2012, and ending on the date of the first commercial sale of a Zurich Licensed Product, we are required to provide the University of Zurich with an annual report detailing our efforts to develop and test Zurich Licensed Products and to use the Zurich Licensed Patent Rights and Zurich Licensed Methods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In consideration for the license granted to us under the Zurich Agreement, we issued 26,744&#160;shares with a nominal value of EUR&#160;2,297 of our common stock to the University of Zurich and agreed to provide them certain antidilution rights, which rights have subsequently expired. We are required to pay the University of Zurich low single digit royalties on net sales of Zurich Licensed Products or Zurich Licensed Methods. We must also pay the University of Zurich percentages ranging from the mid-single digits to 20% of any sublicense fees and consideration we receive from sublicensees, depending on the amount of fees received from sublicensees and the cumulative monetary value of the consideration and fees received from all sublicensees. We are responsible for the prosecution and maintenance of the Zurich Licensed Patent Rights, and the costs related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Zurich Agreement remains in effect on a country-by-country basis until the expiration of the last to expire of the Zurich Licensed Patent Rights in such country. The University of Zurich may terminate the agreement for our uncured breach of any of the terms of the Zurich Agreement or if we oppose or dispute the validity of any of the Zurich Licensed Patent Rights, or assist a third party to do the same. If we fail to use commercially reasonable efforts to market and develop the Zurich Licensed Products in certain countries, and if we fail to agree with the University of Zurich on any amendments to our development and marketing plans within the time specified in the Zurich Agreement upon such demand for amendments from the University of Zurich, the University of Zurich may terminate the Zurich Agreement. We may terminate the Zurich Agreement for convenience upon prior notice. The Zurich Agreement automatically terminates if we file&#160;a petition for bankruptcy, insolvency, or reorganization relating to bankruptcy or insolvency, or in the event of an adjudication that we have become bankrupt or insolvent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">National Institutes of Health License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2013, we entered into a Biological Materials License Agreement with the National Institutes of Health (NIH) which was subsequently amended in April&#160;2017, July&#160;2018, January&#160;2021, and May 2021, hereinafter referred to as the NIH Agreement. Pursuant to the NIH Agreement, the NIH granted us a worldwide, nonexclusive license to make, have made, import and use certain cells and cell clones developed at the Vaccine Research Center of the NIH, or the NIH Licensed Products, to manufacture viral vectors based on our proprietary arenavirus-based vectors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the NIH Agreement, we are required to provide the NIH with an annual report which states the number and description of NIH Licensed Products made or otherwise disposed of. We are further responsible for obtaining and maintaining any required third-party license for the background rights for the commercial use of the respective cells and cell clones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In consideration of the license granted to us pursuant to the NIH Agreement, we paid the NIH a low six figure and a mid-five figure issue royalty, upon execution of the NIH Agreement and the first amendment, respectively. We must also pay the NIH 10% of any consideration we receive from sublicensees. We must also pay the NIH low five figure to mid six figure annual royalty payments, increasing as our most developed product candidate manufactured from NIH Licensed Products proceeds through development stages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the NIH Agreement remains in effect for a term of 20 years from the effective date. We have the option to extend the term of the agreement for additional one year periods, upon prior notice to the NIH. The NIH may terminate the NIH Agreement if we are in default in performing any material obligation under the NIH Agreement and do not remedy such default within a specified period upon notice thereof. We may terminate the NIH Agreement for convenience upon prior notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries have made substantial investments in recent years into the rapid development of novel immunotherapies for the treatment of a range of pathologies, including infectious diseases and cancers, making this a highly competitive market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face substantial competition from multiple sources, including large and specialty pharmaceutical, biopharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed to target various therapeutic areas, such as adoptive cell therapies and active immunization technologies, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i)&#160;obtain support for their research, development and commercialization of products or (ii)&#160;combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the field of immunotherapy and, furthermore, within the treatment of infectious diseases and cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the current standard of care treatments for patients with infectious diseases or cancers, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess novel technologies and product candidates in the field of immunotherapy. Results from these studies and trials have fueled increasing levels of interest in the field of immunotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companies that compete with us directly on the level of the development of product candidates in our therapeutic areas include, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In CMV management, companies such as Helocyte,&#160;Inc., VBI Vaccines&#160;Inc., Moderna,&#160;Inc., SL VaxiGen&#160;Inc., and Merck&#160;&amp;&#160;Co.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In immunooncology for HPV+ cancers, companies such as ISA Pharmaceuticals&#160;B.V., Moderna, BioNTech, Kite, CureVac, Adaptimmune&#160;PLC Transgene, and TCR Cure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In metastatic Hormone Resistant Prostate Cancer, companies such as Bioray Labs, Regeneron, Allife Medical, Gemoab, BioNTech, Inovio and Madison Vaccine are investigating an immuno-oncology approach.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On the technology level, other direct competitors which can potentially develop competing product candidates in areas in and outside of HPV16+ cancers and CMV infection such as neoantigens, oncolytic viruses, bispecific </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">antibodies, engineered cell therapies and tumor specific antigens, and other active immunization technologies, include, among others, Gritstone Oncology,&#160;Inc., in collaboration with bluebird bio,&#160;Inc., Replimune Group,&#160;Inc., in collaboration with Bristol-Myers Squibb Company, Merck &amp; Co., Abalos GmbH, BioNTech, Moderna, Turnstone Biologics&#160;Inc., Adaptimmune&#160;PLC, CureVac AG, Roche Holdings AG, Five Prime Therapeutics,&#160;Inc., and Novartis International AG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have been establishing robust manufacturing processes, reliable assays and strong supply agreements for all of the components used in our product candidates to support ongoing and planned clinical trials. These include the components for our non-replicating based and replicating based product candidates. For GMP production and testing we rely on qualified CMOs to produce and test our clinical material. Currently we do not own or operate manufacturing facilities beyond laboratory scale non-GMP production. We require that our CMOs produce bulk drug substances and finished drug products in accordance with cGMP, and all other applicable laws and regulations. Although we plan to establish our own manufacturing facility, we may continue to rely on CMOs for parts of the process, like filling and labelling of our products for commercial sale, to reduce supply risks and cost of goods sold. We continue to build and maintain agreements with manufacturers that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to ultimately establish our own manufacturing facility. By complementing CMO capacity with our own manufacturing facility, we aim to balance supply risks, reduce supply cycle time and optimize costs. We believe that having control over the whole manufacturing process will allow us to further increase the robustness and consistency of the process. We expect that control over our own manufacturing facility will also help to shorten overall timelines for new product candidates in our development pipeline, as well as help us develop drug formulations or presentations to simplify distribution as well as administration of future immuno-therapeutics. We also believe that having a dedicated manufacturing facility will allow us to optimize commercial scale processes and to develop a suitable workforce capable of supporting market launch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, such as those developed from our non-replicating and replicating technologies and any other product candidates we develop. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">U.S. Biological Product Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations and biologics under the FDCA, the Public Health Service Act (PHSA) and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and any future biological product candidates we develop must be approved by the FDA through a biologics license application (BLA) process before they may be legally marketed in the United States. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity and potency. The FDA review and approval process generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Approval by an Institutional Review Board (IRB) or independent ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (GCP) requirements and other clinical trial related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of a BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A determination by the FDA within 60&#160;days of its receipt of a BLA to accept the filing for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA preapproval inspection of the manufacturing facility or facilities where the biologic will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential FDA audit of the clinical trial sites that generated the data in support of the BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the biologic in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Preclinical Studies and IND</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well designed and well conducted foreign clinical trial not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2 and Phase&#160;3, and may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;1 clinical trials generally involve a small number of healthy volunteers or disease affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;2 clinical trials involve studies in disease affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-approval trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of a BLA. Failure to exhibit due diligence with regard to conducting required Phase&#160;4 clinical trials could result in withdrawal of approval for products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">FDA Review Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. The BLA may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the investigational product to the satisfaction of FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Prescription Drug User Fee Act (PDUFA) as amended, each BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#8217;s fee schedule, effective through September&#160;30,&#160;2022, the user fee for an application requiring clinical data, such as a BLA, is $3,117,218. The sponsor of an approved BLA is also subject to an annual prescription drug program fee, which for fiscal year 2022 is $369,413. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA reviews all submitted BLAs before it accepts them for filing and may request additional information rather than accepting the BLA for filing. The FDA decides whether to accept a BLA for filing within 60&#160;days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The FDA does not always meet its </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before approving a BLA, the FDA will conduct a preapproval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data, pivotal Phase&#160;3 clinical trial(s) as well as other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000&#160;individuals in the United States, or more than 200,000&#160;individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation for a biologic must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA provides programs intended to facilitate and expedite development and review of new products that are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast-track designation, breakthrough therapy designation, priority review, and accelerated approval. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fast-track program is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast-track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast-track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a biologic can request the FDA to designate the product for fast-track status any time before receiving BLA approval, but ideally no later than the pre-BLA meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A product that receives fast-track program designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biologic designated for priority review in an effort to facilitate the review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of approval are not being met, the FDA can withdraw its accelerated approval for such drug or biologic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast-track designation, plus intensive guidance from the FDA to ensure an efficient drug development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fast-track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Pediatric Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the Pediatric Research Equity Act (PREA), a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the biologic for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act (FDASIA) amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (PSP) within 60&#160;days of an end of Phase&#160;2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase&#160;3 or Phase&#160;2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials as well as other clinical development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Post-Marketing Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. Prescription drug and biologic promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the development of additional data or preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy (REMS) to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws, including applicable product tracking and tracing requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violations, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of post-approval problems with a product may result in restrictions on a product, manufacturer or holder of an approved BLA, including recall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">U.S. Healthcare Reform and Other U.S. Healthcare Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufactures to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act (FCA) which may constrain the business or financial arrangements and relationships through which companies sell, market and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">distribute pharmaceutical products. In addition, transparency laws and patient privacy regulations by federal and state governments and by governments in foreign jurisdictions can apply to the manufacturing, sales, promotion and other activities of pharmaceutical manufactures. The applicable federal, state and foreign healthcare laws and regulations that can affect a pharmaceutical company&#8217;s operations include those referenced in the section titled &#8220;Business &#8211; U.S. Healthcare Reform and U.S. Healthcare Laws&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations with respect to certain laws. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ensuring our business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time and resource consuming and can divert a company&#8217;s attention from the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The failure to comply with any of these laws or regulatory requirements may subject companies to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are&#8239;found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March&#160;2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% (70% commencing January&#160;1,&#160;2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition to coverage under Medicare Part&#160;D for the manufacturer&#8217;s outpatient drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since the ACA&#8217;s enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#39;s decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">through August 15, 2021, for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.&#8239;It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&#160;2,&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2&#160;trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April&#160;1,&#160;2013. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, as well as subsequent legislation, these cuts have been suspended from May&#160;1,&#160;2020, through March&#160;31,&#160;2022, due to COVID-19 pandemic. Following the&#8239;suspension, a&#8239;1% payment reduction will occur beginning&#8239;April 1, 2022,&#8239;through June 30, 2022, and the 2% payment reduction&#8239;will resume on July 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives which could limit the amounts that federal and state governments will pay for healthcare products and services and result in reduced demand for certain pharmaceutical products or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, there has also been a lot of legislative activity at the state level with respect to privacy regulation. For example, in California, the California Consumer Privacy Act (CCPA) was enacted in June 2018, became effective on January 1, 2020, and became subject to enforcement by the California Attorney General&#39;s office on July 1, 2020. The CCPA broadly defines personal information, and creates new individual privacy rights and protections for California consumers (as defined in the law), places increased privacy and security obligations on entities handling personal data of consumers or households, and provides for civil penalties for violations and a private right of action for data breaches. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. While there is an exception for protected health information that is subject to HIPAA and clinical trial regulations, the CCPA may impact our business activities if we become a &quot;Business&quot; regulated by the scope of the CCPA. In addition to the CCPA, new privacy and data security laws have been proposed in more than half of the states in the U.S. and in the U.S. Congress, reflecting a trend toward more stringent privacy legislation in the U.S., which trend may accelerate depending on the new U.S. presidential administration. The effects of the CCPA, and other similar state or federal laws, are potentially significant and may require us to modify our data processing practices and policies and to incur substantial costs and potential liability in an effort to comply with such legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">U.S. Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depending upon the timing, duration and specifics of FDA approval of our product candidates and any future product candidates we develop, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Amendments. The Hatch Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office (USPTO) in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009 as part of the ACA. This amendment to the PHSA, in part, attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. A reference biological product is granted 12&#160;years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA issued &#8220;Written Request&#8221; for such a trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Drug Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the European Union (EU) our future products also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014, or Regulation, which replaced the Clinical Trials Directive 2001/20/EC, or Directive, on January 31, 2022. The transitory provisions of the new Regulation offer sponsors the possibility to choose between the requirements of the previous Directive and the new Regulation if the request for authorization of a clinical trial is submitted in the year after the new Regulation became applicable. If the sponsor chooses to submit under the previous Directive, the clinical trial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">continues to be governed by the Directive until three years after the new Regulation became applicable. If a clinical trial continues for more than three years after the Regulation became applicable, the new Regulation will at that time begin to apply to the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The new Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Drug Review and Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, medicinal products can only be commercialized after obtaining a marketing authorization, or MA. There are two types of marketing authorizations.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the EMA and is valid throughout the entire territory of the EU, and in the additional Member States of the European Economic Area (Iceland, Liechtenstein and Norway). The centralized procedure is mandatory for certain types of products, such as medicines produced by biotechnological processes, products designated as orphan medicinal products, advanced therapy medicines (i.e. gene therapy, somatic cell therapy or tissue engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of a marketing authorization application, or MAA, by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant an MA, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">National MAs, which are issued by the competent authorities of the Member States of the EU and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EU, this national MA can be recognized in other Member States through the mutual recognition procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decentralized procedure an identical dossier is submitted to the competent authorities of each of the member state in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics, or SmPC, and a draft of the labeling and package leaflet, which are sent to the other member state, referred to as the Concerned Member States, for their approval. If the Concerned Member States raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the member states (i.e.,&#160;in the RMS and the Concerned Member States).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EU make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized MAs (under the Northern Ireland Protocol, centralized MAs will continue to be recognized in Northern Ireland). All medicinal products with a current centralized MA were automatically converted to Great Britain MAs on January, 1, 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new MA in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required. The MHRA also has the power to have regard to MAs approved in EU Member States through decentralized or mutual recognition procedures with a view to more quickly granting an MA in the United Kingdom or Great Britain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union new Chemical Entity Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon an MA and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU, during a period of eight years from the date on which the reference product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be placed on the EU market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant clinical benefit in comparison with currently approved therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, however, another company could nevertheless also market another version of the product if such company obtained an MA based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Orphan Designation and Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan designation to promote the development of products that: (1) are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (2) either (i) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (ii) it is unlikely that the marketing of the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the necessary investment in its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or, if a method exists, the product would be a significant benefit to those affected by that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EU, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity is granted following grant of an MA. During this market exclusivity period, neither the EMA nor the European Commission nor any of the competent authorities in the EU Members States can accept an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">application or grant an MA for a &#8220;similar medicinal product approval.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. This period may be reduced to six years if the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Market exclusivity may also be revoked in very select cases, such as if (i) it is established that a similar medicinal product is safer, more effective or otherwise clinically superior to the authorized product; (ii) the marketing authorization holder of the authorized orphan product consents to such revocation; or (iii) the marketing authorization holder of the authorized orphan product cannot supply enough orphan medicinal product. Orphan designation must be requested before submitting an application for MA. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Regulatory Requirements After a Marketing Authorization has been Obtained</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If authorization for a medicinal product in the EU is obtained, the holder of the MA is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is sometimes governed by the national anti-bribery laws of the EU Member States, and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization as well as the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the EU Member States, plus Norway, Liechtenstein and Iceland.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Data Collection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The collection and use of personal health data in the EEA is governed by the General Data Protection Regulation, or GDPR, which became effective May 25, 2018. The GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, mandatory data breach notification and &#8220;privacy by design&#8221; requirements, and creates direct obligations on service providers acting as data processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA Member States may result in fines up to &#8364;20 million or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the GDPR grants data subjects the right to claim material and non-material damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR, will require significant time, resources and expense, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, further to the United Kingdom&#8217;s exit from the European Union on January 31, 2020, the GDPR ceased to apply in the United Kingdom at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the United Kingdom&#8217;s data protection regime, which is independent from but aligned to the European Union&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the European Union&#8217;s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the United Kingdom to countries not regarded by the United Kingdom as providing adequate protection. The UK government has confirmed that personal data transfers from the United Kingdom to the EEA remain free flowing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Brexit and the Regulatory Framework in the United Kingdom</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as Brexit), and the UK formally left the EU on January 31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However, the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021, and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore largely aligns with current EU regulations, however it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Rest of the World Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. In addition, many jurisdictions outside of Europe are also considering and/or enacting comprehensive data protection legislation. These laws impose stringent requirements applicable to our collection, use and processing of personal data including identifiable health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sales of our products, when and if approved, will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug or biological products exists in the United States. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, coverage determination is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Factors payors consider in determining reimbursement are based on whether the product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safe, effective and medically necessary; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appropriate for the specific patient; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effective; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of biosimilars for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e.,&#160;new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established the Medicare Part&#160;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part&#160;A and B, Part&#160;D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&#160;D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part&#160;B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the exception of children&#8217;s hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs. In addition, as 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide coverage and reimbursement. Obtaining coverage and reimbursement for newly approved drugs and biologics is a time consuming and costly process, and coverage may be more limited than the purposes for which a drug is approved by the FDA or comparable foreign regulatory authorities. Assuming coverage is obtained for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require copayments that patients find unacceptably high. Additionally, coverage policies and third-party reimbursement rates may change at any time. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of prescribed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February&#160;28,&#160;2022, we had 131 full-time employees and 26&#160;part-time employees. Of our 157&#160;full and part-time employees, 38, or 24.2%, have Ph.D. or M.D. degrees and 123, or 78.3%, are engaged in research and development activities. Pursuant to Austrian law, all of our Austrian employees are covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. To further drive attraction and retention of our high-quality, experienced, and diverse workforce, we invest in the physical, emotional, and financial well-being of our employees. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of stock-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate History</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were originally incorporated as Hookipa Biotech AG under the laws of Austria in 2011. In February&#160;2017, we reorganized to become a corporation under the laws of the State of Delaware as Hookipa Biotech,&#160;Inc., which was a fully-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, Hookipa Biotech,&#160;Inc. changed its name to HOOKIPA Pharma&#160;Inc. and acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech&#160;GmbH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located in New York, New York, pursuant to a lease that expires in February&#160;2024. Our European research and preclinical development operations are located in Vienna, Austria, where we lease and occupy approximately 30,656 square feet of office and laboratory space. Our first facility is leased pursuant to two operating leases, comprised of (i)&#160;a lease of unlimited duration for approximately 15,198 square feet of office and laboratory space and (ii)&#160;a lease set to expire in September 2028 and with no option to extend for approximately 2,357 square feet of storage space. In 2019, we entered into a lease for a second facility located in Vienna, Austria that is set to expire in February&#160;2029, where we occupy approximately&#160;15,440 square feet of office and laboratory space. In May 2021 we signed an agreement to purchase a parcel of land in the north of Vienna and have received building permission to build a GMP manufacturing plant. We are currently in the detailed engineering phase. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are currently a party to a patent opposition proceeding. In April 2021, a third party opposed European Patent No. 3218504, which was granted to the University of Geneva in July 2020 and is exclusively licensed to us. While the opposition was filed in the name and on behalf of Dr. Ursula Sprenzel, we believe that the real party in interest has not identified itself. The patent is directed to our replicating arenavirus platform technology and is part of our strategy to protect current product candidates based on this platform technology, including our lead oncology product candidates HB-201 and HB-202. We filed our formal response to the opposition with the European Patent Office (EPO) on September 3, 2021. It is expected that the EPO&#8217;s opposition division will issue a preliminary opinion within the next 1 to 6 months and will summon the parties to oral proceedings within the next 6 to 12 months. Besides the European opposition proceeding, we are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk34056236"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, are available free of charge on our website located at www.hookipapharma.com, as soon as reasonably practicable after they are filed with or furnished to the SEC. These reports are also available at the SEC&#8217;s Internet website at www.sec.gov. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A copy of our Corporate Governance Guidelines, Code of Conduct and the charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our website, www.hookipapharma.com, under the heading &#8220;Corporate Governance.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_70aa184d_76de_4d68_a3b9_99a5844ca772"></a><a id="RiskFactors_480000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Capital Needs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharmaceutical company with no approved products and a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharmaceutical company with no approved products and a limited operating history. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our product candidates, securing related intellectual property rights and conducting discovery, research and development activities for our programs. As a result, we are not profitable and have incurred losses in each period since our inception in 2011. For the years ended December&#160;31,&#160;2020 and 2021, we reported a net loss of $44.1&#160;million and $75.7&#160;million, respectively. As of December&#160;31,&#160;2021, we had an accumulated deficit of $222.8&#160;million. We expect to continue to incur significant losses for the foreseeable future. We anticipate that our expenses will increase substantially if, and as, we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue the clinical and preclinical development of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage our technologies to advance product candidates into preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract, hire, and retain additional clinical, quality control and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other product candidates and technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">we may never generate revenue that is significant or large enough to achieve profitability. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Accordingly, our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our non-replicating and replicating technologies and our product candidates derived from these technologies. Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs, any future product candidates we may choose to pursue, when we begin to develop our own manufacturing capabilities and other corporate uses. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. Our expenses could increase beyond our current expectations if other unanticipated costs arise or if the FDA, the EMA, or other comparable foreign regulatory authorities requires us to perform clinical trials and other studies in addition to those that we currently anticipate. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current or future product candidates. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or terminate our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, we had approximately $66.9&#160;million in cash, cash equivalents and restricted cash. Based on our research and development plans, we expect that our existing cash and cash equivalents at December&#160;31,&#160;2021, together with the funds we received from our offering in March&#160;2022 and the funds received under the Restated Collaboration Agreement with Gilead in February&#160;2022, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12&#160;months. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities and changes in regulation. Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the stability, scale and yields of our future manufacturing process as we scale-up production and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining regulatory and marketing approvals and developing our ability to establish sales and marketing capabilities, if any, for our current and future product candidates we develop if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our collaboration with Gilead;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of commercialization activities for our current and future product candidates that we may develop, whether alone or with a collaborator;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing oncology and infectious disease therapies and other adverse market developments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any committed external source of funds or other support for our development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements and grant funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders if we issue equity securities, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may evaluate various acquisitions and strategic partnerships, including acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating expenses and cash requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assumption of additional indebtedness or contingent liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of our equity securities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if we undertake acquisitions, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have obtained funding from an agency of the Austrian government that contains certain covenants that may restrict our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the past, we have contracted numerous funding agreements with an agency of the Austrian government to partially finance our research and development programs, such as personnel costs, material costs, third-party services, travel expenses and research and development infrastructure use. These funding agreements include both below market rate loans and grants, which are subject to various criteria linked to certain terms and conditions as well as certain costs attributable to the respective funded research and development program. We have committed to reporting obligations and to obtain the approval for significant changes in the cost structure of the funded research and development programs. If we were to breach these contractual obligations, we may be held liable by the agency of the Austrian government for damages incurred by such agencies resulting from the breach of contract and we could be required to reimburse in full the funding granted by such agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, pursuant to the general terms of each grant, the agency is entitled to re-evaluate the funding granted to us in case of a fundamental change in our ownership structure if such change no longer ensures that the purpose of the funding can be achieved. Any such re-evaluation could negatively impact the funding that we receive or have received from the agency or that we may receive in the future from other agencies of the Austrian government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of our product candidates are in early stages of development, including our lead product candidates, HB-201 and HB-202, which are currently in a Phase 1/2 clinical trial, and as such will require extensive preclinical and clinical testing. We cannot predict with any certainty if or when we might submit an IND, or BLA, for regulatory approval for any of our product candidates or whether any such IND or BLA will be accepted for review by the FDA, or subsequently whether any such IND will go into effect or BLA will be approved upon review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our ability to generate product revenues, which we do not expect to occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Before we are able to generate any revenues from product sales, our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts. The success of our current and future product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of INDs for our planned clinical trials or future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful data from our clinical program that support an acceptable risk-benefit profile of our product candidates in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing our own manufacturing capabilities or agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entry into collaborations to further the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully launching commercial sales of our product candidates, if and when approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product candidate&#8217;s benefits and uses, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events experienced with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the product candidates following approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">qualifying for, maintaining, enforcing and defending intellectual property rights and claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA, the EMA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval from the FDA, the EMA and other comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our current or future product candidates will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, the EMA or other comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or other comparable foreign regulatory authorities that a product candidate is safe, pure and potent or effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or other comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, the EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA, or similar foreign submission to the EMA or other comparable foreign regulatory authority, to obtain approval in the United States, the European Union or elsewhere;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, the EMA or other comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA, the EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have conducted, and intend to conduct, clinical trials of certain of our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA, including compliance with all applicable U.S. laws and regulations. For example, the clinical trial must be well designed and conducted and performed by qualified investigators </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in accordance with GCP, including review and approval by an independent ethics committee and informed consent from subjects. The study population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. There can be no assurance the FDA will accept data from trials conducted outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA, the EMA and other comparable foreign regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, including HB-101, HB-201, HB-202 and any other future product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and, because our product candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales and regulatory and commercialization milestones. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring comparable products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA, the EMA, or other comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA, the EMA or other comparable foreign regulatory authorities will view our product candidates as having efficacy even if positive results are observed in our planned clinical trials. To the extent that the results of the trials are not satisfactory to the FDA, the EMA or other comparable foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our preclinical programs may experience delays or our product candidates may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our product candidates and all of our next generation product candidates are still in the preclinical development stage, and the risk of failure of preclinical programs is high. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies to obtain regulatory clearance to initiate human clinical trials, including based on INDs in the United States and clinical trial applications in Europe. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA, the EMA or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our product candidates. As a result, we cannot be sure that submission of INDs or similar applications will result in the FDA, the EMA or other comparable foreign regulatory authorities allowing clinical trials to begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also encounter challenges in collecting, transporting and analyzing clinical blood samples, which could cause delays or prevent the approval of our drug candidates. For example, we have encountered difficulties in the transport logistics for samples in our HB-101 trial, resulting in the failure of a number of assays, in particular with respect to CD-8 T&#160;Cells, which are a key surrogate marker in the trial. We repeated the testing of samples from the respective patients and established a validated assay with respect to HB-201 samples, and mitigated further impact by changing and improving processes and logistics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim, top line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to regulatory audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim, top line or preliminary data from our clinical trials. We may decide to conduct an interim analysis of the data after a certain number or percentage of patients have been enrolled, or after only a part of the full follow-up period but before completion of the trial. Similarly, we may report top line or preliminary results of primary and key secondary endpoints before the final trial results are completed. Preliminary, top line and interim data from our clinical trials may change as more patient data or analyses become available. Preliminary, top line or interim data from our clinical trials are not necessarily predictive of final results and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available, and we issue our final clinical trial report. These data also remain subject to verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, interim and top line data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our interim, topline or preliminary analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Even if we are able to commence clinical trials, issues may arise that could suspend or terminate such clinical trials. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face similar setbacks. In addition, the results of our preclinical animal studies, including our oncology mouse studies and animal studies, may not be predictive of the results of outcomes in human clinical trials. For example, our oncology product candidates that are in preclinical development may demonstrate different chemical and biological properties in patients than they do in laboratory animal studies or may interact with human biological systems in unforeseen or harmful ways.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our replicating technology is early in clinical development and could therefore prove to be unsafe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our replicating technology is an attenuated viral vector technology which is in a Phase&#160;1/2 clinical trial. If our ongoing Phase&#160;1/2 clinical trial for HB-201 and HB-201/HB-202 causes unexpected side effects that are not tolerable in the treatment of the relevant patient group, the further development of the product candidate and any other potential products based on the replicating technology may be significantly limited or become impossible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concentrated all of our research and development efforts on product candidates based on our non-replicating and replicating technologies, and our future success depends on the successful development of this therapeutic approach. Our non-replicating and replicating technologies utilize arenaviruses to activate CD8+ T&#160;cells and induce pathogen-neutralizing antibodies. There are no approved products that utilize the arenavirus. Because our non-replicating and replicating technologies are novel, regulatory agencies may lack experience with product candidates such as HB-101, HB-201 and HB-202, which may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. We have not yet succeeded and may not succeed in demonstrating safety and efficacy for any of our product candidates in ongoing or late-stage clinical trials or in obtaining marketing approval thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our vectors are live, gene-modified organisms for which the FDA, the EMA and other comparable foreign regulatory authorities and other public health authorities, such as the Centers of Disease Control and Prevention and hospitals involved in clinical studies, have established additional safety and contagion rules and procedures, which could establish additional hurdles for the development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development, manufacturing or commercialization of our product candidates. We may also experience delays in transferring our process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Since the number of patients that we plan to dose in some of our planned clinical trials is small, the results from such clinical trials, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. In the Phase&#160;1 dose escalation portion of our Phase&#160;1/2 trial for HB-201, we expect to enroll two groups of 20 patients each and future trials for HB-201 or other product candidates may similarly enroll a small number of patients. The preliminary results of trials with smaller sample sizes, such as our Phase&#160;1/2 trial for HB-201, can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, making the trial results less reliable than trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials, we may not achieve a statistically significant result or the same level of statistical significance, if any, that would have been possible to achieve in a larger trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities, including IRBs, to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or other comparable foreign regulatory authorities. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug. Because of our dose escalation design for our clinical trials, undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If we do observe severe side effects in our clinical trials, our ongoing clinical trials may be halted or put on clinical hold prior to completion if there is an unacceptable safety risk for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA, the EMA or other comparable foreign regulatory authorities, or local regulatory authorities such as IRBs, could order us to cease clinical trials. Competent national health authorities, such as the FDA, could also deny approval of our product candidates for any or all targeted indications. Even if the side effects presented do not preclude the product from obtaining or maintaining marketing approval, treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates, if approved, to understand the side effect profile of these technologies for both our planned clinical trials and upon any commercialization of any product candidates, if approved. Inadequate training in recognizing or managing the potential side effects of our technologies could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before the manufacturing and infusion of our product candidates or trial completion; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current or potential pandemics that may limit patients, principal investigators or staff or clinical site availability (e.g. the COVID-19 pandemic).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates or similar areas, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for the treatment of infectious diseases and cancers, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic stem cell transplantation, rather than enroll patients in any future clinical trial. Additionally, because some of our clinical trials will be in patients with relapsed or refractory cancer, the patients are typically in the late stages of the disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the trial and requiring additional enrollment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these trials and adversely affect our ability to advance the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have limited experience as a company conducting clinical trials or managing a manufacturing facility for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited experience as a company in conducting clinical trials. In part because of this lack of experience, we cannot be certain that our ongoing clinical trial will be completed on time or if the planned clinical trials will begin or be completed on time, if at all. Largescale trials would require significant additional financial and management resources and reliance on third-party clinical investigators, contract research organizations (CROs), or consultants. Relying on third-party clinical investigators or CROs may force us to encounter delays that are outside of our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have our own manufacturing facility for the production of clinical trial material or future commercial products and therefore depend on third-party contract manufacturing organizations (CMOs) and their knowhow for production of our product candidates. Because of our limited control of our third-party manufacturers and in part because of our inexperience, our third-party manufacturers may fail to produce our product in a reliable and consistent manner and in sufficient quality and quantity. We have encountered problems with our third-party manufacturers in the past, including delays and low yields, and there can be no assurance that we will not encounter similar or other difficulties in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As we continue to progress our product candidates into and through clinical trials, we intend to operate our own manufacturing facility, which will require significant resources, and we have limited experience as a company in expanding or managing a manufacturing facility. In part because of this lack of experience, we cannot be certain that our manufacturing facility will be completed on time, if at all, or if the planned clinical trials will begin or be completed on time, if at all. In addition, if we switch from one manufacturing facility to our own manufacturing facility for one or more of our product candidates in the future, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Failure to successfully create and operate our proposed manufacturing facility could adversely affect the commercial viability of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for our oncology product candidates may be limited to those patients who are ineligible for or have failed prior treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cancer therapies are characterized as first line, second line, or third line, and the FDA often approves new therapies initially only for a particular line of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include hematopoietic stem cell transplantation in certain cancers, chemotherapy, antibody drugs, and small molecule tumor-targeted therapies, more invasive forms of surgery, and new revolutionary technologies. We expect to initially seek approval of our product candidates in most instances at least as a third line therapy, for use in patients with relapsed or refractory metastatic cancer. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved as a third or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If the market opportunities for our product candidates are smaller than we believe they are, even assuming approval of a drug candidate, our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our projections of both the number of people who have the infectious diseases and cancers we are targeting, as well as the subset of people with these infectious diseases and cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, commissioned reports, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates within our addressable patient population, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as first or second line therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of an arenavirus for the treatment of infectious diseases and tumors is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates, if approved, are accepted in the market, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of our product candidates over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects for virus-based therapeutic products, in particular, other prime-boost therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the labeling approved by the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our product candidates as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, although we are not utilizing fully replication competent live virus vectors, our replicating technology uses a replication attenuated vector and adverse publicity due to the ethical and social controversies surrounding the therapeutic use of such technologies, and reported side effects from any clinical trials using these technologies or the failure of such trials to demonstrate that these therapies are safe and effective may limit market acceptance of our product candidates. If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors or others in the medical community, we will not be able to generate significant revenue and we may not become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become subject to unfavorable pricing laws, regulations or third-party payor coverage and reimbursement policies, any of which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. These third-party payors decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford many types of treatments. Sales of these or other product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. See &#8220;Business &#8211; Reimbursement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the requirements governing drug pricing vary widely from country to country. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We cannot predict whether we will receive reimbursement from third-party payors for any product we may successfully commercialize in the future. Any reimbursement we may receive might not be adequate for use to generate significant revenue and we may not become profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are developing, and in the future may develop, other product candidates, in combination with other therapies, which exposes us to additional risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-201 and HB-202 product candidates are being developed to be used in combination with or without an approved checkpoint inhibitor, a currently approved cancer therapy. In the future, we may develop other product candidates to be used with one or more currently approved cancer therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also evaluate our future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Negative developments in the field of immuno-oncology and virus-based therapies could damage public perception of any of our product candidates and negatively affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The commercial success of product candidates based on our replicating technology will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in clinical trials of HB-201 or our other product candidates based on our replicating technology or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for any product candidates based on our replicating technology that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials. In addition, responses by national or state governments to negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, prospects and results of operations and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our product candidates consist of a modified virus. Adverse developments in clinical trials of other immunotherapy products based on viruses, like oncolytic viruses, may result in a disproportionately negative effect for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our non-replicating and replicating technologies as compared to other products in the field of infectious disease and immuno-oncology that are not based on viruses. Future negative developments in the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in our efforts to identify and successfully commercialize additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Part of our strategy involves identifying novel product candidates. We have developed a pipeline of product candidates and intend to pursue clinical development of additional product candidates utilizing our non-replicating and replicating technologies. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be effective in treating their targeted diseases or symptoms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully or economically.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Developing, obtaining regulatory approval for and commercializing additional product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you with any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may choose to focus our efforts on and allocate resources to a potential product candidate that ultimately proves to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we are unable to evaluate the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercial potential or target market for a particular product candidate, identify and successfully commercialize additional suitable product candidates, this would adversely impact our business strategy and our financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other products or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Specifically, we face significant competition in CMV management from companies such as Helocyte,&#160;Inc., VBI Vaccines,&#160;Inc., Moderna,&#160;Inc., SL VaxiGen,&#160;Inc., Merck&#160;&amp;&#160;Co., GlaxoSmithKline plc and Pfizer,&#160;Inc. In immuno-oncology for HPV16+ cancers, we face competition from companies such as Kite Pharma, a Gilead company, Advaxis,&#160;Inc., ISA Pharmaceuticals&#160;B.V., in collaboration with Regeneron Pharmaceuticals,&#160;Inc. and BioNtech AG. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. In addition, other immuno-oncology companies are developing the following technologies, including, but not limited to, neoantigens, bispecific antibodies, engineered cell therapies and tumor specific antigens in areas outside of CMV and HPV16+ cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to commercialize any product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reputational damage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants and inability to continue clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in our share price.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In the future, we may be unable to maintain this insurance coverage, or we may not be able to obtain additional or replacement insurance at a reasonable cost, if at all. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A variety of risks associated with operating our business internationally could materially adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we, and any potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign taxes, including withholding of payroll taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential liability under the Foreign Corrupt Practices Act of 1977 (FCPA), Office of Foreign Assets Control Anti-Money Laundering Program as required by the Bank Secrecy Act and its implementing regulations, or comparable foreign laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geo-political actions, including war and terrorism, as well as the developing conflict between Russia and Ukraine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These and other risks associated with our planned international operations may materially adversely affect our ability to attain or maintain profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Natural disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery or demand of products, which could negatively affect our operations and performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the risk of disruption by earthquakes, floods and other natural disasters, fire, power shortages, geopolitical unrest, war, terrorist attacks and other hostile acts, public health issues, epidemics or pandemics and other events beyond our control and the control of the third parties on which we depend. Any of these catastrophic events, whether in the United States, Europe or abroad, may have a strong negative impact on the global economy, our employees, facilities, partners, suppliers, distributors or customers, and could decrease demand for our products, create delays and inefficiencies in our supply chain and make it difficult or impossible for us to deliver products to our customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The ongoing effect of the COVID-19 pandemic, has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. This virus spread globally and in March&#160;2020 the World Health Organization declared COVID-19 a pandemic. The ongoing pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we have closed our executive offices with our administrative employees continuing their work outside of our offices, and limited the number of staff in any given research and development laboratory. As a result of the COVID-19 pandemic, we have experienced and we expect to continue to experience disruptions that could severely impact our business, preclinical studies and clinical trials, including: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued delays or difficulties in enrolling and retaining patients in our clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving authorizations from regulatory authorities to initiate our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk that we are unable to enroll participants in our clinical trials in adequate numbers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions in preclinical studies due to restricted or limited operations at our laboratory facility; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays to our sourced discovery and clinical activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.05pt;margin:0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.05pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.05pt;margin:0pt;">In addition, the FDA&#8217;s operations have been and may continue to be impacted by the ongoing COVID-19 pandemic. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.05pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.05pt;margin:0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The United Kingdom&#8217;s withdrawal from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe and/or the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.05pt;margin:0pt;">Pursuant to Article 50 of the Treaty on EU, the UK ceased being a Member State of the EU on January 31, 2020. There was a transitional period, during which EU laws, including pharmaceutical laws, continued to apply in the UK, however this ended on December 31, 2020. The UK reached a trade agreement with the European Union on December 24, 2020, which became provisionally applicable on January 1, 2021 and has been formally applicable since May 1, 2021. Under the terms of the deal, the EU and UK have separate regulatory regimes for pharmaceutical products, although there are some provisions for mutual recognition of standards, for example with regards to GMP. For instance, the UK is no longer covered by the centralized procedure for obtaining EU-wide marketing authorizations for medicinal products, and a separate process for authorization of medicinal products will be required in the UK, resulting in an authorization covering the UK or Great Britain (England, Scotland and Wales) only. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently broadly aligns with EU regulations, however it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.2pt;margin:0pt;"><span style="font-size:10.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.05pt;margin:0pt 10.8pt 0pt 0pt;">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom. It is possible that there will be increased regulatory complexities which can disrupt the timing of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 10.8pt 0pt 0pt;">clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.8pt;margin:0pt;"><span style="font-size:9.8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:23.05pt;margin:0pt 4.3pt 0pt 0pt;">In addition, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the European Union. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the European Union would have and how such withdrawal would affect us, and the full extent to which our business could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:23.05pt;margin:0pt 4.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of product candidates, securing related intellectual property rights and conducting discovery, research and development activities for our programs. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other biotechnology and pharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, there can be no assurance that we will be able to develop inhouse sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, umbrella, and directors&#8217; and officers&#8217; insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also expect that firming of the insurance market will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exchange rate fluctuations may materially affect our results of operations and financial conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the U.S. dollar and the euro, may adversely affect us. Although we are incorporated in Delaware in the United States, we have significant research and development operations in Austria, and source third-party manufacturing, consulting and other services in the European Union. As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are fully dependent on our collaboration with Gilead for the development of our hepatitis B virus programs, rely on funding from Gilead for development of our human immunodeficiency virus, and may depend on Gilead or additional third parties for the development and commercialization of our other programs and future product candidates. Our current and future collaborators may control aspects of our clinical trials, which could result in delays or other obstacles in the commercialization of the product candidates we develop. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2018, we entered into a research collaboration and license agreement, or the Original Collaboration Agreement, with Gilead, which was amended and restated in February&#160;2022, the Restated Collaboration Agreement. The Original Collaboration Agreement was entered into to evaluate potential vaccine products using or incorporating our Arenavirus technology platforms for the treatment, cure, diagnosis, or prevention of human immunodeficiency virus, or HIV, and hepatitis B virus, or HBV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Collaboration Agreement, among other things, allocated to us additional research and development responsibility with respect to our HIV candidate and provided for later stage development and commercial milestone payments. The Restated Collaboration Agreement involves a complex allocation of rights, provides for milestone payments to us based on the achievement of specified clinical development, regulatory and commercial milestones, and provides us with royalty-based revenue if certain product candidates are successfully commercialized. Gilead is solely responsible for the preclinical and clinical development of the HBV program. In connection with the Restated Collaboration Agreement, we entered into a Stock Purchase Agreement, the Stock Purchase Agreement, with Gilead. Pursuant to, and subject to the terms and conditions of, the Stock Purchase Agreement, Gilead will be required, at our option, to purchase up to $35,000,000 of our common stock, the proceeds of which we intend to use to fund additional research and development activities of our HIV program. Our lack of control over the clinical development of the HBV program under the Collaboration Agreement could result in delays or other difficulties in the development and commercialization of product candidates, which may prevent completion of intended investigational new drug applications in a timely fashion, if at all. Additionally, Gilead has the right to terminate the Restated Collaboration Agreement at any time for convenience. In the event Gilead terminates the Restated Collaboration Agreement, we would be prevented from receiving any milestone payments, royalty payments and other benefits under that agreement, as well as terminating our rights to future funding under the Stock Purchase Agreement with Gilead, any of which would have a materially adverse effect on our results of operations. We cannot provide any assurance with respect to the success of the Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the future, we may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current collaboration with Gilead poses, and potential future collaborations involving our product candidates may pose, the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, including technology we in-license, products that compete directly or indirectly with our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation, or other intellectual property proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may restrict our right to independently pursue new product candidates. For example, under the Collaboration Agreement, we are prohibited from, directly or indirectly, researching, developing, manufacturing or commercializing product candidates targeted to HIV or HBV; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated by the collaborator, and, if terminated, we may suffer reputational harm, find it more difficult to attract new collaborators and be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our other product candidates, which would harm our business prospects, financial condition, and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with additional biotechnology and pharmaceutical companies with respect to development and potential commercialization. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration that we have entered into or will enter into.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. For example, under the Collaboration Agreement, we have granted worldwide exclusive rights to Gilead for using our technologies to develop treatments for HBV, and during the term of the agreement we will be restricted from granting similar rights to other parties. This exclusivity could limit our ability to enter into strategic collaborations with future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations or do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We depend and will continue to depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs and strategic partners to conduct our preclinical studies and clinical trials under agreements with us. We expect to have to negotiate budgets and contracts with CROs, trial sites and CMOs which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. As a result, we have less direct control over the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under current good manufacturing practices (cGMP) regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely and continue to rely on third parties to manufacture our clinical product supplies, and we may rely on third parties for at least a portion of the manufacturing process of our product candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of clinical product supplies or product candidates or fail to do so at acceptable quality levels or prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture our product candidates. We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to do so for any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The manufacture of biological drug products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up or out, validating the production process and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including lot consistency, stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we do intend to develop our own manufacturing facility, we currently rely on third parties as part of our manufacturing process and may, in any event, never be successful in developing our own manufacturing facility. Our reliance on a limited number of third-party manufacturers exposes us to the following risks:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the production process for our product candidates is complex and requires specific know-how that only a limited number of CMOs can provide, as a result, we compete with other companies in the field for the scarce capacities of these organizations and may not be able to secure sufficient manufacturing capacity when needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA and comparable foreign regulatory authorities must inspect any manufacturers for cGMP compliance as part of our marketing application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a change in manufacturers or certain changes in manufacturing processes/procedures will require that we conduct a manufacturing comparability study to verify that any new manufacturer or manufacturing process/procedure will produce our product candidate according to the specifications previously submitted to the FDA or other regulatory authority, to which we may be unsuccessful; </span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may have little or no experience with viral vector products and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards, of which we do not have control over;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers could breach or terminate their agreements with us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available timely or may not be suitable or acceptable for use due to material or component defects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers and critical suppliers may be subject to inclement weather, as well as natural or man-made disasters; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, since the beginning of the COVID-19 pandemic, three vaccines for COVID-19 have received Emergency Use Authorization by the FDA and two of those later received marketing approval. Additional vaccines may be authorized or approved in the future. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the product candidates needed for our clinical trials which could lead to delays in these trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA and comparable foreign regulatory authorities, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA and comparable foreign regulatory authorities could place significant restrictions on our company until deficiencies are remedied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a (REMS) in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, the EMA or another comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for any such approved product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or our or our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">distributors&#8217;, licensees&#8217; or co-marketers&#8217; failure to comply with changes to regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning or untitled letters or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA, the EMA or other comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, refusal to permit the import or export of our product candidates, or request that we initiate a product recall;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties or monetary fines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s, the EMA&#8217;s and other comparable foreign regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of these events occurs, our ability to commercialize such product candidate may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, and may adversely affect our business model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or our collaborators, may receive for any approved products. See &#8220;Business &#8211; U.S. Healthcare Reform and other U.S. Healthcare Laws.&#8221; We cannot predict the initiatives that may be adopted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may adversely affect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for any of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to set a price that we believe is fair for any of our product candidates, if approved;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenues and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that we are required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical and biologic products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. Compliance with new requirements may increase our operational expenses and impose significant administrative burdens. As a result of these and other new proposals, we may need to change our current manner of operation, which could have a material adverse effect on our business, financial condition, and results of operations. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Legislative and regulatory proposals may also impact our regulatory and commercial prospects, expand post-approval requirements, and restrict sales and promotional activities. We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments, whether regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. Such future price controls or other changes in pricing regulation or negative publicity related to the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our future products, which would adversely affect our anticipated revenue and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device as a condition of approval for our product candidates. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our drug development strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success may depend, in part, on the development and commercialization of companion diagnostic tests to select patients for our drug candidates. If safe and effective use of any of our product candidates depends on an in vitro diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of obtaining or creating such diagnostic is time consuming and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take several&#160;years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting. We will be subject to additional obligations and regimes with respect to such companion diagnostic tests with regulators outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given our limited experience in developing and commercializing diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the medical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales, if any, of any product candidate for which we obtain approval and that requires a companion diagnostic test. In addition, any companion diagnostic collaborator or third party with whom we contract may decide not to commercialize or to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third party may otherwise terminate. We may not be able to enter into arrangements with another provider to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may pursue breakthrough therapy designation from the FDA for our product candidates but such designation may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may in the future seek breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For compounds that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. We cannot be sure that any evaluation we may make of our product candidates as qualifying for breakthrough therapy designation will meet the FDA&#8217;s expectations. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek Fast Track Designation by the FDA for a product candidate that we develop, and we may be unsuccessful. If we are successful, the designation may not actually lead to a faster development or regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may seek Fast Track Designation for the product candidates we develop. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, as we have for single-vector HB-201 and alternating 2-vector HB-202/HB-201, both in combination with pembrolizumab, for the treatment of first-line advanced/metastatic HPV16+ HNSCC, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek Orphan Drug Designation for product candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our business strategy, we may seek Orphan Drug Designation for any product candidates we develop, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similarly, in Europe, the European Commission grants orphan designation after receiving the opinion of the EMA Committee for Orphan Medicinal Products on an orphan designation application. Orphan designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting no more than 5 in 10,000 persons in the EU and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the product in the EU would be sufficient to justify the necessary investment in developing the product. In the EU, orphan designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, if a drug with an orphan designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan designation or if the drug is sufficiently profitable such that market exclusivity is no longer justified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different therapies can be approved for the same condition and the same therapies can be approved for different conditions but used off-label. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek Orphan Drug Designation for applicable indications for our current and any future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we do not currently have any products on the market, if we obtain FDA approval for our product candidates, and begin commercializing those products in the United States, our operations may be directly, or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Finally, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by comparable foreign regulatory authorities in jurisdictions in which we conduct our business that may affect our ability to operate. See &#8220;Business &#8211; U.S. Healthcare Reform and U.S. Healthcare Laws.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource- consuming and can divert a company&#8217;s attention from the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is generally not permitted in the countries that form part of the European Union. Some European Union Member States, and the United Kingdom, through the United Kingdom Bribery Act 2010, have enacted laws explicitly prohibiting the provision of these types of benefits and advantages. Infringements of these laws can result in substantial fines and imprisonment. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments made to physicians in certain European Union Member States (e.g., France or Belgium) must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the European Union Member State national laws, industry codes (e.g. the European Federation of Pharmaceutical Industries and Associations Disclosure and Healthcare Professionals Codes) or professional codes of conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of a product candidate in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval for that product candidate in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, in order to market and sell our drugs in the European Union and many other jurisdictions, we, and any collaborators we may have in the future, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for reimbursement before the drug can be approved for sale in that country. In some cases, the price that we intend to charge for our products is also subject to regulatory approval. We, and any collaborators we may have in the future, may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">European data collection and processing is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The collection, use, storage, disclosure, transfer or other processing of personal data, including personal health data regarding individuals in the European Economic Area is governed by the GDPR. The GDPR is wide ranging in scope and imposes several requirements on companies that process personal data, including requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Economic Area, including to the United States. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national data protection laws of the European Union Member States may result in fines and other administrative penalties, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater, for breach or non-compliance.  The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR regulations may impose additional responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with these and/or new data protection rules. This may be onerous and adversely affect our business, financial condition, prospects and results of operations. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to devise and maintain an adequate system of internal accounting controls. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice (DOJ) and the Securities and Exchange Commission, (SEC) is involved with enforcement of the books and records provisions of the FCPA and may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Recently the SEC and DOJ have increased their FCPA enforcement activities with respect to pharmaceutical companies. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (TCJA) that significantly reforms the Internal Revenue Code of 1986, as amended. The TCJA, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest expense; limitation of the deduction for net operating losses and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&#160;31, 2017 (though any such tax losses may be carried forward indefinitely); and modifying or repealing many business deductions and credits, including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#8220;orphan drugs&#8221;. We continue to examine the impact this tax reform legislation may have on our business in the future. However, the TCJA did not have an impact on us and our affiliates due to our loss making situation. You are urged to consult your tax adviser regarding the implications of the TCJA on an investment in our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to utilize our foreign net operating loss carryforwards may be limited by GILTI taxation introduced through the tax reform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred substantial losses during our operating history. We do not anticipate generating revenue from sales of products for the foreseeable future, if ever, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. The tax reform legislation introduced section&#160;951A, a new tax on so-called &#8220;global intangible low-taxed income,&#8221; or GILTI. GILTI applies to income of a controlled foreign corporation (CFC) that is not otherwise subpart&#160;F income. Our Austrian subsidiary falls under the category of a CFC and GILTI taxation may therefore apply when use of foreign net operating loss carryforwards reduce our foreign income tax to a low level. Tax benefits from the use of our foreign net operating loss carryforwards could be partially offset by U.S. GILTI taxation, which could have an adverse effect on our future results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, and, if we fail to comply with our obligations under these arrangements or resolve related disputes, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We license patents related to our non-replicating and replicating technologies and certain other intellectual property rights from third parties, including from the University of Geneva, the University of Basel and the University of Zurich and expect in the future to be party to other material license or collaboration agreements. These agreements typically impose numerous obligations, such as diligence and payment obligations, including in relation to revenues we may receive from any sublicenses we grant in respect of the licensed patents. If we fail to comply with our obligations under these agreements, our licensors may have the right to terminate our licenses, in which event we might not be able to develop, manufacture or market any product that is covered by the intellectual property we in-license from such licensor and may face other adverse consequences. These licenses do and future licenses may also include provisions that impose obligations and restrictions on us that could delay or otherwise negatively impact a transaction that we may wish to enter into.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Disputes may also arise between us and our licensors regarding the license agreements we have with them, including with respect to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proper interpretation of the license agreement terms, including with respect to our right to sublicense patent rights and any other intellectual property rights to third parties and the amount of fees owed to the licensors as a result of such sublicenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how created by us and our partners using a combination of our own intellectual property and that licensed from our licensors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If disputes arise that prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We rely upon a combination of patents, confidentiality agreements, trade secret protection and license agreements to protect the intellectual property related to our technologies. Such means may afford only limited protection of our intellectual property and may not: (i)&#160;prevent our competitors from duplicating our technology or product candidates; (ii)&#160;prevent our competitors from gaining access to our proprietary technology; or (iii)&#160;permit us to gain or maintain a competitive advantage. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by the third parties to which we grant access to such intellectual property, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. These third parties also may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property-related proceedings that could jeopardize or invalidate our proprietary information and intellectual property. Any disclosure to or misappropriation by third parties of our confidential proprietary information </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on our ability to obtain and maintain patent protection with respect to our non-replicating technology, including our HB-101 product candidate, obtain patent protection with respect to our replicating technology, including our HB-201, HB-202 and HB-300 product candidates, the vaccine product candidates we are developing with Gilead for HBV and HIV, and other proprietary product candidates. Although we own or license from others certain patent applications that cover the foregoing technologies and product candidates, we do not currently own or license from others issued patents covering all of the foregoing. Our reliance on patent applications carries certain risks associated with pending patent applications prior to the issuance of patents, as described below. If we do not adequately obtain and protect our intellectual property rights, competitors may be able to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our product candidates that are important to our business. The patent application and approval process is expensive and time-consuming and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if and when patents will issue from our patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and range of protection any patents that we obtain will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate litigation or administrative proceedings related to obtaining, protecting or enforcing our patents, which may be costly whether we win or lose.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the USPTO or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered patentable by courts in the United States or foreign countries. Certain of our issued patents and pending applications are method of use patents, which protect the use of a product for a specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may induce or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights may be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if patents do successfully issue from such applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. If our patents are rendered invalid or unenforceable, or narrowed in scope, the patent coverage afforded our products could be impaired. Such impairment could significantly impede our ability to market our products, negatively affect our competitive position and harm our business and operating results. In addition, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including significant commercial markets such as Europe, restrict the patentability of methods of treatment of the human body more than United States law does. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our patent protection. No assurances can be given that third parties will not create new products or methods that achieve similar </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">results without infringing upon patents we own. If these developments were to occur, it could have an adverse effect on our sales or market position. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Various post grant review proceedings, such as <i style="font-style:italic;">inter partes</i> review and post grant review, are available for any interested third party to challenge the patentability of claims issued in patents to us. These procedures are relatively new and can be unpredictable. It is also possible for third parties to file observations with various patent offices during the patent application process. In our European patent application directed to our non-replicating technology, an unknown third party submitted such an observation. Despite that submission, the European Patent Office proceeded to grant our patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and certain other development activities in the United States is not considered an act of infringement. If and when any of our another product candidates are approved by the FDA, a third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we are aware of certain third-party patents and applications that relate to similar subject matter as our technologies, we do not believe that any patent claims that could otherwise materially adversely affect commercialization of our product candidates, if approved, are valid and enforceable. We may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we are currently unaware which cover materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license, which may not be available on commercially reasonable terms, if at all, or until such patent expires or is determined to be invalid or unenforceable. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Presently we have rights to certain intellectual property, through licenses from third parties and under patent applications that we own or will own, related to HB-101, HB-201 and HB-202 and certain other product candidates. Because additional product candidates may require the use of proprietary rights held by third parties, such as the rights to use certain antigens, specific to future disease targets, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, while we have patent rights directed to certain non-replicating and replicating technologies we may not be able to obtain intellectual property to all uses of non-replicating and replicating technologies. Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. Similarly, efficient production or delivery of our product candidates may also require specific compositions or methods, and the rights to these may be owned by third parties. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. Even if we are able to obtain a license to use such intellectual property, it may be non-exclusive, which would not restrict the licensor party from giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">license replacement technology. Moreover, the specific antigens that will be used with our product candidates may be covered by the intellectual property rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-grant proceedings, including interference proceedings, provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patents or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not agree to a license on commercially reasonable terms or at all. Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that such patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, <i style="font-style:italic;">inter partes</i> review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidate. Such a loss of patent protection could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology or pharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States continues to adapt to wide-ranging patent reform legislation that became effective starting in 2012. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Furthermore, the specific content of patents and patent applications that are necessary to support and interpret patent scope is highly uncertain due to the complex nature of the relevant legal, scientific, and factual issues. Changes in either patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce our patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have less robust intellectual property rights in certain foreign jurisdictions and may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our key patent families have been filed in the United States, as well as in numerous jurisdictions outside the United States. However, our intellectual property rights in certain jurisdictions outside the United States may be less robust. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Most of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by an employee, consultant, or contractor, as applicable, in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. We may face claims by third parties that our agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. We may be subject to claims that former collaborators or other third parties have an ownership interest in our patents or other intellectual property, including our in-licensed patent rights. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. If we are unsuccessful, we could lose valuable rights in intellectual property that we regard as our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers or our consultants&#8217; or contractors&#8217; current or former clients or customers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees from their normal responsibilities. If we are not successful, in addition to paying monetary damages, we could lose access or exclusive access to valuable intellectual property and personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technologies, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pending patent applications that we own or license may not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents, should they issue, that we own or license, may not provide us with any competitive advantages, or may be challenged and held invalid or unenforceable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology but that is not covered by our owned or in-licensed patents, should any such patents issue;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our licensors, might not have been the first to make the inventions covered by a pending patent application that we own or license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our licensors, might not have been the first to file patent applications covering a particular invention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may assert an ownership interest in our intellectual property, including our in-licensed patent rights, and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop or in-license additional proprietary technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business and results of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employee Matters, Managing Our Growth and Other Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The contractual obligations of Daniel Pinschewer to the University of Basel may present conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Daniel Pinschewer, M.D., Founder and Chief Scientific Officer until March&#160;2020, who serves as our Scientific Advisor to the Chief Executive Officer, provided research services to us pursuant to a consulting agreement and will continue to do so upon execution of a new consultancy agreement. Dr.&#160;Pinschewer is also an employee of the University of Basel where he engages in, among other activities, academic research related to arenaviruses and our technology platform. Pursuant to a separate research service agreement with the University of Basel, the university provides us with on-going services with respect to our technologies, and employs the services of Dr.&#160;Pinschewer to perform some of these services. As an employee of the University of Basel, Dr.&#160;Pinschewer is subject to the university&#8217;s rules of conduct, such as confidentiality, academic objectivity and transparency of research with respect to his academic research. As a result of Dr.&#160;Pinschewer&#8217;s obligations to the University of Basel and his current role as our Scientific Advisor to the Chief Executive Officer, circumstances may arise that could create or appear to create conflicts of interest when, we, the University of Basel or Dr.&#160;Pinschewer are faced with decisions that could have different implications for the University of Basel and our company. Additionally, we would not automatically obtain rights to inventions that are developed by Dr.&#160;Pinschewer unless the inventions were made in the course of his consulting services to us. Furthermore, other research being conducted by the University of Basel may receive higher priority than research and services related to our technology platform. Any potential disagreement or dispute that may arise with the University of Basel relating to the ownership of Dr.&#160;Pinschewer&#8217;s inventions, conflicts of interest or otherwise may result in a delay or termination of the research, development or commercialization of our product candidates or may have other negative consequences for our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. Although we have formal employment agreements with our executive officers, any of our executive officers could leave our employment at any time, or within a contractual </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">termination period that is too short to find an adequate replacement. We currently do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. We primarily conduct our operations at our facility in Vienna, Austria. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To induce valuable employees to join and remain at our company, in addition to salary and cash incentives, we have provided, and intend to continue to provide, stock options that vest over time. The value of these equity grants that vest over time to our employees may be significantly affected by movements in the fair market value of our capital stock that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, many of our employees have become or will soon become vested in a substantial amount of our common stock or a number of common stock options. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accordingly, our future success depends on our ability to continue to attract and retain current and additional executive officers and other key employees. The inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations. Future growth would impose significant added responsibilities on members of management, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of some members of our management team in managing a public company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may also lead to significant costs. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including substantially all aspects of regulatory approval, clinical trial management and manufacturing. Our independent organizations, advisors and consultants may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Ownership of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">An active trading market for our common stock may not be sustainable, and you may not be able to resell your shares of our common stock at or above the purchase price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An active trading market for our shares may not be sustained. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. As a result of these and other factors, it may be difficult for our stockholders to resell their shares of our common stock at or above the prices at which they acquired their shares or sell their shares at the time they would like to sell. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our stock may be volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading price of our common stock could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment or results of the clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse developments concerning our manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to establish collaborations if needed;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated serious safety concerns related to the use of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products or services offered by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to effectively manage our growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our initial cancer target markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully treat additional types of cancers or at different stages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in quarterly operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overall performance of the equity markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ineffectiveness of our internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general political and economic conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which are beyond our control.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the stock market in general, and The Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities analysts publish negative evaluations of our stock, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock depends in part on the research and reports that securities analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our principal stockholders and management own a significant percentage of our stock and exert significant influence over matters subject to stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Class A common stock has no voting rights. As a result, all matters submitted to our stockholders are decided by the vote of holders of our common stock. Our executive officers, directors, and 5% stockholders beneficially own approximately 65% of our outstanding voting stock. These stockholders may be able to determine many matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sale of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock, and impair our ability to raise adequate capital through the sale of additional equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and, if approved, sales of our product candidates. These upfront and milestone payments may vary significantly from period to period and any variance could cause a significant fluctuation in our operating results from one period to the next.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcomes of clinical trials for our current and any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing our current and any future product candidates, which may vary depending on FDA guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to adequately support our future growth;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential unforeseen business disruptions that increase our costs or expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future accounting pronouncements or changes in our accounting policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the changing and volatile global economic environment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. The price of our common stock could decline even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we are no longer an emerging growth company, as defined in the JOBS Act, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will continue to need to hire additional accounting, finance, and other personnel in connection with our efforts to comply with the requirements of being, a public company and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We are continuously evaluating these rules and regulations which are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act (SOX Section 404) we are required to furnish a report by our management on our internal control over financial reporting with our Annual Report on Form 10-K with the SEC. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by SOX Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that special meetings of stockholders be called only by our board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement of approval of (i)&#160;not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action and (ii)&#160;the majority of the outstanding shares of our voting stock to amend specific provisions of our certificate of incorporation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws will designate the Court of Chancery of the State of Delaware, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, or other employees or stockholders arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, (iv)&#160;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws, or (v)&#160;any action asserting a claim against us or any of our current or former directors or officers or other employees that is governed by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation or amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of our initial public offering in April 2019, we became subject to the periodic reporting requirements of the Exchange Act. We are continuing to refine our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an &#8220;emerging growth company,&#8221; our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with our preparation and the audits of our financial statements as of and for the years ended December&#160;31,&#160;2017 and 2018, we and our independent registered public accounting firm identified material weaknesses as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States) in our internal control over financial reporting. We have implemented a variety of controls to remediate the material weaknesses identified which enabled us to broaden the scope and quality of our internal review of underlying information related to financial reporting and to enhance our internal control procedures. We believe that these efforts have remediated the material weaknesses, but we cannot assure that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Nasdaq Stock Market LLC, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">General Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the regulations of the FDA and other comparable foreign regulatory bodies, provide true, complete and accurate information to the FDA and other comparable foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee and other third-party misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve the use of potentially hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We could incur substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of changes to applicable laws and regulations and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of the development programs of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and these third parties rely extensively on information technology systems to conduct and manage our business. Despite the implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. The risk of a security breach or disruption, particularly through cyber attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store sensitive data, including, among other things, legally protected patient health information, personally identifiable information about our employees, intellectual property and proprietary business information. We manage and maintain our applications and data utilizing on-site systems and outsourced vendors. These applications and data encompass a wide variety of business critical information, including research and development information, commercial information and business and financial information. Because information systems, networks and other technologies are critical to many of our operating activities, shutdowns or service disruptions at our company or vendors that provide information systems, networks or other services to us pose increasing risks. Such disruptions may be caused by events such as computer hacking, phishing attacks, ransomware, dissemination of computer viruses, worms and other destructive or disruptive software, denial of service attacks and other malicious activity, as well as power outages, natural disasters (including extreme weather), terrorist attacks or other similar events. Such events could have an adverse impact on us and our business, including loss of data and damage to equipment and data. In addition, system redundancy may be ineffective or inadequate, and our disaster recovery planning may not be sufficient to cover all eventualities. If such events were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, such as the loss of clinical trial data from completed or future clinical trials. Such loss could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may not have adequate insurance coverage to compensate for any losses associated with such events. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Any breach in our information technology systems could lead to the unauthorized access, disclosure and use of non-public information, including information from our patient registry or other patient information, which is protected by HIPAA, and other laws. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, damage to our reputation and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. Damage or extended periods of interruption to our third-party collaborators&#8217;, including Gilead&#8217;s, corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause them to cease or delay development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company and our vendors, including personal information of our employees and patients, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems or those of our vendors or fraudulently induce our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">personnel or the personnel of our vendors to disclose sensitive information in order to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious codes and viruses, phishing and other cyber-attacks. The number and complexity of these threats continue to increase over time. If a material breach of our information technology systems or those of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those of our third-party contractors, or our consultants&#8217; efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, as amended (JOBS Act), enacted in April&#160;2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley Act), being permitted to present only two years of audited financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure, as well as reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the year in which we complete our initial public offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of our initial public offering in April&#160;2019, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700&#160;million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We are a smaller reporting company under Rule 12b-2 of the Exchange Act. For so long as we remain a smaller reporting company, we are permitted and plan to rely on exemptions from certain disclosure requirements, including reduced disclosure obligations regarding executive compensation. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company until our public float exceeds $250&#160;million or our annual revenues exceed $100&#160;million with a public float greater than $700 million.</span></p><a id="_7c627dc6_f152_4771_9d12_ffdbad23d613"></a><a id="UnresolvedStaffComments_377193"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1B.&#160;&#160;Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5aa2f6b4_c47b_4888_a2f9_282c01e60603"></a><a id="Properties_188239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 2.&#160;&#160;Properties</p><a id="_Hlk98840454"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our principal executive offices are located in New York, New York, pursuant to a lease that expires in February&#160;2024. Our European research and preclinical development operations are located in Vienna, Austria, where we lease and occupy approximately 30,656 square feet of office and laboratory space. Our first facility is leased pursuant to two operating leases, comprised of (i)&#160;a lease of unlimited duration for approximately 15,198&#160;square feet of office and laboratory space and (ii)&#160;a lease set to expire in September 2028 and with no option to extend for approximately 2,357&#160;square feet of storage space. In 2019, we entered into a lease for a second facility located in Vienna, Austria that is set to expire in February&#160;2029, where we occupy approximately&#160;15,440&#160;square feet of office and laboratory space. In May 2021 we purchased a parcel of land in the north of Vienna and have received building permission to build a GMP manufacturing plant of approximately 48,440 square feet. In December&#160;2018, we entered into a collaboration and manufacturing agreement which included embedded leases of manufacturing facilities which are located in Solna, Sweden, and expire in April 2022. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_80e279cc_3790_4dbb_a2e8_ca498f44a553"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II&#8212;OTHER INFORMATION</p><a id="LegalProceedings_351583"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In April&#160;2021, a third party opposed European Patent No.&#160;3218504, or the EP &#8217;504 Patent, which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to us. While the opposition was filed in the name and on behalf of Dr. Ursula Sprenzel, we believe that the real party in interest has not identified itself. The patent is directed to our replicating arenavirus platform technology and is part of our strategy to protect current product candidates based on this platform technology, including our lead oncology product candidates HB-201 and HB-202. We filed our formal response to the opposition with the European Patent Office (EPO) on September&#160;3,&#160;2021. It is expected that the EPO&#8217;s opposition division will issue a preliminary opinion in the next three months, and summons the parties to oral proceedings within the next six to nine months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2fdea600_9324_41c9_ae9d_5fc5198cb33b"></a><a id="MineSafetyDisclosures_997431"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;Mine Safety Disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f347ba63_453a_45a8_a462_33abd1135645"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="MarketforRegistrantsCommon_947933"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5.&#160;&#160;Market for Registrant&#39;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity</b><b style="font-weight:bold;"> Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Certain Information Regarding the Trading of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock trades under the symbol &#8220;HOOK&#8221; on The Nasdaq Global Select Market and has been publicly traded since April&#160;18,&#160;2019. Prior to this time, there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of March&#160;4,&#160;2022, there were approximately four holders of record of shares of our common stock, which does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name, and two holders of record of shares of our Class A common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part II of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_1b567e26_e684_4839_aa6e_4c3014b8c700"></a><a id="SelectedFinancialData_379980"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 6.&#160;&#160;Selected Financial Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Reserved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ccdd4b78_1f18_40ec_b7be_82ad6eab5449"></a><a id="ManagementsDiscussionandAnalysis_660301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;Management&#8217;s Discussion&#160;and&#160;Analysis&#160;of&#160;Financial&#160;Condition&#160;and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><a id="_Hlk64378034"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify a T&#160;cell and immune response to disease. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T&#160;cell responses and pathogen-neutralizing antibodies. We believe that our technologies can meaningfully leverage the human </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">immune system for prophylactic and therapeutic purposes by inducing CD8+ T&#160;cell response levels previously not achieved by other immunotherapy approaches. </p><a id="_Hlk64378634"></a><a id="_Hlk64378441"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and next-generation antigens. Our oncology portfolio includes three disclosed programs, HB-200, HB-300 and HB-700, which all use our replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in an ongoing Phase&#160;1/2 clinical trial. HB-300 is in development for the treatment of prostate cancer and expected to move into the clinic after the third quarter 2022 investigational new drug application filing. HB-700 is our newest asset in preclinical development for treatment of KRAS mutated cancers, including, lung, colorectal and pancreatic cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-200 program is comprised of HB-201 single vector therapy and HB-201/HB-202 two vector therapy. Both therapies are being evaluated in an ongoing HB-200 Phase&#160;1/2 study. In November&#160;2021, we announced interim data on our ongoing Phase&#160;1 portion of the study, showing promising anti-tumor activity against advanced/metastatic HPV16+ cancers and favorable tolerability. Data demonstrated responses and stable disease in head and neck cancer patients who failed prior standard of care therapy. We believe that these early-stage data establish proof of concept for our replicating single-vector immunotherapy in oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2022, we dosed the first patient with a combination of HB-201 and pembrolizumab for the treatment of first line advanced/metastatic HPV16+ HNSCC in the Phase&#160;2 expansion portion of the ongoing Phase&#160;1/2 trial. In September 2021, we entered into a clinical collaboration with Merck &amp; Co., Inc. to evaluate the combination of HB-200 and Merck &amp; Co., Inc&#8217;s anti-PD-1 therapy, KEYTRUDA&#174; (pembrolizumab) in a separate randomized Phase&#160;2 study.</p><a id="_Hlk64379414"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our non-replicating prophylactic Cytomegalovirus, or CMV, vaccine candidate, HB-101, is a potential first in-class compound in a Phase&#160;2 clinical trial for patients awaiting kidney transplantation. In November&#160;2021, we reported safety, immunogenicity and efficacy data, whereby the three-dose schedule of HB-101 pre-transplantation showed a trend of reducing incidence of CMV viremia and antiviral use. The trial will continue to follow patients currently on-study with final top-line data readout in the first half of 2023. We have decided to pursue HB-101 further only if we are able to partner the program with a collaborator, thereby enabling greater strategic focus on the immuno-oncology programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have funded our operations to date primarily from private placements of our redeemable convertible preferred stock, with aggregate gross proceeds of approximately $142.5&#160;million, grant funding and loans from an Austrian government agency, and $26.2&#160;million in upfront and milestone payments from Gilead in connection with a research collaboration and license agreement. On April&#160;23,&#160;2019, we completed an initial public offering of our common stock (IPO) in which we issued 6.0&#160;million shares of our common stock, at $14.00 per share, for gross proceeds of $84.0&#160;million, or net proceeds of $74.6&#160;million. On December&#160;11,&#160;2020, we completed a follow-on public offering in which we issued 3.9&#160;million shares of our common stock, at $11.75 per share, and 2,978&#160;shares of our Series&#160;A convertible preferred stock, at $11,750.00 per share, for net proceeds of $75.0&#160;million after deducting underwriting discounts and commissions and offering expenses. As of December&#160;31,&#160;2021, the principal amount outstanding under loans from government agencies was $6.1&#160;million and we had cash, cash equivalents and restricted cash of $66.9&#160;million. In February&#160;2022 we received a $15.0&#160;million initiation fee in connection with Restated Collaboration Agreement with Gilead. In addition, Gilead purchased unregistered shares of our common stock for $5.0&#160;million. In March&#160;2022, we issued and sold 21,700,000&#160;shares of our common stock at $2.00&#160;per share, and 15,800&#160;shares of our Series A-1&#160;convertible preferred stock at $2,000.00&#160;per share in a follow-on public offering resulting in net proceeds of approximately $70.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not expect to generate revenue from any product candidates that we develop until we obtain regulatory approval for one or more of such product candidates, if at all, and commercialize our products or enter into additional collaboration agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk64379547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of our product candidates, including our most advanced oncology product candidate, HB-200, will require substantial additional development time and resources before we would be able to apply for and receive regulatory approvals and begin generating revenue from product sales. Before launching our first products, if approved, we plan to establish our own manufacturing facility to reduce or eliminate our reliance on contract manufacturing organizations (CMOs) which will require substantial capital expenditures and cause additional operating expenses. We currently have no marketing and sales organization and have no experience in marketing products; accordingly, we will incur significant expenses to develop a marketing organization and sales force in advance of generating any commercial product sales. As a result, we will need substantial additional capital to support our operating activities. In addition, we expect to continue to incur legal, accounting and other expenses in operating our business, including the costs associated with operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently anticipate that we will seek to fund our operations through equity or debt financings or other sources, such as government grants and additional collaboration agreements with third parties. Adequate funding may not be available to us on acceptable terms, or at all. If sufficient funds on acceptable terms are not available when needed, we will be required to significantly reduce our operating expenses and delay, reduce the scope of, or eliminate one or more of our development programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses each&#160;year since our inception in 2011, including net losses of $75.7&#160;million for the year ended December&#160;31,&#160;2021 and $44.1&#160;million for the year ended December&#160;31,&#160;2020. As of December&#160;31,&#160;2021, we had an accumulated deficit of $222.8&#160;million and we do not expect positive cash flows from operations in the foreseeable future, if ever. We expect to continue to incur net operating losses for at least the next several&#160;years as we advance our product candidates through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest to establish a commercial manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that the net proceeds from our offering in March&#160;2022, the funds received under Restated Collaboration Agreement with Gilead, both described below, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements at least through the next 12&#160;months from the issuance date of the consolidated financial statement. See &#8220;&#8212;Liquidity and Capital Resources.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Special Note About Coronavirus (COVID-19)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, we announced initial potential business impacts related to the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome 2), or coronavirus, which causes coronavirus disease, or COVID-19. As a result of the ongoing COVID-19 pandemic, we have experienced, and may further experience, disruptions that have and could further adversely impact our business operations as well as our preclinical studies and clinical trials. Specifically, nearly all of the Phase&#160;2 trial sites we utilize for our HB-101 Phase&#160;2 trial had temporarily suspended enrollment of patients, resumed patient enrollment, but suspended enrollment again during periods of increased confirmed infections in the United States and Europe. As a result, the total number of patients in the trial at the conclusion of enrollment in June 2021 was below the originally planned number of patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, certain aspects of our supply chain were temporarily impacted as certain of our third-party suppliers and manufacturers had paused their operations in response to the COVID-19 pandemic or had otherwise encountered delays in providing their services. The uncertainties resulting from the COVID-19 pandemic have led us to temporarily focus on our core program, HB-200, as well as research and development activities under our collaboration with Gilead. Certain earlier stage programs, including HB-300 were temporarily de-prioritized only allocated the resources that could be made available without impacting our core programs. While we have resumed activities for these earlier stage programs in 2021, we continue to evaluate the extent to which potential constraints of our third-party suppliers and manufacturers will impact our ability to manufacture our product candidates for our clinical trials and conduct other research and development operations and maintain applicable timelines. The ultimate impact of the coronavirus pandemic on our business operations as well as our preclinical studies and clinical trials remains uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. We will continue to monitor the situation closely.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, in order to preserve resources and liquidity, all of our officers had waived at least 25% of their cash salaries for the three months ended June&#160;30,&#160;2020, and the vast majority of our employees agreed to a temporary salary reduction of 20% for the three months ended June&#160;30,&#160;2020. We compensated our officers and employees for the forgone cash salaries by issuing restricted stock units in July&#160;2020. Our directors have also accepted to receive equity instead of cash for their accrued board fees. We encourage our staff to work from home where possible, and encourage our Vienna employees to make use of the readily-available PCR testing in order to enhance health and safety, in particular for laboratory work that has to be performed on site. Since October&#160;2021 we have required our employees to be either fully vaccinated, cured from a COVID-19 infection or to have obtained a negative PCR-test to enter our offices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue from collaboration and licensing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue from product sales and do not expect to do so in the near future, if at all. All of our revenue to date has been derived from a research collaboration and license agreement with Gilead.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;4,&#160;2018, we entered into a Research Collaboration and License Agreement, or the Collaboration Agreement, with Gilead to evaluate potential vaccine products using or incorporating our replicating technology and non-replicating technology for the treatment, cure, diagnosis or prevention of HBV and HIV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Collaboration Agreement, we granted Gilead an exclusive, royalty-bearing license to our technology platform for researching, developing, manufacturing and commercializing products for HIV or HBV. We received a non-refundable $10.0&#160;million upfront payment upon entering the Collaboration Agreement. In February 2022, we signed an amended and restated collaboration agreement, the Restated Collaboration Agreement, which revised the terms only for the HIV program, whereby we will take on development responsibilities for the HIV program candidate through a Phase 1b clinical trial. Pursuant to the Restated Collaboration Agreement, Gilead will retain an exclusive right, the Option, to take back the rights for the HIV program, including further development and commercialization in return for an option exercise payment of $10.0 million. Pursuant to the Restated Collaboration Agreement, we are eligible for up to $140.0 million in developmental milestone payments for the HBV program and $50.0 million in commercialization milestone payments. If Gilead exercises the Option, we are eligible for up to $167.5 million in developmental milestone payments for the HIV program, inclusive of the $10.0 million Option exercise payment, and $65.0 million in commercialization milestone payments for the HIV program. Upon the commercialization of a product, we are eligible to receive tiered royalties of a high single-digit to mid-teens percentage on the worldwide net sales of each HBV product, and royalties of a mid-single-digit to 10% of worldwide net sales of each HIV product. Gilead is obligated to reimburse us for our costs, including all benefits, travel, overhead, and any other expenses, relating to performing research and development activities under the Restated Collaboration Agreement with respect to the HBV program, and if the Option is exercised, the HIV program. Through to December&#160;31,&#160;2021, we have received from Gilead the non-refundable upfront payment of $10.0&#160;million and $12.2&#160;million in milestone payments for the achievement of pre-clinical research milestones. In addition, we have recognized $35.6&#160;million of cost reimbursements for research and development services performed under the Collaboration Agreement. In the first quarter of 2022, we received an additional milestone payment of $4.0&#160;million and the initiation payment of $15.0&#160;million due upon execution of the Restated Collaboration Agreement to fund our future performance of development activities under the Restated Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We determined that our performance obligations under the terms of the Restated Collaboration Agreement included one combined performance obligation for each of the HBV and HIV research programs, comprised of the transfer of intellectual property rights and providing research and development services. Accordingly, we recognize these amounts as revenue over the performance period of the respective services on a&#160;percent of completion basis using total estimated research and development labor hours for each of the performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating expenses since inception have only consisted of research and development costs and general administrative costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have focused significant resources on our research and development activities, including establishing our arenavirus platform, conducting preclinical studies, developing a manufacturing process, conducting a Phase&#160;1 clinical trial and the ongoing Phase&#160;2 clinical trial for HB-101 as well as initiating a Phase&#160;1/2 trial for HB-201 and preparing an investigational new drug, or IND, application for HB-202. Research and development activities account for a significant portion of our operating expenses. Research and development costs are expensed as incurred. These costs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations (CROs);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing drug products for use in clinical trials, including under agreements with third parties, such as CMOs, consultants and contractors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laboratory costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The majority of our research and development costs are external costs, which we track on a program-by-program basis. We do not track our internal research and development expenses on a program-by-program basis as they primarily relate to shared costs deployed across multiple projects under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses to increase substantially in the future as we advance our existing and future product candidates into and through clinical trials and pursue regulatory approval. The process of conducting the necessary clinical studies to obtain regulatory approval is costly and time-consuming. Clinical trials generally become larger and more costly to conduct as they advance into later stages and, in the future, we will be required to make estimates for expense accruals related to clinical trial expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any product candidates that we develop from our programs. We are also unable to predict when, if ever, material net cash inflows will commence from sales of product candidates we develop, if at all. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of INDs for our planned clinical trials or future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful data from our clinical program that support an acceptable risk-benefit profile of our product candidates in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing our own manufacturing capabilities or agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidate is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entry into collaborations to further the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully launching commercial sales of our product candidates, if and when approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product candidates benefits and uses, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events experienced with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the product candidates following approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">qualifying for, maintaining, enforcing and defending intellectual property rights and claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our general and administrative expenses consist primarily of personnel costs in our executive, finance and investor relations, business development and administrative functions. Other general and administrative expenses include consulting fees and professional service fees for auditing, tax and legal services, lease expenses related to our offices, premiums for directors and officers liability insurance, depreciation and other costs. We expect our general and administrative expenses to continue to increase in the future as we expand our operating activities and prepare for potential commercialization of our current and future product candidates, increase our headcount and investor relations activities and maintain compliance with requirements of the Nasdaq Global Select Market and the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><a id="_Hlk64379675"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since inception, we have received grants from the Austrian Research Promotions Agency, either under funding agreements or under research incentive programs. In addition, we have received loans under funding agreements that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">bear interest at below market interest rate. We account for the grants received as other income and for the imputed benefits arising from the difference between a market rate of interest and the rate of interest as additional grant income, and record interest expense for the loans at a market rate of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We participate in a research incentive program provided by the Austrian government under which we are entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense results primarily from loans under funding agreements with the Austrian Research Promotion Agency, recorded at a market rate of interest. The difference between interest payments payable pursuant to the loans, which rates are at below market interest rates, and the market interest rate, is accounted for as grant income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income tax expense results from foreign minimum income tax and profit on a legal entity basis. The losses that we have incurred since inception result primary from the losses of our Austrian subsidiary. As of December&#160;31,&#160;2021, we had a deferred tax asset of $58.8&#160;million primarily resulting from foreign net operating loss carryforwards of $219.7&#160;million with no expiry date. We have considered that, at this point in time, it is uncertain whether we will ever be able to realize the benefits of the deferred tax asset, and accordingly, have established a full valuation allowance as of December&#160;31,&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of Years Ended December&#160;31,&#160;2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes our results of operations for the years ended December&#160;31,&#160;2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Revenue from collaboration and licensing </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 18,448</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 19,584</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Operating expenses:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Research and development </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (82,853)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (54,787)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">General and administrative </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (17,269)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (18,082)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="color:#231f20;">Total operating expenses </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (100,122)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (72,869)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Loss from operations </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (81,674)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (53,285)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Other income (expense):</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Grant income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 9,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 6,517</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Interest income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 400</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Interest expense </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (898)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (786)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Other income and expenses, net </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (2,843)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 3,072</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="color:#231f20;">Total other income (expense), net </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 6,010</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 9,203</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net loss before tax </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (75,664)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (44,082)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Income tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (0)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (75,665)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (44,082)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue from Collaboration and Licensing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue was $18.4&#160;million for the year ended December&#160;31,&#160;2021, compared to $19.6&#160;million for the year ended December&#160;31,&#160;2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decrease of $1.2&#160;million for the year ended December&#160;31,&#160;2021 compared to the year ended December&#160;31,&#160;2020 was due to lower revenue from research milestones, and lower recognition of deferred revenue related to upfront and milestone payments, partially offset by higher cost reimbursements received under the Restated Collaboration Agreement with Gilead.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December&#160;31,&#160;2021, revenue included $16.3&#160;million from reimbursement of research and development expenses, $0.6&#160;million from partial recognition of deferred revenue related to the upfront payment of $10.0&#160;million that we received in June&#160;2018 and $1.5&#160;million from partial recognition of the $4.0 million milestone payment that we received in 2020. In the year ended December&#160;31,&#160;2021 we completed the recognition of the deferred revenue related to the upfront payment of $10.0&#160;million that we received in June&#160;2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December&#160;31,&#160;2020, revenue included $13.0&#160;million from reimbursement of research and development expenses, $2.0&#160;million from partial recognition of deferred revenue related to the upfront payment of $10.0&#160;million that we received in June&#160;2018 and $2.4&#160;million from partial recognition of the $4.0&#160;million milestone payment that we received in February&#160;2020, as well as $2.2&#160;million of revenue that was recognized upon the achievement of research milestones in June and December 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December&#160;31,&#160;2021, our research and development expenses were $82.9&#160;million, compared to $54.8&#160;million, for the year ended December&#160;31,&#160;2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The increase of $28.1&#160;million for the year ended December&#160;31,&#160;2021 compared to the year ended December&#160;31,&#160;2020 was due to an increase in direct research and development expenses of $21.2&#160;million, and an increase in internal research and development expenses of $6.9&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The primary drivers of the increase in direct research and development expenses for the year ended December&#160;31,&#160;2021 compared to the year ended December&#160;31,&#160;2020 were an increase in manufacturing and quality control expenses of $9.9&#160;million, an increase in clinical study expenses of $3.2&#160;million, along with an increase in other direct expenses and laboratory expenses of $8.1&#160;million. The increase was mainly due to the progress in the clinical trial of our HB-200 program, particularly, the increased patient recruitment and related clinical trial monitoring and testing activities, as well as manufacturing and quality control work in preparation of a further extension of the trial. Manufacturing and quality control expenses were also driven by the progress towards clinical development in our Gilead partnered programs and other preclinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The increase in internal research and development expenses for the year ended December&#160;31,&#160;2021 compared to the year ended December&#160;31,&#160;2020 was primarily due to an increase in personnel expenses by $4.4&#160;million, and an increase in facility related and other internal research and development expenses by $2.5&#160;million. The increase in personnel-related research and development expenses resulted primarily from our increased research and development </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">headcount and an increase in stock compensation expenses. Other internal research and development costs and facility related costs also increased as a result of our expansion of research and development activities and headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses by product candidate or program (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct research and development expenses by program:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">HB-101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,583</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,020</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">HB-201/202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,563</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,162</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gilead partnered programs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,736</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,129</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other and earlier-stage programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,905</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,298</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Sub-total direct expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,787</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,609</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Internal research and development expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel related (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,251</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,833</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Facility related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,728</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,224</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other internal costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,087</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,121</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Sub-total internal expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,066</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,178</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,853</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,787</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Expenses incurred by us in connection with Gilead partnered programs are reimbursed to us by Gilead and accounted for as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the year ended December&#160;31,&#160;2021 were $17.3&#160;million, compared to $18.1&#160;million for the year ended December&#160;31,&#160;2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decrease of $0.8&#160;million was primarily due to a decrease in personnel-related expenses of $0.4&#160;million, and a decrease in other general and administrative expenses of $0.6&#160;million, partially offset by an increase in professional and consulting fees of $0.2&#160;million. The decrease in personnel-related expenses resulted from decreased stock compensation expenses, partially offset by a growth in headcount along with increased salaries in our general and administrative functions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2021 we recorded grant income of $9.7&#160;million, compared to $6.5&#160;million in the year ended December&#160;31,&#160;2020 from grants, research incentives and imputed benefits from below market interest rates on loans from governmental agencies. The increase of $3.2&#160;million was primarily due to higher income from Austrian research and development incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income and Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income was less than $0.1&#160;million for the year ended December&#160;31,&#160;2021, compared to $0.4&#160;million for the year ended December&#160;31,&#160;2020. This decrease of $0.3&#160;million, despite higher cash balances over almost the entire year, was due to the drop in interest rates in the United States and Europe. Interest income represents interest from cash and cash equivalents held in US dollars resulting from the proceeds from the issuance of common and preferred stock as well as payments received under our Collaboration Agreement with Gilead. During the year ended December&#160;31,&#160;2021 our cash, cash equivalents and restricted cash were mainly held in dollars at U.S. investment grade financial institutions or in money market funds. In addition, smaller amounts were held in euros at our Austrian subsidiary that produced no material interest income due to the low or zero interest rate policy in the European Monetary Union.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expenses for loans from government agencies were $0.9&#160;million for the year ended December&#160;31,&#160;2021, compared to $0.8&#160;million for the year ended December&#160;31,&#160;2020. Interest expense was recorded at the market rate of interest, which exceeded the contractual interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income and Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other expenses were $2.8&#160;million for the year ended December&#160;31,&#160;2021, compared to other income of $3.1&#160;million for the year ended December&#160;31,&#160;2020. The decrease of $5.9&#160;million in the year ended December&#160;31,&#160;2021 resulted primarily from exchange rate differences and foreign currency remeasurements. In addition the prior year effect from the recognition of $0.2&#160;million in support under the Corona Short Term Work Program in Austria contributed to the decrease in other income and expenses in the year ended December&#160;31,&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Discussion of the year ended December&#160;31,&#160;2020 compared with the year ended December&#160;31,&#160;2019 is included in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2020 filed with the SEC on March&#160;18,&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2011, we have funded our operations primarily through private placements of our convertible preferred stock and proceeds from our IPO and follow-on public offering, from grants, research incentives and borrowings under various agreements with public funding agencies, and from an upfront payment, milestone payments and reimbursement of research and development expenses pursuant to the Restated Collaboration Agreement with Gilead. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have raised gross proceeds of approximately $142.5&#160;million from the issuance of our convertible preferred stock and $26.2&#160;million from non-refundable upfront and milestone payments pursuant to the Restated Collaboration Agreement with Gilead of which we received $4.0&#160;million in January&#160;2022. In April 2019, we completed our IPO in which we issued and sold 6,000,000&#160;shares of our common stock, at $14.00 per share, for gross proceeds of $84.0&#160;million, or net proceeds of $74.6&#160;million. On December&#160;11,&#160;2020, we completed a follow-on public offering in which we issued 3,910,000&#160;shares of our common stock, at $11.75 per share, and 2,978&#160;shares of our Series&#160;A convertible preferred stock, at $11,750.00 per share, for net proceeds of $75.0&#160;million after deducting underwriting discounts and commissions and offering expenses. As of December&#160;31,&#160;2021, the principal amount outstanding under loans from government agencies was $6.1&#160;million and we had cash, cash equivalents and restricted cash of $66.9&#160;million. In February&#160;2022 we received a $15.0&#160;million initiation fee in connection with the amended and restated collaboration agreement with Gilead. In addition, Gilead purchased unregistered shares of our common stock for $5.0&#160;million. In March&#160;2022, we issued and sold 21,700,000&#160;shares of our common stock at $2.00 per share, and 15,800&#160;shares of our Series&#160;A-1 convertible preferred stock at $2,000.00 per share in a follow-on public offering resulting in net proceeds of approximately $70.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We entered into various funding agreements with the Austrian Research Promotion Agency (&#214;sterreichische Forschungsf&#246;rderungsgesellschaft, or FFG). The loans by FFG, or the FFG Loans, were made on a project-by-project basis and bear interest at a rate of 0.75%&#160;per annum. In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG and converted to non-repayable grant funding on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of our assets. The debt obligation is $6.1 million, principal repayments are due as follows: $3.1&#160;million are due in 2022, $1.8&#160;million are due in 2023, and the remaining $1.2&#160;million are due upon final maturity in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because the FFG Loans bear interest at below market rates we account for the imputed benefit arising from the difference between an estimated market rate of interest and the contractual interest rate as grant funding from FFG, which is included in grant income. On the date that FFG Loan proceeds are received, we recognize the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income. As of December&#160;31,&#160;2021, the unamortized debt discount related to FFG Loans was $1.1&#160;million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We entered into arrangements with contract manufacturing organizations. As of December&#160;31,&#160;2021, we had total non-cancellable obligations under such contracts of $10.5&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not expect positive cash flows from operations in the foreseeable future, if at all. Historically, we have incurred operating losses as a result of ongoing efforts to develop our arenavirus technology platform and our product candidates, including conducting ongoing research and development, preclinical studies, clinical trials, providing general and administrative support for these operations and developing our intellectual property portfolio. We expect to continue to incur net operating losses for at least the next several&#160;years as we progress clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization of our most advanced oncology product candidate HB-200, continue our research and development efforts relating to our other and future product candidates, and invest in our manufacturing capabilities and our own manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have no products approved for commercial sale. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our product candidates. As a result, we are not profitable and have incurred losses in each period since our inception in 2011. As of December&#160;31,&#160;2021, we had an accumulated deficit of $222.8&#160;million. We expect to continue to incur significant losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue the clinical and preclinical development of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage our technologies to advance product candidates into preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract, hire and retain additional clinical, quality control and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other product candidates and technologies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting and other expenses in operating our business, including ongoing costs associated with operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing and a failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our non-replicating and replicating technologies and our product candidates derived from these technologies. Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs as well as any future product candidates we may choose to pursue, as well as the gradual gaining of control over our required manufacturing capabilities and other corporate uses. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the stability, scale and yields of our future manufacturing process as we scale-up production and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining regulatory and marketing approvals and developing our ability to establish sales and marketing capabilities, if any, for our current and future product candidates we develop if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our collaboration with Gilead;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of commercialization activities for our current and future product candidates that we may develop, whether alone or with a collaborator;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing oncology and infectious disease therapies and other adverse market developments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will need additional funds to meet operational needs and capital requirements associated with such operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements as well as grant funding. Based on our research and development plans, we expect that our existing cash and cash equivalents, including the funds we received from our offering in March&#160;2022 and the funds received under the amended and restated research collaboration and license Agreement with Gilead, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12&#160;months. These estimates are based on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, the ownership interest of our shareholders will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to obtain additional funding on favorable terms when needed, we may have to delay, reduce the scope of or terminate one or more of our research and development programs or clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of the primary sources and uses of cash (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (66,016)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39,339)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,581)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,371)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (235)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 73,420</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (78,832)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,710</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2021, cash used in operating activities was $66.0&#160;million, which consisted of a net loss of $75.7&#160;million, adjusted by non-cash charges of $13.6&#160;million and cash used due to changes in our operating assets and liabilities of $3.9&#160;million. The non-cash charges consisted primarily of stock-based compensation of $7.6&#160;million, depreciation and amortization expense of $4.7&#160;million, and other non-cash items of $1.3&#160;million. The change in our operating assets and liabilities was primarily due to an increase in prepaid expenses and other current assets of $7.1&#160;million, an increase in accounts receivable of $1.9&#160;million, a decrease in operating lease liabilities of $1.6&#160;million, a decrease in other non-current liabilities of $0.4&#160;million, and an increase in receivable research incentives of $0.3&#160;million, partially offset by an increase in accrued expenses and other current liabilities of $4.8&#160;million, an increase of deferred revenues of $1.4&#160;million, an increase in accounts payable of $0.9&#160;million, and a decrease in other non-current assets of $0.4&#160;million. Changes in prepaid expenses and other current assets, accounts receivable, accounts payable, and other non-current assets in the year ended December&#160;31,&#160;2021 were generally due to growth in our business, the advancement of our research programs and the timing of invoicing and payments. Changes in operating lease liabilities in the year ended December&#160;31,&#160;2021 were mainly due to regular lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended December&#160;31,&#160;2020, cash used in operating activities was $39.3&#160;million, which consisted of a net loss of $44.1&#160;million, adjusted by non-cash charges of $12.9&#160;million and changes in our operating assets and liabilities of $8.1&#160;million. The non-cash charges consisted of stock-based compensation of $8.7&#160;million, depreciation and amortization expense of $4.1&#160;million, and other non-cash items of $0.1&#160;million. The change in our operating assets and liabilities was primarily due to an increase in receivable research incentives of $5.8&#160;million, an increase in accounts receivable of $3.6&#160;million, an increase in prepaid expenses and other current assets of $2.3&#160;million, a decrease in operating lease liabilities of $1.8&#160;million, an increase in other non-current assets of $1.1&#160;million, a decrease of accrued </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">expenses and other current liabilities of $0.2&#160;million and a decrease in other non-current liabilities of $0.1&#160;million, partially offset by an increase in accounts payable of $6.3&#160;million and an increase of deferred revenues of $0.5&#160;million. Changes in prepaid expenses and other current assets, accounts payable, accounts receivables and other non-current assets in the year ended December&#160;31,&#160;2020 were generally due to growth in our business, the advancement of our research programs and the timing of invoicing and payments. Changes in operating lease liabilities in the year ended December&#160;31,&#160;2020 were mainly due to regular lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2021 and 2020, cash used in investing activities was $12.6&#160;million and $2.4&#160;million, respectively. The increase of $10.2&#160;million compared to the year ended December&#160;31,&#160;2020 resulted from the acquisition of land and capital expenditures in connection with our own GMP manufacturing facility project and was partially offset by lower expenditures for laboratory and office space extension and purchase of equipment. Cash used in investing activities in the year ended December&#160;31,&#160;2020 resulted from capital expenditures in connection with leasehold improvements to expand our laboratory space and for purchase of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash (Used in) Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2021, cash used in financing activities was $0.2&#160;million and consisted primarily of payments related to finance leases, partially offset by proceeds from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2020, cash provided by financing activities was $73.4&#160;million, which consisted mainly of net proceeds of $75.0&#160;million from our follow-on public offering in December&#160;2020, partially offset by a repayment of a loan of $1.3&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property Licenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2011, we entered into a license agreement with University of Zurich for an exclusive, worldwide, royalty-bearing license for a propagation-deficient arenavirus vector. Pursuant to the license agreement, we are obligated to pay the University of Zurich low single-digit royalties on aggregate net sales of products licensed under the agreement, and to pay percentages ranging from the mid-single digits to 20% of the sublicense fees that we may receive from sublicensing, depending on the amount of fees received from sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2017, we entered into a license agreement with University of Basel for an exclusive, worldwide, royalty-bearing license for a tri-segmented Pichinde virus vector. We are required to use reasonable efforts to make commercially available licensed products. Pursuant to the license agreement, we are obligated to pay nominal milestone payments for each licensed product upon the achievement of certain development and regulatory milestones and to pay royalties of low single digits of net sales of licensed products. We are also obligated to pay a low- to high-single digit percentage of the sublicense fees that we may receive from sublicensing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, we entered into a license agreement with the University of Geneva for an exclusive, worldwide, royalty-bearing license for a tri-segmented arenavirus vector. Pursuant to the license agreement, we are obligated to pay the University of Geneva an annual fee which is fully deductible from any milestone, royalty or sublicense payments. We are also obligated to pay milestone nominal payments for each licensed product upon the achievement of certain development and regulatory milestones and to pay low single-digit royalties on aggregate net sales of products licensed under the agreement, and to pay percentages ranging from the low-single digits to 10% of the sublicense fees that we may receive from sublicensing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In September&#160;2013, we entered into a Biological Materials License Agreement with NIH for a worldwide, nonexclusive license to make, have made, import and use certain cells and cell clones developed at the Vaccine Research Center of the NIH, i.e., the NIH Licensed Products, to manufacture viral vectors based on our proprietary arenavirus-based vectors. Pursuant to the terms of the NIH Agreement, we are obligated to pay the NIH low to mid six figure annual royalty payments, increasing as our most developed product candidate manufactured from NIH Licensed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Products proceeds through development stages. We must also pay the NIH 10% of any consideration we receive from sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In&#160;October 2020, we entered into a license agreement with the University of&#160;Basel&#160;for an exclusive, worldwide, royalty-bearing license for a tri-segmented arenavirus&#160;Split&#160;vector&#160;technology.&#160;We are required to use reasonable efforts to make commercially available licensed products. Pursuant to the license agreement, we are obligated to pay the University of&#160;Basel&#160;an annual fee which is fully deductible from any milestone,&#160;royalty&#160;or sublicense payments.&#160;We are also obligated to pay&#160;nominal milestone payments for each licensed product upon the achievement of certain development and regulatory milestones and to pay royalties of low single digits of net sales of licensed products. We are also obligated to pay&#160;a low double digit to low single digit percentage&#160;of the sublicense fees that we may receive from sublicensing.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2021, we recorded $1.3&#160;million in licensing fees from intellectual property licenses as research and development expenses. At December&#160;31,&#160;2021, $0.3&#160;million payable from sublicensing fees were included in accrued expenses and other current liabilities. In the year ended December&#160;31,&#160;2020, we recorded $1.2&#160;million in licensing fees from intellectual property licenses as research and development expenses. At December&#160;31,&#160;2020, $0.1&#160;million payable from sublicensing fees were included in accounts payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional information on these license agreements, please see &#8220;Business&#8212;Intellectual Property&#8212;License Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with the rules&#160;and regulations of the SEC, and generally accepted accounting principles in the United States, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our critical accounting policies and the methodologies and assumptions we apply under them have not materially changed as compared to those disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2020 filed with the SEC on March&#160;18,&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recognition of revenue from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into the Restated Collaboration Agreement with Gilead for the development and commercialization of certain of its product candidates. Our performance obligations under the terms of this agreement include one combined performance obligation for each research program comprised of the transfer of intellectual property rights (licenses) and providing research and development services. Payments by Gilead to us under this agreement included a non-refundable up-front payment, payments for research and development activities, and may include payments based upon the achievement of defined pre-clinical development and commercial milestones and royalties on product sales if certain future conditions are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We evaluate our collaboration and licensing arrangements pursuant to Accounting Standards Codification 606, or ASC&#160;606. To determine the recognition of revenue from arrangements that fall within the scope of ASC&#160;606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, we satisfy a performance obligation. We present revenues from collaboration and licensing arrangements separately from other sources of revenue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts received by us as non-refundable upfront payment under the Restated Collaboration Agreement prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in our consolidated balance sheets. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis for each of the obligations. Reimbursement of costs for or services under the Restated Collaboration Agreement are presented as revenue and not deducted from expenses. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Contingent milestone payments related to specified preclinical and clinical development milestones are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC 606. The Restated Collaboration Agreement also includes certain sales-based milestone and royalty payments upon successful commercialization of a licensed product which we anticipate recognizing if and when sales from a licensed product are generated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leasing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination whether an arrangement is qualified as a lease is made at contract inception. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. We use the implicit rate when readily determinable and our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as operating lease assets on the consolidated balance sheets. Certain of our arrangements contain lease and non-lease components. We applied an accounting policy choice to separate or not to separate lease payments for the identified assets from any non-lease payments included in the contract by asset class. Operating leases are reflected in operating lease assets, in accrued expenses and other current liabilities and in non-current operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are classified as research and development expenses and expensed as incurred due to the uncertainty about the recovery of the expenditure. Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the relating revenue is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We measure all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. We classify stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#39;s payroll costs are classified. Generally, we issue stock options, with service-only vesting conditions and record expense using the graded-vesting method. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We estimate the fair value of each stock option award using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. We do not estimate and apply a forfeiture rate as we have elected to account for forfeitures as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recognition of other income under government grant agreements and research incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize income from grants, research incentives and the imputed benefit arising from the difference between an estimated market rate of interest and the contractual interest rate on loans received from Austrian government agencies. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, we recognize grant and incentive income in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant income that we have received in advance of incurring qualifying expenses is recorded in the consolidated balance sheets as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have received loans under funding agreements that bear interest below market rates. We account for the imputed benefit arising from the difference between an estimated market interest rate and the actual interest rate charged on such loans as additional grant income, and record interest expense for the loans at a market interest. On the date that loan proceeds are received, we recognize the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is subsequently recognized as additional grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our consolidated financial statements appearing in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status and Smaller Reporting Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As an &#8220;emerging growth company,&#8221; the Jumpstart Our Business Startups Act of 2012 allows us to delay adoption of new or revised accounting standards applicable to public companies until such standards are made applicable to private companies. However, we have irrevocably elected not to avail ourselves of this extended transition period for complying with new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates is less than $700&#160;million and our annual revenue was less than $100 million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250&#160;million or (ii) our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to the risk of fluctuations in foreign currency exchange rates, specifically with respect to the euro. Our functional currency is the U.S. dollar and the functional currency of our wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro. Our cash, cash equivalents and restricted cash as of December&#160;31,&#160;2021 included small amounts of cash balances held by Hookipa Biotech&#160;GmbH in euro. We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and restricted cash of $66.9&#160;million as of December&#160;31,&#160;2021, which included account balances with foreign banks. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, we do not believe that we have any material exposure to changes in the fair value of our investment portfolio as a result of changes in interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2521cc33_b259_4727_8cc5_b8f5089357fd"></a><a id="FinancialStatementsandSupplementaryData_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">I</b><b style="font-weight:bold;">tem 8.&#160;&#160;Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of those financial statements is founded in Item 15 of Part IV of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c804549a_35de_454a_b629_b8df8d38f53d"></a><a id="ChangesinandDisagreements_29131"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9.&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b86374fc_e0e6_4ea8_8a7f_377289cef5be"></a><a id="ControlsandProcedures_489690"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9A.&#160;&#160;Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a 15(e) and 15d 15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial and Accounting Officer, to allow timely decisions regarding required disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31,&#160;2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision of and with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, our management assessed the effectiveness of our internal control over financial report as of December&#160;31,&#160;2021 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#8220;Internal Control-Integrated Framework&#8221; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December&#160;31,&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a 15(f) and 15d 15(f) under the Exchange Act) identified that occurred during the three months ended December&#160;31,&#160;2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5431036e_113d_43ac_9824_27b23903be20"></a><a id="OtherInformation_174221"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9B.&#160;&#160;Other Information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_dbb624fb_519d_4bac_bc31_1df1c3b3b047"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Item9CDisclosureregardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9C.&#160;&#160;Disclosure regarding Foreign Jurisdictions that Prevent Inspections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f7ced854_13ec_4a65_84e6_25f46209a1e2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART III</p><a id="DirectorsExecutiveOfficersandCorporateGo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 10.&#160;&#160;Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates. If the Proxy Statement is not filed within such&#8239;120-day period, the information required by this item will be contained in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission, or the Form 10-K/A.</p><a id="_08267885_6484_4726_a479_339b91e07a9a"></a><a id="ExecutiveCompensation_255286"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 11.&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates. If the Proxy Statement is not filed within such&#8239;120-day period, the information required by this item will be contained in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission, or the Form 10-K/A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ea7b01f4_1fab_4480_a6d8_5a5222949dac"></a><a id="SecurityOwnershipofCertainBeneficial_240"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 12.&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates. If the Proxy Statement is not filed within such&#8239;120-day period, the information required by this item will be contained in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission, or the Form 10-K/A.</p><a id="_bb3dad26_2b05_4e00_95d8_04e908bf8e64"></a><a id="CertainRelationshipsandRelatedTransactio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 13.&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates. If the Proxy Statement is not filed within such&#8239;120-day period, the information required by this item will be contained in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission, or the Form 10-K/A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_08169355_ca28_43d0_b408_e058388b2a91"></a><a id="PrincipalAccountantsFeesandServices_2130"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 14.&#160;&#160;Principal Accountant&#8217;s Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates. If the Proxy Statement is not filed within such&#8239;120-day period, the information required by this item will be contained in an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission, or the Form 10-K/A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b8414575_d868_427b_8eb7_d26d56854727"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part IV</p><a id="Exhibits_364151"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;15.&#160;&#160;Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">(1) Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following documents are included on pages F-1 through F-7 attached hereto and are filed as part of this Annual Report on Form 10-K.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.56%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:93.56%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTERED_34038"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> PCAOB ID <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:AuditorFirmId" id="Narr_pJpRzGFHSkyn1fuMZGG1Ng">1259</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-1</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#BALANCESHEETSUNAUDITED_890928"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-2</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#OPERATIONS_814316"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-3</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#DEFICIT_226113"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-4</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CASHFLOWS_176896"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-5</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#a1Natureofthebusinessandorganization_284"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_788305c9_cf6c_49ca_bd97_355d274b30a7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">(2) Financial Statement Schedules:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-indent:37.15pt;background:#ffffff;margin:0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">(3) Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-indent:37.15pt;margin:0pt;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.15pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:86.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20211231xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of the Company</span></a> </p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465919023112/a19-8744_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Company (filed as Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on April 23, 2019 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Common Stock Certificate (filed as Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465919023112/a19-8744_1ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shareholders Agreement among HOOKIPA Pharma Inc. and certain of its shareholders, dated February 15, 2019 (filed as Exhibit 4.1. to the Company&#8217;s Current Report on Form 8-K filed on April 23, 2019 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20211231xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">HOOKIPA Pharma Inc. 2018 Stock Option and Grant Plan and forms of awards thereunder (filed as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 filed on Mar</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ch 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2019 Stock Option and Incentive Plan (filed as Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Incentive Stock Option Agreement under the Company&#8217;s 2019 Stock Option and Incentive Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Qualified Stock Option Agreement for Company Employees under the Registrant&#39;s 2019 Stock Option and Incentive Plan (filed as Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Qualified Stock Option Agreement for Non-Employee Directors under the Registrant&#39;s 2019 Stock Option and Incentive Plan (filed as Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Award Agreement under the Registrant&#39;s 2019 Stock Option and Incentive Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (filed as Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Award Agreement for Company Employees under the Registrant&#39;s 2019 Stock Option and Incentive Plan (filed as Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Award Agreement for Non-Employee Directors under the Registrant&#39;s 2019 Stock Option and Incentive Plan (filed as Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.29%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2019 Employee Stock Purchase Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (filed as Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director Indemnification Agreement (filed as Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 filed on</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Officer Indemnification Agreement (filed as Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 filed on</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Joern Aldag and the Registrant </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(filed as Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Reinhard Kandera and the Registrant </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(filed as Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Igor Matushansky and the Registrant </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(filed as Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15#*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20211231xex10d15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Klaus Orlinger and the Registrant, dated January&#160;1,&#160;2022</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease by and between the Registrant and Marxbox Bauprojekt GmbH &amp; Co OG, dated February 3, 2012, as supplemented by the Lease Agreement, dated April 2, 2014 (filed as Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease by and between the Registrant and W&#252;stenrot Marxbox GmbH &amp; Co KG, dated May 15, 2018 (filed as Exhibit 10.17 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/tm227839d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Collaboration and License Agreement, by and between Hookipa Biotech GmbH and Gilead Sciences, Inc., dated as of </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">February 15</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">, 2022  (filed as Exhibit 10.1. to the Company&#8217;s Current Report on Form 8-K/A filed on March 1, 2022 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Patent License Agreement, by and between Hookipa Biotech GmbH and the University of Zurich, dated as of October 6, 2011 (filed as Exhibit 10.19 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Patent License Agreement, by and between Hookipa Biotech AG and the University of Basel, dated as of January 16, 2017 (filed as Exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Patent License Agreement, by and between Hookipa Biotech AG and the University of Geneva, dated as of February 8, 2017 (filed as Exhibit 10.21 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.29%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">The National Institutes of Health Biological Materials License Agreement, by and between the National Institutes of Health within the Department of Health and Human Services through the Office of Technology Transfer and Hookipa Biotech AG, dated as of September 25, 2013, as amended by the First Amendment, dated April 12, 2017, and the Second Amendment, dated July 11, 2018 (filed as Exhibit 10.22 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Funding Contract, by and between Hookipa Biotech AG and The Austrian Research Promotion Agency, dated August 8, 2012, as extended by the Funding Contract, dated December 17, 2013, and the Funding Contract, dated May 22, 2015 (filed as Exhibit 10.23 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837021003176/hook-20201231ex1023d1109.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Funding Contract, by and between Hookipa Biotech AG and The Austrian Research Promotion Agency, dated December 16, 2014, as extended by the Funding Contract, dated October 4, 2016, the Funding Contract, dated February 27, 2018, and the Funded Contract dated October 25, 2019&#160;(filed as Exhibit&#160;10.23 to the Company&#8217;s Annual Report on Form 10-K filed on March&#160;18,&#160;2021 (File No. 001-&#160;38869) and incorporated herein by reference</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease by and between the Registrant and W&#252;stenrot Marxbox GmbH &amp; Co. KG, dated February 26, 2019 (filed as Exhibit 10.25 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465922023799/tm226818d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stock Purchase Agreement, by and between the Registrant and Gilead Sciences, Inc., dated as of February 15, 2022 (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 15, 2022 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-21_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of the Company (filed as Exhibit 21.1 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of PwC Wirtschaftspr&#252;fung GmbH, Independent Registered Public Accounting Firm</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Principal Executive Officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Principal Financial Officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1+</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:90.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8224; </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Confidential treatment granted as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"># </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Indicates a management contract or any compensatory plan, contract or arrangement required to be filed as an exhibit pursuant to Item 15(a)(3) of Form 10-K.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">* </span></span>Filed herewith.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Furnished herewith.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8074cc0b_aa31_48d7_a40a_865dcd69dabd"></a><a id="Item16Form10KSummary_412517"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">Item 16. Form 10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1ec7b01a_d924_4c90_a5bd_8bc89754bd1d"></a><a id="SIGNATURES_467"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">HOOKIPA Pharma&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: March&#160;24,&#160;2022</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY AND SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.15pt;margin:0pt;">We, the undersigned directors and officers of HOOKIPA Pharma Inc. (the &#8220;Company&#8221;), hereby severally constitute and appoint Joern Aldag and Reinhard Kandera, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"><tr><td style="vertical-align:bottom;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:44.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title(s)</b></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:24.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joern Aldag</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;24,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joern Aldag</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Reinhard Kandera</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer and Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;24,&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reinhard Kandera</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jan van de Winkel</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jan van de Winkel, Ph.D.</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;24,&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael A. Kelly</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael A. Kelly</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;24,&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Kaufman</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Kaufman</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;24,&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Christoph Lengauer</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Christoph Lengauer, Ph.D.</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;24,&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Julie O&#8217;Neill</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Julie O&#8217;Neill</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;24,&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_4d3a4de4_144c_42bf_8ba9_b24b484f04f4"></a><a id="REPORTOFINDEPENDENT_704895"></a><a id="REPORTOFINDEPENDENTREGISTERED_34038"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the stockholders and the Board of Directors of HOOKIPA Pharma Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the accompanying consolidated balance sheets of HOOKIPA Pharma Inc. and its subsidiary (the &#8220;Company&#8221;) as of December&#160;31,&#160;2021 and 2020, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders&#8217; equity (deficit) and of cash flows for each of the three years in the period ended December&#160;31,&#160;2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31,&#160;2021 in conformity with accounting principles generally accepted in the United States of America</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emphasis of Matter</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As discussed in Note&#160;2 to the consolidated financial statements, the Company will require additional financing to fund future operations. Management&#8217;s plans in regard to this matter are described in Note&#160;2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:AuditorLocation" id="Narr_9IZJ-3Sa9EmXRMML4MDaqg">Vienna, Austria</ix:nonNumeric> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;24,&#160;2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="dei:AuditorName" id="Narr_Kbzb1NIOikG-bODX8iQVBA">PwC Wirtschaftspr&#252;fung GmbH</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Stefano Mulas </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">German Certified Public Accountant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#39;s, or its predecessors, auditor since 2012, which includes periods before the Company became subject to SEC reporting requirements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b37bd6ff_a73a_447b_a717_0bcfff12bcc8"></a><a id="FINANCIALINFORMATION_402800"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 5pt 0pt;">PART&#160;I&#8212;FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_398446"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 5pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="BALANCESHEETSUNAUDITED_890928"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 5pt 0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share </b><b style="font-weight:bold;">amounts</b><b style="font-weight:bold;">)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5a4c391b_9f57_4c9f_b030_61bf23d0dd00"></a><a id="Tc_rExgPziLgkWlEL3q_k09-Q_1_2"></a><a id="Tc_0c6k3JTEIk6PRpdsi3_7nQ_1_5"></a><a id="Tc_f61PbtkHTkGEMmdTHpBd3A_2_2"></a><a id="Tc_TB9U8u2iX0qjyP3l6P_XIw_2_5"></a><a id="Tc_wvoPUiUy7U-sW96QTgrs2w_3_0"></a><a id="Tc_YVgv41IxX067B1KlSu8CmQ_4_0"></a><a id="Tc_QLZ9WE1fNkaynZOm7npDAA_5_0"></a><a id="Tc_VQCFMe5TA06SYZLkdhUdgA_5_2"></a><a id="Tc_lSrYVx-73kWrm43nDEVI8w_5_5"></a><a id="Tc_wTPx22ECPkCu7qQhKWFiBQ_6_0"></a><a id="Tc_bG67HrqXy0uVAVRN68Oy0A_6_6"></a><a id="Tc_DBfIQ8kYeUSzU1G2vp7ouA_7_0"></a><a id="Tc_QMyzJnPYJUKIhFni9gA8Sg_8_0"></a><a id="Tc_fHiZQLd32Em6eMzHi7FGLg_9_0"></a><a id="Tc_LtsphbNeC0iHiEP_ahc-6g_10_0"></a><a id="Tc_CsLscPYT2ECSaZkrU2Qoyw_11_0"></a><a id="Tc_s1tMrdmWsUGVihoRYf7ACw_12_0"></a><a id="Tc_z4y2DekwUE-8LoGGhsnFRg_13_0"></a><a id="Tc_SyFnlbKQeEeUpHT3DZBaMQ_14_0"></a><a id="Tc_ef6v5ATQWkCk4HWA2K5CJA_15_0"></a><a id="Tc_eqCirx82sku0QhX1IRBjzQ_16_0"></a><a id="Tc_pxTViZG2NEGZih9NplzVAw_17_0"></a><a id="Tc_C_yNmsKMRkWNLldzdS6AQg_19_0"></a><a id="Tc_kq_Eu-aL20qRXQO-OFBUlw_19_2"></a><a id="Tc_ZKMQWM37ekeTIqpMNFf73w_19_5"></a><a id="Tc_m5wGF-TPmkeoClBiByB_lg_21_0"></a><a id="Tc_8bRMB0UZS06icqy_09F2Cw_22_0"></a><a id="Tc_g5PzmTHG3k2WZZozPmpUPQ_23_0"></a><a id="Tc_HePpNhVnp0apxV48LMGA9g_23_2"></a><a id="Tc_kVflf39j-UKFXRv2xp9LVQ_23_5"></a><a id="Tc_OUAee3FBcUCdYpU3WJ1m1A_24_0"></a><a id="Tc_kJC4TMm840y1ZjtdQiBtmw_25_0"></a><a id="Tc_kYaz8kYYI0mjgn7wZ3UEzA_26_0"></a><a id="Tc_WSTjwpG8SkOJLHe_uACCvw_27_0"></a><a id="Tc_vAfy4hNdKkGuApbeJUhDMQ_27_6"></a><a id="Tc_6x4HvexJIUWrsACh_d6nTQ_28_0"></a><a id="Tc_uwt7EM4KJEu5XDdC10Ykow_29_0"></a><a id="Tc_8uCVeKIyQE28n-M7Vb0Nyw_30_0"></a><a id="Tc_eZEV8QvLu0imlMjyR_EAQA_31_0"></a><a id="Tc_URjWdVGEoUyFe9fJO7qEiQ_32_0"></a><a id="Tc_3divn1C-L0ikwQegPbFmgw_33_0"></a><a id="Tc_PZsQq4njfUyVSJ1AN4_AoQ_34_0"></a><a id="Tc_b7k0zf8v5ky1HZsupnjGfw_35_0"></a><a id="Tc_W8Wc-nyPCECdabvav47Vhw_37_0"></a><a id="Tc_uLmO-c1VB0G6U3fZGszFXg_39_0"></a><a id="Tc_nWbGcxHseUG9B-w4chT5UA_40_0"></a><a id="Tc_tpFfxN-0ukS6b0FSLM7NTw_41_0"></a><a id="Tc_trsoB6kb10mMATPpVJMMnQ_42_0"></a><a id="_d5002cbf_567f_45e3_8625_66e61c0303b9"></a><a id="_d5002cbf_567f_45e3_8625_66e61c0303b9_2"></a><a id="_d5002cbf_567f_45e3_8625_66e61c0303b9_3"></a><a id="Tc_7wcdOoldb06tohopFjHe-g_43_0"></a><a id="Tc_Q5hGkZRVtUCkA3sgTWMU5w_44_0"></a><a id="Tc_IaXTfkaxgkyIxfDPNy2n0g_45_0"></a><a id="Tc_Fo5u5u9HmUePjyPPFRUmyw_46_0"></a><a id="Tc_0_RBTGUGcUe3_LeC3HPyow_48_0"></a><a id="Tc_ZOgb2JibNUqu1iuiqngj1g_48_2"></a><a id="Tc_sNcdsQ2nUEOHKiEHIPkchg_48_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_qU9Md1EVtEqQrRR5n0tM5Q_5_3">65,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_tb4Z6iCSjUquGPA0d4DZxg_5_6">142,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_7BCKbnWmKkuNWZN4uQ6ggg_6_3">566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_3I5HkeDfqEqOgWQ_ObQcVg_7_3">6,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_jfE4o3KvJkKVC-deL-nyKA_7_6">5,542</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Receivable research incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="3" id="Tc_hvr6zL-8AkWv1D5kEdsNUw_8_3">14,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="3" id="Tc_AtBuHvv3ZkaExpleBmlriA_8_6">15,115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:PrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_OWW2Pkpe4Ea_Ju1GxTKTzw_9_3">14,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:PrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_6Mtzl6hwpk2ChZsDvSiWwA_9_6">8,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_O4Ux8jV6DEC9FtEMuGW-bg_10_3">102,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_UuktNMTV00W1I-NnC6veFg_10_6">171,504</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_69qnNc-Ey0mQUoKksTJIPA_12_3">425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_BGyt-XnL7US5x_WrGKP_9Q_12_6">434</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_WkswnTLHyU25uucHO-iwfQ_13_3">16,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_JjTU_oR9ykeppBZhFvqjOA_13_6">6,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_kbPsjUjRoUih0Wvpq6iu6A_14_3">5,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_CPs9Vj3mHkuoBlPt1tVmLg_14_6">6,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_GqtGTZWWp0SBMmVzDSo98w_15_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_1dzLLNbuukCtUvCFlPgTOQ_15_6">1,298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_X-AZzDXm60yFcr7QdUI0vw_16_3">1,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Wq9hQ_hCJUKxf5gictpXQg_16_6">1,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_VPTqjhgurkq9wftYbLLfyQ_17_3">23,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_exo2qrlK5UyKkB-NuNPKhQ_17_6">16,313</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_5_qfjHAz-UuXwjhU67xZMQ_19_3">126,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_mPvVmti4ckCC1FN7psRPWQ_19_6">187,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_WkO2OlTWlk2HKbNbHNeJkQ_23_3">8,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Tt3X4N8dJ0mGKYgJRsVpcw_23_6">8,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Deferred revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_BAVwJdVlVUuKb5BIGiZ2Eg_24_3">5,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_9SYgI9F_zEOcBs1HPZz1IA_24_6">3,750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_P_qCwv86NUqVm3P-2PZ0aA_25_3">1,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_sVOe-zc0eEKtqW3TWsFtFg_25_6">1,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_ai-3E0YLiEuahSxhrtFcYQ_26_3">8,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_z-FpKWpXqkWkiJit0ekiYw_26_6">7,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loans payable, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="Tc_TTidO0XJp0-UdGhs0Uci9Q_27_3">2,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_vccPHVDUJEyp8M4i9zHHjw_28_3">27,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_yrOimf_ZH0alwdrsMIYY0A_28_6">21,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loans payable, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayable" scale="3" id="Tc_Adi6VcYkCUmWVtMPReKiyw_30_3">2,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayable" scale="3" id="Tc_RbDLv9noOkuKiqgURy2cdg_30_6">4,537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_bIZdyCGzek2lqpsGm-Hj8Q_31_3">3,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_y2rtFnLUR06fTbebcoBgAA_31_6">3,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Deferred revenues, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_flUX8FuBZ0aLpoW6KiKNkw_32_3">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_JQWa7-8fmEuJTzc9hnEi8Q_32_6">784</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_7-d3QwFV9U6pCzZe0Tkcbw_33_3">2,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_OcBexpJ2zkeIPx09KLDbhQ_33_6">1,411</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_YU9XHzimbUKikxptv6iTvA_34_3">8,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_2K-KA3O_DkCCuO6wAE3V9w_34_6">10,551</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_FmpJo8fszkGZokQ_kct3bQ_35_3">36,453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Z5Qlca1PwkaQI3kwud_FgQ_35_6">31,694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Commitments and contingencies (Note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_wJY0DsggskOlH04xPTqo7A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_gq0Ir8RvpUSjub9DQnqQQg">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_4ufsTYxGjUy8gZloRwIvIA"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_TPnLk5SY0UKRt6GGrK5JnQ">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively; Series A convertible preferred stock, <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_IqJOfIwJwkOFwFOwgy7Igg"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_SazCqPF3UEuLRZeaLBrXBw">2,978</ix:nonFraction></ix:nonFraction> shares designated, <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_2U25fhhHAU-y44f0zX9u0g">1,697</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_5QMVn581VECQOyZZTAr6wQ">2,978</ix:nonFraction> shares outstanding at December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_6CUqPbUC3ECw8lhoR6zJgQ_40_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_nh6eZoO-vkCjbsTjT9ymPA_40_6">0</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;">Common stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_IsJqVjrNyki6B_WZQF163Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_pqfqP5PYqEiLsfq2cQUp7w">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3k6zu6jbKkSuAgSrvYVB_A"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_p98ke3KLjkeoVat7O6VNKA">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized at December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_H0Ah6WFpiEKDUFXKqTZzMw">27,383,483</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_zk2Hf08WDk2XbUOCy7rUmw">25,948,712</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_M4QO-ITDuk6l7x8QEJvWqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_ei_Ikp7_JkWHvn3i30w8hQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> at December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Kx6l_DztwEKPRayyPN642A_41_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_cU5NyviGaUyyN128tXS4BQ_41_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Class A common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_jCk-21PY20ePGQLTvXJ-og"><ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_9bLJGf4NBUWJYgI_sqA2iA">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3kL9f2refUm1QeHEk4Pv7w"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_uwiFuC4PTkOJ5X9a-Bsd4g">3,900,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2021 and December&#160;31,&#160;2020; <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_TyRlUQ4hBkitW4RJ2DcW2Q"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_A2FARKpC1EOVKmcbEaCtkQ">3,819,732</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2021 and December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_MZXrZeLmN06dLGOPeYKEVQ_42_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Y4_A8nqJWU66nHExVH5ZwA_42_6">0</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_z48iYgKa20ib7D5lVK5ofQ_43_3">317,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_LpiPZSz0Y0CvIVrgXyavPA_43_6">309,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_zXHTPAcsM0KHUMcjh2ur4w_44_3">4,780</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_BMuO5om7F0S2TN6bml2yrw_44_6">6,067</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_bnph9VMQt0uJt3diSTMicw_45_3">222,766</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_oi4HbWwfgESCg7tnxqS2OQ_45_6">147,101</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GYBnK-O1_UGfJ-V7RNJlug_46_3">89,592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9iFtuiUt30634Sac9Al6wQ_46_6">156,123</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_nOihmEJaAkOBJNrWt3jJVw_48_3">126,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ezYLohE3TUGAfW7feZdhnQ_48_6">187,817</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c2b3a750_6a55_4701_9acc_612f26c94fef"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="OPERATIONS_814316"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26d1accd_16fb_4f34_beea_b9b7b7ffebbb"></a><a id="Tc_e5ik2_C6c0uEpxVL_RGZkA_1_2"></a><a id="Tc_kuj_w9FkRkSoUuPeFX7cBg_2_2"></a><a id="Tc_dTrzDYQYNEiNDGfhH2FQqg_2_5"></a><a id="Tc_Nm5iv9plu0S8_MCN6j4quA_2_8"></a><a id="Tc_eEZIjVicUUKs7udxP39WvA_3_0"></a><a id="Tc_QvTjyZuSXUqlOGILz-JY5A_3_2"></a><a id="Tc_CMN4ECfF-02NSBqlzKhcsg_3_5"></a><a id="Tc_uWjtIb3WlUqHN1b4SdsxZg_3_8"></a><a id="Tc_QzH5gzQ42Uqmf3fkW2HaDQ_4_0"></a><a id="Tc_cAI3qTPEzEmoQrnKOIxeXQ_5_0"></a><a id="Tc_jRtgBwVmNU2pduPRBICVOw_6_0"></a><a id="Tc_m9JoMRVXM0my9z9aEc8N_A_7_0"></a><a id="Tc_2FpDSgSfFEKn5XQ9Qp1I4g_8_0"></a><a id="Tc_MS8574as8km4WGYWGzsHiQ_9_0"></a><a id="Tc_4GkE57fW20izWLsXcUsdtg_10_0"></a><a id="Tc_n7PHluvu6E-weOCbrYOiLg_10_2"></a><a id="Tc_fzVuxdHe9kuvOY-57uYB6w_10_5"></a><a id="Tc_MxG7f7ymCk-vXgttxI6yXQ_10_8"></a><a id="Tc_RQ2b1hjdXUKSRBcwOZUDqw_11_0"></a><a id="Tc_JW6wRzcXJUWQS0JEeC2ozw_12_0"></a><a id="Tc_9AYBXUZMJUC4DzxmES18XQ_13_0"></a><a id="Tc_hCaTf1vdLUSv7TzOC0lfcw_15_0"></a><a id="Tc_cQYRcJbEVU63Otyrpqk_fg_17_0"></a><a id="Tc_uNtDX2DpiUKqtxJA5_tSjA_19_0"></a><a id="Tc_Mt9nLqmr-EWDLFZe4CC6yA_21_0"></a><a id="Tc_Ch0aOiiazE-48gRJis0mdg_24_0"></a><a id="Tc_gL7NTGjTEkWh8fjo-ZdIgg_25_0"></a><a id="Tc_xZ3Sqkj-dEeymT0dx2CKQQ_26_0"></a><a id="Tc_oGkN8_4F80Gq01GX1S0XRQ_26_2"></a><a id="Tc_Qn3bpQtdo02JiePbB_w9fg_26_5"></a><a id="Tc_p0UbYRkypkieCimIW5DWHQ_26_8"></a><a id="Tc_pXfDiXZpZkKbPfL4WF93mA_28_0"></a><a id="Tc_lMyALt1_fECV2djMwhmqyw_28_2"></a><a id="Tc_OGj4Xyu_tE-vcZy3ihOnJA_28_5"></a><a id="Tc_bMIpsnhlNkmLbW_v8QaTMA_28_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue from collaboration and licensing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_8KtK6Y91k02fIZsaz__BAQ_3_3">18,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_lV4JsllaPU6nTD_h3upJOQ_3_6">19,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_UTBOk4uPCUuW-dVISQL-kQ_3_9">11,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_bWkqdeBbMk28dmnzfkEf_g_5_3">82,853</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_5HezugJDSEaSxZLUuN8VCA_5_6">54,787</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_O6x0tGInEUiPdiSL5qJ2Pg_5_9">46,312</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_nF0ysZtGCkOlBko3c48FfQ_6_3">17,269</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_J9NXhgafQ0Sde-UBFgqGwg_6_6">18,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_6pQcRzK9GkanJL5dCWdW2Q_6_9">16,715</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_WnJ2lOehekWWwLBEVreClg_7_3">100,122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_PyjJGZDLY0OvKn-kXTy5-Q_7_6">72,869</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_qtMUiejE4Eurj59VTuvbBQ_7_9">63,027</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_8RMg_d1-UE62EdohVBGGPA_8_3">81,674</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_kjmZJrMGykCpab9_bCLshg_8_6">53,285</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_NxiUT5-AaUuoUhaMuGEZeA_8_9">51,085</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="hook:GrantIncome" scale="3" id="Tc_q7uXq0bXpEyTkhxYD6HtJQ_10_3">9,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="hook:GrantIncome" scale="3" id="Tc_mMTiLeD6vkG5NImh5P8iRA_10_6">6,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="hook:GrantIncome" scale="3" id="Tc_7FB6ww4W8EiAxiBUadpABw_10_9">6,737</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_F1FmO-wdD0G2o6vzbWWPIg_11_3">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_C_IBNGSHzUW-0odMpKU-ug_11_6">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_S5gWrOiz-kSejH6ofqPAtg_11_9">1,587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_RR6PecnytkumpcjZEOQwaA_12_3">898</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_PuuvYk7RxUaIAsCqgE94iw_12_6">786</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_t7aW-2h0p0CslEQISKPikg_12_9">877</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income and (expenses), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_aIsNkjHql0OslitsGGfEJw_13_3">2,843</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_GkpTAZ1wQEms9BYzNA7HfQ_13_6">3,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_aWxoIzu1d0yaMSYYhiWgtg_13_9">601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_e5lDjOFboka9qCZdf1S8ow_15_3">6,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_hnnXMxQvLESVobqDmm9Frg_15_6">9,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_QQ32eVFvbUGjclc8T0H1ig_15_9">8,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_M2igh5e0SUy3Eg4_jV-CqQ_17_3">75,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_-5VUaSUn10eaatSZK3hcMQ_17_6">44,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_ZTJqY1iaREaptkEkIbvbNw_17_9">43,037</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_dcFKf29ZKEuQk-EeU_Vjlw_19_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_WD7g_Sklf0G5_TRUr_Whjw_19_6">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_DsLxSIj7QUCXaVRD3mj1Gw_19_9">0</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sxB2Jrb7nkaIYuu68JMWAw_21_3">75,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gQHg4tV06UaicTCsPQBVHQ_21_6">44,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0Y3LdP3QYU68pPQilexhug_21_9">43,037</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency translation gain (loss), net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_dlZRfq518UqvCzNe0dmnWw_25_3">1,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_2fd69zWnxkiO52Ym678r7A_25_6">1,414</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_pMLFn1DEX0qoe8u8FJtzQg_25_9">933</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_2J6-t67Hi0qZY4OoUSNNqQ_26_3">74,378</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_C8iiST71mkqA2PtIYcK1Og_26_6">45,496</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_kaCCXjUc_06Y9CGbx5w0zQ_26_9">43,970</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share &#8212; basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_LXIKk8UR8Eati8j2LwhyIw_28_3">2.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_qiR0CGgSL0qUlDQj7JBPUQ_28_6">1.69</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rL9GxY-2rkOVeBeCVbxaoQ_28_9">2.41</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_541d7a0a_2bb1_4441_8b84_45587f7a3add"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="DEFICIT_226113"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d962d92c_1dee_47b5_9e82_d2f82e5073b0"></a><a id="Tc_uYCW1Fj_mkytx1sPzE5jAg_1_26"></a><a id="Tc_I5Y6HaiOg0a7NLS7S_D-FA_2_2"></a><a id="Tc_xokc34WV6kiSgVnvk7ApAw_2_8"></a><a id="Tc_A46pH8IDqkuMueHe3Vhjww_2_13"></a><a id="Tc_ctEIJebTjEWGy4FXzOa0rg_2_23"></a><a id="Tc_bdSzhKoq5kWlMK8COv7sMQ_2_26"></a><a id="Tc_oT91VHGSNE-iCr-kceUZqA_2_32"></a><a id="Tc_cQQA9MgrXUKa8tYYfNhQzA_3_2"></a><a id="Tc_IPlgwQJ7dEuhGDhmuap38A_3_8"></a><a id="Tc_rpdATc1YIU2ykGM50GycRQ_3_13"></a><a id="Tc_cEDq7ZbKtke8FBTnGj1TmQ_3_18"></a><a id="Tc_bvZI04Qr9kqEWeqLwmVeUQ_3_23"></a><a id="Tc__gRvy3MWik6XIZX-v3QDRw_3_26"></a><a id="Tc_YCY3B-aNkkm2wZtWpUtICA_3_29"></a><a id="Tc_xs4EfTmTFE6x_93pnG9Wzg_3_32"></a><a id="Tc_wsjwILfi3k6Jzv1RfGLRvA_4_2"></a><a id="Tc_ps4kYbE14kCOhLcDq9OcXw_4_4"></a><a id="Tc_Ax37sqZJyEWCepdu9_iOcw_4_8"></a><a id="Tc_UvjKUYWLR0WTOc8M-pUwug_4_10"></a><a id="Tc_p_YyNnedVkazaxcHn1gw7Q_4_13"></a><a id="Tc_MlD3xQKC50qd7VfsCZJE2w_4_15"></a><a id="Tc_KA_X5yiBv06bUQu4UgvtDw_4_18"></a><a id="Tc_hhUEbFUWR0CrCDyPTbPFlg_4_20"></a><a id="Tc_WyY2u0UPQ0mcigvDP0N_CQ_4_23"></a><a id="Tc_w_-9-IZxjkOcft1WN4Q8Ig_4_26"></a><a id="Tc_ILZgBVx3DEO8BjMskwMouQ_4_29"></a><a id="Tc_urU54Im7X0Cnp_72F3XtQA_4_32"></a><a id="Tc_BZnoT_UA7kS4Xix3DTnNIQ_5_0"></a><a id="Tc_4DGKeJdu30eJw_nucGhs2w_5_8"></a><a id="Tc_OuPgfwhypkigPOAy-Eq-yA_5_11"></a><a id="Tc_ZJAfycU9sUOAzv46AFGOVg_5_18"></a><a id="Tc_xW_YMFsSHkCtilavQtUotA_5_21"></a><a id="Tc_JxHdu78jfkeg39C25FZBWA_6_0"></a><a id="Tc_OhgjdzksU0mUBN7NA-b28A_6_8"></a><a id="Tc_PqxihTsdWkuy57tyzRr4wQ_6_11"></a><a id="Tc_aT-7QdSfd0K10Jap6wBnGg_6_13"></a><a id="Tc_MEreFNVyhk2zRjCCj6WAlQ_6_16"></a><a id="Tc_oaarHIxZb06FO31qp9R6wA_6_18"></a><a id="Tc_uUjA-leraEeBKpkKw7F4Sg_6_21"></a><a id="Tc_XRTvZqBUZ0C2w1blgRDr-w_6_24"></a><a id="Tc_M4ARgiW4ukWWC0tI8jxXEg_6_27"></a><a id="Tc_7fY_j2W30kS0rQAYlex1Fg_6_30"></a><a id="Tc_f6briGdl9Eyirqw2v734Ww_6_33"></a><a id="Tc_CbCAt2XgREi1_brmu_PL7g_7_0"></a><a id="Tc_lrWgv9-QI0GRfJgPfqtjFw_7_2"></a><a id="Tc_m-cwNlx1bUOkT4irBEOT8Q_7_5"></a><a id="Tc__4o2SV1T20OAsuqwnC_4Fg_7_8"></a><a id="Tc_4ECbb5mFEkWDzuT0bGc9kQ_7_11"></a><a id="Tc_JhApGW5cRkWWpt1OplTSQQ_7_18"></a><a id="Tc_koxXQVlWTUiYPkp-VXBrhQ_7_21"></a><a id="Tc_GgFC1OR8vUmuyUprH3zffg_7_27"></a><a id="Tc_v0s8n0tfN0-2n_tVbjRLYg_7_30"></a><a id="Tc_A2qHhqEmi0yQVvRBazQzQA_8_0"></a><a id="Tc_19Jtx3wxDkKTxEwca04rTQ_8_8"></a><a id="Tc_3mYc2l2rk0qqRNEljoNJ6A_8_11"></a><a id="Tc_Uti40qyrok-u4ZUUQ1G9Vw_8_27"></a><a id="Tc_fI_7Jqjj50G8DHEehObV1g_8_30"></a><a id="Tc_ytwxq6MTRU6EazIp5GO6jw_9_0"></a><a id="Tc_pErxf98vpEqiI_HNRlJt1w_9_2"></a><a id="Tc_4dDSyUgofkW-44PVglrmlw_9_5"></a><a id="Tc_frQihZzBzkyF4vV5H-rFNA_9_8"></a><a id="Tc_bZpKjcTWbUqa9AvXHq-K1Q_9_11"></a><a id="Tc_0aB4xQDJK0qinfPklznnCw_9_18"></a><a id="Tc_fjjVF_vQpkexdmgUe_sodA_9_21"></a><a id="Tc_wflr0LUfrkmniskJ529F4A_9_27"></a><a id="Tc_ASrvVih_9kyGbb3ADbd8CQ_9_30"></a><a id="Tc_kQ-pUEZhOUW8Z3X-hyLvpQ_10_0"></a><a id="Tc_Cc7GIMWXbUieyxmXBPRbxA_10_2"></a><a id="Tc_6ImJ2dkVh0-LJQzQGeCGww_10_5"></a><a id="Tc_qCLqRv1zQ0OWhV0WBW2O2A_10_8"></a><a id="Tc_-t9G4k3pXkeyJ8g7GP5yaw_10_11"></a><a id="Tc_RMRjdkPcQ0KvW3cU4Hy_Sw_10_13"></a><a id="Tc_CeYUw_9Cf0mKr_WSxDT5Cg_10_16"></a><a id="Tc_q-3r6JGfAUq2a-wfSRNSOg_10_18"></a><a id="Tc_9Nkjvr3kK0GAnRKhaVxtyg_10_21"></a><a id="Tc_LaNGr1LJEkqR5rXPYBN6Nw_10_24"></a><a id="Tc_38tksWWi70GHa3pNwXS1Pw_10_30"></a><a id="Tc_9CyXoBsrG0uTi1j3kuxzMA_11_0"></a><a id="Tc__UnsPOApkUK1ts776hAqQA_11_2"></a><a id="Tc_HpjEYGI43UCaV4pBnUeR-A_11_5"></a><a id="Tc_xdY5QAerqkSep6-kA_jJMQ_11_8"></a><a id="Tc_mxU7ezHjyEqf3T7Ucu69kQ_11_11"></a><a id="Tc_mivEdOSx1ESYVo38ZWf6zw_11_13"></a><a id="Tc_0ipV7QJNR0uT5omUkTbqNw_11_16"></a><a id="Tc_rPeXBDAqikqA09mzOZRKXQ_11_18"></a><a id="Tc_drmmX58Yikifx3byhnyfAg_11_21"></a><a id="Tc_5_LJop0ObkmFNOnH96Uarw_11_27"></a><a id="Tc_V4qiyfLOMEebqdW3u_vBBw_11_30"></a><a id="Tc_TRVWiOkRNUum8qfZ86-sdg_12_0"></a><a id="Tc_aDtpu7z9akmQlCBLQVUUjg_12_2"></a><a id="Tc__4cu_z3B_kWTbx0TfYOvNQ_12_5"></a><a id="Tc_pKIAYWV3xU-KFgn5JZk_jg_12_8"></a><a id="Tc_8xKLaSIMKEWaUyMi2e_xEg_12_11"></a><a id="Tc_xm4zyt_OZ0Glp1HKDcuuJg_12_13"></a><a id="Tc_7nDQq9GjX0iLwcAV3JiOAg_12_16"></a><a id="Tc__3bWkbpAT0izC1h4OYF7Ww_12_18"></a><a id="Tc_qOkGUcU-qECy4Pr95wffHQ_12_21"></a><a id="Tc_QO3do_3vyU2x8_CRZNEWpw_12_24"></a><a id="Tc_NmO2Y6qfL0K0wpluK4tYtA_12_27"></a><a id="Tc_l2W-zaGT2k-Gxoa62t8SOQ_13_0"></a><a id="Tc_DqtmFj5LYkW2wW_t9FRZ7w_13_2"></a><a id="Tc_nXMHwa9eyUCU_qOlKaJxWg_13_4"></a><a id="Tc_EDCbDA_1xUGYAgJQcrYPOQ_13_5"></a><a id="Tc_UU0a4kyKX0SMGrmnOc8rng_13_8"></a><a id="Tc_GMQB7x0wu0qfPgz5nfwUpg_13_10"></a><a id="Tc_ztAohYinGECv1lOcmFJVuQ_13_11"></a><a id="Tc_8RoYHSeXHE2dDSmzqubi9w_13_15"></a><a id="Tc_RPyGJHc9FUycvMKQsMwJmQ_13_20"></a><a id="Tc_a1d75VnpykOcX8O8-Q3i5A_13_23"></a><a id="Tc_hNd-jwd1jU6s7vBMnMwSrw_13_26"></a><a id="Tc_fLu650E_d0q82VuWmIqaKQ_13_29"></a><a id="Tc_rX2sRb9tZkmR1o3b4RkPgw_13_32"></a><a id="Tc_y7pLsskS706BoG0S3t15ag_14_0"></a><a id="Tc_3CknvCRXAkmOLLAu4JY06w_14_2"></a><a id="Tc_TyrkKfn09kqw3Ggpm35Jpg_14_5"></a><a id="Tc_k5gvme_IjUi6E5nGEDoRFw_14_13"></a><a id="Tc_AzIr0ZLlvUyGiHtVP1wCkQ_14_16"></a><a id="Tc_z6TM5Qxl6EC94dEVHSMJmw_14_18"></a><a id="Tc_VHj2mQI5DkGX56Iz_ywKUw_14_21"></a><a id="Tc_w3zwfSPl30q8QN7JGoGXzA_14_27"></a><a id="Tc_Cpy-64sIxE-EnZweKQUjRQ_14_30"></a><a id="Tc_fhW2Nps3MU-R_MR5Yd0S4g_15_0"></a><a id="Tc_sQASy9HZPE6y7kkMQWXVCQ_15_2"></a><a id="Tc_TqWV3HYzb0WVNTyRK2q9yw_15_5"></a><a id="Tc_WAtGQQXmpUWSbPPFMKAa2Q_15_8"></a><a id="Tc_x4qpVPFl802Zc4VFf7LS2Q_15_11"></a><a id="Tc_GSHvn56oXkChgI1A1rdm_g_15_18"></a><a id="Tc_vj4BU0O0ekCppiUskCj8Iw_15_21"></a><a id="Tc_EcifqZTRu0iuKKH_uEXKeg_15_27"></a><a id="Tc_UIxLYxbGOUqo1h5c7Fj3RA_15_30"></a><a id="Tc_DH_xp4pTMkG8aZ2sBlPEZA_16_0"></a><a id="Tc_BhtlrH4tYkqJTxKzsiHkKQ_16_2"></a><a id="Tc_s6Z6771WlkuIh02d7k1SYg_16_5"></a><a id="Tc_WoUQiSyjAEijZ5HIm0-Sqw_16_8"></a><a id="Tc_isaR3Zv-1k2DtLTZHG_2qw_16_11"></a><a id="Tc_3pGJI7cXokuglB0hYaU2hA_16_18"></a><a id="Tc_8ZATqeU-tkCzOIW4kGGAiQ_16_21"></a><a id="Tc_3Zq_dPJBnkSsiGHANxiMkA_16_27"></a><a id="Tc_68NcNc1KXUuf4nRvLU8Srg_16_30"></a><a id="Tc_jv-7jP8htUGPOP0REl4aUQ_17_0"></a><a id="Tc_mC0so_ai9kKS5u3_VAhzJg_17_2"></a><a id="Tc_NkwzF0x-50eATwkYlw5GIA_17_5"></a><a id="Tc_fK418M18KUe0qYJzEbz6Zw_17_8"></a><a id="Tc_i58OfMp4aEiu4985WHfFrw_17_11"></a><a id="Tc_xgm0F4ercE6YaljA3y453g_17_18"></a><a id="Tc_Xa53h7T9jkCO9xghX3fFvw_17_21"></a><a id="Tc_rUfV6eWgWUOpMFWx0l2_5A_17_27"></a><a id="Tc_kzGE-QImUk6BVOZPkYns7Q_17_30"></a><a id="Tc_5aSlFDlX6EaKraWSt6NtAQ_17_33"></a><a id="Tc_nhYiK1xMPEiToAk2OLHEPw_18_0"></a><a id="Tc_E78Ke1KXcEKKapllnkvmrw_18_2"></a><a id="Tc_XxKr9sYr4Ue9YxvG-CoAfw_18_5"></a><a id="Tc_Npah1yqahUaq_Y9yRbaSIA_18_8"></a><a id="Tc_hxkyTE7eLEOZ5pXxs1ypFg_18_11"></a><a id="Tc_gK4Vq-2ARUW7a_hzD9MXtg_18_18"></a><a id="Tc_NYi5Rzu080Wewo9vhUOk7w_18_21"></a><a id="Tc_vj0JUDhc7E-8PibrakLN8w_18_27"></a><a id="Tc_n2rp1FjaCUGkq_QsiGNxJg_18_30"></a><a id="Tc_gkhBxxxYP02vwWgQELAo2A_18_33"></a><a id="Tc_4UT3-za4m0KI23eV1fdXLQ_19_0"></a><a id="Tc_wR0YcCN3bUiTFgW7GWuJiw_19_2"></a><a id="Tc_xPYc0yjhAEabX-qm-F3Tng_19_5"></a><a id="Tc_q3RIpgQ55EGQE_5_O6ZHlg_19_8"></a><a id="Tc_rElGlEMacEemA4uFDQ6bNg_19_11"></a><a id="Tc_PvlzZJCqhk6DACuuokWsWA_19_13"></a><a id="Tc_lfocBqetm0e9nsvbcp2LHg_19_16"></a><a id="Tc_G0_OCV-iYUmuKzBG7-oeaA_19_18"></a><a id="Tc_Y8YDDRta8EaGMcFhsScZBA_19_21"></a><a id="Tc_ljrRjX0p9UGQmittmfXkog_19_24"></a><a id="Tc_TUwS1VqT2UyEfZWZ7rgIvQ_19_30"></a><a id="Tc_3f1c-cLguUmgumaFgAJhsg_20_0"></a><a id="Tc_G6duaa1OD0OmDxdojw1mng_20_2"></a><a id="Tc_2FK2pLeq10mRDkto5q8xkQ_20_5"></a><a id="Tc_HsLZoHceFE-km2FltYYMqw_20_8"></a><a id="Tc_Ko2-2jCMrUCT9peT8q4NZQ_20_11"></a><a id="Tc_aORZXjLmOUGIU2efKHXOyA_20_13"></a><a id="Tc_VI_qtkuxpkGitlhNsaGPrg_20_16"></a><a id="Tc_7nP3TMjfbku7Ap8LS-fCXg_20_18"></a><a id="Tc_cHyU7zQdLEaK_tOAubgldw_20_21"></a><a id="Tc_K6E05mIeD06Wze-JiKmKYA_20_27"></a><a id="Tc_s_Ja3Kjuz0qbqqLxO1C9RQ_20_30"></a><a id="Tc_tjd7LWKE1kimVobseW-1bw_21_0"></a><a id="Tc__Ow18ejxb0a_U8nsiKUKBA_21_2"></a><a id="Tc_8U46sYbOSke3a11x1YzkBA_21_5"></a><a id="Tc_nXVVcnEMxk2rI1pa0jIySg_21_8"></a><a id="Tc_UW0wWt4QXEiJrGiJbgQFWQ_21_11"></a><a id="Tc__4CAt5GMFEif77u0QZHPCA_21_13"></a><a id="Tc_KKYR2gxOIEqaQ-t6c8-SYw_21_16"></a><a id="Tc_iSIP6uXwMkqBBivuFLEFjw_21_18"></a><a id="Tc_66eQLw356kqc3emOx6o-eA_21_21"></a><a id="Tc_wSB9iWXMCkuEKJSR4Ss8dA_21_24"></a><a id="Tc_whfMsWticUyn1vDtzKjfPg_21_27"></a><a id="Tc_3C4VChsTFUivoQyQYQHCDg_22_0"></a><a id="Tc_qqFwODrmQES3lXFIh_pJMg_22_2"></a><a id="Tc_QxzloseVuUi2gJODkiNHCg_22_4"></a><a id="Tc_5mnlXOsR8kKyY4I2TP8L_Q_22_5"></a><a id="Tc_m_EejqMZIkiVFoEtmBSyiw_22_10"></a><a id="Tc_pGxnzaajE0KUsuJiUBXTWQ_22_15"></a><a id="Tc_CnJdKUdszkGK45HYb_relg_22_20"></a><a id="Tc_5G8NSzU22EKl8OmfMN1KZA_22_23"></a><a id="Tc_jOrTDPqrgUqR9QtPWWsG2w_22_26"></a><a id="Tc_1V5IhhynhUSFMVjY1rkidQ_22_29"></a><a id="Tc_XJqLkktUWkuRbfxLL_sojw_22_32"></a><a id="Tc_8bzoxCvNJEeXXxuIrs5T0Q_23_0"></a><a id="Tc_LpiUzbMsa0SmSVmJAlGg8A_23_2"></a><a id="Tc_r9niN1BtmUSAe5VSOUhi_w_23_5"></a><a id="Tc_l11T8Ge-E0uEi_JqB27MqA_23_18"></a><a id="Tc_ijv30Ixu_EaLQV7aKSsmBQ_23_21"></a><a id="Tc_Si24F5Air0OrGSqwf2mS3A_23_27"></a><a id="Tc_JyGVG7UqTkaPlR3wtSiUVQ_23_30"></a><a id="Tc_6W29xFf99k-F6etBe3DOcw_23_33"></a><a id="Tc_HR5jUnvjnk-ukY2G89UoZA_24_0"></a><a id="Tc_CdjTJXWaREaVTD2S2zBh7A_24_2"></a><a id="Tc_hIGlfoBpvEWGH-hm5C_h-g_24_5"></a><a id="Tc_Wm5p4aCZqUyWMCJJWHVr2g_24_8"></a><a id="Tc_t2bGAp62CkyT4ftrT6CI7w_24_11"></a><a id="Tc_Ql73HL4OZkmEoOG_BRQnBg_24_18"></a><a id="Tc_cFXQPqXcGEqsakbwLqH-wA_24_21"></a><a id="Tc_DjpePy8LVkWERDZaPfWbkQ_24_27"></a><a id="Tc_jtKZIffHhEqrklr53Ia8yg_24_30"></a><a id="Tc_JQFTBr6FGk2wds1DYiSIMw_25_0"></a><a id="Tc_1Ipt_1n6dU6VxhdnQPYcQg_25_2"></a><a id="Tc_KKzq-G7zUEayFBCE_iQDBg_25_5"></a><a id="Tc_rrZ5N0YmE0uLWl8KC3R_Kw_25_8"></a><a id="Tc_m5z4uGIJjEq1HLTSHismPg_25_11"></a><a id="Tc_R1pV01dFLUCQJLgboo2Z4A_25_18"></a><a id="Tc_2_NfjILmqkKHTF3me_Xw0w_25_21"></a><a id="Tc_lEzU8MqJUkub9PBJOSws8w_25_27"></a><a id="Tc_OryQ9m4tXkarGu0uj3d4Qw_25_30"></a><a id="Tc_XMv304eDA0yTkhJA0TiSJg_25_33"></a><a id="Tc_qliAoEuSLUG22OkCabyFGg_26_0"></a><a id="Tc_My1uf5seyEOC-eOK_O-avA_26_2"></a><a id="Tc_XUW5RdML-U6MrVadvfjtRQ_26_5"></a><a id="Tc_oivIn6IrXUmWgLXqu9ofYw_26_8"></a><a id="Tc_3YxlnPLMZEqLJd7FEe52Kg_26_11"></a><a id="Tc_ApIgjsbxLUeLcCIgZlidgw_26_13"></a><a id="Tc_ZEZGh-3NsUCPaZvbcamAyg_26_16"></a><a id="Tc_LRqPV5R-ZkGIqeayfoYvZg_26_18"></a><a id="Tc_946MqlRl4keYxr5-356kxQ_26_21"></a><a id="Tc_nzOqoYijdkOWP57KmxIeOQ_26_24"></a><a id="Tc_okZFpK3AGk6hpS1S5xaRqw_26_30"></a><a id="Tc_qY1XUWSMeUyzYlcXXHz87w_27_0"></a><a id="Tc_6K6tUdnOOUSrtFArRwIj4g_27_2"></a><a id="Tc_KBS0UxVIxUKHzigilNIOiA_27_5"></a><a id="Tc_ZyLGM33ZcUWekLiYIyU3vQ_27_8"></a><a id="Tc_Y-re7RU_70qfZnWV_ZnMmg_27_11"></a><a id="Tc_lDAwrnV-8Uq3Xz2laLuiyA_27_13"></a><a id="Tc_k-KtrgVsZU2a06syc_vEcg_27_16"></a><a id="Tc_CM-OA4pki0uzlJ1WxAZh_g_27_18"></a><a id="Tc_syyo2Qj530uHM9ZdTRCKlA_27_21"></a><a id="Tc_XbOdr-LYWkqggSJSXVlEcg_27_27"></a><a id="Tc_00E2P8YxmkCd6leF5An1Zg_27_30"></a><a id="Tc_KN9psbonrUG1N5Lsehv34w_28_0"></a><a id="Tc_EQyl-Hj2A02_zA8JBda5fw_28_2"></a><a id="Tc_bJTsRQwT4Eq1NCztmmovzA_28_5"></a><a id="Tc_hZkv7CQgRkOuk5u_mbvTxw_28_8"></a><a id="Tc_UHXbku-TVEOVCNCkM2HYIg_28_11"></a><a id="Tc_NL0lOWjceU2DceipseqL-Q_28_13"></a><a id="Tc_B_DxMwxnb0G5xEQwoHkAKw_28_16"></a><a id="Tc_cD0DGOf2gEiv9FKHCXWS6w_28_18"></a><a id="Tc_OiwropGiXkOUFwGZnPfDNA_28_21"></a><a id="Tc_OSbekFu71EWOZIefI7il8Q_28_24"></a><a id="Tc_9f_eb3cjGkShR6rLK1ojBw_28_27"></a><a id="Tc_oE2CkkZWA02MF3CJ4Pnl7g_29_0"></a><a id="Tc_Ck7pcMGuRkeZoKJqqTz2kQ_29_2"></a><a id="Tc_ODvrffcQEk2UB4vbKtnN5Q_29_4"></a><a id="Tc_yOnHZtHsaE2nkKuRAx6vXg_29_5"></a><a id="Tc_ePnYSR_zB0qXlsmMHeDpyg_29_10"></a><a id="Tc_jRNqEgzktUOAk4rn1IGxPw_29_15"></a><a id="Tc_LyeAx9jijkiTECwteLB4vA_29_20"></a><a id="Tc_1xMZpgVmrUavMOF8fyq59g_29_23"></a><a id="Tc_qPkkkHRdPkusuC9L_yMq5A_29_26"></a><a id="Tc_5CHy-kBRlke--genwOpwPA_29_29"></a><a id="Tc_bFGFw_WU2kOESperUXQpbA_29_32"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Redeemable Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;A&#160;Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of January 1,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc__snGCDWg80qxd1palDB1WA_5_2">1,323,506</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_0IENksdGyEGU-rT5XEptlA_5_5">104,774</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mMp048LvZEKwM3usixUYtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Bm2cPzfqPUiIsAjYolFBKw_5_13">1,006,595</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mMp048LvZEKwM3usixUYtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tPAYsXfpDEOSJin-ht5YPg_5_16">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n6WF9srQk0-nfgx2hH6GHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_t_fRx3hTUkmkOYBrfbBUxw_5_24">3,327</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bza-EjmjGkyDiE1cBzmY_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2lPdZnV5qEivPlVnqJPA3g_5_27">3,720</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fJMSYe6Db0aF4O1Ae_jMRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pttGrIqFp0SsIMOmwDR8PQ_5_30">59,982</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_14jML7-qfku23iCFcLkDWQ_5_33">60,375</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series D preferred stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_MW8Mqd0iIEG_9OzHPNz_yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_AUl8TkpmsUekBIfuigJC2A">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_2rHrjRN4ikCe0MkQAF8I5A" decimals="INF" format="ixt:numdotdecimal" name="hook:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_9gdc06xYqEOW4M9fGBaz4Q_6_2">257,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_2rHrjRN4ikCe0MkQAF8I5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_B2C82jtzsUKczhS4I1_TAw_6_5">37,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon initial public offering at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_yBu7KRZGvUyBIFDw4F8mQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_MUIf4Tk7p02xr9vPu-rMwQ">14.00</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7Bp0zhTgI06LSu47f4p2jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_ekt_ddw_A0WYpchpPIQYlA">9,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_GVjWFUiQH0upjVXJAd-SzQ_7_13">6,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_cEN7OiRTAkS29C-cuAK2Bw_7_16">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_7IwVpTTnlk6s5ryDWsRvTg_7_24">74,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_9AfVSkQh2U2wQaIwwuOUFw_7_33">74,615</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_ioF2r0Uas0uFcTusXG0EVw" decimals="INF" format="ixt:numdotdecimal" name="hook:TemporaryEquitySharesConverted" sign="-" scale="0" id="Tc_z0BaG-uNwkmWMoF8KZ8M1A_8_2">1,580,506</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_ioF2r0Uas0uFcTusXG0EVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityEliminationAsPartofReorganization" scale="3" id="Tc_0yMfNXX3D0WLvWcNGuLPHA_8_5">142,048</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_-XwYwEgidkKhJJezbwiaWA_8_13">14,582,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_Ufbk1JxvSUuEbb6OD0t0uw_8_16">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mxgxUBrs5EahlanRFV9dLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_KQxsMaLqQE6aDaKr0-WQyA_8_18">3,819,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mxgxUBrs5EahlanRFV9dLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_U8nQ0taqtUu_yBzvC6PuZg_8_21">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_A9oYF-0FEUOi5G7cBxX2qw_8_24">142,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_f0iSlcqd7kiM2eT53qDp2A_8_33">142,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_AuC1xW22tE-I5CwNHSMe6w_9_13">157,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7Xb1zudHcEqijbQlqIEOVw_9_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_e1kslkKsl0uD__ujlB7zJg_9_24">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_oiWH9NBDo0ShklC3HvXadQ_9_33">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6lqA7X0UVkCwZjjrPXO1kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_5TU1-FBIAUmbQIeDfys66g_10_27">933</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_a29kFE3D2UOH2Y_BWB_BPw_10_33">933</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_e5TIKBBm7EOFgye4GAZEZQ_11_24">5,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_6Whp3pMyWUmvHFaSyUcL2g_11_33">5,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3xEUlzHOy06ZPsj-DQ1mAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_F2noIw1x8UuEfC3lbK4qJA_12_30">43,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_L7m4V8bEAUyVWGPQSNERew_12_33">43,037</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vo3P-fAsj0qkzNtmN_hjhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc__NMKhepmFU6VkYHOgwrR3g_13_13">21,746,392</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vo3P-fAsj0qkzNtmN_hjhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hACGXB5DKUyI2GiQiCh4Mw_13_16">3</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LULifWjM2k2MitqBT78QxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_o0ZciqS6vEmXgueYK9zIEA_13_18">3,819,732</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LULifWjM2k2MitqBT78QxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Mak9jSIcqkWkNDC1OqtHYw_13_21">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8U9btLCFf0-_E1ZmkdKY9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MDhmJ94Ak0-h08l92V3yCg_13_24">225,568</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VASM6wKbREa6i5X-hf4OnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xd8cwAsT5UyGitTip9JNJw_13_27">4,653</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7enHd9VRCkazAjqXa7n2IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jLJA4WlI7k6nR9jlDROlnA_13_30">103,019</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_y7TWZtfo9UG1Ybf33CjWLw_13_33">117,899</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series A convertible preferred stock upon public offering at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_2eUxdenClUy0SHIl-6ePhA">11,750</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_wAHzp7MTe0eWsXdFl7PgAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_mwHomgkTlEmH6MoudBucuw">2,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_C7sFin4R1EaaFWUj-j20vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_qWkMRHKsxUuWdReTwhz-7w_14_8">2,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_C7sFin4R1EaaFWUj-j20vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_H_scjowMhU2V8OVn0xOK3Q_14_11">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SY6vqrZCAUCbmXcKYv08WA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_i6B_dpIMRkmbMPuzDaWdgg_14_24">32,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_wAHzp7MTe0eWsXdFl7PgAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_zcUKUrHhb0K2j7yRBQ_76A_14_33">32,426</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon public offering at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_uZNru85Ne02qO0AHTcuHqA">11.75</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_TFoTZQzTG0eYRQ27zNvfiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_Q5UceYe8A0qtmK4YCQ3-1w">3,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_xqvbSb--MEqanoq1xG6T0w_15_13">3,910,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_6f7JHJv-kEi3OB9eYpvQPA_15_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_80agmUjsCkegGAgDnKF-yQ_15_24">42,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_BdibXaK2Q0CfpYfInbQsEQ_15_33">42,574</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_cfVp-0vGx0q6AqXpGaO3fg_16_13">255,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_sZKEBjYV3U-Pn7J6L89qQA_16_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_SOhaJ7AJT0qyetQxigt-ig_16_24">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_RKCrZ9I7Ek67qCbDCGkWvA_16_33">63</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="INF" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" scale="0" id="Tc_yjyWoMzHok6hWR9ncOMR7Q_17_13">1,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="-3" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested" scale="3" id="Tc_XRTIxkYlXUaLgvN0T6TRPg_17_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested" scale="3" id="Tc_hhfU89gpxk2_hiukUEdzLw_17_24">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of equity grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="INF" format="ixt:numdotdecimal" name="hook:SharesIssuedSharesShareBasedPaymentArrangementVested" scale="0" id="Tc_9LYYVpXW60iwaGXIKDIy9w_18_13">36,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A" decimals="-3" format="ixt:numdotdecimal" name="hook:SharesGrantedValueShareBasedPaymentArrangementVested" scale="3" id="Tc_KQR-p0P4A06EL4nu3EYs4g_18_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:SharesGrantedValueShareBasedPaymentArrangementVested" scale="3" id="Tc_inzvCjFCUEWWJqs8vlpDQA_18_24">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0EmWweoQGke319p9rpY0xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_XAKN36vKeUaYH1kGzcD-og_19_27">1,414</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_pVvfQ7RCCU6agR1M9PxMsA_19_33">1,414</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_TdoIo0v6A0eE9sLMjdFmpA_20_24">8,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lTllba8OiUOneSOhKJaQSw_20_33">8,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MoCC3vP5_Uyo7dm3xckcaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PIuT1gqZCEagskOP1CDhEQ_21_30">44,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WEChPPpWKE6QQ62AqM_f3Q_21_33">44,082</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_go0VxtWuoEOC8lkT9c9QBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_pamvv90ySEi98wB6Snm9iQ_22_8">2,978</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_go0VxtWuoEOC8lkT9c9QBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JOcZndtkjUqnlyA2_o9sgw_22_11">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Kwh0f-7tfEWtcfjIz3sd0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_O__akkU60EmLZVa_HU0KEQ_22_13">25,948,712</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Kwh0f-7tfEWtcfjIz3sd0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XF5cQpJtRUGoZ2m86vCVwQ_22_16">3</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_trtcRd5UvE-g8RW5tXD87Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_XJlXGwzvIkuoeaG3djXNng_22_18">3,819,732</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_trtcRd5UvE-g8RW5tXD87Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1iOJwWDt9kS4Nqm6JhIkqw_22_21">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7wWUwYMC0EOxNoennfjkiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kDrSC4NKB0q-fT1dNpG_4g_22_24">309,288</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_N55shTLEaEarslhWegOJbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6N8CUGxNI0q_sbqvfADqdA_22_27">6,067</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_f2ZtYakwfEGzUa_ReenKsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5UpRNQcrakidps_RhRD4kQ_22_30">147,101</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_B_IlZrF32ESvIBLPPqGgKQ_22_33">156,123</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series A convertible preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember__-4lq1gvk0iz6FWV-SY_DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_BDdWsurj5Ey5xdc_VIoNHg_23_8">1,281</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember__-4lq1gvk0iz6FWV-SY_DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_Mmeg-oUGnESgspzO11JMvQ_23_11">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_dyVHep7Ys0uF0omwglEeZQ_23_13">1,281,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_bGZUgnnO9kmcc08qMOJJiQ_23_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_yGCg-UNmfUWjzf7pocOsgg_23_24">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_TgcIumQNeEOybsWloezeqw_24_13">110,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_jKQrRtDtd0WY3vECqUfE3Q_24_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_OdY7SDAmmkqHdX8AwfiSUQ_24_24">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_0vXymPOE2UqU9fc_QoXsZQ_24_33">203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA" decimals="INF" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" scale="0" id="Tc_0r8wQIWwM06JyskcVreW3w_25_13">43,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA" decimals="-3" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested" scale="3" id="Tc_TPohowCCrEaWFxTWoj77fw_25_16">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA" decimals="-3" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested" scale="3" id="Tc_v0miCQ1g40OHaJlYVE1lZQ_25_24">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IzO1tarH8EWCgudDOfIH8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_lcuRWlWkqUCoYRqHKkAp_w_26_27">1,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_VzBG2eoL2kSUSuhx6_uIZA_26_33">1,287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_5EbmICrHU0GK9GEt61ergA_27_24">7,644</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_TgJ5e9Ula0Kv2jWxkLQCIg_27_33">7,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rtH4Ec9QWkKmuKYhDdJTqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6YF_2OJ1j0aBURG69Yzp5Q_28_30">75,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uOKAXSK3TkSuX7FasCERzQ_28_33">75,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:21.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_KY00BOBu8Uie8DRIDNVBvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_oUkWI66S4kuhOSNsHX9c-A_29_8">1,697</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_KY00BOBu8Uie8DRIDNVBvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xeijjfwUZka64E55C_WeyQ_29_11">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F487s_zlB0qFdik4pgQi0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_hAUVD23pbEaTv4S-ue-KpA_29_13">27,383,483</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F487s_zlB0qFdik4pgQi0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_WWAEmvcT2ECpkGH0XIrrZw_29_16">3</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JCLAhxpWfUK_BCMc8Crq6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_lnLVeOBXxEWHY5NxBGsg1g_29_18">3,819,732</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JCLAhxpWfUK_BCMc8Crq6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wAtrAyMTaU-ejkBT8DwIXw_29_21">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3N0JhOmgVUmYfBmky7vmOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dbUaaG8dxEig34APB4gmaw_29_24">317,135</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OfuYA2C3xke_bo6pMP4VvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_lvkUzAcPqE2zGIDnAjcHCw_29_27">4,780</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lmHisS_hEGTk6TeU1vfOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dvigMDJHYUiTeieVO51qOQ_29_30">222,766</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_30qjEG7VF02yVqhSJBL5Zg_29_33">89,592</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5f5d49dd_e327_4680_b58f_f4be6dfd3f9e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 5pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="CASHFLOWS_176896"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_b6930d0a_5fe4_463b_be7a_d09e41ebc69b"></a><a id="Tc_sG_Pggxw20Og5qXlKta02w_1_2"></a><a id="Tc_hqXtficGQkyAYk7NsXazHQ_2_2"></a><a id="Tc_Dbn2uR0fgUGrCWgNSXBpdg_2_5"></a><a id="Tc_seW4YRgJ40yUMZLPJYimKg_2_8"></a><a id="Tc_tjJta7bJQ0eEJDPRgugj6g_3_0"></a><a id="Tc_6KoY2LEGJkCuqJ7wTgGpBQ_4_0"></a><a id="Tc_633q2TQp0k-d1ExopMoS_Q_4_2"></a><a id="Tc__MpMCBBlaEq61O7s7nhZJA_4_5"></a><a id="Tc_S8KwrVdzlEaV32_k6n4nYQ_4_8"></a><a id="Tc_-kxfSxun-E2fGtj9xA_piA_5_0"></a><a id="Tc_NBmBbY_cPECeaN6sbr6Wlg_6_0"></a><a id="Tc_cxNO1_e4yU-9E2vA_w_qEA_7_0"></a><a id="Tc_re3x8eQuPkayTxqjo16y2w_8_0"></a><a id="Tc_lRhGu0s4u0WP834M8cbBcg_9_0"></a><a id="Tc_12yX3SjyHEaYj1kEQBRpew_10_0"></a><a id="Tc_7p0dvYljnEGdOEBR1PsttQ_11_0"></a><a id="Tc_nTTyLplL-Eu0StjZg__gfg_12_0"></a><a id="Tc_7hf01tRKy02KHp0_83eQ0g_13_0"></a><a id="Tc_MToBP6JfzkykvjSXuVIgzA_14_0"></a><a id="Tc_PFsaE7NDgEukP7345l8Fww_15_0"></a><a id="Tc_T5GjBByNh0OR9Ucr21eBkg_16_0"></a><a id="Tc_pDztQpyKs0KW667H1g4aBA_17_0"></a><a id="Tc_bVlkvRDet0Six-Iq9OIP7Q_18_0"></a><a id="Tc_GhRNxkhXQUSrwv1RRQUlYw_19_0"></a><a id="Tc_VBe_zsoujUSYmp-9yJATPQ_21_0"></a><a id="Tc_W-y6SpD2vUKQHQ4B94CfHQ_22_0"></a><a id="Tc_Fl6NImHIDkqJT2SbO2H0cA_24_0"></a><a id="Tc_8PvcLHRBMEaH4Xfhj3m7oQ_26_0"></a><a id="Tc_FqtmIQDGDUWlON5-E5UoSw_27_0"></a><a id="Tc_kvCLMxzU7kO3Ajh81DtOiQ_28_0"></a><a id="Tc_RcdhCiLuIEKIH7mN9PFgjA_28_3"></a><a id="Tc_YFAPIlZz1Ualc2x4mTNx1A_28_6"></a><a id="Tc_Fpnb85WwkEG-KZzKYl7unw_29_0"></a><a id="Tc_Hz6hUhTBA0iibbL6TVtplg_29_3"></a><a id="Tc_aH5C7UUX6UyfpqSgqxjIWg_29_9"></a><a id="Tc_eiIoZ0glPEmm5y0P1o_9pA_30_0"></a><a id="Tc_pLLaLhVRKUOHW71PJ1tAaA_31_0"></a><a id="Tc_wxNioSHm-kyw6axsjHhXpA_31_3"></a><a id="Tc_G9ZK9hIlHUGw6j07LPA83g_31_9"></a><a id="Tc_MsWpqkaj-0mgbq3fWsmfdw_32_0"></a><a id="Tc_RwVcn9JYlkiPmbCjSbTVhg_32_3"></a><a id="Tc_9mPdsWsuuEalUOlaCeg-6w_34_0"></a><a id="Tc_RJfVGXVFnkSVop3bo3YK3g_36_0"></a><a id="Tc_3KwcXDi6OkSVp40y0wavxA_38_0"></a><a id="Tc_0pXLtDabvEmbvtMzIVOlmw_39_0"></a><a id="Tc_IIrz8zXatEK0Ml1eBNgbgQ_40_0"></a><a id="Tc_uTE5-6XFg02hspYk9IH5Zg_40_2"></a><a id="Tc_ktvetR5DnUqy9YykqHM6ng_40_5"></a><a id="Tc_EL4asdF8NESC6lWU9Ghh3Q_40_8"></a><a id="Tc_5Yfr8Tv_C0SM1BIR81Z6Sw_42_0"></a><a id="Tc_-Pl6Nq8OIEm-Dd6x2msN2Q_43_0"></a><a id="Tc_WEUUrMpbVkqUXNATk_NLwA_43_2"></a><a id="Tc_PU_FcmCtGEq2DZmV7PnfiQ_43_5"></a><a id="Tc_3j8rpUskvkOwfvtKkjMR4A_43_8"></a><a id="Tc_f2jTMPWXCk2kagkrDQzePA_44_0"></a><a id="Tc_ZpJ2rWWBz0--dAzp-HmygA_44_2"></a><a id="Tc_7XF8LHhoPk2RTcfni9q3zQ_44_5"></a><a id="Tc_fC-N0Gaf_UmWmgtK1P4-Dw_44_8"></a><a id="Tc_Jry2bMOHdEGQqvZZqcaweA_44_9"></a><a id="Tc_vayFkv5ipEegH4zY2qdXsw_46_0"></a><a id="Tc_XtDLYIcO-0Sp5wATPGZtFw_47_0"></a><a id="Tc_-HK2Ze_Qw0ey06T24tjG2Q_47_2"></a><a id="Tc_rBWy4zmBPEK9JZCrgYhCMA_47_3"></a><a id="Tc_mes4TY5DI0SH_Skt7S-Ftg_47_5"></a><a id="Tc_bvSBTz-yDkuIoM22eQ78oQ_47_6"></a><a id="Tc_dvrpVJ8BZ0iGkQEf9H9UZA_47_8"></a><a id="Tc_v3BK5qBWQEqy3Er0C9qqAA_48_0"></a><a id="Tc_ok26sr6T9EO70h-Wle4xhA_48_2"></a><a id="Tc_PuzvdMxXNUyH-i6mNt5CPQ_48_5"></a><a id="Tc_heDXWkO4xk62JUrTz3kHUw_48_8"></a><a id="Tc_SndcyduoSUaxv5svOjXNEA_49_0"></a><a id="Tc_xswaL4FhIUeBpGI4wviNug_49_2"></a><a id="Tc_UZlMhplfzESm1Bc_oB3xfw_49_5"></a><a id="Tc_TrBG2bu9xUqDVtIYg-cV-A_49_8"></a><a id="Tc_8OFriH2L0Ee42dUwYT8KUQ_49_9"></a><a id="Tc_0XNFAwNb9UGaiWtklq-SCA_50_0"></a><a id="Tc_nhvcrjIa2keQZpZTrqG4Og_50_2"></a><a id="Tc_XbrNcuPQT0u81vwViff6mQ_50_5"></a><a id="Tc_Jzf5233Yt0efgmeDA-3I1w_50_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_DhRW-EfZzkah3Jit7mqfEw_4_3">75,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_KruL7vdYtE2745s6iJGu3Q_4_6">44,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_4yPkTRNMFEyt3A_3LCSFuA_4_9">43,037</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Sa77FGvbnEG3sd5kp7-Yow_6_3">7,644</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4mwNHFqY6UuoUEZ3vLYGdw_6_6">8,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_mg3olR1wlkmF2T7aWW9PGA_6_9">5,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_B8_Sqjex4EOBZhMgH4BZdA_7_3">4,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_cFbVJ9bucU-G8B2atQtQJA_7_6">4,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_Mo0QO5Sys0mSsttUr6Ahlg_7_9">3,067</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other non-cash items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_SiOVACef8E6Mg4gXtSh13A_8_3">1,226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_uiFVoR0nTEG16PkdDEm91A_8_6">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_LhptCu5PpkajjZug72t-Ow_8_9">52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_076vrEVubEK2ww7ekjJ3Kg_10_3">1,943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_SGNobUFcH02TypYDda6LAA_10_6">3,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_F1-Fv6ISxk-mHfHYHsiuGQ_10_9">3,619</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Receivable research incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInReceivableResearchIncentives" scale="3" id="Tc_riSW7ULl7kCHEwT-lzKT3A_11_3">295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInReceivableResearchIncentives" scale="3" id="Tc_ZCpTxPsAFkuQ_jjsxbXlZQ_11_6">5,825</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInReceivableResearchIncentives" scale="3" id="Tc_5DqfKqzV6EGh5KZV05Z6zw_11_9">5,892</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_N2RpN5Oc0kSEG9UmBQF43w_12_3">7,091</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_yY4NvxRcLECWfAaHNUfCuQ_12_6">2,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_5jgCp6lQ1kO6PxtxcoHSXA_12_9">113</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_lO_IMA_Rj0WJPH4WMr3sPA_13_3">416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_GKcmm1W0B02OTqg7qvLyvQ_13_6">1,080</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_zTAOondAgkW42auvI6Yw-A_13_9">869</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_a4DLX4X_QE-sB64ph5wCrA_14_3">858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_aRFwyCF5fEWHZWJjHmmjNA_14_6">6,298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_ObKwCn-1tkuqcVVwHVbPNQ_14_9">4,203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Deferred revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_S3f3nTJB90CBM0qY9s_XvQ_15_3">1,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_Kq2XmuN7cEWfq-C6QrBLpw_15_6">511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_mNoi3zGWbEe4vmAAYmzISA_15_9">4,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_-q7kXQrXV0OYPxblPgmyDw_16_3">1,588</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_jBZBL8cWRUSLEy30JTfUfw_16_6">1,833</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_zfVVJIhC20yPqbK6rK9rXA_16_9">2,396</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" scale="3" id="Tc_gj0peIBvVEqY1tgsA8zX2w_17_3">4,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" sign="-" scale="3" id="Tc_K_xRddsiVEe7yYUL7ta0Kw_17_6">184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" scale="3" id="Tc_yBTbCGObk0GolD77NWV0yw_17_9">5,142</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_rGgRy7LwREeRrLXezQL0tA_18_3">416</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_JYPO3DNLpUqtTP3X7osADg_18_6">142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_qCDbEaQ3EUGb2Sat-kWevg_18_9">1,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ryaZi627k06wa-I9VvunLA_19_3">66,016</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_HogHOr8TkUCak3A40_eSfA_19_6">39,339</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_D43f8J-aAU-E56oYw-d8VQ_19_9">41,731</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_-JCYcCuDiEWkaKZu_7UlyA_22_3">12,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_zJKfKJ4PRk-SOxe-VQo_QQ_22_6">2,371</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_6YXEGe3xiUGeZx_4YYsyuQ_22_9">1,999</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_iNKVFonYyU6KIFVSu807dw_24_3">12,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Xu2lSVOnMUK-Ed_VPOGmKQ_24_6">2,371</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_K0fkJKHLqUmXAPQ7miUEMw_24_9">1,999</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Payments related to finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_3n2HotDI6ESinT1G5YdloQ_27_3">438</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc__uTYWFidGkmOc4Gyg31N_g_27_6">108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_3yaSzPMvekaipRqMeK0i7w_27_9">1,437</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Tc_oT6EGmdRBUmA5liPuioIdQ_28_9">37,274</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Tc_1rMbFCCZnkmSw5-m6zE9GA_29_6">32,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_fdd5VGM0GUi7kjsJ8IShBg_30_3">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_AUAIo1ntw0aXwd9ACDQ6wQ_30_6">42,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc__XiUXKJurEyE2xJ3OVlLyA_30_9">74,756</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Payments for deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="Tc_SjFSgk4kSkqImxIOr6sz_w_31_6">224</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Repayments of borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_Jb9fHGoF6E-RI2LNFE_L8Q_32_6">1,311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_APEUdjUPOEWJpZCvvMl8hw_32_9">842</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_7PXTH65h9USbCQ8FZ9kj7w_34_3">235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Yeicr4hMnUSphNM0HbLxJQ_34_6">73,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_8HY_M0DeqUWimp-lu5CYbg_34_9">109,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net (decrease) increase in cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_QA1GAjYn7EChj9aX4XN_Ww_36_3">78,832</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_fw8M4vAU_E21_wx68ji_Fw_36_6">31,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_DsbdmYNcD0ytN7ZbW3zLmA_36_9">66,021</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_MRzWFj6nmka5bx2THYHTXw_38_3">143,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_FfHzJ8DTU0K0zIcG8cOzLw_38_6">113,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Q8vF15AhWU-WRLCtVP5_eA_38_9">48,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_0l6NvgoTSUuVZSBak2RDyg_39_3">2,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_XY9oEkGvuUuRJtJAeZluKw_39_6">2,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_0Z-m3XtEgkyllfTdhzUYOQ_39_9">1,026</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_t5GP6ycBp026pBmuxAwOGQ_40_3">66,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_DWL3aa7mXEakylSIbp-R7w_40_6">143,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_6-mucJ9L8E22swm0VUL4Og_40_9">113,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_GimL7VVoiEGcxcw9INFYpA_43_3">48</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_FhCtpQvYwkaYndGdsW6ODQ_43_6">97</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_LLUKttluHEKGVOz8BHtSEA_43_9">64</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_zI_WDLoEY0ynytBE5pEazg_44_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_0Lhb4B0EQ0u4Rd-PKFZEJg_44_6">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of redeemable preferred shares upon the IPO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_gC-qm14oWk2Ichp-YIq6SA_47_9">142,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment additions in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" scale="3" id="Tc_fwCv4-Yc7kSW0Z6XPn496Q_48_3">742</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" sign="-" scale="3" id="Tc_i3l2KaJAdEyxuDhoeDcT7w_48_6">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" scale="3" id="Tc_q9mmpOya6UC6ZQgi7mRPMw_48_9">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Lease assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_QRf_kQyXBUSAW7Xq2FZ00g_49_3">2,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_ksVO0lw0lE2G-RvDF2lhNg_49_6">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Lease assets derecognized upon lease cancellation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseAssetsDerecognizedUponLeaseCancellation" scale="3" id="Tc_dVr_FSpb_UKF5-zCLD0dGw_50_3">1,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseAssetsDerecognizedUponLeaseCancellation" scale="3" id="Tc_toDuKhuxLUi45DiMh6rPdQ_50_6">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseAssetsDerecognizedUponLeaseCancellation" scale="3" id="Tc_aGLWpgRT8UuGPeEos6On_g_50_9">182</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS </p></div><div style="clear:both;max-width:100%;position:relative;"><a id="a1Natureofthebusinessandorganization_284"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:NatureOfOperations" id="Tb_NobjkpUSekWNzVjVnhsi5g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;Nature of the business and organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HOOKIPA Pharma&#160;Inc. (&#8220;HOOKIPA&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body&#8217;s immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the name of Hookipa Biotech,&#160;Inc. under the laws of the State of Delaware in February&#160;2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, the Company changed its name from Hookipa Biotech,&#160;Inc. to HOOKIPA Pharma&#160;Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April&#160;2019, the Company closed its initial public offering (&#8220;IPO&#8221;) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol &#8220;HOOK&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company&#8217;s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_O_vUcEdsBk6RvdvanGGDEQ" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;Summary of significant accounting policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_MgaBQXUznEmUuR7xqqzOcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:GoingConcernPolicyPolicyTextBlock" id="Tb_smTFUcNqckm88VBj-6GuYg" continuedAt="Tb_smTFUcNqckm88VBj-6GuYg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company&#8217;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2021, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_q4SF1H_e4k2fiMEnv4VKyA">75.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_0ZAj_QGhHEm_KNQnhwP6yg">44.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr__dr_aBTyu0mTJnyQJrgfmw">43.0</ix:nonFraction>&#160;million for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. As of December&#160;31,&#160;2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_xdCf7PwGrEqlMQDRBdRj1A">222.8</ix:nonFraction>&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;24,&#160;2022, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents, together with the net proceeds from the offering in March&#160;2022, and the funds received under the Restated Collaboration Agreement with Gilead, both described below, would be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont1" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont2"><ix:continuation id="Tb_smTFUcNqckm88VBj-6GuYg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will seek additional funding in order to reach its development and commercialization objectives. The Company will seek funds through further equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:UseOfEstimates" id="Tb_StuVcBnq30mVRSmuv69hSA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;11,&#160;2020, the World Health Organization designated COVID-19 as a global pandemic. The Company believes the extent of the COVID-19 pandemic&#8217;s impact on the Company&#8217;s business, results of operations and financial condition has been and will continue to be driven by many factors, most of which are beyond the Company&#8217;s control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent the pandemic will impact its operations. The Company&#8217;s accounting estimates and assumptions may change over time in response to COVID-19 and the change could be material in future periods. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_yr2A-AAb2UGiQgXDyqxbdg" continuedAt="Tb_yr2A-AAb2UGiQgXDyqxbdg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency for the Company is the United States dollar and the functional currency for the Company&#39;s wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Redeemable Convertible Preferred Stock, Convertible Preferred Stock and Stockholders&#39; Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont2" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont3"><ix:continuation id="Tb_yr2A-AAb2UGiQgXDyqxbdg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_UX5qvD-A20OjbhNIaP2qKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 the net proceeds from the Company&#8217;s offerings have been deposited in interest-bearing bank accounts with investment grade U.S. financial institutions and have been partially invested in a money market fund. The money market fund, held in U.S. dollars, is primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the Company&#8217;s cash and cash equivalents included smaller amounts of cash balances held in accounts with European banks at the Company&#8217;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively, Gilead accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019 Gilead accounted for the majority of the Company&#8217;s revenues. No other customers accounted for more than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_xGYgUBCpnkiod27JFa_qdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020 cash equivalents consisted of money market funds.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:DeferredOfferingCostsPolicyPolicyTextBlock" id="Tb_4wPT5JfhM0CRePJnMaa8tw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_2z1DVlGInE67tl6HPhEIRg" continuedAt="Tb_2z1DVlGInE67tl6HPhEIRg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont3" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont4"><ix:continuation id="Tb_2z1DVlGInE67tl6HPhEIRg_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;4).</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_Jt-zq2SSXEmv5wqzyZXnoQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_8UkNQJeqjE2lW5yH5YkcMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__YrrPJBfXEKiNjwR_7k7OA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_TKcN8z0yR06dkohgKi4IoQ">2</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NyQzVSOZCUW4XmIPhFet_A" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_A82YiNNnf0mxrr6x-l0gLQ">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4BwGZSWxKES82uxhJw-yBA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_KzyhWZDzekKE_vyeq1hj6Q">2</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_qytkKxk8CEm7bN6P8U8VzA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_Mym7M1GQk0O85XI_05eWDQ">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_RnEWI9I70EeTbY-Xi8vklA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ICxeW2m8AkiKXcXXv9_1pg">2</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_ANXP3tESvE-8MHgi_Ck3uQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_wggnkiP05EeRE5S2JV0Ssw">4 years</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_O_0qV1LiI0ys84CHmciE5g" continuedAt="Tb_O_0qV1LiI0ys84CHmciE5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the new leasing standards as of January&#160;1,&#160;2019. For leases with an initial term of 12&#160;months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#8220;ROU&#8221;) assets and lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont4" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont5"><ix:continuation id="Tb_O_0qV1LiI0ys84CHmciE5g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#8217;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#8220;ASC&#8221;)&#160;360.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="Tb_V_qNqQwHukaGFMqWyiv-yg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capitalized Software Development Cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of less than $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="Narr_GinHQi6wWUe-vwKqsokFXg">0.1</ix:nonFraction>&#160;million associated with the Company&#39;s cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2021. <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="Narr_atmuR86F4EeXElRDG4Yv4A">No</ix:nonFraction> amortization expense associated with the Company&#39;s cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2020 (see Note&#160;5). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Tb_8PA0Tq4Prkm-_MAO-oSElw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_0VZ2sm155kWO7TZFDbWSsw"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_1oLPj02TwUmVv6v4dQga-Q"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_Hd6MGJYyvU-aeYO-PVqNyw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t record any impairment losses on long-lived assets during the years ended December&#160;31,&#160;2021, 2020 and 2019.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_AidEhkPxKkeA4giyw_07Yw" continuedAt="Tb_AidEhkPxKkeA4giyw_07Yw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#39;s singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company&#39;s resources. The majority of the Company&#39;s tangible assets are held in Austria.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont5" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont6"><ix:continuation id="Tb_AidEhkPxKkeA4giyw_07Yw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_P03SVtzUS0Km5vLOql7PlA" continuedAt="Tb_P03SVtzUS0Km5vLOql7PlA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a collaboration and license agreement (the &#8220;Gilead Agreement&#8221;) with Gilead whereby the parties agreed to collaborate with respect to <ix:nonFraction unitRef="Unit_Standard_Program_p93h6a_140eCP-r_hTy6gg" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt-sec:numwordsen" name="hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms" scale="0" id="Narr_cR9Rf11QYUuMbQYL1LIu0Q">two</ix:nonFraction> preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#8220;HBV&#8221;) and the human immunodeficiency virus (&#8220;HIV&#8221;). The Company&#8217;s performance obligations under the terms of this agreement include <ix:nonFraction unitRef="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfCombinedPerformanceObligationForEachResearchProgram" scale="0" id="Narr_uKaMxs3KCk6Rl46uzP1ZHA">one</ix:nonFraction> combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The licenses do not represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under this agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, the Company applies significant judgement to evaluate whether the obligations under the collaboration and licensing arrangement, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of when milestone payments are probable of being received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Upfront payment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company under the Gilead Agreement is recorded as deferred revenue and allocated between the <ix:nonFraction unitRef="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfResearchProgramPerformanceObligations" scale="0" id="Narr_abS2WV7oIky4PyIkaRD8NQ">two</ix:nonFraction> research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reimbursement for services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Agreement, the Company incurs employee expenses as well as external costs for research and manufacturing activities presented as operating expenses or prepaid expenses. Based on the nature of the Company&#39;s responsibilities under the collaboration arrangement, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues in the period in which the goods or services are received and external costs are recognized. Unpaid reimbursement amounts are presented as Accounts receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development milestones</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Gilead Agreement includes contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont6" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont7"><ix:continuation id="Tb_P03SVtzUS0Km5vLOql7PlA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">uncertainties and the required commitment from Gilead. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales-based milestones and royalty payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Agreement also includes certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost to fulfill contracts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_Sz0qG0yZq0i2k3x937Pdew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are classified as research and development expenses and expensed as incurred due to the uncertainty about the recovery of the expenditure. Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" id="Tb_DCTwM5t0V02FgBXm2eB8UA" continuedAt="Tb_DCTwM5t0V02FgBXm2eB8UA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#39;s estimates. The Company&#39;s historical accrual estimates have not been materially different from the actual costs.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont7" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont8"><ix:continuation id="Tb_DCTwM5t0V02FgBXm2eB8UA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" id="Tb_sBgFN150ZUCkTspwv2fD4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government grant agreements and research incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes funding from grants and research incentives received from Austrian government agencies as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_8NQ3nwHXlUS2RF7zHm8_Ag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company&#39;s common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient&#39;s payroll costs are classified or in which the recipient&#39;s service payments are classified.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_jwL8GMSjmkGpPUOCAGtUaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss and foreign currency translation adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="Narr_aJ9uS3t3H0aK92YMNIuGkw">1.3</ix:nonFraction>&#160;million of foreign currency translation gain adjustments. For the years ended December&#160;31,&#160;2020 and 2019, comprehensive loss included $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="6" id="Narr_ifdFyeFMd0e0HYTCRlFh9A">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="6" id="Narr_dk346pk7YUWfOng36G2fYQ">0.9</ix:nonFraction>&#160;million of foreign currency translation loss adjustments, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:EarningsPerSharePolicyPolicyTextBlock" id="Tb_6_t3viUH80KvH2P8evpG4A" continuedAt="Tb_6_t3viUH80KvH2P8evpG4A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont8" continuedAt="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont9"><ix:continuation id="Tb_6_t3viUH80KvH2P8evpG4A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2021, 2020 and 2019.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_gtX4G3xp7EenNuJtv6kD7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company&#39;s tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_ymyjoCtbHUSJe-aQFkjukg" continuedAt="Tb_ymyjoCtbHUSJe-aQFkjukg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2021, the FASB issued ASU&#160;2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain disclosures when they have received government assistance and when they use a grant or contribution accounting model by analogy to other accounting guidance (e.g., a grant model under IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or ASC 958-605, Not-For-Profit Entities &#8212; Revenue Recognition). Topic 832 requires the annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy of information about the nature of the transactions and the related accounting policy used to account for the transactions, the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, significant terms and conditions of the transactions, including commitments and contingencies. The guidance in ASU 2021-10 is effective for all entities for fiscal years beginning after December&#160;15,&#160;2021. Entities may apply the ASU&#8217;s provisions either prospectively to all transactions within the scope of ASC 832 that are reflected in the financial statements as of the adoption date and all new transactions entered into after the date of adoption or retrospectively. Early adoption is permitted. The Company analyzed ASU 2021-10 and does not believe the guidance will have a material impact on its consolidated financial statements since the Company has already provided disclosures regarding Government Assistance on its consolidated financial statements.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_vUcEdsBk6RvdvanGGDEQ_cont9"><ix:continuation id="Tb_ymyjoCtbHUSJe-aQFkjukg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_dJxBSxpgBUCjGOyd0bTN1A" continuedAt="Tb_dJxBSxpgBUCjGOyd0bTN1A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Collaboration and Licensing Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gilead Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2018, the Company entered into the Gilead Agreement whereby the Company and Gilead agreed to collaborate with respect to <ix:nonFraction unitRef="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfPreclinicalResearchPrograms" scale="0" id="Narr_eYkXYJQDuUKEtYBMHTbpeg">two</ix:nonFraction> preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of HBV and HIV. In February&#160;2022, the Company signed an Amended and Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic (see Note&#160;17).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Agreement, the Company granted Gilead an exclusive, royalty-bearing license to the Company&#8217;s technology platforms. Upon entering into the agreement, the Company received a non-refundable $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromNonRefundableUpFrontPayment" scale="6" id="Narr_0D9pfCaKVU6BkEslnUrkxw">10.0</ix:nonFraction>&#160;million upfront payment from Gilead. Gilead is also obligated to make additional payments to the Company upon the achievement of pre-clinical, development and commercial milestones. The development milestones amount to over $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_Xf3pHxRC4UOPsU0Tyuw4UQ" decimals="-6" format="ixt:numdotdecimal" name="hook:TotalMilestoneAmount" scale="6" id="Narr_19IdLksEgES3b47GRQgi6Q">300</ix:nonFraction>&#160;million. The commercial milestones amount to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7WLlmoedJEi4B7q-431RSw" decimals="-6" format="ixt:numdotdecimal" name="hook:TotalMilestoneAmount" scale="6" id="Narr_IOtidBmko0W4e8EXnBWVRA">115</ix:nonFraction>&#160;million. Additionally, Gilead is obligated to pay royalties on net sales for each program. Payments from Gilead generally have a <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg" format="ixt-sec:durday" name="hook:CollaborativeArrangementTermOfRoyaltyPayment" id="Narr_rheIe1TrZESAMZgF94k6Ag">60</ix:nonNumeric>&#160;days payment term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromNonRefundableUpFrontPayment" scale="6" id="Narr_otVdMLofvUW8b-iOvfjEtQ">10.0</ix:nonFraction>&#160;million upfront payment and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromMilestonePayment" scale="6" id="Narr_Psfc1V5wZEeUzMGZsvO2JQ">8.0</ix:nonFraction>&#160;million in milestone payments were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2021, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA" decimals="-5" format="ixt:numdotdecimal" name="hook:DeferredRevenuesUpfrontAndMilestonePayments" scale="6" id="Narr_gGfDjytLoEupOuw4RMtPfQ">4.3</ix:nonFraction>&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current. As of December&#160;31,&#160;2020, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw" decimals="-5" format="ixt:numdotdecimal" name="hook:DeferredRevenuesUpfrontAndMilestonePayments" scale="6" id="Narr_leNoNAIXbEuQ7CEaNbyhfQ">2.5</ix:nonFraction>&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current and non-current.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA" decimals="-5" format="ixt:numdotdecimal" name="hook:DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_AFKat8oCT0CAHsexRsNDVA">1.2</ix:nonFraction>&#160;million of cost reimbursements for research and development services were included as a liability in deferred revenues. As of December&#160;31,&#160;2020, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw" decimals="-5" format="ixt:numdotdecimal" name="hook:DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_FX-lDfI31EOgxtyf83KcaQ">2.0</ix:nonFraction>&#160;million of cost reimbursements for research and development services were included as a liability in deferred revenues. Reimbursements for external costs are recognized as revenues in the period in which the services are provided and external costs are recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the year ended December&#160;31,&#160;2021, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg" decimals="-5" format="ixt:numdotdecimal" name="hook:RevenueRecognizedUpfrontPayment" scale="6" id="Narr_IAxr9E28LU2vNMSvEQ9qSg">0.6</ix:nonFraction>&#160;million of the upfront payment received in 2018 and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsOneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_X8z0GhjTXEaCy2ODr2m1sQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_XhVijxvKDUyirzVod4dkNQ">1.5</ix:nonFraction>&#160;million of a $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromMilestonePayment" scale="6" id="Narr_JpwZRda320K9D9kaYKZsUw">4.0</ix:nonFraction>&#160;million milestone payment received in 2020. Furthermore, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_ow3gvham7kOXx_HRIKCoMg">16.3</ix:nonFraction>&#160;million revenue from cost reimbursements for research and development services, of which $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" scale="6" id="Narr_qWlvhtN04EeVS3VsOeNagQ">2.2</ix:nonFraction>&#160;million were initially recorded as deferred revenue in the consolidated balance sheet. <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsTwoMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4hozc3IA_UemHLG5L4Tssg" decimals="-5" format="ixt-sec:numwordsen" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_hEC4a4dIC0qkCFtz--0KtQ">No</ix:nonFraction> revenue has yet been recognized for another $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA" decimals="-5" format="ixt:numdotdecimal" name="hook:DeferredRevenuesMilestonePayments" scale="6" id="Narr_TjNIH96pEE2jTs2w8_472Q">4.0</ix:nonFraction>&#160;million milestone payment that was recorded as deferred revenue in December 2021. For the year ended December&#160;31,&#160;2020, revenue from reimbursement of research and development expenses was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_pZgI4XXjNEeEi-VfzQ_n0g">13.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" scale="6" id="Narr_79Kgb-8uc0a6hE-86hILoQ">1.1</ix:nonFraction>&#160;million were initially recorded as deferred revenue in the consolidated balance sheet. Furthermore, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromNonRefundableUpFrontPayment" scale="6" id="Narr__bpXzPJgokSDSn7RWJChYg">2.0</ix:nonFraction>&#160;million of the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:RevenueRecognizedUpfrontPayment" scale="6" id="Narr_6Xrie4Af2Ue_xJnIERZ7jw">10.0</ix:nonFraction>&#160;million received in 2018 and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_BTXxhdFSPUaldd3zgkFxPA">2.4</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromMilestonePayment" scale="6" id="Narr_hTrta8U-cU2f4Gy1kHwAGw">4.0</ix:nonFraction>&#160;million milestone payment received in 2020 as revenue. In addition, the Company fully recognized revenue for $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromMilestonePayments" scale="6" id="Narr_qMAwxLeyu0y9WHNXogoO5g">2.2</ix:nonFraction>&#160;million milestone payments for milestones achieved in the year ended December&#160;31, 2020. For the year ended December&#160;31,&#160;2019, revenue from reimbursement of research and development expenses was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_Se6NDYDDGEyeNQM-YICntw">4.3</ix:nonFraction>&#160;million, and revenue </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dJxBSxpgBUCjGOyd0bTN1A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">from partial recognition of the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ" decimals="-5" format="ixt:numdotdecimal" name="hook:RevenueRecognizedUpfrontPayment" scale="6" id="Narr_-i5b0CKSZUCtTL19FHBAAg">10.0</ix:nonFraction>&#160;million received in 2018 was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_kRKK4hhFqUmimB34ezmG7Q" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_NXBHuCz5vEmAhrSD8Pg1GQ">4.4</ix:nonFraction>&#160;million. Additionally, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromMilestonePayments" scale="6" id="Narr_iCYiOYFUEk-t8nYQGayf1Q">3.2</ix:nonFraction>&#160;million in milestone payments for milestones achieved in the year ended December&#160;31,&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the contract asset and the liability relating to the sublicense payment was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment" scale="6" id="Narr_E5mgZEaTDkmGr4ofVR4unA">0.3</ix:nonFraction>&#160;<span style="-sec-ix-hidden:Hidden_l0XBTDSRf02Br1mMnKhitQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span> and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment" scale="6" id="Narr_f4aeGS59-06fz5qMpfopPg">0.1</ix:nonFraction>&#160;<span style="-sec-ix-hidden:Hidden_0ppv5nVtqUW_59qTfEqsxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_0a82675e_bbfd_430e_a516_6e393c4f9708"></a><a id="Tc_kALANFu4bk29JG1lI4b04g_1_2"></a><a id="Tc_xKexgUReTEG5Jpzv08AINw_2_2"></a><a id="Tc_aJ3A4RDKfki4Ce91HG9tTA_2_5"></a><a id="Tc_V3BdQS1Aj06R0A-B9DajbQ_2_8"></a><a id="Tc_fa3f45otqES2uHjhkIX45A_2_11"></a><a id="Tc_yMVIEFNUtUq1at_adZI9JA_3_0"></a><a id="Tc_D_l3HgvQ1E2cn_jYg5VXWw_4_0"></a><a id="Tc_ycm11bVI4EWu74Ew7dKgZA_4_2"></a><a id="Tc_-AUbCKuIsUWkCsdC6R3iIQ_4_5"></a><a id="Tc_CL7pYzkvPUeruLr1Px0Tfw_4_6"></a><a id="Tc_QOPmD_6tD0eRPQ3KA89qvw_4_8"></a><a id="Tc_THFJmdfTvUuql1JC-N_LrA_4_9"></a><a id="Tc_o3Y5_J8nFUW728nVGtINUw_4_11"></a><a id="Tc_0lu_ZxdH5ka-3fM-t7mVYA_5_0"></a><a id="Tc_KEq91k6EgEaZZZ_ZgNtMgA_5_2"></a><a id="Tc_k1pF5jWrHU6Qugc_IaePRg_5_5"></a><a id="Tc_lLZSr3BOdUGcqhxGe3hyFA_5_6"></a><a id="Tc_AL94y800-Em-CIn6U7TQVA_5_8"></a><a id="Tc_5lVDvrpp3kSQ0ftgPE21zA_5_9"></a><a id="Tc_MUI0if8rqE2OwsuVe1DROg_5_11"></a><a id="_673bab4c_33f3_40ea_9ab0_de22b09266b2"></a><a id="Tc_iFOucsx1N0SQJ3gTRcvHYg_1_2"></a><a id="Tc_WFpEaLP9h0Sbye2q8P_3Cw_2_2"></a><a id="Tc_H6jzlrWCbE6YDrTM7Bu25Q_2_5"></a><a id="Tc_zFs5utu5G0iQu_goH9NLQA_2_8"></a><a id="Tc_clJmpZ8TOkyl3TsG7BoHSA_2_11"></a><a id="Tc_7htjtWS6xkugI98Ko8XFFg_3_0"></a><a id="Tc_bbEUTKBrlEmDNVs_RTKqsg_4_0"></a><a id="Tc_yqTnJn9HZE6mbwSBK7Bq3w_4_2"></a><a id="Tc_5JiKEznerUioeqzLJeAR-A_4_5"></a><a id="Tc_2OEkLw2N2EeSadPPQupUow_4_6"></a><a id="Tc__PtuwKPPk0GEeF9-Emj9Eg_4_8"></a><a id="Tc_jEqe1UTs5keEjyQ9YrPk_Q_4_9"></a><a id="Tc_R43GiX1nQ0mPI_WPhsg3FQ_4_11"></a><a id="Tc_Mt2TD1LjjUODCwfDqI3eFg_5_0"></a><a id="Tc_VHiBNZ41IkS5Tr7Uow4WGg_5_2"></a><a id="Tc_ARFNdCjlgUOBNLVMBEv1Iw_5_5"></a><a id="Tc_zET6lvb2REmgdPvWISDuWw_5_6"></a><a id="Tc_3_aW_KmQM0GsFulr004w6g_5_8"></a><a id="Tc_f7eFWq6dakW5TJc-jBPunw_5_9"></a><a id="Tc_BhL8KA8inEiY8whEc0lJWw_5_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_m-ijQPNgJ0q3k8mQJVRj4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Fair Value of Financial Assets</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Group_xULbqDTXFE-5L6h5SLDzRQ" continuedAt="Group_xULbqDTXFE-5L6h5SLDzRQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p></ix:nonNumeric><ix:continuation id="Group_xULbqDTXFE-5L6h5SLDzRQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2021 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OLb_2bn0qEy2UW_m4JwHoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_BRC26Bwz9k2BoeQb8vkH9Q_4_3">35,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHJvZ8_EJ0OzSnSQBM0_6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_nCv9Qa78WkCHIyELvNufhQ_4_12">35,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0cA_3wN87kC_T3pK3UXc2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_cmSqxyv42EOcOwEagF2GpQ_5_3">35,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DNp-TcR4d0uu2uDNfHmJLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_N4Ej_mePt0eQ1QEC1rxX0w_5_12">35,403</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2020 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ld1bC-KnG0yjbLLvZcbh9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_pz6S730AnkKUS4mn81cOxw_4_3">35,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U3zEzG1qXkK9lJ83V5wUyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Fci7b1IpA0W5pyQeVIzrfQ_4_12">35,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Hi8vNfG0OketOKVTNEWdKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_7Z1ZPNwV7UWFMmJjp2DbMg_5_3">35,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3LNaEjX6U06CsywOTygF8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_W6voE-_XP0yUF_-6iybv0w_5_12">35,397</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the </span><span style="-sec-ix-hidden:Hidden_Ig22UHVZRkKGX2x0KG_1_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">year</span></span><span style="font-weight:normal;"> ended </span><span style="-sec-ix-hidden:Hidden_ilfqJ_zyb0aZGfg-9XrTsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2021</span></span><span style="font-weight:normal;">, there were </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="3" id="Narr_iOAiQtdDx0yKD8KIev0uBw">no</ix:nonFraction></span><span style="font-weight:normal;"> transfers between Level&#160;1, Level&#160;2 and Level&#160;</span><span style="-sec-ix-hidden:Hidden_yp-p9Vk_-kOWrEU_xREtbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span><span style="font-weight:normal;">.</span></p></ix:nonNumeric><a id="_324612f0_fbe2_4388_9704_940a5b976acb"></a><a id="Tc_mHcc1J2ayUi5uTvskWVbGw_1_2"></a><a id="Tc_yoGYd3Z7akiHky_tdKn0Fg_1_5"></a><a id="Tc_DLXGsLFXnE2SQ2A3vVPr-Q_2_2"></a><a id="Tc_rzykTvmBrEiNV6GQrpHuYA_2_5"></a><a id="Tc_3sk5ty3UTUmt-bt1EYFi7g_4_0"></a><a id="Tc_0f9kyd6GzkK8KR2ly7LLIw_4_2"></a><a id="Tc_SVD0Htvnrk6LLDFRJhS0oA_4_5"></a><a id="Tc_T7z9ORn9Kkaq5CLqHi1PUA_4_6"></a><a id="Tc_01n6A-fzq0mW88XjpJ9BMg_5_0"></a><a id="Tc__GCSpPtsTEa3z7a0jOZrEQ_6_0"></a><a id="Tc_uje-NTsdwU2VPYrAHu8wNg_7_0"></a><a id="Tc_fMi3v3U8-0qaUrt2MvpMUA_8_0"></a><a id="Tc_uQtoauZT7kS1qTh1LFH3Sg_9_0"></a><a id="Tc_FuekpiTCt0in6T_jM-UUsA_10_0"></a><a id="Tc_C-PXnRrQSEWJ5RuoEvI1UA_11_0"></a><a id="Tc_ClIZQBIXlk-u2j9K8bexKA_12_0"></a><a id="Tc_Pc0k-Yb55E6NBLz1VezJoQ_12_2"></a><a id="Tc_hwbObjJNDkqwp1eePiTxrA_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_JTMsB8Xf8kOlLgaT7sljtw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Property, plant and equipment, net</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_yOScjkf45UG26Oo0tKRv6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_zjRiqY7na0mdESnAmAgN5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_my05pBGDBEmas4lyOYcWnw_4_3">2,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oM1lWRGbvEiE-FT3XrMDcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_5qwb9h73x02A22QCK-a24Q_5_3">3,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j9QTccxA8kSS8q3279Cm-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0HVxQjyCjUqY73BnJYS14A_5_6">3,322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_p1qmf6wjLk6uR_JhX4mV2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8TebJHZqy0e3J7jUz-cgrQ_6_3">7,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_B5fIRUIsikiF5KXD5x6cHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_qS5ZQD712kOb7uap_zXA6g_6_6">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kZ2Gy961l0-3UxadFPp3yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_CY-gy6Zcz0S8JiBUOgXu7w_7_3">7,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mmAIdyTOBEGGYm394Dfgdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6Iy8VNEjW0q1lLLSoSn7XA_7_6">5,982</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_h3bbPTbCck67We_5POyRoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_KGF3RFGRSU6bUJ0x2HGOTA_8_3">651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_7otYFkeHoUKeaKz76AWKEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_NqzF40QFrkaThwkHWhAXZw_8_6">430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_03RMuix68kaDY62cZtc7HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HqSlVH5ndkSn9PVB4M5EdA_9_3">1,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Ft-tF1iTN0Gyv_gaYiFXZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_dtGOaaEGzEid7b9Be5FwQQ_9_6">1,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_GshhRIlgBE-BBuB_6DMGig_10_3">22,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Kv124O4tvUyLIAqIU8HhkA_10_6">11,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_ZZ3tN50wYU-pTNluZIETOw_11_3">6,366</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_HWgusHq39UOKN70jHygg0A_11_6">5,097</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_L5rbciMCjk6ximB6VO7cGg_12_3">16,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_IT4CyRtTuE60E-LAuJkSYw_12_6">6,219</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depreciation expense for the years ended December&#160;31,&#160;2021, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_tujc6h8vWU6c5EGAAU8l7Q">2.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_qSzs0GaB4kij7gDc2zz_mg">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_6ZbcglxPDEKyKs-p9j4MBA">1.1</ix:nonFraction>&#160;million, respectively. Construction-in-progress as of December&#160;31,&#160;2021 related to investments in connection with the Company&#8217;s GMP manufacturing facility project. Construction-in-progress as of December&#160;31,&#160;2020 related to implementation costs for a cloud computing arrangement which is a service contract.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:ReceivableResearchIncentiveTextBlock" id="Tb_vwkZEq0UA0iOsY_66C5_Hw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6.&#160;Receivable research incentive<span style="font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company participates in a research incentive program provided by the Austrian government under which it is entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority. Reimbursements received in excess of the recognized receivable research incentive for a certain period are recorded within other long term liabilities for potential repayment until such time that an audit has taken place, upon expiration of the potential reclaim period, or when it is no longer probable that a reclaim will happen. The years 2018 to present remain open to examination by the authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, the Company recognized receivables of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="6" id="Narr_dNOWAGIdO0KQOpuBiAKySw">14.3</ix:nonFraction>&#160;million from the research incentive program, which are reported in research incentive receivables in the Company&#8217;s consolidated balance sheet. As of December&#160;31,&#160;2020, the receivables from the research incentive program were $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-5" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="6" id="Narr_U_gJb3IvK0-v4toMAGjoCw">15.1</ix:nonFraction>&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_zHAlf82x9EqkOmyW6AXKUA">8.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_JhZYQ5m1QE6APq9Al0pCzw">5.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_L4XHPUiAuk6eTcIM52cuaA">5.9</ix:nonFraction>&#160;million, respectively, of income related to the incentive program within the Company&#8217;s consolidated statements of operations as part of the grant income.</p></ix:nonNumeric><a id="_91b3cec4_62ce_4e70_8416_fa9daf80d7aa"></a><a id="Tc_zsCRNdrdAUqsIXtNLmxzmg_1_4"></a><a id="Tc_D-CjYvZOtECos0CY5wUILQ_1_7"></a><a id="Tc_iHKMPi8L3EyfMgfQbPM8Pg_2_2"></a><a id="Tc_daASpBEpjUehIvwmXi71bg_2_4"></a><a id="Tc_goFHEgiJuEmbPpZyqAxSKw_2_7"></a><a id="Tc_ytmHRZZdwkeBA1N8vw9wAA_3_0"></a><a id="Tc_-Lb1cLuv-0C9vAM2Oq0Peg_4_0"></a><a id="Tc_TSh7CBSdU0KTF3gDuzmmOg_4_2"></a><a id="Tc_mLkPYgkKJ0aCLINq0aeXXA_4_4"></a><a id="Tc_w960IZJo_kqNLqw3AV2LsQ_4_7"></a><a id="Tc_e0CTXtHyb0-Hgt3nS-CQDA_5_0"></a><a id="Tc_mraMCmpT7Ui63n-b7zsWAQ_5_2"></a><a id="Tc_x9JV3V-rQ0-rCqFIv1R_8Q_6_0"></a><a id="Tc_sCyNeV2UbUuZAnPLGkoeIQ_7_0"></a><a id="Tc_0exXuqF_qkeQTSfY2aBmCA_8_0"></a><a id="Tc_udhhQ1sznES5kqeDG_ngfw_8_2"></a><a id="Tc_YSwLltA-40C5gRR4FFNbEw_9_0"></a><a id="Tc_fK0ddRn8dEad4JvvUC70MA_10_0"></a><a id="Tc_1wqW3UzGAEiiKVlWUf72_Q_11_0"></a><a id="Tc_LnbAqMIpNE6X2L3qDqEGOg_11_2"></a><a id="Tc_pkeP7DytPESTGi7lzVZMeg_12_0"></a><a id="Tc_8pYU2hiot06Ssvl3dzEIBw_12_5"></a><a id="Tc_QWnFsk8dLUu_zqvOD77pOw_13_0"></a><a id="Tc_3UoFPVImZkmSm_8rDY9CIg_14_0"></a><a id="Tc_G1niGzckUUWJqlLlD9S9Tg_14_4"></a><a id="Tc_shngANLtekWiG4GBEmrknA_14_7"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:LeaseDisclosureTextBlock" id="Tb_Tkk-oSQXXkamZDwFivRHLA" continuedAt="Tb_Tkk-oSQXXkamZDwFivRHLA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases real estate, including office and laboratory space and has entered into various other agreements with respect to assets used in conducting its business. The Company&#8217;s leases have remaining lease terms ranging from less than <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ilxWs-hFzUu1oK7UGRu04Q" format="ixt-sec:duryear" name="hook:LesseeLeaseRemainingTermOfContract" id="Narr_EszXiXf95k2vWCqsh_BsVA">1</ix:nonNumeric>&#160;year to <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA" format="ixt-sec:duryear" name="hook:LesseeLeaseRemainingTermOfContract" id="Narr_nPo9irIVAUyDRSlm0ih2XA">4</ix:nonNumeric>&#160;years. Some of the lease agreements contain rent holidays and rent escalation clauses that were included in the calculation of the right of use assets and lease liabilities. The Company is required to maintain a cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_JLhukfkj6EyF25fX0pOyfw">0.4</ix:nonFraction>&#160;million to secure letters of credit associated with real estate leases. This amount was classified as non-current restricted cash in the consolidated balance sheet as of December&#160;31,&#160;<span style="white-space:pre-wrap;">2021.  </span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:ScheduleOfOperatingAndFinanceLeasesTableTextBlock" id="Tb_gNRCyLbspUKKQebGnGdKvw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain of the Company&#8217;s leases qualify as operating leases, and certain of its leases qualify as finance leases. The following table summarizes the presentation in the consolidated balance sheets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;sheet&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_jyACD6av40aDkkdCs6XeyQ_4_5">5,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_htap-gkRfkG3TjxINz40eg_4_8">6,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_NKejLptzv0ykFsYiKBLHVQ_5_5">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_jZUflAotYk-KB6AU3_MmnA_5_8">1,298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseRightOfUseAsset" scale="3" id="Tc_4cI_aEuH_ESDQHxiIaP6hA_6_5">5,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseRightOfUseAsset" scale="3" id="Tc_0LfzRkW-R0aut6nRCoq0Zg_6_8">7,750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_yHaAAhITTESo9te_OuNlmg_8_5">1,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_PF9YYDSCgU6u4_CaqVyLRQ_8_8">1,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current finance lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_oRmXSROYc0OcSjQ6MQGWpg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_QhGPPbkpwkWu7RzYsWxdxw_9_5">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_I2_qmO1THEqHGFPD1twKnA_9_8">155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseLiabilityCurrent" scale="3" id="Tc_RfSYwIn8V0SdsPGYtRLTgQ_10_5">1,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseLiabilityCurrent" scale="3" id="Tc_95VqjQ0kFECwMoXKPWsP5w_10_8">2,153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Jgpo4_hpt0m2pu9l7yT8zg_11_5">3,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_CZrOmO53WkKvuKyxB-QmAw_11_8">3,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current finance lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qGfyuLYvk0GVroGAArA9Ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other non-current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_i_C4yTEoy0qfTEWvBryGww_12_8">258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total non-current lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseLiabilityNoncurrent" scale="3" id="Tc_sFzciaZeZkWKs0wBl0m9Ow_13_5">3,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseLiabilityNoncurrent" scale="3" id="Tc_EdEU9m18WEqUV18p-LQSUg_13_8">4,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseLiabilityTotal" scale="3" id="Tc_0oUXyEFCbky5GnCynCpybg_14_5">5,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseLiabilityTotal" scale="3" id="Tc_JmghNCSdrUu-fpnWSlgb6A_14_8">6,230</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the years ended December&#160;31,&#160;2021 and 2020 the Company terminated leases of parking spaces and derecognized the relating right of use asset and the lease liability which were insignificant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_3b03472e_bcfb_4ea6_896a_4e1976dfb433"></a><a id="Tc_8QgSA2dCNUu31BH20nWXIQ_1_4"></a><a id="Tc_9d0fOXg6NUK4HCHIfsp9RA_1_7"></a><a id="Tc_Y52Vo0fgNU2ybUUVcI-IIg_2_2"></a><a id="Tc_ZOKWTiBzOUKH484-0jjwLw_2_4"></a><a id="Tc_Hwrh5FKhZUmuPLR1FfM78w_2_7"></a><a id="Tc_y0w2EeDJoEO2PtVU2eJSdg_3_0"></a><a id="Tc_p_poH0E3ZEywXS3V2o24Bg_3_2"></a><a id="Tc_SY3b9cb-yk-PoBrvI5iw1w_3_4"></a><a id="Tc_tCQVp1G_7keM9ukJc8QHmw_3_7"></a><a id="Tc_zAvKY7hq7kuSO9AXYM1I9Q_4_2"></a><a id="Tc_5NZzrxmAC0SLZcG3iNG-_w_5_0"></a><a id="Tc_bTvrvZrlt0-FW03x4NvKjg_5_2"></a><a id="Tc_3iFejTjX1UWwuYUD_0KnUg_6_2"></a><a id="Tc_5vVQAM_2S0uJ9TD3_hCILQ_7_0"></a><a id="Tc_Fk_pSiicOk-R4EYBTISxRw_7_2"></a><a id="Tc_3n2niXHi206yMy0_8jZd0A_8_0"></a><a id="Tc_LyULQltEgkinH7fh0_Kb4Q_8_2"></a><a id="Tc_eYak_GHar0OPMMwbPaxlig_9_0"></a><a id="Tc_cgBbqjqr8UOnG2DysMgG2A_9_4"></a><a id="Tc_F22p0dbtxUu3efnMGgcq2g_9_7"></a><a id="_e48b4274_19cc_4294_ba73_67d3c36395ef"></a><a id="Tc_DHEJ_LjOvUmp7ZmdzJWwHg_1_2"></a><a id="Tc_kxl6SD-keUm9iosy7JSc1w_2_2"></a><a id="Tc_2ONooCNdBEWdeN7scCHLjA_2_5"></a><a id="Tc_8mowg4d_VEWNQ2qFmghN2Q_2_8"></a><a id="Tc_QVcXr4yf-E6poT6rnR_Nsw_3_0"></a><a id="Tc_ae-Bw6H_GkGCEDq7J7K1vA_4_0"></a><a id="Tc_bXEgaVo0rUazRDpAju27dw_4_6"></a><a id="Tc_BCI3_fCGjE6F4qdpUdFFKA_5_0"></a><a id="Tc_rvdqXH91tEaCi7qNX4ytaA_5_6"></a><a id="Tc_XLv-F-2oTEqbX4jwcvGdow_6_0"></a><a id="Tc_DId2Qc3hK0utb5QHJa_RLA_6_6"></a><a id="Tc_yu_NCzMzD0uOKjyTxeAwMw_7_0"></a><a id="Tc_4ooRN4k6f0O_QYnRAXpIdQ_7_3"></a><a id="Tc_jTk8iyRT5U-Ud0TRTfurTw_7_6"></a><a id="Tc_8aVV2T5ksUe0yxYYz1vx-Q_7_9"></a><a id="Tc_GpGErSQ3k0afUABFGqVaCw_8_0"></a><a id="Tc_-qu4BZjUHkmP9keHbX3jew_8_3"></a><a id="Tc_3G5qBayDe0insKxHahS5Dg_8_6"></a><a id="Tc_MVOcS1D6ZEudydzXgirpRA_8_9"></a><a id="Tc_Gof0kjP6s0CbemcBlNWFdQ_9_0"></a><a id="Tc_E_-tnia7EkyOfif2CAQWSw_10_0"></a><a id="Tc_7jUSlE-N2UuybgTGVC5NZw_11_0"></a><a id="Tc_teujiXwTIkGGfBZaIG3cqw_11_2"></a><a id="Tc_hJkzjZjvQEWMC_6l8cWScA_11_5"></a><a id="Tc_1DvhH3JzQ0-REU6zplBz7Q_11_8"></a><a id="_e51bb9cc_035a_4dd5_9be4_88a37cc8cb08"></a><a id="Tc_BRcG7x9bOEWZDDS2krgfIg_1_2"></a><a id="Tc_FUici-I0X0KSHjqO2fp8Cw_1_5"></a><a id="Tc_gcT40xghPkaEmh-GaYAlrw_2_2"></a><a id="Tc_pUtaSh19M0y8wXp25tv2Sg_2_5"></a><a id="Tc_Af-UxfUhSEKNSvBI5EfQVg_3_0"></a><a id="Tc_aRDNqPxzqEOg8IgVKMQL_g_4_0"></a><a id="Tc_nPel0h0o00qi5nl_XIh10g_4_3"></a><a id="Tc_tfnphV4V1EeiU0JkFhWiiQ_4_6"></a><a id="_08fd9d2a_8eaa_4f72_9fb6_0e04e906e8ba"></a><a id="Tc_eLOu9auyUke7VerDrxjvvw_1_2"></a><a id="Tc_yBtwUS6jYEO5nFRaGhWlvA_1_5"></a><a id="Tc_8GqNgXRTSEuvnV_yuwhRww_2_2"></a><a id="Tc_eUXliAqwoUuBUiaXyBaUSQ_2_5"></a><a id="Tc_YYPbv_kYvUmy5W5qQw8emg_3_0"></a><a id="Tc_yHOE7Pp-HkqUA9TOEdfQXw_4_0"></a><a id="Tc_EQ0eMjtypkmhqYKJNyRYOQ_4_3"></a><a id="Tc_lStD6GQHkUiJz5bO82Y7fA_4_6"></a><ix:continuation id="Tb_Tkk-oSQXXkamZDwFivRHLA_cont1" continuedAt="Tb_Tkk-oSQXXkamZDwFivRHLA_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:LeaseCostTableTextBlock" id="Tb_SOeqZRgQMEOTPxpVM9gp0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income&#160;statement&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_h6ExScbGzkCtq_0wHPkGRA_3_5">1,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_DJo8XqFi8keeSDukjfop-w_3_8">1,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_6UkbMQaYN0GqwIHnrOlHCg_4_5">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_7pMJdPjFAk6yfLaLah-L7g_4_8">376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_jy8rQp3-mE6rGZ8tGN5XXw_5_5">425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_KHEjzrDhi0mXYn7xFYo-ew_5_8">395</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_vAv-IPozXU2yv48lUBGm3w_6_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_ZSXAnhbQDEWlvpWgTrIhtg_6_8">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_lfUPt9xHTECs1PBzglCNhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_STfK_VLrAUuHf6x-lYCNtA_7_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_Ayr8wO2i8EqBHFydPDrBIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_P9j2geKSIE2ByUmjOF-GUA_7_8">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_1-rISPKNH0inC5yV4XqosA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_itYmrbzS50yk3oSip2Igpg_8_5">40</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_iaIK2Z0eQUemaaWm5dk9Hw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_H6oEEB7QbUWM_8phBALCRQ_8_8">155</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_Bf2YmTBzr0Wx1uRcKdfWtg_9_5">2,510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_cQDsPrCb_EWAOqlfmvFhnQ_9_8">2,299</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb_YbiTq7T9RUCBscxaaKFAGw" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_qdRP1J8bxkqEN70ap-Ukkg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_PJX7TXWVQUma-3xO0mDvmw_3_3">1,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_L1zL58hghU-OjwFLsb9R-A_3_6">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_xLG21SXjI0WrXVOiPjiSAw_3_9">1,606</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_qxdP_cSsIUaSYWzy0GLYDQ_4_3">1,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_1Q3mVbdzukapbswOYpBehQ_4_9">1,547</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_gyh36sqJT0WZ3JcKCGA-SA_5_3">1,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_uPvo82g4X0iWW7GdOCIrNg_5_9">1,340</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_aIE9VKY9QkO4VSlR9lT1OQ_6_3">1,242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_D_y8LUgiyEeSr2nyVetkuw_6_9">1,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_4-sA7mObpkOzc5rJTUwjzA_9_3">5,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_Gs8DTdc2_kCDuft_m2hMwA_9_6">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_6ZQ4ByyFM02kdYVQQNWWYw_9_9">5,735</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_VNdncnANO0-wOO5YjNzuHA_10_3">121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_rUXrEkp300qNVNQXYV_VsQ_10_6">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_0m3cf6Bsn0y1cxTLSr7isg_10_9">121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_7W3YpsJdVUWPXD3UeL3RwQ_11_3">5,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_rNRMMlWfdkStu_EIYPrTzw_11_6">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:OperatingAndFinanceLeaseLiability" scale="3" id="Tc_Yjv-GacSWkW_EO9J-YFH3Q_11_9">5,614</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" id="Tb_QMRkltc3YUWBPFNEjWtmzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_ZNLqCW0z90-kwSQwonj8GA_3_2"> 3.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_b2N4ruMAN0SFJKOTWBXY_g_3_5"> 3.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Gf1JdFy-8E-RdYslP-5Apw_4_2">1.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_FxTGsqZYHUu1KP-siUP4Ng_4_5">2.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases" id="Tb_Ke5kzAM4uE6BzS9RDBsuXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of finance leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_-5k5KV_JMUuV7yUPwQ1RvQ_3_2"> 0.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_dn1csC0k6Uyf1gFqRTbroA_3_5"> 3.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_WBCmw5PM_UGFFCOeQ3jOdA_4_2">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_BQSx1Fjl1kS08dfvDhMDrQ_4_5">1.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December&#160;2021 the Company extended the lease term of existing operating leases for the office and laboratory space in Vienna, Austria. The respective lease liabilities were remeasured and the amounts resulting from the remeasurement of the lease liability were recognized as an adjustment to the corresponding right of use asset. Also in December&#160;2021, the Company reduced the lease term for existing operating and finance leases related to an agreement </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Tkk-oSQXXkamZDwFivRHLA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with a contract manufacturing organization for the production of clinical trial material and accounted for the proportionate decrease in the lease liability and the right of use asset with the difference recognized as a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_FbkMEjEJl0WQtmJecOY1vw" decimals="-5" format="ixt:numdotdecimal" name="hook:LeaseModificationLoss" scale="6" id="Narr_tgGpxFxLHkGWyJJhDoWeNg">1.0</ix:nonFraction>&#160;million on lease modification in operating research and development expenses on the income statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until March&#160;2021, the Company subleased certain of its leased real estate that it did not utilize to a third party. The sublease was qualified as an operating lease. The Company recognized sublease income in its consolidated statements of operations and comprehensive loss. The sublease had no influence on the Company&#8217;s accounting for the head lease.</p></ix:continuation><a id="_50b91dcb_7572_4708_88f8_2bf223e60501"></a><a id="Tc_81vLV_SL7EinYMnWetSxZg_1_2"></a><a id="Tc_gVVJ3qIdP0qQbJsMwx7dhA_1_5"></a><a id="Tc_FLMw-dvkCUe2t31sHxA2GQ_2_2"></a><a id="Tc_7K2rWckHRUGIlD3j0gP6Hw_2_5"></a><a id="Tc_rWpkwhcxvkumpacQgAMa9g_3_0"></a><a id="Tc_PJJEHwcY6UCRJGNr_M7mmQ_4_0"></a><a id="Tc_1lNNwcJQBkC4wa-FnIdBgA_5_0"></a><a id="Tc_KmxzsKcpfEGqnsQY9d7O7Q_6_0"></a><a id="Tc_XFmVl9xVf0y5gjaE0nvxsA_6_6"></a><a id="Tc_o-h6aRDm5E2JqEavGL6oRg_7_0"></a><a id="Tc_9H_378Nw2k23Mky7nxnX1w_8_0"></a><a id="Tc_YOvrEXpeuke4oy7qZbx2Qw_9_0"></a><a id="Tc_mRQ8BGAyhUK09npfZUzdMQ_9_6"></a><a id="Tc_bQDn1NAxMUmvZR4btMUzgw_10_0"></a><a id="Tc_vQcDEhvI70OFo08ifuLzHg_11_0"></a><a id="Tc_DM0IIl0gKUuHrwpIQ4S9Nw_12_2"></a><a id="Tc_Ir1TO0Exoke9pNrznEDDqg_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_cislyinUjkqN-FMDxoiGqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;Accrued expenses and other current liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" id="Tb_oq3n_ardDEmb9S1aztcOcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Salaries and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_wDe8V82p70KeK29R73tWqA_3_3">4,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_fjNHea_0RECtWj9a2xcYJA_3_6">4,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Social security contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedSocialSecurityContributionsCurrent" scale="3" id="Tc_lYg40UAyVki16b_TsAaSCw_4_3">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedSocialSecurityContributionsCurrent" scale="3" id="Tc_27QD2vmy5k69qRGI4gzZDg_4_6">211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned grant income (current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedUnearnedGrantIncomeCurrent" scale="3" id="Tc_JOzFl90zAkKSXoDG4NZcmA_5_3">693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedUnearnedGrantIncomeCurrent" scale="3" id="Tc_fQlfZ6UZbUCFRgc4chfLew_5_6">878</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublicense fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedSubLicenseFees" scale="3" id="Tc_oWNYTJUmCUuz1fbRKmefTA_6_3">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalResearchAndDevelopmentExpenses" scale="3" id="Tc_StGaxMC4sUarFq-Cr5kIvQ_7_3">2,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalResearchAndDevelopmentExpenses" scale="3" id="Tc_lqJShWScpEOa_ZuW1lAeow_7_6">895</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external general and administration expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalGeneralAndAdministrationExpenses" scale="3" id="Tc_lFdNXZGjhU28TYZaOrGQqw_8_3">629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalGeneralAndAdministrationExpenses" scale="3" id="Tc_d6LYNIzWzESxBqlArC3kVw_8_6">634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued for property and equipment acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesForPropertyAndEquipmentAcquisitions" scale="3" id="Tc_HRZWCPA-Ok2g6lnhZknYmg_9_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_jWRMN8ojRUGiyPHui6B6Vg_10_3">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_hdz5kqDxO0im4b2zUyvffw_10_6">155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="Tc_5LP8r5e4jEuRHMqhNESK5g_11_3">57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="Tc_lM8BvIEM00WTIcdCBTvDnw_11_6">232</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_vb5xFTJww0qb3MB0QvL9kQ_12_3">8,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_gw54ffbFI02grW1Vex3GUg_12_6">7,386</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_169030fa_6a57_4e7a_94bd_d7a0eb5e62b1"></a><a id="Tc_Jh6tbLCMvEOj05CCLUromQ_1_2"></a><a id="Tc_v3Aqb-vBQUCWFtnHJu8V9g_1_5"></a><a id="Tc_-WDIVX_xoEWVWp4r5u7e0A_2_2"></a><a id="Tc_p2DqQk3efk-ac36anNofWQ_2_5"></a><a id="Tc_IborogFtwEe2aprH5s2S5g_3_0"></a><a id="Tc_wTr-oAmm4kqfp5iTLllZnw_3_2"></a><a id="Tc_JH6dDdnhX0eYSIoX2ppuwQ_3_5"></a><a id="Tc_Pdgdv4-J70W1IcjPT2WcAg_4_0"></a><a id="Tc_N6S8en-Pf0O8E26ghn0mpA_5_0"></a><a id="Tc_FCVme5VmZU6ldcsjpm9sjA_5_2"></a><a id="Tc_UUNCHaxdA0OBtHBEK0n5Cg_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:DisclosureOfLongTermLoansPayableTextBlock" id="Tb_Jyq2Wy3UdECpC9WSJ_rVOw" continuedAt="Tb_Jyq2Wy3UdECpC9WSJ_rVOw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Loans payable</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="hook:DisclosureOfLongTermLoansPayableTableTextBlock" id="Tb_JcAZGxeVfUqRd1iqZEYcwQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, loans payable consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loans from FFG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LongTermLoansPayableGross" scale="3" id="Tc_J2ebBs717k2eDFB8rJ-rCA_3_3">6,074</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:LongTermLoansPayableGross" scale="3" id="Tc_ezvtkALsJEm-H5tqgpO9vw_3_6">6,564</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unamortized debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" scale="3" id="Tc_i_vL1s0d30STJPhlqkeCaQ_4_3">1,063</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" scale="3" id="Tc_GZI9p6t5R023fCYW6aoIxg_4_6">2,027</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_x0lIaUAzx06Ok8eqU5HNCA_5_3">5,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_vT-cIZDoOUSX0ofkt2-cgw_5_6">4,537</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the funding agreements with the Austrian Research Promotion Agency, (<i style="font-style:italic;">&#214;sterreichische Forschungsf&#246;rderungsgesellschaft, </i>or &#8220;FFG&#8221;), the Company has received various loans (&#8220;FFG Loans&#8221;). The FFG Loans were made on a project-by-project basis. Amounts due under the FFG Loans bear interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_fedfuroZikeEnO0bD5LFLw">0.75</ix:nonFraction>%&#160;per annum and mature at various dates between June&#160;2022 and March&#160;2024. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FFG Loans bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between an estimated market rate of interest and the rate of interest charged by FFG as grant income from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company recognized grant income of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FgZEcu-x6ESzKZv_nwLtiw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_Dg90mXQLkEi_rbGMOVDVOA">0.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_M7e0-G2Jc0mMZbDTVrVaQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_vZnTBbbttEWQwAltXarxAA">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_WVL2EC15ZUqXg0iRX6l96w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_1xw2Z9lmsUKYLTiWx9ETWw">0.8</ix:nonFraction>&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, related to the recognition of the unearned income recorded for the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_92a13a5d_28a2_401f_92b3_b30b5091f1b4"></a><a id="Tc_Gu1zysFeq0-b641yB7gsYg_1_0"></a><a id="Tc_bFnY_LQVvk-21jD2-8uI-A_1_2"></a><a id="Tc_A5Q1E-3r6U2TPYGslngRBg_2_0"></a><a id="Tc_Xc4JbmPZ_kq8rT9C0ypJLw_3_0"></a><a id="Tc_SVrpYaaJrE6Gh1v9TxmuPQ_4_0"></a><a id="Tc_677jAQOR00Oh4ZQWPUiotg_5_0"></a><a id="Tc_ce_s-4Qt4EqZ1FRCo_Qhbg_5_3"></a><a id="Tc_eAHEjvxMRUSdxaTGkza3zA_6_0"></a><a id="Tc_7qRKf9aq80iPd0JyphacBQ_6_3"></a><a id="Tc_5W7qp1NMK0CUJKx1Kj88fg_7_0"></a><a id="Tc_0opTNOuy0k-WXpik4tySCQ_7_3"></a><a id="Tc_QR5y_A8FlUuXK1xrz8XxFg_8_0"></a><a id="Tc_C-7e6Wuh602XQbl2xIW2EA_8_2"></a><ix:continuation id="Tb_Jyq2Wy3UdECpC9WSJ_rVOw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">imputed benefit of FFG Loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG Loans at below-market interest rates was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_tyTRnlIXPUi1yW0nB28asw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_1rUnXJJeXki2lhLfUha71A">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_VGIrjRmoLU2n3YXR5TnwLQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_HGAVlmT0AUGDuBLR2n_bWA">0.9</ix:nonFraction>&#160;million as of December&#160;31,&#160;2021 and 2020, respectively, and unearned income (non-current) presented under loans payable non-current related to such benefit was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_tyTRnlIXPUi1yW0nB28asw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_UGAXcez2F02_IW5n95dm3A">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_VGIrjRmoLU2n3YXR5TnwLQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_fFaSjUf7uE-soSyFC1X6vA">1.1</ix:nonFraction>&#160;million as of December&#160;31,&#160;2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has recorded a discount to the carrying value of each FFG Loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of December&#160;31,&#160;2021 and 2020, the unamortized debt discount related to FFG Loans was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_0mR7nIdhC0iemdOtJ5QWpg">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_IwHtVwf1kUmTCsV0nvgM1w">2.0</ix:nonFraction>&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized interest expense of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_LTXqQzQV2kWL3ZqkFykLTA">0.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_iKdmzKZUIUijWIUDiLDS4A">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_fzZVSX6b9E26ARwCFpdLcg">0.9</ix:nonFraction>&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, related to the FFG Loans, which included interest expense related to the amortization of debt discount of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_haWUF8gpYUKhyWnbk0CLig">0.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_ygKFaR9L20u0hfGtqzFLMA">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_w0KZ71dGW0it-rqhQuJFnw">0.8</ix:nonFraction>&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_S9826B1wj0K5tz1AcaO0Rg">No</ix:nonFraction> principal payment and a principal payment of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_FMYCjlZKIU-e6H78TE2K3w">1.3</ix:nonFraction>&#160;million was made in the years ended December&#160;31,&#160;2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses an estimated market rate of <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="hook:DebtInstrumentEstimatedMarketRatePercent" scale="-2" id="Narr_juA1yaHR0E2VF2Xjxtkk_Q">20</ix:nonFraction>%, which was determined based on an average of the available interest rates on unsecured loans to comparable companies. A <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInEstimatedMarketRate" scale="-2" id="Narr_bcWEQb3yZEOpXMrlAM69yA">10</ix:nonFraction>% increase or decrease in the estimated market rate of interest would have no material impact on grant income or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of the Company&#39;s assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2019, the Company agreed to an earlier repayment schedule for $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_11_1_2019_To_11_30_2019_1iZi9iUIoEu0KQgEUiQByw" decimals="-5" format="ixt:numdotdecimal" name="hook:LongTermLoansEarlyRepayment" scale="6" id="Narr_kW3BW0vzY0aAli0IPSGSFg">3.3</ix:nonFraction>&#160;million of the outstanding loans with FFG. As a result of the change, the Company reduced the deferred income attributable to the imputed benefit from below market interest by $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_11_30_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_kFwGKKMO6U2oE6qi3AFdmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" sign="-" scale="6" id="Narr_UwpQTXXHYEijqbAmLwj_fQ">0.3</ix:nonFraction>&#160;million and increased the carrying value of the loans by the same amount. The change had no effect on the income of the year ended December&#160;31,&#160;2019 and the effect on the aggregate future cash flows under the loans is immaterial.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="Tb_NB8pQthc306Wczz4G4Si1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31,&#160;2021, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Calendar&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2022</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_XFQEQ59cPECcbAmaX0XUQg_2_3">3,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2023</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_xZBIjWnhYE2rlooJxEDZrA_3_3">1,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2024</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_xMYKLMzkJ0auPJEr_qX8TQ_4_3">1,199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2026</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_xVxFSM0C00mJE2NfNopc1A_8_3">6,074</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_RxT0UtfCjEGYZiysUEltkw" continuedAt="Tb_RxT0UtfCjEGYZiysUEltkw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Common stock, Class A common stock and convertible preferred stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s capital structure consists of common stock, Class A common stock and preferred stock. As of December&#160;31,&#160;2021, the Company was authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr__qBWwvtrzEuqzy5is342QA">100,000,000</ix:nonFraction> shares of common stock, <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_CK-MMSNfYk-zepc4IUSWIg">3,900,000</ix:nonFraction>&#160;shares of Class&#160;A common stock and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_50MjNT2fakqL7CNnc2_LrA">10,000,000</ix:nonFraction> shares of preferred stock. The Company has designated <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_4iRG8wu76kajQ84EheeD8A">2,978</ix:nonFraction> of the <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_YcFx596ymkW6fNzhroKxEg">10,000,000</ix:nonFraction> authorized shares of preferred stock as non-voting Series A convertible preferred stock. As of December&#160;31,&#160;2021, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_XzZhVWdeV0ukG5uMrbmWyA">27,383,483</ix:nonFraction>&#160;shares of <span style="-sec-ix-hidden:Hidden_0vCtFWOMdU6TUe8bLbDs8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common stock</span></span>, <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_8lRJTO8roE-8GuxZt78vfg">3,819,732</ix:nonFraction>&#160;shares of <span style="-sec-ix-hidden:Hidden_lsKpVaKZlU2VrubLnN7E_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class&#160;A common stock</span></span> and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_DblSBhd-b0mUSu9qjF69XA">1,697</ix:nonFraction>&#160;shares of preferred stock outstanding and <span style="-sec-ix-hidden:Hidden_qvPF7Qsm3kquM23a168syQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_RxT0UtfCjEGYZiysUEltkw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On April 23, 2019, the Company closed its IPO of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_eO1pZ2CYFE6ZVkdJTEHN0A">6,000,000</ix:nonFraction> shares of common stock, at an offering price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9-wYstNW-kqgqsk59PAAeQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_GZAiTQKEq0ObRhvtdMZjhw">14.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_Oi9QQOAmYUGRYaCkmfovQw">74.6</ix:nonFraction> million, after deducting $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="Narr_X3B84qMGQ0yu29EGTJTawA">9.4</ix:nonFraction> million in underwriting discounts and commissions and offering expenses. Upon the closing of the Company&#8217;s IPO all then outstanding shares of Preferred Stock converted into <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_NFEgg-7L7kKUdGMo__0AuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_9FkvIEtEB0KdGdhLdGLHKA">14,582,161</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TievCB1XuUO1RkPCD7kOtQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_CK56ZXYuf0CXVMIftAeVng">3,819,732</ix:nonFraction> shares of Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December&#160;11,&#160;2020, the Company closed a public offering of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_12_11_2020_To_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_KcIuT04yhEWxmnluDeFr0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_QqHUHpGlIkKSM_43JlvXPQ">3,910,000</ix:nonFraction> shares of its common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares and of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_DDij82CjqUCydxqkEFWIhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_tgLQfNziZEed4rBdeReJHw">2,978</ix:nonFraction>&#160;shares of Series&#160;A convertible preferred stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_YG3CoyW76UCnds2S4wKCbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_7LVvDZSCcUCKOmVSG3d4Gg">11.75</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_DDij82CjqUCydxqkEFWIhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_lGuKYG75LUa4gyzMOkDpQg">11,750.00</ix:nonFraction> per share, respectively, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_12_11_2020_To_12_11_2020_lwzbDOodv0Si697Xzru_Bw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_RPR9Vq5StUieY7WGeUxMqQ">75.0</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_t09LAWcUrk2_inHGi-A6Ng" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfVotes" scale="0" id="Narr_L-q1tJClMkeTRHjEKlZlOA">one</ix:nonFraction> vote for each share held on all matters submitted to a vote of the stockholders. The holders of Class A common stock and Series&#160;A convertible preferred stock are not entitled to vote, except as required by law. The holders of common stock and Class A common stock do not have any cumulative voting rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each holder of Class A common stock has the right to convert each share of Class A common stock into <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_HNQ1RpgYeke7cwk7fsoeRA" decimals="INF" format="ixt-sec:numwordsen" name="hook:ConversionOfStockCommonStockIssuedForEachShareConverted" scale="0" id="Narr_oPgGZHAvjEC8NVXxrMZ1Rg">one</ix:nonFraction> share of common stock at such holder&#39;s election. Each holder of Series&#160;A convertible preferred stock has the right to convert each share of Series&#160;A convertible preferred stock into <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9NpKAk2xnE-XmHW-HPDY4w" decimals="INF" format="ixt:numdotdecimal" name="hook:ConversionOfStockCommonStockIssuedForEachShareConverted" scale="0" id="Narr_E8v3kTnbGU2DDEymfFymjw">1,000</ix:nonFraction>&#160;shares of common stock at any time at the holder&#8217;s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series&#160;A preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q" decimals="4" format="ixt:numdotdecimal" name="hook:ThresholdPercentageForConversion" scale="-2" id="Narr_4j_hLlFLa024xSPHKq7-lw">9.99</ix:nonFraction>% of the total number of shares of our common stock then issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock and Class&#160;A common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Holders of Series&#160;A preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of our common stock. Holders of common stock and Class&#160;A common stock have no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the event of a liquidation, dissolution, or winding up of the Company, holders of our Series&#160;A preferred stock will receive a payment equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_1xRhA9mHkEi6diGe1C8-UQ">0.001</ix:nonFraction> per share of Series A preferred stock before any proceeds are distributed to the holders of common stock. Then, holders of common stock and Class A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_AtQn4KkHR0-Q7UlxWlzU7w">1,697</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_S9F_qSJwYES3DqcF73wDEA">2,978</ix:nonFraction> shares of Series&#160;A convertible preferred stock outstanding as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. In October&#160;2021 and December&#160;2021 certain of the Company&#8217;s stockholders elected to convert an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_yxLDZPy_JkCTBy3vQ0rANw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_R7un5g52YE-iXs6lb-I6-A">1,281</ix:nonFraction> shares (<ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_hounmkd6wkGAMVpwq87DJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_6FHBRVvFRU2wwA-soTpbRg">55</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_y8byg_XyWUKkNI6G_f1TrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_30eT7ZrTJ06qWTbiG4Z9rA">1,226</ix:nonFraction> shares, respectively) of Series A convertible preferred stock owned by such holders into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_76blQDrh8EykPQMtShDiPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_FKdwBpvIaEOrVwH_udo-GQ">1,281,000</ix:nonFraction> shares of the Company&#8217;s common stock. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_jtQ7-7a4wE2IovdqtsDZ6w" continuedAt="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2018 Stock Option and Grant Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with a transaction between entities under common control by which the Company became the reporting entity in June&#160;2018, the Board of Directors approved the 2018 Stock Option and Grant Plan, by which options granted by the previous reporting entity under the 2016 Stock Option Plan and outstanding at the time of the effectiveness of the transaction were replaced at similar commercial terms. In the accompanying consolidated financial statements and notes, options issued under previous stock option plans and respective compensation expenses are </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont1" continuedAt="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">retrospectively presented as if such options had been issued and outstanding under the 2018 Stock Option and Grant Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The exercise price for options granted as a replacement of the 2016 Stock Option Plan is the U.S. dollar equivalent of &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_590Vq7m6Nk2ruyUEdyuF7Q" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_twPgggzgsEqZUfvcKLhARA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_3MGCT5LIvkWrwexgSGbVAw">0.09</ix:nonFraction>, except for <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_9n3p1gHKx0CGfWWuBr4x9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_cdKEybHyBUaGiXvSQhACXw">23,286</ix:nonFraction> options granted to an US employee, for which the exercise price is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2018_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo2.93DollarsPerShareMember__xThJ8xgwECdT4PnUdSrEA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_lkgutgTIq0u5tZAp9WPQcw">2.93</ix:nonFraction> following a repricing of these options in December&#160;2018. For any new options, the exercise price shall not be less than <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_2dw45hjqck2FIlWYMhpGDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_r5KRpyXpOEeQbvkleJc7Mw">100</ix:nonFraction>% of the fair market value of the common stock on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Options granted under the 2018 Stock Option and Grant Plan generally vest over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_4UVSVApoFESt0pKFq_aAcA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_TF968Uw4U0Gmrthtk0mVfw">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_NvEZsiucNEarngOHkIEwqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_jdsg4SAzp0eJPjw1IctTPg">25</ix:nonFraction>% of the options vesting upon the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rLd-8jjIakKEuR52k7XE-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_GbOdQ_cY7UCsK1tznnS7mw">75</ix:nonFraction>% of the options vesting in <ix:nonFraction unitRef="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rLd-8jjIakKEuR52k7XE-A" decimals="0" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" scale="0" id="Narr_SrxXp8LUAEWbjyXtTx7OKQ">12</ix:nonFraction> equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. As of December&#160;31,&#160;2021, <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_beVG5N6ZTEC9isTgGKHBeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_63buD-EhMEW-tzJCgOYqdA">968,504</ix:nonFraction>&#160;options granted under the 2018 Stock Option and Grant Plan remained outstanding. Any authorization to issue new options under the 2018 Stock Option and Grant Plan was cancelled upon the effectiveness of the 2019 Stock Option and Incentive Plan and no further awards will be granted under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2019 Stock Option and Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;1,&#160;2019, the Company&#8217;s stockholders approved the 2019 Stock Option and Incentive Plan, which became effective as of the effective date of the registration statement in connection with the Company&#8217;s IPO. The plan provides for the grant of shares of restricted stock, long term incentive awards, stock options or other equity-based awards. The maximum number of shares of the Company&#8217;s common stock that may be issued under the Company&#8217;s 2019 Stock Option and Incentive Plan is <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_mveODV43Qk2j2ktXiQesTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_4iPLaG8oj0i8KIxQMv2NoA">3,630,686</ix:nonFraction>&#160;shares which shall be cumulatively increased each year by up to <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_UozogPZl3kqm-mLqR-1Ajw" decimals="3" format="ixt:numdotdecimal" name="hook:StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" scale="-2" id="Narr_cB-utWDkAEqcBpI1tz7Brg">4.0</ix:nonFraction>% of the then outstanding number of shares. Options granted under the 2019 Stock Option and Incentive Plan generally vest over <ix:nonNumeric contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_UozogPZl3kqm-mLqR-1Ajw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_thtCmTWM6kC9TD6jg5ZdsA">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tspqlK_mSEuko-7EX1OHCQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_6GPCGfazMUWQVkn6xIgUqg">25</ix:nonFraction>% of the options vesting upon the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GB1HtsQo9UWwp1QaQ-17vg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_uty-CKaHOEylVQ6mLezJxw">75</ix:nonFraction>% of the options vesting in <ix:nonFraction unitRef="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q" contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GB1HtsQo9UWwp1QaQ-17vg" decimals="INF" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" scale="0" id="Narr_BTjRL-eb10uLI84UiXh8Zg">12</ix:nonFraction> equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. Initial options granted to non-executive directors upon their election generally vest over a <ix:nonNumeric contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_fmE0VmQhIk2B4XyRkIcu2w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_q0x34mFHq0yKxbrQYfoKqQ">three-year</ix:nonNumeric> term with <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Qyh0v6uhbEG1Th-ftOQ75Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_3VFJ7uhT30u3EkPzdjaprw">33</ix:nonFraction>% of the options vesting upon the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_tBzOSNE1VEeWs3G7uVNFMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_FJl6IqF5YkC_UQ8HJqQuYw">67</ix:nonFraction>% of the options vesting in <ix:nonFraction unitRef="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q" contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_tBzOSNE1VEeWs3G7uVNFMA" decimals="INF" format="ixt-sec:numwordsen" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" scale="0" id="Narr_yYWhtmmnBECMSPU0Smp17g">eight</ix:nonFraction> equal quarterly installments following the first anniversary of the grant date. Option re-grants to non-executive directors generally vest on the first anniversary of the grant date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. For each option the beneficiary is entitled to receive <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_4_1_2019_To_4_1_2019_XDfkQ2lQ5UGH271C7716Aw" decimals="INF" format="ixt-sec:numwordsen" name="hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" scale="0" id="Narr_FIDwZ8wcbkWwHpo-nSmg9g">one</ix:nonFraction> share of common stock upon the exercise of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock option valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the option&#8217;s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, volatility, the risk-free interest rate, the dividend and employee exercise behavior. Forfeitures are accounted for when they occur. Expected volatilities utilized in the Black-Scholes model are based on historical volatilities of a group of comparable companies. The group of representative companies have characteristics similar to the Company, including the stage of product development and focus on the life science industry. Management believes that this represents the most accurate basis for estimating expected future volatilities under the current conditions. The risk-free interest rate is derived from the yields for U.S.&#160;Treasuries with a remaining term approximating the expected life of the options. The expected term represents the period of time that the options granted are expected to be outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options granted during:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_soK5Xqd_NkqJPkMITet7Tg" continuedAt="Tb_soK5Xqd_NkqJPkMITet7Tg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IeHrB_K7u0GR8ZWmUg4_rA_1_1"></a><a id="Tc_42yry9hpFUKqV39CQCtVxQ_2_1"></a><a id="Tc_eHKEeXmqQUqLZPTZVATApw_3_1"></a><a id="Tc_KsgNzvg7kUmmpD88qoq3sg_3_3"></a><a id="Tc_XIsOcxrKIEOKVa2Q7oKl1A_3_5"></a><a id="Tc_shjgi5MsuEO0edsGZCcjkQ_5_0"></a><a id="Tc_IDYvxzMp30KK9mqV1BA_Gg_5_2"></a><a id="Tc_c9qvQcfck0WyzhVVa8J1Nw_5_4"></a><a id="Tc__g81A7TbHk6PHD5jEUewkg_5_6"></a><a id="Tc_Yp-ILhqhX0mPFFAze1KyPQ_6_0"></a><a id="Tc_q48K6mrmWUO9Gym8289G4Q_7_0"></a><a id="Tc_xRcxCcg3CEGg2n-Pu-3ZIw_7_2"></a><a id="Tc_EtogjqDTOUensnscRVKgmg_7_4"></a><a id="Tc_6mFczkU0_UeGZMj0exq3-g_7_6"></a><a id="Tc_07nYpSyGs0-LJrPM5NIapQ_8_0"></a><a id="Tc_cr719kvjI0G53E5DTNEe7Q_8_1"></a><a id="Tc_jMSUNCmjekCBgRmlD0OEyQ_8_2"></a><a id="Tc_sUZLCLumkUyenXgdlfGHNg_8_3"></a><a id="Tc_IYlT7A66K0uoHtgg3B-wkA_8_4"></a><a id="Tc_2sKGSTsWzUaUpiUDVCFVsA_8_5"></a><a id="Tc_TZIH-zm5yECmsVcbUVfdng_8_6"></a><a id="_09570cce_2139_48e2_8298_f8dcd10d9816"></a><a id="Tc_FtNZvBEcFkKsGt827Q4KTg_1_7"></a><a id="Tc_p-P8Gv2CkkScYVnj-dj1yQ_2_4"></a><a id="Tc_V0GLC-KTXU6HDx3xxBFhAg_2_7"></a><a id="Tc_wFo-K6M7mE6VPzU22n301Q_3_4"></a><a id="Tc_NwBxPTS9a0qrcAy843Dahg_3_7"></a><a id="Tc_4OlseaC16kioWjApshCK8Q_3_9"></a><a id="Tc_xsyjFOtHW0GH_aieBBElFw_4_2"></a><a id="Tc_sqRQna9kk0eGbStGxXbwuA_4_4"></a><a id="Tc_PJMxDDmU70WctOvVtfuSnw_4_7"></a><a id="Tc_EB-P_TqzAUGbd43cQE6naQ_4_9"></a><a id="Tc_qJQFc0hD10Crns8UM_H7sA_5_2"></a><a id="Tc_uz_fVyLddkaKZFnABCQc7Q_5_4"></a><a id="Tc_IQ-kXrTCyEO9pkWZbamzXw_5_7"></a><a id="Tc_fvGEz9bHNkCZQYO3e-2c5w_5_9"></a><a id="Tc_OlEJ0zTRVESkSzxfmBQhgg_6_7"></a><a id="Tc_bV6iWyqq7kuwfkqVzbEYOQ_7_0"></a><a id="Tc_bWUDwIm0okW9NkWK9tnVRA_7_4"></a><a id="Tc_LnvkkkQVFUiDGJ66NEB-UQ_7_9"></a><a id="Tc_wPlw4iD33Uequ6GY-8bauw_8_0"></a><a id="Tc_-b1GN5RfnkyaEegMHY0rGQ_9_0"></a><a id="Tc_jMixjLyP7ECOaaBb5uQ8ig_10_0"></a><a id="Tc_gzojpVG88U-LEmOx-IbCjg_11_0"></a><a id="Tc_1MU13fC2fU-Z0vyzYn9MKg_11_4"></a><a id="Tc_w_wzj5GfDEi6uKhiVKXz-A_11_9"></a><a id="Tc_bo01pQYhL0-cg7_fpf4Lpg_13_0"></a><a id="Tc_U-IA3Bsr3UG4aKZz6PePCg_13_4"></a><a id="Tc_8vOnikBjrUeJRxP3uyaftQ_13_9"></a><a id="Tc_1lSjoqxN6EubR8qWBbQTJQ_14_0"></a><a id="Tc_OONvG2p8202KXNfrhLi-UA_14_4"></a><a id="Tc_qW7rERuNXEORlsjRDLTHSA_14_9"></a><ix:continuation id="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont2" continuedAt="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont3"><ix:continuation id="Tb_soK5Xqd_NkqJPkMITet7Tg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_lFIFsl2jl0OOwW9gCB-BDg_5_1">1.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_f6jDVEayAky4AsoerBF4YQ_5_3">0.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_aE10nKOwskC4FBIex3nRpg_5_5">2.21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_zYznBODGbkGDuecBGeWZBw_6_1"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_C-PnU0NEfEq2eXitcu6KjA_6_3"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_C4kU9D1SJE-YNpiLwZxfMA_6_5"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_9uYoDzyTME6vCYIMs4iDuA_7_1">85.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_05R3pkNf6Eq_UNgF1zoQrQ_7_3">80.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_LWqnDL2RpEm5BNSkT21foA_7_5">74.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the 2019, 2020 and 2021 grants, the Company used the simplified method in developing an estimate of the expected term due to a lack of historical exercise data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock option activity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_JiukM-EqKUyWGMsGtoDpNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity since January&#160;1,&#160;2021 (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zwRFkdrJWUe9L_FhY5xQ9A_7_2">3,555,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_XNaSezI4SkKyXJgR4Xg_cQ_7_5">8.45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_pEsKsJ-x-kOjjZ4MTgh-Yg_7_7"> 7.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_yJl6Jq7RaE2Mc6B3VrYdUQ_7_10">12,839</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_L94xINWmB0mbcrrVT30unw_8_2">990,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_VXiC0MdT9EKz9mfNzDOsuQ_8_5">11.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_zsv4lqLuUkWW0pUgx2euZQ_9_2">125,020</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_kYM_DGWFpkOVyF_FnsgD6g_9_5">1.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_q-BjHq0J5k-hbKDsEeiqfA_10_2">190,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_yJcxKEkXNkWHnYjRRCVlDg_10_5">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_AHRVu971CkWMFZwRjA9X0A_11_2">4,231,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_JpMQlw65JU-rPj0VdbIdSA_11_5">9.21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_hu75LsMumEGOuzmqtLBmrg_11_7"> 7.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_C0OIH-YXakKNddhZ_pZzqQ_11_10">1,640</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_guASU-Zb2k-5WmuD0bHPEQ_13_2">2,224,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_P11fpwVNg0i12kHR-2ovcA_13_5">7.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_N6nJsXzOQke9jTtq7IoPfw_13_7"> 6.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_LE2QG12LNUeoRKFq23aLbg_13_10">1,624</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options unvested as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_fbN2J2z5rkSrybLcuSYhnA_14_2">2,006,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_jLk8m5426keFfeziUJ24Gw_14_5">10.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" format="ixt-sec:duryear" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" id="Tc_3WJ0f4F0fE-TRscAcAqMOQ_14_7"> 8.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue" scale="3" id="Tc_XpW8k-xASEWynGi7pz2XMQ_14_10">16</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The fair value per common stock used for calculating the intrinsic values as of December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019, was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" scale="0" id="Narr_E04niB7ZcECumtrBsYAPmg">2.33</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" scale="0" id="Narr_by5HtLk7UU6W2MwjFsqBig">11.09</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" scale="0" id="Narr_vdr1C0lgNUGvrbxy1mm48w">12.23</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December&#160;31,&#160;2021, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_OkSJf5B_KUSLabGTT8RqvQ">1.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_Rp_AkeZLY021hYqOW1ci6A">2.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_DfL_mHiOmUeBYlvblhe0cA">1.4</ix:nonFraction>&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31,&#160;2021, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_DyhhW5c_iUm5DwrT8vXQVA">11.46</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_XWg81TWSc0iob4A8uyvyGA">8.95</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_LN96tOMbSUGS1eJ4EZX9oQ">7.92</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total fair value of stock options vested during the years ended December&#160;31,&#160;2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_lxj0fOtoi0mF0LI77Uflmw">6.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_u_aF3KFgkEOOtU-W6s_3Uw">5.6</ix:nonFraction>&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash received from stock option exercise under share-based payment arrangements for the years ended December&#160;31,&#160;2021, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_kr03pHDIUEaa3yo5M8v0nw">203</ix:nonFraction>&#160;thousand, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_L7Yf9QfvPUmuTROT_j1e0Q">63</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_unyOJIhb00uegphltqQEKQ">16</ix:nonFraction>&#160;thousand, respectively.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_0shTpwJyBkCQINFvtDbVUQ_1_4"></a><a id="Tc_-UIncFkZMEumF-j1yVHyYg_2_4"></a><a id="Tc_9ZEOEIWm60WOa4vHCwSEXw_3_2"></a><a id="Tc_BIhu8Ht6REal40106tavCw_3_4"></a><a id="Tc_EZ5HoHX5EEaDr1GVKW1ssA_4_2"></a><a id="Tc_rJzFYOfTDUGizr5PPMB0wg_4_4"></a><a id="Tc_QVxFrKIYSEio_HnukZt93g_5_0"></a><a id="Tc_a2QyS_DBX06Ibsc_JSzI1A_5_4"></a><a id="Tc_hRKvbaW6HUOw7Yp3QEN57g_6_0"></a><a id="Tc_HM2DrGAx10ivPC4PLyKFvQ_6_2"></a><a id="Tc_iI1DM1stikeczu2rEsUMHA_6_5"></a><a id="Tc_mesQmhJXcEuWK40LcyojJw_7_0"></a><a id="Tc_pWrx5cTef0WRHb7iQN1w-Q_8_0"></a><a id="Tc_Bh2-EWPwJ0C6qhuTHiBOiw_8_2"></a><a id="Tc_9jcX_N2KtEidBemsKvTCgQ_8_5"></a><a id="Tc_wusMQeHyZU6K4U_EY2mLQA_9_0"></a><a id="Tc__3GAmfYOmkur17m_ZQxGFA_9_2"></a><a id="Tc_xFRXEIjbvEKqCB9Y89pCWg_9_4"></a><a id="Tc_5n-k3SJfpkmK8h1Q72Y-dw_9_5"></a><a id="_98bcaf9f_3ffb_4770_908b_7a0da2118d95"></a><a id="Tc_cca2G1Gx9kOHA8yH6BMhxQ_1_2"></a><a id="Tc_ZrH2b2qGuEaxBzdwoxenYg_2_2"></a><a id="Tc_ajnxN2Q4vUalGZ1ooszocw_2_5"></a><a id="Tc_9oW4iCB1-EqeprZUAGW1aw_2_8"></a><a id="Tc_HN_ojKIjqUmlEm7GqVlsWQ_3_0"></a><a id="Tc_Sw-rDzYmO0mmF48-2Yu14A_3_2"></a><a id="Tc_sDsH0tu3MkKO2MUFLl6zpg_3_5"></a><a id="Tc_aNC7pdZ560G1-dQtgILTnA_3_8"></a><a id="Tc_ZXNHA6hnG0aM3-JJPzOfEg_4_0"></a><a id="Tc_YaHAolP6w0mMQ-CA7YVHIQ_5_2"></a><a id="Tc_Sp2r0AYoC0KpP1Q-WK3FEg_5_5"></a><a id="Tc_8y0412Z5PkeOR6ib4Ubr1Q_5_8"></a><ix:continuation id="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont3" continuedAt="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2020, the Company granted restricted stock units with time-based vesting conditions to officers, employees and a consultant to compensate them for a temporary salary or fee reduction in response to the coronavirus pandemic. The restricted stock units are subject to time-based vesting conditions and generally vested in <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA" decimals="INF" format="ixt-sec:numwordsen" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" scale="0" id="Narr_TGInkyirzE-BzXrWbEXlZA">four</ix:nonFraction> equal installments between March 2021 and November 2021. The Company measures the fair value of restricted stock units on the date of grant using the grant date market price of the underlying shares. Expenses are recorded using the graded-vesting method. The table below summarizes the Company&#8217;s restricted stock unit activity since December&#160;31,&#160;2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_3Af90ofexUixSDABdyTtNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UzL7A7Iha0WXUjRxbCPtMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Ka-rQhR7yki0F3Zxef7HTA_5_2">43,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UzL7A7Iha0WXUjRxbCPtMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_-kRyacl4e0etUokMHJk8iQ_5_5">11.87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_YYE9DXFylEiS2BrslShxbg_7_2">43,700</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_VBCkueadc0usDeKnIR0FdQ_7_5">11.87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The total fair value of restricted stock vested during the year ended December&#160;31,&#160;2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_t3rG9OF9U0qrOhRvey6T6Q">0.5</ix:nonFraction>&#160;million. The total fair value of restricted stock vested during the year ended December&#160;31,&#160;2020 was insignificant. The Company had <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yxPIhqNASUaCbZD8h1tf_w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_HCx5yGQ5LUCJ_0Xy9Vtctw">no</ix:nonFraction> restricted stock outstanding in the year ended 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2020, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_ONQf7ioip0-k6jfRo_ULHg">36,249</ix:nonFraction>&#160;unrestricted shares of common stock to the non-executive members of its Board of Directors. The Company&#8217;s directors received equity instead of cash as their 2020 board remuneration as part of the Company&#8217;s response to the coronavirus pandemic. The total fair value of common stock awards issued during the year ended December&#160;31,&#160;2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg" decimals="-5" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" scale="6" id="Narr_0-YECkkD30ieibAKD0Tu0g">0.3</ix:nonFraction>&#160;million. The grant date fair value per share of common stock was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" scale="0" id="Narr_bE4MIhLqHkmskrxRAK46Vw">9.56</ix:nonFraction> and was measured at the closing price of the common stock on the date of grant. Expenses were recorded immediately and are included in stock based compensation in the year ended December&#160;31,&#160;2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the years ended 2021 and 2019, the Company has <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_Y24Eexf4xkCs_eHMPufkaQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_CckXWRjr10mPA2YYdh8R9A"><ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hpzhb_Bppk67Nw3sDM-ihg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_jrUW7izaKUSfYI9N8BHwgQ">no</ix:nonFraction></ix:nonFraction>t issued common stock awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock-based compensation</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_Kj92_HQur02g0d6qiOE-bA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4bfhHn40qUGhMs4ZUiYxWg_3_3">3,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gtKau0RANkOCGuv1dFU-Ig_3_6">3,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-DFpbMUslEae1ED399zLwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_IH2XWbtwWUadd04mfg0dHA_3_9">1,981</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Cr_5sk-eJECAXPN0yX0kow_4_3">4,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_WOBlthfffkyjExwQ2jwiAg_4_6">5,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_22rnLqSJCUSZdw6cMXG4eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_iogGm1GTo0GYew_xKzlMNA_4_9">3,584</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_vgeEphVJ90Ou1yXidz9IUw_5_3">7,644</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_uD7tfmGOV0iMvWZRJKxcmQ_5_6">8,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_1Vx_yyboXUCcer7QqhhThw_5_9">5,565</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_jtQ7-7a4wE2IovdqtsDZ6w_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2021 total unrecognized compensation cost related to the unvested stock-based awards was $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_H2dxTbO1-EebsxtGtxtdGQ">5.7</ix:nonFraction>&#160;million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Y3Ad9tMQZkGOnzWJ0_nVQA">1.6</ix:nonNumeric>&#160;years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ad54a640_b934_4abd_9486_d14fcfe3b977"></a><a id="Tc_5ehvrjeSi02DBfO5v4kDqA_1_2"></a><a id="Tc_QNJdvpPzSkGuBkFv56ya0g_2_2"></a><a id="Tc_QYnm247zG0mOd0h0n5Kghw_2_5"></a><a id="Tc_G90yC25ELkqWhOfBv0ngIg_2_8"></a><a id="Tc_q4sFXWnQkUWPVEGwvcY5yQ_3_0"></a><a id="Tc_POyKOWBu5kOOWc9-BZsM8Q_3_2"></a><a id="Tc_eBxt_mvIe0OG4i0NP_RkPA_3_5"></a><a id="Tc_jzsoPNf8okS2jYz42ZxwTw_3_8"></a><a id="Tc_B0bavNnWu06KAJirctDXDg_4_0"></a><a id="Tc_FeQkZMxRIUiC22xGbJFQXA_5_0"></a><a id="Tc_y1c2KhRpUEqMYvZb1uuwXA_5_2"></a><a id="Tc_zTOs-AAtdkmAFzmZ0L4Dng_5_5"></a><a id="Tc_0MTuu3xcxEiVd1pCfiPLQA_5_8"></a><a id="_3beb9c49_f1b3_4147_9690_eed96b9b15f9"></a><a id="Tc_5oFmYkoYlUKaB55QwlHeBA_1_2"></a><a id="Tc_mxuCfohYdEumGnJQLb0ogA_2_2"></a><a id="Tc_SzQ9erl7hEu6qmKKpFl0HA_2_5"></a><a id="Tc_HMsjNAVB9EOh3Rs4gv640w_2_8"></a><a id="Tc_9CTnx7AKj0u0E0pd_vX0qA_3_0"></a><a id="Tc_cWWNqvR5RkKdbp_JxNNkFA_3_4"></a><a id="Tc_uX_XX5CnnUumB2iJVxfyKQ_3_7"></a><a id="Tc_sPImjHG1skm_6FirOujAww_3_10"></a><a id="Tc_yFb7kV3Sg0i-J4dtS-jouA_4_0"></a><a id="Tc_Bep_39C3qEKsxiC028s8iA_4_3"></a><a id="Tc_Iz9HpU1QSkKsvMGiwsMYWg_4_6"></a><a id="Tc_iGqGwRMinkmjsYzcICvTRQ_4_9"></a><a id="Tc_5WZBvjS64020qm8xKXjEWw_5_0"></a><a id="Tc_tw7Ic5juXEKMRfvBigOK-A_6_0"></a><a id="Tc_ov4podYxrEOj-MOSC_JBJg_7_0"></a><a id="Tc_lZJWHdKZDk6pqSH1fI2QyQ_8_0"></a><a id="Tc_linnJyLH6kaxY7dkXTzGCw_9_0"></a><a id="Tc_fmugcRqrdUaZOr_80ABKMA_10_0"></a><a id="Tc_jLuw-VOgDkeydHLpenAahQ_10_3"></a><a id="Tc_1GBdGgddLUCEr8Lfy2YOeQ_10_4"></a><a id="Tc_JDFgtlh7PkGrAVw4EwNfOg_10_6"></a><a id="Tc_kQsFfiRBPE2G1fkqmz_PGA_10_7"></a><a id="Tc_em0l-ciLcUaovfUWyiSI4w_10_9"></a><a id="Tc_m_Ui7lqeDEOOmlsgGNesyQ_10_10"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_lsKm-JUa_kqX65csJmq6kA" continuedAt="Tb_lsKm-JUa_kqX65csJmq6kA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt-sec:numwordsen" name="hook:IncomeTaxBenefitsNetOperatingLossesIncurred" scale="0" id="Narr_LBxhVvIMAkK4RLCsRopg9A"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt-sec:numwordsen" name="hook:IncomeTaxBenefitsNetOperatingLossesIncurred" scale="0" id="Narr_-JxHf356YU-fxAFcJnPt7g"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt-sec:numwordsen" name="hook:IncomeTaxBenefitsNetOperatingLossesIncurred" scale="0" id="Narr_pXfZdq1U50ei2flqNSoeuA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> income tax benefits for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items. The Company&#39;s losses before income taxes were generated in the United States and Austria.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_jf_Lv36zWUujbAlWzYLlcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2021, 2020 and 2019 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_bVi8n0OiBkyzxv3ka7wfMw_3_3">11,403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_PdbhVsDvbkiWcDI0kH5BLA_3_6">11,603</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_3YFQiBxhh02N4CTe7un6Vg_3_9">7,886</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign (Austria)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_FDWmUFW9F0m7VSZroBy2nA_4_3">64,261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_ydao3mQ0j0a6lYkVxgea2A_4_6">32,479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_No-fgHvb8ky84j-tERhC_g_4_9">35,151</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_0PxwfLxnY0uBi1ILiO3yHg_5_3">75,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_lrLMmVmz1UyN-kxGngLK2A_5_6">44,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_VfhGMrb2PUeez2qVvw13ag_5_9">43,037</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company&#39;s worldwide effective tax rate for the years ended December&#160;31,&#160;2021, 2020 and 2019 was <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_MdkYCmDj6EiiVPN0yzTVOw">0.0</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_SohQMUiZiUi3vMbS6ZTblw">0.0</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_J2gB5GDPHEmzl6ZoxUZbmw">0.0</ix:nonFraction>%, respectively. The tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, which is expected to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. The following items had the most significant impact on the difference between the statutory U.S. federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_VyN0Hy_0u0mWxT-lK66p1w"><ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_9txa-dx3y0mHbFrsAzf-yQ"><ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_ef8t0g7MRkCLli2d7CEicw">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>%<span style="white-space:pre-wrap;"> for the years ended December&#160;31,&#160;2021, 2020 and 2019 and the effective tax rate:</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_dzTaeLpW-EWjqBn0d0kZYg" continuedAt="Tb_dzTaeLpW-EWjqBn0d0kZYg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_gxgFZilpbkO-Q7i6KTTOxQ_3_3">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_aQGnmsIdCU-rSQsqOj6Tlw_3_6">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_LUf9ho1miEeuFPkqh3PvOQ_3_9">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign tax rate differential<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_nDhsaiwKnUabRpheqyOmyA_5_3">4.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_84yQ5ME4kUaDsw0N1XSIFQ_5_6">4.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_7B3xNT1elkqcevWTOk78pw_5_9">4.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Not taxable government grants<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="Tc_WiZwYdX2nkqxDunhPAcXYg_6_3">3.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="Tc_T5p3KFUEBEiaA73bHWmyjw_6_6">4.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="Tc_Q47Fu3MI_USR_AWc-8P84Q_6_9">5.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_Le0zEZSiakaCLhW1HN_s2Q_7_3">1.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_vBzfwRWUfEWQSbRVICRipQ_7_6">1.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_9ugqUbJsS0OkmavYtVNPYw_7_9">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_e6ysHK82Jk6CHKElUmTCbg_8_3">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_BoKSxfgbmkeM0PaGwMEZzQ_8_6">0.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_uQ7oBxxSeUKYqO3pz_tCDw_8_9">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in deferred tax asset valuation allowance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_-yOiVeR9TkqeCr7yuT4_zg_9_3">30.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_tZl16rCljE-MV0ROl_Pc7A_9_6">30.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_vV26Hg7B6Uuw1u0WqoqAZg_9_9">31.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Narr_1JY8vSsCsEWfL0qy1MlYYg"><ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Narr_mbdWQy2lK02ROjZ0OXxlqQ"><ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Narr_LAk5PryDi0isHabpzSM3CQ">4</ix:nonFraction></ix:nonFraction></ix:nonFraction>% increase for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_8aWV_Z5u30CrNnuDLkmpsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_SscgaiiQZEmHQJvDpjI8TQ">25</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="Narr_PvrOP77ux0eebEKtGjxnVg">3.8</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="Narr_Qn9GpFibz0GzuxfOVKwIpw">4.7</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="Narr_mUG-0J2owUGaWmZ1sH5N0g">5.4</ix:nonFraction>% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Narr_-RLYymBaHEyHX6SxoxUr5g">1.5</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Narr_0wDbjM1KIk67YZlyme2a7w">1.0</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Narr_qqyT4GCnIkiqdXfJIX3Q4Q">0.3</ix:nonFraction>% increase, respectively, resulted from non-taxable Stock-based compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Narr_09p5gI1hYUqEtIcjLW4gpA">30.2</ix:nonFraction>% reduction, <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Narr_W8O4L988BESGOPQABz_1jQ">30.2</ix:nonFraction>% reduction and <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Narr_CMhn9gxlR0iUs5z03tX_EA">31.0</ix:nonFraction>% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company&#39;s research activities and the inherent uncertainties the deferred tax assets have been fully impaired.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b142edfd_b2f8_4850_a66a_e36f664a2589"></a><a id="Tc_oUgUB4k3B0SWNElgTm8itQ_1_2"></a><a id="Tc_ZdOWXgEJGES84uJcGXQi8g_2_2"></a><a id="Tc_TH80g0tIaU6dz0fDlKChfg_2_5"></a><a id="Tc_VZuTtxVOWkKUG8dvVIRQ6g_3_0"></a><a id="Tc_Q6wlx0-E4ECW0BtH07w0fg_4_0"></a><a id="Tc_uopyvzxObUmMMUtLsa1-ug_4_2"></a><a id="Tc_MUYneN_6Rkit3EtN-mZMAA_4_5"></a><a id="Tc_LEgbv3lyfk6ualfh1dNjGQ_5_0"></a><a id="Tc_pFMXWARXCUiuQC12xsp3aA_6_0"></a><a id="Tc_xDe2VJI10UGN8vOwrWZ1GA_7_0"></a><a id="Tc_XNnJen5CWEeuq2CL0rf1bQ_8_0"></a><a id="Tc_Tuvx2RTZOEeEYo4Z8s7p5Q_9_0"></a><a id="Tc_NmEz0uluwk-mmQDH56yypA_10_0"></a><a id="Tc_SeT2HG7kWUOcvTYHfWxOKA_11_0"></a><a id="Tc_6iM13ZCrcECFmRww09Qf-A_12_0"></a><a id="Tc_k48htFOEvUO_cAo99BuhOg_14_0"></a><a id="Tc_487HbT2UBUCSzfDsnZEP_A_15_0"></a><a id="Tc_hKhcWgfo3EWCyxaYBoDT4Q_15_6"></a><a id="Tc_NDz1GPsuDkaer8NfMzfSzA_16_0"></a><a id="Tc_HP9arrVHUk-MGcznjrYkQg_16_6"></a><a id="Tc_A3Jsic0780CyuyHx4H3juw_17_0"></a><a id="Tc__muO6no5U0SLstJk4lsEDQ_18_0"></a><a id="Tc_Lx3W-i5JZkiXYOuvuMCYVA_19_0"></a><a id="Tc_fmeasl5bUkClFnHqzkRO2w_21_0"></a><a id="Tc_JoRdYcZuOE21_oWrHaiDlg_21_2"></a><a id="Tc_FelGkHGVI0u0r0bLJTRlng_21_3"></a><a id="Tc_Z1gyndUmrUWpiREuZQ5q7A_21_5"></a><a id="Tc_Qc6Y_MWmIEK2IgHMafcvag_21_6"></a><a id="_13248276_e6c0_415a_9005_b38b59538dbf"></a><a id="Tc_SpckOKH3lEKaeJBTtl6JPg_1_2"></a><a id="Tc_FFDo0UYVZUSx-Qs_cq_Kyw_2_2"></a><a id="Tc_2E4gR_oizUKgx-1csxEmlQ_2_5"></a><a id="Tc_fT_y71vdcU28sA1FXy9zdQ_2_8"></a><a id="Tc_yWY8ZN7uzUaHFa-ejTkNnA_3_0"></a><a id="Tc_EpM6k_0yN0umZvW2VSLX0g_3_2"></a><a id="Tc_T-rbQ6yNbEWtbfus7NK8yA_3_5"></a><a id="Tc_HTXBpQWQEUWpAPKVXdBwSw_3_8"></a><a id="Tc_MetrvjgrUEuLLyuBWk7J6g_4_0"></a><a id="Tc_C4RAzAWFTUW3ds2xEJnM1w_5_0"></a><a id="Tc_RR_mpDZDskyTq85_a4Cnow_5_2"></a><a id="Tc_oOe2s3Bh5UGWCI5dml9IGA_5_5"></a><a id="Tc_9vzoZX7-wUac1NoXdMnZgA_5_8"></a><ix:continuation id="Tb_lsKm-JUa_kqX65csJmq6kA_cont1" continuedAt="Tb_lsKm-JUa_kqX65csJmq6kA_cont2"><ix:continuation id="Tb_dzTaeLpW-EWjqBn0d0kZYg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_zr6XFXolREWT_1H7AE_KuA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2021 and 2020 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_bIez4ttyUUenUQQzNYU8rQ_4_3">55,752</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_7v0syH5LbkWjO0ViJBU47A_4_6">43,563</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_Ekf1FneNgUGkrye3eURWxw_5_3">64</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_N3Kl9w8rj0ymbImXbj7Bhg_5_6">64</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" scale="3" id="Tc_EcaJCV-lhk6j45xoCubilA_6_3">357</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" sign="-" scale="3" id="Tc_icDvG2Bma0m8Lwj3cPB6TA_6_6">36</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_TOMKLrWbxUOfp1mo0QCPbA_7_3">1,209</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_u4XcJe4HWUCR7_bPK2BIeg_7_6">2,725</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_uQR6mVXBPUi7FbeDf7Zb3A_8_3">1,378</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_4LqYSzGI70uNK0yzEXHRGQ_8_6">1,513</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Finance lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsFinanceLeaseLiabilities" scale="3" id="Tc_sd7xibsWkECx6SX61JQqxQ_9_3">5</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsFinanceLeaseLiabilities" scale="3" id="Tc_FwWvXfQld0eQb2i8oYT02A_9_6">103</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_XuziYHFCrkCDLtSh-sceKA_10_3">58,765</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_D0y8726T6Ea69gyDbaK1fg_10_6">47,932</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_35BIFMVvHUCDN_3uHiIthQ_11_3">53,728</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_VRv10JcEqU2CXeaC0_OrAw_11_6">46,064</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_dPCh4yfn2Eq1pWBYa6dhuw_12_3">5,037</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Ps-A9RFPXU6R1CpjJesiMA_12_6">1,868</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_ghfenzjP90S2R_RCs9f47Q_15_3">3,604</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Fixed assets and intangible assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="Tc_FH2BWLVKxUegP0-u0O7eIg_16_3">11</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_fap_0nDrVkKJ8wjg3h21_g_17_3">1,400</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_bdMfbNN3qkGpfqZSzvu0xw_17_6">1,614</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Finance lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" scale="3" id="Tc_xj6958GZEUmppXwrbuo7ZQ_18_3">22</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" scale="3" id="Tc_hirNNytpcU6euRxOtCR5LA_18_6">254</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_t4kiQDqHRUOBjFaNmjvObw_19_3">5,037</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_MX1tC7hdLE2HKul4f334zg_19_6">1,868</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, 2020 and 2019, the Company had Austrian net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_gHDM5dWWTEuXar6FbiCeBg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_qLZkrdG980mBfpP9sDsBTA">219.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AT_VDTF1Hi9ZEmGsqw3fw3zPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_PYrHwb5fhkaF-3GQGjyhDg">163.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AT_bcqjl_Vcukegg0RdiMWQ4A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_piHtgZdX_kuQ_HXbvpf-Pg">112.3</ix:nonFraction>&#160;million, respectively, and US Federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wlEd_mxNOkeq4y6xJ7gacw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_cDho9DSmsU-P-85PnlBouQ">17.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_G_2_M_kOZUillKcUGB9iFQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_cGTmLPXYhEGqzpMIVmzwZg">8.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_g5-9_PFDAkeum_3TPJDJ1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_xCNSagANpEinY8Eo5cUXrA">4.9</ix:nonFraction>&#160;million, respectively, all of them with no expiry date. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#39;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&#160;31,&#160;2021, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of losses is no longer present and additional weight may be given to subjective evidence. The tax years in which the tax carryforwards were generated may still be adjusted upon examination by the tax authorities.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="Tb_EygdMEPTGE6puc3u3x11-A" continuedAt="Tb_EygdMEPTGE6puc3u3x11-A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_PD9fonnEtk6mXvEAoGrv1A_3_3">46,064</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_gIA5CF9oOUW3NCFR9_1IOg_3_6">32,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Q5XYzZOVg0Cr2uIMSzHQgA_3_9">19,156</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Increases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Tc_0kPSSW9aD0iNQjujjHbQVg_4_3">7,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Tc_f_-aymMPokm9oEj4RwpFMg_4_6">13,481</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Tc_X-t-nGH-Gka6sqceby5iJA_4_9">13,427</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_gUnzmNpp4U-W4HqBX_s_aA_5_3">53,728</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_qFRSZlCf30OjM7Mw16yJXA_5_6">46,064</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_G7vCOsLdAUe_2wCblglAPw_5_9">32,583</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lsKm-JUa_kqX65csJmq6kA_cont2"><ix:continuation id="Tb_EygdMEPTGE6puc3u3x11-A_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;22,&#160;2017, the United States enacted the Tax Cuts and Jobs Act (&#8220;Tax Reform Legislation&#8221; or &#8220;TCJA&#8221;). The Tax Reform Legislation introduced section 951A, a new tax on so-called &#8220;global intangible low-taxed income,&#8221; or &#8220;GILTI&#8221;. GILTI applies to income of a controlled foreign corporation (&#8220;CFC&#8221;) that is not otherwise subpart F income, and consists of the excess &quot;tested income&quot; over a <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="hook:GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" scale="-2" id="Narr_l2gky_hg3kSVxWKxGeNVjA">10</ix:nonFraction>% return on the CFC&#39;s &#8220;qualified business asset investment,&#8221; or &#8220;QBAI&#8221;. QBAI is the total tax basis of the CFC&#39;s depreciable, tangible property used in the production of tested income. The full amount of GILTI is included in taxable income. The GILTI inclusion is then reduced by <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="hook:GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" scale="-2" id="Narr_JyOHuhqI80G9GZIMrQjnRA">50</ix:nonFraction>% (reduced to <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2026_To_12_31_2026_Z5BVccme10iEHOgWw4JA2w" decimals="3" format="ixt:numdotdecimal" name="hook:GlobalIntangibleLowTaxedIncomePercentageOfInclusion" scale="-2" id="Narr_cvYhsUGhfkCf-m_wcBQ1kg">37.5</ix:nonFraction>% after 2025). However, that reduction in GILTI may be limited based on the level of U.S. taxable income. A limited allowance for foreign tax credits is allowed that would reduce the U.S. tax cost. GILTI foreign tax credits can only reduce U.S. taxes owed on GILTI and are not eligible for carryforward. The Company&#39;s Austrian subsidiary falls under the category of a CFC and due to the nature of its business model as a technology company, there may not be a material amount of tangible assets if this subsidiary starts to generate profits. GILTI taxation therefore may be applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in New York. The tax years from 2018 to present remain open to examination by the jurisdictions in which the Company is subject to tax. <span style="background:#ffffff;">There are currently no pending income tax examinations in the U.S. </span>Furthermore, the Company files income tax returns in Austria. The tax years 2018 to present remain open to examination by the jurisdiction. There are currently no pending income tax examinations in Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31,&#160;2021 and 2020, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" id="Narr_474Kn7edj0O1QH-YOccJlw"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" id="Narr_h2xEoI-hwE-6OJiohedNRw">no</ix:nonFraction></ix:nonFraction> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_jHK4eeMyh0-Ugu2b9904kw" continuedAt="Tb_jHK4eeMyh0-Ugu2b9904kw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Commitments and contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contract manufacturing arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into arrangements with contract manufacturing organizations (&#8220;CMOs&#8221;) for manufacturing of materials for research and development purposes, including manufacturing of clinical trial materials. These contracts generally provide for non-cancellable obligations or cancellation penalties depending on the time of cancellation. As of December&#160;31,&#160;2021, the Company&#8217;s total non-cancellable obligations under contracts with CMOs, excluding embedded lease liabilities, were $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="Narr_MjUbeFu4RUu-yuCHtc4KOg">10.5</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="6" id="Narr_OtmiSQAz802FvNXE1VUTVg">10.4</ix:nonFraction>&#160;million relate to 2022 deliverables and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="6" id="Narr_JyoZq-BbaEm735SyJYirhw">0.1</ix:nonFraction>&#160;million relate to 2023 deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the Company entered into an agreement with a contract manufacturing organization for the production of clinical trial material, including seed lots, drug substance for toxicology studies, stability studies and clinical studies as well as related technology transfer, quality control and process optimization activities which commenced in February 2019. Under the financial terms of the agreement the Company is obliged to pay non-cancellable minimum service fees totaling $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="Narr_IMbWDp6xDkqX1PbRFoA57A">13.9</ix:nonFraction> million through January&#160;<span style="white-space:pre-wrap;">2022. The Company has determined that the agreement includes embedded leases which resulted in recognition of operating and finance lease assets and corresponding liabilities on the Consolidated Balance Sheet. The agreement was not extended beyond the initial term and its wind-down during the first quarter of 2022 has been agreed.  </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_jHK4eeMyh0-Ugu2b9904kw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intellectual property licenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into certain license agreements under which it is obligated to make milestone payments upon the achievement of certain development and regulatory milestones, to pay royalties on net sales of licensed products, and to pay a percentage of the sublicense fees which the Company receives from its sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="hook:LicensingFeesIntellectualPropertyLicenses" scale="6" id="Narr_ChY7HFLGjkmgOZ2d7KedTQ">1.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="hook:LicensingFeesIntellectualPropertyLicenses" scale="6" id="Narr_UJhZdKqz9Ea4mGy3gEzcXw">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-5" format="ixt:numdotdecimal" name="hook:LicensingFeesIntellectualPropertyLicenses" scale="6" id="Narr_tS9vXnwuQEmagFIfWekr_g">1.9</ix:nonFraction>&#160;million, respectively, in licensing fees related to intellectual property licenses as research and development expenses. These amounts mainly related to the upfront payment and milestone payments received by the Company under the Gilead Agreement. The amounts recognized as expenses have been agreed to by the licensors but calculation of sublicensing fees on future payments may be subject to interpretation and may change until agreed to by the receiving party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Indemnification agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31,&#160;2021 or December&#160;31,&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Legal proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently a party to a patent proceeding opposing European Patent No.&#160;3218504, which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to the Company. While it is not feasible to predict the outcome of these matters with certainty, and some lawsuits, claims or proceedings may be disposed or decided unfavorably, the Company does not expect that the pending patent opposition, and any asserted or un-asserted legal claims or proceedings, individually or in the aggregate, will have a material adverse effect on the Company. However, if, as a result of the current patent proceeding, the Company would lose all, or at least part, of the protection under the opposed patent, such loss could erode the Company&#8217;s competitive position and harm its business and ability to achieve profitability. The Company expenses the costs related to the pending and other such legal proceedings as incurred.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_XLVZy3cr70iHTiwDX-41xg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. 401(k) Savings Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_HOFDpMZwBUi9Ioh77X7JqQ">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_Gdph7E8isES2mIBg0_ZEZA">4</ix:nonFraction>% of each employee&#8217;s contribution. During the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 expenses recognized for the 401(k) Plan were $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_IshliPwmY0G9UHnP60hfqA">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_t1yYkeqBMUy9LZH57bER4w">0.2</ix:nonFraction>&#160;million, respectively. During the year ended December&#160;31,&#160;2019 expenses recognized for the 401(k) Plan were insignificant.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_e1d7c50e_5a8a_494d_8948_19b3593ccf55"></a><a id="Tc_4etSeq-c8kKoNXShbaPHhA_1_2"></a><a id="Tc_2dIEHmtDYEa_OmRq_Vxq6A_2_2"></a><a id="Tc_r2uSh23sTEG7tsmjRSfkig_2_5"></a><a id="Tc_BE1qqxR-TUadmNFLGWaKdw_2_8"></a><a id="Tc_Ly-rM5esFESxg4hSAMk41g_3_0"></a><a id="Tc_WwihpZeIW0-vjLjdf9O1NQ_4_0"></a><a id="Tc_NWcFQfJDgU2DmtdQJiFTLQ_4_2"></a><a id="Tc_JcNxslsYYkmpxAIzsIHa7A_4_5"></a><a id="Tc_Fg9-tzeEREqFF_I5N843Cg_4_8"></a><a id="Tc_nK-hIj2LK0WEvYwWVkTxoA_6_0"></a><a id="Tc_uJsiFTsr_0-UwyI35T-Dkw_7_0"></a><a id="Tc_330xIatk80S6IbBiBkFYUA_8_0"></a><a id="Tc_B6r96eSJG0-emWfU7VdUpg_8_9"></a><a id="Tc_k9sJVOUhhUm3zL3nu8Uxow_9_0"></a><a id="Tc_p84l6IKjmUW59Ntpg_26jQ_11_0"></a><a id="Tc_NR9z3L_75U27KdEc7Vf3zA_1_2"></a><a id="Tc_4iTATLlZykKvAZs2Lwen5Q_2_2"></a><a id="Tc_qR34RY2kkUKVrvOCh8i68Q_2_4"></a><a id="Tc_eyVYS3eRBUumTIUFhDeNew_2_6"></a><a id="Tc_R-ZfUzrl1USh1_vtoNI1aA_3_0"></a><a id="Tc_QYRRwiqt8EG8SFJpkerNgg_4_0"></a><a id="Tc_7b4Bfp384EC1C2ejczurtQ_4_2"></a><a id="Tc_AB7LhZFc4EaWeZ6AdaFAAg_4_6"></a><a id="Tc_d7MCIEWp9kW36yPBcmEknA_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:EarningsPerShareTextBlock" id="Tb_6QWKQ5OUzU-OdPI_mxZ7kw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Net loss per share</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_7XjgnV5XL0mcIZZjYbCHdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FoQN-7iEWkClyvHupa1wiw_4_3">75,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_P43MtwoSsE2rgKf5tCqvwg_4_6">44,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WLmEZOBL2kCGuakqraPf3A_4_9">43,037</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="0" format="ixt:numdotdecimal" name="hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" scale="0" id="Tc_2A4O9oJkeEKpKWvA0ZugYg_7_3">29,945,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="0" format="ixt:numdotdecimal" name="hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" scale="0" id="Tc_4IdQG1SAw0eEN9XSYUobiA_7_6">25,876,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="0" format="ixt:numdotdecimal" name="hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" scale="0" id="Tc_6v46pRVssEGaJ2Q8XKzvQA_7_9">17,859,935</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="0" format="ixt:numdotdecimal" name="hook:WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" scale="0" id="Tc_t_P5hbgpNkSUFXJ3sllEmg_8_3">2,887,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="0" format="ixt:numdotdecimal" name="hook:WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" scale="0" id="Tc_EPkhACv_S0i9mtDFUFPn3g_8_6">162,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total number of shares used to calculate net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_fWr4Gr_SPUmgIsuRC-kRqw_9_3">32,833,590</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_93i55LzlVkytZ5ELTj9k5w_9_6">26,039,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_fJZqCBM8IEKrR141Iq9lYQ_9_9">17,859,935</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_xm72ylqy7EWXDfD5Rmo5kg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_adO60mBtx0yeicCPOakmNg_11_3">2.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ix31qi0nv0-3tRNXPNStAg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_3IBnabV51Em9GPlXR9UM4g_11_6">1.69</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_6TH1JwQjZkq-oybyyIOUrA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_AHs_FXD-D06rcuRLPG3Q-Q_11_9">2.41</ix:nonFraction>)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Series&#160;A convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#8217;s common stock. Series&#160;A convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Series A convertible preferred stock is convertible into <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_1j4XzeMz-ESnuMmVKiBDbQ">1,000</ix:nonFraction> shares of common stock. <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ" decimals="INF" format="ixt:numdotdecimal" name="hook:ConvertiblePreferredStockSharesIssuableUponConversion" scale="0" id="Narr_INJgIlcWO06qRzAaAwbnRg">1,697,000</ix:nonFraction> shares of the Company&#8217;s common stock are issuable upon conversion of Series A convertible preferred stock (see Note&#160;10).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares (Common Stock and Class A Common Stock) outstanding would have been anti-dilutive. Potentially dilutive securities (upon exercise) that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb__xf7lEYD70WWS3rfhI2cWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8ArpbU0oC0yIg8CJBYRJmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_qebFqiJlp0G5rDsH8bs3IA_3_2">4,231,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_5rBz_7VLf0GCJz8u9a-5hw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_-uTg87tcE0i_COET2RwNGw_3_4">3,555,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_g4i69HykyUOop1GtYNoS3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_MwqJPqCTH0udQo9Lw6Hw9g_3_6">2,999,284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Tblo1dfAsE-WhYeQhF--_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_MFspW3CzaEa3HMfP9DzNJA_4_4">43,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8eV2nbT30UOc1mqicBBUJw_5_2">4,231,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ntWud2xjckCOdjoD-HSqFA_5_4">3,599,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_zWvXAgQ4Zk6QH3HU0x9t-w_5_6">2,999,284</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_0-SQ_GR1Bka9kK1FHbzt6w" continuedAt="Tb_0-SQ_GR1Bka9kK1FHbzt6w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Related parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following the expiry of the consultancy agreement between the Company and its Chief Scientific Officer, Daniel Pinschewer, on March 19, 2020 the Company entered into a new consultancy agreement with Daniel Pinschewer on March&#160;20, 2020, pursuant to which he serves as Scientific Advisor to the Chief Executive Officer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is party to research and service arrangements with the University of Basel. Daniel Pinschewer, formerly Chief Scientific Officer, and his spouse are employees of the University of Basel and both involved in providing the services under these arrangements. Payments to the University of Basel during Daniel Pinschewer&#8217;s term as Chief Scientific Officer were reported as related party transactions but payments following the expiry of that role in March 2020 were no longer considered related party transactions.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0-SQ_GR1Bka9kK1FHbzt6w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2021, the Company did not record any related party transactions. In the years ended December&#160;31,&#160;2020 and 2019, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_pZ8SP9MhHUePH3GzlSb8nw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_kFaCZ_rSdUGsGiTnHoEBOg">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_mXlTlYVhXE--Iu97sO2IOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_eEWoiuxNG026MIpgvlozCQ">0.3</ix:nonFraction>&#160;million, respectively, in research and development expenses for service fees paid to the University of Basel, which represented related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The University of Basel is also entitled to receive de minimis royalties on the net sales of any product that is based on a patent created by the Company&#8217;s Scientific Advisor to the Chief Executive Officer in the course of his consulting services to the Company. In the years ended December&#160;31,&#160;2021, 2020 and 2019, <ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_gifEUz7mSku6eu-AYJEHoQ" decimals="-5" format="ixt-sec:numwordsen" name="hook:RelatedPartyTransactionPaymentsForRoyalties" scale="6" id="Narr__5sVD2hMNk-2YyGhtR8NNQ"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_YCN1Wdur2kOhWvhtqG7FTQ" decimals="-5" format="ixt-sec:numwordsen" name="hook:RelatedPartyTransactionPaymentsForRoyalties" scale="6" id="Narr_10iHSw-yukaJLzBWCR1UEQ"><ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_lRtNrbT0JEmwrX6k2vVYAw" decimals="-5" format="ixt-sec:numwordsen" name="hook:RelatedPartyTransactionPaymentsForRoyalties" scale="6" id="Narr_44jMzuJPGkaAzaltAuCBkA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> royalties were paid pursuant to the terms of this arrangement.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A" name="us-gaap:SubsequentEventsTextBlock" id="Tb_65KCIF_CeE2l0DF358geVg" continuedAt="Tb_65KCIF_CeE2l0DF358geVg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Subsequent events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock option and equity grant to senior management</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February&#160;1,&#160;2022, members of the Company&#8217;s executive team received <ix:nonFraction unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA" contextRef="Duration_2_1_2022_To_2_1_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_zDBbt61-QkWRp1SuDXvEgw" decimals="2" format="ixt:numdotdecimal" name="hook:PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" scale="-2" id="Narr_AgmIJbte3EOqXsRkIzk1ag">50</ix:nonFraction>% of their 2021 annual bonus in the form of a grant of fully vested stock options, determined based on a value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bmkwQPPsg0m3l7ZM8QwDVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_01UiJleZNEiYdYp8-3MCNw">3.00</ix:nonFraction> per share and resulting in the issuance of a total number of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_2_1_2022_To_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b78AfSk_ikSR3aA4hEpw6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_RD1pAPYhn02c_o6bQsfWkw">145,071</ix:nonFraction> options. The granted options have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="Duration_2_1_2022_To_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b78AfSk_ikSR3aA4hEpw6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_BjHXDvuNnECS67lvgo5B7A">1.50</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on January 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At the same time, the members of the Company&#8217;s executive team agreed to convert a portion of their base salaries, for the six months ending June&#160;30,&#160;2022 for shares of the Company&#8217;s fully vested common stock having a value equal to their foregone salary, determined based on a value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fDr8f-o960agj3wW41LU3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_moUQYjISIkCpEIuOCbM14A">3.00</ix:nonFraction> per share, resulting in the issuance of an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rb58nqtF00-ccIOKSQPjSQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_Y7bGtvncJU6OZoueN5aedg">112,551</ix:nonFraction>&#160;shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Amended and restated research collaboration and license agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In February&#160;2022, the Company and Gilead entered into an amended and restated research collaboration and license agreement. For the future performance of development activities under the amended agreement, the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw" decimals="-6" format="ixt:numdotdecimal" name="hook:ProceedsFromMilestonePayment" scale="6" id="Narr_uT0nlqaRBEyP5FGacKaHEg">4</ix:nonFraction>&#160;million milestone payment and a $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementProgramInitiationFee" scale="6" id="Narr_1OLxCN7-HkmvSGSxEPzKew">15.0</ix:nonFraction>&#160;million program initiation fee, which have been initially recorded as deferred revenue in the consolidated balance sheet and will be recognized as revenue when revenue recognition criteria are met. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the Restated Collaboration Agreement, the Company entered into a stock purchase agreement with Gilead. Pursuant to, and subject to the terms and conditions of, the stock purchase agreement, Gilead will be required, at the Company&#8217;s option, to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw" decimals="0" format="ixt:numdotdecimal" name="hook:StockPurchaseAgreementObligationToPurchaseCommonStockAmount" scale="0" id="Narr_5eXo5La0PE-P65MA01G9mg">35,000,000</ix:nonFraction> of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_r8XLGskgdEyxWiQ5NQyIKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ntEAmpuiY0yXuz1gtKobwA">0.0001</ix:nonFraction> per share. In February&#160;2022 Gilead purchased an initial amount of <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_1Ph6sgJssEOng2qrp-V1jw">1,666,666</ix:nonFraction> unregistered shares of the Company&#8217;s common stock for $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_tbYuHrrdPUOPjwhv2m9bmA">5.0</ix:nonFraction>&#160;million, corresponding to a purchase price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_r8XLGskgdEyxWiQ5NQyIKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_oofE7hQZ20SwoHGiaKEgrA">3.00</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Follow-on public offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In March 2022, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_CHI8dxT2OkidwL8Mu4XUrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_V_JhGXWjo0SN9nTj0VtOFA">21,700,000</ix:nonFraction>&#160;shares of its common stock, and <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_GPWyabmAdEKvKH-pRh2Odg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_bNelnGhHnkKzV7onA1HXZw">15,800</ix:nonFraction>&#160;shares of its Series&#160;A-1 convertible preferred stock in a follow-on public offering at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_P9-ctvWwd0qVNZJLztP7lw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_GTk4c5Vvl0WpQsjpMOOwag">2.0</ix:nonFraction>&#160;per share of common stock and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ" contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_n0YxpBmAWUqt8sgKu-qHDA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_UTW4ouw1B0C0TqfOy_Z7Aw">2,000</ix:nonFraction>&#160;per share of Series&#160;A-1 convertible preferred stock, resulting in net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember__DCiYylTbUSqoGmdQ3GRYw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_POQJMKHiGkGcmU3_kNTsLQ">70.5</ix:nonFraction>&#160;million after underwriting discounts and commission but before other offering expenses. The Company granted the underwriters an option for a period of <ix:nonNumeric contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_paPyAdbqWE-j29GBmOS_lg" format="ixt-sec:durwordsen" name="hook:PeriodGrantedToUnderwritersToPurchaseAdditionalShares" id="Narr_zxcj8O8JKk61i28Ic0C2KA">30 days</ix:nonNumeric> to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_paPyAdbqWE-j29GBmOS_lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wnHOwSW2TE2-Xx0mZKcdmg">5,625,000</ix:nonFraction>&#160;additional shares of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">War between Russia and Ukraine</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February&#160;24,&#160;2022, Russian forces began an invasion of the Ukraine. While we have no operations in the Ukraine or Russia and do not perform research, conduct clinical trials, or otherwise do business in these two countries, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_65KCIF_CeE2l0DF358geVg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the geopolitical effects of the war and its potential further escalation, including the effects of other nations&#8217; responses and economic sanctions, are currently unpredictable and may adversely affect our business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>hook-20211231xex3d1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:20:36 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 3.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF INCORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">HOOKIPA PHARMA INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">HOOKIPA Pharma Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), hereby certifies as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The name of the Corporation is HOOKIPA Pharma Inc.&#160; The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was February&#160;15, 2017 (the &#8220;Original Certificate&#8221;).&#160; The name under which the Corporation filed the Original Certificate was HOOKIPA Biotech,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Amended and Restated Certificate of Incorporation (the &#8220;Certificate&#8221;) amends, restates and integrates the provisions of the Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware on February&#160;15, 2019&#160; (as amended, the &#8220;Amended and Restated Certificate&#8221;), and was duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The text of the Amended and Restated Certificate is hereby amended and restated in its entirety to provide as herein set forth in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The name of the Corporation is HOOKIPA Pharma Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The address of the Corporation&#8217;s registered office in the State of Delaware is c/o The Corporation Trust Company, 1209 Orange Street in the City of Wilmington, County of New Castle, 19801.&#160; The name of its registered agent at such address is The Corporation Trust Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;III</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;IV</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CAPITAL STOCK</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The total number of shares of capital stock which the Corporation shall have authority to issue is one hundred thirteen million nine hundred thousand (113,900,000) shares of which (i)&#160;one hundred million (100,000,000) shares shall be a class designated as common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), (ii)&#160; three million nine hundred thousand (3,900,000) shares shall be a class designated as Class&#160;A common stock, par value $0.0001 per share (the &#8220;Class&#160;A Common Stock&#8221;) and (iii)&#160;ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#8220;Undesignated Preferred Stock&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Except as otherwise provided in any certificate of designations of any series of Undesignated Preferred Stock, the number of authorized shares of the class of Common Stock or Undesignated Preferred Stock may from</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section&#160;242(b)(2)&#160;of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be determined in accordance with, or as set forth below in, this Article&#160;IV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">A.&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">COMMON STOCK; CLASS&#160;A COMMON STOCK</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Subject to all the rights, powers and preferences of the Undesignated Preferred Stock and except as provided by law or in this Certificate (or in any certificate of designations of any series of Undesignated Preferred Stock):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the holders of the Common Stock shall have the exclusive right to vote for the election of directors of the Corporation (the &#8220;Directors&#8221;) and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>,&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate (or on any amendment to a certificate of designations of any series of Undesignated Preferred Stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Undesignated Preferred Stock if the holders of such affected series&#160; of Undesignated Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (or pursuant to a certificate of designations of any series of Undesignated Preferred Stock) or pursuant to the DGCL;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the holders of the Class&#160;A Common Stock shall be non-voting shares, except as required by law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; dividends may be declared and paid or set apart for payment upon the Common Stock out of any assets or funds of the Corporation legally available for the payment of dividends, but only when and as declared by the Board of Directors or any authorized committee thereof; in the event that such dividend is paid in the form of shares of capital stock of the Corporation, holders of Common Stock shall receive Common Stock and holders of Class&#160;A Common Stock shall receive Class&#160;A Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the net assets of the Corporation shall be distributed pro rata to the holders of the Common Stock and Class&#160;A Common Stock, treated equally and identically;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in connection with any merger or consolidation of the Corporation with or into any other entity, shares of Common Stock and shares of Class&#160;A Common Stock shall be treated equally, identically and ratably, on a per share basis, with respect to any consideration into which such shares are converted or any other consideration paid or otherwise distributed to stockholders of the Corporation in the merger or consolidation, unless different treatment of the shares of each class is approved by the affirmative vote of the holders of a majority of the outstanding shares of Common Stock and Class&#160;A Common Stock, each voting separately as a class; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;">(f)&#160;&#160;&#160; in no event shall any stock dividends or stock splits or combinations of stock be declared or made on Common Stock or Class&#160;A Common Stock unless the shares of Common Stock and Class&#160;A&#160; Common Stock at the time outstanding are treated equally and identically, except that such dividends or stock splits or combinations shall be made in respect of shares of Common Stock and Class&#160;A Common Stock in the form of shares of Common Stock or Class&#160;A Common Stock, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">B.&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">CONVERSION OF CLASS&#160;A COMMON STOCK</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each holder of shares of Class&#160;A Common Stock shall have the right to convert each share of Class&#160;A Common Stock held by such holder into one share of Common Stock at such holder&#8217;s election, which shall be made upon written notice to the Corporation delivered, provided that, the shares of Class&#160;A Common Stock may only be converted into shares of Common Stock during such time or times as immediately prior to or as a result of such conversion would not result in the holder(s)&#160;thereof beneficially owning (for purposes of Section&#160;13(d)&#160;of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities Exchange Act of 1934, as amended, and the rules&#160;and regulations promulgated thereunder (collectively, the &#8220;Exchange Act&#8221;)), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section&#160;13(d)&#160;of the Exchange Act, in excess of the Beneficial Ownership Limitation.&#160; The &#8220;Beneficial Ownership Limitation&#8221; means initially 4.99% of any class of securities of the Corporation registered under the Exchange Act, which percentage may be increased or decreased by a holder of outstanding shares of Class&#160;A Common Stock to such other percentage as such holder may designate in writing upon 61 days&#8217; notice the Corporation, provided, however, that such increase or decrease shall only be applicable to such holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In order for a holder of Series&#160;A Common Stock to voluntarily convert shares of Class&#160;A Common Stock to Common Stock, such holder shall deliver written notice to the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of the Corporation that such holder elects to convert all or any number of the shares of the Class&#160;A Common Stock to Common Stock.&#160; Such notice shall state such holder&#8217;s name or the names of the nominees in which such holder wishes the certificate or certificates for shares of Common Stock to be issued.&#160; The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice shall be the time of conversion, and the shares of Common Stock issuable upon conversion of the Class&#160;A Common Stock set forth in the notice shall be deemed to be outstanding of record as of such date. &#160;&#160;For any remaining fraction of a share of Common Stock, the Corporation shall, in lieu of issuing a fractional share, pay cash to such holder equal to the product of such fraction multiplied by the fair market value of one share of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The one-to-one conversion ratio for the conversion of the Class&#160;A Common Stock into Common Stock shall in all events be equitably adjusted in the event of any recapitalization of the Corporation by means of a stock dividend on, or a stock split or combination of, outstanding Common Stock or Class&#160;A Common Stock, or in the event of any merger, consolidation or other reorganization of the Corporation with another corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of Class&#160;A Common Stock, such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Class&#160;A Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If any shares of Class&#160;A Common Stock shall be converted pursuant to this Article&#160;IV(B), the shares so converted shall be retired and returned to the authorized but unissued shares of Class&#160;A Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">C.&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">UNDESIGNATED PREFERRED STOCK</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;">The Board of Directors or any authorized committee thereof is expressly authorized, to the fullest extent permitted by law, to provide by resolution or resolutions for, out of the unissued shares of Undesignated Preferred Stock, the issuance of the shares of Undesignated Preferred Stock in one or more series of such stock, and by filing a certificate of designations pursuant to applicable law of the State of Delaware, to establish or change from time to time the number of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;V</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">STOCKHOLDER ACTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Action without Meeting</u>.&#160; Any action required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders and may not be taken or effected by a written consent of stockholders in lieu thereof.&#160; Notwithstanding anything herein to the contrary, the affirmative vote of not less than two thirds (2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than two thirds (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Article&#160;V, Section&#160;1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Special Meetings</u>.&#160; Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office, and special meetings of stockholders may not be called by any other person or persons.&#160; Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;VI</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">DIRECTORS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">General</u>.&#160; The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided herein or required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Election of Directors</u>.&#160; Election of Directors need not be by written ballot unless the By-laws of the Corporation (the &#8220;By-laws&#8221;) shall so provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Number of Directors; Term of Office</u><font style="font-size:10pt;">.&#160; The number of Directors of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors.&#160; The Directors, other than those who may be elected by the holders of any series of Undesignated Preferred Stock, shall be classified, with respect to the term for which they severally hold office, into three classes.&#160; The initial Class&#160;I Directors of the Corporation shall be Joern Aldag, Jan van de Winkel and David Kaufman; the initial Class&#160;II Directors of the Corporation shall be Sander van Deventer, Graziano Seghezzi and Michael A. Kelly; and the initial Class&#160;III Directors of the Corporation shall be Julie O&#8217;Neill, Christoph Lengauer and Reinhard Kandera. The initial Class&#160;I Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2020, the initial Class&#160;II Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2021, and the initial Class&#160;III Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2022. The mailing address of each person who is to serve initially as a director is c/o HOOKIPA Pharma Inc., 350 Fifth Avenue, 72</font><font style="font-size:6.5pt;">nd</font><font style="font-size:10pt;">&#160;Floor, Suite&#160;7240, New York, New York 10118.&#160; At each annual meeting of stockholders, Directors elected to succeed those Directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election.&#160; Notwithstanding the foregoing, the Directors elected to each class shall hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Notwithstanding the foregoing, whenever, pursuant to the provisions of Article&#160;IV of this Certificate, the holders of any one or more series of Undesignated Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect Directors at an annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of this Certificate and any certificate of designations applicable to such series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Notwithstanding anything herein to the contrary, the affirmative vote of not less than two thirds (2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than two thirds (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Article&#160;VI, Section&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Vacancies</u>.&#160; Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors and to fill vacancies in the Board of Directors relating thereto, any and all vacancies in the Board of Directors, however occurring, including, without limitation, by reason of an increase in the size of the Board of Directors, or the death, resignation, disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining Directors then in office, even if less than a quorum of the Board of Directors, and not by the stockholders.&#160; Any Director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director&#8217;s successor shall have been duly elected and qualified or until his or her earlier resignation, death or removal.&#160; Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors, when the number of Directors is increased or decreased, the Board of Directors shall, subject to Article&#160;VI, Section&#160;3 hereof, determine the class or classes to which the increased or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">decreased number of Directors shall be apportioned;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>,&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that no decrease in the number of Directors shall shorten the term of any incumbent Director.&#160; In the event of a vacancy in the Board of Directors, the remaining Directors, except as otherwise provided by law, shall exercise the powers of the full Board of Directors until the vacancy is filled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Removal</u>.&#160; Subject to the rights, if any, of any series of Undesignated Preferred Stock to elect Directors and to remove any Director whom the holders of any such series have the right to elect, any Director (including persons elected by Directors to fill vacancies in the Board of Directors) may be removed from office (i)&#160;only with cause and (ii)&#160;only by the affirmative vote of the holders of not less than two thirds (2/3) of the outstanding shares of capital stock then entitled to vote at an election of Directors.&#160; At least forty-five (45) days prior to any annual or special meeting of stockholders at which it is proposed that any Director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall be sent to the Director whose removal will be considered at the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;VII</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">LIMITATION OF LIABILITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of his or her fiduciary duty as a Director, except for liability (a)&#160;for any breach of the Director&#8217;s duty of loyalty to the Corporation or its stockholders, (b)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c)&#160;under Section&#160;174 of the DGCL or (d)&#160;for any transaction from which the Director derived an improper personal benefit.&#160; If the DGCL is amended after the effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Directors, then the liability of a Director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any amendment, repeal or modification of this Article&#160;VII by either of (i)&#160;the stockholders of the Corporation or (ii)&#160;an amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a Director at the time of such amendment, repeal or modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Notwithstanding anything herein to the contrary, the affirmative vote of not less than two thirds (2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than two thirds (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Article&#160;VII.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;VIII</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">AMENDMENT OF BY-LAWS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Amendment by Directors</u>.&#160; Except as otherwise provided by law, the By-laws of the Corporation may be amended or repealed by the Board of Directors by the affirmative vote of a majority of the Directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Amendment by Stockholders</u>.&#160; Except as otherwise provided therein, the By-laws of the Corporation may be amended or repealed at any annual meeting of stockholders, or special meeting of stockholders called for such purpose, by the affirmative vote of not less than two thirds (2/3) of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ARTICLE&#160;IX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">AMENDMENT OF CERTIFICATE OF INCORPORATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter prescribed by statute and this Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation.&#160; Except as otherwise required by this Certificate or by law, whenever any vote of the holders of capital stock of the Corporation is required to amend or repeal any provision of this Certificate, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">THIS AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this 23</font><font style="font-size:6.5pt;">rd</font><font style="font-size:10pt;">&#160;day of April, 2019.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.45pt;margin:0pt;">HOOKIPA PHARMA INC.</p></td></tr><tr><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:52.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.53%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:47.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:47.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">HOOKIPA PHARMA INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">RIGHTS AND LIMITATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SERIES A CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PURSUANT TO SECTION 151 OF THE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">DELAWARE GENERAL CORPORATION LAW</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">HOOKIPA PHARMA INC.</b><font style="font-size:11pt;">, a Delaware corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Corporation</b><font style="font-size:11pt;">&#8221;), in accordance with the provisions of Section&#160;103 of the Delaware General Corporation Law (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DGCL</b><font style="font-size:11pt;">&#8221;) does hereby certify that, in accordance with Sections 141(c) and 151 of the DGCL, the following resolution was duly adopted by a committee of the Board of Directors of the Corporation on December 8, 2020:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:12pt 0pt 18pt 0pt;"><b style="font-size:11pt;font-weight:bold;">RESOLVED</b><font style="font-size:11pt;">, pursuant to authority expressly set forth in the Amended and Restated Certificate of Incorporation of the Corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Certificate of Incorporation</b><font style="font-size:11pt;">&#8221;), the issuance of a series of Preferred Stock designated as the Series A Convertible Preferred Stock, par value $0.0001 per share, of the Corporation is hereby authorized and the designation, number of shares, powers, preferences, rights, qualifications, limitations and restrictions thereof (in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series) are hereby fixed, and the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock is hereby approved as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SERIES A CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;1</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:11pt;">. For the purposes hereof, the following terms shall have the following meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Affiliate</b><font style="font-size:11pt;">&#8221; means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder will be deemed to be an Affiliate of such Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Beneficial Ownership Limitation</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Business Day</b><font style="font-size:11pt;">&#8221; means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Class A Common Stock</b><font style="font-size:11pt;">&#8221; means the Corporation&#8217;s class A common stock, par value $0.0001 per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;"> &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Closing Sale Price</b><font style="font-size:11pt;">&#8221; means, for any security as of any date, the last closing trade price for such security prior to 4:00 p.m., New York City time, on the principal securities exchange or trading market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">reporting service mutually acceptable to and hereafter designated by Holders of a majority of the then-outstanding Series A Preferred Stock and the Corporation), or if the foregoing do not apply, the last trade price of such security in the&#160;principal trading market for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the Nasdaq Global Select Market. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors of the Corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Commission</b><font style="font-size:11pt;">&#8221; means the Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Common Stock</b><font style="font-size:11pt;">&#8221; means the Corporation&#8217;s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed into.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Date</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Price</b><font style="font-size:11pt;">&#8221; shall mean $11.75, as adjusted pursuant to paragraph 7 hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Ratio</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Shares</b><font style="font-size:11pt;">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A Preferred Stock in accordance with the terms hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Daily Failure Amount</b><font style="font-size:11pt;">&#8221; means the product of (x)&#160;.005 multiplied by (y)&#160;the Closing Sale Price of the Common Stock on the applicable Share Delivery Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DGCL</b><font style="font-size:11pt;">&#8221; shall mean the Delaware General Corporation Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Distributions</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DTC</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DWAC Delivery</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exchange Act</b><font style="font-size:11pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Fundamental Transaction</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section 7(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Holder</b><font style="font-size:11pt;">&#8221; means any holder of Series A Preferred Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Issuance Date</b><font style="font-size:11pt;">&#8221; means December 11, 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Junior Securities</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Notice of Conversion</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Parity Securities</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Person</b><font style="font-size:11pt;">&#8221; means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Securities Act</b><font style="font-size:11pt;">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Senior Securities</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A Preferred Stock</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;2(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A Preferred Stock Register</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;2(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Share Delivery Date</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(d)(i).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Stated Value</b><font style="font-size:11pt;">&#8221; shall mean $11,750.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Day</b><font style="font-size:11pt;">&#8221; means a day on which the Common Stock is traded for any period on the principal securities exchange or if the Common Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities market on which the Common Stock is then being traded.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Designation, Amount and Par Value; Assignment</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">The series of preferred stock designated by this Certificate of Designation shall be designated as the Corporation&#8217;s Series A Convertible Preferred Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A Preferred Stock</b><font style="font-size:11pt;white-space:pre-wrap;">&#8221;) and the number of shares so designated shall be 2,978.  Each share of Series A Preferred Stock shall have a par value of $0.0001 per share. The Series A Preferred Stock may be issued in certificated form or in book-entry form at the election of the Holder. To the extent that any shares of Series A Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">The Corporation or its designee shall register shares of the Series A Preferred Stock, upon records to be maintained by the Corporation for that purpose (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A Preferred Stock Register</b><font style="font-size:11pt;">&#8221;), in the name of the Holders thereof from time to time. The Corporation may deem and treat the registered Holder of shares of Series A Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation or its designee shall register the transfer of any shares of Series A Preferred Stock in the Series A Preferred Stock Register, upon surrender of the certificates evidencing such shares to be transferred, duly endorsed by the Holder thereof, to the Corporation at its address specified herein. Upon any such registration or transfer, a new certificate evidencing the shares of Series A Preferred Stock so transferred shall be issued to the transferee and a new certificate evidencing the remaining portion of the shares not so transferred, if any, shall be issued to the transferring Holder, in each case, within three (3) Business Days. The provisions of this Certificate of Designation are intended to be for the benefit of all Holders from time to time and shall be enforceable by any such Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;3</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Dividends</u><font style="font-size:11pt;">. </font><font style="font-size:11pt;">Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation) to and in the same form, and in the same manner, as dividends (other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series A Preferred Stock, and the Corporation shall pay no dividends (other than dividends in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Voting Rights; Amendments</u><font style="font-size:11pt;">. Except as otherwise provided herein or as otherwise required by the DGCL, the Series A Preferred Stock shall have no voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend this Certificate of Designation, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock or (c)&#160;enter into any agreement with respect to any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;5</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Rank; Liquidation</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">The Series A Preferred Stock shall rank (i) senior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms junior to any Series A Preferred Stock (&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Junior Securities</b><font style="font-size:11pt;">&#8221;); (ii)&#160;on parity with the Common Stock, Class A Common Stock and any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms on parity with the Series A Preferred Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Parity Securities</b><font style="font-size:11pt;">&#8221;); (iii)&#160;junior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms senior to any Series A Preferred Stock (&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Senior Securities</b><font style="font-size:11pt;">&#8221;), in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (all such distributions being referred to collectively as &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Distributions</b><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">Subject to the prior and superior rights of the holders of any Senior Securities of the Corporation, upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, each holder of shares of Series A Preferred Stock shall be entitled to receive, in preference to any distributions of any of the assets or surplus funds of the Corporation to the holders of the Junior Securities and </font><i style="font-size:11pt;font-style:italic;">pari passu</i><font style="font-size:11pt;"> with any distribution to the holders of Parity Securities, an amount equal to $0.001 per share of Series A Preferred Stock, plus an additional amount equal to any dividends declared but unpaid on such shares, before any payments shall be made or any assets distributed to holders of Junior Securities. If, upon any such liquidation, dissolution or winding up of the Corporation, the assets of the Corporation shall be insufficient to pay the holders of shares of the Series A Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to holders of the shares of the Series A Preferred Stock and Parity Securities </font><font style="font-size:11pt;">in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conversion</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conversions at Option of Holder</u><font style="font-size:11pt;">. Each share of Series A Preferred Stock shall be convertible, at any time and from time to time from and after the Issuance Date, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as&#160;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Annex A</b><font style="font-size:11pt;">&#160;(a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Notice of Conversion</b><font style="font-size:11pt;">&#8221;), duly completed and executed. Other than a conversion following a notice provided for under Section&#160;7(b) or Section 7(d)(ii) hereof, the Notice of Conversion must specify at least a number of shares of Series A Preferred Stock to be converted equal to the lesser of (x)&#160;100 shares (such number subject to appropriate adjustment following the occurrence of an event specified in Section&#160;7(a) hereof) and (y)&#160;the number of shares of Series A Preferred Stock then held by the Holder. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DTC</b><font style="font-size:11pt;">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DWAC Delivery</b><font style="font-size:11pt;">&#8221;). The &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Date</b><font style="font-size:11pt;">&#8221;, or the date on which a conversion shall be deemed effective, shall be defined as the Trading Day that the Notice of Conversion, completed and executed, is sent by facsimile or other electronic transmission to, and received during regular business hours by, the Corporation; provided that the original certificate(s) (if applicable) representing such shares of Series A Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2)&#160;Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original share certificate(s) (if applicable) of Series A Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conversion Ratio</u><font style="font-size:11pt;">. The &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Ratio</b><font style="font-size:11pt;">&#8221; for each share of Series A Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Beneficial Ownership Limitation</u><font style="font-size:11pt;">. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of the Series A Preferred Stock, and a Holder shall not have the right to convert any portion of the Series A Preferred Stock, to the extent that, immediately prior to or after giving effect to an attempted conversion set forth on an applicable Notice of Conversion, such Holder (together with such Holder&#8217;s Affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section&#160;13(d) or Section&#160;16 of the Exchange Act and the applicable regulations of the Commission, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Attribution Parties</b><font style="font-size:11pt;">&#8221;)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series A Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained herein. For purposes of this Section&#160;6(c), beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. For purposes of this Section&#160;6(c), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A)&#160;the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B)&#160;a more recent public announcement by the Corporation that is filed with the Commission, or (C)&#160;a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within three (3)&#160;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined immediately prior to or after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series A Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">last publicly reported or confirmed to the Holder. The &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Beneficial Ownership Limitation</b><font style="font-size:11pt;">&#8221; shall be 9.99% of the number of shares of the Common Stock outstanding immediately prior to or after giving effect to the issuance of shares of Common Stock pursuant to such Notice of Conversion (to the extent permitted pursuant to this Section&#160;6(c)); provided, however, that by written notice to the Corporation, which will not be effective until the 61st day after such notice is delivered to the Corporation, the Holder may waive or amend the provisions of this Section 6(c) to change the Beneficial Ownership Limitation to any other number less than or equal to 19.99%, and the provisions of this Section 6(c) shall continue to apply. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Mechanics of Conversion</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Certificate or Electronic Issuance Upon Conversion</u><font style="font-size:11pt;">. Not later than three (3) Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series A Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Share Delivery Date</b><font style="font-size:11pt;">&#8221;), the Corporation shall (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series A Preferred Stock or (b)&#160;in the case of a DWAC Delivery, electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series A Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series A Preferred Stock unsuccessfully tendered for conversion to the Corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(ii)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Obligation Absolute</u><font style="font-size:11pt;">. Subject to Section&#160;6(c) hereof and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section&#160;6(d)(i) above, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series A Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to Section&#160;6(c) hereof and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section&#160;6(d)(i) above, in the event a Holder shall elect to convert any or all of its Series A Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series A Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">would be converted the Series A Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to Section&#160;6(c) hereof and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section&#160;6(d)(i) above, issue Conversion Shares upon a properly noticed conversion. If the Corporation fails to deliver to a Holder such certificate or certificates, or electronically deliver (or cause its transfer agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to Section&#160;6(d)(i) on or prior to the fifth (5th)&#160;Trading Day after the Share Delivery Date applicable to such conversion (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), then, unless the Holder has rescinded the applicable Notice of Conversion pursuant to Section&#160;6(d)(i) above, the Corporation shall pay (as liquidated damages and not as a penalty) to such Holder an amount payable, at the Holder&#8217;s option, either (a)&#160;in cash or (b)&#160;to the extent that it would not cause the Holder or its Attribution Parties to exceed the Beneficial Ownership Limitation, in shares of Common Stock that are valued for these purposes at the Closing Sale Price on the date of such calculation, in each case equal to the product of (x)&#160;the number of Conversion Shares required to have been issued by the Corporation on such Share Delivery Date, (y)&#160;an amount equal to the Daily Failure Amount and (z)&#160;the number of Trading Days actually lapsed after such fifth (5th)&#160;Trading Day after the Share Delivery Date during which such certificates have not been delivered, or, in the case of a DWAC Delivery, such shares have not been electronically delivered; </font><i style="font-size:11pt;font-style:italic;">provided</i><font style="font-size:11pt;">, </font><i style="font-size:11pt;font-style:italic;">however</i><font style="font-size:11pt;">, the Holder shall only receive up to such amount of shares of Common Stock such that Holder and its Attribution Parties and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section&#160;13(d) of the Exchange Act (including shares held by any &#8220;group&#8221; of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than the Beneficial Ownership Limitation. Nothing herein shall limit a Holder&#8217;s right to pursue actual damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief; provided that Holder shall not receive duplicate damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(iii)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compensation for&#160;Buy-In&#160;on Failure to Timely Deliver Certificates Upon Conversion</u><font style="font-size:11pt;">. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to Section&#160;6(d)(i) (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Buy-In</b><font style="font-size:11pt;">&#8221;), then the Corporation shall (A)&#160;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x)&#160;such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&#160;the product of (1)&#160;the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&#160;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&#160;at the option of such Holder, either reissue (if surrendered) the shares of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Series A Preferred Stock equal to the number of shares of Series A Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section&#160;6(d)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover&#160;a&#160;Buy-In&#160;with&#160;respect to an attempted conversion of shares of Series A Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&#160;of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&#160;Trading Days after the occurrence of&#160;a&#160;Buy-In,&#160;indicating&#160;the amounts payable to such Holder in respect of&#160;such&#160;Buy-In&#160;together&#160;with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series A Preferred Stock as required pursuant to the terms hereof; provided, however, that the Holder shall not be entitled to both (i)&#160;require the reissuance of the shares of Series A Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&#160;receive the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section&#160;6(d)(i).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(iv)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Reservation of Shares Issuable Upon Conversion</u><font style="font-size:11pt;">. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of Section&#160;7) upon the conversion of all outstanding shares of Series A Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, nonassessable and free and clear of all liens and encumbrances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(v)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Fractional Shares</u><font style="font-size:11pt;">. No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the conversion of the Series A Preferred Stock. As to any fraction of a share which a Holder would otherwise be entitled to receive upon such conversion, the Corporation shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(vi)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transfer Taxes</u><font style="font-size:11pt;">. The issuance of certificates for shares of the Common Stock upon conversion of the Series A Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series A Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Status as Stockholder</u><font style="font-size:11pt;">. Upon each Conversion Date, (i)&#160;the shares of Series A Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series A Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series A Preferred Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Certain Adjustments</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Stock Dividends and Stock Splits</u><font style="font-size:11pt;">. If the Corporation, at any time while this Series A Preferred Stock is outstanding: (i)&#160;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series A Preferred Stock) with respect to the then outstanding shares of Common Stock; (ii)&#160;subdivides outstanding shares of Common Stock into a larger number of shares; or (iii)&#160;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this Section&#160;7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Fundamental Transaction</u><font style="font-size:11pt;">. If, at any time while this Series A Preferred Stock is outstanding, (i)&#160;the Corporation enters into a binding agreement to effect any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization,&#160;spin-off, share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation would be the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (ii)&#160;the Corporation enters into a binding agreement to effect any sale of all or substantially all of its assets in one transaction or a series of related transactions, (iii)&#160;any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (iv)&#160;the Corporation announces its intent to effect any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by Section&#160;7(a) above) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Fundamental Transaction</b><font style="font-size:11pt;">&#8221;), then at least 20 calendar days prior to the anticipated date prior to when such Fundamental Transaction is expected to be consummated or closed, the Company shall provide written notice all Holders of such Fundamental Transaction to allow such holder to give notice of conversion and entitle such holders to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of Common Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Alternate Consideration</b><font style="font-size:11pt;">&#8221;). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series A Preferred Stock following such Fundamental Transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Calculations</u><font style="font-size:11pt;">. All calculations under this Section&#160;7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section&#160;7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notice to the Holders</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Adjustment to Conversion Price</u><font style="font-size:11pt;">. Whenever the Conversion Price is adjusted pursuant to any provision of this Section&#160;7, the Corporation shall promptly deliver to each Holder a notice setting forth the Conversion Ratio after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(ii)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Other Notices</u><font style="font-size:11pt;">. If (A)&#160;the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock or Class A Common Stock, (B)&#160;the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock or Class A Common Stock, (C)&#160;the Corporation shall authorize the granting to all holders of the Common Stock or Class A Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&#160;the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock or Class A Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock or Class A Common Stock is converted into other securities, cash or property, or (E)&#160;the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of this Series A Preferred Stock, and, except if such notice and the contents thereof shall be deemed to constitute material non-public information shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock or Class A Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 4.3pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:11pt;">. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Conversion, shall be in writing and delivered personally, by facsimile, via email or sent by a nationally recognized overnight courier service, addressed to the Corporation, at 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, New York 10118, facsimile number +43 1 890 63 60 399, email&#160;Reinhard.Kandera@hookipapharma.com, or such other facsimile number, email address or mailing address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of such Holder appearing on the books of the Corporation, or if no such facsimile number or address appears on the books of the Corporation, at the principal place of business of such Holder. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i)&#160;the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number, or via email at the email address, specified in this Section prior to 5:30 p.m. (New York City time) on any date, (ii)&#160;the date immediately following the date of transmission, if such notice or communication is delivered via facsimile at the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 4.3pt;"><font style="font-size:11pt;">facsimile number, or via email at the email address, specified in this Section between 5:30 p.m. and 11:59 p.m. (New York City time) on any date, (iii)&#160;the second Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv)&#160;upon actual receipt by the party to whom such notice is required to be given.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 12pt 4.3pt;"><font style="display:inline-block;text-indent:0pt;width:36.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Lost or Mutilated Series A Preferred Stock Certificate</u><font style="font-size:11pt;">. If a Holder&#8217;s Series A Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series A Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership thereof, reasonably satisfactory to the Corporation and, in each case, customary and reasonable indemnity, if requested. Applicants for a new certificate under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Corporation may prescribe.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 12pt 4.3pt;"><font style="display:inline-block;text-indent:0pt;width:36.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Waiver</u><font style="font-size:11pt;">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series A Preferred Stock granted hereunder may be waived as to all shares of Series A Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series A Preferred Stock then outstanding, unless a higher percentage is required by the DGCL, in which case the written consent of the Holders of not less than such higher percentage shall be required.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 12pt 4.3pt;"><font style="display:inline-block;text-indent:0pt;width:36.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Severability</u><font style="font-size:11pt;">. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 12pt 4.3pt;"><font style="display:inline-block;text-indent:0pt;width:36.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Next Business Day</u><font style="font-size:11pt;">. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 12pt 4.3pt;"><font style="display:inline-block;text-indent:0pt;width:36.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Headings</u><font style="font-size:11pt;">. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 8pt 4.5pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Status of Converted Series A Preferred Stock</u><font style="font-size:11pt;">. If any shares of Series A Preferred Stock shall be converted or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A Preferred Stock.</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:11pt;">, the undersigned has executed this Certificate of Designation this 11th day of December 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ J&#246;rn Aldag</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">J&#246;rn Aldag, Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">SIGNATURE PAGE TO CERTIFICATE OF DESIGNATION OF PREFERENCES,<br>RIGHTS AND LIMITATIONS OF SERIES A PREFERRED STOCK</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ANNEX A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">NOTICE OF CONVERSION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">TO CONVERT SHARES OF SERIES A PREFERRED STOCK)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series A Preferred Stock indicated below, represented by stock certificate No(s).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Preferred Stock Certificates</b><font style="font-size:11pt;">&#8221;), into shares of common stock, par value $0.0001 per share (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Common Stock</b><font style="font-size:11pt;">&#8221;), of HOOKIPA Pharma Inc., a Delaware corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Corporation</b><font style="font-size:11pt;">&#8221;), as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Certificate of Designation</b><font style="font-size:11pt;">&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on December 11, 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section&#160;13(d) or Section&#160;16 of the Exchange Act and the applicable regulations of the Commission, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Attribution Parties</b><font style="font-size:11pt;">&#8221;)), including the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series A Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in Section&#160;6(c) of the Certificate of Designation, is 9.99%. For purposes hereof, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Conversion calculations:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Date&#160;to&#160;Effect<br>Conversion:</font></p></td><td colspan="2" style="vertical-align:bottom;width:50.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:31.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;">Number&#160;of&#160;shares&#160;of&#160;Series<br>A&#160;Preferred&#160;Stock&#160;owned&#160;prior&#160;to Conversion:</font></p></td><td colspan="2" style="vertical-align:top;width:31.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Number&#160;of&#160;shares&#160;of&#160;Series<br>A&#160;Preferred&#160;Stock&#160;to&#160;be Converted:</font></p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.27%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:37.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Number&#160;of&#160;shares&#160;of&#160;Common&#160;Stock&#160;to&#160;be<br>Issued:</font></p></td><td style="vertical-align:bottom;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:31.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Address&#160;for&#160;delivery&#160;of&#160;physical certificates:</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">or</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:11pt;">for&#160;DWAC&#160;Delivery:</font></p></td><td style="vertical-align:bottom;width:41.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.16%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:11pt;">DWAC&#160;Instructions:</font></p></td><td style="vertical-align:top;width:41.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:39.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:23.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><font style="font-size:11pt;">Broker&#160;no:</font></p></td><td style="vertical-align:bottom;width:37.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 24pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 24pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:23.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><font style="font-size:11pt;">Account&#160;no:</font></p></td><td style="vertical-align:bottom;width:37.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">HOOKIPA PHARMA INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">RIGHTS AND LIMITATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SERIES A-1 CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PURSUANT TO SECTION 151 OF THE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">DELAWARE GENERAL CORPORATION LAW</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">HOOKIPA PHARMA INC.</b><font style="font-size:11pt;">, a Delaware corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Corporation</b><font style="font-size:11pt;">&#8221;), in accordance with the provisions of Section&#160;103 of the Delaware General Corporation Law (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DGCL</b><font style="font-size:11pt;">&#8221;) does hereby certify that, in accordance with Sections 141(c) and 151 of the DGCL, the following resolution was duly adopted by a committee of the Board of Directors of the Corporation on March 1, 2022:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 24pt 0pt;"><b style="font-size:11pt;font-weight:bold;">RESOLVED</b><font style="font-size:11pt;">, pursuant to authority expressly set forth in the Amended and Restated Certificate of Incorporation of the Corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Certificate of Incorporation</b><font style="font-size:11pt;">&#8221;), the issuance of a series of Preferred Stock designated as the Series A-1 Convertible Preferred Stock, par value $0.0001 per share, of the Corporation is hereby authorized and the designation, number of shares, powers, preferences, rights, qualifications, limitations and restrictions thereof (in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series) are hereby fixed, and the Certificate of Designation of Preferences, Rights and Limitations of Series A-1 Convertible Preferred Stock is hereby approved as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SERIES A-1 CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;1</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:11pt;">. For the purposes hereof, the following terms shall have the following meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Affiliate</b><font style="font-size:11pt;">&#8221; means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder will be deemed to be an Affiliate of such Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Beneficial Ownership Limitation</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Business Day</b><font style="font-size:11pt;">&#8221; means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Class A Common Stock</b><font style="font-size:11pt;">&#8221; means the Corporation&#8217;s class A common stock, par value $0.0001 per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;"> &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Closing Sale Price</b><font style="font-size:11pt;">&#8221; means, for any security as of any date, the last closing trade price for such security prior to 4:00 p.m., New York City time, on the principal securities exchange or trading market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">reporting service mutually acceptable to and hereafter designated by Holders of a majority of the then-outstanding Series A-1 Preferred Stock and the Corporation), or if the foregoing do not apply, the last trade price of such security in the&#160;principal trading market for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the Nasdaq Global Select Market. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors of the Corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Commission</b><font style="font-size:11pt;">&#8221; means the Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Common Stock</b><font style="font-size:11pt;">&#8221; means the Corporation&#8217;s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed into.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Date</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Price</b><font style="font-size:11pt;">&#8221; shall mean $2.00, as adjusted pursuant to paragraph 7 hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Ratio</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Shares</b><font style="font-size:11pt;">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A-1 Preferred Stock in accordance with the terms hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Daily Failure Amount</b><font style="font-size:11pt;">&#8221; means the product of (x)&#160;.005 multiplied by (y)&#160;the Closing Sale Price of the Common Stock on the applicable Share Delivery Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DGCL</b><font style="font-size:11pt;">&#8221; shall mean the Delaware General Corporation Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Distributions</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DTC</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DWAC Delivery</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exchange Act</b><font style="font-size:11pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Fundamental Transaction</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section 7(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Holder</b><font style="font-size:11pt;">&#8221; means any holder of Series A-1 Preferred Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Issuance Date</b><font style="font-size:11pt;">&#8221; means March 4, 2022.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Junior Securities</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Notice of Conversion</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Parity Securities</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Person</b><font style="font-size:11pt;">&#8221; means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Securities Act</b><font style="font-size:11pt;">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Senior Securities</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;5(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A-1 Preferred Stock</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;2(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A-1 Preferred Stock Register</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;2(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Share Delivery Date</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Section&#160;6(d)(i).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Stated Value</b><font style="font-size:11pt;">&#8221; shall mean $2,000.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Day</b><font style="font-size:11pt;">&#8221; means a day on which the Common Stock is traded for any period on the principal securities exchange or if the Common Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities market on which the Common Stock is then being traded.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Designation, Amount and Par Value; Assignment</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">The series of preferred stock designated by this Certificate of Designation shall be designated as the Corporation&#8217;s Series A-1 Convertible Preferred Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A-1 Preferred Stock</b><font style="font-size:11pt;white-space:pre-wrap;">&#8221;) and the number of shares so designated shall be 15,800.  Each share of Series A-1 Preferred Stock shall have a par value of $0.0001 per share. The Series A-1 Preferred Stock may be issued in certificated form or in book-entry form at the election of the Holder. To the extent that any shares of Series A-1 Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">The Corporation or its designee shall register shares of the Series A-1 Preferred Stock, upon records to be maintained by the Corporation for that purpose (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Series A-1 Preferred Stock Register</b><font style="font-size:11pt;">&#8221;), in the name of the Holders thereof from time to time. The Corporation may deem and treat the registered Holder of shares of Series A-1 Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation or its designee shall register the transfer of any shares of Series A-1 Preferred Stock in the Series A-1 Preferred Stock Register, upon surrender of the certificates evidencing such shares to be transferred, duly endorsed by the Holder thereof, to the Corporation at its address specified herein. Upon any such registration or transfer, a new certificate evidencing the shares of Series A-1 Preferred Stock so transferred shall be issued to the transferee and a new certificate evidencing the remaining portion of the shares not so transferred, if any, shall be issued to the transferring Holder, in each case, within three (3) Business Days. The provisions of this Certificate of Designation are intended to be for the benefit of all Holders from time to time and shall be enforceable by any such Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;3</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Dividends</u><font style="font-size:11pt;">. </font><font style="font-size:11pt;">Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series A-1 Preferred Stock equal (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation) to and in the same form, and in the same manner, as dividends (other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series A-1 Preferred Stock, and the Corporation shall pay no dividends (other than dividends in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Voting Rights; Amendments</u><font style="font-size:11pt;">. Except as otherwise provided herein or as otherwise required by the DGCL, the Series A-1 Preferred Stock shall have no voting rights. However, as long as any shares of Series A-1 Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series A-1 Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A-1 Preferred Stock or alter or amend this Certificate of Designation, (b)&#160;issue further shares of Series A-1 Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A-1 Preferred Stock or (c)&#160;enter into any agreement with respect to any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;5</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Rank; Liquidation</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">The Series A-1 Preferred Stock shall rank (i) senior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms junior to any Series A-1 Preferred Stock (&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Junior Securities</b><font style="font-size:11pt;">&#8221;); (ii)&#160;on parity with the Common Stock, Class A Common Stock, Series A Preferred Stock and any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms on parity with the Series A-1 Preferred Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Parity Securities</b><font style="font-size:11pt;">&#8221;); (iii)&#160;junior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms senior to any Series A-1 Preferred Stock (&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Senior Securities</b><font style="font-size:11pt;">&#8221;), in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (all such distributions being referred to collectively as &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Distributions</b><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">Subject to the prior and superior rights of the holders of any Senior Securities of the Corporation, upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, each holder of shares of Series A-1 Preferred Stock shall be entitled to receive, in preference to any distributions of any of the assets or surplus funds of the Corporation to the holders of the Junior Securities and </font><i style="font-size:11pt;font-style:italic;">pari passu</i><font style="font-size:11pt;"> with any distribution to the holders of Parity Securities, an amount equal to $0.001 per share of Series A-1 Preferred Stock, plus an additional amount equal to any dividends declared but unpaid on such shares, before any payments shall be made or any assets distributed to holders of Junior Securities. If, upon any such liquidation, dissolution or winding up of the Corporation, the assets of the Corporation shall be insufficient to pay the holders of shares of the Series A-1 Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to holders of the shares of the Series A-1 Preferred Stock and Parity Securities </font><font style="font-size:11pt;">in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conversion</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conversions at Option of Holder</u><font style="font-size:11pt;">. Each share of Series A-1 Preferred Stock shall be convertible, at any time and from time to time from and after the Issuance Date, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as&#160;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Annex A</b><font style="font-size:11pt;">&#160;(a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Notice of Conversion</b><font style="font-size:11pt;">&#8221;), duly completed and executed. Other than a conversion following a notice provided for under Section&#160;7(b) or Section 7(d)(ii) hereof, the Notice of Conversion must specify at least a number of shares of Series A-1 Preferred Stock to be converted equal to the lesser of (x)&#160;100 shares (such number subject to appropriate adjustment following the occurrence of an event specified in Section&#160;7(a) hereof) and (y)&#160;the number of shares of Series A-1 Preferred Stock then held by the Holder. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DTC</b><font style="font-size:11pt;">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DWAC Delivery</b><font style="font-size:11pt;">&#8221;). The &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Date</b><font style="font-size:11pt;">&#8221;, or the date on which a conversion shall be deemed effective, shall be defined as the Trading Day that the Notice of Conversion, completed and executed, is sent by facsimile or other electronic transmission to, and received during regular business hours by, the Corporation; provided that the original certificate(s) (if applicable) representing such shares of Series A-1 Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2)&#160;Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original share certificate(s) (if applicable) of Series A-1 Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conversion Ratio</u><font style="font-size:11pt;">. The &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conversion Ratio</b><font style="font-size:11pt;">&#8221; for each share of Series A-1 Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(h)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Beneficial Ownership Limitation</u><font style="font-size:11pt;">. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of the Series A-1 Preferred Stock, and a Holder shall not have the right to convert any portion of the Series A-1 Preferred Stock, to the extent that, immediately prior to or after giving effect to an attempted conversion set forth on an applicable Notice of Conversion, such Holder (together with such Holder&#8217;s Affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section&#160;13(d) or Section&#160;16 of the Exchange Act and the applicable regulations of the Commission, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Attribution Parties</b><font style="font-size:11pt;">&#8221;)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series A-1 Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series A-1 Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained herein. For purposes of this Section&#160;6(c), beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. For purposes of this Section&#160;6(c), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A)&#160;the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B)&#160;a more recent public announcement by the Corporation that is filed with the Commission, or (C)&#160;a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within three (3)&#160;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined immediately prior to or after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series A-1 Preferred Stock, by such Holder or its</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Beneficial Ownership Limitation</b><font style="font-size:11pt;">&#8221; shall be 9.99% of the number of shares of the Common Stock outstanding immediately prior to or after giving effect to the issuance of shares of Common Stock pursuant to such Notice of Conversion (to the extent permitted pursuant to this Section&#160;6(c)); provided, however, that by written notice to the Corporation, which will not be effective until the 61st day after such notice is delivered to the Corporation, the Holder may waive or amend the provisions of this Section 6(c) to change the Beneficial Ownership Limitation to any other number less than or equal to 19.99%, and the provisions of this Section 6(c) shall continue to apply. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><font style="font-size:11pt;">&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Mechanics of Conversion</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Certificate or Electronic Issuance Upon Conversion</u><font style="font-size:11pt;">. Not later than three (3) Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series A-1 Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Share Delivery Date</b><font style="font-size:11pt;">&#8221;), the Corporation shall (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series A-1 Preferred Stock or (b)&#160;in the case of a DWAC Delivery, electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series A-1 Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series A-1 Preferred Stock unsuccessfully tendered for conversion to the Corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(ii)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Obligation Absolute</u><font style="font-size:11pt;">. Subject to Section&#160;6(c) hereof and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section&#160;6(d)(i) above, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series A-1 Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to Section&#160;6(c) hereof and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section&#160;6(d)(i) above, in the event a Holder shall elect to convert any or all of its Series A-1 Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series A-1 Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series A-1 Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to Section&#160;6(c) hereof and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section&#160;6(d)(i) above, issue Conversion Shares upon a properly noticed conversion. If the Corporation fails to deliver to a Holder such certificate or certificates, or electronically deliver (or cause its transfer agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to Section&#160;6(d)(i) on or prior to the fifth (5th)&#160;Trading Day after the Share Delivery Date applicable to such conversion (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), then, unless the Holder has rescinded the applicable Notice of Conversion pursuant to Section&#160;6(d)(i) above, the Corporation shall pay (as liquidated damages and not as a penalty) to such Holder an amount payable, at the Holder&#8217;s option, either (a)&#160;in cash or (b)&#160;to the extent that it would not cause the Holder or its Attribution Parties to exceed the Beneficial Ownership Limitation, in shares of Common Stock that are valued for these purposes at the Closing Sale Price on the date of such calculation, in each case equal to the product of (x)&#160;the number of Conversion Shares required to have been issued by the Corporation on such Share Delivery Date, (y)&#160;an amount equal to the Daily Failure Amount and (z)&#160;the number of Trading Days actually lapsed after such fifth (5th)&#160;Trading Day after the Share Delivery Date during which such certificates have not been delivered, or, in the case of a DWAC Delivery, such shares have not been electronically delivered; </font><i style="font-size:11pt;font-style:italic;">provided</i><font style="font-size:11pt;">, </font><i style="font-size:11pt;font-style:italic;">however</i><font style="font-size:11pt;">, the Holder shall only receive up to such amount of shares of Common Stock such that Holder and its Attribution Parties and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section&#160;13(d) of the Exchange Act (including shares held by any &#8220;group&#8221; of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than the Beneficial Ownership Limitation. Nothing herein shall limit a Holder&#8217;s right to pursue actual damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief; provided that Holder shall not receive duplicate damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(iii)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compensation for&#160;Buy-In&#160;on Failure to Timely Deliver Certificates Upon Conversion</u><font style="font-size:11pt;">. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to Section&#160;6(d)(i) (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Buy-In</b><font style="font-size:11pt;">&#8221;), then the Corporation shall (A)&#160;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x)&#160;such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&#160;the product of (1)&#160;the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&#160;the actual</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&#160;at the option of such Holder, either reissue (if surrendered) the shares of Series A-1 Preferred Stock equal to the number of shares of Series A-1 Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section&#160;6(d)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover&#160;a&#160;Buy-In&#160;with&#160;respect to an attempted conversion of shares of Series A-1 Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&#160;of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&#160;Trading Days after the occurrence of&#160;a&#160;Buy-In,&#160;indicating&#160;the amounts payable to such Holder in respect of&#160;such&#160;Buy-In&#160;together&#160;with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series A-1 Preferred Stock as required pursuant to the terms hereof; provided, however, that the Holder shall not be entitled to both (i)&#160;require the reissuance of the shares of Series A-1 Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&#160;receive the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section&#160;6(d)(i).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(iv)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Reservation of Shares Issuable Upon Conversion</u><font style="font-size:11pt;">. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A-1 Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A-1 Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of Section&#160;7) upon the conversion of all outstanding shares of Series A-1 Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, nonassessable and free and clear of all liens and encumbrances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(v)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Fractional Shares</u><font style="font-size:11pt;">. No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the conversion of the Series A-1 Preferred Stock. As to any fraction of a share which a Holder would otherwise be entitled to receive upon such conversion, the Corporation shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(vi)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transfer Taxes</u><font style="font-size:11pt;">. The issuance of certificates for shares of the Common Stock upon conversion of the Series A-1 Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series A-1 Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(j)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Status as Stockholder</u><font style="font-size:11pt;">. Upon each Conversion Date, (i)&#160;the shares of Series A-1 Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series A-1 Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series A-1 Preferred Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Certain Adjustments</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Stock Dividends and Stock Splits</u><font style="font-size:11pt;">. If the Corporation, at any time while this Series A-1 Preferred Stock is outstanding: (i)&#160;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series A-1 Preferred Stock) with respect to the then outstanding shares of Common Stock; (ii)&#160;subdivides outstanding shares of Common Stock into a larger number of shares; or (iii)&#160;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this Section&#160;7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Fundamental Transaction</u><font style="font-size:11pt;">. If, at any time while this Series A-1 Preferred Stock is outstanding, (i)&#160;the Corporation enters into a binding agreement to effect any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization,&#160;spin-off, share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation would be the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (ii)&#160;the Corporation enters into a binding agreement to effect any sale of all or substantially all of its assets in one transaction or a series of related transactions, (iii)&#160;any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (iv)&#160;the Corporation announces its intent to effect any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by Section&#160;7(a) above) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Fundamental Transaction</b><font style="font-size:11pt;">&#8221;), then at least 20 calendar days prior to the anticipated date prior to when such Fundamental Transaction is expected to be consummated or closed, the Company shall provide written notice all Holders of such Fundamental Transaction to allow such holder to give notice of conversion and entitle such holders to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of Common Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Alternate Consideration</b><font style="font-size:11pt;">&#8221;). If holders of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series A-1 Preferred Stock following such Fundamental Transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Calculations</u><font style="font-size:11pt;">. All calculations under this Section&#160;7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section&#160;7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(h)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notice to the Holders</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Adjustment to Conversion Price</u><font style="font-size:11pt;">. Whenever the Conversion Price is adjusted pursuant to any provision of this Section&#160;7, the Corporation shall promptly deliver to each Holder a notice setting forth the Conversion Ratio after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(ii)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Other Notices</u><font style="font-size:11pt;">. If (A)&#160;the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock, Class A Common Stock or Series A Preferred Stock, (B)&#160;the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, Class A Common Stock or Series A Preferred Stock, (C)&#160;the Corporation shall authorize the granting to all holders of the Common Stock, Class A Common Stock or Series A Preferred Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&#160;the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, Class A Common Stock or Series A Preferred Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock, Class A Common Stock or Series A Preferred Stock is converted into other securities, cash or property, or (E)&#160;the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of this Series A-1 Preferred Stock, and, except if such notice and the contents thereof shall be deemed to constitute material non-public information shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock, Class A Common Stock or Series A Preferred Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8</u><font style="font-size:11pt;">.&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(h)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:11pt;">. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Conversion, shall be in writing and delivered personally, by facsimile, via email or sent by a nationally recognized overnight courier service, addressed to the Corporation, at 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, New York 10118, facsimile number +43 1 890 63 60 399, email&#160;Reinhard.Kandera@hookipapharma.com, or such other facsimile number, email address or mailing address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of such Holder appearing on the books of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Corporation, or if no such facsimile number or address appears on the books of the Corporation, at the principal place of business of such Holder. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i)&#160;the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number, or via email at the email address, specified in this Section prior to 5:30 p.m. (New York City time) on any date, (ii)&#160;the date immediately following the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number, or via email at the email address, specified in this Section between 5:30 p.m. and 11:59 p.m. (New York City time) on any date, (iii)&#160;the second Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv)&#160;upon actual receipt by the party to whom such notice is required to be given.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Lost or Mutilated Series A-1 Preferred Stock Certificate</u><font style="font-size:11pt;">. If a Holder&#8217;s Series A-1 Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series A-1 Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership thereof, reasonably satisfactory to the Corporation and, in each case, customary and reasonable indemnity, if requested. Applicants for a new certificate under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Corporation may prescribe.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(j)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Waiver</u><font style="font-size:11pt;">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series A-1 Preferred Stock granted hereunder may be waived as to all shares of Series A-1 Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series A-1 Preferred Stock then outstanding, unless a higher percentage is required by the DGCL, in which case the written consent of the Holders of not less than such higher percentage shall be required.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(k)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Severability</u><font style="font-size:11pt;">. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(l)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Next Business Day</u><font style="font-size:11pt;">. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(m)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Headings</u><font style="font-size:11pt;">. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(n)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Status of Converted Series A-1 Preferred Stock</u><font style="font-size:11pt;">. If any shares of Series A-1 Preferred Stock shall be converted or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A-1 Preferred Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 8pt 4.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:11pt;">, the undersigned has executed this Certificate of Designation this 3rd day of March 2022.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ J&#246;rn Aldag</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">J&#246;rn Aldag, Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">SIGNATURE PAGE TO CERTIFICATE OF DESIGNATION OF PREFERENCES,<br>RIGHTS AND LIMITATIONS OF SERIES A-1 PREFERRED STOCK</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ANNEX A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">NOTICE OF CONVERSION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">TO CONVERT SHARES OF SERIES A-1 PREFERRED STOCK)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series A-1 Preferred Stock indicated below, represented by stock certificate No(s).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Preferred Stock Certificates</b><font style="font-size:11pt;">&#8221;), into shares of common stock, par value $0.0001 per share (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Common Stock</b><font style="font-size:11pt;">&#8221;), of HOOKIPA Pharma Inc., a Delaware corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Corporation</b><font style="font-size:11pt;">&#8221;), as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series A-1 Convertible Preferred Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Certificate of Designation</b><font style="font-size:11pt;">&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on March 3, 2022.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section&#160;13(d) or Section&#160;16 of the Exchange Act and the applicable regulations of the Commission, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Attribution Parties</b><font style="font-size:11pt;">&#8221;)), including the number of shares of Common Stock issuable upon conversion of the Series A-1 Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series A-1 Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in Section&#160;6(c) of the Certificate of Designation, is 9.99%. For purposes hereof, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Conversion calculations:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Date&#160;to&#160;Effect<br>Conversion:</font></p></td><td colspan="3" style="vertical-align:bottom;width:52.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:30.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td><td colspan="4" style="vertical-align:bottom;width:64.15%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="3" style="vertical-align:middle;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Number&#160;of&#160;shares&#160;of&#160;Series A-<br>1&#160;Preferred&#160;Stock&#160;owned&#160;prior&#160;to Conversion:</font></p></td><td colspan="2" style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:30%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:35.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Number&#160;of&#160;shares&#160;of&#160;Series A-<br>1&#160;Preferred&#160;Stock&#160;to&#160;be Converted:</font></p></td><td style="vertical-align:bottom;width:31.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:32.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:61.66%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Number&#160;of&#160;shares&#160;of&#160;Common&#160;Stock&#160;to&#160;be<br>Issued:</font></p></td><td style="vertical-align:bottom;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:30.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Address&#160;for&#160;delivery&#160;of&#160;physical certificates:</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">or</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:18.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:11pt;">for&#160;DWAC&#160;Delivery:</font></p></td><td colspan="2" style="vertical-align:bottom;width:38.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:43.33%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:18.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:38.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:18.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:11pt;">DWAC&#160;Instructions:</font></p></td><td colspan="2" style="vertical-align:top;width:38.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:18.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:38.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><font style="font-size:11pt;">Broker&#160;no:</font></p></td><td style="vertical-align:bottom;width:36.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.33%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:36.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><font style="font-size:11pt;">Account&#160;no:</font></p></td><td style="vertical-align:bottom;width:36.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.33%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>hook-20211231xex4d3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:20:38 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:right;margin:7.5pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 4.3</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DESCRIPTION OF SECURITIES REGISTERED UNDER <br>SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following description of the registered capital stock of HOOKIPA Pharma Inc. (&#8220;us,&#8221; &#8220;our,&#8221; &#8220;we&#8221; or the &#8220;Company&#8221;) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our amended and restated certificate of incorporation (&#8220;Certificate of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Bylaws&#8221;), which are incorporated by reference as exhibits to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, and applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Our common stock, par value $0.0001 per share (the &#8220;common stock&#8221;) is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended. The summaries below do not purport to be complete statements of the relevant provisions of our Certificate of Incorporation, our Bylaws or the DGCL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our authorized capital stock consists of 100,000,000 shares of common stock, 3,900,000 shares of Class A common stock, par value $0.0001 per share (the &#8220;Class A common stock&#8221;) and 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share (the &#8220;preferred stock&#8221;), of which 2,978 shares are designated as Series A convertible preferred stock (the &#8220;Series A preferred stock&#8221;) and 15,800 shares are designated as Series A-1 convertible preferred stock (the &#8220;Series A-1 preferred stock&#8221;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;min-height:14.4pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Annual Meeting</i><font style="font-family:'Times New Roman','Times','serif';">. Annual meetings of our stockholders are held on the date designated in accordance with our Bylaws. Written notice must be mailed to each stockholder entitled to vote not less than ten (10) nor more than sixty (60) days before the date of the meeting. The presence in person or by proxy of the holders of record of a majority of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders may be called for any purpose only by the board of directors pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office. Except as may be otherwise provided by applicable law, our Certificate of Incorporation or our Bylaws, all elections of directors shall be decided by a plurality, and all other questions shall be decided by a majority, of the votes cast by stockholders entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Voting Rights</i><font style="font-family:'Times New Roman','Times','serif';">. Holders of common stock are entitled to one vote for each share held of record on all matters to be voted upon by stockholders and do not have cumulative voting rights.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Dividends</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the rights, powers and preferences of any outstanding preferred stock that we may designate and issue in the future, and except as provided by law or in our Certificate of Incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by our board of directors.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Liquidation, Dissolution and Winding Up</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the rights, powers and preferences of any outstanding preferred stock that we may designate and issue in the future, in the event of our liquidation, dissolution or winding up, our net assets will be distributed pro rata to the holders of common stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Other Rights</i><font style="font-family:'Times New Roman','Times','serif';">. Our common stock has no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. Holders of common stock are not required to make additional capital contributions.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#8220;HOOK.&#8221;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:justify;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Class A Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The rights of the holders of our common stock and class A common stock are identical, except with respect to voting and conversion. The shares of class A common stock do not have associated voting rights and each share of class A common stock is convertible at any time at the election of the holder into one share of common stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:justify;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our board of directors has the authority to designate and issue up to ten million (10,000,000) shares of preferred stock in one or more series. The authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Our board of directors may also designate the rights, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">17,552 shares of preferred stock are outstanding as of the date of our Annual Report on Form 10-K with which this Exhibit 4.3 is filed as an exhibit, consisting of 1,752 shares of Series A preferred stock and 15,800 shares of Series A-1 preferred stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:justify;margin:0pt 0pt 7.5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series A Preferred Stock</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Rank. </i><font style="font-family:'Times New Roman','Times','serif';">The Series A preferred stock will rank:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">on parity with our common stock, Class A common stock and Series A-1 preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">on parity with any class or series of capital stock hereafter created specifically ranking by its terms on parity with the Series A preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">senior to any class or series of our capital stock hereafter created specifically ranking by its terms junior to the Series A preferred stock; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">junior to any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A preferred stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">or involuntarily.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conversion. </i><font style="font-family:'Times New Roman','Times','serif';">Each share of the Series A preferred stock is convertible into 1,000 shares of our common stock (subject to adjustment as provided in the related certificate of designation of preferences rights and limitations) at any time at the option of the holder, provided that the holder will be prohibited, subject to certain exceptions, from converting Series A preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to us.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Liquidation Preference. </i><font style="font-family:'Times New Roman','Times','serif';">In the event of our liquidation, dissolution or winding up, holders of the Series A preferred stock will receive a payment equal to $0.001 per share of Series A preferred stock </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">pari passu </i><font style="font-family:'Times New Roman','Times','serif';">with the common stock, Class A common stock and Series A-1 preferred stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Fundamental Transaction</i><font style="font-family:'Times New Roman','Times','serif';">. Upon consummation of a Fundamental Transaction (as defined below) pursuant to which holders of shares of our common stock are entitled to receive securities, cash or property, then upon any subsequent conversion of the Series A preferred stock, the holder thereof shall have the right to receive, in lieu of the right to receive the shares of our common stock underlying the Series A preferred stock, for each share of </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">common stock that it would have otherwise been entitled to receive upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of our common stock. If holders of our common stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Series A preferred stock shall be given the same choice as to the consideration it receives upon any exercise of the Series A preferred stock following such Fundamental Transaction.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">A &#8220;Fundamental Transaction&#8221; means:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">we effect any merger or consolidation with or into another person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another person (other than such a transaction in which we are the surviving or continuing entity and our common stock is not exchanged for or converted into other securities, cash or property);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">we effect any sale of all or substantially all of our assets in one transaction or a series of related transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">any tender offer or exchange offer (whether by us or another person) is completed pursuant to which more than 50% of the common stock not held by us or such person is exchanged for or converted into other securities, cash or property; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">we effect any reclassification of our common stock or any compulsory share exchange pursuant (other than specified dividends, subdivisions or combinations) to which our common stock is effectively converted into or exchanged for other securities, cash or property.</font></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Voting Rights. </i><font style="font-family:'Times New Roman','Times','serif';">Shares of Series A preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding shares of Series A preferred stock will be required to amend the terms of the Series A preferred stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Dividends. </i><font style="font-family:'Times New Roman','Times','serif';">Shares of Series A preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Redemption. </i><font style="font-family:'Times New Roman','Times','serif';">We are not obligated to redeem or repurchase any shares of Series A preferred stock. Shares of Series A preferred stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exchange Listing. </i><font style="font-family:'Times New Roman','Times','serif';">We do not plan on making an application to list the Series A preferred stock on The Nasdaq Global Select Market, any national securities exchange or other nationally recognized trading system. We expect the common stock issuable upon conversion of the Series A preferred stock to be listed on the Nasdaq Global Select Market.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The transfer agent and registrar for shares of our Series A preferred stock (and the underlying shares of common stock) is American Stock Transfer &amp; Trust Company, LLC. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:justify;margin:0pt 0pt 7.5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series A-1 Preferred Stock</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk97913849"></a></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Rank. </i><font style="font-family:'Times New Roman','Times','serif';">The Series A-1 preferred stock will rank:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">on parity with our common stock, Class A common stock and Series A preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">on parity with any class or series of capital stock hereafter created specifically ranking by its terms on parity with the Series A-1 preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">senior to any class or series of our capital stock hereafter created specifically ranking by its terms junior to the Series A-1 preferred stock; and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">junior to any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A-1 preferred stock;</font></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">or involuntarily.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conversion. </i><font style="font-family:'Times New Roman','Times','serif';">Each share of the Series A-1 preferred stock is convertible into 1,000 shares of our common stock (subject to adjustment as provided in the related certificate of designation of preferences rights and limitations) at any time at the option of the holder, provided that the holder will be prohibited, subject to certain exceptions, from converting Series A-1 preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to us.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Liquidation Preference. </i><font style="font-family:'Times New Roman','Times','serif';">In the event of our liquidation, dissolution or winding up, holders of the Series A-1 preferred stock will receive a payment equal to $0.001 per share of Series A-1 preferred stock </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">pari passu </i><font style="font-family:'Times New Roman','Times','serif';">with the common stock, Class A common stock and Series A preferred stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Fundamental Transaction</i><font style="font-family:'Times New Roman','Times','serif';">. Upon consummation of a Fundamental Transaction (as defined below) pursuant to which holders of shares of our common stock are entitled to receive securities, cash or property, then upon any subsequent conversion of the Series A-1 preferred stock, the holder thereof shall have the right to receive, in lieu of the right to receive the shares of our common stock underlying the Series A-1 preferred stock, for each share of common stock that it would have otherwise been entitled to receive upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of our common stock. If holders of our common stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Series A-1 preferred stock shall be given the same choice as to the consideration it receives upon any exercise of the Series A-1 preferred stock following such Fundamental Transaction.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">A &#8220;Fundamental Transaction&#8221; means:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">we effect any merger or consolidation with or into another person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another person (other than such a transaction in which we are the surviving or continuing entity and our common stock is not exchanged for or converted into other securities, cash or property);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">we effect any sale of all or substantially all of our assets in one transaction or a series of related transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">any tender offer or exchange offer (whether by us or another person) is completed pursuant to which more than 50% of the common stock not held by us or such person is exchanged for or converted into other securities, cash or property; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">we effect any reclassification of our common stock or any compulsory share exchange pursuant (other than specified dividends, subdivisions or combinations) to which our common stock is effectively converted into or exchanged for other securities, cash or property.</font></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Voting Rights. </i><font style="font-family:'Times New Roman','Times','serif';">Shares of Series A-1 preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding shares of Series A-1 preferred stock will be required to amend the terms of the Series A-1 preferred stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Dividends. </i><font style="font-family:'Times New Roman','Times','serif';">Shares of Series A-1 preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Redemption. </i><font style="font-family:'Times New Roman','Times','serif';">We are not obligated to redeem or repurchase any shares of Series A-1 preferred stock. Shares of Series A-1 preferred stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exchange Listing. </i><font style="font-family:'Times New Roman','Times','serif';">We do not plan on making an application to list the Series A-1 preferred stock on The Nasdaq Global Select Market, any national securities exchange or other nationally recognized trading system. We expect the common stock issuable upon conversion of the Series A-1 preferred stock to be listed on the Nasdaq Global Select Market.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The transfer agent and registrar for shares of our Series A-1 preferred stock (and the underlying shares of common stock) is American Stock Transfer &amp; Trust Company, LLC. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-height:14.4pt;text-align:justify;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Registration Rights </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the terms of our shareholders&#8217; agreement, dated as of February 15, 2019, certain of our stockholders are entitled to rights with respect to the registration of their shares under Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Demand Registration Rights.</i><font style="font-family:'Times New Roman','Times','serif';">&#160;Pursuant to the terms of our shareholders&#39; agreement, certain holders of shares of our common stock are entitled to demand registration rights. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Short-Form Registration Rights. </i><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the terms of our shareholders&#39; agreement, certain holders of shares of our common stock are entitled to short-form registration rights. If we are eligible to file&#160;a registration statement on Form&#160;S-3, upon the written request of a majority of our stockholders to sell securities at an anticipated aggregate price of at least $10.0&#160;million, we will be required to use commercially reasonable efforts to effect a registration of such shares. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Piggyback Registration Rights.</i><font style="font-family:'Times New Roman','Times','serif';">&#160;Pursuant to the terms of our shareholders&#39; agreement, certain holders of shares of our common stock are entitled to piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-style:italic;">Expiration of Registration Rights</i>. The demand registration rights and short form registration rights will terminate as to a given stockholder at such time as Rule&#160;144 or another similar exemption under the Securities Act is available for the sale of all of such stockholder&#39;s shares without limitation during a three-month period without registration. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover Effects</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The provisions of Delaware law and our Certificate of Incorporation and Bylaws could discourage or make it more difficult to accomplish a proxy contest or other change in our management or the acquisition of control by a holder of a substantial amount of our voting stock. It is possible that these provisions could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or in our best interests. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. Such provisions also may have the effect of preventing changes in our management.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Board of Directors</i><font style="font-family:'Times New Roman','Times','serif';">. Our Certificate of Incorporation and Bylaws provide for a board of directors divided into three classes. Each class is elected to a term expiring at the annual meeting of stockholders held in the third year following the year of such election. The number of directors comprising our board of directors is fixed from time to time by the board of directors.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Removal of Directors by Stockholders</i><font style="font-family:'Times New Roman','Times','serif';">. Our Certificate of Incorporation provides that members of our board of directors may only be removed for cause by a vote of the holders of at least two-thirds (2/3) of the outstanding shares entitled to vote on the election of the directors.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Issuance of Preferred Stock</i><font style="font-family:'Times New Roman','Times','serif';">. Our board of directors is authorized, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, and to fix the designations, powers, preferences and the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The issuance of preferred stock could impede the completion of a merger, tender offer or other takeover attempt.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Stockholder Nomination of Directors</i><font style="font-family:'Times New Roman','Times','serif';">. Our Bylaws provide that a stockholder must notify us in writing of any stockholder nomination of a director not earlier than the close of business on the 120</font><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';"> day and not later than the close of business on the 90</font><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';"> day prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, that if the date of the annual meeting is advanced by more than 30 days before such anniversary date, delayed by more than 60 days after such anniversary date or if no annual meeting were held in the prior year, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (x) the 90th day prior to the date of such meeting and (y) the 10th day following the day on which public announcement of the date of such annual meeting is first made by us.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">No Action By Written Consent</i><font style="font-family:'Times New Roman','Times','serif';">. Our Certificate of Incorporation provides that our stockholders may not act by written consent and may only act at duly called meetings of stockholders.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exclusive Forum Selection</i><font style="font-family:'Times New Roman','Times','serif';">. Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for state law claims for (1) any derivative action or proceeding brought on behalf of the Company, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to the Company or our stockholders, (3) any action asserting a claim arising against the Company or any of our current or former directors, officers, or other employees pursuant to any provision of the DGCL or our Certificate of Incorporation or Bylaws, (4)&#160;any action to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or Bylaws, or (5)&#160;any action asserting a claim against the Company or any of our current or former directors, officers, or other employees that is governed by the internal affairs doctrine. In addition, our Bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. &#160;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:11pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law. </b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">We are subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 11pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock</font></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 36pt;">plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least&#160;two-thirds&#160;of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table><div style="margin-top:11pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">Section&#160;203 defines a business combination to include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 11pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">any merger or consolidation involving the corporation and the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 11pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 11pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 11pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></td></tr></table><div style="margin-top:11pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>hook-20211231xex10d15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:20:41 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><a name="_Hlk98761029"></a><b style="font-weight:bold;">Exhibit 10.15</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;text-align:center;margin:3.04pt 134.5pt 0pt 131.65pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">EMPLOYMENT</b><b style="font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.8pt 0pt 5pt;">This Employment Agreement (&#8220;Agreement&#8221;) is made between HOOKIPA Biotech GmbH (the &#8220;Company&#8221;), and Klaus Orlinger (the &#8220;Executive&#8221;) and is made effective as of January 1, 2022 (the &#8220;Effective Date&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 8pt 0pt 5pt;">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.95pt 0pt 5pt;">WHERAS,<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Executive<font style="letter-spacing:-0.3pt;"> </font>was<font style="letter-spacing:-0.25pt;"> </font>previously<font style="letter-spacing:-0.25pt;"> </font>employed<font style="letter-spacing:-0.25pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Company<font style="letter-spacing:-0.25pt;"> </font>as<font style="letter-spacing:-0.25pt;"> </font>EVP<font style="letter-spacing:-0.1pt;"> </font>Research and is currently classed as follows under the applicable collective bargaining agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 298.7pt 0pt 41pt;">Service<font style="letter-spacing:-0.75pt;"> </font>category:<font style="letter-spacing:-0.75pt;"> </font>VI Years of service: 3</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 7.8pt 0pt 5pt;">and based on this classification, the minimum wage under collective bargaining agreements and the<font style="letter-spacing:-0.05pt;"> </font>basic<font style="letter-spacing:-0.05pt;"> </font>wage<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:-0.1pt;"> </font>40 hours<font style="letter-spacing:-0.05pt;"> </font>per<font style="letter-spacing:-0.05pt;"> </font>week as defined in &#167;2 Sec<font style="letter-spacing:-0.05pt;"> </font>2 Nr. 9 AVRAG<font style="letter-spacing:-0.05pt;"> </font>in connection with &#167;2g AVRAG, excluding the monthly extra allowance for dirt work (&#8220;SEG&#8221;) amount to EUR 4,396.90 gross per month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 8.05pt 0pt 5pt;">NOW,<font style="letter-spacing:-0.25pt;"> </font>THEREFORE,<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>consideration<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>mutual<font style="letter-spacing:-0.25pt;"> </font>covenants<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>agreements<font style="letter-spacing:-0.25pt;"> </font>herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;">1.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Employment</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 8.05pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Term</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the provisions hereof (the &#8220;Term&#8221;).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0.05pt 7.7pt 0pt 5pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Position</u><u style="letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">and</u><u style="letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Duties</u>.<font style="letter-spacing:-0.25pt;"> </font>During<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Term,<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Executive<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.2pt;"> </font>serve<font style="letter-spacing:-0.4pt;"> </font>as<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>Chief<font style="letter-spacing:-0.25pt;"> </font>Scientific<font style="letter-spacing:-0.25pt;"> </font>Officer of<font style="letter-spacing:-0.7pt;"> </font>HOOKIPA<font style="letter-spacing:-0.7pt;"> </font>Pharma<font style="letter-spacing:-0.65pt;"> </font>Inc.<font style="letter-spacing:-0.65pt;"> </font>(&#8220;Parent&#8221;)<font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>Company,<font style="letter-spacing:-0.7pt;"> </font>and<font style="letter-spacing:-0.65pt;"> </font>shall<font style="letter-spacing:-0.6pt;"> </font>have<font style="letter-spacing:-0.7pt;"> </font>supervision<font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.65pt;"> </font>control over<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>responsibility<font style="letter-spacing:-0.15pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>day-to-day<font style="letter-spacing:-0.15pt;"> </font>business<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>affairs<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>Parent<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Company<font style="letter-spacing:-0.15pt;"> </font>and shall have such other powers and duties as may from time to time be prescribed by the Chief Executive Officer of Parent or the Board of Directors of Parent (the &#8220;Board&#8221;). The executive shall<font style="letter-spacing:-0.4pt;"> </font>report<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Head<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>Research<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>Chief<font style="letter-spacing:-0.5pt;"> </font>Medical<font style="letter-spacing:-0.25pt;"> </font>Officer.<font style="letter-spacing:-0.5pt;"> </font>The<font style="letter-spacing:-0.45pt;"> </font>Executive<font style="letter-spacing:-0.5pt;"> </font>shall<font style="letter-spacing:-0.4pt;"> </font>devote<font style="letter-spacing:-0.5pt;"> </font>his full<font style="letter-spacing:-0.05pt;"> </font>working<font style="letter-spacing:-0.05pt;"> </font>time<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>efforts<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>business<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>affairs<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Company.<font style="letter-spacing:-0.1pt;"> </font>Notwithstanding<font style="letter-spacing:-0.05pt;"> </font>the foregoing,<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Executive<font style="letter-spacing:-0.75pt;"> </font>may<font style="letter-spacing:-0.75pt;"> </font>serve<font style="letter-spacing:-0.75pt;"> </font>on<font style="letter-spacing:-0.75pt;"> </font>other<font style="letter-spacing:-0.75pt;"> </font>boards<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.75pt;"> </font>directors,<font style="letter-spacing:-0.75pt;"> </font>with<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>approval<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Board, or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not materially interfere with the Executive&#8217;s performance of his duties to the Company as provided in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.9pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Place of Employment</u><font style="font-size:12pt;">. The place of employment of the Executive is Vienna. The Company reserves the right to change the place of employment due to business </font><font style="font-size:12pt;letter-spacing:-0.1pt;">reasons.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;">2.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Compensation</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">and</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Related</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Matters</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Base</u><u style="font-size:12pt;letter-spacing:-0.35pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Salary</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">During</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Term,</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">initial</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">annual</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">base</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">salary shall be gross EUR 237,609 (two hundred thirty seven thousand six hundred and nine Euros) payable in 14 equal monthly instalments. The Executive&#8217;s base salary shall be re-determined</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 5pt;"><font style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">1</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 7.85pt 0pt 5pt;">annually<font style="letter-spacing:-0.55pt;"> </font>by<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Compensation<font style="letter-spacing:-0.55pt;"> </font>Committee<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Board<font style="letter-spacing:-0.55pt;"> </font>(the<font style="letter-spacing:-0.45pt;"> </font>&#8220;Compensation<font style="letter-spacing:-0.55pt;"> </font>Committee&#8221;).<font style="letter-spacing:-0.55pt;"> </font>The base<font style="letter-spacing:-0.1pt;"> </font>salary<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>effect<font style="letter-spacing:-0.05pt;"> </font>at<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>given<font style="letter-spacing:-0.1pt;"> </font>time<font style="letter-spacing:-0.15pt;"> </font>is<font style="letter-spacing:-0.05pt;"> </font>referred<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>herein<font style="letter-spacing:-0.05pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>&#8220;Base<font style="letter-spacing:-0.1pt;"> </font>Salary.&#8221;<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.1pt;"> </font>Base<font style="letter-spacing:-0.1pt;"> </font>Salary shall be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for senior executives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Incentive Compensation</u><font style="font-size:12pt;">. During the Term, the Executive shall be eligible</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">receive</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">cash</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">incentive</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">compensation</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">determined</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Compensation</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Committee from time to time. The Executive&#8217;s target annual incentive compensation shall be 40 percent of his Base Salary.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Expenses</u><font style="font-size:12pt;">. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 8.05pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Other Benefits</u><font style="font-size:12pt;">. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company&#8217;s employee benefit plans in effect from time to time, subject to the terms of such plans.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Equity</u><u style="font-size:12pt;letter-spacing:-0.45pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compensation</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">also</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">eligible</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">participate in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Parent&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">2019 Stock</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Option</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">and Incentive</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Plan on</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">terms</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">and conditions</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">determined by the Compensation Committee.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(f)</font><font style="font-size:12pt;">The compensation provided for in (a) to (e) compensates the Executive for</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">services</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">performed</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">him</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">also</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">outside</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">regular</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">working</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">hours. It is well understood that the Executive will render such extra services, as well as additional services on Saturdays, Sundays and holidays if required.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(g)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Vacations</u><font style="font-size:12pt;">. During the Term, the Executive shall be entitled to vacation of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">25 paid working days in each year. The</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">shall also be</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">entitled to all paid holidays given</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">by the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">to its executives. The</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Austrian Leave</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Entitlement</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Act (</font><i style="font-size:12pt;font-style:italic;">Urlaubsgesetz</i><font style="font-size:12pt;">) applies in its currently valid version.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.65pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(h)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company phone and laptop.</u><font style="font-size:12pt;"> The Company agrees to provide the Executive</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">with a</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">company</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">mobile</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">phone</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">and a</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">company</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">laptop at its</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">own</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">expense</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">and agrees to</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">pay</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">reasonable</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">related</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">costs</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">incurred,</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">both</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">business</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">reasonable</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">private</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">use.</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Upon termination of his employment, the Executive shall return his company laptop, company mobile</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">phone</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">assets</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">supplied</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">course</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">his</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">employment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 8.05pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.85pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination</u><font style="font-size:12pt;">. During the Term, the Executive&#8217;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:76.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Death</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:2.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Executive&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">employment</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">hereunder</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">terminate</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">upon</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:justify;">his</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 5pt;"><font style="letter-spacing:-0.1pt;">death.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:76.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.25pt;padding:0pt;">(b)</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Disability</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">. For</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">the termination</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">the Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">case</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">disability</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:justify;">of</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 8.15pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:27.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;">the</font></font><font style="font-size:12pt;letter-spacing:-0.1pt;">Executive,</font><font style="display:inline-block;width:14.32pt;"></font><font style="font-size:12pt;letter-spacing:-0.2pt;">the</font><font style="display:inline-block;width:13.99pt;"></font><font style="font-size:12pt;letter-spacing:-0.1pt;">Austrian</font><font style="display:inline-block;width:14.07pt;"></font><font style="font-size:12pt;letter-spacing:-0.2pt;">Act</font><font style="display:inline-block;width:13.97pt;"></font><font style="font-size:12pt;letter-spacing:-0.3pt;">on</font><font style="display:inline-block;width:13.9pt;"></font><font style="font-size:12pt;letter-spacing:-0.2pt;">the</font><font style="display:inline-block;width:13.99pt;"></font><font style="font-size:12pt;letter-spacing:-0.1pt;">Employment</font><font style="display:inline-block;width:14.36pt;"></font><font style="font-size:12pt;letter-spacing:-0.3pt;">of</font><font style="display:inline-block;width:14.1pt;"></font><font style="font-size:12pt;letter-spacing:-0.1pt;">Disabled</font><font style="display:inline-block;width:27.95pt;"></font><font style="font-size:12pt;letter-spacing:-0.1pt;">Persons </font><font style="font-size:12pt;">(</font><i style="font-size:12pt;font-style:italic;">Behinderteneinstellungsgesetz</i><font style="font-size:12pt;">) as amended from time to time shall apply.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination by Company for Cause</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Company may terminate the Executive&#8217;s employment hereunder with immediate effect for Cause.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">For purposes of this Agreement,</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">&#8220;Cause&#8221;</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:1.65pt;"> </font><font style="font-size:12pt;">mean</font><font style="font-size:12pt;letter-spacing:1.75pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:1.65pt;"> </font><font style="font-size:12pt;">particular:</font><font style="font-size:12pt;letter-spacing:4pt;"> </font><font style="font-size:12pt;">(i)</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">conduct</font><font style="font-size:12pt;letter-spacing:1.65pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">constituting</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">a</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3pt 7.65pt 0pt 5pt;">material<font style="letter-spacing:-0.6pt;"> </font>act<font style="letter-spacing:-0.6pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>misconduct<font style="letter-spacing:-0.6pt;"> </font>in<font style="letter-spacing:-0.6pt;"> </font>connection<font style="letter-spacing:-0.6pt;"> </font>with<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>performance<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>his<font style="letter-spacing:-0.45pt;"> </font>duties,<font style="letter-spacing:-0.6pt;"> </font>including,<font style="letter-spacing:-0.6pt;"> </font>without limitation,<font style="letter-spacing:-0.7pt;"> </font>misappropriation<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>funds<font style="letter-spacing:-0.75pt;"> </font>or<font style="letter-spacing:-0.65pt;"> </font>property<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>Parent<font style="letter-spacing:-0.65pt;"> </font>or<font style="letter-spacing:-0.65pt;"> </font>any<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>its<font style="letter-spacing:-0.7pt;"> </font>subsidiaries<font style="letter-spacing:-0.75pt;"> </font>or<font style="letter-spacing:-0.65pt;"> </font>affiliates other than the occasional, customary and de minimis use of Parent or Company property for personal purposes; (ii) the commission by the Executive of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or any conduct by the Executive that would<font style="letter-spacing:-0.25pt;"> </font>reasonably<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>expected<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>result<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>material<font style="letter-spacing:-0.25pt;"> </font>injury<font style="letter-spacing:-0.35pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>reputational<font style="letter-spacing:-0.3pt;"> </font>harm<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>Parent<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>any of its subsidiaries and affiliates if he were retained in his position; (iii) continued non- performance<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Executive<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>his<font style="letter-spacing:-0.15pt;"> </font>duties<font style="letter-spacing:-0.15pt;"> </font>hereunder<font style="letter-spacing:-0.15pt;"> </font>(other<font style="letter-spacing:-0.25pt;"> </font>than<font style="letter-spacing:-0.15pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>reason<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>Executive&#8217;s physical<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.3pt;"> </font>mental<font style="letter-spacing:-0.25pt;"> </font>illness,<font style="letter-spacing:-0.25pt;"> </font>incapacity<font style="letter-spacing:-0.25pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>disability)<font style="letter-spacing:-0.1pt;"> </font>which<font style="letter-spacing:-0.25pt;"> </font>has<font style="letter-spacing:-0.1pt;"> </font>continued<font style="letter-spacing:-0.1pt;"> </font>for<font style="letter-spacing:-0.1pt;"> </font>more<font style="letter-spacing:-0.3pt;"> </font>than<font style="letter-spacing:-0.15pt;"> </font>30<font style="letter-spacing:-0.25pt;"> </font>days following written notice of such non-performance from the Board; (iv) a breach by the Executive of any of the provisions contained in Section 6 of this Agreement; (v) a material violation<font style="letter-spacing:-0.35pt;"> </font>by<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Executive<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>Parent<font style="letter-spacing:-0.35pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.4pt;"> </font>written<font style="letter-spacing:-0.25pt;"> </font>employment<font style="letter-spacing:-0.35pt;"> </font>policies,<font style="letter-spacing:-0.35pt;"> </font>including without limitation, Parent or Company policies concerning substance abuse or sexual harassment; or (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by Parent or the<font style="letter-spacing:-0.05pt;"> </font>Company<font style="letter-spacing:-0.05pt;"> </font>to cooperate,<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>willful<font style="letter-spacing:-0.1pt;"> </font>destruction<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>failure<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>preserve<font style="letter-spacing:-0.05pt;"> </font>documents<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. Sec 27 of the Austrian Salaried Employees Act (<i style="font-style:italic;">Angestelltengesetz</i>) applies in its currently valid version.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination Without Cause</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Agreement, which runs for an indefinite</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">period,</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">terminated</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">either</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">party</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">at</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">end</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">each</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">calendar</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">month</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">giving six months&#39; prior notice.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination by the Executive for Cause</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Executive may terminate his employment hereunder for cause without respecting the notice period and notice date mentioned under (d) for the following reasons:</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">(i) a material diminution in the Executive&#8217;s responsibilities, authority or duties; (ii) a material diminution in the Executive&#8217;s Base Salary except for across-the-board salary reductions based on the Company&#8217;s financial performance similarly</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">affecting</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">substantially</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">senior</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">management</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">employees</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Company;</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">(iii) a material change in the geographic location (outside of Austria) at which the Executive provides services to the Company; or (iv) the material breach of this Agreement by the Company. Sec 26 of the Austrian Salaried Employees Act (</font><i style="font-size:12pt;font-style:italic;">Angestelltengesetz</i><font style="font-size:12pt;">) applies in its currently valid version.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(f)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Termination</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Except for termination as specified in Section 3(a),</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">termination</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">termination by the Executive shall be communicated by written Notice of Termination to the other party </font><font style="font-size:12pt;letter-spacing:-0.1pt;">hereto.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(g)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Date of Termination</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">&#8220;Date of Termination&#8221; shall mean:</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">(i) if the Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">terminated</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">his</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">death,</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">date</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">his</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">death;</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">(ii)</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Executive&#8217;s employment is terminated on account of disability according to the Austrian Act on the Employment of Disabled Persons (</font><i style="font-size:12pt;font-style:italic;">Behinderteneinstellungsgesetz</i><font style="font-size:12pt;">), the date respecting the notice</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">notice</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">date;</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">(iii)</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">terminated</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company or</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Executive under</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Section 3(d), the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">date respecting the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">notice</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">and notice</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">date; (iv) if the Executive&#8217;s employment is terminated for cause by the Company the date Notice of Termination</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">given</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">received,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">(v)</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">terminated</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the Executive for cause the date Notice of Termination is given and received.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:4.5pt 7.75pt 0pt 0pt;"><font style="font-size:12pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:43.2pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;">4.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Compensation</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Upon</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Termination</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination Generally</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If the Executive&#8217;s employment with the Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">terminated</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">any reason,</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">pay</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">provide</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">(or to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">his</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">authorized</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">representative</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">estate)</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Base</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Salary</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">earned</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">until</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Date</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Termination and unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement).</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Unused</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">vacation</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">accrued</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">until</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Date</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Termination</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">paid</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">according to</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Austrian</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Leave</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Entitlement</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Act</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">(</font><i style="font-size:12pt;font-style:italic;">Urlaubsgesetz</i><font style="font-size:12pt;">).</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Any</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">vested</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">benefits</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">may have under any employee benefit plan of the Company through the Date of Termination shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#8220;Accrued Benefit&#8221;).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination by the Company Without Cause or by the Executive with</u><font style="font-size:12pt;"> </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cause</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">During</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Term,</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">terminated</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">without Cause as provided in Section 3(d), or the Executive terminates his employment for cause as provided in Section 3(e), then the Company shall pay the Executive his Accrued Benefit.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">In addition, subject to the Executive signing a separation agreement containing, among other provisions,</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">general</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">release</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">claims</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">favor</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">related</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">persons</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">(the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">&#8220;Separation</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Release&#8221;)</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Separation</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">and Release</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">becoming</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">irrevocable</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">within</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">time</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">set</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">forth</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Separation</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">and Release, and in no event longer than 60 days after the Date of Termination:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.65pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">the Company shall pay the Executive an amount equal to 100 percent</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">annual</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Base</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Salary</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">(the</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">&#8220;Severance</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Amount&#8221;);</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">provided</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">that the Severance Amount shall be reduced by the amount of any payment Executive receives in lieu of the notice period specified in Section 3(d) above. Notwithstanding the foregoing, if the Executive breaches any of the provisions contained in this Agreement or the Separation Agreement and Release, all payments of the Severance Amount shall immediately cease; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.85pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">continued participation at active employee rates in the benefit plans set forth under Section 2(d) for the 12-month period following the Date of Termination; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.85pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:12pt;">the amounts payable under this Section 4(b) shall be paid out in 14 equal installments in accordance with the Company&#8217;s payroll practice over 12 months</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">commencing</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">within</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">60</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">days</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">after</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Date</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Termination;</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">provided,</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">however, that</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">60-day</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">begins</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">one</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">calendar</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">year</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">ends</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">second</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">calendar</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">year, the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Severance</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Amount</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">begin</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">paid</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">second</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">calendar</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">year</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">last</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">day of</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">60-day</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">period;</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">provided,</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">further,</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">initial</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">include</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">catch- up</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">cover</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">amounts</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">retroactive</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">day</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">immediately</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">following</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Date</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">of </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Termination.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change in Control Payment</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive&#8217;s rights and obligations upon the occurrence of a Change in Control.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">These provisions</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">are</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">intended</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">assure</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">encourage</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">advance</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">continued</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">event.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">These</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">provisions</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">apply</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">lieu</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">of,</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">expressly</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">supersede, the</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">provisions</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:1.4pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">4(b)</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">regarding</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">severance</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">pay</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">benefits</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">upon</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">termination</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;letter-spacing:-0.25pt;">of</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 7.85pt 0pt 5pt;">employment,<font style="letter-spacing:-0.3pt;"> </font>if<font style="letter-spacing:-0.3pt;"> </font>such<font style="letter-spacing:-0.3pt;"> </font>termination<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>employment<font style="letter-spacing:-0.15pt;"> </font>occurs<font style="letter-spacing:-0.15pt;"> </font>within<font style="letter-spacing:-0.1pt;"> </font>12<font style="letter-spacing:-0.3pt;"> </font>months<font style="letter-spacing:-0.15pt;"> </font>after<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>occurrence of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>first event<font style="letter-spacing:-0.1pt;"> </font>constituting<font style="letter-spacing:-0.1pt;"> </font>a<font style="letter-spacing:-0.15pt;"> </font>Change<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.1pt;"> </font>Control.<font style="letter-spacing:2pt;"> </font>These<font style="letter-spacing:-0.15pt;"> </font>provisions<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.1pt;"> </font>terminate<font style="letter-spacing:-0.1pt;"> </font>and be<font style="letter-spacing:-0.15pt;"> </font>of no further force or effect beginning 12 months after the occurrence of a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change</u><u style="font-size:12pt;letter-spacing:-0.7pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">in</u><u style="font-size:12pt;letter-spacing:-0.65pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Control</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:1.7pt;"> </font><font style="font-size:12pt;">During</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Term,</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">within</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">12</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">months</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">after</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Change in Control, the Executive&#8217;s employment is terminated by the Company without cause as provided in Section 3(d) or</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">terminates</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">his employment for cause as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, within the time period</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">set</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">forth</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Separation</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Release,</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">no</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">event</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">longer</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">than</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">60</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">days after the Date of Termination,</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.9pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">the Company shall pay the Executive a lump sum in cash in an amount equal to 1.0 times the sum of (A) the Executive&#8217;s current annual Base Salary (or the Executive&#8217;s annual Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive&#8217;s target annual incentive compensation; provided that any amounts payable under this Section 5(a)(i) shall be reduced by the amount of any payment Executive receives in lieu of the notice period specified in Section 3(d) above; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.85pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">continued participation at active employee rates in the benefit plans set forth under Section 2(d) for the 12-month period following the Date of Termination; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.9pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:12pt;">notwithstanding</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">anything</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">contrary</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">applicable</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">option agreement or stock-based award agreement, all stock options and other stock-based awards held by the Executive shall immediately accelerate and become fully exercisable or non-forfeitable as of the Date of Termination; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 8pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-size:12pt;">The amounts payable under this Section 5(a) shall be paid or commence</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">paid</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">within</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">60</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">days</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">after</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Date</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Termination;</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">provided,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">however, that</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">60-day</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">begins</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">one</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">calendar</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">year</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">ends</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">second</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">calendar</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">year, such</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">paid</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">commence</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to be</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">paid</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">second calendar</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">year</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the last day of such 60-day period.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">For purposes of this Section 5, the following terms shall have the following meanings:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 41pt;">&#8220;Change<font style="letter-spacing:-0.1pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>Control&#8221;<font style="letter-spacing:-0.05pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>mean<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the <font style="letter-spacing:-0.1pt;">following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.8pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">&#8220;person,&#8221;</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">term</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">used</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Sections</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">13(d)</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">14(d)</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">of the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Securities</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Exchange</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Act</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">1934,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">amended</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">(the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">&#8220;Act&#8221;)</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">(other</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">than</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Parent,</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">with all &#8220;affiliates&#8221;</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">and &#8220;associates&#8221; (as such terms are</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">defined in Rule</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">12b-2 under the Act) of such person, shall become the &#8220;beneficial owner&#8221; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of Parent representing 50 percent or more of the combined voting power of Parent&#8217;s then outstanding securities having the right to vote in an election of the Board (&#8220;Voting Securities&#8221;) (in such case other than as a result of an acquisition of securities directly from Parent); or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.8pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:3pt 7.9pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">the date a majority of the members of the Board is replaced during</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">12-month</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">directors</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">whose</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">appointment</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">election</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">endorsed by a majority of the members of the Board before the date of the appointment or election; or</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 7.8pt 0pt 41pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:33.65pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:12pt;">the consummation of (A) any consolidation or merger of Parent where the stockholders of Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">defined</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Rule</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">13d-3</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Act),</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">directly</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">indirectly,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">shares</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">representing in the aggregate more than 50 percent of the voting shares of Parent issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">arranged</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">party</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">single</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">plan)</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">substantially</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the assets of Parent.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.95pt 0pt 5pt;">Notwithstanding the foregoing, a &#8220;Change in Control&#8221; shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities<font style="letter-spacing:-0.4pt;"> </font>by<font style="letter-spacing:-0.4pt;"> </font>Parent<font style="letter-spacing:-0.35pt;"> </font>which,<font style="letter-spacing:-0.4pt;"> </font>by<font style="letter-spacing:-0.4pt;"> </font>reducing<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>number<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>shares<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>Voting<font style="letter-spacing:-0.4pt;"> </font>Securities<font style="letter-spacing:-0.4pt;"> </font>outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to 50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>beneficial<font style="letter-spacing:-0.4pt;"> </font>owner<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>any<font style="letter-spacing:-0.4pt;"> </font>additional<font style="letter-spacing:-0.4pt;"> </font>shares<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>Voting<font style="letter-spacing:-0.4pt;"> </font>Securities<font style="letter-spacing:-0.4pt;"> </font>(other<font style="letter-spacing:-0.45pt;"> </font>than<font style="letter-spacing:-0.45pt;"> </font>pursuant to<font style="letter-spacing:-0.75pt;"> </font>a<font style="letter-spacing:-0.75pt;"> </font>stock<font style="letter-spacing:-0.75pt;"> </font>split,<font style="letter-spacing:-0.75pt;"> </font>stock<font style="letter-spacing:-0.75pt;"> </font>dividend,<font style="letter-spacing:-0.75pt;"> </font>or<font style="letter-spacing:-0.75pt;"> </font>similar<font style="letter-spacing:-0.75pt;"> </font>transaction<font style="letter-spacing:-0.75pt;"> </font>or<font style="letter-spacing:-0.75pt;"> </font>as<font style="letter-spacing:-0.75pt;"> </font>a<font style="letter-spacing:-0.75pt;"> </font>result<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.75pt;"> </font>an<font style="letter-spacing:-0.75pt;"> </font>acquisition<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.75pt;"> </font>securities directly from Parent) and immediately thereafter beneficially owns 50 percent or more of the combined voting power of all of the then outstanding Voting Securities, then a &#8220;Change in Control&#8221; shall be deemed to have occurred for purposes of the foregoing clause (i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;">6.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Confidential</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Information,</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Noncompetition</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">and</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Cooperation</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidential Information</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">As used in this Agreement, &#8220;Confidential Information&#8221; means information belonging to Parent or the Company which is of value to Parent or the Company in the course of conducting its business and the disclosure of which could result in a competitive or other disadvantage to Parent or the Company.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Confidential Information includes, without limitation, financial information, reports, and forecasts; inventions, improvements and other intellectual property; trade secrets; know-how; designs, processes or formulae; software; market or sales information or plans; customer lists; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">facilities)</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">have</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">been</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">discussed</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">considered</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">management</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Parent and/or the Company.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Confidential Information includes information developed by the Executive in the course of the Executive&#8217;s employment by the Company or function as an executive of Parent, as well as other information to which the Executive may have access in connection with the Executive&#8217;s employment.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Confidential Information also includes the confidential information of others with which Parent or the Company has a business relationship.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Notwithstanding the foregoing, Confidential Information does not include information</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">public</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">domain,</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">unless</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">due</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">breach</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">duties</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Section 6 (b).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Executive understands and agrees that the Executive&#8217;s employment creates a relationship of confidence and trust between the Executive and the Company with respect to all Confidential Information.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">At all times, both during the Executive&#8217;s employment with the Company and after its termination, the Executive will keep</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3pt 7.75pt 0pt 5pt;">in<font style="letter-spacing:-0.2pt;"> </font>confidence<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>trust<font style="letter-spacing:-0.1pt;"> </font>all<font style="letter-spacing:-0.2pt;"> </font>such<font style="letter-spacing:-0.25pt;"> </font>Confidential Information<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>will<font style="letter-spacing:-0.2pt;"> </font>not<font style="letter-spacing:-0.2pt;"> </font>use<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.3pt;"> </font>disclose<font style="letter-spacing:-0.1pt;"> </font>any<font style="letter-spacing:-0.25pt;"> </font>such Confidential<font style="letter-spacing:-0.15pt;"> </font>Information<font style="letter-spacing:-0.05pt;"> </font>without<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>written<font style="letter-spacing:-0.15pt;"> </font>consent<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>Parent,<font style="letter-spacing:-0.05pt;"> </font>except<font style="letter-spacing:-0.05pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>may<font style="letter-spacing:-0.15pt;"> </font>be<font style="letter-spacing:-0.25pt;"> </font>necessary<font style="letter-spacing:-0.15pt;"> </font>in the ordinary course of performing the Executive&#8217;s duties to the Company.<font style="letter-spacing:2pt;"> </font>For avoidance of doubt,<font style="letter-spacing:-0.25pt;"> </font>nothing<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>Agreement<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>interpreted<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>applied<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>prohibit<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Executive<font style="letter-spacing:-0.35pt;"> </font>from making any good faith report to any governmental agency or other governmental entity concerning any act or omission that the Executive reasonably believes constitutes a possible violation of law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Documents, Records, etc</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">All documents, records, data, apparatus, equipment</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">physical</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">property,</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">whether</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">pertaining</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Confidential</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Information, which are furnished to the Executive by Parent or the Company or are produced by the Executive</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">connection</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">remain</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">sole</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">property of Parent or the Company, as applicable.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Executive will return to the Company all such materials and property as and when requested by the Company.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">In any event, the Executive will return all such materials and property immediately upon termination of the Executive&#8217;s employment</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">reason.</font><font style="font-size:12pt;letter-spacing:1.1pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">retain</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">material or property or any copies thereof after such termination.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.65pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Noncompetition and Nonsolicitation</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">During the Executive&#8217;s employment with the Company and for 12 months thereafter (subject to automatic extension for</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">additional</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">equal</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">breach</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">covenants</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">6</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">(d), within</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">framework</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Sec</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">7,</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">36</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">38</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Austrian</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Salaried</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Employees</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Act</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">(</font><i style="font-size:12pt;font-style:italic;">Angestelltengesetz</i><font style="font-size:12pt;">), the Executive (i) will not, directly or indirectly, whether as owner, partner, shareholder, consultant, agent, employee, co-venturer or otherwise, engage, participate, assist or invest in any Competing Business (as hereinafter defined); (ii) will refrain from directly or indirectly employing, attempting to employ, recruiting or otherwise soliciting, inducing or influencing any person to leave employment with Parent or the Company (other than terminations of employment of subordinate employees undertaken in the course of the Executive&#8217;s employment with the Company); and (iii) will refrain from soliciting or encouraging any customer</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">supplier</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">terminate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">otherwise</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">modify</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">adversely</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">its</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">business</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">relationship</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">with Parent</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Company.</font><font style="font-size:12pt;letter-spacing:1.65pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">understands</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">restrictions</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">set</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">forth</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Section 6</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">(d)</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">are</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">intended</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">protect</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Parent&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">interest</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">its</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Confidential</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Information and established employee, customer and supplier relationships and goodwill, and agrees that such restrictions are reasonable and appropriate for this purpose.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">For purposes of this Agreement,</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">term</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">&#8220;Competing</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Business&#8221;</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">mean</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">business</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">conducted</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">anywhere</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the world</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">primarily</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">engaged</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">viral</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">immunotherapy</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">(for</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">prophylactic</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">therapeutic</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">use) in</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">indication</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">areas</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">active</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">at</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">time</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">termination</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Executive&#8217;s employment.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Notwithstanding the foregoing, the Executive may own (i) up to one percent (1%) of the outstanding stock of a publicly held corporation which constitutes or is affiliated with</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Competing</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Business,</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">(ii)</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">up</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">five</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">percent</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">(5%)</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">companies</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">do</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">directly compete with the Company.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.9pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Third-Party Agreements and Rights</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#8217;s use or disclosure of information or the Executive&#8217;s engagement in any business.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Executive represents to the Company that the Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">execution</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Agreement,</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and the performance of the Executive&#8217;s proposed duties for the Company will not violate any obligations</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">have</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">previous</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">employer</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">party.</font><font style="font-size:12pt;letter-spacing:4pt;"> </font><font style="font-size:12pt;">In</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">the</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3pt 8pt 0pt 5pt;">Executive&#8217;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other<font style="letter-spacing:-0.45pt;"> </font>tangible<font style="letter-spacing:-0.45pt;"> </font>embodiments<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>non-public<font style="letter-spacing:-0.45pt;"> </font>information<font style="letter-spacing:-0.4pt;"> </font>belonging<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.45pt;"> </font>obtained<font style="letter-spacing:-0.4pt;"> </font>from<font style="letter-spacing:-0.25pt;"> </font>any<font style="letter-spacing:-0.4pt;"> </font>such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.7pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(f)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Litigation and Regulatory Cooperation</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">During and after the Executive&#8217;s employment, the Executive shall cooperate fully with Parent or the Company in the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">defense</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">prosecution</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">claims</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">actions</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">now</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">existence</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">brought in the future against or on behalf of Parent or the Company which relate to events or occurrences that transpired while the Executive was employed by the Company.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">full</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">cooperation</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">connection</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">claims</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">actions</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">include,</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">but</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">be limited</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to,</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">being</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">available</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">meet</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">counsel</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">prepare</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">discovery</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">trial</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">act</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">a witness on behalf of Parent or the Company at mutually convenient times.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">During and after the Executive&#8217;s employment, the Executive also shall cooperate fully with Parent and the Company in connection with any investigation or review of any authority as any such investigation</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">review</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">relates</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">events</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">occurrences</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">transpired</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">while</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">was employed by the Company.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Parent and the Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive&#8217;s performance of obligations pursuant to this Section 6 (f).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(g)</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Injunction</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Executive agrees that it would be difficult to measure any damages caused to the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">which might result from any breach by the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the promises set forth in this Section 6.</font><font style="font-size:12pt;letter-spacing:4pt;"> </font><font style="font-size:12pt;">In event of violation of the provision 6 (d) Noncompetition and Nonsolicitation, the Executive shall be obliged to pay the Company a contractual penalty in the amount of his last net monthly remuneration multiplied by six. The contractual penalty is due at the time of the violation of the contractual provision. The agreement to pay a contractual penalty does not eliminate any claim to cease and desist such actions or any other damage.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;">7.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Inventions.</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0.05pt 7.75pt 0pt 5pt;">The<font style="letter-spacing:-0.4pt;"> </font>Executive<font style="letter-spacing:-0.4pt;"> </font>assigns<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Company<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>exclusive<font style="letter-spacing:-0.4pt;"> </font>right<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>use<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>exploitation,<font style="letter-spacing:-0.35pt;"> </font>unrestricted in time, territory and content, for all work output which is capable of copy right protection or of<font style="letter-spacing:-0.55pt;"> </font>protection<font style="letter-spacing:-0.55pt;"> </font>under<font style="letter-spacing:-0.55pt;"> </font>trademark,<font style="letter-spacing:-0.55pt;"> </font>patent,<font style="letter-spacing:-0.55pt;"> </font>registered<font style="letter-spacing:-0.55pt;"> </font>design<font style="letter-spacing:-0.5pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>utility<font style="letter-spacing:-0.5pt;"> </font>model<font style="letter-spacing:-0.55pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>other<font style="letter-spacing:-0.6pt;"> </font>intellectual property rights, which the Executive produces during the period of his relationship with the Company, insofar as they relate to his duties under this Agreement. The Executive is obliged to notify the Company immediately of any invention. The provisions of the Austrian Patent Act<font style="letter-spacing:-0.2pt;"> </font>(<i style="font-style:italic;">Patentgesetz</i>),<font style="letter-spacing:-0.1pt;"> </font>as<font style="letter-spacing:-0.1pt;"> </font>amended<font style="letter-spacing:-0.05pt;"> </font>from<font style="letter-spacing:-0.2pt;"> </font>time<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>time,<font style="letter-spacing:-0.05pt;"> </font>apply<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>inventions<font style="letter-spacing:-0.15pt;"> </font>made<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.2pt;"> </font>the <font style="letter-spacing:-0.1pt;">Executive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 7.9pt 0pt 5pt;">The assignment of the use and exploitation rights<font style="letter-spacing:-0.15pt;"> </font>includes the authorization to further modify and<font style="letter-spacing:-0.15pt;"> </font>issue<font style="letter-spacing:-0.2pt;"> </font>licenses and<font style="letter-spacing:-0.15pt;"> </font>is<font style="letter-spacing:-0.15pt;"> </font>fully<font style="letter-spacing:-0.15pt;"> </font>compensated<font style="letter-spacing:-0.15pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font>by<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>remuneration<font style="letter-spacing:-0.15pt;"> </font>set<font style="letter-spacing:-0.15pt;"> </font>out<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font>this<font style="letter-spacing:-0.15pt;"> </font>Agreement. The Executive expressly waives all other rights as holder of copyright or other intellectual property rights in the work output, in particular the right to determining a name and to make the work accessible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 8.2pt 0pt 5pt;">This applies mutatis mutandis to all inventions, discoveries, designs, developments and improvements<font style="letter-spacing:-0.05pt;"> </font>that<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:-0.15pt;"> </font>not<font style="letter-spacing:-0.05pt;"> </font>capable<font style="letter-spacing:-0.1pt;"> </font>of copyright<font style="letter-spacing:-0.05pt;"> </font>protection<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>protection under<font style="letter-spacing:-0.1pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>trademark, patent, registered design and/or utility model or any other intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;">8.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Data</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Protection.</u></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.95pt;"></td><td style="font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;"></td><td style="padding:0pt;"></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 8pt 0pt 5pt;">The Executive acknowledges that the Company will process the Executive&#39;s personal data electronically in order to manage the employment relationship and fulfill legal obligations. Furthermore,<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Company is<font style="letter-spacing:-0.05pt;"> </font>obliged<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.2pt;"> </font>law<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>transfer<font style="letter-spacing:-0.1pt;"> </font>certain<font style="letter-spacing:-0.05pt;"> </font>personal<font style="letter-spacing:-0.05pt;"> </font>data<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Company to authorities or legal entities. Such communications are made only to the extent required by <font style="letter-spacing:-0.2pt;">law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 7.8pt 0pt 5pt;">In<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>context<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>his<font style="letter-spacing:-0.45pt;"> </font>work<font style="letter-spacing:-0.4pt;"> </font>for<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>Company<font style="letter-spacing:-0.5pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>well<font style="letter-spacing:-0.55pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>for<font style="letter-spacing:-0.55pt;"> </font>Parent<font style="letter-spacing:-0.4pt;"> </font>personal<font style="letter-spacing:-0.45pt;"> </font>data<font style="letter-spacing:-0.55pt;"> </font>(Art<font style="letter-spacing:-0.55pt;"> </font>4<font style="letter-spacing:-0.55pt;"> </font>Paragraph 1 General Data Protection Regulation) will become accessible to the Executive. He therefore is obliged to data protection and data security (Art 32 General Data Protection Regulation), whether data is processed automatically or not. He must always carefully store user IDs, passwords and other access authorizations available to him. He is obliged to follow the data protection<font style="letter-spacing:-0.25pt;"> </font>rules<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>currently<font style="letter-spacing:-0.25pt;"> </font>applicable<font style="letter-spacing:-0.3pt;"> </font>version<font style="letter-spacing:-0.25pt;"> </font>(Art<font style="letter-spacing:-0.3pt;"> </font>5<font style="letter-spacing:-0.3pt;"> </font>General<font style="letter-spacing:-0.2pt;"> </font>Data<font style="letter-spacing:-0.3pt;"> </font>Protection<font style="letter-spacing:-0.25pt;"> </font>Regulation) for each processing of personal data. Additionally, he must comply with all company regulations concerning the use of personal data in the currently applicable version. Personal data may only be processed for the legitimate performance of official duties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 7.95pt 0pt 5pt;">The Executive is also obliged to maintain data secrecy in accordance with the data protection laws in force at the time, currently Sec 6 DSG 2018 (<i style="font-style:italic;">Datenschutzgesetz</i>). He will treat all personal data as confidential for an unlimited period of time, even after the end of the employment relationship, and will keep it secret from everyone.<font style="letter-spacing:2pt;"> </font>This applies also to data regarding his executive function of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 7.75pt 0pt 5pt;">The Executive is prohibited from making personal data available to unauthorized bodies or third parties or from making it possible or easier for them to gain knowledge of it. He is also prohibited from using data for any purpose other than required for the lawful performance of his or her duties. He will only disclose accessible personal data as a result of his work, if expressly<font style="letter-spacing:-0.15pt;"> </font>ordered<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>do<font style="letter-spacing:-0.15pt;"> </font>so<font style="letter-spacing:-0.15pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Company<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>its<font style="letter-spacing:-0.15pt;"> </font>representative<font style="letter-spacing:-0.2pt;"> </font>verbally<font style="letter-spacing:-0.15pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font>writing.<font style="letter-spacing:-0.15pt;"> </font>Only<font style="letter-spacing:-0.15pt;"> </font>if there<font style="letter-spacing:-0.65pt;"> </font>is<font style="letter-spacing:-0.45pt;"> </font>a<font style="letter-spacing:-0.65pt;"> </font>legal<font style="letter-spacing:-0.6pt;"> </font>obligation<font style="letter-spacing:-0.5pt;"> </font>for<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>processing<font style="letter-spacing:-0.6pt;"> </font>of<font style="letter-spacing:-0.55pt;"> </font>personal<font style="letter-spacing:-0.6pt;"> </font>data<font style="letter-spacing:-0.5pt;"> </font>by<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Executive,<font style="letter-spacing:-0.6pt;"> </font>an<font style="letter-spacing:-0.5pt;"> </font>explicit<font style="letter-spacing:-0.55pt;"> </font>order from the Company is not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0.05pt 8pt 0pt 5pt;">The violation of data secrecy can make the Executive liable for damages and/or have consequences under Austrian labor law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.85pt;text-indent:0pt;white-space:nowrap;">9.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 409A.</u><font style="font-size:12pt;letter-spacing:4pt;"> </font><font style="font-size:12pt;">This Section 9 shall apply only to the extent the Executive is</font><font style="font-size:12pt;letter-spacing:4pt;"> </font><font style="font-size:12pt;">subject to U.S. income tax.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:37.3pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-size:12pt;">Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#8217;s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#8217;s separation from service, or (B) the Executive&#8217;s death.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">catch-up</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">covering</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">amounts</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">would</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">otherwise</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">have</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">been</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">paid</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">during</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-size:12pt;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">All reimbursements shall be paid as soon as administratively</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">practicable,</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">but</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">no</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">event</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">reimbursement</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">paid</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">after</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">last</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">day of</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">taxable</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">year</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">following</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">taxable</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">year</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">expense</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">was</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">incurred.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.95pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-size:12pt;">To the extent that any payment or benefit described in this Agreement constitutes</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">&#8220;non-qualified</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">deferred</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">compensation&#8221;</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">409A</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Code,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">the extent that such payment or benefit is payable upon the Executive&#8217;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#8217;s &#8220;separation from service.&#8221;</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 7.85pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="font-size:12pt;">The parties intend that this Agreement will be administered in accordance</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">409A</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Code.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">To</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">extent</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">provision</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">manner</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">so</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">payments</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">hereunder</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">comply</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">409A</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Code.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Each payment pursuant to this Agreement is intended to constitute</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">separate</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">payment for</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">purposes of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Treasury</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Regulation</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">1.409A-2(b)(2).</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">parties</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">agree</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 8.1pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.3pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="font-size:12pt;">The Company makes no representation or warranty and shall have no </font><font style="font-size:12pt;letter-spacing:-0.1pt;">liability</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">or</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">any</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">other</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">person</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">if</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">any</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">provisions</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">this</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">are</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">determined </font><font style="font-size:12pt;">to constitute</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">deferred compensation subject to Section 409A</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Code</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">but do not satisfy</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">an exemption from, or the conditions of, such Section.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.9pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">10.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Consent to Jurisdiction</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The locally competent courts in Austria shall have jurisdiction over any disputes arising from this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.95pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">11.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Integration</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter. For the avoidance of doubt, the Executive shall remain entitled to all benefits, including holiday entitlement, accrued through the Executive&#8217;s ongoing employment with the Company up until the effective date of this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 8.1pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">12.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Withholding</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">All payments made by the Company to the Executive under this Agreement shall be net.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.65pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">13.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Successor</u><u style="font-size:12pt;letter-spacing:-0.35pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">to</u><u style="font-size:12pt;letter-spacing:-0.3pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">the</u><u style="font-size:12pt;letter-spacing:-0.35pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Executive</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">This</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">inure</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">benefit</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">be enforceable by the Executive&#8217;s personal representatives, executors, administrators, heirs, distributees, devisees and legatees.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">In the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">event of the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">death after</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">his termination of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">but</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">prior</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">completion</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">payments</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">due</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">him</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">this Agreement,</font><font style="font-size:12pt;letter-spacing:3.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:3.6pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:3.6pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:3.65pt;"> </font><font style="font-size:12pt;">continue</font><font style="font-size:12pt;letter-spacing:3.55pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:3.65pt;"> </font><font style="font-size:12pt;">payments</font><font style="font-size:12pt;letter-spacing:3.65pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:3.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:3.6pt;"> </font><font style="font-size:12pt;">Executive&#8217;s</font><font style="font-size:12pt;letter-spacing:3.55pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">beneficiary</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:3pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 8.15pt 0pt 5pt;">designated in writing to the Company prior to his<font style="letter-spacing:-0.05pt;"> </font>death (or to his estate, if<font style="letter-spacing:-0.1pt;"> </font>the Executive fails to make such designation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">14.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Enforceability</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">declared</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">illegal</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">unenforceable</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">court</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">competent</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">jurisdiction</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Austria,</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">15.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Waiver</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">16.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid,</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">return</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">receipt</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">requested,</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">at</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">last</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">address</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Executive</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">has</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">filed</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">in writing with the Company or, in the case of the Company, at its main offices, attention of the </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Board.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.75pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">17.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendment</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. In addition, the Company requires approval by resolution of the Board. This provision shall also apply to any waiver of the requirement of written form.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;">18.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Governing</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Law</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:2.8pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">This</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">exclusively</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">governed</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Austrian</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;">law.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">19.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">This</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">executed</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">number</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.8pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">20.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Successor to Company</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Company shall require any successor (whether direct</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">indirect,</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">purchase,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">merger,</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">consolidation</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">otherwise)</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">substantially</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">of the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">business</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">assets</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">expressly</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">assume</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">agree</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">perform</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Agreement to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">same</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">extent</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">would</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">required</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">perform</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">it</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">no</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">succession</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">had</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">taken place.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 8.05pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">21.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">D&amp;O Insurance.</u><font style="font-size:12pt;"> The Parent has concluded a directors and officers insurance policy (D&amp;O insurance) at its own expense for the benefit of the Executive, which includes civil and criminal defense coverage.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 7.9pt 0pt 5pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:34.9pt;text-indent:0pt;white-space:nowrap;">22.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Gender</u><u style="font-size:12pt;letter-spacing:-0.55pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Neutral</u><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:1.7pt;"> </font><font style="font-size:12pt;">Wherever</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">used</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">herein,</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">pronoun</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">masculine</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">gender</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">shall be</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">considered as including the feminine gender unless the context clearly indicates otherwise.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 5pt;">[SIGNATURE<font style="letter-spacing:-0.55pt;"> </font>PAGE<font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:-0.1pt;">FOLLOWS]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 5pt;"><font style="letter-spacing:-0.1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:always;width:78%;border-width:0;"><div style="max-width:100%;padding-left:11.25%;padding-right:10.75%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:4.5pt 0pt 0pt 239.05pt;">HOOKIPA<font style="letter-spacing:-0.45pt;"> </font>Biotech<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">GmbH.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.4pt 5.05pt 0pt 239.05pt;">By: <u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Joern Aldag</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:220.1pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u> Its:<font style="letter-spacing:3.05pt;"> </font><u style="letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;">CEO</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:175.47pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:4.5pt 0pt 0pt 239.05pt;">Date<font style="letter-spacing:-0.15pt;"> </font>signature:<font style="letter-spacing:-0.1pt;"> </font>31 December,<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.2pt;">2021</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:17pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 239.05pt;"><font style="letter-spacing:-0.1pt;">EXECUTIVE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="height:1pt;left:51.46%;max-width:48.54%;position:relative;top:0pt;width:217.35pt;z-index:-9223372036603117568;"><div style="height:0.6pt;left:0pt;padding-bottom:0.4pt;position:relative;top:0pt;width:217.35pt;"><img src="hook-20211231xex10d15001.jpg" alt="Graphic" style="height:0.6pt;width:217.35pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.15pt 0pt 0pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">/s/ Klaus Orlinger</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.64pt 0pt 0pt 239.05pt;">Klaus<font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">Orlinger</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 238.9pt;">Date<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">signature:</font><font style="display:inline-block;width:13.03pt;"></font>14 March 2022</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.25%;margin-right:10.75%;margin-top:30pt;page-break-after:avoid;width:78%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>hook-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:20:42 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Georgia';font-size:11pt;font-style:italic;font-weight:bold;line-height:13pt;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;font-style:italic;font-weight:bold;line-height:13pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No.&#160;333-238311) and Form S-8 (Nos.&#160;333-230995 and 333-237285) of HOOKIPA Pharma Inc. of our report dated March&#160;24,&#160;2022 relating to the financial statements, which appears in this Form&#160;10-K. </font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vienna, Austria </font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">March&#160;24,&#160;2022</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">PwC Wirtschaftspr&#252;fung GmbH</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Stefano Mulas</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">German Certified Public Accountant</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>hook-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:20:45 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS <a name="_Hlk34745580"></a>PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Joern Aldag, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">I have reviewed this Annual Report on Form 10-K of HOOKIPA Pharma Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:38.8pt;text-indent:-38.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:40.5pt;text-indent:-40.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 27.8pt 0pt 0pt;">Date: March&#160;24,&#160;2022</p></td><td style="vertical-align:top;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">/s/ Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>hook-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:20:47 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Reinhard Kandera, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">I have reviewed this Annual Report on Form 10-K of HOOKIPA Pharma Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="line-height:1;">. JK</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Date: March&#160;24,&#160;2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">/s/ Reinhard Kandera</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Reinhard Kandera</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Chief Financial Officer </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>hook-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/24/2022 11:20:50 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font><b style="font-weight:bold;">.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of HOOKIPA Pharma Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December&#160;31,&#160;2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of their knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:4.95pt;"><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><div style="height:4.95pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt;"><div style="height:4.95pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March&#160;24,&#160;2022</p></td><td style="vertical-align:top;width:46.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March&#160;24,&#160;2022</p></td><td style="vertical-align:top;width:46.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Reinhard Kandera</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reinhard Kandera</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>hook-20211231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (& Y@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^FN$BBP."XSWKV_P!?:O?^$+.77(9(]04;)-_5L=#0!T]%%% !1110 4444
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MJ* /.9/@_IGFRPVVKZI:Z5--YTFG0S;8BV<\=P*]"MX([:WC@B!$<:A%!.<
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MB.]UZWA9;^]4+,Y;(('M^% 'E?AS1-+\9^.O%:>*$\]M.9;>UM992JP1 8W
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M=3M'BM;B&R@@:/9&V')/?-7AH.GHKJFFW"J\'V<@-_!_C1:BNG]?>+]Z^O\
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MSF1LDUG5C3M:"U+INI>\MC3HJK]KE_Y\YJ/M<O\ SYS5S\K-[HM455^UR_\
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MWV*DBGAG!,,J2 =2C9Q1="<)+5HDHHHIDA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44I!'4$?A24 %%%&#C/:@ HHP?0T4 %%+
M@XS@XHP?0_E0 E%+M.<8.?I24 %%%% !1110 4444 %%%% !1110 5)'T-1U
M)'T- #Z*** "BBB@ HHHH **** "BBB@ HHHH *\^^*7_'MIW^^U>@UY]\4O
M^/;3O]]JQK_PV>GDW^^P^?Y,\UHHHKS#[\**** $/0U[UI7_ "![+_K@G\J\
M%/0U[UI7_('LO^N"?RKLPF[/F>)/X=/U94\2:['X;T634Y8&F1'1"BL ?F.,
MY-9^H^-+2PUB33TA^T%+![XR12*1A?X?K4_C30IO$GAB?2X#&'ED0GS.A4-D
MC\JP+KX=Q0:[/=Z+;6EG;3:7):,B @F1NA/M7:?)D^C?$*34M2TNUN]$>T35
M$+6\BW*2]L_,J\K^-=%K^K76CVT+6FDW.I7$TFQ(82% ]V8\ 5P6@?#S5['5
M-$G:TTG35T__ %UQ9,QEN1C!!SQSUK>USPUK\>AS:?X?U2:1[N;=<27LQ++'
MW1#VS0!1_P"%K6[VXE@T2[E\E&DO@)%'V50VTG/\7/I5ZQ^(UGJ&LPVT6GW'
M]G7%P;6'4"PV/*!G;MZ_C6%/X UY[9X;./2[**\LQ8W<*EF$:!L[U/=CWS5G
M2?AYJ>F:E8V?VNV;0[&]-]$V#YS,1]T]L9H ](Z'%8NL>(X-&U?2;":+/]HR
M-&)2X58\#.3FMH\DFN6\5>%%\2ZOH<MQ'#-964SO<0R_Q@K@8H J:E\0X+&V
MU26'3WNC8WD5H DJ@2L_0@] *J)\3UBU9=,U#1)K2X6:.*8B=)$C5_NL6''7
MC%5+SX:2/I^KZ?9I:PV5YJ,%S'"N0!&GWA]36_J7@/2'\+ZCI6E6<-I+<J&6
M0#)\Q>5)/7@T 3/XAO-3O-<TW1;9#<Z<JJ+B=OW;2$9VX'.15C2[_4=.\)?;
M_%#0)<P1-).80<8']:B\%>'[CP[H M[Z99]1GD,UU,O\;G_]5:FM:9'K6B7N
MF2N42ZB:,L.JY'6@#"T;QE=ZG>6BW'AR^L[.]4O;7;,'4CJ"X'W<CUK0'C#P
MXQG UFTS;@M+E\;0#@G\ZQ]&TCQE UC:7NHV$5A8Q&,&W4E[GC"E@>F*Y&Z^
M&'B2^E>6ZN[225H7A9RY(;+9!QT48["@#TNW\3Z%=VEQ=0:M:O!;8,T@?B//
M3-1_\)AX<^QK=_VS:?9V?8'W]6],=:Y75/A_?7UUJ4L,UM$L]O:K$I'REXN2
M& [&J^K^!M>UC4+?59DTV"XCWHUK:LT2LK #)8=30!VC^*_#\=P;=]8M!*$\
MPKOZ+C.?I5K3-:TS68W?3;V*Z6,X<QD\5Q6E_#V6PM-;M_+M"E[:QPPHY9@I
M&<@GKC)K4\#^'-8T W8U*ZC>WD5%A@5BY3'4[CSCVH U-.M9[?Q/JLC-.\,L
M490R-E0<G(7TK;HHH **** "BBB@ KS7XG?\A.Q_ZXG^=>E5YK\3O^0G8_\
M7$_SK#$_PV>OD?\ OL?1_D<+^)_.C\3^=%%>:?=A^)_.C\3^=%% !^)_.C\3
M^=%% $T-G<W$;R0P2R(GWF49 J/RI/+,FQ]@.-W.,UMZ!,EN1+)=1")"=T,C
M$$<?>7U-07FM"[0Q/ &B$@;&XC<!TJ^56N<WM:CJ.*C=(R<'W_.I#;3";R3&
MXEZ[#U]:OZQ?6=[-"UI:B$(BJQ#$Y]N:U)X[<Z]]O>ZM'MG0# E!.=F.1]:.
M5 Z\DDW&UT_PZ',?B?SH_$_G73+=::T:0RK;>2MLK$JHW%]W//KBJ^OR6;Q(
M+=;?[Y*-$1G9Z'%#AI>XHXAN:BXO4R#970FCB,$HDD&47!RP]14+*4<HV0RG
M!!/0UVHU6P,EI<M<Q_:+1%2/Z'_#FJOGZ:Q9V>T-L=_F@@>8SEN".^,53IKH
MS*.+G]J']?U8Y/\ $_G3XX99L^6COCKMR<5U'VO3)9W$HM $D A(0 =._J,U
M+;WMK"IC,]HMP54S,F C$-V]\4E!=RI8N26D-3D&5D=D8%64X()Y!I/Q/YUU
MJ7NG75R\US]F\WSI1&=H QCY2?;WH^TZ<&V#[%&SRJ'<*&&,<D4<B[A];ELX
M,Y+\3^='XG\Z[=DLI(I'M&LC.D)W/(%*J<]\<519M-DM[RY6*(_9<%2J_+(Q
M&,#VS0Z?F*.-O]EG+?B?SH_/\Z.O-%9G<'XG\Z/Q/YT44 'XG\ZU-"UVZT&^
M$\!+1GB2,GAA67133:=T14IQJP<)JZ9[OI6JVNL6*75JX93]Y>ZGT-7:\V^'
MNF:D+IK]9&ALB,,I'^M^G^->DUZE*;G&[1^>YAAH8:NZ=.5U^7D%%%%:'$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZ]+)#X?U"6)V218&*
MLIP0?45H5%<VT5Y:RVTZEHI5*. <9!H XF.*;08M"OX-1O9FO"J3P7,YD$@(
MR2,],52UGQOJIBFM[1+5#-N$,\:N0N#_ 'NC?A76:?X2TC39TFBCGE>-2L?V
MF=I1&#_=!Z5'_P (5H61FVE(7=L4S,0@/4*.PH QU\9WT%Y:6\L-M-$SI#(T
M08D,0.2W0?3K3-2UB[TKXB232W3_ -EI"L<D1/R(3_%_2MR/P9H<3HRP381Q
M(JF=BH<=&QZU<OO#VEZDURUY;>:;D*LN6/S!>10!Q.EZWJ*/=3WTLLOFWZ[$
MWD"-". /;':M6#7-5U+6-'G988=/N9G"K&YWD#CYQT/X5T)\/:69-_V8[MZR
M?>.-RC J*#POI-MJ27\4$BSQL6C'FG8A/7"]!F@#GO$KWMI?S2:;J-U<:HN9
M5A5OW,$0'1UZ'^=5E>YC;3PVMW,,6HVK3W4KR;MF.?D_N^G%=(?"&D_VG-J"
MF\2>=]\H2Z8(Y]UZ8]J9/X)T*YAEBDMYBDAZ"=ALYSA?[H]A0!SR";^SIKFZ
MU/4XM+,I%A!YA^T7!QQSUQGM79:&E\FBVRZD2;O;\^>H] ??%94G@71I3"SR
M:BSPD^6YOGW)GT-;]I;)9VL=O&TC(@P#*Y=C]2>M $U%%% !1110 4444 5S
M=J+T6ODS[BN[S/+/E_3=ZU8HR<8S10 4444 %21]#4=21]#0 ^BBB@ HHHH
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MD=0K FG_ (T %%''K36=$(#R*I/ W'&: '44FY<$[A@=>>E!90NXL O7)/%
M"T4TRQ!0QECVMT.X8-!= X0R)O/1=PR: '44U71R0LBL5Z@,"13J "BBB@ H
MHHH **** "BBB@ HHHH *DCZ&HZDCZ&@!]%%% !1110 4444 %%%% !1110
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M8#R#:6\+2] @"LV.>*TP   .@&!0 M%%% !14$]Y:VS*L]S%$S= [@$U,"&
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M_7!/Y5MA-V>;Q)_#I^K+=%%%=I\F%%%% !1110 4444 %%%% !1110 4444
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M-5UD6:07T$<$7S302)E9F'3/M[54E\)W\R3Q?;X$@NF62X1(?XUZ;?05UM%
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MN\L9%2T[W1O3G3Y>2:>]]#+T7Q=I>LE8DD,-R?\ EC)U/T/>O-_&?_(VW_\
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M$WE*I9&(4X&,XKAVQO; (&3P>M;5>AYN7I^]=6_K;=Z?<-/0U[UI7_('LO\
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M44?B*[3Y,**!@]"#]#10 448HH ***,@=2!]30 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 44 @YP0<=<'-';)X [T %%';/&/7M10 449&,Y&/7/%'<#(R>
MGO0 44=\9&1VHH **** "BBB@ HHHH **** "BBB@ J2/H:CJ2/H: 'T444
M%%%% !1110 4444 %%%% !1110 5Y]\4O^/;3O\ ?:O0:\^^*7_'MIW^^U8U
M_P"&ST\F_P!]A\_R9YK0.H^M% QD9QC/>O,/OSTF>_DM+=+>]\16RS+"/W8L
MMV 5X&<5YPYS(QSG+'GUKT:\U59(D%GXBTF* 0*HADA#,OR\C-><OS(QR#R>
M1WK:L]OZ_4\K+(V4FU9^EO\ VU?FQAZ&O>M*_P"0/9?]<$_E7@IZ&O>M*_Y
M]E_UP3^5;83=GG<2?PZ?JSF_B;//;>!KJ6W=DF$T6TJ^W)W#C-<KJNI:Z_BZ
MZ75(%L&70)V2."YW@X_B]C7J5W9VU_;FWNX$FA)!*.,@D=*9/IEC<W!N)[2*
M28Q&$NRY.P]5^E=I\F>+^%YIM.USPC</_H\=VFR1H-1-RUPQ7(WIGY17;^)-
M2T_Q#H[V]R]]I<B3,L$5VYM5NI .!O\ [M=)8>%?#^EW2W-CHUG;SK]V1(@"
M/IZ5=U'3+'5[;[-J-I#=PYSLF0,,^M '@T>J2WFD7$UUJUV+K3-/1M/)N"OF
M2B3!Q_?';Z5L>'-1NI=>T;47OYWUF[U2:"]MC*2%A"\#R^P'K7K,OAW19C:F
M32;-C:#%OF(?N_IZ5)'HVEPZF^IQ:?;)?.,-<+& Y'UH OGJ:\X^)RW$VK^&
M+6"WENO.N9 UK'<F#S0%Z%A7HU0365K<W$$\T$<DT!+1.PR4)ZD4 >8:)_PE
MOAS5-/T%I[>W74I9ITAG<W#6\:C.P-W-7+3QYK$CV=](;%[6[OGLA8J")H\9
M&\G/MD\=*]#DL[:6[ANY($:XA!$<I'S(#UP:K1Z%I,.HMJ$>FVJ7C9W3",;C
MGKS0!Y5J7CG7KS1]5M+B_MK*[:"1X5BA/16P=D@/I6CKGCK5-!T^RBM+ZUNI
MX+&*:X7R2=V[');/ KT"/PUH<+3-'I%FK3 K(1$/F!ZC\:9)X5T"98UET>S<
M1)Y:;H@=J^GTH \TL/&&MZ3IGB#4'NH[R9]3C@B0J6\G< <XSTYX%>@>#M7U
M36--N'U6U\F:&8HD@7:)5[-C)P?:M#_A']&Q<#^S+4BX $P,8_> =,^M6;'3
M[/3+?[/8VT=O#G.R-<#/K0!R6K>)M57Q5>:997>FV$%C!',[WV?W^X\@'MBN
M9O/B=JL.HM]FFL[JSD$PC80E%5D7/!)YYKTV^T32M3GCGOM.MKF6/[CRQ@D5
M7/A7P^96E_L:R\QB26$0!YX- '$)X]UZP@FDOUL[IGTE-0A$"%=A) P?4<YI
M-2\;:_I<=E;?:],O;B]=2LMK&6,(*YPRYZ^G->AC2-.5@PL8,B'R!\@_U?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ K.UX%O#VH@#)-N^!^%:-&.V,T
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M>8?2@"2BH_,/I1YA]* )**C\P^E'F'TH DHJ/S#Z4>8?2@"2BH_,/I1YA]*
M)**C\P^E'F'TH DHJ/S#Z4>8?2@"2BH_,/I1YA]* )**C\P^E'F'TH DHJ/S
M#Z4>8?2@"2BH_,/I1YA]* )**C\P^E'F'TH DHJ/S#Z4>8?2@"2BH_,/I1YA
M]* )**C\P^E'F'TH DHJ/S#Z4>8?2@"2BH_,/I1YA]* )**C\P^E'F'TH DH
MJ/S#Z4>8?2@"2BH_,/I1YA]* )3T%)4?F'TH\P^E $E%1^8?2CS#Z4 245'Y
MA]*/,/I0!)14?F'TH\P^E $E%1^8?2CS#Z4 245'YA]*/,/I0!)14?F'TH\P
M^E $E%1^8?2CS#Z4 245'YA]*/,/I0!)14?F'TH\P^E $E%1^8?2CS#Z4 24
MO:HO,/I3E;<* '4444 %%%% !1110 4444 %%%% !1110 5YG\8/^/33/]]J
M],KS/XP?\>FF?[[5U8+^/$Y\7_!D>44445]$>&%%%% "'H:^D-'_ .0'I_\
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MM7IT<B31+)&X=&&593D$5SUJ$Z+M-&U*M"JKQ'4445B:A1110 4444 %%%%
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M_0-'_?1H_P"%>^&/^@:/^^C73T4?6*O\S^\/8T_Y4<Q_PKWPQ_T#1_WT:/\
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MAX?ECBC?2XBL1)3#,"">O.<UM44 9*^&-$62*0:=%OBP$))/3IGGG\:UJ**
M"BBB@ HHHH *0@'J ?J,TM% #=B;]_EIO_O;1G\Z!'&HPL:+SGA0.?6G44 -
M,<9QF*,XY&5%+M4'(1<^N.:6B@!HCC 8"- &^]A1\WU]:545!A$51Z*,4M%
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M&L6\6AW5R;PCR95QY?W<?,>U=M10!SODZAH'@V*"SLOM]_"@"Q+R-Q/)^@K
ML+#4+34(=9_LG4)KHH\=UYJ@2.S="HS]T5Z#10!YO;V6KQ+;Z5?:+>OIL3>:
M_P!F4'SW)R QST%:^C'4+[Q#]KU;1KRV\K*6J; (85]<YY8UV-% !1110 53
MOX-XBF";FA;<!5RB@J,N5W1P_B'43X<LFN-*2(/>2'<<<BIO 6EWEM;3W]Z"
M)+D[@&ZD>M=)/H]A<W,=Q-;JSIRH/3/KBKP    P!VJ%#WKL[IXR/L/916KW
M?7R1DWFF7(OOMVGW"Q3%=KHXRKU3'AVXELKF.>Y3SKB02,57@8KHJ*L\\QY]
M+O!>Q7-I=1QLD80ATSFBYTN^EO(;N*ZA69$VMN3(-;%% &3/I4U]]F%[+'(D
M1RZ*N QIAT%4%XEM((HKA<!,<*?6MFB@#$71[N:.&"\NT>WBP0D:X+8]:WH@
M N .!3*DCZ&@!]%%% !1110 4444 %%%% !1110 4444 %>9_&#_ (]-,_WV
MKTRO,_C!_P >FF?[[5UX+^/$YL7_  9'E<*A[B)6&59P"/49KU35-.O;>"=-
M/T+P\UBL/R2O(/-QMY/UKS72I]/M[X2:G9O=VV#F)'V$GUS6W+JO@]H9%B\.
M7B2%2$8W9(4]C7L5XRE)63_KYH\NC)1B[O\ K[F9WA73X-4\265I<(SPNQ+(
M.K  G'Z5V=G/>:KJ8TN]\(6\&FRLT8=+<JT0YPV[UKSNUNKBRN$N+:5HIDY5
MUX(K4/B_Q$1@ZQ=8_P!ZG6I2G*Z_70*52,59F3=Q""ZN(0<B.1D!^AQ7T7H_
M_(#T_P#Z]T_E7SC(S.6=CEF)))[FOH[1_P#D!Z?_ ->T?\JX\S^&)U9?\4B[
M1117CGIA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%<OXK\:Q>%KJW@DLI+@S(7!5P,<U=.G*I+EBM29SC!<TMCJ**\W_
M .%NVO\ T!Y_^_HH_P"%NVO_ $!Y_P#OZ*W^I5_Y?R,?K='^8](HKS?_ (6[
M:_\ 0'G_ ._HH_X6[:_] >?_ +^BCZE7_E_(/K='^8](HKS?_A;MK_T!Y_\
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M1"25V-CK6^&J*G54Y;&->#G3<4?.M%>W?\*L\-_W+G_OZ:/^%6>&_P"Y<_\
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M:AMM)O(K.>*2!GWJ =[ L3GGGTKI:* ,$V-Z288X3&GF%@^_C 'R@"JTUI+
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MP 8G)8 5HT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^%'_"P6_P"@<O\ W\/^%%%+ZM2[%K$5>XO_  L%O^@<O_?P_P"%)_PL%O\
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M%%%+V<>Q:A$/^$^;_H'K_P!_#_A1_P )\W_0/7_OX?\ "BBE[./8KV<>P?\
M"?-_T#U_[^'_  H_X3YO^@>O_?P_X444<D2E2AV#_A/F_P"@>O\ W\/^%'_"
M?-_T#U_[^'_"BBER1*5&'8/^$^;_ *!Z_P#?P_X4?\)\W_0/7_OX?\***GE1
M2H4^PG_"?-_T#U_[^'_"C_A/F_Z!Z_\ ?P_X444<J*6'I]@_X3YO^@>O_?P_
MX4?\)^W_ $#U_P"_A_PHHJ>5%+#TNP?\)^W_ $#U_P"_A_PH_P"$_;_H'K_W
M\/\ A1119%?5J783_A8#?] ]?^_A_P */^%@/_T#U_[^'_"BBILBEA:/8/\
MA8#_ /0/7_OX?\*/^%@/_P! Y?\ OX?\***+%+"4?Y0_X6 __0.7_OX?\*3_
M (6 _P#T#E_[^'_"BBD5]3H_R_F'_"P7_P"@<O\ W\/^%'_"P7_Z!R_]_#_A
M112*6#H?R_F)_P +"?\ Z!R_]_#_ (4?\+"?_H'+_P!_#_A112N4L%0_E_,/
M^%A/_P! Y?\ OX?\*/\ A83_ /0.7_OX?\***5V4L#A_Y?S$_P"%AO\ ] Y?
M^_A_PH_X6&__ $#E_P"_A_PHHI792P&'_E_,/^%B/_T#E_[^G_"C_A8C_P#0
M-7_OZ?\ "BBES,?U##_R_BQ/^%B/_P! U?\ OX?\*/\ A8K_ /0-7_OX?\**
M*7,REE^&_E_%_P"8G_"QG_Z!J_\ ?T_X4?\ "QG_ .@:O_?T_P"%%%+G97]G
M8;^7\7_F'_"QG_Z!J_\ ?T_X4G_"QW_Z!J_]_3_A112YY%++L+_+^+_S#_A8
M[_\ 0-7_ +^G_"D_X60__0-3_OZ?\***7/(?]FX7^3\7_F'_  LA_P#H&)_W
M]/\ A2?\+)?_ *!B?]_3_A112]I+N5_9F%_D_%_YA_PLE_\ H&)_W]/^%)_P
MLI_^@8G_ ']/^%%%+VDNXUEF$_D_%_YA_P +*?\ Z!B?]_3_ (4A^);_ /0,
M3_OZ?\***7M9]REE>$_D_%_YB?\ "S'_ .@8G_?T_P"%'_"S7_Z!:?\ ?T_X
M444O:S[E?V5A/Y/Q?^8?\+-?_H%I_P!_3_A2?\+.?_H%I_W]/^%%%+VL^XUE
M6#_D_%_YB?\ "SG_ .@6G_?T_P"%'_"SW_Z!:?\ ?T_X444O;3[E?V3@_P"3
M\7_F)_PM!_\ H%I_W]/^%'_"T'_Z!:?]_3_A112]M/N5_9&#_D_%_P"8G_"T
M7_Z!2?\ ?T_X4?\ "T7_ .@4G_?T_P"%%%+VU3N/^R,%_)^+_P Q/^%I2?\
M0*3_ +^G_"D_X6G)_P! I/\ OZ?\***7MZG<?]CX+^3\7_F'_"U)/^@4G_?T
M_P"%)_PM63_H%)_W]/\ A112]O4[C_L?!?R?B_\ ,0?%5\@'24Q_UU/^%%%%
/"KU.XI9/@OY/Q?\ F?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>hook-20211231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )[ Q@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "LWQ!_R +[_KD:TJS?$'_( OO^N1JH_$B9?"R_#_J8_P#='\J?4<1
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M&A/EQA<GIT)Z5QF@RP:II_@O3KAFDT\BX$J2$A7=?N@^N!7KZ1K);*C@%60
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q_$VISZ1H[75L$,@=5^<9&":U+>0RVT4C8RR!CCW%5=5
MTN#5[(VEPSK&6#90X/%7(XQ%$D:YPJA1GVJVX\B74A*7.WT'4445!84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (?NGZ5XK>?\?U
MQ_UU;^9KVH]#7G4/@N_O+N::X=+:$R,<MR2,^E=V"J1AS.3.+&4Y3Y5%')UZ
M!\/X98[6[=XV579=I(QGBHPGA?P]PQ%Y=#M]\Y^G05T&AZG/JD<LDEBUK"I
MBW=6'K6F)K.=-I+3N9X>BH5$V]>QK52U>[DL=)NKJ(*9(HRR[NF:NU!>VD=]
M92VLI8)*I5BIYQ7GQLI*^QWRORNQ7T6\EU#1[6[F"B25-S;1@5?JM86<>GV,
M5I"6,<2[5+')JS1-IR=M@C=15]PHHHJ2@HHHH **** "BBB@ HHHH YS7_!.
MC^(9Q=3I-;WH&T75K(8Y /J.OXUEV?PPTB*827]]J>J*I!6.]N2Z CV[UA^-
M_$^I6'B*_BAU^/2EL+5)K:W>,-]M<]1SU].*B\):Y=_\)-I")XH&M#4X7>[M
MN#]F8+G(Q]WGC!HBK[!+3<]6CC2&)8XT5$0855& !3J*BN;F*TMI+B9ML<:E
MF.,X%&X;$M%90\06I (@O<'_ *=7_P */[?M?^>%[_X"O_A5<DNQ/-'N:M%9
M+>(+15+-#>@ 9)^RO_A6E!,EQ!'-$=T<BAE/J#R*3BUN--/8DHHHI#"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRM3->NB0@@$N,C/:K",KHK(<J0",>E:.3]FHVZLS45[1ROV'4445F:!1110
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &#XOL[F^T)X;6%I93(IVKUP#6S:JR6D*L,,$4$>AQ4&IZG;Z39F
MZNBPC#!?E7)R:M1N)8UD7[K $?C6C<N1*VAFE'G;OJ.HHHK,T"BBB@ HHHH
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M'T45R^H^-K;3M0FM'LYG:)MI8,,&E"G*;M%#G4C!7DSJ**XW_A8=I_SX3_\
M?0J]I'C"WU?44LX[66-F!.YF!'%:/#U8J[1"Q%)NR9TE%%%8&P4444 %%>=>
M.;B>+7(UCFD0>2#A7('4US/VV[_Y^I_^_A_QKMIX)SBI7W.*IC%"3C;8]KHK
MQ:.]N_-3_2I_O#_EH?7ZU[/'_JD^@K*OAW1MK>YK0KJK?2UAU%%%<YT!6)XN
M_P"19O/]T?SK;K$\7?\ (LWG^Z/YUI1_B1]3.K_#EZ'E%%%%>^>$>H^"O^1:
M@_WF_G70USW@K_D6H/\ >;^==#7@U_XDO4]RA_#CZ!11161J(?NGZ5XK>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH'@+5L?ZRU_[[/\ A1_P@>K?\]+7_OL_X5[GUBE_,>+]7J_RFS\/?^0==_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  G%%%% !1110 4444
M%%%%  .:*, 44 %%%% !1110 4444 %%%% !1110 4444 %%(""2 1QUHQSF
M@!:*** "BBB@ HHHH 3(! ]:6D90PP:6@ HHHH **** "BBB@ HHHH ****
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M&.WKB/#E@FE>,;G2+C%[]GLUGTZ[E;?-# S,IA9CR<'[K=2I(SQ7;T %%%%
M!1110 45DZUXBT_05B^UN[22L L42[WQD N1V49&6/ ^N!6M0 4444 %%%%
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MEE2XB@C1=12)L[7X^25"W)7AE((P17I%<WI7A22RU*WO+[6KW4_L:/'9K<A
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MU[-=QQ,1"\WWUC_A0G^+:.,GDT 3:,UZ^B6+ZDH6^:WC-PH[2;1N_7-7:**
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M6J** "BBD.3C!QZT +1U%8VL:P-/U/2]/EA=8-3>2W%RK[?*DV%E'U8!L'U
M]:\V\-W_ (GTR=-(T>\N-6U"RFD@U&PU$DQ1*I.V5;@_,GF#:0IW=3T H Z.
M>QUSPEK&J>)EE:^L+NZ,E[I\66,<(5566(?WU"DLO\0/'(%=)=6]OXF@L\Q:
M;J&@W$1E<2H7+DX,;)VQUYZ],5;T:_N=2TY;B[TRXTZ?<5>WN"K$$=P5)!'H
M>]7D18T"(H55&  , 4 0V5C::;9QVEE;16]O&,)%$@55_ 58HHH **** "LK
MQ'K/]@Z'-?K")I%9(XXR^P,[N$7+=AEAD]A4?BG7'\.Z#+J,5J;N99(HX[96
MPTK.ZJ%7WYXHAGTCQIX:? %SI]Y&T<D;@JP[,K#JK \'N"* .?NM:\2K?V^C
M7CZ?I-_.Q:TNEC:YMKO ):+DHT;]^^0#CN*K?#BZU^'28--N-.L9;*WN+BV>
MZ@NBK1E)7&#&R],\##=,9IT.C:[JNGV.FOJ&G:EI,%U%/!K E)N-D3A@NT#:
M9,KM+ANF21FN[@MH+5&6"%(E9VD8(N,LQRQ/N2<T 16.G6>FQ21V5O' DDK3
M.L8P"['+'ZDU:HHH **** "N*U&;5=3\:7>CPZW-I!@LX[BR6*)'%P26#LVX
M'<%(4%01][.>12:OXCUG0O%5U=W-H[^%H(88YY?+^:%V+$S+Q\T8&T-Z=>QK
M3\2:=8:W'IA*WGGF;=9:CIX!:U8J3OW<@(0,'.0<@$4 <)?Z?=ZQ)%<&?5++
MQ!8:Q;1WT-K<-+"-YVB>*-]RA2C$]!C# ]*]/TBTO[.R\K4=3_M";<2)C L1
MV]@0O&??CZ56T/0CI,EW=7%]/?7]V5,]Q,JKD*,*H50 H&3^)-;% !1110 4
M45BZCXHTW2=?TW1[V4Q3ZBKFW=ON%E*C:3V)W<>N,=: &ZSXC.F7T.GVFFW6
MI7TL33^1;E%*1J0"Q+D#J0 .I-<;XI\7ZE>Z VIZ78"33+6[MVF9;HPW4,B3
M(7BEB90!Z8W=#GD5U7B31[^6[M-<T0Q_VM9*R"&5ML=U"V"T3'L<@%6[$>F:
MR++1I/$6O:G>7VB76FZ=?64<%W;W+J&N)E?(;",?NKE=V1G(]* -<I:^-=*G
ML]2TC4K Q2*5^TH(I(Y!RKQ.I(R#_$#_ (5T:KM4#).!C)ZFEQBB@ HHHH *
MIZIJMEHNG27^H3B"UBV[Y&!(7) !..V2*N=*S-3TRP\2:8EO<.)[-I(YB(V!
M278P8 ]05) R.] $?B+21XA\/3V<-SY,D@62"=?F"2*0Z-[C< ?<5QE_J5UJ
MEYH_F:5=V?B^RNXT*I"YA>$L!,?-QM,+)D\G(( QD5T.A:;J/AO56TB&-[GP
M_*K26DFX;K(]X3GDH<_*>HY!XQ70:?9#3[*.V%Q<7 3/[RXD+N<DGD]^N/H*
M *^CZ1!HMK-!;O(R2W,UR=YZ-(Y<@>V36C110 4444 %46UBP36DTAKE5OWA
M,Z0G@L@."1V.#VJW)-%$4$DB(7;:@9@-QZX'J>#7.Z[X+L=;O)=1\Z:#5!'&
MMK=H1NM60LP9/J6^8'AAQ0!!K]O?Z/X@B\3:?;2WL+0"UU"TB&9&B#%EDC'=
ME+-E>X8XY K'T72;/7;S6(;!;R#0)IK>\B+0M#MNE??)Y8< @':A/&,DX[UT
M^F1ZGJNF6W]LQS6%_:7&9/LLV([@I_$,<F-NNT\]CTK=H **** "BBJ][?6N
MG0">[G2&(NL89S@;F(51^)(% %BLFZ\3:-9ZY:Z-/J$":A<Y$<&[YB<9P?0G
MMGKVK.UGQ1=0:J=(T+3HM3U**(SW$+W(A$4?&.2#EFS@#IP<D5PT,_\ :&@:
MY;+H4M]#J5U)-#=[XXWM;AL9CN"S!HGB;&&&> N/< Z[5+2]T'6KO4K>Q?4M
M$U)1_:-E$F^2-P-OFHG\8*X#*.> 1GD4WPCX9T&-UU.POKC48;=FCL([EB5L
M%/+1HK#*GG&6^8# Z5>\"ZC?:CX?87]PEW+:W#VJWL8PMVJ8'F#ZG(..,J:Z
M:@ HHHH ***HZGK6F:-'')J>H6MFDC;$:XE"!F]!F@"]7G5UIT%UJ][X9U">
M2TO6N&U+0[Y?O*3RP0]V5MV5[JWUJO=ZEJUXVL:]#KGV:\T&YE TIMJP-  "
M/,_B)D7#!\X!/ X.>IM7T7Q_X;AFN;,O$6^:&8%);:9>HR,,CJ>X(_6@"CI4
MGC'5KJW@U.&/28+%Q]JFA(<W[ \>6#]R,C!)//.T8P37954TVP.G6@M_M=U=
M $D/=2;W ]-V 3^.3[U;H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHH/(H R-1\4:'I&HV^GZAJEK;W=QCRXI'P3DX&?0$\ G&361K>HS:]
M9:GIVC%6O]/FVW>G7:;!=Q%3E,]0K@G:XXR.>,UQ]UI%_9ZA<^"[UK>.#7IY
M)V\03 --<QCYO)((QYPZ G"A1D+D8K3T+1/^$IO-0NI-8U&>"RG-OIVM6\@A
MGGA*CS8BRJ!)&'X#8ZYP>,T -\/Z-:^(-,C@T]Y6\-RDW-DXD\NZT:Z1N8US
MG@$G'IR.5(KTQ1A0"22!U/>H+&RM]-L8+.TB$5O @CC0=@!@?6K% !1110 4
MC ,,'I2USOC72-6UGP\\.B:I/I]_$ZS1-$^SS"O/EL<' /KZXSD9% &-XV\5
MW.DZW9:,)9=+MKN'S5UA465(9 X7;(C#[ARH+9&-PZ<FLKQ7K&MZ=96EUK>D
M$7FEW275MJ&G*TMO.H^5T8<O$61F&#E<X^:LVXU?6M6TFUN+S27U@V%UY4_D
MP 7$>[Y)K>Y@Z<HQ^9,J<*< 5Z5X<T:70=.;3S?R7=K'(?L@E'SPP\;8RV<M
MMY )YQ@=J (M!T0Z1?ZS/%*ALM1NA>1PA,-&[(!)D]]Q&?;)K=HHH **** "
MJ-UK.F66HVVG7-_;0WMT"8())0KR8] >M7JY3QOX+M?%=BDJQ6XU.URUK+/'
MN1O6.0=2C=\<CJ.10!QOB'=!XUU*/Q1F\T56CN+>Z3,=QI:N-HEC=<,(PZE7
MQT^5CD$UT4?AWQ)!XCT2]35+?5+*T=U-S<?)<"!TPR,5&V7D(0V%.5&<\UG^
M&-#U"_O]/U!;J>.TM//L[[2]40RRPAE :))C_K(\A&!;/ Z]17H5A86NEV$%
MC90K#;0($CC7.%4= ,T ,TO2[/1K!+*PA\FW1G94!) +,6.,]LD\=JN444 %
M%%% #)(UE3:V<9R0#C-<1\0O$%]HSZ=:I#<KIEZ)%NKRR<BYM]H#!HQ@@X 9
MB,$D*<5T/BK03XE\.7>EK>W%D\RC9/ Y5E8'(S@C(R!D=Q7FJS>+)M'N=+*_
MVEJFDR1S&UF<"Z@D0Y22-S@3PO@CG#88@DD4 :GB!O$C>%7$BIKUL%2[T_5M
M.0><DB$/&SQ#A@2 "T?8GY:[#1M,_P")M/XA4S6_]J6D!GLI$P4D4'YCZ-M8
M*1_LBG^&]"BT2&X%JTT-I<N)X[!\%;1F&75,= 2<XZ YQUK<H **** "BC/.
M** "N9U_Q/)I^KP:39) +@PF\N;F\;9!;VRL [D\;F[ #IG)('7:U;48M(TB
M\U*<,T5K"\SA>I"@DX_*O/M;^VZE=:#=>)]'LI+:6X5[)K*X;,4S#*0S;AAH
MW(4$CC<!D8YH [C2M:T3Q-;M+IUW:WT<,@W;<,8W'()!Y![@_E4$'AT6/B:;
M5K"X-O!=H?MMGLRDT@QME']U\<$_Q#&>1FL_0[#4[KQ5/X@U#2TTHM9+:&W$
MZRO,P;=O8KQA>B]^3TX%=90!'#!#;1+%!$D4:YPB*% R<]!4E%% !114<TT5
MM"\T\J11(I9W=@JJ!U))Z"@!SDJC%0"P' )QFO-=#\:Z@S7MW<6.J:I?AC]M
MT^R1!'I:HS+L^8@O(<$\9+#!  QG5U77H=;UG1]/L->-MI=_',5O;"1"9ID*
MXA60@A3@LV.IVX]:J:-;:_<76K:?9ZO9PW-E=^5<ZB;!9&O T:E"V"H$J#Y3
MV/'':@#M[&]L]:TJ"]M76>SNH@Z-CAE8=P?Y4S2=)M-$T]+"P1H[6-F,<9<L
M$!).T9Z*,\#H!Q1H^E6^B:1:Z;:ES#;QA%9SEF]2?<G)_&KU !1110 445DZ
MYKBZ0MM%':RWE]=R&*VM8BH:0@%B26("J "230!!:>*+:_U:ZMK6)GL;3*3Z
M@SA81-G'E*3]YASDC@'CKQ4VJ^&M(UL3F_LTF:>W^S,Q)SLW;ACT(8 @CG(%
M>>QVNA7.L:E>:QI.H2(DP$^@/:?:5MIY =UP A(9'"C# '!W="37:^!K*ZL/
M#207$4\,0FE:T@N&S)#;ER8T;D\A<<9X&!VH =I>BWLFD'2_$4B7ZVTZFWN0
M[+),BD,C28QAP1@XX;&>^*Z*BB@ HHHH *:\B1QL[L%11EF)X J.[D:*UD9'
MC23:0AE/R[NV?QKRN74+K7-)U1KK0TB97":_I$>[[1-&44+<19 ((VDJ!G<
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M%2:=I&GZ2LPL+*WMO/<RR^3$$\QSU8XZFKM #(H8[>%(88TCB0!51% "@=
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M)8I95)'F*I.W(Z$C)YZXXZ5=HHH **** "BBB@ HHHH **** "BBB@ HHHH
M*K-86CZ@E^UM$;R.-HEGVC>$)!*Y],@'%6:* "BBB@ HHHH *R=9\2Z/H!B7
M4[^*V:4$HK9)('4X )P.YZ5F>-[BX:QM-,TY[E-7O9O]":"41A'0%RSD\% !
MRN#NSC'<<5=/K>L:Y))+97!NA;16>N:792HDY12S(\$CL 89"QW8(/&,Y!H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%0W=Y;6%L]S>7$5O!&,O+,X15'N3P*
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M[8.-2"/E7"M\H4$*77D[O;KZU56YTVSO+FUN;BVCDGM7+P2,OS1L1@D'MP:
M.7M_!3:E>M<>+H]*U6>$!;>YAMG@=UZD2KO*L,]N1UKL54*H50  , #M2T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>hook-20211231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %\ ET# 2(  A$! Q$!_\0
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M%;L.< _C2M_7J!TE%8?A;6;G6;"Z^VI"MW9W<MI,800C,A^\H)) ((XR:W*
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MT2ZC,?RK$&B4L&(5MFX],?,6XJU_PGW_ %*7BK_P6_\ V5'_  GW_4I>*O\
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M6@W R+%!F0,03N4Q[!T'*J"/6K/_  GW_4I>*O\ P6__ &5'_"??]2EXJ_\
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M\%O_ -E1_P )]_U*7BK_ ,%O_P!E1["IV#VD>YU]%<A_PGW_ %*7BK_P6_\
MV5'_  GW_4I>*O\ P6__ &5'L*G8/:1[G7T5R'_"??\ 4I>*O_!;_P#94?\
M"??]2EXJ_P#!;_\ 94>PJ=@]I'N=?17(?\)]_P!2EXJ_\%O_ -E1_P )]_U*
M7BK_ ,%O_P!E1["IV#VD>YU]%<A_PGW_ %*7BK_P6_\ V5'_  GW_4I>*O\
MP6__ &5'L*G8/:1[G7T5R'_"??\ 4I>*O_!;_P#94?\ "??]2EXJ_P#!;_\
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M1%)*-=&IM;69L! KK;[]J^=YX'R@YW9W]NE:/C&#Q!<SZ'-?VIC$%Y(WFZ1
M]ZR(8R 61H\9)..A'-$KW^8(]#L[ZTU&U6ZL;J"ZMWSME@D#H<'!P1QUJ>O*
MM1MM:OE)L;CQ&D,&BSR1LD#V;27*R?(&C15&XCH,<CUJ]IL/B>3Q=96=R^I#
M3I/+U.6X9G"@^5M:W)Z#]Y\VS]*$K_UYO_)L'I_7I_F>CT5CS6WB1IY#!JVD
MI"6)C233)'95SP"PN "<=\#Z"H_LOBK_ *#.C?\ @IE_^2:0&Y16']E\5?\
M09T;_P %,O\ \DT?9?%7_09T;_P4R_\ R30!N45A_9?%7_09T;_P4R__ "31
M]E\5?]!G1O\ P4R__)- &Y16']E\5?\ 09T;_P %,O\ \DT?9?%7_09T;_P4
MR_\ R30!N53?5M-CAGF?4+18K>3RIG,R@1/Q\K'/!Y'!]16?]E\5?]!G1O\
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M[,W**Y[PEKUWK]KJ,MY:+:26U_+;+#D%E5<?>()!;DYP<5T- !1110 4444
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M1GGK6_13N#U,[2=&M]&%Z+=Y6^V74EW)YA!P[XR!@#CBM&BBD 4444 %%%%
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M_"6>'/\ H8-*_P# R/\ QH_X1/PY_P!"_I7_ (!Q_P"%'_")^'/^A?TK_P
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M]*UM-/$^G>1AK(/M;S%9NK')X [#O74U$X.#LRHRYE=!1114C"BBB@ HHHH
M**** "BBB@ HHHH **** .;N?"'VF[FN/^$B\01>:[/Y<5[M1,G.%&W@#L*B
M_P"$)_ZF?Q)_X'__ &-=314>SCV.M8[$)64OP1R^J^';F/P-K.DV=U?:C<W5
MO*(C>3AW+,F H8X ''?U-<7-\/-:35HEM(D73Y=)GC93(H%O<R0A&&,Y(8J#
MQD9)KURBJ44KI?UO_F<\YRG+FEOO^7^1XW?^$_%6JV%PK:&;>0:);V"(;J)B
M\D<RL>0V , G_P"OQ7>>#-(OM)_MW[;!Y7VK59KB'YU;=&P7!X)QT/!YKJ**
MOF?Y_B[D=+?UM8****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,G7M.U#4+11IU[%;S(3F.X@$L,P_NNO7\01^-8<7_"
MQ'"6YB\-6J#@W"&:0 ?[,?'Y$UJ^*;C7[33/M.@'2P\6YYSJ(D*^6 3\NSG-
M<=:>+/'"VFB:GJ'_  C TW4KB&/$'G&4+(1T&[&?SQW[T1U=O3\1O:YZ)IUM
M<6EC'#=7LEY.,EYW4*6).>@X [ >GK5AD5\;E#8.1D9P:=7*>.KC4;#21>Z?
MK%Q9S9$,-O##$_VB9R @)=3CGT[9H;$D=76'=?\ (]:3_P!@R]_]&VM<1K'B
M#Q/I!U%6U@/)H5E;33@VT>+UY&.[/'RC P-N*ZO5]3AL/%^BW$\=TROIUXH6
MWM9)V!,EJ>5C5B!QUQC\Z=@.HHJ"SNX[ZU2YA694?.!/"\+\''*. PZ=Q[U/
M2 Y;7?\ D??"7_;Y_P"BA74UR/B:YM[/QKX5N+J>*"%/M>Z25PJC,8 R3QU-
M;7_"3:!_T'--_P# N/\ QK*+2E*_?]$=]>E4G2HN,6_=?3^_(U**R_\ A)M
M_P"@YIO_ (%Q_P"-.B\0Z)/*D46L:?)([!41+E"6)X  SR:OFCW.5X>JOLO[
MF:5%%%49!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <AX>_Y*-X
MS_[<?_1)KKZ\^&J7/AWQ[XEN9=!UJ]@O?LODRV5F9%.R+#<Y ZG'&>AK2_X3
M[_J4O%7_ (+?_LJZ:E*<FFET7Y(RC-)6?=_F=?17(?\ "??]2EXJ_P#!;_\
M94?\)]_U*7BK_P %O_V59^PJ=BO:1[G7T5R'_"??]2EXJ_\ !;_]E1_PGW_4
MI>*O_!;_ /94>PJ=@]I'N=?17(?\)]_U*7BK_P %O_V5'_"??]2EXJ_\%O\
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M0@!+G_>[>G-9M-.S+3NKH[BBBBD 4444 %%%% !1110 4444 %%%% !1110
M4444 5[ZXCL]/N;F9=T4,32.N,Y &37CWAXZ=8:M'K<GA+2K8RW5H$\B1V:%
M+@'8P#';N!VYV@=37J'BG65T+0I[QM,O-17!0P6L7F'!!Y89X7CD]J\I\.PZ
M<^HZ;=V'A7QA(\LL#QQ7H;[!!C^-6[A025S[=,T0^+[OZ^82^'[SV^J=_I=E
MJ;VK7D/FFTG6XA^8C;( 0#P>>IX/%7*Y3QAXWA\*365MY$,US=!W47%TMO&J
MKC.7(/))  Q^5%PM<TM3\*:)K&H17]_8K-<QA0&\QE#!3N 900' /(# TRZ_
MY'K2?^P9>_\ HVUK#U'XAFR=FCT@S6]K;07-_(+I,P+*< *%!$A')X(&.A-;
M=RP;QQI# Y!TR](/_;2UIVL@-VBBBD!5O-,L-1V?;K&VNO+SL\^)7VYZXR..
M@_*JO_",Z!_T ]-_\!(_\*U**3BGT-(UJD5:,FEZF7_PC.@?] /3?_ 2/_"N
M=\5:/IFGR^'I;+3K2VD.M6REX8%0D?,<9 Z<#\J[:N6\;?\ ,N_]ANV_]FK.
MI%*.QV8*O5E7BG)]>ODSJ:***U//"BBB@ HHHH **** "BBB@ HHHH ****
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MS ?[Q'Y_DSJ:***LXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/112 **** "BBB@ HHHH P/&NFW>K>$KZQL8O-N9?+V)N"YQ(I/)('0&JO\
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M06=E:Z=:I:V5M#;6Z9V0PQA$7)R< <#DD_C4]( HHHH **** "BBB@ HHHH
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M (JB\^R^_P#X <F$_GE_X"O_ ),ZFBN6_P"%<^%/^@5_Y,2__%4?\*Y\*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MAW7_ "/6D_\ 8,O?_1MK7G?Q V_\)-JWVG?_ &E]EM?[!QNW>9YAW^7C^+.,
M^V*]"U.SU?\ MG3=3T^"RN&@M)[>6.YN6AYD:%@05C?./*/&!U%"U5P>CL;U
M%8?VKQ5_T!M&_P#!M+_\C4?:O%7_ $!M&_\ !M+_ /(U &E=ZA%9W-A!(KEK
MV<P1E0,!A&\F3STQ&WKR15JN5OX/%5[>:9<?V7HR?8;EKC;_ &I*=^89(\?\
M>_'^LSGGICOFKWVKQ5_T!M&_\&TO_P C4 ;E5=0U"+3;9)YE=E>>& ! "=TD
MBQJ>3TRXS[9ZUF_:O%7_ $!M&_\ !M+_ /(U4=6@\5:I9QV_]EZ-%LN;>XW?
MVI*V?*F23'_'N.NS&>V<\]* .JHK#^U>*O\ H#:-_P"#:7_Y&H^U>*O^@-HW
M_@VE_P#D:@#2U/4(M)TF\U&=7:&T@>>18P"Q5%+$#) S@>M6JY76H/%6KZ%J
M&F?V7HT7VRVDM_,_M25MF]2N<?9QG&>F:O?:O%7_ $!M&_\ !M+_ /(U &Y5
M74]0BTG2;S49U=H;2!YY%C +%44L0,D#.!ZUF_:O%7_0&T;_ ,&TO_R-5'6H
M/%6KZ%J&F?V7HT7VRVDM_,_M25MF]2N<?9QG&>F: .JHK#^U>*O^@-HW_@VE
M_P#D:C[5XJ_Z VC?^#:7_P"1J -RJNF:A%JVDV>HP*ZPW<"3QK( &"NH8 X)
M&<'UK-^U>*O^@-HW_@VE_P#D:J.BP>*M(T+3],_LO1I?L=M';^9_:DJ[]BA<
MX^SG&<=,T =516']J\5?] ;1O_!M+_\ (U'VKQ5_T!M&_P#!M+_\C4 :6GZA
M%J5L\\*NJI/- 0X .Z.1HV/!Z90X]L=*M5RNDP>*M+LY+?\ LO1I=]S<7&[^
MU)5QYLSR8_X]STWXSWQGCI5[[5XJ_P"@-HW_ (-I?_D:@#<JK::A%>7-_!&K
MAK*<02%@,%C&DF1STQ(OIR#6;]J\5?\ 0&T;_P &TO\ \C51L(/%5E>:G<?V
M7HS_ &ZY6XV_VI*-F(8X\?\ 'OS_ *O.>.N.V: .JHK#^U>*O^@-HW_@VE_^
M1J/M7BK_ * VC?\ @VE_^1J -*TU"*\N;^"-7#64X@D+ 8+&-),CGIB1?3D&
MK5<II\?BBTO-4G73=%D^VW0G*C5)1Y9$,<>W_CWY_P!7GMUQVS5_[5XJ_P"@
M-HW_ (-I?_D:@#<JK'J$4FK7&G!7\Z""*=F(&TK(TB@#G.<Q-GCN/PS?M7BK
M_H#:-_X-I?\ Y&JC%!XJBUV[U/\ LO1C]HMH+?R_[4E^7RVE;.?L_.?-Z8XV
M^_ !U5%8?VKQ5_T!M&_\&TO_ ,C4?:O%7_0&T;_P;2__ "-0!I2:A%'JUOIQ
M5_.G@EG5@!M"QM&I!YSG,JXX['\;5<K+!XJEUVTU/^R]&'V>VGM_+_M27YO,
M:)LY^S\8\KICG=[<WOM7BK_H#:-_X-I?_D:@#<JK=ZA%9W-A!(KEKV<P1E0,
M!A&\F3STQ&WKR16;]J\5?] ;1O\ P;2__(U4;^#Q5>WFF7']EZ,GV&Y:XV_V
MI*=^89(\?\>_'^LSGGICOF@#JJ*P_M7BK_H#:-_X-I?_ )&H^U>*O^@-HW_@
MVE_^1J -*[U"*SN;""17+7LY@C*@8#"-Y,GGIB-O7DBK5<K?P>*KV\TRX_LO
M1D^PW+7&W^U)3OS#)'C_ (]^/]9G//3'?-7OM7BK_H#:-_X-I?\ Y&H W*JZ
MAJ$6FVR3S*[*\\, " $[I)%C4\GIEQGVSUK-^U>*O^@-HW_@VE_^1JHZM!XJ
MU2SCM_[+T:+9<V]QN_M25L^5,DF/^/<==F,]LYYZ4 =516']J\5?] ;1O_!M
M+_\ (U'VKQ5_T!M&_P#!M+_\C4 :6IZA%I.DWFHSJ[0VD#SR+& 6*HI8@9(&
M<#UJU7*ZU!XJU?0M0TS^R]&B^V6TEOYG]J2MLWJ5SC[.,XSTS5[[5XJ_Z VC
M?^#:7_Y&H W**P_M7BK_ * VC?\ @VE_^1J/M7BK_H#:-_X-I?\ Y&H TM,U
M"+5M)L]1@5UANX$GC60 ,%=0P!P2,X/K5JN5T6#Q5I&A:?IG]EZ-+]CMH[?S
M/[4E7?L4+G'V<XSCIFKWVKQ5_P! ;1O_  ;2_P#R-0!N55TS4(M6TFSU&!76
M&[@2>-9  P5U# '!(S@^M9OVKQ5_T!M&_P#!M+_\C51T6#Q5I&A:?IG]EZ-+
M]CMH[?S/[4E7?L4+G'V<XSCIF@#JJ*P_M7BK_H#:-_X-I?\ Y&H^U>*O^@-H
MW_@VE_\ D:@#2T_4(M2MGGA5U5)YH"' !W1R-&QX/3*''MCI5JLKP[8W6G:2
M8;T0K</<W-PZPN71?-F>0 ,54G <#.!TK5H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O'M?\ ^1XO]^__ (2#^U++^S/O;OLV
M%W[?]C[^[MUS7L-8>J>(O[-\4Z#HGV7S/[6^T?OO,QY7E('^[CYLYQU&/>A:
M23!ZIHW**** .%\?6:?VQX4O?,G\S^UX(MGG-Y>/F.=F=N??&:[JBBA:*W]=
M >KOY?YA7F7Q4GT07-E;7\V[4)X)([6.XG$=M;YQFX8XSN7'&.3TQWKTVBDT
M-.Q1T;']AV&+S[8/L\?^D_\ /;Y1\_X]?QJ]115-W=R4K*QPWQ*;2CI]I!JH
M\M9#)Y$]PA>UCD"\>: P))&=O7FMCP+)/)X&T9KF.:.;[*H83G+G'&3GUZ_C
M70T4EHFAO6P5Q_Q%>_?P^;.ULKN>VN XO'M-N](PI./F(X8X!/IFNPHI25U8
M<79W.;^'\QF\ :&S0R18LXUQ(!DX&,C!/!ZCV/:NDHHJY/F;9*5E8YGX@QK-
MX(U"%Y_(C<(LDIB:0*N]<DJO.,=?:L_X:/"=*U&*UMK);2*\*Q7=E 88KH;5
M^<*2>G3.2.*[:BI6E_,;UL%<_P".!?'P1K']FF07?V9MGEYW>^,<YQFN@HI-
M75AIV=SSKX6&&,ZM;V:6LMDC0LMW9I)'%(Y3YE",S ,O )'7//->BT453=R4
MK$5S;PW=K+;7$:R02H4D1AD,I&"#7#_#S1-+%SJ?B.PL8+5+F9[:U2%=H6"-
MMN?JS*2?H*[VBDM'<;U5@JO?N8].N75)'98F(6/[QX/ ]ZL44FKJPT[.YX[\
M)"J:^RQ-;R;]*1IC:!@$D\P\3YZS<]>.AXKV*FJBIG:H&3DX'4TZJ;N3;6X5
MXWI4=Q#\4(8;5H;B\&I7#WETKRB8VY4X21&4 (OR@')!.,5[)126DKC>JL%0
M7EJE[9RVTCRHDB[2T,C1N/HRD$?A4]%)JZL!XQ9K"GP[\.I?DG15UF8:@9"2
MIC\R7;YA[KNVYSWQ7=_#CS?^$/BW;_L_GS?9-^<^1YC>7UYQMQCVQ76455]_
MZ[?Y ]7?^NO^9'/$)X)(69U612I:-RK#([$<@^XKSSPEID4WA+Q18--=")-5
MNU#I<NLA"XQEP=QZ<\\]Z]'HJ6M_-6&GMY._YG+_  Y_Y)WH7_7JM=16'X/\
M1?\ "5^%K+6_LOV7[3O_ '/F;]NUV3[V!G[N>G>MRJD[MLE*RL>3F#3-*G^(
M46HWVH1:>AM?,E2<O.P*9VAFR3N)V_0XXK<^%[6<NG:E/83VRVL]P)(]/MY?
M,6S4J %)Z;CC) XS7>44EI]R0WK]]PKSVVMHM.^(GB@J;Z=6TF.9E69I)22S
MY6,L>/8 @#MBO0J*5A_U^)Y?\-GLO^$HU8:. VERVD,BF)640OEALE#$YFQ]
MX@]NE>H4453=R>IP-S;_ &#XN?:;<7%Q+)HLTOE/,S L)%PJ!CA0<=!@5G?#
MV2]'CK7_ .T+&^BO;FV@FN6N @"OE^!ACA<'"^RG.._I]%*.EOZZM_UZ#>M_
MZ[!7#>)[-(_B-X0NQ).7DFG0HTK&, 0MT3. >>H'-=S11UN'1H\B\*K;VWQ%
M A2QO[NYNKM[IA9O'<V7)(+N3@@YVC@9XQFO7:**.B78'JV^YPOCZS3^V/"E
M[YD_F?VO!%L\YO+Q\QSLSMS[XS7*3_:(?BG+/<K#<WYU:-+>V9)5G%L4'[Q'
M5@!&O.5(()SFO9:*(Z/^O+_+\0>OW6_/_/\  *X;XGV:2Z'979DG#PW]L%19
MF5#NE7.Y0<,?3(XKN:*.J?8.C1Y[XI\.:+KOCO2].?3;8W$JF^O;C9^\:./"
MJF?=B ?85Z$!@8'2BBA:*P/5W"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K#\1>#]"\5_9O[;L?M7V;=Y7[YTV[L;ONL,_='7TK
M<HH X?\ X5!X$_Z 7_DW/_\ %T?\*@\"?] +_P FY_\ XNNXHH X?_A4'@3_
M * 7_DW/_P#%U7U#X7_#K2]/GOKW2!#;0(9))#=7!VJ.O ?)_"O0*XKXI:19
M:CX&U*YNHW>6SMWDAQ*Z@-QR5! ;H.H-*3LKE15W8QM2\#?"O2+.VNKZP2&*
MY ,/^DW+-(,9X4,6/'MQ5ZQ^%WPZU.RBO++2H[BVE&Y)([V<AA_WW3]8UC3=
M#T_P]<_9([K7Y;40:>CR[ N4&]F). HXR>O:MOP3I":+X5@LQ=PW;[GDEE@.
M4+LQ9@N.P)Q5-6OY$)W2?<XD^&/@^NH_83#")_,\K/VJY\O?G&WS-VW=[9S3
M[[PE\)=-EOXKNQ\M]/\ +^U#S;L^7YGW.0><^W3OBLF2Y&A^%[W^R]:TK5-$
MAN'#:+JMN%G5O,R4!!R6W<C(K7M=-7Q%XK\>6$D1C^UV%HH1NJ,8LC\0<?E2
MZ7+MJU_6]B[=?#KX:6>H6-A/I6VZORWV:,7%RV_:,GD-@ #N<54UWP9\*O#4
MEO'JVG- ]R&,2K)=R%MN,_<)]12?#R[F\4^((=4ND?.BZ;'8'>/^7@D^8?KA
M1^=6_']S=VGCOPG-8W.GVUPJ76V74"1"/E7.[!!^G/6FU9I>OZV)3O>Y2M?"
M?PEO-)N=4BLMME;,%EEFENHMI/08=@3G(Z"GP>#OA-<Z//JT=K$+*W;9-(]U
M<(8V_NE2P8'D<8SS3?%E]JE_X<TJ2ZU30II8=:@,TUD6:WB3G:9 6)^][@=*
MQ]9U'4+V"6%Y=+D6Q\06HFU6&W"0S J2&D ;G:Q7/S>G-"5_Z]/\Q_U^?^1L
MP^$/A+/H\VK):Q"R@?RY7>YN5*-_=*E@V>1QC-6]*^'GPRUNQ:\T[3!/"C%7
M(N;@,C#J&4L&!]B,U@:AJEQ<R@7K6$]MIWB*T^TZG:PB*.X4J3EQD\J2 3GN
M*[#P9(MSXP\975M(DEC)=0JCH<JSK$-^".O:A*Z?]=O\Q-V_KU_R.>/A?X0K
MI%GJK6BBRO)_L\$IFNOFDR1C&[(Y!Y( K2B^''PUFUF?2(])W7T$2RRQ"XN?
ME5NAW;L<^F<UQMYI$USJ^M^$U1O+TPWNI0<<#>BF+'T+-5J+7-0/A?4_%EF9
MHI-8U.WM#.A57C@10I(+X526W#)X&>M):Z_UKI^=QM-.WK^&OY';?\*@\"?]
M +_R;G_^+JEJOPV^&VB6)O=1TGR;<.J%_M-PW+$ #"L3U(KFKKQ)XATS3-2@
MM[F\-B;NUB2::_MY[FV5\[P75V S@8+D8W=:KZY?ZJ_A/7[9WN+FR@N;-[5;
MN^AN)D8R#*,T;MP< C=0M7]WZ?YB>B.MU;X;?#;0]-EU'4=)\FTBQOD^TW#8
MR0!PK$]2*N+\(? ;*&&A\$9'^ES_ /Q=<=JNH7>H_#?Q;)J]Q<#68[N..YLW
MD)CME$B[!&N<;2.=W>K^LZCK%CKVH>%H=0O1-K,]K+I\HF;=!$Q_?!3GY0-A
MX'K32O9=_P#@#>U_7\#?N/A1\/K2VDN+G2$A@B4L\DE[,%4#J22_%8^D>$OA
M'KUVUIIEO#/<*"WE_:KA2P'==S#</<9K>^*4$K> I@B22P130O<J,LS0JX+9
M]>.35@ZYX2U/7-$M[4P:A?;6>T:T(?[,@7DL0?E&.,'Z8I(3V,C2_AM\-M:L
MS=Z?I/G0"1HRWVFX7YE.&&"P/45=_P"%0>!/^@%_Y-S_ /Q=<7H[7VD^'M,U
M:TU6]1I/$+6S6P<>08WE8,"N.3QG)YJQJ/B.]&NP:C8:O?%7UQ;$QS7:JA3=
MM9%MQGC_ &S@T1UMY_\  _S&]+_UW_R-*7P9\*(/M'F6&W[/=K92_OKH[9FQ
MM7[W.<CD<>];7_"H/ G_ $ O_)N?_P"+KCM5_P"9A_[&NU_]EHO/$GB&?5-4
MNH;F\BOK35/L\$#7]O#;"(,!L:)W#,6&?FQW&#1#WDO/_*/ZL):-_P!=7_D=
MC_PJ#P)_T O_ ";G_P#BZ/\ A4'@3_H!?^3<_P#\77*ZO>ZNMAXSU:+7-2AE
MTK45^RPI/^[7A,J0>J\_=Z5?UK6+FX\1:XE]XAN-(33]-CGL8XIA&LS,A+.0
M?O\ S87']:5]+_UM<:3;_KO8V_\ A4'@3_H!?^3<_P#\71_PJ#P)_P! +_R;
MG_\ BZXN/Q#K%W#H-C<7NJ"!M&6Z\VVOHH))IBQ&YI)67<%Q]W)SGGBK-SJ_
MB6[L-$DN[_S&^PN\]M8ZI';S.P<@3AP=DBX ^4-C.:IJW]>O^1*U_KT_S.K_
M .%0>!/^@%_Y-S__ !='_"H/ G_0"_\ )N?_ .+K>\(ZB-6\)Z;?">>?S80?
M-N(PCM@XRP'&>.HX/6MJAJSL).ZN</\ \*@\"?\ 0"_\FY__ (NC_A4'@3_H
M!?\ DW/_ /%UW%%(91T?1[#0-*ATS3(/(LX=WEQ[V;;EBQY8D]2>]7J** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKFV@O+>2
MWNH8YX)!M>.5 RL/0@\&I:* ,Z]\/Z+J0B%_I%A="%=D7GVR/L7T7(X'TJS9
M6%GIML+:PM(+6!22(H(PB@GKP!BK%% %)]'TN2_%\^FV;7@Z7!@4R#_@6,U-
M'8VD-W-=Q6L"7,X EF6,!Y .FYNIQVS4]% %>UL+.Q$HL[2"W\Z0RR>3&$WN
M>K''4GUJ'4=%TK5S&=3TRRO3'G9]I@63;GKC<#CH*O44 9]KH.CV-O-;VFDV
M%O!/_K8X;9$63_> &#^-31:9I\%@;"&QMH[,@@VZ1*(\'J-H&*M44 5(M+T^
M"P-A%8VL=F00;=(5$>#VVXQ4EI9VMA;+;6=M#;0)]V*% BK] .*GHH KBPLQ
M>27@M(!<RH(Y)A&-[J.BEL9(]J;#IEA;V'V"&QMHK/!'V=(E6/!Y/R@8JU10
M!3@TG3;6R:RM]/M(;1L[H(X56,YZY4#%,30](CL/L":78K9[@_V<6Z"/<#D'
M;C&<BLB]\7II_B>\T>YL]B0::VH1W'F\2!3AEQCC&.N3658_$?[=H.D7Z:05
MNM1U$6'V0W',1R<L6V\X !Q@=:%KM_6MOS!Z;_UI?\CK9]$TJZDGDN-,LIGN
M%59FDMU8RA>0&)'(&!C-9I\,F;QE%X@NKP2K;0-#9VP@"^3N W$MG+$X..!C
M-:T>IV$M\]C'?6SW<8R\"RJ9%'NN<BB/4["6^DLH[ZV>[C&7@653(H]USD4+
M34'V+) 8$$ @]0:JV>EZ?I[2-96%K;-(<N8850L?? YK(\/^+;36=+CO+HP6
M#2W4EK%%+< F1D8K\N0,DXS@"M:+5=.GOGL8M0M9+N/[\"3*9%^JYR* $&CZ
M6+=+<:;9B!)?/2/R%VK)G.\#& V><]:9)H6D2S232:58O+(ZR.[6Z%F8<AB<
M<D=C5BYO[.R,8NKN" RDK&)9 N\@9(&>O )IL.IV%S9&]@O;:6U&<SI*K(,=
M?F!Q0 Q]'TN3S-^FV;>;*)Y,P*=\@Z.>.6'KUI7TG39;]+^33[1[Q!A;AH5,
MB_1L9%.MM2L;RU:ZM;VVGMUSF:*5608Z\@XK-U+Q=HNG:!=ZR+^WNK6V'S?9
MID<LW]T<XW'TS1L&YH/I&F217,4FG6C1W3;[A&@4B9O5QCYCP.OI6%X@\(3Z
MU>B:+4XH(O*,7ERV,<QB!!!:)C@HV#[CVK<L]6LK_1X]5@N(VLWB\WS%<, ,
M<Y(R..<_2N3A^(=Q-;1ZJ/#-_P#V#+($2^$BER"V-_DCYMN>_7VH:ULP3TNC
MHK;PQI$.BV.DS6,%W;64:I$+J)9",#KR.M6[O2=-OXHXKS3[6YCBQY:30JX3
M'3 (XK'L?&-E<ZWJVG736]F+&>.&.26X \\NF[@$#![8R:V+S5M-TZ2*.^U"
MTM7E.(UGF5"Y]@3S3>NO<2[+H6D18T5$4*BC 51@ 4ZN3UGQM_9&IZO9C3_.
M_L_2_P"T=_G;?,Y(V8VG'3KS]*V(->L#I^GW5Y=6UF][$CQQ33JI)8 [1G&[
MK2WU_KK_ ),>VG]=/\S4HJE=:SI=E(\=WJ5G Z*'=99U0JI. 2"> 3TJ2YU&
MQLH$GNKVW@A<@))+*JJQ/3!)P<T 6:*I?VQI@M);LZC:?9H7*2S>>NQ&'4,V
M< CT-68+B&Z@2>WFCFA<962-@RL/8CK0!)1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MORKI:*&[W\Q'+^$?"U]X;>Z:[U6'4&N3ODF^Q^7+(^?O.Y=MW' & !74444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>hook-20211231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &$ KP# 2(  A$! Q$!_\0
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MU[_H5)__  ,B_P : .BHKG?[<U[_ *%2?_P,B_QH_MS7O^A4G_\  R+_ !H
MZ*BN=_MS7O\ H5)__ R+_&C^W->_Z%2?_P #(O\ &@#HJ*YW^W->_P"A4G_\
M#(O\:/[<U[_H5)__  ,B_P : .BHKG?[<U[_ *%2?_P,B_QH_MS7O^A4G_\
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MM4@6 3W9B3!B7SC^Z(.05[C'\N*M0Z39P1VZ)&<0;]NYB22_WB2>I.223W-
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M$A4;1V&WF@#L/A[_ ,B;:?[\G_H9KJ*Y/X;2-+X%L)'C:-F+L4;JIWG@UUE
M!7&>,B!K&D@D EACW_>)79USWBV-#:V4A4%UO(@&QR/FJ9;$3^%G0CH*HZII
M-GK%LL%['YD:L' R1@CZ5>'04&J3:U19B>&($MM.F@CSY<=Q(J@DG S[UMUS
MN@7<B:A?Z;-;R12)(TRLW1U)XQ715<_B$C'N?#.G7=S)<2H_F2'+$.1FHO\
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MA%;W.JVU[,2MP8([<XV%-F0V/7O^%;>DWE[:G4(0]QJ9ACCDC5G7>2R@E<G
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M)=0LI+9F*JXQD=150:4DV3)732)XC^Z3_=%.S7/CPU.!@:Q>8^HI?^$;N/\
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MB?\ 7\/_ $!JV6BC<Y:-6/J1F@"AX?C2+P_81QSQ3HL*@2PQ^6C#U5>PK2I
M HP  !V%+0 4R;_42?[I_E3ZX:Q\<F6]U--66VLM/C1C;SM)]X!BAW9Z'(H
MT?A[_P B;:?[\G_H9KJ*\Z\#^-/#-EX4MH+G7+&*56D)1Y0",N371?\ "?>$
MO^AAT_\ [_"@#HZP?%T'VK2$M]VWS9D3=C.,G%1?\)]X2_Z&'3_^_P *S=9\
M9^&KRW@2WURQD9)T=@LP.%!R30!5TVS\06'B>'2Y=6M9A'IX:-UM-N%#!<'Y
MCFKMN^K:;J"EKR"6"XU!HY$$&#SGD'/M6>?&GAG_ (3M;K^W;'R/[.,?F>:,
M;O,!Q3;SQ;X?>>U9=8LRJZCYQ/FCA,'YOI64E9W1E**3NCT3M6'?:5J3:LU]
MI^H16Y>(1LLD'F9P<^HJ#_A/O"7_ $,.G_\ ?X4?\)]X2_Z&'3_^_P *V4G'
M8U+'AZ\OKDW\-_-'++;7!B#QQ[ 1@'ID^M;=<'HGC3PU;WFK/-KEBBS79>,M
M*!N7:.16S_PGWA+_ *&'3_\ O\*J?Q"6QT=%<Y_PGWA+_H8=/_[_  H_X3[P
ME_T,.G_]_A4#.CHKG/\ A/O"7_0PZ?\ ]_A1_P )]X2_Z&'3_P#O\* .CHKG
M/^$^\)?]##I__?X4?\)]X2_Z&'3_ /O\* .CHKG/^$^\)?\ 0PZ?_P!_A1_P
MGWA+_H8=/_[_  H Z.BN<_X3[PE_T,.G_P#?X4?\)]X2_P"AAT__ +_"@#HZ
M*YS_ (3[PE_T,.G_ /?X4?\ "?>$O^AAT_\ [_"@#HZ*YS_A/O"7_0PZ?_W^
M%'_"?>$O^AAT_P#[_"@#HZ*RM,\3:)K4[0:9JEK=RJNYDAD#$#UK5H *P/#O
M_(5\3?\ 84'_ *305OU@>'?^0KXF_P"PH/\ TF@H WZ*** "BBB@ ) &2<"F
M)+'*"8Y%?'7:<US/CJ"]N-'1;8@0*Y:Y)D9!L [E2#C/H:S/!MMX:O98[K1K
MB6*]A13<1132E#GL0YP?KUH6H/0['5"%TNZ)MFN0(V_<KU?CH*XA+2Z%W%JD
MUA<R.\<D<L*6^T(64!0J^@P<FO0J*!W/,3H.J'2'TD6DWVIIS.)\?*$*'Y=W
MKVQ72Z/9W5V=1EC6XTT3)'&CE '#*H!8 @CMCFNIHIW!NYRGA^TGLO%VL17%
M_->O]G@/FS*H./FX^4 5U,F_RV\LJ'QQN'%8-A_R.^K_ /7M;_\ LU=!2$<A
MKT^H32"U90RI\Q,2$ G\:UM&N=0NH$\WRE"':X9#N(]<YQ6S@>E&,4 5=0L8
MM2LVM9\^6S*3COA@<?I7.-\/M-:82F[O"X1%R64\H9B#T]9FXZ?*OX[^KVLU
M[8?9X))(RTT1=HY6C;8)%+@,I!&5!'!KC/[&\4VUVWVBZGN[9Y FR&ZEC:3D
MD-NWG8 "0=H7/'H, &Y9^&K&'6ENQJ,D]W$YD=&\O.X[SD@+D<2]L<8]3E^I
M>$["\D>:6YEBWM)OX0AA)MR/F!_NC\^_%8<'AKQ%;ZA)/+<O<1LT;S+#=M"U
MPPAB0G*XQ\R,?PJ/4/#GB>\NV+2?Z,C1.L2WTI#,DT+CEG/\*R<X7DC.>M &
M_<^$;"[:9X+F>&*YA6*5(BK!U5G8'+ D<R-T/I45QX+LGO#<F_NHU:YCN&C!
M3:S((@HY7/\ RQ7OW-4;S2-:M=.^TFYNWE1CYJ174IW1;!\JJ#P=PZ@9Z^IJ
MQI=O?-X?TQKN*Z9EOIGV3NTDB1M))Y18MECA60<\@=>E %:R\'Z +:UMK75F
ME6.&.  2QOYB*BX&,=2(\Y'OZ#"ZCX?M;N!4T:_@:Y*?9B3<)@+LD[;&R?F)
M['"]>H,-AX&NK73="62]EEO+:)8IW<H!"HM98\)L5<X>0<G)QWK1?2=3?328
M+"RM+VU6'[*4;[[INZL!PA#$8ZX9O6@".S\&Z=#L>'4I/-MW:567RSY;%R6Z
MJ>-P;@_TXMW'AC1]0T73],FN#+;VD(M5.]<R (  <#&?E5N,<J.U+;Z3-;S-
M;0!A&FF^0[-TED))'/?'S_\ ??UING:!<VNJ6\DAC^R1QK*8QU^T>6(RW_?(
M_6@!J>"+".\CN1<7!95PP.W#\Q,2>.I:%3QZFK.H^'$NM)2PB9M@:3+%PI <
M,#_"?[Q[5O44#3LSD(_",RW<MW*_GSRS1S,SS@<H8V4<1#C,2CZ9[U%-X(::
M.2)I"(7DEDV"=?O.CH3GRL_=D;C/4"NTHI6\RN=?RK\?\S$U?PZFMR6\EQ=3
M0>4 #%"5*DAE;J5SU7';BJ-QX&L9S&1=W*&.W2W& A&U59<D%2"2&_2NIHID
M&+-X;MI-%.F1S2Q1_:4N5D4*65EE$HZ@@C*@<CI5 >!K 2.YNKD^8=\@(3YG
MVD;A\O'7H/3W.>IHH Y6\\(^5%:R:;(_VFV#JA>14&&8L2?D8$Y/I2#PC)+I
M6E:;/=X@M=.%E<&)1F7Y4!QD' .T\C!YKJZ* .<'@RP%S%+YTQ"!0T;!2K[9
M&<9R..6/3^?-,C\%6<)MY(KRZ6>W+,LIV,2693SE<' 55'L!7344 <L/ UF(
M! +ZZ\D*H",L9&X(B;N5ZXC7V';%,_X0N.&XLO(N)7C6X$EP\C@,R!?]7@+@
MJ6"9''"UUE% &'J/AF'49KES>7$*W#)(Z1A,;U  ()4GH!QG''N<UU\&V@A9
M6N[EY6E,QE;9G<99)#P%QC,K#&.F.XS7244 <]8>$K;3[RTN(KN<K;.9!$5C
M"LY0H2<*#T8\ @9JM?>#4EBD\FYD:5OEC:0JHA4R;V(VKECQW_3)SU5% &3>
M>'[:\O+.X:21/LJ!%1<8(#*PSD>J"LP>!K2-&6*_NXP2V,",D*=WRY*Y/WSU
M]!G/.>IHH YFV\$V%M&D8GG=4C\M0VW@;D;T]8Q^9IDW@33II)6-Q<!91\Z8
M0C.",@E<C@_I[G/4T4 95IH-O9:K<7\<LA><,'0XV\[>G&?X?UK*A\!:9"LB
MK<71W[!RR_+M96XX[A$7Z(*ZJB@#&T[PW:Z:]N\<LKM"SL"V/F+*JG.!Z**V
M:** "BBB@ HHHH P]?\ ^/\ T3_K^'_H#5N5AZ__ ,?^B?\ 7\/_ $!JW* "
MBBB@ KD;+P):0WNH27\B7UK< B*WGC!6(%BQ^O)KKJR_$C2IX;U)H<B06[X(
MZ]* ,31?A[X9LM+BMY=)TV\=2Q\YK9"6R2?TZ5H?\(/X5_Z%W2__  %3_"LC
MX8%?^$<N%A=WM%NG%NS$G*X4G!/^UNKMJ ,#_A!_"O\ T+NE_P#@*G^%'_"#
M^%?^A=TO_P !4_PK?HH P/\ A!_"O_0NZ7_X"I_A39/!OA.)"\F@Z4BCJS6R
M #]*Z&N.^)D0N/"+P-<V]O&\\6][@L$P&!P=OKC% #='^'_A>SCGCETW3+MY
M9GF0M A*JQX ]A6I_P (/X5_Z%W2_P#P%3_"O-O!LZ3>,-.F17AO2?+, 9MJ
MVPA)! /;=BO:* ,#_A"/"QZ^'M,_\!4_PH_X0?PK_P!"[I?_ ("I_A6_10!@
M?\(/X5_Z%W2__ 5/\*:W@GPFN-WA[2ADX&;9.OY5T-<GXSM99+K0KE+F5%BU
M"(>2IPKDGJ?I0!!8?#_PO97>HSSZ;IDT<TP=4>!,0C &T>GK6F/ _A0C(\.Z
M7_X"I_A7BT<OFK=I>7%P+*6<-J+%V&V;=)@9[=%_2O</"CROX4TMIRQD-NNX
MMUZ=Z (?^$'\*_\ 0NZ7_P" J?X4?\(/X5_Z%W2__ 5/\*WZ* ,#_A!_"O\
MT+NE_P#@*G^%-;P3X309;P_I2CU-L@_I70UROCZS>YT!9%N985@N(G*QG'F?
M.O!]J *T'@+PK!K=_=2:?I;QR(@%NT"8BVCDX[9K37P3X390R^'M+(/0BV3_
M  KRO5V5?$_B 3RP207%S&+J2)G#P0><@*MD #(]/>O3OA^S-X,L<L[( PC9
MSDE QV_IB@"?_A!_"O\ T+NE_P#@*G^%'_"#^%?^A=TO_P !4_PK?HH P/\
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ML?R-4[[PK:7^IF]DN)U8S)/L4KMWJ ,],\A5_*JMYX&T^\A1&N;I&C=V1T8
MC<[,>W^V1^5 '3JRNBNC!E89!!R"*6H;2VBLK."TA!$4$:QH"<X51@?RJ:@
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M< >6MS)"OE^5D,2G/+%A_P !JDMKJ=IJ;6^I2ZC<:7OVN]NLI9F\I-F-F6V
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M"@_])H* -^BBB@ HHHH S]<D$6A7TAMA<A86/DD9#\=*X[X=7,<E[?0Q6>G
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MV2>^ET/1KF5KB:W$3-,R%E:4[?W3/L&[!ZD =^E=:RJZ%'4,K#!!&010
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M2&1+&-%\MI(RI+<YZ_A70549*2NC*I3E3ERRW"BBBJ,PHHHH **** "BBB@
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MU16?8:[I6J3-#8:A;W$B+N98G#$#IFM"@ HHHH **** "BBB@ HHHH ****
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M\7_? IKVEIL.^"$+CG*"I0SD--\9:!+.FHRV:6".K1)=RJ%&W.<$]@2*V/\
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MEQ#?V\$?EQI)'/;F3=LD$@_B& 2,'U% &QX,6,^&;:9$M@\N2S6ZH W) R4
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M0@=<=S7NM-\M "-BX/48ZT+1W&]K'+^ !(- EX<6QNI3:A\Y\K=\O7MBNJI
M HP  /04M-NXD%%%%( HHHH **** ,/7_P#C_P!$_P"OX?\ H#5N5AZ__P ?
M^B?]?P_] :MR@ HHHH *1_N-]*6D?[C?2@#DOAS_ ,BY/_U_W/\ Z,-==7(?
M#G_D7)_^O^Y_]&&NOH **** .3\56EY=:UI!L+E(+A2^UW7(Z>E,TV?7;/Q5
M;Z?J5_%<Q30/)\D>W!&*T]3_ .1ATGZO_*JMU_R/^G?]>DG\Q6/5OS.:WO-^
M:_0Z:BBBMCI"LKQ-_P BSJ/_ %P;^5:M97B;_D6=1_ZX-_*JA\2''=%C1_\
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M-;PP-'L3S$;.=RYQSQP?:NMK,TO0-.T>21[&#RS)U&XD#V /05IT!U"BBBD
M4444 %%%% !1110 4444 %%%% &'K_\ Q_Z)_P!?P_\ 0&K<K#U__C_T3_K^
M'_H#5N4 %%%% !7FQ\0ZA:^-M1=IY[F!%G3[!& <"-4*D#KDEC7I-46T[3K:
M\FU3[-$ER8\23X^8J* /)/!WQ&FTS1I8%\+ZO<!KJ:3?%"2!N<G'U%=!_P +
M7G_Z$_7?_ <UTWA'5]*U2TNETNV:V6&8[XF7:26^;=]#G-='B@#S;_A:\_\
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M%A;G!P,5/_PM>?\ Z$_7?_ <UZ3BC%(&>;?\+7G_ .A/UW_P'-'_  M:<_\
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M;]8'AW_D*^)O^PH/_2:"@#?HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@##U_\ X_\ 1/\
MK^'_ * U;E8>O_\ '_HG_7\/_0&K<H **3GVHY]J %J&[@%U9S0$X$B%,_48
MJ7GVHY]J .5\&>&KO0#?2WTL3RW#(JB/. B+M7\375TG-'/M0 M%)S[4<^U
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MA7Q-_P!A0?\ I-!0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!AZ_P#\?^B?]?H_] :M
MRJ&JZ1;:Q#''<M,OE.)$>&0HRMTX(^M9W_"(VG_00U;_ ,#G_P : .@HKG_^
M$1M/^@AJW_@<_P#C1_PB-I_T$-6_\#G_ ,: .@HKG_\ A$;3_H(:M_X'/_C1
M_P (C:?]!#5O_ Y_\: .@HKG_P#A$;3_ *"&K?\ @<_^-'_"(VG_ $$-6_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>hook-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $/ \ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;SPZC9V^LWMKIU^YFDLX]A02'N"1G&><9Q76:?;1Z?IMK9K)O6WB6(,<9(4
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M*SNT?3P7D3:-MV<<+DCY1GGCFJR1>(=0N+"\ECDTJS3=]JA !+XY!^8$@=L
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MD H_4T#3[V08N-5FZ]((UC!]NA/ZT :512W5O!_K9XX_]]P/YU2.A64@Q/\
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M;3!\_@VTTJ:W99"SN]JY_AN4,?Y$\'\#0!HT4U'61 R,&4C((.0:=0 4444
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M$?"T\$5YX?>1"P=(;B"=F$3'.6 /?-+FB].GH!+X4TB\T1[B]UC5IY)BJQO
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M>16J]U7O="(KC5]5M/$6E07+Z;;K<N8G1^9G '8CW_G6U).MG/# 8Y98[B3
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MGI)=Z<MQ/<A'TV.)/L\-LA:08'.?45A^&K[2K;3M9UBVTV\M(/-)F24%B_\
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MUTE;._M$N[J]=[=%1L1\C^/O^5+WI63]1&;X=\1Z-IE_<1MXAN[M;V?">?&
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MJ3>,Y]-T**Z:PNKFVN5 2\\KY >SE?0XK=M+G2+RUNKYW,-NTAA87J[5+=.
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M%CJ%O!>2I=VI$AEGX#9ZH/Z?C5VPDAU>RFF>S: 2EHIDD3:SXXZ]Q3M9.^J
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MWY6M&B@"F-)TU?NZ?:CZ0K_A4BV-HGW;6%?I&!_2K%% #5C1/NHH^@Q3J**
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M[1=DF,E,@ M^&<_A6!HG@O2M"OM'U:U\57T=U=IF5)[L2#42R[B,,?7GC/\
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M#,D8W,<C:R%>_7K0!Z%17FD_CW6H[J+3I18V=]#8PW%V7L;B=3+("1$HCR5
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MH,X^M;<4<-O&$@BCC0=%10H'Y4UY*CVD5I%?U_7F:>PF]9RO_7W?@9CG6+J
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MUMM7RUS&EO&S[B@7B0C<%P!\OUP1FNK^PG_G[NO^_G_UJ/L)_P"?NZ_[^?\
MUJ ,.Z\&6MWK>B:I+<R;]-C"-&J@+<;1\A;TVM\P]S27/@R&XU>34#>R*SZG
M#J.P(, QQB,+]#C.:W?L)_Y^[K_OY_\ 6H^PG_G[NO\ OY_]:@#GM8\&2:C?
M:E-:ZU<V,.J0"&]BCB1]^U2H*LPRIP<'^E07_@)[RR6Q36KA+-[6.UN()($F
M1@B[0Z!\^6Q'4CVXXKJ/L)_Y^[K_ +^?_6H^PG_G[NO^_G_UJ );2VCLK*"T
MASY4$:QIN.3A1@9/?I4U5/L)_P"?NZ_[^?\ UJ/L)_Y^[K_OY_\ 6H 35?\
MD&3_ .[56;_D7!_UR%+J%H8["9_M-PV%Z,^0?TI)O^1<'_7(4F,O6'_'A!_U
MS'\JL5FVEF7LX6^TW"Y0' ?@?I4_V$_\_=U_W\_^M3 R?$OAB/Q/=:9%?/')
MI=M,9[BT="?/8*0@)ST!.<=\"L6]^&UG#<W#^'Q:Z7#>6$]E=0I"=LF\?(^
M1RI_,$UV'V$_\_=U_P!_/_K4?83_ ,_=U_W\_P#K4".8U?P1]NCT:>)[&2]T
MRW^S[;ZT$\$R%5!RN00<J""#Q[T_3/!DM@^D2->P,]G=RW4JQ6JQ(2\93:BK
M]T#(ZY/'6ND^PG_G[NO^_G_UJ/L)_P"?NZ_[^?\ UJ .1U7P)<7S7$B7EH^_
M5/MXM[JW,D$@\L)LD4,-V,;@?7'%+9> &ATC7[&XNK7_ (FK+*AM;7R4MW5
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MJWDY"G(4DD?E55-7D@\M+F('/&]&Y/OBM6*5)XQ)&P9#T(K1-/8EW0Y5"J%
M  & !2TA(4$DX [FLQ]6-PQBTN+[4X.#+G$*?5N_T7/X50B_<7,-I TT\BQQ
MJ,EF. *SC]JU@#B2TL3USE991_-!^OTJ6#2P9UN;Z7[5<J<J2,)'_NKV^IR?
M>M&@".""*VA2&&-8XT&%51@ 5)110 4444 %%%% "/\ </TK-T'_ )!W_ S6
MD_W#]*S=!_Y!W_ S2ZC.&\:>);^V\1S3:??&*U\.0Q75[;K*%^U>8WS1D'KM
MB#,/<BNGU+Q/=1:O9:;I.EIJ,EW9M=I(UT(HPBLHY.T]=XQ@'^M06/P^T5?M
MLVL6-CJU]>7,EQ+<W%HI8;C\J+G)"JH"CGMFE\.^#7T&?39'U-KI=/LI;&(-
M%M)C:163)R>550OOUXIB,N/Q=JNK:]X5>QL_)L[T70NH);@!E>,[6!PISM()
M&#\V>U.T+QA<W.EZ19Z5I=Q?WDUE]LE%W? &*+>RKND*_,S$$ 8'0Y(Q6A:>
M"YK&71Y;?4U$FG7-U*V^WR)4G<LR_>^4C(PW/3I6!-H5YX0DTH:=+J3S0V!M
M);NWTW[5',H<NJF,/N1P6)#<KR0: +R_$V*73M+D73X8+Z_\]OL]Y?) D*12
M&-B\A!Y)  4 ]^PS4]O\0O[1ATQ=+TL7=W>7%Q:O%]K4)#+"N6RX!#+_ +0[
M$<<XK.T+P%>_\(]HMS+.EIK5M'.LGVNV2Y5XYI3*5D7(&X':<J1@Y'(K?T_P
M>;*XT>XDU-[B6PDN)9&:(*)6E7!"@<(J]@,\#'O0!H^'-=;7;*XDFLVL[FUN
M9+6XA+APLB8SM88W*000<#KTJ32O^/S4/^NO]31HNC_V0VI'S_-^VWLEW]S;
MLW!1MZG.-O7WHTK_ (_-0_ZZ_P!32>XS4HHHIB"BBB@ K%USQ)%H4D*2:;JU
MYYH)!L+"2X"X_O%1QU[UM44 (IW*&P1D9P1@TM%% !1110 4444 %9^M?\@N
M7ZK_ #K0K/UK_D%R_5?YTGL!6U7_ )!=K_O)_*MFL;5?^07:_P"\G\JV:%N,
M****8@HHHH Y*YO=4UWQ7>Z/IVHMIMIIL437,T42/++))DA5W@JJA1DG!)SV
MQ6+JFM^)-*&KZ8+T7=YID$.IP3B%5>YM@Y$D3J!C=A2,J!G(Z&NBU#0]3MM?
MEUO0;BU6>YB2&[MKM6\N783M<,O*L 2.A!&/2I-%T"Y@U"^U?5[F*YU&]C2%
MEA0K%#$N<(H.2>6))/7T&* *^I:Y/>ZQX=L-'N=JWI^W3RJH;_144''(.-[,
MBYZ\G'2L>\\5ZG#XU,ZR?\4W;7<>EW " CSY%SYF[&0%9HT/./F/<5H^%/"%
MUX=>_EENH;F0(+73\@CR;92S(C'URW..RKZ5EQ_"72)O#4MO?KYVM7"/)/?K
M+(,W#DMO"YQPQ&..PH ]$HJII:7D6E6D>HR127J1*L[Q9VLX&"1GG!/-6Z "
MBBB@ K*M/^0Y>_[H_I6K65:?\AR]_P!T?TI,867_ "&K[Z"L[5M7U.X\2Q^'
MM&:WMYEMOM=U=W$9D$498JH5 1N8D-U. !WK1LO^0U??05G:MI&IVWB5?$.C
MI;W,S6HM+JTN)#&)$#%E97 .&!+=1@@]L4(&96H^(/$&C:%K\D\^G7C65F;B
MUOH %5FYRDD6\D$<'(."#V-,T'7KJ]E,B^-]"U4I;M*]G:6RK)]WKD2L0 2.
MU9MSX#U"]&NWL&D:1I$E[I;V45I:N#O=F#%Y'"@=L< _6N^734CTHP1P0I.8
M/+RJ@<[<=0/6F(\]3Q9XCL_"%CXFGU_1KKSHH96TT6?EN^_'R*XD)W<\?+U[
M5WOB+66T70I;V.+S+@E8H(F_BE=@J ^VXC/MFLKPCX)TG0]#TH3Z+IB:K;6T
M:2W$=NA<R!0"=^,GGO4OCNUEFT".[AC:1].NX+XQKU98W#,/KMSQ[4 13^++
M?0YM1&KWYF%F+2.18+)@5>7(R""=P8CH!\OOFI8?'6F3:C]@-MJ,5RL:RS++
M9NH@1LX:0GA1\IZUBZMX8U#6-0U'4+)K>2UO;C3;B!_-^\D+EG/3T(QZUJ7'
MA>YOM9\3O,ZQ6FJV$5K'(K992 X8D?\  A0!+#XXTV^C=;5;J)Y8'ELY+FU>
M..Y"J3F,L!NXY[$CGI533/'<!T'2);V*ZN=1NK".[FBL+1Y?+5ARY"YVKG..
MYQQFL/2? VI0S6*W&FV<!L(74W']HSW'GOY913&C';$.<G(/H/6H8? &J6$=
MA/\ 8(;^7^R[>SFB&IS6ODRQ @,&3AU.[H>1CCJ: .\L_%&DWT\L<%SN"6B7
M@D(PKPMGYE/?&"#Z5GR>/M(6W@EAAU&Y\VV6[9+>S>1HH6SM=P!\H."0.IQT
MK"U'P#J']B:+9Z;):P31PM8Z@8MRH;:4AI=F222".,GN:D\0^%-8O]9NDBMX
MKK3);5(;2,ZA);1VQ4$$NB#]X.1C)XQCO0!N77CK1X)HXH1>7CR6B7R"SM7E
MS Q.'X' X^M5(_&1U/Q/;Z7ID<CVEWIINH;U;<LFXD;23D?*,\^^!4/A/PQJ
M6D75M)=K"%CT.WL&V2;OWL;.3VZ8(YJMX=\/ZKX;GT6YNH[4V]MI3V=XXN,>
M20X?<,CYAQCM0!NV&KMK7A-[F5!'<QEX+E%Z+*C;6Q[9&1[$5=F_Y%P?]<A6
M#X9MI(_"-_?2(R?VE=SWR(W54=OD_-0I_&MZ;_D7!_UR%2QEZP_X\(/^N8_E
M5BJ]A_QX0?\ 7,?RJQ5""BBB@ KDYM5UC6_$-_I>BW%K96^F[$N;J: S,\K+
MN"(NY0 %()))ZX KK*Y.72]9T3Q%J&J:-;6U];:EL>XM99S"\<JKMWHV"""H
M (..1F@#+O?%^MZ=::E%<Q6K7FBSP2WC1(=EQ9N>70$Y1@ V02<%?0UOZIK5
MS_PD.BZ5IK1,;HO<7#E=P6W0<D<\%F90#[FH='\.7+3:S?ZW]G:ZU95BD@A)
M:.&%00J;B 6/S,2<#D^U9WA?PWK6C6NHW5Z8+G48[=;&PQ)P8(L^7N.."Q(W
M=>@H 2'QE>MXZ-HZ0C07N#IL4VT[C=JF\\Y^[U7&/O"NYKS)OA=*GA-$CU74
M#K:8NQNO7^S_ &O.\ML^[C?GG'2O1[5IWM(7N8UCG9%,B*VX*V.0#W&>] $U
M%%% !1110!ES_P#(PV__ %S/]:U*RY_^1AM_^N9_K6I20V%%%%,04444 %%%
M% !1110 54O--M;XJTT?[Q/N2H2KI]&'(JW10!F8U2Q)QMU"'MDA)1_[*WZ?
MC4MOJUI/*(2[0W'_ #QG4H_X ]?PS5ZH;FUM[R+RKF&.5/[KJ"* )J*S?[+F
M@.;&^FB Z1RGS4_\>^8?@:3[9J5OQ<Z?YP'_ "TM'!S_ ,!;!'X$T :=%4(]
M:L'<1M/Y,I_Y9SJ8F_)@*O@@C(H **** "BBB@ HHHH **** "FO&DB%'4,I
MZ@C-.HH CA@BMXQ'#&J(.RCBG-&C_>56^HIU!H 3 [4M%% !1110 445#<7=
MM:*&N)XX@>F]PN?SH FJCJ5@;V#;&563(PQ[>_UJ+^V4G!^P6UQ=\<.J;$_[
MZ; /X9H\O5[K_63062?W8AYK_P#?1P!^1^M)J^X%.\LIH;=O/GMC%_STE;RR
M#ZYZ9HTZXN$A:*RB>[9CDSR+Y4.?4'JWX#FM"+2+..02R(UQ./\ EK<-YC?A
MG@?@!5^DHI;#;;,O^R7NFW:G<&Y&>(%&R(?5?XO^!$_2M-45$"HH50,  8 %
M+15""BBB@ HHHH **** "BBB@!&&5(]JQ;:TU6UB\J)H N<\G/\ 2MNBDT!E
M;-9_YZV_Y?\ UJ7R]9_Y[0?E_P#6JV^H6:2+&UU$':7R0N\9WXSM^N.<4^WN
M[:ZC5X)XY%;.THP.<'!Q^-+3N6XR2NT4?*UC_GXA_+_ZU'D:O_S\P_\ ?/\
M]:M2BG8FYE_9]7/_ "]Q?]\__6H^RZM_S^Q_]\__ %JU**+!<R_LFJ_\_P G
M_?/_ -:HH],U"%W:.\16D.6(7J:V:*+!<ROL>J_\_P"O_?/_ -:C['JO_/\
MK_WS_P#6K5HHL%S*^QZK_P _Z_\ ?/\ ]:C['JO_ #_K_P!\_P#UJU:*+!<R
MOL>J_P#/^O\ WS_]:C['JO\ S_K_ -\__6K5HHL%S*^QZK_S_K_WS_\ 6H^Q
MZK_S_K_WS_\ 6K5HHL%S*^QZK_S_ *_]\_\ UJ/L>J_\_P"O_?/_ -:M6BBP
M7,K['JO_ #_K_P!\_P#UJ/L>J_\ /^O_ 'S_ /6K5HHL%S*^QZK_ ,_Z_P#?
M/_UJ9-INHSQF.6]5D/4%:V**+!<H7MC)<V44*.JLA!R1Z#%0_8]5_P"?]?\
MOG_ZU:M%%A7,K['JO_/^O_?/_P!:C['JO_/^O_?/_P!:M6BBP[F5]CU7_G_7
M_OG_ .M1]CU7_G_7_OG_ .M6K118+F5]CU7_ )_U_P"^?_K4?8]5_P"?]?\
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MZ"<_Z_XUJ44607,O^RKG_H)S_K_C1_95S_T$I_U_QK4HHL@N90TFX4 +J,P
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MH **** "BBB@!DL,4Z%)8TD0]5=015 Z'9+G[,);0_\ 3M*R#_OD?+^E:5%
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MF'0JC")3_P!\ ']:GM]*L+5M\5I$).\A7+'ZL>35RB@ HHHH **** "BBB@
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M=?)9F7#9^7=@]=N[;GG%1P^%+>-;5);_ %"X2T93 DLJD1@(R <*,\.>3DG
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MFMG=9$D;D*KE WT)%5]!\,2:/<6<K7:RBWL/LA C*[CO#;NO'3&*RIO"D_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(W9. 1QR">XXI#JUD#CS2> W",>"2H[=R"!ZU5BTJW? COI7E@*J&#(3&%!
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MS*S$G*A0,G'8#&/E'&,4 6+K4DAL5N(D9R[A$5E8<DXY&,C\J0:Q9%<^:<Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>hook-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  VX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0,  8 H SAI/VDA]2F-T>OE?=B'_  'O^.:T0 H    Z 4M% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %47TR*35([]R
MS2Q*509X7/6KU% !1110 4444 %%%% %:[L;:^51/&"R'*.#AD/JI'(JJ4U*
MQYC/V^$?P,0LH'L>%;\<?6HM5D<W<4(=E15+MM.,G.!2KJC0(#*I= >2.H'K
M3L*YH6]W!= ^6_S#[R,,,OU!Y%3U5GLK>[*S8*R@?)-&<./QJ%;FXL0$OB)(
M^@N47'_?2]OJ./ITI#-"BD5E=0RD,I&00<@BEH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBJUW>QV@4$,\KG$<2#+,?\/?I0!89@JEF("@9)/05G
M_;I[PK_9\2M"PS]ID^YCU4=6^O3WIR6<MT5EU J<886Z'**?<_Q?B/PJ_P!!
M@4 4H-,@CN#<R[I[D_\ +64[BOLHZ*..@Q5VBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHIK.J?>8#ZF@!U%5VO;5>L\?_?5(-0M
M&Z7$?YT 6:*C6>)_NRH?H:DH **** "BBB@ HHHH *S]1O);8QI %WN>2W(
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MI&:UG+8NTVGC*,<O:DX4^I3^Z?;H?UJW:W<5Y&7B)RIVNC##(WH1V-3U2NK
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M*F5: $5*<5XIX%(U(9 XJNXJR]5W-,1 RU#)@(Q]!4['-4[Q]L14=33$8$Q
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MZ'OMZ@?TJS-XDLIQO5+A@?2(UF2ZM;?;E<K*J/'MR4/4'_Z].ZT9$5*TH/\
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MKW4':1%G7G_@)_D/SJ_0 445#=R&*SFD! *H2"?7% %72LRBZO"V1<S%DYR
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M"-".Q;N?89Z=JY?4-5N[SY9+J0*1CRX"8U_,?,?S_"JCR-(5R $4855& !Z
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M.TK7?K9:?B_NL:L]QX;M].O;E?L4L"[9+@0;7_BRI('OS5N74-*N[1S=RP"
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MPDN.OL?0T*33M(&NJ-ZBD!'K2UH2<WXBM]5N9,VT*&"$"6-PP#!Q]>V.*P=
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MZ\9VD>-G;.T '\A74Z!\,H;=XI)T<1;OE\X89CZ*G]3CZ&JN%FR_\.](33M
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M_J@C&3!:,&<]FD[#WV]?KBF26-/MWM[-5EQYSY>7'3>>3^';\*M444 %%%%
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M2W!'RQCT']YO;H.2>P+";G5 -ADM;(YW'[LLH]O[@]^OTK0BAC@B6*)%1%&
MJC % #+6UBLX!%$,#.23R6/<D]S4U%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 C*KH4=0RL,$$9!%9PT^:QV_P!FR*L(SFUD^Y_P$]5^G3VK2HH
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M"#]0: 'T5GC2(8E(LY9K7T6-\J/^ G('X8I?+U2(';-;S@8P'0H3^(S_ "H
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M]"Q5[-&: *7V^Z_Z!-WT[21?_%T?;[KC_B4W?/\ MQ<?^/U=S1F@"E]ONO\
MH$W?7'WXO_BZ#?77.-*NO;,D7/\ X_5W-&: *'VO4V_U>F(O_76Y"_\ H(:E
M$NKL!FTL8_4BY=__ &F*O9HS0!1\K5FSF[LXQZ+;,Q'XE_Z4"QNC_K-4N#GJ
M%1%'X?+G]:O9HS0!GG1X'&)9KJ4>CSL1_.IDTRQ0AA:PEAT9EW'\S5K-&:
M  8 &*,49HH ,48HHH 7%&*,T9H ,4M)FES0 449HH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS1F@ JO/86ERQ::W
MC9R,;]OS?GUJ?-&: *7]EH@/DW-U#Z;920/P.12?9M2C8^5J$<BXZ3V^3^:E
M?Y5>S1F@"@)]53_6V%NX]8;DY/X,H _.E_M&53^]TV\C'J K_P#H+&KV:,T
M4?[7M@<.L\9_Z:0L/Z4HUBP(S]I4#U((_I5W-(0",$9'O0!6_M2PQG[;;CZR
M 4O]I6.<?;;;/_75?\:E,$)ZQ1GZJ*3[/ ?^6,?_ 'R* $%[:'I=0G_MH*0W
M]F.MW /K(*0V5HW6VA/_   4OV.U Q]GBQ_N"@!IU*P[WMM_W]7_ !IIU2P'
M_+W$?]UL_P JF^SP?\\8_P#OD4X1QK]U%'T% %0ZO98^64L?148G^5-_M5&^
MY:7C?]N[#]36A10!GF\O7R(M+E![&:5%4_D6/Z4@&L2=?L-MS_MS9_\ 0*T*
M* *']GW$F?/U&=@?X8@L8'TP,_K2C2+/),D1E)ZF5BV?SJ]10 R.&.% D2*B
M#HJC %/Q2T4 &***7- !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>hook-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $I YH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEI']69_Z"E,6I,.;NW7_ ';<_P!7J[10!2^S7QZZAC_=A7^N:0VEY_T$I/\
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MU^]&PPR_44 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBGB(>)8_M4;EA@(23N'&6)8YY]*](\$6-Y9^$Q>740.J7Y:\N%/&9'YV\^G
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M(A_V5[?7D^]688(K>)8H45(U& JC %24 %%%% !1110 4444 %%%% !1110
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M^\W]!^=78HHX8Q'$BH@Z*HP!3Z* "BBB@ HHHH **** "BBB@ HHHH ****
M"N3\3>(-5TG7-/MK.W66VF1GDV6[3R?*1N^56! P1R W/:NFO':.RG=)%B=8
MV*R.,JIQU(]!7C>D>+-4GF?5([Z*\O!;&+$Z+*(0"3NQ$!(HSSS&PQWH ](\
M.>++?Q&]XMO RBV;'F@[D?/X AO52,BLK2_%=_=7T222VTJEF\Z)+=U:)!GY
MBQ.".*U?!FK1:SX>CDB@6(1DQL8@/+<CJR$<$'Z"K2^&K%(K9%,P-N6*ON&X
MANJGCD'TK>C*G%-31R8FG6E*+I.UM_P_X)43QCILUO-(L<S^5M;8-C%@3@$
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MZT )';R7LBW%XNU%.8K<]%_VF]6]N@]SS6A110 4444 %%%% !1110 4444
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M **** "BBB@ HHIKNL:,[L%51DDG@"@!U,DECAC,DKJB+R68X _$UYO/XO\
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M=%:35I^FQ5[ "LJZUXV]Y%&UM)*),[I%("I]:T+Z6+4-*N)K.+_2X,L(E/+
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M4 %1W$GDV\DG]U2:DJGJC8L64=78+^9H ?81F.RB!ZD;C]3S5FD    Z"EH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4[PPQB&(_OY>A_NCN:ON
MP1"S'  R37.AVN9I+ENLA^4>BCH*:0FRI<>58+%=O&S06^3*JC)*GJ<=\$9J
M&;Q EPL,<[2HA3SV,;-N"'I\N,M]/>M<+D8(R#VK-NM'E="EK(@1F!99"P8
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M&H5X&/2E))XJR"1IL<+R:C)9SECF@+4JI2&/A"KR<?C7'^*Y\RMCI79!#M(
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M?Z#_ .O5ZJ5@#,TEXP(,IPF>R#I^?6KM !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "J*_Z%>E#_J)SE>/NOZ?C5ZHKB!+F!HI!\K?I[T
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MTER/N1^H!_B;Z=.]-&FM<?\ '_=/<+_SQ0>7%^('+?B36C&%C0(BA548"J,
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M>>U<_'I'B>/4=(O)](FG_LM(;=G:8$LC ^;A?XQ\PYS_  5KS$<I--X:BFU
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MYT?VI"O^NBN(?^ND+8_,9%7J* *\5_9SG$5U"Y]%<9_*K%0S6UO/_KH(I/\
M?0'^=5SI=AG*Q>7_ -<W9/Y$4 7J*H'3D!S'>7B?2<M_Z%FE^R3C[NIW'_ E
MC/\ [+0!>HK/^SWPZ:B/Q@7_ !IWDWW_ #_Q_C /\: +U%4#!?\ _000?]L!
M_C0+:[/WM3<?[D2#^8- %^BJ#6+O]_4KL_1D7^2THTRV/WY+B3_?N'/]: +;
MRQQ+ND=4'JQQ54ZM8A]BW*R-_=BS(?\ QW-*FFV"'*VL);U* G\S5M5"@!0
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M*XTZ.UW+ODVDR*@SO. ,#C^\P[54E\2RQVBN;4>:"V]2' VC'(^7(R3CG'-
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MX&.Y.1P!0!MT5B1:M=3!=\<<3"=4**VXE3GKD?CD5?TVXDN;7?(<L'9<XQD
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MJH"_E4U% %=["SDN/M#VL+38QYA0%OSI$TZRCDCD2T@5XAM1A&,J/0>E6:*
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MRJ(T (7;N[D?6IJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>hook-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- [T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKGO&YND\(W\UG>S6DL,9
MDWPX#,!_#GMGU'- '0T5YUK&H7<7B>[%K?7/]K)<B.WL1(2C6WV<L6\OH1OR
M=W7( SVJUX4U";[/J#:5/<ZS"D%M(HFNMQ\]@WFKO?[I VL5[$XP,XH [O(-
M%<3H^K>(%N-6V>&B^;UBP^WQ_*=B<?Y]:T_[8\1_]"L?_!A%_A0!T=%<I?\
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MKNC^*8-;UB:TM(9A!';)<+-+$T?F!F905# 94A<@B@#?HHHH **** "BBB@
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ML+-EFAE5P+HE;AO,C>/.X%N A&6)P3P,5I#P9J$D\]Y)&BW22(]FWVACY/\
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M& HP$7E!0&23'W@,CJ>.*[J49A<8S\IXYY_*O-?A]!]GU"UBDA\F9+8JT;:
M;9D(QP9R<MCWY;K0!Z;14%[>VVG64UY>3)#;PJ7DD<\*!6.WC3P^FG"^;4,0
MF4PX,,F\.!N(*;=PP.3D<#GI0!OUC:[_ ,?FA_\ 81'_ *)EIW_"3Z+_ &G!
MIPU")KF=5:-5!*MN!*_,!M!(!(!.2.E-UW_C\T/_ +" _P#1,M &SVHH[44
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M:V:QM=_X_-#_ .P@/_1,M &SVHH[44 %%%% !1110 4444 %%%(2 "2< =:
M/ -2\+>'M?\ VAI],N-/\RR>!WN<2N/,N-GF$Y!XP&7@<5[]'&L421H,*@"@
M>@%>*^#_ /2_'/A_7&^]K-QJ]X"?^>>8TC_#:@_.O;* "BBB@ HHHH ****
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M@^M.HH 0@'J,TM%% !1110 @ '08I:** "BBB@ HHHH **** "BBB@ HHHH
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M0!EV^E+H?C+X>:6HQ]ETJ[B/N0D>3^>:]+KB-=_Y*SX0_P"O2_\ _08Z[>@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M110 4444 %8VN_\ 'YH?_80'_HF6MFL;7?\ C\T/_L(#_P!$RT ;/:BCM10
M4444 %%%% !5;4+5[[3[BUCNIK5Y4*"> @/&3W7.1FK-8'C;5KK0O!>KZI9%
M!<VMLTD>]=PR/44 >6>"H]0U/XPW-G?ZQ?ZE'X?>Z*?:W#!2=L:'@#YB"^?H
M*]RKYJ^"GBS4M1^*&H>>(,ZNKSW3+'@[E!(V^@R3Q7TK0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYHL/$:2:T--336@LVEFM[:X#+MDDB^^-@Y4<-@]]IZ<98A?M'C#_ *!FB?\
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M_0,T3_P82_\ QFC[1XP_Z!FB?^#"7_XS715'/,+>WDF*.X12VV-2S'V '4T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\D CID]:ELO"D5CK2WJ7L[6L3O+;V9"[(I'7:S;OO'C. >FX^V.AHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y>Y\,7D^O-.M[$NF2WD5_+"8CYOFQJH #9QM)1">,\$=^
M(=9\!Z1J&I6MV-/#NUX9;IC/(,J4<$@;O[Q7I775POB_4KVWU&^>#5);3^S;
M".[@@0KMN)&D92'!&6'RJN!W?UQ0!J?\*_\ #/\ T#3_ .!$O_Q5'_"O_#/_
M $#3_P"!$O\ \573#I10!S/_  K_ ,,_] T_^!$O_P 51_PK_P ,_P#0-/\
MX$2__%5TU% ',_\ "O\ PS_T#3_X$2__ !5'_"O_  S_ - T_P#@1+_\5734
M4 <S_P *_P##/_0-/_@1+_\ %52'P]T4:X7.G9L?LZ@*;F0CS-QSQN],5U\X
ME,$@@9%E*D(SKE0>Q(!&1^->?0WVI7NEZ1:7>O3V[2MJ#S7D>R-Y&AD(0<@@
M#&3CT3TS0!T)\!>'&SOL"V6W#]\XQ[#!'%)_P@'AK_H'M_X$R_\ Q=:?AZ\G
MU'PYIE[<@">XM8I9,# W,H)XK2JI2E-WD[LBG3A3CRP5EY'-CP'X<!7&GX4
M@KYKD-GUR<FD7P#X:5@?[.SCD;IY2/R+5TM%-U).UWML*-*G&]HK7?S]3FO^
M$!\.%0&L"Q&?F,\@/Z,*4> _#B[=M@5PVX_OG.[ZY)KI**?M9\W/=W[B]A2<
M/9\JY>UM#F?^$ \-#IIQ'L+B4#_T*J>G> -'C>\-W89S</Y!-Q(VV,@ 8RQQ
MWK2\62+'I\);4KVT!DVK%8A?/N7(.V-20<<\_AR0,UR[ZCK<$PDO=5D6^T_^
MSX3:1E/+N6F($A88^8G+ $8P4X[U";3NMRY14ERM:'1_\(#X;(7=IY) QN\^
M0$_7#"E'@/PX"H&GX4 @KYKD-GUR<FNDHJE4FI.2>K(="DXJ#BK+96.:7P#X
M:5@1IV<<C=/*1^1:C_A ?#A4!K L1GYC/(#^C"NEHI*<E'E3T*=.#FIM:KJ<
MU_P@'AK_ *![?^!,O_Q='_" >&L\Z<3[&XE(_P#0JZ6BI+.8F\!>'GAD'V#<
MYRRYF<8..Q!'%5M-^'NA)I=HM[IY:Z$*"8_:93E]HW<[O7--\87=W97EO>VN
MK21K:R0&>U21 $B:3#.R$$R;A\H&1C!(R:KZ!J=_+K]C)+J,T_\ :)O1/:,5
M*6_DR;4V #*X^Z<]2:J4Y3=Y.[(ITX4X\L%9>1J?\*_\,_\ 0-/_ ($2_P#Q
M5'_"O_#/_0-/_@1+_P#%5TU%26<S_P *_P##/_0-/_@1+_\ %4?\*_\ #/\
MT#3_ .!$O_Q5=-10!S/_  K_ ,,_] T_^!$O_P 51_PK_P ,_P#0-/\ X$2_
M_%5TU% ')7/@;2;7[/<:59&.[AN89%?[1)PHD4MU;!^7=Q76UYCJ7CFZ.OZH
M+6YEB6#3;L6]L]LX DB9/WK$K@_QX&<8 [M74>%YIX]3U;36U&;4+>U,+17$
M[*SY=-S*64 'H"/3=Z8H Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX-\UC;LTDA+,L8D9F"H2!@X &23Z"F?\)IJ%]:326]A!:106R-<M<7.V2-Y
MV/+7;AL$#J1G. ,B@#J]4T32]:CC34["WO$C)9!/&&"DC!(S[4Q- T>*:SF3
M3+19;)/+MG$*[H5]%/85R-GXRUB'3+:WNK*T.HRV]K)"3<.WFK(K$DA4R7'E
ML2%!&#G. :SU\=7D\EMJI,L5H4MYI+5"&X\J[+J"1SDQ+Z=!TH ]0HK@[7QO
MK-V+>WCT:W6\N9HTB+S.L6UXY'R24!)7R\' P<@@TD?CZ]N(8;F+3+80(;5+
ML271#J\S[/W8V_.![XSVZ&@#O:*Y/PMXNNO$-WMET[R+>: W-O(K,?EW ;6W
M*!NY!^4D=1GCG,N_%M]96J:BL1N7N&NVBMS*(T 2:.%5/!]<Y[$GKV ._HKE
MU\4W-OX=U>^O[*);K3)F@>*&;*.P"E2&(& 0ZY)''-83^+];L+G5HYX;&6\C
MN0J6ZW#LBHMNCL5VH6.2><@8SR>E '<76D:;>WMO>75A;3W-OS#-)$&:/Z$]
M*6WTK3[2^N+ZWL;>*[N?]=,D8#R?[QZFN77QU-+#%Y.F![B>!+R& S %H&@,
MF[)& 0XV>F2#18^*KF\;3II L4OV_P"PW5JJNI7?'N4E74,I! ]B"3DYH [2
MBBB@ HHHH **** (GM8))A*\2-($:/<PR=K8ROT.!Q[5#I^F6.DVWV;3K."T
M@W%O+@C"+D]3@=ZMT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG.>@%/M_#6F64MI]CMH[:&UD:9(8E"J9"NW>?4A20/K["M>B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>hook-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &' D # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*V\9:Q.GVF.Y0PZ:+9;I'B :Y:5MK8],?T-2KXEU1],OH-0_TP7NCF_B%O&
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M:6UDW'.<#:< >@Z\5T=9GB.1(_#6IM(ZHOV6098X'*F@!GA?_D5-(_Z\XO\
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MB@ HHHH **** "BBB@ HI&95^\P'U--\Z/\ YZ)^= #Z*9YT?_/1/SH\Z/\
MYZ+^=%@N/HHHH **** ,#PC_ ,@V_P#^PK??^E$E0:1_R/GB/_KG;?\ H!J?
MPC_R#;__ +"M]_Z425!I'_(^>(_^N=M_Z : .FHHJ*YG6UM9KA_NQ(7/T S0
M!+17G:?%&:1 \?A;4G1AE6 ."/7[M=CX?UF/Q!HL&I11/"LN?W;]5()!!_*@
M#3KB+C7];D-U9!X+:ZDU9;&*0+N$2&$29]SP?SKMZS+W0--OX+F&XMPRW$HF
MD(.#O  # ]C@"@#A;?QKK-TKW0DA2+3/(2ZBV9^TF1RA*^G3(JQ:^(I9H9(?
M$42ZA97>G)J8CAASY2EL;,=\<'/L:ZL^$]%,]G+]B0-:*JQ ' PO*Y'?!Y&:
MJW?A_3=&T'6I+&W$336LFXYS@;3P/0<GB@#1\/2V$^A6LNF6K6UDZ[HHF39@
M$^GOUHUK6H-%M?.FCE<$'&Q<@$>OI3/"_P#R*FD?]><7_H JUJ.F6NJVXM[M
M"\6=VW.,FKI\O,N?8SJJ;@_9[]"AX?\ $<.O0 QQ2)(J@R97Y0>X!KE?$?CC
M4-*T_P 6"*WN'GL9"+:=(08XQY2-\QSZL?SKMM,T>RT>.1+*/RU<Y89SS5:\
M\-:??:?J]E,K^3JK%KG#<DE57CTX44ZK@YODV%1514TJKO(Y;2O'ERT=ZC6L
ME]<0--*Z@K&$BC"9QZ\MQ5O3_&=S)JDXFLV;3Y;JWABE# &+S84901WY;D^]
M5->^':RPB/2)##YSR^<S,V[]X%!Y!'R_*.*Z.U\)Z?;VR1'>Q6:"<MNQEXD5
M5/Y(*S-3$U:\\07_ (_ET72M4CLH8-.2Z^>$.'8NRX/MP*CLOB0LFE+=RZ=)
M(MM#$^H21L (2Y*@J#]X<9^AK7UOP1IVNZO_ &G-<7D%P81;O]GF*!T!)P<?
M4TEUX"T.ZGMG\J2**&..-H(W*QS+&<H''?% &=%\2K)[34;B6QEB6S<)L=P'
M+&3RP"N,KDD'/(P:WO#7B*'Q)937$431&&8PN,Y!. <J<#(P16;'\/-%C^W@
M_:)!>(4P\A/E N'^7T^8 _@*V="T.VT"Q:UMWEDWR&6225MS.Q[G\ * -.BB
MB@ HHHH **** "BBN2\>>)Y]!L+6RTY!+J^IRBVM(^I4G@OCN%SF@#9@US3=
M0UF\T:&7SKFVC!N%"Y5-W12>F?:E@\.:+;3)-!I=I'+&=R.L0!4^HJMX4\,6
MGA31EL;=FEE9C)/<2<O-(>K$UN4 %%%% !1110 4444 %%%% !1110 4444
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M]"6P4444AF!X1_Y!M_\ ]A6^_P#2B2H-(_Y'SQ'_ -<[;_T U/X1_P"0;?\
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MH/(MF'%E#U"#_:/&36+X0LY_'<VGZ_J*C^P+"-5TNT;K)*H"M,X^H( KU"@
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M@*;-X2@TO1=2GFN'O&BTU[6W\U1^ZB4,P7CJ<]_84 ;OA?\ Y%32/^O.+_T
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MM0FFM++PK89^W:[)]G)7_EG;C'FO_P!\G'XUV-K;0V5I#:VZ!(84$:*.R@8
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M=ZXG2=-N(M9A>[%J\PF)9UL'!/\ P+H* /1*I6^KZ?=W;VMO=Q23I]Y%//\
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MKOS'E\]B64YPFW&/U[5V=>>6]JH\3B<B8:<;G8ARN3("2,C&<9)H ]#HHHH
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M+ZQC6"RU"VE$+O<']Y*2 00QY(YKM^HS7D7B)[E/%UZTT\T>HK<)_9\:2Q+
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MYPLFX;!] !6U**LW(B;=TD=;:^'KW6KT:AXF*/&OS6^G+S'#[M_>:NL "@
M #@ 4M%9RDV4E8*XOXAZUIVG:08)D$]](K"",?PY&-QQV%:.I:]/<W1TO0%2
M>\SB6<C,5N.Y)[GVI8/#MKI.D7SN3<W<T;/-<3<L[8/Y#VK:G%0:E/[C.;<D
MU'[S!^&5K:7FF/JD@\R^5_*.]<>4 !@*.V1SFO0*IZ5&D>EVNQ%7,*$X&,_*
M*N5%:?/-LJG'EBD!&1BLR+1((;K[0MQ=F3C):=CD D@'VY/YUIT5FI-;%-)A
M1112&%%%% !7G3V5K>:^$_L,;3<%9V*N#DDX(/3H,D^]>@W!F$#FW5&EQ\H<
MX!/O64NN>1=PVNHVC6TTS;8V5@Z,?8]?TH UH84MX4AC&$084>@I]%% &?JW
MW+7_ *^4_K6A6?JWW+7_ *^4_K6A0 4444 %%%% !6!XI\6V7A.U@GO8II%F
M8JHB )!%;]>6_&W_ ) VF?\ 79_Y"M*,5*:BR*DG&#:+7_"Z- _Y]+W_ +Y'
M^-'_  NC0/\ GTO?^^1_C7A-%>C]4IG#]:J'OME\7=#OKZ"TCM;P/-(L:DJ,
M DX]:]!KY4\._P#(RZ7_ -?4?_H0KZK'2N/$THTVE$Z:%24TVR&[_P"/*?\
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M7;R#D;3GC. /;%)-X-DM]'OIM6GBN1:Z2;*V6-"OR)E@S<_>R%_*@#JO"_\
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MAIAW$?H/]JA+&^\5RQW&IQM:Z2!NCLMWS3>C2>@_V:ZF**.&)8HD5$4855&
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MZ&M@HHHI#,#PC_R#;_\ ["M]_P"E$E0:1_R/GB/_ *YVW_H!J?PC_P @V_\
M^PK??^E$E0:1_P CYXC_ .N=M_Z : .FJOJ%NUWIMU;(0K30O&">@)!%6**
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MHHH S]6^Y:_]?*?UK0K/U;[EK_U\I_6M"@ HHHH **** "O+?C;_ ,@;3/\
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M0;?_ /85OO\ THDJ#2/^1\\1_P#7.V_] -3^$?\ D&W_ /V%;[_THDJ#2/\
MD?/$?_7.V_\ 0#0!TU%%% !1110 50U;5H-'M8YIXYI3)*L4<<";G=CG  _
MU?K$\56^M76BM!H4D$=V[A6DE.-J8.2IP<-Z'M0!43QUHTCVH0W#+.$W.(N(
M2[%5$G/RDD$5'-XGT_7="U>*U$R.MC)*HF3;YD95@'7U7(-8<7@K5D46\<=G
M#:WR6RWJJ[$P^2V1L/?< .3WS3)O!]X=(OY=9:()9:2;*W%L[*9$3+!V]"<#
MCZT =GX7_P"14TC_ *\XO_0!6M63X7_Y%32/^O.+_P! %:U !1110 4444 %
M%%% !7GJQOX^\:?:/,#>&M#F*+'U6[NAU;T*IGCWJ[XZU>]N);;PEHF3J6J
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M=O\ \>\7^Z/Y5)7R3W/T-;!1112&8'A'_D&W_P#V%;[_ -*)*@TC_D?/$?\
MUSMO_0#4_A'_ )!M_P#]A6^_]*)*@TC_ )'SQ'_USMO_ $ T =-1110 4444
M %%%% !6=X@_Y%S4_P#KTE_] -:-9?B2,2^&-51BP!M)>58J?NGN* &^%_\
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MQ3H7LKW(KX=5K7=K'R]]GG_YXR?]\&C[//\ \\9/^^#7U#Y4?_/-?RH\J/\
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M*:$I@!4QD-D#Z8ZFO0#(@<(74.1D+GG%0VU_:7EM%<6]Q')#-_JW#<-]/RH
ML44SSHR@?S$V,<!MPP:4R(IP74'!."?2@!U%0VEW;WUJES:RK+#(,HZG((J:
M@#SSQ)H.K:YK=U;1:6+6SVN8KN-DS+,T10/(<[@%!P ![]JUO!^E7MG=W-S<
MZ>+!&M;:V$0927:,-N?Y>,?, ._%=;10 4444 %0W8W6<P\GS\H?W60-_'3G
MUJ:B@#R^+PU?W=G+/>Z!<6\QN8F6VM+B.,1Q(K!50@\X)R<XSGVQ7=^&[:^M
M/#ME;ZBVZZ1"'R<D#)P"1U(& 3ZYK5HH **** "BBB@ HHHH **** "BBB@
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MW=>-I!!.3WKU^B@#SZ\\,SW'@+PO9#2B9M-N+62:U++N4(</@YP>YZUR=SX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 8'A'_D&W_\ V%;[_P!*
M)*@TC_D?/$?_ %SMO_0#4_A'_D&W_P#V%;[_ -*)*@TC_D?/$?\ USMO_0#0
M!TU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!@>$?^0;?_\ 85OO_2B2H-(_Y'SQ'_USMO\ T U/X1_Y!M__ -A6
M^_\ 2B2H-(_Y'SQ'_P!<[;_T T =-1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 8_ANSN+&RNX[F/RV>_NIE&X'*
MO,[*>/8BHM-L+F#Q;K5[+%MM[A(!$VX'<54@\9R/QHHH W:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>hook-20211231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H Q(# 2(  A$! Q$!_\0
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M'8W.I>'[NSLWV3RJ%5@VWN,\_3- &GYB?WU_.CS$_OK^=8(\%Z)M&;>7./\
MGX?_ !I?^$+T3_GWE_\  A_\: -WS$_OK^='F)_?7\ZPO^$+T3_GWE_\"'_Q
MH_X0O1/^?>7_ ,"'_P : -WS$_OK^='F)_?7\ZPO^$+T3_GWE_\  A_\:/\
MA"]$_P"?>7_P(?\ QH W?,3^^OYT>8G]]?SK"_X0O1/^?>7_ ,"'_P :/^$+
MT3_GWE_\"'_QH W#(G]]?SK@+&?Q=_PGLHN)H_[(8^4LOE$ [?F^[NP,YQN[
MXKHO^$+T3_GWE_\  A_\:7_A#-$_Y]Y?_ A_\: .<M;WQ=_PGTB3/%_9#'RU
ME,;;3MYX7/!(.-W3BO0/,3^^OYUA?\(9HG_/"7_P(?\ QI/^$+T3_GWE_P#
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M*R17,<\;EC._W0WS#D^E '5T444 %%%% !1110 4444 %%%% !1110 4444
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MT 6ZXW2?^2I>(/\ KTM_ZUV(.1D5QVD_\E2\0?\ 7I;_ -: .RHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHY)X8CB26
M-#Z,P% $G:N4^'__ " ;K_L(7/\ Z&:Z475N[!5GB+'H X)-<U\/_P#D W7_
M &$+G_T,U:^!_(M?"SJZ***@@**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!DO\ J7_W37&?"O\ Y$X_]?D__H9KLY?]2_\
MNFN,^%?_ ")Q_P"OR?\ ]#- ';5YQ\22/[<T+G^"Y_\ 19KT.=S'!(X7<54D
M#UXKY"E\8ZIK_B>\EU.YD,CR-Y2DX$0!QM [<5K1BI5$F[">Q]5>&&4^&=-
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MDV.5_P!@GC/L<?6@#GO^$PUQ?WLG@O45M^I99HV<#_=S71Z3J]KK-F+FU\P
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M:<(@^QMS J1CY<>N:W/MTGAM?&&F:E;7$E]JDGGVGE0LXN#)$%V@@8&&!'-
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MPV/KBKM<'\)[-;3PM*K0".X^TNLI[DC'7Z5WE9U8J$W%= 3N@HHHK,84444
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M_H)KN: "BBB@ KS/Q;]NGUA9)X'CB=_)M@?XC[?6O3*Y#QQ_Q\:#_P!?P_\
M036-?#+$+DD[(Z,+5=.=TC6\+R22:#;"1&5E&WYN_O6E>VD-_8SVEP@>&9"C
MJ>X(JGX?_P"0':_[O]:TZ>'NJ4?1&=;6I+U/-?"OPNLK2*[.LPF:7SBL)61E
MQ&.AX/>NB_X5[X:_Y\7_ / B3_XJNHHKKEB*DG>YDHI'+_\ "O?#7_/B_P#X
M$2?_ !5'_"O?#7_/B_\ X$2?_%5U%%3[:I_,PLCE_P#A7OAK_GQ?_P ")/\
MXJC_ (5[X:_Y\7_\")/_ (JNHHH]M4_F861R_P#PKWPU_P ^+_\ @1)_\51_
MPKWPU_SXO_X$2?\ Q5=111[:I_,PLCE_^%>^&O\ GQ?_ ,")/_BJ/^%>^&O^
M?%__  (D_P#BJZBBCVU3^9A9'+_\*]\-?\^+_P#@1)_\51_PKWPU_P ^+_\
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M'RSD@<'< 2#^)KJ/$5O%:?#;5+>! D4>F2*JCL/+-=%!4Z7+*FFG>VKOHO\
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MO;Q]$25?S//)ITX<LW7C-MR6NEO0TKXEJ].*M;J)X?\ !^D>&)9Y-,BDC:<
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MK%F56<DAUDS\WOQ5,VUL/A/:ZHB*-8.IQR+,H_>&<SXQGKTR,4 >L_V!H_\
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M0!Z5>6=KJ5G+9W<2303+M>-N0PK,TKPGH^D3236]N[RO'Y1DGE:5A'_<!8G
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M+B*UAU1;>22-(W)1!C(Y]0/UK-\'>)]3O!I^G:E#$9VTE+UID8DOG@9]SU-
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M6R+3F03,GF,(WD'1V3.TL/4BNBKS:#X@:]?K86=KI%JNI7=U<VI5Y3LC,/\
M%GO3-7^(FI:/J4JW":8(K>9(6M1*6GDS@%QCA1D\ T >@:EIUGJ]A-I][&);
M>48=,XR*S=7\':+KCVDE[!*7M$,<+1S/&44]1E2/2O+IM2\40:]J5[;FW#OK
M,5MDS-]W&0F.@![UT=]X^\16UIJ6HQ:79-9:9>BSE0R'?*Q8+E?3!84 =,?
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M][/_ +^M_P#$T>9K/_/O9_\ ?UO_ (F@#2HK-\S6?^?>S_[^M_\ $T>9K/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME"0R;NQYS76.WAN4@R16+D *"T0. .@Z4^6;P_/:K:RBS>W7[L31@J/H,<4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &F-&.612?4BD
M\F+_ )YI_P!\BBB@ \F+_GFG_?(H\F+_ )YI_P!\BBB@ \F+_GFG_?(H\F+_
M )YI_P!\BBB@ \F+_GFG_?(H\F+_ )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI
M_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\
MBBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@
M \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/
M_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG
M_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H
M\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F/_
M )YI_P!\BBB@ \F/_GFG_?(H\F/_ )YI_P!\BBB@ \F/_GFG_?(H\F+_ )YI
M_P!\BBB@ \F+_GFG_?(H\F+_ )YI_P!\BBB@ \F+_GFG_?(H\F+_ )YI_P!\
MBBB@ \F+_GFG_?(H\F+_ )YI_P!\BBB@ \F+_GFG_?(H\F+_ )YI_P!\BBB@
M \F+_GFG_?(H\F+_ )YI_P!\BBB@ $48.1&H/TI]%% !1110 4444 %%%% !
>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>hook-20211231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F M # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  CUS_T'M2_[^"C_ (1ZY_Z#VI?]_!6'MJW_ #[_ !1T>QH_\_/P9O45@_\
M"/7/_0>U+_OX*/\ A'KG_H/:E_W\%'MJW_/O\4'L:/\ S\_!F]16#_PCUS_T
M'M2_[^"C_A'KG_H/:E_W\%'MJW_/O\4'L:/_ #\_!F]16#_PCUS_ -![4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]@.W_P#1\E '94444 %%%% !1110 4444 %%%% !1110 AZ&N2\ ?\>>M?\
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MV'K7=W-I!>(B7$8D5'615/3<.0??!YJ>@#@O!PL8-6=;;3O%\3O$07U<S-"
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MC90VPOMLT=S R#!:-T8;@>RMP/QKTY%*HJEBQ QD]30 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KC;?\ Y+%J'_8#M_\ T?)795QMO_R6+4/^P';_
M /H^2@#LJ*** "BBB@ HHHH **** "BBB@ HHHH 0]#7)> /^//6O^PO<?\
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M,J3*HR/4<T/J%E&J,]W JN,J6E4!A[<\T 6:*A%W;&#SQ<1&'_GIO&W\^E3
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M["]Q_P"RUUIZ&N2\ ?\ 'GK7_87N/_9:[*/^[5/^W?U)>Z.NHHHKC*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **Q]:U#5K-HTT[0FU)'4[V%TD.SV^;K7SOJ6B>+QXY&D*FIQ/<N
M9H[;[<6(BSD_.#CVS7KY=E2QBDY5%"RONGZZ7NK>9G.?+T/J"HKFWAN[:2WN
M(DEAD4J\;C*L#V(K$\/WNLNR6=]X>>PMXHL+,]ZDQ)'&,#G\:WG=8T9W8*BC
M+,QP /6O,JTW3ERMKY-/\FRT[GGVC^&-!M-3\3SV^CV,4MK,1 Z0*#&# N=I
M[=3^=8^A:KKGAS1='E.H_;K6XT2>YBLFMU41-$BE0&'S'.<'->I0VUF5FEAC
MB(NOFD=,$2<8R3WX %0C3-,M4MG^S6\26<9CA8@ 1(< @>@.!68SRRP\7>*5
MT^^FGN+IQ)IDETDES';*(Y!C!C$;$E.?XAV'/-6_$FM^(]-MH;2SUR[N+V*R
M-]<2)%;0JH8G:6,G&P8(VJ"?4UWUMX3\.V@N?LNBV$/VM2LQC@5?,4]C@=/:
MI-1\,Z'J[P/J6D65VT VQ&>%7VCTY[>U '#ZIINF>(M#\*ZUJ6E6,U_?W%M]
MHE,"DN#&Q(SZ>U;5Q:6\'B,Z=;Q16]EI^E/-!!$H55=V92P ] N/^!&ND-AI
M<$%E9M#;QQ0N/LL1P K*#C:/4#/2HKO1UN-:MM21U5XXG@F4KD2Q-SC\",CZ
MGUH \T\+^%[R]M/#ES;^%M,TH0-%</JD=R#-*@7D;57.6SSD]Z=:):W.E:+8
M:JP&C7&KWXN5=ML<CB1S&CGT)R<'@D"O6+>WAM;:.WMXUCAC4*B*,!0.@%57
MT32I=-DTZ33[:2RE9F>!XPR,2=Q)!XSDY^M '*?V1X7MEU_3-%=8)GLQ-/;V
MS'R86&[9(,?*CY /7/R@XJO>>([[5/ M]%/HUXJ3:))*U\=GD,Q@S@?-NZG'
M2NED\+V%MH%UI.C6]OID5R"LC6\04X;ACQU;;D GI6I_9]J=-.GM"C6AB\DQ
M,,J4QC:?;% '!>$?#CVM[:W%QHOA&&/R2/,L%;S^5QW&.03FG:7X;T63Q5J^
MJ6&E6=I#I2/9VY@A";I2F97..N 0@^C>M=+8>"?#.E7L=Y8:'96]S'G9+'$
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M=1117&4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5 UE;/>I>-!&;E$,:RE?F"GDC/I4]%--K8 K+\
M2?\ (KZM_P!><W_H!K4ILD:31/'(BNC@JRL,@@]0:0'D5KJ>N^&-%B>'5IKT
M2Z$;I(98D"0NI4 H !P W0D].:SI]3UG4M!U>RO-5N_L?V:&Y\Z6\M99$;S
M#@Q<!".<'IBO9UT^S4H5M808XS$A"#Y4/\(]O:H+?0=(M+>>WM]+LH8;C_71
MQVZJLG^\ .?QH \IN_%'B&+7;E+:^N-MC<Q6\,;75JD4J';RZO\ O&+@D@K[
M8K3N]5UF.+4;Q_$%Q;0R:R=.W%4\NSAR<N,C[V0%!;@;A7H9T'2#<P7!TNR,
M\"A89# NZ,#H%.,C%3MIUD\$\#VD#0SL6FC:,%9">I8=Z /*Y-4NQJ]G FIG
M6TTW5)!:W3;2TA^R._EDH,,0W&14?_"5ZMI^G6^H6?B;^V+F^TZ>YN+8K&5M
M&500ZJHRJJ205;KCUS7JEOI&FVD4$5OI]K#';L7A6.%5$;$8)4 <'!-0/H%A
M'%>FPMH+"ZND*O<V\"!\GN>/F_&@#S*YU_4='N;^.R\8R:I%_9\$K3R^4XM&
MDF"-)\H P%)8 ]/I5N;Q!>Z5)?6D'B=]3LK>:QD:]D:,F+S)=KQLR@#&T \]
M U=1X:\#1Z+>75W>7%K=RSPB#9#81VT83))RJ_>))Y)K?@T/2;:QEL8-,LXK
M27/F0) H1_JH&#0!YQKOB/5+R?55T?6XS#'J4<*K'=Q0M(GD!F2*1P5#;N3G
MK@C(KM?!.JMK'A:UNI+BXN)07C>2X1%<LK%3G82IZ=5X/6K[>'M&:S:S;2;$
MVK8S";==AP,#C&.!5VWMH+2W2WMH8X88QA(XU"JH] !P* ):*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***#P* /(
M_B!9V>O>+7M(_AY+X@NK*"-IKI;W[-A6W%5SQN'!_6NW\):-:VME!J1T%-'U
M"6V2WDMA('\J-"=J CC'?CKGFO-?%%HVO^(6U*;P;XK-ZT"+(+/4$CV*"0 0
M.F<9_&O4?!EN;7PE80FSO;,JA_<7TOF3)\Q^\W?_  H WJ*** "N-M_^2Q:A
M_P!@.W_]'R5V5<;;_P#)8M0_[ =O_P"CY* .RHHHH **** "BBB@ HHHH **
M** "BBB@!#T-<EX _P"//6O^PO<?^RUUIZ&N2\ ?\>>M?]A>X_\ 9:[*/^[5
M/^W?U)>Z.NHHHKC*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#Q?X@7VEZ'X\N+P^.K[1+ZYMHEEM[33_.!5<[2QZ9ZX
MSS7I/@N\^W^$=/NO[0N-0$B$B[N8?*>4;CABO;V]JX[QK%X<'BB6SDUV]L=:
MU!;>2,6D.\P21%O+DSCY<@LN">178^"HM/A\':8NEWTE]9F+?'<R?>DW$DDC
ML<D\=NE &_11TKR^R^*$DVL:N9[O2H[&P:Z*6HBE^TSI"#ED<G8>F<#D"@#U
M"N-M_P#DL6H?]@.W_P#1\E1>%?%^J7VHFRUZWL;=IM-35()+9VVI$QP5?=_$
M,CD<4W3+ZTU#XN:C-9W,-Q$-%@4O#(' /G2<9!Z\T =S1110 4444 %%%% !
M1110 4444 %%%% "'H:Y+P!_QYZU_P!A>X_]EK2\6ZS>>'_#EUJ=E8K>O;C>
MT1D*?+W.0#T%>6?#3XDO<ZO<Z;+96MM;W-S+>2W$UV%$8;' !'/2O7PF!KUL
M%5JTU=*W5=#.4DI),]OHK,_X2+1/^@OI_P#X%)_C1_PD6B?]!?3_ /P*3_&O
M-]A5_E?W%W1IT5F?\)%HG_07T_\ \"D_QH_X2+1/^@OI_P#X%)_C1["K_*_N
M"Z-.BLS_ (2+1/\ H+Z?_P"!2?XT?\)%HG_07T__ ,"D_P :/85?Y7]P71IT
M5F?\)%HG_07T_P#\"D_QH_X2+1/^@OI__@4G^-'L*O\ *_N"Z-.BLS_A(M$_
MZ"^G_P#@4G^-'_"1:)_T%]/_ / I/\:/85?Y7]P71IT5F?\ "1:)_P!!?3__
M  *3_&C_ (2+1/\ H+Z?_P"!2?XT>PJ_RO[@NC3HK,_X2+1/^@OI_P#X%)_C
M1_PD6B?]!?3_ /P*3_&CV%7^5_<%T:=%9G_"1:)_T%]/_P# I/\ &C_A(M$_
MZ"^G_P#@4G^-'L*O\K^X+HTZ*S/^$BT3_H+Z?_X%)_C1_P )%HG_ $%]/_\
M I/\:/85?Y7]P71IT5F?\)%HG_07T_\ \"D_QH_X2+1/^@OI_P#X%)_C1["K
M_*_N"Z-.BLS_ (2+1/\ H+Z?_P"!2?XUYOXM^,LWAO79;&#2K2^MP T=Q%>Y
M# ^N <&NG"Y=B<5/V=*.OGI^8I3C%79ZW16+X4UB\U[P[:ZG>V*V4EP-XA#E
M\+V.2!6U7)4IRIS<);K0:=]0HHHJ!A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIEA:V4!T6!S%;0K&I;SI!G"@#/ Y]J[VN-M_^2Q:A_V [?\ ]'R4 =E1110
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M+6C_ /@#%_\ $T?\(9X6_P"A:T?_ , 8O_B:VZ*/K-?^=_>PY48G_"&>%O\
MH6M'_P# &+_XFC_A#/"W_0M:/_X Q?\ Q-;=%'UFO_._O8<J,3_A#/"W_0M:
M/_X Q?\ Q-'_  AGA;_H6M'_ / &+_XFMNBCZS7_ )W][#E1B?\ "&>%O^A:
MT?\ \ 8O_B:/^$,\+?\ 0M:/_P" ,7_Q-;=%'UFO_._O8<J,3_A#/"W_ $+6
MC_\ @#%_\31_PAGA;_H6M'_\ 8O_ (FMNBCZS7_G?WL.5&)_PAGA;_H6M'_\
M 8O_ (FC_A#/"W_0M:/_ . ,7_Q-;=%'UFO_ #O[V'*C$_X0SPM_T+6C_P#@
M#%_\31_PAGA;_H6M'_\  &+_ .)K;HH^LU_YW][#E1B?\(9X6_Z%K1__  !B
M_P#B:Y_Q-\+="US[";.QL]/-O.'D^SP+'YB=U.T5W=%:4L=B:4U.$W=>8G%/
MH,BB2"%(HU"HBA5 [ 4^BBN3<H**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#RWQC=^)O#WC*?4-/\2>&;"SOH8HTMM9
MN9 2R9RRJ!QUZ@XZ9KT#0'U*30[1]7ELI;YDW2O9$F%LG@KGG&,5Y9\1XK?3
M/&<M^UQX1N9+VS2(VVOYWP!2V&3'\)R<^XKT'P#;6]GX&TFWM;^&_ACAP+B'
M[CG<<[?]D'('L* .DHHHH *XVW_Y+%J'_8#M_P#T?)795QMO_P EBU#_ + =
MO_Z/DH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'O%4>HG
MXEZG_9>G^&)6-E;F4ZZP)?E\-&.H Z'MTKTKPN+E?#=F+N+3HI]IWIIW^H')
M^Y[?UKSOQ_X7OM4\4S7<'@O0]50Q(/M-W?-%(V!TVA@.*[3X=R13> ]*DALK
M:R0QMBWMG+I'\YR 22>O7WS0!T]%%% !7&V__)8M0_[ =O\ ^CY*[*N-M_\
MDL6H?]@.W_\ 1\E '94444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,<
M*3Z"EI",@B@#P277?A3XM":KXT,::\P:*X2)KE54*Q50 IQ]T#\Z]D\*R:++
MX9L6\.A!I/EXMMBD#:"1_%SUSUIN@>&;#P_HMOID*"=(=Q$DR*6;<Q;G ]ZV
M$18T"HH51T"C % #J*** "N-M_\ DL6H?]@.W_\ 1\E=E7&V_P#R6+4/^P';
M_P#H^2@#LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KC;?_DL6H?\ 8#M__1\E=E7&V_\ R6+4/^P';_\ H^2@#LJ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC;?_DL6H?]@.W_
M /1\E=E7&V__ "6+4/\ L!V__H^2@#LJ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N.\3:5XSN+Z6ZT3Q5;:=9+'D6\FGI,<
M@<G<?6NQJ"\_X\I_^N;?R- 'D_@N7XB>*=#@UEO&=I! 975X6TN,G",0>>.N
M*]3TO4[+5[!+NPNX;N DKYL394D'!_45POPA_P"28)_UUN/_ $-JD^"Y!^&]
MN,Y(N;C/_?UJ .PA\0Z1<:;<:C#J5L]G;EA-.L@*(5ZY/;%59_&7AJVNX+6?
M7=/CGG4-'&UPH9@>G&>]>5>&S_Q97QA_UWN?YUH1>$="'P#><Z= US-I@NY+
MAU#2&7;NW;CS_P#6XH ])O?%?A_3=1CT^]UFPM[N3&V&2=0QSTXS6I+/#! T
M\TJ1Q(-S.[ *!ZDFO(X_"FB#X$37+V$4MU/IOVJ2YE4/*TNW.[>>?_K54U^>
M;5/!_P .M(NY7:SU.6(7@SCS0JJ0I/H<T >GZ=XS\-:O>_8]/UW3[FY[117"
MEC]!W_"K]YK&FZ?<Q6UY?6\$TJ-(B22!257ECSV%>>_%CPWHUA\/+C4K*QM;
M&]TPQRVDT$8C:-MZC ('3GI61XQLHO$?C?X?VNIJSPW5N[3Q@D"3"AMI]B0,
MB@#U?2=:TS7;5KG2K^WO(%<H9('# ,.V14U_J-EI5F]WJ%U#:VZ?>EF<(H_$
MTEAIEAI<)BT^RM[2-CN*01! 3C&<#OQ7G7BVWAUSXQ>&]&U)%FTZ&TDO!;R#
M*22Y(&1T.,9_"@#L$\2Z1KFC7\NC:K:WABA?<;:8,4.TXSCD5B?"*\N+OX:Z
M=<7EQ+-*6EW23.68XD;J36U>^'='LH[_ %.TTZWM[QK*2%I84";DP3@@<'IU
MKQ\7]U8?LT6WV1G5KBX-NY0X.QI6R,]LXQ^- 'L=MXS\,WFI_P!G6VO:=+>;
MMHA2X4L3Z#GDU?U36=,T2V%QJE_;6<). \\H0$^V>M>/ZYHFJZGX/.C:?\+#
M92QHIM+I+VV#PN""'R"#GUYYS74>(-4TVP3PW;:WX=;7/$\EO^XM$B61E;:/
M,;+?*HR.OM0!V>C^(]&U]'?2-4M+T1G#^1*'*_4#I4-YXLT#3TNFO-8LH!:R
M"*8R3!=CD9"GWQVKR_1I[H?'2P:7PU_PCSW.E2"6W66-_. 8X<^7QV YYXJU
MX3\.Z7K/Q:\;76IVD=X;2X188IU#QJ74[FVGC.% SZ4 >BZCXN\.Z3%#+?ZW
M86RSH)(O,G4;U/0@=Q[U>T[5M/U:R%[IU[;W5L<_O89 R\>XK@M9U70K3Q?+
MIFC>"QKFN06Z+.8HHU2WCQ\BEWX7CL*QOAG),OBSQ[;/I?\ 9*9BE_L\,K"%
MBC9QM^7GKQ0!Z%/XX\+6UE;7D^OZ=';W.3#(UPH$@!()'J,@C/M6Y!/%<P)/
M!*DL4BAD=&#*P/0@CJ*\C^"_A?1+[X>_;+W3+>ZN+R6:*5YT#G8'*A1G[H]A
MWYK&TS4KS2OV>/$(M)Y%-I=SVD+ G*1F10<'MPS?G0!ZY'XT\,RZI_9D>O:<
MU[NV"$7*[BWIUZ^U7=6UW2M!MUN-6U&VLHF.%:>4(&/H,]:Y_1? WA@^#]-L
M&T>REA6"*0/Y0#L^ =^[[V2><YK@KF\U"^^,_B"8^%6\1'3(H8+6)IXT6V5A
MN+ 2<$L<\B@#V#2]7T[6K07>F7UO>6Y./,@D#C/IQWJ[7E_@K2-<MOB-J.JM
MX7;P_I%Y9 2VXN(G1YU888*AX.">WKZUZA0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5QMO_P EBU#_ + =O_Z/DKLJXVW_ .2Q:A_V
M [?_ -'R4 =E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4R:/S8'CSC<I7/ID4^B@#G?!?A?_A$O#4>D-=B[VR2.9/+V9W,3
MC&3Z^M<Y;_#/4M-EO+32/%MW8:'=RM+)91VZF1-WW@DI.5!^E>BT4 <)I/PV
M32/ FK>&(M29TOFD*SM%DQANF1GYL>N1FMA?"NWX?#PL+SD6'V/[3Y?^SMW;
M<_IFNCHH YL>%,?#_P#X1;[9S]A^R?:?+_V<;MN?TS5*]^'MEJ7@G3?#]W=2
MB73UC^SWL V/'(@P' R?RKL:* //'^'6L:P]K#XI\73ZMIMM(L@LX[1+<2E>
MGF,"2WTXK<U?P>NJ>+]!UU;SR5TI9 (!'GS-PQUSQCZ&NGHH *Y7Q=X+3Q+/
M8:A::C-IFKZ>Q:UO(E#[<]593PP/I7544 <GI/A;6HI;N?6_%-QJDL]NUND:
MVZP0Q _Q! 3EO<FH-*^'EE:_#H>#]1G-[;D.&F5/+.2Y8$#)P02/RKLZ* .
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M6H?]@.W_ /1\E=E7&V__ "6+4/\ L!V__H^2@#LJ*** "BBB@ HHHH ****
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M: .4_P"%NK_T(WC+_P %G_V5'_"W5_Z$;QE_X+/_ +*O1E(90RD$$9!!ZTM
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MCW.>F:]KIJQ(C,RHH9OO$#!/UIU !1110!ROC[4=2L?#QCTNSOKB:Y<0N]E
M9GA0_><*.IQT]Z\=T6;3/[*T=-9M9TT*VFO8V;4H<(TI!V9SD%OZU]&5&8(3
M'Y9B383G;M&,_2@#F_ATDZ> =(6X656\GY1+G<%R=N<^V*ZB@# P** "BBB@
M#PW49OLOQ#O9[2?3[[5)[[RAIT^F#[3&NSB2.4_, /4<5/\ #Y;(^*M#6PC4
M:C%:7 U@QKA@^\X\W_:],U[1Y4?F^;L7S,8W8&<?6E6-$=G5%#-]X@<GZT .
MHHHH *X#XNI/)X1A".J6_P!MB^TO)&718\\EU[J.XZ>M=_2,H=2K $'J#0!\
M]02Z7MLSK$.FMX?B%['#<0VWE6MQ,1\KJG*JQ[8XSTKV+P EPG@71UN1(L@M
MQQ+G<!VSGVQ70&"(QB,QH4'1=HP/PJ3I0 4444 %>7ZGH>G:W\1;U+;2[.-]
M(M#<%XK=!)-<R [26 R<<=>]>H4T1HKEPJAFZD#DT >,?#E;$^*-%&FQJMY'
MIDBZN8UP1-OX\W_:SGKS7M--6-$9F5%#-RQ P3]:=0 4444 <#\6_+_X1>U$
M@C"_;HB7N03;I@GF8#JE>9Z>=)CLM,;6X[5M$7^T K[/]$:<GY3$". 1]WOZ
M<U]$.BR*5=0RGJ",@TTP1&,1F-"@Z+M&!^% '/?#]+E/ FCK="02BW7B3[P'
M;.?:NEHZ44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<?X^\3:IX:M]*;3;$W)NKZ."3E>%)Z#)')Z ]!78
M5S_BWPY)XET^VA@O?L<]K=1W44IB\P;D.0"N1D4 <XWQ%&F-JCWEO>7?DZG'
M8QP11H&0NH.!S\W/<TY?BM:K(RW&@:M;I#=K9W<CK&5MW8@+G#?-G(Z9Q4DO
MPX::>>9]4!>;58=2;$&!E% *]>^.O:G7WPZ^VP:K%_:6S[?J45_GR<[-FWY>
MO.=O6@"67XFZ5%KS:?\ 9;EK9+H63WP*>6LQ_AQNW8SP3C&:V_$WB-/#6G+=
MO9SW6YP@6-D0+[L[D*H]R:Y@?"RUC\3RZG#=6XM9KO[7)#)81O+OZE5E/(4G
MG&,^AK9\9>#CXJ&GO'>K;36,_G();=9XVX(^9&X/7@T <CK7Q-U+4;/PZ_AB
MSEC&J7C6\CR+&[*5X* ;MI)Z@YQBK.E_$Z\AMM2DUG29_,34OL-G'$8P9'P/
MD)+8!')))QS5W3_AFUBFBJVJ^;_9FI/?;OLX7S-W\. <#G/3\JBU#X6F_P#M
MR/JL9BEO_P"T+=);)9!'+C#!P3AU(XQQ0!;?XH6/]G65Q!I5_<7-S>M8&TCV
M&2.8 G!.[:0<=0<5<\:>)M4T'P0^L6>G,+SY,PRE6\K)P<X.#CV-5;'X=BSB
MT<?;H?,L;\WLAALTA20E2NT*O"@9Z\FN@\5: /$WAVZTK[2;8S 8E";MI!R.
M.] &1#X]B$&J_:=.N89]+LTN;B,LI)W G:,'&>*S[[XJVEF\H71-2N$@LHKZ
M9X=A$<3C.3EAR/05%J/PWU2]DO9(O$WV=M1LTMK[;9*?,*\ KEOEX^M66^'&
MZTU2#^TO^/[2X=/SY/W-BXW]><^E %BS^)6FRMJ'VVPO]/6TM%O0;A%S+">
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>hook-20211231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &I >4# 2(  A$! Q$!_\0
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M>.HD\(Q:KJDK323S.D*0IEY #P HI-=^(MM;>#I]8TZ*9IHY%C:%XR'C)/\
M$*XZX\(ZJ_AW1[V[TRZ)M)Y6GL[.7RY5#'@J:T;;PW*?!FLSZ=HNH6]Q<,CB
M.\N/,EF"G/X4 =?<^/-.L--L)IHKF2YNHA*+>*(M(J]R0.@J:\\=Z)9Z1;:D
MTLCPW+;(PB$L6_NX]:X#Q!H=W<ZQ9^([C2=6FMKBQ2!H;*?RYH'7LV.H-:^G
M^&I;2TT!;729[:);TSRQ3R>8R C[S'UH V9_BAH-J_ES+=)(NTR)Y1S&K=V]
M!5FV\>Z/JEY=V%K/+',D!FCE:,A9%Q]Y,]<5DWVB7DMUXRD%B6^UP*D!Q_K/
MEZ"JUUH>HG4/#+1V+!+?29(9<#&QRF /SH U6^(6E:3I]B+N>XNY[F(R1F.$
MEI #R<#I6@_CO1AH,&KQM--#.VQ(XHBSENXP.E<YX;T/4+?5=&EN;)E6&P>-
MV;^!B3Q65<V7B33-"1;2SNHX&OY7N1:A?.V$\%<]!0!T.H?$NQ;PGJ>IZ?#<
M?:[+"O;2Q$.A/0D>E7M+\4Q7\^GSS7;VXFLO/>WDCQTZL3VKA=$\/ZTUOXN9
MM+O(OMT"-;?:I0\DF!T)]?:MO^RM3UQ[1_L$MJ'T@VS>;_ X&,&@#H-.^(^@
MZEJJ6$;SIYK;(9I(BL<I]%-0S?%#P_!J3V;M<9BG\B:41'9$^<?,:YU$UW6[
M;2?#LGAM[$V$Z//>,PV )W3'<U;DT*_/@CQ):BP)N+F_9XTP,R+O7!_2@#TI
M6#J&4Y4C(([TM5[!&CT^W1QAEC4$>AQ5B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IAAC,PF* R 8#8Y I]% !1110 4444 %%%% !15.WU6PN[J6U
MM[N*2>+[\:MDK]:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I10>E
M 'B7PT_Y*[XEY/\ '_Z%7MM>)?#3_DKOB7_@?_H5>VTH@PHHHI@%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%'2LF3Q1H44C1OJM
MHKJ<$&09!H UJ*Q_^$KT#_H+V?\ W]%'_"5Z!_T%[/\ [^B@#8HK'_X2O0/^
M@O9_]_11_P )7H'_ $%[/_OZ* -BBL?_ (2O0/\ H+V?_?T4?\)7H'_07L_^
M_HH V**Q_P#A*] _Z"]G_P!_11_PE>@?]!>S_P"_HH V**Q_^$KT#_H+V?\
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M/AB9-%%%>P>6%%%% !111D>M ';?#6%;C4=2B8JNZV(W,.![UK0Z$FB^ ]>
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MX'O'AW_D7K#_ *XBM.LSP[_R+UA_UQ%:=>I'X4?GN(_BR]7^844451B%%%%
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M )_H/R-'_"H;W_G^@_(UZ]11_:%?O^ ?4J/8\A_X5#>_\_T'Y&C_ (5#>_\
M/]!^1KUZBC^T*_?\ ^I4>QY#_P *AO?^?Z#\C1_PJ&]_Y_H/R->O44?VA7[_
M (!]2H]CR'_A4-[_ ,_T'Y&C_A4-[_S_ $'Y&O7J*/[0K]_P#ZE1['D/_"H;
MW_G^@_(T?\*AO?\ G^@_(UZ]11_:%?O^ ?4J/8\A_P"%0WO_ #_0?D:/^%0W
MO_/]!^1KUZBC^T*_?\ ^I4>QY#_PJ&]_Y_H/R-=KX)\+3>%[.Z@FG24S2!QM
M[8&*ZFBLZN+JU(\LGH73PU.G+FBM0HHHKF.@**** "N+\5>"[C7]5%W'<1HH
MC";6![9KM**F<%-69T8;$U,-/VE)V9Y?_P *NN_^?R'\C1_PJZ[_ .?R'\C7
MJ%%9?5J?8]#^W<;_ #+[D>7_ /"KKO\ Y_(?R-'_  JZ[_Y_(?R->H44?5J?
M8/[=QO\ ,ON1Y?\ \*NN_P#G\A_(T?\ "KKO_G\A_(UZA11]6I]@_MW&_P R
M^Y'E_P#PJZ[_ .?R'\C1_P *NN_^?R'\C7J%%'U:GV#^W<;_ #+[D>7_ /"K
MKO\ Y_(?R-'_  JZ[_Y_(?R->H44?5J?8/[=QO\ ,ON1Y?\ \*NN_P#G\A_(
MT?\ "KKO_G\A_(UZA11]6I]@_MW&_P R^Y'E_P#PJZ[_ .?R'\C1_P *NN_^
M?R'\C7J%%'U:GV#^W<;_ #+[D>7_ /"KKO\ Y_(?R-'_  JZ[_Y_(?R->H44
M?5J?8/[=QO\ ,ON1Y?\ \*NN_P#G\A_(T?\ "KKO_G\A_(UZA11]6I]@_MW&
M_P R^Y'E_P#PJZ[_ .?R'\C1_P *NN_^?R'\C7J%%'U:GV#^W<;_ #+[D>7_
M /"KKO\ Y_(?R- ^%]V#G[9#^1KU"BCZM3[!_;N-_F7W(J:7:-8:9;VKL&:)
M I([U;HHK=*VAY,I.4G)]0HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HH)P,U@)JFK71DDL[.-H%8JK,V"<4 ;
M]%8D?B!'CLW95C\XL'W'A-O6M1;RV>W\]9T,7]_/% $]%007EM=*S03I(J]2
MIZ4V'4+2XE,4-Q&[CJJMS0!9HJN+ZU-QY N(S+_<W<T^XN(K6!IIFVHO4T 2
MT5G:5J@U43R1QLL2-M4MU:EEU:WBU-;$LN\KN))Z4 :%%4IM0B*[;::%Y=P&
MTMZU(^H6D4PADN(UE/\ "6YH LT52:^(U5+-5!!3>S>E37%Y;6@!N)DC!Z;C
MB@">BHOM$/[O]ZO[S[G/WOI2&\MQOS,@V'#<]* )J*KQWUK,LABG23R_O;3G
M%5K358I-/2[N62!')"[CU&<4 :-%0B[MS )A,GE'H^>*C;4K)(O-:YB"$XW%
MN,T 6J*B:Y@2#SVE018SO)XJBNK)-J<5K;E)8V0NSJ>E &G15>6_M(9A#)<1
MI(>BEN:JW&L6\&H?8]P+B,N>>F.U &E16=IVK07L2;I(UF?)\L-SBK+W]I'.
M('N(Q*>B%N: +%%037EM;MMEG1#Z$TL]U!;1B2>9(T/0L<4 345 ;RV%O]H,
MZ>3_ '\\5&^HV_V&6ZAD25$!.5.: +=%4;#4X+V*,"6/SF7<T8;)%2_;[3[1
M]G^T1^=_<W<T 6:*K3ZA:6V[SKB-"O4%JK6FM6ES9?:FE2./<5!9J -*BHDN
M8)(//25&B SO!XK(_P"$BADMXI8MI#S&/D] .] &Y14$5Y;31-+%.CQKU8'@
M4Q-2LY4D>.YC<1C+8;I0!:HJGINH1ZE;&>/&W<5QFDN]4M;590T\?FHI;9NY
MH NT5G6=_)<K S*B!X][C=ROI4=[K<$21_97CGD>41[5;IF@#5HJ&:Z@ML>=
M*D>?[QQ1'>6\L!GCF1HAU<'B@":BJBZE9O;RSQW$;QQC+%6Z4FGZA'?V0ND(
M"'/?I0!<HJJNHV3,5%U$6 R1N'2GQWEM+"TT<\;1KU8-P* )Z*AM[RWNE+03
M)(!U*G.*;'?VDLK11W$;2+U4-R* +%%4;#5(=0GN(X6!$+;<YZ^]7J "BBB@
M HHHH **** "BBB@ HHHH KWTOD6,\G]U#BL+3=!DDT^-GU"ZC60;FB1L#FN
ME(!&",B@# P* .;73[5]9\GR@;:R@^53TW'O5%G^SZ4B^6D<-Q.S%W4E8QVX
MKL=HR3@9/6D*(5VE5*^F* ..TZ15.IW#!YH0@C)BCV9!ZD"BQV"5X; +=*D+
M&.8)M>,^A/>NP41C(4+Z'%*J(F=J*N?08IW$<+8VQGDMH4NR\N_<ZK"0R'OE
MJ[><(MLQ=0P1<\C/2GA$4DJJ@GJ0*7*MD9!]:0S,\/QE=+$C+M:9VD(^IK'O
MY(6OM2.P?:-JQH-O//>NL  & ,"F[$+9*KGZ4 <ZUC%;7>FVT,0RBF5^.6('
M%8EU<&[1F+1I/+* T"PDLO/=NU=]@9S@9]:3RTR3L7)ZG%.X&1ID9?5KN;G$
M:K$N?IS6+JV\:W<O<7/DX4")7B+AQ[>]=D !T %(R(Q!95)'3(I <F\4D.BV
MUE$LDE\Q,L?&#$/4^E)=FV31[./#D32@SG'S$CKFNNVC=NP,^M5)K&&2]BN7
M;'E @+VYH$<[+);M)=76GQ%($@\HNJX#L?\ "G,+2ROH%U)"8([91#E<J6[_
M (UU01 NT*H7T H9$< ,JMCU&: .1CMOM$<,!A:*WN;@R+&>R#^51:E"+?6)
M=\RVL:(!"AAWAQWQ[UVFT9!P..E(R(Y!95..F13N,X_REL[;3EU#S&LV=G;<
MIP&[ CTJ[HJPW&J7]Y:PF./:$3*XR?6NB?RSA7VG/0&G!0OW0!]!2 XS?9M8
MSV\MN\NJ2N05*G<#GKGL*?*(T:_#C-W'#'"/EY.1@G-=?L3=NVKN]<<T%$)R
M47)[XI@<T=.AM;K3[>WAVR1QEV8#DG'K]:QHX'GS";HFZEE^>+R3O4YZ[O2N
M_P #.<#/K2!$#;@J[O7'-%Q&%8V<=YK5W<SIO\D+"FX<9 Y-1:C+:PZYOU)2
M8%B_<@KE2>_XUT8 &< #UI"J2 $A6';C-(9RDRV<$MG)/;R0Z<VY]C X#=LB
MHI56:"^DM86BM;ITAC&,;CW8"NP8(V%8*<] :7:N -HP.@QTI@<U+8QV^HQQ
M64.QX+9CD#J:I*;&XL[>TM8'?4&D!=BIW(<\DFNQ&S<2,9[TBK&')55#=\#F
M@1S'D12P:KJ,T?F-DHF1G  QG'UJO<?V>EI9QB0P%(]\<ICS&Y/4$>M=CM7!
M&!CN,4TI$R#*H5'3@8%(9B6<FWPW-,;41%D8E%'#>^*H6EE:WEQIL"H'@BA,
M[X& 6/'-=8-I7C!6D"(G15';@4 <D[BVLKR6*%5BGN-ARIVHH[XJM;L!<7DR
M.LT4=L5RD6T'/MWKM]BE2NT8/;%((T P$4#Z4P,_38XXM$C^R 9\K((&,MBN
M7>6QETO[,8'?4)9<294[E.>Y]*[D *,  "D\M,[MBY/?%(#DKM9!#?2*C[$V
M0ML'(0=<4L']GWNOV":? 1' A=I N ?;W-=;M7G@<]>*141?NJH^@H Q+FWB
MO_$($Z;XK>+.".,FLHHD=DDDD;+8R71:4*#@ =/PKL<#).!DT;%*[=HV^F*
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M$99.5/TJO-H$@AM/LTL0F@39^]3<K#Z5?TS3S8PMO=7E<Y8JN!^% & ]Q/\
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MV10B =54"F,S+SQ%/:S-\MN8T8*5WY8_2KD3M<^(B<G9%"/E]S5#_A&KLQI
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M[DTH96Z$'Z5QMO\ 9W_=ZK,P2&$-&A.,@]_>M+1 UOX>FN(M[EMSIN.3CM2
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M2RVL$\8CEA1T'12.!7/:2\S7CK'>3F;9F2*Y7&X^J^U:VD_;1:,;S&X$X]:
M+:6EO&J*D**J'*@#H:7[/#Y;1^4NQCEEQP36#9ZW<>9/)/ Y1IQ%$,UIW&JQ
MV]S-$R$^3#YK-G]* *>H:)<7DYVW,:P$8VM&"5'L:UK6V2TMHX(Q\B# K&C\
M2,YB!T^8><N8O5O\*E7Q"AM/,-M()S(8Q .230!IQ65M#*TL<$:.W5@O-/\
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>hook-20211231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (+ Z(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(_\ PF2^'_[+O-A@,WVW8?)X_ASZUY'\1M"CUCXC>#))KV\B;5%59#%)M\K
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M7,F_2H8HO+VC$H3IFL&+XA^,_$VI:G_PB.BV$ECI\K1,;N7$DA&<X /M78^
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MH.IKL+36=,O[A[>TO[:>9/O)'*&(_ 4NKZE%H^D7>HS([QV\32%4&6; Z 4
M1>(-(37M!O=*DE:)+J,QEU'(S7FEO\#C#:)8MXOU?[ !M-O&^U2O<8Z5 ?BO
MXJL+*R\0ZMX;@@\.WDXB1ED/G*">"17L,,JSPQS(<HZAE/L1F@#FY/ .@2>"
M_P#A%/LNW3=N  ?F#==^?[V>]<O8?!R);RS_ +8\0:AJFG6+[K:RF.$7'3=Z
MUZ?10!PVO_#ZXO\ Q ^N:+XBOM'O94$<HCP\; #'W3P*KVOPCT.+PE?:'<37
M%P]],+B>[8@2>:.C#T^E>@T4 <!H'PWN=/UNUU/5O$^I:JUDNRUBD;8BCMN
M^]^-1:I\*HKCQ)=ZMI6N7VE+?_\ ']!;D8ESUQZ$UZ)10!Y;-\.#X6^'6NZ3
MHUWJ$]Q>2"2$P\2*V1@9!Z>I],UZ%H=K<66@V%M=N7N(H$65B<Y8#GGOS6A1
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 =J\!<9\>_%+_KR/_H*U[]7-GP+H!U'5[\VK_:-6C\N[;S6^=?8=NG:
M@#PV?PEI"?L^6WB#[.3JI(D%R7.Y<.0 /08'2MRX2W\1?$?PAIGB1S+IG]BQ
MS1QROA)92F<GU)/\J]7?P/H4GA!/"[6KG2D&%B\UL]<_>Z]346M_#WPWX@TN
MRT_4+$O%9(([=U<JZ*!@#<.: ."O=*\*:)X8\>6/AS4'>46;M<68?='"<?P_
MRKE=RQV?PFD<A4$@RQ. /G%>SZ;\/?#6DZ!>Z+9V&RTO5*7!+DO(#ZMUIE_\
M./#.I>'+/0;FQ9K&R.;<"0AX_HW6@#@];NED_:'L#:.LLT6FRX53G#>6Q KF
MO">A>&]7^%_B/6]:9'UK?.9)Y)<21L!\@'/<_G7K^D?#;PQH>J6FIV%@T=Y:
MHR)*968D,,'=D\GGO56[^$O@V]U:;4IM+S+,29(UD81L3WVCC- 'C=Q_R0KP
MK_V&5_K74C0-/\1?'^^M-3A\^U334E,)8A7("@9'<<UZ,_PX\-/X>M-#-F_V
M"TG^T0Q^<V5?USG)ZUHV_A32+7Q/+XABMV&I2PB!Y-Y(*#'&.G84 >!V[7&@
MZ)\3[#2&EBM[:2(1HC']VK,0Q'X<4[QEH/A'3_A#H=]I30KJ4[0Y=)?GF)&9
M PSS@_E7LM]X-M=+L?$%YH&GPRZIJB9ECNG+1S$=B#TZFO&Y_ ^H:K8QZ/8?
M#Z32M0FN%>YOI)RT2*IYV9Z ^E 'T+H?_(!T[_KVC_\ 017C/CK6;^X^(KOJ
MGAW4K[1]*B86<4$>4>8C_6-ZX[?2O;K*W%I8V]L#D11K'GUP,5)+$LT3QN,J
MZE2/8T ?,.DZC/J'P#UW2HM/N4^RSBY-P1\C@RC*CW'>NB\7W=OJ/A[X:6UG
M(DD[W$+*J') & :]DT;PGHVA:%)HME: :?(7+PR,7#;NN<UDZ%\+_"?AS5_[
M4T_3BMTN=ADD+B//]T'I0!TVHC&DW8_Z8/\ ^@FOG_X7^!M1\1^'KN]M?%.H
MZ7&+V1/(MFPI(QS]>:^B)8EFA>)QE'4JP]CQ65X<\,:5X4T^2RTF!H8))3*R
MLY;YCU.3]* /#?AY;O:>'OB3;23-,\6Y&E?JY&\9/UK/L-+NO"G@?PS\0-%A
MW%89(-3A'21&9@&/^?2O=;#P'X?TV+5XK:U=4U8DW8,K'?G/3TZGI5VQ\,:3
MI_AD>'H;4'3!&T7DNQ;*L22,GZT >+^ -3T6T^#&MW&O6LT^ES7[I+'$N6 ;
M&#[8]:K:EH,W@SPPOBGP=XWE&GJHDCL[APP8'^$#IGVQ7M&B^"= T'0KC1;*
MQ']GW#%I896+ALC!ZUST7P4\#Q7BW TR1MK;A$T[%,_3- '!>,]6GN]4^&_C
M#4XO(LV"FX.#MC<L#G\N:]2\4?$+0/#%E9W-U.+G[5(%BCMR'=L_Q 5MZGH.
MEZQI#:5?644UD5"B$KPH'3'IBN9T;X1^#M"U./4+736>XB.8S/*T@0^H!XH
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MK(?4$=*SM*^&OAG1=5M=3L;.2.]ME*K,9F+,#UW9/S?C0!YM\,M!T>W^(GC
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M6C>/6HJ* )=X]:-X]:BHH EWCUHWCUJ*B@"7>/6C>/6HJ* )=X]:-X]:BHH
MEWCUHWCUJ*B@"7>/6C>/6HJ* )=X]:-X]:BHH EWCUHWCUJ*B@"7>/6C>/6H
MJ* )=X]:-X]:BHH EWCUHWCUJ*B@"7>/6C>/6HJ* )=X]:*BHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_7<3_S\?WLZ#_A-M>_Y_/\ QVC_ (3;7O\ G\_\=KGZ*/J]'^5?<'UW$_\
M/Q_>SH/^$VU[_G\_\=H_X3;7O^?S_P =KGZ*/J]'^5?<'UW$_P#/Q_>SH/\
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M;?YA1117E'T 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%']I8?O^ ?V)C.R^]'GE%>A_\*_T_P#Y^[G\A1_PK_3_ /G[N?R%']I8?O\
M@']B8SLOO1YY17H?_"O]/_Y^[G\A1_PK_3_^?NY_(4?VEA^_X!_8F,[+[T>>
M45Z'_P *_P!/_P"?NY_(4?\ "O\ 3_\ G[N?R%']I8?O^ ?V)C.R^]' 0?\
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M')>_"R:)\PR7'B8JPS]PL<?IFO:/#_AV+P]-J,D-Q),;VX,[!P!M/H,5B?\
M"N;0Z(=+_M"?8=4_M+?L&=V<[?I[U+INQ:J1O]QQ4VL7,U_X<T'5"1JNDZF(
MI,_\M(\?*_XBIO$/A^Z7Q+J^I3:,OB*PN&_UD,Y\VWP.5 '3%=YKG@BPUKQ-
MIVO-+);WEDP)V*")0.@-4M2^'<5SJ=S>Z;K>HZ3]K.ZXBMF^60]SSTH<&"J1
M.1O[RTU?0/!NC6=S=)I%]=M#<><^)"%_@)]C790>#?#N@^([.]L)VT^Z",BV
MRR<7 QW!ZU/-X T67PO!H.R588&\R*96_>+)U+9]:BT3P%!IFL1ZK?:K>ZM>
M0KM@>[/^J'L*:B[ZHES36C.8\'>'-,\91:QJ^OHUW>27<D6&D(\A1P !VKN_
M"EC9:;H,5GI^HM?VT3LJ3,^XCG[N?:L34OAQ;76HW-YIVL7^E?:SFYBM6^64
M]\^E=+H>B6?A[28=-L(RD$7/)R6)ZD^YIPBT]43.2:T9PZ:MXMU?Q#XIM-/U
M2VMK?2I?W6^ ,3\N=OT]Z>OBW5-7\.:-=6VHVNF7-R72=3$99'9>/W:]Q5;3
M_"=_J?B[QA*;R_TN.>Y54EC7Y9XRO.,]?K6[<?#RQ"Z4VG7USI\NFH8XY8@&
M+J>N<]_>I2DRVX+^O(XC6->UGQ)\,Y;FXNECDMM4^RRE8]IF (VDCM]*Z%]4
MN](\<6$-ZT%T8="DN))A"%D8CH >P]JU(OAS91>&;[0_M]RT-U<_:A*P&^-_
M7WJY;^#(DUFUU.[U">[E@L&L6$B "56[GT-"C('.&QQFA>/]<O+_ $RXD=[J
MWO)]DUHEFRB!">")/XL5,WB/Q==VOBN]M=2MHK?1;J0(K0 EU7G;^7>NJT;P
M4^B74'V;7+XV%NY:*R(&T ]B>I%/M_!5O;Z9XBLEO)676Y7EE;:,Q%AC ]:?
M+*P.<+Z(XW5;K5M<\3^"K^&_%M]MM_-1-F1&V/F^N:=J/C77K/Q%=6UYJ$>E
MK'<"."&XM2T4L?=C(.E=5<^!(9K30XX-3N+>?1XQ'#.B@EUQ@Y'O4.I_#]=4
MDN(Y]=OS8W+AYK5@&!QV#'D"ERR!3AU-CQ1KIT#PC>:Q&JRM#$&0#[K$X /T
MYKS_ %F/Q#_:7@^;6K^WNA<7:R+Y4>PQDC.WW&#7IM[I%GJ&BR:3<1[K22+R
MBOH .*Y:'X<*MSIL]QKU_=?V=(&MEE PJC^'_P"O53C)LF$HI%*/7?%'B%=:
MU32+RUL['3II(H[>2+<9BGWMQ[50U3Q]J]QINBZC:[].TZ\MC)-=+;^?MD!Q
MMQZ>]='>?#^":\O9++5KVPM;YM]U:PXV2$]<?W<^U6;WP9&\5E'I>J7>EI:1
M>2B0@.A7W4\9]Z7+(?- YK4?'M]:>$]'EBOK:>]U"X,)NX(BPC Y)V==V.U0
M1_$'5K+0-9DN$:ZEM3&MI=R6YA$A<XY4^AKHQ\.],308=-BN;B.>&X-TEXN/
M,$IZMCI^%6QX/2XT2]TS5M3NM26ZQF24!2A'0J!TQ1RS#FIG'ZA!KMOXW\(C
M6[Z"\9V9U>*/9M)'*X[CWKU4]37&6OP_$6K:;J-UKM]>SZ><1><HQM_N_P#U
MZ[.K@FKW(FT[6"BBBK("BBB@ HHHH *U!TK+K4'2L:W0ZL-U"D?[C?2EI'^X
MWTK ZC/HHHH$%%%% !1110!YIXVM]"TZ6_L;#3!?^)-=78(V.\IGC?S]T#K5
MJZTGP_X0\-:+?>(5^V7NEV_V>!"VX2.?X0O?ZU-?_#&WOM?NM9&N:C;W=P22
MT6!M']T'TIVJ_#2WUA-.%UK=^7L$VQ/P23G.X^]2,E^&NB7>E:-=W=[ +634
M;@W"VHZ0J>@QV-5M7U/6];\?GPOI.H+IL-O:_:)IMFYW/H/:NC\.>'V\/P3Q
MMJEYJ!E8-NN3DKCL*IZ_X+MM:U2+5;>_NM-U*-/*^TVIY9/0BGT \Q\5:QK&
MK^%KG3]1O%:XTK58H))(TPL^X_(WL1Z5N:A8:LWQ5T&R@U,+?'1BKWC1@G;N
MY('K74/\.=(?PO-H@FG!FF%Q)=DYD:4=&/\ A5RP\'PV6O:=K,NH7-U=V5H;
M0-*!^\4G.3[TK <2GCK6M(\(>(FNITN[W3K\6<%P4QD,<!B.^*N>&?$NM#Q#
M!937=WJ-G<VKO)+-:&'R)0,C'JM=(O@'2FM-9M9WEFBU6?SY >#&_8K]*=HW
M@M-+U#[;<:Q?:A*D)@A$YPL:$8Z#K19@87PVN_$GB&UBUO4M75[-9)8A;+&
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MI][J7[BO8TCXJADUO1]-M8?/;4(#<LX/$4>.I_E70UY?\)M,D>74-5FF\^*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(!&",B@!GGQ_WJ//C_O5#+;E>4Y'I4% BQ/(CH IR<U7HHH **** +,,J+&
M3@U)Y\?]ZJ5'6@"[Y\?]ZGJP89'2J\5OW?\ *K/04#"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M&57&&&15*6W:/E>5_E5ZBKC-Q,YTU/<RZ*N36P;YDX/I50@J<$8-=$9*6QQ3
MIN#U$HI55G;"C)J[%;K'R>6HE-1"%-SV(8;8M\S\#TJV %& ,"EHKFE)RW.Z
M%-06@4445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5%) 'Y'#5+10!GLI4X(Q25?=%<8854DA:/GJ/6@1'114L
M4!?D\+0 Q$9SA15N.%8^>I]:>JA1@# I:!A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU_[^"C^W]'_Z"=K_ -_!7@FU?[H_*C:O]T?E1];EV#_5NE_._N1[W_;^C_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)_JG_W3_*OE]_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN.@^E>$0_P#'Q%_UT7^8KW<=!]* "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#?1H^M5_Y5]X?5J/\ ,SQS_A%]?_Z ]Y_W[-'_  B^O_\ 0'O/^_9KV/\
MX2VX_P"?:/\ [Z-'_"6W'_/M'_WT:/K5?^5?>'U:C_,SQS_A%]?_ .@/>?\
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MPKKI&#:2D>A:N_\ ^$CF_P">"?\ ?1H_X2.;_G@G_?1H \__ .$4US_GS?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!#]T_0UYLWWF^I_G7I)^Z?H:\V;[S?4_P Z[<'U.7$]!*@O;R*P
MLY+J;=Y<8R=HR?P%3U1UB[FL=(N+FVMC<SHO[N(#.YNU=K=D<JW**^*].-K/
M,_FI)"ZQM"R_/N;[H ]ZT--U*WU6S^TVQ.T,496&"K#J#7"6VE7LFGKJ,D5Q
M/J:W\=W=AEQN4 C:GTS74>%;.XMM/OYKB)HFN[N2X6-NJJ>F:RA.3>II*,4M
M#:2Y@E?9'-&S8S@,":CFU&S@MYYWN(_+@4M(0V=H%>;^'K2YN?[/ELK*430W
MEQ)-<%OED3)&W\3@46FCZI=W4YDT]XO.L)HWC"[4$G4#KS]:7M6UL/V:ON=_
M9:Y97\QC@<E1 MQYAX7:??UJ[]I@\M9/.CV-T;<,&O,FT;59[*1+*UF@5;&W
M1D(^\5?YP!WJY!H5]);68FCF>WDU193&5V!8P,'C/ )H5278'"/<[BYU>PM'
MM4EN4!NGV0X.=QJTL\+R-&DJ,Z]5#9(KSU=%NH)K1WL))+>UUB5U4<E8F'!'
MMFK/AW3KVP\3(L=I,]J6D,DMRN'ASTYS\PIJI*^J$X*VYV6HZG::5 DUY,(T
M=Q&I/=CTJ87-N6*B>,E<D@,.*P/&MA)?Z1;>7;&X,%U'*R+UV@\USTV@W\^C
MZ[+:V\D=S-?!HP?O-!P< 4Y3DG:PE%-7N>@?:8/)\[SH_*_O[AC\ZKSZM8V]
MU:VTEP@ENL^2 ?O8ZUPJ:=JD.F,1:O+;7%Z&*M%@Q+C&Y4SWJ.PT:_B@T22>
MQF9[>6Y1BW+1[ON$^U3[278?(NYZ0DT4C,J2(S)]X YQ]:IIJ]I)JRZ;'('F
M:$S KR-H..M<!I7A_7!%<QYFCN5LY8G)7:'<GCYL\GWK5\-6$D7B6UN$TV:T
MB33A%(TG\4@/--5).V@."5]3N:***V,SI_"7^JN_]Y:Z2N;\)?ZJ[_WEKI*\
MK$?Q&=]'X$%<_KO_ !^Q_P#7,?SKH*Y_7?\ C]C_ .N8_G7-4V._!_Q3+HHH
MK ]<Q+SQ3I]CJ)LYQ,H618GFV'8KM]T$^]$'BK3+C5_[-1WWF1HDD*_(\B\E
M0?45SNNM>:QXMALKJTN8]%M)%D_=IG[3*.A)_NBJUAHNI+J6GZ:]I(B6>J37
MKW/\!C8?+@^M59'.ZD[Z=ST*6XA@QYTR1YY&YL9I)+JWB5&DGC17^Z68#=]*
MXKQIY1\8^'?/M)+N'RYRT$9Y;CT[USMWHNNCP_:6$VGR/FUF,;@;Y$).5CSG
MCCO1RCE6:;26QZ+?^)=-T^:Y@DFWW%M$LLD2#+;2<"M)+F&1D02()'4.$)^;
M!]J\MU#1+_;<R#3YGGN=)MXDD7J)%8;@3ZXJ6S\/ZX/$L9G,RR?;$G$X3(\H
M+C&[/3MC%'*B55G?8],%W;%BHN(B0"<!AG ZU5L=;TW4;$7MO=QFW+E Y;'(
M.#7 V/AV\B?1Y_L<JSG4[DW#$G_5-G&?;I5)- N8= LXQ8W<%W:3SAE$>^*3
M<3C<,]QWHY4/VLNW]:'K8(8 @@@]"*S[37-,OO/\B[B(@E,3DMC##J*3P\+E
M=!L5O+9;:<1 /"IR$]J\]_X1VX^WI:MILJI_;K7$C#A6A(XY]*$BYSDDFD>G
M+<0-(L:S1EV&X*&&2/6FM>VJ>;FXBS$I:0;AE0.N:\X;P]K \92E1*B'4!/#
M(B9 A';=G@=L5#:Z5JUUXEAFGTUX WVF.957"#<#MR<_-GUHY2/;2['HUEK&
MGZAI\-];W49MYCA')QDYQBG:EJEKI-E+=74@5(T+E<\D#T%>5?V!JRZ5I<:V
M4T<,-K+;R1"/>1,3][&1U'1JNZOH.I1PWL5Y97&HRSZ7%#:R*?\ 5NOW@?0T
M^5"]M.VQZ?;3I=6L-Q'G9*@D7/H1D5+5/28WAT6PBD4JZ6\:L#V(49JY4'0M
MA1]X?45V8Z#Z"N,'WA]179CH/H*UI]3S\?\ 9^?Z!45S_P >DW_7-OY5+45S
M_P >DW_7-OY5J>><4.@^E% Z#Z44 %9FK:W;Z08EEBFE>0,P6)"V%'))K3KD
M_&UWJ8MX-/TV"4"ZRMQ=1IDQ1]P/<T 7+CQEI4$,4X,TL#Q"=I8XR51"<9)K
M<^T0^0LYD41, 0Y. 0>E>>:O%/)::;X>LK*[@T185^U3+'F20#^#\>];'CX*
MOP_E6)&5 T(5 <$#<.* .J%S 8FE$\9C7@MN&!56ZUK3[,VHFNHP;M_+AP<[
MFK@YK#4574[BPTEX]/GDMU%O*"Q7:!OD"YYJO9:'>Q6^GR7.GSR);:Q)*48?
M,L3+P<>F: /1+'6+2^LENE?RHV<QJ)?E)(.*M/=6\3[))XU;CAF //2O)#H&
MNFT@:6&<PM'/&B;-Y1V?@XR,''0]JU-1\-W\JZN9H9KBX32[>."3)R9 ><>X
MH [Z+6+";4;JP2Y3[1:J&F4G&T&K<4L<R!XI%=#_ !*<BO-[C09WNM86>RNP
MUW:6[1SVXRVY0-WZ]171>"(;Z"RO([NT6&/SOW4@7:91CJ5[4 ;<FL6$6J?V
M:]RBW0B\TH3C"^M6/MEKM#?:(MI.T'>,$^E<-XMTFXEU^_N8;&27[3I+0QRH
M.DN[_"L_6?#FH1P:1]FMY!;#3O*=%3>1.>Y&>OO0!Z6]Q!'(L<DT:N_W5+ $
MU5M]8L+JZO+:&Y0R69 G!.-I-><:_I.MND=J;.666"W@V7"+EY"I^;+9XQZ5
M+J6@ZD;C6UM;.1&FNH+C>HR)(@!N'OSSB@#TS[1!Y(F,T8B/1]PQ^=5=*U6V
MUBWEGM22D<S0MG^\O6N!@T748;:PN;FWN+K3EU%YI;,+L(0K@$+GIGM72> [
M*>PT*YBGMGMR][+(D;]0I/% '44444 *G^L3_>'\Z[FN&3_6)_O#^==S0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (?NGZ&O-F^\WU/\ZZG4?%:6.KRZ9#I.HWT\48>0VT88*#TYS6
M3_:=M_T)FM?]^1_C710K*G>YC6IN=K&71FM3^TK;_H3-:_[\C_&C^TK;_H3-
M:_[\C_&NCZW#L8?5I=S+S[T5J?VE;?\ 0F:U_P!^1_C1_:5M_P!"9K7_ 'Y'
M^-'UN'8/JTNYC06\-K%Y4$:QQY)VKTR>M2Y]ZU/[2MO^A,UK_OR/\:/[2MO^
MA,UK_OR/\:/K<.P_J\NYEY]Z,^]:G]I6W_0F:U_WY'^-']I6W_0F:U_WY'^-
M'UN'87U:7<R\^]&?>M3^TK;_ *$S6O\ OR/\:/[2MO\ H3-:_P"_(_QH^MP[
M!]6EW,O-&:U/[2MO^A,UK_OR/\:/[2MO^A,UK_OR/\:/K<.P_JTNYEY]Z,^]
M:G]I6W_0F:U_WY'^-']I6W_0F:U_WY'^-'UN'87U:7<R\T9]ZU/[2MO^A,UK
M_OR/\:/[2MO^A,UK_OR/\:/K<.P?5I=S+HK4_M*V_P"A,UK_ +\C_&C^TK;_
M *$S6O\ OR/\:/K<.P?5I=S3\)?ZJ[_WEKI*Y&U\0_8@PM_".MQA_O8A'/ZU
M/_PEUS_T*VN?]^!_C7'5FIS<D=5./+%)G3US^N_\?L?_ %S'\Z@_X2ZY_P"A
M6US_ +\#_&H)O$1N'#R^$M;9@,9,(_QK&2NK'30J*G/F9#13O[;3_H3]:_[\
MC_&C^VT_Z$_6O^_(_P :S]FSN^O0[,3)]:3-._MM/^A/UK_OR/\ &C^VT_Z$
M_6O^_(_QH]FP^O0[,@>V@DN(KAXE::+(C<CE<]<5+DT[^VT_Z$_6O^_(_P :
M/[;3_H3]:_[\C_&CV;#Z]3[,3)]:3-._MM/^A/UK_OR/\:/[;3_H3]:_[\C_
M !H]FP^O0[,;DTN3ZTO]MI_T)^M?]^1_C1_;:?\ 0GZU_P!^1_C1[-A]>AV8
MVC)]:=_;:?\ 0GZU_P!^1_C1_;:?]"?K7_?D?XT>S8?7H=F-S1DT[^VT_P"A
M/UK_ +\C_&C^VT_Z$_6O^_(_QH]FP^O0[,3)]:3)%._MM/\ H3]:_P"_(_QH
M_MM/^A/UK_OR/\:/9L/KT.S&T4[^VT_Z$_6O^_(_QH_MM/\ H3]:_P"_(_QH
M]FP^O0[,0?>'U%=F.@^@KC?[;3_H3]:_[\C_ !K2T[Q4E]J\6F3:3J-C/+&7
MC-S&%# =><U<(N)RXFO&K:W0Z"HKK_CTF_ZYM_*I:1E#J589!&"*LY3A1T'T
MI:Z[^R;'_GW7\S1_95C_ ,^Z_F: .1HSCH:Z[^RK'_GW7\S1_95C_P ^Z_F:
M .2R?6H;BV@NX3#<1++&2"589&1TKL_[*L?^?=?S-']E6/\ S[K^9H Y'./P
MHS[UUW]E6/\ S[K^9H_LJQ_Y]U_,T <CGWHS[UUW]E6/_/NOYFC^RK'_ )]U
M_,T <CGWHSFNN_LJQ_Y]U_,T?V58_P#/NOYF@#D<X[T9]ZZ[^RK'_GW7\S1_
M95C_ ,^Z_F: .1S[T9]ZZ[^RK'_GW7\S1_95C_S[K^9H Y'/O1FNN_LJQ_Y]
MU_,T?V58_P#/NOYF@#D:*Z[^RK'_ )]U_,T?V58_\^Z_F: .23_6)_O#^==S
M5,:58@@_9UX]ZN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '-:?_R4#6O^O6*K!NI\G]ZW7UJOI_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#FM/_Y*!K7_ %ZQ4X]3]:33_P#DH&M?]>L53&VGR?W3]?2MJ+W,JBV(
MJRO$VD/KWAN]TJ.987N4"B1AD#G-;7V:?_GD_P"5'V:?_GD_Y5M=&=F</XC\
M IKEJQCOY(+QK>&W+=4VICM[XJQXXTV[N? DUA9I)<7 \I5VC+'##FNP^S3_
M //)_P J/L\XZ1/^5*T1ZG 7/@G5+Y;V\EU.%-0NG@/R*1&8X^B-WY[U':>
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MI:0E-I]3ZUT_DR_\\V_*CR9?^>;?E1J/2][F'X4T23P[X<M=+EF69X=V9$&
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MI/[?L/6;_ORW^%&DD_:]6_Z_#_Z M:F3ZT 9?]OV'K-_WY;_  H_M^P]9O\
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M?&]['J6H3Z="7:]U"T@1+A_E021YX':NP'@'1)+.Q@N86E>VMTMF=6*^<B]
MP[BK3>#]%:[:Y^S;9&N([GY3@!T&%_(4 <O!X]U:>6'21:VPU=]4EL#(6_=
M(-Q;\1VKHO!.OW?B/1KFZO8HXYH;R6V(C.5PIZU3U[P1'=VQ_LH0Q7#WQO9&
MESDN1@[2.E:/@[PW_P (MH)L#,)9))WGD8#C<QY H WZ*** "IZ@J>@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .$.B:W:Z7=:<ND7$K7L=N?,7&V/9+E@WOCFFMH>LR>)HI_[*N8Y%O)C+(B
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M1CJ*[S[;JG_0)_\ (PH^VZI_T"?_ ",* .4?P7>)IVIP0P6X>>.U6'#9QY;
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MD;HIH;2!)O8914ZVCGJ0*E6T7^)B:AU(HT5&;Z%.E )Z FKZP1KT7\Z> !T
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M2$S.X6-5WEB> ,9S7/\ _";Z+)8WUS;S/(;6%IBGED%U'=?4>XH T/[2O/\
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MBN@;I25QCY21U /0FG:_JTFD6"200">ZFE6&",G +,>Y]!0 [^TKS_H$7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCC*"+8Y(7:!CWK$ET2^>ZDDQ&5.Y>6ZJ>@_2IIM&NIH& *0LVYMD9X!(Q@4
M;):VEA9R8GB_B)P1QZTGG6@5#OAVO@+R.?I69#I4\.D2P85Y96!9&;C'H"*2
MWTNYBDBWPP2+C!R?]5]/6@#48VDCLK>2S)RP(!*^].26 QF2-X_+!Y93Q6%#
MHM[Y\KS%/WB[6.[[PW9/Z5;FTR9=/N(+<(IDFW!0<#9Z4 :1NK<1JYFCV-T;
M=P:;)=P1.J-(N]B %!YYK(@T69;;9,L;,%8*IZ L>?R%26^E3QWL+.D1CB??
MYV?G;C % &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9F
MD_\ 'UJW_7X?_05K3K)%CJ5O=W<EK<6PCGE\W$BDD' ']* -".TMXKB2X2%%
MFD^^X')J:LSR]:_Y^++_ +X-'EZU_P _%E_WP:;;>XDDMC)U[PM=ZEJ,]U97
ML4"WEN+:Z66/?\@/5/0UHVNA+:ZW!?B8M'!8BTBC;DCG);/KVJ7R]:_Y^++_
M +X-'EZU_P _%E_WP:0RMK'AR/6)96DD5$:!HT"KR'/&\GOQQ4_A_2'T>WG6
M69999Y3*Q484< <#\*=Y>M?\_%E_WP:/+UK_ )^++_O@T <AHWA#5KS2+>#4
M[I8K>!IW@M_+^='?<H+'N,-FM>]\%K?6UI!+=X2#3_LF57DME2&_-1Q6SY>M
M_P#/Q9?]\&D\O6O^?BR_[X- &!-X/U'4_.GU;4X9;LJD<311%55%;)R/4UO:
M_I+ZQ8Q1PSB"YMYTN8)&&0'7ID=Q2^7K7_/Q9?\ ?!H\O6O^?BR_[X- &=#X
M<OI+JWO-0U))[E()HG*QX7YQV]A6,GPZ>WD@:"YLVS!%%<//;[VR@P"F>G%=
M5Y>M?\_%E_WP:/+UK_GXLO\ O@T 95OX9U"SO;F.VU-(]+GDDF:'R_G+N.1G
M^[GFL*\\$7^D:3':Z-< H]Q!*8PF0DBMEI/H>XKLO+UK_GXLO^^#2^7K?_/Q
M9?\ ?!H P3X0U 2#4EU*+^V_M!F,QC/E$8QLV]<8J-O LLL3/-J"M=3><]PX
M3AGDQR!V "BNA\O6O^?BR_[X-'EZU_S\67_?!H Q+[P=/<7#7$%\D<PBMDCW
M)D PD\GZYKI;VV:]TVXM2X5IHFC+8X!(QFJOEZU_S\67_?!H\O6O^?BR_P"^
M#0!AQ>"7CTVYM/MJDSR0/NV=/+0+C\<4DW@AY=.L[7[:H-N+D;MG7S1C]*W?
M+UK_ )^++_O@T>7K7_/Q9?\ ?!H Y\^#-0-Q<1#5(AIMT\3W$7E_.=@ PI]\
M4YO!#DA!>IY+FX292ART4O8>A'K6]Y>M?\_%E_WP:/+UK_GXLO\ O@T <\_@
MS4;Z$Q:GJD4JP6S6UIY<6-H/&YO4X&*ZZ&W$=E';,=P6(1D^O&*I>7K7_/Q9
M?]\&CR]:_P"?BR_[X- '-VW@C4(I$\[4[>6*WMIK:WC:'(VNP;YO7IBJZ?#J
M7^SR)+NV:[6Y%Q%&8RUNF!C;M/8UUGEZU_S\67_?!H\O6O\ GXLO^^#0 :#I
M;Z1I:VTCPM(6+N88PB9/8#TK3K,\O6O^?BR_[X-'EZU_S\67_?!H TZ*S/+U
MK_GXLO\ O@T>7K7_ #\67_?!H TZ*S/+UK_GXLO^^#1Y>M?\_%E_WP: -.BL
MSR]:_P"?BR_[X-'EZU_S\67_ 'P: "[_ .1ATO\ ZYS_ ,A6G67%97[ZG;W=
MY/ RP(ZJL:D$[L?X5J4 %%%% !1110 4444 %%%% &9?ZJ;*X\K8"=@?_@.>
M35:3772Y@C6)2KLH;GD!NGZ5K2VL$[%I8U8E=A)]/2FO8VKSB9H5,@Q@_3I0
M!7L;^6ZNIXW1%1 2N#DD>M4[?7VN'F(A"QHA=23V!Z?C6M!:06S,T,00MU(I
MBZ?:(6*P*-QR: *2:G//Y7DQQ@R+YF';&%[#ZT1ZFRERY7:V]TR>@& !^=7F
ML;9FC9H5)C^[[4CZ?:R;-\*G9]WVYS0!E3:S/B.0(J1%\-@_-P,GBEMM=EN%
MP(%$C$;26PH'N:U?L%KYS3>0GF-U.*;_ &;9^1Y/D+LSNQ[T ,TN>6YLA+,1
MO9VX'0#/%7:CB@C@7;$@4 8 %24 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !13E4&G;!0!'2;O8U+L%&P4
M 1;O8T;O8U+L%&P4 1;O8T;O8U+L%&P4 1;O8T;O8U+L%&P4 1;O8T;O8U+L
M%&P4 1;O8T;O8U+L%&P4 1;O8T;O8U+L%&P4 1;O8T;O8U+L%&P4 1;O8T;O
M8U*4&*CH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[
M&C=[&EIRKD4 ,W>QHW>QJ78*-@H BW>QHW>QJ78*-@H CHJ38*:PP: &T444
M /C[T^F(<9IV1ZT +129'K1D>M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M
M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0 IZ&H:E)&#S45
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M_P"?R7_OJC^U]0_Y_)?^^J7LV/V#[GK=%>1_VOJ&?^/R7_OJC^U]0_Y_)?\
MOJCV97U9]SURBO(_[7U#_G\E_P"^J/[7U#_G\E_[ZI<A7U5]SURBO(O[7U#_
M )_)?^^J/[7U#_G\E_[ZI<H_J<NYZ[17D7]KZAC_ (_)?^^J3^U]1_Y_)?\
MOJCE']2EW/7J*\A_MC4?^?R;_OJD_MC4?^?R;_OJE8KZA+N>OT5Y!_;&H_\
M/Y-_WU1_;&H_\_DW_?5%A_V?+^8]?HKQ_P#MC4?^?R;_ +ZI/[8U'_G\F_[Z
MI#_LZ7\Q[#17CW]L:C_S^3?]]4G]L:C_ ,_DW_?5*Y7]FS_F/8J*\<_MG4O^
M?V;_ +ZH_MG4O^?V;_OJBX_[+G_,CV.BO&_[9U+_ )_9O^^J/[9U+_G]F_[Z
MI<P_[*G_ #(]DHKQK^V=2_Y_9O\ OJC^V=2_Y_9O^^J7./\ LF?\R/9:*\9_
MMG4O^?V;_OJD_MK4O^?V;_OJCG'_ &1/^9'L]%>,?VUJ7_/[-_WU1_;6I?\
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6>U7_ )_Y_P#OJBCZTNP?ZN5?YT?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>hook-20211231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &' V$# 2(  A$! Q$!_\0
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MG>^$=!TMX(=1\4FWN)8$F\L6+N%##(Y!J9.,=QI2>QSW_"0:S_T%K[_P(?\
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M>D\-3P7.IV\\R*]C;^?E1E9%XQ@^^:Q*<73G\)-15J?QW1=_MC4O^?\ N?\
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MO/%OA[4IHX_M5]H4TMPRH )'"L-Q'3-<Y-JMYX7\&^'?[&D^R2ZA%)<W-RB
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M.?/;5]//U/GS[//_ ,\)?^^#1]GG_P">$O\ WP:^@Z*/[6?\GX_\ K_5U?\
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M,T"M<?(Q<=L=>F#]#1_:S_D_'_@!_JZO^?GX?\$\F^SS_P#/"7_O@T?9Y_\
MGA+_ -\&O?[>XAN[>.XMY4F@E4.DD;!E93T((ZBI*/[6?\GX_P# #_5U?\_/
MP_X)\^?9Y_\ GA+_ -\&C[//_P \)?\ O@U]!T4?VL_Y/Q_X ?ZNK_GY^'_!
M/GS[//\ \\)?^^#1]GG_ .>$O_?!KZ#HH_M9_P GX_\  #_5U?\ /S\/^"?/
MGV>?_GA+_P!\&C[//_SPE_[X-?0=%']K/^3\?^ '^KJ_Y^?A_P $^?/L\_\
MSPE_[X-'V>?_ )X2_P#?!KV3Q7XG7PM8VD_]GW5_+=7*VL5O;8WL[ D=2/[I
MJGI/C_2[[3]1N=2BFT5]-D6.[AU#"-&6&4Z$@[@>,4?VL_Y/Q_X ?ZNK_GY^
M'_!/)_L\_P#SPE_[X-'V>?\ YX2_]\&O9YO&?AN#2(=5DUJS%C.Q2*;S,AV'
M4#'.1CD=JB3QOH$WB*RT.&^26ZO;7[5 T?S(Z=L,."2,D>P-']K/^3\?^ '^
MKJ_Y^?A_P3QW[//_ ,\)?^^#1]GG_P">$O\ WP:^@Z*/[6?\GX_\ /\ 5U?\
M_/P_X)\^?9Y_^>$O_?!H^SS_ //"7_O@U]!T4?VL_P"3\?\ @!_JZO\ GY^'
M_!/GS[//_P \)?\ O@U)#%+',CO%(%4Y)V'@5[_5'6O^0#J/_7M)_P"@FG'-
M7)VY/Q_X!,N'U&+E[3;R_P""9/\ PGGAW_G];_OR_P#A17C-%;?V71[O^OD<
MO]OXKM'[G_F?15%%%> ?8!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D^*/^12UG_KQ
MG_\ 0#6M63XH_P"12UG_ *\9_P#T U4?B0I;,/"__(I:/_UY0_\ H K6K)\+
M_P#(I:/_ ->4/_H K6HE\3".R"BBBI&%,?H*?3).@H 91110 5P_B#P!!XH\
M<_VCJBR-IJ::MNGDW+Q.9?,).=N,KM/K7<5YOJ_Q'U.SNM9B@T4JFFZI;60D
M8A_.60KN  8'>0V5[=,\\4 ;-KX2.G>,8[RPMX(=*@T/^SH$#?,C^9NQCTQW
MS7-:=X'\2:)IU@UM;:=>7)T1](N89[@JD.79A(IVG<OS?,N!G YKH)OB7I=M
MITD]S97D%Y'?'3S8S-$C^:%W\N7V!=ISN+8I8OB1I][_ &0NF:9?ZA-JBS&.
M.'RP8S$0'#DL ,$]02#VZB@!/"/A"\\.:\TTLL<]NFCVEA'-GYV:+=N..PY&
M*RKKP;KWVW4IK>*SE5-?36[,23D+<?(%:)QM.PC&0W/..*UX_B/IC>(I]%DL
M[R&X1)GC+F,^9Y0)8;0Q9. <;@,U5A^*=A)IPO9=%U:WBEL6O[;S5CS<Q)CS
M-F&/*@YP<9'(H V/"&BWVE1ZM=ZB(8KK5+Y[Q[:W<ND&550N[ W'Y<DX&2:Z
M2LC3_$5IJFMWFF6B22?9((9I+@8\L^:"54'KG:,_0BM>@ HHHH D3[M-?[U.
M3[HIK_>- #:**YKQ=XGN?#;Z,EKICWS:C?K:$*ZJ5!!/&2,DX..W!S0!+XXT
M>[\0>"M4TFRV&YNH@B>8VU?O G)[< UAWWPLT>/PUK%CHRO!?:A L7VFYG>8
MX5@P0EB2$)'('K2>'OB(][>+::KI\T/G:E<V,%Y&@$!:,L54Y8MG:IR<8S3[
M'XKZ#?B[,,=P%BM)KR$EHR;B.+[VT!B4/<!PI(YH S[[P;K6MOJVJ:CIFG1W
M-S%:PQ:?#?.@'DL6\P3*H*OD_+P0 ,&DL?"/BFU@T.ZN)8KRXL-7DNO(GNMS
MK \93#3!!YC@DMDCG.*U+WXDV^GZ#;:O=Z%J<-O<J9(A*T*$QA0V_E\<YX7[
MQP>*6[^)FGPRD6ND:I?1)IT>IR2VZ)M2W?)W'<P.0!T'/ITH [;\:*Y-_B#I
M:V]U)';W,KPW5M;1Q(%W7!G"M$R<_=(8GG'W3Z5UE !4B?=J.I$^[0 ZBBB@
M#.\0?\BUJO\ UYS?^@&OE:'[J_05]4^(/^1:U7_KSF_] -?*T/W5^@KT<%LS
MAQ>Z+D7:KT-48NU7H:]&!XU<Z[P).8/%U@<X#.4/XJ1_6O<J^>]"G-MK-C,#
MC9.C?DPKZ$KSLQC[\7Y'?D\KPG'L_P"OR,"V_P"1YOO^O*/_ -"-;]8%M_R/
M-]_UY1_^A&M^N2MNO1?D=^%^&7^*7YA1116)TA1110 4Q^M/J-^M #:*** "
MO/C\,=.U;Q5KNJZ_;M/%=74<EM&ETZHT:QJ"'0$ _,#USQ7H!) ) +$#H.]>
M9V7Q-U:^_L25?#LH2_O+RW-M&5>201 [=AW@#!&&+8'!QQS0!=U+P9J=S8^/
M88$M@VN>6+/+XX6)4PW''(-4]4\#:[<G6=.MTL6L=<DM99KR24B6T,2H&"KM
M^?[GRG(QFM*Z^*VA6VF:=>K!=2&]@DN/(W1QO%'&Q5RV]@"0P("J23@X%:$'
MCJTOM9&GZ=IM]>Q_9(KUKJ$)Y:PR E6.6#$\= ": )_"VAW6D77B.2Z$8&HZ
MG)<PLC;B8RBJ-WH<@\5R6C^#_$VA6^A7,5GI]W=:.EU:"WENBJ312MN$JMM.
MUAT*D'([UIQ?%C1WL-7N7L;V-],ACGE@W1.SH[!005<@')Y4D$5=3XAV2W1M
M;S2]1L;A;FW@DCN%0%%GR(Y3AB-I8;3W!/(H U/!VA2^&O"=AI$\RS30*Q=D
MR$#,Q8A<_P (S@>PK<K+T77(-<_M!K:*58K.\DLS(^-LK)@,5P>@.1GU!K4H
M **** )1T%1GJ:D'05&>IH 2BBN1\1>+[S1_$]IHUMI;3I/83W;7)=<)LZ<9
M!P#C/?D8[T 2>.O#$GBRTTBR !MX=1CGNOWIC;R@K [2.<\CTK-U#X>VVG:7
M8CPQ;1BXLM3CU)HKN=B+ME!7:\AR0<'@\@$4S0?B=;7.C0W&N65S83?V2-3:
M4QCRID& YC 8M]XC ;!.14D?Q5T=])O+W[%>&6TD@22UC>*20B9MJ,I1RIYZ
MC.1W% &1=^ ]9GLYKY[.W.IW.I37P2SU)[9[/S$5,1RA"&)"_-E<'-:VA>&O
M$6E>(=!U"]DM;TQ:4^GWTBOY90F3S%95"X?H%[>M6-7^)%GH$UI'JVD:A:&<
M(9-[PYBW-M' ?+^IV X!YITOQ%L8-5N[632M16UL[];"XO\ :GDQR-@+GYMV
M"6 X'&1GK0!V5%<Q9>-["^ETJ"*UNA<ZA=7%MY!"[H&@R)"_/ &!TS]X5T]
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M"'/R.7?IV^XS8/A];PQV"&_D<6FKS:I@QCYS)ORAYZ?.>?:JFG?#*'3M,O\
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MB2SBF$D<DIDQL<$!E)X;^=;8\$VOVO5Y7NYC'J>G1Z>ZJJH45%9=P(XR=Y[
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MB@#E-4^)?@[1=3GT[4=<AM[N [9(FC<E3C/9<="*T?#WBS0O%4<\FAZC'>)
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M_*^V6T<_EYSMW*#C]:TJ "BBB@ K)\4?\BEK/_7C/_Z :UJR?%'_ "*6L_\
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M\:/^$NO/^A5UK_OTO^-=111RR_F#V]#_ )]+[W_F<O\ \)=>?]"KK7_?I?\
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M\BEK/_7C/_Z :UJR?%'_ "*6L_\ 7C/_ .@&JC\2%+9AX7_Y%+1_^O*'_P!
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M[M4]8_J=7]O?_GPN_P E_P#BJ/M[_P#/A=_DO_Q57**T.,I_;W_Y\+O\E_\
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MSC5C&HY):,VJ8>=2C&,G=IIZZIVZ/^O,X!8H9+#Q0+5%?2D :WXR@DQR5_\
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M&FK/UN[:WNO,X+RHY?#OB@R1JY2_9EW#.T[L9'YFM">"*"]\(+#$D:L"Q"*
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M4 %%%)SD<<4 +112*-JXR3[F@!:S/$7_ "+FH_\ 7N_\JTZS/$7_ "+FH_\
M7N_\J3V+I_&O4\Z;_4?#C_KJ/Y"O6*\G;_4?#C_KJ/Y"O6*RH;/Y?DCTLV_B
M1_[>_P#2Y!1116QY0$X&36<[#^WX#GC[,_\ Z$M72&**-IY^]EN15"51_;L
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M^12UG_KQG_\ 0#6M63XH_P"12UG_ *\9_P#T U4?B0I;,/"__(I:/_UY0_\
MH K!^(MB^H6FDQQVMKJ31WHE.D7,PC%\ C_(">"5^^ >/EYK>\+_ /(I:/\
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M%% &;!_R,5Y_U[Q?S>M*LV#_ )&*\_Z]XOYO6B3B@!:*** "BBB@ K,\1?\
M(N:C_P!>[_RK3K,\1?\ (N:C_P!>[_RI/8NG\:]3S8M+GX<J47R=P(?/.[TQ
MZ8KURO)V_P!1\./^NH_D*]8K*AL_E^2/2S;^)'_M[_TN04445L>45_-:.4*Q
MW1L/E;J2?3 [55E;9X@@./E^S..!SG<M3\6_S%F"9YX+')-0N/\ BH(>G_'L
M_P#Z$M-B+GEY1@<\MGK35&XYZ@DJ0W?'<5,5R<D\8Z4QU1@IVY ;(V]CZT#$
M2+87  "G 4=L?2G;#C[QSG/-/HI7 **** ,[7O\ D7=2_P"O63_T$U2\%?\
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M)^E+0 4444 9VO?\B[J7_7K)_P"@FJ7@K_D2='_Z]4_E5W7O^1=U+_KUD_\
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M\A0#S5^J=G<?:[*WN0NT31+)M],@''ZU<H S8/\ D8K[_KVA_P#0I*YOX?\
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MO^?D?O\ ^ =517*^7X\_Y[Z!_P!\2T>7X\_Y[Z!_WQ+1S^3#ZHO^?D?O_P"
M=57*_$#_ )%V'_K^M_\ T8*/+\>?\]] _P"^):SM8TOQ=J=M!;ZC/HXM_M43
MGR5D#9#@CK4SDY1:29T82C&E7A4E4C9.^_\ P#NZHZU_R =1_P"O:3_T$U>J
MCK7_ " =1_Z]I/\ T$UTT_C1X]7^'+T9X'1117UQ^<'T51117QQ^EA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5D^*/^12UG_KQG_\ 0#6M63XH_P"12UG_ *\9_P#T
M U4?B0I;,/"__(I:/_UY0_\ H J+Q1H5MKNCRI)8V]Y=0(\MDMPH9%GVD(2#
MP>3WXJ7PO_R*6C_]>4/_ * *YOQ1\/#X@\4V>JIJE[#;$&.]MH[R2(. ,*R;
M3PP/4="/>B7Q,([(Z?P[%?P^'-.CU58UU!;=!<B,*%$F/FP%XQGTXK@?B!;:
MKKOB#3K";PE_:6G6TLCI"^JQPB\!098+D-E">_J?6NW\.^&++PQ#/%97%],L
MS!F-W<M,00,<%NE4/$?P_P!#\4ZQ:ZGJ*W7GV\;1CR+AX@P/KM(/'MCWS4C,
M+2+.TL/ NM6MKX?CT-HY\2VB7@N3NPAR2"=IQCC\>];/B?2[W4_$FD&QNS93
MV\<LBW!BWKDX&,'C.,TESX:TKPOX+U*STFW:**5O.D+RM(SN2HR68DG@ ?A4
MUWK2#XE:=H?EG>=.ENM^3C&\+C'3M2E%25F:4:TZ,^>&_P!^^G4C_L+Q=_T-
MJ?\ @ G^-']A>+O^AM3_ , $_P :ZRBH]DO/[V=/U^KVC_X!'_(Y/^PO%W_0
MVI_X )_C3&T?Q6F=WBY?_ !?\:P_$'B?7+[6K[2]+N(K.TMW$,DI7,K-C)QZ
M#WKG+F^UW3(FU%-;EDR=[1W(QD]. >E:JA2]I&E*=IO979A+-9I-\L;)V;Y(
M[_<=G'I'B<:M<#_A*%67R8R[FR7D$M@8SQC!_.K8TCQ82 OBU"<XQ]A0$?K7
M)^%_%NJZQ?RQO9/)(\"@31 ]%)QUQW)SS7HX=VVH(F6 ]9 N,>O/;%.IA>1V
MD_Q9<<QJ-:*/_@$?\C!&A>*0C*OBN$MGE?L*<MU]:F70_%^T;O%D8/<"Q3_&
MNBE8A=\@<8/\'4GTJRIRH(!(QG)ZUDZ2\_O9:QU3M'_P"/\ D<K_ &%XN_Z&
MU/\ P 3_ !H_L+Q=_P!#:G_@ G^-=912]DO/[V/Z_5[1_P# (_Y')_V%XN_Z
M&U/_   3_&JU_H'BA[&:.?Q4CQ.NUU^PJ,@\=<UVM5M0_P"/&3\/YBCV4?/[
MV'U^JND?_ (_Y'GGB?1I-+3P5I\%VZW45T+:*X$&55L9W-V'3@=_PKH/["\7
M?]#:G_@ G^-9?C;Q-]D\;^$?#HMMQO;Q;@S;R-H3(QCOG->@4>RC_38?VA6?
MQ6>^\8O=WZKNSD_["\7?]#:G_@ G^-(=#\6@9/BY /\ KQ3_ !KK:Y/Q7XGN
M=,NXM.L(@;J10YDD'R*N?UJHT%+K^+(GF,X+FDH_^ 1_R$&A^+C_ ,S:G_@
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M14=D:%%%%(84444 %%%% &?KO_(!O_\ K@_\JNP_ZB/_ '1_*J6N_P#(!O\
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MY%,E@BG0I+&CJPP0PSD5)10!'!;PVL7E01)%'G.U%P*R-)_Y&7Q!_P!=(/\
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MC[-ILEJ'$\<+$'S),[E9MK8QP..M3)KVO>)?%-G9Z1J,>F:?<:)!J99[99I
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M@##@T[6K>X@B&JHUFL15OW"APPVA?J,;L_A5PV=_O4C57"\[AY"9/IVK0HH
MRVLM5VG;J_S?-C-NF/\ 9_+OZ^U07-CKX"&VU>-CYR;E>V4?N]PW8/KMSCWK
M;HH SVL[\E=NJN!GYLPH<C\JC:QU7/RZOWZ&W7IG_#/XUJ44 8@LM?6]M\ZO
M&]J0WG?Z.JL#CY=O7\:M?V?=/,AGU%Y(E97">4HR0<\D#Z5HT4 %4=:_Y .H
M_P#7M)_Z":O51UK_ ) .H_\ 7M)_Z":NG\:,ZO\ #EZ,\#HHHKZX_.#Z*HHH
MKXX_2PHHHH \X@T'5[WXB>+;FPUB\TD.;2,LMNLB3+Y(R5WC&X'C<.F>1706
M?@FQTZZ\/R6<\J1:,LZHC_,9C*,,SMZYR?<FL+7/$6K6A^(?D7C+_9=E!+9
M(I\IFA9B1QSD@'G-8VBWD^I75C%%\8XKBYF*'[(EM;%G/4H,<^U '9ZAX0N6
MUJ[U31-<N-(GOU5;U4A2592HPK@-]UP.,CVXJ)O %I::?I46BWUQIMYI8D6W
MNP!*S"0YD$BMP^X\GISR,5@6OC75=.^)^L66J2"3PZUW#8P2$ ?99VB5U!P,
M[7R1DYP<=*Z31M5OKGXA^*--FN"]G9Q6C6\6T80NC%N<9.2!UH IQ?#F![#Q
M#;:AJUW>OK;123SLJH\<B 89<# P0"!C P!4]GX*NO\ A(;#6M6\07&IW%G!
M+;A'MTCC9)  ?E7H>.3W]L5N:YKUAX>LTN+]W_>R"*&**,R232'HJ*O)/!JG
MH?C#2O$&HW6GV?VI+RTC62XAN+=HFBW$@ A@.>,_0B@#)L_AZMLUE9R:U=SZ
M%83BXM--=$PC*<H&DQN9%)R%/H,YQ4USX#@N8M00W\H^V:O%JI/ECY&0H=@]
MCLZ^]=?10!SNL^'([S5WUIE:Z:/3)[+[#PJSAR&(W=L[<?C7FMM9WNM-X;TJ
MVO-=F6PO[>9K"\L3$+".,Y82S%0)2 -JX/.<U[910 5CZ-H*:/J&L7:7#2G4
M[H7+*5 \L[%3 ]?NYK8HH QM)\/1Z5K.MZBMPTK:K.DSQLH CVH$P/7IFN?L
MOACIVFP^*K>QNY8;?7XS&8@@(MLA@=GJ,N2!VZ5W-% %>PM18Z=;6@<N((EB
M#$8)V@#/Z5+)$DL;QR(&1P592."#U%/HH \^O/AA)>:&WA]O$U^NAQC_ $6T
M$2;HB#E 9,;G53@@''09/%=/X@\.1>)/#;:1>W$BEO+83Q@9$B$,K8.0?F .
M#Q6U10!R%MX,O3XCTK7=2\17-]>:>)45#;I'$4==I 5>AZ'.3G %+_P@D/\
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M'R*Q;OC/M7I%2,Q_%/\ R+-]_N#_ -"%;%8_BG_D6;[_ '!_Z$*V* "BBB@
MHHHH ***X_3YC/KMPLTQ)%Y(BDZD5( / $53*5K&]&A[12=]CL**Y[37GC:[
MOH?MEW!YOD0PF;=D*<,_S'US^ JE/XDO89)U9[927VQ97<@7S F=P/8'D$#F
MI]HDKLU6#G*3C!W_ *_0ZZBN/F\2:A'++;Q^3(T'F'[0% 27:1@<L,=<'&:G
MEUNZDM+B=I;= -ZBTR1(NT@9R#^?3@BCVJ']0JJU[:G4T5Q=OJU[;3%7G622
M:>5!+)G;$/." D9Q@"M:^O;C^P/,^UQM^_6*6YM^ J;]K,/0XZ^E"J)BG@YQ
MDE?=V-ZBN2U)K.VD2VM]2G2!KF$3 3G;&#NZ/G(S@9&?YU3GO)_.:SLKZ2XM
M!*_E227)0-B,$CS>^UB,#Z^E)U+%PP+FKI^>JMI_G_5SN:*YFUM-2U!](U%-
M2D$0M\R!HE!R0N>.^<'Z5-KUH'U'36%S=1^?<>4ZQ3L@*[&/0'U JN=VO8R^
MKQYU!R[_ "M?T['045C:G?36ES!:0W$-NH@>4S7.6!VX&WJ/7)/6L:;Q#J%Q
M'=@*L4>R=1@@,FP<,#G)S[@=10ZB0Z>#J5$I+9G945Q\>N7EM* TR& 3/O9A
MO89DV@$9!"XZ$ \]:["G&2D9U\/*C;FZA1115& 4444 %%%% &=X@_Y%K5?^
MO.;_ - -?*T/W5^@KZI\0?\ (M:K_P!><W_H!KY6A^ZOT%>C@MF<.+W1<B[5
M>AJC%VJ]#7HP/&KEZ.K"U7CJPM=,3R*NYWOPP_Y"FH?]<5_]"KTVO,OAB"-3
MO_>%?_0J])8G<>:\',/]X?R_(^JR;_=(^K_,79[TH7!SFF9/K2H?FKB/4.*^
M)#ZK/;V&EZ3XEL]$FN_.+M.&#RHBAF"L!\N!DD\'T-+\/-%U+1[,;O\ A'FT
MJ:$212Z6DOF3,<$.[NQWY&>>O-9OQ8L!<RZ+=+>7MM- +J-3;:6][E98PC9"
MD;?E)P3_ $H^&%Y?HRZ/+J=[<V-E9K'!'<:&]GM"E5!\QB=QQV_'M0!Z5111
M0 4444 %%%% %2^U.TTT1FZD9?-8J@6-G+'&>B@GI4#Z[IT<<;R3.BR %2\+
MCJ<#.1QSZU6\0:?=WKV,MJC.8)&9@EP86P5(X8#WIT5C=S'3OM"%8K8-(\;S
MF5FDZ)EL<XR3]<>E0W*[1V1IT?9QE)ZZWU7GTW)[C7M.M9S!).YE&<K'"[D8
MQG[H/J*E75;)[I+83?O7Q@%&')&X G& <<X/-<_<:)J27-M/&CRMY#";R;PP
M'S&?>>0.1S4\6C:@FI/*K/#YL_G/.L^[:IC"E-IX)R,YQ[^U3S3OL:/#X?EN
MI='U6_YG2[E#!2PW$9QGFD\Q-I;>NT<$YX%<IJFC7RW$UQ$&FQ 0T\C*S,!&
MPX  *MS_  \'N*@30;^:VAFCMDMXP(=]HK*?-VHP+'<-N<L.H_A]:?.[["6$
MI.*E[1?U\_ZZV.Q>5(P2S 8!;'4X'MWJ"+4;6>X:"*0M(N-P"GY<@-@G& <$
M5SD6@7D,;1-;13.T2B.X>;YK?"$;1QD\GMQSSTILOAF](E,7DH\@.XAB-_[J
M-<$^Y5A^.:.>78%AJ%[.I^1U4MS!!;/<RRHL*+N9R> *HMK^G)%))++)'Y94
M,CPN'^8X7"XR<GT%5SIDLVBSP16<%E(\PECA#;ERI4C=C@9V]JCOX-6OD686
M<,9BFA>.%I1N?:^YLN!@#L!0Y2Z$0HTF[2?7NEV]?,NC7M,-N)Q<Y4N4V[&W
MA@,D%<9''/3I3QK6G->PVBWD)EE3S$ D'(XQWZG<,5AW>C:C=W#7TT"AI'.Z
MW@N"C*-FP'S,#U.1Z8ZXK7L-&@@CLI;B&%KR" 1%U0 =N1Q_LC%"<VRJE+#P
MC>[;]5O_ ,#OUZ#[O7=/L;L6MQ+(LS?=58';/&>"%(-7RZC;E@-W3/>J=W:2
MSZGIUPFWR[=W+Y//*$#'XFJ6I:;//JRW M8KJ-HT1?,DV^0P?)8=^1CIS\HI
MW:N9*G2ERI.VFNV]_EZ[FK-=P0 &655RZQCO\QZ"EM[J"ZBCEAD5TD0.A'=3
MWQ7*67AR_BFC:0@M')'O<R+B7$FXM@+G./[QSSBIM,T*^LM0LI&BBQ&BB60N
M&& FWY>-RG/;.W'.,TE.78VEAJ*B[5-5^)U5%%%:' %%%% !5'6O^0#J/_7M
M)_Z":O51UK_D ZC_ ->TG_H)JZ?QHSJ_PY>C/ Z***^N/S@^BJ***^./TL**
M** /-/$&DZE/_P ++\FPN7^VV$"6NV,GSV$+ A/[Q!..*['2/#VDVEI93+H]
MC#=1Q(=ZVR*ZMM&><9!K:HH X"P\,#5]6\>V6KV4JV&I7,/E.RE0X$*C>A]5
M8=1T(K,\%:'XH_MKQ5#K,]U9W1CM+>'588P?M"Q!@)%W@J25QNX."37J5% '
MGVMZ5J.BZEX=U:6^OM>-A=S-)$Z1>>4DBV9C1%7>4ZX +8+4WPKJ#ZK\5/$-
MV=/N;)&TVT")<Q^7(PW2?,R]5SR #S@"NMU[P[8>(H($O/.26WD\VWN+>4QR
MPOC&Y6'3CCT-)H?ANQT'[1);M<3W5T5-Q=74IEEEVC"[F/8#H!@4 :]%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
M/BC_ )%+6?\ KQG_ /0#6M63XH_Y%+6?^O&?_P! -5'XD*6S#PO_ ,BEH_\
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M8?\ ?I__ (JC;K7_ #VL/^_3_P#Q5:-%:'&9VW6O^>UA_P!^G_\ BJ-NM?\
M/:P_[]/_ /%5HT4 8T5QK,M]<6V^P'DJAW>6_.[/^U[58VZU_P ]K#_OT_\
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M#_XUJ45L>49>-=_OZ;_WP_\ C5=[K6TU"*T)T[=)&T@;:_&T@8Z^];E9<_\
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M?\B[#_U_6_\ Z,%=57*_$#_D78?^OZW_ /1@K"K\#.W+_P#>J?JCJJHZU_R
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M)!SU^E(8*BJ20,9.33J**0!1110!1UK_ ) 6H?\ 7M)_Z":S_!7_ ")6C_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)\4?\
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M8''%@O\ C71")II?,D78RYV'/*G^1%6/F&W '7G/?WK-TH]W][*6.J?RQ_\
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M)_Z":NG\:,ZO\.7HSP.BBBOKC\X/HJBBBOCC]+"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K)\4?\BEK/\ UXS_ /H!K6K)\4?\BEK/_7C/_P"@&JC\2%+9AX7_ .12
MT?\ Z\H?_0!6M63X7_Y%+1_^O*'_ - %:U$OB81V04445(S*\20RW'AZ\BAC
M:21E&U5&2>15B^:>.6":&V>XV%@R(R@\CKR15VFR*SQLJN8V((#J 2I]>>*
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MR#"_#+_%+\Q****Q.D*5?O"DI5^\* ):HSSZFD[+!8021#[KM<[2?PVFKU%
M&9]JUC_H&6W_ (%G_P"(H^U:Q_T#+;_P+/\ \16G10!F?:M8_P"@9;?^!9_^
M(H^U:Q_T#+;_ ,"S_P#$5IT4 9GVK6/^@9;?^!9_^(H^U:Q_T#+;_P "S_\
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M_@6?_B*/M6L?] RV_P# L_\ Q%:=% &9]JUC_H&6W_@6?_B*/M6L?] RV_\
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M-'_"RO"'_0:B_P"_4G_Q-5[*?9D\\>YU=%<I_P +*\(?]!J+_OU)_P#$T?\
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ME7"A5YE[K^YF=7%X=PDE-;=T>/44[8WI17U)\ ?1%%%%?''Z6%%%% !1110
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M0A,' 8COC].*U&LG?6DOFD!CCMS$B8Y#%@2?R % %ORT_N+^5&Q/[H_*G44
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>hook-20211231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &O C@# 2(  A$! Q$!_\0
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MV?S[.X7?%)L9=PSCHP!'3N*NUQGPF_Y)9X?_ .O8_P#H35V= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16)XJU
M6]TC2H)M/6W:YFO;:U7[0"4'FS+&2<$'@-6'+K7BS%_96T%K>7]E=)&\EK9
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M;4=>U-'T*>VCMHK2]NHXI@Y+R8;/ X '3KS]* .JHKCDUW5OM,-\UU9FREU
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M\_\ )*KW_KO#_P"AB@#8^$W_ "2SP_\ ]>Q_]":NSKC/A-_R2SP__P!>Q_\
M0FKLZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#0Q0!L?";_ ))9X?\ ^O8_^A-79UQGPF_Y)9X?_P"O8_\ H35V= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45S.O^.]$T#=
M')/]HNA_RP@PQ!]ST%<@;[QKX[^6SC_LK2W_ .6F2NX?[WWF_# KOH9=5J1]
MI/W(=WI]W<ES2T1V.O\ CG1/#^Z.:X\^Z'_+O!\S9]^P_&N..I^-?'1V:?#_
M &7IC?\ +7)7</\ >ZM_P$8]:Z/0/AOHNCE9KE/M]T.=\P^4'V7I^>:[(
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M+>%9;?5A)%;K*2<%.&VDCV]* /0O#1UXZ)#_ ,)(MF-3R?,%IG9CMU[TWQ6
M/"VI/_9T6HND#,MK(FY9"!T([UH6.HV6J6JW6GWEO=V[' EMY5D0GZ@D54\1
MZE+H_AS4-1@6)IK:!I$65PJD@<9- 'B,'B62W\,KK$?Q)TFWO(H]ZZ.NE1!%
M(_Y8A?O^V:]M\,ZC=ZOX9T[4+^U^RW5Q LDD/]PD=.:\277+F32/^$KD^(7A
M0:CY7G?V;_9<!?=_<W9\W/;I7K?A#QEIWB/2K'?J6EG5I8!)/96MY'*R''/
M8G H Z>BBF2N8X7=49RJDA%ZMCL* 'T5Y/IOQ7U*]_L:5K"P>74M0:RDT>"5
MC>V@4D,[@]<!<D%5X(Y%;=YXXU2YUCQ)::)96CP^'XD:X:Y9LSNREMB;?N\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXS@_[*]!^I]ZZNBBO"K5ZM>7/5E=FJ26P4445D,**** "BBB@ HHHH ****
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M$W_)+/#_ /U['_T)J[.N,^$W_)+/#_\ U['_ -":NSH **** "BBB@ HHHH
M**** "BBB@ HHHH 0D*"20 .237CFL7,_P 1?&\6FVCL--MB1O'0*/O/]3T'
MX5TOQ,\3G3]/&C6;$WEV,2;>JH>WU/3Z5J> O# \.Z&K3H/MUR \Q[KZ+^'\
M\U[6$2P6'>+E\<M(_J_Z_4SE[SY3I;2UAL;2*UMHQ'#$@1%'8"IJ**\9MMW9
MH%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([B9+>V
MEGDSLC0LV!DX STKQ99/#?B=UUNS^$M[?03L72Y41QK+SRQ4-@\CO7LM_P"8
M=/N!#O\ -\MMFS&[..,9[U\_Z%X7OK/3A'J?@[Q?+>%V>6:VU,1K*22=VT,,
M'UZ_6@#W+PW<-<:) 3HTFCA,HMG(%!C4=.%XQ5?7-%UF^F$^D>);G2Y0N/+-
MM%/"WN58;OR84SP3;_9?#447V#4+'#M^XU"?S91]6R:TM;O+K3]$O;RRM#=W
M,,3/' O5V Z4 <K_ &/\2-VS_A*M'V=/,_LL[OKC?BMK1-%UFRG^T:OXFN=3
MDVX$2VT4$(]]JC<3]6->0V_Q@U-7O5O/$5@MR]H'@@&F2*(;C=_J2"-S$CC/
M3FO:?#=_>ZIX<T^^U*T^R7D\*O+!@C8Q'(P>1^- &I1110!E:/X<TS0;C4I]
M/@:*34;EKJY)<MOD8DD\GCKT'%4]6\$Z#K5W<75W;2K+=1B&Y,%S)"+A!_#(
M$8!AVY[<=*Z&B@"*VMH+.UBMK:)(H(D"1QH,!5'  %><_'G_ ))5>_\ 7>'_
M -#%>EUYI\>?^257O_7>'_T,4 ;'PF_Y)9X?_P"O8_\ H35V=<9\)O\ DEGA
M_P#Z]C_Z$U=G0 4444 %%%% !1110 4444 %%%% !6?K6KV^AZ3/J%R?DB7A
M>[-V K0KR#Q=J5QXV\66_A_3&S:POAG'0G^)C[#M_P#7KNP&$^LU;2TBM6_(
MF4K(D\"Z3<>*O$EQXFU0;XHY,Q@]&?MCV4?T]*];JGI>FV^D:;!8VJ;8H5VC
MW]2?<U<I8_%_6:O,M(K1+L@C&R"BBBN(H**** "BBB@ HHHH **** "BBB@
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M,3!]O7;CG%>3Z-H6BZCX7TMO#/C:*QGTXRQ6]U);QF18G/S1RQ.1DY[\=N*
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MMRM<QQ4:U10IZ0CHO\_F*$;+7<****\\L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@""\C::RGC6..1G0J$D^ZW'0^U
M>,S_  _UR""27_A O [[%+;5EFR<>F0!7LM^85T^X-SGR!&QDVG!VXYQ7S_(
MO@2XL=.:R\*Z]>7&IO)]EM#J<BF2%.#(3OP >>/:@#UCX8W,5WX(MIHK"QL0
M9'!MK+=LC(.".>];^O2:A#H-[)I,?F:@L1-NF!R_;KQ65X!N]%O/!]H^@V+6
M-BI9!;/]Z-@<,"<G)SWR:9XAUWQ9INHB'1?!G]L6NP$W']J16^#W&UAG\: .
M3T_5O%"Q13ZE\*$FU-0/,NHKBV!=O49Y'YUZ5I=S<WFFP7%W8O8W$B O;.X<
MQGT)'!_"N*_X2WXA_P#1,/\ ROV_^%=II5Q>7>F6\^H6'V"[= 9;7SA+Y3>F
MX<'ZB@"Y1110 45&\\,4D<<DJ(\APBLP!;Z#O22W5O Z+-/%&SG"!W +'VSU
MH EKS3X\_P#)*KW_ *[P_P#H8KTNO-/CS_R2J]_Z[P_^AB@#8^$W_)+/#_\
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M2:T&U+2?"OQ'\:2>+"J0ZA; Z>\UNSK)'@_*IP>Q KVC4KK1=%M3=ZE-8V<
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M#L5=3GKCY3BOHDQH8_+**4QC:1QBJ%SH.CWEH]K<:79RV\ART;0*5)]<8ZT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_&NKQ^'7M]5O/$<F
MFV:QR1_9A;AUGD(^7YL':1V]:\NTOQNM]HT-Y>?%NZL;ET+/:/IL;LA!/&0N
M#T_6O=]34-IESFV2YQ&Q$+C(<XZ5X!:^)/$.G:)I5Y)K.CZ+I%T98RD>CJZ6
M,JDXA<#+ GWZ9H ]=^'&K7&M^#;>_N+RYO&DD?;/<Q+&SJ#@'"\8KK*Y+X;:
MG?ZQX*M;[4IY+BXE=R97C$8=<X!10!A<=.,UUM !1110 4444 -,:&02%%W@
M8#8YQ]:&C1RI9%8J<@D9P:=10 5YI\>?^257O_7>'_T,5Z77FGQY_P"257O_
M %WA_P#0Q0!L?";_ ))9X?\ ^O8_^A-79UQGPF_Y)9X?_P"O8_\ H35V= !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 0WDQMK*>=0I,<;, S;0<#N>U>(6
M'C'6M<T>36;GXF^'](DRS'1VM() NTG"EF;>V<#E<^U>M:]XI\.Z"4M]<U.T
MM?M"G;'<'AUZ'CN.:XW^U?@Q_P \_"7_ (!Q?_$T :W@'Q[9^(]!L?[0U31T
MUB;*FUM[I-S8Z$1YW#(['FNWK@]"U#X7S:Q;IH2>'!J1/[DVMK&LF?8A0:[R
M@ HHHH **** "O/K[QYJDMSXF;1[&TDM/#JCSS.S;[E]I9E3'W< 8R<Y->@U
MYM=^"=?L;GQ;%HS6$MIXB&[S+B9HWM)""K' 1@XY)'(]/>@#N="U>#7]"LM6
MM@5BNX5E52<E<]1^!R*X3X\_\DJO?^N\/_H8K>/PZT"]\'Z5X<UBU^WVVGJN
MP^8\67 (+?(P/.3QD]:S/^%)?#S_ *%__P G;C_XY0!=^$W_ "2SP_\ ]>Q_
M]":NSKS_ /X4E\//^A?_ /)VX_\ CE'_  I+X>?]"_\ ^3MQ_P#'* /0**\_
M_P"%)?#S_H7_ /R=N/\ XY1_PI+X>?\ 0O\ _D[<?_'* /0**\__ .%)?#S_
M *%__P G;C_XY7G&E?#OPK<_'C7/#4VE[M(M=/6>&W^T2C:Y$/.[=N/WVZGO
M0!]#T5Y__P *2^'G_0O_ /D[<?\ QRC_ (4E\//^A?\ _)VX_P#CE 'H%%>?
M_P#"DOAY_P!"_P#^3MQ_\<H_X4E\//\ H7__ "=N/_CE 'H%%>?_ /"DOAY_
MT+__ ).W'_QRC_A27P\_Z%__ ,G;C_XY0!Z!17G_ /PI+X>?]"__ .3MQ_\
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MYB[XAC+,2.&;ICK0!]#45Y__ ,*2^'G_ $+_ /Y.W'_QRC_A27P\_P"A?_\
M)VX_^.4 >@45Y_\ \*2^'G_0O_\ D[<?_'*/^%)?#S_H7_\ R=N/_CE 'H%%
M>?\ _"DOAY_T+_\ Y.W'_P <H_X4E\//^A?_ /)VX_\ CE 'H%%>?_\ "DOA
MY_T+_P#Y.W'_ ,<H_P"%)?#S_H7_ /R=N/\ XY0!Z!17G_\ PI+X>?\ 0O\
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M;;RW8\,T@SM Z]#]* .FU;5['0].DO\ 4)_)MTP"0I8DDX "@$DDG&!7FO\
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M<6LA&=@?&9".A/YUTOAOP-XBM]8M[W6KZQ01,SW+6<LLDFH.> 92X "CLH!
M[8KT6**.",1Q1I&@Z*@P!^% &=H>A6^@Z>EK%<7=VRYS<7LQFF?)SRQ_D.*U
M*** "BBB@ HHHH **CN+B&UMY+BXE2*&-2SR.<*H'4DUDZIXFL;#PK<>(;=O
MMUG%"9E-LP;S!['I_A0!;N];TJPO([2\U&UM[B1#(D<TH0LHZD9K.\6:=J.L
M:((-+U*2T4N'F> 9DEB')1"#P6Z9'K7DNM^)?#_CFRCG\1Z?<SB%AY5YHD4C
MQV1;_GI*^T.0<<!2*]*\*6GC2RFCM=7OM*O=)B3$-TD;K<S#^'<O"K@=>N:
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M/?#^@W-M?P::L=["A$8^TRRQP%A\WE!R0N>F0 <5UE% !1110 4444 %%%%
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M;<0P!BYY)9V/5F8\LQ[DUH444 %%%% !1110 4444 9^LZWI^@:>U]J5QY,
M8*"%+LS'@!54$DGT KRWQ3XPM/$VL:='8R:G>Z';%QJVGV*RPW:D@;&9!MD,
M8SSBNS\9^"#XCGL]4L-0EL-:T]M]I/G?'D'.'0\$>XY^O2N:\)6>L:Q\0CJ?
MBRT>RUK2X&BC6TLV2VG1N-_G;FW^RG;CTZT -\(:'+>ZWJEO9?VW%X/EMU$*
M7[RQ2)+GGR68B0+CO_.O0M%\.Z5X>@DCTVU$1E;=+(S%Y)6]7=B68_4UJ44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!DZ]X9T?Q-!##JUDEP()!)$^2KQL"#E74AAT'0\UJ@!5 '0<4M% !1110
M4444 %%%% !1110 4444 ( !G  SR<4M%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>hook-20211231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $B 84# 2(  A$! Q$!_\0
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MI'S<G( !K%WKDTFFZC927/\ I?BI8HX'=XT6VCCDBPVW/R,T9DZ8.]:],HH
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MY@;9P.2-V00N1W%% ' 64;7^H7UCI6H7X@N]-;R[@SSR/!,",-*).(I,OP@
M)"MD8  GAU6\N6A\5NE[!:QM':RV6&;Y&7$C;!QO69E4MSA8FP<,37<44 9F
ME)+:Q06MS=*UTT;3S1%R[;V;<Q4DYV L0!C@8 P!BL-O[4MO%&L:G;S7,]O
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M3[^GS]-N?]G/:@#UFRL+/3;5+6PM(+6W3[L,$81%^@' KA_C;_R2'7?^W?\
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M'CC4A<+)_P )0MQ)Y[D*9=I&9' ^Z#WZ8)S0![S1110 445SGCBXOK?PR_\
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MH ]0\"?\D\\-?]@JU_\ 12UT%<_X$_Y)YX:_[!5K_P"BEKH* "BBB@ HHHH
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M7_8*M?\ T4M=!7/^!/\ DGGAK_L%6O\ Z*6N@H **** "BBB@ HHHH ****
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M]<]V;'8<\\E>E>F:#X;L/#\!6V3?.X DN' WM[<<*H[*.!6G)&EK4U?;_/\
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M* "BBB@ HHHH **** "J]]>P:=92W=TX2&)=S'^@]ZL=!DUS$1'B;4Q=R?\
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MD?Y%^/\ F8_E^(I>#<:9;C_9A>4C\V6L%=$UJW\17EY-']MBF:(ED6%!+M4
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M!_\ T*FA_P#@NA_^)H /^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
MXJC_ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XF@ _X3OP?_P!#
M7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ/\ A!/!_P#T*FA_^"Z'_P")H_X0
M3P?_ -"IH?\ X+H?_B: #_A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_
M .*H_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)H YGQOXJT34
M=*M$TC7M/N[F*\24K9W:2.BA6^;"-G@D<Y'4<UP6I:U>WL3+<7T[Q)DAI)),
MCC!X9V XS7J>L_#C0+ZR$.F:;IFE2[\O-;V$8+I@Y0XQD$D'TXZ5QW@OX:ZE
M+!'<Z_:+ICP70_T"0I=":(;3RRM@ \KM(.,9[UFX7>_;HCV,)C*5*DE+5I2Z
MOKMHEK]YRVC:?8WB^8FHZ?&2>6NKZ*(8]^=P/_ ?QKT/2;?3[2R$$_CJQA@Z
M^5IT\,7/N_5C[XR:ZYO"'AEOO>'=)/ULH_\ XFF'P7X58Y;PSHQ/O81?_$UU
M3E3D[N]_4\OZS7Y>5626R25E_7?<YWROA]')]IN-3MKF?&#-->L[GZX-2CQ!
M\.+,[OM.D9/.XQAS^>#6T? OA G)\*Z&3_V#HO\ XFD_X03P?_T*FA_^"Z'_
M .)K.U/M^/\ P!>VK_S_ )_YF7_PL[P):$HNMVL?LD+X_1:@?XQ>!D!_XG49
M(_A"'/ZUM_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-.\.S
M^_\ X!E[_?\ K[S%/Q>\';E":G$Y/I-$,?FXI/\ A;?A<N52YC8#O]NM%'ZS
M"MO_ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFCFCV"S[F'_PM
M;0V4E)+,GL&U>R7_ -K4I^)^ED+MN-&!/4/KMJ,?DQK;_P"$$\'_ /0J:'_X
M+H?_ (FC_A!/!_\ T*FA_P#@NA_^)HYE_*OQ_P PY7W,0_$JQ+X2]\,!<?>?
MQ#$/Y*:0?$.W?=C6/!J>F_7U/\DK<_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
M0J:'_P""Z'_XFCF7\J_'_,.5]S#_ .$]A,8QXF\%(_?_ (FH8?TI6\;P,XV^
M-/!2+WS<!C_Z-%;?_"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$T
M<_9(.7S,,>,+9B=WQ"\(H.VTH?YST#Q38&/#_$SPZ&_O(8!^AD-;G_"">#_^
MA4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$T>T?E]R#D7]-F&WB326V9^*&
MEKC[VR:S&?SSBN<37K#3O%>H7Z>*=+U&"=HF#G5K*+S=J 8<$<#M\N.E=_\
M\()X/_Z%30__  70_P#Q-<'\6?AC%JOA6U@\'^&--34%O4>0VL,-NWE;'!RQ
MVY&XKQGT]*J-9QNK+7R)=-.VIM>%_%GAZTGU>XOO$&@VIO+KSDB758'PNT#J
M&]JZ+_A._!__ $->A_\ @QA_^*H_X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (FHE+F=RXJRL'_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\
M\&,/_P 51_P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-2,/^$[\
M'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJC_ (03P?\ ]"IH?_@NA_\
MB:/^$$\'_P#0J:'_ ."Z'_XF@ _X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?
M_@QA_P#BJ/\ A!/!_P#T*FA_^"Z'_P")H_X03P?_ -"IH?\ X+H?_B: #_A.
M_!__ $->A_\ @QA_^*K4TW5M-UFW:XTO4+2^@5RC26LRRJ&P#@E21G!!Q[BL
MO_A!/!__ $*FA_\ @NA_^)K4TW2=-T:W:WTO3[2Q@9R[1VL*Q*6P!DA0!G
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MLK7-L-C(5EE1MLF0QXQQW+4 =;9WMKJ-I'=V5S%<VTHW)+"X=6'L1P:GH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>hook-20211231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %X U4# 2(  A$! Q$!_\0
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M%K_WY7_"K=% %3^RM._Y\+7_ +\K_A1_96G?\^%K_P!^5_PJW10!4_LK3O\
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M?V5IW_/A:_\ ?E?\*MT4 5/[*T[_ )\+7_ORO^%']E:=_P ^%K_WY7_"K=%
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M"U_[\K_A1_96G?\ /A:_]^5_PJW10!4_LK3O^?"U_P"_*_X4?V5IW_/A:_\
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M /015NJFE?\ ('LO^O>/_P!!%6Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;QEBU_4D8DE8S,V!CU]JIX22ZF<<]HR^RSZ$HKPZPU_5+A(3<7UZRL 2Z7+
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MQ^E5O^%I>"?(\_\ X2"W,?.6".<8..?EX_&O)?#^C6>C7][<HI97?$2C++M
M)VC'?KSVKD;J*_'A':;-9[&]_>)(L@,EN_F$X]U['/<U,L-RQN]]36CG;JU7
M&*7+>-KZ;WOZM6/J?1=<TWQ%IRZAI-VEU:,Q42H" 2#@CD"N>\<?$G1O ,ME
M'JMO>RF\5VC^S(K8VXSG+#^\*Q_@4I3X8VZD8(NIP1_P,UP?[2__ !^^&_\
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M.WN8K:ULF>X*>5*)7+!Y#W4+C';@YJB(6:N]_P"NA<U5++5=56XBGN8VGN&
M:\F4A;< !,M_>P"#VZ8K'U6VM[35+B&VN/M-M&Q\F8#_ %B=CTJ?4YEO&-RR
MQ13@F)K6*,H(0H !'7K_ #K,<[V+!0OLO04I;C5WN:7A^66T\06-Q &D:.X0
M@("<\C/ YZ5]&!64HZ8&W=A-ZG;\Q7D]MH)^O>O'/AIH\L^MQZFX46EB?,E=
MGVC)4A5'J<D'VKV"?RF58I69R>%BCP.V>1[=<]!UKT,)!J#;/CN(,1&6(C"-
MFUO_ )/Y?F06Q$=A&@*!#"Z;)#C=M#'@<@'."?3'M3AY"6YCMYC&@;RC&N6"
M'@N%SR>"#NZ=ZAC)6]EMRJ2,(_-0.  AW?=]SU.>V*?J%_!86LUY?S8M(E\Q
MV (*+R,C X+'"XS_ #KITM=GA^\Y\D=6W=?IH>7?$36[NZUF/PQ8SNUK;I'%
M+$0 LDWJ2?3@9/O7"N,,T1=%<':VQ1TSSR.N*GU._DU;5KW4)<E[B9I,8X )
MX_2K6AZ)>:[J<5G9P A/GFD PL:GJ6/88Z5Y4FYS;[GZ!AZ<,+AXQ>G*M?U$
M73Y;YBVGVUS="&,/,_E;L'J22,\>F:SC()KOS+@A]S[G8# Y.23BO4XM0T?X
M=Z?J5K:W]Q+JLY"^4T)1DD52 <]  QW>_'6O,[BUBCN+=4O(93<1AW(R!&Q)
MX8D=>_'K1.'+;N3A<0ZO,[-1Z/77N0$1Q32"-$F4,0&93C'8C/3\:L".XLK6
MVNFCVP7 ;9Q\LFTX.?7!-=E=3:/8Q/I\VE6KZG:*\;+;MNAN"5!1@PZE2<\C
M)Z5ASVFDL3 T$]C<VMFK[68S"XFQECQP@/7';&*3A;9EPQ"DGSQ:_K\O0KP:
M'8W^EM?'5K6QG,VP6\ZMM?(SE"H. .G-4KOP]J,$0N(K66>T;=MFB'F+\H!;
M)7CC(S5B%6G:T)VRHLGR6\0RW!'WAVSGCUKW=+B.#2/[!DTI[6XU%!:I#O\
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M *"*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI\BPWZD8V!PJ/RW8'U''/X5#/%]M+6=Q'M0Y 0#/ _BS7+SS3Z:CVR%O*9L
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M"YO-&6REMK>:1'#BX*$W.T# 7?GE .V.*]GU?PS8:GJMI=S023"U+-L*;O-
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MDJ5[GN",U,*T)_"S7$9=B<*E[6&FUTUNR>*W?3H(H+=A#;0!6PL8'G<'*X/
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M2B_> [U'-[R=S;V,O9R@X^A]:V QIUJ,Y_=)SC&>!7A/[1O_ "$?#W_7*?\
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M_01^1$[>4NY3*V5P6Q_#CG%2Z)X9LX[N9=8OVLK8L5CNHR&W@9X"]1NQD,<
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M)P#@<8]Z+\WD19TKJ/O<S]'KW.N\/>/_  M! MQ+I#:;).SEQ;*) 6)ZA<C
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M"N&^#K;OA1H38QE)<#/0>:_%=S63.T**** .2\;?\N/_ &T_]EHH\;?\N/\
MVT_]EHH Z+2O^0/9?]>\?_H(JW532O\ D#V7_7O'_P"@BK= !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9^MZ4FMZ1/I\DK1++MRZ#)&&!_I7$R?"*R<1_\3>Z5E)RP1?F'H:]&HJX
MU)15DSGJX6C5ES5(W9P,?PMLXD;9J=QYI^Z[(IV_0=*9_P *ILQ<)*-4G&WG
M;Y*X)]:]!HJO;5.YBLMPJ=U#\SR^?X*Z?<SM-+K-X79S(<1H.3_3VHC^"NGQ
M7+3)K-VI8Y.(TS^=>H44G5F^IL\)1>\3S3_A3EFSH6UJ\^5@QVQJI./<=J<_
MP=T^6%HI-6NV#').Q02:])HH]K/N1]0P_P#*>4ZM\#K'5;Z&Z_MV\@\E%6-(
MXDPN.<CZGFK0^#>GK+(RZK<A)!AHQ$N,^M>F44O:2O>Y3P=!Q4>71'F$_P $
MM&N;.*WFU"Z/E$E'50I&3D].M1#X':2@1%U6\,:N'VR(K'Z9ZXKU2BCVD@6#
MHI6M^+//;7X56]M;S0'6;N1'0HFZ-<QCM@]>*B?X16GGQRQ:S=PLJ;&V1I\X
M[Y^N>:]'HJO;3VN9K+L*FWR;GE__  I335B=$U>[7<<Y\M>*'^"M@?+*:S=(
M5&#^Z0@_@:]0HJ?:2[E_4Z'\IY>GP4TQ$8?VM=[V.68(H_2K4?PCL8"LEOJD
MT<X7:TODJ2U>C44U5FNHG@</+>/YGE</P3M8)&=/$-[\S;CF%#S5VS^$-G:0
MRQ'6;N1'.X QJ-I[]*]'HH56:V8YX+#S5I1. C^%EI%),\>L7JF10ORX!4#T
M-9P^">E2SF:]U?4+ULD@7#;@H] *]0HH=:;W9,<!AX7Y8VOYO_,\IM_@9I<+
M'=J]U*F[*!HDR@] :TH?A%IL5U:W/]H7#2VS*\;%!P0<BO1**7M)6L6\)1<N
M;EU^85R_B[P5;^+7LGGNY+<VC%EV(K;N0><_2NHHJ8R<7=&\HJ2LSSF[^$=E
M>-(\FL7@DD.69449/O58_!;320XU6Y$G<B-<$^N.G3BO3Z*MU9OJ<RP.'6T?
MS/-+CX-:9<2M,VIW'G94H_EJ2F.GU_&DN/@SIMP4_P")I<(H)+!8D&_/7=QS
MFO3**/:S[@L!AU:T=O4\EN?@/IL\<J1Z[?0^<Q,FQ%PPSG&/\]!52V_9XTBW
MG65M<O)=N<*\*8SV/OBO9:*ER;=S:-&G&/*EH>.1?L_V<%V;J'Q/J,4Q).](
MD7K]*L7'P(L);I[B+Q#J,+2 &3:JG<W=N?6O6Z*.9]P="FW=Q/+8O@CIL<01
M]8NY#NW[VC3=GZBH?^%#Z.#*4U:]#2MN8[5X^GI7K%%/VDNY"PE%;+\SR[_A
M2E@S2;]:NRK @*(U&*KI\"K!/)/]OWS-&"N6C3D'M7K-%#J2?4%A:*^R>1R?
M 73GE9TUV]CST41(0OTS44W[/VES6JPG7KX8;=N$:?E7L-%+F9:H4U:R/%/^
M&<M*_P"AAOO^_*58M/V>](M7WG6KJ4_]-($/Y5['124FBG"+5FCS5OA##(C0
M3:]=-:E=JP) B*H[ 8]*SQ\";&.5)(?$-_&5.YOW:'<?7FO6J*MU9O5LS>&I
M.3ERZO<\N_X4M9QQ10VVN7<,<9R,0H6)]23WIJ_!.S1F*:[=*"" %MXQC/N!
MFO4Z*7M)=R?J=#^5'D/_  H#1E<R1ZQ>K(1]YD5N?7!XJ]!\$]*B\L2:G=2J
M@QM*@!L]2>>2?TKU"BA3DMARPM*2M)?F9>@:*F@Z:;)+B2=?,9]\@&>>W%1>
M(M"?7K(VJWGD1NC)(CPB5'4]05/!K9HI<SO<T]C#D5.VBM^&QXQ+^SQID\L\
MTVO7<DTQR7:!./H.@_I@5$_[-VBLZM_;U_@ !@8TY]?I7ME%3<OE2/'9?V>-
M =I_+U6_B1O]2BJF(N>_'S<<=J2Q_9YT:UG6276[Z95).WRT&3^1KV.BG=DN
MG%JS1P\7PTLX-/ALH=3O(XH6RN-N<<9!]B!SC&:MV/@.STZ23[+<&*)UP8TB
M4 MD'<3U)XKK:*T]O4[G$\JP;;;AOYO_ #.<L_"-O:1.HGP[R>:QAA6,,_'S
M$#J<#&37-:_\'=)UQ;@?;IX&N)FF=_+5V!.,A2>@XZ5Z112=6;5FS2.7X:$E
M*,=?F>0:E\ [#4[R2YF\07BO)@,%@3! & *Z/2/A9IFE^%?[ ^VW$L.68R[5
M5]Q;<&Z=1QCTQ7>44E.2=[FDL+1G!4W'1?IL>4Q_ ^RMF9K7Q!?PL7+JXC0L
M"?4XYXXZ4[2/@K'H5Z;O3O$]_!*5VMMACPPZ\CZUZI12YY=Q_5J5FN7<\<N?
MV?-,O&:2XUZ\>9F#-*(4#'KG/8DYZT2?L^:2]M#"-:NE\MBS.($W/]37L=%*
M[-5"*5DCQB']G;1X9 YUN\?!SM:),?I5J3X"V'DO!;>(+^V@DQYD<<:X<^_K
M7KM%',R73BW=H\4;]G33F(+>)=08C^]$AIO_  S=I&<GQ!?_ (1(*]MHI7+Y
M4>)#]F[1PA'_  D&H;NQ\I, ?2I$_9UTN(#R]?NU;^]]G0GKG\*]IHIW$XI[
MGB<_[.6FW,GF3>)=0D;U:)#4?_#->D?]#!??]^4KW"BD-))61B^$_#L7A/PQ
M9:'!</<1V@8++( &;+%N0/\ >K:HHH&%%%% ')>-O^7'_MI_[+11XV_Y<?\
MMI_[+10!T6E?\@>R_P"O>/\ ]!%6ZJ:5_P @>R_Z]X__ $$5;H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVZ8>15PI<]/^!'_ZYH5&,)N,S:FN63C56NOW^OD>V+^T;"1_R*TH_P"WU?\
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MNI9YT7_73,^62, Y(9L]/2NA\2^&A:W5JEK>6MEI+(L;,[D;7'4D@9?/7)(
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M\^NE?]^7_P#BZ\QQ2A<T<J%[:?<^NO VN77B3P9INKWJQ+<W*L7$2D*,.R\
MD]@.]=#7&?"<8^&.B?\ 7.3_ -&/79UD]ST(.\4PHHHI%')>-O\ EQ_[:?\
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M)^;UQZ_I4>1I4@XRMV(Q+L92JJQ QEU!S^%)Y8:+?C'S;>HIZP,_F/&OF)&
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M_P!X],\XJTJP26,S21&*X\P+&(WR-IZY]*U4I7NM+7,74E=.-DUKV_X(V&:
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MFAFXTI=3O)Y+<3.FXX\L*W'!_G[4WX5)?1_$'Q\FIRPRWJW$ EDA3:KD!_F
MR<9&#BND\0^ ;G4M9T_7M)U^?3-<M(/LS7A@243Q^CIP,YR?3GIP*?X)\!2>
M$-7UO4)=9FU*356C=WFC"N&7=N)(.#DL>,#'2@#LZ*** "BBB@#C_BDGF?#C
M5U#[25CP<9_Y:+Q7R^]M&(Y]R-]FA.TRY!*D]"1UQGKBOIKXML5^&&LD-M^6
M+G'_ $U2OF*WDGD1#" 9(OG^9@JX4Y[^GIWKHHM;-')6_BQ=M ,<5S&L.^.-
M8N#*%P9 3G<<]2*G%E#:)="#48)E3A6''F=P0IY'7'YU'?QVSZQ)* PC:7><
M'Y>>H&.W-5?LKP7\DR?,D3] >2>HP#]*U;2;;5^ES-RC)OF=UW+]P,PV\20J
MEP&X=,'?G&58Y]QCZFAW>"YA5F^RO')\FZ,'&?O'=Z=/UJFLIF0.D6] V0K'
MD'T_Q]:V;2TN]72>XOFDCBMXBJ;8QE3C/0]1Z]^E;4[U)6BM?T-Z$)UJG)!>
M]T\TN^WWB)&\@>5H[>YCWL)I3P67(W8R1QT(Z&K^H:A;ZGHSQLT*0M<89I(U
M,FT="N!Q]>_(K!L].6[M)920%1LM%N^9A@\@=2/Y5;NK>5=-A:0"WDF"A8G)
M 8#OGH!34Y<MHK<YYU912ITU9/\ 3L[=-NOF8@MK55$G[Q'!*R0LI"_4-^N*
MELM(U&\BNI8H6*0QDKG@,"<?+ZUT,+1+ /,M4\QP40.@8N6&,*W0<Y-.T@76
ME3I'<L(K6<E926W*^.1D]@,U$*4=&V2L3RTU)-<SO9,XYK.?".H+,R,S+T*[
M>N?PYJLFX2[E!)'(Q79^)-(@NOMNJ?;55X[AH8HU(97 Y #9]"?RKE+*[-G<
M1S1J1(KA@P;YL="OI@_2LJM+V<TI:'H^SY7%3LGI>SO_ %?=7+-E/#</(EW'
M;JLB%?-*G<IZ[A[TU(K$3RQR+.(\'RG5=QW=@1Z'\ZB-M%A)BXVN6WQA<&(]
M@1Z4Y9I9D2.*)(WC7+&($%PO.X\\D52>B4DK_F;J6T9*[7XD2K 9V+-*(BN"
M2.=V.GYYJ_9^3J-F+21762!693 @+.., _3DY-5(F:6"15B38'#NS'E0>.OI
MGTYJ]))<3:JL-K"D7V/"J$7;A0>2YZD>Y[4Z5EKNGY;_ /#6"@K:[K;;>_\
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MD\T=POER(Q1HR""I'4?AC%1 LN)5.TH000>1Z8H]"FN:UT2NRDJZ!@2"7)(
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M &T_]EHH Z+2O^0/9?\ 7O'_ .@BK=5-*_Y ]E_U[Q_^@BK= !1110 4444
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MJ^LEE);R13B9VC4F-';(521D#/3//K]*S+@VL<A$,>^-L[5;)V__ %_ZU+#
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M3S1&R.C_ &46^U@1<>0VQS)C)P1P/QJU90#4&GFFC)B 5 %D$8DY^^3R<<5
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M=5-*_P"0/9?]>\?_ *"*MT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&[;Z'&P:WXWN(%6![AO,;!?R0')]V(]^M>@>%KR/4?"I6^2XDUB&4Q3X^3#
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MH7-@T,C[3$R#("K,"PYQTX_#CFDM=3FCB-LLCI 6+LB' =B,<_AQ5264.P.
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MBK=5-*_Y ]E_U[Q_^@BK= !1110 4444 %%%% !1110 4444 %%%% !1110
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M+>6V;RY2 0!D>GX4ELBRN!)*L:^I4L3] *;DWN13P\:;?(M?ZZDRVT@^XOF
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MI?PX^B"BBBD:')>-O^7'_MI_[+11XV_Y<?\ MI_[+10!T6E?\@>R_P"O>/\
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M9MX3UAC_ .^12^5'_P \T_[Y%/HH **** &"*,# C4?04&*,D$QJ2.A(I]%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR1B4+M#GGDXXYK9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO@  $DYQTP,_C4*:T7$!6%<.45P&)(+'''&/?G'%6Y=-@E, 9<10H56,<#G
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M(ULH%2W),*A  A(P<>F0344GA[1YHX$DTRT=8%VQ!H@=@]![5M]9IVLXZ?\
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M.!_+-9L=E=1RJTD5W]V1MT3KNW,_0G/]U5KHZ* ,L0W=II:H(HKADB51;J@
MW<<Y)Y'>JWV.Y1O-2.2266)U+/A=LC$#<1G@8 Z9X%;M% &=;6'D:A&X0;(K
M81*^!ECGG]%'YU#>6US-?.0CG)C\F4-A8P#EN,]3^O%:]% &2+.=-$G54)NY
MU;=ELG+$^_;/Z56O]+G&4A\^6);?RURX)&YE!QG'(4&M^B@#*M+:Z$\\J,\8
M8(JFX =R!G(X/ Y_G5>XM;F^^T[K9XMNX0H-H#9.&8D'EF&?H#6[10!B2QW8
MF>:.V=3</C< I:%%7' S]X\_2D_LR64VXV/$@D55 89BB0$K^);!/X>E;E%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]JZ=_P _]K_W^7_&C^U=._Y_[7_O\O\ C110 ?VKIW_/_:_]_E_QH_M73O\
MG_M?^_R_XT44 ']JZ=_S_P!K_P!_E_QH_M73O^?^U_[_ "_XT44 ']JZ=_S_
M -K_ -_E_P :/[5T[_G_ +7_ +_+_C110 ?VKIW_ #_VO_?Y?\:/[5T[_G_M
M?^_R_P"-%% !_:NG?\_]K_W^7_&C^U=._P"?^U_[_+_C110 ?VKIW_/_ &O_
M '^7_&C^U=._Y_[7_O\ +_C110 ?VKIW_/\ VO\ W^7_ !H_M73O^?\ M?\
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M_O\ +_C110 ?VKIW_/\ VO\ W^7_ !H_M73O^?\ M?\ O\O^-%% !_:NG?\
M/_:_]_E_QH_M73O^?^U_[_+_ (T44 ']JZ=_S_VO_?Y?\:/[5T[_ )_[7_O\
MO^-%% !_:NG?\_\ :_\ ?Y?\:/[5T[_G_M?^_P O^-%% !_:NG?\_P#:_P#?
MY?\ &C^U=._Y_P"U_P"_R_XT44 ']JZ=_P _]K_W^7_&C^U=._Y_[7_O\O\
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M?^U_[_+_ (T44 ']JZ=_S_VO_?Y?\:/[5T[_ )_[7_O\O^-%% !_:NG?\_\
M:_\ ?Y?\:/[5T[_G_M?^_P O^-%% !_:NG?\_P#:_P#?Y?\ &C^U=._Y_P"U
M_P"_R_XT44 ']JZ=_P _]K_W^7_&C^U=._Y_[7_O\O\ C110 ?VKIW_/_:_]
M_E_QH_M73O\ G_M?^_R_XT44 ']JZ=_S_P!K_P!_E_QH_M73O^?^U_[_ "_X
MT44 ']JZ=_S_ -K_ -_E_P :/[5T[_G_ +7_ +_+_C110 ?VKIW_ #_VO_?Y
M?\:/[5T[_G_M?^_R_P"-%% !_:NG?\_]K_W^7_&C^U=._P"?^U_[_+_C110
M?VKIW_/_ &O_ '^7_&C^U=._Y_[7_O\ +_C110 ?VKIW_/\ VO\ W^7_ !H_
MM73O^?\ M?\ O\O^-%% !_:NG?\ /_:_]_E_QH_M73O^?^U_[_+_ (T44 <M
7XQO;6?[%Y-U#)MWYV2 X^[1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>hook-20211231x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %[ AL# 2(  A$! Q$!_\0
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MJ"RT>YO]/N[R(H(K49?)Y_"M>7#V;LNQS.>,32O*[5]WL6_^$OU[_H(RT?\
M"7Z]_P!!&6JE[H]S86%K>2E/+N1E,'G\:SZJ-*C)745]Q$Z^)@[2DU\V;?\
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MA;E=\449D*?WB*JZEK9U'2[&R,&P6J[=V<[J?X6FG@UZ%[>XBADP0/.^Z_\
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M]*PJZ,+3=.'*U;5G'CZRK5>=.^B_(****Z#B-O6/^0-H_P#UR;^=8E;>L?\
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MY)^^,;LGUJ.R\.^(]+M1I5E)I1LD?]U=RQ S(F<XQC!/O7:T4<J"Y$\.^T:
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M+8EH85\U!M'YU#_9Q_Y[)230VBE15W^SC_SV2C^SC_SV2GS(5F4J*N_V<?\
MGLE']G'_ )[)1S(+,R[JS@O419TW!'#J0<%6'<58R?4U<_LX_P#/9*/[./\
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MB)+:YEN8'E>1))8]AP3V7L/2LW2(FD\6^,/*4"=D14;'.=O'-=D % "@ #@
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M2 D#'&1754TQ1F42F-3(!@/CD#TS3JI(05)-]Y?]T5'4DWWE_P!T4 1T444
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MHZSFK,I,****D9D:U]Z'\?Z5CRRQP1-+-(L<:C+,QP!6QK7WH?Q_I7'^,/\
MD3]3_P"N5;1^$A[FTK*Z!T8,K#((Z$4M5-(_Y UCZ>0G\JXF7QM<70N[VVUG
M3;2*WD9(K&:,L\P4X)+=L]J;DD*QZ#17)7OB*YGLM/NX-2L=)M;J+>9;A?,D
M+?W53T]ZHV?C6^ET&=P(+B_^VBRMY0A1)">CE3R/I2YD%CMGN8(YDA>9%E<$
MHA/+ =2*6"XAN8A+!*LD9. RG(KB9HM8MO'VCIJES;W>VVG:*:*/9S@94BF6
M_B'6I[+0X[$VD4U]/+'(3%A5 )Y '>CF'8[VBN._X2;4='37(-6>&\GT]$>&
M6)-@EW\ $=N:2YU#Q3I5WHPO;FSG@OYU241Q;3#D9VCGGZT<R%8[$D*I9B !
MR23TH5E=0R,&4\@@\&LGQ8D[>%]26WF$+B%OF*[N.XKG].U#6+?2- T:TN8'
MOKR#S/M,D?RPQ ?W<\FFW9A8[>BL#1]2U$:W>:'JSPS7$$:SQ7,2[1+&?5>Q
M!I-3U'4Y_$$6B:3-#;2B'SYKB5-^T=@!1<+&NVH62+(SW40$3!)"6^ZQZ ^]
M6:\TMK[4-,L/$5Q.ENUX-2B1\IN1LD#(!]JUM4\2:BGB&[T]-3LM*$"H;=+N
M(D79(R?GZ =J7,.QVM%<U>ZKJ\]]I^DV+6MM>W$!FN)R/,2,#^[ZYIEUK6N:
M;H\<=W:PG59[D6UN_2.3/_+3';CM3YD*QU%%<PFI:SI&LPZ=JUS;WB7D+O!<
M11>64D49*D9Y'O6/!X@\3KX<M_$-Q<V36YFV/:B+EEW8W;L\'VI<P['>&6,.
M4,BA@-Q7/('K203Q7,*S02+)$WW74Y!KC(UU ?$749Q>H81IXD\HQ=5[+G/Z
MU%:Z_K=S:^&(+%K2&74EE\YC%\J!>A '\J.8+'>45Q4GB+6;"QUVWNIK>:^T
M[8T=PD>T.K>J^M:NH:Q=VUUX>CC*;;^3;/E>HVYX]*?,A6.@IID175"ZAV^Z
MI/)KA=<\3ZGIQO9CK6F02V[$QZ<D1E9U']YAT)_2EFDU#4?&WAR\BNT@2>S:
M41>7NV\ L,YYS2YAV.WAN(;E6:"59%5BK%3G!':I*XBW\2:@UB+>TBMA?W6H
M26\+;,(BCJQ ZFKG]KZOI6H7.EZG/!=2-9275K=1Q[,E1RK+1S(5CJZ*X2#7
MO$L&C:3K=[<6<EM=NB26J18(#' 8-GK[5W9IIW"P=JLWO^M3_KF*K=JLWO\
MK4_ZYBCJ!6HHHI@%%%% !113)A*8)!"564J=A;H#VS0!)@@9(.*2N.:UO='U
MK2D35[F[O[IS]J@=LQE.[ ?P@5M>([Z6TLH8+9MMS>SK;1L/X<]6_ 4KA8V
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M/NVFO+6PEEG;-Q=>:2^/11V'M5_Q3"PM;'4$4M_9]VD[@#G9T;]*W:0@,""
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M5$5$4*BC"J!@ 4_RW_N'\J/+?^X?RH ;13O+?^X?RH\M_P"X?RH ;13O+?\
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MV+_='KTIOE1@D[%R>O%/HH KW-G%=H%D! _V3C-2)!$BH%10$&%XZ5)10 @
M'08I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>hook-20211231x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &8 GT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4\G@<<50TCP]K-K9::;O3K@S_P!C7-DZA0=CF0LH8C@9'2@#T7_A)-$V._\
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MPR>E;V@?:+V9]7G10MU:P"(@\D;2S<=OF8TW3Y$VPN3^'O\ CSN_^O\ NO\
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M5+478\^/;OBZ9'XD<>XIJZ=K$]C/97$>GQ1RV[1;X0=V2N!VJ"\\(M?826Y
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M\5?]!-?^_2UO?$]H_B9?N>[_  *7_"'^)_\ H#WW_?)H_P"$/\3_ /0'OO\
MODU=_P"%E^*O^@FO_?I:/^%E^*O^@FO_ 'Z6B^)[1_$/W/=_@4O^$/\ $_\
MT![[_ODT?\(?XG_Z ]]_WR:N_P#"R_%7_037_OTM'_"R_%7_ $$U_P"_2T7Q
M/:/XA^Y[O\"E_P (?XG_ .@/??\ ?)H_X0_Q/_T![[_ODU=_X67XJ_Z":_\
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M^_[Y-7?^%E^*O^@FO_?I:/\ A9?BK_H)K_WZ6B^)[1_$/W/=_@4O^$/\3_\
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M4>Y\U_\ "'^)_P#H#WW_ 'R:/^$/\3_] >^_[Y-?2E%']JU/Y4'U*/<^:_\
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MJ_Z!'_Y,=QX>M=.T&VFA74X9?,?=DL!CBMG^U+#_ )_(/^^Q7EW_  B&N_\
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M]0P__/U?@']L8W_H'?X_Y'J/]J6'_/Y!_P!]BC^U+#_G\@_[[%>7?\(AKO\
MSY-_WV/\:/\ A$-=_P"?)O\ OL?XT?4,/_S]7X!_;&-_Z!W^/^1ZC_:EA_S^
M0?\ ?8H_M2P_Y_(/^^Q7EW_"(:[_ ,^3?]]C_&C_ (1#7?\ GR;_ +['^-'U
M##_\_5^ ?VQC?^@=_C_D>H_VI8?\_D'_ 'V*/[4L/^?R#_OL5Y=_PB&N_P#/
MDW_?8_QH_P"$0UW_ )\F_P"^Q_C1]0P__/U?@']L8W_H'?X_Y'J/]J6'_/Y!
M_P!]BC^U+#_G\@_[[%>7?\(AKO\ SY-_WV/\:/\ A$-=_P"?)O\ OL?XT?4,
M/_S]7X!_;&-_Z!W^/^1ZC_:EA_S^0?\ ?8H_M2P_Y_(/^^Q7EW_"(:[_ ,^3
M?]]C_&C_ (1#7?\ GR;_ +['^-'U##_\_5^ ?VQC?^@=_C_D>H_VI8?\_D'_
M 'V*/[4L/^?R#_OL5Y=_PB&N_P#/DW_?8_QH_P"$0UW_ )\F_P"^Q_C1]0P_
M_/U?@']L8W_H'?X_Y'J/]J6'_/Y!_P!]BC^U+#_G\@_[[%>7?\(AKO\ SY-_
MWV/\:/\ A$-=_P"?)O\ OL?XT?4,/_S]7X!_;&-_Z!W^/^1ZC_:EA_S^0?\
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M_?X_YGC_ /;^M?\ /_=?]]&C^W]:_P"?^Z_[Z->P?9K?_GA%_P!\"C[-;_\
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M>I_*@_U;H_SO\#QO^PM:_P"?*Y_(T?V%K7_/E<_D:]DHH_M>I_*@_P!6Z/\
M._P/&_["UK_GRN?R-']A:U_SY7/Y&O9**/[7J?RH/]6Z/\[_  /&_P"PM:_Y
M\KG\C1_86M?\^5S^1KV2BC^UZG\J#_5NC_._P/&_["UK_GRN?R-']A:U_P ^
M5S^1KV2BC^UZG\J#_5NC_._P/&_["UK_ )\KG\C1_86M?\^5S^1KV2BC^UZG
M\J#_ %;H_P [_ \;_L+6O^?*Y_(T?V%K7_/E<_D:]DHH_M>I_*@_U;H_SO\
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MB8YJZLO8VY>FQL?\+!L?^@=+_P!]"C_A8-C_ - Z7_OH5C_V'I__ $#?$/\
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MG8?%T=Q'YD6C:RZ[BN1:'J#@CKZ@U)_PE'_4#UK_ ,!#_C0!O45@_P#"4?\
M4#UK_P !#_C1_P )1_U ]:_\!#_C0!O45@_\)1_U ]:_\!#_ (U$_C"*.>*%
M]'UD22YV+]D.6QU[T ='16#_ ,)1_P!0/6O_  $/^-'_  E'_4#UK_P$/^-
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M488-/U>WBMM2CD0E]J$D&,^I!(YJ>T\%W=M/8-Y\.RVUF;4"!GF-U90OUYH
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M1110 4444 ! /6BBB@ (!&",BBBB@ P!T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>hook-20211231x10k021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '; EH# 2(  A$! Q$!_\0
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M:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH
M3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#T
MHP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]
M*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:*
M $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3
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M;,6+B6UNH7_?1R#G?GN3DY]<U:\->%(O#SW5U+?76HZC=D>?>71!=@.B@#@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:$DWY-&_1114&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%!.!F@
MHK*C2;4W>1IGBMP2J+&<%O<FI/['A_Y^+O\ [_&KY4MV1S-[(T:*SO['A_Y^
M+O\ [_&C^QX?^?B[_P"_QHM'N%Y=C1HK._L>'_GXN_\ O\:/['A_Y^+O_O\
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M>X7EV-&BL[^QX?\ GXN_^_QH_L>'_GXN_P#O\:+1[A>78T:*SO['A_Y^+O\
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M4,KKM/\ &K,HVD&@#W"LC1O$-IKEQJ$%JDRM8SF"7S%P"P].>17$6%M?>/\
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ML:'_ )^+K_O\:/[&A_Y^+K_O\:T:*/:2[A[./8SO[&A_Y^+K_O\ &C^QH?\
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M-<&BOJUO_:1!/V=2688&3G' X[&M.PU"SU2RCO+"YCN+:0926-L@T 6:***
M"BBN3UWQY;:/JDFFVVE:GJEU!&);A;*#>(5/3<3W/I0!UE%<M=>/M&@\,6NN
MQ_:+B&[81V\$,>9I)"<; O\ >!!SZ8JUX:\5VGB3[3$EM=65[:L!/:7<>R1,
M]#[@^HH WZ\&^.?_ "//A'_?/_H:U[S7@WQS_P"1Y\(_[Y_]#6@#W.[_ ./.
M?_KFW\J\!TS_ )!=K_US_J:]^N_^/.?_ *YM_*O =,_Y!=K_ -<_ZFO7R?\
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M#?W/$G_80'_H-7F_\*/J9<-?[Q/T_5%/X]*K:'HH901_:"\$9_A->0?9K?\
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M88/RC_XBN:A^&_Q1@A2)+O1 B# RW_V%?05%:4ZLZ;O!V,:V'I5DE5BG;N>
M_P#"O?BI_P _>A_]]?\ V%7-)\(?%W1;J>YLKW0EDG54<L<\+G'\'O7N5%5/
M$59KEG)M$4L'AZ4N:G!)^2/%]5T#XRZUILUA>7^@M!*,,%&#^>VLG_A7OQ4)
M_P"/O0_^^O\ ["O?J*FG6J4_@DT56PM&M9U8IV[H\!_X5[\5/^?O0_\ OK_[
M"K>@^#_BYX<%V-.O="3[7+YLN\[LMC'&5XKW.BG4KU*BM.38J.%H47>E!)^2
M/"?$G@KXM>*[:W@U6]T.2.WE$T>P[<,!CLM8G_"GOB+_ ,_&C_\ ?T__ !-?
M2-%*%6<-(NQM*$9?$CYM/P=^(K*0;C1\$8_UI_\ B:Z?1/#GQC\/Z/;Z7I]_
MH*6MNNV-6^8@9SUV^]>UT4IU)S^)W",(Q^%'SQXH^%WQ-\87\5[J]UHLDT2>
M6ICD*#'T"UA_\*"\;_\ /72?_ AO_B:^HZ*N&(JTURPDTAM)GRZOP#\<*ZL)
MM)RI!'^D-V_X#7HD5A\;88DB34?#X5%"CY1T'_ :]>HJ*E6=1WF[@E8^>]8^
M&GQ0UW5)-1OKK16N9%56*OM&!TXVU1_X4]\1?^?C1_\ OZ?_ (FOI*BJC6J1
M5E)DNE!N[1\ZV/PJ^)>G:C;7UO<Z*)[>021DR$@'Z;:Z_P"R_&__ *"/A_\
M[Y'_ ,37K=%1*<IN\G<<8J*LD?/X^'?Q3#2,+O1,R.TC?-W)R?X*=_PKWXJ?
M\_>A_P#?7_V%>_45JL56BK*;^\Y99?A92<I4TV_)'@-M\/?BI::S:ZK%=Z(+
MJV#+&Q;@ ]>-G-;E[I/QIO[*>TGU#0##,A1P!@X(P?X:]BHK*<Y3?-)W9TTZ
M<*45""LCYKA^#?Q$@A2)+G2 B# _?'_XFG_\*@^(W_/SH_\ W]/_ ,37TC16
MBQ%5:*3%[&GV1X'X=\ ?%;PO=W5SIEYHB2W("R%VW9 Z=5XK8OO^%Y6=JTT<
MVCW3 X\JW12Q_P"^@!^M>R45DVV[LM))61X-_;/QY_Z!47_?F'_XJC^V?CS_
M - J+_OS#_\ %5[S12&>-6!^.5[;":272+0Y(\NX1 WU^4$?K65XL\2_%SP9
MIL=_JFH:,87D$8$,08Y^A45[U7.>,?!FG^-M+CT_49;B**.02 P,%;/X@U4;
M77-L!\Z_\+R\??\ /[9?^ JT?\+R\??\_ME_X"K7J/\ PSSX4_Y_]6_[_)_\
M31_PSSX4_P"?_5O^_P G_P 377SX/^27WDVD5M-E^-.JZ;;7]OJ.@B&XC$B;
MT .#Z_+6%XC\8_%CPOJ$5E?ZAI!EEC\Q?*B5AC./05[OI>G1:3I5MI\#.T5O
M&(T+G)('K7B_QF_Y&^P_Z\S_ .A&L,/!5*BB]B:LG&#DCF?^%I_$K_G^TW_P
M'7_"HY_BU\2+>%I7OM.VKUQ;K_A6-5/5/^0;-^'\Q7I5,#2C%M7.*.*J.23/
M8[>/XV7-O'.FHZ!LD4.N5&<$9_NUR>H>/OBKINI7UE-=Z:SV3A)G2!2H)&1S
MBO?M(_Y UE_UP3_T$5X=J.HVUM\3/$UG=*/+N)D&X]/N]#7E4X\TK6N=\W9;
MV,VQ^(WQ-O[@01ZEI*.>GF0J,_I5N?QK\6+?4[&P>\TKS+V3RHG$*E=WN<<5
MEZYH;Z;+]IMLFW)R".J&IM-UM]0\0>&+:<$S1Z@#O_O#:?UKJJX>')[2EJC"
MG6ES<D]SMVM_C<B%CJ7A_ &?NC_XFN/L?B!\4M0MO/AO]*V;F3YH5!R#@]J^
MA[C_ (]9?]P_RKYS\,?\@;_MO+_Z&:,!AX5ZCC/:QQYQC*N$H*I2WO;7YE[_
M (3+XK_\_P#I'_?I?\*LZ9XE^+FJZHFG6^H:,)WC:4;XU P" ?X?>EK;\#_\
MCY;?]>4O_H2UW8O+Z-*BYQO='DY;G&)Q&*C2J6L[]/(9=+\;+.SFN9=1T#RX
M8VD;"#. ,G^&N&7XJ_$ET#"^T[!&1_HZ_P"%?1.O_P#(NZG_ ->DO_H!KY6@
M_P"/>/\ W17!@Z$*K?-T/HL15E32Y3H?^%I_$K_G^TW_ ,!U_P *W_#/B3XN
M^*TNFT[4-& MG"/YL07DC/&%-<'7K?P0_P!1KG_7PG_H K7%86G2I\T2*%><
MYV9E>(M5^,7AC1I=4O\ 4=$-O&RJPBC#-EC@<;1ZUF#QG\5R ?[0TCG_ *9+
M_A7HOQD_Y)O>_P#7:'_T,5P:_<7Z"JR_"4\0I<_0\W.LQK8-P]E;6^_R*P\9
M?%<G']H:1_WZ7_"K_AO7/C!XILI[O3]0T41PSM WFQA3N7KT4\5&OWA]:Z[X
M+?\ (LZG_P!A2;^8IYA@Z=",7#J3DV95\9.<:MM%T*^G6WQD&I6IO]0T)K,2
MKYX11N*9^;'R]<5ZD.G-%%>6?0!1110 4P]33Z8>IH ?1110!#=74%E:RW5U
M,D,$2EGD<X50.Y-<4?BWX;+YAAU:XM\\74.GR-$1ZAL<BG?%B6&'P:C70)L_
MMUO]I7:6!B\P%@0.2,"H4^,'@2*,1IJ;JBC"JME* ![#;0!V&CZUIVOZ<E_I
M=W'=6KY =#W'4$=0?8U>/0XKSOX=:IINJ^)_%=UHISILTT$B8B:,&0IAS@@<
MDBMKQKJ^K67]E:9HDD$%]JEU]G6YF3>L*A2Q;;W.!P* /+I?"%I&LFIZUX7O
M;^\LM5E&IEE:1KBWDW%7CP?F"C;P.E>C?"^S2R\,3I;:9+I]@]Y*]I'.NV5H
MB>&<'D'Z]L5A10>+M>\2W'A?4/$TMK'ID"W$M]IL0AEN3(3L!SD*!@YQUKI_
M .IZA?:7?VFIW)NKG3;^6R-R5"F8)C#$#O@T =91110 445Q^N>+=:M]8GT[
M0/#,NJ-:H'N9GG6%%SR%4G[QQ0!V%%<5-\0X6\+Z?J=AIEQ<W^H3&VM]/R%?
MS@2&5B> !@Y-7_"_BJXUF[O=,U32WTO5K,*TEN91(K(W1U8=1QB@#IJ\&^.?
M_(\^$?\ ?/\ Z&M>\YKP7XY_\CSX1_WS_P"AK0![U1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>.?%OP]K^J>([*ZTG1KB_B6V*.T3*-IW9[FO8Z*N$W"7-'<F
M45)69\N_\(AXT_Z%"_\ ^_D?^-0W7@CQK=6SPCPG?*6Q\Q=..?K7U116[QE9
MJS9DL-33ND5-,B>'2[2*12KI"BLI[$ 5X-XR\'^);GQYK-[:Z#>W-M<2!HY8
M@I# #W85]"45C3J.G+FB:3@IQY6>#:18>*(+9K34O"^J20XPK!$8X]"-U4]/
M\&:ZOCC1[JWT#48;&&Z$CO.J*$&/9C7T+15.O)W\Q*E'3R(YE+6\B@9)4@#\
M*\"T?P]XBTVQ:VG\.:H7$TC9CC0@@L2.=U?0-%.AB)T)<T-S'&8.EBX>SJWM
M>^AX;_9FN_\ 0M:O_P!^D_\ BJWO!&E:M'XPBN[K1[VTMX[61#)<*JC<2, 8
M)]*]4HK:MF%:K!PE:S.3#9-AL-556G>Z\_\ @&=K_P#R+NI_]>DO_H!KY6@_
MX]X_]T5]4Z__ ,B[J?\ UZ2_^@&OE:#_ (]X_P#=%:Y=O+Y'1C-D25ZW\$/]
M1KG_ %\)_P"@"O)*];^"'^HUS_KX3_T 5T9A_"^9EA/XAN_&3_DF][_UVA_]
M#%<&OW%^@KO/C)_R3>]_Z[0_^ABN#7[B_0563[3^7ZGB\3;T_G^@Y?O#ZUUW
MP6_Y%G4_^PI-_,5R*_>'UKKO@M_R+.I_]A2;^8JLX^"/J9\-?Q:GHOS/2J**
M*\$^P"BBB@ IAZFGTP]30 ^BBB@#(\3Z[!X;T&XU*>%Y]F%CA0?-+(QPJCZD
MBN633/B3=P_:WUC1;&5OF6Q%F9$3_99\Y)]Q6[XWT6[USPU)!IY07T$L=U;"
M3[K21L&"GV.,?C6)'\5-/BA\O4-%URUU%1A[,6#NQ?N%8<,,]Z -KPAX@N-9
MM[RUU*S2SU?3YO(O(4.4)QE70]U8<BI?%'A&Q\60VB7ES>VS6LIEBELYO*<-
MC'7Z&J'@NPU)[K5O$.K6OV.YU65&CM"<M#"B[4#?[1Y)]*ZXG S0!YVOP?TA
M+F2Y37O$JSR*%>4:DP9@.@)QD@5U/ACPO9>%-/FL[*:ZF6:9IY)+J7S'9SC)
M)_"N3L_%/CWQ )[W0M$T5=.6>2&+[;<N)6V,5)(48'(Z5V/AZ77I=/9O$-M8
MP7F\X6RD9TV]N6YSUH UJ*** .>\17?BNWG@'A[3-.O(BI\UKNX,94]L8'-8
MOB+Q?.+M/#MA=6%GJKPJ][=7$P6*S5AVSC>W7 _$UW=85_X+\,ZI>/=W^AV-
MS</]Z26$,Q_$T <??QZ1X8;P;<P7<<ND6ES)%+>F0,N^1"-[,..6/)]ZTM#O
M;;6?BCJM[ITJ3VMMI\=M)/$0R&0ONVY'7 _G74P^']'@T@Z3%IMJNGG.;81#
MR^>O'2I].TNPTBT6UTZS@M;=>1'"@4?I0!Y[K'A7XG76L7<^F^-;6ULI)2T$
M#0 E%[#[AKRKQ_I/BK2O&'AM/%&NQ:K(\H,+1IMV#<N>PZ\5]15X+\<_^1Y\
M(_[Y_P#0UH ]ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,[7_^1=U/_KTE_P#0#7RM!_Q[Q_[HKZIU_P#Y%W4_^O27
M_P! -?*T'_'O'_NBO2R[>7R.+&;(DKUOX(?ZC7/^OA/_ $ 5Y)7K?P0_U&N?
M]?"?^@"NC,/X7S,L)_$-WXR?\DWO?^NT/_H8K@U^XOT%=Y\9/^2<7O\ UUA_
M]#%<&OW%^@JLGVG\OU/%XFWI_/\ 0<OWA]:Z[X+?\BSJ?_84F_F*Y%?O#ZUU
MWP6_Y%G4_P#L*3?S%5G'P1]3/AK^+4]$>E4445X)]@%%%% !3#U-/IAZF@!]
M%%% '.>-]:O-#\.-/IPC^VSS1VT#2C*H\C!0Q]AG-<_JUSXB&H:)X.LM<*ZC
M+ ]S?ZK]G4NL:\#"= 68X_"NRUW0[+Q%H\^F7Z,UO,!DHVUE(.0RGL00#6)H
MO@A=!.H7D&JWEYK%U"(1?7S"1HU'W5 X& >?>@!O@S4M6-[J^@ZU=)>W>ERH
M%O%389HW7<I91P&'0XKK3T-8'A3PN/#=K=-->RW^H7LOG7=W* #(^,# '  '
M %;Y. : /"-+?PU=W&J3ZS\1+S2]2>^E\ZWL+\6\/#84J ,'@#)]:]3\$C2U
MT5QI/B&YURW\TYN;BY\]@V!\N[T]O>N+MK'7O%[W6IZ+8^&-/TY;B2*%+K3Q
M-+-L8@LQ'W<D'BNP\!ZF-1T2='TZTT^\M+J2UNH;10(O,4\E< 9!&* .IHHH
MH ***P?%_B>#PIH,U^\9FGP1!;KUE?&<?3@DGT% &]17':AXSNK?PSHUW::<
MMWJVKJBVUHLFU-[+N)+'HH'>K'A;Q/?ZG?WNCZWI\=AJ]FJR/'#)YD<D;='4
M^G&* .IKP+X])))XQ\*I%+Y4C%@L@&=IWKSCO7OM>"_'/_D>?"/^^?\ T-:
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M\?VGC"T\8>&QXNU&SO)6E'D&V4 *-RYS\H]J^HJ\&^.?_(\^$?\ ?/\ Z&M
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MKP;XY_\ (\^$?]\_^AK0![S1110 4444 %%%% !1110 4444 %%%% !1110
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M_?/_ *&M>\UX-\<Q_P 5SX1_WS_Z&M 'O-%%% !1110 4444 %%%% !1110
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M1:/<+R[&+K6B7FO>+]+:XB"Z1IF;D$L#YTYX48[!1SGU-=76=_8\7_/S=_\
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M_A7K=% 'DG_"B++_ *&O7_\ O^/\*/\ A1%E_P!#7K__ '_'^%>MT4 >2?\
M"B++_H:]?_[_ (_PH_X419?]#7K_ /W_ !_A7K=% 'DG_"B++_H:]?\ ^_X_
MPH_X419?]#7K_P#W_'^%>MT4 >2?\*(LO^AKU_\ [_C_  H_X419?]#7K_\
MW_'^%>MT4 >2?\*(LO\ H:]?_P"_X_PH_P"%$67_ $->O_\ ?\?X5ZW10!Y)
M_P *(LO^AKU__O\ C_"C_A1%E_T->O\ _?\ '^%>MT4 >2?\*(LO^AKU_P#[
M_C_"C_A1%E_T->O_ /?\?X5ZW10!Y)_PHBR_Z&O7_P#O^/\ "C_A1%E_T->O
M_P#?\?X5ZW10!Y)_PHBR_P"AKU__ +_C_"C_ (419?\ 0UZ__P!_Q_A7K=%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %,/4T^F'J: 'T5%N/K1N/K0!+146X^M&X^M $M%1;
MCZT;CZT 2T5%N/K1N/K0!+146X^M&X^M $M%1;CZT;CZT 2T5%N/K1N/K0!+
M146X^M&X^M $M%1;CZT;CZT 2T5%N/K1N/K0!+146X^M&X^M $M%1;CZT;CZ
MT 2T5%N/K1N/K0!+146X^M&X^M $M%1;CZT;CZT 2T5%N/K1N/K0!+146X^M
M&X^M $M%1;CZT;CZT 2T5%N/K1N/K0!+146X^M&X^M $M%1;CZT;CZT 2T5%
MN/K1N/K0!+146X^M&X^M $M%1;CZT;CZT 2T5%N/K1N/K0!+146X^M&X^M $
MM%1;CZT;CZT 2T5%N/K1N/K0!+146X^M&X^M $M%1;CZT;CZT 2T5%N/K1N/
MK0!+146X^M&X^M $M%1;CZT;CZT 2T5%N/K1N/K0!+146X^M&X^M $M%1;CZ
;T;CZT 2T5%N/K1N/K0!+3#U--W'UI,T ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>hook-20211231x10k022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &V QH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P BS>?[H_F*VZQ/%W_(LWG^Z/YB@#7M_P#CVB_W!_*I*CM_^/:+_<'\JDH
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M^<P.3L5<\<$$9% T:=%&1ZT9'K0(**,CUHR/6@ HHR/6C(]: "BC(]:,CUH
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M'_"7>(?^@Q=_]_*]@_X17X8?\]X__ BC_A%?AA_SWC_\"*/93_F_$/[0P_\
MSZ?_ (">/_\ "7>(?^@Q=_\ ?RC_ (2[Q#_T&+O_ +^5[!_PBOPP_P">\?\
MX$4?\(K\,/\ GXC_ / BCV4_YOQ#^T,/_P ^G_X";_PJOKK4/!4,]Y<23RF1
M@7<Y-=M7(Z)JWA#P_IRV.GZC!' I)"F3/)K1_P"$R\/?]!6V_P"^ZZX-**39
M\[B(3J593C%V;[&[16%_PF7A[_H*VW_?='_"9>'O^@K;?]]U7-'N8^PJ_P K
M^XW:*PO^$R\/?]!6V_[[H_X3+P]_T%;;_ONCFCW#V%7^5_<;M%87_"9>'O\
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MRC\2L3T4451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^B/^%A>'O^@:_P#WZ6C_ (6%X>_Z!K_]^EH]G3_F#ZUC/^@=_>?._P!ENO\
MGA/_ -\&C[+=?\\)_P#O@U]$?\+"\/?] U_^_2T?\+"\/?\ 0-?_ +]+1[.G
M_,'UK&?] [^\^=_LMU_SPG_[X-'V6Z_YX3_]\&OHC_A87A[_ *!K_P#?I:/^
M%A>'O^@:_P#WZ6CV=/\ F#ZUC/\ H'?WGSO]ENO^>$__ 'P:/LMU_P \)_\
MO@U]$?\ "PO#W_0-?_OTM'_"PO#W_0-?_OTM'LZ?\P?6L9_T#O[SYW^RW7_/
M"?\ [X-'V6Z_YX3_ /?!KZ(_X6%X>_Z!K_\ ?I:/^%A>'O\ H&O_ -^EH]G3
M_F#ZUC/^@=_>?._V6Z_YX3_]\&C[+=?\\)_^^#7T1_PL+P]_T#7_ ._2T?\
M"PO#W_0-?_OTM'LZ?\P?6L9_T#O[SYW^RW7_ #PG_P"^#1]ENO\ GA/_ -\&
MOHC_ (6%X>_Z!K_]^EH_X6%X>_Z!K_\ ?I:/9T_Y@^M8S_H'?WGSO]ENO^>$
M_P#WP:/LMU_SPG_[X-?1'_"PO#W_ $#7_P"_2T?\+"\/?] U_P#OTM'LZ?\
M,'UK&?\ 0._O/G?[+=?\\)_^^#1]ENO^>$__ 'P:^B/^%A>'O^@:_P#WZ6C_
M (6%X>_Z!K_]^EH]G3_F#ZUC/^@=_>?._P!ENO\ GA/_ -\&C[+=?\\)_P#O
M@U]$?\+"\/?] U_^_2T?\+"\/?\ 0-?_ +]+1[.G_,'UK&?] [^\^=_LMU_S
MPG_[X-'V6Z_YX3_]\&OHC_A87A[_ *!K_P#?I:/^%A>'O^@:_P#WZ6CV=/\
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M?\^!_P"^A5G_ (6'KG]]/RH_X6'KG]]/RHM1\PYLS[0_$K?\(+XB_P"? _\
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M4?\ "J6_Z"I_[XKTJBCZO3[!_;6-_G_!?Y'FO_"J6_Z"I_[XH_X52W_05/\
MWQ7I5%'U>GV#^VL;_/\ @O\ (\V3X5LDB/\ VH3M8'[E>CHNR-5ZX %.HJX4
MXP^$Y,3C:^*M[9WL%%%%6<H4444 %%%% !1110 4444 %%%% !1110 4444
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MKQ4ROT-:2B[\W9_>=QY4?_/-?RH\J/\ YYK^5/HJC.[&>5'_ ,\U_*CRH_\
MGFOY4^B@+L9Y4?\ SS7\J/*C_P">:_E3Z* NP  & ,"BBB@04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_#U-:>%8;6ZBG$[$HV<4U&I<F>(P;BTDK^AT-%%%=!X84444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/YD7_P#A$+[_ )Z1T?\ "(7W_/2.J']OZE_S\FC^W]2_Y^31>'8.3&?S(O\
M_"(7W_/2.C_A$+[_ )Z1U0_M_4O^?DT?V_J7_/R:+P[!R8S^9%__ (1"^_YZ
M1T?\(A??\](ZH?V_J7_/R:/[?U+_ )^31>'8.3&?S(O_ /"(7W_/2.C_ (1"
M^_YZ1U0_M_4O^?DT?V_J7_/R:+P[!R8S^9'H4"&.WC0]54 U)7G::_J1D4&X
M."17H2'**3W%;PFI;'C8K"SH-.3W'44459RA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$ C!&12UG:Y?R:9
MH\]W$JL\8! ;IUH T:*9$Q>%'/5E!-/H **** "BBB@ HHHH **** "BBB@
MHHHH Y_6/^1ET3_??_T&I-8\,V^KW:W1GF@E\LPNT38WH>QHU:"63Q!H\B1L
MR1N^]@.%X[UN4 <M=>![*>[:2.>:&!X8X9(8S@,B=!52VT.TOO$NJHY*^6(U
M50>@"UVE<AI/_)0M9'_3-/Y4FD]S6BY1DY1=FD7O^$1LO[ST?\(C9?WGKH:*
MGV<>QI]<K_S,Y[_A$;+^\]'_  B-E_>>NAHH]G'L'URO_,SGO^$1LO[ST?\
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M*9%>-NJL.#0 EO\ \>T7^X/Y5+2 !0 !@#@4M !1110 4444 %%%% !1110
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M_P#/W!_W\%'V^S_Y^X/^_@K-_P"$1T'_ *!L/Y4?\(CH/_0-A_*@#2^WV?\
MS]P?]_!1]OL_^?N#_OX*S?\ A$=!_P"@;#^5'_"(Z#_T#8?RH TOM]G_ ,_<
M'_?P4?;[/_G[@_[^"N3\.>&=&GAOC)I\3%;N11G/ !K:_P"$1T'_ *!L/Y4
M:7V^S_Y^X/\ OX*/M]G_ ,_<'_?P5F_\(CH/_0-A_*C_ (1'0?\ H&P_E0!I
M?;[/_G[@_P"_@H^WV?\ S]P?]_!6;_PB.@_] V'\J/\ A$=!_P"@;#^5 &E]
MOL_^?N#_ +^"C[?9_P#/W!_W\%9O_"(Z#_T#8?RK&\/^&-&G;5O,L(F\O494
M7/8 +Q0!U?V^S_Y^X/\ OX*/M]G_ ,_<'_?P5F_\(CH/_0-A_*C_ (1'0?\
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M1D9H Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMY&,6I1W"J%.75<9QZ\9K<\+'[;J&L:RL4D<-[+&(O,0JQ5$"YP?>NFP/2@
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M7&IV,OB3P8-&N)KG6-1$]K=*G[LQL022?;%>ZJH484 #T H*J6#%06'0XYH
M\2N=-N8?#GCF#[/(S_:(50[>7P%&177^/H;A_A:C0P2320BWE:-!EB%()XKO
M?+3GY%YZ\=:4J"NT@$>E 'DFBV\^OZGXXGM[::(:A9Q>1YJ[228^E<GX2TJ6
MWL+Z?2=#U.+6+#3WCDFNGRGF]"J*>O'-?0RHJ_=4#Z"E"J,X4#/7 ZT ?-_A
MZPN[H>(Y(;75'>[T0X:\'S22 _,%]O05T5M<2ZQJ<=[%97,:?\(N\.)(R"'7
M@C]*]M$:#HBCMP*!%&.B*.,=.U 'A$FAWNHVFA6<-O(KOX>EC^[C#9SCZUE:
M3HUN_A7Q#+9:)JD-S!I1MY9KIR=TA(RB+Z<5]&!$!!"J".!QTH\M,$;%P>HQ
MUH \AO[&ZDUWP^L5M)_R+4T9PO 8H, ^]:NB3MJOP2EMA;SP3063P.DJ[3N4
M'.*])V+D':,@8!QTILD$<D#PE!L=2K#'4&@#Q$Z]%X?U?P9K4UI=W%HNCF-C
M;QER":AU277;W1-;\51V-[:6^IZA"GE(O[];5!@L!V)KV/0M"@T32(M.0^;'
M$6V%QD@$YQ6IL4KMVC;Z8XH ^?=-TV:U^'GB"Z@M[J*:QOUOK;[9_K"H'5CW
M)%:VHZ;#;_#+1)M2TJ\N8YIC=7%Q9-B>V9^=R^OI7IOBOPM%XIT^.RDNI;:$
M2!Y1$<>:H_A/M6W#;106L=LB#RHU"*I'&!0!XK:'5)O GAJ#44F$TNNH;83+
MB0PALJ6'KBO;ZR=1T*'4M7TN_E<@:>S/'&.A8C&3]*UJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:-YH DHJ/>:
M-YH DHJ/>:-YH ;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% %+4]6LM(@$U[.(U8[5&,LQ] !R
M:9IFMZ?K$<CV5P'\LX=6!5E^H/-8FM31Z;XRT_4]0^6P6UDB2=AE(92PY;TR
M.,^U<OK&J3:C!KJQ26MS$88Q]NL8V7/SCY"W0G'I0!Z@9H@ 3*@!Z'<.:=D<
M\CCKSTKRKQ9%86SR:9#;06Y@T_?'+<R.=Q*DXB0'EL]33K.2\2/1(%>=_P#A
M(=/MXY)-Q^22,#>WL=I.?I0!ZD70,%+J&/09Y-5K_4[+3(1+>7"1(75!D_Q,
M0JC'N2*\PNXIYM?U$7FJ6]C>17BBU$D;M,(QC;Y>#@@\]JK:Y]ADM)3J<CGQ
M"-:@VJ2=QC\U=N%_N;: /8F(4$L0 .I)H#*0"&!!Z8/6N6\;L@&E"\9ETIKP
M"]()"[<';N(Z+G%<K:W266HVEU'-(F@0ZLP@F=CL"&/GG^[NZ4 >E3ZC:6UW
M;6LTZ+/<L5B0GEB!D_I2W&H6MK=6]M/,J2W!81*W\6!D_I7EVF?8KSQ#I%_<
M_/$=8NECED) Y0E /J<8KI?&ZZ:VO>'/[7?99B:7>22%_P!6<;B.@H [-I$5
M0S.H4]"3P:#(@ )=0#TR>M>2274+6MO931QFS>>9K*XO9'$2Q \8 Y8]<#TJ
M3PE;+JEQX>6_:69(;.=MI+ ;ED^4X]NV: /5PZ,Q4,I8=0#R*"ZJ0&903T!-
M>9>#Y(K3Q/;6\<T6HM,LNZ[B9UE7DD^>A_  \5LZM9?;/'SML:22#2S) A8[
M?,W<''3- ':!T+%0ZEAU /(H61&)"NI(ZX/2O(]"1WDMIQK%NM_Y<QN[>.)_
M.<[&R),G"X.#GBFZ0]C_ &/H;:)<2R7;:?)_:+!V+;?+ZOZ'=C% 'KOFQA2W
MF)@'!.X4K2(H!9U /0D]:\FN;'[)9^'8FE@MM.N+4R3RW>]HWFX^^01@XS4=
M]!%#IUB\^M6]Z(H)-D%TLD,<J[^L;?W@.!U[4 >NLZ(0&=5STR<9H,B*0&=0
M3V)KR34)9=1U,MJ5S%IL#:=;O9)?J[,N5^;:01EP<9[]*EN;#SH_$-W=2S7-
MU:6=L89FW(=P'W@O8F@#T^WU"TNKJYM8)U>:V8+,@/*$C(_0U.9$#;2ZACVS
MS7$^#(;:/Q/K[E%2\E\B0Y)W,IB4D_3.:P-9;33KGB_S;B7^UTF@^PH';(;R
MUQL ]^M 'JID0.$+J&/\)/-4XM8L)G=(KA79)O(8+SM?T->3^(+SSKMYML=M
M?P74*R;Y':X<Y7<0!PJ=:T((HK2[N$LE\N[.NJ752<D%25S[$YH ]4#H6*AU
M+#J,\BF27,,4<DCRH%C4LYST [UY-X;2>1]/N9M6MX]5^?[9;I$YN&;#;EDY
MP!GOC' IUOIL5OIVA-''*TE_;7*7)9F)E&PD _CTH ]4MKZUO+6*Z@G1X91F
M-\\,*L5XS-%I\.A:7+%=6K+%88-C.SH&8$[C&XZ2=L<]J[S7[B\F^'AN+..X
MAFDMXF9,DR(IQN'UQF@#J%D1AE74C..#0710274 =<FO.;^7P]9V]M<:%<-]
MFBO('NGC=FC1>F2>@/K6?+)#K>IS*LLDUE-XEB7*LP5T^SDX'^R?RH ]6$B$
MX#J3C.,T"1&4LKJ0.X->87VGR0P>,[K3XY!=6UW%! P+'RH?+CW;1GT+52DM
MT&D:@+/5X)X)4B#16*.JJ2PY+$G#8ZB@#U2\U*RL+87%S<1QPEUCWD\;B< 4
MMMJ%I>3W$-O,KR6S^7*H_A; ./R(KRSQ!IUG;3ZQ8^3BPA-A/L8L50DX=ORZ
MU8N93I5_J^O6H<I8ZJH*H3AHGA1?Q R#0!ZH#GIS31(C%@'4E>N#TK%MK:\L
MO!KI%N-^;9Y,$Y(E8%L?@3BO/V>T6PA;1I96O&TJZ.J;68D'RCC?GHV[.* /
M6E=')"NK$=<'.*KC4K,ZBVG^>GVI8_-://(7.,UPWANSCTKQ#X=CM1(HO-'+
MW)9B?,<!2"V>_)JMXOM[:'Q+K<^W9<R:,?+<$AF.[G'OB@#TDRQA=QD0+G&=
MPQ2M(B %W50>F3C->7:M8I9W>D6LDUK::6UEO5[P.T;S'&<D$?-CIGWJK?RQ
M_8-/T^[N(;F1+%Y([Z\\Q%=2[;5CCZLV HSZ8/>@#U0:A:-?M8B=/M*H)#'G
MG;ZU-YT6,^8F,X^\.M>.:>D1L!=3EA?RZ" DC$AV8'!Q[@5>&AV:ZC<VXCE,
M0\/_ &G:9&P9N?GZ_>H ]69T0@,ZJ3TR<9H,B*<,Z@GL37C;/<W\J'5M2M[7
M.F6KVDEVCDG,?S-'@C+;NHZ]*O7U@)/^$BO+F2:XNK.SMFAE8LN'"YW!>Q-
M'I]OJ%I=75S;03J\ULP69 >4)&1^AJQN7^\.N.O>N)\&0VL7BC7WV*EW*8)#
MG.YE,:DGZ9S6!X@^VVOB:_TJ%IQ'#-_;J,A/* #<GXOOXH ])OM6LM-#-=SB
M)50R,Q' 4=<FB'5["XNFMHKJ-IEC24KG^%ONG\<5Y7K<4FH6IN9UE<7^G7%T
M8VSP,KM!'J!5B;2]/O)]7G2/?';Z% UN48X5MK'(QWS0!ZNSHI 9E!/0$XS2
M[@,Y(XZ\]*\IGN+6Z@O)]<FE&H-IUL^F?,P8DQY)C ZMOZ_A27^IRVFBZ_:Z
MC</%J<\-LRQDD,S87<5_'.<4 >GVVH6EW<7$$$Z22V[;)5!Y4XS4L5Q#.7$4
MJ.48JP4YVD=0:X[P9;6=MXAU\(BI=,\3,,G<5*#GZ9S52_N[&Y\4.8;^QTB6
M&;;)+]H'FSD'&"@X_.@#MI=3LH;^&QDN8UNI@3'%GYF Z\599E1=S,%'J3BN
M0U+3;6W\=Z)>0PCSY_,\R;J6 7BG>/8HY;.Q\R_AM@LS,$N0WD3'8<*Y'3U'
MO0!UA=%4,SJ%/<GBAI(UQN=1GID@9KR^RNK.[CT,:Q";70DBND >9C$TP<!3
MOX)4KN*YJEXHN=.GAEMK$*J06.;:XO'D+..<")."3QU^E 'KK2(I 9U!/8FG
M5Y!]D74;/6KVZ,TLUMHUM)"Q=OE?83N'OD5ZGI,KSZ+832DF22VC9B>Y*@F@
M"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>hook-20211231x10k023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (& K # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** &OT%1U(_05'0!-1110 4444
M%%%% !1110 4444 %%8_B/5[O2+!6L--FO[R9O+BBCX /JQ[**YOX=>(]1U+
MP7>ZKK<OF7$-S.) O10A/RCV&* .\HKQM+KQYJ'AB;QS;Z\D40#7,.E>3E&A
M4G@GKD@5MZMXBUCQ1-X?TGP[>C3GU*T^W7%V%W&.,?PJ/4F@#TFBN%\(7NNZ
M;XGO_"^O:@-1:.!;JUO"NUG0G!4CU!KNJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *Y-_P"AM0!W%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 -?H*CJ1^@J.@":BBB@#BOBG<WUMX-/V*Y>U66ZBBN;A#@Q0L<,V>
MW:L>+X-^'984==:UJ16 (<7YPWO71_$*T\/W?A*<>)YY8=,C=9',3E22.@XZ
M]>E>.>9\(HXSB^\0JB<<22@#T^E 'OVBZ5!HFCVVFVTDLD-NNU7F?>Y&<\GO
M5^L+P9]C_P"$/TPZ?%<QVABS$MT29-N3C<36[0 4444 %%%% !574KY-,TNZ
MOI1E+>)I6 ] ,U:K+\26,FI>&=3LH?\ 6SVSHGU(.* /)8;WQ)JMK'K/_"=0
MV.M7/[ZTT4L@CV'[J,#SDBNIUZ\\1:_K^E^&+*_;1Y&L_M>H7$(#.O. B]N3
M7!Q_\*VA^'$D%S;QC7XX3$R.I^U?:!P,=^O2NCL-2E\)>(_#NI>*)3"E[HRV
MLMS(/E293NPQ[<4 ='X,O=9T[Q+J?A76M0;46M8DN;:[=0KO&W&&]P:[NO//
M"NHP>)_B1K.N:<3+IL%HEG'< ?+(^=S8]0*Q-8\$?%"ZUJ]N+#QFL%G+,[PQ
M;V&Q">!T["@#K?BM_P DN\0?]>O_ +,*@^#_ /R2K0?^N3?^AM7E_C'P;\2=
M/\(:G=ZOXO6[T^*'=/!O8^8N1QTKU#X/_P#)*M!_ZY-_Z&U '<4444 %%%%
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MD8K+Z^%BI559/S.OHHHK0X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 -?H*CJ1^@J.@":BBB@#SGQ;XXT&[:_P!
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MC>)O"NB-IR^!=0N 9Y)MY61?OMG&-G:OHFBG"G&&L41B<?B,2E&K*Z7H?/\
MXE^*/B?Q%X:U#1SX"OX!=PF+S )&VY[XV5Y?_9_B/'_(M:C_ . [_P"%?:%%
M$Z<9_$3A\76P]_9.USXO^P>(_P#H6M1_\!W_ ,*Z'P7K'B7PAXA.K+X0U&Y/
MD-#Y9BD7J0<YVGTKZOHI1HPB[I&E;,<36@X5)73\D>*?\+K\4?\ 1/+_ /\
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M7]VW?S2_S/,I?C?XDAB>67X?WJ1H"S,Q<  =R=E0CX]ZVP!'@>X((R")'_\
MB*]9\8G'@K7,?\^,W_H!KSVR+?8+;D_ZI/\ T$5-2?*:X/"+$7N[6,G_ (7S
MKG_0C7/_ '\?_P"(I#\>];#HI\#W&YV"H/,?+$] /DZUO9;U-59BW]M^'\D_
M\A6'^M1&JV[6.JMEL:=-SYMBI_PNOQ1_T3R__P#(G_Q%4Y/V@=7BF>*3P7,D
MB'#HTK J?<;*]WKP#Q,3_P )UXAY/_'TO_HM:NK/DCS'-EV$6+K^R;MHR;_A
MH/5/^A-E_P"_S?\ Q%'_  T)JG_0FR?]_F_^(K)R?4TUR?+;D]#7+];?8][_
M %;I_P#/Q_<=%!\<?$5S"DT'@&\EB<95T9R&'L0E1W/QXUVSV?:O MS#O.$\
MQW7<?;*5Z7\./^2=:%_UZK_6N9^+YY\/?]?$O_HNNR4N6+9\UAZ*JUHTF]W8
MY3_AH/5/^A-E_P"_S?\ Q%'_  T'JG_0FR_]_F_^(K)R?4T9/J:X_K;['TW^
MK=/_ )^/[C;MOCUKEY(Z6W@>XF= "RQR.Q4'IG"5/)\;O$L4;22?#Z]1%!9F
M8R  #J3\E:/PD)_X2;7N?^7>W_F]>C^)_P#D5-8_Z\IO_0#79"7-%2/FL715
M"O*DG>S/(%^/>MLH9? ]P5(R")'Y_P#'*7_A?.N?]"-<_P#?Q_\ XBM/3F/]
MEV?)_P!0G_H(JSN;U-8^V?8])95%J_,8+?'S6E*AO!%P"[!%!D;DGH!\G6K7
M_"Z_%'_1/+__ ,B?_$5+J+'[9HO)_P"0K;?^AU[-6L)<RN>?B\.J%3D3OH>#
MW?[06K6,PAN_!DMO(1N"2S,IQZX*5!_PT=>?]"I_Y,G_ .)J#XX'_BN[;_KP
M7_T-J\VR?6L*F(<)<MCT\%E$,3155RM?R/4/^&CKS_H5/_)D_P#Q-7[?XY^(
M;N!)[;P%=S0N,K)&SLK#V(2O(,GUKZ?^%?\ R3'0O^O<_P#H1JZ-5U+W1S9E
ME\<&HVE>]SSZZ^.VOV4!GN_ =U!$" 7E=U49Z<E*H_\ #1UY_P!"I_Y,G_XF
MN_\ C1_R36\_Z[P_^C!7SCDYZT5JSIM)(K+LNCBXRDY6L>G_ /#1UY_T*G_D
MR?\ XFK%G\?]8U!W2S\%37#H 66*5F*@]SA*\GR?6O5O@(?^*DUW_KTA_P#0
MFJ:5=SERV-<=E,<+1]HI7^1>_P"%U^*/^B>7_P#Y$_\ B*JI\?=9D7<G@F=E
MR1D2L>1P?X*]U/2O$_#K'^R6Y/\ Q\W'_HUJVG+E5SS\)AEB)N+=M"#_ (7S
MKG_0C7/_ '\?_P"(IK_'W6DV[_!$Z[F"C,K<D]!]RM[<WJ:S=:8[-.Y/_(2M
M?_1@K-56W:QV5<LC"FY\VR&_\+K\4?\ 1/+_ /\ (G_Q%;_@WXEZYXE\11:;
M?>$+O38'1F-Q)OP"!TY4=:],HK<\@**** "BBB@!K]!4=2/T%1T 34444 0F
MTMB23;Q$GDDH*/L=K_S[0_\ ? KS>.?Q)\0=7U-=/UI]%T2QN&M5>V4&:9U^
M\<GH,TZ]\*^,/#6GSZEI/C&\U*2W0RM:ZBH99% R0".AQ0!Z6JJBA44*HZ #
M %17=PMI9S7# E8D+D#O@9JAX:UE/$/ANPU9$V"ZA#E?0]"/S!J;5]5TO2;%
MI=6O+>UMF^0M,X4'/;F@#RBW\8>/M3_LJ_M(M&L[;696CMO,0LPP"1N/OBNM
M\ ZIXBO;[6+3Q)/:+>64BQBUMDVA%(R&SWS7,:QI_@SP_P"$([67Q-="TN+D
M7>ER0-YLEL1WCQU KJ/AOI^DK8W>K6&N3ZU<7KC[1=S\/E1@*1VQZ4 =Q111
M0 4444 %%&1G&>:* "BCK10!QWQ6_P"27>(/^O7_ -F%0?!__DE6@_\ 7)O_
M $-JG^*W_)+O$'_7K_[,*@^#_P#R2K0?^N3?^AM0!W%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 5M0L8=3TZYL+D,8+F)HI IP=K#!P:X]?A9HZ*%74];"J, "^/ _*NYHI-)
ME1G*/PNQQ'_"KM(_Z"FN?^!Q_P *EL_AKH]GJ-I>_;-5GDM91-&L]V77<.A(
MQS794460W4FU9R?WA7SUXMN[>V\>>(%GF6,FY4@-W'EK7T+43VT$C%GAC9CW
M*@FIJ04X\K.C!8N6$J^UBKGS3_:=C_S]Q?G2/J=B4;%U'T/>OI;[';?\^\/_
M 'P*/L=M_P ^\/\ WP*Y_JD>Y['^L=7^1?>SG?AP"/AUH601_HJ]?QKF?B_U
M\/?]?$O_ *+KTU5"J%4  = !7F/QA94_X1XLP4?:)>2<?\LZWJ? SR, _P#:
MZ;_O+\SSZBF>=%_SUC_[[%'G1?\ /6/_ +[%>4?HET=O\)/^1FU[_KWM_P";
MUZ/XG_Y%36/^O*;_ - ->;_")U?Q-KQ5E;_1[?H<]WKTCQ/_ ,BIK'_7E-_Z
M :]6C_#1^?9G_OE3U/,]._Y!=G_UP3_T$59JMIW_ ""[/_K@G_H(JS7*?0QV
M10U'_C\T7_L*VW_H=>SUXQJ/_'YHO_85MO\ T.O9ZZ:/PG@9I_'7I_F?/'QP
M_P"1\MO^O!?_ $-J\WKTCXX?\CY;?]>"_P#H;5YO7'B/XC/H\G_W./S_ #"O
MI[X5_P#),="_ZX'_ -"-?,-?3WPK_P"28Z%_UP/_ *$:UPG4X.(-J?S_ $*'
MQH_Y)K>?]=X?_1@KYP[U]'_&C_DFMY_UWA_]&"OG#O4XOXD7D'\.?J@KU;X"
M?\C)KO\ UZ0_^A-7E->K? 3_ )&37?\ KTA_]":HPW\0Z<Z_W1^J/>3TKQ+P
M[_R"6_Z^;C_T:U>VGI7B7AW_ )!+?]?-Q_Z-:NRM\)X.5?Q7Z?JC5K-UK[FG
M?]A*U_\ 1@K2K-UK[FG?]A*U_P#1@K"'Q(]C%?P9^C/:J***[#Y0**** "BB
MB@!K]!4=2/T%1T 34444 >0Z59_$3P@VJ0V&E:-+97%]-<I+<W6TX=B1GD=J
MMMKGQ,U2UFMX='\.2+(C(3%?%B 1CL:33](C^)^NZIJ.LSW#:/873V=MIZ2%
M$8IPSOCKSTJWKWPPTO3M/FU3PN9=(U6T0RQR12MM?:,[64G!!H Z?P+I%YH/
M@G2],OU1;JWB*R!&R =Q/!_&N*\9S^'?^%J6">+)K8:;%IS/$EVW[OS"P[="
M<5WWA+6CXB\*:;JS)L>YA#,OHW0_J#5B_P!!TC595EU#3+2ZD48#30JY _$4
M >/^&-9\ :5\1=:O%U/3H;".)%L=TG[M-W,FP=!SCI72_#J]TV]\;^+I=&GA
METZ26*1# ?D+%?F(]\UV'_"&>&/^@!IO_@,G^%7M/T;3-)#C3K"VM _WO)B"
M;OKB@"]1110 5%=>=]EE^S;?/V'R]W3=CC-/D4O&RJQ4D$ CM7$V/AS5O#]]
M+K&H^++V\LH%>1[9T&W&">W/% '+Z_X.U#0_"5WXCU#Q7J"Z] IG\Q)<1;\\
M1JGIVK3UA]7\6:KX=\/27EQI\,]A]NU!K<[7;H F>P)KG+3QOH/B75UUCQ3J
M$L=M!)FRTE87*)@\/(<?,WMT%=-XBUR+1?%NA^+O*FET2YLVM998HRQCR=RL
M5ZXH L^$H;WPSXVOO"\^I3WU@]JMW9M<MN>/G#+GN*[IKZT1BK74"L."#( 1
M7!>%=1'B[X@W_B*UMIDTRVM!9V\TJ%/-8MEB >U9>K? ;1=7UB\U*76=4CDN
MIFF9$9=JECG XZ4 =!\4[RUD^&&OHES"S&V. ) 2>11\'_\ DE6@_P#7)O\
MT-J\U\:?!#1_#G@[5-8@UC4II;2'S%CE9=K'('.![UZ5\'_^25:#_P!<F_\
M0VH [BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAJFB:7K<4<6J
M6%O>)&VY%F0,%/J*OT4 <Y_P@'A+_H7=._[\"C_A /"7_0NZ=_WX%='10!FZ
M5X?T?0S*=+TVVLS+CS##&%W8Z9IGB?\ Y%36/^O*;_T UJU%=6T5Y:36LZ[X
M9D:-USC*D8(_*@#R33@?[+L^#_J$_P#015G!]#73+\,/#"J%6"\"@8 %[+P/
M^^J7_A67AG_GC>?^!TO_ ,57/[%]SVUFL$K<K.)U$$7FB\?\Q6V_]#KV:N3M
M_AQX:MKRWNDMKAI;>198_,NY' 93D'!;%=96L(\JL>=B\0J]3G2MH?/'QP_Y
M'RV_Z\%_]#:O-Z](^.'_ "/EM_UX+_Z&U>;UPXC^(SZK)_\ <X_/\PKZ>^%?
M_),="_ZX'_T(U\PU]/?"O_DF.A?]<#_Z$:UPG4X.(-J?S_0H?&C_ ))K>?\
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MCAMGWG8^O!K#L(O%GB[0KSQ?;>)9[#YI)+"T1 8O*3.-P[YP: /3M T>+0-
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M'C+XD^,-7\(:G87_ ()GLK6>';)<,'Q&,CGD5Z?\'_\ DE6@_P#7)O\ T-J
M.XHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5!\'_P#DE6@_]<F_]#:I_BM_R2[Q!_UZ_P#LPJ#X/_\ )*M!_P"N3?\ H;4
M=Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &?=WTOVC[+9H'FQEB>BBH_)U@_\O5N/;8:-+^:^U!CRPEQGVQ6I6K?+
MHD917/JV9?D:Q_S]V_\ WP:/(UC_ )^[?_O@UJ45/M'V7W#]FN[^\R_(UC_G
M[M_^^#1Y&L?\_=O_ -\&M+>I<H&&X#)7/-.H]H^R^X/9KN_O,OR-8_Y^[?\
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M?D94?A?J_P V%%%%0:A1110 4444 %%%% !1110 U^@J.I'Z"HZ )J*** .
M^*%OIUIH4=\-&L;O4Y[N&"W>XB! D;(4L>I &>*Y75S?W'B"YT?0]*\/))I%
MBMQJ$TUFI5Y",[1QP.*]$\>6^BW'A&[77IW@LE*OYL9^='!^4K_M9KRK2+GP
MW)X1\36KP^(D,<D4NH7$JXN958D#Z* #GV- 'L'A'64\0>$]-U5(1 MQ"&\M
M>BD<$#VXK:K-\/QZ;%X?L$TC;_9XA7R-O3;VK2H **** "BBB@!LB[XV3)&X
M$9'45PC?#4HEZW_"0ZM=&XAEC$%Q-NCRP(''MFN]HH \/_X2*VL/ S^"I?!]
M]_:X@-J(%MLQNYX#[^GOFM>X@U+P%)X7UF[M;F^M[73O[/OA;J7=">0V.XSQ
M7K&T9S@9]:4C(P>E 'GOA"[G\5^-;WQ3]@N+33H[46=I]I38\AW99L=A5+5/
M@1X4U?5KO4;B?41-=2M,X290-S')Q\M>G@ # &!10!X+XX^"7A?P[X+U75[.
M?4&N+6'S(Q)*I7.0.1M]Z]"^#_\ R2K0?^N3?^AM4_Q6_P"27>(/^O7_ -F%
M0?!__DE6@_\ 7)O_ $-J .XHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0[FA15#^VM/_ .?@?D:/[:T__GX'Y&CDEV#VD.Y)JG_(+N?^N9J2S_X\8/\
MKFO\JS;J\.IK]DLU9E<C?(1@ 5KQH(XU0=% %5)6C9BB^:3:'4445F:!1110
M 4444 %%%% !1110 4444 9EA_R&-5_WX_\ T 5IUF6'_(8U7_?C_P#0!6G5
MU-_DOR,J/POU?YL****@U"BBB@ HHHH **** "BBB@!K]!4=2/T%1T 34444
M <K\0=!O/$'AD0Z>$:\MKB.[AC?[LC(<[3]:\WM]0\8?\)%XFG@\&70N=8BB
MA03,/*B*J58ENXYXK=CU[QOXEN]6U30KNPL],TVXD@6VFBW-.8_O$MVSCBJ>
MG6OBKQEX>N/& \37>F.RO)9V-OS$JIGA_7)!H ]'\(Z*_AWPGINDRR>9);0A
M78="<Y/\ZVJPO!FLS>(/!^EZK<*%FN(0T@'3<"0?Y5NT %%%% !1110 444C
M,%4L3@ 9)H 6BO-)?BK=!9M5A\-W<OAN"4QR7X8;N#@L$ZE:W_$OC9='73[?
M3+&34]2U)=]K;1G&5QDLQ["@#K**Y7PGXQ;7[J\TR_TZ73=7L@K3VTAW?*>C
M*>XKJJ ..^*W_)+O$'_7K_[,*@^#_P#R2K0?^N3?^AM4_P 5O^27>(/^O7_V
M85!\'_\ DE6@_P#7)O\ T-J .XHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ (!&#3/)B_YYI_WR*?10 SR8O\ GFG_
M 'R*/)B_YYI_WR*?13N*R(G6"-=SK&H]2!4/VG3_ /GK;_F*I00KJMU/-<$M
M%&Y1(^W'>KG]E6'_ #Z1?]\U;45HV9IREK%:"_:=/_YZV_YBC[3I_P#SUM_S
M%)_95A_SZ1?]\T?V58?\^D7_ 'S1>'F.T_(7[3I__/6W_,4?:=/_ .>MO^8I
M/[*L/^?2+_OFC^RK#_GTB_[YHO#S"T_(7[3I_P#SUM_S%'VG3_\ GK;_ )BD
M_LJP_P"?2+_OFC^RK#_GTB_[YHO#S"T_(7[3I_\ SUM_S%'VG3_^>MO^8I/[
M*L/^?2+_ +YH_LJP_P"?2+_OFB\/,+3\A?M.G_\ /6W_ #%'VG3_ /GK;_F*
M3^RK#_GTB_[YH_LJP_Y](O\ OFB\/,+3\AXO;)1\L\(^C"E^WVG_ #\Q?]]"
MH_[*L/\ GTB_[YH_LJP_Y](O^^:7N>8>_P"1)]OM/^?F+_OH4?;[3_GYB_[Z
M%1_V58?\^D7_ 'S1_95A_P ^D7_?-'N>8?O/(D^WVG_/S%_WT*/M]I_S\Q?]
M]"H_[*L/^?2+_OFC^RK#_GTB_P"^:/<\P_>>1)]OM/\ GYB_[Z%'V^T_Y^8O
M^^A4?]E6'_/I%_WS1_95A_SZ1?\ ?-'N>8?O/(D^WVG_ #\Q?]]"C[?:?\_,
M7_?0J/\ LJP_Y](O^^:/[*L/^?2+_OFCW/,/WGD2?;[3_GYB_P"^A1]OM/\
MGYB_[Z%1_P!E6'_/I%_WS1_95A_SZ1?]\T>YYA^\\B3[?:?\_,7_ 'T*5;VU
M8X6XC)] PJ+^RK#_ )](O^^:1M(L&4@6R+[J,&CW/,/WGD0V'_(8U7_?C_\
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M((;'PM?ZLCZE*QEMF "G<>#FNBOK3Q/\2O$&C&^\/R:+I.G7(N7:X<&1V'0
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M (2OP]_T&]/_ / A?\:/^$K\/?\ 0;T__P "%_QK@?\ AG[P9ZW_ /W_ /\
MZU'_  S]X,];_P#[_P#_ -:@#OO^$K\/?]!O3_\ P(7_ !H_X2OP]_T&]/\
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M+DCV.O\ [2\'?]!'3/\ P)7_ !H_M+P=_P!!'3/_  )7_&N0_P"&?O!GK?\
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M  S]X,];_P#[_P#_ -:CGEW#DCV.O_M+P=_T$=,_\"5_QH_M+P=_T$=,_P#
ME?\ &N0_X9^\&>M__P!__P#ZU'_#/W@SUO\ _O\ _P#UJ.>7<.2/8Z_^TO!W
M_01TS_P)7_&C^TO!W_01TS_P)7_&N0_X9^\&>M__ -__ /ZU'_#/W@SUO_\
MO_\ _6HYY=PY(]CK_P"TO!W_ $$=,_\  E?\:/[2\'?]!'3/_ E?\:Y#_AG[
MP9ZW_P#W_P#_ *U'_#/W@SUO_P#O_P#_ %J.>7<.2/8Z_P#M+P=_T$=,_P#
ME?\ &C^TO!W_ $$=,_\  E?\:Y#_ (9^\&>M_P#]_P#_ .M1_P ,_>#/6_\
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M!WW_  E?A[_H-Z?_ .!"_P"-'_"5^'O^@WI__@0O^-<#_P ,_>#/6_\ ^_\
M_P#6H_X9^\&>M_\ ]_\ _P"M0!WW_"5^'O\ H-Z?_P"!"_XT^#Q)HEU.D$&K
M64LKG:B).I+'T S7GW_#/W@SUO\ _O\ _P#UJO:-\$_"FAZS::I:&]^T6LHE
MCWS9&1ZC% 'H]%%% !1110 U^@J.I'Z"HZ )J*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :_05'4C]!4= $U%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 -?H*CJ1^@J.@":BBB@ HHHH **** "BBB@ HHHH ****
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MHLQQKP3TCHMM?^ 9#RV]]':6UJ"(?,R1MQ@+S27EM%<^(K=9H@Z"!N"..M;
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M91*44R 8#8Y KE=#\2W4_@Z]U#4A&MW8F6*5D^ZS)W'UJOIVL:L/%6BZ;=W
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MN;%@UO-82[XQTY4\B@#3^'?_ "3O0/\ KRC_ )5TA1"X<JN\# ;'-<W\._\
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M%C1410JJ,  8 %.--^@JN+BU9>]ZI?H<AK?B>ZCNHM"L)+9-5>(-<3RN!';
M]^>I]!65KVEVFF> Y!8W"WKP74=U=S*P9I"'!9CC_.*Z;4/!/AW5+Z2\O=-C
MFN)3EW8G)_6K>E^&M(T:">"PL8XHI_\ 6)R0WUS0X2;=Q1KTH1CR7NK-Z;_.
M_P!QR_B[6M/UFRT6PT^YCN9[V[B=%B;)" Y+'TQ5G7?$D]]JLWA_2+J&U>+
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M-67X;T@Z#X;T_2FE$QM(%B,@&-V!UQ6I0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 U^@J.I'Z"HZ )J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH :_05'4C]!4= $U%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
5%%%% !1110 4444 -?H*CHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>hook-20211231x10k024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (F WT# 2(  A$! Q$!_\0
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M>YMT5B?\)AX=_P"@S9_]_!1_PF'AW_H,V?\ W\%')+L'/'N;=%8G_"8>'?\
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M"C_A,/#O_09L_P#OX*.278.>/<VZ*Q/^$P\._P#09L_^_@H_X3#P[_T&;/\
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MP\._]!FS_P"_@K9CD2:-9(V#(PRK#H12<6MT--/8=7SI\644_$&Y) /[F/\
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MKT+ =*U/#FDSZ-H\8DU&WMKB:[+2F8X,B@]!67M9J+N]?ZV\C7V46U9:+?\
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M5Z]I,XUC3K/4;N" W)AE4L(P,@=.*Q?"<:C0(9#&H;^T>&V\_G6GMWJFMO\
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M5J^%=)CUCQ#!:3Y$(RTGT'45M*$.779:F2E).Z]"S:^.;^&\O[B2&WN6OO\
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M\J\<^,O_ "-D'_7 5['X6_Y%C3O^N"_RKQSXR_\ (V0?]<!7EX;^._F=]?\
MA+Y'G5%%%>H< 4444 %%%% !1110!IKKMROAYM%$<?V9I/,+_P 6:?X?\0W'
MAV_,\*I+'(NR6%_NNM9-=EX=T^SN/"-]<36T<DR3HJNPY )Z5$^6,6VM_P#A
MBHW;27]=2OK/C>"\TYM.TK3;?3K61@THCZN:;!\0-4@U!+R*. 2);_9]O8KZ
M_6MCQ7KEKX?U4:?:Z!I+1B%3NDBRQ)%7I_#ECK'PWCO[:U@AU/!E_=C!8=Q7
M/>"@FXZ/]3>TY2Y>;7^F<S8>/M2L+801V]M)M9F#N.06ZUFZ1XBO=&U*:^@"
MR23!ED20Y5@:UO$EA:VWA30YX;=(YY4/FN!RQ]ZY<6]PRJRV\I5SA2%.&/M6
MT8P=W;R,I.:M=^9MZ!XJFT2YN=]M%<6=T3Y]L_W2/:I]<\9KJ5O#8:=8P6%A
M"XD$,?\ $WO6;H&E'5=?M;"4,@=_W@(P0.]=A<ZYX535[G1KC1;>&P0&,7:K
M^\##^*IFHJ2:5W_D5!R:>ME_F8UQ\1+^99 ;.SC>6-8Y''5@.AJO_P )OJ#:
ME-?B& R30>0P'0+C&?K6]'+I^A^"8M0M],LK]WN602W$>2R=JT(O"^C>*8+3
M6X;<VEL8V-S;0<98?W:ANFKMQTV*49NR3U_X)R>G^.-3TVWM(((8"ELS$!A]
M_/4'VJY<?$C49HH(H]-L;>.&3S56($ FG:]X8TYM+L]1T2*YA^T2F(V]P?FS
MZBL/7_#EYX>FBCN2&$B!@P]^U4O92>JU)?M(JR>EC:C^).I+CS;"RGD1R\3R
M+DQ$^E1'Q_?M<7LSZ?9O]LV^:A!QD=#]:N:IHEO/I.CV&EV"G4;F+S6E+8W>
MU8,/A75'$3SQK;0RR^2))6QAN_%$8TGTL-RJV3OOJ:,?Q U-=1GNWM;:5)XQ
M');./D('2DN/'VJ7#W&;>W2*:#R!$H^6-?\ 9J?Q+X-@T?5-)TZTN#-+>*-\
MF<KD]Q[5IR>"M"OI+S2M(EN3J]FH+EVRDA[X%3>C9.W](:]K>U^QQUUK]Q=:
M';:1(D8@MV+(P^\2?6LRO6(_"VD:=<V^G7.G/+)+:LS3,, .!7E4JA)Y%'0,
M0/SK2E4C)OE1$Z<HQ3?]=1E%%%;&04444 %%%% !1110 =Q]17U?H/\ R +#
M_K@G\J^4.X^HKZOT'_D 6'_7!/Y5P8[9'7A-V:%?.OQ8_P"2@7/_ %QC_E7T
M57SI\66 ^(-SG/\ J8^WM6."_B?(UQ7P'%T4W>OO^5&]??\ *O5//'44W>OO
M^5&]??\ *@!U%-WK[_E1O7W_ "H =13=Z^_Y4;U]_P J '5Z5X2!/@ZS_P"P
MHE>9[U]_RJ>._N88Q'%<S)&&W!5) #>OUJ9QYE;T'&7*[^OY'9^,O%%P-?U3
M3_[-TW9YFSS?('F?7/K7076K)INKZ%;77-E>V"PS*>G/0UY1).TTC2RR/)(Q
MRSMDDFG2WDTY0S3RR&,83=D[1[5DJ"Y8Q[;_ '6-'6?,VOE]Z9Z9X^?0]*UZ
MTAU#3I[WRK91 T<NT#'3/K45SXD6Z\&7.KR1HMW,/L:J!_!7G%Q>SW;![FXE
MF91@&0DD#TK8FUBP;P9#I:(_VQ;@R,VTXQ4^PM!)ZN_ZZEJM[[:T_P" M/Q-
M+X=W,,6ORVDSA!>0-"K'H"1Q5C3O DEM<:E-XAB>WT^S5B'SCS&[;3WKB5EV
M,&1F5AR" <BK=SK.HWD(ANM0NIXA_!(Y(K2<)-WB[7T,XSBE:2OK<[7Q)I-_
MJGA;PTNG64\Z;& *+D*,\9KLK9Y=+TL6]D%GUC3K''D YY/48[UXW!KVK6L(
MAM]4O(HEX"(Y %-M=9O[*_\ MUO>3K==Y,G+?6LY4)25KZ7;^\N-:,7S6['H
M7BK6M5M]$T36KC-GK!8AH0-HV^ZUQ&GWD]_XGM;FYD+RR3@DGZU3U+6+W5[G
M[1?W,D\G8MGCZ4S3KN.TU*VN'W%8Y QP#VK2E3Y%KN9UI\ZLNQZ!:P73_%BZ
MN('\N&W;?<.>@3'.:H_$".>7Q9:WPE\VPN-IMF7[H&>@K'\4:Y97VLS7FC37
M,4=RO[\'(W'T^E8+7L[Q1Q/<2M''_JU).%^E12IRO&3Z*QK5FGSQ74]2N+B.
MV^*5J)6"B6T6,$^I7BJ5O::CX3\-^(+BY+VDTTVVW;.&;GJ*\ZDO)YIA-+<2
MR2KT=B21^-2W6J7U\JK>7MQ<*OW1*Q(%+V#LE?U^^XE65V[?U:QW'AC7M2UV
M>_;4;@S-#8LBD^F*\_[GZUTWA;7-)T>QU%KH3&\GB,<6U3C!]:Y?>/?\JTA&
MTW9::?J1*5X*[UO_ )#J*;O7W_*C>OO^5:F8ZBF[U]_RHWK[_E0 ZBF[U]_R
MHWK[_E0 ZBF[U]_RHWK[_E0!8M/^/VW_ .NJ_P Z^L[/_CR@_P"N:_RKY*M'
M'VZWZ_ZU>WO7UK9_\>4'_7-?Y5Y^.^R=F$ZGSI\3O^1]O?\ =6N1KK?B<P'C
MV]Z_=7M7(;U]_P J[*/\./H<U3XV.HIN]??\J-Z^_P"5:$#J*;O7W_*C>OO^
M5 #J*;O7W_*C>OO^5 #J*;O7W_*C>OO^5 '>^'@3X O/^OM/YU:\<>)KBPUD
MV2Z=ITB_9U'F2PAGZ>M>>I>SQQ&&.XE6(G)0$X)]:2:ZDN9/,GFDE?&-SY)Q
M6+HWGS/^M$:JK:"BOZU/2O[8?1] \.79'[IV9)5[%3UJWX[&AZ=:Z2+JRFO;
M-E+Q+%)LQGFO*WNYI(DBDGE>)/N(<X7Z4LU[/<(B3W$TJ)PBN20OTJ70O)2O
MU;&JUH\OD>DZ;XE@N]!N[XVZPC3T,5LAY(4]B>]<QX&OHX/%<;7#A$N R%CV
M)JI8ZQ86WA:_T^1'-U.X*$*<8K#63:006!'0@'BJC22<ET?^0I5&XQ\CN[;P
M'<+K]\VM1-%I<.Z0S9P'';!J6[T^>_\ AS;QZ7:37""[;:$7<0.V:XJ;6M2N
M8/(GU&[EA_YYNY*TMKK6I6,7E6FHW5O'_<C8@4O9S:5WM;\!^TAK9;W/7O#E
MLVD:38Z?-QJD4;3I!GG/8$5DZ]JVKW'@]=3U2,V&H07.($5=FX?3O7FJZM?+
M>K>_;;@W2G(E+'=^=2ZIK^HZTZMJ%Y+/M&%#9P*CV$G+F?\ 7H4JR4>7^OF.
MN]4O-7U1+J]E+RLX^@^E=S=VUW<?$+3FM&*&*%'D?LJ@<YKS>.54E1SG"L#T
MKI_$_B*PU"2WN=*FN8;CR1'/P0#@5I.+3BHKN9PE?FYGT7YFK\3EFN=2MK^*
M42Z=(-L13A01UK3N)TM-?\*R2L%0P!<GW%>9->3O L#SRM"IRL9)P#]*)+R:
M;9YL\K^7PFXD[?I2C1M%1OM<<JMY.7='ID&GWOAS_A)=2N@8$ER(),XW$]"M
M9?A/Q)JVL:Y:6M_=M-'#&VW=U/'>N,N-6OKN)8KF^N9HE^ZDC$@5L^#]7TK1
MM1EN]0$I<(1$$4GD^M2Z346Y:NWZ#]I=I1TU,:__ .0E=?\ 75OYU7I]S.DU
MW-*N<.Y8<'O46]??\JZ([(SFTY-H=13=Z^_Y4;U]_P J9(ZBF[U]_P J-Z^_
MY4 .HIN]??\ *C>OO^5 #J0]*3>OO^5!=<=_RH ^JO"W_(L:=_UP7^5>.?&7
M_D;(/^N KV/PM_R*^G?]<%_E7C?QF8#Q;!G/^H':O+PW\=_,[Z_\)'G=%-WK
M[_E1O7W_ "KU#@'44W>OO^5&]??\J '44W>OO^5&]??\J '44W>OO^5&]??\
MJ '5W?A8$^"=1_Z^8_YUP6]??\JECO9XHFBCN)4C8Y**2 34SCS1M_6XXNTD
M_P"MCT3QQXFN-/U@V:Z=ITJ^0O[R:$,_(]:>=8?1_#WAF]( C=V651T*GJ*\
MWFNI;F3S+B:25\8W/DG%*]W-+"D,D\KQ)]Q&R0OTK)4$HI&KK7;9ZOX[_L"P
ML-*^UV,U[:2*6B$,NS;GFLOPEKL-S;7$$D*1VFG SVRMRR^Q/>O/9;V>>-(Y
MKB:2.,817)(4>U;&@:Q8:;8ZG%=([27$.R(A3UJ71Y:;6[*]MS33V+/AK6%3
MQQ%?SD*D\I#$] #6RW@*ZE\77)OXF72 3,]SG"E.O!]:\_#@>OY&KKZWJ<EO
M]GDU*[:#&/++G;CZ5I*F[WAII8S51:J75W.YU+3GO/A]%%H]K/<0)>,(PB[C
MM[$UU7AFVET/PU#9LH_M=(FG2V)Y^A%>-VNM:E8Q^7::C=01_P!V-B!0FLZA
M'?+?"^N#=+TE+$M6<J$I)QOHRU6BFI6V/0?%=_J5[X+L]2U:(V6IQW!$2*NS
MY?7%<'JNMW^M2))?3&0HH51VXINIZ[J&LRK+J%W+.RC #9P*H%Q[_E6E*ERK
M5?\  )J5.;8]%O;6\N[_ ,*QV)*S"$-N'\(!Y-.^*0EO#:7UO.LVG@>63'P%
MD'7-8FL>)-/N]$TU;*6YAU*VC\IV4$ K]:Y@WDY@,!N)3"6W&,D[<^N*B-.3
MDI=F_P 64ZB4;=TOP1Z)K$Z6>J>#YI3A%A7)/:M&'3KW1-?\0ZW-F*V,),$^
M<!R>F#7E4MW-.$$T\L@080-D[1Z"IIM6O[BW%O/?W,D"](W8E1^%$J+:LGW_
M !=Q1JI.[7;\#MO"?B/5-<UR.+4+EID@MY F[KT[UPEQ_P ?4W^^?YUO^#]9
MTG1;FYNK\2F8Q%(0BDCD=ZYV257F=QG#,3TJXQM-V6EO\Q.5Z>KUO^@E%-WK
M[_E1O7W_ "K4R'44W>OO^5&]??\ *@!U%-WK[_E1O7W_ "H =13=Z^_Y4;U]
M_P J '=Q]17U?H/_ " +#_K@G\J^3MXR.O4=J^L-!_Y %A_UP3^5<&.V1UX3
M=FC56?3+&YE,L]G!)(>"SQ@FK5%>=>QW%'^Q=+_Z!UK_ -^EH_L72_\ H'6O
M_?I:O44^9]Q611_L72_^@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^
M@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_
M 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^
M@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_
M 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^
M@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_
M 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^
M@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_
M 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^
M@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_
M 'Z6KU%',^X611_L72_^@=:_]^EH_L72_P#H'6O_ 'Z6KU%',^X611&C:8""
M-/M01T_="KP    P!110VV.Q4FTNPN)3)-902.>K-&"33/[%TO\ Z!UK_P!^
MEJ]11=BLBC_8NE_] ZU_[]+1_8NE_P#0.M?^_2U>HHYGW"R*/]BZ7_T#K7_O
MTM']BZ7_ - ZU_[]+5ZBCF?<+(H_V+I?_0.M?^_2T?V+I?\ T#K7_OTM7J*.
M9]PLBC_8NE_] ZU_[]+1_8NE_P#0.M?^_2U>HHYGW"R*/]BZ7_T#K7_OTM']
MBZ7_ - ZU_[]+5ZBCF?<+(H_V+I?_0.M?^_2T?V+I?\ T#K7_OTM7J*.9]PL
MBC_8NE_] ZU_[]+1_8NE_P#0.M?^_2U>HHYGW"R*/]BZ7_T#K7_OTM']BZ7_
M - ZU_[]+5ZBCF?<+(H_V+I?_0.M?^_2T?V+I?\ T#K7_OTM7J*.9]PLBC_8
MNE_] ZU_[]+1_8NE_P#0.M?^_2U>HHYGW"R*/]BZ7_T#K7_OTM']BZ7_ - Z
MU_[]+5ZBCF?<+(H_V+I?_0.M?^_2T?V+I?\ T#K7_OTM7J*.9]PLBC_8NE_]
M ZU_[]+1_8NE_P#0.M?^_2U>HHYGW"R*/]BZ7_T#K7_OTM']BZ7_ - ZU_[]
M+5ZBCF?<+(H_V+I?_0.M?^_2T?V+I?\ T#K7_OTM7J*.9]PLBC_8NE_] ZU_
M[]+1_8NE_P#0.M?^_2U>HHYGW"R*/]BZ7_T#K7_OTM']BZ7_ - ZU_[]+_A5
MZBCF?<+(:B+&@1%"J!@ # %07&G65TX>XM(96'&70$U9HI7'8H_V+I?_ $#K
M7_OTM']BZ7_T#K7_ +]+5ZBGS/N*R*/]BZ7_ - ZU_[]+1_8NE_] ZU_[]+5
MZBCF?<+(H_V+I?\ T#K7_OTM']BZ7_T#K7_OTM7J*.9]PLBC_8NE_P#0.M?^
M_2T?V+I?_0.M?^_2U>HHYGW"R*/]BZ7_ - ZU_[]+1_8NE_] ZU_[]+5ZBCF
M?<+(H_V+I?\ T#K7_OTM']BZ7_T#K7_OTM7J*.9]PLBC_8NE_P#0.M?^_2T?
MV+I?_0.M?^_2U>HHYGW"R*/]BZ7_ - ZU_[]+1_8NE_] ZU_[]+5ZBCF?<+(
MH_V+I?\ T#K7_OTM']BZ7_T#K7_OTM7J*.9]PLBC_8NE_P#0.M?^_2T?V+I?
M_0.M?^_2U>HHYGW"R*/]BZ7_ - ZU_[]+1_8NE_] ZU_[]+5ZBCF?<+(H_V+
MI?\ T#K7_OTM']BZ7_T#K7_OTM7J*.9]PLBC_8NE_P#0.M?^_2T?V+I?_0.M
M?^_2U>HHYGW"R*/]BZ7_ - ZU_[]+1_8NE_] ZU_[]+5ZBCF?<+(H_V+I?\
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M+%XPU*X%O(Q@CB+$RNOS!1GCI6E=ZG>:S<6]E;R3V <DF4 98#TJ2/P'I5I
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M<^GZ:JR)(20&.>2:V[*#[/90Q;0I5 "!VIV5@,'0_M,-Q?RW>I3SQPL0%<#
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M_P J .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?"__(Q>)?\ KZ7_
M - %=57*^%_^1B\2_P#7TO\ Z * .JHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#EO"/\ R$-=_P"OO^E=37+>$?\ D(:[_P!??]*ZF@ HHHH **** "BB
MB@ HHHH Y'QIJ5Q;K#;0N4#\L1UJEX/U*Y-\UK)(SQL,C)Z5T>O:$FLP*-_E
MRI]UL57T'PTND2--)+YLI& <=*\B>'Q#QJJ)^[_6AZ\,1AU@G3?Q'04445ZY
MY 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7+:3_R/.L_]<X_Y5U-<MI/_ "/.L_\ 7./^5 '4T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5ROA?_D8O$O_ %]+_P"@"NJKE?"__(Q>)?\ KZ7_ - %
M '54444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!RWA'_ )"&N_\ 7W_2NIKE
MO"/_ "$-=_Z^_P"E=30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+:3_ ,CS
MK/\ USC_ )5U-<MI/_(\ZS_USC_E0!U-%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<KX7_P"1B\2_]?2_^@"NJKE?"_\ R,7B7_KZ7_T 4 =51110 444
M4 %%%% !1110!#=7"VMK)._W44L:XF+QM=F]#/$OD,V-O<"NSU"V^V6$UOG!
M=2 :\YA\-ZFUZ+<V[* W+GICUKR<QJ8F,X>QO;R/6RZGAY0DZUK^9Z9%(LL2
MR*?E89%/J.WB$%O'$.B*!4E>JKVU/*=KZ!1113$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!RWA'_D(:[_ -??]*ZFN6\(
M_P#(0UW_ *^_Z5U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]M?W?ZT/7^MT?J7LK>]_6ITU%4H]8TR618X]0M7=C@*LJDG]:NUZYY 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MROA?_D8O$O\ U]+_ .@"NJKE?"__ ",7B7_KZ7_T 4 =51110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '+>$?^0AKO\ U]_TKJ:Y;PC_ ,A#7?\ K[_I74T
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M2^%8=1OUNC<.[*2DY P#CI7LVM_\@.^_ZX/_ "-<C\'_ /D0+?\ ZZR?^A4
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M_)/[3_KH_P#.NJU__D7[_P#ZX/\ RKE?A#_R3^T_ZZ/_ #H [NBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **H:QK-EH=BU
MW?2^7$#CIG)]*S+WQ?:V8MBMK<3><@D/EKGRU/=J%J!T5<MI/_(\ZS_USC_E
M730S)<0I+&<HXR#7,Z3_ ,CSK/\ USC_ )4 =31110 4444 %%%% !1110!0
MUO\ Y =]_P!<'_D:Y'X/_P#(@6__ %UD_P#0JZ;Q%>V]MI-Q%+(%>:-D0>I(
MK ^%UJ=.\)1V$LB-/'(Q8*>F3D5G[6GS^SOKV-/95.3VEM.YVU%%%:&84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!:CJ-
MGJWB*?2YG%O;V\@)C\L[KB7'!STP*AT&437FE:8JN+JQ>0W *D!.>.?>O0/*
MC+;C&N[UQS2A%#%@H#'J0.333LDAMW31FZY_;?V5/[#^R>?O^?[5G;M]L=ZY
M_P #?;_[3\0_VGY'VS[4N_R,[/NC&,UVE<KX7_Y&+Q+_ -?2_P#H I".JHHH
MH **** "BBB@ KG/&/A"V\8Z;%97-Y<VJQR"0/;MM)]JZ.B@#R?_ (41I7_0
M?UG_ +_UR;?#2S7XEIX8_MC5/LK6AG,GG'?N]/I7T)7F4G_)?X?^P8?YT 5/
M^%$:5_T']9_[_P!>A>&M!B\-:'!I<%Q-/'#G$DQRQR>]:U% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWBR,/;6C>4'83K@[
M<D<UT-(0#U - T['GMY*%NKG22)/M<]PLD8VG!7ZUV>I+J:Z9MTHV_VL !?M
M&=GXXJ]L4MNVC<.^.:=0M%8FVMSC? 7VS=K']H>3]K^U?O/)SLZ=LUV5<MX1
M_P"0AKO_ %]_TKJ:!A1110 4444 %8?B+Q1:>'%@-S'+(T[;46,9)-;E<7XP
M /B7P[D9_P!(/\J $_X6-:?] J__ ._='_"QK3_H%W__ '[KL_+3^XOY4>6G
M]Q?RH X#5OB!:W&CWD0TR^4O"PR8^!Q7/_#CQG;Z3X-MK5["[E97<[HTR.M>
MG:\B#0+\A%_U#]O:N6^$2*?A_:94']X_;WH G_X6-:?] N__ ._='_"QK3_H
M%W__ '[KL_+3^XOY4>6G]Q?RH P/#_BZS\07,UO!!-#+$,LLJXKH:Y'2@!X^
MU+  _=+T%==0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!E^(HUDT.Z!C#_(< KFN+O+A;!%$ZR#[59"*+"$Y;T]J]((!&#33&C8RBG'3
M(Z4+05M4^QA^3K$'AFVBTO[,+U448N<[<=^E8WA+^U/^$KUC^V/LWVK9'_Q[
M9VXQ[UV]<MI/_(\ZS_USC_E3;N[C1U-%%%( HHHH **** "BBB@#A/'$<HO(
M';)C*\>QIO@B.7^T9G (CV8)[5U>O11R:+=M)&KE(F9<CH0*YGX47,MYX)AN
M)WWRM*^6/7K7F/+W];]O?0]/Z^OJOL+:['<4445Z9Y@4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ROA?_D8O$O\
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MN[ 8!)K/^(__ "3[6?\ KW:IO 7_ "(>B_\ 7JG\J8CHZ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#EO"/_ "$-=_Z^_P"E
M=37+>$?^0AKO_7W_ $KJ: "BBB@ HHHH *XOQ?\ \C+X=_Z^#_*NTKB_%_\
MR,OAW_KX/\J .THHKRWQ5:_$B'5;FZTW7;"VTTG]RDH&X"DY**NQQBY.R/0=
M?_Y %_\ ]<&_E7C.@L)=#MY$4[#D XZG-6X-/^*NLVLL2>(],D1E*NNT9P:;
MIO@7XH:3I\=A9:MIB6T9+*K)NP3[XKAQF&CC*:Y9;'=A,3+"5'S1/2O!D$L.
MDDR*5#ME0?2NDKS#1='^*<&KVKZGK5A)8JX\V.- "5]N*]/KJH4E2IJFNARU
MZKJU'4?4Y'2_^1^U/_KDM==7(Z7_ ,C]J?\ UR6NNK4R"BBB@ HHHH ****
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MJ\'>QM5HU:#M-6N>FT445N8'+?$?_DGVL_\ 7NU3> O^1#T7_KU3^50_$?\
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MHHH **** .6\(_\ (0UW_K[_ *5U-<MX1_Y"&N_]??\ 2NIH **** "BBB@
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M00KM1!@"O)P.$K4:\YS>C_$];'8NC5HQA#=?@<Y\1_\ DGVL_P#7NU3> O\
MD0]%_P"O5/Y5#\1_^2?:S_U[M4W@+_D0]%_Z]4_E7K'DG1T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <B_B6XD\5OID<UK'&A (=
ML,WTKI;V_M=-M6N;VXC@A7J[G %<MJ>A:E?:J4^QVGD&4.+L<2*!VKJY[.WN
MK;R+F%)X\<K(H8'\#0OA0/XCE_!%U!>SZU<6LR30O=Y5T.0>*Z^N2\%P16UU
MK<,$211+=_*B# ''I76T %%%% !1110 5Q?B_P#Y&7P[_P!?!_E7:5Q?B_\
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M<_\ 7:+_ -"% '::3_R![+_K@G\A5RJ>D_\ ('LO^N"?R%7* "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 5RVD_\ (\ZS_P!<X_Y5U-<MI/\
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M^A-G_P# E*!G945QO_"3^*?^A-G_ / E*/\ A)_%/_0FS_\ @2E '945QO\
MPD_BG_H39_\ P)2C_A)_%/\ T)L__@2E '95QWB>/S_%F@QDX"2%Z3_A)_%/
M_0FS_P#@2E9&H7OBN]UJQOQX1E5;;.5-RN3F@#TFBN-_X2?Q3_T)L_\ X$I1
M_P )/XI_Z$V?_P "4H [*BN-_P"$G\4_]";/_P"!*4?\)/XI_P"A-G_\"4H
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MT9M-U+5+LS>8+V82!<8V8&,5K44 %%%% !1110 4444 %%%% !1110 4444
M%(PW*1ZC%+10!E>'](;1=.:U:;S2TSR;L8^\<XK5HHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+@2<.DD9*,/SSGO6;:>$(K&5Y+:VTR-WB\AV%L<L@[')YSWHOY J:?VE^/\
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MM17C5A^T7X?N=3%O<Z7>6MLS8%P6#8]RHZ?K7K]M=0WEI'<VTBRQ2J'1E/#
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M+QJ5!_ ]*6Y\/Z3>6T5O<6,4D47W%(^[5Z"WAM8%A@C6.-!A548 H DHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\1_:-L[V70=
M,N8@QM(I6$N.@)'!/ZU[=5>]L;74K22TO;>.XMY!M>.1<@B@#X( R<#K7V7\
M*;2]LOAQI,5^&67RRP#]0I.1^E1V/P@\#Z?J8OX-%0RJVY5DD9T4^RDXKM6C
M5HC&  I&W '04 >7:Z?L-W)XKT]A-+IE^R7*1$$O"V P_#K1=%4\9^%+Z[=8
M[F^EFF97(!4%1M7\!BNUMO#$5D9#:206YE^_Y5I&F[TS@<BFW'A.VO+@7%R;
M>>88 EELXF< ?[1&:F[[&WLX?SK\?\CB-7OKC3]5\;26$LA:-+8ML<LR(?OE
M>>.,UHW,FA6V@ZAJ?A2Y5KUK'+K:2%UQ_>90?O\ 7D\UU$/AB.VN)+B"2"*>
M0?/)':1JS>N2!DCVJ2U\/?85=+.Z6W1SEA#;1IN]S@<GWHN^P>SA_.OQ_P C
MC_!J6EQK]KJ&G>(--E$MMB>SL86!?_;DR[88>I&:O>-K:TN_%OAJVNI#Y<TD
MJ21B8H'7;T(!KHK7P^;%W>TN8X&D.Z0Q6T:;SWS@<T_4?#UOJ%Y'=2+;M-$!
ML>6U21@1TPQ&0/:B[["Y(WMS+\?\CS?58K1M:U30[O5=.TI;9$%@;U'9XX]H
MPT3>8.<Y]35ZWN-*OM:U'3/%U_&S1VT/V.6X;R=R;>7CR>&W>G-=M<>'OM<L
M4ES<I.\1_=O+;1LR?0D<'WI;CP^;R2.6YN8YY8CNC:6UC;8?;(XHN^P_9P_G
M7X_Y' Z[<6UUX@FTF_U6RL[3[%&;&35$<\8.71MZC>#CD\U<6)1XF\(6USJ!
MOS):3I)*^5$Z[0 2A)ZBNRNO#WV[RQ=W*7 C.4\ZVC<K[C(X/O3)/#*37:7<
MLL#W28V3-:1EE^A(R!Z>E%WV#V</YU^/^1QFEZ/!9ZMJ'@F2Q5K:2X%['(4R
M# 3D@GU##;]*==BVBUWQI;K-LB33XR%$Q&P[6Z<\=NE=U_9=WYGF?VD^_&W=
MY2YQV&?Y^M47\(6DLDLDBVC23?ZUFL8B7SR<G'/MGI[T7?8/9P_G7X_Y'$:)
M';6.J^![FVG*3WMG(MPYF+>8!&" <GL:I6^D0Z]<VT$\4-SJ<&JM+-J#R(R2
M1!C\O)R?3;CBO0AX-LT*/&EDDD7^K86$7R$=,<<>^.OM7.0_#S49;YGU#^P7
M7>6^UQ6.)R<YS@C ;WR:+OL+V</YU^/^1O\ Q!0#P!JJ*,*(,<=A7)G0[*'7
M=+&C;IDO;"0ZE$9FE21-GRLP)(SNZ5Z,;&X-CY#7K,_0N8U((],=*IVGA\V"
MLEG=+;JQRPAMHTSZ$X'7U]:+OL"A%_:7X_Y'F5K<Z;_PC_@=O/@^UP:BL3G>
M-\:Y;*MZ#('!K=T[2]"F\>>+1)9V#[88C\T:'!*MN_/O76IX:2-RZ31*Q?S"
M5M8P2_=NG7T/4>]0GP=9&624I9F23.]S8Q9;ZG'.>_K[47?8?LX?SK\?\CSC
M3YK72OAUH4UK]CM;6XO"E_.8MR%<MM\S802N<#K4FKVMM:^#-7:VUZUN[5[R
MW>*.PW1PVY+@,J'><Y'.,\5Z/!X5@M8);>W>"&"7B2..SB57'?( P?;TIK^$
M[>2T2U?[*]O&=R0M91%%;V7&![T7?8/9P_G7X_Y&AIVEVFD:?*FFQ;5D+38W
MEMSD=<DGK7">%I]!U:SM+S4+H+XFANG\U1+MN#(&(V%1R4QCCIBN_L["2T@,
M(N6:,+MC 15"#V XJBOA]DO6O4N8ENV&&G%K&'/L3C./;-%WV$H1O\2_'_(\
M\=H[_P (:UJ-S*8_%%I>R!)-Q$T;A_W:+WVD8&.AS4T]G;:EXF\01ZJV^1='
MAEDB\]@JRX;)QGC! KO6\.[[P7;7*-<J,"<VT9D _P![&<U!)X0M9II)Y5LW
MFE_UCM8Q$N3UR<9(HN^P_9P_G7X_Y' V:Z=?7WP_O=4%K,\MA())I]I+,$&,
MD]P:6PLP/#7BC5]-$D^K6-[=+;.LS,T:G .!GGC->@)X5@CBCA1[=8HFW1HM
MG$ A]0,<'U/>G6?AI=.+FQFAM3)]_P BTCCW>N<#GV]/>B[[![.'\Z_'_(Y&
M)+.#5/"-]X;D7S+PXO!&^?.BV$LTGJ0<<GG-;'P[D22+Q!L=6_XF\_0Y]*V+
M?P[]D>5[:XBA>7F1H[6-2Y[9P.??U]JGTC0K?1WE:W2!/,Z^5;I%D^IV@9II
MOL3*$4KJ2?W_ .1JT444S,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>hook-20211231x10k025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ G4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***CFN(;9-\\J1IG&YV % $E%,::-%5FD4*Q !)X-/H **S8-?TFY
MU:72H=0MWOXL[[=7!=<=<BE37])DU=M)34+=M049:W#C>/PH T:*** "BH_/
MA,Y@\U/- SLW<X]<5)0 450;6M-6YN[9KV$3VD8DN$WC,:GH3Z"I+?4[&ZMX
M+B"[A>&X&87#C#_3UH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+_P )-I=N
MSPW5ZJS(Q#*5/'/TK:KQS7?^0[>_]=373AJ,:LFI'/B:KI131Z3_ ,)9H?\
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M5[+_ (]5_P!YOYFK% !1110 4444 %%%% !5>[_U<?\ UU3^8JQ5>[_U<?\
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MZ7_<7^M6*KI_Q_2_[B_UH L4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %&!C&.*** "BBB@ HHHH **** "BBB@ KQS7?^0[>_\
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M **** "BBB@ HHHH *KI_P ?TO\ N+_6K%5T_P"/Z7_<7^M %BBBB@ HHHH
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M/^/Z7_<7^M %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KJ/ 7_(PO_U[M_,5R]=1X"_Y&%_^O=OYBL<1_"D;8?\
MBQ/2Z***\(]L*KI_Q_2_[B_UJQ5=/^/Z7_<7^M %BBBB@ HHHH **** "BBB
M@ HHHH 9,I>&11U*D"O#]4^%.OS>#M-^Q1)%J\<K17D'G*%G@\WS%RW3*D _
MC7N=% 'EFN^$?$9O_$]E8:;97MGXAD5_MTUP$:T^4*0RD$MC&5Q3-2\!:O)!
MXIABMHYS>:;;VMI*\B@R,@ .<GY>G>O5J* . U;P3JMUHM^\.LZB\TVEO;)I
M;3*+;S#%L'Z\YS6)KW@+6Y-(\(3:?!(UQI5A]FN;2UO5MGW-&H8K(05X*G/J
M#7K5% 'B<VD:AX;\2>$+2QTA+J\BM+ES97%Z&Y)!($I4#/X>M:NB> ]=TZZ\
M/2S0PG[.E\]R(Y1MA:895!GKC.,BO53%&TBR%%+KP&(Y'XTZ@#QW1/!OBGPU
M;:#?PZ-::E<V^ER:?<6,MTJ>43*SAPQR",'! YI_B_PKXUUJ*:U@TRP%O<6"
M1;;6Y6%(I <E6RNYQZ#(%>OT4 >5:GX1\0O>ZP;?38I8M3T 66_[0BF&98V
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M117JGEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=1X"_Y
M&%_^O=OYBN7KJ/ 7_(PO_P!>[?S%8XC^%(VP_P#%B>ET445X1[8573_C^E_W
M%_K5BJZ?\?TO^XO]: +%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>.:[_P AV]_ZZFO8Z\<U
MW_D.WO\ UU-=V ^-^AQ8[X%ZF?1117JGEA1110 4444 %%%% !1110 4444
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MZ>U&T$YP,CO2T4 )M&<X&?6EHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>hook-20211231x10k026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &: H # 2(  A$! Q$!_\0
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M&NH1-<H#L#?Q'M0!N45!<WEO9QB2YF2)"<!G. 34P(8 CD&@!:*** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBE!.^XC->G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]QI-G()(+?'/'0'Z4 =XI#*"#D'FEI  !@=*6@04444 %%%% !1110 4444
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M780"01)YI!?'S$>M1"?-T-JU!TK7:=^Q+1115F 4444 %%%% !1110 4444
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M!POVC2]2UW07T"*87D+JMPXC*?NL<AO6O3J8L<2'*H@/L *?0 4444 %%%%
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M* "BBB@#SS0?^2N^(/\ KDG\J]#KSS0?^2N^(/\ KDG\J]#H **** "BBB@
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MG>I'+>U=[7E'AB/[)KEL\-_HI\UOF6/)<CT7/2O5A0 M%%% !1110!YYH/\
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M %T%3!-1DF:3:<H-?UH=)BBBBLC8**** "BBB@ HHHH **** "BBB@ HHHH
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M=K$5LV/P^T&SQFW,Y'_/4YJQ;>//"MV 8==LF)[>8 :U[;5=/O,?9KV"7/\
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M27\HQM'J*Y7PU\)EN/B3?:9?W!EL;$ARI).\'H#7T1INDV&D6JVUA:QV\2C
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MI\5Q#$T4;C*JPP15?Q#>V]AH-[/=2B*(0L"Q^E<T_B9UP5HI'*?![_D18_\
MKL_\Z[^O-_@Q?VMQX/\ LT4H::.5F=.X!/%>D5)04444 %%%% !7G?QD_P"1
M1@_Z_(_YUZ)7)>,_ EMXT%NMW?W-O'#R$BZ$^IH Z33O^0;:_P#7)?Y59K/T
M32AHNCV^GK<27 A7:))/O'ZU>DD6*-I'.%49)H X#P]_R5CQ)_USC_E7H->2
M^&/%&F3_ !7UHI(^+H)'$2A 8CK7K5 ',?$/_D1-5_ZXFK/@K_D2M'_Z]4_E
M47C'PS<>*M)_L^+5)K&-L^88U!WCTJ7PEX>N/#6CQZ=-J<M\L8Q&T@ *KZ4
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M6@ HI,CU%+D>M !129'J*7(]: "BC(]:,CUH **3(]:7(]: "BDR/6C(]10
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MM@Z\]: /0-+22+2;2.7/F+"@;/KBK=9VA:K%K6AV>HPG*3QAOQ[UHT %%%%
M#)8Q+$T;9PPP<5Y#INF6.C?&6_CCBV6OV(O*6YSZYKV&HC:V[2M(T$1D88+%
M!DCTS0!X78ZMH'B;QO'';K%86%@[_9(D3:\\N",GVJG9M&]IIVD)$W]LQZL7
MD3;\X7/4^U>\II.FQR"1-/M5<'(80J"/QQ4@L;1;C[0MK )S_P M!&-WY]:
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MO'!'Y%EING3E[>)$P]Q,/Z9KWIE# A@"#U!JHNDZ:L@D73[4.#D,(5R#]<4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>hook-20211231x10k027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'F \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10LZDC/(%>,_"WXQ:CK_ (A?2/$4L!>;_CVD2,)\P_A.*]AU[_D :A_U[O\
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MU>/#AMP /I53XG>#-=\0>/O#^I:;9B:TM-OG/O VX?/0^U>H?VSI?_01M?\
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M-K_W]7_&C^V-+_Z"-K_W]7_&@#Q+6_!_CWQ/XNT/Q!J=A @BD7=;0R#_ $=
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MK\X['GD5[/\ VSI?_01M?^_JT?VSI?\ T$;7_OZM 'BGA^W^+7AS3;?3=/\
M#]A#;1X!P5R?4DYY-3^(_"/B[2OB</%VEZ1%JZ3QJ6AD8?NVV@$<GC!Z5[(=
M9TL_\Q&U_P"_J_XT?VQI?_01M?\ OZO^- 'C=EX2\;S?%33?%.J:= (C_K(X
M)!BW7&-I]3]*/$_A?QGH_P 6)/%7AS3([Y)DVC<PPN1@@Y(KV3^V-+_Z"-K_
M -_5_P :/[9TO_H(VO\ W]7_ !H \M\0>#_$.J?%[0/$2V(-G!##]H<./D89
MW#'7C-+XW\!^(K3QLGC+PAY<MY@>=;.0-W;OZBO4?[8TL_\ ,1M?^_J_XT?V
MQI?_ $$;7_OZO^- 'C3>$?&_Q&\3V%[XNM(M-TRR8,($()?!S@ $]?6M?Q=X
M,UO4?B_H.M65F'TRS6)9)-X&W!.>*]-_MC2\Y_M&VS_UU7_&E_MG2_\ H(VO
M_?U?\: /.?B_X0UKQ1=Z"^DVHG6UF+R_,!M&1ZUZ=;*4M8488944$>G%5_[9
MTO\ Z"-K_P!_5_QH_MG2_P#H(VO_ ']7_&@"_15'^VM+_P"@C:_]_5_QH_MK
M2_\ H(VO_?U?\: +U%41K.F$@#4+4D]O-6KW6@ HHHH **** "BBB@ HHHH
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M_C7=44 <+_PI[P/_ - 8?]_6_P :/^%/>!_^@,/^_K?XUW5% '"_\*>\#_\
M0&'_ '];_&C_ (4]X'_Z P_[^M_C7=44 <+_ ,*>\#_] 8?]_6_QH_X4]X'_
M .@,/^_K?XUW5% '"_\ "GO _P#T!A_W];_&C_A3W@?_ * P_P"_K?XUW).*
M,T <-_PI[P/_ - 8?]_6_P :/^%/>!_^@,/^_K?XUVRS1LS*KJS+]X*<D?6G
MALT <-_PI[P/_P! 8?\ ?UO\:/\ A3W@?_H#+_W];_&NY!S7->+?$EYH4FFV
M]A81W=S?3>2BR2;%!QGDX- &5_PI_P #_P#0&'_?UO\ &E_X4]X'_P"@,O\
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MMLZ%L[G&[CCJ,5U%K8ZUX.UO4&LM%;4+'4DB,?V=P#!(J!-K;OX>!S7HM&:
M/)]$\-:Y&/#37EB8Y(+VYEN IXC#YQ]>M5;S3/$\7@S4O"L/A^261IV=;L2+
MY;QE]V1SG=[5[%10!PFCZ+J-OJWBV66V9$O(H5@;^^1#M./QK//A_5O^%=>&
MM/\ L;F[M;F)YX\\J Y)->ET4 <KXVT:^U33;.XTZ,2W>GW274<+' EV]5SV
M.*YN\LM>\7^)H)KG1)M,L/[,NK7?,RE_,< <@$_+Z?2O3J* /+);;Q/JWAJS
M\)3Z"]L\/EQ3WQD4P^6A'S+SDD@=*HZ_X:U*;4KLV_AJYAU;<!9ZIIMUY2,!
MT,H)[=^*]AHH \@U#P;>67B"ZU#4]%NM<6^AB)DL[DQ-',JX8,-P!!/.:IZ_
MI$FC>'?"EO-I\5A*^MK*UO%(7VY]6/5O6O:Z\X^*_P!_PO\ ]A:/^1H ]&'0
M?2EI!T'TI: "BBB@ HHHH **** "BBFLZ(,LRJ/<XH =14?VB#_GM'_WT*>K
MJP!5@0>X- "T444 %%%% !7G7QDFU>+P5<K86D,UHZD7;N^#&N1@J.]>BUYW
M\8]9BT[P3=6<D%Q(UXNQ7C3*I@CECV% '7>%QCPKI8_Z=D_E6M63X7&/"VEC
M_IV3^5:U !1110 4UO6G4AZ4 <+XCMM07Q'91PZO=0QWC[=B8PF/2NUMXVBA
M1&<N54 N>K>]<UXB_P"1ET'_ *Z-_*NJ[U$-V=6(;=.GZ?J+1115G*%(>E+2
M-]TT <FC*/B,Y+#_ (]!_.NKKR2Z>"P^(;O)<3-;1N"Y!/R9['VKU>*1)8TD
MC8,C#((Z$5E3E>YZ&.HN"IOO%$U%%%:GGA1110 4444 %%%% $%U(T-O)*D;
M2,JDA%ZD^E<VWB?457<_A^\48R2<=*ZHTR1=X((RI&"*N$HQ?O*YC5ISG\,K
M'"6/CZXNKZ:%--DF.<QQIC<!WS6[9:_?W5Y'#)HEW!&QP9'QA:TH-(L;6;SH
M;2))!T95P:O#..:TG.D_@C8PHT<0M:DP7..:\Z^*&F)K&H>']/?_ );2R!3Z
M-L)!_.O1Q61JN@PZIJFF7TDK(]A(9$ Z-D8YK [3S36=2;Q3X0T_2I3EK>SG
MN+Y?>%"H!^K?RJG:>(KV2'1M#2\U6SL[;2+>X=M+M_,DD=QP"<':HQ^->A6W
M@/3[2YUV>*64-JZ-&X[1A@<[?Q)-0-X!BABL'T[5+NQO+.U6T^T18)EC7H&!
MX- '+VGB/Q%JD.FZ$UU=64US=O%_:$L&R9X5&<@'HQZ9JKJ"ZKX7U?Q=.-7E
MNKF'2H7M[F51YBC<?O=B?>NU?P#9-I,5H+V\%W#,;A+XOF42'J?I[56_X5S"
M\6JFZU2[N9]3MEMYYI,9P#D$#M0 _0=:U"[\9WMC/<%[:/2;:X5,=)&!W'\:
MYBWU[Q%J]UI%C'K$EN+R^NH9I412VQ#QMST-==?>!H[C4H=0L]4O+"Y6U6TF
M:''[V->@.>_O2:3X LM(FTR2&YG<6$LLB;^2Q?KF@#DX8_$MQ%XEM3XLOE31
M"QMY51?,D.S=^\..1V[5V=EX@N#\-X?$,RA[G^S_ +0R@8!?;G^=6H/"\$+Z
MXPF<G5\^9_L97;Q^%6M.T2WT_P .6^B',UM% (#O_B7&.: /,-8TW6I?#NAZ
MS?>()[LW=Y!+-;.H$2Y.0$QTQ6Q!_P )!XIAU?6+?Q%<Z<MI-)':VT"KY?[O
MO)GKG%:7_"MHBMM ^LW\EE:3+-;6K$;8R#D#/4CZU/?> 8[BZO'L]7OK"UOB
M6NK:$C;(3U(S]W/?% ''WWB;7M4M-'U.>;5++2+BP$DDVD1AV6X#$$N""=G&
M0!3[_P 8WUQ#HFF6^M7EQ'<0O+/?Z=:YF<*<!0O\)]>*[&[\#1>?:RZ3J5WI
M;06PM<0$%7C'3(/&>O-,/P\L8;"TBL+RZM+NT9G2\C(WL6Y;=V(/I0!YQXFU
M75+SP1J-E?-?36]OJ%J;:YO8/*E=2W(;U(/>O=HO]2G^Z*\E^(WAX:'X"N)'
MO;F]N;G4+=I9YVR3AN !T KUJ+_4I_NB@!]%%% !1110 4444 %%%% !1110
M 4AZTM-/)P: /$O%_B:ZU#6]0L+Z&P*6UUY,&FS6KM/.N<!U<=,]17:Z;X7U
MO0;VUETC4S)ISD>=97OSM&IZA'Z\>]<-J?Q'U" ^);4WMDNJPZJ+.P:6-0T4
M+'!8>N*V=+O/$WA/QII6DZKXD778-34Y1D >$XSN&.U 'K*]*6D'2EH ****
M "FR;O+;9C=CC/K3J;("R$!BI((!':@#R3PW_;?_  O&Z_MT6WVC^RSY?V?[
MNS>,9]Z]=KR/PYIE]I?QQNH=0U:;4Y7TPNLLJA2BEQ\O'I7KE !1110 4444
M %%(>E,W#L<^U $E%- [TZ@ IIZ4ZJ&KWJZ?I5S=,0!&A/XTGL.,7*22ZGGW
MB9O[4NM7O3S%9*L$?^\3R:Z/X=_\BG"?^FC_ ,ZYG4773? T4$@/VK4'\YO4
M9.:TO T^F6N8X[^X61UQ]EN.%#=RM;>QG[&,[::A5Q=%5ZE#FM:R7G:YWDD:
M2QE'4,K#!!'!%<?=:=?>%KI[_25:>P8YFM.Z^ZUV2G(XZ4$;A@UBU<NE6<--
MT]T4=*U:TUBR6YM) Z'J.ZGT(K0%<CJF@76FWC:QX?.R;K/:_P $P^G8UJZ'
MKUOK4!:,>5.G$L#_ 'D/TI*6O*RZE*-O:4W>/Y$^MZE-I=D;F&S>ZVGYE0XP
M.YJKX;UV;7;=[A[*2VBX,;.<[QSTJQK%Y;1:==123QHYA;"LV">*J^"_^11T
M[/7R_P"IH:ES:[!%TW0;^U=(WZ**#5& 4A(Q0:R-8T*/61&'N[FWV=#!)MS]
M:&5%)NS=B;4M7LM)C62\G6)&.T,>F:=IFJV>K0&>SF$L8."PZ5S-]\/H+BT=
M%U&^=\?()I=RY^E%G\/K>WM4C_M&^1L9812E5S]*SYIWV.OV6%]G\>OH=KD>
MM!Z5DZ-HD>C)(L=S<S[SDF>0MCZ5K5H<<K)V3N<EI/B.:X\;>)-*O+B!+:Q\
MC[.K$*?G4EOK5*Y\53KXEURR_M""&PL[!)TG"A_+8M@DXZUFV/A;2]=^)?BV
M35]-%PJ"V\EGW ?<.<$$9[5BZOH-OI&K>,+?3-/,%NVD1[5C5B&;=VSU- CO
MKWQQHNC_ &6"\O))IY(ED801%\*?XV ^Z*R-:^(5G;W'AR]T^^CDTB]N9HIY
M0A;=M7@+WSNK)T74[?PIJ]_)K-O/MOK6%K>183)O 3!CX'!SV-8OA:/[5#X)
MFCM'2'^V+U_+*?ZH?-C([4 >JZ%XGTOQ(DWV"5S) V)8I4*.GIE33-<\6:5X
M>EABOI9#/-RD,,9D<@=3@=!61H\4B?%37W\LK&]G"0V."<FJ>J7:>&OB/)J^
MIPRFPN[)88KA(RX1U/*G'3- $GA[Q];7&D:UJ^J7L:V%MJ#6]O($P67 V@#J
M6YK:TSQMH6J0W<D=R\)M4\R:.YC,;HO][![5YG:K*\)UY=,N1IUIXE>[FMO)
M^?RRF ^SO@G-:^J3VOB[Q%-J-CIUW>:9:Z=+%<LD9C:<MT1<XR1UH ['2?'>
MA:U?BQM9Y4N'4O&L\+1^8HZE2>HJ-/B%X<DU,6*WDF3+Y*SF)O)+_P!W?TKS
M_1Y;Z:]M]+T/5;W4K6:WDC>'4+3$E@-I Q+@=^,5F6UN6\,P>'KO5M>:Z#+
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M;_D0O^WZW_\ 0Z] B_U2?[HH =1110 4444 %%%% !1110 4444 %(:6F]Z
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M#TIU)1SBK.06N2\92&[:PT>,G==3 N/]D=:ZOBN1TX?VMXWO;P\PV2>3&?\
M:[U$[['1AM).H_L_TC(\?R 26%C"HQ" [<=!D 5UL^AV&J:="EQ N0@*NO#+
MQV-<;K(-\=:U#JB2) A]@>:]%M/^/.'_ '!_*N^JW"G!1Z'A8>*JUZDIK<Y?
MR]=\.G]VQU*P'\)_UB#^M:^EZ_8ZJN(9=LH^]$_# _2M?&1BL35?#5EJ3^<
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MKUN&-((4CC4*BK@ =A6U1MR^2.>%.$:*<6VVWOZDPHH%%0(*\X^*_P!_PO\
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MZ8L9>'SMT*=MI.345;QU1UY<H5GRS?PI_<>C^$+!K+086D'[^<F:3/JW-/\
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M-.S'44@Z4M,04444 %%%% !1110 4444 %%%% !1110 4444 >>_&;_D0O\
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M\)3K;Z)J.NW/RB0ELG^Z@P*L^!+60Z9/JMPO^D:C,9CGJ%_A%=%7W92\M/\
M,YL)K3B^^O\ D-U3_DI6C'_IUDKL!R*Y&^\$->ZT-4.M7D<JME N,(,\J/:N
MM0;449S@8S6%1Q:C9[([::DF[BXJ*>WANH6AGB62-AAE89!J:DQ65V:M7.(N
M/#6I^&YWO/"\V^W)W2:;,V4/KL/8UKZ'XLLM89K=@UK?I_K+:?A@?;U%= 5Y
MS6#K_ABPUF/SI$,5U&"T=Q%PZGZUKSJ>D_O,N1PUC]QEVQS\4;S_ *\D_G79
M*<BOGFTUK68/$Z2K<W$]P)!$>>9%!^[7JH\9:E!_Q\^&;Y?7;@UO7P\ERVUT
M,:-:-G?34[*BN/'Q!M$_X^-,U&+ZP$U,GQ"T%CAY9H_]^)A7.Z,^QO[6'<ZJ
MBL"/QKX>EQMU2 'T8XJ[%K^DS_ZK4+9O^V@J7"2Z%*<7LS2HJ!+RVD^Y<1-G
MT<5*&#="#]#2L.XZBDR:,TABT4F:,T +129HS0 M%)2T )5'5[RYL=.EN+2T
M-W*G(B#;<_C5[O4-T/\ 1IO]P_RH6Z$]F>46CW?CGQ))<PXTUX5#*6_>?,#^
M%>J6,<T-E%%<2^=,J@/)C&X^N*X7P)X=L;FQ74G\T7"W#D%7('!]*]"Q6^(Y
M.?W3'#3J>RY9][BBEI!2U@;A7G'Q7^_X7_["T?\ (UZ/7G'Q7^_X7_["T?\
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M9VY?Z%N*Y/Q@?[7U;6I^L&EVHC4]O,8\UW4/<E#R7YGFR][G?=V^XM^'9I_
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M/EF 8 3>,9]Z]<KR+PWH_P#8OQPNK?[?<7OF:89-\[;BN7' ]J]=H ****
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MI"O/_C'_ ,B')C_GZA_]#% &E\-K/5['P+IT&M.S783/S'+!3T!-=<*KV/\
MQX6W_7)?Y58H **** "O./BO]_PO_P!A:/\ D:]'KSCXK_?\+_\ 86C_ )&@
M#T8=!]*6D'0?2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "N"^+NJ
M65CX#U"VN;A(I[J/;"C'F0Y'2N]KAOBS96MQX U.>:".26&/,3LN2AR.0>U
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M&(C)[(328TEU/3XY& M=)M!+(S=-[#//TZTW38Y/$4^I>)[D'[.L3PV"-_<
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MT?\ (T >C#H/I2T@Z#Z4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M;\-V)@O[[?+<QLL:0#S#TQDXZ"N24W.?,SHC!0ARHT? /_(G67T/\ZZ:N.\
MZKIY\&6#?;K<!E)&Z0 ]?0UTAU73\?\ '_:_]_5_QIU?C84[\J*?BO\ Y%;4
M?^N#4>%8T'AK36"*#Y"\X]JY/Q_\1?#.CV$^D7%]OO+F$A4A&\+GIN(Z5T?A
M?4]/7PQIN;ZW!\A>#*/3ZT7_ '?S"WOG1T52;5=/(_X_[;_OZO\ C7+ZO\4O
M"6B:Y'I%WJ)-R^,F-=Z)GIN8=*S-#M:*H+J^FLJLNH6I4C(/FK_C3_[5T_\
MY_[;_OZO^- %RBJ?]JZ?_P _]M_W]7_&C^U=/_Y_[;_OZO\ C0!<HJG_ &KI
M_P#S_P!M_P!_5_QKE8?BIX1G\3-H2:G_ *4K;-Y7]T6] _2@#MJ*I_VKI_\
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M4JG)IU(R04CLJ(78@*!DD]J6F2QI-$\<BAD<$,#W% SRWP=J^FR?%OQ7Y=]
MWVCR5AQ(#YA .<>M>JUS5CX#\,:=?QWUGI%O%=1L6211RI]:Z6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *\X^*_W_"__ &%H_P"1KT>O.?BO][PO_P!A:/\ D: /
M11T'TI:0=!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !7F7QM\-V^
MM>"Y+Z1V2;3OWD>.^>"#7IM<;\4_^2;ZS_UR_J* /-_#'P+LYM.L;R\NEF29
M%E=<$<'G%=X/@UX&P/\ B3\_]=6_QKI_"_\ R*NE?]>L?\JUJIS;L2HVN>1>
M*O@1H6I6T9T1CILT9^8DEPX_$UQVF_"O3/[06QGDG<?=$YB(!;Z>E?1M,\M
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MTKVJC% '!_\ "G/ W_0&_P#(S_XT?\*;\#?] ?\ \C/_ (UWE% '!_\ "F_
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MM_PC?Q/_ .ATT[_P!-'_  C?Q/\ ^ATT[_P!->DT4 >;?\(W\3_^ATT[_P
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MO_ $U!?:+\3;&PN+M_&6GLL,;2%19<G S7IYJ&Y6&6VDBN-ODNI5PQP"#VH
M\F\,1_$GQ1X>M=7A\6V,"7"EA&]GDKSZBM?_ (1OXG_]#IIW_@":[K2;&PTR
MPBL]-CCCM8QA%C.0*OT >;?\(W\3_P#H=-._\ 31_P (W\3_ /H=-._\ 37I
M-% 'FW_"-_$__H=-._\  $UE^([?XD^'/#][J\WB^PF2UC,C1K9X+>U>NGI5
M&_LK+5;2;3KU$G@E7$D+'J* /.M,TGXF:GIEK?)XQL$6XB64*UER 1G%6O\
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MX#C_ !KTBB@#S?\ X6W_ -2=XB_\!Q_C1_PMO_J3O$7_ (#C_&O2** /-_\
MA;?_ %)WB+_P''^-5U^,]J]V]HOAC73=1J'>$0C<JGH2,]*]0KF;/PQ):^/M
M1\2&Y#)=VL=N(=O*[>^: .=_X6V?^A.\1?\ @./\:/\ A;?_ %)WB+_P''^-
M>D44 >;_ /"V_P#J3O$7_@./\:/^%M_]2=XB_P# <?XUZ110!YO_ ,+:)_YD
M_P 1?^ X_P :@@^,UK=231V_A?797@;9,J0@F-O0\\&O3N]<SX9\,/H.K>(+
MUKE91JMY]I"A<>7QC'O0!SW_  MHC_F3O$7_ (#C_&C_ (6W_P!2=XB_\!Q_
MC7HXZ4M 'F__  MO_J3O$7_@./\ &C_A;?\ U)WB+_P''^->D44 >:M\70JE
MF\'^(0JC))MQP/SJ*U^,UM?6ZW%GX6UZXA;($D< *G'OFO2+N'[1:30 X,D;
M)GTR,5B>"?#C^%/"]MH[W G:$L?, QG)STH YG_A;?\ U)WB+_P''^-'_"V_
M^I.\1?\ @./\:](HH \W_P"%M_\ 4G>(O_ <?XT?\+;_ .I.\1?^ X_QKTBB
M@#S*X^,<-K;R3W/A/7X88QN>1X  H]2<TL7Q?CGB26'PEX@DB<;E=8 0P]N:
M[7Q1H[>(/#&HZ2LHB:[A,0D(SMSWJ?1-/;2M#L=/9Q(;:%(BP'WL#&: .'_X
M6W_U)WB+_P !Q_C1_P +;_ZD[Q%_X#C_ !KTBB@#S?\ X6W_ -2=XB_\!Q_C
M1_PMO_J3O$7_ (#C_&O2** /"OB)X_/B#PREA_PCNL66Z\A;SKJ':@PW3->Y
M1?ZE/]T5SOC;PT_BOP^-,2X6W/GQS;RN?NG.*Z-%VQJO7  H =1110 4444
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MPB=HY->LY!+:O%=?+ITKEFMEQTSWS7I]<OX3\'Q^&9;VZFOY]0U"^</<74X
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MM]<L[=($MXMJ6JK\N_/W\YZUW8H 6BBB@ HHHH **** "BBB@ HHHH ****
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M %%%%  1FDVTM% "8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7T7Q5H6B:3:V\TFJ;UW2D_*0.M<Q'XZ\;S2>(-/2#3S<Z$2T\^#ME4= H]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>hook-20211231x10k028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231x10k028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %I Y,# 2(  A$! Q$!_\0
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MV#Y !].:]9R,XR,^E)O7.-PSZ9IJMK=H3I:;GE?B&UAU3P]I4FBV.HQV6FW
M$L:PE)=N/O*.Y]Z=::#;:Q::S)I@ULWDMH81+J"[5DZ';S],5ZI11[=I60_9
M*]V>,ZQ?SW_@/3]#AT+4$N[-XQ/FW(5-IP2#WS7JMW%))X>EB129&MBH7OG;
MTK0!!) (R.M&1G&1GTJ9U.:UD.,+=3QZ.SOM0\!V5K!87;7.DW:S3VTD142K
MNSA<]:VKVYE\9^(-$_L[3+RUCL9/.GN+B$Q[!_<&>M>D453K=;?TQ*ETN<7\
M3K66\\+)#%#),3<QY5%+'&>>E<]XX\#:38^#S<Z5I3?;=T8_=AF;GKQ7JC.J
M_>8#ZFA65ONL#]#2A6E!*W0<J:E>YY!XJM[9/'4%QJ>BWFH60T^-=L,;'#\]
MQ5CPCIT]UXCOFT>POM'TF6V*.)@0=_8KGO7K%%/V[Y>6Q/LM;W.<\.>&;K0Y
MYI+C6KO4%D4 +.<A2.XK&\+6,[:[XQ22&2-9[@A&=2 P(/(/>N\HJ/:/6_4O
MD6ENAXM'%JLFAP>#/['NUF2\W-<%#Y>S=G.:[7XBV<K^"1;V\3RNLL0VQJ6)
MP?05VE%4ZUY)VV)5*R:N16H(M(01@A%X_"N#U,S^'OB%)K=S8W5U87%N(EDM
MXS(8V'L*]!HJ(SY6_,N4;GD-]IU_>:!XKU9;"X@AU!XS;V[1G>P#?>V]17I^
MB1>1H.GQ;-FVVC!4C&#M%7Z*<ZG,K"C#E=SS/4O#,6O_ !1NEOH+@6@M%*R)
ME06]-U:NO>%['1/ >KVNDVC;Y8\MC+NYR/Q-=MD9QD9]*6G[:6G9"]FM?,\Q
MN]0U/3T\/VTEO?QZ=_9Z;Y;.#?+YFW[IXRM85GHNIW7A+5TCL;I9H]16Y\B5
M3O=!S^)KVNBJ5>VR)=*^[.+MM?'B$/IMGHU]"[VC1M=SP^6(CM(QSU_"N&TC
M1[86$&C:O;>(A=1S%6@A0F'.[(8'IBO;&95&68 >YIOFQDX$B_G1&KRZ)#=.
M^[/,OMCZ!\2-1O9M+OKBT-ND8EB@+E>/UK,_X1W5K[PUJ.HPV$JB74ENTLW7
M:SQCVKV.BA5[;+M^ >RONSS34KF;QIK&A1:=IE[:BRF$T\]Q"8Q&!_"/6NQ\
M6QO+X4U*.-&=V@8!5&2?PK:HJ'4U5EL4H;WZGG7A?X=Z)/HNGWE];3M.8U=X
MI78#=[K5J:RD_P"%Q6<RV[_9X].VB0(=@/S<9Z5W=%-UI-ML7LTDDCR#4]*;
M3?%>L/J:ZU]GO#OA?3U+!Q_=;%=-#X.:]T'3H=-U75-+@B5B(WX<Y.?FKN:*
M;K2:0E22/.+R&XT/XBZ/<7$5Y=VZZ<+4W*1%RS\C+8Z=15KP;;W=G!XEF6U<
M3M<NT0D0C?P<=>HKO:0D 9)Q2=6ZM8:IV=SQ#4Y]3UC3]/-Q9ZJUW!>*]PAM
MRL,0S_" .:[;3;27_A:VLW+02>4UE&$D*':3A> :[JBJE6NK)"5*SO<\AL=-
M'_"*:Q'?Z3?SQ_VF[JL"E709.' /4?2KGA1]4&J7T<+ZA/I M'W2W\&QU;'"
M@GK7J5,FC$T$D1. ZE21[BAUKIIK<%2M;4\5\/ZJ1\-+G1DTB\GN;MY$@DCA
MW(Y)QDMVQ6]#I6H:;XJ\-1M!)(]MISJ[!25#XZ$]/:NX\-:!#X9T9--@F>6-
M79]SC!Y.:UZ<ZRN^5::BC2=E<\/UJYU;5]&,5W9:H;V*\WR1);E8(TS@$8')
MKLK:VED^+S79MY/(_LQ0LI0[<\<9]:[ZBDZUU9+^F-4K.]SRBTTV\;PYXSA2
MTFWR73&--A&\9/3UKN?!UZMWX:M%$-Q"T,8B=9XRAR!S@'M6]14SJ<RM8<8<
MK"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** *FH:99ZK L%];K/$K!PC=,BK0 4  8 X %+11< HHHH ****
M"BBB@ HHHH **** "J]G8VVGQ-%:PK$C.TA5>[,<D_G5BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZY)\$=4FDU"Y^U6>H"&.5FQ(%ST)KTG4OAC/+XOOM>TGQ#<Z:=00)=QQH&+
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M@]E/LRY15/\ M73_ /G]M_\ OX*/[5T__G]M_P#OX*+H/93[,N453_M73_\
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M8_[Z_G1YL?\ ?7\Z 'T4SS8_[Z_G1YL?]]?SH ?13/-C_OK^='FQ_P!]?SH
M?13/-C_OK^='FQ_WU_.@!]%,\V/^^OYTJNC'"L#]#0 ZBBB@ HHHH **** "
MBBB@ HHHH **** &211S)LEC5U_NL,BG !0 H  X %+10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO?\ O'\Z-[_WC^=-HJ3<=O?^\?SHWO\ WC^=-HH =O?^\?SHWO\ WC^=-HH
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M_P"19TW_ *]D_E7@7>O??#?_ "+.F_\ 7LG\JZL)\3/GN)/X,/7]#4K$N/\
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M<S.%$CF=RIQW"9P,U'J&O->Z<+)+<Q1[@WS3-)@_[.>@KO?^%6Z?_P _T_\
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M<Q48Q]U>@Z51_MZ47$\P@3=--'-C/0H<@5W_ /PJW3_^?Z?_ +Y%'_"K=/\
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M"[201R,NUF0,5SG!(Z5D3^$]&N+V2ZDM3OE?S)$60A)&]67.":V@   !@"@
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MSO-0T.ZM;"X^SW4B8CDR1@^F1TSTS7&6/@O54U9-0DM;*VS:2V[)'</*Q+#
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M9/Y5X%WKWWPW_P BSIO_ %[)_*NO"?$SYSB3^##U_0U*Q+C_ )'6Q_Z\9O\
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M)())81*PBD8=V7H:UH-*M+;4[G4(H]MQ<HB2-GJ$SMX_&KM% !1110 4444
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M@6;[0UO/;2*.6$B_>7T%=SH5G=Z?H=G:7]T;JZBC"R3,22Y^IZUH44 %%%%
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M=8EQ_P CK8_]>,W_ *&E>(>L;=4M3_X]A_O5=JEJ?_'L/]Z@#&HHHH ****
M"BBB@!KND:,\CJB*,EF. *2*:*>,20R))&>C(P(/XBJ.LZ7;ZO:QV]RS&-9
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MK)KNO^%5:_ZP?]]T?\*JU_U@_P"^ZUCB*$5;F1G*A5;ORG"U]$>!O^1*TO\
MZX_U->8_\*JU_P!8/^^Z]9\,Z=-I7ARRL;C;YL,>UMIXSFN+,*U.=-*+OJ=>
M"I3A-N2MH:U8EQ_R.MC_ ->,W_H:5MUB7'_(ZV/_ %XS?^AI7DGI&W5+4_\
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M_9T-UNF+%%;8=CL.JANA-;5 !1110 4444 %:FE='_"LNM32NC_A0!I4444
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MS'H7_"WM:_Y\[+_OEO\ &C_A;VM?\^=E_P!\M_C7GM%'U2A_*'UFM_,>A?\
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M?^AI6W6)<?\ (ZV/_7C-_P"AI7E'I&W5+4_^/8?[U7:I:G_Q[#_>H QJ***
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MVBQ!+29C+?R,IC:/)(9!UWG/>NVHHH **** "BBB@ K4TKH_X5EUJ:5T?\*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC7H%<A\0]#OM>T2&VL(Q)(LP<@G'&#6^%DHUHMF.(3=*21X+177?\*U\2_\
M/FO_ 'V*/^%:^)?^?-?^^Q7O_6*7\R/%]A4_E9R-%==_PK7Q+_SYK_WV*/\
MA6OB7_GS7_OL4?6*7\R#V%3^5G(T5UW_  K7Q+_SYK_WV*/^%:^)?^?-?^^Q
M1]8I?S(/85/Y6<C177?\*U\2_P#/FO\ WV*/^%:^)?\ GS7_ +[%'UBE_,@]
MA4_E9R-%==_PK7Q+_P ^:_\ ?8H_X5KXE_Y\U_[[%'UBE_,@]A4_E9R-%==_
MPK7Q+_SYK_WV*/\ A6OB7_GS7_OL4?6*7\R#V%3^5G(T5UW_  K7Q+_SYK_W
MV*/^%:^)?^?-?^^Q1]8I?S(/85/Y6<C177?\*U\2_P#/FO\ WV*/^%:^)?\
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>hook-20211231xex10d15001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20211231xex10d15001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  # ;4# 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>37
<FILENAME>hook-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:19:52 AM-->
<!--Modified on: 3/24/2022 11:19:52 AM-->
<xsd:schema targetNamespace="http://www.hookipapharma.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:hook="http://www.hookipapharma.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" id="DisclosurePropertyPlantAndEquipmentNetDetails">
        <link:definition>40501 - Disclosure - Property, plant and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40701 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" id="DisclosureLeasesLeaseCostsDetails">
        <link:definition>40702 - Disclosure - Leases - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" id="DisclosureLeasesMinimumLeasePaymentsDetails">
        <link:definition>40703 - Disclosure - Leases - Minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40801 - Disclosure - Accrued expenses and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" id="DisclosureLoansPayableDetails">
        <link:definition>40901 - Disclosure - Loans payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" id="DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails">
        <link:definition>40902 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails">
        <link:definition>41202 - Disclosure - Income taxes - Losses before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails">
        <link:definition>41203 - Disclosure - Income taxes - Effective income tax reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails">
        <link:definition>41204 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41501 - Disclosure - Net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails">
        <link:definition>40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails">
        <link:definition>40203 - Disclosure - Summary of significant accounting policies - Others (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails">
        <link:definition>40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" id="DisclosureCollaborationAndLicensingAgreementsDetails">
        <link:definition>40301 - Disclosure - Collaboration and Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" id="DisclosureFairValueOfFinancialAssetsDetails">
        <link:definition>40401 - Disclosure - Fair Value of Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" id="DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails">
        <link:definition>40704 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" id="DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails">
        <link:definition>41001 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" id="DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails">
        <link:definition>41101 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" id="DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails">
        <link:definition>41102 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" id="DisclosureStockBasedCompensationStockOptionValuationDetails">
        <link:definition>41103 - Disclosure - Stock-based compensation - Stock option valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>41104 - Disclosure - Stock-based compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" id="DisclosureStockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>41105 - Disclosure - Stock-based compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" id="DisclosureStockBasedCompensationCommonStockAwardsDetails">
        <link:definition>41106 - Disclosure - Stock-based compensation - Common Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" id="DisclosureStockBasedCompensationStockBasedCompensationDetails">
        <link:definition>41107 - Disclosure - Stock-based compensation - Stock-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails" id="DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails">
        <link:definition>41205 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" id="DisclosureCommitmentsAndContingenciesOthersDetails">
        <link:definition>41301 - Disclosure - Commitments and contingencies - Others (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" id="Disclosure401KSavingsPlanDetails">
        <link:definition>41401 - Disclosure - 401(k) Savings Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>41502 - Disclosure - Net loss per share - Antidilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" id="DisclosureRelatedPartiesDetails">
        <link:definition>41601 - Disclosure - Related parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41701 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization" id="DisclosureNatureOfBusinessAndOrganization">
        <link:definition>10101 - Disclosure - Nature of the business and organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements" id="DisclosureCollaborationAndLicensingAgreements">
        <link:definition>10301 - Disclosure - Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets" id="DisclosureFairValueOfFinancialAssets">
        <link:definition>10401 - Disclosure - Fair Value of Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet" id="DisclosurePropertyPlantAndEquipmentNet">
        <link:definition>10501 - Disclosure - Property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive" id="DisclosureReceivableResearchIncentive">
        <link:definition>10601 - Disclosure - Receivable research incentive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10701 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10801 - Disclosure - Accrued expenses and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayable" id="DisclosureLoansPayable">
        <link:definition>10901 - Disclosure - Loans payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" id="DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock">
        <link:definition>11001 - Disclosure - Common stock, Class A common stock and convertible preferred stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11101 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11301 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlan" id="Disclosure401KSavingsPlan">
        <link:definition>11401 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11501 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>11601 - Disclosure - Related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11701 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables" id="DisclosureFairValueOfFinancialAssetsTables">
        <link:definition>30403 - Disclosure - Fair Value of Financial Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables" id="DisclosurePropertyPlantAndEquipmentNetTables">
        <link:definition>30503 - Disclosure - Property, plant and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30703 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30803 - Disclosure - Accrued expenses and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableTables" id="DisclosureLoansPayableTables">
        <link:definition>30903 - Disclosure - Loans payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31103 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31503 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" id="DisclosureReceivableResearchIncentiveDetails">
        <link:definition>40601 - Disclosure - Receivable research incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41201 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:element id="hook_GoingConcernPolicyPolicyTextBlock" name="GoingConcernPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_DeferredOfferingCostsPolicyPolicyTextBlock" name="DeferredOfferingCostsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" name="ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" name="GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_EarningsPerSharePolicyPolicyTextBlock" name="EarningsPerSharePolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" name="CollaborativeArrangementNumberOfPreclinicalResearchPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborativeAndLicensingArrangementAbstract" name="CollaborativeAndLicensingArrangementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_MilestoneAxis" name="MilestoneAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_MilestoneDomain" name="MilestoneDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_CommercialMilestonesMember" name="CommercialMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ProceedsFromNonRefundableUpFrontPayment" name="ProceedsFromNonRefundableUpFrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_CollaborativeArrangementTermOfRoyaltyPayment" name="CollaborativeArrangementTermOfRoyaltyPayment" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" name="CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" name="CollaborativeArrangementContractAssetRelatingToSublicensePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_PrepaidExpensesAndOtherCurrentAssets" name="PrepaidExpensesAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_GrantIncome" name="GrantIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases" name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_LesseeLeaseRemainingTermOfContract" name="LesseeLeaseRemainingTermOfContract" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_LeaseRightOfUseAsset" name="LeaseRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_LeaseLiabilityCurrent" name="LeaseLiabilityCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_LeaseLiabilityNoncurrent" name="LeaseLiabilityNoncurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_LeaseLiabilityTotal" name="LeaseLiabilityTotal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" name="OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" name="LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" name="LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" name="LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" name="LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" name="OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_OperatingAndFinanceLeaseLiability" name="OperatingAndFinanceLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" name="AccruedExpensesAndOtherLiabilitiesCurrentAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_AccruedSocialSecurityContributionsCurrent" name="AccruedSocialSecurityContributionsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedUnearnedGrantIncomeCurrent" name="AccruedUnearnedGrantIncomeCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_OtherAccruedExpensesAndLiabilitiesCurrent" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_NumberOfVotes" name="NumberOfVotes" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_LicensingFeesIntellectualPropertyLicenses" name="LicensingFeesIntellectualPropertyLicenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_StockOptionAndGrant2018PlanMember" name="StockOptionAndGrant2018PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_StockOption2016PlanMember" name="StockOption2016PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_StockOptionAndIncentive2019PlanMember" name="StockOptionAndIncentive2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ExercisePriceRangingTo0.09EuroPerShareMember" name="ExercisePriceRangingTo0.09EuroPerShareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ExercisePriceRangingTo2.93DollarsPerShareMember" name="ExercisePriceRangingTo2.93DollarsPerShareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_UniversityOfBaselMember" name="UniversityOfBaselMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_RelatedPartyTransactionPaymentsForRoyalties" name="RelatedPartyTransactionPaymentsForRoyalties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock" name="ScheduleOfOperatingAndFinanceLeasesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_DisclosureOfLongTermLoansPayableTextBlock" name="DisclosureOfLongTermLoansPayableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_LongTermLoansPayableGross" name="LongTermLoansPayableGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_DisclosureOfLongTermLoansPayableTableTextBlock" name="DisclosureOfLongTermLoansPayableTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NumberOfPreclinicalResearchPrograms" name="NumberOfPreclinicalResearchPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" name="StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NonExecutiveDirectorsMember" name="NonExecutiveDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" name="ConversionOfStockCommonStockIssuedForEachShareConverted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_TemporaryEquitySharesConverted" name="TemporaryEquitySharesConverted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CommonStockOtherThanClassMember" name="CommonStockOtherThanClassMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_IncomeTaxBenefitsNetOperatingLossesIncurred" name="IncomeTaxBenefitsNetOperatingLossesIncurred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" name="LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_IncreaseDecreaseInEstimatedMarketRate" name="IncreaseDecreaseInEstimatedMarketRate" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_DebtInstrumentEstimatedMarketRatePercent" name="DebtInstrumentEstimatedMarketRatePercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ReceivablesTaxResearchPremiumCurrent" name="ReceivablesTaxResearchPremiumCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_LongTermLoansEarlyRepayment" name="LongTermLoansEarlyRepayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" name="DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" name="PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_TotalMilestoneAmount" name="TotalMilestoneAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborativeArrangementRevenueFromMilestonePayments" name="CollaborativeArrangementRevenueFromMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" name="CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" name="GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" name="GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" name="ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" name="GlobalIntangibleLowTaxedIncomePercentageOfInclusion" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NumberOfResearchProgramPerformanceObligations" name="NumberOfResearchProgramPerformanceObligations" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" name="NumberOfCombinedPerformanceObligationForEachResearchProgram" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" name="CollaborationAgreementMilestonePaymentsRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_ProceedsFromMilestonePayment" name="ProceedsFromMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_SeriesaConvertiblePreferredStockMember" name="SeriesaConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ThresholdPercentageForConversion" name="ThresholdPercentageForConversion" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" name="StockIssuedDuringPeriodValueRestrictedStockAwardVested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_SharesGrantedValueShareBasedPaymentArrangementVested" name="SharesGrantedValueShareBasedPaymentArrangementVested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" name="SharesIssuedSharesShareBasedPaymentArrangementVested" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ConvertiblePreferredStocksMember" name="ConvertiblePreferredStocksMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_RedeemableConvertiblePreferredStocksMember" name="RedeemableConvertiblePreferredStocksMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_DeferredTaxAssetsFinanceLeaseLiabilities" name="DeferredTaxAssetsFinanceLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_ConvertiblePreferredStockSharesIssuableUponConversion" name="ConvertiblePreferredStockSharesIssuableUponConversion" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" name="WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" name="WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_DeferredRevenuesUpfrontAndMilestonePayments" name="DeferredRevenuesUpfrontAndMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" name="DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_RevenueRecognizedUpfrontPayment" name="RevenueRecognizedUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_PreferredStockSharesDesignated" name="PreferredStockSharesDesignated" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_ReceivableResearchIncentiveAbstract" name="ReceivableResearchIncentiveAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ReceivableResearchIncentiveTextBlock" name="ReceivableResearchIncentiveTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_GrantIncomeIncentiveProgram" name="GrantIncomeIncentiveProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" name="CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedExternalResearchAndDevelopmentExpenses" name="AccruedExternalResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedExternalGeneralAndAdministrationExpenses" name="AccruedExternalGeneralAndAdministrationExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" name="AccruedExpensesForPropertyAndEquipmentAcquisitions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element name="AccruedSubLicenseFees" id="hook_AccruedSubLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" id="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" id="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockPurchaseAgreementObligationToPurchaseCommonStockAmount" id="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredRevenuesMilestonePayments" id="hook_DeferredRevenuesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MilestonePaymentsOneMember" id="hook_MilestonePaymentsOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentsTwoMember" id="hook_MilestonePaymentsTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborativeArrangementProgramInitiationFee" id="hook_CollaborativeArrangementProgramInitiationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LeaseAssetsDerecognizedUponLeaseCancellation" id="hook_LeaseAssetsDerecognizedUponLeaseCancellation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FollowOnPublicOfferingMember" id="hook_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodGrantedToUnderwritersToPurchaseAdditionalShares" id="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="Seriesa1ConvertiblePreferredStockMember" id="hook_Seriesa1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInReceivableResearchIncentives" id="hook_IncreaseDecreaseInReceivableResearchIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LeaseModificationLoss" id="hook_LeaseModificationLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>38
<FILENAME>hook-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:19:52 AM-->
<!--Modified on: 3/24/2022 11:19:52 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosurePropertyPlantAndEquipmentNetDetails" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesLeaseCostsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesMinimumLeasePaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLoansPayableDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" />
  <calculationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637837175898366359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637837175898366359" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637837175898366359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637837175898366359" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637837175898366359" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_637837175898366359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637837175898366359" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_637837175898366359" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637837175898366359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637837175898366359" xlink:to="us-gaap_AccountsReceivableNetCurrent_637837175898366359" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637837175898366359" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets_637837175898376360" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637837175898366359" xlink:to="us-gaap_RestrictedCashCurrent_637837175898376360" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637837175898376360" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637837175898376360" xlink:to="us-gaap_RestrictedCashNoncurrent_637837175898376360" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637837175898376360" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637837175898376360" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637837175898376360" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637837175898376360" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637837175898376360" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637837175898376360" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637837175898376360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637837175898376360" xlink:to="us-gaap_OtherAssetsNoncurrent_637837175898376360" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637837175898386465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637837175898386465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637837175898386465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637837175898386465" xlink:to="us-gaap_LiabilitiesCurrent_637837175898386465" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637837175898386465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637837175898386465" xlink:to="us-gaap_AccountsPayableCurrent_637837175898386465" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637837175898386465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637837175898386465" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637837175898386465" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637837175898386465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637837175898386465" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637837175898386465" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_637837175898386465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637837175898386465" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_637837175898386465" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_637837175898386465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637837175898386465" xlink:to="us-gaap_LoansPayableCurrent_637837175898386465" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637837175898386465" xlink:to="us-gaap_LiabilitiesNoncurrent_637837175898396364" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637837175898396364" xlink:to="us-gaap_LoansPayable_637837175898396364" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637837175898396364" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175898396364" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637837175898396364" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637837175898396364" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637837175898396364" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637837175898396364" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637837175898396364" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637837175898396364" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637837175898396364" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637837175898396364" xlink:to="us-gaap_CommonStockValue_637837175898396364" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637837175898406360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637837175898396364" xlink:to="us-gaap_PreferredStockValue_637837175898406360" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637837175898406360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637837175898396364" xlink:to="us-gaap_AdditionalPaidInCapital_637837175898406360" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637837175898406360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637837175898396364" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637837175898406360" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637837175898406360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637837175898396364" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637837175898406360" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637837175898406360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637837175898406360" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637837175898406360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637837175898406360" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637837175898406360" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637837175898416361" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637837175898406360" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175898416361" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175898416361" xlink:to="us-gaap_NonoperatingIncomeExpense_637837175898416361" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GrantIncome" xlink:label="hook_GrantIncome_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637837175898416361" xlink:to="hook_GrantIncome_637837175898416361" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637837175898416361" xlink:to="us-gaap_InvestmentIncomeInterest_637837175898416361" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637837175898416361" xlink:to="us-gaap_InterestExpense_637837175898416361" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637837175898416361" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637837175898416361" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175898416361" xlink:to="us-gaap_OperatingIncomeLoss_637837175898416361" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637837175898416361" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637837175898416361" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637837175898416361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637837175898416361" xlink:to="us-gaap_CostsAndExpenses_637837175898416361" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637837175898416361" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637837175898426358" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637837175898416361" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637837175898426358" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637837175898426358" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637837175898426358" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_637837175898426358" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637837175898426358" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637837175898426358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637837175898426358" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175898426358" xlink:to="us-gaap_RepaymentsOfDebt_637837175898436357" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637837175898436357" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637837175898436357" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637837175898436357" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_ProfitLoss_637837175898436357" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_ShareBasedCompensation_637837175898436357" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_OtherNoncashIncomeExpense_637837175898436357" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637837175898436357" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637837175898436357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637837175898436357" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637837175898446360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637837175898446360" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_637837175898446360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="hook_IncreaseDecreaseInReceivableResearchIncentives_637837175898446360" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_637837175898446360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_637837175898446360" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637837175898446360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637837175898446360" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637837175898446360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637837175898446360" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637837175898446360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637837175898446360" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_637837175898446360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_637837175898446360" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637837175898456360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175898436357" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637837175898456360" order="13" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property, plant and equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637837175898496369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637837175898496369" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637837175898496369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637837175898496369" order="2" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityTotal" xlink:label="hook_LeaseLiabilityTotal" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityNoncurrent" xlink:label="hook_LeaseLiabilityNoncurrent_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseLiabilityTotal" xlink:to="hook_LeaseLiabilityNoncurrent_637837175898506366" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseLiabilityNoncurrent_637837175898506366" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637837175898506366" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseLiabilityNoncurrent_637837175898506366" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175898506366" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityCurrent" xlink:label="hook_LeaseLiabilityCurrent_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseLiabilityTotal" xlink:to="hook_LeaseLiabilityCurrent_637837175898506366" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseLiabilityCurrent_637837175898506366" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637837175898506366" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseLiabilityCurrent_637837175898506366" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637837175898506366" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseRightOfUseAsset" xlink:label="hook_LeaseRightOfUseAsset" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637837175898506366" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637837175898506366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637837175898506366" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Lease costs (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_637837175898516358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense_637837175898516358" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637837175898516358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637837175898516358" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637837175898516358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637837175898516358" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637837175898516358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome_637837175898516358" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Leases - Minimum lease payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175898516358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175898516358" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_637837175898516358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_637837175898516358" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_637837175898516358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_637837175898516358" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_637837175898526358" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175898526358" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637837175898526358" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637837175898526358" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637837175898526358" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637837175898526358" order="4" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accrued expenses and other current liabilities (Details)">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637837175898526358" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637837175898526358" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637837175898526358" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedSocialSecurityContributionsCurrent" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_637837175898536359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedSocialSecurityContributionsCurrent_637837175898536359" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedUnearnedGrantIncomeCurrent" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_637837175898536359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedUnearnedGrantIncomeCurrent_637837175898536359" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_637837175898536359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_OtherAccruedExpensesAndLiabilitiesCurrent_637837175898536359" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_637837175898536359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExternalResearchAndDevelopmentExpenses_637837175898536359" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_637837175898536359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExternalGeneralAndAdministrationExpenses_637837175898536359" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_637837175898536359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_637837175898536359" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedSubLicenseFees" xlink:label="hook_AccruedSubLicenseFees_637837175898536359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedSubLicenseFees_637837175898536359" order="9" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Loans payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_637837175898546359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_637837175898546359" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross_637837175898546359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="hook_LongTermLoansPayableGross_637837175898546359" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637837175898546359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637837175898546359" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637837175898546359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637837175898546359" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637837175898546359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637837175898546359" order="3" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income taxes - Losses before income taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637837175898546359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637837175898546359" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637837175898546359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637837175898546359" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income taxes - Effective income tax reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175898556360" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637837175898556360" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_637837175898556360" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637837175898556360" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637837175898556360" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637837175898556360" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_637837175898556360" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637837175898556360" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637837175898556360" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637837175898556360" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637837175898556360" xlink:to="us-gaap_DeferredTaxAssetsGross_637837175898566359" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637837175898566359" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637837175898566359" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637837175898566359" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637837175898566359" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637837175898566359" xlink:to="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637837175898566359" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637837175898566359" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637837175898566359" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsFinanceLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsFinanceLeaseLiabilities_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637837175898566359" xlink:to="hook_DeferredTaxAssetsFinanceLeaseLiabilities_637837175898566359" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637837175898566359" xlink:to="hook_DeferredTaxAssetsOperatingLeaseLiabilities_637837175898566359" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637837175898566359" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637837175898566359" xlink:to="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_637837175898566359" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_637837175898566359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637837175898566359" xlink:to="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_637837175898566359" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637837175898576363" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637837175898566359" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637837175898576363" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_637837175898576363" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637837175898566359" xlink:to="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_637837175898576363" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Net loss per share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" xlink:label="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_637837175898576363" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_637837175898576363" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" xlink:label="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_637837175898576363" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_637837175898576363" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" xlink:label="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_637837175898586399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_637837175898586399" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" xlink:label="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_637837175898586399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_637837175898586399" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>39
<FILENAME>hook-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:19:52 AM-->
<!--Modified on: 3/24/2022 11:19:52 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCollaborationAndLicensingAgreementsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureFairValueOfFinancialAssetsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosurePropertyPlantAndEquipmentNetDetails" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesLeaseCostsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLoansPayableDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationCommonStockAwardsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#Disclosure401KSavingsPlanDetails" roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.hookipapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="hook-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_1" xlink:title="hook_AccruedExpensesAndOtherCurrentLiabilities_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To hook_AccruedExpensesAndOtherCurrentLiabilities_1" order="6" priority="0" />
  </definitionLink>
  <link:definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis_1" xlink:title="hook_MilestoneAxis_1" />
    <link:loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain_1" xlink:title="hook_MilestoneDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="hook_MilestoneAxis_1" xlink:to="hook_MilestoneDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:hook_MilestoneAxis_1 To hook_MilestoneDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CountryRegion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LoansPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_PreferredStockSharesDesignated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RedeemableConvertiblePreferredStocksMember" xlink:label="hook_RedeemableConvertiblePreferredStocksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="hook_RedeemableConvertiblePreferredStocksMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConvertiblePreferredStocksMember" xlink:label="hook_ConvertiblePreferredStocksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="hook_ConvertiblePreferredStocksMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesDConvertiblePreferredStockMember" xlink:label="hook_SeriesDConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesDConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityEliminationAsPartofReorganization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TemporaryEquitySharesConverted" xlink:label="hook_TemporaryEquitySharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="hook_TemporaryEquitySharesConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:to="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="hook_SharesGrantedValueShareBasedPaymentArrangementVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:to="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesDConvertiblePreferredStockMember" xlink:label="hook_SeriesDConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesDConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="hook_ComputerEquipmentAndSoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of significant accounting policies - Others (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfResearchProgramPerformanceObligations" xlink:label="hook_NumberOfResearchProgramPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="hook_NumberOfResearchProgramPerformanceObligations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaboration and Licensing Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="hook_MilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="hook_MilestoneAxis" xlink:to="hook_MilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DevelopmentMilestonesMember" xlink:label="hook_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_MilestoneDomain" xlink:to="hook_DevelopmentMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestonePaymentsOneMember" xlink:label="hook_MilestonePaymentsOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_DevelopmentMilestonesMember" xlink:to="hook_MilestonePaymentsOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestonePaymentsTwoMember" xlink:label="hook_MilestonePaymentsTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="hook_DevelopmentMilestonesMember" xlink:to="hook_MilestonePaymentsTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommercialMilestonesMember" xlink:label="hook_CommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="hook_MilestoneDomain" xlink:to="hook_CommercialMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfPreclinicalResearchPrograms" xlink:label="hook_NumberOfPreclinicalResearchPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_NumberOfPreclinicalResearchPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromNonRefundableUpFrontPayment" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_ProceedsFromNonRefundableUpFrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TotalMilestoneAmount" xlink:label="hook_TotalMilestoneAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_TotalMilestoneAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementTermOfRoyaltyPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_ProceedsFromMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesUpfrontAndMilestonePayments" xlink:label="hook_DeferredRevenuesUpfrontAndMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_DeferredRevenuesUpfrontAndMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesMilestonePayments" xlink:label="hook_DeferredRevenuesMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_DeferredRevenuesMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RevenueRecognizedUpfrontPayment" xlink:label="hook_RevenueRecognizedUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_RevenueRecognizedUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementRevenueFromMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value of Financial Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property, plant and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="hook_ComputerEquipmentAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeLeaseRemainingTermOfContract" xlink:label="hook_LesseeLeaseRemainingTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="hook_LesseeLeaseRemainingTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseRightOfUseAsset" xlink:label="hook_LeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="hook_LeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityCurrent" xlink:label="hook_LeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="hook_LeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityNoncurrent" xlink:label="hook_LeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="hook_LeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityTotal" xlink:label="hook_LeaseLiabilityTotal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="hook_LeaseLiabilityTotal" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseModificationLoss" xlink:label="hook_LeaseModificationLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="hook_LeaseModificationLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Loans payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hook_LongTermLoansPayableGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LongTermLoansEarlyRepayment" xlink:label="hook_LongTermLoansEarlyRepayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hook_LongTermLoansEarlyRepayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DebtInstrumentEstimatedMarketRatePercent" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hook_DebtInstrumentEstimatedMarketRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInEstimatedMarketRate" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hook_IncreaseDecreaseInEstimatedMarketRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_PreferredStockSharesDesignated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfVotes" xlink:label="hook_NumberOfVotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_NumberOfVotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ThresholdPercentageForConversion" xlink:label="hook_ThresholdPercentageForConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_ThresholdPercentageForConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_StockOptionAndGrant2018PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOption2016PlanMember" xlink:label="hook_StockOption2016PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_StockOption2016PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="hook_NonExecutiveDirectorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ExercisePriceRangingTo0.09EuroPerShareMember" xlink:label="hook_ExercisePriceRangingTo0.09EuroPerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="hook_ExercisePriceRangingTo0.09EuroPerShareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ExercisePriceRangingTo2.93DollarsPerShareMember" xlink:label="hook_ExercisePriceRangingTo2.93DollarsPerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="hook_ExercisePriceRangingTo2.93DollarsPerShareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_StockOptionAndIncentive2019PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="hook_NonExecutiveDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Stock-based compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Stock-based compensation - Common Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" xlink:title="41107 - Disclosure - Stock-based compensation - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income taxes - Effective income tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AT" xlink:label="country_AT" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AT" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AT" xlink:label="country_AT" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AT" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" xlink:label="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xlink:type="extended" xlink:title="41401 - Disclosure - 401(k) Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Net loss per share - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Related parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_UniversityOfBaselMember" xlink:label="hook_UniversityOfBaselMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="hook_UniversityOfBaselMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RelatedPartyTransactionPaymentsForRoyalties" xlink:label="hook_RelatedPartyTransactionPaymentsForRoyalties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="hook_RelatedPartyTransactionPaymentsForRoyalties" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_FollowOnPublicOfferingMember" xlink:label="hook_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hook_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" xlink:label="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hook_ProceedsFromMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementProgramInitiationFee" xlink:label="hook_CollaborativeArrangementProgramInitiationFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hook_CollaborativeArrangementProgramInitiationFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" xlink:label="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:label="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>40
<FILENAME>hook-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:19:52 AM-->
<!--Modified on: 3/24/2022 11:19:52 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CommonStockOtherThanClassMember" xlink:to="hook_CommonStockOtherThanClassMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CommonStockOtherThanClassMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classification of common stock other than Class A common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CommonStockOtherThanClassMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Country Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ReceivablesTaxResearchPremiumCurrent" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables Tax Research Premium, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentive</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PrepaidExpensesAndOtherCurrentAssets" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for costs and other other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash balance maintained to secure a letter of credit associated with a real estate lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned income (current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenues, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned income (non-current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 13)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2021 and December 31, 2020, respectively; Series A convertible preferred stock, 2,978 shares designated, 1,697 shares and 2,978 shares outstanding at December 31, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SeriesaConvertiblePreferredStockMember" xlink:to="hook_SeriesaConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A Convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PreferredStockSharesDesignated" xlink:to="hook_PreferredStockSharesDesignated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares designated as preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares Designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares Designated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from collaboration and licensing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GrantIncome" xlink:label="hook_GrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GrantIncome" xlink:to="hook_GrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income and (expenses), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation gain (loss), net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RedeemableConvertiblePreferredStocksMember" xlink:label="hook_RedeemableConvertiblePreferredStocksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RedeemableConvertiblePreferredStocksMember" xlink:to="hook_RedeemableConvertiblePreferredStocksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RedeemableConvertiblePreferredStocksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to redeemable convertible preferred stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RedeemableConvertiblePreferredStocksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConvertiblePreferredStocksMember" xlink:label="hook_ConvertiblePreferredStocksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConvertiblePreferredStocksMember" xlink:to="hook_ConvertiblePreferredStocksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConvertiblePreferredStocksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to convertible preferred stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConvertiblePreferredStocksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesDConvertiblePreferredStockMember" xlink:label="hook_SeriesDConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SeriesDConvertiblePreferredStockMember" xlink:to="hook_SeriesDConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to convertible series D preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series D convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:to="us-gaap_TemporaryEquityEliminationAsPartofReorganization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Elimination as Part of Reorganization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TemporaryEquitySharesConverted" xlink:label="hook_TemporaryEquitySharesConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_TemporaryEquitySharesConverted" xlink:to="hook_TemporaryEquitySharesConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_TemporaryEquitySharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of securities classified as temporary equity that have been converted into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_TemporaryEquitySharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares, Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_TemporaryEquitySharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of unregistered shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into common stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued upon conversion of Preferred Stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:to="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate value of stock related to Restricted Stock Awards vested during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares related to Restricted Stock Award vested during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:to="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of vested shares granted under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Granted, Value, Share-based Payment Arrangement, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of equity grants</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:to="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares (or other type of equity) vested during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Shares, Share-based Payment Arrangement, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of equity grants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:to="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in amount of receivable research incentives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Receivable Research Incentives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentives</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expenses and Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:to="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments related to finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Financing and Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable preferred shares upon the IPO</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" xlink:label="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" xlink:to="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of property and equipment additions in accounts payable and accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment Additions in Accounts Payable and Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment additions in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseAssetsDerecognizedUponLeaseCancellation" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseAssetsDerecognizedUponLeaseCancellation" xlink:to="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of right of use assets derecognized upon lease cancellation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Assets Derecognized Upon Lease Cancellation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease assets derecognized upon lease cancellation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the business and organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the business and organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeAndLicensingArrangementAbstract" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeAndLicensingArrangementAbstract" xlink:to="hook_CollaborativeAndLicensingArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and Licensing Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and Licensing Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivableResearchIncentiveAbstract" xlink:label="hook_ReceivableResearchIncentiveAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ReceivableResearchIncentiveAbstract" xlink:to="hook_ReceivableResearchIncentiveAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ReceivableResearchIncentiveAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ReceivableResearchIncentiveAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentive</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivableResearchIncentiveTextBlock" xlink:label="hook_ReceivableResearchIncentiveTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ReceivableResearchIncentiveTextBlock" xlink:to="hook_ReceivableResearchIncentiveTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ReceivableResearchIncentiveTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for receivable research incentive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ReceivableResearchIncentiveTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable Research Incentive [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ReceivableResearchIncentiveTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentive</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseDisclosureTextBlock" xlink:label="hook_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseDisclosureTextBlock" xlink:to="hook_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_LongTermLoansPayableAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DisclosureOfLongTermLoansPayableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DisclosureOfLongTermLoansPayableTextBlock" xlink:to="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of loans payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Long Term Loans Payable [Text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Class A common stock and convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Class A common stock and convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Savings Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Savings Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GoingConcernPolicyPolicyTextBlock" xlink:label="hook_GoingConcernPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GoingConcernPolicyPolicyTextBlock" xlink:to="hook_GoingConcernPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for going concern.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going Concern, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency and currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of credit risk and of significant suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:to="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for deferred offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Software Development Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition from contracts with customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:to="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for research and manufacturing contract costs and accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Manufacturing Contract Costs and Accruals, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and manufacturing contract costs and accruals</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xlink:to="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for government grant agreements and research incentives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grant Agreements and Research Incentives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grant agreements and research incentives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_EarningsPerSharePolicyPolicyTextBlock" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_EarningsPerSharePolicyPolicyTextBlock" xlink:to="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for earnings per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful life of each asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock" xlink:label="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock" xlink:to="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of operating and finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Operating and Finance Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of operating and finance leases presentation in the consolidated balance sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the effect of lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xlink:to="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of weighted average remaining lease term and weighted average discount rate of finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Weighted Average Remaining Lease Term and Discount Rate of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average remaining lease term and weighted average discount rate of operating leases</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases" xlink:to="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of weighted average remaining lease term and weighted average discount rate of operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Weighted Average Remaining Lease Term and Discount Rate of Finance Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average remaining lease term and weighted average discount rate of finance leases</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xlink:to="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses and Other Liabilities, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DisclosureOfLongTermLoansPayableTableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DisclosureOfLongTermLoansPayableTableTextBlock" xlink:to="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of loans payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Long Term Loans Payable [Table Text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of loans payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of aggregate minimum future principal payments due in connection with the FFG Loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of summary of restricted stock unit activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of losses before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of the net deferred tax assets or liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Valuation Allowance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in the valuation allowance for deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities that were not included in the diluted per share calculations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ComputerEquipmentAndSoftwareMember" xlink:to="hook_ComputerEquipmentAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Computer Software, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment losses on long-lived assets</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xlink:to="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of preclinical research programs in collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Number of Preclinical Research Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preclinical research programs</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xlink:to="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of combined performance obligation for each research program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Combined Performance Obligation for Each Research Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of combined performance obligation for each research program</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfResearchProgramPerformanceObligations" xlink:label="hook_NumberOfResearchProgramPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfResearchProgramPerformanceObligations" xlink:to="hook_NumberOfResearchProgramPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of research program performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Program Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of research program performance obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Subsidiary or Equity Method Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation (loss)/gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MilestoneAxis" xlink:to="hook_MilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by characteristics of milestone payments recognized under the milestone method by arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MilestoneDomain" xlink:to="hook_MilestoneDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of milestones that an entity engage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DevelopmentMilestonesMember" xlink:label="hook_DevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DevelopmentMilestonesMember" xlink:to="hook_DevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to development milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestones</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestonePaymentsOneMember" xlink:label="hook_MilestonePaymentsOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MilestonePaymentsOneMember" xlink:to="hook_MilestonePaymentsOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MilestonePaymentsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to development milestones payment one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MilestonePaymentsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments One</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestonePaymentsTwoMember" xlink:label="hook_MilestonePaymentsTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MilestonePaymentsTwoMember" xlink:to="hook_MilestonePaymentsTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MilestonePaymentsTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to development milestones payment two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MilestonePaymentsTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Two</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommercialMilestonesMember" xlink:label="hook_CommercialMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CommercialMilestonesMember" xlink:to="hook_CommercialMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gilead Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and Licensing Agreements</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfPreclinicalResearchPrograms" xlink:label="hook_NumberOfPreclinicalResearchPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfPreclinicalResearchPrograms" xlink:to="hook_NumberOfPreclinicalResearchPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of preclinical research programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Preclinical Research Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preclinical research programs</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromNonRefundableUpFrontPayment" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ProceedsFromNonRefundableUpFrontPayment" xlink:to="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash inflow from non-refundable upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Non-Refundable, Up-front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TotalMilestoneAmount" xlink:label="hook_TotalMilestoneAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_TotalMilestoneAmount" xlink:to="hook_TotalMilestoneAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_TotalMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total milestone amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_TotalMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Milestone Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_TotalMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total milestone amount</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:to="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Term of Royalty Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment term (in days)</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ProceedsFromMilestonePayment" xlink:to="hook_ProceedsFromMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ProceedsFromMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount received from milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ProceedsFromMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ProceedsFromMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesUpfrontAndMilestonePayments" xlink:label="hook_DeferredRevenuesUpfrontAndMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredRevenuesUpfrontAndMilestonePayments" xlink:to="hook_DeferredRevenuesUpfrontAndMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredRevenuesUpfrontAndMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront and milestone payments included as a liability in deferred revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredRevenuesUpfrontAndMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenues, Upfront and Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredRevenuesUpfrontAndMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestone payments included in deferred revenues</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesMilestonePayments" xlink:label="hook_DeferredRevenuesMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredRevenuesMilestonePayments" xlink:to="hook_DeferredRevenuesMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredRevenuesMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payments included in deferred revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredRevenuesMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenues Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredRevenuesMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments included in deferred revenues</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" xlink:to="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cost reimbursements for research and development services included as a liability in deferred revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenues, Cost Reimbursements for Research and Development Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost reimbursements for research and development services included in deferred revenues</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RevenueRecognizedUpfrontPayment" xlink:label="hook_RevenueRecognizedUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RevenueRecognizedUpfrontPayment" xlink:to="hook_RevenueRecognizedUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RevenueRecognizedUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payment recognized as revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RevenueRecognizedUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognized, Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_RevenueRecognizedUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from upfront payment</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:to="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments revenue recognized under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Milestone Payments, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from milestone payments</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of revenue from cost reimbursements for research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Revenue from Cost Reimbursements for Research and Development Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from cost reimbursements for research and development services</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cost reimbursements for research and development services, of which initially recorded as deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Revenue From Cost Reimbursements For Research And Development Services Recorded As Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from cost reimbursements for research and development services initially recorded as deferred revenue</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:to="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of revenue from milestone payments for milestones achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Revenue from Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from milestone payments for milestones achieved</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:to="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contract assets relating to sublicense payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Contract Asset Relating to Sublicense Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract asset relating to the sublicense payment</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:to="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contract liability relating to sublicense payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Contract Liability Relating to Sublicense Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liability relating to sublicense payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from Level 1 to Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from Level 2 to Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from into Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from out of Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GrantIncomeIncentiveProgram" xlink:label="hook_GrantIncomeIncentiveProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GrantIncomeIncentiveProgram" xlink:to="hook_GrantIncomeIncentiveProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GrantIncomeIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income recognized related to the incentive program during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GrantIncomeIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income, Incentive Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GrantIncomeIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income related to the incentive program recorded as grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeLeaseRemainingTermOfContract" xlink:label="hook_LesseeLeaseRemainingTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LesseeLeaseRemainingTermOfContract" xlink:to="hook_LesseeLeaseRemainingTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LesseeLeaseRemainingTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LesseeLeaseRemainingTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Remaining Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LesseeLeaseRemainingTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and Liabilities, Lessee [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Presentation of leases in condensed consolidated balance sheets:</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseRightOfUseAsset" xlink:label="hook_LeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseRightOfUseAsset" xlink:to="hook_LeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's right to use underlying asset under operating and finance lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="hook_LeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current finance lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityCurrent" xlink:label="hook_LeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseLiabilityCurrent" xlink:to="hook_LeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="hook_LeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current finance lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityNoncurrent" xlink:label="hook_LeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseLiabilityNoncurrent" xlink:to="hook_LeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">"Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. "</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="hook_LeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityTotal" xlink:label="hook_LeaseLiabilityTotal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseLiabilityTotal" xlink:to="hook_LeaseLiabilityTotal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseLiabilityTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">"Present value of lessee's discounted obligation for lease payments from operating and finance lease. "</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseLiabilityTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="hook_LeaseLiabilityTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease amortization expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net lease expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Liabilities, Payments, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Lease Liabilities Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in next twelve months following latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating And Finance Lease Liability Payments Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in second fiscal year following latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating and Finance Lease Liability Payments Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in third fiscal year following latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating and Finance Lease Liability Payments Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in fourth fiscal year following latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating and Finance Lease Liability Payments Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating and Finance Lease Liability Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating and finance lease liabilities undiscounted excess amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Lease Liability Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: interest</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OperatingAndFinanceLeaseLiability" xlink:label="hook_OperatingAndFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_OperatingAndFinanceLeaseLiability" xlink:to="hook_OperatingAndFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_OperatingAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating and finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_OperatingAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="hook_OperatingAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, Weighted average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease, Weighted average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease, Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseModificationLoss" xlink:label="hook_LeaseModificationLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseModificationLoss" xlink:to="hook_LeaseModificationLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseModificationLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of loss from lease modification for existing operating and finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseModificationLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Modification, Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeaseModificationLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease modification loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salaries and bonuses</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedSocialSecurityContributionsCurrent" xlink:label="hook_AccruedSocialSecurityContributionsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedSocialSecurityContributionsCurrent" xlink:to="hook_AccruedSocialSecurityContributionsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Social Security Contributions, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Social security contributions</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedUnearnedGrantIncomeCurrent" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedUnearnedGrantIncomeCurrent" xlink:to="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of accrued unearned grant income (current).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Unearned Grant Income , Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned grant income (current)</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedSubLicenseFees" xlink:label="hook_AccruedSubLicenseFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedSubLicenseFees" xlink:to="hook_AccruedSubLicenseFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedSubLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued sub license fees at the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedSubLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Sub License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedSubLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublicense fees</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount as of balance sheet date of accrued external research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued External Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued external research and development expenses</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:to="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount as of balance sheet date of accrued external general and administration expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued External General and Administration Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued external general and administration expenses</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:to="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses for Property and Equipment Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued for property and equipment acquisitions</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of other accruals and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Expenses and Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accruals and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LongTermLoansPayableGross" xlink:to="hook_LongTermLoansPayableGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LongTermLoansPayableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of loans payable, gross.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LongTermLoansPayableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Loans Payable, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LongTermLoansPayableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans from FFG</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Loans payable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LongTermLoansEarlyRepayment" xlink:label="hook_LongTermLoansEarlyRepayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LongTermLoansEarlyRepayment" xlink:to="hook_LongTermLoansEarlyRepayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LongTermLoansEarlyRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow from the repayment of long-term borrowing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LongTermLoansEarlyRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Loans Early Repayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LongTermLoansEarlyRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scheduled early repayment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income reduced</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DebtInstrumentEstimatedMarketRatePercent" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DebtInstrumentEstimatedMarketRatePercent" xlink:to="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the estimated market rate under the debt instrument arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Estimated Market Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated market rate</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInEstimatedMarketRate" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInEstimatedMarketRate" xlink:to="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated market rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease in Estimated Market Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold for change in estimated market rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from public offering</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfVotes" xlink:label="hook_NumberOfVotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfVotes" xlink:to="hook_NumberOfVotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of votes for each share held .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:to="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of new common stock issued in the conversion of each stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Common Stock Issued for Each Share Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issued upon conversion of each share</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ThresholdPercentageForConversion" xlink:label="hook_ThresholdPercentageForConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ThresholdPercentageForConversion" xlink:to="hook_ThresholdPercentageForConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ThresholdPercentageForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percent of common stock that can be owned after conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ThresholdPercentageForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage For Conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares elected to convert</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon conversion of redeemable convertible preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockOptionAndGrant2018PlanMember" xlink:to="hook_StockOptionAndGrant2018PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockOptionAndGrant2018PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2018 stock option and grant plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockOptionAndGrant2018PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Stock Option and Grant Plan</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOption2016PlanMember" xlink:label="hook_StockOption2016PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockOption2016PlanMember" xlink:to="hook_StockOption2016PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockOption2016PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2016 stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockOption2016PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Stock Option Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting upon first anniversary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting in equal quarterly installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NonExecutiveDirectorsMember" xlink:to="hook_NonExecutiveDirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NonExecutiveDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to non executive directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NonExecutiveDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Executive Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ExercisePriceRangingTo0.09EuroPerShareMember" xlink:label="hook_ExercisePriceRangingTo0.09EuroPerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ExercisePriceRangingTo0.09EuroPerShareMember" xlink:to="hook_ExercisePriceRangingTo0.09EuroPerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ExercisePriceRangingTo0.09EuroPerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to exercise price ranges to 0.09 euros per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ExercisePriceRangingTo0.09EuroPerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 0.09 euros</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ExercisePriceRangingTo2.93DollarsPerShareMember" xlink:label="hook_ExercisePriceRangingTo2.93DollarsPerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ExercisePriceRangingTo2.93DollarsPerShareMember" xlink:to="hook_ExercisePriceRangingTo2.93DollarsPerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ExercisePriceRangingTo2.93DollarsPerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to exercise price ranges to 2.93 dollars per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ExercisePriceRangingTo2.93DollarsPerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price $2.93</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price for options granted as a replacement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares granted to US employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share price with fair market value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of options vesting</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of quarterly installments of vesting of share-based compensation awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Vesting, Number of Quarterly Installment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of quarterly installments for vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockOptionAndIncentive2019PlanMember" xlink:to="hook_StockOptionAndIncentive2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockOptionAndIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 stock option and incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockOptionAndIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Stock Option and Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number stock option authorized</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:to="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plan Arrangement, Cumulative Annual Increase In Issuance Of Percentage Of Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding were cumulatively increased</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:to="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock entitled for each option upon the exercise of the option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Number of Common Stock Entitled for Each Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock entitled for each option upon the exercise of the option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used in the Black-Scholes option-pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option unvested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Averaged Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option unvested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, option exercisable</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, option unvested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, option exercisable</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount by which current fair value of underlying stock exceeds exercise price of non- vested options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, option unvested</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value per common stock used for calculating the intrinsic values.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value used for Calculating Intrinsic Values</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value per common stock used for calculating intrinsic values</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value per share of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of stock options vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from option exercise under share-based payment arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal installments of award vesting under the share based compensation arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Vesting Number Of Equal Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal installments of vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of restricted stock vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based awards granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Awards</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of share-based awards granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate fair value of share-based awards granted</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average grant date fair value price of shares issued at grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to the unvested stock-based awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average periods over which expense is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xlink:to="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income tax benefits recorded for the net operating losses incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax benefits, Net Operating Losses Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefits for the net operating losses incurred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign tax rate differential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in tax rate differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not taxable government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in non-taxable research subsidies received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in non-taxable stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in change in deferred tax asset valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory corporate tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign (Austria)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company's worldwide effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AT" xlink:label="country_AT" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AT" xlink:to="country_AT_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AT_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Austria</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Reserves and Accruals Accrued Liabilities and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsFinanceLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsFinanceLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxAssetsFinanceLeaseLiabilities" xlink:to="hook_DeferredTaxAssetsFinanceLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxAssetsFinanceLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from finance lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxAssetsFinanceLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Finance Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredTaxAssetsFinanceLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:to="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from fixed assets and intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed assets and intangible assets</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Operating Lease Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right of use asset</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:to="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from finance lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Finance Lease Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right of use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" xlink:to="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold return percentage on the controlled foreign corporation ("CFC")'s "qualified business asset investment," or "QBAI" over which global intangible low-taxed income," or "GILTI" applies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Global Intangible Low-taxed Income, Return Threshold Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold return percentage of GILIT</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" xlink:to="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction percentage of inclusion for "global intangible low-taxed income," or "GILTI".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Global Intangible Low-taxed Income, Reduction Percentage of Inclusion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction percentage of inclusion for GILTI</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" xlink:label="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" xlink:to="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of inclusion for "global intangible low-taxed income," or "GILTI".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Global Intangible Low-taxed Income, Percentage of Inclusion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of inclusion for GILTI</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized income tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cancellable obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Due in Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 deliverables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Due in Second Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 deliverables</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LicensingFeesIntellectualPropertyLicenses" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LicensingFeesIntellectualPropertyLicenses" xlink:to="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of licensing fees from intellectual property licenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing fees, Intellectual Property Licenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing fees from intellectual property licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matching contribution to defined contribution savings plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer's Matching contribution to defined contribution savings plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses recognized for the 401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" xlink:label="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" xlink:to="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS), before taking into consideration Series A convertible preferred shares outstanding converted into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted, Before Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" xlink:label="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" xlink:to="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average Series A convertible Preferred Shares Outstanding, Converted into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares used to calculate net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares used to calculate net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issued upon conversion of each share of Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:label="hook_ConvertiblePreferredStockSharesIssuableUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:to="hook_ConvertiblePreferredStockSharesIssuableUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConvertiblePreferredStockSharesIssuableUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issuable upon conversion of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConvertiblePreferredStockSharesIssuableUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issuable upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ConvertiblePreferredStockSharesIssuableUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issuable upon conversion of Series A convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_UniversityOfBaselMember" xlink:label="hook_UniversityOfBaselMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_UniversityOfBaselMember" xlink:to="hook_UniversityOfBaselMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_UniversityOfBaselMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to University of Basel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_UniversityOfBaselMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">University of Basel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service fees paid</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RelatedPartyTransactionPaymentsForRoyalties" xlink:label="hook_RelatedPartyTransactionPaymentsForRoyalties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RelatedPartyTransactionPaymentsForRoyalties" xlink:to="hook_RelatedPartyTransactionPaymentsForRoyalties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RelatedPartyTransactionPaymentsForRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash paid for royalties, resulting from transactions with related parties during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RelatedPartyTransactionPaymentsForRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Payments for Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_RelatedPartyTransactionPaymentsForRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive team</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_FollowOnPublicOfferingMember" xlink:label="hook_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_FollowOnPublicOfferingMember" xlink:to="hook_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to follow on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-allotment option</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_Seriesa1ConvertiblePreferredStockMember" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A-1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" xlink:label="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" xlink:to="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual bonus paid through issuance of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Annual Bonus Paid Through Issuance Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual bonus paid through stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementProgramInitiationFee" xlink:label="hook_CollaborativeArrangementProgramInitiationFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementProgramInitiationFee" xlink:to="hook_CollaborativeArrangementProgramInitiationFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementProgramInitiationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of program initiation fee received as part of amended and restated research collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementProgramInitiationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Program Initiation Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementProgramInitiationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program initiation fee</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" xlink:label="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" xlink:to="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of common stock need to be purchased under the stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement, Obligation To Purchase Common Stock, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of common stock to be purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price per share</label>
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:label="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:to="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period granted to the underwriters to purchase additional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Granted to Underwriters to Purchase Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period granted to purchase additional shares</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>41
<FILENAME>hook-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/24/2022 11:19:52 AM-->
<!--Modified on: 3/24/2022 11:19:52 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureNatureOfBusinessAndOrganization" roleURI="http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCollaborationAndLicensingAgreements" roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureFairValueOfFinancialAssets" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosurePropertyPlantAndEquipmentNet" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureReceivableResearchIncentive" roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeases" roleURI="http://www.hookipapharma.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLoansPayable" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#Disclosure401KSavingsPlan" roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureNetLossPerShare" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureRelatedParties" roleURI="http://www.hookipapharma.com/role/DisclosureRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureFairValueOfFinancialAssetsTables" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosurePropertyPlantAndEquipmentNetTables" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesTables" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLoansPayableTables" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCollaborationAndLicensingAgreementsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureFairValueOfFinancialAssetsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosurePropertyPlantAndEquipmentNetDetails" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureReceivableResearchIncentiveDetails" roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesLeaseCostsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesMinimumLeasePaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLoansPayableDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationStockOptionValuationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationCommonStockAwardsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureStockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureCommitmentsAndContingenciesOthersDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#Disclosure401KSavingsPlanDetails" roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable_637837175899476785" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637837175899476785" xlink:to="us-gaap_StatementClassOfStockAxis_637837175899476785" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899476785" xlink:to="us-gaap_ClassOfStockDomain_637837175899476785" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899476785" xlink:to="hook_CommonStockOtherThanClassMember_637837175899476785" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899476785" xlink:to="us-gaap_CommonClassAMember_637837175899476785" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637837175899476785" xlink:to="dei_DocumentInformationLineItems_637837175899476785" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_DocumentType_637837175899476785" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_DocumentAnnualReport_637837175899476785" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637837175899476785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_DocumentPeriodEndDate_637837175899476785" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_CurrentFiscalYearEndDate_637837175899486777" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_DocumentTransitionReport_637837175899486777" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityFileNumber_637837175899486777" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityRegistrantName_637837175899486777" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityIncorporationStateCountryCode_637837175899486777" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityTaxIdentificationNumber_637837175899486777" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityAddressAddressLine1_637837175899486777" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityAddressCityOrTown_637837175899486777" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637837175899486777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityAddressStateOrProvince_637837175899486777" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityAddressPostalZipCode_637837175899496847" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_CountryRegion_637837175899496847" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_CityAreaCode_637837175899496847" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_LocalPhoneNumber_637837175899496847" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_Security12bTitle_637837175899496847" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_TradingSymbol_637837175899496847" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_SecurityExchangeName_637837175899496847" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityWellKnownSeasonedIssuer_637837175899496847" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637837175899496847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityVoluntaryFilers_637837175899496847" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityCurrentReportingStatus_637837175899506831" order="22" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityInteractiveDataCurrent_637837175899506831" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityFilerCategory_637837175899506831" order="24" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntitySmallBusiness_637837175899506831" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityEmergingGrowthCompany_637837175899506831" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityExTransitionPeriod_637837175899506831" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_IcfrAuditorAttestationFlag_637837175899506831" order="28" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637837175899506831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityShellCompany_637837175899506831" order="29" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637837175899516765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityPublicFloat_637837175899516765" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637837175899516765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityCommonStockSharesOutstanding_637837175899516765" order="31" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637837175899516765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_AuditorName_637837175899516765" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637837175899516765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_AuditorFirmId_637837175899516765" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637837175899516765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_AuditorLocation_637837175899516765" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637837175899516765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_EntityCentralIndexKey_637837175899516765" order="35" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637837175899526772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_DocumentFiscalYearFocus_637837175899526772" order="36" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637837175899526772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_DocumentFiscalPeriodFocus_637837175899526772" order="37" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637837175899526772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637837175899476785" xlink:to="dei_AmendmentFlag_637837175899526772" order="38" use="optional" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637837175899526772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637837175899526772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637837175899526772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899526772" xlink:to="us-gaap_StatementClassOfStockAxis_637837175899526772" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637837175899526772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899526772" xlink:to="us-gaap_ClassOfStockDomain_637837175899526772" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_637837175899526772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899526772" xlink:to="hook_CommonStockOtherThanClassMember_637837175899526772" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899526772" xlink:to="us-gaap_CommonClassAMember_637837175899536767" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899526772" xlink:to="us-gaap_StatementLineItems_637837175899536767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899536767" xlink:to="us-gaap_AssetsAbstract_637837175899536767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637837175899536767" xlink:to="us-gaap_AssetsCurrentAbstract_637837175899536767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637837175899536767" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637837175899536767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637837175899536767" xlink:to="us-gaap_RestrictedCashCurrent_637837175899536767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637837175899536767" xlink:to="us-gaap_AccountsReceivableNetCurrent_637837175899536767" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637837175899536767" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_637837175899536767" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637837175899536767" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets_637837175899536767" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637837175899536767" xlink:to="us-gaap_AssetsCurrent_637837175899536767" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637837175899536767" xlink:to="us-gaap_AssetsNoncurrentAbstract_637837175899536767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637837175899536767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637837175899536767" xlink:to="us-gaap_RestrictedCashNoncurrent_637837175899536767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637837175899536767" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637837175899546751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637837175899536767" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637837175899546751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637837175899536767" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637837175899546751" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637837175899536767" xlink:to="us-gaap_OtherAssetsNoncurrent_637837175899546751" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637837175899536767" xlink:to="us-gaap_AssetsNoncurrent_637837175899546751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637837175899536767" xlink:to="us-gaap_Assets_637837175899546751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899536767" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637837175899546751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" xlink:to="us-gaap_AccountsPayableCurrent_637837175899546751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637837175899556760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637837175899556760" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_637837175899556760" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" xlink:to="us-gaap_LoansPayableCurrent_637837175899556760" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637837175899546751" xlink:to="us-gaap_LiabilitiesCurrent_637837175899556760" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637837175899556760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637837175899556760" xlink:to="us-gaap_LoansPayable_637837175899556760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175899556760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637837175899556760" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175899556760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637837175899566754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637837175899556760" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637837175899566754" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637837175899566754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637837175899556760" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637837175899566754" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637837175899616761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637837175899556760" xlink:to="us-gaap_LiabilitiesNoncurrent_637837175899616761" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637837175899616761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" xlink:to="us-gaap_Liabilities_637837175899616761" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637837175899616761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" xlink:to="us-gaap_CommitmentsAndContingencies_637837175899616761" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637837175899616761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" xlink:to="us-gaap_StockholdersEquityAbstract_637837175899616761" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637837175899626763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637837175899616761" xlink:to="us-gaap_PreferredStockValue_637837175899626763" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637837175899626763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637837175899616761" xlink:to="us-gaap_CommonStockValue_637837175899626763" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637837175899626763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637837175899616761" xlink:to="us-gaap_AdditionalPaidInCapital_637837175899626763" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637837175899626763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637837175899616761" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637837175899626763" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637837175899626763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637837175899616761" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637837175899626763" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637837175899626763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637837175899616761" xlink:to="us-gaap_StockholdersEquity_637837175899626763" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637837175899546751" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637837175899636789" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637837175899636789" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899636789" xlink:to="us-gaap_StatementClassOfStockAxis_637837175899636789" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899636789" xlink:to="us-gaap_ClassOfStockDomain_637837175899636789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899636789" xlink:to="hook_SeriesaConvertiblePreferredStockMember_637837175899636789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899636789" xlink:to="hook_CommonStockOtherThanClassMember_637837175899636789" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899636789" xlink:to="us-gaap_CommonClassAMember_637837175899636789" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637837175899636789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899636789" xlink:to="us-gaap_StatementLineItems_637837175899636789" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637837175899646748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="us-gaap_PreferredStockSharesAuthorized_637837175899646748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="hook_PreferredStockSharesDesignated_637837175899646748" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="us-gaap_PreferredStockSharesOutstanding_637837175899646748" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637837175899646748" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="us-gaap_CommonStockSharesAuthorized_637837175899646748" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="us-gaap_CommonStockSharesIssued_637837175899646748" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899636789" xlink:to="us-gaap_CommonStockSharesOutstanding_637837175899646748" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637837175899646748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637837175899646748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637837175899646748" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637837175899646748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637837175899646748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637837175899646748" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637837175899646748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637837175899646748" xlink:to="us-gaap_CostsAndExpenses_637837175899656755" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637837175899656755" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637837175899656755" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GrantIncome" xlink:label="hook_GrantIncome_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637837175899656755" xlink:to="hook_GrantIncome_637837175899656755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637837175899656755" xlink:to="us-gaap_InvestmentIncomeInterest_637837175899656755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637837175899656755" xlink:to="us-gaap_InterestExpense_637837175899656755" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637837175899656755" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637837175899656755" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637837175899656755" xlink:to="us-gaap_NonoperatingIncomeExpense_637837175899656755" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175899656755" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637837175899656755" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637837175899656755" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637837175899656755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637837175899656755" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637837175899656755" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637837175899666749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637837175899666749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637837175899666749" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637837175899666749" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637837175899666749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899666749" xlink:to="us-gaap_StatementEquityComponentsAxis_637837175899666749" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RedeemableConvertiblePreferredStocksMember" xlink:label="hook_RedeemableConvertiblePreferredStocksMember_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175899666749" xlink:to="hook_RedeemableConvertiblePreferredStocksMember_637837175899666749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConvertiblePreferredStocksMember" xlink:label="hook_ConvertiblePreferredStocksMember_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175899666749" xlink:to="hook_ConvertiblePreferredStocksMember_637837175899666749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637837175899666749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175899666749" xlink:to="us-gaap_CommonStockMember_637837175899666749" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175899666749" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637837175899676751" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175899666749" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637837175899676751" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175899666749" xlink:to="us-gaap_RetainedEarningsMember_637837175899676751" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175899666749" xlink:to="us-gaap_EquityComponentDomain_637837175899676751" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899666749" xlink:to="us-gaap_StatementClassOfStockAxis_637837175899676751" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899676751" xlink:to="hook_CommonStockOtherThanClassMember_637837175899676751" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899676751" xlink:to="us-gaap_CommonClassAMember_637837175899676751" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesDConvertiblePreferredStockMember" xlink:label="hook_SeriesDConvertiblePreferredStockMember_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899676751" xlink:to="hook_SeriesDConvertiblePreferredStockMember_637837175899676751" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899676751" xlink:to="hook_SeriesaConvertiblePreferredStockMember_637837175899676751" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899676751" xlink:to="us-gaap_ClassOfStockDomain_637837175899676751" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899666749" xlink:to="us-gaap_StatementLineItems_637837175899676751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899676751" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637837175899676751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637837175899676751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637837175899686788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637837175899686788" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637837175899686788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637837175899686788" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637837175899686788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637837175899686788" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization_637837175899686788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="us-gaap_TemporaryEquityEliminationAsPartofReorganization_637837175899686788" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TemporaryEquitySharesConverted" xlink:label="hook_TemporaryEquitySharesConverted_637837175899686788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="hook_TemporaryEquitySharesConverted_637837175899686788" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637837175899686788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637837175899686788" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_6378371758996867881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637837175899676751" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_6378371758996867881" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899676751" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_StockholdersEquity_637837175899696499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_SharesOutstanding_637837175899696499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637837175899696499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637837175899696499" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637837175899696499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637837175899696499" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637837175899696499" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637837175899696499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637837175899696499" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637837175899696499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637837175899696499" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637837175899696499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_637837175899706852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_637837175899706852" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_637837175899706852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_637837175899706852" xlink:to="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_637837175899706852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637837175899706852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637837175899706852" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_637837175899706852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="hook_SharesGrantedValueShareBasedPaymentArrangementVested_637837175899706852" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_637837175899706852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_SharesGrantedValueShareBasedPaymentArrangementVested_637837175899706852" xlink:to="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_637837175899706852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637837175899706852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637837175899706852" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637837175899706852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_NetIncomeLoss_637837175899706852" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637837175899716765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_StockholdersEquity_637837175899716765" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637837175899716765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637837175899696499" xlink:to="us-gaap_SharesOutstanding_637837175899716765" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637837175899716765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637837175899716765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637837175899716765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899716765" xlink:to="us-gaap_StatementClassOfStockAxis_637837175899716765" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637837175899716765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175899716765" xlink:to="us-gaap_ClassOfStockDomain_637837175899716765" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesDConvertiblePreferredStockMember" xlink:label="hook_SeriesDConvertiblePreferredStockMember_637837175899716765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899716765" xlink:to="hook_SeriesDConvertiblePreferredStockMember_637837175899716765" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_637837175899716765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899716765" xlink:to="hook_SeriesaConvertiblePreferredStockMember_637837175899716765" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175899716765" xlink:to="hook_CommonStockOtherThanClassMember_637837175899726765" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899716765" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637837175899726765" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637837175899726765" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637837175899726765" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637837175899726765" xlink:to="us-gaap_IPOMember_637837175899726765" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175899716765" xlink:to="us-gaap_StatementLineItems_637837175899726765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899726765" xlink:to="us-gaap_SharePrice_637837175899726765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175899726765" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637837175899726765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" xlink:to="us-gaap_ProfitLoss_637837175899726765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" xlink:to="us-gaap_ShareBasedCompensation_637837175899726765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637837175899726765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637837175899726765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" xlink:to="us-gaap_OtherNoncashIncomeExpense_637837175899736767" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637837175899736767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="hook_IncreaseDecreaseInReceivableResearchIncentives_637837175899736767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_637837175899736767" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637837175899736767" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637837175899736767" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637837175899736767" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637837175899736767" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_637837175899736767" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637837175899736767" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637837175899736767" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175899736767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637837175899726765" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637837175899736767" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637837175899746765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637837175899746765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637837175899746765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637837175899746765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637837175899746765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637837175899746765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637837175899746765" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_637837175899746765" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637837175899746765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_RepaymentsOfDebt_637837175899746765" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175899756772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637837175899746765" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637837175899756772" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637837175899756772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637837175899756772" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637837175899756772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637837175899756772" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637837175899756772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637837175899756772" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378371758997567721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378371758997567721" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637837175899756772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637837175899756772" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637837175899756772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637837175899756772" xlink:to="us-gaap_InterestPaidNet_637837175899756772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_637837175899756772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637837175899756772" xlink:to="us-gaap_IncomeTaxesPaidNet_637837175899756772" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637837175899766766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637837175899766766" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_637837175899766766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637837175899766766" xlink:to="us-gaap_ConversionOfStockAmountConverted1_637837175899766766" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses" xlink:label="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses_637837175899766766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637837175899766766" xlink:to="hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses_637837175899766766" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637837175899766766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637837175899766766" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637837175899766766" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseAssetsDerecognizedUponLeaseCancellation" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_637837175899766766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637837175899766766" xlink:to="hook_LeaseAssetsDerecognizedUponLeaseCancellation_637837175899766766" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of the business and organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637837175899776938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637837175899776938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637837175899776938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637837175899776938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements" xlink:type="extended" xlink:title="10301 - Disclosure - Collaboration and Licensing Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeAndLicensingArrangementAbstract" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637837175899776938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_CollaborativeAndLicensingArrangementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637837175899776938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value of Financial Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637837175899776938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637837175899776938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet" xlink:type="extended" xlink:title="10501 - Disclosure - Property, plant and equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637837175899786777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637837175899786777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive" xlink:type="extended" xlink:title="10601 - Disclosure - Receivable research incentive" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivableResearchIncentiveAbstract" xlink:label="hook_ReceivableResearchIncentiveAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivableResearchIncentiveTextBlock" xlink:label="hook_ReceivableResearchIncentiveTextBlock_637837175899786777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ReceivableResearchIncentiveAbstract" xlink:to="hook_ReceivableResearchIncentiveTextBlock_637837175899786777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10701 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseDisclosureTextBlock" xlink:label="hook_LeaseDisclosureTextBlock_637837175899786777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="hook_LeaseDisclosureTextBlock_637837175899786777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10801 - Disclosure - Accrued expenses and other current liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637837175899796528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637837175899796528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayable" xlink:type="extended" xlink:title="10901 - Disclosure - Loans payable" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DisclosureOfLongTermLoansPayableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_637837175899796528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="hook_DisclosureOfLongTermLoansPayableTextBlock_637837175899796528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" xlink:type="extended" xlink:title="11001 - Disclosure - Common stock, Class A common stock and convertible preferred stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637837175899796528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637837175899796528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11101 - Disclosure - Stock-based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637837175899806417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637837175899806417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637837175899806417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637837175899806417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11301 - Disclosure - Commitments and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637837175899806417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637837175899806417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/Disclosure401KSavingsPlan" xlink:type="extended" xlink:title="11401 - Disclosure - 401(k) Savings Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637837175899806417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637837175899806417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11501 - Disclosure - Net loss per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637837175899816754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637837175899816754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureRelatedParties" xlink:type="extended" xlink:title="11601 - Disclosure - Related parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637837175899816754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637837175899816754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11701 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637837175899816754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637837175899816754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637837175899816754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637837175899816754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GoingConcernPolicyPolicyTextBlock" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_GoingConcernPolicyPolicyTextBlock_637837175899826423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637837175899826423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637837175899826423" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637837175899826423" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637837175899826423" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_DeferredOfferingCostsPolicyPolicyTextBlock_637837175899826423" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637837175899826423" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637837175899826423" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637837175899826423" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_637837175899826423" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_637837175899826423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_637837175899826423" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637837175899836767" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637837175899836767" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637837175899836767" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_637837175899836767" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_637837175899836767" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637837175899836767" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637837175899836767" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_EarningsPerSharePolicyPolicyTextBlock" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_EarningsPerSharePolicyPolicyTextBlock_637837175899836767" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637837175899836767" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637837175899836767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637837175899836767" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of significant accounting policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637837175899846765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637837175899846765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value of Financial Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637837175899846765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637837175899846765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property, plant and equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637837175899846765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637837175899846765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock" xlink:label="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock_637837175899856762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637837175899856762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637837175899856762" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_637837175899856762" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_637837175899856762" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases_637837175899856762" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Accrued expenses and other current liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_637837175899856762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableTables" xlink:type="extended" xlink:title="30903 - Disclosure - Loans payable (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DisclosureOfLongTermLoansPayableTableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_637837175899856762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="hook_DisclosureOfLongTermLoansPayableTableTextBlock_637837175899856762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637837175899866769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637837175899866769" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31103 - Disclosure - Stock-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637837175899866769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637837175899866769" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637837175899866769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637837175899866769" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637837175899866769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637837175899866769" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637837175899866769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637837175899866769" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637837175899866769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637837175899866769" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637837175899866769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637837175899866769" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637837175899876785" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_637837175899876785" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31503 - Disclosure - Net loss per share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637837175899876785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637837175899876785" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss_637837175899876785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637837175899876785" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899876785" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637837175899876785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899876785" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637837175899876785" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637837175899876785" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899886757" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899886757" xlink:to="us-gaap_EquipmentMember_637837175899886757" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899886757" xlink:to="us-gaap_FurnitureAndFixturesMember_637837175899886757" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899886757" xlink:to="hook_ComputerEquipmentAndSoftwareMember_637837175899886757" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899876785" xlink:to="srt_RangeAxis_637837175899886757" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637837175899886757" xlink:to="srt_RangeMember_637837175899886757" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637837175899886757" xlink:to="srt_MinimumMember_637837175899886757" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637837175899886757" xlink:to="srt_MaximumMember_637837175899886757" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899876785" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899886757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637837175899886757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899886757" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637837175899886757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of significant accounting policies - Others (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637837175899896512" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637837175899896512" xlink:to="srt_RangeAxis_637837175899896512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637837175899896512" xlink:to="srt_RangeMember_637837175899896512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637837175899896512" xlink:to="srt_MaximumMember_637837175899896512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637837175899896512" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637837175899896512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637837175899896512" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1_637837175899896512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637837175899896512" xlink:to="us-gaap_AssetImpairmentCharges_637837175899896512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637837175899896512" xlink:to="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_637837175899896512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637837175899896512" xlink:to="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_637837175899896512" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfResearchProgramPerformanceObligations" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_637837175899896512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637837175899896512" xlink:to="hook_NumberOfResearchProgramPerformanceObligations_637837175899896512" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637200539053968672" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637200539053968672" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637837175899906779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaboration and Licensing Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeAndLicensingArrangementAbstract" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_CollaborativeAndLicensingArrangementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637837175899906779" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637837175899906779" xlink:to="hook_MilestoneAxis_637837175899906779" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_MilestoneAxis_637837175899906779" xlink:to="hook_MilestoneDomain_637837175899906779" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DevelopmentMilestonesMember" xlink:label="hook_DevelopmentMilestonesMember_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_MilestoneDomain_637837175899906779" xlink:to="hook_DevelopmentMilestonesMember_637837175899906779" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestonePaymentsOneMember" xlink:label="hook_MilestonePaymentsOneMember_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_DevelopmentMilestonesMember_637837175899906779" xlink:to="hook_MilestonePaymentsOneMember_637837175899906779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_MilestonePaymentsTwoMember" xlink:label="hook_MilestonePaymentsTwoMember_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_DevelopmentMilestonesMember_637837175899906779" xlink:to="hook_MilestonePaymentsTwoMember_637837175899906779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommercialMilestonesMember" xlink:label="hook_CommercialMilestonesMember_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_MilestoneDomain_637837175899906779" xlink:to="hook_CommercialMilestonesMember_637837175899906779" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637837175899906779" xlink:to="us-gaap_TypeOfArrangementAxis_637837175899906779" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637837175899906779" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637837175899906779" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637837175899906779" xlink:to="us-gaap_CollaborativeArrangementMember_637837175899906779" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637837175899906779" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfPreclinicalResearchPrograms" xlink:label="hook_NumberOfPreclinicalResearchPrograms_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_NumberOfPreclinicalResearchPrograms_637837175899916765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromNonRefundableUpFrontPayment" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_ProceedsFromNonRefundableUpFrontPayment_637837175899916765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_TotalMilestoneAmount" xlink:label="hook_TotalMilestoneAmount_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_TotalMilestoneAmount_637837175899916765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_CollaborativeArrangementTermOfRoyaltyPayment_637837175899916765" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_ProceedsFromMilestonePayment_637837175899916765" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesUpfrontAndMilestonePayments" xlink:label="hook_DeferredRevenuesUpfrontAndMilestonePayments_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_DeferredRevenuesUpfrontAndMilestonePayments_637837175899916765" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesMilestonePayments" xlink:label="hook_DeferredRevenuesMilestonePayments_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_DeferredRevenuesMilestonePayments_637837175899916765" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices_637837175899916765" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RevenueRecognizedUpfrontPayment" xlink:label="hook_RevenueRecognizedUpfrontPayment_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_RevenueRecognizedUpfrontPayment_637837175899916765" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_637837175899916765" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_637837175899916765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_637837175899916765" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue_637837175899926774" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_CollaborativeArrangementRevenueFromMilestonePayments_637837175899926774" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_637837175899926774" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637837175899906779" xlink:to="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_637837175899926774" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value of Financial Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637837175899926774" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637837175899926774" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637837175899926774" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637837175899926774" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637837175899926774" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637837175899926774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637837175899926774" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637837175899926774" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637837175899926774" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637837175899936756" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637837175899936756" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637837175899936756" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637837175899936756" xlink:to="us-gaap_FairValueInputsLevel1Member_637837175899936756" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637837175899926774" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637837175899936756" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637837175899936756" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637837175899936756" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637837175899936756" xlink:to="us-gaap_MoneyMarketFundsMember_637837175899936756" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637837175899926774" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637837175899936756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" xlink:to="us-gaap_AssetsFairValueDisclosure_637837175899936756" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637837175899936756" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637837175899936756" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_637837175899936756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_637837175899936756" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637837175899936756" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_637837175899946433" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property, plant and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899946433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899946433" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637837175899946433" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637837175899946433" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" xlink:to="us-gaap_LandMember_637837175899946433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" xlink:to="us-gaap_LeaseholdImprovementsMember_637837175899946433" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" xlink:to="us-gaap_ConstructionInProgressMember_637837175899946433" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" xlink:to="us-gaap_EquipmentMember_637837175899946433" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" xlink:to="us-gaap_FurnitureAndFixturesMember_637837175899946433" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637837175899946433" xlink:to="hook_ComputerEquipmentAndSoftwareMember_637837175899946433" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637837175899946433" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899946433" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637837175899946433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899946433" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637837175899946433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899946433" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637837175899956765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899946433" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637837175899956765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637837175899946433" xlink:to="us-gaap_Depreciation_637837175899956765" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Receivable research incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivableResearchIncentiveAbstract" xlink:label="hook_ReceivableResearchIncentiveAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ReceivableResearchIncentiveAbstract" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_637837175899956765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GrantIncomeIncentiveProgram" xlink:label="hook_GrantIncomeIncentiveProgram_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ReceivableResearchIncentiveAbstract" xlink:to="hook_GrantIncomeIncentiveProgram_637837175899956765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637837175899956765" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637837175899956765" xlink:to="srt_RangeAxis_637837175899956765" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637837175899956765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637837175899956765" xlink:to="srt_RangeMember_637837175899956765" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637837175899956765" xlink:to="srt_MinimumMember_637837175899966775" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637837175899956765" xlink:to="srt_MaximumMember_637837175899966775" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637837175899956765" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637837175899966775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeLeaseRemainingTermOfContract" xlink:label="hook_LesseeLeaseRemainingTermOfContract_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899966775" xlink:to="hook_LesseeLeaseRemainingTermOfContract_637837175899966775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899966775" xlink:to="us-gaap_RestrictedCashNoncurrent_637837175899966775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899966775" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637837175899966775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637837175899966775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseRightOfUseAsset" xlink:label="hook_LeaseRightOfUseAsset_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="hook_LeaseRightOfUseAsset_637837175899966775" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637837175899966775" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637837175899966775" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637837175899966775" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityCurrent" xlink:label="hook_LeaseLiabilityCurrent_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="hook_LeaseLiabilityCurrent_637837175899966775" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175899966775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637837175899966775" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637837175899976768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637837175899976768" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637837175899976768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637837175899976768" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityNoncurrent" xlink:label="hook_LeaseLiabilityNoncurrent_637837175899976768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="hook_LeaseLiabilityNoncurrent_637837175899976768" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseLiabilityTotal" xlink:label="hook_LeaseLiabilityTotal_637837175899976768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637837175899966775" xlink:to="hook_LeaseLiabilityTotal_637837175899976768" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637837175899976768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637837175899976768" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637837175899976768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637837175899976768" xlink:to="us-gaap_IncomeStatementLocationAxis_637837175899976768" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637837175899976768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637837175899976768" xlink:to="us-gaap_IncomeStatementLocationDomain_637837175899976768" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175899976768" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637837175899986802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175899976768" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637837175899986802" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175899976768" xlink:to="us-gaap_InterestExpenseMember_637837175899986802" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175899976768" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_637837175899986802" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637837175899976768" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637837175899986802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899986802" xlink:to="us-gaap_OperatingLeaseCost_637837175899986802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899986802" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637837175899986802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899986802" xlink:to="us-gaap_FinanceLeaseInterestExpense_637837175899986802" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899986802" xlink:to="us-gaap_SubleaseIncome_637837175899986802" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637837175899986802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175899986802" xlink:to="us-gaap_LeaseCost_637837175899986802" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Leases - Minimum lease payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637837175899996468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637837175899996468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637837175899996468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637837175899996468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637837175899996468" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637837175899996468" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_OperatingLeaseLiability_637837175899996468" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175899996468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_637837175899996468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637837175899996468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_637837175899996468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637837175899996468" xlink:to="us-gaap_FinanceLeaseLiability_637837175899996468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637837175900006781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo_637837175900006781" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree_637837175900006781" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour_637837175900006781" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue" xlink:label="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" xlink:to="hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue_637837175900006781" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" xlink:to="hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_637837175900006781" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OperatingAndFinanceLeaseLiability" xlink:label="hook_OperatingAndFinanceLeaseLiability_637837175900006781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract_637837175900006781" xlink:to="hook_OperatingAndFinanceLeaseLiability_637837175900006781" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637837175900016758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637837175900016758" xlink:to="us-gaap_IncomeStatementLocationAxis_637837175900016758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637837175900016758" xlink:to="us-gaap_IncomeStatementLocationDomain_637837175900016758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175900016758" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637837175900016758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637837175900016758" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637837175900016758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175900016758" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637837175900016758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175900016758" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637837175900016758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175900016758" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637837175900016758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175900016758" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637837175900016758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LeaseModificationLoss" xlink:label="hook_LeaseModificationLoss_637837175900016758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637837175900016758" xlink:to="hook_LeaseModificationLoss_637837175900016758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accrued expenses and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637837175900026780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedSocialSecurityContributionsCurrent" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedSocialSecurityContributionsCurrent_637837175900026780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedUnearnedGrantIncomeCurrent" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedUnearnedGrantIncomeCurrent_637837175900026780" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedSubLicenseFees" xlink:label="hook_AccruedSubLicenseFees_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedSubLicenseFees_637837175900026780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExternalResearchAndDevelopmentExpenses_637837175900026780" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExternalGeneralAndAdministrationExpenses_637837175900026780" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_637837175900026780" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637837175900026780" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_OtherAccruedExpensesAndLiabilitiesCurrent_637837175900026780" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_637837175900026780" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Loans payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_DebtInstrumentTable_637837175900026780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637837175900026780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637837175900026780" xlink:to="srt_ProductOrServiceAxis_637837175900026780" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637837175900026780" xlink:to="srt_ProductsAndServicesDomain_637837175900036769" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637837175900036769" xlink:to="us-gaap_GrantMember_637837175900036769" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637837175900026780" xlink:to="srt_RestatementAxis_637837175900036769" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_637837175900036769" xlink:to="srt_RestatementDomain_637837175900036769" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_637837175900036769" xlink:to="srt_RestatementAdjustmentMember_637837175900036769" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637837175900026780" xlink:to="us-gaap_DebtInstrumentLineItems_637837175900036769" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="hook_LongTermLoansPayableGross_637837175900036769" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_637837175900036769" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_LongTermLoansPayable_637837175900036769" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637837175900036769" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LongTermLoansEarlyRepayment" xlink:label="hook_LongTermLoansEarlyRepayment_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="hook_LongTermLoansEarlyRepayment_637837175900036769" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_ContractWithCustomerLiability_637837175900036769" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_RepaymentsOfDebt_637837175900036769" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_637837175900036769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_637837175900036769" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_InterestExpenseDebt_637837175900046775" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637837175900046775" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DebtInstrumentEstimatedMarketRatePercent" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="hook_DebtInstrumentEstimatedMarketRatePercent_637837175900046775" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncreaseDecreaseInEstimatedMarketRate" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="hook_IncreaseDecreaseInEstimatedMarketRate_637837175900046775" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637837175900046775" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637837175900046775" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637837175900036769" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637837175900046775" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_637837175900046775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_637837175900046775" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637837175900046775" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637837175900056779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637837175900046775" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637837175900056779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637837175900046775" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637837175900056779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637837175900046775" xlink:to="us-gaap_LongTermDebt_637837175900056779" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_637837175900056779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175900056779" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637837175900056779" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637837175900056779" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637837175900056779" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637837175900056779" xlink:to="us-gaap_IPOMember_637837175900056779" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175900056779" xlink:to="us-gaap_StatementEquityComponentsAxis_637837175900056779" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637837175900056779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637837175900056779" xlink:to="us-gaap_EquityComponentDomain_637837175900056779" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637837175900066751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637837175900056779" xlink:to="us-gaap_CommonStockMember_637837175900066751" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637837175900066751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175900056779" xlink:to="us-gaap_StatementClassOfStockAxis_637837175900066751" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637837175900066751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175900066751" xlink:to="us-gaap_ClassOfStockDomain_637837175900066751" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_637837175900066751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175900066751" xlink:to="hook_CommonStockOtherThanClassMember_637837175900066751" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175900066751" xlink:to="us-gaap_CommonClassAMember_637837175900116792" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175900066751" xlink:to="hook_SeriesaConvertiblePreferredStockMember_637837175900116792" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637837175900056779" xlink:to="us-gaap_StatementLineItems_637837175900116792" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_CommonStockSharesAuthorized_637837175900116792" order="1" use="optional" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_CommonStockSharesIssued_637837175900116792" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_CommonStockSharesOutstanding_637837175900116792" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_PreferredStockSharesAuthorized_637837175900116792" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="hook_PreferredStockSharesDesignated_637837175900116792" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_PreferredStockSharesIssued_637837175900116792" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637837175900116792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_PreferredStockSharesOutstanding_637837175900116792" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637837175900127002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637837175900127002" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637837175900127002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_SharePrice_637837175900127002" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637837175900127002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637837175900127002" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637837175900127002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637837175900127002" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637837175900127002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637837175900127002" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637837175900127002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637837175900127002" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NumberOfVotes" xlink:label="hook_NumberOfVotes_637837175900127002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="hook_NumberOfVotes_637837175900127002" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_637837175900136818" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_637837175900136818" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ThresholdPercentageForConversion" xlink:label="hook_ThresholdPercentageForConversion_637837175900136818" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="hook_ThresholdPercentageForConversion_637837175900136818" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_637837175900136818" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_PreferredStockLiquidationPreference_637837175900136818" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637837175900136818" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637837175900136818" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_637837175900136818" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637837175900116792" xlink:to="us-gaap_ConversionOfStockSharesIssued1_637837175900136818" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900147014" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900147014" xlink:to="us-gaap_PlanNameAxis_637837175900147014" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637837175900147014" xlink:to="us-gaap_PlanNameDomain_637837175900147014" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637837175900147014" xlink:to="hook_StockOptionAndGrant2018PlanMember_637837175900147014" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOption2016PlanMember" xlink:label="hook_StockOption2016PlanMember_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637837175900147014" xlink:to="hook_StockOption2016PlanMember_637837175900147014" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900147014" xlink:to="us-gaap_VestingAxis_637837175900147014" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637837175900147014" xlink:to="us-gaap_VestingDomain_637837175900147014" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637837175900147014" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637837175900147014" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637837175900147014" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637837175900147014" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900147014" xlink:to="srt_TitleOfIndividualAxis_637837175900147014" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637837175900147014" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637837175900147014" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637837175900147014" xlink:to="hook_NonExecutiveDirectorsMember_637837175900147014" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637837175900147014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900147014" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637837175900147014" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637837175900147014" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637837175900156760" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ExercisePriceRangingTo0.09EuroPerShareMember" xlink:label="hook_ExercisePriceRangingTo0.09EuroPerShareMember_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637837175900156760" xlink:to="hook_ExercisePriceRangingTo0.09EuroPerShareMember_637837175900156760" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ExercisePriceRangingTo2.93DollarsPerShareMember" xlink:label="hook_ExercisePriceRangingTo2.93DollarsPerShareMember_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637837175900156760" xlink:to="hook_ExercisePriceRangingTo2.93DollarsPerShareMember_637837175900156760" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900147014" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637837175900156760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637837175900156760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637837175900156760" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637837175900156760" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637837175900156760" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_637837175900156760" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637837175900156760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900156760" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637837175900156760" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900166789" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900166789" xlink:to="us-gaap_PlanNameAxis_637837175900166789" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637837175900166789" xlink:to="us-gaap_PlanNameDomain_637837175900166789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637837175900166789" xlink:to="hook_StockOptionAndIncentive2019PlanMember_637837175900166789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900166789" xlink:to="us-gaap_VestingAxis_637837175900166789" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637837175900166789" xlink:to="us-gaap_VestingDomain_637837175900166789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637837175900166789" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637837175900166789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637837175900166789" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637837175900166789" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900166789" xlink:to="srt_TitleOfIndividualAxis_637837175900166789" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637837175900166789" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637837175900166789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637837175900166789" xlink:to="hook_NonExecutiveDirectorsMember_637837175900166789" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900166789" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637837175900176765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" xlink:to="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_637837175900176765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637837175900176765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637837175900176765" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_637837175900176765" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900166789" xlink:to="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_637837175900176765" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stock-based compensation - Stock option valuation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007036907995380" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007036907995380" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637837175900176765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637837175900176765" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637837175900176765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637837175900176765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637837175900176765" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637837175900176765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637837175900176765" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637837175900186783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Stock-based compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637837175900186783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637837175900186783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637837175900186783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637837175900186783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378371759001867831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378371759001867831" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637837175900186783" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637837175900186783" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637837175900186783" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637837175900186783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637837175900186783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637837175900186783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637837175900196792" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637837175900196792" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637837175900196792" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637837175900196792" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637837175900186783" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637837175900196792" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637837175900196792" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637837175900196792" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637837175900196792" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637837175900196792" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637837175900196792" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_637837175900196792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637837175900196792" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_637837175900196792" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637837175900206842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378371759002068421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378371759002068421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637837175900206842" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue_637837175900206842" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_637837175900206842" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637837175900206842" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637837175900206842" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637837175900206842" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637837175900206842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637837175900206842" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Stock-based compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900216851" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900216851" xlink:to="us-gaap_AwardTypeAxis_637837175900216851" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637837175900216851" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637837175900216851" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637837175900216851" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900216851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900216851" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments_637837175900216851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637837175900216851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637837175900216851" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637837175900216851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637837175900216851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637837175900216851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637837175900226755" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637837175900226755" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900216851" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637837175900226755" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637837175900226755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637837175900226755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637837175900226755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637837175900226755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378371759002267551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637837175900226755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378371759002267551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Stock-based compensation - Common Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037846361893" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037846361893" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900226755" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900226755" xlink:to="us-gaap_AwardTypeAxis_637837175900226755" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637837175900226755" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637837175900226755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637837175900226755" xlink:to="us-gaap_StockCompensationPlanMember_637837175900226755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900226755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900226755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900226755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900226755" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637837175900236749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900226755" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_637837175900236749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900226755" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_637837175900236749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" xlink:title="41107 - Disclosure - Stock-based compensation - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637502792358011410" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637502792358011410" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900236749" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900236749" xlink:to="us-gaap_IncomeStatementLocationAxis_637837175900236749" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637837175900236749" xlink:to="us-gaap_IncomeStatementLocationDomain_637837175900236749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175900236749" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637837175900236749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175900236749" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637837175900236749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637837175900236749" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900236749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900236749" xlink:to="us-gaap_ShareBasedCompensation_637837175900236749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900236749" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637837175900236749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637837175900236749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637837175900236749" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637837175900236749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_637837175900246770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637837175900246770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_637837175900246770" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637837175900246770" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637837175900246770" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175900246770" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income taxes - Losses before income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637837175900246770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637837175900246770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175900246770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637837175900246770" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637837175900256495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income taxes - Effective income tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637837175900256495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637837175900256495" xlink:to="srt_StatementGeographicalAxis_637837175900256495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637837175900256495" xlink:to="srt_SegmentGeographicalDomain_637837175900256495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AT" xlink:label="country_AT_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637837175900256495" xlink:to="country_AT_637837175900256495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637837175900256495" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175900256495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637837175900256495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_637837175900256495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637837175900256495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637837175900256495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637837175900256495" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637837175900256495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900256495" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637837175900256495" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637837175900266778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637837175900266778" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637837175900266778" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637837175900266778" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="hook_DeferredTaxAssetsOperatingLeaseLiabilities_637837175900266778" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxAssetsFinanceLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsFinanceLeaseLiabilities_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="hook_DeferredTaxAssetsFinanceLeaseLiabilities_637837175900266778" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="us-gaap_DeferredTaxAssetsGross_637837175900266778" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637837175900266778" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637837175900266778" xlink:to="us-gaap_DeferredTaxAssetsNet_637837175900266778" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_637837175900266778" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637837175900266778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637837175900266778" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637837175900266778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637837175900266778" xlink:to="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_637837175900276746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637837175900266778" xlink:to="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_637837175900276746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637837175900266778" xlink:to="hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_637837175900276746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637837175900266778" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637837175900276746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637837175900276746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637837175900276746" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637837175900276746" xlink:to="srt_StatementGeographicalAxis_637837175900276746" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637837175900276746" xlink:to="srt_SegmentGeographicalDomain_637837175900276746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AT" xlink:label="country_AT_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637837175900276746" xlink:to="country_AT_637837175900276746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637837175900276746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637837175900276746" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637837175900276746" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637837175900276746" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637837175900286771" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637837175900286771" xlink:to="us-gaap_DomesticCountryMember_637837175900286771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637837175900276746" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="us-gaap_OperatingLossCarryforwards_637837175900286771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637837175900286771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637837175900286771" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_6378371759002867711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_6378371759002867711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637837175900286771" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage_637837175900286771" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion" xlink:label="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion_637837175900286771" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion" xlink:label="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion_637837175900286771" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_637837175900286771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637837175900286771" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_637837175900286771" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Commitments and contingencies - Others (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligation_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondYear_637837175900296773" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_LicensingFeesIntellectualPropertyLicenses" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="hook_LicensingFeesIntellectualPropertyLicenses_637837175900296773" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xlink:type="extended" xlink:title="41401 - Disclosure - 401(k) Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637837175900296773" xlink:to="srt_RangeAxis_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637837175900296773" xlink:to="srt_RangeMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637837175900296773" xlink:to="srt_MaximumMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637837175900296773" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_637837175900296773" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637837175900296773" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637837175900296773" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637837175900296773" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_637837175900296773" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637837175900296773" xlink:to="us-gaap_NetIncomeLoss_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion" xlink:label="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637837175900296773" xlink:to="hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock" xlink:label="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637837175900296773" xlink:to="hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637837175900296773" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637837175900296773" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637837175900296773" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637837175900296773" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637837175900296773" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637837175900296773" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637837175900296773" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ConvertiblePreferredStockSharesIssuableUponConversion" xlink:label="hook_ConvertiblePreferredStockSharesIssuableUponConversion_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="hook_ConvertiblePreferredStockSharesIssuableUponConversion_637837175900296773" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1_637837175900296773" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Net loss per share - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637837175900296773" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637837175900296773" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637837175900296773" xlink:to="us-gaap_EmployeeStockOptionMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637837175900296773" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637837175900296773" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637837175900296773" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637837175900296773" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Related parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637837175900296773" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637837175900296773" xlink:to="us-gaap_RelatedPartyDomain_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_UniversityOfBaselMember" xlink:label="hook_UniversityOfBaselMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637837175900296773" xlink:to="hook_UniversityOfBaselMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637837175900296773" xlink:to="us-gaap_IncomeStatementLocationAxis_637837175900296773" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637837175900296773" xlink:to="us-gaap_IncomeStatementLocationDomain_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637837175900296773" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637837175900296773" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637837175900296773" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637837175900296773" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_RelatedPartyTransactionPaymentsForRoyalties" xlink:label="hook_RelatedPartyTransactionPaymentsForRoyalties_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637837175900296773" xlink:to="hook_RelatedPartyTransactionPaymentsForRoyalties_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637837175900296773" xlink:to="us-gaap_SubsequentEventTypeAxis_637837175900296773" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637837175900296773" xlink:to="us-gaap_SubsequentEventTypeDomain_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637837175900296773" xlink:to="us-gaap_SubsequentEventMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637837175900296773" xlink:to="us-gaap_GranteeStatusAxis_637837175900296773" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637837175900296773" xlink:to="us-gaap_GranteeStatusDomain_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637837175900296773" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637837175900296773" xlink:to="us-gaap_TypeOfArrangementAxis_637837175900296773" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637837175900296773" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637837175900296773" xlink:to="us-gaap_CollaborativeArrangementMember_637837175900296773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637837175900296773" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637837175900296773" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637837175900296773" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_FollowOnPublicOfferingMember" xlink:label="hook_FollowOnPublicOfferingMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637837175900296773" xlink:to="hook_FollowOnPublicOfferingMember_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637837175900296773" xlink:to="us-gaap_OverAllotmentOptionMember_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637837175900296773" xlink:to="us-gaap_StatementClassOfStockAxis_637837175900296773" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637837175900296773" xlink:to="us-gaap_ClassOfStockDomain_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175900296773" xlink:to="hook_CommonStockOtherThanClassMember_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637837175900296773" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_637837175900296773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637837175900296773" xlink:to="us-gaap_SubsequentEventLineItems_637837175900296773" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions" xlink:label="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions_637837175900296773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions_637837175900296773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637837175900354579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_SharePrice_637837175900354579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637837175900355247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637837175900355247" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637837175900356369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637837175900356369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="hook_ProceedsFromMilestonePayment_637837175900356369" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_CollaborativeArrangementProgramInitiationFee" xlink:label="hook_CollaborativeArrangementProgramInitiationFee_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="hook_CollaborativeArrangementProgramInitiationFee_637837175900356369" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount" xlink:label="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount_637837175900356369" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637837175900356369" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637837175900356369" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637837175900356369" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="us-gaap_SharesIssuedPricePerShare_637837175900356369" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20211231.xsd#hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:label="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares_637837175900356369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637837175900296773" xlink:to="hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares_637837175900356369" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981088212984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HOOKIPA PHARMA&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5395687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 Fifth Avenue, 72nd Floor, Suite&#160;7240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">+43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">890 63 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HOOK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PwC Wirtschaftspr&#252;fung GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Vienna, Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001760542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,868,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094678616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,921<span></span>
</td>
<td class="nump">$ 142,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">5,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ReceivablesTaxResearchPremiumCurrent', window );">Receivable research incentives</a></td>
<td class="nump">14,271<span></span>
</td>
<td class="nump">15,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_PrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,482<span></span>
</td>
<td class="nump">8,104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">102,135<span></span>
</td>
<td class="nump">171,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">16,352<span></span>
</td>
<td class="nump">6,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">6,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">1,910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">23,910<span></span>
</td>
<td class="nump">16,313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">126,045<span></span>
</td>
<td class="nump">187,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,762<span></span>
</td>
<td class="nump">8,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,880<span></span>
</td>
<td class="nump">7,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, current</a></td>
<td class="nump">2,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,654<span></span>
</td>
<td class="nump">21,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable, non-current</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">4,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">3,911<span></span>
</td>
<td class="nump">3,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">8,799<span></span>
</td>
<td class="nump">10,551<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,453<span></span>
</td>
<td class="nump">31,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2021 and December 31, 2020, respectively; Series A convertible preferred stock, 2,978 shares designated, 1,697 shares and 2,978 shares outstanding at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">317,135<span></span>
</td>
<td class="nump">309,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,780)<span></span>
</td>
<td class="num">(6,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(222,766)<span></span>
</td>
<td class="num">(147,101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">89,592<span></span>
</td>
<td class="nump">156,123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">126,045<span></span>
</td>
<td class="nump">187,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs and other other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivablesTaxResearchPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivablesTaxResearchPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094633560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares Designated</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">25,948,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">25,948,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,819,732<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,819,732<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares designated as preferred shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087465192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration and licensing</a></td>
<td class="nump">$ 18,448<span></span>
</td>
<td class="nump">$ 19,584<span></span>
</td>
<td class="nump">$ 11,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(82,853)<span></span>
</td>
<td class="num">(54,787)<span></span>
</td>
<td class="num">(46,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(17,269)<span></span>
</td>
<td class="num">(18,082)<span></span>
</td>
<td class="num">(16,715)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="num">(100,122)<span></span>
</td>
<td class="num">(72,869)<span></span>
</td>
<td class="num">(63,027)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(81,674)<span></span>
</td>
<td class="num">(53,285)<span></span>
</td>
<td class="num">(51,085)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_GrantIncome', window );">Grant income</a></td>
<td class="nump">9,724<span></span>
</td>
<td class="nump">6,517<span></span>
</td>
<td class="nump">6,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(898)<span></span>
</td>
<td class="num">(786)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income and (expenses), net</a></td>
<td class="num">(2,843)<span></span>
</td>
<td class="nump">3,072<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">6,010<span></span>
</td>
<td class="nump">9,203<span></span>
</td>
<td class="nump">8,048<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax</a></td>
<td class="num">(75,664)<span></span>
</td>
<td class="num">(44,082)<span></span>
</td>
<td class="num">(43,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,665)<span></span>
</td>
<td class="num">(44,082)<span></span>
</td>
<td class="num">(43,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain (loss), net of tax</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
<td class="num">(933)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (74,378)<span></span>
</td>
<td class="num">$ (45,496)<span></span>
</td>
<td class="num">$ (43,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082915256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Redeemable Convertible Preferred Stock </div>
<div>Series D convertible preferred stock</div>
</th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Common stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class A common stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the beginning of the period at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock, net of issuance costs</a></td>
<td class="nump">$ 37,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock, net of issuance costs (in shares)</a></td>
<td class="nump">257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityEliminationAsPartofReorganization', window );">Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (142,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_TemporaryEquitySharesConverted', window );">Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,580,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="num">$ (3,720)<span></span>
</td>
<td class="num">$ (59,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,582,161<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,568<span></span>
</td>
<td class="num">(4,653)<span></span>
</td>
<td class="num">(103,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,899<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,746,392<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,426<span></span>
</td>
<td class="nump">42,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,426<span></span>
</td>
<td class="nump">42,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_SharesGrantedValueShareBasedPaymentArrangementVested', window );">Vesting of equity grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_SharesIssuedSharesShareBasedPaymentArrangementVested', window );">Vesting of equity grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,082)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,288<span></span>
</td>
<td class="num">(6,067)<span></span>
</td>
<td class="num">(147,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,123<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">25,948,712<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
<td class="nump">1,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,665)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317,135<span></span>
</td>
<td class="num">$ (4,780)<span></span>
</td>
<td class="num">$ (222,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,592<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_SharesGrantedValueShareBasedPaymentArrangementVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of vested shares granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_SharesGrantedValueShareBasedPaymentArrangementVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_SharesIssuedSharesShareBasedPaymentArrangementVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) vested during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_SharesIssuedSharesShareBasedPaymentArrangementVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award vested during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards vested during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_TemporaryEquitySharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_TemporaryEquitySharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityEliminationAsPartofReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption of temporary equity as the result of a triggering event associated with the temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityEliminationAsPartofReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087592216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesDConvertiblePreferredStockMember', window );">Series D convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 9,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082800312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (75,665)<span></span>
</td>
<td class="num">$ (44,082)<span></span>
</td>
<td class="num">$ (43,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,644<span></span>
</td>
<td class="nump">8,657<span></span>
</td>
<td class="nump">5,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,943)<span></span>
</td>
<td class="num">(3,576)<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_IncreaseDecreaseInReceivableResearchIncentives', window );">Receivable research incentives</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(5,825)<span></span>
</td>
<td class="num">(5,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(7,091)<span></span>
</td>
<td class="num">(2,286)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">416<span></span>
</td>
<td class="num">(1,080)<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="nump">4,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="num">(4,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,588)<span></span>
</td>
<td class="num">(1,833)<span></span>
</td>
<td class="num">(2,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">4,776<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="nump">5,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(1,130)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(66,016)<span></span>
</td>
<td class="num">(39,339)<span></span>
</td>
<td class="num">(41,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(12,581)<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
<td class="num">(1,999)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(12,581)<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
<td class="num">(1,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments related to finance leases</a></td>
<td class="num">(438)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(1,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">42,637<span></span>
</td>
<td class="nump">74,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments for deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,311)<span></span>
</td>
<td class="num">(842)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(235)<span></span>
</td>
<td class="nump">73,420<span></span>
</td>
<td class="nump">109,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(78,832)<span></span>
</td>
<td class="nump">31,710<span></span>
</td>
<td class="nump">66,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">143,177<span></span>
</td>
<td class="nump">113,575<span></span>
</td>
<td class="nump">48,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,567<span></span>
</td>
<td class="num">(2,108)<span></span>
</td>
<td class="num">(1,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">66,912<span></span>
</td>
<td class="nump">143,177<span></span>
</td>
<td class="nump">113,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable preferred shares upon the IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses', window );">Property and equipment additions in accounts payable and accrued expenses</a></td>
<td class="num">(742)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">2,727<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LeaseAssetsDerecognizedUponLeaseCancellation', window );">Lease assets derecognized upon lease cancellation</a></td>
<td class="nump">$ 1,061<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInReceivableResearchIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount of receivable research incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInReceivableResearchIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseAssetsDerecognizedUponLeaseCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of right of use assets derecognized upon lease cancellation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseAssetsDerecognizedUponLeaseCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of property and equipment additions in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095998440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the business and organization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the business and organization</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;Nature of the business and organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HOOKIPA Pharma&#160;Inc. (&#8220;HOOKIPA&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body&#8217;s immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the name of Hookipa Biotech,&#160;Inc. under the laws of the State of Delaware in February&#160;2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, the Company changed its name from Hookipa Biotech,&#160;Inc. to HOOKIPA Pharma&#160;Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April&#160;2019, the Company closed its initial public offering (&#8220;IPO&#8221;) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol &#8220;HOOK&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company&#8217;s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981186299864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company&#8217;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2021, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $75.7&#160;million, $44.1&#160;million and $43.0&#160;million for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. As of December&#160;31,&#160;2021, the Company had an accumulated deficit of $222.8&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;24,&#160;2022, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents, together with the net proceeds from the offering in March&#160;2022, and the funds received under the Restated Collaboration Agreement with Gilead, both described below, would be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will seek additional funding in order to reach its development and commercialization objectives. The Company will seek funds through further equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;11,&#160;2020, the World Health Organization designated COVID-19 as a global pandemic. The Company believes the extent of the COVID-19 pandemic&#8217;s impact on the Company&#8217;s business, results of operations and financial condition has been and will continue to be driven by many factors, most of which are beyond the Company&#8217;s control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent the pandemic will impact its operations. The Company&#8217;s accounting estimates and assumptions may change over time in response to COVID-19 and the change could be material in future periods. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Redeemable Convertible Preferred Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 the net proceeds from the Company&#8217;s offerings have been deposited in interest-bearing bank accounts with investment grade U.S. financial institutions and have been partially invested in a money market fund. The money market fund, held in U.S. dollars, is primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the Company&#8217;s cash and cash equivalents included smaller amounts of cash balances held in accounts with European banks at the Company&#8217;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively, Gilead accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019 Gilead accounted for the majority of the Company&#8217;s revenues. No other customers accounted for more than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020 cash equivalents consisted of money market funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 4 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the new leasing standards as of January&#160;1,&#160;2019. For leases with an initial term of 12&#160;months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#8220;ROU&#8221;) assets and lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#8217;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#8220;ASC&#8221;)&#160;360.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capitalized Software Development Cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of less than $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2021. No amortization expense associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2020 (see Note&#160;5). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31,&#160;2021, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a collaboration and license agreement (the &#8220;Gilead Agreement&#8221;) with Gilead whereby the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#8220;HBV&#8221;) and the human immunodeficiency virus (&#8220;HIV&#8221;). The Company&#8217;s performance obligations under the terms of this agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The licenses do not represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under this agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, the Company applies significant judgement to evaluate whether the obligations under the collaboration and licensing arrangement, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of when milestone payments are probable of being received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Upfront payment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company under the Gilead Agreement is recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reimbursement for services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Agreement, the Company incurs employee expenses as well as external costs for research and manufacturing activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangement, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues in the period in which the goods or services are received and external costs are recognized. Unpaid reimbursement amounts are presented as Accounts receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development milestones</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Gilead Agreement includes contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">uncertainties and the required commitment from Gilead. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales-based milestones and royalty payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Agreement also includes certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost to fulfill contracts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are classified as research and development expenses and expensed as incurred due to the uncertainty about the recovery of the expenditure. Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government grant agreements and research incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes funding from grants and research incentives received from Austrian government agencies as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss and foreign currency translation adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments. For the years ended December&#160;31,&#160;2020 and 2019, comprehensive loss included $1.4&#160;million and $0.9&#160;million of foreign currency translation loss adjustments, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2021, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2021, the FASB issued ASU&#160;2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain disclosures when they have received government assistance and when they use a grant or contribution accounting model by analogy to other accounting guidance (e.g., a grant model under IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or ASC 958-605, Not-For-Profit Entities &#8212; Revenue Recognition). Topic 832 requires the annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy of information about the nature of the transactions and the related accounting policy used to account for the transactions, the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, significant terms and conditions of the transactions, including commitments and contingencies. The guidance in ASU 2021-10 is effective for all entities for fiscal years beginning after December&#160;15,&#160;2021. Entities may apply the ASU&#8217;s provisions either prospectively to all transactions within the scope of ASC 832 that are reflected in the financial statements as of the adoption date and all new transactions entered into after the date of adoption or retrospectively. Early adoption is permitted. The Company analyzed ASU 2021-10 and does not believe the guidance will have a material impact on its consolidated financial statements since the Company has already provided disclosures regarding Government Assistance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096010824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeAndLicensingArrangementAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and Licensing Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Collaboration and Licensing Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gilead Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2018, the Company entered into the Gilead Agreement whereby the Company and Gilead agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of HBV and HIV. In February&#160;2022, the Company signed an Amended and Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic (see Note&#160;17).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Agreement, the Company granted Gilead an exclusive, royalty-bearing license to the Company&#8217;s technology platforms. Upon entering into the agreement, the Company received a non-refundable $10.0&#160;million upfront payment from Gilead. Gilead is also obligated to make additional payments to the Company upon the achievement of pre-clinical, development and commercial milestones. The development milestones amount to over $300&#160;million. The commercial milestones amount to a total of $115&#160;million. Additionally, Gilead is obligated to pay royalties on net sales for each program. Payments from Gilead generally have a 60&#160;days payment term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $10.0&#160;million upfront payment and $8.0&#160;million in milestone payments were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2021, $4.3&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current. As of December&#160;31,&#160;2020, $2.5&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current and non-current.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, $1.2&#160;million of cost reimbursements for research and development services were included as a liability in deferred revenues. As of December&#160;31,&#160;2020, $2.0&#160;million of cost reimbursements for research and development services were included as a liability in deferred revenues. Reimbursements for external costs are recognized as revenues in the period in which the services are provided and external costs are recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the year ended December&#160;31,&#160;2021, the Company recognized $0.6&#160;million of the upfront payment received in 2018 and $1.5&#160;million of a $4.0&#160;million milestone payment received in 2020. Furthermore, the Company recognized $16.3&#160;million revenue from cost reimbursements for research and development services, of which $2.2&#160;million were initially recorded as deferred revenue in the consolidated balance sheet. No revenue has yet been recognized for another $4.0&#160;million milestone payment that was recorded as deferred revenue in December 2021. For the year ended December&#160;31,&#160;2020, revenue from reimbursement of research and development expenses was $13.0&#160;million, of which $1.1&#160;million were initially recorded as deferred revenue in the consolidated balance sheet. Furthermore, the Company recognized $2.0&#160;million of the upfront payment of $10.0&#160;million received in 2018 and $2.4&#160;million of the $4.0&#160;million milestone payment received in 2020 as revenue. In addition, the Company fully recognized revenue for $2.2&#160;million milestone payments for milestones achieved in the year ended December&#160;31, 2020. For the year ended December&#160;31,&#160;2019, revenue from reimbursement of research and development expenses was $4.3&#160;million, and revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">from partial recognition of the upfront payment of $10.0&#160;million received in 2018 was $4.4&#160;million. Additionally, the Company recognized $3.2&#160;million in milestone payments for milestones achieved in the year ended December&#160;31,&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the contract asset and the liability relating to the sublicense payment was $0.3&#160;<span style="-sec-ix-hidden:Hidden_l0XBTDSRf02Br1mMnKhitQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span> and $0.1&#160;<span style="-sec-ix-hidden:Hidden_0ppv5nVtqUW_59qTfEqsxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeAndLicensingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeAndLicensingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096089416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Fair Value of Financial Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2021 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2020 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the </span><span style="-sec-ix-hidden:Hidden_Ig22UHVZRkKGX2x0KG_1_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">year</span></span><span style="font-weight:normal;"> ended </span><span style="-sec-ix-hidden:Hidden_ilfqJ_zyb0aZGfg-9XrTsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2021</span></span><span style="font-weight:normal;">, there were </span><span style="font-weight:normal;">no</span><span style="font-weight:normal;"> transfers between Level&#160;1, Level&#160;2 and Level&#160;</span><span style="-sec-ix-hidden:Hidden_yp-p9Vk_-kOWrEU_xREtbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span><span style="font-weight:normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096133960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Property, plant and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,322</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,982</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,554</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,316</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,097)</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,219</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depreciation expense for the years ended December&#160;31,&#160;2021, 2020 and 2019 was $2.1&#160;million, $1.7&#160;million and $1.1&#160;million, respectively. Construction-in-progress as of December&#160;31,&#160;2021 related to investments in connection with the Company&#8217;s GMP manufacturing facility project. Construction-in-progress as of December&#160;31,&#160;2020 related to implementation costs for a cloud computing arrangement which is a service contract.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096027448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Receivable research incentive<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ReceivableResearchIncentiveAbstract', window );"><strong>Receivable research incentive</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ReceivableResearchIncentiveTextBlock', window );">Receivable research incentive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6.&#160;Receivable research incentive<span style="font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company participates in a research incentive program provided by the Austrian government under which it is entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority. Reimbursements received in excess of the recognized receivable research incentive for a certain period are recorded within other long term liabilities for potential repayment until such time that an audit has taken place, upon expiration of the potential reclaim period, or when it is no longer probable that a reclaim will happen. The years 2018 to present remain open to examination by the authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, the Company recognized receivables of $14.3&#160;million from the research incentive program, which are reported in research incentive receivables in the Company&#8217;s consolidated balance sheet. As of December&#160;31,&#160;2020, the receivables from the research incentive program were $15.1&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded $8.9&#160;million, $5.8&#160;million and $5.9&#160;million, respectively, of income related to the incentive program within the Company&#8217;s consolidated statements of operations as part of the grant income.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivableResearchIncentiveAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivableResearchIncentiveAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivableResearchIncentiveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for receivable research incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivableResearchIncentiveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095981528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LeaseDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases real estate, including office and laboratory space and has entered into various other agreements with respect to assets used in conducting its business. The Company&#8217;s leases have remaining lease terms ranging from less than 1&#160;year to 4&#160;years. Some of the lease agreements contain rent holidays and rent escalation clauses that were included in the calculation of the right of use assets and lease liabilities. The Company is required to maintain a cash balance of $0.4&#160;million to secure letters of credit associated with real estate leases. This amount was classified as non-current restricted cash in the consolidated balance sheet as of December&#160;31,&#160;<span style="white-space:pre-wrap;">2021.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain of the Company&#8217;s leases qualify as operating leases, and certain of its leases qualify as finance leases. The following table summarizes the presentation in the consolidated balance sheets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;sheet&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,452</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,750</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,998</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current finance lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_oRmXSROYc0OcSjQ6MQGWpg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,153</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,819</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current finance lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qGfyuLYvk0GVroGAArA9Ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other non-current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 258</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total non-current lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,077</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,230</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the years ended December&#160;31,&#160;2021 and 2020 the Company terminated leases of parking spaces and derecognized the relating right of use asset and the lease liability which were insignificant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income&#160;statement&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,654</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 376</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 395</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (155)</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,299</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,606</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,547</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,340</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,242</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,735</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,614</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of finance leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December&#160;2021 the Company extended the lease term of existing operating leases for the office and laboratory space in Vienna, Austria. The respective lease liabilities were remeasured and the amounts resulting from the remeasurement of the lease liability were recognized as an adjustment to the corresponding right of use asset. Also in December&#160;2021, the Company reduced the lease term for existing operating and finance leases related to an agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with a contract manufacturing organization for the production of clinical trial material and accounted for the proportionate decrease in the lease liability and the right of use asset with the difference recognized as a loss of $1.0&#160;million on lease modification in operating research and development expenses on the income statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until March&#160;2021, the Company subleased certain of its leased real estate that it did not utilize to a third party. The sublease was qualified as an operating lease. The Company recognized sublease income in its consolidated statements of operations and comprehensive loss. The sublease had no influence on the Company&#8217;s accounting for the head lease.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096099112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;Accrued expenses and other current liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Salaries and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,381</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Social security contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned grant income (current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 878</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublicense fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 895</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external general and administration expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 634</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued for property and equipment acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,386</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096072856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayableAbstract', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DisclosureOfLongTermLoansPayableTextBlock', window );">Loans payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Loans payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, loans payable consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loans from FFG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,564</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unamortized debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,063)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,027)</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,537</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the funding agreements with the Austrian Research Promotion Agency, (<i style="font-style:italic;">&#214;sterreichische Forschungsf&#246;rderungsgesellschaft, </i>or &#8220;FFG&#8221;), the Company has received various loans (&#8220;FFG Loans&#8221;). The FFG Loans were made on a project-by-project basis. Amounts due under the FFG Loans bear interest at a rate of 0.75%&#160;per annum and mature at various dates between June&#160;2022 and March&#160;2024. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FFG Loans bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between an estimated market rate of interest and the rate of interest charged by FFG as grant income from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company recognized grant income of $0.8&#160;million, $0.7&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, related to the recognition of the unearned income recorded for the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">imputed benefit of FFG Loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG Loans at below-market interest rates was $0.7&#160;million and $0.9&#160;million as of December&#160;31,&#160;2021 and 2020, respectively, and unearned income (non-current) presented under loans payable non-current related to such benefit was $0.4&#160;million and $1.1&#160;million as of December&#160;31,&#160;2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has recorded a discount to the carrying value of each FFG Loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of December&#160;31,&#160;2021 and 2020, the unamortized debt discount related to FFG Loans was $1.1&#160;million and $2.0&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized interest expense of $0.9&#160;million, $0.8&#160;million and $0.9&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, related to the FFG Loans, which included interest expense related to the amortization of debt discount of $0.8&#160;million, $0.7&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. No principal payment and a principal payment of $1.3&#160;million was made in the years ended December&#160;31,&#160;2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses an estimated market rate of 20%, which was determined based on an average of the available interest rates on unsecured loans to comparable companies. A 10% increase or decrease in the estimated market rate of interest would have no material impact on grant income or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of the Company's assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2019, the Company agreed to an earlier repayment schedule for $3.3&#160;million of the outstanding loans with FFG. As a result of the change, the Company reduced the deferred income attributable to the imputed benefit from below market interest by $0.3&#160;million and increased the carrying value of the loans by the same amount. The change had no effect on the income of the year ended December&#160;31,&#160;2019 and the effect on the aggregate future cash flows under the loans is immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31,&#160;2021, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Calendar&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2022</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,054</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2023</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,821</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2024</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,199</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2026</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,074</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DisclosureOfLongTermLoansPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DisclosureOfLongTermLoansPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094273832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, Class A common stock and convertible preferred stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common stock, Class A common stock and convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common stock, Class A common stock and convertible preferred stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Common stock, Class A common stock and convertible preferred stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s capital structure consists of common stock, Class A common stock and preferred stock. As of December&#160;31,&#160;2021, the Company was authorized to issue 100,000,000 shares of common stock, 3,900,000&#160;shares of Class&#160;A common stock and 10,000,000 shares of preferred stock. The Company has designated 2,978 of the 10,000,000 authorized shares of preferred stock as non-voting Series A convertible preferred stock. As of December&#160;31,&#160;2021, the Company had 27,383,483&#160;shares of <span style="-sec-ix-hidden:Hidden_0vCtFWOMdU6TUe8bLbDs8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common stock</span></span>, 3,819,732&#160;shares of <span style="-sec-ix-hidden:Hidden_lsKpVaKZlU2VrubLnN7E_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class&#160;A common stock</span></span> and 1,697&#160;shares of preferred stock outstanding and <span style="-sec-ix-hidden:Hidden_qvPF7Qsm3kquM23a168syQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On April 23, 2019, the Company closed its IPO of 6,000,000 shares of common stock, at an offering price to the public of $14.00 per share. The Company received net proceeds of $74.6 million, after deducting $9.4 million in underwriting discounts and commissions and offering expenses. Upon the closing of the Company&#8217;s IPO all then outstanding shares of Preferred Stock converted into 14,582,161 shares of common stock and 3,819,732 shares of Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December&#160;11,&#160;2020, the Company closed a public offering of 3,910,000 shares of its common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares and of 2,978&#160;shares of Series&#160;A convertible preferred stock at a public offering price of $11.75 and $11,750.00 per share, respectively, for net proceeds of $75.0&#160;million after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of Class A common stock and Series&#160;A convertible preferred stock are not entitled to vote, except as required by law. The holders of common stock and Class A common stock do not have any cumulative voting rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each holder of Class A common stock has the right to convert each share of Class A common stock into one share of common stock at such holder's election. Each holder of Series&#160;A convertible preferred stock has the right to convert each share of Series&#160;A convertible preferred stock into 1,000&#160;shares of common stock at any time at the holder&#8217;s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series&#160;A preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock and Class&#160;A common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Holders of Series&#160;A preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of our common stock. Holders of common stock and Class&#160;A common stock have no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the event of a liquidation, dissolution, or winding up of the Company, holders of our Series&#160;A preferred stock will receive a payment equal to $0.001 per share of Series A preferred stock before any proceeds are distributed to the holders of common stock. Then, holders of common stock and Class A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were 1,697 and 2,978 shares of Series&#160;A convertible preferred stock outstanding as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. In October&#160;2021 and December&#160;2021 certain of the Company&#8217;s stockholders elected to convert an aggregate of 1,281 shares (55 and 1,226 shares, respectively) of Series A convertible preferred stock owned by such holders into an aggregate of 1,281,000 shares of the Company&#8217;s common stock. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096078824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2018 Stock Option and Grant Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with a transaction between entities under common control by which the Company became the reporting entity in June&#160;2018, the Board of Directors approved the 2018 Stock Option and Grant Plan, by which options granted by the previous reporting entity under the 2016 Stock Option Plan and outstanding at the time of the effectiveness of the transaction were replaced at similar commercial terms. In the accompanying consolidated financial statements and notes, options issued under previous stock option plans and respective compensation expenses are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">retrospectively presented as if such options had been issued and outstanding under the 2018 Stock Option and Grant Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The exercise price for options granted as a replacement of the 2016 Stock Option Plan is the U.S. dollar equivalent of &#8364;0.09, except for 23,286 options granted to an US employee, for which the exercise price is $2.93 following a repricing of these options in December&#160;2018. For any new options, the exercise price shall not be less than 100% of the fair market value of the common stock on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Options granted under the 2018 Stock Option and Grant Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. As of December&#160;31,&#160;2021, 968,504&#160;options granted under the 2018 Stock Option and Grant Plan remained outstanding. Any authorization to issue new options under the 2018 Stock Option and Grant Plan was cancelled upon the effectiveness of the 2019 Stock Option and Incentive Plan and no further awards will be granted under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2019 Stock Option and Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;1,&#160;2019, the Company&#8217;s stockholders approved the 2019 Stock Option and Incentive Plan, which became effective as of the effective date of the registration statement in connection with the Company&#8217;s IPO. The plan provides for the grant of shares of restricted stock, long term incentive awards, stock options or other equity-based awards. The maximum number of shares of the Company&#8217;s common stock that may be issued under the Company&#8217;s 2019 Stock Option and Incentive Plan is 3,630,686&#160;shares which shall be cumulatively increased each year by up to 4.0% of the then outstanding number of shares. Options granted under the 2019 Stock Option and Incentive Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. Initial options granted to non-executive directors upon their election generally vest over a three-year term with 33% of the options vesting upon the first anniversary of the grant date and the remaining 67% of the options vesting in eight equal quarterly installments following the first anniversary of the grant date. Option re-grants to non-executive directors generally vest on the first anniversary of the grant date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. For each option the beneficiary is entitled to receive one share of common stock upon the exercise of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock option valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the option&#8217;s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, volatility, the risk-free interest rate, the dividend and employee exercise behavior. Forfeitures are accounted for when they occur. Expected volatilities utilized in the Black-Scholes model are based on historical volatilities of a group of comparable companies. The group of representative companies have characteristics similar to the Company, including the stage of product development and focus on the life science industry. Management believes that this represents the most accurate basis for estimating expected future volatilities under the current conditions. The risk-free interest rate is derived from the yields for U.S.&#160;Treasuries with a remaining term approximating the expected life of the options. The expected term represents the period of time that the options granted are expected to be outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options granted during:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the 2019, 2020 and 2021 grants, the Company used the simplified method in developing an estimate of the expected term due to a lack of historical exercise data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock option activity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity since January&#160;1,&#160;2021 (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,555,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,839</p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 990,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (125,020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (190,295)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,640</p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,224,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,624</p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options unvested as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,006,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The fair value per common stock used for calculating the intrinsic values as of December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019, was $2.33, $11.09 and $12.23, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December&#160;31,&#160;2021, 2020 and 2019 was $1.0&#160;million, $2.9&#160;million and $1.4&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31,&#160;2021, 2020 and 2019 was $11.46, $8.95 and $7.92, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total fair value of stock options vested during the years ended December&#160;31,&#160;2021 and 2020 was $6.0&#160;million and $5.6&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash received from stock option exercise under share-based payment arrangements for the years ended December&#160;31,&#160;2021, 2020 and 2019 was $203&#160;thousand, $63&#160;thousand and $16&#160;thousand, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2020, the Company granted restricted stock units with time-based vesting conditions to officers, employees and a consultant to compensate them for a temporary salary or fee reduction in response to the coronavirus pandemic. The restricted stock units are subject to time-based vesting conditions and generally vested in four equal installments between March 2021 and November 2021. The Company measures the fair value of restricted stock units on the date of grant using the grant date market price of the underlying shares. Expenses are recorded using the graded-vesting method. The table below summarizes the Company&#8217;s restricted stock unit activity since December&#160;31,&#160;2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.87</p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,700)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.87</p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The total fair value of restricted stock vested during the year ended December&#160;31,&#160;2021 was $0.5&#160;million. The total fair value of restricted stock vested during the year ended December&#160;31,&#160;2020 was insignificant. The Company had no restricted stock outstanding in the year ended 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2020, the Company issued 36,249&#160;unrestricted shares of common stock to the non-executive members of its Board of Directors. The Company&#8217;s directors received equity instead of cash as their 2020 board remuneration as part of the Company&#8217;s response to the coronavirus pandemic. The total fair value of common stock awards issued during the year ended December&#160;31,&#160;2020 was $0.3&#160;million. The grant date fair value per share of common stock was $9.56 and was measured at the closing price of the common stock on the date of grant. Expenses were recorded immediately and are included in stock based compensation in the year ended December&#160;31,&#160;2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the years ended 2021 and 2019, the Company has not issued common stock awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock-based compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,981</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,584</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,565</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2021 total unrecognized compensation cost related to the unvested stock-based awards was $5.7&#160;million, which is expected to be recognized over a weighted average period of 1.6&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096063064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items. The Company's losses before income taxes were generated in the United States and Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2021, 2020 and 2019 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,603)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,886)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign (Austria)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,151)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,037)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company's worldwide effective tax rate for the years ended December&#160;31,&#160;2021, 2020 and 2019 was 0.0%, 0.0% and 0.0%, respectively. The tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, which is expected to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. The following items had the most significant impact on the difference between the statutory U.S. federal income tax rate of 21%<span style="white-space:pre-wrap;"> for the years ended December&#160;31,&#160;2021, 2020 and 2019 and the effective tax rate:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign tax rate differential<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Not taxable government grants<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in deferred tax asset valuation allowance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The 4% increase for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 25%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, 3.8%, 4.7% and 5.4% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, 1.5%, 1.0% and 0.3% increase, respectively, resulted from non-taxable Stock-based compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, 30.2% reduction, 30.2% reduction and 31.0% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets have been fully impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2021 and 2020 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 55,752</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 43,563</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 64</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 357</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (36)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,209</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 2,725</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,378</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,513</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Finance lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 103</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 58,765</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 47,932</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (53,728)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (46,064)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 5,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,868</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (3,604)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Fixed assets and intangible assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (11)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,400)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,614)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Finance lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (22)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (254)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (5,037)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,868)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, 2020 and 2019, the Company had Austrian net operating loss carryforwards of $219.7&#160;million, $163.2&#160;million and $112.3&#160;million, respectively, and US Federal net operating loss carryforwards of $17.9&#160;million, $8.3&#160;million and $4.9&#160;million, respectively, all of them with no expiry date. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company's history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&#160;31,&#160;2021, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of losses is no longer present and additional weight may be given to subjective evidence. The tax years in which the tax carryforwards were generated may still be adjusted upon examination by the tax authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,583)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,156)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Increases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,481)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,427)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (53,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,583)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;22,&#160;2017, the United States enacted the Tax Cuts and Jobs Act (&#8220;Tax Reform Legislation&#8221; or &#8220;TCJA&#8221;). The Tax Reform Legislation introduced section 951A, a new tax on so-called &#8220;global intangible low-taxed income,&#8221; or &#8220;GILTI&#8221;. GILTI applies to income of a controlled foreign corporation (&#8220;CFC&#8221;) that is not otherwise subpart F income, and consists of the excess "tested income" over a 10% return on the CFC's &#8220;qualified business asset investment,&#8221; or &#8220;QBAI&#8221;. QBAI is the total tax basis of the CFC's depreciable, tangible property used in the production of tested income. The full amount of GILTI is included in taxable income. The GILTI inclusion is then reduced by 50% (reduced to 37.5% after 2025). However, that reduction in GILTI may be limited based on the level of U.S. taxable income. A limited allowance for foreign tax credits is allowed that would reduce the U.S. tax cost. GILTI foreign tax credits can only reduce U.S. taxes owed on GILTI and are not eligible for carryforward. The Company's Austrian subsidiary falls under the category of a CFC and due to the nature of its business model as a technology company, there may not be a material amount of tangible assets if this subsidiary starts to generate profits. GILTI taxation therefore may be applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in New York. The tax years from 2018 to present remain open to examination by the jurisdictions in which the Company is subject to tax. <span style="background:#ffffff;">There are currently no pending income tax examinations in the U.S. </span>Furthermore, the Company files income tax returns in Austria. The tax years 2018 to present remain open to examination by the jurisdiction. There are currently no pending income tax examinations in Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31,&#160;2021 and 2020, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981091561624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Commitments and contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contract manufacturing arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into arrangements with contract manufacturing organizations (&#8220;CMOs&#8221;) for manufacturing of materials for research and development purposes, including manufacturing of clinical trial materials. These contracts generally provide for non-cancellable obligations or cancellation penalties depending on the time of cancellation. As of December&#160;31,&#160;2021, the Company&#8217;s total non-cancellable obligations under contracts with CMOs, excluding embedded lease liabilities, were $10.5&#160;million, of which $10.4&#160;million relate to 2022 deliverables and $0.1&#160;million relate to 2023 deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the Company entered into an agreement with a contract manufacturing organization for the production of clinical trial material, including seed lots, drug substance for toxicology studies, stability studies and clinical studies as well as related technology transfer, quality control and process optimization activities which commenced in February 2019. Under the financial terms of the agreement the Company is obliged to pay non-cancellable minimum service fees totaling $13.9 million through January&#160;<span style="white-space:pre-wrap;">2022. The Company has determined that the agreement includes embedded leases which resulted in recognition of operating and finance lease assets and corresponding liabilities on the Consolidated Balance Sheet. The agreement was not extended beyond the initial term and its wind-down during the first quarter of 2022 has been agreed.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intellectual property licenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into certain license agreements under which it is obligated to make milestone payments upon the achievement of certain development and regulatory milestones, to pay royalties on net sales of licensed products, and to pay a percentage of the sublicense fees which the Company receives from its sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded $1.3&#160;million, $1.2&#160;million and $1.9&#160;million, respectively, in licensing fees related to intellectual property licenses as research and development expenses. These amounts mainly related to the upfront payment and milestone payments received by the Company under the Gilead Agreement. The amounts recognized as expenses have been agreed to by the licensors but calculation of sublicensing fees on future payments may be subject to interpretation and may change until agreed to by the receiving party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Indemnification agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31,&#160;2021 or December&#160;31,&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Legal proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently a party to a patent proceeding opposing European Patent No.&#160;3218504, which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to the Company. While it is not feasible to predict the outcome of these matters with certainty, and some lawsuits, claims or proceedings may be disposed or decided unfavorably, the Company does not expect that the pending patent opposition, and any asserted or un-asserted legal claims or proceedings, individually or in the aggregate, will have a material adverse effect on the Company. However, if, as a result of the current patent proceeding, the Company would lose all, or at least part, of the protection under the opposed patent, such loss could erode the Company&#8217;s competitive position and harm its business and ability to achieve profitability. The Company expenses the costs related to the pending and other such legal proceedings as incurred.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096140904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. 401(k) Savings Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to 100% of the first 4% of each employee&#8217;s contribution. During the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 expenses recognized for the 401(k) Plan were $0.4&#160;million and $0.2&#160;million, respectively. During the year ended December&#160;31,&#160;2019 expenses recognized for the 401(k) Plan were insignificant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096103032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75,665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,037)</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,945,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,876,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,859,935</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 162,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total number of shares used to calculate net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,833,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,039,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,859,935</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_xm72ylqy7EWXDfD5Rmo5kg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ix31qi0nv0-3tRNXPNStAg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.69)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_6TH1JwQjZkq-oybyyIOUrA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.41)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Series&#160;A convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#8217;s common stock. Series&#160;A convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Series A convertible preferred stock is convertible into 1,000 shares of common stock. 1,697,000 shares of the Company&#8217;s common stock are issuable upon conversion of Series A convertible preferred stock (see Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares (Common Stock and Class A Common Stock) outstanding would have been anti-dilutive. Potentially dilutive securities (upon exercise) that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,555,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,999,284</p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,599,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,999,284</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096152936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related parties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Related parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following the expiry of the consultancy agreement between the Company and its Chief Scientific Officer, Daniel Pinschewer, on March 19, 2020 the Company entered into a new consultancy agreement with Daniel Pinschewer on March&#160;20, 2020, pursuant to which he serves as Scientific Advisor to the Chief Executive Officer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is party to research and service arrangements with the University of Basel. Daniel Pinschewer, formerly Chief Scientific Officer, and his spouse are employees of the University of Basel and both involved in providing the services under these arrangements. Payments to the University of Basel during Daniel Pinschewer&#8217;s term as Chief Scientific Officer were reported as related party transactions but payments following the expiry of that role in March 2020 were no longer considered related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2021, the Company did not record any related party transactions. In the years ended December&#160;31,&#160;2020 and 2019, the Company recorded $0.3&#160;million and $0.3&#160;million, respectively, in research and development expenses for service fees paid to the University of Basel, which represented related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The University of Basel is also entitled to receive de minimis royalties on the net sales of any product that is based on a patent created by the Company&#8217;s Scientific Advisor to the Chief Executive Officer in the course of his consulting services to the Company. In the years ended December&#160;31,&#160;2021, 2020 and 2019, no royalties were paid pursuant to the terms of this arrangement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096139464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent events.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Subsequent events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock option and equity grant to senior management</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February&#160;1,&#160;2022, members of the Company&#8217;s executive team received 50% of their 2021 annual bonus in the form of a grant of fully vested stock options, determined based on a value of $3.00 per share and resulting in the issuance of a total number of 145,071 options. The granted options have an exercise price of $1.50 per share, the closing price of the Company&#8217;s common stock on January 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At the same time, the members of the Company&#8217;s executive team agreed to convert a portion of their base salaries, for the six months ending June&#160;30,&#160;2022 for shares of the Company&#8217;s fully vested common stock having a value equal to their foregone salary, determined based on a value of $3.00 per share, resulting in the issuance of an aggregate of 112,551&#160;shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Amended and restated research collaboration and license agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In February&#160;2022, the Company and Gilead entered into an amended and restated research collaboration and license agreement. For the future performance of development activities under the amended agreement, the Company received a $4&#160;million milestone payment and a $15.0&#160;million program initiation fee, which have been initially recorded as deferred revenue in the consolidated balance sheet and will be recognized as revenue when revenue recognition criteria are met. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the Restated Collaboration Agreement, the Company entered into a stock purchase agreement with Gilead. Pursuant to, and subject to the terms and conditions of, the stock purchase agreement, Gilead will be required, at the Company&#8217;s option, to purchase up to $35,000,000 of the Company&#8217;s common stock, par value $0.0001 per share. In February&#160;2022 Gilead purchased an initial amount of 1,666,666 unregistered shares of the Company&#8217;s common stock for $5.0&#160;million, corresponding to a purchase price per share of $3.00.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Follow-on public offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In March 2022, the Company issued and sold 21,700,000&#160;shares of its common stock, and 15,800&#160;shares of its Series&#160;A-1 convertible preferred stock in a follow-on public offering at a public offering price of $2.0&#160;per share of common stock and $2,000&#160;per share of Series&#160;A-1 convertible preferred stock, resulting in net proceeds of $70.5&#160;million after underwriting discounts and commission but before other offering expenses. The Company granted the underwriters an option for a period of 30 days to purchase up to 5,625,000&#160;additional shares of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">War between Russia and Ukraine</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February&#160;24,&#160;2022, Russian forces began an invasion of the Ukraine. While we have no operations in the Ukraine or Russia and do not perform research, conduct clinical trials, or otherwise do business in these two countries, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the geopolitical effects of the war and its potential further escalation, including the effects of other nations&#8217; responses and economic sanctions, are currently unpredictable and may adversely affect our business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981091417272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_GoingConcernPolicyPolicyTextBlock', window );">Going concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company&#8217;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2021, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $75.7&#160;million, $44.1&#160;million and $43.0&#160;million for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. As of December&#160;31,&#160;2021, the Company had an accumulated deficit of $222.8&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;24,&#160;2022, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents, together with the net proceeds from the offering in March&#160;2022, and the funds received under the Restated Collaboration Agreement with Gilead, both described below, would be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will seek additional funding in order to reach its development and commercialization objectives. The Company will seek funds through further equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;11,&#160;2020, the World Health Organization designated COVID-19 as a global pandemic. The Company believes the extent of the COVID-19 pandemic&#8217;s impact on the Company&#8217;s business, results of operations and financial condition has been and will continue to be driven by many factors, most of which are beyond the Company&#8217;s control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent the pandemic will impact its operations. The Company&#8217;s accounting estimates and assumptions may change over time in response to COVID-19 and the change could be material in future periods. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency and currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Redeemable Convertible Preferred Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk and of significant suppliers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 the net proceeds from the Company&#8217;s offerings have been deposited in interest-bearing bank accounts with investment grade U.S. financial institutions and have been partially invested in a money market fund. The money market fund, held in U.S. dollars, is primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the Company&#8217;s cash and cash equivalents included smaller amounts of cash balances held in accounts with European banks at the Company&#8217;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively, Gilead accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019 Gilead accounted for the majority of the Company&#8217;s revenues. No other customers accounted for more than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020 cash equivalents consisted of money market funds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredOfferingCostsPolicyPolicyTextBlock', window );">Deferred offering costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;4).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 4 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the new leasing standards as of January&#160;1,&#160;2019. For leases with an initial term of 12&#160;months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#8220;ROU&#8221;) assets and lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#8217;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#8220;ASC&#8221;)&#160;360.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Capitalized Software Development Cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capitalized Software Development Cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of less than $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2021. No amortization expense associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2020 (see Note&#160;5). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31,&#160;2021, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition from contracts with customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a collaboration and license agreement (the &#8220;Gilead Agreement&#8221;) with Gilead whereby the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#8220;HBV&#8221;) and the human immunodeficiency virus (&#8220;HIV&#8221;). The Company&#8217;s performance obligations under the terms of this agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The licenses do not represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under this agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, the Company applies significant judgement to evaluate whether the obligations under the collaboration and licensing arrangement, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of when milestone payments are probable of being received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Upfront payment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company under the Gilead Agreement is recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reimbursement for services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Agreement, the Company incurs employee expenses as well as external costs for research and manufacturing activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangement, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues in the period in which the goods or services are received and external costs are recognized. Unpaid reimbursement amounts are presented as Accounts receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development milestones</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Gilead Agreement includes contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">uncertainties and the required commitment from Gilead. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales-based milestones and royalty payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Agreement also includes certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost to fulfill contracts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are classified as research and development expenses and expensed as incurred due to the uncertainty about the recovery of the expenditure. Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock', window );">Research and manufacturing contract costs and accruals</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock', window );">Government grant agreements and research incentives</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government grant agreements and research incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes funding from grants and research incentives received from Austrian government agencies as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss and foreign currency translation adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments. For the years ended December&#160;31,&#160;2020 and 2019, comprehensive loss included $1.4&#160;million and $0.9&#160;million of foreign currency translation loss adjustments, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_EarningsPerSharePolicyPolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2021, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2021, the FASB issued ASU&#160;2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain disclosures when they have received government assistance and when they use a grant or contribution accounting model by analogy to other accounting guidance (e.g., a grant model under IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or ASC 958-605, Not-For-Profit Entities &#8212; Revenue Recognition). Topic 832 requires the annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy of information about the nature of the transactions and the related accounting policy used to account for the transactions, the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, significant terms and conditions of the transactions, including commitments and contingencies. The guidance in ASU 2021-10 is effective for all entities for fiscal years beginning after December&#160;15,&#160;2021. Entities may apply the ASU&#8217;s provisions either prospectively to all transactions within the scope of ASC 832 that are reflected in the financial statements as of the adoption date and all new transactions entered into after the date of adoption or retrospectively. Early adoption is permitted. The Company analyzed ASU 2021-10 and does not believe the guidance will have a material impact on its consolidated financial statements since the Company has already provided disclosures regarding Government Assistance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredOfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredOfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_EarningsPerSharePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_EarningsPerSharePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government grant agreements and research incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and manufacturing contract costs and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096102472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of estimated useful life of each asset</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 4 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096066472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial assets measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2021 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,403</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2020 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,397</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095980056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,322</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,982</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,554</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,316</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,097)</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,219</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094809976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock', window );">Schedule of operating and finance leases presentation in the consolidated balance sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain of the Company&#8217;s leases qualify as operating leases, and certain of its leases qualify as finance leases. The following table summarizes the presentation in the consolidated balance sheets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;sheet&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,452</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,750</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,998</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current finance lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_oRmXSROYc0OcSjQ6MQGWpg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,153</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,819</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current finance lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qGfyuLYvk0GVroGAArA9Ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other non-current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 258</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total non-current lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,077</p></td></tr><tr><td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,230</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of the effect of lease costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income&#160;statement&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,654</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 376</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 395</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (155)</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,299</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of operating lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,606</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,547</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,340</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,242</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,735</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,614</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of finance lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance&#160;lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,606</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,547</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,340</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,242</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,735</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,614</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases', window );">Schedule of weighted average remaining lease term and weighted average discount rate of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases', window );">Schedule of weighted average remaining lease term and weighted average discount rate of finance leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of finance leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted average remaining lease term and weighted average discount rate of operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted average remaining lease term and weighted average discount rate of finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981096066472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Salaries and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,381</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Social security contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned grant income (current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 878</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublicense fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 895</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external general and administration expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 634</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued for property and equipment acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,386</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095924296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayableAbstract', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DisclosureOfLongTermLoansPayableTableTextBlock', window );">Schedule of loans payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, loans payable consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loans from FFG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,564</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unamortized debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,063)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,027)</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,537</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of aggregate minimum future principal payments due in connection with the FFG Loans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31,&#160;2021, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Calendar&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2022</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,054</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2023</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,821</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2024</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,199</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2026</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,074</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DisclosureOfLongTermLoansPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DisclosureOfLongTermLoansPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981091747800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity since January&#160;1,&#160;2021 (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,555,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,839</p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 990,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (125,020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (190,295)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,640</p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,224,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,624</p></td></tr><tr><td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options unvested as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,006,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of summary of restricted stock unit activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.87</p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,700)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.87</p></td></tr><tr><td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,981</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,584</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,565</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981090467816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of losses before income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2021, 2020 and 2019 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,603)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,886)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign (Austria)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,151)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,037)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign tax rate differential<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Not taxable government grants<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in deferred tax asset valuation allowance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The 4% increase for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 25%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, 3.8%, 4.7% and 5.4% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, 1.5%, 1.0% and 0.3% increase, respectively, resulted from non-taxable Stock-based compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4) </sup>For the years ended December&#160;31,&#160;2021, 2020 and 2019, 30.2% reduction, 30.2% reduction and 31.0% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets have been fully impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the net deferred tax assets or liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2021 and 2020 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 55,752</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 43,563</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 64</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 357</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (36)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,209</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 2,725</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,378</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,513</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Finance lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 103</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 58,765</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 47,932</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (53,728)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (46,064)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 5,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,868</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (3,604)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Fixed assets and intangible assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (11)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,400)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,614)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Finance lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (22)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (254)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (5,037)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,868)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Changes in the valuation allowance for deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,583)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,156)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Increases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,481)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,427)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (53,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,583)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981090470776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75,665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,037)</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,945,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,876,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,859,935</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 162,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total number of shares used to calculate net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,833,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,039,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,859,935</p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_xm72ylqy7EWXDfD5Rmo5kg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ix31qi0nv0-3tRNXPNStAg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.69)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_6TH1JwQjZkq-oybyyIOUrA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.41)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Series&#160;A convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#8217;s common stock. Series&#160;A convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Series A convertible preferred stock is convertible into 1,000 shares of common stock. 1,697,000 shares of the Company&#8217;s common stock are issuable upon conversion of Series A convertible preferred stock (see Note&#160;10).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,555,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,999,284</p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,599,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,999,284</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981090504168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Going concern (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="nump">$ 75,665<span></span>
</td>
<td class="nump">$ 44,082<span></span>
</td>
<td class="nump">$ 43,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 222,766<span></span>
</td>
<td class="nump">$ 147,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094732488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Property and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087437592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Others (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>Program</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms', window );">Number of preclinical research programs | Program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_NumberOfCombinedPerformanceObligationForEachResearchProgram', window );">Number of combined performance obligation for each research program | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_NumberOfResearchProgramPerformanceObligations', window );">Number of research program performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of preclinical research programs in collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfCombinedPerformanceObligationForEachResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of combined performance obligation for each research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfCombinedPerformanceObligationForEachResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfResearchProgramPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfResearchProgramPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094106200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Comprehensive loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation (loss)/gain</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="num">$ (0.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087187496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements (Details) - Gilead Collaboration and License Agreement<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_NumberOfPreclinicalResearchPrograms', window );">Number of preclinical research programs | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ProceedsFromNonRefundableUpFrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementTermOfRoyaltyPayment', window );">Payment term (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ProceedsFromMilestonePayment', window );">Milestone payment received</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredRevenuesUpfrontAndMilestonePayments', window );">Upfront and milestone payments included in deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredRevenuesMilestonePayments', window );">Milestone payments included in deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices', window );">Cost reimbursements for research and development services included in deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_RevenueRecognizedUpfrontPayment', window );">Revenue recognized from upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborationAgreementMilestonePaymentsRevenueRecognized', window );">Revenue recognized from milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices', window );">Revenue recognized from cost reimbursements for research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue', window );">Revenue recognized from cost reimbursements for research and development services initially recorded as deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementRevenueFromMilestonePayments', window );">Revenue recognized from milestone payments for milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment', window );">Contract asset relating to the sublicense payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment', window );">Contract liability relating to sublicense payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_MilestoneAxis=hook_DevelopmentMilestonesMember', window );">Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_TotalMilestoneAmount', window );">Total milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_MilestoneAxis=hook_MilestonePaymentsOneMember', window );">Milestone Payments One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborationAgreementMilestonePaymentsRevenueRecognized', window );">Revenue recognized from milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_MilestoneAxis=hook_MilestonePaymentsTwoMember', window );">Milestone Payments Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborationAgreementMilestonePaymentsRevenueRecognized', window );">Revenue recognized from milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_MilestoneAxis=hook_CommercialMilestonesMember', window );">Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_TotalMilestoneAmount', window );">Total milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborationAgreementMilestonePaymentsRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments revenue recognized under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborationAgreementMilestonePaymentsRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contract assets relating to sublicense payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contract liability relating to sublicense payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from cost reimbursements for research and development services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost reimbursements for research and development services, of which initially recorded as deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementRevenueFromMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from milestone payments for milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementRevenueFromMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementTermOfRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementTermOfRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost reimbursements for research and development services included as a liability in deferred revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredRevenuesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments included in deferred revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredRevenuesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredRevenuesUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront and milestone payments included as a liability in deferred revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredRevenuesUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfPreclinicalResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of preclinical research programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfPreclinicalResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ProceedsFromMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received from milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ProceedsFromMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ProceedsFromNonRefundableUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ProceedsFromNonRefundableUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_RevenueRecognizedUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_RevenueRecognizedUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_TotalMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total milestone amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_TotalMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_MilestoneAxis=hook_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_MilestoneAxis=hook_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_MilestoneAxis=hook_MilestonePaymentsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_MilestoneAxis=hook_MilestonePaymentsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_MilestoneAxis=hook_MilestonePaymentsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_MilestoneAxis=hook_MilestonePaymentsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_MilestoneAxis=hook_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_MilestoneAxis=hook_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981091454824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfers from Level 1 to Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfers from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers from into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers from out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">35,403<span></span>
</td>
<td class="nump">$ 35,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">35,403<span></span>
</td>
<td class="nump">35,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">35,403<span></span>
</td>
<td class="nump">35,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 35,403<span></span>
</td>
<td class="nump">$ 35,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981088442952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 22,718<span></span>
</td>
<td class="nump">$ 11,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(6,366)<span></span>
</td>
<td class="num">(5,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">16,352<span></span>
</td>
<td class="nump">6,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">3,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,746<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,025<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,876<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095022872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Receivable research incentive (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ReceivableResearchIncentiveAbstract', window );"><strong>Receivable research incentive</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ReceivablesTaxResearchPremiumCurrent', window );">Receivable research incentive</a></td>
<td class="nump">$ 14,271<span></span>
</td>
<td class="nump">$ 15,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_GrantIncomeIncentiveProgram', window );">Income related to the incentive program recorded as grant income</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GrantIncomeIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant income recognized related to the incentive program during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GrantIncomeIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivableResearchIncentiveAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivableResearchIncentiveAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivablesTaxResearchPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivablesTaxResearchPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087108056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Cash balance maintained to secure a letter of credit associated with a real estate lease</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Presentation of leases in condensed consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">6,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">5,763<span></span>
</td>
<td class="nump">7,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liability</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities.<span></span>
</td>
<td class="text">Accrued Expenses and Other Current Liabilities.<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LeaseLiabilityCurrent', window );">Total current lease liabilities</a></td>
<td class="nump">$ 1,703<span></span>
</td>
<td class="nump">$ 2,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">$ 3,911<span></span>
</td>
<td class="nump">3,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">$ 3,911<span></span>
</td>
<td class="nump">$ 4,077<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LeaseLiabilityTotal', window );">Total lease liabilities</a></td>
<td class="nump">$ 5,614<span></span>
</td>
<td class="nump">$ 6,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LesseeLeaseRemainingTermOfContract', window );">Remaining lease term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LesseeLeaseRemainingTermOfContract', window );">Remaining lease term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>"Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. "</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseLiabilityTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>"Present value of lessee's discounted obligation for lease payments from operating and finance lease. "</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseLiabilityTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating and finance lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LesseeLeaseRemainingTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LesseeLeaseRemainingTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087154584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease expenses</a></td>
<td class="nump">$ 2,510<span></span>
</td>
<td class="nump">$ 2,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">1,910<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease amortization expenses</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease amortization expenses</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (155)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094741848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum lease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">5,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_OperatingAndFinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in next twelve months following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating and finance lease liabilities undiscounted excess amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087505768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Weighted average remaining lease term and weighted average discount rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, Weighted average remaining lease term (in years)</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, Weighted average discount rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease, Weighted average remaining lease term (in years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, Weighted average discount rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LeaseModificationLoss', window );">Lease modification loss</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseModificationLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from lease modification for existing operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseModificationLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087138712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Salaries and bonuses</a></td>
<td class="nump">$ 4,754<span></span>
</td>
<td class="nump">$ 4,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedSocialSecurityContributionsCurrent', window );">Social security contributions</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedUnearnedGrantIncomeCurrent', window );">Unearned grant income (current)</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedSubLicenseFees', window );">Sublicense fees</a></td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">2,165<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExternalGeneralAndAdministrationExpenses', window );">Accrued external general and administration expenses</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExpensesForPropertyAndEquipmentAcquisitions', window );">Accrued for property and equipment acquisitions</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accruals and liabilities</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 8,880<span></span>
</td>
<td class="nump">$ 7,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesForPropertyAndEquipmentAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesForPropertyAndEquipmentAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExternalGeneralAndAdministrationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of balance sheet date of accrued external general and administration expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExternalGeneralAndAdministrationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of balance sheet date of accrued external research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedSocialSecurityContributionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedSocialSecurityContributionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedSubLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued sub license fees at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedSubLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedUnearnedGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of accrued unearned grant income (current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedUnearnedGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of other accruals and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981086979256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LongTermLoansPayableGross', window );">Loans from FFG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,074<span></span>
</td>
<td class="nump">$ 6,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,063)<span></span>
</td>
<td class="num">(2,027)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Total Loans payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,011<span></span>
</td>
<td class="nump">4,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LongTermLoansEarlyRepayment', window );">Scheduled early repayment</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DebtInstrumentEstimatedMarketRatePercent', window );">Estimated market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_IncreaseDecreaseInEstimatedMarketRate', window );">Threshold for change in estimated market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,448<span></span>
</td>
<td class="nump">19,584<span></span>
</td>
<td class="nump">11,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Unearned income (current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Unearned income (non-current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred income reduced</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Unearned income (current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Unearned income (non-current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DebtInstrumentEstimatedMarketRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated market rate under the debt instrument arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DebtInstrumentEstimatedMarketRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInEstimatedMarketRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated market rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInEstimatedMarketRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LongTermLoansEarlyRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of long-term borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LongTermLoansEarlyRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LongTermLoansPayableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans payable, gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LongTermLoansPayableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981090546680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans payable - Schedule of aggregate minimum future principal payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 6,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981083053496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, Class A common stock and convertible preferred stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 23, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering | $</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">25,948,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">25,948,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">3,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 11.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_NumberOfVotes', window );">Number of votes | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ConversionOfStockCommonStockIssuedForEachShareConverted', window );">Number of common stock issued upon conversion of each share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares Designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 11,750.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ConversionOfStockCommonStockIssuedForEachShareConverted', window );">Number of common stock issued upon conversion of each share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ThresholdPercentageForConversion', window );">Threshold Percentage For Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares elected to convert</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,910,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,582,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,582,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ConversionOfStockCommonStockIssuedForEachShareConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new common stock issued in the conversion of each stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ConversionOfStockCommonStockIssuedForEachShareConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of votes for each share held .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares designated as preferred shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ThresholdPercentageForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percent of common stock that can be owned after conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ThresholdPercentageForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095168376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - 2018 Stock Option and Grant Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>installment </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted to US employee</a></td>
<td class="nump">990,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">4,231,178<span></span>
</td>
<td class="nump">3,555,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember', window );">2018 Stock Option and Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">968,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember', window );">2018 Stock Option and Grant Plan | Vesting upon first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember', window );">2018 Stock Option and Grant Plan | Vesting in equal quarterly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment', window );">Number of quarterly installments for vesting | installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOption2016PlanMember', window );">2016 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of share price with fair market value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOption2016PlanMember', window );">2016 Stock Option Plan | Exercise price 0.09 euros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price for options granted as a replacement | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted to US employee</a></td>
<td class="nump">23,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOption2016PlanMember', window );">2016 Stock Option Plan | Exercise price $2.93</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price for options granted as a replacement | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly installments of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_StockOption2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_StockOption2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=hook_ExercisePriceRangingTo0.09EuroPerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=hook_ExercisePriceRangingTo0.09EuroPerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=hook_ExercisePriceRangingTo2.93DollarsPerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=hook_ExercisePriceRangingTo2.93DollarsPerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082855976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>installment </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption', window );">Number of common stock entitled for each option upon the exercise of the option | shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number stock option authorized | shares</a></td>
<td class="nump">3,630,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares', window );">Number of shares outstanding were cumulatively increased</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Non Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting upon first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting upon first anniversary | Non Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting in equal quarterly installments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment', window );">Number of quarterly installments for vesting | installment</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting in equal quarterly installments | Non Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment', window );">Number of quarterly installments for vesting | installment</a></td>
<td class="nump">8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly installments of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock entitled for each option upon the exercise of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=hook_NonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=hook_NonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981094590520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock option valuation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used in the Black-Scholes option-pricing model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.07%<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">2.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">80.20%<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087235560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="nump">3,555,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">990,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(125,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(190,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="nump">4,231,178<span></span>
</td>
<td class="nump">3,555,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Option exercisable</a></td>
<td class="nump">2,224,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Option unvested</a></td>
<td class="nump">2,006,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Averaged Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance</a></td>
<td class="nump">$ 8.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance</a></td>
<td class="nump">9.21<span></span>
</td>
<td class="nump">$ 8.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Option exercisable</a></td>
<td class="nump">7.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Option unvested</a></td>
<td class="nump">$ 10.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, option exercisable</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term, option unvested</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, beginning balance</a></td>
<td class="nump">$ 12,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, ending balance</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">$ 12,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, option exercisable</a></td>
<td class="nump">1,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, option unvested</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues', window );">Fair value per common stock used for calculating intrinsic values</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 11.09<span></span>
</td>
<td class="nump">$ 12.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, options exercised</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share of stock options granted</a></td>
<td class="nump">$ 11.46<span></span>
</td>
<td class="nump">$ 8.95<span></span>
</td>
<td class="nump">$ 7.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of stock options vested</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercise under share-based payment arrangements</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value per common stock used for calculating the intrinsic values.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of non- vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082945880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Restricted Stock Units (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments', window );">Number of equal installments of vesting | $</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock vested | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance | shares</a></td>
<td class="nump">43,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(43,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance | $ / shares</a></td>
<td class="nump">$ 11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">$ 11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal installments of award vesting under the share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981091870824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Common Stock Awards (Details) - Common Stock Awards - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based awards granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue', window );">Aggregate fair value of share-based awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue', window );">Grant date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant date fair value price of shares issued at grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095203672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock-based compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,644<span></span>
</td>
<td class="nump">$ 8,657<span></span>
</td>
<td class="nump">$ 5,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to the unvested stock-based awards</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average periods over which expense is expected to be recognized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">3,084<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,444<span></span>
</td>
<td class="nump">$ 5,573<span></span>
</td>
<td class="nump">$ 3,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981091517384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_IncomeTaxBenefitsNetOperatingLossesIncurred', window );">Income tax benefits for the net operating losses incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Increase in tax rate differences</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Increase in non-taxable research subsidies received</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Increase in non-taxable stock-based compensation</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Reduction in change in deferred tax asset valuation allowance</a></td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncomeTaxBenefitsNetOperatingLossesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax benefits recorded for the net operating losses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncomeTaxBenefitsNetOperatingLossesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082897096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Losses before income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (11,403)<span></span>
</td>
<td class="num">$ (11,603)<span></span>
</td>
<td class="num">$ (7,886)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign (Austria)</a></td>
<td class="num">(64,261)<span></span>
</td>
<td class="num">(32,479)<span></span>
</td>
<td class="num">(35,151)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax</a></td>
<td class="num">$ (75,664)<span></span>
</td>
<td class="num">$ (44,082)<span></span>
</td>
<td class="num">$ (43,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Company's worldwide effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082752600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Effective income tax reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Not taxable government grants</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(5.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Reduction in change in deferred tax asset valuation allowance</a></td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AT', window );">Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="num">(25.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981088404568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Components of the net deferred tax assets or liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 55,752<span></span>
</td>
<td class="nump">$ 43,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit carryforwards</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">357<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredTaxAssetsFinanceLeaseLiabilities', window );">Finance lease liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">58,765<span></span>
</td>
<td class="nump">47,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(53,728)<span></span>
</td>
<td class="num">(46,064)<span></span>
</td>
<td class="num">$ (32,583)<span></span>
</td>
<td class="num">$ (19,156)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,037<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Accrued expenses and other</a></td>
<td class="num">(3,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets', window );">Fixed assets and intangible assets</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="num">(1,400)<span></span>
</td>
<td class="num">(1,614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset', window );">Finance lease right of use asset</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (5,037)<span></span>
</td>
<td class="num">$ (1,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxAssetsFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxAssetsFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from finance lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from fixed assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087284872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46,064,000)<span></span>
</td>
<td class="num">$ (32,583,000)<span></span>
</td>
<td class="num">$ (19,156,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,664,000)<span></span>
</td>
<td class="num">(13,481,000)<span></span>
</td>
<td class="num">(13,427,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (53,728,000)<span></span>
</td>
<td class="num">$ (46,064,000)<span></span>
</td>
<td class="num">$ (32,583,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage', window );">Threshold return percentage of GILIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion', window );">Reduction percentage of inclusion for GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion', window );">Percentage of inclusion for GILTI</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized income tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AT', window );">Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,700,000<span></span>
</td>
<td class="nump">$ 163,200,000<span></span>
</td>
<td class="nump">$ 112,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of inclusion for "global intangible low-taxed income," or "GILTI".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction percentage of inclusion for "global intangible low-taxed income," or "GILTI".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold return percentage on the controlled foreign corporation ("CFC")'s "qualified business asset investment," or "QBAI" over which global intangible low-taxed income," or "GILTI" applies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082866792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Others (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Non-cancellable obligations</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2022 deliverables</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2023 deliverables</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_LicensingFeesIntellectualPropertyLicenses', window );">Licensing fees from intellectual property licenses</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LicensingFeesIntellectualPropertyLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of licensing fees from intellectual property licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LicensingFeesIntellectualPropertyLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981095124120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses recognized for the 401(k) Plan</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contribution to defined contribution savings plan</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer's Matching contribution to defined contribution savings plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981091456120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (75,665)<span></span>
</td>
<td class="num">$ (44,082)<span></span>
</td>
<td class="num">$ (43,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion', window );">Weighted-average common shares outstanding, basic and diluted</a></td>
<td class="nump">29,945,954<span></span>
</td>
<td class="nump">25,876,376<span></span>
</td>
<td class="nump">17,859,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock', window );">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock</a></td>
<td class="nump">2,887,636<span></span>
</td>
<td class="nump">162,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total number of shares used to calculate net loss per share, basic</a></td>
<td class="nump">32,833,590<span></span>
</td>
<td class="nump">26,039,108<span></span>
</td>
<td class="nump">17,859,935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total number of shares used to calculate net loss per share, diluted</a></td>
<td class="nump">32,833,590<span></span>
</td>
<td class="nump">26,039,108<span></span>
</td>
<td class="nump">17,859,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common stock issued upon conversion of each share of Preferred Stock</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ConvertiblePreferredStockSharesIssuableUponConversion', window );">Number of common stock issuable upon conversion of Series A convertible preferred stock</a></td>
<td class="nump">1,697,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ConvertiblePreferredStockSharesIssuableUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issuable upon conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ConvertiblePreferredStockSharesIssuableUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS), before taking into consideration Series A convertible preferred shares outstanding converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981088426296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Antidilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">4,231,178<span></span>
</td>
<td class="nump">3,599,645<span></span>
</td>
<td class="nump">2,999,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">4,231,178<span></span>
</td>
<td class="nump">3,555,945<span></span>
</td>
<td class="nump">2,999,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981087235720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties (Details) - University of Basel - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_RelatedPartyTransactionPaymentsForRoyalties', window );">Royalties paid</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hook_UniversityOfBaselMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Service fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_RelatedPartyTransactionPaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties, resulting from transactions with related parties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_RelatedPartyTransactionPaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hook_UniversityOfBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hook_UniversityOfBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139981082380536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="nump">$ 42,637,000<span></span>
</td>
<td class="nump">$ 74,756,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of unregistered shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Gilead Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ProceedsFromMilestonePayment', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">145,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Follow-on public offering | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of unregistered shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Follow-on public offering | Series A-1 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of unregistered shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of unregistered shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares', window );">Period granted to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Gilead Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_ProceedsFromMilestonePayment', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_CollaborativeArrangementProgramInitiationFee', window );">Program initiation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount', window );">Amount of common stock to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of unregistered shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Executive team</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions', window );">Percentage of annual bonus paid through stock options</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementProgramInitiationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of program initiation fee received as part of amended and restated research collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementProgramInitiationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual bonus paid through issuance of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period granted to the underwriters to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ProceedsFromMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received from milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ProceedsFromMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock need to be purchased under the stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=hook_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=hook_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>hook-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:hook="http://www.hookipapharma.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hook-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:RedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_1-rISPKNH0inC5yV4XqosA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_iaIK2Z0eQUemaaWm5dk9Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SY6vqrZCAUCbmXcKYv08WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_GPWyabmAdEKvKH-pRh2Odg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_CHI8dxT2OkidwL8Mu4XUrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_11_2020_To_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_KcIuT04yhEWxmnluDeFr0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_C7sFin4R1EaaFWUj-j20vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rb58nqtF00-ccIOKSQPjSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember__-4lq1gvk0iz6FWV-SY_DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TievCB1XuUO1RkPCD7kOtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-23</endDate>
        </period>
    </context>
    <context id="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_NFEgg-7L7kKUdGMo__0AuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mxgxUBrs5EahlanRFV9dLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lmHisS_hEGTk6TeU1vfOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3N0JhOmgVUmYfBmky7vmOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OfuYA2C3xke_bo6pMP4VvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_f2ZtYakwfEGzUa_ReenKsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7wWUwYMC0EOxNoennfjkiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_N55shTLEaEarslhWegOJbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7enHd9VRCkazAjqXa7n2IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8U9btLCFf0-_E1ZmkdKY9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VASM6wKbREa6i5X-hf4OnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fJMSYe6Db0aF4O1Ae_jMRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n6WF9srQk0-nfgx2hH6GHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bza-EjmjGkyDiE1cBzmY_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JCLAhxpWfUK_BCMc8Crq6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F487s_zlB0qFdik4pgQi0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_KY00BOBu8Uie8DRIDNVBvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_trtcRd5UvE-g8RW5tXD87Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Kwh0f-7tfEWtcfjIz3sd0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_go0VxtWuoEOC8lkT9c9QBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LULifWjM2k2MitqBT78QxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vo3P-fAsj0qkzNtmN_hjhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mMp048LvZEKwM3usixUYtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_n0YxpBmAWUqt8sgKu-qHDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_P9-ctvWwd0qVNZJLztP7lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fDr8f-o960agj3wW41LU3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bmkwQPPsg0m3l7ZM8QwDVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-01</instant>
        </period>
    </context>
    <context id="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_YG3CoyW76UCnds2S4wKCbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_yBu7KRZGvUyBIFDw4F8mQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9-wYstNW-kqgqsk59PAAeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_2dw45hjqck2FIlWYMhpGDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_beVG5N6ZTEC9isTgGKHBeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2022_To_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b78AfSk_ikSR3aA4hEpw6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_9n3p1gHKx0CGfWWuBr4x9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hook:ExercisePriceRangingTo0.09EuroPerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_mveODV43Qk2j2ktXiQesTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_twPgggzgsEqZUfvcKLhARA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hook:ExercisePriceRangingTo0.09EuroPerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo2.93DollarsPerShareMember__xThJ8xgwECdT4PnUdSrEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOption2016PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hook:ExercisePriceRangingTo2.93DollarsPerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UzL7A7Iha0WXUjRxbCPtMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yxPIhqNASUaCbZD8h1tf_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hpzhb_Bppk67Nw3sDM-ihg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_Y24Eexf4xkCs_eHMPufkaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_NvEZsiucNEarngOHkIEwqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Qyh0v6uhbEG1Th-ftOQ75Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tspqlK_mSEuko-7EX1OHCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_4UVSVApoFESt0pKFq_aAcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_fmE0VmQhIk2B4XyRkIcu2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-DFpbMUslEae1ED399zLwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_22rnLqSJCUSZdw6cMXG4eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FgZEcu-x6ESzKZv_nwLtiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_M7e0-G2Jc0mMZbDTVrVaQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_WVL2EC15ZUqXg0iRX6l96w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_pZ8SP9MhHUePH3GzlSb8nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_mXlTlYVhXE--Iu97sO2IOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4BwGZSWxKES82uxhJw-yBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__YrrPJBfXEKiNjwR_7k7OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_RnEWI9I70EeTbY-Xi8vklA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_qytkKxk8CEm7bN6P8U8VzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NyQzVSOZCUW4XmIPhFet_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_ANXP3tESvE-8MHgi_Ck3uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oM1lWRGbvEiE-FT3XrMDcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_zjRiqY7na0mdESnAmAgN5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_h3bbPTbCck67We_5POyRoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kZ2Gy961l0-3UxadFPp3yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_p1qmf6wjLk6uR_JhX4mV2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_03RMuix68kaDY62cZtc7HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j9QTccxA8kSS8q3279Cm-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_7otYFkeHoUKeaKz76AWKEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mmAIdyTOBEGGYm394Dfgdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_B5fIRUIsikiF5KXD5x6cHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Ft-tF1iTN0Gyv_gaYiFXZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_11_2020_To_12_11_2020_lwzbDOodv0Si697Xzru_Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember__DCiYylTbUSqoGmdQ3GRYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_DDij82CjqUCydxqkEFWIhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IzO1tarH8EWCgudDOfIH8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0EmWweoQGke319p9rpY0xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6lqA7X0UVkCwZjjrPXO1kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wlEd_mxNOkeq4y6xJ7gacw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_gHDM5dWWTEuXar6FbiCeBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_G_2_M_kOZUillKcUGB9iFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AT_VDTF1Hi9ZEmGsqw3fw3zPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_g5-9_PFDAkeum_3TPJDJ1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AT_bcqjl_Vcukegg0RdiMWQ4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rtH4Ec9QWkKmuKYhDdJTqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MoCC3vP5_Uyo7dm3xckcaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3xEUlzHOy06ZPsj-DQ1mAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_lfUPt9xHTECs1PBzglCNhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_Ayr8wO2i8EqBHFydPDrBIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_8aWV_Z5u30CrNnuDLkmpsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_76blQDrh8EykPQMtShDiPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_y8byg_XyWUKkNI6G_f1TrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_yxLDZPy_JkCTBy3vQ0rANw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_hounmkd6wkGAMVpwq87DJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_tyTRnlIXPUi1yW0nB28asw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_VGIrjRmoLU2n3YXR5TnwLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_kFwGKKMO6U2oE6qi3AFdmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_r8XLGskgdEyxWiQ5NQyIKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OLb_2bn0qEy2UW_m4JwHoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHJvZ8_EJ0OzSnSQBM0_6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ld1bC-KnG0yjbLLvZcbh9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U3zEzG1qXkK9lJ83V5wUyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0cA_3wN87kC_T3pK3UXc2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DNp-TcR4d0uu2uDNfHmJLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Hi8vNfG0OketOKVTNEWdKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3LNaEjX6U06CsywOTygF8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8ArpbU0oC0yIg8CJBYRJmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Tblo1dfAsE-WhYeQhF--_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_5rBz_7VLf0GCJz8u9a-5hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_g4i69HykyUOop1GtYNoS3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_wAHzp7MTe0eWsXdFl7PgAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_TFoTZQzTG0eYRQ27zNvfiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7Bp0zhTgI06LSu47f4p2jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_MW8Mqd0iIEG_9OzHPNz_yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_Xf3pHxRC4UOPsU0Tyuw4UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7WLlmoedJEi4B7q-431RSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_2rHrjRN4ikCe0MkQAF8I5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:RedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_ioF2r0Uas0uFcTusXG0EVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:RedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_UozogPZl3kqm-mLqR-1Ajw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_1_2019_XDfkQ2lQ5UGH271C7716Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rLd-8jjIakKEuR52k7XE-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_tBzOSNE1VEeWs3G7uVNFMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GB1HtsQo9UWwp1QaQ-17vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_lRtNrbT0JEmwrX6k2vVYAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_YCN1Wdur2kOhWvhtqG7FTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_gifEUz7mSku6eu-AYJEHoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hook:UniversityOfBaselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_paPyAdbqWE-j29GBmOS_lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2022_To_2_1_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_zDBbt61-QkWRp1SuDXvEgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2019_To_11_30_2019_1iZi9iUIoEu0KQgEUiQByw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ilxWs-hFzUu1oK7UGRu04Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_FbkMEjEJl0WQtmJecOY1vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_12_31_2026_Z5BVccme10iEHOgWw4JA2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_HNQ1RpgYeke7cwk7fsoeRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9NpKAk2xnE-XmHW-HPDY4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsTwoMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4hozc3IA_UemHLG5L4Tssg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:MilestonePaymentsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsOneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_X8z0GhjTXEaCy2ODr2m1sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:MilestonePaymentsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_kRKK4hhFqUmimB34ezmG7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_2Vq0EfxlZkK7tBpSzeg_iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Sx4TWQDqgU-t8yTvWjEuDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_1YzcX0Wm8UuRD0c642O46A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_Program_p93h6a_140eCP-r_hTy6gg">
        <measure>hook:Program</measure>
    </unit>
    <unit id="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA">
        <measure>hook:item</measure>
    </unit>
    <unit id="Unit_Standard_Vote_t09LAWcUrk2_inHGi-A6Ng">
        <measure>hook:Vote</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q">
        <measure>hook:installment</measure>
    </unit>
    <unit id="Unit_Divide_EUR_shares_590Vq7m6Nk2ruyUEdyuF7Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      id="Hidden_gvgzIMj6nUeUWxe0_y-Jwg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      id="Hidden_zCSNkhGMCk6qJSihJFzovQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Hidden_GjhzT8Q77EKyUG4HLJai2Q"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Hidden_WAlIWKg3_kGPFwdfEOmjyg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-1.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Hidden_PQ_AJu4vDU-8R34Q01Wvxg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      id="Hidden_gFfph1YY2UKzJMfVCi4-aw">http://www.hookipapharma.com/20211231#AccruedExpensesAndOtherCurrentLiabilities</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      id="Hidden_tvmVHvIJdU2wwY7HpN_TxA">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="0"
      id="Hidden_Y2uUY9PnaEu425eLIIFSWQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">32833590</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="0"
      id="Hidden_9GsyheM0nk2Vq9EwIxi8jw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">26039108</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="0"
      id="Hidden_xeQBGPQR4ESWq7MOG3v3-w"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">17859935</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA"
      decimals="INF"
      id="Hidden_6-gyEFXupUu6flBiLprClQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="INF"
      id="Hidden_SpzvgrlBO0K58lHSEpRDng"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_bFSzj01QKUScEVMlQ6O1Cw_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg"
      decimals="INF"
      id="Hidden_M4QO-ITDuk6l7x8QEJvWqQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">25948712</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Hidden_ei_Ikp7_JkWHvn3i30w8hQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">27383483</us-gaap:CommonStockSharesOutstanding>
    <hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA"
      decimals="-5"
      id="Hidden_l0XBTDSRf02Br1mMnKhitQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">300000</hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw"
      decimals="-5"
      id="Hidden_0ppv5nVtqUW_59qTfEqsxA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">100000</hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Hidden_Ig22UHVZRkKGX2x0KG_1_A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Hidden_ilfqJ_zyb0aZGfg-9XrTsA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Hidden_yp-p9Vk_-kOWrEU_xREtbA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      id="Hidden_oRmXSROYc0OcSjQ6MQGWpg">http://www.hookipapharma.com/20211231#AccruedExpensesAndOtherCurrentLiabilities</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      id="Hidden_qGfyuLYvk0GVroGAArA9Ww">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Hidden_0vCtFWOMdU6TUe8bLbDs8w"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">27383483</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="INF"
      id="Hidden_lsKpVaKZlU2VrubLnN7E_w"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Hidden_qvPF7Qsm3kquM23a168syQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1697</us-gaap:PreferredStockSharesIssued>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Hidden_xm72ylqy7EWXDfD5Rmo5kg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Hidden_ix31qi0nv0-3tRNXPNStAg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-1.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Hidden_6TH1JwQjZkq-oybyyIOUrA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.41</us-gaap:EarningsPerShareDiluted>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_rDrX29g05UuEen2MIS8mCg">0001760542</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_NIqVUY_kOkqGL6eJubJxDQ">2021</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_N18IXFMr2kCzIoRm46dp7Q">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_w7QHGDGu_UmVYz8JC1y1Jw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_VWPC3f7maU2x3T5JJR0_6A">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_Y43p7SMldkyGCJYoIF0SJw">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_GS6L7-CsBkKhL44CCPgsKQ">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_e7sV4mAB-kKfYYHo4AR8dw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_bAxI-O_jDEu64elICaGpnA">001-38869</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_sjd4NmsKRUqTYNUhBBMRwA">HOOKIPA PHARMA&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_ti4TJIzaF0isRIFbl3OZKw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_vafhyZ-K6UucDn0PRLj3Ew_1_1">81-5395687</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_9Pvo966ryEebhnrX_t1TOw">350 Fifth Avenue, 72nd Floor, Suite&#160;7240</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr__VeSy4HbsUuHW-2sIxuLDw">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_vyKFdOwPF0K_JS_qu3UeLg">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_tEGE8o2HtUuXo0sfkNqiuA_4_1">10118</dei:EntityAddressPostalZipCode>
    <dei:CountryRegion
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_GGtvWN2RZEyenFyJ1bNz-g">+43</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_6Hynt1qiY0GdjFP7da8iag">1</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_9fvXT5lPO06okvRmG4kX_A">890 63 60</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_3TwWFk2bN0ejhJJCismJqw_3_0">Common Stock, $0.0001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_ZbAjs1wW-UatAYDbHSMoIA_3_1">HOOK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_mSg7lKxiXUmZsdP9Vr_few_3_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_pQTbw0K1eUqIpdvVPPDd0w">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_2_32KWVS20SQflAWV_oCrA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_3Gg5anRwQ0y8CORJ3YEtXg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_K_NrxIoyOUqJcQhplesi_A">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_InOgc55q0EGs6vXVA1pEfQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_WlQhpwbA80SLIKBoaGFMCA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_UihmZO1jgEWyl7yT0OfELA">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_wIbfQFpU60CtkbMPckYyMQ">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_IfEW-8zq60-3rRZu6i3_Jg">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_pHsy58WfZUyB_sROCgXnGQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_2Vq0EfxlZkK7tBpSzeg_iQ"
      decimals="-5"
      id="Narr_hW8wKVXPokS3ig98nVOIEw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">237900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_1YzcX0Wm8UuRD0c642O46A"
      decimals="INF"
      id="Narr_YaxxYAwl5ESXcBCjXFw4bA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">50868668</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Sx4TWQDqgU-t8yTvWjEuDw"
      decimals="INF"
      id="Narr_MXgx3FqyTke-xFXYZ51lUQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_pJpRzGFHSkyn1fuMZGG1Ng">1259</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_9IZJ-3Sa9EmXRMML4MDaqg">Vienna, Austria</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_Kbzb1NIOikG-bODX8iQVBA">PwC Wirtschaftspr&#xfc;fung GmbH</dei:AuditorName>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_qU9Md1EVtEqQrRR5n0tM5Q_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">65921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_tb4Z6iCSjUquGPA0d4DZxg_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">142743000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_7BCKbnWmKkuNWZN4uQ6ggg_6_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">566000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_3I5HkeDfqEqOgWQ_ObQcVg_7_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6895000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_jfE4o3KvJkKVC-deL-nyKA_7_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5542000</us-gaap:AccountsReceivableNetCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_hvr6zL-8AkWv1D5kEdsNUw_8_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">14271000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_AtBuHvv3ZkaExpleBmlriA_8_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">15115000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:PrepaidExpensesAndOtherCurrentAssets
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_OWW2Pkpe4Ea_Ju1GxTKTzw_9_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">14482000</hook:PrepaidExpensesAndOtherCurrentAssets>
    <hook:PrepaidExpensesAndOtherCurrentAssets
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_6Mtzl6hwpk2ChZsDvSiWwA_9_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8104000</hook:PrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_O4Ux8jV6DEC9FtEMuGW-bg_10_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">102135000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_UuktNMTV00W1I-NnC6veFg_10_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">171504000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_69qnNc-Ey0mQUoKksTJIPA_12_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">425000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_BGyt-XnL7US5x_WrGKP_9Q_12_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">434000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_WkswnTLHyU25uucHO-iwfQ_13_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16352000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_JjTU_oR9ykeppBZhFvqjOA_13_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6219000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_kbPsjUjRoUih0Wvpq6iu6A_14_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5673000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_CPs9Vj3mHkuoBlPt1tVmLg_14_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6452000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_GqtGTZWWp0SBMmVzDSo98w_15_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">90000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_1dzLLNbuukCtUvCFlPgTOQ_15_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1298000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_X-AZzDXm60yFcr7QdUI0vw_16_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1370000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_Wq9hQ_hCJUKxf5gictpXQg_16_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1910000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_VPTqjhgurkq9wftYbLLfyQ_17_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">23910000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_exo2qrlK5UyKkB-NuNPKhQ_17_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16313000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_5_qfjHAz-UuXwjhU67xZMQ_19_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">126045000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_mPvVmti4ckCC1FN7psRPWQ_19_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">187817000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_WkO2OlTWlk2HKbNbHNeJkQ_23_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8762000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_Tt3X4N8dJ0mGKYgJRsVpcw_23_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8009000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_BAVwJdVlVUuKb5BIGiZ2Eg_24_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5538000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_9SYgI9F_zEOcBs1HPZz1IA_24_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3750000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_P_qCwv86NUqVm3P-2PZ0aA_25_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1682000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_sVOe-zc0eEKtqW3TWsFtFg_25_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_ai-3E0YLiEuahSxhrtFcYQ_26_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8880000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_z-FpKWpXqkWkiJit0ekiYw_26_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7386000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LoansPayableCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_TTidO0XJp0-UdGhs0Uci9Q_27_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2792000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_vccPHVDUJEyp8M4i9zHHjw_28_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">27654000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_yrOimf_ZH0alwdrsMIYY0A_28_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21143000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LoansPayable
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_Adi6VcYkCUmWVtMPReKiyw_30_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2219000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_RbDLv9noOkuKiqgURy2cdg_30_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4537000</us-gaap:LoansPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_bIZdyCGzek2lqpsGm-Hj8Q_31_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3911000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_y2rtFnLUR06fTbebcoBgAA_31_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3819000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_flUX8FuBZ0aLpoW6KiKNkw_32_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_JQWa7-8fmEuJTzc9hnEi8Q_32_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">784000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_7-d3QwFV9U6pCzZe0Tkcbw_33_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2648000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_OcBexpJ2zkeIPx09KLDbhQ_33_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1411000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_YU9XHzimbUKikxptv6iTvA_34_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8799000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_2K-KA3O_DkCCuO6wAE3V9w_34_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10551000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_FmpJo8fszkGZokQ_kct3bQ_35_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">36453000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_Z5Qlca1PwkaQI3kwud_FgQ_35_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">31694000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="INF"
      id="Narr_wJY0DsggskOlH04xPTqo7A"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Narr_gq0Ir8RvpUSjub9DQnqQQg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="INF"
      id="Narr_4ufsTYxGjUy8gZloRwIvIA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Narr_TPnLk5SY0UKRt6GGrK5JnQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg"
      decimals="INF"
      id="Narr_IqJOfIwJwkOFwFOwgy7Igg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</hook:PreferredStockSharesDesignated>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"
      decimals="INF"
      id="Narr_SazCqPF3UEuLRZeaLBrXBw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"
      decimals="INF"
      id="Narr_2U25fhhHAU-y44f0zX9u0g"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1697</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg"
      decimals="INF"
      id="Narr_5QMVn581VECQOyZZTAr6wQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_6CUqPbUC3ECw8lhoR6zJgQ_40_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_nh6eZoO-vkCjbsTjT9ymPA_40_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg"
      decimals="INF"
      id="Narr_IsJqVjrNyki6B_WZQF163Q"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Narr_pqfqP5PYqEiLsfq2cQUp7w"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg"
      decimals="INF"
      id="Narr_3k6zu6jbKkSuAgSrvYVB_A"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Narr_p98ke3KLjkeoVat7O6VNKA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Narr_H0Ah6WFpiEKDUFXKqTZzMw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">27383483</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg"
      decimals="INF"
      id="Narr_zk2Hf08WDk2XbUOCy7rUmw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">25948712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="-3"
      id="Tc_Kx6l_DztwEKPRayyPN642A_41_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg"
      decimals="-3"
      id="Tc_cU5NyviGaUyyN128tXS4BQ_41_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA"
      decimals="INF"
      id="Narr_jCk-21PY20ePGQLTvXJ-og"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="INF"
      id="Narr_9bLJGf4NBUWJYgI_sqA2iA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA"
      decimals="INF"
      id="Narr_3kL9f2refUm1QeHEk4Pv7w"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3900000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="INF"
      id="Narr_uwiFuC4PTkOJ5X9a-Bsd4g"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3900000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA"
      decimals="INF"
      id="Narr_TyRlUQ4hBkitW4RJ2DcW2Q"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="INF"
      id="Narr_A2FARKpC1EOVKmcbEaCtkQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="-3"
      id="Tc_MZXrZeLmN06dLGOPeYKEVQ_42_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cqxRPsR1U0a-Mdbo9r4TxA"
      decimals="-3"
      id="Tc_Y4_A8nqJWU66nHExVH5ZwA_42_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_z48iYgKa20ib7D5lVK5ofQ_43_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">317135000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_LpiPZSz0Y0CvIVrgXyavPA_43_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">309288000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_zXHTPAcsM0KHUMcjh2ur4w_44_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-4780000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_BMuO5om7F0S2TN6bml2yrw_44_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-6067000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_bnph9VMQt0uJt3diSTMicw_45_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-222766000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_oi4HbWwfgESCg7tnxqS2OQ_45_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-147101000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_GYBnK-O1_UGfJ-V7RNJlug_46_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">89592000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_9iFtuiUt30634Sac9Al6wQ_46_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">156123000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_nOihmEJaAkOBJNrWt3jJVw_48_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">126045000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_ezYLohE3TUGAfW7feZdhnQ_48_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">187817000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_8KtK6Y91k02fIZsaz__BAQ_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">18448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_lV4JsllaPU6nTD_h3upJOQ_3_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">19584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_UTBOk4uPCUuW-dVISQL-kQ_3_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">11942000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_bWkqdeBbMk28dmnzfkEf_g_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">82853000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_5HezugJDSEaSxZLUuN8VCA_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">54787000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_O6x0tGInEUiPdiSL5qJ2Pg_5_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">46312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_nF0ysZtGCkOlBko3c48FfQ_6_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">17269000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_J9NXhgafQ0Sde-UBFgqGwg_6_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">18082000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_6pQcRzK9GkanJL5dCWdW2Q_6_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16715000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_WnJ2lOehekWWwLBEVreClg_7_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">100122000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_PyjJGZDLY0OvKn-kXTy5-Q_7_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">72869000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_qtMUiejE4Eurj59VTuvbBQ_7_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">63027000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_8RMg_d1-UE62EdohVBGGPA_8_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-81674000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_kjmZJrMGykCpab9_bCLshg_8_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-53285000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_NxiUT5-AaUuoUhaMuGEZeA_8_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-51085000</us-gaap:OperatingIncomeLoss>
    <hook:GrantIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_q7uXq0bXpEyTkhxYD6HtJQ_10_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">9724000</hook:GrantIncome>
    <hook:GrantIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_mMTiLeD6vkG5NImh5P8iRA_10_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6517000</hook:GrantIncome>
    <hook:GrantIncome
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_7FB6ww4W8EiAxiBUadpABw_10_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6737000</hook:GrantIncome>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_F1FmO-wdD0G2o6vzbWWPIg_11_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">27000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_C_IBNGSHzUW-0odMpKU-ug_11_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_S5gWrOiz-kSejH6ofqPAtg_11_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1587000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_RR6PecnytkumpcjZEOQwaA_12_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">898000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_PuuvYk7RxUaIAsCqgE94iw_12_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">786000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_t7aW-2h0p0CslEQISKPikg_12_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">877000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_aIsNkjHql0OslitsGGfEJw_13_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-2843000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_GkpTAZ1wQEms9BYzNA7HfQ_13_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3072000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_aWxoIzu1d0yaMSYYhiWgtg_13_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">601000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_e5lDjOFboka9qCZdf1S8ow_15_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6010000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_hnnXMxQvLESVobqDmm9Frg_15_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">9203000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_QQ32eVFvbUGjclc8T0H1ig_15_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8048000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_M2igh5e0SUy3Eg4_jV-CqQ_17_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_-5VUaSUn10eaatSZK3hcMQ_17_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44082000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_ZTJqY1iaREaptkEkIbvbNw_17_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_dcFKf29ZKEuQk-EeU_Vjlw_19_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_WD7g_Sklf0G5_TRUr_Whjw_19_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_DsLxSIj7QUCXaVRD3mj1Gw_19_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_sxB2Jrb7nkaIYuu68JMWAw_21_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_gQHg4tV06UaicTCsPQBVHQ_21_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_0Y3LdP3QYU68pPQilexhug_21_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43037000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_dlZRfq518UqvCzNe0dmnWw_25_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1287000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_2fd69zWnxkiO52Ym678r7A_25_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1414000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_pMLFn1DEX0qoe8u8FJtzQg_25_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-933000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_2J6-t67Hi0qZY4OoUSNNqQ_26_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-74378000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_C8iiST71mkqA2PtIYcK1Og_26_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-45496000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_kaCCXjUc_06Y9CGbx5w0zQ_26_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43970000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Tc_LXIKk8UR8Eati8j2LwhyIw_28_3"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Tc_qiR0CGgSL0qUlDQj7JBPUQ_28_6"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Tc_rL9GxY-2rkOVeBeCVbxaoQ_28_9"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA"
      decimals="INF"
      id="Tc__snGCDWg80qxd1palDB1WA_5_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1323506</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA"
      decimals="-3"
      id="Tc_0IENksdGyEGU-rT5XEptlA_5_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">104774000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mMp048LvZEKwM3usixUYtg"
      decimals="INF"
      id="Tc_Bm2cPzfqPUiIsAjYolFBKw_5_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1006595</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mMp048LvZEKwM3usixUYtg"
      decimals="-3"
      id="Tc_tPAYsXfpDEOSJin-ht5YPg_5_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n6WF9srQk0-nfgx2hH6GHA"
      decimals="-3"
      id="Tc_t_fRx3hTUkmkOYBrfbBUxw_5_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bza-EjmjGkyDiE1cBzmY_A"
      decimals="-3"
      id="Tc_2lPdZnV5qEivPlVnqJPA3g_5_27"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-3720000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fJMSYe6Db0aF4O1Ae_jMRw"
      decimals="-3"
      id="Tc_pttGrIqFp0SsIMOmwDR8PQ_5_30"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-59982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg"
      decimals="-3"
      id="Tc_14jML7-qfku23iCFcLkDWQ_5_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-60375000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_MW8Mqd0iIEG_9OzHPNz_yA"
      decimals="-3"
      id="Narr_AUl8TkpmsUekBIfuigJC2A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">158000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <hook:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_2rHrjRN4ikCe0MkQAF8I5A"
      decimals="INF"
      id="Tc_9gdc06xYqEOW4M9fGBaz4Q_6_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">257000</hook:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_2rHrjRN4ikCe0MkQAF8I5A"
      decimals="-3"
      id="Tc_B2C82jtzsUKczhS4I1_TAw_6_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">37274000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_yBu7KRZGvUyBIFDw4F8mQA"
      decimals="2"
      id="Narr_MUIf4Tk7p02xr9vPu-rMwQ"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">14.00</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7Bp0zhTgI06LSu47f4p2jg"
      decimals="-3"
      id="Narr_ekt_ddw_A0WYpchpPIQYlA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">9386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw"
      decimals="INF"
      id="Tc_GVjWFUiQH0upjVXJAd-SzQ_7_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw"
      decimals="-3"
      id="Tc_cEN7OiRTAkS29C-cuAK2Bw_7_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg"
      decimals="-3"
      id="Tc_7IwVpTTnlk6s5ryDWsRvTg_7_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">74614000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_9AfVSkQh2U2wQaIwwuOUFw_7_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">74615000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <hook:TemporaryEquitySharesConverted
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_ioF2r0Uas0uFcTusXG0EVw"
      decimals="INF"
      id="Tc_z0BaG-uNwkmWMoF8KZ8M1A_8_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">-1580506</hook:TemporaryEquitySharesConverted>
    <us-gaap:TemporaryEquityEliminationAsPartofReorganization
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember_ioF2r0Uas0uFcTusXG0EVw"
      decimals="-3"
      id="Tc_0yMfNXX3D0WLvWcNGuLPHA_8_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">142048000</us-gaap:TemporaryEquityEliminationAsPartofReorganization>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw"
      decimals="INF"
      id="Tc_-XwYwEgidkKhJJezbwiaWA_8_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">14582161</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw"
      decimals="-3"
      id="Tc_Ufbk1JxvSUuEbb6OD0t0uw_8_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mxgxUBrs5EahlanRFV9dLg"
      decimals="INF"
      id="Tc_KQxsMaLqQE6aDaKr0-WQyA_8_18"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mxgxUBrs5EahlanRFV9dLg"
      decimals="-3"
      id="Tc_U8nQ0taqtUu_yBzvC6PuZg_8_21"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg"
      decimals="-3"
      id="Tc_A9oYF-0FEUOi5G7cBxX2qw_8_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">142046000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_f0iSlcqd7kiM2eT53qDp2A_8_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">142048000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw"
      decimals="INF"
      id="Tc_AuC1xW22tE-I5CwNHSMe6w_9_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">157636</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9KzKvAUoEK6XmRcAqO2Jw"
      decimals="-3"
      id="Tc_7Xb1zudHcEqijbQlqIEOVw_9_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg"
      decimals="-3"
      id="Tc_e1kslkKsl0uD__ujlB7zJg_9_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_oiWH9NBDo0ShklC3HvXadQ_9_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6lqA7X0UVkCwZjjrPXO1kA"
      decimals="-3"
      id="Tc_5TU1-FBIAUmbQIeDfys66g_10_27"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-933000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_a29kFE3D2UOH2Y_BWB_BPw_10_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-933000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MO2TirZpXk2xaJHhzCkPxg"
      decimals="-3"
      id="Tc_e5TIKBBm7EOFgye4GAZEZQ_11_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5565000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_6Whp3pMyWUmvHFaSyUcL2g_11_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5565000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3xEUlzHOy06ZPsj-DQ1mAQ"
      decimals="-3"
      id="Tc_F2noIw1x8UuEfC3lbK4qJA_12_30"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43037000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_L7m4V8bEAUyVWGPQSNERew_12_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43037000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vo3P-fAsj0qkzNtmN_hjhQ"
      decimals="INF"
      id="Tc__NMKhepmFU6VkYHOgwrR3g_13_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">21746392</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vo3P-fAsj0qkzNtmN_hjhQ"
      decimals="-3"
      id="Tc_hACGXB5DKUyI2GiQiCh4Mw_13_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LULifWjM2k2MitqBT78QxQ"
      decimals="INF"
      id="Tc_o0ZciqS6vEmXgueYK9zIEA_13_18"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LULifWjM2k2MitqBT78QxQ"
      decimals="-3"
      id="Tc_Mak9jSIcqkWkNDC1OqtHYw_13_21"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8U9btLCFf0-_E1ZmkdKY9A"
      decimals="-3"
      id="Tc_MDhmJ94Ak0-h08l92V3yCg_13_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">225568000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VASM6wKbREa6i5X-hf4OnA"
      decimals="-3"
      id="Tc_xd8cwAsT5UyGitTip9JNJw_13_27"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-4653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7enHd9VRCkazAjqXa7n2IA"
      decimals="-3"
      id="Tc_jLJA4WlI7k6nR9jlDROlnA_13_30"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-103019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w"
      decimals="-3"
      id="Tc_y7TWZtfo9UG1Ybf33CjWLw_13_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">117899000</us-gaap:StockholdersEquity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg"
      decimals="3"
      id="Narr_2eUxdenClUy0SHIl-6ePhA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11750</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_wAHzp7MTe0eWsXdFl7PgAw"
      decimals="-3"
      id="Narr_mwHomgkTlEmH6MoudBucuw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2565000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_C7sFin4R1EaaFWUj-j20vQ"
      decimals="INF"
      id="Tc_qWkMRHKsxUuWdReTwhz-7w_14_8"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_C7sFin4R1EaaFWUj-j20vQ"
      decimals="-3"
      id="Tc_H_scjowMhU2V8OVn0xOK3Q_14_11"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SY6vqrZCAUCbmXcKYv08WA"
      decimals="-3"
      id="Tc_i6B_dpIMRkmbMPuzDaWdgg_14_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">32426000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_wAHzp7MTe0eWsXdFl7PgAw"
      decimals="-3"
      id="Tc_zcUKUrHhb0K2j7yRBQ_76A_14_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">32426000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_5KKVr_YsDECIGZIdnT_iDg"
      decimals="2"
      id="Narr_uZNru85Ne02qO0AHTcuHqA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.75</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_TFoTZQzTG0eYRQ27zNvfiQ"
      decimals="-3"
      id="Narr_Q5UceYe8A0qtmK4YCQ3-1w"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="INF"
      id="Tc_xqvbSb--MEqanoq1xG6T0w_15_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3910000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="-3"
      id="Tc_6f7JHJv-kEi3OB9eYpvQPA_15_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA"
      decimals="-3"
      id="Tc_80agmUjsCkegGAgDnKF-yQ_15_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">42574000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_BdibXaK2Q0CfpYfInbQsEQ_15_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">42574000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="INF"
      id="Tc_cfVp-0vGx0q6AqXpGaO3fg_16_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">255011</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="-3"
      id="Tc_sZKEBjYV3U-Pn7J6L89qQA_16_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA"
      decimals="-3"
      id="Tc_SOhaJ7AJT0qyetQxigt-ig_16_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">63000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_RKCrZ9I7Ek67qCbDCGkWvA_16_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">63000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="INF"
      id="Tc_yjyWoMzHok6hWR9ncOMR7Q_17_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1060</hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="-3"
      id="Tc_XRTIxkYlXUaLgvN0T6TRPg_17_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested>
    <hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA"
      decimals="-3"
      id="Tc_hhfU89gpxk2_hiukUEdzLw_17_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested>
    <hook:SharesIssuedSharesShareBasedPaymentArrangementVested
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="INF"
      id="Tc_9LYYVpXW60iwaGXIKDIy9w_18_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">36249</hook:SharesIssuedSharesShareBasedPaymentArrangementVested>
    <hook:SharesGrantedValueShareBasedPaymentArrangementVested
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0bDwaHTdu0ye7xjdHHF63A"
      decimals="-3"
      id="Tc_KQR-p0P4A06EL4nu3EYs4g_18_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:SharesGrantedValueShareBasedPaymentArrangementVested>
    <hook:SharesGrantedValueShareBasedPaymentArrangementVested
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA"
      decimals="-3"
      id="Tc_inzvCjFCUEWWJqs8vlpDQA_18_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:SharesGrantedValueShareBasedPaymentArrangementVested>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0EmWweoQGke319p9rpY0xg"
      decimals="-3"
      id="Tc_XAKN36vKeUaYH1kGzcD-og_19_27"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1414000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_pVvfQ7RCCU6agR1M9PxMsA_19_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1414000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-rGLC0zRskK1oUvOSEgWvA"
      decimals="-3"
      id="Tc_TdoIo0v6A0eE9sLMjdFmpA_20_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8657000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_lTllba8OiUOneSOhKJaQSw_20_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8657000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MoCC3vP5_Uyo7dm3xckcaA"
      decimals="-3"
      id="Tc_PIuT1gqZCEagskOP1CDhEQ_21_30"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_WEChPPpWKE6QQ62AqM_f3Q_21_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44082000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_go0VxtWuoEOC8lkT9c9QBg"
      decimals="INF"
      id="Tc_pamvv90ySEi98wB6Snm9iQ_22_8"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_go0VxtWuoEOC8lkT9c9QBg"
      decimals="-3"
      id="Tc_JOcZndtkjUqnlyA2_o9sgw_22_11"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Kwh0f-7tfEWtcfjIz3sd0w"
      decimals="INF"
      id="Tc_O__akkU60EmLZVa_HU0KEQ_22_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">25948712</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Kwh0f-7tfEWtcfjIz3sd0w"
      decimals="-3"
      id="Tc_XF5cQpJtRUGoZ2m86vCVwQ_22_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_trtcRd5UvE-g8RW5tXD87Q"
      decimals="INF"
      id="Tc_XJlXGwzvIkuoeaG3djXNng_22_18"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_trtcRd5UvE-g8RW5tXD87Q"
      decimals="-3"
      id="Tc_1iOJwWDt9kS4Nqm6JhIkqw_22_21"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7wWUwYMC0EOxNoennfjkiA"
      decimals="-3"
      id="Tc_kDrSC4NKB0q-fT1dNpG_4g_22_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">309288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_N55shTLEaEarslhWegOJbw"
      decimals="-3"
      id="Tc_6N8CUGxNI0q_sbqvfADqdA_22_27"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-6067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_f2ZtYakwfEGzUa_ReenKsA"
      decimals="-3"
      id="Tc_5UpRNQcrakidps_RhRD4kQ_22_30"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-147101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_B_IlZrF32ESvIBLPPqGgKQ_22_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">156123000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember__-4lq1gvk0iz6FWV-SY_DQ"
      decimals="INF"
      id="Tc_BDdWsurj5Ey5xdc_VIoNHg_23_8"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">-1281</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember__-4lq1gvk0iz6FWV-SY_DQ"
      decimals="-3"
      id="Tc_Mmeg-oUGnESgspzO11JMvQ_23_11"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA"
      decimals="INF"
      id="Tc_dyVHep7Ys0uF0omwglEeZQ_23_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1281000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA"
      decimals="-3"
      id="Tc_bGZUgnnO9kmcc08qMOJJiQ_23_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA"
      decimals="-3"
      id="Tc_yGCg-UNmfUWjzf7pocOsgg_23_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA"
      decimals="INF"
      id="Tc_TgcIumQNeEOybsWloezeqw_24_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">110071</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA"
      decimals="-3"
      id="Tc_jKQrRtDtd0WY3vECqUfE3Q_24_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA"
      decimals="-3"
      id="Tc_OdY7SDAmmkqHdX8AwfiSUQ_24_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">203000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_0vXymPOE2UqU9fc_QoXsZQ_24_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">203000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA"
      decimals="INF"
      id="Tc_0r8wQIWwM06JyskcVreW3w_25_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">43700</hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XWLme9in7kSB4R5iSRXcqA"
      decimals="-3"
      id="Tc_TPohowCCrEaWFxTWoj77fw_25_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested>
    <hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA"
      decimals="-3"
      id="Tc_v0miCQ1g40OHaJlYVE1lZQ_25_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IzO1tarH8EWCgudDOfIH8A"
      decimals="-3"
      id="Tc_lcuRWlWkqUCoYRqHKkAp_w_26_27"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1287000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_VzBG2eoL2kSUSuhx6_uIZA_26_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1287000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n232Gzk_g0eybc36mti7iA"
      decimals="-3"
      id="Tc_5EbmICrHU0GK9GEt61ergA_27_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_TgJ5e9Ula0Kv2jWxkLQCIg_27_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rtH4Ec9QWkKmuKYhDdJTqg"
      decimals="-3"
      id="Tc_6YF_2OJ1j0aBURG69Yzp5Q_28_30"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_uOKAXSK3TkSuX7FasCERzQ_28_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_KY00BOBu8Uie8DRIDNVBvg"
      decimals="INF"
      id="Tc_oUkWI66S4kuhOSNsHX9c-A_29_8"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1697</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_KY00BOBu8Uie8DRIDNVBvg"
      decimals="-3"
      id="Tc_xeijjfwUZka64E55C_WeyQ_29_11"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F487s_zlB0qFdik4pgQi0A"
      decimals="INF"
      id="Tc_hAUVD23pbEaTv4S-ue-KpA_29_13"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">27383483</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F487s_zlB0qFdik4pgQi0A"
      decimals="-3"
      id="Tc_WWAEmvcT2ECpkGH0XIrrZw_29_16"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JCLAhxpWfUK_BCMc8Crq6w"
      decimals="INF"
      id="Tc_lnLVeOBXxEWHY5NxBGsg1g_29_18"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JCLAhxpWfUK_BCMc8Crq6w"
      decimals="-3"
      id="Tc_wAtrAyMTaU-ejkBT8DwIXw_29_21"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3N0JhOmgVUmYfBmky7vmOQ"
      decimals="-3"
      id="Tc_dbUaaG8dxEig34APB4gmaw_29_24"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">317135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OfuYA2C3xke_bo6pMP4VvA"
      decimals="-3"
      id="Tc_lvkUzAcPqE2zGIDnAjcHCw_29_27"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-4780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lmHisS_hEGTk6TeU1vfOw"
      decimals="-3"
      id="Tc_dvigMDJHYUiTeieVO51qOQ_29_30"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-222766000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_30qjEG7VF02yVqhSJBL5Zg_29_33"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">89592000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_DhRW-EfZzkah3Jit7mqfEw_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75665000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_KruL7vdYtE2745s6iJGu3Q_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44082000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_4yPkTRNMFEyt3A_3LCSFuA_4_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43037000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_Sa77FGvbnEG3sd5kp7-Yow_6_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7644000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_4mwNHFqY6UuoUEZ3vLYGdw_6_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8657000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_mg3olR1wlkmF2T7aWW9PGA_6_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5565000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_B8_Sqjex4EOBZhMgH4BZdA_7_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4640000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_cFbVJ9bucU-G8B2atQtQJA_7_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4150000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_Mo0QO5Sys0mSsttUr6Ahlg_7_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3067000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_SiOVACef8E6Mg4gXtSh13A_8_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1226000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_uiFVoR0nTEG16PkdDEm91A_8_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-53000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_LhptCu5PpkajjZug72t-Ow_8_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-52000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_076vrEVubEK2ww7ekjJ3Kg_10_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1943000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_SGNobUFcH02TypYDda6LAA_10_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3576000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_F1-Fv6ISxk-mHfHYHsiuGQ_10_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3619000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <hook:IncreaseDecreaseInReceivableResearchIncentives
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_riSW7ULl7kCHEwT-lzKT3A_11_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">295000</hook:IncreaseDecreaseInReceivableResearchIncentives>
    <hook:IncreaseDecreaseInReceivableResearchIncentives
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_ZCpTxPsAFkuQ_jjsxbXlZQ_11_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5825000</hook:IncreaseDecreaseInReceivableResearchIncentives>
    <hook:IncreaseDecreaseInReceivableResearchIncentives
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_5DqfKqzV6EGh5KZV05Z6zw_11_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5892000</hook:IncreaseDecreaseInReceivableResearchIncentives>
    <hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_N2RpN5Oc0kSEG9UmBQF43w_12_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7091000</hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_yY4NvxRcLECWfAaHNUfCuQ_12_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2286000</hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_5jgCp6lQ1kO6PxtxcoHSXA_12_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">113000</hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_lO_IMA_Rj0WJPH4WMr3sPA_13_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-416000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_GKcmm1W0B02OTqg7qvLyvQ_13_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1080000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_zTAOondAgkW42auvI6Yw-A_13_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-869000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_a4DLX4X_QE-sB64ph5wCrA_14_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">858000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_aRFwyCF5fEWHZWJjHmmjNA_14_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6298000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_ObKwCn-1tkuqcVVwHVbPNQ_14_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4203000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_S3f3nTJB90CBM0qY9s_XvQ_15_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1422000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_Kq2XmuN7cEWfq-C6QrBLpw_15_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">511000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_mNoi3zGWbEe4vmAAYmzISA_15_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-4442000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_-q7kXQrXV0OYPxblPgmyDw_16_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1588000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_jBZBL8cWRUSLEy30JTfUfw_16_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1833000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_zfVVJIhC20yPqbK6rK9rXA_16_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-2396000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_gj0peIBvVEqY1tgsA8zX2w_17_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4776000</hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities>
    <hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_K_xRddsiVEe7yYUL7ta0Kw_17_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-184000</hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities>
    <hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_yBTbCGObk0GolD77NWV0yw_17_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5142000</hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_rGgRy7LwREeRrLXezQL0tA_18_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-416000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_JYPO3DNLpUqtTP3X7osADg_18_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-142000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_qCDbEaQ3EUGb2Sat-kWevg_18_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1130000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_ryaZi627k06wa-I9VvunLA_19_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-66016000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_HogHOr8TkUCak3A40_eSfA_19_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-39339000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_D43f8J-aAU-E56oYw-d8VQ_19_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-41731000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_-JCYcCuDiEWkaKZu_7UlyA_22_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">12581000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_zJKfKJ4PRk-SOxe-VQo_QQ_22_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2371000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_6YXEGe3xiUGeZx_4YYsyuQ_22_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1999000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_iNKVFonYyU6KIFVSu807dw_24_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-12581000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_Xu2lSVOnMUK-Ed_VPOGmKQ_24_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-2371000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_K0fkJKHLqUmXAPQ7miUEMw_24_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1999000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_3n2HotDI6ESinT1G5YdloQ_27_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">438000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc__uTYWFidGkmOc4Gyg31N_g_27_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">108000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_3yaSzPMvekaipRqMeK0i7w_27_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1437000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_oT6EGmdRBUmA5liPuioIdQ_28_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">37274000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_1rMbFCCZnkmSw5-m6zE9GA_29_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">32426000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_fdd5VGM0GUi7kjsJ8IShBg_30_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">203000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_AUAIo1ntw0aXwd9ACDQ6wQ_30_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">42637000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc__XiUXKJurEyE2xJ3OVlLyA_30_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">74756000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_SjFSgk4kSkqImxIOr6sz_w_31_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">224000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_Jb9fHGoF6E-RI2LNFE_L8Q_32_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1311000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_APEUdjUPOEWJpZCvvMl8hw_32_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">842000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_7PXTH65h9USbCQ8FZ9kj7w_34_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-235000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_Yeicr4hMnUSphNM0HbLxJQ_34_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">73420000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_8HY_M0DeqUWimp-lu5CYbg_34_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">109751000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_QA1GAjYn7EChj9aX4XN_Ww_36_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-78832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_fw8M4vAU_E21_wx68ji_Fw_36_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">31710000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_DsbdmYNcD0ytN7ZbW3zLmA_36_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">66021000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_MRzWFj6nmka5bx2THYHTXw_38_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">143177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w"
      decimals="-3"
      id="Tc_FfHzJ8DTU0K0zIcG8cOzLw_38_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">113575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg"
      decimals="-3"
      id="Tc_Q8vF15AhWU-WRLCtVP5_eA_38_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">48580000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_0l6NvgoTSUuVZSBak2RDyg_39_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2567000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_XY9oEkGvuUuRJtJAeZluKw_39_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-2108000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_0Z-m3XtEgkyllfTdhzUYOQ_39_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1026000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_t5GP6ycBp026pBmuxAwOGQ_40_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">66912000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_DWL3aa7mXEakylSIbp-R7w_40_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">143177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w"
      decimals="-3"
      id="Tc_6-mucJ9L8E22swm0VUL4Og_40_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">113575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_GimL7VVoiEGcxcw9INFYpA_43_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">48000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_FhCtpQvYwkaYndGdsW6ODQ_43_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">97000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_LLUKttluHEKGVOz8BHtSEA_43_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">64000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_zI_WDLoEY0ynytBE5pEazg_44_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_0Lhb4B0EQ0u4Rd-PKFZEJg_44_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_gC-qm14oWk2Ichp-YIq6SA_47_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">142048000</us-gaap:ConversionOfStockAmountConverted1>
    <hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_fwCv4-Yc7kSW0Z6XPn496Q_48_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">742000</hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses>
    <hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_i3l2KaJAdEyxuDhoeDcT7w_48_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-16000</hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses>
    <hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_q9mmpOya6UC6ZQgi7mRPMw_48_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10000</hook:PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_QRf_kQyXBUSAW7Xq2FZ00g_49_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2727000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_ksVO0lw0lE2G-RvDF2lhNg_49_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">12000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <hook:LeaseAssetsDerecognizedUponLeaseCancellation
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_dVr_FSpb_UKF5-zCLD0dGw_50_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1061000</hook:LeaseAssetsDerecognizedUponLeaseCancellation>
    <hook:LeaseAssetsDerecognizedUponLeaseCancellation
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_toDuKhuxLUi45DiMh6rPdQ_50_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">30000</hook:LeaseAssetsDerecognizedUponLeaseCancellation>
    <hook:LeaseAssetsDerecognizedUponLeaseCancellation
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_aGLWpgRT8UuGPeEos6On_g_50_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">182000</hook:LeaseAssetsDerecognizedUponLeaseCancellation>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_NobjkpUSekWNzVjVnhsi5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;Nature of the business and organization&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;HOOKIPA Pharma&#160;Inc. (&#x201c;HOOKIPA&#x201d; or the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body&#x2019;s immune system.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company was incorporated under the name of Hookipa Biotech,&#160;Inc. under the laws of the State of Delaware in February&#160;2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, the Company changed its name from Hookipa Biotech,&#160;Inc. to HOOKIPA Pharma&#160;Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April&#160;2019, the Company closed its initial public offering (&#x201c;IPO&#x201d;) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol &#x201c;HOOK&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company&#x2019;s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_O_vUcEdsBk6RvdvanGGDEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;Summary of significant accounting policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Going concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception, the Company&#x2019;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2021, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $75.7&#160;million, $44.1&#160;million and $43.0&#160;million for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. As of December&#160;31,&#160;2021, the Company had an accumulated deficit of $222.8&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;24,&#160;2022, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents, together with the net proceeds from the offering in March&#160;2022, and the funds received under the Restated Collaboration Agreement with Gilead, both described below, would be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will seek additional funding in order to reach its development and commercialization objectives. The Company will seek funds through further equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;11,&#160;2020, the World Health Organization designated COVID-19 as a global pandemic. The Company believes the extent of the COVID-19 pandemic&#x2019;s impact on the Company&#x2019;s business, results of operations and financial condition has been and will continue to be driven by many factors, most of which are beyond the Company&#x2019;s control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent the pandemic will impact its operations. The Company&#x2019;s accounting estimates and assumptions may change over time in response to COVID-19 and the change could be material in future periods. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency and currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Redeemable Convertible Preferred Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 the net proceeds from the Company&#x2019;s offerings have been deposited in interest-bearing bank accounts with investment grade U.S. financial institutions and have been partially invested in a money market fund. The money market fund, held in U.S. dollars, is primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the Company&#x2019;s cash and cash equivalents included smaller amounts of cash balances held in accounts with European banks at the Company&#x2019;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively, Gilead accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019 Gilead accounted for the majority of the Company&#x2019;s revenues. No other customers accounted for more than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020 cash equivalents consisted of money market funds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted the new leasing standards as of January&#160;1,&#160;2019. For leases with an initial term of 12&#160;months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#x201c;ROU&#x201d;) assets and lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#x2019;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#x201c;ASC&#x201d;)&#160;360.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Capitalized Software Development Cost&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of less than $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2021. No amortization expense associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2020 (see Note&#160;5). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31,&#160;2021, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition from contracts with customers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a collaboration and license agreement (the &#x201c;Gilead Agreement&#x201d;) with Gilead whereby the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#x201c;HBV&#x201d;) and the human immunodeficiency virus (&#x201c;HIV&#x201d;). The Company&#x2019;s performance obligations under the terms of this agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The licenses do not represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under this agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC&#160;606, the Company applies significant judgement to evaluate whether the obligations under the collaboration and licensing arrangement, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of when milestone payments are probable of being received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Upfront payment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The non-refundable upfront-payment received by the Company under the Gilead Agreement is recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reimbursement for services&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gilead Agreement, the Company incurs employee expenses as well as external costs for research and manufacturing activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangement, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues in the period in which the goods or services are received and external costs are recognized. Unpaid reimbursement amounts are presented as Accounts receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and development milestones&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Gilead Agreement includes contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;uncertainties and the required commitment from Gilead. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sales-based milestones and royalty payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gilead Agreement also includes certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cost to fulfill contracts&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are classified as research and development expenses and expensed as incurred due to the uncertainty about the recovery of the expenditure. Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Government grant agreements and research incentives&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes funding from grants and research incentives received from Austrian government agencies as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss and foreign currency translation adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments. For the years ended December&#160;31,&#160;2020 and 2019, comprehensive loss included $1.4&#160;million and $0.9&#160;million of foreign currency translation loss adjustments, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2021, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2021, the FASB issued ASU&#160;2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain disclosures when they have received government assistance and when they use a grant or contribution accounting model by analogy to other accounting guidance (e.g., a grant model under IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or ASC 958-605, Not-For-Profit Entities &#x2014; Revenue Recognition). Topic 832 requires the annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy of information about the nature of the transactions and the related accounting policy used to account for the transactions, the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, significant terms and conditions of the transactions, including commitments and contingencies. The guidance in ASU 2021-10 is effective for all entities for fiscal years beginning after December&#160;15,&#160;2021. Entities may apply the ASU&#x2019;s provisions either prospectively to all transactions within the scope of ASC 832 that are reflected in the financial statements as of the adoption date and all new transactions entered into after the date of adoption or retrospectively. Early adoption is permitted. The Company analyzed ASU 2021-10 and does not believe the guidance will have a material impact on its consolidated financial statements since the Company has already provided disclosures regarding Government Assistance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#x201c;own stock&#x201d; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_MgaBQXUznEmUuR7xqqzOcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <hook:GoingConcernPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_smTFUcNqckm88VBj-6GuYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Going concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception, the Company&#x2019;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2021, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $75.7&#160;million, $44.1&#160;million and $43.0&#160;million for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. As of December&#160;31,&#160;2021, the Company had an accumulated deficit of $222.8&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;24,&#160;2022, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents, together with the net proceeds from the offering in March&#160;2022, and the funds received under the Restated Collaboration Agreement with Gilead, both described below, would be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will seek additional funding in order to reach its development and commercialization objectives. The Company will seek funds through further equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;</hook:GoingConcernPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_q4SF1H_e4k2fiMEnv4VKyA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_0ZAj_QGhHEm_KNQnhwP6yg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr__dr_aBTyu0mTJnyQJrgfmw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_xdCf7PwGrEqlMQDRBdRj1A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-222800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_StuVcBnq30mVRSmuv69hSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;11,&#160;2020, the World Health Organization designated COVID-19 as a global pandemic. The Company believes the extent of the COVID-19 pandemic&#x2019;s impact on the Company&#x2019;s business, results of operations and financial condition has been and will continue to be driven by many factors, most of which are beyond the Company&#x2019;s control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent the pandemic will impact its operations. The Company&#x2019;s accounting estimates and assumptions may change over time in response to COVID-19 and the change could be material in future periods. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_yr2A-AAb2UGiQgXDyqxbdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency and currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Redeemable Convertible Preferred Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_UX5qvD-A20OjbhNIaP2qKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 the net proceeds from the Company&#x2019;s offerings have been deposited in interest-bearing bank accounts with investment grade U.S. financial institutions and have been partially invested in a money market fund. The money market fund, held in U.S. dollars, is primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the Company&#x2019;s cash and cash equivalents included smaller amounts of cash balances held in accounts with European banks at the Company&#x2019;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively, Gilead accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019 Gilead accounted for the majority of the Company&#x2019;s revenues. No other customers accounted for more than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_xGYgUBCpnkiod27JFa_qdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020 cash equivalents consisted of money market funds.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <hook:DeferredOfferingCostsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_4wPT5JfhM0CRePJnMaa8tw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</hook:DeferredOfferingCostsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_2z1DVlGInE67tl6HPhEIRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;4).&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_Jt-zq2SSXEmv5wqzyZXnoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_8UkNQJeqjE2lW5yH5YkcMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__YrrPJBfXEKiNjwR_7k7OA"
      id="Narr_TKcN8z0yR06dkohgKi4IoQ">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NyQzVSOZCUW4XmIPhFet_A"
      id="Narr_A82YiNNnf0mxrr6x-l0gLQ">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4BwGZSWxKES82uxhJw-yBA"
      id="Narr_KzyhWZDzekKE_vyeq1hj6Q">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_qytkKxk8CEm7bN6P8U8VzA"
      id="Narr_Mym7M1GQk0O85XI_05eWDQ">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_RnEWI9I70EeTbY-Xi8vklA"
      id="Narr_ICxeW2m8AkiKXcXXv9_1pg">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_ANXP3tESvE-8MHgi_Ck3uQ"
      id="Narr_wggnkiP05EeRE5S2JV0Ssw">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_O_0qV1LiI0ys84CHmciE5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted the new leasing standards as of January&#160;1,&#160;2019. For leases with an initial term of 12&#160;months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#x201c;ROU&#x201d;) assets and lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#x2019;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#x201c;ASC&#x201d;)&#160;360.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_V_qNqQwHukaGFMqWyiv-yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Capitalized Software Development Cost&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of less than $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2021. No amortization expense associated with the Company's cloud computing arrangements has been recognized during the fiscal year ended December&#160;31,&#160;2020 (see Note&#160;5). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA"
      decimals="-5"
      id="Narr_GinHQi6wWUe-vwKqsokFXg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">100000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_atmuR86F4EeXElRDG4Yv4A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_8PA0Tq4Prkm-_MAO-oSElw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31,&#160;2021, 2020 and 2019.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_0VZ2sm155kWO7TZFDbWSsw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_1oLPj02TwUmVv6v4dQga-Q"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_Hd6MGJYyvU-aeYO-PVqNyw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_AidEhkPxKkeA4giyw_07Yw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_P03SVtzUS0Km5vLOql7PlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition from contracts with customers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a collaboration and license agreement (the &#x201c;Gilead Agreement&#x201d;) with Gilead whereby the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#x201c;HBV&#x201d;) and the human immunodeficiency virus (&#x201c;HIV&#x201d;). The Company&#x2019;s performance obligations under the terms of this agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The licenses do not represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under this agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC&#160;606, the Company applies significant judgement to evaluate whether the obligations under the collaboration and licensing arrangement, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of when milestone payments are probable of being received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Upfront payment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The non-refundable upfront-payment received by the Company under the Gilead Agreement is recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reimbursement for services&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gilead Agreement, the Company incurs employee expenses as well as external costs for research and manufacturing activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangement, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues in the period in which the goods or services are received and external costs are recognized. Unpaid reimbursement amounts are presented as Accounts receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and development milestones&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Gilead Agreement includes contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;uncertainties and the required commitment from Gilead. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sales-based milestones and royalty payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gilead Agreement also includes certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cost to fulfill contracts&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Narr_cR9Rf11QYUuMbQYL1LIu0Q"
      unitRef="Unit_Standard_Program_p93h6a_140eCP-r_hTy6gg">2</hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms>
    <hook:NumberOfCombinedPerformanceObligationForEachResearchProgram
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Narr_uKaMxs3KCk6Rl46uzP1ZHA"
      unitRef="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA">1</hook:NumberOfCombinedPerformanceObligationForEachResearchProgram>
    <hook:NumberOfResearchProgramPerformanceObligations
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Narr_abS2WV7oIky4PyIkaRD8NQ"
      unitRef="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA">2</hook:NumberOfResearchProgramPerformanceObligations>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_Sz0qG0yZq0i2k3x937Pdew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are classified as research and development expenses and expensed as incurred due to the uncertainty about the recovery of the expenditure. Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <hook:ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_DCTwM5t0V02FgBXm2eB8UA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;</hook:ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock>
    <hook:GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_sBgFN150ZUCkTspwv2fD4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Government grant agreements and research incentives&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes funding from grants and research incentives received from Austrian government agencies as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.&lt;/p&gt;</hook:GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_8NQ3nwHXlUS2RF7zHm8_Ag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_jwL8GMSjmkGpPUOCAGtUaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss and foreign currency translation adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments. For the years ended December&#160;31,&#160;2020 and 2019, comprehensive loss included $1.4&#160;million and $0.9&#160;million of foreign currency translation loss adjustments, respectively.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_aJ9uS3t3H0aK92YMNIuGkw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1300000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_ifdFyeFMd0e0HYTCRlFh9A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-1400000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_dk346pk7YUWfOng36G2fYQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-900000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <hook:EarningsPerSharePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_6_t3viUH80KvH2P8evpG4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2021, 2020 and 2019.&lt;/p&gt;</hook:EarningsPerSharePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_gtX4G3xp7EenNuJtv6kD7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_ymyjoCtbHUSJe-aQFkjukg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2021, the FASB issued ASU&#160;2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain disclosures when they have received government assistance and when they use a grant or contribution accounting model by analogy to other accounting guidance (e.g., a grant model under IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or ASC 958-605, Not-For-Profit Entities &#x2014; Revenue Recognition). Topic 832 requires the annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy of information about the nature of the transactions and the related accounting policy used to account for the transactions, the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, significant terms and conditions of the transactions, including commitments and contingencies. The guidance in ASU 2021-10 is effective for all entities for fiscal years beginning after December&#160;15,&#160;2021. Entities may apply the ASU&#x2019;s provisions either prospectively to all transactions within the scope of ASC 832 that are reflected in the financial statements as of the adoption date and all new transactions entered into after the date of adoption or retrospectively. Early adoption is permitted. The Company analyzed ASU 2021-10 and does not believe the guidance will have a material impact on its consolidated financial statements since the Company has already provided disclosures regarding Government Assistance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#x201c;own stock&#x201d; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_dJxBSxpgBUCjGOyd0bTN1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Collaboration and Licensing Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Gilead Collaboration and License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2018, the Company entered into the Gilead Agreement whereby the Company and Gilead agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of HBV and HIV. In February&#160;2022, the Company signed an Amended and Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic (see Note&#160;17).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gilead Agreement, the Company granted Gilead an exclusive, royalty-bearing license to the Company&#x2019;s technology platforms. Upon entering into the agreement, the Company received a non-refundable $10.0&#160;million upfront payment from Gilead. Gilead is also obligated to make additional payments to the Company upon the achievement of pre-clinical, development and commercial milestones. The development milestones amount to over $300&#160;million. The commercial milestones amount to a total of $115&#160;million. Additionally, Gilead is obligated to pay royalties on net sales for each program. Payments from Gilead generally have a 60&#160;days payment term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The $10.0&#160;million upfront payment and $8.0&#160;million in milestone payments were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2021, $4.3&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current. As of December&#160;31,&#160;2020, $2.5&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current and non-current.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2021, $1.2&#160;million of cost reimbursements for research and development services were included as a liability in deferred revenues. As of December&#160;31,&#160;2020, $2.0&#160;million of cost reimbursements for research and development services were included as a liability in deferred revenues. Reimbursements for external costs are recognized as revenues in the period in which the services are provided and external costs are recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In the year ended December&#160;31,&#160;2021, the Company recognized $0.6&#160;million of the upfront payment received in 2018 and $1.5&#160;million of a $4.0&#160;million milestone payment received in 2020. Furthermore, the Company recognized $16.3&#160;million revenue from cost reimbursements for research and development services, of which $2.2&#160;million were initially recorded as deferred revenue in the consolidated balance sheet. No revenue has yet been recognized for another $4.0&#160;million milestone payment that was recorded as deferred revenue in December 2021. For the year ended December&#160;31,&#160;2020, revenue from reimbursement of research and development expenses was $13.0&#160;million, of which $1.1&#160;million were initially recorded as deferred revenue in the consolidated balance sheet. Furthermore, the Company recognized $2.0&#160;million of the upfront payment of $10.0&#160;million received in 2018 and $2.4&#160;million of the $4.0&#160;million milestone payment received in 2020 as revenue. In addition, the Company fully recognized revenue for $2.2&#160;million milestone payments for milestones achieved in the year ended December&#160;31, 2020. For the year ended December&#160;31,&#160;2019, revenue from reimbursement of research and development expenses was $4.3&#160;million, and revenue &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;from partial recognition of the upfront payment of $10.0&#160;million received in 2018 was $4.4&#160;million. Additionally, the Company recognized $3.2&#160;million in milestone payments for milestones achieved in the year ended December&#160;31,&#160;2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, the contract asset and the liability relating to the sublicense payment was $0.3&#160;&lt;span style="-sec-ix-hidden:Hidden_l0XBTDSRf02Br1mMnKhitQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million&lt;/span&gt;&lt;/span&gt; and $0.1&#160;&lt;span style="-sec-ix-hidden:Hidden_0ppv5nVtqUW_59qTfEqsxA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <hook:NumberOfPreclinicalResearchPrograms
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw"
      decimals="INF"
      id="Narr_eYkXYJQDuUKEtYBMHTbpeg"
      unitRef="Unit_Standard_item_RvabO_H730ypKSeYkyGVcA">2</hook:NumberOfPreclinicalResearchPrograms>
    <hook:ProceedsFromNonRefundableUpFrontPayment
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw"
      decimals="-5"
      id="Narr_0D9pfCaKVU6BkEslnUrkxw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10000000.0</hook:ProceedsFromNonRefundableUpFrontPayment>
    <hook:TotalMilestoneAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_Xf3pHxRC4UOPsU0Tyuw4UQ"
      decimals="-6"
      id="Narr_19IdLksEgES3b47GRQgi6Q"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">300000000</hook:TotalMilestoneAmount>
    <hook:TotalMilestoneAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7WLlmoedJEi4B7q-431RSw"
      decimals="-6"
      id="Narr_IOtidBmko0W4e8EXnBWVRA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">115000000</hook:TotalMilestoneAmount>
    <hook:CollaborativeArrangementTermOfRoyaltyPayment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg"
      id="Narr_rheIe1TrZESAMZgF94k6Ag">P60D</hook:CollaborativeArrangementTermOfRoyaltyPayment>
    <hook:ProceedsFromNonRefundableUpFrontPayment
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw"
      decimals="-5"
      id="Narr_otVdMLofvUW8b-iOvfjEtQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10000000.0</hook:ProceedsFromNonRefundableUpFrontPayment>
    <hook:ProceedsFromMilestonePayment
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw"
      decimals="-5"
      id="Narr_Psfc1V5wZEeUzMGZsvO2JQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8000000.0</hook:ProceedsFromMilestonePayment>
    <hook:DeferredRevenuesUpfrontAndMilestonePayments
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA"
      decimals="-5"
      id="Narr_gGfDjytLoEupOuw4RMtPfQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4300000</hook:DeferredRevenuesUpfrontAndMilestonePayments>
    <hook:DeferredRevenuesUpfrontAndMilestonePayments
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw"
      decimals="-5"
      id="Narr_leNoNAIXbEuQ7CEaNbyhfQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2500000</hook:DeferredRevenuesUpfrontAndMilestonePayments>
    <hook:DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA"
      decimals="-5"
      id="Narr_AFKat8oCT0CAHsexRsNDVA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1200000</hook:DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices>
    <hook:DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw"
      decimals="-5"
      id="Narr_FX-lDfI31EOgxtyf83KcaQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2000000.0</hook:DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices>
    <hook:RevenueRecognizedUpfrontPayment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg"
      decimals="-5"
      id="Narr_IAxr9E28LU2vNMSvEQ9qSg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">600000</hook:RevenueRecognizedUpfrontPayment>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsOneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_X8z0GhjTXEaCy2ODr2m1sQ"
      decimals="-5"
      id="Narr_XhVijxvKDUyirzVod4dkNQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1500000</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:ProceedsFromMilestonePayment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr_JpwZRda320K9D9kaYKZsUw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4000000.0</hook:ProceedsFromMilestonePayment>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg"
      decimals="-5"
      id="Narr_ow3gvham7kOXx_HRIKCoMg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16300000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0ptuopdoQUesOSTjmghjhg"
      decimals="-5"
      id="Narr_qWlvhtN04EeVS3VsOeNagQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2200000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_hook_MilestoneAxis_hook_MilestonePaymentsTwoMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4hozc3IA_UemHLG5L4Tssg"
      decimals="-5"
      id="Narr_hEC4a4dIC0qkCFtz--0KtQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:DeferredRevenuesMilestonePayments
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA"
      decimals="-5"
      id="Narr_TjNIH96pEE2jTs2w8_472Q"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4000000.0</hook:DeferredRevenuesMilestonePayments>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr_pZgI4XXjNEeEi-VfzQ_n0g"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">13000000.0</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr_79Kgb-8uc0a6hE-86hILoQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1100000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue>
    <hook:ProceedsFromNonRefundableUpFrontPayment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr__bpXzPJgokSDSn7RWJChYg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2000000.0</hook:ProceedsFromNonRefundableUpFrontPayment>
    <hook:RevenueRecognizedUpfrontPayment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr_6Xrie4Af2Ue_xJnIERZ7jw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10000000.0</hook:RevenueRecognizedUpfrontPayment>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr_BTXxhdFSPUaldd3zgkFxPA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2400000</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:ProceedsFromMilestonePayment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr_hTrta8U-cU2f4Gy1kHwAGw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4000000.0</hook:ProceedsFromMilestonePayment>
    <hook:CollaborativeArrangementRevenueFromMilestonePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_FfBLyV2CFkKpXGoMV5GbmQ"
      decimals="-5"
      id="Narr_qMAwxLeyu0y9WHNXogoO5g"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2200000</hook:CollaborativeArrangementRevenueFromMilestonePayments>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ"
      decimals="-5"
      id="Narr_Se6NDYDDGEyeNQM-YICntw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4300000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices>
    <hook:RevenueRecognizedUpfrontPayment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ"
      decimals="-5"
      id="Narr_-i5b0CKSZUCtTL19FHBAAg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10000000.0</hook:RevenueRecognizedUpfrontPayment>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_kRKK4hhFqUmimB34ezmG7Q"
      decimals="-5"
      id="Narr_NXBHuCz5vEmAhrSD8Pg1GQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4400000</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:CollaborativeArrangementRevenueFromMilestonePayments
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tgrdVXPiLESVTTwQiGHBlQ"
      decimals="-5"
      id="Narr_iCYiOYFUEk-t8nYQGayf1Q"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3200000</hook:CollaborativeArrangementRevenueFromMilestonePayments>
    <hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_M4WTlrtYe0yH9LlFxeSWFA"
      decimals="-5"
      id="Narr_E5mgZEaTDkmGr4ofVR4unA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">300000</hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_eR2iZPyn1kipN-DiMGNnqw"
      decimals="-5"
      id="Narr_f4aeGS59-06fz5qMpfopPg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">100000</hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_m-ijQPNgJ0q3k8mQJVRj4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;Fair Value of Financial Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2021 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2020 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;During the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Ig22UHVZRkKGX2x0KG_1_A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; ended &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_ilfqJ_zyb0aZGfg-9XrTsA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;December&#160;31,&#160;2021&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, there were &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; transfers between Level&#160;1, Level&#160;2 and Level&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_yp-p9Vk_-kOWrEU_xREtbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Group_xULbqDTXFE-5L6h5SLDzRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2021 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2020 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OLb_2bn0qEy2UW_m4JwHoA"
      decimals="-3"
      id="Tc_BRC26Bwz9k2BoeQb8vkH9Q_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35403000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHJvZ8_EJ0OzSnSQBM0_6A"
      decimals="-3"
      id="Tc_nCv9Qa78WkCHIyELvNufhQ_4_12"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35403000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0cA_3wN87kC_T3pK3UXc2w"
      decimals="-3"
      id="Tc_cmSqxyv42EOcOwEagF2GpQ_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DNp-TcR4d0uu2uDNfHmJLg"
      decimals="-3"
      id="Tc_N4Ej_mePt0eQ1QEC1rxX0w_5_12"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ld1bC-KnG0yjbLLvZcbh9Q"
      decimals="-3"
      id="Tc_pz6S730AnkKUS4mn81cOxw_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35397000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U3zEzG1qXkK9lJ83V5wUyQ"
      decimals="-3"
      id="Tc_Fci7b1IpA0W5pyQeVIzrfQ_4_12"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35397000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Hi8vNfG0OketOKVTNEWdKg"
      decimals="-3"
      id="Tc_7Z1ZPNwV7UWFMmJjp2DbMg_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35397000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3LNaEjX6U06CsywOTygF8Q"
      decimals="-3"
      id="Tc_W6voE-_XP0yUF_-6iybv0w_5_12"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35397000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Narr_iOAiQtdDx0yKD8KIev0uBw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_JTMsB8Xf8kOlLgaT7sljtw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Property, plant and equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Property, plant and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,982&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,366)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,097)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Depreciation expense for the years ended December&#160;31,&#160;2021, 2020 and 2019 was $2.1&#160;million, $1.7&#160;million and $1.1&#160;million, respectively. Construction-in-progress as of December&#160;31,&#160;2021 related to investments in connection with the Company&#x2019;s GMP manufacturing facility project. Construction-in-progress as of December&#160;31,&#160;2020 related to implementation costs for a cloud computing arrangement which is a service contract.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_yOScjkf45UG26Oo0tKRv6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Property, plant and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,982&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,366)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,097)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_zjRiqY7na0mdESnAmAgN5Q"
      decimals="-3"
      id="Tc_my05pBGDBEmas4lyOYcWnw_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2072000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oM1lWRGbvEiE-FT3XrMDcw"
      decimals="-3"
      id="Tc_5qwb9h73x02A22QCK-a24Q_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3348000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j9QTccxA8kSS8q3279Cm-g"
      decimals="-3"
      id="Tc_0HVxQjyCjUqY73BnJYS14A_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3322000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_p1qmf6wjLk6uR_JhX4mV2w"
      decimals="-3"
      id="Tc_8TebJHZqy0e3J7jUz-cgrQ_6_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7746000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_B5fIRUIsikiF5KXD5x6cHA"
      decimals="-3"
      id="Tc_qS5ZQD712kOb7uap_zXA6g_6_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">28000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kZ2Gy961l0-3UxadFPp3yw"
      decimals="-3"
      id="Tc_CY-gy6Zcz0S8JiBUOgXu7w_7_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7025000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mmAIdyTOBEGGYm394Dfgdg"
      decimals="-3"
      id="Tc_6Iy8VNEjW0q1lLLSoSn7XA_7_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5982000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_h3bbPTbCck67We_5POyRoQ"
      decimals="-3"
      id="Tc_KGF3RFGRSU6bUJ0x2HGOTA_8_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">651000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_7otYFkeHoUKeaKz76AWKEA"
      decimals="-3"
      id="Tc_NqzF40QFrkaThwkHWhAXZw_8_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_03RMuix68kaDY62cZtc7HQ"
      decimals="-3"
      id="Tc_HqSlVH5ndkSn9PVB4M5EdA_9_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Ft-tF1iTN0Gyv_gaYiFXZg"
      decimals="-3"
      id="Tc_dtGOaaEGzEid7b9Be5FwQQ_9_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1554000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_GshhRIlgBE-BBuB_6DMGig_10_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">22718000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_Kv124O4tvUyLIAqIU8HhkA_10_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">11316000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_ZZ3tN50wYU-pTNluZIETOw_11_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6366000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_HWgusHq39UOKN70jHygg0A_11_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5097000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_L5rbciMCjk6ximB6VO7cGg_12_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16352000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_IT4CyRtTuE60E-LAuJkSYw_12_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6219000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_tujc6h8vWU6c5EGAAU8l7Q"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_qSzs0GaB4kij7gDc2zz_mg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_6ZbcglxPDEKyKs-p9j4MBA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1100000</us-gaap:Depreciation>
    <hook:ReceivableResearchIncentiveTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_vwkZEq0UA0iOsY_66C5_Hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6.&#160;Receivable research incentive&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company participates in a research incentive program provided by the Austrian government under which it is entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority. Reimbursements received in excess of the recognized receivable research incentive for a certain period are recorded within other long term liabilities for potential repayment until such time that an audit has taken place, upon expiration of the potential reclaim period, or when it is no longer probable that a reclaim will happen. The years 2018 to present remain open to examination by the authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2021, the Company recognized receivables of $14.3&#160;million from the research incentive program, which are reported in research incentive receivables in the Company&#x2019;s consolidated balance sheet. As of December&#160;31,&#160;2020, the receivables from the research incentive program were $15.1&#160;million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded $8.9&#160;million, $5.8&#160;million and $5.9&#160;million, respectively, of income related to the incentive program within the Company&#x2019;s consolidated statements of operations as part of the grant income.&lt;/p&gt;</hook:ReceivableResearchIncentiveTextBlock>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_dNOWAGIdO0KQOpuBiAKySw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">14300000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-5"
      id="Narr_U_gJb3IvK0-v4toMAGjoCw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">15100000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_zHAlf82x9EqkOmyW6AXKUA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8900000</hook:GrantIncomeIncentiveProgram>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_JhZYQ5m1QE6APq9Al0pCzw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5800000</hook:GrantIncomeIncentiveProgram>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_L4XHPUiAuk6eTcIM52cuaA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5900000</hook:GrantIncomeIncentiveProgram>
    <hook:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_Tkk-oSQXXkamZDwFivRHLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases real estate, including office and laboratory space and has entered into various other agreements with respect to assets used in conducting its business. The Company&#x2019;s leases have remaining lease terms ranging from less than 1&#160;year to 4&#160;years. Some of the lease agreements contain rent holidays and rent escalation clauses that were included in the calculation of the right of use assets and lease liabilities. The Company is required to maintain a cash balance of $0.4&#160;million to secure letters of credit associated with real estate leases. This amount was classified as non-current restricted cash in the consolidated balance sheet as of December&#160;31,&#160;&lt;span style="white-space:pre-wrap;"&gt;2021.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Certain of the Company&#x2019;s leases qualify as operating leases, and certain of its leases qualify as finance leases. The following table summarizes the presentation in the consolidated balance sheets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;sheet&#160;location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current finance lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_oRmXSROYc0OcSjQ6MQGWpg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,703&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,153&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current finance lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qGfyuLYvk0GVroGAArA9Ww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-current lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In the years ended December&#160;31,&#160;2021 and 2020 the Company terminated leases of parking spaces and derecognized the relating right of use asset and the lease liability which were insignificant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the effect of lease costs in the Company&#x2019;s consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income&#160;statement&#160;location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,910&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest on finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expense)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (155)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average remaining lease term and weighted average discount rate of finance leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December&#160;2021 the Company extended the lease term of existing operating leases for the office and laboratory space in Vienna, Austria. The respective lease liabilities were remeasured and the amounts resulting from the remeasurement of the lease liability were recognized as an adjustment to the corresponding right of use asset. Also in December&#160;2021, the Company reduced the lease term for existing operating and finance leases related to an agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;with a contract manufacturing organization for the production of clinical trial material and accounted for the proportionate decrease in the lease liability and the right of use asset with the difference recognized as a loss of $1.0&#160;million on lease modification in operating research and development expenses on the income statement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Until March&#160;2021, the Company subleased certain of its leased real estate that it did not utilize to a third party. The sublease was qualified as an operating lease. The Company recognized sublease income in its consolidated statements of operations and comprehensive loss. The sublease had no influence on the Company&#x2019;s accounting for the head lease.&lt;/p&gt;</hook:LeaseDisclosureTextBlock>
    <hook:LesseeLeaseRemainingTermOfContract
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ilxWs-hFzUu1oK7UGRu04Q"
      id="Narr_EszXiXf95k2vWCqsh_BsVA">P1Y</hook:LesseeLeaseRemainingTermOfContract>
    <hook:LesseeLeaseRemainingTermOfContract
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA"
      id="Narr_nPo9irIVAUyDRSlm0ih2XA">P4Y</hook:LesseeLeaseRemainingTermOfContract>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_JLhukfkj6EyF25fX0pOyfw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">400000</us-gaap:RestrictedCashNoncurrent>
    <hook:ScheduleOfOperatingAndFinanceLeasesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_gNRCyLbspUKKQebGnGdKvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Certain of the Company&#x2019;s leases qualify as operating leases, and certain of its leases qualify as finance leases. The following table summarizes the presentation in the consolidated balance sheets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;sheet&#160;location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current finance lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_oRmXSROYc0OcSjQ6MQGWpg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,703&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,153&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current finance lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qGfyuLYvk0GVroGAArA9Ww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-current lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</hook:ScheduleOfOperatingAndFinanceLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_jyACD6av40aDkkdCs6XeyQ_4_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5673000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_htap-gkRfkG3TjxINz40eg_4_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6452000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_NKejLptzv0ykFsYiKBLHVQ_5_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">90000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_jZUflAotYk-KB6AU3_MmnA_5_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1298000</us-gaap:FinanceLeaseRightOfUseAsset>
    <hook:LeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_4cI_aEuH_ESDQHxiIaP6hA_6_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5763000</hook:LeaseRightOfUseAsset>
    <hook:LeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_0LfzRkW-R0aut6nRCoq0Zg_6_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7750000</hook:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_yHaAAhITTESo9te_OuNlmg_8_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1682000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_PF9YYDSCgU6u4_CaqVyLRQ_8_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_QhGPPbkpwkWu7RzYsWxdxw_9_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_I2_qmO1THEqHGFPD1twKnA_9_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">155000</us-gaap:FinanceLeaseLiabilityCurrent>
    <hook:LeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_RfSYwIn8V0SdsPGYtRLTgQ_10_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1703000</hook:LeaseLiabilityCurrent>
    <hook:LeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_95VqjQ0kFECwMoXKPWsP5w_10_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2153000</hook:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_Jgpo4_hpt0m2pu9l7yT8zg_11_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3911000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_CZrOmO53WkKvuKyxB-QmAw_11_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3819000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_i_C4yTEoy0qfTEWvBryGww_12_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">258000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <hook:LeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_sFzciaZeZkWKs0wBl0m9Ow_13_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3911000</hook:LeaseLiabilityNoncurrent>
    <hook:LeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_EdEU9m18WEqUV18p-LQSUg_13_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4077000</hook:LeaseLiabilityNoncurrent>
    <hook:LeaseLiabilityTotal
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_0oUXyEFCbky5GnCynCpybg_14_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5614000</hook:LeaseLiabilityTotal>
    <hook:LeaseLiabilityTotal
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_JmghNCSdrUu-fpnWSlgb6A_14_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6230000</hook:LeaseLiabilityTotal>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_SOeqZRgQMEOTPxpVM9gp0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the effect of lease costs in the Company&#x2019;s consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income&#160;statement&#160;location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,910&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest on finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expense)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (155)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ"
      decimals="-3"
      id="Tc_h6ExScbGzkCtq_0wHPkGRA_3_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1910000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA"
      decimals="-3"
      id="Tc_DJo8XqFi8keeSDukjfop-w_3_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1654000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g"
      decimals="-3"
      id="Tc_6UkbMQaYN0GqwIHnrOlHCg_4_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">203000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w"
      decimals="-3"
      id="Tc_7pMJdPjFAk6yfLaLah-L7g_4_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">376000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ"
      decimals="-3"
      id="Tc_jy8rQp3-mE6rGZ8tGN5XXw_5_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">425000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA"
      decimals="-3"
      id="Tc_KHEjzrDhi0mXYn7xFYo-ew_5_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">395000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g"
      decimals="-3"
      id="Tc_vAv-IPozXU2yv48lUBGm3w_6_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w"
      decimals="-3"
      id="Tc_ZSXAnhbQDEWlvpWgTrIhtg_6_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_lfUPt9xHTECs1PBzglCNhg"
      decimals="-3"
      id="Tc_STfK_VLrAUuHf6x-lYCNtA_7_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_Ayr8wO2i8EqBHFydPDrBIw"
      decimals="-3"
      id="Tc_P9j2geKSIE2ByUmjOF-GUA_7_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_1-rISPKNH0inC5yV4XqosA"
      decimals="-3"
      id="Tc_itYmrbzS50yk3oSip2Igpg_8_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">40000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_iaIK2Z0eQUemaaWm5dk9Hw"
      decimals="-3"
      id="Tc_H6oEEB7QbUWM_8phBALCRQ_8_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">155000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_Bf2YmTBzr0Wx1uRcKdfWtg_9_5"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2510000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_cQDsPrCb_EWAOqlfmvFhnQ_9_8"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2299000</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_YbiTq7T9RUCBscxaaKFAGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_qdRP1J8bxkqEN70ap-Ukkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_PJX7TXWVQUma-3xO0mDvmw_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1585000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_L1zL58hghU-OjwFLsb9R-A_3_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_xLG21SXjI0WrXVOiPjiSAw_3_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1606000</hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_qxdP_cSsIUaSYWzy0GLYDQ_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1547000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_1Q3mVbdzukapbswOYpBehQ_4_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1547000</hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_gyh36sqJT0WZ3JcKCGA-SA_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1340000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_uPvo82g4X0iWW7GdOCIrNg_5_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1340000</hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_aIE9VKY9QkO4VSlR9lT1OQ_6_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_D_y8LUgiyEeSr2nyVetkuw_6_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1242000</hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_4-sA7mObpkOzc5rJTUwjzA_9_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5714000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_Gs8DTdc2_kCDuft_m2hMwA_9_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_6ZQ4ByyFM02kdYVQQNWWYw_9_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5735000</hook:LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_VNdncnANO0-wOO5YjNzuHA_10_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">121000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_rUXrEkp300qNVNQXYV_VsQ_10_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <hook:OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_0m3cf6Bsn0y1cxTLSr7isg_10_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">121000</hook:OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_7W3YpsJdVUWPXD3UeL3RwQ_11_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5593000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_rNRMMlWfdkStu_EIYPrTzw_11_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21000</us-gaap:FinanceLeaseLiability>
    <hook:OperatingAndFinanceLeaseLiability
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_Yjv-GacSWkW_EO9J-YFH3Q_11_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5614000</hook:OperatingAndFinanceLeaseLiability>
    <hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_QMRkltc3YUWBPFNEjWtmzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.&lt;/p&gt;</hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      id="Tc_ZNLqCW0z90-kwSQwonj8GA_3_2">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      id="Tc_b2N4ruMAN0SFJKOTWBXY_g_3_5">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="3"
      id="Tc_Gf1JdFy-8E-RdYslP-5Apw_4_2"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.013</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="3"
      id="Tc_FxTGsqZYHUu1KP-siUP4Ng_4_5"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.023</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_Ke5kzAM4uE6BzS9RDBsuXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average remaining lease term and weighted average discount rate of finance leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.&lt;/p&gt;</hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      id="Tc_-5k5KV_JMUuV7yUPwQ1RvQ_3_2">P0Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      id="Tc_dn1csC0k6Uyf1gFqRTbroA_3_5">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="3"
      id="Tc_WBCmw5PM_UGFFCOeQ3jOdA_4_2"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.004</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="3"
      id="Tc_BQSx1Fjl1kS08dfvDhMDrQ_4_5"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.017</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <hook:LeaseModificationLoss
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_FbkMEjEJl0WQtmJecOY1vw"
      decimals="-5"
      id="Narr_tgGpxFxLHkGWyJJhDoWeNg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1000000.0</hook:LeaseModificationLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_cislyinUjkqN-FMDxoiGqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;Accrued expenses and other current liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Salaries and bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Social security contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned grant income (current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 693&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 878&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublicense fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external general and administration expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 629&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 634&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued for property and equipment acquisitions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accruals and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_oq3n_ardDEmb9S1aztcOcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Salaries and bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Social security contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned grant income (current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 693&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 878&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublicense fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external general and administration expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 629&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 634&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued for property and equipment acquisitions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accruals and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_wDe8V82p70KeK29R73tWqA_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4754000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_fjNHea_0RECtWj9a2xcYJA_3_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4381000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <hook:AccruedSocialSecurityContributionsCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_lYg40UAyVki16b_TsAaSCw_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">250000</hook:AccruedSocialSecurityContributionsCurrent>
    <hook:AccruedSocialSecurityContributionsCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_27QD2vmy5k69qRGI4gzZDg_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">211000</hook:AccruedSocialSecurityContributionsCurrent>
    <hook:AccruedUnearnedGrantIncomeCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_JOzFl90zAkKSXoDG4NZcmA_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">693000</hook:AccruedUnearnedGrantIncomeCurrent>
    <hook:AccruedUnearnedGrantIncomeCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_fQlfZ6UZbUCFRgc4chfLew_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">878000</hook:AccruedUnearnedGrantIncomeCurrent>
    <hook:AccruedSubLicenseFees
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_oWNYTJUmCUuz1fbRKmefTA_6_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">304000</hook:AccruedSubLicenseFees>
    <hook:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_StGaxMC4sUarFq-Cr5kIvQ_7_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2165000</hook:AccruedExternalResearchAndDevelopmentExpenses>
    <hook:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_lqJShWScpEOa_ZuW1lAeow_7_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">895000</hook:AccruedExternalResearchAndDevelopmentExpenses>
    <hook:AccruedExternalGeneralAndAdministrationExpenses
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_lFdNXZGjhU28TYZaOrGQqw_8_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">629000</hook:AccruedExternalGeneralAndAdministrationExpenses>
    <hook:AccruedExternalGeneralAndAdministrationExpenses
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_d6LYNIzWzESxBqlArC3kVw_8_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">634000</hook:AccruedExternalGeneralAndAdministrationExpenses>
    <hook:AccruedExpensesForPropertyAndEquipmentAcquisitions
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_HRZWCPA-Ok2g6lnhZknYmg_9_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7000</hook:AccruedExpensesForPropertyAndEquipmentAcquisitions>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_jWRMN8ojRUGiyPHui6B6Vg_10_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">21000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_hdz5kqDxO0im4b2zUyvffw_10_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">155000</us-gaap:FinanceLeaseLiabilityCurrent>
    <hook:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_5LP8r5e4jEuRHMqhNESK5g_11_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">57000</hook:OtherAccruedExpensesAndLiabilitiesCurrent>
    <hook:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_lM8BvIEM00WTIcdCBTvDnw_11_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">232000</hook:OtherAccruedExpensesAndLiabilitiesCurrent>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_vb5xFTJww0qb3MB0QvL9kQ_12_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8880000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_gw54ffbFI02grW1Vex3GUg_12_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7386000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <hook:DisclosureOfLongTermLoansPayableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_Jyq2Wy3UdECpC9WSJ_rVOw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Loans payable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, loans payable consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Loans from FFG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,074&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,063)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,027)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Loans payable, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the funding agreements with the Austrian Research Promotion Agency, (&lt;i style="font-style:italic;"&gt;&#xd6;sterreichische Forschungsf&#xf6;rderungsgesellschaft, &lt;/i&gt;or &#x201c;FFG&#x201d;), the Company has received various loans (&#x201c;FFG Loans&#x201d;). The FFG Loans were made on a project-by-project basis. Amounts due under the FFG Loans bear interest at a rate of 0.75%&#160;per annum and mature at various dates between June&#160;2022 and March&#160;2024. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The FFG Loans bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between an estimated market rate of interest and the rate of interest charged by FFG as grant income from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as grant income over the term of the funding agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company recognized grant income of $0.8&#160;million, $0.7&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, related to the recognition of the unearned income recorded for the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;imputed benefit of FFG Loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG Loans at below-market interest rates was $0.7&#160;million and $0.9&#160;million as of December&#160;31,&#160;2021 and 2020, respectively, and unearned income (non-current) presented under loans payable non-current related to such benefit was $0.4&#160;million and $1.1&#160;million as of December&#160;31,&#160;2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company has recorded a discount to the carrying value of each FFG Loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of December&#160;31,&#160;2021 and 2020, the unamortized debt discount related to FFG Loans was $1.1&#160;million and $2.0&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized interest expense of $0.9&#160;million, $0.8&#160;million and $0.9&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, related to the FFG Loans, which included interest expense related to the amortization of debt discount of $0.8&#160;million, $0.7&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively. No principal payment and a principal payment of $1.3&#160;million was made in the years ended December&#160;31,&#160;2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses an estimated market rate of 20%, which was determined based on an average of the available interest rates on unsecured loans to comparable companies. A 10% increase or decrease in the estimated market rate of interest would have no material impact on grant income or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of the Company's assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2019, the Company agreed to an earlier repayment schedule for $3.3&#160;million of the outstanding loans with FFG. As a result of the change, the Company reduced the deferred income attributable to the imputed benefit from below market interest by $0.3&#160;million and increased the carrying value of the loans by the same amount. The change had no effect on the income of the year ended December&#160;31,&#160;2019 and the effect on the aggregate future cash flows under the loans is immaterial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December&#160;31,&#160;2021, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payments&#160;Due&#160;by&#160;Calendar&#160;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</hook:DisclosureOfLongTermLoansPayableTextBlock>
    <hook:DisclosureOfLongTermLoansPayableTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_JcAZGxeVfUqRd1iqZEYcwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, loans payable consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Loans from FFG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,074&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,063)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,027)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Loans payable, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</hook:DisclosureOfLongTermLoansPayableTableTextBlock>
    <hook:LongTermLoansPayableGross
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_J2ebBs717k2eDFB8rJ-rCA_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6074000</hook:LongTermLoansPayableGross>
    <hook:LongTermLoansPayableGross
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_ezvtkALsJEm-H5tqgpO9vw_3_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6564000</hook:LongTermLoansPayableGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_i_vL1s0d30STJPhlqkeCaQ_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1063000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_GZI9p6t5R023fCYW6aoIxg_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2027000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_x0lIaUAzx06Ok8eqU5HNCA_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5011000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_vT-cIZDoOUSX0ofkt2-cgw_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4537000</us-gaap:LongTermLoansPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="4"
      id="Narr_fedfuroZikeEnO0bD5LFLw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FgZEcu-x6ESzKZv_nwLtiw"
      decimals="-5"
      id="Narr_Dg90mXQLkEi_rbGMOVDVOA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_M7e0-G2Jc0mMZbDTVrVaQg"
      decimals="-5"
      id="Narr_vZnTBbbttEWQwAltXarxAA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_WVL2EC15ZUqXg0iRX6l96w"
      decimals="-5"
      id="Narr_1xw2Z9lmsUKYLTiWx9ETWw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_tyTRnlIXPUi1yW0nB28asw"
      decimals="-5"
      id="Narr_1rUnXJJeXki2lhLfUha71A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_VGIrjRmoLU2n3YXR5TnwLQ"
      decimals="-5"
      id="Narr_HGAVlmT0AUGDuBLR2n_bWA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_tyTRnlIXPUi1yW0nB28asw"
      decimals="-5"
      id="Narr_UGAXcez2F02_IW5n95dm3A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_VGIrjRmoLU2n3YXR5TnwLQ"
      decimals="-5"
      id="Narr_fFaSjUf7uE-soSyFC1X6vA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_0mR7nIdhC0iemdOtJ5QWpg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1100000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-5"
      id="Narr_IwHtVwf1kUmTCsV0nvgM1w"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2000000.0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_LTXqQzQV2kWL3ZqkFykLTA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_iKdmzKZUIUijWIUDiLDS4A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">800000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_fzZVSX6b9E26ARwCFpdLcg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_haWUF8gpYUKhyWnbk0CLig"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">800000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_ygKFaR9L20u0hfGtqzFLMA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">700000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_w0KZ71dGW0it-rqhQuJFnw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">800000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_S9826B1wj0K5tz1AcaO0Rg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_FMYCjlZKIU-e6H78TE2K3w"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1300000</us-gaap:RepaymentsOfDebt>
    <hook:DebtInstrumentEstimatedMarketRatePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_juA1yaHR0E2VF2Xjxtkk_Q"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.20</hook:DebtInstrumentEstimatedMarketRatePercent>
    <hook:IncreaseDecreaseInEstimatedMarketRate
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_bcWEQb3yZEOpXMrlAM69yA"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.10</hook:IncreaseDecreaseInEstimatedMarketRate>
    <hook:LongTermLoansEarlyRepayment
      contextRef="Duration_11_1_2019_To_11_30_2019_1iZi9iUIoEu0KQgEUiQByw"
      decimals="-5"
      id="Narr_kW3BW0vzY0aAli0IPSGSFg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3300000</hook:LongTermLoansEarlyRepayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_11_30_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_kFwGKKMO6U2oE6qi3AFdmw"
      decimals="-5"
      id="Narr_UwpQTXXHYEijqbAmLwj_fQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-300000</us-gaap:ContractWithCustomerLiability>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_NB8pQthc306Wczz4G4Si1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December&#160;31,&#160;2021, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payments&#160;Due&#160;by&#160;Calendar&#160;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_XFQEQ59cPECcbAmaX0XUQg_2_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3054000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_xZBIjWnhYE2rlooJxEDZrA_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1821000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_xMYKLMzkJ0auPJEr_qX8TQ_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1199000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_xVxFSM0C00mJE2NfNopc1A_8_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6074000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_RxT0UtfCjEGYZiysUEltkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Common stock, Class A common stock and convertible preferred stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s capital structure consists of common stock, Class A common stock and preferred stock. As of December&#160;31,&#160;2021, the Company was authorized to issue 100,000,000 shares of common stock, 3,900,000&#160;shares of Class&#160;A common stock and 10,000,000 shares of preferred stock. The Company has designated 2,978 of the 10,000,000 authorized shares of preferred stock as non-voting Series A convertible preferred stock. As of December&#160;31,&#160;2021, the Company had 27,383,483&#160;shares of &lt;span style="-sec-ix-hidden:Hidden_0vCtFWOMdU6TUe8bLbDs8w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;common stock&lt;/span&gt;&lt;/span&gt;, 3,819,732&#160;shares of &lt;span style="-sec-ix-hidden:Hidden_lsKpVaKZlU2VrubLnN7E_w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class&#160;A common stock&lt;/span&gt;&lt;/span&gt; and 1,697&#160;shares of preferred stock outstanding and &lt;span style="-sec-ix-hidden:Hidden_qvPF7Qsm3kquM23a168syQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On April 23, 2019, the Company closed its IPO of 6,000,000 shares of common stock, at an offering price to the public of $14.00 per share. The Company received net proceeds of $74.6 million, after deducting $9.4 million in underwriting discounts and commissions and offering expenses. Upon the closing of the Company&#x2019;s IPO all then outstanding shares of Preferred Stock converted into 14,582,161 shares of common stock and 3,819,732 shares of Class&#160;A common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On December&#160;11,&#160;2020, the Company closed a public offering of 3,910,000 shares of its common stock, which included the full exercise of the underwriters&#x2019; option to purchase additional shares and of 2,978&#160;shares of Series&#160;A convertible preferred stock at a public offering price of $11.75 and $11,750.00 per share, respectively, for net proceeds of $75.0&#160;million after deducting underwriting discounts and commissions and offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of Class A common stock and Series&#160;A convertible preferred stock are not entitled to vote, except as required by law. The holders of common stock and Class A common stock do not have any cumulative voting rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each holder of Class A common stock has the right to convert each share of Class A common stock into one share of common stock at such holder's election. Each holder of Series&#160;A convertible preferred stock has the right to convert each share of Series&#160;A convertible preferred stock into 1,000&#160;shares of common stock at any time at the holder&#x2019;s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series&#160;A preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Holders of common stock and Class&#160;A common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Holders of Series&#160;A preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of our common stock. Holders of common stock and Class&#160;A common stock have no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In the event of a liquidation, dissolution, or winding up of the Company, holders of our Series&#160;A preferred stock will receive a payment equal to $0.001 per share of Series A preferred stock before any proceeds are distributed to the holders of common stock. Then, holders of common stock and Class A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;There were 1,697 and 2,978 shares of Series&#160;A convertible preferred stock outstanding as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. In October&#160;2021 and December&#160;2021 certain of the Company&#x2019;s stockholders elected to convert an aggregate of 1,281 shares (55 and 1,226 shares, respectively) of Series A convertible preferred stock owned by such holders into an aggregate of 1,281,000 shares of the Company&#x2019;s common stock. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Narr__qBWwvtrzEuqzy5is342QA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="INF"
      id="Narr_CK-MMSNfYk-zepc4IUSWIg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3900000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Narr_50MjNT2fakqL7CNnc2_LrA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"
      decimals="INF"
      id="Narr_4iRG8wu76kajQ84EheeD8A"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Narr_YcFx596ymkW6fNzhroKxEg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Narr_XzZhVWdeV0ukG5uMrbmWyA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">27383483</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_g_Fog_YEAk6ckXqjJDDN0g"
      decimals="INF"
      id="Narr_8lRJTO8roE-8GuxZt78vfg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"
      decimals="INF"
      id="Narr_DblSBhd-b0mUSu9qjF69XA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1697</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ"
      decimals="INF"
      id="Narr_eO1pZ2CYFE6ZVkdJTEHN0A"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9-wYstNW-kqgqsk59PAAeQ"
      decimals="2"
      id="Narr_GZAiTQKEq0ObRhvtdMZjhw"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">14.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ"
      decimals="-5"
      id="Narr_Oi9QQOAmYUGRYaCkmfovQw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">74600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_br73MQ3iEkqJFq0tTFjzyQ"
      decimals="-5"
      id="Narr_X3B84qMGQ0yu29EGTJTawA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">9400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_NFEgg-7L7kKUdGMo__0AuA"
      decimals="INF"
      id="Narr_9FkvIEtEB0KdGdhLdGLHKA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">14582161</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_4_23_2019_To_4_23_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TievCB1XuUO1RkPCD7kOtQ"
      decimals="INF"
      id="Narr_CK56ZXYuf0CXVMIftAeVng"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3819732</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_11_2020_To_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_KcIuT04yhEWxmnluDeFr0w"
      decimals="INF"
      id="Narr_QqHUHpGlIkKSM_43JlvXPQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3910000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_DDij82CjqUCydxqkEFWIhg"
      decimals="INF"
      id="Narr_tgLQfNziZEed4rBdeReJHw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_YG3CoyW76UCnds2S4wKCbQ"
      decimals="2"
      id="Narr_7LVvDZSCcUCKOmVSG3d4Gg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.75</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_11_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_DDij82CjqUCydxqkEFWIhg"
      decimals="0"
      id="Narr_lGuKYG75LUa4gyzMOkDpQg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11750.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_12_11_2020_To_12_11_2020_lwzbDOodv0Si697Xzru_Bw"
      decimals="-5"
      id="Narr_RPR9Vq5StUieY7WGeUxMqQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">75000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <hook:NumberOfVotes
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_81IkXlL5YUulirFJyl_Pcg"
      decimals="INF"
      id="Narr_L-q1tJClMkeTRHjEKlZlOA"
      unitRef="Unit_Standard_Vote_t09LAWcUrk2_inHGi-A6Ng">1</hook:NumberOfVotes>
    <hook:ConversionOfStockCommonStockIssuedForEachShareConverted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_HNQ1RpgYeke7cwk7fsoeRA"
      decimals="INF"
      id="Narr_oPgGZHAvjEC8NVXxrMZ1Rg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1</hook:ConversionOfStockCommonStockIssuedForEachShareConverted>
    <hook:ConversionOfStockCommonStockIssuedForEachShareConverted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9NpKAk2xnE-XmHW-HPDY4w"
      decimals="INF"
      id="Narr_E8v3kTnbGU2DDEymfFymjw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1000</hook:ConversionOfStockCommonStockIssuedForEachShareConverted>
    <hook:ThresholdPercentageForConversion
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"
      decimals="4"
      id="Narr_4j_hLlFLa024xSPHKq7-lw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.0999</hook:ThresholdPercentageForConversion>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"
      decimals="INF"
      id="Narr_1xRhA9mHkEi6diGe1C8-UQ"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.001</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_9aNP2CzeRUi4SQzGml3M6Q"
      decimals="INF"
      id="Narr_AtQn4KkHR0-Q7UlxWlzU7w"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1697</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_5qWz93sGj0WS1IT2Rtijyg"
      decimals="INF"
      id="Narr_S9F_qSJwYES3DqcF73wDEA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2978</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_yxLDZPy_JkCTBy3vQ0rANw"
      decimals="INF"
      id="Narr_R7un5g52YE-iXs6lb-I6-A"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1281</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_hounmkd6wkGAMVpwq87DJQ"
      decimals="INF"
      id="Narr_6FHBRVvFRU2wwA-soTpbRg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">55</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_y8byg_XyWUKkNI6G_f1TrA"
      decimals="INF"
      id="Narr_30eT7ZrTJ06qWTbiG4Z9rA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1226</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_76blQDrh8EykPQMtShDiPw"
      decimals="INF"
      id="Narr_FKdwBpvIaEOrVwH_udo-GQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1281000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_jtQ7-7a4wE2IovdqtsDZ6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;2018 Stock Option and Grant Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In connection with a transaction between entities under common control by which the Company became the reporting entity in June&#160;2018, the Board of Directors approved the 2018 Stock Option and Grant Plan, by which options granted by the previous reporting entity under the 2016 Stock Option Plan and outstanding at the time of the effectiveness of the transaction were replaced at similar commercial terms. In the accompanying consolidated financial statements and notes, options issued under previous stock option plans and respective compensation expenses are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;retrospectively presented as if such options had been issued and outstanding under the 2018 Stock Option and Grant Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The exercise price for options granted as a replacement of the 2016 Stock Option Plan is the U.S. dollar equivalent of &#x20ac;0.09, except for 23,286 options granted to an US employee, for which the exercise price is $2.93 following a repricing of these options in December&#160;2018. For any new options, the exercise price shall not be less than 100% of the fair market value of the common stock on the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Options granted under the 2018 Stock Option and Grant Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. The options expire on the 10&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; anniversary of the grant date. As of December&#160;31,&#160;2021, 968,504&#160;options granted under the 2018 Stock Option and Grant Plan remained outstanding. Any authorization to issue new options under the 2018 Stock Option and Grant Plan was cancelled upon the effectiveness of the 2019 Stock Option and Incentive Plan and no further awards will be granted under the 2018 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;2019 Stock Option and Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;1,&#160;2019, the Company&#x2019;s stockholders approved the 2019 Stock Option and Incentive Plan, which became effective as of the effective date of the registration statement in connection with the Company&#x2019;s IPO. The plan provides for the grant of shares of restricted stock, long term incentive awards, stock options or other equity-based awards. The maximum number of shares of the Company&#x2019;s common stock that may be issued under the Company&#x2019;s 2019 Stock Option and Incentive Plan is 3,630,686&#160;shares which shall be cumulatively increased each year by up to 4.0% of the then outstanding number of shares. Options granted under the 2019 Stock Option and Incentive Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. Initial options granted to non-executive directors upon their election generally vest over a three-year term with 33% of the options vesting upon the first anniversary of the grant date and the remaining 67% of the options vesting in eight equal quarterly installments following the first anniversary of the grant date. Option re-grants to non-executive directors generally vest on the first anniversary of the grant date. The options expire on the 10&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; anniversary of the grant date. For each option the beneficiary is entitled to receive one share of common stock upon the exercise of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Stock option valuation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the option&#x2019;s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, volatility, the risk-free interest rate, the dividend and employee exercise behavior. Forfeitures are accounted for when they occur. Expected volatilities utilized in the Black-Scholes model are based on historical volatilities of a group of comparable companies. The group of representative companies have characteristics similar to the Company, including the stage of product development and focus on the life science industry. Management believes that this represents the most accurate basis for estimating expected future volatilities under the current conditions. The risk-free interest rate is derived from the yields for U.S.&#160;Treasuries with a remaining term approximating the expected life of the options. The expected term represents the period of time that the options granted are expected to be outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options granted during:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 74.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;For the 2019, 2020 and 2021 grants, the Company used the simplified method in developing an estimate of the expected term due to a lack of historical exercise data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock option activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity since January&#160;1,&#160;2021 (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,555,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 990,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (125,020)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (190,295)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,224,349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,624&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options unvested as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,006,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The fair value per common stock used for calculating the intrinsic values as of December&#160;31,&#160;2021, December&#160;31,&#160;2020 and December&#160;31,&#160;2019, was $2.33, $11.09 and $12.23, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options exercised during the years ended December&#160;31,&#160;2021, 2020 and 2019 was $1.0&#160;million, $2.9&#160;million and $1.4&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31,&#160;2021, 2020 and 2019 was $11.46, $8.95 and $7.92, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The total fair value of stock options vested during the years ended December&#160;31,&#160;2021 and 2020 was $6.0&#160;million and $5.6&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash received from stock option exercise under share-based payment arrangements for the years ended December&#160;31,&#160;2021, 2020 and 2019 was $203&#160;thousand, $63&#160;thousand and $16&#160;thousand, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the year ended December&#160;31,&#160;2020, the Company granted restricted stock units with time-based vesting conditions to officers, employees and a consultant to compensate them for a temporary salary or fee reduction in response to the coronavirus pandemic. The restricted stock units are subject to time-based vesting conditions and generally vested in four equal installments between March 2021 and November 2021. The Company measures the fair value of restricted stock units on the date of grant using the grant date market price of the underlying shares. Expenses are recorded using the graded-vesting method. The table below summarizes the Company&#x2019;s restricted stock unit activity since December&#160;31,&#160;2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,700)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The total fair value of restricted stock vested during the year ended December&#160;31,&#160;2021 was $0.5&#160;million. The total fair value of restricted stock vested during the year ended December&#160;31,&#160;2020 was insignificant. The Company had no restricted stock outstanding in the year ended 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Common Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the year ended December&#160;31,&#160;2020, the Company issued 36,249&#160;unrestricted shares of common stock to the non-executive members of its Board of Directors. The Company&#x2019;s directors received equity instead of cash as their 2020 board remuneration as part of the Company&#x2019;s response to the coronavirus pandemic. The total fair value of common stock awards issued during the year ended December&#160;31,&#160;2020 was $0.3&#160;million. The grant date fair value per share of common stock was $9.56 and was measured at the closing price of the common stock on the date of grant. Expenses were recorded immediately and are included in stock based compensation in the year ended December&#160;31,&#160;2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the years ended 2021 and 2019, the Company has not issued common stock awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,573&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31,&#160;2021 total unrecognized compensation cost related to the unvested stock-based awards was $5.7&#160;million, which is expected to be recognized over a weighted average period of 1.6&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_twPgggzgsEqZUfvcKLhARA"
      decimals="2"
      id="Narr_3MGCT5LIvkWrwexgSGbVAw"
      unitRef="Unit_Divide_EUR_shares_590Vq7m6Nk2ruyUEdyuF7Q">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo0.09EuroPerShareMember_9n3p1gHKx0CGfWWuBr4x9w"
      decimals="0"
      id="Narr_cdKEybHyBUaGiXvSQhACXw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">23286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2018_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_hook_ExercisePriceRangingTo2.93DollarsPerShareMember__xThJ8xgwECdT4PnUdSrEA"
      decimals="2"
      id="Narr_lkgutgTIq0u5tZAp9WPQcw"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">2.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOption2016PlanMember_2dw45hjqck2FIlWYMhpGDA"
      decimals="2"
      id="Narr_r5KRpyXpOEeQbvkleJc7Mw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_4UVSVApoFESt0pKFq_aAcA"
      id="Narr_TF968Uw4U0Gmrthtk0mVfw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_NvEZsiucNEarngOHkIEwqw"
      decimals="2"
      id="Narr_jdsg4SAzp0eJPjw1IctTPg"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rLd-8jjIakKEuR52k7XE-A"
      decimals="2"
      id="Narr_GbOdQ_cY7UCsK1tznnS7mw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rLd-8jjIakKEuR52k7XE-A"
      decimals="0"
      id="Narr_SrxXp8LUAEWbjyXtTx7OKQ"
      unitRef="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q">12</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_beVG5N6ZTEC9isTgGKHBeQ"
      decimals="INF"
      id="Narr_63buD-EhMEW-tzJCgOYqdA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">968504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_mveODV43Qk2j2ktXiQesTw"
      decimals="INF"
      id="Narr_4iPLaG8oj0i8KIxQMv2NoA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3630686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <hook:StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares
      contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_UozogPZl3kqm-mLqR-1Ajw"
      decimals="3"
      id="Narr_cB-utWDkAEqcBpI1tz7Brg"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.040</hook:StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_UozogPZl3kqm-mLqR-1Ajw"
      id="Narr_thtCmTWM6kC9TD6jg5ZdsA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tspqlK_mSEuko-7EX1OHCQ"
      decimals="2"
      id="Narr_6GPCGfazMUWQVkn6xIgUqg"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GB1HtsQo9UWwp1QaQ-17vg"
      decimals="2"
      id="Narr_uty-CKaHOEylVQ6mLezJxw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment
      contextRef="Duration_4_1_2019_To_4_1_2019_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GB1HtsQo9UWwp1QaQ-17vg"
      decimals="INF"
      id="Narr_BTjRL-eb10uLI84UiXh8Zg"
      unitRef="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q">12</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_fmE0VmQhIk2B4XyRkIcu2w"
      id="Narr_q0x34mFHq0yKxbrQYfoKqQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Qyh0v6uhbEG1Th-ftOQ75Q"
      decimals="2"
      id="Narr_3VFJ7uhT30u3EkPzdjaprw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_tBzOSNE1VEeWs3G7uVNFMA"
      decimals="2"
      id="Narr_FJl6IqF5YkC_UQ8HJqQuYw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment
      contextRef="Duration_4_1_2019_To_4_1_2019_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_tBzOSNE1VEeWs3G7uVNFMA"
      decimals="INF"
      id="Narr_yYWhtmmnBECMSPU0Smp17g"
      unitRef="Unit_Standard_installment_ED_DitCOm0mniQlqKMu72Q">8</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment>
    <hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption
      contextRef="Duration_4_1_2019_To_4_1_2019_XDfkQ2lQ5UGH271C7716Aw"
      decimals="INF"
      id="Narr_FIDwZ8wcbkWwHpo-nSmg9g"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1</hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_soK5Xqd_NkqJPkMITet7Tg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 74.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="4"
      id="Tc_lFIFsl2jl0OOwW9gCB-BDg_5_1"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="4"
      id="Tc_f6jDVEayAky4AsoerBF4YQ_5_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="4"
      id="Tc_aE10nKOwskC4FBIex3nRpg_5_5"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.0221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_zYznBODGbkGDuecBGeWZBw_6_1">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      id="Tc_C-PnU0NEfEq2eXitcu6KjA_6_3">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      id="Tc_C4kU9D1SJE-YNpiLwZxfMA_6_5">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Tc_9uYoDzyTME6vCYIMs4iDuA_7_1"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Tc_05R3pkNf6Eq_UNgF1zoQrQ_7_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Tc_LWqnDL2RpEm5BNSkT21foA_7_5"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_JiukM-EqKUyWGMsGtoDpNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity since January&#160;1,&#160;2021 (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,555,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 990,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (125,020)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (190,295)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,224,349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,624&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options unvested as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,006,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="INF"
      id="Tc_zwRFkdrJWUe9L_FhY5xQ9A_7_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3555945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="2"
      id="Tc_XNaSezI4SkKyXJgR4Xg_cQ_7_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">8.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      id="Tc_pEsKsJ-x-kOjjZ4MTgh-Yg_7_7">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_yJl6Jq7RaE2Mc6B3VrYdUQ_7_10"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">12839000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Tc_L94xINWmB0mbcrrVT30unw_8_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">990548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Tc_VXiC0MdT9EKz9mfNzDOsuQ_8_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Tc_zsv4lqLuUkWW0pUgx2euZQ_9_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">125020</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Tc_kYM_DGWFpkOVyF_FnsgD6g_9_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Tc_q-BjHq0J5k-hbKDsEeiqfA_10_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">190295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Tc_yJcxKEkXNkWHnYjRRCVlDg_10_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Tc_AHRVu971CkWMFZwRjA9X0A_11_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">4231178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="2"
      id="Tc_JpMQlw65JU-rPj0VdbIdSA_11_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">9.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_hu75LsMumEGOuzmqtLBmrg_11_7">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_C0OIH-YXakKNddhZ_pZzqQ_11_10"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Tc_guASU-Zb2k-5WmuD0bHPEQ_13_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2224349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="2"
      id="Tc_P11fpwVNg0i12kHR-2ovcA_13_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">7.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_N6nJsXzOQke9jTtq7IoPfw_13_7">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_LE2QG12LNUeoRKFq23aLbg_13_10"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1624000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Tc_fbN2J2z5rkSrybLcuSYhnA_14_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2006829</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="2"
      id="Tc_jLk8m5426keFfeziUJ24Gw_14_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">10.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tc_3WJ0f4F0fE-TRscAcAqMOQ_14_7">P8Y6M</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_XpW8k-xASEWynGi7pz2XMQ_14_10"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16000</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_E04niB7ZcECumtrBsYAPmg"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">2.33</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Narr_by5HtLk7UU6W2MwjFsqBig"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.09</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Narr_vdr1C0lgNUGvrbxy1mm48w"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">12.23</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_OkSJf5B_KUSLabGTT8RqvQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_Rp_AkeZLY021hYqOW1ci6A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_DfL_mHiOmUeBYlvblhe0cA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_DyhhW5c_iUm5DwrT8vXQVA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Narr_XWg81TWSc0iob4A8uyvyGA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Narr_LN96tOMbSUGS1eJ4EZX9oQ"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">7.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_lxj0fOtoi0mF0LI77Uflmw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">6000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_u_aF3KFgkEOOtU-W6s_3Uw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Narr_kr03pHDIUEaa3yo5M8v0nw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">203000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Narr_L7Yf9QfvPUmuTROT_j1e0Q"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">63000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Narr_unyOJIhb00uegphltqQEKQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">16000</us-gaap:ProceedsFromStockOptionsExercised>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA"
      decimals="INF"
      id="Narr_TGInkyirzE-BzXrWbEXlZA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_3Af90ofexUixSDABdyTtNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,700)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UzL7A7Iha0WXUjRxbCPtMA"
      decimals="INF"
      id="Tc_Ka-rQhR7yki0F3Zxef7HTA_5_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">43700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UzL7A7Iha0WXUjRxbCPtMA"
      decimals="2"
      id="Tc_-kRyacl4e0etUokMHJk8iQ_5_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA"
      decimals="INF"
      id="Tc_YYE9DXFylEiS2BrslShxbg_7_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">43700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA"
      decimals="2"
      id="Tc_VBCkueadc0usDeKnIR0FdQ_7_5"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA"
      decimals="-5"
      id="Narr_t3rG9OF9U0qrOhRvey6T6Q"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yxPIhqNASUaCbZD8h1tf_w"
      decimals="INF"
      id="Narr_HCx5yGQ5LUCJ_0Xy9Vtctw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg"
      decimals="INF"
      id="Narr_ONQf7ioip0-k6jfRo_ULHg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">36249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg"
      decimals="-5"
      id="Narr_0-YECkkD30ieibAKD0Tu0g"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">300000</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_p4jGB6jyV0OQulMv03rYOg"
      decimals="2"
      id="Narr_bE4MIhLqHkmskrxRAK46Vw"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">9.56</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_Y24Eexf4xkCs_eHMPufkaQ"
      decimals="INF"
      id="Narr_CckXWRjr10mPA2YYdh8R9A"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hpzhb_Bppk67Nw3sDM-ihg"
      decimals="INF"
      id="Narr_jrUW7izaKUSfYI9N8BHwgQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_Kj92_HQur02g0d6qiOE-bA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,573&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2sIjCJbsXUC748mnQI16xQ"
      decimals="-3"
      id="Tc_4bfhHn40qUGhMs4ZUiYxWg_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_62xLAWodm0CGBjjwj-eADA"
      decimals="-3"
      id="Tc_gtKau0RANkOCGuv1dFU-Ig_3_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3084000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-DFpbMUslEae1ED399zLwQ"
      decimals="-3"
      id="Tc_IH2XWbtwWUadd04mfg0dHA_3_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1981000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jyPjOBYFUUWz4lV6UIVF9g"
      decimals="-3"
      id="Tc_Cr_5sk-eJECAXPN0yX0kow_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4444000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JJMpvfkqGUuPY4tFs1Hb-w"
      decimals="-3"
      id="Tc_WOBlthfffkyjExwQ2jwiAg_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5573000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_22rnLqSJCUSZdw6cMXG4eQ"
      decimals="-3"
      id="Tc_iogGm1GTo0GYew_xKzlMNA_4_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3584000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_vgeEphVJ90Ou1yXidz9IUw_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7644000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_uD7tfmGOV0iMvWZRJKxcmQ_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8657000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_1Vx_yyboXUCcer7QqhhThw_5_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5565000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_H2dxTbO1-EebsxtGtxtdGQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Narr_Y3Ad9tMQZkGOnzWJ0_nVQA">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_lsKm-JUa_kqX65csJmq6kA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items. The Company's losses before income taxes were generated in the United States and Austria.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2021, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,603)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,886)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign (Austria)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,479)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,151)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss before tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,037)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company's worldwide effective tax rate for the years ended December&#160;31,&#160;2021, 2020 and 2019 was 0.0%, 0.0% and 0.0%, respectively. The tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, which is expected to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. The following items had the most significant impact on the difference between the statutory U.S. federal income tax rate of 21%&lt;span style="white-space:pre-wrap;"&gt; for the years ended December&#160;31,&#160;2021, 2020 and 2019 and the effective tax rate:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Foreign tax rate differential&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Not taxable government grants&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Stock-based compensation&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Change in deferred tax asset valuation allowance&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The 4% increase for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 25%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2) &lt;/sup&gt;For the years ended December&#160;31,&#160;2021, 2020 and 2019, 3.8%, 4.7% and 5.4% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3) &lt;/sup&gt;For the years ended December&#160;31,&#160;2021, 2020 and 2019, 1.5%, 1.0% and 0.3% increase, respectively, resulted from non-taxable Stock-based compensation expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(4) &lt;/sup&gt;For the years ended December&#160;31,&#160;2021, 2020 and 2019, 30.2% reduction, 30.2% reduction and 31.0% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets have been fully impaired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2021 and 2020 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 55,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 43,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (36)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 58,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 47,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (53,728)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (46,064)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 5,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (3,604)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Fixed assets and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (11)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,400)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,614)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Finance lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (22)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (254)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (5,037)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,868)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2021, 2020 and 2019, the Company had Austrian net operating loss carryforwards of $219.7&#160;million, $163.2&#160;million and $112.3&#160;million, respectively, and US Federal net operating loss carryforwards of $17.9&#160;million, $8.3&#160;million and $4.9&#160;million, respectively, all of them with no expiry date. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company's history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&#160;31,&#160;2021, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of losses is no longer present and additional weight may be given to subjective evidence. The tax years in which the tax carryforwards were generated may still be adjusted upon examination by the tax authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,583)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,156)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Increases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,481)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,427)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (53,728)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,583)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;22,&#160;2017, the United States enacted the Tax Cuts and Jobs Act (&#x201c;Tax Reform Legislation&#x201d; or &#x201c;TCJA&#x201d;). The Tax Reform Legislation introduced section 951A, a new tax on so-called &#x201c;global intangible low-taxed income,&#x201d; or &#x201c;GILTI&#x201d;. GILTI applies to income of a controlled foreign corporation (&#x201c;CFC&#x201d;) that is not otherwise subpart F income, and consists of the excess "tested income" over a 10% return on the CFC's &#x201c;qualified business asset investment,&#x201d; or &#x201c;QBAI&#x201d;. QBAI is the total tax basis of the CFC's depreciable, tangible property used in the production of tested income. The full amount of GILTI is included in taxable income. The GILTI inclusion is then reduced by 50% (reduced to 37.5% after 2025). However, that reduction in GILTI may be limited based on the level of U.S. taxable income. A limited allowance for foreign tax credits is allowed that would reduce the U.S. tax cost. GILTI foreign tax credits can only reduce U.S. taxes owed on GILTI and are not eligible for carryforward. The Company's Austrian subsidiary falls under the category of a CFC and due to the nature of its business model as a technology company, there may not be a material amount of tangible assets if this subsidiary starts to generate profits. GILTI taxation therefore may be applicable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction as well as in New York. The tax years from 2018 to present remain open to examination by the jurisdictions in which the Company is subject to tax. &lt;span style="background:#ffffff;"&gt;There are currently no pending income tax examinations in the U.S. &lt;/span&gt;Furthermore, the Company files income tax returns in Austria. The tax years 2018 to present remain open to examination by the jurisdiction. There are currently no pending income tax examinations in Austria.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company evaluates tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31,&#160;2021 and 2020, the Company had no unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <hook:IncomeTaxBenefitsNetOperatingLossesIncurred
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Narr_LBxhVvIMAkK4RLCsRopg9A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:IncomeTaxBenefitsNetOperatingLossesIncurred>
    <hook:IncomeTaxBenefitsNetOperatingLossesIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Narr_-JxHf356YU-fxAFcJnPt7g"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:IncomeTaxBenefitsNetOperatingLossesIncurred>
    <hook:IncomeTaxBenefitsNetOperatingLossesIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Narr_pXfZdq1U50ei2flqNSoeuA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:IncomeTaxBenefitsNetOperatingLossesIncurred>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_jf_Lv36zWUujbAlWzYLlcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2021, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,603)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,886)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign (Austria)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,479)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,151)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss before tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,037)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_bVi8n0OiBkyzxv3ka7wfMw_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-11403000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_PdbhVsDvbkiWcDI0kH5BLA_3_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-11603000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_3YFQiBxhh02N4CTe7un6Vg_3_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-7886000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_FDWmUFW9F0m7VSZroBy2nA_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-64261000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_ydao3mQ0j0a6lYkVxgea2A_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-32479000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_No-fgHvb8ky84j-tERhC_g_4_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-35151000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_0PxwfLxnY0uBi1ILiO3yHg_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_lrLMmVmz1UyN-kxGngLK2A_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44082000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_VfhGMrb2PUeez2qVvw13ag_5_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Narr_MdkYCmDj6EiiVPN0yzTVOw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Narr_SohQMUiZiUi3vMbS6ZTblw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Narr_J2gB5GDPHEmzl6ZoxUZbmw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Narr_VyN0Hy_0u0mWxT-lK66p1w"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Narr_9txa-dx3y0mHbFrsAzf-yQ"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_ef8t0g7MRkCLli2d7CEicw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_dzTaeLpW-EWjqBn0d0kZYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Foreign tax rate differential&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Not taxable government grants&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Stock-based compensation&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Change in deferred tax asset valuation allowance&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The 4% increase for the years ended December&#160;31,&#160;2021, 2020 and 2019, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 25%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2) &lt;/sup&gt;For the years ended December&#160;31,&#160;2021, 2020 and 2019, 3.8%, 4.7% and 5.4% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3) &lt;/sup&gt;For the years ended December&#160;31,&#160;2021, 2020 and 2019, 1.5%, 1.0% and 0.3% increase, respectively, resulted from non-taxable Stock-based compensation expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(4) &lt;/sup&gt;For the years ended December&#160;31,&#160;2021, 2020 and 2019, 30.2% reduction, 30.2% reduction and 31.0% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets have been fully impaired.&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Tc_gxgFZilpbkO-Q7i6KTTOxQ_3_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="INF"
      id="Tc_aQGnmsIdCU-rSQsqOj6Tlw_3_6"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="INF"
      id="Tc_LUf9ho1miEeuFPkqh3PvOQ_3_9"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Tc_nDhsaiwKnUabRpheqyOmyA_5_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Tc_84yQ5ME4kUaDsw0N1XSIFQ_5_6"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Tc_7B3xNT1elkqcevWTOk78pw_5_9"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Tc_WiZwYdX2nkqxDunhPAcXYg_6_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Tc_T5p3KFUEBEiaA73bHWmyjw_6_6"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Tc_Q47Fu3MI_USR_AWc-8P84Q_6_9"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Tc_Le0zEZSiakaCLhW1HN_s2Q_7_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Tc_vBzfwRWUfEWQSbRVICRipQ_7_6"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Tc_9ugqUbJsS0OkmavYtVNPYw_7_9"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Tc_e6ysHK82Jk6CHKElUmTCbg_8_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Tc_BoKSxfgbmkeM0PaGwMEZzQ_8_6"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Tc_uQ7oBxxSeUKYqO3pz_tCDw_8_9"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Tc_-yOiVeR9TkqeCr7yuT4_zg_9_3"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.302</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Tc_tZl16rCljE-MV0ROl_Pc7A_9_6"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.302</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Tc_vV26Hg7B6Uuw1u0WqoqAZg_9_9"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.310</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Narr_1JY8vSsCsEWfL0qy1MlYYg"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Narr_mbdWQy2lK02ROjZ0OXxlqQ"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_LAk5PryDi0isHabpzSM3CQ"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_8aWV_Z5u30CrNnuDLkmpsQ"
      decimals="2"
      id="Narr_SscgaiiQZEmHQJvDpjI8TQ"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Narr_PvrOP77ux0eebEKtGjxnVg"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Narr_Qn9GpFibz0GzuxfOVKwIpw"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Narr_mUG-0J2owUGaWmZ1sH5N0g"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Narr_-RLYymBaHEyHX6SxoxUr5g"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Narr_0wDbjM1KIk67YZlyme2a7w"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Narr_qqyT4GCnIkiqdXfJIX3Q4Q"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="3"
      id="Narr_09p5gI1hYUqEtIcjLW4gpA"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.302</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="3"
      id="Narr_W8O4L988BESGOPQABz_1jQ"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.302</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="3"
      id="Narr_CMhn9gxlR0iUs5z03tX_EA"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.310</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_zr6XFXolREWT_1H7AE_KuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2021 and 2020 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 55,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 43,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (36)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 58,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 47,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (53,728)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (46,064)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 5,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (3,604)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Fixed assets and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (11)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,400)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,614)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Finance lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (22)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (254)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (5,037)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,868)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_bIez4ttyUUenUQQzNYU8rQ_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">55752000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_7v0syH5LbkWjO0ViJBU47A_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">43563000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_Ekf1FneNgUGkrye3eURWxw_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">64000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_N3Kl9w8rj0ymbImXbj7Bhg_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">64000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_EcaJCV-lhk6j45xoCubilA_6_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">357000</hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_icDvG2Bma0m8Lwj3cPB6TA_6_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-36000</hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_TOMKLrWbxUOfp1mo0QCPbA_7_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1209000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_u4XcJe4HWUCR7_bPK2BIeg_7_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">2725000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <hook:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_uQR6mVXBPUi7FbeDf7Zb3A_8_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1378000</hook:DeferredTaxAssetsOperatingLeaseLiabilities>
    <hook:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_4LqYSzGI70uNK0yzEXHRGQ_8_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1513000</hook:DeferredTaxAssetsOperatingLeaseLiabilities>
    <hook:DeferredTaxAssetsFinanceLeaseLiabilities
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_sd7xibsWkECx6SX61JQqxQ_9_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5000</hook:DeferredTaxAssetsFinanceLeaseLiabilities>
    <hook:DeferredTaxAssetsFinanceLeaseLiabilities
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_FwWvXfQld0eQb2i8oYT02A_9_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">103000</hook:DeferredTaxAssetsFinanceLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_XuziYHFCrkCDLtSh-sceKA_10_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">58765000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_D0y8726T6Ea69gyDbaK1fg_10_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">47932000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_35BIFMVvHUCDN_3uHiIthQ_11_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">53728000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_VRv10JcEqU2CXeaC0_OrAw_11_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">46064000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_dPCh4yfn2Eq1pWBYa6dhuw_12_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5037000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_Ps-A9RFPXU6R1CpjJesiMA_12_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1868000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_ghfenzjP90S2R_RCs9f47Q_15_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">3604000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_FH2BWLVKxUegP0-u0O7eIg_16_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">11000</hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_fap_0nDrVkKJ8wjg3h21_g_17_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1400000</hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_bdMfbNN3qkGpfqZSzvu0xw_17_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1614000</hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <hook:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_xj6958GZEUmppXwrbuo7ZQ_18_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">22000</hook:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset>
    <hook:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_hirNNytpcU6euRxOtCR5LA_18_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">254000</hook:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_t4kiQDqHRUOBjFaNmjvObw_19_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5037000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_MX1tC7hdLE2HKul4f334zg_19_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1868000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_gHDM5dWWTEuXar6FbiCeBg"
      decimals="-5"
      id="Narr_qLZkrdG980mBfpP9sDsBTA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">219700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AT_VDTF1Hi9ZEmGsqw3fw3zPw"
      decimals="-5"
      id="Narr_PYrHwb5fhkaF-3GQGjyhDg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">163200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AT_bcqjl_Vcukegg0RdiMWQ4A"
      decimals="-5"
      id="Narr_piHtgZdX_kuQ_HXbvpf-Pg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">112300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wlEd_mxNOkeq4y6xJ7gacw"
      decimals="-5"
      id="Narr_cDho9DSmsU-P-85PnlBouQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">17900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_G_2_M_kOZUillKcUGB9iFQ"
      decimals="-5"
      id="Narr_cGTmLPXYhEGqzpMIVmzwZg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">8300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_g5-9_PFDAkeum_3TPJDJ1g"
      decimals="-5"
      id="Narr_xCNSagANpEinY8Eo5cUXrA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_EygdMEPTGE6puc3u3x11-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,583)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,156)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Increases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,481)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,427)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (53,728)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,583)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_PD9fonnEtk6mXvEAoGrv1A_3_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">46064000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w"
      decimals="-3"
      id="Tc_gIA5CF9oOUW3NCFR9_1IOg_3_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">32583000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg"
      decimals="-3"
      id="Tc_Q5XYzZOVg0Cr2uIMSzHQgA_3_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">19156000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_0kPSSW9aD0iNQjujjHbQVg_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">7664000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_f_-aymMPokm9oEj4RwpFMg_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">13481000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_X-t-nGH-Gka6sqceby5iJA_4_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">13427000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-3"
      id="Tc_gUnzmNpp4U-W4HqBX_s_aA_5_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">53728000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="-3"
      id="Tc_qFRSZlCf30OjM7Mw16yJXA_5_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">46064000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2019_PQ-ki-kJhE-yooht2OnA0w"
      decimals="-3"
      id="Tc_G7vCOsLdAUe_2wCblglAPw_5_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">32583000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <hook:GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_l2gky_hg3kSVxWKxGeNVjA"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.10</hook:GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage>
    <hook:GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Narr_JyOHuhqI80G9GZIMrQjnRA"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.50</hook:GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion>
    <hook:GlobalIntangibleLowTaxedIncomePercentageOfInclusion
      contextRef="Duration_1_1_2026_To_12_31_2026_Z5BVccme10iEHOgWw4JA2w"
      decimals="3"
      id="Narr_cvYhsUGhfkCf-m_wcBQ1kg"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.375</hook:GlobalIntangibleLowTaxedIncomePercentageOfInclusion>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA"
      decimals="0"
      id="Narr_474Kn7edj0O1QH-YOccJlw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="0"
      id="Narr_h2xEoI-hwE-6OJiohedNRw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_jHK4eeMyh0-Ugu2b9904kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Commitments and contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Contract manufacturing arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into arrangements with contract manufacturing organizations (&#x201c;CMOs&#x201d;) for manufacturing of materials for research and development purposes, including manufacturing of clinical trial materials. These contracts generally provide for non-cancellable obligations or cancellation penalties depending on the time of cancellation. As of December&#160;31,&#160;2021, the Company&#x2019;s total non-cancellable obligations under contracts with CMOs, excluding embedded lease liabilities, were $10.5&#160;million, of which $10.4&#160;million relate to 2022 deliverables and $0.1&#160;million relate to 2023 deliverables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2018, the Company entered into an agreement with a contract manufacturing organization for the production of clinical trial material, including seed lots, drug substance for toxicology studies, stability studies and clinical studies as well as related technology transfer, quality control and process optimization activities which commenced in February 2019. Under the financial terms of the agreement the Company is obliged to pay non-cancellable minimum service fees totaling $13.9 million through January&#160;&lt;span style="white-space:pre-wrap;"&gt;2022. The Company has determined that the agreement includes embedded leases which resulted in recognition of operating and finance lease assets and corresponding liabilities on the Consolidated Balance Sheet. The agreement was not extended beyond the initial term and its wind-down during the first quarter of 2022 has been agreed.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intellectual property licenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into certain license agreements under which it is obligated to make milestone payments upon the achievement of certain development and regulatory milestones, to pay royalties on net sales of licensed products, and to pay a percentage of the sublicense fees which the Company receives from its sublicensees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the years ended December&#160;31,&#160;2021, 2020 and 2019, the Company recorded $1.3&#160;million, $1.2&#160;million and $1.9&#160;million, respectively, in licensing fees related to intellectual property licenses as research and development expenses. These amounts mainly related to the upfront payment and milestone payments received by the Company under the Gilead Agreement. The amounts recognized as expenses have been agreed to by the licensors but calculation of sublicensing fees on future payments may be subject to interpretation and may change until agreed to by the receiving party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Indemnification agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31,&#160;2021 or December&#160;31,&#160;2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Legal proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently a party to a patent proceeding opposing European Patent No.&#160;3218504, which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to the Company. While it is not feasible to predict the outcome of these matters with certainty, and some lawsuits, claims or proceedings may be disposed or decided unfavorably, the Company does not expect that the pending patent opposition, and any asserted or un-asserted legal claims or proceedings, individually or in the aggregate, will have a material adverse effect on the Company. However, if, as a result of the current patent proceeding, the Company would lose all, or at least part, of the protection under the opposed patent, such loss could erode the Company&#x2019;s competitive position and harm its business and ability to achieve profitability. The Company expenses the costs related to the pending and other such legal proceedings as incurred.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_MjUbeFu4RUu-yuCHtc4KOg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10500000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_OtmiSQAz802FvNXE1VUTVg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">10400000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="-5"
      id="Narr_JyoZq-BbaEm735SyJYirhw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">100000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2018_HjkeJi3uGU2VTLOBewH-bg"
      decimals="-5"
      id="Narr_IMbWDp6xDkqX1PbRFoA57A"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">13900000</us-gaap:ContractualObligation>
    <hook:LicensingFeesIntellectualPropertyLicenses
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_ChY7HFLGjkmgOZ2d7KedTQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1300000</hook:LicensingFeesIntellectualPropertyLicenses>
    <hook:LicensingFeesIntellectualPropertyLicenses
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_UJhZdKqz9Ea4mGy3gEzcXw"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1200000</hook:LicensingFeesIntellectualPropertyLicenses>
    <hook:LicensingFeesIntellectualPropertyLicenses
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-5"
      id="Narr_tS9vXnwuQEmagFIfWekr_g"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">1900000</hook:LicensingFeesIntellectualPropertyLicenses>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_XLVZy3cr70iHTiwDX-41xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14. 401(k) Savings Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to 100% of the first 4% of each employee&#x2019;s contribution. During the years ended December&#160;31,&#160;2021 and December&#160;31,&#160;2020 expenses recognized for the 401(k) Plan were $0.4&#160;million and $0.2&#160;million, respectively. During the year ended December&#160;31,&#160;2019 expenses recognized for the 401(k) Plan were insignificant.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA"
      decimals="2"
      id="Narr_HOFDpMZwBUi9Ioh77X7JqQ"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_o1wk3eB5lUCMM0lTaoCyRA"
      decimals="2"
      id="Narr_Gdph7E8isES2mIBg0_ZEZA"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-5"
      id="Narr_IshliPwmY0G9UHnP60hfqA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-5"
      id="Narr_t1yYkeqBMUy9LZH57bER4w"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_6QWKQ5OUzU-OdPI_mxZ7kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15. Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75,665)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,037)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,945,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,876,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,859,935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 162,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total number of shares used to calculate net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,833,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,039,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,859,935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xm72ylqy7EWXDfD5Rmo5kg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ix31qi0nv0-3tRNXPNStAg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.69)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_6TH1JwQjZkq-oybyyIOUrA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; Series&#160;A convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#x2019;s common stock. Series&#160;A convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Series A convertible preferred stock is convertible into 1,000 shares of common stock. 1,697,000 shares of the Company&#x2019;s common stock are issuable upon conversion of Series A convertible preferred stock (see Note&#160;10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares (Common Stock and Class A Common Stock) outstanding would have been anti-dilutive. Potentially dilutive securities (upon exercise) that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,555,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,999,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,599,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,999,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_7XjgnV5XL0mcIZZjYbCHdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75,665)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,037)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,945,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,876,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,859,935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 162,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total number of shares used to calculate net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,833,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,039,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,859,935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xm72ylqy7EWXDfD5Rmo5kg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ix31qi0nv0-3tRNXPNStAg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.69)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_6TH1JwQjZkq-oybyyIOUrA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; Series&#160;A convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#x2019;s common stock. Series&#160;A convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Series A convertible preferred stock is convertible into 1,000 shares of common stock. 1,697,000 shares of the Company&#x2019;s common stock are issuable upon conversion of Series A convertible preferred stock (see Note&#160;10).&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="-3"
      id="Tc_FoQN-7iEWkClyvHupa1wiw_4_3"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="-3"
      id="Tc_P43MtwoSsE2rgKf5tCqvwg_4_6"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-44082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="-3"
      id="Tc_WLmEZOBL2kCGuakqraPf3A_4_9"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">-43037000</us-gaap:NetIncomeLoss>
    <hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="0"
      id="Tc_2A4O9oJkeEKpKWvA0ZugYg_7_3"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">29945954</hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion>
    <hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="0"
      id="Tc_4IdQG1SAw0eEN9XSYUobiA_7_6"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">25876376</hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion>
    <hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="0"
      id="Tc_6v46pRVssEGaJ2Q8XKzvQA_7_9"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">17859935</hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion>
    <hook:WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="0"
      id="Tc_t_P5hbgpNkSUFXJ3sllEmg_8_3"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2887636</hook:WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock>
    <hook:WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="0"
      id="Tc_EPkhACv_S0i9mtDFUFPn3g_8_6"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">162732</hook:WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="0"
      id="Tc_fWr4Gr_SPUmgIsuRC-kRqw_9_3"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">32833590</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="0"
      id="Tc_93i55LzlVkytZ5ELTj9k5w_9_6"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">26039108</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="0"
      id="Tc_fJZqCBM8IEKrR141Iq9lYQ_9_9"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">17859935</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="2"
      id="Tc_adO60mBtx0yeicCPOakmNg_11_3"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="2"
      id="Tc_3IBnabV51Em9GPlXR9UM4g_11_6"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="2"
      id="Tc_AHs_FXD-D06rcuRLPG3Q-Q_11_9"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">-2.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Narr_1j4XzeMz-ESnuMmVKiBDbQ"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <hook:ConvertiblePreferredStockSharesIssuableUponConversion
      contextRef="As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ"
      decimals="INF"
      id="Narr_INJgIlcWO06qRzAaAwbnRg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1697000</hook:ConvertiblePreferredStockSharesIssuableUponConversion>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb__xf7lEYD70WWS3rfhI2cWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,555,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,999,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,599,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,999,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8ArpbU0oC0yIg8CJBYRJmg"
      decimals="INF"
      id="Tc_qebFqiJlp0G5rDsH8bs3IA_3_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">4231178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_5rBz_7VLf0GCJz8u9a-5hw"
      decimals="INF"
      id="Tc_-uTg87tcE0i_COET2RwNGw_3_4"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3555945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_g4i69HykyUOop1GtYNoS3A"
      decimals="INF"
      id="Tc_MwqJPqCTH0udQo9Lw6Hw9g_3_6"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2999284</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Tblo1dfAsE-WhYeQhF--_w"
      decimals="INF"
      id="Tc_MFspW3CzaEa3HMfP9DzNJA_4_4"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">43700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      decimals="INF"
      id="Tc_8eV2nbT30UOc1mqicBBUJw_5_2"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">4231178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw"
      decimals="INF"
      id="Tc_ntWud2xjckCOdjoD-HSqFA_5_4"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">3599645</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_hAs8axhHBkahU6UKaGiQGg"
      decimals="INF"
      id="Tc_zWvXAgQ4Zk6QH3HU0x9t-w_5_6"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">2999284</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_0-SQ_GR1Bka9kK1FHbzt6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16. Related parties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Following the expiry of the consultancy agreement between the Company and its Chief Scientific Officer, Daniel Pinschewer, on March 19, 2020 the Company entered into a new consultancy agreement with Daniel Pinschewer on March&#160;20, 2020, pursuant to which he serves as Scientific Advisor to the Chief Executive Officer. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is party to research and service arrangements with the University of Basel. Daniel Pinschewer, formerly Chief Scientific Officer, and his spouse are employees of the University of Basel and both involved in providing the services under these arrangements. Payments to the University of Basel during Daniel Pinschewer&#x2019;s term as Chief Scientific Officer were reported as related party transactions but payments following the expiry of that role in March 2020 were no longer considered related party transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the year ended December&#160;31,&#160;2021, the Company did not record any related party transactions. In the years ended December&#160;31,&#160;2020 and 2019, the Company recorded $0.3&#160;million and $0.3&#160;million, respectively, in research and development expenses for service fees paid to the University of Basel, which represented related party transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The University of Basel is also entitled to receive de minimis royalties on the net sales of any product that is based on a patent created by the Company&#x2019;s Scientific Advisor to the Chief Executive Officer in the course of his consulting services to the Company. In the years ended December&#160;31,&#160;2021, 2020 and 2019, no royalties were paid pursuant to the terms of this arrangement.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_pZ8SP9MhHUePH3GzlSb8nw"
      decimals="-5"
      id="Narr_kFaCZ_rSdUGsGiTnHoEBOg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_mXlTlYVhXE--Iu97sO2IOw"
      decimals="-5"
      id="Narr_eEWoiuxNG026MIpgvlozCQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <hook:RelatedPartyTransactionPaymentsForRoyalties
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_gifEUz7mSku6eu-AYJEHoQ"
      decimals="-5"
      id="Narr__5sVD2hMNk-2YyGhtR8NNQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:RelatedPartyTransactionPaymentsForRoyalties>
    <hook:RelatedPartyTransactionPaymentsForRoyalties
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_YCN1Wdur2kOhWvhtqG7FTQ"
      decimals="-5"
      id="Narr_10iHSw-yukaJLzBWCR1UEQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:RelatedPartyTransactionPaymentsForRoyalties>
    <hook:RelatedPartyTransactionPaymentsForRoyalties
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_lRtNrbT0JEmwrX6k2vVYAw"
      decimals="-5"
      id="Narr_44jMzuJPGkaAzaltAuCBkA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">0</hook:RelatedPartyTransactionPaymentsForRoyalties>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A"
      id="Tb_65KCIF_CeE2l0DF358geVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17. Subsequent events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock option and equity grant to senior management&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February&#160;1,&#160;2022, members of the Company&#x2019;s executive team received 50% of their 2021 annual bonus in the form of a grant of fully vested stock options, determined based on a value of $3.00 per share and resulting in the issuance of a total number of 145,071 options. The granted options have an exercise price of $1.50 per share, the closing price of the Company&#x2019;s common stock on January 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;At the same time, the members of the Company&#x2019;s executive team agreed to convert a portion of their base salaries, for the six months ending June&#160;30,&#160;2022 for shares of the Company&#x2019;s fully vested common stock having a value equal to their foregone salary, determined based on a value of $3.00 per share, resulting in the issuance of an aggregate of 112,551&#160;shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amended and restated research collaboration and license agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In February&#160;2022, the Company and Gilead entered into an amended and restated research collaboration and license agreement. For the future performance of development activities under the amended agreement, the Company received a $4&#160;million milestone payment and a $15.0&#160;million program initiation fee, which have been initially recorded as deferred revenue in the consolidated balance sheet and will be recognized as revenue when revenue recognition criteria are met. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In connection with the Restated Collaboration Agreement, the Company entered into a stock purchase agreement with Gilead. Pursuant to, and subject to the terms and conditions of, the stock purchase agreement, Gilead will be required, at the Company&#x2019;s option, to purchase up to $35,000,000 of the Company&#x2019;s common stock, par value $0.0001 per share. In February&#160;2022 Gilead purchased an initial amount of 1,666,666 unregistered shares of the Company&#x2019;s common stock for $5.0&#160;million, corresponding to a purchase price per share of $3.00.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Follow-on public offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In March 2022, the Company issued and sold 21,700,000&#160;shares of its common stock, and 15,800&#160;shares of its Series&#160;A-1 convertible preferred stock in a follow-on public offering at a public offering price of $2.0&#160;per share of common stock and $2,000&#160;per share of Series&#160;A-1 convertible preferred stock, resulting in net proceeds of $70.5&#160;million after underwriting discounts and commission but before other offering expenses. The Company granted the underwriters an option for a period of 30 days to purchase up to 5,625,000&#160;additional shares of its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;War between Russia and Ukraine&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On February&#160;24,&#160;2022, Russian forces began an invasion of the Ukraine. While we have no operations in the Ukraine or Russia and do not perform research, conduct clinical trials, or otherwise do business in these two countries, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;the geopolitical effects of the war and its potential further escalation, including the effects of other nations&#x2019; responses and economic sanctions, are currently unpredictable and may adversely affect our business in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <hook:PercentageOfAnnualBonusPaidThroughIssuanceOfOptions
      contextRef="Duration_2_1_2022_To_2_1_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_zDBbt61-QkWRp1SuDXvEgw"
      decimals="2"
      id="Narr_AgmIJbte3EOqXsRkIzk1ag"
      unitRef="Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA">0.50</hook:PercentageOfAnnualBonusPaidThroughIssuanceOfOptions>
    <us-gaap:SharePrice
      contextRef="As_Of_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bmkwQPPsg0m3l7ZM8QwDVg"
      decimals="2"
      id="Narr_01UiJleZNEiYdYp8-3MCNw"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">3.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_1_2022_To_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b78AfSk_ikSR3aA4hEpw6w"
      decimals="INF"
      id="Narr_RD1pAPYhn02c_o6bQsfWkw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">145071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_1_2022_To_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b78AfSk_ikSR3aA4hEpw6w"
      decimals="2"
      id="Narr_BjHXDvuNnECS67lvgo5B7A"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">1.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fDr8f-o960agj3wW41LU3g"
      decimals="2"
      id="Narr_moUQYjISIkCpEIuOCbM14A"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">3.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rb58nqtF00-ccIOKSQPjSQ"
      decimals="INF"
      id="Narr_Y7bGtvncJU6OZoueN5aedg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">112551</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <hook:ProceedsFromMilestonePayment
      contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw"
      decimals="-6"
      id="Narr_uT0nlqaRBEyP5FGacKaHEg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">4000000</hook:ProceedsFromMilestonePayment>
    <hook:CollaborativeArrangementProgramInitiationFee
      contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw"
      decimals="-5"
      id="Narr_1OLxCN7-HkmvSGSxEPzKew"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">15000000.0</hook:CollaborativeArrangementProgramInitiationFee>
    <hook:StockPurchaseAgreementObligationToPurchaseCommonStockAmount
      contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw"
      decimals="0"
      id="Narr_5eXo5La0PE-P65MA01G9mg"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">35000000</hook:StockPurchaseAgreementObligationToPurchaseCommonStockAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_r8XLGskgdEyxWiQ5NQyIKQ"
      decimals="INF"
      id="Narr_ntEAmpuiY0yXuz1gtKobwA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw"
      decimals="INF"
      id="Narr_1Ph6sgJssEOng2qrp-V1jw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">1666666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_1_2022_To_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_uWfxrNv7yU-hhPbbSqtbIw"
      decimals="-5"
      id="Narr_tbYuHrrdPUOPjwhv2m9bmA"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_r8XLGskgdEyxWiQ5NQyIKQ"
      decimals="2"
      id="Narr_oofE7hQZ20SwoHGiaKEgrA"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">3.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_CHI8dxT2OkidwL8Mu4XUrA"
      decimals="INF"
      id="Narr_V_JhGXWjo0SN9nTj0VtOFA"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">21700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_GPWyabmAdEKvKH-pRh2Odg"
      decimals="INF"
      id="Narr_bNelnGhHnkKzV7onA1HXZw"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">15800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_P9-ctvWwd0qVNZJLztP7lw"
      decimals="2"
      id="Narr_GTk4c5Vvl0WpQsjpMOOwag"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">2.0</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember_n0YxpBmAWUqt8sgKu-qHDA"
      decimals="0"
      id="Narr_UTW4ouw1B0C0TqfOy_Z7Aw"
      unitRef="Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ">2000</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_hook_FollowOnPublicOfferingMember__DCiYylTbUSqoGmdQ3GRYw"
      decimals="-5"
      id="Narr_POQJMKHiGkGcmU3_kNTsLQ"
      unitRef="Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw">70500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <hook:PeriodGrantedToUnderwritersToPurchaseAdditionalShares
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_paPyAdbqWE-j29GBmOS_lg"
      id="Narr_zxcj8O8JKk61i28Ic0C2KA">P30D</hook:PeriodGrantedToUnderwritersToPurchaseAdditionalShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_paPyAdbqWE-j29GBmOS_lg"
      decimals="INF"
      id="Narr_wnHOwSW2TE2-Xx0mZKcdmg"
      unitRef="Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ">5625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M"3QX5*(7,FZL!@  5QT  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
M66UOVS80_MS]"L(MBA:+8XF27](F 1P[7KTVJ1?W!=FP#XQ$VT(DTB.I./GW
M.\HO=#/Y) SHET22=0\?WE'/W9&G*ZGN]8)S0QZS5.BSQL*8Y;M62T<+GC%]
M+)=<P"\SJ3)FX%;-6WJI.(L+HRQM4<_KM#*6B,;Y:?%LHLY/96[21/")(CK/
M,J:>+G@J5V<-O[%]<)/,%\8^:)V?+MF<3[GYNIPHN&OM4.(DXT(G4A#%9V>-
MOO]N&':L0?'&MX2O]-XUL5.YD_+>WHSCLX9G&?&41\9",/CWP <\32T2\/AG
M ]K8C6D-]Z^WZ*-B\C"9.Z;Y0*;?D]@LSAJ]!HGYC.6IN9&K#WPSH;;%BV2J
MB[]DM7ZWW6F0*-=&9AMC8) E8OV?/6X<L6<0T@,&=&- GQGXX0&#8&,0U#4(
M-P9AX9GU5 H_#)EAYZ=*KHBR;P.:O2B<65C#]!-AXSXU"GY-P,Z<#V640Q@-
M82(FE\(DYHF,Q7H]V;@TR=?ID+QY]9:\(HD@5TF:PF-]VC(PN(5H19N!+M8#
MT0,#^91<26$6&D:)>?PC0 M8[ZC3+?4+BB(.>71, O^(4(_Z)80&N/D54\?$
M#PMS6F(^Q,U_SP6,[I6-_L-L@ET@@@(OJ K$OO?_^@1OD;'AF?X;&2/<C1$6
M8X158WQY6O*R$.+FOM?\B+!H[UBTZ['H"Y&SE-SPI52FC Z.8U3.$3J='9U.
M/3H3KA)I/X*8P*=4ZI\*I,V"_.7%BXI%T=UQZZ*(@UPI2VV4Z @\=<N90OGA
M:,VF3YL!QJNWX]6KN9 4@Q10K-7#8<2Q9BS56!Q/=IQ.4)R->(V2E)/K/+OC
MJHP+CN%Y?C/H]3HG"!_?<]+JU6%TP^>)-N H0ZY95AJW"J /GS]_'$_Z9/*A
M?W/5?_W2[WCOQ]>#8XSE7@+PZ[ <BT@JB& A/$=D:F")$:G(0.;"J"?X'Y=3
MQ]&'EQA)ZDC2.B2_L$<RCF'A);,D6DODX5!70/;\9CLX:7=Z78RADV\_J,.P
M'\>*:WVTO2"%@G\6Y;[#(8.V!\MY9A:D_\!%SH](E\+'/TJE5!"A/#%\O1:Z
M-/2P2;C\X.,*_WP2 WL'B^"+7(G2">!PUU#VW4+9AW%S6</'Y?XYM]T*G2CY
MD(BHW,,XYO4M1LUE$!\7_N?4)E(;D.L_D^7ASP9']#W?[V'<7 ;Q*U+(YONU
M*B3+@X@#_!H&&!&7,GQ<YXNUU(?>Y+!/<  L<?DN2_BXQ'^2-I-.%E)@::("
MI'?BD4Y .MA71UV>H+B\?TD,Y"PY(SY]<_>63'F4*W!6&:\*I(',,M#$J9'1
M_1%YY1U[D-'(!*J&;RS-.5ER1:8+IK!\2UWFH+BV0_*/$S$GTZ?L3J:E='$
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M8"#WY/3I-/Y BN.1G>,'$]$C>V,@#"S?SSK:..A6KH='*!0ICD=VCK?NTV/
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MXWU(D$,"_5R"[5R"WSN7CA(- Z5$?>@&CO&."K<3"W]1@YJ$2NK% MH0EHK
M&/EMT&<5U.<WC>3J7(-RPS! ;=BE!N8YV'?U28..4*?.;VB;DV;45M_D.UTW
M- 6\(Z?A(9VSIL=%GL[YXOZSNWM"P7O03GR[3<HDF"90PVG2DFD@NQGQB0>)
M5&<#S)0VP8[03H_*-#KNTPE4F<]SZC]#*(+Z('E%"^KL-MK@B))OZ8;Y6P.1
M[^(&TEJD58OUY)H8<(96# 4U0SLWOS(3G25S-7&Z 8(>E).C(G$ 0Q\CPY0$
MI</].5WE#/I,BS@I=U9AOJJDO4YS3)J1K!54"1\JU;-BVM,4B@#:)<&!T^RL
MH*_&ZOH>-L4K6!_::7^2%S1YR$"\Y@LLBW\ 5D19R7<L]=G>_+_KDBUIQK:R
MBT7/VLV5AKU#C.6,=Z#:<Q $#^T,7[?X?G6(.*]RON);MDW\]+FZIMJ=9:B$
MXKJ>*P?<@6KOF 2W(CNW?N&Y3 T;2J029)]@SNA2:-VX=G""1Q%\#?%3+OVL
M2BG4K==FC)80DEJ-!B+?Q0VD)=L1+T @"2H-KD\\5QKQ7 >##JZGT,ZM"H30
M#\+0D-N=O?*K-LMJ;BUR2I]G514@R'4!#F7:TR"MG1T)!8'P+Q!>2,@$9)<)
M^PBO$>ID^4DWY),&@A%!GKQ.51U ^/Y2DG 7^WF[[/36SIL0%6C_#?\^LF&$
M5#& 0C^0TZB1#"$TZT$D) /Z99(!=4L&I,H!3R8P.Z8]32$9T&^1#$B5#+QW
M.A :XA62 =DEPS=:LF8CR,=F11(SRRG_I/%F3;VJ"TR+1X@"9!<%EB@[,Z>R
M/G0\0T18L#ZVL_X;22VL(7Y(E/UB)ZP]"R$/L%T>[.25UCT=//!I: \')[B;
MXK%*M:9$"Y;%=I8UA=A5=ZRA2 \1 ^OCG0-H^Q;[$'V*U5UVX+FR".Q"M0,6
M#(OM#&O3IUAEISXACG(NU8UK!R=H#-MI[)7ZM#I74W^QP^JYM2P/-!!9PG9[
MF6(-.SHA"F0)J\'U/<>3"GZN@T'B0P?*Z==L^5T/(@-;84'*V$[*/R%A#:70
MG,VK*D.'<D,2^% 6NAJD5>AB0=38_P5"%PNBQ:\YDC_D/&R,.\EWT@V9XKWY
M&0M^QG9^?MLCKC%6.;L/40#ER6JHG:.,8I4(=B=V=G]#L=J,9*L(4=D=.;):
MU?C9!;4G*@0 L0N _Y-<);H]M^/X<F/3X9#K(%,!A6H@>ZN&?60M44_VE2*I
M>L(4I= 2Q*XE?D+6$E4L$.P;5_[.+]9VM?!&NI9H#M-1("L>HNZA6ZCV'(2H
M('91<8A$(RK%^AZ1=7@7JAVPH&%BIV&;1",J _9]UU-.-[MQ[> $41+[CO:U
M$@WJ.CI1?^B6J4L#D25:MY>IS@OT(9;2]5F#ZQ,_D'^WU<$00KXGG_-H@$'H
MA@:90H1L(';9\#,*35\)E?ZA%_IR,504\G& 2:#41$7J%=I@Y^G*ZF'FRZAX
M2#B5I/2>6SH?JX=YB\WSP9LW+%_5#US>Y8SER_IR02,NS"H __X^S]G+F^H9
MSNU3VB?_ U!+ P04    "  )/'A4EA@+4*$"   +!@  &    'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;*54;6_:,!#^*Z>HTD":&@AO;05(0((:K2V,T$[[
M:)*#6$UL9AOHI/WXV4[(V%KXLB_$+W?/RYF[_H&+5YDB*GC+,R8'3JK4]LYU
M99QB3N0UWR+3-VLN<J+T5FQ<N15($IN49Z[7:'3=G%#F#/OV;"Z&?;Y3&64X
M%R!W>4[$SS%F_#!PFL[Q8$$WJ3('[K"_)1N,4#UOYT+OW HEH3DR23D#@>N!
M,VK>C7LFW@:\4#S(DS48)RO.7\TF3 9.PPC"#&-E$(C^['&"66: M(P?):93
M49K$T_41?6J]:R\K(G'"LV\T4>G N7$@P37996K!#_=8^ND8O)AGTO["H8QM
M.!#OI.)YF:P5Y)057_)6UN$DH=4\D^"5"9[571!9E3Y19-@7_ #"1&LTL[!6
M;;861YEYE$@)?4MUGAI.9D_1["'T1\O AVBI/X_!TS*"V13TU4NP6(;CAP#F
MBV :+!8V9C;Y J.G<G4_>_"#1?0)@J_/X?([U/Q@&D["91UJ<R*0J105C4E6
MARN@#)8IWTG"$MEWE59O-+AQJ71<*/7.*&UZ\,@UGH2 )9C\#>!JVY5W[^A]
M[%U$]#&^AE;S,WB-YNUSY$/MJGX%+LA4*Y<7"%I5<5N6H'V&($)!48(/,6=[
M%(JN,@3=.VL4 A/0CQN_7J!I5S3MBS2AE#O"8M0T4GU8V2*_9_--F^Z'S<Y-
MW]U_0-JI2#L722<\SW5760_P"\+Y[(*3;@7:O5PP4WE=(:K-U/3?Q3S*%D7Q
M(G5-<^YY"IO=]S;;'[OL58)Z_UG:WCO.V]9-]Q]6]Z1!<Q0;.X:D!MTQ5?1J
M=5I-NE'1X'_"BS'Y2,2&,@D9KG5JX[JGGTD4HZ?8*+ZU[;[B2@\/NTSUM$9A
M O3]FG-UW!B":OX/?P-02P,$%     @ "3QX5/F\AE0G"   "",  !@   !X
M;"]W;W)K<VAE971S+W-H965T-RYX;6RM6EUOV[@2_2N$L0\MT-0BJ2\728#$
M;K$%VL:HNW>?%8F.=2N)7DG.Q_[Z.Z04R29'3+I[7Q+9/ASQ#(=S9BB=/\CZ
M9[,3HB6/95$U%[-=V^X_S.=-NA-ETKR7>U'!+UM9ETD+'^N[>;.O19+I064Q
M9YX7SLLDKV:7Y_J[=7UY+@]MD5=B79/F4)9)_70M"OEP,:.SYR^^YW>[5GTQ
MOSS?)W=B(]H_]NL:/LT'*UE>BJK)945JL;V87=$/*Y^I 1KQGUP\-$?71%&Y
ME?*G^O YNYAY:D:B$&FK3"3P[UXL15$H2S"/OWJCL^&>:N#Q];/U3YH\D+E-
M&K&4Q9]YUNXN9O&,9&*;'(KVNWSX7?2$ F4OE46C_Y*''NO-2'IH6EGV@V$&
M95YU_Y/'WA%' V@X,8#U Y@YP)\8P/L!_+4#_'Z KSW34=%^6"5M<GE>RP=2
M*S184Q?:F7HTT,\KM>Z;MH9?<QC77BYOOFUNOGQ>7?WXN"*;'_#OZ\=O/S;D
MYA-97FU^)Y^^W/RY(6?DC\V*O/GM+?F-Y!7YL9.')JFRYGS>PAR4I7G:W^^Z
MNQ^;N!]EY*NLVEU#/E:9R$X-S&'R P/VS.":.2VN1/J></J.,(]19$++UP_W
MD.&K5P^G"P<;/JP'U_;XA+V;O:B3-J_NNAV1M[EH/CCL^H-=7]OU)^Q^@Q12
MR 9=L6YDI$>J/'%_>18%81B<S^^/_8C ?-^+V2ELA<&XQZ,!=C+_8)A_X/3+
M5?9?V R0<-J&M!(R3BJK-"\$J7IBZEMUG2;-CAP:D:E E;_HS7"83>CTYJ:5
MZ<\SE6\RDLH2DG"3Z#0F'M6UP+S<60R/_!*%OF_XV ;%81 9'K9!07"T6B>,
MHH%1Y&2T$B ;:=ZQ@*U-DE+6;?[WB[0B:S)^Z'L&+01$ P.TLD'<"R?")AYH
MQ4Y:-^U.U*22U9F.B[P5);H%8NO>E+'08&&# FYP0" ,9[ 8&"R<@;_<)=6=
M:(QH;AH!&T&M4Y$GMWGQ8F13;Q0$S^FRJS25![7-(!Y$?I_<%NBZ]U:.J9[1
MA6\X9(G!>! 9KEVAL%!E5,QW]$C=J)/,]X$#T&E$4J<0!%4*:02J#5R^J#T3
MMC!S(88*8A:8M%#88B(D*!MI,2>M=2WV29X][\LN$J2.]?10UT"O#Q&4(;,G
M%7D+:E)$8(S%ULHA,$KY!,-1!BE_[<9]F1!'THNY>1'0&?5B,PDAL#B<"L-1
M?*E;?8<]M4^>)C>4;]\YB$T6-BADB]@D8:-\YDVMR2C!-'A!([8"UB*#K70O
MJL/$_@GL5.HS9O*P40&E)@T;!!6'/[5[1O&F;O4>:ZQ"@(0?IU"4D:VW9S2(
MK:7!8#$W%0*#,;X()TB-^DW= @XA5A\$FA)>XH>H<V1FZ"6" GJ^R<Y&!71R
MQ485IZ^6\3X;O,3)%N(S)"<@J./9]IPP%.7>!*E1V.GBQ9+\Q6H5);>P)Q2&
MGDT/P?$%YPN3((+S:<0ISI"-I03SG+7+YPI$]A?*;S;J.G/K^OH 2IZH,)=;
MLJ^5Y]HG'?+BKT.^5WT"YCF&Z#%E06QJ'X9C/#(3%&INL9B0"S;*.W/+NQ49
M.>)(E!\FQA@_3-L1?IBY:7ZCN#-WD_LIKQ+HWEX?%Z/0,K?0KI.GKD>L19&T
MX#SH"K?Z;J)+]KC;;+V$GM5,\!@**@C39QC*GVI_V2B^S"V^ZUJF0F0-V=:R
M)'G3'#0I"']09"%*7>-"4WP/.R%7U]#/]7+=J&[UG>Z. 3X,366#UE,K9NLN
MCUCD3U 8=9>Y=7>:PO]EWDMF2RMG/IN05C9**W-+JVO>90GM\2].])K9*GE<
MGO5L$%EF(3</ Q!8Y$?!%.E1<IE;<H>=M)6U.DCMED1NX4)MW.E%0-22L:G8
M&<62N<7R.S0\_83 Q;>R!@LP#]R]MIZ9!Q((Y(QRJP+%8/%4.<-'7>3N%GO(
M[V_Z!/]6:=A]GL&'VZ<^8;V<[3G2-#-NMJH(*N(^,QL?!$:]111,% %\E&KN
MEFI%]DTFTEJEW[>J^]972M:4#]YUGE"R?9\4>H&5C$.WWM9YJE*X^AVECZAO
M%,?<[#40'*<1M1Q@PZ"H8E/\1S'G;C%?OIHD25IR*^[RJE)KKPH;V&LR0[G;
MR@PB0Z/(Y([@* \B\Z "P?G0?4[4N/SH--O=QG^$?)'JK"@>4WV21:#$A=38
MGVK)?QT$=K_.@M!R ]+\,UN[,1CUI@2$CU4)=U<EOQ8"0C5NSL5'#@'"!;7B
MWH9A,;+"<*<Q<DI[+%FX^\Q^<]CO"Z&2=E*0+&_20C:'NA-.Q75;@,6\ZAY>
MYK)RE8!\K#*XN\I0SB;Z=$PI5UZU0OD8]2/2BOMFU8>!%I8+$5 XH7E\K#NX
MN^XPF4"U(4B;/$ZH =:@FV1LS-06'PL%'O_351[.W3%%<Z[V6!=P=UVPU)6C
M?@I]6@H?E9&[!"* '/: :7>"?%[?8%4OM[6>@DP>!<3I@[=1[7VWVJ_1]I0D
M69:KJ-='^XEQ0-@]@C&.=-!G=T@-$)E'&$L$99X6K#!+="(Z_%']?;?Z?]%:
MWS^OD+=M K_KEG;0 Q7;E7@X.OUXU:F<;\LU@R;%)&ZCZ$3YYH^*[KL5_813
M)M2SR+LJ_QMXZ1CKII^J%J H=&)#Y\^LYZ34"\T-BZ"X6;A@EF*3Y/SH%8%2
MU'?Z58N&Z*CKGK4/WPZO<USIEQB,[Z_IAU7W4L9HIGM'Y&M20^W2 /\MF/3>
M1Z .=??:1?>AE7O](L*M;%M9ZLN=2,"!"@"_;Z5LGS^H&PPOOUS^#U!+ P04
M    "  )/'A4![X7QI\%  #N#   &    'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;*U7V6[;1A3]E8$*%"T@:[/3N/$"V%ELMX@MQ%W0QR%Y*4XTG*%GD:)^
M?<\=4I24.$$?\F)QEGONN?OX?&W=TE=$07RJM?$7@RJ$YM5X[/.*:NE'MB&#
MD]*Z6@8LW6+L&T>R2$*U'L\FDU_&M51F<'F>]N;N\MS&H)6AN1,^UK5TFVO2
M=GTQF ZV&Q_4H@J\,;X\;^2"'BG\V<P=5N,>I5 U&:^L$8[*B\'5]-7U"=]/
M%_Y2M/9[WX(MR:Q=\N*NN!A,F!!IR@,C2/RLZ#5IS4"@\=1A#GJ5++C_O45_
MEVR'+9GT]-KJOU41JHO!Z4 45,JHPP>[OJ7.GA>,EUOMTU^Q;N^>3 8BCS[8
MNA,&@UJ9]E=^ZORP)W#Z-8%9)S!+O%M%B>4;&>3EN;-KX?@VT/@CF9JD04X9
M#LIC<#A5D N7]S)$1\*6(E0DLNAQ[KV0IA"(M#3J7\G>.Q\'*&.1<=X!7[?
MLZ\ 3V?BO36A\N*M*:@X!!B#94]UMJ5Z/?LFXAO*1^)X.A2SR6SZ#;SCWO3C
MA'?\/4T_T'32:SI)FDZ^OY._#3P=B?^)+6X?'GZ_FU^)>261S.+.P)D__?C#
MZ6PV.>O.TFIZ!KF$U1V^MG4CS:8[_%DH@(L<3%0NM? !I2LR99N$FU,,:3]O
MI5 @*Q1^H\P"4@9%FFL)>J"KZCH:"T5.-DG*I_(";2-4\*)QMG&* EJ%D(Z,
M7"D7L:UEX%X$BC(PF8*\6AC(!8LN :F%DW7K#%LDVM.79[Y51\)O?*!Z)/[
M>6>96$L<F]RZQCH9@!21L:T/C*R3;V_15E0CQ;6R@?)JV/IO=T_+M=_&X#$
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MIDC'37AD,=*-Z4R.SYY[$HWWWJ"P<I%>VMPW$)_V.=KO]H_YJ_8-N[O>_B>
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MI]BCIF96M].O"$(?")XW3(NR'7LA_@2?SC_:#O32SR#504;\VNWR1J4[6*7
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M@XB^M8E&\,U>59<<3(+=F9Z&K^,%KR\]&>L/1G)7:V3D6%$]@ZQ-!0G5O@V
M]7YV46TG(2%S#>-$@I:><MJR?A7"!_R.$?-ZF]6X8IOE/*$_M'MP&"^AU^N8
M;BU4/*HE%'AK"F47.Y<U]=G+QW[0XE;"W4T.<(,5;=X:A/[2+5><4'@.(*K
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MF</$<J\-]\U#H8#RH5OOUJLP+P]FB_C=U76&KR4PIX.<9C#S4TR\O$E>P[B
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MLAW*^?D4I]&<X=![5US5&_A2&T)IMERUW5AKH9W1-%STD[>L! ?,(/NC.4J
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M"8=DYY!XWET@S_**63:?:K4%[:P)S6U\JMZ;R''I#F5A-;WEY&?G%V6I6ZP
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M,3<N>&ULO5AK<]LV%OTK&&UVMYFA)5&2+3FU/>,D[30?.O$DV^YGB(1$;$"
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M8A:/VK]#4+H1BVD\Q?Y%$J?XF$_XHUW8P*-CKD;I0]P\]8UX_L%T15KD=4%
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M/%0_Y2=>?QVKPT.M\2Q*40_799^3]C'9\)&8!\OA.+W@,W@QX<KA2R@#L=M
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MZTYX)RLQ'HV?1/S)X_ZQ5-76<\AOO%&WC#3LDMF#P9*=$'Y$-L$>$"'+P9E
MMUE KD;2L8K_A-]7F>;$Y.V;9"Y5+GDWLK"U@>O!WH+Y8C>F<0]RLQZ!2.PV
M&MP@DKK>>I'@O$MH0^HROVDMV+C&P0P9DE-E@8#D>"]Y97L;RG25ELH%C\8B
MZ9!W$ )2;)3(4.A90UH30L:R=D+B9(UU788<&VZ8G>5OK\>]#WGZ&^EU4-C*
MB0HZTBN=2A(8QYXB<'FY,PT12X60A.VYG5)^N(*%U\Z6-^+CZ/U(K%2&>))W
MHR&?&?29Q$^^SD::0SJTN;_?[1\;!NX(!\UP3T=[U=W6UH$O)_%H_%0\><
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M.A[-9T>^[],\.+OEOZ,LK7.VX)\;)>&+- 'O5]:ZYH$8M/]/>OE?4$L#!!0
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M'6Z!<PN$-/[L,;V=2VNX_SZ@?W"Q8RPKJN%6\F^L--65EWFDA#5MN?DLM[]
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M#SK'_!0@)F\&E]*C2^OT5<1[S*8PGTT@3=+9*WCS(<1YP)O_3(@GB%<#XE5
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M:C)]^R8"VXTXW<*;.HP5U*=H2 F?)4V%:%F S@MC_''!!H8Y<_4=4$L#!!0
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M^J77)%99!!C6!:^?!'.4VB.'$5%6..42I8JL &4$!,VT-7H$=?^E=9#\1Q%
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M7W]\M#B!T;SL<"=8G$Y;P2@0<%8P5&)DZLBJ6^GV6XA)6RH^[,!!,5#LUMK
M48J=;MX!3I;A^@&>VF"UGZ;1/-*2T*IZ]+ *FV%5\28!7;?!+@7R(0T#[\<@
M7O;8<Y&;[."E'WC7@U3&;0T;WY+I, Q\T$3(7^5GS@^(%$/A6';&H_=QX]CT
M-B2;'$1D[&Q*5TT?J0ZY S6Q+G1T>&P>(G8&E$?<E,,ATX(6#H-HW.5R?5<]
M2EA[#+5>HZ)K57G)U<TRK<2FH$;!XW2*NV!/F-X^]'F<Z?OD/[@^=HI9'IP%
M6[+;<.)U,6[Q6#B_G0_5U_$LN5\>3^1H45N%1#>T@6B6GJ\7PL93;GSPI@LG
MR])XG%/#[0X=FRPOP/>-0=C'!S8P_ZOAZE]02P,$%     @ "3QX5*< EBCD
M*P  \9@  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULQ7UK=]PVDNA?
MX?%F=^QS6K(DVXD3)SG'CSCQWLS8:R69SQ2)[N:8378(4K+FU]]Z @6^+"?9
MLU]L=3<)% J%>E?AVYNV^^#WSO79QT/=^._N[?O^^,W#A[[8NT/N3]NC:^"7
M;=L=\AX^=KN'_MBYO*27#O7#B[.S+Q\>\JJY]_VW]-V[[OMOVZ&OJ\:]ZS(_
M' YY=_O"U>W-=_?.[^D7[ZO=OL<O'G[_[3'?N4O7_WI\U\&GAV&4LCJXQE=M
MDW5N^]V]Y^??O+AX@B_0$[]5[L:;OS-<RE7;?L /;\KO[ITA1*YV18]#Y/#?
MM7OIZAI' CA^ET'OA3GQ1?NWCOZ:%@^+N<J]>]G6_ZS*?O_=O:?WLM)M\Z'N
MW[<W/SE9$ %8M+6G?[,;?O;)U_>R8O!]>Y"7 8)#U?#_^4=!A'GAZ=G""Q?R
MP@7!S1,1E*_R/O_^VZZ]R3I\&D;#/VBI]#8 5S6X*Y=]![]6\%[__27O1M9N
M,U_MFFI;%7G3 [**=FCZJMEEQ[:NBLKY[/X[^>O!MP][F!H'>%C(-"]XFHN%
M:<XOLK^W3;_WV0]-Z<IT@(< <P#\0@%_<;$ZXBM7G&:/SC?9Q=G%^<IXCP(B
M'M%XC_XT(E8F>QPF>TR3/5Z8[$7N*X]3P4GRKNESI- YK/Z!8;)?]BY[V1Z.
M>7/[7__Q].+\JV<^*]K& _AEWKLRVU9-WA157F<>7G%PQGJ?[?-KEUTYU^!@
MQ[R#YZH&W\.37_6W0)?]/D%'5\$@QQHH8^<:U^5U?8N_NV//[_8 QZ]-A9\N
M<1Z"]/G!=8#9[#Z"=G'V[,?GS]_1G^?/'IP2Z#@% 8^3?!IN *(>2D>S"70T
M41^QD.4-  1?W^Q;!+*]:6 T/USYJJQ@ST^SYW4- _6N*_0-'0E?[;N\\3EQ
M$8LG5U=P(/,^8$H@A<=.5VCD2:"1)ZN;^V,K""A<-TL;G_%Z=@EH<H@KV!V
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M]+G8-+P[_VP[D(T_@60!'O&VV^6-2AC0C.$@L#K]]K<WKT[.OQ9&6;=7@$U
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MS,A(>](8S8'A@\Q6GXC'9$18Y' D^ *F-MF_AG+''+U%UG!=>7ZI "6>5,;
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MVKAM_#.)-@3X\XJ(MT80&!_>Y5]02P,$%     @ "3QX5#&HM1CH @  * D
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M?!A!.P/\7RME1\$YF)[:S7]02P,$%     @ "3QX5##IX>7C!0  ?!H  !D
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MB@CP^T1*LUJ0@/:_&N._ %!+ P04    "  )/'A4"\P46YL%  #7%   &0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;,56VX[;-A#]%<(MBEU
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ME96O6@FX<*"&^5$03/T&4^YEJ8O=RRP5G6:4P[U$JFL:+%\7P,1Z[H7>)O!
MJUK;@)^E+:Y@"?JQO9=FYX\L!6V *RHXDE#.O9OP.I_8?)?PB\):;:V1=;(2
MXLENOA=S+[""@ '1E@&;QS/< F.6R,CX,W!Z8TD+W%YOV+\X[\;+"BNX%>PW
M+70]]ZX\5$").Z8?Q/H;#'Z<0"*8<K]H/>0&'B*=TJ(9P$9!0WG_Q"]#'[8
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MU$@9SCYC2'H8+,/&JMZWVJ.RV+A^V>(L!NT,\+Y6RNXVSL$TW?,_4$L#!!0
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MB* +J6B^SND2_<9C&SCI&EVO%6,014:CBSDSE O]$?V(?N("0A@U6;+*#GU
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M\]3F7N@E)-3+%2@RS!3 + 7D1TD+/;?J"C"]\M[OB,(TDQ_ 1_#M80?>O_L
MW@'*P+]'7DJ=(%>NTE0,H)O4P]Y5PZ(+PT($OG"FCA+\Q5*2G@.XNH:F$/1:
MR!V:1-R1Y!KX\ H@#\$10MNWIWLCZ;LWI\/E1#5^,RV^Q?-_,2WG\S$!'#3
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MPWHCRX-Z>:/%RIYUGX2&D[.]7#*:,FD,X/U<"+V],0/4GTNF/P!02P,$%
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M !?S@#)GE!,-&#\S/T@NA5%L5]M].$K:F%N>041)T ,=D0DG.)..,YGE?!1
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M@S$1.P_R+CS/UA%@9TC0[DB/J5HE*<L3H/;5($XQW9!R3T-.EEKS0WCXPE[
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MSA8(H>O#8CVPJO0'M&ME\;CG+S,\8(-V#^#\7BG[,'!GOO;(OOD'4$L#!!0
M   (  D\>%0UJ1@MK@(  "H(   9    >&PO=V]R:W-H965T<R]S:&5E=#4S
M+GAM;*U6;6^;,!#^*Q92I4Y:> _MJB124SIM'RI5C;9]=N$2K!C,;-,T_WYG
M0VBZ$19I^P)^>YZ[>\[<,=L)N54%@":O):_4W"FTKF\\3V4%E%2YHH8*=]9"
MEE3C5&X\54N@N065W M]/_%*RBIG,;-KCW(Q$XWFK()'2513EE3NE\#%;NX$
MSF'AB6T*;1:\Q:RF&UB!_E8_2IQY/4O.2J@4$Q61L)X[M\%-FICS]L!W!CMU
M-"8FDF<AMF;R-9\[OG$(.&3:,%!\O< =<&Z(T(V?':?3FS3 X_&!_;.-'6-Y
MI@KN!/_!<EW,G6N'Y+"F#==/8O<%NGBFAB\37-DGV;5G$]\A6:.T*#LP>E"R
MJGW3UTZ'(T 8G0"$'2 \%Q!U@.A<0-P!8JM,&XK5(:6:+F92[(@TIY'-#*R8
M%HWAL\JD?:4E[C+$Z<5*BVP[,<KE)!,EWB9%;4(FQ&X14=OI"^5-NW&9@J:,
MJP\S3Z,#AL;+.F/+UEAXPE@0D@=1Z4*1^RJ'_#V!AY[W[H<']Y?A*&,*F4NB
MX",)_3 8<.CN?+@_ $_/A@>?1J*)^F1$EB\ZP7>K\.NS>BO2F(RPBN@"R))3
M3-(J*P0'U65D4DN6L6I#2I$#'S$>]\9C:SP^8?R)J>UD+0'0J@8)2A-)-0QE
M>9PH</VKBZ%<C,-\-XZ'8.DX+'3#X&(D_&D?_G24Y_ZUQE*$FF/L);E$Y?=
MY? M'V=*6B0),#5XV4E"<KI70X+\)Y[TWWG>29;TDB7G2?8B.-8&SO1^2*UQ
MDNNI._4'K\M?<+X;#N+2<=Q5_">NC=X[JJ(ER(WM1@JK8E/IMB+UJWW#N[5U
M_K?U)3;"MF^]T;1=]('*#<./F\,:*7WW"C,GV\[43K2H;:U^%AHKOQT6V,Q!
MF@.XOQ9"'R;&0/][L/@%4$L#!!0    (  D\>%2T=-YT; 4  )86   9
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MF4] 1M9X7XC/]/DO8@*:*GLI+;C^"YZ-;# !Z9X+6AIEZ4&95_5__&(FHJ.
M(HL",@JHKQ!;%$*C$/84H TA,@J1GIDZ%#T/*RSP<L'H,V!*6EI3#WHRM;8,
M/Z]4WA\%DU]SJ2>6CX*F/Z[5S&4@I:5<3ASKA%P#_0G079N?7+R"MRLB<%[P
M=U+BZ^,*O'WS#KP!/N!;S @'>06^5KG@5W)0/G_9TCW'5<87OI#>*DP_-9[=
MU9XABV<0@4^T$EL./E09R4X-^#+,)E9TC/4..2VN2.J!$%X!%" XXM#]Y>K!
MB/KJ8G68.*()F\R%VEYHL??WOGPB#- U>-13[S 9-28C;3*RF+PCF[RJ\FHC
MMU*!JY2,9:TV$6L3BE4.RW ZG2;1=.$?1K"G#?;4B?TGPY7HI[E&G X0DR28
M1O-QP+@!C)V 'UX(2W,^#AD/(*\AFNJ\CV'.&LR9$U-2U9KDEC!G(YA)@!++
MQ,X;S+D[SBH[D]'Y #A"(82S=H+K[3&4<V8^:1Q,G [^4S,,J?.!GXI1)Y,!
M.$(H"J-D'!P&+0$&E\#OJP/AELP8"R?@LJ[.D0V\P[[0N8F_Z[HDN??V0)BL
MLQDX+DOPP/)^NDY!4 N"_ONV-C:23HQS+XJ2[L\2;<M8,/S=/6XT(>S@0^A%
ML06SI33HYC3G-C>ZIZA>$EI 6RZ#;C)S[G.CVP_5LHM@RV?P#*&=W>C&P ER
MXB$8='ZPM^F-SN^LBY85H9L6+V, 8^3$^YD7(PMZRX_039"7$,!\, DP\!+;
MXFR9#R:_M/W!9Z)Z=97&>]G[,-EU[7$!OA!6NOJ?ENN0F^M^ 0^\E>W;*\&,
MOQN;D3- LUH5Q*#4/=QHMW69"1@8&P!%(,.OKD8'M<2+X/\U$U?''OC,^CR#
M&)MX9L=PXK/1M R/W S_.]&XUOL9N+DSNZ<QM,4!N8O#[6;#R 8+ CY*CW-Y
MLDS!-USLR15XNJ2 &?.S[AY%\]!"3J@M(,A=0!Q^D;.,BX;=,HRCH,>Q1NI2
MU]LRA-QER.'ZA4MZV'K#&$46O]I*A=R5ZKQ?SL49#V?+PL2H+4'H3&>.<P8.
MR@>PDZ<J>1262QMP?03>J\/QFLI17*3[0IZ/9=+SQG.M-7K -9C=LH&\,.QG
M?R@EVX$@.15;C8DA#UEZ%=26/^0N?V>3P8^KQ)*.^3 =LH_H!SF40DE?:C5F
M*PHLAR[4EEGD/F$T](@-/6Y4(WJ=J:#7IXG7UQCJ4,T[MQ^\5K#$GXREK].X
MF@D8BLV]Q-)'F=D8JLR\Q-+OA&T3$+H+ZQ<J9"WHQ#V(UK[WC.EN@N)ALD>D
MIK$MC6%;LT-W!;W'? L824E^4!N2T;)'8T3R1G9,HKG4VN'7DE0"8"93N"'J
M>72O&NR3!1KTM^J(4-R368W(#.C)[US8E81M],4GEZRSKT1]G]6,-I>KM_I*
ML3=^!]^OZBO2UDQ]8_L),UDT.2C(6IH,O)FD<E9?@M8O@N[TM> 3%8*6^G%+
ML)P^)2"_KRD5QQ<%T%Q%+W\"4$L#!!0    (  D\>%38'B"@&@,  +X)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;)56VV[B,!#]%2OJ0RMMR:WE
M4@%2@>WN/G15E6W[;,( 5AV;V@YTI?WX'3LA0$M"X2'8SLR9<V:<L;MKJ5[U
M L"0]Y0+W?,6QBQO?%\G"TBI;L@E"'PSDRJE!J=J[NNE CIU3BGWHR!H^BEE
MPNMWW=J#ZG=E9C@3\*"(SM*4JK\#X'+=\T)OL_#(Y@MC%_Q^=TGG, ;SM'Q0
M./-+E"E+06@F!5$PZWFWX<TPC*V#LWAFL-8[8V*E3*1\M9-?TYX76$; (3$6
M@N+?"H; N45"'F\%J%?&M(Z[XPWZG1./8B94PU#R%S8UBY[7]L@49C3CYE&N
M?T(AZ-KB)9)K]R3KPC;P2))I(]/"&1FD3.3_]+U(Q(Y#W*IPB J'Z*-#582X
M<'"9\W-F3M:(&MKO*KDFREHCFAVXW#AO5,.$+>/8*'S+T,_TQT8FKY<V$5.2
MR!1WAZ8NOY?D$;11+#'XQEF1)\&,)N<C,)1Q?;%OHIU)9DVZOD%F%M]/"A:#
MG$54P2*,R+T49J')=S&%Z3Z CY)*7=%&UR"J11Q!TB!Q^(U$010^C4?D_.SB
MC/A$+Z@"G3\/\!Q^'36HA]MC'9?5B!U^?&(U:J"O2N@K!WU5 ?T[2R>@B)P1
M>,LH)TQH0SG'+Q)KBJLK+"43<_*/G!VJ7P[>=."V-:SZ5UU_=8#/=<GGNI;/
M'XGAR8PR15:49V YJ(_;R9+"206G/$!KA]-U8'^'B35+8LW:&FP3-3Y6UE8)
MV:K5.H Y$\)F=T(Y%0F@HLHM.&A]3G7<VE&5;]3/5A6ZVR7)=BW)YTVNJYFU
M/\6\W*>V%[A3!N[4!L9/_HNI&7:.I&8O?AAL>V!06_(7U^Q1_.T*%!Y>Y(>B
MPA!LJ$#N[ Y]MCNT9B.$.^TV/'DK;!O)P<Z9 W9V1(=AH]VJ$!UMF41?J_>1
M\-%)X;>=+HQ/JWHMC6&!=HR&OW,2IJ#F[H*@L9=FPN2'1[E:7D)NW='[87U@
M+R?NA-W"Y#>;>ZJPA)IPF"%DT&AA&U+Y92&?&+ETY^U$&CR]W7"!%RQ0U@#?
MSZ0TFXD-4%[9^O\!4$L#!!0    (  D\>%3&N,1@DP(  /\&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;)55VV[B,!#]%2OJ0RNUY ;9I8)(0/;V
M4*DJZNZSFTP2JXZ=M0WI_GU]"5G* F)?B"]SCL^9,>-9Q\6KK $4>FLHDW.O
M5JJ]]WV9U]!@.>(M,+U3<M%@I:>B\F4K !<6U% _"H+$;S!A7CJS:X\BG?&-
MHH3!HT!RTS18_%D"Y=W<"[W=PA.I:F46_'36X@K6H)[;1Z%G_L!2D :8))PA
M >7<6X3W66+B;<!/ IW<&R/CY(7S5S/Y4<R]P @""KDR#%A_MK "2@V1EO&[
MY_2&(PUP?[QC_VJ]:R\O6,**TU^D4/7<^^RA DJ\H>J)=]^A]S,Q?#FGTOZB
MKH\-/)1OI.)-#]8*&L+<%[_U>=@#A,D)0-0#HD/ ^ 0@[@'QI8!Q#QC;S#@K
M-@\95CB="=XA8:(UFQG89%JTMD^8*?M:";U+-$ZE:\7SUSN3N0+EO-&W26);
MD#NTXDVC!S8"+3HL"HFN,U"84'ES8O\./:\S='UU@ZZ0CV2-!4A$&'IF1,E;
MO:C'#X12?8*<^4H;,#+\O!>[=&*C$V+#"#UPIFJ)OK "BH\$OG8^V(]V]I?1
M6<8,\A&*PUL4!5%X1-#J<GAP!)Y=# ^G9]S$0S%CRQ?_9S'/4(\'ZK&E'I^B
M-J7LJ;&K=24P4X=5<$EW7(GE,HUGF^KL;/?S^F]$G$3CZ<>H[!S/!QN3P<;D
MK(U%50FHL )48B+0%M,-(%ZZFWJIO94[8[(O:Q0?%Y8,PI*SPKZ9TU!QH*P%
MX:0=4^$(IWLJIJ-)<B##WVL-#8C*MEBI;\>&*?<W&5:'+KZPS>M@?:F[NVO&
M?VG<T_" 14681!1*31F,/NG$"-=NW43QUC:@%ZYT.[/#6K]0($R WB\Y5[N)
M.6!X\])W4$L#!!0    (  D\>%272"-Y-P,  '8*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4W+GAM;*U6VT[C,!#]%2OB :2%W)L6M96 LI<')$27Y=DD
MT\8BL;NVV\)^_8Z=-(0V1"#QTMK.G.,Y'GMFQELAGU0.H,ES67 U<7*M5^>N
MJ](<2JK.Q HX?ED(65*-4[ETU4H"S2RH+-S \P9N21EWIF.[=BNG8['6!>-P
M*XE:ER65+Y=0B.W$\9W=PAU;YMHLN-/QBBYA#OI^=2MQYC8L&2N!*R8XD;"8
M.!?^^<P/#,!:_&&P5:TQ,5(>A7@RDU_9Q/&,1U! J@T%Q;\-7$%1&";TXV]-
MZC1[&F![O&/_;L6CF$>JX$H4#RS3^<09.B2#!5T7^DYL?T(M*#9\J2B4_27;
MVM9S2+I66I0U&#TH&:_^Z7-]$"U $+X#"&I L ?PHW< 80T(/PJ(:D!D3Z:2
M8L]A1C6=CJ78$FFLD<T,[&%:-,IGW,1]KB5^98C3T[D6Z=.I.;F,I*+$ZZ2H
M#<@I>??3\0PT984Z0:/[^8P<'YV0(\(X^9V+M:(\4V-7HV]F!S>M_;BL_ C>
M\<,/R(W@.E?DFF>0O25P452C+-@INPQZ&6>0GI'0_T8"+_ ['+KZ.-SK@,\^
M#/='/6K")DZAY0L_&:<>ZJBACBQU]-DK ,]F#%W!K!@3RVA2RV::#*)H[&[:
M!WQH-!S$R5NCV:%1' _BQNB-HKA1%/<JNN<24K'D[-^^I%0HC>FJH!J_:$%T
M#F3--Z#,7+4.@FZI[+['\:'#B>=U.SQH'![T.OQ@TY/9=@,2TRU9@60B4T3@
MG&QSEN:[:!"F[#"M%3P">17;Y6__SCYY 2I)0LKJ]0U(1E]4SZU*&DE)+_$=
M*"1&OS$?8"+>8(598;W0.QU]>PR;/89?_2A&#?7HRQ_%Z.!FA$'K9E2/HC(:
MM(V\X=[+F1T:^:.AWWW'?.\UU7N]FGX Q]M5V(A<9%A,F-*2FKI+KKM4O=VF
M55'\KXZ*'[R2!U\>EYJR'9@H.LA6'59QG(1[D>FP"N-6_"I9;JL@ER"7MK%1
MZ/":ZZJ"-:M-\W1A6X:]]4O35-E"_TI3=60W5"X95Z2 !5)Z9PGF)5DU.=5$
MBY4M^X]"8Q-AASDVAB"- 7Y?"*%W$[-!TVI._P-02P,$%     @ "3QX5*":
MVE@^ P  %@L  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULG59A3]LP
M$/TK5K1)((TD3=(64%L)R*;Q 0G1L7UVDTMCX=B=[5#X]SL[;590FA:^M+'C
M]\[W+GZ^R5JJ)UT"&/)2<:&G7FG,ZC((=%9"1;4O5R#P32%510T.U3+0*P4T
M=Z"*!U$8CH**,N'-)F[N7LTFLC:<";A71-=51=7K-7"YGGH#;SOQP):EL1/!
M;+*B2YB#>5S=*QP%+4O.*A":24$4%%/O:G"97MCU;L%O!FN]\TQL)@LIG^S@
M-I]ZH=T0<,B,9:#X]PPWP+DEPFW\W7!Z;4@+W'W>LO]PN6,N"ZKA1O(_+#?E
MU#OW2 X%K;EYD.N?L,EG:/DRR;7[)>MF[2CR2%9K(ZL-&'=0,='\TY>-#CN
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M"ECB-577?/,)M@6-#5_.J;2_:-/,G<0>RM=2\7H+UAG4A#7_^&$KQ X@FO0
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MTK<G$&:"'E]RKIX:)D!['YO_ 5!+ P04    "  )/'A41TP7 -@#  !_#@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6RME]^/VC@0Q_\5*^I#*QV;
M.+]9 5(+N[H^]&[5;7O/)ABPUK$YVRSTO[]QR 9(G)1*]P)Q,M_QQQY[QIX<
MI'K16TH-.I9<Z*FW-69W[_NZV-*2Z#NYHP*^K*4JB8&FVOAZIRA95:*2^V$0
MI'Y)F/!FD^K=DYI-Y-YP)NB30GI?ED3]_$2Y/$P][+V]^,HV6V-?^+/)CFSH
M,S7?=T\*6G[C9<5**C23 BFZGGH?\?T#SJR@LOC!Z$%?/",[E*64+[;Q>37U
M DM$.2V,=4'@[Y7.*>?6$W#\6SOUFCZM\/+YS?MC-7@8S))H.I?\'[8RVZF7
M>VA%UV3/S5=Y^)/6 TJLOT)R7?VB0VT;>*C8:R/+6@P$)1.G?W*L)^)"@.,>
M05@+PEL%42V(;A7$M2"^59#4@FKH_FGLU<0MB"&SB9('I*PU>+,/U>Q7:I@O
M)NQ">38*OC+0F=EG4<B2(D..5*,1FLMR)P451B.Y1F9+D8#%"A-/E:(K:X:(
MUM1^5H@SLF2<&0;2]PMJ"./Z SCY_KQ []]]0.\0$^C;5NXU$2L]\0WPVE[]
MHF;[=&(+>]@6M+A#$?X#A4&('?+Y[?+ (5_<+,=CA_SA=GE^+?<A1DV@PB90
M8>4OZO77B<']@-NH<1M5;N,>MW]!>"'K*&*8V" NM48%4>HGI* #4>ZHG3QF
ME4>;B%YG29(EX<1_O0Q.URJ.DC1JK*YPXP8W'L2=PPPP\VO$DY?THO,T;O$-
MFES!)0U<,@CWL2C4'B)$CY#&-6P*6/9(PB92+L2DTW^49"W&KLTH2MV0:0.9
M#D(^&UF\C&QN72'8^I:4V)3M0DP[W>,P&+<8NT9A%B9NR*R!S 8A_SZO2 JD
MEYG&Q9EU.:,L;W$ZC!+<LQSSAC,?Y'QD@HB"WD:9=P"2%F+7 @<]A..&<#Q(
M^$T:PET)W$4X[A+F6=JF[%K%V3@*W9PX.!>B8)#T!^%[<CH\<#B^V'EUEHR@
MNR>2* O;X7;9Q6G03@.+VBZ[VF-ADD?7=@\N.SS&2<]VQ!<%&/]_$:I]784H
MB-IIPV&%\S3O(3U7(/P;)>ABL0_5(7PN1'BX$OU>]JR=M5)CT)/!\;F^X.$"
M\\B.P%"?<2P!$X:(#5MR.A26;C$98=S#<BXG>+B>M+.@LH=>>R[;ZQK&R>(H
M&C@.@O8:<9FEN&\"S^4%#]>7ZY1X(W*WAHS"]GG":93T\9XK#1XN-8[M]XL\
M7CN\R@2N3>@P<^Q"_^+L;J]F7XC:,*%A_M:@"^XRB),ZW79.#2-WU7%^*0U<
M#JK'+=P0J;(&\'TMI7EKV!M"<^><_0=02P,$%     @ "3QX5%"4^_45!
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M>N[-/%3!&G=4W?/M5Q@$I8:OY%3:7[3M8R>)A\I.*MX,8'V#AK#^B5\&(_8
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M8,I[,T;(^QTW^:\?/_&46W [Z< VW'B8YJ+MN] W!AV?9-2[)WSD3PAG4\G
M*R49XRMC[H%AEO-<>DHWO!;4!4OY8."NF<&]8'DR)G)9QS81S-^IO7P'6,]
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M.X6W;N;@7#M_B&4QFPR(=7*K@$K A.&MV2TP>0S([5$4LG0W;7I$!O,@,(>
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M%"8"  !C*   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+3N-
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M/LO.-OU;/AO_FK=X 5!+ 0(4 Q0    (  D\>%0'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    "  )/'A4*H^1#!8%  #N$P  &
M    @(%Z&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M"3QX5&5RD9-K"   L2T  !@              ("!QAX  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    (  D\>%26& M0H0(   L&   8
M          " @6<G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    "  )/'A4^;R&5"<(   ((P  &               @($^*@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ "3QX5 >^%\:?!0  [@P
M !@              ("!FS(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    (  D\>%3?:I_@2B@  &^%   8              " @7 X  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  )/'A4(_449&H&
M   I%   &0              @('P8   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    (  D\>%1=Z36+" ,  (@)   9              "
M@9%G  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ "3QX
M5 ,, EVG P  .PD  !D              ("!T&H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    "  )/'A43.,+&%,$  !."@  &0
M        @(&N;@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   (  D\>%2M):!P00@  (\;   9              " @3AS  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ "3QX5*0=#:P1 P  *0@
M !D              ("!L'L  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    "  )/'A45\^:[AD'  !K%   &0              @('X?@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  D\>%0C]&D7
M$ <  .X4   9              " @4B&  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ "3QX5+8N%&9>#0  ^2P  !D
M ("!CXT  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  )
M/'A40#-AR/<+  "K)   &0              @($DFP  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  D\>%0?0K.G0 D  $$7   9
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M970R-"YX;6Q02P$"% ,4    "  )/'A4IP"6*.0K  #QF   &0
M    @(&2PP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M  D\>%1OO/F^:@(  (0%   9              " @:WO  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ "3QX5#&HM1CH @  * D  !D
M             ("!3O(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    "  )/'A47N/Y*OL"  !V!P  &0              @(%M]0  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  D\>%0PZ>'EXP4
M 'P:   9              " @9_X  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ "3QX5,V>6_8? P  ! @  !D              ("!
MN?X  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  )/'A4
M?2:<(@P#   T"   &0              @($/ @$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    (  D\>%1C&H+F, 4  .$0   9
M      " @5(% 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ "3QX5 O,%%N;!0  UQ0  !D              ("!N0H! 'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  )/'A4SWZJN>,#   T"P
M&0              @(&+$ $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    (  D\>%1V*'37> (  &\&   9              " @:44 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ "3QX5-\]2 _=
M @  T@L  !D              ("!5!<! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    "  )/'A4#:<N!PL#  !]"0  &0
M@(%H&@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  D\
M>%3<X];Z80(  .D%   9              " @:H= 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ "3QX5,X#8*3^!   /18  !D
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M=#0S+GAM;%!+ 0(4 Q0    (  D\>%3(&*X!3P,  (X+   9
M  " @1XT 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M"3QX5(/)S-$G P  0PP  !D              ("!I#<! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    "  )/'A4A&81#_<"  "U"0  &0
M            @($".P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    (  D\>%0\=LIB1@,  %,*   9              " @3 ^ 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ "3QX5&1<)NR)!
M?Q(  !D              ("!K4$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    "  )/'A4!:STM4L"  !'!0  &0              @(%M
M1@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  D\>%2H
MU%_PA 8  /\C   9              " @>]( 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ "3QX5"$.]U4A!   FA   !D
M     ("!JD\! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  D\>%3&N,1@DP(  /\&   9              "
M@:=C 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ "3QX
M5)=((WDW P  =@H  !D              ("!<68! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    "  )/'A4H)K:6#X#   6"P  &0
M        @('?:0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   (  D\>%0_:.NRS@(  $,(   9              " @51M 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ "3QX5.)$'Z=W P  FPT
M !D              ("!67 ! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    "  )/'A41TP7 -@#  !_#@  &0              @($'= $
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (  D\>%10E/OU
M%00  (L/   9              " @19X 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ "3QX5/B.N.JY @  U@<  !D
M ("!8GP! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  )
M/'A48RR(!J0"  !@!P  &0              @(%2?P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (  D\>%2Z\?N?RP,  " -   9
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M 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ "3QX5.>
M=$91 P  %!4   T              ( !M9$! 'AL+W-T>6QE<RYX;6Q02P$"
M% ,4    "  )/'A4EXJ[',     3 @  "P              @ $QE0$ 7W)E
M;',O+G)E;'-02P$"% ,4    "  )/'A4=;FW.8,%   %+0  #P
M    @ $:E@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "3QX5!;=:Q0F
M @  8R@  !H              ( !RIL! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ "3QX5.'L7A'T 0  HB<  !,
M ( !*)X! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $P 3 #+%   3: !
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>183</ContextCount>
  <ElementCount>406</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of the business and organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization</Role>
      <ShortName>Nature of the business and organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements</Role>
      <ShortName>Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value of Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets</Role>
      <ShortName>Fair Value of Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet</Role>
      <ShortName>Property, plant and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Receivable research incentive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive</Role>
      <ShortName>Receivable research incentive</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Accrued expenses and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued expenses and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Loans payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayable</Role>
      <ShortName>Loans payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Common stock, Class A common stock and convertible preferred stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock</Role>
      <ShortName>Common stock, Class A common stock and convertible preferred stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/Disclosure401KSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureRelatedParties</Role>
      <ShortName>Related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value of Financial Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables</Role>
      <ShortName>Fair Value of Financial Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property, plant and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables</Role>
      <ShortName>Property, plant and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Accrued expenses and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued expenses and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Loans payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayableTables</Role>
      <ShortName>Loans payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLoansPayable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails</Role>
      <ShortName>Summary of significant accounting policies - Going concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of significant accounting policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of significant accounting policies - Others (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails</Role>
      <ShortName>Summary of significant accounting policies - Others (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails</Role>
      <ShortName>Summary of significant accounting policies - Comprehensive loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Collaboration and Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails</Role>
      <ShortName>Collaboration and Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value of Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails</Role>
      <ShortName>Fair Value of Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property, plant and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails</Role>
      <ShortName>Property, plant and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Receivable research incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails</Role>
      <ShortName>Receivable research incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Leases - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Leases - Minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails</Role>
      <ShortName>Leases - Weighted average remaining lease term and weighted average discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Accrued expenses and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued expenses and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Loans payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayableDetails</Role>
      <ShortName>Loans payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLoansPayableTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails</Role>
      <ShortName>Loans payable - Schedule of aggregate minimum future principal payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails</Role>
      <ShortName>Common stock, Class A common stock and convertible preferred stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails</Role>
      <ShortName>Stock-based compensation - 2018 Stock Option and Grant Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails</Role>
      <ShortName>Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Stock-based compensation - Stock option valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails</Role>
      <ShortName>Stock-based compensation - Stock option valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Stock-based compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41105 - Disclosure - Stock-based compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41106 - Disclosure - Stock-based compensation - Common Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails</Role>
      <ShortName>Stock-based compensation - Common Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41107 - Disclosure - Stock-based compensation - Stock-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails</Role>
      <ShortName>Stock-based compensation - Stock-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income taxes - Losses before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Losses before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Income taxes - Effective income tax reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails</Role>
      <ShortName>Income taxes - Effective income tax reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails</Role>
      <ShortName>Income taxes - Components of the net deferred tax assets or liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails</Role>
      <ShortName>Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Commitments and contingencies - Others (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails</Role>
      <ShortName>Commitments and contingencies - Others (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41401 - Disclosure - 401(k) Savings Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails</Role>
      <ShortName>401(k) Savings Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/Disclosure401KSavingsPlan</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Net loss per share - Antidilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net loss per share - Antidilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails</Role>
      <ShortName>Related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureRelatedParties</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="hook-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="hook-20211231x10k.htm">hook-20211231x10k.htm</File>
    <File>hook-20211231.xsd</File>
    <File>hook-20211231_cal.xml</File>
    <File>hook-20211231_def.xml</File>
    <File>hook-20211231_lab.xml</File>
    <File>hook-20211231_pre.xml</File>
    <File>hook-20211231xex10d15.htm</File>
    <File>hook-20211231xex23d1.htm</File>
    <File>hook-20211231xex31d1.htm</File>
    <File>hook-20211231xex31d2.htm</File>
    <File>hook-20211231xex32d1.htm</File>
    <File>hook-20211231xex3d1.htm</File>
    <File>hook-20211231xex4d3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>hook-20211231x10k001.jpg</File>
    <File>hook-20211231x10k002.jpg</File>
    <File>hook-20211231x10k003.jpg</File>
    <File>hook-20211231x10k005.jpg</File>
    <File>hook-20211231x10k006.jpg</File>
    <File>hook-20211231x10k007.jpg</File>
    <File>hook-20211231x10k008.jpg</File>
    <File>hook-20211231x10k009.jpg</File>
    <File>hook-20211231x10k010.jpg</File>
    <File>hook-20211231x10k011.jpg</File>
    <File>hook-20211231x10k012.jpg</File>
    <File>hook-20211231x10k013.jpg</File>
    <File>hook-20211231x10k014.jpg</File>
    <File>hook-20211231x10k015.jpg</File>
    <File>hook-20211231x10k016.jpg</File>
    <File>hook-20211231x10k017.jpg</File>
    <File>hook-20211231x10k018.jpg</File>
    <File>hook-20211231x10k019.jpg</File>
    <File>hook-20211231x10k020.jpg</File>
    <File>hook-20211231x10k021.jpg</File>
    <File>hook-20211231x10k022.jpg</File>
    <File>hook-20211231x10k023.jpg</File>
    <File>hook-20211231x10k024.jpg</File>
    <File>hook-20211231x10k025.jpg</File>
    <File>hook-20211231x10k026.jpg</File>
    <File>hook-20211231x10k027.jpg</File>
    <File>hook-20211231x10k028.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="706">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "hook-20211231x10k.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "contextCount": 183,
   "dts": {
    "calculationLink": {
     "local": [
      "hook-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hook-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "hook-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hook-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hook-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hook-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 591,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 25,
    "http://www.hookipapharma.com/20211231": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 31
   },
   "keyCustom": 104,
   "keyStandard": 302,
   "memberCustom": 19,
   "memberStandard": 33,
   "nsprefix": "hook",
   "nsuri": "http://www.hookipapharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Collaboration and Licensing Agreements",
     "role": "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements",
     "shortName": "Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value of Financial Assets",
     "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets",
     "shortName": "Fair Value of Financial Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Property, plant and equipment, net",
     "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet",
     "shortName": "Property, plant and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ReceivableResearchIncentiveTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Receivable research incentive",
     "role": "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive",
     "shortName": "Receivable research incentive",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ReceivableResearchIncentiveTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Leases",
     "role": "http://www.hookipapharma.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Accrued expenses and other current liabilities",
     "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued expenses and other current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:DisclosureOfLongTermLoansPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Loans payable",
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayable",
     "shortName": "Loans payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:DisclosureOfLongTermLoansPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Common stock, Class A common stock and convertible preferred stock",
     "role": "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock",
     "shortName": "Common stock, Class A common stock and convertible preferred stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Stock-based compensation",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Income taxes",
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Commitments and contingencies",
     "role": "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - 401(k) Savings Plan",
     "role": "http://www.hookipapharma.com/role/Disclosure401KSavingsPlan",
     "shortName": "401(k) Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Net loss per share",
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShare",
     "shortName": "Net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Related parties",
     "role": "http://www.hookipapharma.com/role/DisclosureRelatedParties",
     "shortName": "Related parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Subsequent events",
     "role": "http://www.hookipapharma.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)",
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of significant accounting policies (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of significant accounting policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair Value of Financial Assets (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables",
     "shortName": "Fair Value of Financial Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Property, plant and equipment, net (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables",
     "shortName": "Property, plant and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ScheduleOfOperatingAndFinanceLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Leases (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ScheduleOfOperatingAndFinanceLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Accrued expenses and other current liabilities (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued expenses and other current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Loans payable (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableTables",
     "shortName": "Loans payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Stock-based compensation (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Income taxes (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - Net loss per share (Tables)",
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails",
     "shortName": "Summary of significant accounting policies - Going concern (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__YrrPJBfXEKiNjwR_7k7OA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Summary of significant accounting policies - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__YrrPJBfXEKiNjwR_7k7OA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of significant accounting policies - Others (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails",
     "shortName": "Summary of significant accounting policies - Others (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_EVB3mDUFsUqp6ZQHDjicxw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ComprehensiveIncomePolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails",
     "shortName": "Summary of significant accounting policies - Comprehensive loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ComprehensiveIncomePolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "hook:NumberOfPreclinicalResearchPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_RvabO_H730ypKSeYkyGVcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Collaboration and Licensing Agreements (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
     "shortName": "Collaboration and Licensing Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_hIKGB1gLR0u8qyPSf54UKw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "hook:NumberOfPreclinicalResearchPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_RvabO_H730ypKSeYkyGVcA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair Value of Financial Assets (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails",
     "shortName": "Fair Value of Financial Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Property, plant and equipment, net (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
     "shortName": "Property, plant and equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "hook:ReceivablesTaxResearchPremiumCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Receivable research incentive (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails",
     "shortName": "Receivable research incentive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "hook:ReceivableResearchIncentiveTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-5",
      "lang": null,
      "name": "hook:GrantIncomeIncentiveProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Leases (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfOperatingAndFinanceLeasesTableTextBlock",
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "lang": null,
      "name": "hook:LeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Leases - Lease costs (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
     "shortName": "Leases - Lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Leases - Minimum lease payments (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails",
     "shortName": "Leases - Minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails",
     "shortName": "Leases - Weighted average remaining lease term and weighted average discount rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Accrued expenses and other current liabilities (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued expenses and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "hook:LongTermLoansPayableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Loans payable (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
     "shortName": "Loans payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "hook:LongTermLoansPayableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails",
     "shortName": "Loans payable - Schedule of aggregate minimum future principal payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_hook_RedeemableConvertiblePreferredStocksMember__CR23emU8USQieByZHoKiA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
     "shortName": "Common stock, Class A common stock and convertible preferred stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_12_11_2020_To_12_11_2020_lwzbDOodv0Si697Xzru_Bw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
     "shortName": "Stock-based compensation - 2018 Stock Option and Grant Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_4UVSVApoFESt0pKFq_aAcA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_4_1_2019_To_4_1_2019_XDfkQ2lQ5UGH271C7716Aw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
     "shortName": "Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_4_1_2019_To_4_1_2019_XDfkQ2lQ5UGH271C7716Aw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Stock-based compensation - Stock option valuation (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails",
     "shortName": "Stock-based compensation - Stock option valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - Stock-based compensation - Stock option activity (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-based compensation - Stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41105 - Disclosure - Stock-based compensation - Restricted Stock Units (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-based compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T4IEc7xV-0WOuhzppOponA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hpzhb_Bppk67Nw3sDM-ihg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41106 - Disclosure - Stock-based compensation - Common Stock Awards (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
     "shortName": "Stock-based compensation - Common Stock Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hpzhb_Bppk67Nw3sDM-ihg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41107 - Disclosure - Stock-based compensation - Stock-based compensation (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
     "shortName": "Stock-based compensation - Stock-based compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Income taxes (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Income taxes - Losses before income taxes (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails",
     "shortName": "Income taxes - Losses before income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_MW8Mqd0iIEG_9OzHPNz_yA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_hook_SeriesDConvertiblePreferredStockMember_MW8Mqd0iIEG_9OzHPNz_yA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Income taxes - Effective income tax reconciliation (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails",
     "shortName": "Income taxes - Effective income tax reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure__TI3G8o3vE2Ow-4dU875pA",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41204 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails",
     "shortName": "Income taxes - Components of the net deferred tax assets or liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_XruS7bjykUOvWhvWo-pOZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41205 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
     "shortName": "Income taxes - Changes in the valuation allowance for deferred tax assets and others (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Commitments and contingencies - Others (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails",
     "shortName": "Commitments and contingencies - Others (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_jqpGNAjmU0yO4nTBfrO5kQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - 401(k) Savings Plan (Details)",
     "role": "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
     "shortName": "401(k) Savings Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Net loss per share (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "Net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "0",
      "lang": null,
      "name": "hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41502 - Disclosure - Net loss per share - Antidilutive securities (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net loss per share - Antidilutive securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "hook:RelatedPartyTransactionPaymentsForRoyalties",
       "hook:RelatedPartyTransactionPaymentsForRoyalties",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_lRtNrbT0JEmwrX6k2vVYAw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "hook:RelatedPartyTransactionPaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Related parties (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails",
     "shortName": "Related parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "hook:RelatedPartyTransactionPaymentsForRoyalties",
       "hook:RelatedPartyTransactionPaymentsForRoyalties",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_hook_UniversityOfBaselMember_lRtNrbT0JEmwrX6k2vVYAw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "hook:RelatedPartyTransactionPaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_2dGjG-4Kikmjs1wZ1RB0HQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Subsequent events (Details)",
     "role": "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "As_Of_2_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bmkwQPPsg0m3l7ZM8QwDVg",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_9hQsPTvyr0qnNktN35j2qQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_7pqb1O8EUU2ryyxKV0yIrw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of the business and organization",
     "role": "http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization",
     "shortName": "Nature of the business and organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "hook-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_G37MQTvugE2L9w-6ReV71A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "country_AT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Austria"
       }
      }
     },
     "localname": "AT",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "hook_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.",
        "label": "Accrued Expenses and Other Current Liabilities.",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrentAbstract",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "hook_AccruedExpensesForPropertyAndEquipmentAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions.",
        "label": "Accrued Expenses for Property and Equipment Acquisitions",
        "terseLabel": "Accrued for property and equipment acquisitions"
       }
      }
     },
     "localname": "AccruedExpensesForPropertyAndEquipmentAcquisitions",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_AccruedExternalGeneralAndAdministrationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of balance sheet date of accrued external general and administration expenses.",
        "label": "Accrued External General and Administration Expenses",
        "terseLabel": "Accrued external general and administration expenses"
       }
      }
     },
     "localname": "AccruedExternalGeneralAndAdministrationExpenses",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_AccruedExternalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of balance sheet date of accrued external research and development expenses.",
        "label": "Accrued External Research and Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_AccruedSocialSecurityContributionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions.",
        "label": "Accrued Social Security Contributions, Current",
        "terseLabel": "Social security contributions"
       }
      }
     },
     "localname": "AccruedSocialSecurityContributionsCurrent",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_AccruedSubLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued sub license fees at the balance sheet date.",
        "label": "Accrued Sub License Fees",
        "terseLabel": "Sublicense fees"
       }
      }
     },
     "localname": "AccruedSubLicenseFees",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_AccruedUnearnedGrantIncomeCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of accrued unearned grant income (current).",
        "label": "Accrued Unearned Grant Income , Current",
        "terseLabel": "Unearned grant income (current)"
       }
      }
     },
     "localname": "AccruedUnearnedGrantIncomeCurrent",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborationAgreementMilestonePaymentsRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments revenue recognized under the collaboration agreement.",
        "label": "Collaboration Agreement, Milestone Payments, Revenue Recognized",
        "terseLabel": "Revenue recognized from milestone payments"
       }
      }
     },
     "localname": "CollaborationAgreementMilestonePaymentsRevenueRecognized",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborativeAndLicensingArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeAndLicensingArrangementAbstract",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contract assets relating to sublicense payment.",
        "label": "Collaborative Arrangement, Contract Asset Relating to Sublicense Payment",
        "terseLabel": "Contract asset relating to the sublicense payment"
       }
      }
     },
     "localname": "CollaborativeArrangementContractAssetRelatingToSublicensePayment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contract liability relating to sublicense payment.",
        "label": "Collaborative Arrangement, Contract Liability Relating to Sublicense Payment",
        "terseLabel": "Contract liability relating to sublicense payment"
       }
      }
     },
     "localname": "CollaborativeArrangementContractLiabilityRelatingToSublicensePayment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of preclinical research programs in collaborative arrangement.",
        "label": "Collaborative Arrangement, Number of Preclinical Research Programs",
        "terseLabel": "Number of preclinical research programs"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfPreclinicalResearchPrograms",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hook_CollaborativeArrangementProgramInitiationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of program initiation fee received as part of amended and restated research collaboration and license agreement.",
        "label": "Collaborative Arrangement Program Initiation Fee",
        "terseLabel": "Program initiation fee"
       }
      }
     },
     "localname": "CollaborativeArrangementProgramInitiationFee",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue from cost reimbursements for research and development services.",
        "label": "Collaborative Arrangement, Revenue from Cost Reimbursements for Research and Development Services",
        "terseLabel": "Revenue recognized from cost reimbursements for research and development services"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost reimbursements for research and development services, of which initially recorded as deferred revenue.",
        "label": "Collaborative Arrangement Revenue From Cost Reimbursements For Research And Development Services Recorded As Deferred Revenue",
        "terseLabel": "Revenue recognized from cost reimbursements for research and development services initially recorded as deferred revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborativeArrangementRevenueFromMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue from milestone payments for milestones achieved.",
        "label": "Collaborative Arrangement, Revenue from Milestone Payments",
        "terseLabel": "Revenue recognized from milestone payments for milestones achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueFromMilestonePayments",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_CollaborativeArrangementTermOfRoyaltyPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Collaborative Arrangement, Term of Royalty Payment",
        "terseLabel": "Payment term (in days)"
       }
      }
     },
     "localname": "CollaborativeArrangementTermOfRoyaltyPayment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hook_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to commercial milestones.",
        "label": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_CommonStockOtherThanClassMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock other than Class A common stock.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockOtherThanClassMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_ConversionOfStockCommonStockIssuedForEachShareConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new common stock issued in the conversion of each stock.",
        "label": "Conversion of Stock, Common Stock Issued for Each Share Converted",
        "terseLabel": "Number of common stock issued upon conversion of each share"
       }
      }
     },
     "localname": "ConversionOfStockCommonStockIssuedForEachShareConverted",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_ConvertiblePreferredStockSharesIssuableUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issuable upon conversion of convertible preferred stock.",
        "label": "Convertible Preferred Stock, Shares Issuable upon Conversion",
        "terseLabel": "Number of common stock issuable upon conversion of Series A convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuableUponConversion",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_ConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible preferred stocks.",
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStocksMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_DebtInstrumentEstimatedMarketRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated market rate under the debt instrument arrangement.",
        "label": "Debt Instrument, Estimated Market Rate Percent",
        "terseLabel": "Estimated market rate"
       }
      }
     },
     "localname": "DebtInstrumentEstimatedMarketRatePercent",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hook_DeferredOfferingCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred offering costs.",
        "label": "Deferred Offering Costs, Policy [Policy Text Block]",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost reimbursements for research and development services included as a liability in deferred revenues.",
        "label": "Deferred Revenues, Cost Reimbursements for Research and Development Services",
        "terseLabel": "Cost reimbursements for research and development services included in deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredRevenuesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments included in deferred revenues.",
        "label": "Deferred Revenues Milestone Payments",
        "terseLabel": "Milestone payments included in deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenuesMilestonePayments",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredRevenuesUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront and milestone payments included as a liability in deferred revenues.",
        "label": "Deferred Revenues, Upfront and Milestone Payments",
        "terseLabel": "Upfront and milestone payments included in deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenuesUpfrontAndMilestonePayments",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredTaxAssetsFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from finance lease liabilities.",
        "label": "Deferred Tax Assets Finance Lease Liabilities",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsFinanceLeaseLiabilities",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other liabilities.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves and Accruals Accrued Liabilities and Other",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from finance lease right of use asset.",
        "label": "Deferred Tax Liabilities Finance Lease Right of Use Asset",
        "negatedLabel": "Finance lease right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from fixed assets and intangible assets.",
        "label": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets",
        "negatedLabel": "Fixed assets and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use asset.",
        "label": "Deferred Tax Liabilities Operating Lease Right of Use Asset",
        "negatedLabel": "Operating lease right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to development milestones.",
        "label": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_DisclosureOfLongTermLoansPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of loans payable.",
        "label": "Disclosure of Long Term Loans Payable [Table Text block]",
        "terseLabel": "Schedule of loans payable"
       }
      }
     },
     "localname": "DisclosureOfLongTermLoansPayableTableTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_DisclosureOfLongTermLoansPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of loans payable.",
        "label": "Disclosure of Long Term Loans Payable [Text block]",
        "terseLabel": "Loans payable"
       }
      }
     },
     "localname": "DisclosureOfLongTermLoansPayableTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_EarningsPerSharePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for earnings per share.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyPolicyTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_ExercisePriceRangingTo0.09EuroPerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to exercise price ranges to 0.09 euros per share.",
        "label": "Exercise price 0.09 euros"
       }
      }
     },
     "localname": "ExercisePriceRangingTo0.09EuroPerShareMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_ExercisePriceRangingTo2.93DollarsPerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to exercise price ranges to 2.93 dollars per share.",
        "label": "Exercise price $2.93"
       }
      }
     },
     "localname": "ExercisePriceRangingTo2.93DollarsPerShareMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to follow on public offering.",
        "label": "Follow-on public offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_GlobalIntangibleLowTaxedIncomePercentageOfInclusion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of inclusion for \"global intangible low-taxed income,\" or \"GILTI\".",
        "label": "Global Intangible Low-taxed Income, Percentage of Inclusion",
        "terseLabel": "Percentage of inclusion for GILTI"
       }
      }
     },
     "localname": "GlobalIntangibleLowTaxedIncomePercentageOfInclusion",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hook_GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction percentage of inclusion for \"global intangible low-taxed income,\" or \"GILTI\".",
        "label": "Global Intangible Low-taxed Income, Reduction Percentage of Inclusion",
        "terseLabel": "Reduction percentage of inclusion for GILTI"
       }
      }
     },
     "localname": "GlobalIntangibleLowTaxedIncomeReductionPercentageOfInclusion",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hook_GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold return percentage on the controlled foreign corporation (\"CFC\")'s \"qualified business asset investment,\" or \"QBAI\" over which global intangible low-taxed income,\" or \"GILTI\" applies.",
        "label": "Global Intangible Low-taxed Income, Return Threshold Percentage",
        "terseLabel": "Threshold return percentage of GILIT"
       }
      }
     },
     "localname": "GlobalIntangibleLowTaxedIncomeReturnThresholdPercentage",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hook_GoingConcernPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for going concern.",
        "label": "Going Concern, Policy [Policy Text Block]",
        "terseLabel": "Going concern"
       }
      }
     },
     "localname": "GoingConcernPolicyPolicyTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government grant agreements and research incentives.",
        "label": "Government Grant Agreements and Research Incentives, Policy [Policy Text Block]",
        "terseLabel": "Government grant agreements and research incentives"
       }
      }
     },
     "localname": "GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_GrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant income.",
        "label": "Grant Income",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_GrantIncomeIncentiveProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant income recognized related to the incentive program during the reporting period.",
        "label": "Grant Income, Incentive Program",
        "terseLabel": "Income related to the incentive program recorded as grant income"
       }
      }
     },
     "localname": "GrantIncomeIncentiveProgram",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_IncomeTaxBenefitsNetOperatingLossesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax benefits recorded for the net operating losses incurred.",
        "label": "Income Tax benefits, Net Operating Losses Incurred",
        "terseLabel": "Income tax benefits for the net operating losses incurred"
       }
      }
     },
     "localname": "IncomeTaxBenefitsNetOperatingLossesIncurred",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_IncreaseDecreaseInEstimatedMarketRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in estimated market rate",
        "label": "Increase Decrease in Estimated Market Rate",
        "terseLabel": "Threshold for change in estimated market rate"
       }
      }
     },
     "localname": "IncreaseDecreaseInEstimatedMarketRate",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets.",
        "label": "Increase (Decrease) in Prepaid Expenses and Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_IncreaseDecreaseInReceivableResearchIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount of receivable research incentives.",
        "label": "Increase (Decrease) in Receivable Research Incentives",
        "negatedLabel": "Receivable research incentives"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivableResearchIncentives",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LeaseAssetsDerecognizedUponLeaseCancellation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of right of use assets derecognized upon lease cancellation.",
        "label": "Lease Assets Derecognized Upon Lease Cancellation",
        "terseLabel": "Lease assets derecognized upon lease cancellation"
       }
      }
     },
     "localname": "LeaseAssetsDerecognizedUponLeaseCancellation",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LeaseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeaseDisclosureTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "hook_LeaseLiabilityTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current.",
        "label": "Lease, Liability, Current",
        "totalLabel": "Total current lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "hook_LeaseLiabilityTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. \"",
        "label": "Lease, Liability, Noncurrent",
        "totalLabel": "Total non-current lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityNoncurrent",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LeaseLiabilityTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Present value of lessee's discounted obligation for lease payments from operating and finance lease. \"",
        "label": "Lease Liability, Total",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityTotal",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LeaseModificationLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from lease modification for existing operating and finance leases.",
        "label": "Lease Modification, Loss",
        "terseLabel": "Lease modification loss"
       }
      }
     },
     "localname": "LeaseModificationLoss",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating and finance lease",
        "label": "Lease, Right-of-Use Asset",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LesseeLeaseRemainingTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Lease, Remaining Term of Contract",
        "terseLabel": "Remaining lease term (in years)"
       }
      }
     },
     "localname": "LesseeLeaseRemainingTermOfContract",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease.",
        "label": "Lessee Operating and Finance Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in next twelve months following latest fiscal year.",
        "label": "Lessee Operating And Finance Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee Operating and Finance Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee Operating and Finance Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "hook_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee Operating and Finance Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LicensingFeesIntellectualPropertyLicenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of licensing fees from intellectual property licenses.",
        "label": "Licensing fees, Intellectual Property Licenses",
        "terseLabel": "Licensing fees from intellectual property licenses"
       }
      }
     },
     "localname": "LicensingFeesIntellectualPropertyLicenses",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LongTermLoansEarlyRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of long-term borrowing.",
        "label": "Long Term Loans Early Repayment",
        "terseLabel": "Scheduled early repayment"
       }
      }
     },
     "localname": "LongTermLoansEarlyRepayment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_LongTermLoansPayableGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermLoansPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loans payable, gross.",
        "label": "Long Term Loans Payable, Gross",
        "terseLabel": "Loans from FFG"
       }
      }
     },
     "localname": "LongTermLoansPayableGross",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by characteristics of milestone payments recognized under the milestone method by arrangement.",
        "label": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hook_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of milestones that an entity engage.",
        "label": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_MilestonePaymentsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to development milestones payment one.",
        "label": "Milestone Payments One"
       }
      }
     },
     "localname": "MilestonePaymentsOneMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_MilestonePaymentsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to development milestones payment two.",
        "label": "Milestone Payments Two"
       }
      }
     },
     "localname": "MilestonePaymentsTwoMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_NonExecutiveDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to non executive directors.",
        "label": "Non Executive Directors"
       }
      }
     },
     "localname": "NonExecutiveDirectorsMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_NumberOfCombinedPerformanceObligationForEachResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of combined performance obligation for each research program.",
        "label": "Number of Combined Performance Obligation for Each Research Program",
        "terseLabel": "Number of combined performance obligation for each research program"
       }
      }
     },
     "localname": "NumberOfCombinedPerformanceObligationForEachResearchProgram",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hook_NumberOfPreclinicalResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of preclinical research programs.",
        "label": "Number of Preclinical Research Programs",
        "terseLabel": "Number of preclinical research programs"
       }
      }
     },
     "localname": "NumberOfPreclinicalResearchPrograms",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hook_NumberOfResearchProgramPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research program performance obligations.",
        "label": "Number of Research Program Performance Obligations",
        "terseLabel": "Number of research program performance obligations"
       }
      }
     },
     "localname": "NumberOfResearchProgramPerformanceObligations",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hook_NumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of votes for each share held .",
        "label": "Number of Votes",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberOfVotes",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hook_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating and Finance Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hook_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease.",
        "label": "Operating and Finance Lease Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating and finance lease liabilities undiscounted excess amount.",
        "label": "Operating and Finance Lease Liability Undiscounted Excess Amount",
        "terseLabel": "Less: interest"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of other accruals and liabilities.",
        "label": "Other Accrued Expenses and Liabilities, Current",
        "terseLabel": "Other accruals and liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_PercentageOfAnnualBonusPaidThroughIssuanceOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual bonus paid through issuance of options.",
        "label": "Percentage Of Annual Bonus Paid Through Issuance Of Options",
        "terseLabel": "Percentage of annual bonus paid through stock options"
       }
      }
     },
     "localname": "PercentageOfAnnualBonusPaidThroughIssuanceOfOptions",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hook_PeriodGrantedToUnderwritersToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period granted to the underwriters to purchase additional shares.",
        "label": "Period Granted to Underwriters to Purchase Additional Shares",
        "terseLabel": "Period granted to purchase additional shares"
       }
      }
     },
     "localname": "PeriodGrantedToUnderwritersToPurchaseAdditionalShares",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hook_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares designated as preferred shares",
        "label": "Preferred stock shares Designated",
        "terseLabel": "Preferred stock shares Designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_PrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs and other other current assets.",
        "label": "Prepaid Expenses and Other Current Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_ProceedsFromMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount received from milestone payment.",
        "label": "Proceeds From Milestone Payment",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "ProceedsFromMilestonePayment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_ProceedsFromNonRefundableUpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from non-refundable upfront payment.",
        "label": "Proceeds from Non-Refundable, Up-front Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromNonRefundableUpFrontPayment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of property and equipment additions in accounts payable and accrued expenses.",
        "label": "Property and Equipment Additions in Accounts Payable and Accrued Expenses",
        "negatedLabel": "Property and equipment additions in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_ReceivableResearchIncentiveAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a.",
        "label": "Receivable research incentive"
       }
      }
     },
     "localname": "ReceivableResearchIncentiveAbstract",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "hook_ReceivableResearchIncentiveTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for receivable research incentive.",
        "label": "Receivable Research Incentive [Text Block]",
        "terseLabel": "Receivable research incentive"
       }
      }
     },
     "localname": "ReceivableResearchIncentiveTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_ReceivablesTaxResearchPremiumCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Receivables Tax Research Premium, Current",
        "terseLabel": "Receivable research incentives",
        "verboseLabel": "Receivable research incentive"
       }
      }
     },
     "localname": "ReceivablesTaxResearchPremiumCurrent",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_RedeemableConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to redeemable convertible preferred stocks.",
        "label": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStocksMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_RelatedPartyTransactionPaymentsForRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties, resulting from transactions with related parties during the current period.",
        "label": "Related Party Transaction, Payments for Royalties",
        "terseLabel": "Royalties paid"
       }
      }
     },
     "localname": "RelatedPartyTransactionPaymentsForRoyalties",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for research and manufacturing contract costs and accruals.",
        "label": "Research and Manufacturing Contract Costs and Accruals, Policy [Policy Text Block]",
        "terseLabel": "Research and manufacturing contract costs and accruals"
       }
      }
     },
     "localname": "ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_RevenueRecognizedUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment recognized as revenue.",
        "label": "Revenue Recognized, Upfront Payment",
        "terseLabel": "Revenue recognized from upfront payment"
       }
      }
     },
     "localname": "RevenueRecognizedUpfrontPayment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued expenses and other current liabilities.",
        "label": "Schedule of Accrued Expenses and Other Liabilities, Current [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_ScheduleOfOperatingAndFinanceLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of operating and finance leases.",
        "label": "Schedule of Operating and Finance Leases [Table Text Block]",
        "terseLabel": "Schedule of operating and finance leases presentation in the consolidated balance sheets"
       }
      }
     },
     "localname": "ScheduleOfOperatingAndFinanceLeasesTableTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of estimated useful life of each asset"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted average remaining lease term and weighted average discount rate of operating leases.",
        "label": "Schedule of Weighted Average Remaining Lease Term and Discount Rate of Finance Leases",
        "terseLabel": "Schedule of weighted average remaining lease term and weighted average discount rate of finance leases"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfFinanceLeases",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted average remaining lease term and weighted average discount rate of finance leases.",
        "label": "Schedule of Weighted Average Remaining Lease Term and Discount Rate of Operating Leases",
        "terseLabel": "Schedule of weighted average remaining lease term and weighted average discount rate of operating leases"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hook_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to convertible series D preferred stock.",
        "label": "Series D convertible preferred stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_Seriesa1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A-1 convertible preferred stock.",
        "label": "Series A-1 convertible preferred stock"
       }
      }
     },
     "localname": "Seriesa1ConvertiblePreferredStockMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_SeriesaConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A Convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesaConvertiblePreferredStockMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value",
        "terseLabel": "Aggregate fair value of share-based awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value per common stock used for calculating the intrinsic values.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value used for Calculating Intrinsic Values",
        "terseLabel": "Fair value per common stock used for calculating intrinsic values"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of non- vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, option unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, option unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal installments of award vesting under the share based compensation arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Number Of Equal Installments",
        "terseLabel": "Number of equal installments of vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualInstallments",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of quarterly installments of vesting of share-based compensation awards.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vesting, Number of Quarterly Installment",
        "terseLabel": "Number of quarterly installments for vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant date fair value price of shares issued at grant date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock entitled for each option upon the exercise of the option.",
        "label": "Share-based Payment Arrangement, Option, Number of Common Stock Entitled for Each Option",
        "terseLabel": "Number of common stock entitled for each option upon the exercise of the option"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_SharesGrantedValueShareBasedPaymentArrangementVested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of vested shares granted under share-based payment arrangement.",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, Vested",
        "terseLabel": "Vesting of equity grants"
       }
      }
     },
     "localname": "SharesGrantedValueShareBasedPaymentArrangementVested",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_SharesIssuedSharesShareBasedPaymentArrangementVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) vested during the period.",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, Vested",
        "terseLabel": "Vesting of equity grants (in shares)"
       }
      }
     },
     "localname": "SharesIssuedSharesShareBasedPaymentArrangementVested",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan.",
        "label": "Stock Incentive Plan Arrangement, Cumulative Annual Increase In Issuance Of Percentage Of Outstanding Shares",
        "terseLabel": "Number of shares outstanding were cumulatively increased"
       }
      }
     },
     "localname": "StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award vested during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested",
        "terseLabel": "Vesting of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards vested during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Vested",
        "terseLabel": "Vesting of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardVested",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_StockOption2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2016 stock option plan.",
        "label": "2016 Stock Option Plan"
       }
      }
     },
     "localname": "StockOption2016PlanMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_StockOptionAndGrant2018PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2018 stock option and grant plan.",
        "label": "2018 Stock Option and Grant Plan"
       }
      }
     },
     "localname": "StockOptionAndGrant2018PlanMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_StockOptionAndIncentive2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 stock option and incentive plan.",
        "label": "2019 Stock Option and Incentive Plan"
       }
      }
     },
     "localname": "StockOptionAndIncentive2019PlanMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_StockPurchaseAgreementObligationToPurchaseCommonStockAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock need to be purchased under the stock purchase agreement.",
        "label": "Stock Purchase Agreement, Obligation To Purchase Common Stock, Amount",
        "terseLabel": "Amount of common stock to be purchased"
       }
      }
     },
     "localname": "StockPurchaseAgreementObligationToPurchaseCommonStockAmount",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_TemporaryEquitySharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been converted into common stock.",
        "label": "Temporary Equity, Shares, Converted",
        "terseLabel": "Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesConverted",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_ThresholdPercentageForConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percent of common stock that can be owned after conversion of preferred stock.",
        "label": "Threshold Percentage For Conversion"
       }
      }
     },
     "localname": "ThresholdPercentageForConversion",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hook_TotalMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total milestone amount.",
        "label": "Total Milestone Amount",
        "terseLabel": "Total milestone amount"
       }
      }
     },
     "localname": "TotalMilestoneAmount",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hook_UniversityOfBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to University of Basel.",
        "label": "University of Basel"
       }
      }
     },
     "localname": "UniversityOfBaselMember",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS), before taking into consideration Series A convertible preferred shares outstanding converted into common stock.",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted, Before Conversion",
        "terseLabel": "Weighted-average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock.",
        "label": "Weighted-average Series A convertible Preferred Shares Outstanding, Converted into Common Stock",
        "terseLabel": "Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock"
       }
      }
     },
     "localname": "WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock",
     "nsuri": "http://www.hookipapharma.com/20211231",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of aggregate minimum future principal payments due in connection with the FFG Loans"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r234",
      "r257",
      "r315",
      "r316",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r551",
      "r554",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r234",
      "r257",
      "r315",
      "r316",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r551",
      "r554",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r186",
      "r290",
      "r292",
      "r505",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r186",
      "r290",
      "r292",
      "r505",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r234",
      "r257",
      "r295",
      "r315",
      "r316",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r551",
      "r554",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r234",
      "r257",
      "r295",
      "r315",
      "r316",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r551",
      "r554",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r123",
      "r124",
      "r126",
      "r128",
      "r129",
      "r131",
      "r132",
      "r146",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r146",
      "r201",
      "r202",
      "r360",
      "r389",
      "r420",
      "r424",
      "r425",
      "r426",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r146",
      "r201",
      "r202",
      "r360",
      "r389",
      "r420",
      "r424",
      "r425",
      "r426",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r290",
      "r293",
      "r553",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r290",
      "r293",
      "r553",
      "r567",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r190",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r489"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r7",
      "r33",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r48"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Salaries and bonuses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43",
      "r208"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r36",
      "r59",
      "r60",
      "r61",
      "r540",
      "r562",
      "r566"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r68",
      "r69",
      "r70",
      "r114",
      "r115",
      "r116",
      "r410",
      "r557",
      "r558",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r34",
      "r360",
      "r489"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r357",
      "r358",
      "r359",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r319",
      "r322",
      "r362",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r270",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering costs",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r81",
      "r93",
      "r247",
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r93",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "verboseLabel": "Impairment losses on long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r107",
      "r169",
      "r178",
      "r184",
      "r196",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r405",
      "r411",
      "r436",
      "r487",
      "r489",
      "r522",
      "r538"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Presentation of leases in condensed consolidated balance sheets:"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r56",
      "r107",
      "r196",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r405",
      "r411",
      "r436",
      "r487",
      "r489"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r107",
      "r196",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r405",
      "r411",
      "r436",
      "r487"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r323",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r584",
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r40",
      "r95"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r89",
      "r95",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r89",
      "r445"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r104",
      "r107",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r150",
      "r151",
      "r152",
      "r196",
      "r220",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r255",
      "r256",
      "r259",
      "r263",
      "r436",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r399",
      "r400",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Gilead Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r53",
      "r216",
      "r526",
      "r544"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r217",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Class A common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32",
      "r489"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Savings Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r74",
      "r529",
      "r546"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r156",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and of significant suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r279",
      "r280",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "negatedLabel": "Deferred income reduced"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r291"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues",
        "verboseLabel": "Unearned income (current)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r291"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current",
        "verboseLabel": "Unearned income (non-current)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Non-cancellable obligations"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, Due in Next Fiscal Year",
        "terseLabel": "2022 deliverables"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, Due in Second Year",
        "terseLabel": "2023 deliverables"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable preferred shares upon the IPO"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Number of shares elected to convert"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Shares issued upon conversion of redeemable convertible preferred stock (in shares)",
        "verboseLabel": "Shares issued upon conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r30",
      "r31",
      "r266",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of common stock issued upon conversion of each share of Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Operating Costs and Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r50",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Loans payable"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r106",
      "r112",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r253",
      "r254",
      "r271",
      "r274",
      "r275",
      "r276",
      "r455",
      "r456",
      "r458",
      "r459",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Loans payable"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r238",
      "r455",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "verboseLabel": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "auth_ref": [
      "r455",
      "r459"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermLoansPayable",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Noncurrent",
        "negatedLabel": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r27",
      "r28",
      "r375",
      "r523",
      "r536"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r381",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "verboseLabel": "Credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "negatedPeriodEndLabel": "Valuation allowance at end of period",
        "negatedPeriodStartLabel": "Valuation allowance at beginning of period"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses recognized for the 401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer's Matching contribution to defined contribution savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Matching contribution to defined contribution savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r93",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r167"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r134",
      "r136",
      "r140",
      "r141",
      "r142",
      "r146",
      "r147",
      "r425",
      "r426",
      "r530",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r136",
      "r140",
      "r141",
      "r142",
      "r146",
      "r147",
      "r425",
      "r426",
      "r530",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "verboseLabel": "Company's worldwide effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r110",
      "r369",
      "r393"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "U.S. federal statutory income tax rate",
        "terseLabel": "U.S. federal statutory income tax rate",
        "verboseLabel": "Statutory corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Reduction in change in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedLabel": "Foreign tax rate differential",
        "terseLabel": "Increase in tax rate differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedLabel": "Stock-based compensation",
        "terseLabel": "Increase in non-taxable stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "negatedLabel": "Not taxable government grants",
        "terseLabel": "Increase in non-taxable research subsidies received"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted average periods over which expense is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to the unvested stock-based awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r68",
      "r69",
      "r70",
      "r114",
      "r115",
      "r116",
      "r119",
      "r129",
      "r132",
      "r149",
      "r200",
      "r270",
      "r277",
      "r357",
      "r358",
      "r359",
      "r388",
      "r389",
      "r424",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r557",
      "r558",
      "r559",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value of Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Transfers from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Transfers from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r240",
      "r251",
      "r252",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r311",
      "r428",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r427",
      "r428",
      "r430",
      "r431",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Assets"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r240",
      "r296",
      "r298",
      "r303",
      "r311",
      "r428",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Transfers from into Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Transfers from out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r240",
      "r251",
      "r252",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r311",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r463",
      "r467",
      "r476"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities, Payments, Due [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r461",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      },
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "hook_LeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current finance lease liability",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "hook_LeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Non-current finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r464",
      "r470"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments related to finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "hook_LeaseRightOfUseAsset",
       "weight": 1.0
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease right of use assets",
        "verboseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r463",
      "r467",
      "r476"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease amortization expenses"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r473",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance lease, Weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r472",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance lease, Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency and currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense.",
        "negatedLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r318",
      "r320",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r109",
      "r392"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r521",
      "r527",
      "r532",
      "r548"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r109",
      "r392"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign (Austria)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails",
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails",
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r370",
      "r373",
      "r380",
      "r390",
      "r394",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r111",
      "r131",
      "r132",
      "r168",
      "r368",
      "r391",
      "r395",
      "r549"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r366",
      "r367",
      "r373",
      "r374",
      "r379",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "negatedLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r92",
      "r503"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r92",
      "r470"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r166",
      "r454",
      "r457",
      "r531"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r81",
      "r245",
      "r250",
      "r253",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest expenses"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r87",
      "r90",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r79",
      "r165"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r474",
      "r476"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease expenses"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of the effect of lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r107",
      "r179",
      "r196",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r406",
      "r411",
      "r412",
      "r436",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r107",
      "r196",
      "r436",
      "r489",
      "r525",
      "r542"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r107",
      "r196",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r406",
      "r411",
      "r412",
      "r436",
      "r487",
      "r488",
      "r489"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r25",
      "r26",
      "r107",
      "r196",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r406",
      "r411",
      "r412",
      "r436",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r25",
      "r524",
      "r537"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans Payable.",
        "terseLabel": "Loans payable, non-current"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "terseLabel": "Loans payable, current"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r25",
      "r239",
      "r249",
      "r251",
      "r252",
      "r524",
      "r539"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r112",
      "r218",
      "r243"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r112",
      "r218",
      "r243"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r112",
      "r218",
      "r243"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans Payable, Noncurrent",
        "totalLabel": "Total Loans payable, net"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans payable"
       }
      }
     },
     "localname": "LongTermLoansPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r153",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the business and organization"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r89",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r62",
      "r64",
      "r70",
      "r73",
      "r94",
      "r107",
      "r118",
      "r123",
      "r124",
      "r126",
      "r127",
      "r131",
      "r132",
      "r139",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r196",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r426",
      "r436",
      "r528",
      "r545"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net losses",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126",
      "r133",
      "r146",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r219",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r386",
      "r387",
      "r388",
      "r389",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r477",
      "r506",
      "r507",
      "r508",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r169",
      "r177",
      "r180",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r468",
      "r476"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "hook_LeaseLiabilityCurrent",
       "weight": 1.0
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liability",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "hook_LeaseLiabilityNoncurrent",
       "weight": 1.0
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liability",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "hook_LeaseRightOfUseAsset",
       "weight": 1.0
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r473",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r472",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the business and organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r403",
      "r404",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation (loss)/gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment, net of tax",
        "verboseLabel": "Foreign currency translation gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income and (expenses), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-allotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "negatedLabel": "Payments for deferred offering costs"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r295",
      "r297",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "401(k) Savings Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r323",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r31",
      "r104",
      "r259",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference per share"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r31",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r31",
      "r489"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2021 and December 31, 2020, respectively; Series A convertible preferred stock, 2,978 shares designated, 1,697 shares and 2,978 shares outstanding at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from IPO"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "positiveLabel": "Purchase price",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Net proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r84",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from option exercise under share-based payment arrangements"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r62",
      "r64",
      "r70",
      "r88",
      "r107",
      "r118",
      "r131",
      "r132",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r196",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r403",
      "r407",
      "r408",
      "r413",
      "r414",
      "r426",
      "r436",
      "r532"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r43",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r42",
      "r207"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r209",
      "r489",
      "r533",
      "r543"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r209",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r305",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Service fees paid"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r305",
      "r480",
      "r484",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r478",
      "r479",
      "r481",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of borrowings",
        "terseLabel": "Principal payment"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r365",
      "r504",
      "r585"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense.",
        "negatedLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails",
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r203",
      "r204",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Software Development Cost"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r6",
      "r16",
      "r101"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r24",
      "r101",
      "r568"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Cash balance maintained to secure a letter of credit associated with a real estate lease"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r277",
      "r360",
      "r489",
      "r541",
      "r561",
      "r566"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r114",
      "r115",
      "r116",
      "r119",
      "r129",
      "r132",
      "r200",
      "r357",
      "r358",
      "r359",
      "r388",
      "r389",
      "r424",
      "r557",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r163",
      "r164",
      "r176",
      "r181",
      "r182",
      "r186",
      "r187",
      "r189",
      "r289",
      "r290",
      "r505"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from collaboration and licensing",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r471",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Lease assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities that were not included in the diluted per share calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of the net deferred tax assets or liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of losses before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r43",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r335",
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r323",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of summary of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r329",
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Share-based awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used in the Black-Scholes option-pricing model"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price for options granted as a replacement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number stock option authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Option exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Option exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares granted to US employee",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant-date fair value per share of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r331",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Averaged Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r321",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Vesting upon first anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Vesting in equal quarterly installments"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r318",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Executive team"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of options vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r346",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, option exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, option exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Option unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Option unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "verboseLabel": "Total fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of share price with fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r102",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r104",
      "r107",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r150",
      "r151",
      "r152",
      "r196",
      "r220",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r255",
      "r256",
      "r259",
      "r263",
      "r270",
      "r436",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r55",
      "r68",
      "r69",
      "r70",
      "r114",
      "r115",
      "r116",
      "r119",
      "r129",
      "r132",
      "r149",
      "r200",
      "r270",
      "r277",
      "r357",
      "r358",
      "r359",
      "r388",
      "r389",
      "r424",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r557",
      "r558",
      "r559",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r149",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Common Stock Awards"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r54",
      "r242",
      "r270",
      "r271",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock (in shares)",
        "verboseLabel": "Stock issued upon conversion of Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "positiveLabel": "Issuance of unregistered shares",
        "terseLabel": "Issuance of stock (in shares)",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r270",
      "r277",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r55",
      "r270",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r270",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r270",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r37",
      "r38",
      "r107",
      "r193",
      "r196",
      "r436",
      "r489"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, Class A common stock and convertible preferred stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common stock, Class A common stock and convertible preferred stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r469",
      "r476"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r452",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r452",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r452",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r452",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events."
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r490",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Changes in the valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r220",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityEliminationAsPartofReorganization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption of temporary equity as the result of a triggering event associated with the temporary equity.",
        "label": "Temporary Equity, Elimination as Part of Reorganization",
        "negatedLabel": "Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityEliminationAsPartofReorganization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized income tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Increases"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsAndOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r142"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Total number of shares used to calculate net loss per share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r142"
     ],
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Total number of shares used to calculate net loss per share, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r587": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r588": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r589": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r590": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r591": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r592": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r593": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r594": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r596": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r597": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r598": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r599": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r600": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r601": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r602": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r603": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r604": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r605": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r606": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r607": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r608": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0001558370-22-004211-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-004211-xbrl.zip
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M)76)[>0FTSHL.C#?G;P_&64GTU#HC\8.Q1HPM1HT%/RC ;L;XX= ^%]Z4"M
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MJS]S^ /LQ*2B; ?97I#>D33.KR6#HG!G(./"#!*59NR"XH!8E6B8?I']FO/
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MMNK24871J[X=+HF&'\^FC_[Q7U!+ P04    "  )/'A4!X()*((\  #6 00
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M$W%@M5CMHBM'B]6\L^;' Q0:8C0VS6GO__A D5>SG6C.(PA#(7UGX/K5C](
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M[L"A*MQ6*;^ZG0Y%!6!.O,.>AX(A<'"Y( 4!)+/_;CF_'1\^9E3 &;LFSB!
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MU LEAKX:RZ@[A5RN/.6#W>.&Z"ZTH[HLKUQB -NB6.I:V)8*]0 $K30GDC(
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MIRIA>LKW\.[P"P]Q!AD=,Y2D))ZS%N@*1X'RL?=F31WA%E@SA@='5>S8XOA
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M+K/B"AR*VAGX'KV(3[7<DUSE?K%L(VQER1@X./.3^"$BDU--!9(6]?H%L4'
MRH$G</CE/5^QLC&84DWY?O%J*X EYZ5[OW\;Z.#YHL$<?XD95R^L1T3H858>
M!T&8]9J1J@@%UVFH7[ :1)B:,%GK.-I?WV<R#K/36__Q_P%02P,$%     @
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M=G35-[D4(2?MQ!G%XK6>.S;;+L8A6U1L=TFIX2*<LDU>6VY9U&V=TS'/&/^
M:]>^FW'\.6(';%6EROWD#Y$Z6KN,QGE?2<W.5H2%5]?6FZLP]F(_9%&4B'T\
MQ?N4 [LB=4H3 [0^R];1#Z$K&XEO?)-X_?%^?7-]<?9P>4'>G]V<?3R_)/=_
MN;Q\N,?@\FW/8"H;+<6-3YZ^;&^Q!->T\]QE14[UQJ45A7*:9O0&D58N NI&
M\8109\.E!-:)<JW!=8/XP2 -82VXXXWZ?:"9(VT"]1Q&V5F6T3SKR<E.&B&/
MKG:EY,AJMD <50I!C6<(G%S'<^'S!-,D6CF/HN(&BU8PG;9=1$PI5#P-K:.&
MZ"-,)>\XEUQ5-_)P1)QM+4OM/$[]9Y</GWK9]BP.X)_+?QS"9R]B<F5G^;F7
MIB]A_/2K%QU4LS+=OL@C=) )&B^FZG1$','#Y#?V=4:>>'% ^ \2HQ7Q<E+R
M(IR9FQB?V0X^_$!K1@ZC_XXR0 O]G'+EVV\<][5%'MV=*LK1W-H0<?1VRVOJ
MI355'J\KU?7B>2)S<ATA%EWFO[X/A4*S.^I3!@>/$?U(\^XP[.F"/!IU%&XD
MQ1WM$<>FEMC&*7)!G-345X31=QRK\^B<5M2-PC9)?N>Q^.Z'(A+A+W^O1<X>
MO"\,'BASZ>UM2G?A8=<>CD/Z(8W)P:I#8&IW<AR=07%>H.VPYG =C(L4;BG)
M#CLH?^GMA /[@G3T(KDR@2^$Y-X7]C<A!]D+0;XE5TE*_(A-%,--R :L1X^)
MXC.J6\KGR2G=0Q^@G#-F?CFQY-PD%BOV,4NWPZP2A'[94SX&Y@EY9#V3*!*_
M?P[S;1@3* G[ H=_F ! .H9'YR.2["F\,L4R=O_%![KAAD1)_$33;R?!G3:8
MG>\+E)CP=XI*-J3@XPAS71B@]DUXPB&& C0G4Q<K6C_3]#%!K;?%H8>)O??"
MX)(%8YS1C$U#URS8TG+!B:\/M1E!LQ_FH6>(ZM70H],)^] S2 ?S,TU\!("1
M!P@R+XZ\ NW9%Y.% 16/!1(0A;DV\8)G/K)L8,!),C9"P&)% I(5__4;JY8S
MP_TL1BN8D)(+-P'G4RU(M^^9S #WLQJ R@9H^_:Q;!KI+-OCQ<%.E92;0Y@G
MOJUR6MH,FB;HDMR+M'> QL\(@!VV6/K(/'3 'FQK\T5$F%K1TV [;8L^[CI$
M'AN"-6DD6[(3Z,I(OFU&ILN=V>;:=ZVNUE)YHSGRT.Q35+U)4[=%')J](EO;
MJJEI8]BMF4;3M@V;J5<=)M>/;PV7*WL[+V1SQS 6<[4,'IV@Q",1S7.8B6V(
MG](@Y B5^*%7KMBQ)BEEJ06OJD59<T;9(7K=IK!0F+_<,J5R-E>!C?4]S(H_
M4A6"]71!CF(Z"LM(UM4>,9IIB6T^^Q3$5X23YY//B@'?XW(#;#,IO:^4IK72
M\51*]\U[9E%:0]L906M=[FW< 'K>A4_;?+WYE%&><2K,U-<'.6QIJ2SC5F<'
MQ,"E)[>I/U?4"2>_(IS!VV3SEK$0:X9NH&LNM7F^05*@#SG*@?W2OK@Q5[+F
M0''XNM6*SXACX@XI'8!BW3V08YB&NC*"=31'C%\Z4IMZ<T$;&W;-H3(ZW)I9
M:328Q3>SCI?V5-BN:(L<ISI5;.18;0T18U.WO,9C+-]V/%V =I1(3:AC?++P
MC&A+2',5'G_XZ43>@H+.NB_.%6EZ&ZX6%1-[K@B#K-, 2PDH=1BA#YZ)+E#/
M&2:6@L-Y0-R$WF,8A7G(3S;Q^N/;) K8J SKCOE+S\&$ =V1!]500\AAI]L7
M<6 .5L'4[R5&U3Y#_N+\<(,S_6567Q?6P($'>N4A.CLL)^8U"D6H6R\CKFT7
M4Y!(XZD;,:&^I8I1S0+!%=9;[P5N2^A=7CUIC#Q NY5LN[#:;(DX,'L$'GUA
MLZ"+Y'+J5%KN!5V7A5R2F,/+7\-\>W[(\F1'TQ*$7KJC4K,K\A@=8H!&%1>-
M?HCC=Y#XQD-.P42<-"O9K$C%R'%XSV*$"[JAC%) 4OI,X\/\MQ]GU?933+T4
M#B&&L<\8D#?%VMDW:,[G:*);;R?DN*:GM/J(SH*P3%-P:X=TL,#7Q'J7$X;D
MZ-!*.8$XF>>[.:,SX??=U)=/%!5;'".N<K-D,#U0U05-:4)X9(W!G9$"EID1
MJIO=VCVQ7^\>KLCX.][U3]7-W5#LGP7D\9"3.,G)"\W%9>\X2=FGSTGHPX4*
M(=:*+P)*$2(7'?&RYAW@F:]^SVA0P:GK_K?$;AHS=-\"G]\6'5?!.U:@IMT#
MF]D4?(_,Y6)XXL5Z"VSM+9$.&!KJ-=:]3YLASF6[I#5>Z0::2%;4IM-O7^HW
M)D6;:A=*>[E_ 6&G5*Y[MPEST*F%M;F[Y.; QP3*-:M1X-A0DM34KDO1UV<Y
MD:A7H:*SPS+B<X+Z#8U0152P8EJMY:H52")82@TTLH<%Q&>+0JK,%'/TM8EI
M)1>=>28\H4)5\BD=%\:WX]%_0T:C'_*@TU9=8^MC$0?Z]66?8@/$^?V:R;67
M!\JE;(5,\N6W[(;@0+O.C>U>S-/OC1SY!II!^S#+(E!PJ 83'FEQ#8ESF>+D
M8$LG'J XY6)1^Y.#+I+N3@^[P&9&Z]11-81T=4 .>?W*GMR/;FV-&-@TA!YW
MBUBQ_.'PNO24VL;XECT&Q.I"PU0[0I<6G--XZJP1.6#[8-*[U>B"L=\>BPJ\
MGG!;1I#9#"WGX60IB' $SGFRVX4Y''"#$S60A(?Q$XU]=2!U]T >6!KJ-N?7
MRN:( T]':O-Y=$5;O/(K4W>T+S"GOKY,G;SYF.24O/O1Y<1Q</&$)9=+&%8@
M89$E$28L M!VZ9^<Y7D:/AYR_OA9GI!;#\4N^FQFH)RXRZ<?;M-B18X+UGA_
M_L@H[2V1QVR'>LT*Z2?-$$=IE[2F?EG1%-4Y5H2379'K+#O0P-7"[+2:9D+3
M__K]M]]___T[LO=2\@PL_CMY]_V*_0G^3[(MPR0V_A[R;9*&_X0K"CFYH#[=
M/=*4_/AN12"R^/A\_-?OX<W4#)X^#9]I]/+?R3U-8>0^@Y&<:9^' 'O[8WE^
M6/WTW_ZMY!O0+'R*X>F%%7FW^M-/_ZT2B#%LM$P.>9:SO\*VFZF(CB<#2=R+
M0BW-D$.02K'C7%]N@QA\E**.R7*3>#[8T4KII]"0A[?+\BE!$,)%,B^Z]<+@
M.C[W]F'N*<M8*%LCC[<>-1L55-J;(HZ^/HF-;V!5=,EM\4AK0=I1$97I]83[
MB6^9GGZ[GO/6-3KL#OS-7'&M+-FQI&!+XXP-RM=\J_@FR;*/-%]O'KPO*I,-
MIH(]D,W,<E0B:0@)S(%OJ,F(*YDEO_)6JLR17!<G&(#I-_R])+@1S#@[*[KD
MS#S%1=6&>2+&S.F#CN)9MTLOC=E\()/$O:";T _53SMJ=$2.&_K*-Y][[.N%
M&!T&"&_J\24+4O(@;^0@*-B<+$:/4_TGH7I,GX!)%P#,8 %9W4#0=/7X)09=
MG6XS:"_<XH<KM7+=VPF(X:A#V!FV#R8)RCU-PR2XC#M!: *]WQ=/M7HY86D&
MH5 88\-_%!)-J.Q][J6Y6W4?Z5,8 \;-H'3O,8P)U!6G,;*6/2$<YYE:ZX(K
MS*/1#3D2ZRH^I X^8I36%MW"P2FI[KWS,U33*'MRL(JK;"VTV^O B0TE[[S>
M3FKNF'W@FSU')AG6$VG,&JA?E7_3ZX:]]MM +<SG?7LF/C^#%,:;)-UQ@6 @
MADD(#,TL\:HV-L_5&YLS5W*;R3RMFA]MIJ,YWL'RXW7*TCHVJ^,[6[<TO8?-
M8ZW=]X[.2#'"S CJ<R&JGHC'^($*6#L]PCB1)"6"E]C4)8P;X>S<K)K,;HKB
M.$=UK(2\"6,2)%'DI1G@ISBXX?+X9M,D7/_LK#KHHF7'EDZ+0@.5TFH4..ZQ
MF.A7"FXMZ@4'4K/ <6YL0L6+&#\Y)&8QQV_3Y:(Z%=:6^O3V0!JA ]2M<OGN
MYMAS>$WI1]Z8._ 3?\GF]$PAE%N6TG3^\;QI^L06.(K4T@(U!P=UE;&I[#CA
M6-?G5@>@>;,74D ;J'9?SB%U65C2T2:Y[:Q#XH$I[9A&]6;>D:A5=W.">^!"
M@UY/Y$$^0'W%T>\%KB\,D=[. 7&$*PLS&@'_FH)D#,T%A>X>RXEZG:6$CN;+
MB'+K<^EF=,^S@C DHJ=2V.K*P42A*V[AZ-JH:KVTD&VJV1FNHNF20O5(8IMA
MBN::UA2:-N,S='H-=AY5A8X\HQ!:HTHC^I<)>KHL#95Z%@BZVB\)GVS.C]M!
M:NJ%@>%(-8'.V@L"SC!K.J7EF^\XT$O<..+SP%W_DS+JUL@QJT=-&:X431$C
M59_$QKZ[_GB_OKF^.'NXO"#W#^R?#Y<?'^[)^HJL;R_OSAZN60-R]O&"G*\_
MW-Y=_N7RX_WUKY?D9GU_[_1*&2_8?,4<H*U<\N47/SI !)YE&67_"]075<TH
M(0^%$>9IWD(;3 9Q"(W1QOR\(N=)X.LAJLKK%6=2LG9W==6YD7Q8/GQ,4G&P
M4[S-Z\,]5G?)@T.;8'B!IWIGMCMOZ&J/'"Y[56U]:>>X,6+HZY?9N"9Y];A*
M]72TZWIY<RA;O@WMLEC>'<TH<_+M61Q<,+2(DCUDAH722BCK[H,\4+54;F8P
M'1T0!ZR>W.:#BZ!>%&&KZ)<Q;/ERQ)![\[.I'=3T'<;P+S1FD!(Q?<^"71B'
M %10_*X[BOM[(8]C3;7E2.[I@CB6=24W=>N"/O?J)@?G\3RGZEZ#@]/-@HR7
MWR[3#^62Y$DSY%&K4JRY$=!L@S@NE:*.3P\Y:7'+N" ^900^]%TWMJZI.,J=
MG*3#&*:K=7VMOOE!HR7RV.M0KW5R6C=#'(%=THX/PD91.#?W_*=0$(B(I;(B
M_I+8:=Q!O;F/29PT52V@IF_-2+<S]N@<9(23%_UZ>V*.X6$*&(<U+VLH\ZGB
MNV#UC?N%ISE-43[:60R]WYBM1+5?\OLE]>)<"'^D:LO'2$-3I4AU5T_Z#/O%
MO#91C5.W+27>+CG$O$3J$U N?&GFDA@VE>*T"D!P<(?.OBIAJRJSGAEYIAE_
M[4GH=1TS$["_**"OHSE2?-!5M'ELI+TMXN&Y5V13/ZT)%W&W(B5M-Z/OA)H*
M0AB"4DC2O3I\V@I]"+:JU8R\1A/4 =<NZ6CO*PBZ6LJ=3"_:KA>:*:Q1LH\_
MZ/24UI^J(@Y)3<$GG)IBG(_:G8?"6G<Y%X4G&&+J<EMU:# O.(X'A? 2HW<Z
M!W80LGT+QM,I6VS92#'K.DCK-?'R9&48'YC>ZVI9^SW=)&GQ8,J#]X5FEU_R
MU$O2((R]].4ZI[N,&0P>(F;6C;C)>F:I4W)$#A0SF/OTBL4D[!"#U1Q:FV?<
MTGY8?2)="$AJ"<DC%[%$1"[DBC2%FGBNWP>3F,T,CT_!@TNE&?/3H_RS@RRS
M0#&.O*<QW2@?7%*W7@2X*=4\!::3INA!12WQ2$!@A,O%!?*FH.WLY:2)=67!
MB&#!@4%$[RF5XS;( [!5I<;40VZ .-C:Y1PS&#3'W3E>"=(/-_O:PM W4=G.
MW@6/:;1Q-!.<19>Y5UE[7L*\35+(WN08>4A$A.B<)+)"'3G06C;CR0+O>-*(
MP=VVAN.63L_UWK!=D4(DQ=B!X]P3&JOZ)T_?NKRDUV6;*S8]#)_B\T/*S."_
M/*1>G#$[@)GB@/\6\<GL6?"?![&SW?/H]F3,%HR)XXVL"Y'FG!:*F!84GA!
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MN_Q"4S_,E.]EF-!9)M+WFT8W/6TELCP\U]!EPC14-"DXDXHU*M">T$*J6;%
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MS?JO]PZ=^B/-0>G;-'D. QJ\?_F4L0".URP9\F#KYXS-@9_YU=$>5S<BA#P
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MEK EN\ '%U=A[,6^A6E+-Z%EPH>&<31@I(/*\N!$1YF)8*5BO8!IRY1FJNV
M8]HBY*'\@,!M&C+1]O!H@$C3%&;KZX,<+[14EJ&ALP-B%-"3>YPG4W'Z944J
M!N6;S,Z.S4^K=C792FD$DL"D:U.8@I^&<9DG,"3S*0VR*^;PY9L<Z\T=#2C=
MP<G?\X3E-6D>LA]OT^)@'Z^3IYJOC:"'' 5&F^JHN+@9,<3H,5XG\]MJ@C.!
M;ZQ^7XC-XVON1&)/*O[B:2)GY<I1V"N4[)76]O(E>^TK>V4@P(K7[67-0RS/
M^+3;T@YZO3K,LH!4KP>?7*#20J#(!0"]"M39[9+8!&?D?@M%EA/5=;"DZK1
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MB@R$\TJ &$P=&<+XR08FP$I LB3'BM0BB@]A)GC\MT8'(3IIN9DI/VI<:D!
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M&?&EO_)TU!?%=,.CHK?P.3K?US\L-Z3_(B-"\YB<=N?%Q<D4B]DRIZ^)X$6
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M.SW.RY]($$_MWH79[^<I#<(<?E+8L[L'<IC14+=Y/%?9'#%4Z$AM?BQ=HDV
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MLX47_8UZ:;DO4HK;"9XVZ"&%4FNF F =30SAIJ,]G<P+$57<2<U^180 !"3
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MO_JM[J[NM@1WUY!^//BOB,+UW3_5T6:(K!J=.A_LT.RZ0/=7&:#/_X_[+2P
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MM.@J6E4-[FB+O1BPCNBFKLAILYDI$)??3> 55]F_18'ML.0K9K#>C@0'O@D
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MEH+$*P"48TWFPQ'@S' D<5D[>S[[L%!V^B+U$'49Y^[G'H;1>4VP(9O&&#B
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MG_\+VX_5TNL",HHTO4#G9?ON&M#)O=_<&MVJBT,FP %::V<MXMGC>:XF-J9
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MAT6@H?G%$V@6/>RH*ZZ.A\)\3HP/E(MJE-P7@^0(H8MBA%R3 7+!M'^DPV,
MZF:D..3:#,*J\G(&1#CF\$Q:;&P8C_8T+<-[12ND! GV-AX*=G"]D3O?H%2L
MU5M=U 'FZB&FGWTGY0[(<W9T!R) ;-(P<=5;M '4NTV"1"?PPQHX@:A/W8XE
M)^%V'N=8%A?^ZL[1"I0M+"F/B(4E6:3BC&<)+A>1@I?@T8M8>APA-@[PCE;<
MI)@^6 :0C*H)]VBFUY)E8\N@J&8V;":1S90EO+&;L<<323K#XDA=LV#=TTL<
M*6/4TUH"3CL3X&E<HQW;#&#ZF6+-A$NV;:LW*G55D! 7C'(BV5I<T29&%2O+
M2Z4BX,Y@\4MIM!CV_(,(GI/_:L!J,*XX  QZ@J&39B8U!)1EIH-3!@"U6H$>
MXYMFU S#B)VS:1E(BK"'A9"<'<B&LG.%G]5]'V?Z55]<S7(H[-$_X&T>XKO=
M690%;#(;O.)'[.<)>W?SZP\_S+=X>T78[B)^?LGY4+_;?16[M_<X89!WW4,V
M+@2H,Y@75'DV:E8"X(GJ3(;J$D"A#AW9LD*HT@@5*O%\ I)2[%I'<>B!Z,5I
M%<!-[(G0GK^W-]#QENV\$H'3PP)PRUPQHSC Q+&$U=HGK!3,8?V)WW:;;[UG
MW/G4[X!J3@[)8\/[QU55Q[G!T:*ZX1Z^0E0&A#>!B^N5;,UP]T))H/-=X*[R
MP/MVKZERIU86!MR;^W76[<:\,9M9GR:ZL9N>%#H&FP<^"DP#:7"&=>- <A[C
M)IJ>.XU>==VHL_LLL[\ "M(O):9IJ8J[M-?Y +.IMD^;\-1/-1MI^'2ISM [
MQ89X;I[WG1>B.(-02OS&-@A A-P?,#U6LKWWDNQ]G7A1ZK%G\-+S]]I?!D76
MQ[4%G+LF0=0>)Q_1$&!NFF:/B:BW:!VQYI$L>84V[XT_VP]M#X.I(U(]J@'@
MPVH\&/)8&EX;\ #2,$)WU#2&@NW8KFQ?9S2WM:!#/5L=L3TNY4A/-125;?3(
M*5'8]E-B3U' CCYD[W>[<R(R;(VI]A0%VM6&&%B>Y5*4@WY:JT]M_8XG+H:E
M*(AV<?+L%<\]9Z0'LMP!,:J$TWD&$[_PR:NYS&^Q#(@CD%Q@7ZAX0#6@(W>L
MX0,F/2Z$; >K;L:=2"( !%<7,_Z%2+ ;*U686J1'I%$6>:;[>Y =Y"KC !S1
MJIML,!:V 60QM$GWN&2T9<:I9H7*-* L("IK@=Z(&O6(!"@R6@R]1YR\!C[F
MKQR]>(')A#,*V^Z]=SK33*_BY"%^]T+*D6U3KG'5@5**+A#E<F%$7>A+"!U3
MS+SQYGOI@?5NE@4X*:2L$+$S#UD2,D81V1%%)'5?CK9YPO.98>3G"<O'2I8J
M0;Q=>#VR))8=#%O(8[B6$BU<^E@4CZ(E?<(TM%V4;U+\9TX,_/I*_J=S-ZB]
M*%#6'&)@;2^GI1S@*5.GNMJ>O&P4L58![+ T[20".[93U*4=ZZ4-,[LZJBCJ
M4%]M:FRLN]*6[6^%M)C;N2/25=Z];JO>'U$6=JOK&MHM471>^V?7&R9WGEM7
ME76KVZK/J[<6=*>[&MI@D+HJILU:[)S?R+P\HV?QO2SON@'85@YXIU2:)G?(
MHT* .Z-:5]V.*%I$O$G[GKYF8:>/;R_I4H]4^_668J[T2D.^O-DO 3AQ=LN4
M*+<5X8NSA.BXQ_2?MW&$Q9VF;N<^L@W@O5D+DMID8$P#@$> GAWZ[ZAAGQ^-
MSK#W;'!KX"H.P_CM+KK/-V'@W^UVF(95U4>">LH#[;V#32VC_5V%H8?W!^D^
MZS&A'=, T=^9#B@62BP<G)\5"=[XEV,C+7JLNU><G!&U,MI!!ER9[BH/="P/
M-E7V.LK"@#U,O\[:5Z9)RU^\HFD4L[8-.A6>3\O[59D 3.U?AE<%VCUU "B]
MSL!ZT!W06#-F]45%<K<OOP+*'[@40L.,AQ,GO>DYX-I1'"@?##6T(V!ZX\!!
MUEZ5S>VFWM@^M[J$K2Q$K'=BM=TGWV," ^'L/4O3%^5>>!Y'>7KO!=OU(8GS
M_8'EXR3]^&XG4JJT$9=>,T#'YE1@2K^MT09T'S[%)-W^7\FD9\4\)A5MJ%A^
M9BSC@GDN5R*9EN*3UW1A_VT9G3N:V9*AP\0B*A<)P:B03$LIDB,M< X,<O_A
M&8%CZXFCV$R/YZB_9,<9[]D)1CEW_56<B)/!RBG1V$: DO$T4&K3IU$M0)Y4
MZ1FB/?U@PT(\[\ %(BZQR"Z^*OY*3YD6<BU-PA;&AF=7YX\\&'VS(21MQ?3-
MY%<L;2'<)_$^\9ZOHR +F(^^PLT3I3KU@8Y];2BDAQF&5X8^]=*R13OQ3GDV
M_X4WCX*R?7H9!278QT0/]EHD/7S/7"M19RM>%R<09.Q4.@W%D&]]0'ZE/VF#
ME@G)&(Q2C+Q]@IDIBS_7L""B-6%(DH:$.%3)0T2@E9<9%L3COK5?F0PW4U=P
M3Q Z$'EG11>[VX3!GHE;Q\4?I==96]//&6@.,L,: *H*5>NW!9U_39@VG8YK
MKY=$F+]SM\'H1<C>HIQP<,)N0/%"Q5^LT:Q-X/CDM6@?E=)7J)*/UG%50GYO
MVDX&/NN8*3I;HY_9/H E9O/W"9E$%%D'58N"CO) B7FPJ4>'J-H*0U[,]NH\
M<6W&FUXAUGB577.6,?V*DTW<LT"=S=Z2PEZ8I>5#IV9W"\ABFI_(W*[C)^II
MWI* 4EE%2&?;;4 IR@NYK8HPH%9#0$?K='#D/8/QK4"?.DTS:LH=<W[Y&^VY
M:.K#Z,0HEQ2@OU53I%('D6QV^0T$"T!QJ>A;!=)3 Z!J E4!]-B:C7>9/01[
M($D]2=UK9%#^^U\J V[(O\B/Q4^B[?_Y?U!+ P04    "  )/'A437@YB29?
M  !U* < %0   &AO;VLM,C R,3$R,S%?<')E+GAM;.V]:W/C.-(N^'TC]C]H
M^WS8>2.FNBU?)'MBYIR0;S6.<5D^LJO[S'[IH"E(XML4J>'%9?>O7P D)5(D
M0( $"!#27,JV!(#,?!XD@$0B\??_];%V!^\@"!W?^\=/PY]/?AH S_;GCK?\
MQT]Q^,4*;<?YZ7_]S__[__K[__/ER_^YGCT.YKX=KX$7#>P 6!&8#WXXT6KP
MZF\VEC?X!H+ <=W!=>#,EV PN/IY]//ER?GISV>CR^')X,N7M*5K*X0U?6^
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M$)6X<ZW&55:4F9HDN+*LD7"R2TK<KC8IC[=.J#9:O#*)1PG#%KUPE9U&6"?
MF'1?6MOP"RMJ3:I9-N$>0\DIHJBU*2WS^FWCS.MU-8U!K:W,HA:H.B30-P/&
M1C+KM0(5=I%%CQ'E%%&OA:.P'.TZ =AH+DJ72VI"754YVA\\.P!6"&Y!\O/!
M>P5P:158P6>RTIKYKGOO!S^L@!2DP=.$OH2A8U\F36NIC=RJW=/!C14$GRAK
MU]J/O:@JYI+ *>YVM"-6:WZ4*2=&*8)XMX'S%Q]%]@11B7UC/=C'FI>SKEI1
MC9>C\:7Z%&J2N<6F T&GXVE4NM2$2FA&EZ2XO8T#J(]G_,XX3_83^(&_(4V;
MFC1UB)1KK!>I$S-^ E:OCMFD3?H=B5'-&S*93X*U(O6L_E /<W;G.FO'2_!&
M=P='_F(&8,.6Y_R)/V4S9;7-F$P[H3II>U!:>+I!-B.&NU/JPJJ^G8=>PV1^
M-!5?ZNT)FM@?5>M"LQ@F5BF"3G<GD_D[KVR$S%\5&N]R8%2"H#/:9"JI6A66
M-5P^P='$84IMI:CCJ]'YE2X1M>U]IOR"&YF1KZP&XA;,?D'MV"$"Y*H]&B;!
M.W!N7JCB"..X56.CS64(D]P=N"Q5I?1NXZ-LX'PSETB-=2'5$:G,[C3Q5/)5
MUHY8S2G 3"<6%4C=(E;E"J#I-O&,A%#*0J* %V##DI'3R'S5MJD=^[HW:\UT
M9*2GG-I=!?.3L5'M""J>2IQFLQ5?#\><)E'Z6,SP[@,$MA,24^UPMZ,=*[LW
MF^QZD7I=MI8S0P'<HS2D'?G$T(33#'+S3U8"0?X+3PA'""A:G($P"AP[RM)%
MH3[\*_RL>M^Q64L%W8U/1I<7IR;9--&:D;I5*9E320\20JJZIK1AE6C\V9C5
M2#U&WL]D6LY?\RRD N6)RJHN:&I(,**X#^-+U4 ZJ4E3EH+YL_6)DUX&\-LE
MWA>D6- &[1A..;%ZD9 >7<*0C*5-1HIT)MN"37SM:,,FL;A7\DF 9HP<AW>6
M.7SU"1F@L+Y0_M8Y&@;@&( Y,0.P=X=.!%Y \.[8()GAS(#M+SW<"L:0,"++
M?JPVU)8[-BM1HZB,ZUJ%G;2[W\9<AM7++"HCNUY\$!6&-!Z.QB/UU]5T'X:4
M"2XJ<3LY K+?44@&$X1)[HP?8L*0JOBQ=8?W*L]_$IZ^ I%C(V7D64!)^G_1
M5=+_P5\*+WB\!*"?EP#H8'UD7 *P;UT,FYO(R)^H%17(B%)HP"2>E,3_>J6/
MT@I))E#*H#***#?%?Z?9^'1 C5'K^QZVYL)V@5]':?CZCE\C8>5FPY2<@'9\
MVE?$FDBIUY4,+_%;Z,P=*_A\L5S ,(<AE=<.T69S&"[QI.2 %H3K[O6?K#7\
M-;<G3)W3U%?4#VDNT"I ;R:R7BFD'YZGU,S1V^_U@Z^9^LLXTD74"RY1&4ZU
M +#5:I$NEY$93K%']CEP;**G:%M 7[#IN!'<T&29)(<#J_(1,>T,[X(4T;^6
M9X,;/XQ(%J%-D^;02;@6!!W#)A%PK'SWPPI7]Z[_8TNKFDV,<ZZ;BR<O_QS<
M/TY_>^G/!L16(>S[#A555$5)H%=Y#OQW!V)W_?D]A!3WIAL00/YXRPF</+WC
M4V<ULO$WI*\%H2"Z%TDA0F0).QI*J 3UL' B2K3-KH!VT N"LLR1&IF-W,TJ
M#*@H ,VS'1<4XHY>?3%61\:C#H><G6G/S+Q6VZ#C?!@F;1U6*JP=U3IC!&%5
MQZ8A(ZWF+8!O;SM8:OB["])#-Y.U'T3TS,4L58]4$Z O(^T8WF]Z@NJ'NDYT
M?_>!^A_)I40L7U39&4J5>+ 4XU-26]]D38;LD3891;>*3?TJ-=,[]@:TXYZT
M25M+G4AU@ZLR866=3&P;)8@.8:\'SCLEE)*EJG;D:LD!%E(Q:J'M5$RXY:J.
M.RG+MY-K!N&#JD=F&JK=>:^^F82O!7,9(TH9;:=2-<3ASUC%2ISG &PL9YX.
MYR&<-B;GZ?&)^6@2AJ"TW]*BI8,C4F.E2)Y#J3J35*'O;&I)81QG;7-9)D(1
M;5-!]F9VGHWYS]9GHQE36N\0V<2B JEY\O29>M_X'M;E;TZTNH'K;[CV#1X=
MZ\UQR6=N.5LY1(;Q*T1J!C-]^+;5]"/ZFY]IA/J'R#$>54A-[20J&4^EH0YB
M^&ZI;,YNBIG[B&W^SM24N302KA7-TCMU-'\GTZY)$^;239@V3,UVP^AN;AV_
MI1W%I+G:6^I$U!4"/NPDNA/MP7L'H8B 04I#126?J]_"%A0PR"NRA%UH-0&#
M2:X^%'5M_R=V4$R_#[M6]/GL6EX$9PTH8<0&%2$%%#(WH!UU!%&A(N"PG4ZT
MV\_IVFJUME:'0[66.A%EQBJ'1\V(=N]XEF<+&!XI#6E'/$'#(Z_($B(<E% I
MD1M@5\QSX$ 5;-"II,2\$UA#K:,=000!7F82OQHDCWNJ9NM0M38 \_ >ZCT[
MN#9=S, <@#7:IR!F""$?X6C6WN%P3ZR*C(PXK5:1&"X>&2A$,4;>]DI2S#;U
M#B?3MO6.W**K0NIEFLJL6#*?F"YV6DVSO[*<O6>L?4#,:J&0MI$5FL9^S< F
MG;-.%[?@C;14W"]V.)QADKQM&(2FY&!7:FL/0U&M%Z/Q6/'-"-((U5(GHF(B
MM-KQ00I!_T>.XW?+!?A00';?'?H"VNGB![F2R2TDY3U;VXU1 OF[#WN%+NJ9
MP:YUMU@ HCNLVY?0CO"\KC0-U"5A][-_])?!YL,F)XUK;2-KDQLGH#A!I))Q
M2:>:+O(=;>K)X*&$)_6>G5WI1$)T[M$^$K0][!<%)8@O:&:Z?R>/HDS3FXV+
M]6FYF3X?O(4?K!-0:Y*PL=7NO1UK(Z>$2%Q%P;?P%6!'0;D<X=*.&%];**4?
M\BV0K(J?K9?6T"B@)!''J_4!PCI&[!<TGA1, DL^M#U6.(5!^MOF:\D"F+QY
MA>?GU@EMUP_C -2,-&V;+4(P&L'_]6L(DJ( ">'[:DB']V-#^/+9/0-K=((T
MW:8%\R&)577UM*.-%!I4L*V18J3FDKL4=(PMB^'-A^]FF:K#TN%CE,DL.825
M95&H.L_6MLU#HYD\I4D>597M7CK+%1PIOH< YU:8OD66XZ'=E,RS<N\'?&=W
M6[1X:&R5I3)!<4&DW/:BTO9@29*4'K=PM6/[2\_Y$\R_;WP/?W6#X@E<MRJI
M)G?]0Z.6& 5)#0G:TDC2%0D[G3U9$?QWNKB.0]BO0GS6.5A:WE["5NH-"<,3
M^-_!E\&N5?A'TO# 7PRB%1B\I<T/+&\.55=X@,Z7).1UL;M.(LFV^IS#8!OU
M@Z[:R&Z:J%E>"6I;3?!&2IO4],*W)P5IE H6>]-X='5VJ=;<",6X$(S!)GLW
MV:"E6Y*7>+VV@D^X=G&@+5TX-CJNE\PGH;U^AEJU<[$\-0;EM&Q0TO:110EW
M3QA8VT<,-KMGZ&Q3RDJINR2 4D'-!@8-X5<(ZK5+#D9FJZR=E:A'K;!YT5Q(
M0\S!C0]G3V]^D%G21\>&*T@T<UL& !3.@-78@K.R+2@TCN<4V^8'A?;EV '2
MW<#;EWH'!8F# *U4\%J[NJ<WJ*_(YY=_Q=UK[<"IZ_T<+6AC AJC6_3NM1-<
MJEDXZ\PLW%M.\*OEQB WFRIF *VQ!N=E:X#:'.!&T>1@V^Q@VZ[.LX&M0G8B
MU<T'Z%74G/6M>*4Z4T"MHTWGY\&I<(276SI#>C@Q7T=NN[JFCU^4^WC6ZE\'
M&Q=/^^&8#[*6_SKP<-LZ]W.:6FKZ.UM552<2JU^-?4; TT2QWUR.QF/%J;MX
M4-T[AMA.:$.,!27M/J.M&)5MQ:[109"V.G!RS7:Y** (2%L+,%43LM- >1*I
MYS+7TZ:[\D*QW29H+*4A_1/OA;!.S<?EKKBMK_/0G+QDS2"\7TC<-E_]4$DM
MJTTGHZNSN/-V8,/<7A3%WJ4@%1ET:WK:9;FGI8\8@/09R4X;>LH@S2L[< O/
MZ7(4),B?$SR['X4R)C9H1,WUP7M!-"SYI'-^TT2&NEFSV(<4^][5Z.)4I:NM
M,5L*=P/+5Y AGOI'W_+VKTRIL3]7%2,]:F6PV3:C]8#O>\M7$*SSDM<-_]0J
M0B8#.W5.%U6/H\X.F"MKT]5YP-A.'MJ)*;7#=A>SD\M6=.-:89C[&QJUVC1D
M]+X]/*G:;D,/&(2HE;\.\#,'DX&=^Q3/-NS=DW<:3;[7W"!@_:Q\%](C1*Z8
MZ//)C^I,0ETE-5OSE2_%[HUCKJ^='6'#L+!)WTI60T9_K(32M?6,MJ(B[@^W
M]P7U9&00"BWJ; 'R TM>$3/@HJ!TG+KK!2H18,FR5*PU%J)MHTHL"/-+7^=?
MNLZNM&RUT ,O3T;G0\5.#C%\R5LC&1HRQ'V2.]W):)@JX@>31@91VHK.QF@K
M+_-136H-M6>5V><>M"K:&0 &C"H/*+/*9DC714L')TJ,'UZ;H$!(X+&' @\K
MP_^VC68+CT*S.O=MBD+8#V;SM:$H5)#A'>NC!7D:T<Y&-,*Z&#386GY#EBGG
M)\-_O5CO4/P0Q4PPVHZ*8$'XT5_^^*]!VM8@;4QSB[&=#.+$29$3[(6.UML+
M]A;4Q!&A6%K\<M@G_PPGN\'V+:^!!Q9.Q&$WFC:GHP7AQ;X09B12#X;,2)Y
M].B'*$DH7DTQ6I**D$38T #^$0XV(!B$:5LZ&Y([*_"P 4U%K[$:Y.)JLDKN
MO4Z=#2"6+Y)[.!I?G*OMY'6X%+([<DEE2)=-72#/5L >(S&L# S$[0PVVX9T
M[JXYJ3]? PN. C8^1%K3;>NK*;H+H/JUV =UCA:TZ^*L6!8O!V@GKR$S_Y?X
M+03_B6%;=^_LIP:'%<&(NY8&(&M*9P.P+WEM8E!2<4593HNO4[OS2"JO76>N
MPZ68Q91'*D/&:[94 %PI 2#)3DZ;IP08_"5[VG]IWNG[GQW@V@J=<+K8>Z_/
MY-\Z*\!663N3P)<=H(60W0SJ+2/9OOI0IAO?LT'@L8#/5JFHC]/1^>E9'T!O
M(9S4RS//%)F'[R&8+N["R%G#V2TI;5"Q4$^1YQ!&ZG65JBY>NO<# (?E));:
M+JY[O#G^,TFP%K*-#8W;ZSE_Q,IMY%V6V+1Z49(09N:$?]Q .9P(_4;<$R'6
MZ#E=>"43=/F09H1(;AG9OQF,R<XPU>T[21K+*.'>GS:Y?@EG*=)7F2[@3SSU
M"C/I&*:B[+5[R@(14HJZ*U(KL['-VO(-6,C)@/9)>9:OS/5[2APQ<DJXGD<]
M=8@I/=B8PUJ]Y\1I)::$JS/4\^81A"%($RVP4852H^?LX)4L\X:=&,6(+-7(
M+7@'KI_<T>#AXSDQ?-$7?Q']@'IGXTJCMGK.(G$R9_S2Q=TJ*#1_O8'#-[X'
M*;AUPHT?6FYRG/;1>0?S)&WB]KKD!PBUMT2'.I,O>*9#$I[4<VYVI9&,N56^
MXXQ_IZIVAL$2*6 &-G[ NS_$5+>HD;/1>*0XC),S>71C&3/4J_S(JE&?H9B+
M&-Q#Q:! =B3\;TZTNHG#R%^CV%2VX8RGD9[S0("P&2',\O9F SP<U7-C?)HO
M)E%+S72(4K/WI&DF8<847=S I&R%6^F^65Z\@$J($]]5TC^P#RN[MLQRV5U^
M0AKN*74D*R!CEAR/,?\V-BEFX1T$'NHK7P/DFMC>(I#<55[,_<C.*P'-]IE5
MLL3/."7'^ZPJ-()T[)]QVXJM=D_I)$+*C#5F.9Z11@*P0D>]WM-4"3PK*M;J
M!O"FL9@9<73Q/%</8?MG@Y@'*::*/<6_I8!9")X<#[.J@6:;C8+1C4<HWE-*
M-!(K(X(<5["J.XZ?P(^<S@+?@[_:R0R-9PSA;:;GQ!$B;D8H.=&]NMW[^(JR
M<[(=]3@[.3TY:W/4(WG6\: '[_SAQ5Z!>>R"Z8*X2_\]!(O8?706X+4V)6V+
MYHH=YAQVF(L^V <I8AN2M)9\\1N7:3@OFP;Z]6]],0>&W0.7*#^-#IM/X5(=
MW4( ^P\^^\0<1L?8C';VHO%M<6T$-N3T*.U.+2Y;<5&V%?77R/7%7AS8?7*-
MPR?UM1'"[XX[".N0! =RV8%QV0XDK?2EKZN[H&HWF9U"SEEH @P9E\RQ\E P
M+@08&RGR]P+R]U1M5ZVYTDJ,@-U,]%50%VW04&E24[I'?&@BB=1CWFK#VK?]
M >LCNVKI\YN%@@NB3T92<+?42\*(D=+,D^0Y4]J,1!PM]) \;:73[$QXW5SD
M-^ L5Q&83]YA;UF"&5A;CI=U&G0E% I^@],]Y+*;65%^7"Y>:%H]2VG=?(\8
MU(GHFITP%T^OPE1/-+D*C1\2M>H%EWH67</K8;F6O9?E92_?);'RE\>]OBVV
MSHPPOP'/"KIAH]J8C?87O$I4B"DNLOR%F#P6XZK"49:_UK4W_K)^WN_:_I)7
M/?L\#RSL-[V:X5 +@RC':_C7/J?A1[]G9S!BRYV^N<X2@W8/%62Y_P96D"WT
M,J-()5+K]HJJ'D%57_6#5G(D[\9YI^@:4)[18SBLB-HB7 ;:EX'D>"OH]DSR
M=L)5NH-R\L,*DANFIYC\(0ID2 Q &,;KY#,F)YW8AVAGJ,3?&=J!PC1+."R/
MS7E$\GJ;V)'SSNIF;M_P@;)6@)*,W$:KT]4,0#T[-@0":^V[YT#=HZXOE+:<
M3SER6(C&C-S*JU.<4-X>Z=E>,=WL#79YASC7JJ;B+$K^)O&^K&1,N%)\1^KD
MW:[!PL\!>PM_A)%CH]"K)&,ZIPUIU*IVQH3S8G(9XAN^9KA;+ "RGSLMH?W*
M&;!]SW9<9^<Y8:<>?Y/F\$Z0[(9/_[-LW5 ]R1D1V"/W=X;9^<;56E'=X]'X
M4G'D?&.JM1=;ZIQ<U2GP[1'>G8_(=?T?*/BB_M:^^JJ]YT]3&0V9.N_=F,TU
M?:XX@U6^-[LOD^A^7Z"=&W'W7@R=+;1Q^)4;1\@Z\LU=>%K3SA;P7+XM4N9N
M8DV446SB1<X<*0/.ZU[0&58\P-Y]H,3&8)ZD-$7YN#'497VRLT_4@PPAIE1U
MF++7S92Q)']EXRV(+,=E&_/.3TZKKIYF3E_R98"?/+"31P_^DCY<]\&Q_Q?7
MPHE),C-$LQW"2Q?*:&<S>-,8U<G2=I"Z2KJ>!Y;(CYUV>44IHV$G\L \,WA0
M4_$ZQNYUN"B$JB*QM+YBSUG04,"V8P&%&IH, -DY^_P1>]Z!H,V5Y;ML%<4T
M%<<10<%\EIQT 4WU:V>I].H]MR"MQ*0,,:IOK"!*<_WY"A\^^7!(LP2&FMIA
MW@K%,BF:JJ"/?$ "W?KH/!LO'W8UB\JX'(TO%*?$; H@!Q5JI"=200GZV[?^
M!M9O(" @O5>J/ZC68%%&E452O1"\C^$,-T+.?I2<Y0/]%E+!)%<P&%=.H8GK
M "%GIK)+^[;BP)?*+O"KA(ZQEH'XM9&<N*O9V1&GF>4MJV94A>^T0TW0G*E>
M2,IJ6_"LB!VMROZW]ZTVB-6KN (.52,;$P;?',]9QVLB"H7O]<.!\EY%).KE
MT  +ZX..1?[[/F-1*X>HZ8#D%=NCXX&'"*RY%_#;BMJ@V/7ZG:X!(\\L,"1R
MY^71KJ9V1&J(/ >%:H0W) T'VRX#SE82\NXKM+D?X\L@>>9Q'Z'#G67BA3'3
MX&:%QN '+U_"\6QGD^8?(.Y$MVBSV.^N1A=#Q;E!A%W TU#V[MS.LI;#&H H
M'A:F-7(]A#S#ABLN2D'F6EHAW/50,*ZE^PU<BT6?#N!1WHMYT:<M@)V-T'4+
MR=;M:D.<+HR\7*T9>4+LQMHXD>4Z?R8'O)'S/W/X3]9^$#E_8G(,"?QDK6X,
M#>D4*5.QE8+ZD(&.?SF&3LX]K#>6$R!U0UT'RU+68WKA@V43ASH$6:MW$+SY
M0MA#VJ%U(>0^R@'^#B9!@%2%+S&*T70!.2.!#5MQ;,N=05@A)"NHWV5@E8;,
MMLT='*FD*$RJ W<DB'29<- BOZ'8Y6<0+/Q@C4YDYM(Z^L&=9:_VI*XB78OF
M#I-THA76B_LG,J'W!*J4O=*V<35PV,1JKJ)N[IK09/, S4@#L )>"(T_.L7#
MNX]PWFH?H?#XY$SW >XI(!I"@2[.KM#_1Y>CL:H Y>36B#PHR?FN-'-/D@C?
M_GR%DX00OCBR'=X<_^4FEF3^WW$8I5=03A>OUL<S6N' +Z(H<-[B"!]K]I^Q
MK2#HJ=-W*%B JY/1>*PX"0XG2\H+!/7JD[!F[<AFYJ;"6"V/CHU4Z"TGRP D
M(Q6??3PK'^0M/ .?R]H^9;![3 =FD&4UEE?!;F5 NS6%K[[B,UFDI0_*ZO/D
MPVY3_76N[X1LI[=$/4@;<]68*]7'OJ3J1\K.;'7O^>:X((Q\KVKGM5Q &S0[
M!F1OREZO$Q4(5A['JBJB#8J,RB1IGR*-J/A8PK4VX!VX?G(2*'N9ZF,U=<4U
MA8*BV3TP>&63"\SV%;*$P5./<F:&7%HO6'AU3.HO;&(JW=EFA/7UA\\!Z[:T
MV;#2Q12TMR(25KCF6X/ =BR7Q8J22^L%:P,CRBF:7@<.T&F]Z2(_@28G":@L
MJPU\RB:5_.KI[G <OYNQI":K6C/4<\B<K6C'(78H*W;,!<BNUS%T4C^B4H!>
M23O$1:!6$8O#KX1^0,]A0A]K @Y%/D([6BD;C*1K5;-S<_0=<,Z8'MY0E*OA
M:#Q2G U).N"$C6]>'6D685C-&RB!#< \1.EGG]"U1HO8FZ/>]WT#/_*B=-%6
MQ1W&J@?/GS9ZDAH7S9^*NII#KWZ46Q%.UFB;M8HP5>4.GAW,2NG%,$32'KH$
M>KJ8^9^6&WU2; I/_8.G3FME]2*V+V\^]WV)=</2?OF#IPRW<J3&[(D:@+*[
M@V;@'7@Q"+]O%FA@A3HL.9^K][V8JQ\\@=KJ*N73J%=\:L2B(W?JN,/%F+'6
MRZA]T="]L#/@K-]B^%0LV[T?9*M&=!G-;D_M!03OCETZI26JV2/K).DPY>6E
MUI8L%1K=V+CTT$')U%Y3YD\U50Z>3TWTDW+E2FNN%&-TLX#9DI$NR5^SCN-J
MZ^#9)51QF0?RI"^\*^@PE3&Y&$O(<"KG24?.=J?6C-&ZW%_=):-19X?BSR?A
MWI2F.ZH37Z$(UBFDR?FQ#W2M[ZQSZ+U;P* IIO5VDW:.-!6EM(QK<K8C+B5S
M[0;.U]'9&9SS8P;0^3QO^>J_Q&\N/FE#\R^W;?/(01D*S/@H9R]#MNW+1,\N
MO/\4S$F6=H^\E*7$C)N2-U&D'^*]MYS@5\N-P71Q[WB6AP+!<6?E/+M[7CZ[
MBYH>X+91>H-MZX.D^=ZD+MAJ:"=<7?(">A4UES%EKY1H'Y\_3:COH'A_"[WC
M?.K-T!W6 3J4BOMCD/V)+ERGGMX5UKYV)HL%_\*%3E(UH?%]?5O!KS]3,9'U
MO _ ?V*40X%R-(.AIKZTD (SA5:<.NH#8:H$HE[PR%!37\)P DBA J?T>@7G
M5TD1;KL+_:) AJKZXL^)&AO^3.)K2H#KS^VO_W1 @%QGGX_(<<8V9% J%[5P
M-AI?C#0A0?>C!J^:-#[F5]D!RO)Q#R'$-O3E$3^NC/:$2Q6:&I8';Q-'(5;'
MD&U *=?0%_K&:%$8P"B_7GC?6"'::T$_T)U7[Y:+/4KDP8-<05^T.QHP.%5#
M.<"@>I"8 ;A&=^P(S*MEJOZ4:B;:-*D=LSB1+E-%N#;TLBK?? ]\?K."/T!T
M'WMS.C.J"VN'N7#(RJS@T(1>>(NPM(\UI\6%/D,[=BE;W$C3IF:'J61.ERK<
MW%RSIXKZ1A*43AC6"16KMKJYFU7%C38<A".6/Q*,6SM&7LJUI_9D^?KJXY^G
M.'8 BA96'F)OTL21=B(4IMG9=WE,/$VU,FS.1%(31R:*4)B1L[PJ-^%O3K3Z
M[OEO(0C>T3P[\?:A@&3/AAAAHLP*6&"5;G7XX$6)6L\XG.KB'GIDNQH5=W/'
MCP']8QI'TT7G'23WU")\YZ/SL[-C#^E"QU)3('1W#=9SX&] $'T^NQ;._X!6
MK/CPRA.(^.)!+\KQH%GC?QUL7'S)E3<?@.P!?QUX(.I-3"A-3S6QH6Q5%5_U
M0GQ)M@M<Z-6U,U(\:%;?R-) 8*F>'?Z+/R7WB^M/E)28LB7+4%,[WK3"OTRG
MIBK0.,*3K!?X:&IX#D--[?C0%$ .*M1(K]>.VB,<X:F[IKL"_<&R!H$REC5"
M*KWR1!#.<)X-5KX[?UAO O\]B4BB T^N83(3.*76ZZZ-&]^#4Z$8'\)[\'"6
M9!#28:95,1AG;K&)KG E0&\%IV*[5\I@.%DD);J0U?BVXL!S(KCJAG+?.Q_H
M-WI')5<P&%=.H8E>4%'W46UBN)C;B@-?ZL5?1#^@0JCW4M74,A"_-I(3_71Z
M+8\>:^+(ZBMJAWM7BV6Z!HP,?R#JXFO@A]P4PI6THT]#O#F(0Y9;JJM.%6DF
MMAVO8]>*P/P60$'L9!,$_NX"C*LWGZS17?9_XL^):B/%; EJO@C(A?I$?,*(
M*%5#;>W<54)9#RS1^^GO7WX"3?9;S"47M]2BHK'0S2?:!)KF^Q6!'ODBYM*A
M5LIN0J"D[U_/@ T<O,&?Y6!\\&S8LO,.^+:O1^7MZUW;@R!M?.!DK7>P<TU*
M!DZ4F+ 1S5Y-4+;R[$GAJ_6QNV0-K)UX?1,'07D.P5Q/FP[+"T4N\7A#*07-
M2=]!\.8+V4"N1O]K "T75(._!EMEI!?L58%.*=Y_K'F%Z^:>..DV&>]Z<&:3
M&Y?-;]),;R*$DM>MB07:+Z1H]RX,08+2+0CMP,$\HP7Z4&IHTTOI.!1WY?BD
MZ2[<(@RB'(SPKWT(X4>_SU!*RXK FL)W&L+"I_0=;/5RZ0A0I0M_[UMM0*I7
M<04<%!FD1J4P8?#-\9QUO":B4/B^*,-H-!ZKQH&BVR(2]7)H@(7U0<<B_WV?
ML:B50Z_XCFJ37+<355-+&_S:#SQM))8ZE><?S*K7:CG!9@#MPZ)TV/C:V2Q;
M=M62K;Y63SA 1W!O+==0:B./\Q>3RJ L[I5>G;KBAM&DD;B"[ 3)JZ-LK['B
M\%>BW9H%<GU%0UG34' CS]1/-R# =S,DYM99KJ+IXGN8'"DD$(=:1SO.-$2[
M3!M^L27[D2\4<2:Y;0)P,(92PUR^\ HM>7P2M>O  #NQG'E@\XEJ9"! T2YN
M+_VIWGYDJV0>3UK(;68&E9QQ9*0,K8JYA.&6VLR$(A0MO$!@\7&OW"U;SW[H
M(+GOT"9HZ+RYL%;8A%CLC1\F!5OJAY+:0[P'KM[4D N:ARZGK"E2XT.8NM2Z
MV6KKF4>7=J*G[+DT?U"JY4Y-K:+ZQJ/QZ-(0YC01/.7-U2'Q1LY\IDG[!\O%
MEBK*_'XG8O).2/+AU)LL:EGSR,$O;@9TZSU'0;,B%K1?T;/J@<;%#@)CLJ09
MO*U#"^CP=A0EC/^]\4/>VZ?')Z>$>.'TEX&-&CU&#W<4-20D>EB#OBPP>GBO
MOVJ8K"TYFK"=5SRB1R%5DY/V46IH""4?4&6H>:7M']34C'S4.MK!S0L6,]P4
M>?7*OI<=3((SD5N4N-C')T?O/C9P:5 =C\Y1LRC_Y>CRY%1+O"EH589J-9);
M+]R_ @\$EHO2!\S7CN>@L0L=-6-!GJFND=@WEURO*.X'+P(0 :9^7EG62'39
M)=4K%=\T6H$ +O#]S*.=*(,%7):J1F+=6'"]<OAU<!Q# \#;S\J;2*S9<0P9
M&X7(B<*T,X@*]H06=%#K]@&)@AJ9WHL2V9G/*L4?#)NO;2AOVDAO9(+!O$+V
MIE(,!-JK<0"D89'8R*,:+S$<N+$"T)2+P(UB(4/IP"!DVZ!937/TU4T_3)]U
M,$TV6H>^5F[7=9=H+=D82=,-X#^>K4]\GP'OQMT9<>,N;7V ^]%@D[9_W,.3
MO'+(;5MO,8WK#FKR-%'L%U>C<]5[!?6[?*W%,W*-D=A+0K1E3C-/L/N__@#N
M._CF>]&*[KO@;TX[/K5F"\G+(4@WDL]\ZD['?P,K>/WAMV1AVLJ1?&PJ,7)=
MS*48^&1Z2 Q'.T?6L2K%R&4VCVKN_9A\"QM?,T?6,>K$R..PK)II2;8CR6IT
MT8T'02=R???F3FC[L1>!^=V'#8M.UNBO)DPCM77PM.-2C-3K[E4Y+@F*X?)X
M?!X"CWA$%W0F5US&&'GGX[@<9NP-:,>H>G=92^&,7"M6'N?C=Y+Q-J,=>UIR
M@XUL1Y<8FVX:DNQ(*JEV2ZN9>:4F.&?D7&T<*+F:S+_E>+5TFE.19M^590^4
M.3)=4+(S-6Z7$O@.[H9SZA8M[71W=0+_,QI?#G6=7(N64JH-$9<7H."R($C-
M,8\6U*HVO!'-BCV^2=*4U'"(H3+N5>\LMVOLR+0F"NKF[CPU!*O82&[;W)%D
MS51DZ!A*V#=NV=J19(TT)'4S61W'Q'#KR"DNS4C=.Q;%I5HI&;U/[1H[%&:)
M59#4C6'^RT0:$JP1D8Z$H2E"\C[PEAH=G7SY#:!SH6 ^@2]D+7=WP.%OT45P
M4#E[96[37C2S(L![2.:<>$@F>\C 2IXR"+)72<_-P*ZT'EC>?/!COV36K0<0
M3G \5B,IIDEX:CS4J8:C\87V40"\T@AR"J49:77*J]8VA9XVD/,!6J8$K[3F
M4D)$JCU-:,$+*C,M*/(:0(R.\O/I31(*Q&6:-)7; +)(S@:E"4G:#S!-)!:T
M5Z"2'L6(W-K%R9# %]YF>D(@.OQE$@E1@V9;G!WP++_ ?0:!#1CO)JIOYA!Y
MQJH&J3N=JGB6]RLUMF9\C1C*,0%*D+K)J2'#V.T87R.'QS!.&R9GBU-<.! 4
M\)L_=Q9.LG9Y]$-"=%E%0</ YQ14ZH6OP\Y\_Q/;#F*T"X97G.B.'YQL.+V3
M,K>UPN??OSP9[OOWTR<-0/HH[,'WT<,&Z65/ W?WN Z<]]5]@J"0G"92W= B
M=QLTHF3(R-YSO7']3P"N@0<63A32;X2F5RIVEM/1^/)$X9YA8S3SPT$#@35+
MCD6E^HN/+MI[ ; 7HMMH?2\*G+<8O3"!"'R5#2*$ ,%[$<69BOC= U;@@?G7
MP/*BQ-M93PAR)4.)P"EP+^(K,X[';X^.C?1S#T#EQ+"RH*% ,PC9BUG_5B'P
M,?#EJ%L0--#9&C"4#"V$E[IR$&P!,C&K[Q)"U_(RTZ2N"<.)TDA\J;&'PJF2
M"'+O!\\!NJDF^H3"WOTG=G"7F-CPM^0N9SI;F%LQEC#M-" H+%$49R0>I*8O
M4VE5#*).8W%3GEQJDQ^$$-F,5%'64%DYE1'.K)4-(H0 P5-J7&EB0K@<=67/
M)8>#KES9-&*T$SQS:YWT_:X'W_+080$4AL/GV+XJ.[9Q8^@R!]1:?X+.?6^)
M-DCSJJ@+0:=643(ON 5OT8,'7R%&<R-:('I%26WZ-@\F^3&?52;-O-&5T(=!
ME(,=_K4/.?SH=S@AGL=V- U>0/#NV* B"IU43#NP6<';P<XE6G=7M?,@AP:<
M],W#RGAQ:MFBH&>C\>A*#89<2%0"R"B<9O=P(Q<W_;;M70D=P6+4>MG2ULDE
M%2>F#C8#81:)3K"*>R6TP:>=0621BK+IIL(6YEZ9: -+9;2!BU7I1)A4F3ON
M;C3_[SB,T&^5)J^FM*YX,9F])K+I-505C<ECS:D20FEM,&QN(IM(*'6+FM_0
M$F(7*]9*7P-2_"*IL.8(TW':<^WP"6GD88ZB]KY[5G*W-9AG8;M/OF=3=PTX
M6C"$.Z(D;QO95'/WK[)K7"IZ%8=_S#"2,(LH:@S1*G%X47?9E>CH*  ^!3Q/
M#P182S8G)*T!PWC34G#-;A]CF)'<68'[.0/I%<^U<Y)B<4/ ;R2FU.@H0:M\
M;L.!PX,M._K-B58W<"GEKW>;=J1\\-0ZAC"DN:QM(Z-J9AMC91DTLDOAIPND
M4@(W]HL91@<F\:3&.:FZ,*)V$MYTV6(80YK)JUW(DZA\3,ET*@WJH-B-BI)%
M19V/QN.+/A.#54*I(4ZJB#!)>@%&*[&<67=X#L#:B=<$6M36,XPDS>05%OPD
M=152U,Q=&#EK-,/Y9@5_ ,KY?ZZZAM"AO<P9)73QHE93XL&S@^10?/+SP:L0
MLXH/3!5-(D-S@3,FF)6T9@;>@1>#>ZC?JB7:W8?MQG.4-SD,4>Z%^:OU05RQ
M<+=D"+%$:R!C6EO7*FD6JXIK5!\ _:@'2U7#V-18Y(P^LJ[1TY(^M=M^C+4/
MB40U4F<\:NNHK>51IX<!7NP5F,<NF"XFRV6 G8/?',]9Q^O[.()EGP/'LV%K
M[O:F <[3 Z?TTP-?!MD;#/S%P,K>8;!.7F*PP&^!U)2\QB!SE!W/'2B1 O6_
MZ\]O5H2S@##*45U).]O">QJA@7C=!:FW0CB5Q0%AWC.]M04/'N--]ZW:+"KP
M BI0L0>W =YTTHA121\.N\AE8_6=G6V:.G*/J@FI29WZ0[F*6SS;-7:D78TN
MI$;JZD \!CJ93Q(:]*U#HA2?Q+[QUVO?>XE\^X\;UPK#W-\3;PX7J'!]&#EP
MYOF<B86_XUIV#4_*A[:3YPQ"U-A?!_C1@\G SGV*\Y/:NQ?8*3;]OB\K+JRP
ME>]"OH0HC0Q:VD=U:ZZZ2DHLP_:N%=I![V(A[:P#&QIY4\ @D)%SWI?X+73F
MCA5\OEC((Y,8!?*]8\3R&G*@%M$*&G")I_'*.O?Z3]8:_OH:6%X(R>_4W"%6
M7U$_I+E JP"]F<AZG<5[>)Y2#XUOO]</OF;JKPA+HHJH%UQ;ZY0,3W"FM/$]
MM#"AV5Y:'?U@;61_N47L[M@Y-\9[,E#-;F59?3%EAJ<,,;ND>O78W**):FA+
MY8JRC4;C"T47?/,C4+6;R2*=7LAM68M7H QS7%)Y[9!L9V.9Q*-XOU3;U_S[
M4XUKN:"^2#*!4M$OV404U3&K8R!SQ@$G/'Q=61Y^L4J#R5)%.YP8];P#J+&4
M>MG01 +\SA.&X2]?L"#=<#@:7YWV#$-.V8A34B&=[ 4$#@@MHM>6W-?8:O8?
MKK;"$H<\M;.7QYK\.N6"VD'9;KY"ETOJ\75U9YJW \?+"JHWG,31"K[3G[L-
M&/+R8[^&OG2@(TM=A3 )R>"H5748M23*0QC&[.@FI0U&EB*@H(@0W4Z:EE0P
MC:,PLCQT;H&5%KDJ!G.C3DI!D1NZ$:0XD6$<%^B5S"%) SDI,P?1"?6JWNX6
MA,[20\??JB;M]!K]QZVID%)3V.C4LZGS 7*%_C.CH8R4I#6J9_-5DM0/[C6U
MS ::<8BO2E"C&FTL14+4VSB  CP#^$[S1*XG\ -_15[,LU0NJN1T?'+25^Q;
MR&MHPADL^G/@V,08O&T!@VA EXF24$9U;W\.?!N >8B.GB.RHGOB'CPG<BSW
M.7YS'7NZ@&2D67G&^N: W4YDN9EB5+F#=EG@PU=_,I\[B5#/EC-_\&ZLC1-9
M;LY69FJ[\<.(-)2T:=(<L@G7@MRT-*IR(U+'X60S)<0)G7(;*R_ 3L_7-)G,
MU#9J#@<EZ$%42AS2[$<5#ZO&AFF0A(HF\4L<XVBQHCE\:BBK[.0VHK*L/<5H
MBW:Z^-6/JB\8+13H/ZR,,HE*+B/WYMB\.4M.GNV\]XD)O/>#.\M>8>N7&KQJ
M%VC#IHK*.QM=#B_[2 B1THO*)R.7.N@H;HA.;^T2UD,1=WJHXDA='4/(T$C,
M#/7&>;Q3U%U=TE 5'86/#ASJYAB[Y O@$7TF##7[SY2VPF9\D9/U6]VV^IX=
MS4^[H<$<$BA36\\<PC03-:-+6P>L7EDY";I(1EQ.KJ25C"<*3<Z,)6V3@:M/
M98<%OK9",$=':( 7XB9/3X:728 W%FSBS?%UML^NY?'E41B6\RC@=K^@W 8H
M6<+NF? K]-CD^T'R8)Q1 3]Z@)[=FP0*.X&1^V,GXPRX* 8 ^^$PR[ :LLR
M-0D6VC:JQ@6W38^(7ZW$M$D T5WB?AM>?^[*I*\_^6$%<VKN!E'M%_OY^?AD
M>*[6GHGA4,%C)U57&N</0+8#G<:F')/+%]&."G*!JYAKURFC!UA3S] 5"VF'
M=ZW^R9!1)))[7*YBNH"&<_1>E$,\=96TA8:BYSTO1S,9.P,+OLN(&:1B8;/
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MR<&?E6@JW/RJ@J3OUAO7_P3@!03OC@VJ%;(-1$W"'K&CMQB'&49/?O1O$,V
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M/5J#3H>+!WB9YD&OJ]L[#&,SBCM-I1>[+9S<Y O7AD%$/J_=,:/*BMC7599
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MF4_RB-@O7*DN V)Y[;&E <0$;V_<!'OO3G4,5);M Y9<;@!V*?5"\BN<^44
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MKWM!K>,:H#',FJ:([% ,O0T&HBCB0,>4. .AAWR8U>+]CF+:=X!VRYEKI;@
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MW2OH(\]I(J"Y'(0R^W&:JZN:,1M.IJ6NT[R+VT6+*0]BD7,G?2).$P6T.41
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M1?[A-MFEDWG+G3<Z[JB8CJQ^^>T08=^"I2Q:EPP5!\?)VWB+T(; XA>2XLA
M+IJZZG4')X,UAD'9>A.8[;%H(G!N'V#]O@354'07 "\09."1?"1*9TUCT*7U
M/.U61NG\5>ZN=:5&EK6=$%:A&Q=V >N8&!>AXHGG"Z?> SUQ^I())=M/ ^UJ
M$%%[N^NC:&>@Z(P\S%I\K#^^ S?C8BPF1-;>>!<4?19@)T/3*!1R?22:[N:B
M"3/W**1ZUT.ZE+]Z3#L9,988?V\4?7\N&@'TW-F&YV/1<Q2'R4S9G;C=AFXP
M)?NNKK>YR,:]OB9Z1J(1T(LMQ XJ5IEGRX]&JM8!-.A;MW)1235'V<ARP8@7
MJT2 F[T575Y*L>L4]<[]S6.G1(.[U@V;>JS/AC"RAFN$4NRB@R!Q@>66\F[U
MX=""ZW!R__;+BI:]&IH-_YV!F>)J-QSD)].KXI2V.\6'Q^B&V8Y>I+W_S+NO
M)UKVA0B >DHA&(^QW'Y"<.W1=VR5^#:N]A;<3>4,^G'<&57HY'7;B:>&<8-]
MB*SWY52<\-.A\$?K<6]%84^E*;RDQ]7ZZ=I4IF&%+PF9QF.Y67\4W,B:"_OI
M<2]M^GNCR_/WX,@RQ*.)2E.$<D7+BP:T125 E@;;@>:]<3MA%^)5>?R8GS0_
M__5)SVWY*Z/*DR@%X1LUJ #+1H!:L9)0J\+EKYN2\* BS-LA9Y07K7R\VVA:
M7;KC.O-X-W)J'>$P:^#QN<XS\#E<#D:F]#)R48Q]T1>K*L"4(*+IDV!OJG^M
MJ#J0KW@8SZ6FL3C'M-J1<X7LQ-[=X#DC[\F0]\1:W7Y"GXS8 C( JHA&VCEH
M0"VL638?6O4XG.0!79O<9(OI2N*[ZHK'4D/(6O8_A*^LD+Q1=WTM&D.]R)IT
M5[1HIRAU'.NV1/.]R/'K,_H<K! <T_316(XM/4Z$$0W<@<0E51NF8/1Y7P1-
MGRB(W[=V_MO;+_A&G_AM_UH%&:BE)NU<O)6 [=:M-(T^EGV8CS!Z75 _$+7C
M(2&Z_#O M:8B:G51#9E%H6AX5D/$+^%=S@!^"S\<%#;IC_JH>:]PDZD:4Z^G
MK1B3?8BLL SO,E#S]MGF:6,@^XK%M4<C']D]E-?1@\)<+'=DAW9!:O$@E\O%
M9'035<Z\;I/7?8JDA0,TOIA9NL[3CRUK4F7T[JS1YD?]6?3Q,XH:WP>G+VP1
MB[>%X>2&56X2W5*933'Y5(I)GCY]Z3-*CUV:\DL*!>DJBGL$A92)X-T>OF97
M&ZWW>"3Y?*(%9(R["+V]NRSFHBEWT% ([IVY[H]C7LNQ],-#19Q4>:>58">I
M6SX66=)\42G9 JK#Y44(QJ'VD/L#^1OIR+AA; ?:.,N@HLEP!F7'OQR$X'5=
MU_@%D$B*:0&:0+)U<U,)>JMZ?2R*L'./C7:=9WH\Z%M<*>7TZL5:Y"@"MZ_=
M"FB?+)Z!].$$<73;X-.3XL?*EY.8J\>BIU*.*=O6C9[I]N<&<R/>Q)C4++*9
M#F?4CA9JOU0%2B"QV>3ZA<*X>(674HM>C.XWG/&C8320?A\Y!K\T,\([_.A2
MMBCXFW>6LFU%!0*=,.V$.)P1?RCED@]NCV[<.$IM1G/F72.RG&D'(CRSP:]I
MA+[ $5I 01/(3;0D%[-(2Y3P:U;.#?^R$H:(<F; M-#&&T/,: .?A=*RZ^:@
M0U_QZMR\34[86>\NNE4Y^^_:%VH[MOTM.<>Q4.8N7V?ZLF.RD\:X/QO;TU*J
MV(E<[MVG09D(<)F=:13'0ID1'/+=QY3:GCA)X,2R=U=\63^CS&=*G7C#G1>O
MJ0[-B/4FFW\$K2Z,MV\>2ZK"U9*1Q9#H58=&Y%:,UQQY8MI_S'!6Z8'NMYE*
MAVW9\,&-K%X:Z2,_?ELBSM,E6"P8.!\!CG7]TLLU< T$PZRBZ.2FJK5F!8;8
M=+/R8-KG8P]LII13&VU!B2[2?-#M2WN4PNT$\<D4'39&<WLJ.N31HRHZ; B?
MEW\'Z$;"*8#<B^Y8.SR 3=$EZ>BKG/.ZK@&_3\06!'\]>3P6<@,[R<1N)OV6
MP;2=PNV,'T76%'L"LVW>O#V =AQD/R*1'0'-][VG>./1]U?.7LK823.5R:UR
MG;CK.@HTBU>N(C2EZ'+;Z/1B.(4ZMN1E2<&_\0?QLJ1_L67Z.)5)XTJUE&-&
MURW:24_=9GN8B'>KD>5!D2P68M(Q.KFG=48>7=V3>0R#?LVB7UU[RL![F('=
MBLX[=/5FQ'?A3<Z-8/H*\PK#ECDRZ+9[7,GEL!AU"!WA3S6H0=51@^(09=&W
M8N/B8]=A]&JJ6VHY=#QREBNY!S;8A7<M[-HVOK1'=(\C%1>A(]69^80#N832
MS==JM-(1];S;BESH;-N1AK?Q18^4?3XP4M$D705+5>!:E[Q8\D;@%.!^UUFT
MG%4E-K_ P:5 ER\.)C7^@;]2Z/Z-K5X!J7''S"(K"9_9]5HP]:5MGQ!GF'VU
MXG<+C/"]'*<6ND6K.S62]S?EP@.4%E&3B9&,#XRS5EI<C,NYB3CN)KM5L01O
M2E&X:O+#W>2;.)=<P[FD<)_(]21)!0P-^7)CU)_'K[*GOQ[EM3B7W!_GDM$I
MN%NO'%F[DKE<OV%:QN@.3$!*FD]20TL'T9/H>QBRZU4;I[J2.4+B_J#JRWV#
M3W6CFIVP"XV/W:KE?JS<+-S%(ROKHQ>)^#3H<I!OA#9L1S=D_:8+K$:[\Z".
MQ@_CR#K#(ND;B0)R[$QV. @Y[)$I]VZ;\)IO]SJ=^0TLE7-*Y+P D4:.C]77
MU@-$;/J8 <^#,,OI#Q=F?99RN['QN#D8M*?VH!)=X?1!$<](8O2K8T%L^H2Q
MH(.PL!;O=Q33O@.T6\Y<*\4%:/>+D56@(X,-[YJ6<] !@Q8+[YNNQDR@48\5
M8*U4UZ:193-1/.!WNQML5]O"Y5=^V-U:52<=!47B8_U1XBI9H0O4\G4I<1WO
M6%;D%."=;0MW@^>KBI\(:-MO1]Z&MIE6<UC'V/0C71H_=&YY,>^RC8+)JHP5
M.05]?^1=@N>,O.]?2G$0)A:'N6NWQ^:+DZIQ6])KO41IH$8.$Z.-'%$(BJ37
M_ A'2L"9M*K5^'A<G'95J.:X.'A42ZDS<KS*CY#>WX^0/EEYQ,/4*-6S#VJ7
M=AMQK9,;FHW$Y.0'&163Y-9TVJG!@SOI-F;]\:ROQXS&_<G-Q0_2U[W=^YEX
MZ.C9WI3FAPOE?E)-V3FC_0A&PNEOL'KMT:]EGAVZ>4Y@XAL>L[>$Z=J+>*=_
M4YB.NC$[[79F_0?>*436"/WP,%WH/$G&/!/_B//<*Y.8N7N4;NF^FNXZK0(M
M)>-L(YZ,K/\HFIG$1SOCEVRT$I>JW71FSHAGKS/S6+(%>BDF"MS[0PP$1X,>
MV'#W"4P'FBR:LF#A*@=+8.720RD6K\*)^F Q\WNFE:/+*V:O>E?4__;72-X)
MY@E^"S[CB5Z8M-LN""EC.F ::;[;94W7751[M%LQYT]FA)8>9YG4+_3* 1,V
M37UDBJI@9+AQ4D1<@0;Y9LP4QATW.1H]F910A__. ;,:Z'E!Z%2X4EKG9CS;
MF,?B<C>=2AC9'9#%;QPP(43D+K1FXJ AE%,<[1K5-KB;N*6>]'1"LD?\P@'S
M]70;"#:=N<[VI:XY806HE4LPEDW6=\ 4O_#Z^0JX8Q8@6..C:V9\8S4[,]>D
MIUI]8M>YQ ,[7:$K:;$%PH/5'14@;J&;;\2O)^_C+PM TU6H;1MV7T)9&^+G
M^NI?<>Z8ARH*YL8"7T#PLO,-E58U>*-,JS4GQ3ZE9._X5^^]^53X;BLXE42&
M[DU3:K(^84W'[?*RZQ13!YT*&CS2I_(3+GZAL73'E(#E?1P#429R +WP^Q_T
M'\JR706)$U5<Q.90ML>_&)K^K[\-49:A-HHI8&C_BE_&4ZNO3#@:+[_3+=*X
M%$VC$ /T[Q\;HYHCJ,5LW?C%,I=)P_X[- =ZU @>'")Q$!N**E3<7__I(&7!
MHNI@3K5T5=3^<^%]@_ZUD! 9_N=O\K0%'P$:"(WIS?(+_4GA_W/^'W@"D1J;
M8/COCS\ZC3SZ:!FBMC8E^?N7IINJJ'C#S@'9G__5C]\=?($#I0^I/)98FHV.
M!H^"0"BB_QM;0"DI0#1_#71[_/<F5+>!ZS@P"$X'36OKZB\F]!6&/OZ,Y6U,
M5.!(^X7[C@'3^P9J6#_ T/M[H)L(.Y9C7&) 6KH"9>H/FOPO> (/R6WY>742
M?V^%-EDN^C$,Z8&NR/Z+RYE9],P,6G  %:2G_!I#&:T1#?G??Z19FOM[>03&
ML<#W,FSVV1I[W*V)A)T) XY.I3/)N$!GF)00!XPDB"(S$(9R/#,0Z11@$_0/
M#Q]/!8SUS0_69@GO]<?O;KW2X0M4NY/M\.U_?@Y.>TC[KZO-Y[NM2J?"MZEL
MO4#QM_ERME[BJ7RC5JNTVY5&/4*+[6?;Y4J]U&G4+ZC"9?Z28I$^GWGG!6Y'
M\<1[4B9[(!R+C5:-(F!#HD_3-2*1H43YQD<+2X8WVFF4)F(K3 ;P5T&7'-7/
MP_E!2+8NFJ8P3]V42X62(W35WMUC^BK/N,S5_(45,W2LZIWSVHJC<>Y/UKLG
M(MA$A/I#^A)$PFYKPP*_@C]\T?*+QFNPD8IBR\$K),56$A5_U60#2 +]/1\C
M"R&&YI&P")^;HA&H%^F5^ NV=1S@O<#=5X*"B$A_ZG7D&V+-PO[W!US@(72D
M+&BVZ2#,.0U69C7-$946,'33#F%GK]_,<\.4*G;9!==)7%VU:('XBIX<?P"J
M-ACI@.I6J+:KHJV'09/>@,Q2>?KO/S*I>'*%#%N0^J<MA\\Z.J>VG0XRN[::
MK=>[V6NJQ3<;K0[5[+;:W6R]0W4:%!(]'21?*(:C&BV*2?PI_T4UBE2GS%,A
MJ;242-E\!__,9+AXF(@(G'YBPOA)Z.GSLH./D*];T320$KI)V6- #:&%F SE
M(NV= DCQD[>)CC#URMB!B<8;RZ*+WP+:J8BX29QGO.=2"U'Q79PS4NV:(D_<
M4O[J3J\4Z3:1,?LM^O@+SCLF H-=)*"\0S!YNN92.WF=BN6MW*0ZOH['\_GF
MR*K>O.K$"D#RW,K8W;A%6.X_T@6%-_;E).[!ZTX?J'DU6I]-6STK*2\H*4-1
ML4ZFI9 6D,0W\D13 2FK%U>SN=BD.KR[*^OQ;"LMST^BJ<2_A:;2:67K[0I1
M279K*__]!Y.D__YJ*LLGU5!P*!1:.'R*E!3$I30'2[]?IS=M>1(G+*(YZV3*
M$%D.LHM*K"$\%'@G&0=*)2^6#-+Z?O]MT303X]+I9":R\O>#/1W/^R!/?_ M
M,(*6C9O0X7LL0H=O/<CQNFI56]UIYZ[>'>=RM=;\Z>&O'W>YT:A6FEFJ6<ZV
M:EF/P53J^<O3G?X>6LR?_$*4;+)S[.0WESNF1(NR#"#AP+E,08V"MD5)8]%$
M0_SUF9 S\"(/:1K$&2!D$I(HQ$$*"(,4DQ8&&2XEI88LXMV2[T7VWNA(@C%/
MS7.W><.9M&_G[4)^:MZ)<"2P KWY9-T!R:;1F9<F_72N/.=5;7R5FN."O\TG
MA:%4;-^;^HA."K7^32ZA#.KQD1!_.N;]HM>9].^FU2ZPBDT("HYQI6>%Q-,G
MD_,AR]XJS0&?;&9!@9'Y6C<]1T\&L^^GW(5.!H>JQA[VXAB.Y,5^UL-B["67
M"(59O+B8_^5ZF,LV@[G],1GO;'=KCWJ@)2;0""&$""D=%)HJ[H>\O#]/$5';
MC8+I_5%P0W/Z!ILE6L_S!L('[_HEOK/3'HA90,*)0#8P3'V&&>?QW0B>^,$-
METQ#]P8CZ6)YW=%LT\WKLB^-$/';,-ZYJCR*11I:K4IQH'"-^^H<S4R_TJ>@
MB',1)[CLD$;11N+7'><I3JLC+BI^IIG7&"NL,J)SFHG#L7L?JR:[CE30Z&;K
M^H'C\3DQKSJG-!-+<)E$,IUZ_J0B38'[*"8$X;%.0K(?J2O'A)8,R2T)^%L8
M)@Y*-ZF&.1(U^$@^_Q5MC-UG^Y7+UF7[DN*]1L8FM8Y;5%V__.N3'/8!:MY6
M&O@20O>#X/'Y$>7TC#PKRR:P+/^?:Z@!)F3Z99HS/9-,FBX/!F/-O!5LIM-X
M&M9^CH5S"9HJPJ$]IK(SH#G@@DJQFDP5%5TW+ZBV VW@68<I-DX?Z.#_9V!2
M/W^_DZ/$!UD>7U)C=O2Y%H*;T -M-UX>6%VGW(^Q5F7A7!=>!S>,1'>Z.3DX
MYO%\7.O]%#P?7D32-<PFF@U)M;"?8>96BW)CWBS25>&J+4P=K@NN1Q\!-&H9
MS_C<?/7=B*"IX^S=>VBL*^M\B4_K;-GN.K<Z;0TG]2ETLOBFV5<=*D,S3/J+
MZW\^'+&N9YB(+J A*A0(+F)&7R-="%A?0--#.((040:;^MQQ@P:1<_F^)>UT
M?PI9N6[_^P\N\[=%V4 !QEC7@NC!!;8@% >?/X7,7I$<P3N$%'P3'J]/#\O'
M4LF>]>MLZYYW@59TKYA!_3'V.E;_/W'N*%S^I-O''!*!>\45R>Z395>SF2F\
MHTOR0[&9DL4T%%^W^T-3(4Z_=]PQ6VEB''P23<H,9[>=A-)LT$E],FNII?CD
M5GA=-"F=H:DD1R6W:XR?R&'_X<D;;21C3&A#-)\7#P$FD"G#,2T'!T9LG4)/
M$"N<8?\<_(4E%,Z?RDKVK\AD?;S52O2C):*42$O)1$I@183?\7A<%$1FF!12
M24X<<@-)2K#B9A0BGX?-Y-!N-B9NZ?YAB*P<-:EB!Q>[^:0>;Z6++E< 75>O
M7[>& Q8*;'9;7&6AYM6X7M3[O&O-5*:1+G"U479;7"6?K3&=AU2GQ*M58VRV
M5*WJ#/&3P>S'BH'X^0<D!"(ZMAY\X<4_R#=K89)P=8KW#'W,  F7N60SN[2:
MC7*DT. Z&G"HZ/, &8+/,9RA\VN ./0D-D= >K'$:?F[.+!TQ;'!WT%FQFE+
MG8X3JR"U2_Y_]]0A.?J22YX!_KX CY\!?B2 O\8N?)&W?+0O],BNX!=)^Z/W
M>VI?^(ND]N&Z&4[$H1I#BA>E,<4OI#'N][3NFXH6AA^V8?*F#"0_SH45%MW\
M%92;;OZJ0 W\<I#Q;.*_GOQ,)OE%*E9Q&B2TO<)> DK26>35/K[3$TQTP6>*
MQ'?@Y=C^B1U1;P!>E(GMA,!K:%1_#!':M9;V591I^,,]R[Y%ZC+L@)#MTI_,
M=>;]XH0=U&GP,+ZZRD-+O9K.!>Z5R1]>KR&*-!NZH/XO?8F[Z%!-T:1ZHN(
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M ]^+@3.0=LZFZA86.]BP55Q/(P5X<X@6=4T.[OZ9.EY_;Y)6(!I([UQ 1+8
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M9PK\G!2X"V](F=-0-U>YHY:7]"YDXJD,=["H2WQAFCL-[+QA277-KBH9?NI
MV[U ORLDMY84*/BU1S5<G6UZE1O>E1)4TS&EL6AYY0;>NZ$6WM^ HEGZ^U!T
MVV]P40PJZ''K7H%+93+I@SVYR:]+S,<'6S BM1R2]*@^D]N7(K?:LO&%A;4D
MAQ2J(-Z;U43%M: E)),T1Q^LNJ:^+N6=%(*UIWU)5I,0&1E,@V7CBE+SNB9[
M38#P,RU@.8I-'FD8P&MM<):;7XN0EV>_K,"RT-&W'<-0R"?1=(E(.)22TU^7
MDD\+PA5QKH8GU+DVP7>1L5SZ^Y!FGG2ML?#YRXA[BR,3>,<OL!GF<+=0YNM2
MY$D@YP^*>PQA\EL;URO;S7K=M+!!C&M=LZOF6OB%D#Z\]"M]!XK]1FXE7%9E
MZ@IF_\1[+Q-W9#R=268.-D(S7SB=Z/AP"T8DE+<:\TQO7XK>2%.9RJHJ7V!2
M<98]7#)^X12CHX*,#$:%1OL&]!7_1L8A)HE,?J6NX"9Q)EY@43?1V]J58T)+
MAM+!!)?_N@1W6ABNQJ66 U/^R%0PM-?:A?0T:9I@ACNB5#3+\#K*?@>9^/5I
MUD]1JGP)VGE#XX"OA[1OAL+71/ 50RWX/24M/N@FV?":26+S(1]T7BKI!]=O
MT%]7*)T6ALO1+ZCE^%0P@7=G]7(.JH3+[[%GY#LX0^+,]Z'3Y='C1M9 LSQS
M@TTDV'3R8-K\PC6*QX?;B@C#0Y[)[4N1FY_9Y#;F&N*R8VCHPSS:BPBU'-
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M>*&I?DYM^X$:0KI>50&<C@$Y"*C2''$8GT%,[&()[&QRN"]#" ?/\]85#EL
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MQ?][KVQ37VOP043Z%^F-EHHGF5K)AU83!XUXW<)K$<^* AX7TN PGJ0(P@[
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MU#VK4Y+Z%V_+^MINHQ9 FT(MLJ4? 4/#P_1Q0%Z@6<7&%MFQCT&QO.4J));
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MB&8W/2X*TB)$;CG,2PO :J-@9;[4';9_[RLL$[A\XU9"'8E,TJR H(A$\<"
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M7"'*CCI"+7_'+2:5U]9$A9Z2O"INS(D6.)MY!)X(K/$U(0760@H$5[2*C*-
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M"FYGC(,ECF^6)09ZH,,Y3I=62]155"O#ZG4>R3!V]ZZ:#?$M-U\]_$+W'T_
MM!Z9<$_2,SO>>F9;S^RS/;/#T_[1P==QS:S9-%OO8=B?729H"^/X8R-" '+]
MY*WH.67!"F]].KGPK_!,U5O6:TUC8M$I_\2K.\A&A/?W8[F)3S[U)AX>]T\.
M/O,J/CCL_TO>Q"T#'=C&6TLJN(Q>J804@47. 0C%77+21&ZD0(2;5V\L\#W#
M%!=-X8:_/+I&DF,L06I4'(^4T[1M*_-S]&*&$<\7]22KA?/WK<]MM.,ASFNP
MX'3'G1PY_:WA6%JOYR+@'0.LKZN\>$_7DLS9&DIV_)A/<*J'MV%Q:+M&.L][
M7'M=+RIT&ZS$X/?(U"IK@C9U/RR-$-4[QR$:1#6\6>:7SB(4$@1Z+!KC]%,U
M!OGC9Z=K-$;_Z#[5+X='9_VSX3^MUOC:;"@?7ZO23(]\]12=.RIY ;[O6D,%
M<4A04ZPXK%+6+-AWA;O0:<UR/FV?/7WC5 QJCTAUH+.H*S+RGI)&(F2HHI_5
M^\CN*$,2GG8P40[.+=P9-MT.>F^J$4,6T&V"]IOCB:P&=R,*$U3C7/ ZY#PE
MPZ-^PM?050Y2E50)VAG]T!'-X)G34%Q8(ZH(5)+MX-<N9F[?%\ 1(SJ\_1;%
MO+%G+384\?.XH[K;?C'K=*=Q8]1* ,[MYWFF\K$9CQ->"3)NQ3;C9^[XT+J$
M2IK1;'Z.,KL&91RR3-I]O"$N6)\[UB7U5 <!)U6O<ZU['.9'R0ANE*LL7BY9
MQ-:B#8^"24I:.!F<?A/)@<LR&IV52T Z<V&I2XB)9,M2N2+HP<'30[A^_VGZ
MQ"=;GWCK$W^V3WQPU-__2CYQ5,+->A'W!EOW;&<+1XA+BHG1"L43@@SDZ$<F
M]ZIDF<^5A:DQIS$?B8EZ]LGAY</^P3JGEG-2=T>83_HG#YMX^L3R@N_*(I],
MTE[RARLP^#&CI43\@B$VGD%<_2ZN%=SC,CM. %<+\/6S)2(TWY9#]ET-633V
MPNQ(%/200L)^\G<2QX)&,)NE\SXNWR%M4Z(D;4)R;GU2']J<OG_[WC?:E.2%
M:TJRF;'\^!U)]#Z&@V282TN]"YO?_/CF]\'Q?V*H9#,^Y#@_+K/(C$*.7\CW
M;N'(18LBK@XZ:^H$Q.AEFX<,(:WN(S7&D$I9!TT*;@C^R8,8"#B^:9=IK4ZK
MF4V85,#.=:'W?&_&TJV%:R*A=#JRG-KDF.VT#A%P*^C9#IC'",\ILM'[I/['
M(ITR>3&.VRBMZ)3!.]GY\9>W+U[LTI_)MC-<:LJM)/B1_<3/70:4H9) N/YK
MB<O0I>$@Q&I?MCBBTDZ6J$UNY["]G3#9[[N=[,IT[2FMBBR9+MUPQ=+!BI_,
MT4PZC'K9.@H$FI_3(R\F01,'G["7#[[5Y^MO-'O_\%?P_8GSPN&Y,^M0!047
M[P(W&S6O2"=[;3!Z'O3_B@0>P&H!)K!8(9(QRL;?!G%(/0O2](>]+CDD!I>"
M5EK[[J553M=ZG+)_IG;2P[ZUJ7N2?04O'CK&UN$P:%F7:KZHOL(.&U<V?>T>
MA\_"8%5  X![0,:ZTZ612"+8;;\$B0.?!5=3PI&KGYC:<;3$X7EQ759Y2;)/
MD^8R'ZE<B"IT=A]3#]?][1'9^!%Q%Y&C%MOP,0DOUKN.C)26\?AWUE[LT9EY
MDX^N<2_:^8#IX,['4^L<^KJS-53/V1\<H@VL/,'"A'U6#<$<!R2QM$&408BL
M#H7[@_30?SH GVZ%;Y256@:=\="+BK6*8N <[[5$>!>C$;WX<H%DJ(5D+=+O
M QK"AW)'1*.?A"V^&$6@PZ\<\W7$W"JU8'@IL]Q&IHG.J9.2ELUF#BR7DS"%
M:N@%H5$61AR$&&8@=CYW/&=(UMY)/,7TF[.YKU=;8VTB;GM;!H'H%52@%[8\
M72'K3'F)HP(F/DV6+E8@5<PACA:7A2S-9+FNFT.34CR?,NVMZZ[0S@!MR+V@
MX_0R&V73"Z#G]P=G4NXTRRRM;Z[]-;9Z\.U0B7=W?GGQ;O]P<+H_'(#X-2]N
MD 2ZDDU@B=%?:$'J;$ZB^:=G3)9/A_(IK6I:U$KR$!!UYX@ O5Q4MC]&X 38
M@*2G-8;/7^WY\:ZP@X3)B17&V&73LYHD4L:-P=0!ZQ&-YE?ZO2S-<+]'6I7.
MP(2M>P<)C&^5%<J\?=G0L;Q*6;ZT@D%(_V8I6G]D$UT8'9OA;YY:?N)TFY_8
MYB<VVW[LXU3A+]#1>MX'4&MS()F\+L.]16I*E4RGSV]>?B/:Q3=H7BS4!+DN
M;V&K37..T734"+&6O$QORDHI!!#-5M*$IHDCH!\;+ ]26AH%KM3Q,+CRKTL/
M*<ARSKFLU9MEE=QE/$NE5D>$(UZ&/I=)MY(WQGH $(1X96'_XR@XJ*"#:#*7
M:3[A.!A(OV$UC=.*^=A&VK]=#,$9Z_G%U/_ES<N=GW8'/L;72[3F>4.W<700
M0V>++HD]=K=83$<EJ;DH9 DQC(27#%CIWHI/?LO0)3PKX!'8S?L2%\S.;V^&
M+W=Y[^Z\.,&V6$V!]V.HP5_38@%3DUXV9*-!N-2Y,P^##'2'7$@U9B (')H9
MC1HM%?Y<3-.+[D,E3T0&;)V,<7C8*DELGMZX@+49<%"2Q5YR('6=:=-/^&S9
MPQJ/D!]P>PR4[I'5),DF;R:T@H *J;C?5'@MW#I\W$)&2&);U+O-D\YHK50B
MK)"AVWR"C&HD'^\ E^%+NK=V-8)]Q<G]F+71U])!ZBG!:;PT<>8A-M+::_4J
M&N3\&A,+AHK$(%>C5>4H\UR3BZ*B9Y$6_S-;:=*"Q?7C1&ZCV-YW[OP*BP?N
M#IM96DUUWZ*%]GZ9.@OM0TWK%1YAJ/F/V>M46Z",\ED:4'WJ,ZSJ&9KH:3&*
M@'/B#=L^Y)]O-#,*[@Z41CE:G'DI.0G@NLE/EKIJLV4<-T[$6!X!N<[.Y!>6
MJG-)/PFL'&M@!=O;,XK5FY1&Y[_+<G(JX*\@RZ>UE]/T[V6E%%*^@9#/HSA&
MDJPJY\N9,<<> S>(8E &U3EZ08N#T _X,3!5S72::WMZ!WZ>I+4+-K 2'3&A
M;B$(OE'*T04\ZN4OYZ2BZ+!D7(V57556IT&K2_XGC8';$]'W%,YX7=:&A)^G
M[S->+2 QZ1L] ;9I:L_-[]4QK].KDY@FJDVZ7&>>E8E6,F$Z'L87SC/K>X)L
M*.=<E[0"%O1Q_=Z >*PX_ 94"IQE?:ZC=)?)ZD:5FV- XAWF"EUN_&J2)OO)
M,E*[RMYZ6K[/-7J73D;E=3EA&1AGC->DCWJ-1S55DR([Z9M]LT%D?^K\ Z><
ML:=T>9:%,%:YDT3W#CKF+$G8>OZ7XSR]*MB8RHN@,=_Q_CYWI6GR4REZ]/B(
M/RUH/5D"%4-KOQX<]H[HXS%=BM=UT%E45>G?BAR2^58:Y::3LLC<7"2MZ(J.
M[2ZK^$3"5X'57,ZNR1HL/O30MY/^5PC8EC/[NPBE(B_:-CI;H-'2(19795?T
M)6;XDW5G8L(%)-S=[G2VH6"XNN2FG*!)5Y0?[2&9/_7_JM)Q[N-0]0)-1I<]
M*Z,>D=OAN*AO4HD-7@2!5BS15>:W4$'6YL$(?[FSG//,D;;Y-H%RG=5U.<H#
M:O718IZY?M-2O)%=7C)5JM>QT\6(KPL4IM^FUO]RO*PO%\5(ZJS'%0*3B_EU
M3_DYBKGTKB6O:JJZH>0:CXF'(3,Y!O/Y=V:LP["O[)(K64/CE<)[5MR^RX$G
M-%_ML^2TN9ZOT1-7F$YVM(ZD9$-0E@-L6/,P)RX(H)&. C:%+U$NE\=&,/3>
M6A2FSAMQ[6-IA40O2]NYX+EB_/'\K^FFIP'?H EA5T\W!P)OM5^+UQ$-=.4Q
M4GR?%DN[)EC60S1XVTC&*++*QI&'S3K'Y8*C YAAZW?2N&K-\!\)/YU:C4@^
M1(D':\,<M&#V1OV<J2'J\.9V2KGGV 1(\^ZMB@<DO_[6B?YI6:[62H!MU9VL
M?]7OB36[%SLN_,]=>WP?<+B2#5/+;N!9&FT)KY#2_1LL,_*W4;F8C*,4B5\:
MK4EKH7[T!E:U@=/ ,1DZ/VWH6JA7.0'#'SG"'-(PM3"PDHU%V_BTS&I (]^6
MDP7O:8Q-K)^U4ZE?K2+HN]*GVA2D$"9T)2T+"0TS6BL@7G6(\1*R3[12O,H*
MTM'(;$%K<"4-)[)6,/)YE$4_Z#9LW8ATJ,W\*8F8/EPN6GY\@P@AM;S8FN:O
M8?XR4%,ZXKTUO2Z#)L*&^(NSPC8#L@+2"QKH+6SK4#\'&$^G6(/.Q'Q(9Z1;
M\QKLY=:',0OOXG2,K-:-6+_^CN,,=%#S1<H!21UVBER3>;XF'75CV.XE;G#9
MD<%=&Z?K3. &[>S=G+55;'15I2.Z2.7W3S+;=+;--FVS39O--JTV>LBD2,?^
MYE?GH<[F<W8;6\6B"BD)-*PEA52Q=M20LKOH"&_J,*S/'ATTTRT7.7B\ZMJ*
MTM95^67M@+7<N]R]2(I'?<B#)O*.U^!<R?@V!:*0V(XM&SFJTB++A8<\7H!&
MB1 )LQ0JOMV:#IG9VJ0#\O/%%1^%>:1%LD((+'RC5</-8(S$95%V26]F+C.X
M'"7SV$KV\#+CF("$>(WHFV/>M444^'O58C875D0<3R,P4%@5^FVJ-[HI#X.,
MO<N<FWG3ZBDR1RV'NIQ((2PLGP8(2HZF.G2X2H,>67X/G%T2FB0]XV,/>R-T
MQ.9\EW,SFYH-%9:N(?>=3;]]W(&,J4S"M8R]"0Y(Y8PU7[GM2I=]_0:')"Y,
MB'1?/=.=B!DMAT1AS02%$N$8L=7)B#_!SY:&D+!UQ!<)NZMM3(VH0@MINW\3
M@-?FLBU!*P0=WDJ,(BQQ5-L;L//=BT&3QCH%Y6"!FL%"$NDJU:^.OR5Q".M"
M\.!^:..;_F>V?G548^*P,F9"F7 /;\,OLHTMP[TAYVNJY?)15H#NW^GTOVAR
M;1;1DSZW24*1HY4WXK(VG'03D5PB%7Y 5L!B]M_LNPA,48(J:;LMW"77&-;6
M$"[HEA#B:R<Q0M2"Y^$>"$3-]T<!)6Y [D0"4H Z?);\QV3^7,XJNJSL\@\G
M$P?[%/:X%O-Y? G743NZM,GA#7@JPH5)P/6B823-)TA\?BT?3)L*IH&%# AF
MN7DAW"J.,[=D4QHR(@'<T8.  ZL"I@S@'PUW)3!9Q--4[<&[FQ<!?A4MH*JE
M"[]Q\!ZU1Y*S8.4?1"TE2FM!;VM"^I6JCYJ%S[=-8\]=&-:]PYP\-@)IHT=E
MQ<:J[9 L1V0;=DH]LT34</XTSB/'P$Z!U,\U[<C.)TGY]*I'=6TX\YI*CQ(U
M2+I,UEHO"IHD[=E[.7_QS/K)6[T!!4V,:&KSX&+;E4D4QBWM&OT/N@&Y4$HI
M 8 ,DF9N\\YOB+C \<Y'*!R>T<GE+0A(KB,AOU@&P5=T.6Z$?1>%'6]#B[^4
M]I;N7'$PM\;Z@!*R,0UD)XHK?)_-DX$D?.BY _P'_X-&W#'@GFFN*WY]M4Z#
M15UDZ@69&G4 O"9?B6- /HC("_(4 P+#_6U 8!L0^.SVE&>'LZ_"C<'6TH3D
M:[STU'9Z*B65XY!)@?)@Q.)@G6[H)^>324MA\M7/P0"!ECI5;[1/CX2_C83\
M$]MNGAVPL*_DQL"VWDWY..3O_:N0M]WE.@TCU^FMU%YMLBZ^Q^W^W/7IS D<
M'>U+%CE =BVOZ #4_.(*1V$HQT?3RVRGU@:V#&Y.@$NZ_0SVE2)_2PW<T-MJ
M^@:3)8YR7;)]EA=NTDT/(++NR><&YF2R=!5E'/2/^TC,HUS\NVMOJ;M<8[NI
ME%\,0<NHO?B8B-L'@T]EUJ'K_&A=V][^X7W('P_.AOWCJ'/O4S.A!EL3:FM"
M?3;#V,EI_VCP0%;44^.62AX!K=3GJ-!AH$)?7)-UV:.[2N!]MV0LOB<K<X0_
M_\>_#?:?\_][F=6C*I\)QFX!7E$+E+F:Z7LJX9/^V6"=$CZ^CPX^.NT?GOW3
MVG ?<13BFNSN(%3N+W5+^@TD.1 :*SYIR!3=%LP1((7!A4FEC+6!KS2J=891
MD=4(TE99N[58)N#)4AT=-SCCH9YIS7PK5:GQ:LYR,GIUHW;R?O+"S*5W[0J/
MS6P_4%'('W(S@#:>J-?.]O84W8S <U2ZHECZ;X<-N$H\S?N0@&V* .J>A7:/
MNS1^6QNOG6'?,7A;$@*D=82X3>=OBQW6836W3,G5V@5N_"8'_Z[3RTQ!&&$]
M+JT*XS_#MSLVKN[:WEJ:,0K:[+=7+UZ_?9<,^G!@&S%]>66O_<[-WB2U,6[O
MP<I;T.-#.;,E3Z76P5=*VN$I@U-!#CA@@RAI()&H)>OETD".F.V?B=7LU+J#
M/DW*IJ]-D?1;N1!8?'SK/VOWD;XA#=7J(_V(^+^VTK1Y:7K9O'0?D7SL;\7C
M$8@'VR>CZVQ,#O^S!/UPEFRD</^^9.=_AW_L(NFB'_C6?O31P1]KU,U]Z-2>
M6GQPN(T/;N.#GYUB'3@2R\W'NPX^-=^HDY!)#P^_2.+P4SW<QQJ2^FC*I6[?
MU<>J/IN@R-HD?BHYTY:+Z>&YF%:@"5&7N41YYY6"F3(>;UY?8_?BTDNL"!*9
M866=K.^>KEU,JHU^)!HKVQPQ8ZH!VYY5!;1/!JE3:2F6-TY2DA78.Q2 C_):
M:&0+%]=P83O@A+48A '<BA0#8498+1+&1LPTTF*43M\L<.#%<;^/[;,UM__U
MS.W7OS<EIZ/:-,P+O'[7^,%S80VX9&0MS@E]0Z02%1P7:"Y$^LNS[T%JZ:UE
M@;)0I:Y:Z G2X_&(*</YQ&R%].L*Z;L@ODXN'J+"H8]XE\B2P]@24OJ;HQE!
MF'2UK/*W_4NW(KL5V7N*;,B0Q<9".AI52D#*76*<T D-@!"[J"W7DE@S'=IV
M@HDD/V -G?S7J+-X3&#*CRE85*[,EV2KYY.-5;%VT(B&5B9H(.?E7"A((B<F
M(@MJUE&.1<@D06A:3<LD//O\OB=.^;X$$T*C.).E,VS[V=GUOAV5"RGJAOLK
M'*_8U0H2X2M_$28SR0/;"W\Z_-::*KV[I5\N]_AP>AJVP^"A.X/#>PZE^<7[
MC&!7.Z1R+R=< SM<S,F-6>=@@ .VJ:#;@3RYW7YR[GT.VN1AN,-XS-A(R4"2
M5G$=ET [6*5D'V:3DO/1VL51KT=V);^ED8&CY'Z-ONK%!30+>:AO&,Z>TUF=
MBRCYZ2=3>GNJ[';8[@;Q5K(3%=/\F54E#Q,HE6)74JJG)]_P4]&_(!<!"E[0
MU07,;NTG2<@^/-B&:[?AVL\.UQX/'KAA[.?$:P\_-5Y[3,)RNA9=>!^(]^'Q
M4"S3?TITX6<9-0X"]UU.+ZN %$7 \1&$PU< OMZMM7X,T3/VT;,+-S$+4X?V
M0F3CF!OW^G??L&_'6R:#579&: #LW]\ L.BP$IA;N6<4ZPW(]WH6>N;6 FJ"
M,'E<URM0ICK+QTRY*9Q9#:)$CI-+0_8V)/H_%1--M_OYG77ZS$T7MPV2^'R5
M8>7%M972&W@ZBCN+J< "1AR\) .+-1"C#EH'BA60HW6/\@LE2#Y1W1U]JKK;
M/Q08]"IU=Q]==_3EDEJR'']?U//\<OE8U-_'.$]3H/=17=6A'2Z!@2ZN:A/R
M#B4C[1J<CGGR4?..3?VX@,^1E%AM.N)#!N+PZ(D$?7YVU 1G0JCNKA15FFEA
M7-69(P'JULU\:=%7A@IM41BG14'58V=X[(Z=N_P+F1R=<Y6ZGN3\O[[-O_Y"
MKVLJ^M1<PL.M2[AU"3_;)3P\Z)_HM;3I"VE5OF%[(VWR1CIJW$B(ND6M-COO
M(?,IV%7)/J#WCA;?*'ACG%_E<U!=0-$!"()0(-UVD[%CMLZKT4*+6/2ALS)H
M:E%K5>*$:98*,!Q585-7+5\KF7[#M??<Z*7WW:.[]+9G?GOF34Z:)UU(]=.<
M62[R<E9S;/Z <TCN6[MFHC+/JR/00H.>?&(]D2?6^QT/>/?ZIWJ7,6(-JS8R
M8\7ARBO+'&WTW+[8S+E]3"G9]H(]5H>^(2'1F+W[\0Q;FGR?<B^I@+)7:0L;
M'E:C*3B+9\$P1J:&]$G!5S^]?CLKY\]B3AKW'/> W7[RDOEN0"-;TXA<HT T
M[9*$&+WC)J>[+ YX\?%X'C1Y:U;_.GRI-,C(QH^%T^7X4R-@9J.J2CT]V(:R
M_(+?0]B_$V%?;=,YUC)C(=0V/T*!U+343&<'G,%.P.ME/<^FS9C$3O=IX.]\
MU)%8/UT[,#S;KD,3 FNB$ M-+WT?'&\-H@"AS9%I7RJ$SC0:[T9;Q#:? 4JQ
ME\FX6EQ])?SQ)TKG4PMW'&W#'=MPQT-DP ^.'DL&_.23,^ Z"[L0CQ[^0GS\
MM]\GV7ULR3]+WK%&A[;./^!_U+T9-VX%N"K)3M[/^DWG)'!NQ$%Y<&Z83Y2I
MTT\ESCL[Z*_CS;M/EO'@M'_V!0B;'J]M]C HB[?"3K(YB(4FA3Q\'3CC@.D]
M75$RAVJMRWQB]64W-$YD\/<,/]'9I</ULN/N%I ]9J69AST$N[K[=6'ZI-A-
M4(MTH=.K&)J@ <1U>%AEA$$!@& LI>$%]]&"1[>RT@\=( W_[QIG*U2UAN<(
M'])H>WODH4DCF5P+\[C I6[77?&XA9;4 !3&O;1G!/+I^(86#J!0C^RLF'M.
M4!C'Q]_8U&WLVF+V]!N8PR0F& E4UEW/%IS)596.L^0 H1II9?F%/,D'.]5/
MS:8]WMJT6YOVLVW:_6'_^-%4X9]]JOUQ>M8?!#;M,8GKUI3X6%/B%1A-T]$F
MC8G[X#7=,&^Y#8?+W1GOX.$J4*654[>YWNRB70*<Z2K^>LFTO.$;KTS^]_B/
MW;6ES\Q$Q4/HH#WLK,KGNJFD?75?9\(M:U/T)D;04]0U\NMF"W"4XSL!-%4F
M8+]L@#R;CXBCP3O<92=\%CDU&B&6(3MX:PPVE0#?=947[R7ZEQP=Q.'#G<$1
M_CT\#>I5XA$'/)1:_.'ZD)?%WB6<,=<$:6?ZYONWNWC@0?_P2$D1+>NK/5MJ
M9Y$N-4UE+5]A5]:T"@(AI2?QR/J.7!%K5^3<YTJ:1',KZ.%_-JKHDIWOLZK*
M:Z$<[B6_O/KKS^"2/'Z>')P</4L&IT?'>X/3XY/=+P S_2Q=H%+S5J3J=Q&)
M=RH2CT _?.^0SC$[@CLPQF"_FB&!+5]'[C@X[!"[9 =ZH[M<2B32!'&>HZEC
M$1_ZP?X).0S+>HU9+L7#*M27VFU+S>_.(3V2-,SPD_MRF)VA&?;!<?_TB][0
MG3/[%_ *3K9>P=8K^&ROX."DO_^@#9 ^CF:V91!%S$IFP5C'P&; R%7L0&F3
M@7B95U-8?+\E.X>#;YHV"= D!3JFQ-\\WN_Z9NI8D;3C( <[L"4G].2=P3[K
M_RX%+A='EST4IU,?BZ+_U!XJPP/2[(=K8L%,EW8G??^^T/S_*Q*I/8 !9V;[
M>6#COR,;_S$;=-\:^_SGVW5?PJ@[.?IXFP[QT"=AU0T_F?WPM+^NNJP_N,]9
M/_L"E;1?^*0_-:OP=&L5;JW"S[8*CTZ_! / YJW"@Y56(6":_)7AV4>:@Z<P
M!P>?8 Z>/$IS\)/Y<8].^F<'GWU%''ZI</Z].9)H@XMLY#/*[1RQU/**9/[6
MT56$*>B#3N>K&[*@H7HU9?0M6E;^-2T6Z#)";QER-QIAY/$X0A46)62*LM\^
M$@QYF]%P24KS/SE^V=FH1Y[(<<TU7+(2[]2Z9IN@!TTBK6P]J*^SN(O0JIXY
M0J%KSVH\P3=L01P:#46D!YOO/M.J/:BY.\L]9Q('[C]N'?O)6^L"VNN,KG=W
MO6G0^1H?;KI:=HQQ+10/F/(97\*]M:L1;"M;IA^Q-OI:.AJ]9"'<R-'2Q F/
MN/=/>ZU>18.4?E_!4$$\BRV>527*ODS$%D5%SRJG='A7MDH*6_U\A,19PL=C
MXKE^K(D@B8^.GS/,IEG]H L.,2^$_RJ@R-!'7*<3ICB&,M@01S%6[?N7YTPD
M>$7[@D%R+<2[BNS(Y&6&_FXJ&V6#;SDX1/<A,NE9A]P[-J2W1IGMW6O5-\_W
M;#0F)KM%V1;ZNYJO 4N4O,UF\\@QIN4NR+@?";V9_9P+],A,#];TYZRB#?R/
M=#I[3M9DOT>WSZB7_$]6Y)-;4LC7O>27O_:2O[T][_'.,EA=\5]W;I&T,NLX
MQMHDJO, W7/O0!7NCPP-3-N5<5_S%ONU7B9%<(,&I^K@P7L(JL%^44[&ZR,W
M!^@K)XVO6)[IOS';+'G!L+<O&F-JC?1C% *3@V+!WV:TCN=2VKLA/LLF:SSX
MWV]RM(42!5,GTQ2]YI)T1I?,C&1A+F89P'E:E8Q.W>A^F;R3GH=1_9;]7J[L
M;&%M3J=96M :7"XF+(_<9E-<%A(UU^TL)BD:NS+GD**^W:91FG%*=1D]33NJ
MXKM5>;% &1IX[+.@" 7*1+P+M*[5>=7*+<QD^GGMIV3A-7KV.),"'?-.Z(*[
MA3E4M(A$7-(=3D_]-*D1S[:!D6U@Y),"(YL(@J"9:]P@48F9:U5Q_IS7=3G*
M R(Z*80VYK:+I5R@[%\*/:T^L!8'EA_'==;@;X4.2>AF1Q&$6MCVIAZIP_?0
M-]?9E!0F?PEWK/!%7VJA=M1E@Q5O.KKFE_MN%[!3Z/FS154OK+_I&$00Y<SY
M-&W%Z) <T/-!.V]T&J&W3UD1RF B3=C#Q*)%(Z."GC_/\D)5,D;#./,E=P(G
M3P.8(['(:S)KQK:J8(E 8P$ PJ9\%T3?%8$T]KOOLE$*;KJ&7JYP"9&>84,J
MJ^9IXX=A7PY1S/QG#82)]I?Z2?*+:%UHN<'3K7<3.GE<%21RND\,9:+C4O@I
M0\&[7\K%,%:3= I/B:X+_JXK=HXGP)Y3/ [I?@YWYGV!:Y#>JE]PG=3%!;/;
MI[S M$4\41^=9]6>777T3J95FTN7'HA!33?0Z!J/K?/98I*19$_VWO5,:&#M
MDO7WVZ^_O_KEAU=XYDMRJJM,&J+0RH[T[JY[<LN3L=OG91@M*A(D]*9VKZ1?
MOTV+67E+5O4/</GD)S"2Y;]^FH_)7N9+GX:'Q(]TUIYC_J0]ZEP*(%B4R%+.
M6FLA5ZQR*'9LZ[S4B>.;++0B!W:)?]G>URW[,+Y\3AN*;(__LJ9A-E39VW*R
MD)Z>:OQ^6:/WXXQ(G$B5)&:WIO%.2R[:5<+S4/Z]1A*_(N<3G?9T8KU8386V
M'AVHZT*Z<\-,= X.R1*=_E)LNKQFCL&9+8V4P?3]6EE+)I*\? QS,5D4^3\6
MD3L\0TR-_CP7]&BLDR]4*S5>H;I'U1GT^X(=2ZO=]B0'3A&PV'-7#!P_7Y:C
M%U7?]MHNKKE5T\DU9,]Y9D/!LT>D:V?793VC9\/XW'ES_H9\73?8YBCH"V_/
ME>R[_:4IW-*TR,)O_WR^NZ$(@):M9]@X: $70=0R*6Z;+*>^Y7)4S)M2M,Q_
MUC-%QZKV$EJY'CSU3%6VZ4?2Q&4RXJ2)^QNBD;.LJL$+SRZ[DZ:>>M,Y^DA5
MV924&AT6TJXY]DN$QL72+LKQLI=,RG0LMP\;)#0.:W12T!- YR^ZC;]BC*X2
M$9!; N))$W(*W?6Q$">+UTF=$^>9Y$4CJO"1!^Q7K@YCW'"1JQL6*(5XR@$)
MO9+38E#A!23A4RDYBVBP@"N83/Q^K7PP@.HD,#RD2?:A9]/S!S&0$;J^BL4E
M72G2,)YCJK40D-R4$X:VYV3(B"(*-LT7@&'3U!:;WL&?D'T@H_%&Z!.\R9DT
M/$_>;(/.9ZZ/O;P<-UR4]TJ3?/Q__O+__3AY?WQP?#(\'9[]1:SWC5C>*]2V
MD\,,?0<RKD6@F2 CF"H-1-!> ?9,;4AT,["<V<P6JUG8SIA5\XN.?'E;DQ!I
MWP56R2ZPX!::F]AQ1K*>5V0FL9EM]Y :V9Z"6H+=8Y^G&&6"<V=%06J4-PX*
M,GX#HBH23T'^ XI+3)TT7*8]N?9:9CN/@_Y%<CXA7ZJR.X&.")V<&1>%7BX8
MWL^OS_FW9L>?OWE!HFFV7T/M]"RP)UK'&$!XD3.M$L$7%SB>*OVXEN^B!PG%
M6P\23; CTA,&>*1N<BJ\X,THCX6C,+,)&F30KFHT1^K%.V)/M0D,[5,YYHI2
MTQ]_6'$+OD+>*SI=9ZI.UCRO*Z/#E'?M@3H;AF/R/[WX^7>1C=<O?I?@;I#H
MTKY5KMD53%LX=Y.T*+2DAHM_:>ZO?WEI:=$#"22O2G<D3S'$=+"_#3%M0TR?
MC;TY.>P_%NJ1X2<WWZ!)K(4&WP<+<GAX]"6@P8^DDO/C&W==+A"6XQO5ZW^U
M4>G#BHW-KHS"%5DG ,%*VZ8HF.,0+FG.Y@@7]B\DLF7==N7:N$3H@HP3/@3Q
M5;PW=VDAH5?0Q$/Z7C-ZS =FQHYZ.RBL=':/7'?U/)^"RG7=-;:YG-V)ABU\
M#NSGQ9SCKO_SV_E;[M68LEN"99&01H^T!2EZNE7IHI0_\07YTX)^O<FHATXG
MKU>'*[HBK!B[P):0^+=*W# /;UVVV6KA.LY@C?K\_WO<A*09*A81ZB5Y'?BZ
MB 062]_/^F?\"[FT"CV3^1=HUR(+ZUTGV!_>2RIA\^A7T,X0:")$[>K%Q9YB
M.HS'C3$JP7=K\4?A6(E(\T[SE+CC,ALZ))I9,-AQ?GF9(:CHUJ+$'VIQ<UV0
MA./E9*C>.CS8G+T'<C"*[)+,8#7_HM7E%WCNH04>[!J@39=5GH[CX6]&NM[J
MVD.-]/1TP%]XGS$I"HZXT"T+6S.  Y<6^N6VY.K4DS_#GH8/<$A@3HNX.6RK
MXH6 =;F'EM[B=K%>@]+())7J]\S%WCDY0<:SE%D?2'$..%FN%[0>7N@Z]KPY
M"O?,F=< N@\[IV2*T5Z>[7^SBW",4P?V>3R,0_H:K\$$*J+[.P?#;W;[R8_E
M+7HA2EJ YUDM6(7[H=+23<@YF&M/QLMRM-##3C)0E!IMTUN8-C#9^6$P?-E+
MZ/__SO__-PFLT7^]D%'Y+Q_@RP<O:4X5 &SFW]?A4B-X/9]7QI7J$T71T6>'
M!NY">)U!&_'"NU-NQP2_7W4$@N5/25!+WW%PY\WY^<ON#7CQVXM@R9N_^^EO
M]+NO1]%X7DC;^^X.]_Z>;0CE39XVVGMP4W<E_2%G^QW=WE*D#C%%A7I?_N;6
M-XV?F3"XLR$:N^+]12C4 *E#*XEWK65V5F+GY_+VB$*@O/B[GE92$EKT;V=2
M*FQXAX(73K):SC0V?P$QG"SQ.@R$?28%CTN$ <_B.6(J>V..QMY)1-T7/E10
M2^"H]Y(:>3_2 )-LM.#PA2.9\KL37GK:6M-GJMC7U3B":*YIKBZT@V;$"*8Z
M.NVXHQJGPBX].^U\YPD<K^=OPGA_=VPI7NP&7/E=2@U'H*F#M)81RPN#C1PH
MF'BJ,T/MY-Z"I_,6D5C*E:D-KNE@\J)@TVX1-@Q#9F*S-J3= D)-;:7*ZN"E
M38AU-;X\Q1ZVYO8D@PR#;9!A&V38+(YEM>6W$S%#H[(:1S+Z(UI7X1:QY"J.
M/0>ASU_V HMMLH0609":'=X(Z,>=RP4\G2PJ>)Q<T E]R9'?P([(R#Y0\\-I
M2LF[A7#T#=G);UK68A[Q'#7MWDE&TZ>[AU5%RFR!_>37&VYNTDN:"GJ_1\>>
M/8R1L7"WS=,9_=\2I4^I7'(XZK1AD_("QCL2"B/)5O:XAW(ZR0R_,$4[O(GE
MF-M/1K+$TG1L@DPC7O'QPJ6$)D"4#X]X'-P2NOFH=#0BA3:7G1OT3YVE;A[6
MQ0+>%H<1#OO'C8])%E)0^K#]VGJV?5AQ@8%:!"0_Y0)'$=8,C9!7:+A_O"_^
M('?#]/.O-(\(J"B:9 NR)=<Z!:3&6V\-\3I31&?HMIYPMA68'$R%TS2TS8PY
MJLD>H1NH5J]Q@KXUJ%TFTQD7IC.'+S+&F^C7)??):1^_)8MZH>]-T;^;;70[
MBIR *4:+2KN]T-W03\Y'$ J-Y.-AY],,M$F%!33>EB2(\Z6\J11I3([V>,TB
MX.@*0<$YCD3W[)M^<A87Q[5,33/>0;K;DZ$FX.5J[6.>F7>O J:&X3A/KPI2
MD<C'^IQ=E[I(*_E7!B"5ZAL:9<&]BC:D.>[#GO:BY>KD$H2@U:C&HE%T%6BM
MG%)9)K=E-1G339)9)M<5M622(Q8 B8OVR!FR&AO5%^*Z-$? +&<(\PF;*,VI
M?Y;0:DU@D8J:8O=DN-]SIV _^(J>5C?"YDMIAD)!RERS@NCSIC=KD<HX5B6+
MJ2J*,^0%O6<\GF22BIR4M[0;?*#\#\<+AES<9LAI%_F?RLKZCA&,*6(.+.CP
M1]JS%\_KE%?AZ.@;^5GG26F)_H1\4D%FJ*7=M;ETM9(T7R +>G#::-T '\1M
MMJ'"Q=74@_[ZLJDKZEFEV4H:'=N4K ;RNEYD@H6LKE))^'^K6!:D ?DDL0M%
MVFR<*7*Q<YXTAI/A-UWOUK->"QH%!UF!&Z13'76O9'[7/7UPJ,NL2DXRM%,0
MUM)NL#^"YXI8M]:4EN^ZG%TOR7M4  !IAHD,R-]M(?**'91>D'7/BG%9C\H9
M0Y8XM'6E">-17C,:MJ)#9;&07AP: >B#!)_--S ;3_T'S;B(1&I(@V0%\POC
M15FU5$G&&TFIIQV6D"VT!COK(.18.Y0C;AP8)*K=W3+SE&@=,DGU7I.0T-5H
M<UY*A1^;?T@H%-=RSW!:FT4/!8XC 06;<J&EO2I+07-!CPL+,I":N(PF2/)?
M2<K"OB&9_M;F6< HZ@"'1UM)N3OX'NHF*HC9'W/5":9:TBENW26= EK7Q(-5
M:Z0MN.D<_Y09KI?H" P##5V"%V12:5Y<^ ='^,Z$N:II3%F!PY=L-,'T4Q!L
MU$N"KP>4I[)B[M#W7@DK>S0"3$ZUDT_65-II42S$J#R/KGL$2.G98<"S$=\3
M?9HB8L\!^P2F$[V$ >L<CI%>@F'(])>W+WY"9(.>++$ CF*X,%_]CT6*SN'R
MRRC>]_;%KMWYT2K0VS4GP(]R88RF^7(HH1$>@%PT[16=5?1M.IWAD+UZ5F#$
MWPH.YKR=<]$-JBUG] ?)&;@CNE[],5A],.0(](!NG,V(U\=#J@3T@ISCE2BB
M()^D**A&3,A%J[S[T),X(/)MM&$D=G0OE5>EH*H08);@DFA<SAWPD#S URG*
M+A3322>*Z7GB4VLN2^8+$QX5H$G!7&%;LVA15W2.=N(\SJP3FI7OLSUU RUP
ME:I%'5U/[39(86DPXXQVI"IX=\\CCN1/0_J3)"L-I<274Q,7RLC210%L5C:6
M(./]VY#J^@/01]*-\96M.AQ!UN%>ZP!AV>9K\4WX"@_$0B,10X@^+/IJ0\GQ
M7[!8/_CRC3>*07CA, A?+W^2C/A$P38)D0?8QQ" 7X=%&^%!M1-^N6"Q**Y0
MW6R5,Y(SF'"N]HZC+*058Z0CH7$4Q&D93GF0Y8Y=!7UXSOK)CRD#=^]XD<%#
M,>"]YH %%B\):MR37J'N9'29D%=4[[HZ%3W7:'[&6>Q\1+I6@!KS>3:=S=4\
MHP>.<QJ]W*LA&8.^EZO)]/D]1V;AH_X:5=%;'@B;P<ES+EG+;_+Q@D-<?^=N
M$O6\Y&S 7'$YAH9.=G[^D:[IT22M:RWIP?RR25:["J9@::&7IDB&*:J@NR+"
MY<XP8+XY?3$5FX11J51805RH(%WP):2?^^FX&=*@XS%;&JD.#!6DNH 0OEZ@
MAFD<  K0>X,ON^Q#S@TI%5,P6TS4#_WC&E!+J4K1VKO.[647#K@&V8TB*W6[
M5/E$M0 V47LB1IO/10?B_N:LDZ6<"Q>BA6[+JGF92RFA5(:I+O8UBW$A'CG:
M$T @$DY4^Y1GF,L6?^Z";AE:AY1O7Q! =(F_%??U)",V1EHQZYG!%=22C%4D
MI#A0":1"EW2.2ZT.JBOTU;7?-_O5+__WU=M?![WDY_,?7DEBZYR++MBWZG[<
MT\Q$#;>9J&TFZK%FHKQQ*(H'NF1,BI[C49R_ )9*[JTI^WN^%O0BXR(:E">+
M?BSCXJ!^ C)3?H#H,_8+.]2%X,TN_3FW:/^BX%'1@P2VB=Q(3SQ$O4I7J,NH
MC)AS!>Q01H7(9>4^A?^<CW*95@B)TW'S/<"%W:[VA]Q<A+&FOI!/' ]#) 2%
MVIMCTC$^-KE'$51ELYQ5%CO0K.]A I!G?]T@P.$@0$[Z#>5RN!$\%=C+M+K-
MBQ\Y/(.:.(S__Y;5^^0%C ^Y&R_RDKP]'!2RPK3 ![ \>G0F6*2"1C>)OQ==
MG@YTRQX$0_T09$*?&?7VR)X.RJ%))&!"#$EU=EX???YT\#R!HWU5"G\:UUT4
M8QU,>+V%5R6Y8D5-)O-L'I3".T&AT<MAT5!Z [KA!<J?@IX4+QDS+BD>'7IY
M>;E'D]NKK[/)I0W8&2F7=J!B].5+GR4T]JYX+U%U@XA>)R8:([^AV\R<^>;6
MN;>K=8?0@E3/S:H\FR- DTZNT KX>BIU-VP:,NE0 M><5(-M''ZX;J;-/95Y
M[H6*(JRZ0FPJ,]8!AMTR81IJ^FIG?<JR.^;DMIO#IJF')0D^KTZG\;OD,1=T
M5!CWR\P&P#W1$9'7<O8+L0ZK]4U% NG;<L%CT=U"<Z\]:!#8S1@0 E;AFC9W
M(5CBUYPT94L>6RJ3GLTF<BYXY/:><?!#O%]0F[5:96[)2&!G%LWK.%<K#M3&
M0.8#]#M)X4'/KI<3Q%9&R>_I: 1R+)R1%TNR_[*K=%(*-'OGQ<^_/WA/T7MC
MR&FT@NQ51C<?.HM@Y8C3KHC_L<Y1G[OF"DJ[:&C/@ZWVM>*SXZ->$.JA^7?'
MJ41Q77W'7Z87C,AEP9>+;$%*CSP;$7;R+,LQW^F(LY!<2CZB]FXSQ#Z'#U_E
M]?L8?BKTDXN9HP ):1P"IUTX1#A;)BD3L#Q(O2_T+\"OJ!@<Y3.!H^ <8.&4
M"JX!!V2N 2S]K3&%"+.$X7QELIPJK$J>Y!AP"[;HHN5J44DAND2/.QPFZ'Q$
M^C2K7%#,9[G2:DHC-'\:F$@ZJN4%:X=Q5-C(WL_+PXX86,!QLFI3ED'1![C8
M Z9$"7IS9$PEC\2.#1[=Z$"(/%F7?G>5!'!= IM2P-VX!0BAF[)=C'U=/V)7
M<X-QZA -D H2A#@06C?LP 4]@[WGM-DY7B:.,] 5OJ2K#" I%V!IGCL=B,]<
M2C01OGMM1 .(A#%V'Z"JM"A0&__.T;4&H@CC@AZJ#49=8RT3EW-2]Q/.Y&NP
M@90MGO-7DNM"6 !?ZV&CH_52R)4W!<2R JL2NY#\8T'WN^0#G64I1*W"J^B9
M#7N*$]JCR4<LK@T&0BUZ9759J,!?23+69^AOTYQWZ7T^+K)EH!GDLN(<&.E)
MQC?3$\2K AM#67!M]G>F<N5-+NC4V8K7'5<[W9*?,&2WCRF)&D52%B7N5F5&
MLHT+K19%++5!.OD#G;,$525:/N8"9L&BE=>E! RC27CE=[^%B'Z,>S%<4UD1
M7T&C))"2<F:1Y&2$,N^*<1EG+3#2<;6X2G9>__)RETT0/D3P'@P/-6$>EX"R
M6=%A;("K+18S7XI5KD:<M!;NA98Y-H@5>&#1>;'Q\<1:.QU*85YKF9RHA"M!
M:K!>J!UDQ'^,$"&?<R_X+9D5V31/^0H*6:^%42#H(RS6N-L#8VB_S[28@#<O
M-&X67AZI-H9VPV%UN<?\OS=L!LDFU,"N 7Z/*U ;3M/@V"*(($A\1<B4>O8%
M:&OA UO4F87(4??(WU:>]]8"#.(%"(@>])KMF+&\<+QR2 P2S$J$,!O]*W%)
M<&]H+P,]@8;6<^>M6L$ A@\U*AZ::_0<;=\&&83M$*@H-W0CZEN$KI^F7RUR
ML3%PLF";"*\M-Z<.FGTR+7H_^2$7]JW,(REXO6)Z;+G)Z8SV@C.Q2KD$L%2Z
M/(6>]\6OO[]^N3<X W9Q3-NFH,IY";")QXZXT<GK ]W*\X2D,EC!@-#\CBJG
MA>.+EPD3@)PX\A,%&%8?:EW7,2QYH+"$<:&,0]XTIR.HD\%PC]M:TCT$WWQO
M,5._F7U:@4MZ)*[= <QL F^*D9OVP]6D#?HR(%\FUD8]'>_!3Q9,WX&:<<90
MW&SL$W!G\2O(XN0819R&->71[!-_FQE:*8=7R)D+3O);7A\'@^:1E^(<^IHS
MM[0!WT_N;1-K_.!A4PKM)=NHOLYG(I[-$.&CI?!M>)!?+3/;]%S%;^3_E%1L
M[6.9+,;3?*Z*C,S:R?@:H#"^1O@:3TG]S_&W)ISHV%<F_:W_MA^8,@'8Y /0
M6F,%)4A!$9<>HY:)8Z6R_U R?S@TK$H>"@WF6HEPR_DV/@5LF(LNE\N:O""<
M4Q9$#R#U<6DW"#I5*! ]$\2F>T0@C>[G(;+PQ36=-)[!D\P>'6RS1]OLT6/-
M'KVF4Y[VVH>U[YQ63N; _$JX.?1EQD49HC\X?<Z&VL@5\(BF$[Y[&J!5=-"!
M1GIH&51,.GQ"$%CR/&T64NH,'/4<L# *9B7,':J$H_BWQ\-JU4SD]9?514[&
M[;(7U+A(&1<=+7K0W^6IVI)$L)*W)=GD69'2Y5M[T[X14I,:(T_N(,:1FT>=
MS><,3'NMO&9TZUK+<9VA!PC@T>;P,=XD,((7A:GOGBMA$*L/OS*711F1<>_P
MBXR8T$+#,G@#<_".X'KG<EVQ5FU,(:T760ACW6R%SW/X+68WMH@BVU?J6-;&
MT&RF1,?LF1H.#UU&,^EQ 90?I@D.@[T]F%L9!<=2DN11.\$6,#QP##\QFE0H
M.X#JBI0K8YV+.Z1*HNOS;M(W0L,G.<.? .M@-"_?D=DL8WM!:U(PJF6[WB_&
MUPX&4MD6U39(B$$W*PRW!I.SN,($X!E#(P<W;7A/:Y)NA9?@\F#L@7>9'R,!
MU#?2NU8 -Y09(%.&H^C(']UK! NJO>PY3@HQED":^O1<VYS.N8A+$HK=&H%3
MVVE%DQISSLI-/"BBL8/ Z&H'CX]=5J]-6@5;X,Y(A1"0-:+*E1PY2:;'!^^%
MI-H#DUI@93?Z1S, '04 .^;BFC6WM4X6\WPB&"WSZV=A^D0U@*/*%+J!*X[Y
MAR0:=;/HBTU1B&0N#IIR8DMC!ATMAU7YG>8FB$G(X"B9^G4ZG7%6&E%96K0@
M.B!LI*,')73^..=<];?'/K F1T5,6HUKD>0JDZ0JG%@(6K 9W2?M67L#9DBS
MSYS:C3X/BEV"$WW%SKW?4X3C:M=MM>*F&@77%4A<W;V]SVU)^$="N:AA'U:E
M6EP5QF!$'44"?;+/B/F#8RY5;@?8W$"!K0L=;'.K?Y43@ >P!K-D$J^?BT<%
M>(\ZT]J3;)I5@*P64:#*)U\\%R[9C#/M&^=7=\5B<FZ\YK)J+!OX*C)F<YF'
M84.]("-U+S!ES;B7U=+*%)"ZE=NUYH N&I5U#AAJA;=2/+M22Z\E=1:8'?([
MT-#6/8WH^I6ZD.)+5P?+.69:^RADEY0CDN.5"\*K'5@C_&TK#DVEQE?B'!)7
M#24J(MMIRB1C%3$QS)D'Q';C/.)[\AG+<-*J#QJ>W06L'SJV57GK-09VYPHU
M12/VH'O(C@;_YB4AE5U>RJ>B8!B!'S[ALJSI0!=@@@F_WVC0P(N*\+=741$#
M$EC@7*1,\^:Z[\;I8]4J<\_GO$8IN&(M+7R..5;<X[D'1=%]% WT8;954 0=
MVUDN@= 36 M<%XOYN3J+N,CFR41SH*[^1]35.[]&%D3<6')-TFB-*N\AVT#&
M"AB;>(<#_K#[>JFA9I%S@N7CHC.<AFRI:M91GBZ<WG;:'WX34<S0X(Y:-6EB
MQ4$^]CCMW[X#@HR5PQN)=1![/:0\W%/"+!>3 ETR58 DP9-V3M"G>=H3<V*<
MM#*!KPM1=BOL8.],=I\+-Y^+;'Z+J^9 $F9G^]P8O77A^E!S1;-";(Z_,#B5
M[S_>PQ-VIC!0Q>:Q-,VL_0IF[:AJQ3-G.B_0-V=1*(+5$4G> *:L^TB81>\(
M&DA6$:[?:-E/_(C9*6:7&&>9S,?F!!BG$95N/>-5GBO-A,3[.#BWQ^B^69T]
ML_]X_@ 1'@M\8L&?!Q$WWB0,8F^2+LDW>G:9?\C&8;C-0H82&)M7]']C1[L@
M#8M/^R?RZ;?S<?CQ9XT;I@UR9!I-94FB$3\/J1Z*DHD>=+2G' 3E"*0.]S_^
M[>SXY.QY<USQE]K1O0<XFNM"@XRM$1R*(98%T A'V)=YXB\0F^.CY/U+ ;QH
M5<=S"+&+)V)NWV)?ON6-W(!0[6]E:M,RE4HMU\?(U=5W)D_]U;+4':=G+>)R
M!!MH6&1!38N8L?<0M"80CQ-')J]#5 *8;DHQM]\% 2<4V'MT>F!;,8HL>HD/
M[(8%P8Y)T:X3?C>[G5RD;"$_C:%'0!:>B8Y"[;$871G85,X;Y+ERA"7BC^3
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MEFPK^F97*4>KF #-9%8VLVX%^Q6?DVLFX@;-9C9]8MF63"%.(12;DIDU^;X
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MQ'.G5;.5(%8;J9Z- 8:S&D3YHM_?@DYL.[GWZNSM_22E[CJ6(OUS"450+PM
MI)L)@^D*85P2'YT]X\A==EY4-7;UGLQ6L"B>LXCQI^VL*:<1@3K:RW3R1NI-
M[F<[XA6[6GF_;QQ#1KHC@B"UM6D,P;PK^AO_(9!J9L&\<.$%6!J9#RQ(K_0
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MU!_9^V:91O=F9ZYITB<Y^Z!<T\CUN\LX[=A/R3NA3$C&"B2QM@Q(.0REV8-
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M!L8B8!RN.F+ANVZ+O]D/3SY"W,="@5B-)RX&Q2N(01PM\VW=;?ZV*'\OYCX
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MAK]6;0Q:04,JZ024BVWDY5=4ACTVGZ\@Z381/JR $(WRNJRP(D(PX[&-! <
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MI'VP[*E!UH_F*VYYR?88&Y\//J>L1(I0'TUOA 1P/]N;:3N#75G?3'UIY)X
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M6/2%5MCL A86+#IGQK'8$9*I;H4V,3AV2:>H<"8U&A).B$_61I0YA[P-'8"
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M98L S/X[J9$T=;,/P59*%-&8#!36J:BM 56!W!=&G[5&)^:\M_?IS,U9O>O
M2KD4*Z'1U+F(ZC"BR*V<*I>=F&('-++)>REI_5J6Q27N'-8UTJ5!41LV#F[V
MI"K.(T0G7TW+\PY&S?NO15+9(=[Z91%<N>/)4^ROH'97&@84]; UDV4$ !OC
M@.+C[:.LR&TU@I6G.\SORET$G&Q6Z4J&I)15'PW)L@(+#"RMQ%VF]8P=18:1
MT2P&R^.YB$XYQEP*7C/9.%7MVUTD'6.<<S? =<H#M.Y9;R"=SF,YHOW8YH!!
M.E)8!VM&0\7[&?H.(W)^":J$U$<[:\CIQ)3!&#OYA9Y.BM&(7)_^\AQ,KJV
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MP5AY%GL7?;+<8(3V,3T43LRF%)12Z*;' E!=BT"'G[36<DVJ0F\-%>S5UH#
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M>E='^JMO[#N9&]8PN0<&SX#Y8FK)7@53+07^AL*NA&S9Y4[F(77)9R89G[,
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MF%+V@EZ2U-$>TZ(/2F22" [S3T:!=,(.'"?(_!,"Q('HX_QQ++@EB5)_W#.
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M]CM5+<BXJ;EGQ\F=?I@/$GHJ)9 H:7/,*Y&&R'Q)3($<-O]/5WE EK:,MSP
M0POA77NIQ)<0:&/E-A5(X &J+:!;!])ZZ!3&&AXX144IJE@F-#QAYD.?A)D
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M@]HI<[,8^N!Y>"=$>HH<%-,7S?BE *+<1E (T?Z7?>PE(1675JIV:66O=0P
M&2/;X_N[O[:>\D)0 -QRIR?B!,@-YBVUH#"T&<W-%'PFL0.VLL :-/4C;U:,
M&IXPLU(;2*A <N(K6:%I)(B9NAFVT28HP1W2YGND-?92SU8_O.?-K,+W@1X)
MQE*'W+#%_B92(SI1Z06^^/KS_ZD=NS5U["0K#.N!FNM5<UG4C^IP(RU5AO@'
M^_*BV91QO)A]@J&1';Z8/(;> \I.=A^$FHBS->_U4/QS8<VRJ?H<=GH5@A>/
M[L&).?&:D8/FW6 N*[K&)QY"Q0-6A;H9^V69J;?)H1#VD(H /UF*:N]ZG1ZF
M@3C7%IXLO\V! +Q0Q+'H=5Y(N#<T>$JFB#1>P<3C1"%!IY'G"SQ4NXJ3&E3)
M>,3C3A-$G[?,*O"QC:3QGKQ&$M72 _,9+'HV(=C,4,=\M MV#N:2IKT,05FW
MZV0>GVQBA);X)?/G\3M<!14!0_^9S,R4?N@%TGR$OU^7'>R,4CX27J-KO6:#
M4D*$JX8J0XSENVXJ02X/$ZU,$ :^<1[!@,Y>J"N37]+%VX/.3\3N2%J2MJOY
M:UT=VDU5Q"G*9%#.,:6M9)I0[%%>CV9_>A7>E?F&9UD!M9!H1-N=$T6VH7W.
M3GE.!"G^'F4GO._.C2"4$?@0PU]YW85\PDBTE',@&0M!3;Q&KR*Z)W4E!X%(
M:!]UR,85E\'?NON]4PA#YHC<ECR'"+SA?]'DT:^*F=Z42G$1JXD^\4+J2]A]
M6$[#8ZN=AW1-X_K!S+0#M-*GHL*$,JYG9I1NNK9QIG%H1>^46D*Y2/34L=>Z
MOB**APWGA.WEN.+LW_H5.3P&K6I$\TN5L^YK;LQFJ2"#TDO_AEAF0O9!Q5O?
M6=DVT_P:TF*A=FFDJZ 0'[P(C.[A\4CF)'"7]'-^^^:&0F3'XL;9>Q2WW(:<
M.V?@-$]<Y7X:<,R([>P$U13Z;Y^CL?D57?AUZ383YBRZD4$^-TSC4-[A? W(
M<'305_U-P^D6SHDGCZ/Q8S8[CZI)#ILJP8]A_F:Z/)W",/3'<MX2$UN-28%F
M(!G6/:%12[I T?KWY(Z].RV#3/ANR@X03JPAPRW+>EL=R,\:7YKKEL8,Z2J7
M5&H;K)P*A-?EYN!V&Y)%/H-'DX86X,9-W#;$%+.Z"*'[AB."W:$&"73(O'3X
M/$683#@%OTBYNH.IA4Z  CQ_ZEV-E/WHGADBNIZ,AP6XSAZ(7FS<&E7"_ZCH
M\9(G':<'=U4"-6*/YCYIB![NJ]_^\P*_4$(0FKN^5?:##ZJ: #,X 2(J'O7C
M*)C6V"V@_B*KSN66#[+Q\^G2^%D:/Q^PGNE,"0P0.M00Z#>)62'MI&3HWRA[
M4%++1%F<>@IZTFF%WG6MK_(*9T393I:A,X_I+B>CDDR'8^F$#H']$-.(@R[C
MDT5_R07Y5NE$S*-X,^\&Z^*2>>/ R?</G'+W%<?]/+?6UIB;2S \8O[@"8P'
MR;+O*+W\\2L.PA!QM8=]>!]65<&;FQ(J'?$*,+@P_$7X$'>9F*O*TE.Y8EB
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M-,([%B#(%K/GG6.-9;"X.K6< JX-:R<909T;-5Z]0906Y<I.J-DKXP,XZ#;
MY1\3 Z(!!^)C*87"B^8J-L$)FB0Y+ =(U&S.RN(>G:]OJ^WLPP:B%9/7#[KE
MHF;M<E7*6V->94^.,%\?;>8!T9#05+A=ZWAL$LO)>'!+WM0F?4V_P%+-%B9,
M=FR=-$=8K(A1_<GC+[_241HPK)]_N?K1&] 9/G7^Y?WX][\0MCZ<;#)BA,D_
M'25@ICXL7?C5#7=4-V4'3R\JQA="HB=Z.U.KG#A7[N<FNP,3;T=_Y)/S>6>#
MD'3@ZN0<F/IPG+">\:K<892$/L?W#I]D9Q%!EEL9@Y*GZDACE08#,9PASXX9
MC7+BK+LO$553U>4AD7'9"<NDC')8'9[B I\(/3F%O"6K=N[XR S+1[/XI)U*
MZI[V(K%D%0VVRFI@TS.O0%45=51<Y'\FNH%+F=4S<4HY/##$&:E&.A[<S_N!
MTYPX2R3JFXW@1M'>!H#S]+JEH_#D  _^?>2U[^VUNJP4'E[<''(WD#HE1$6'
MCA:B(A!-7[@$SB9Y\4;D+UE5E+:%B3;$O1B#FES\&"?[N !\Y?,WKS.9/E5+
M.%N]#LZ9.8! ];??,^$B*![7F&VX(;('7%M_6S/L<+:$/(ZV4DZ*FBR.:H+0
M1S>BI?''[^>&?C_"CJ&,; I?X;L$HQ/M7LTQKFDV^B;L7N+:B [MR$D/_@B>
M'+P'%31V ;AD-LP,HQ=ET@[\#@S+C]T* 7UI"AO!Z7),RG$^#:Y]&[Y?O(,:
MNR@L'\)/%,%Q!H_9U.IP.F*Y-2@_"4>^*C L)\D#PGWQWE@/#.-1QYQ<25E[
M\K(X#-"K.'PBG8RS&#E[=Z3)]^CUQF5\G@4&T9CS9?._>W78D=(V9O";.%3E
M+\MGV3K5.5;Z4YD:M).(R329,$KH=T[H@,+I2=77(JQQU2Z9)9UPG:!.:?G,
MG!!<"5E3\G9TEV.D,E^1EBTF.=G-Z+S3:,'  =4G3,?YAKB.<WDO.)[+MI"/
MUO)G>1^=1I8?) G*%TL?>NE#/U02E'04U@HJS#FWK_*UAG83>]J/["$_/D4K
MR-RS<DC17USE$ERX7=X.<V\'P@.+9!H,F3M&M!A"42*;M'K<?*,V;W&F\ FK
M<>6)XO'W(?0-:=^:<V#[U2H_U.NKB 0<''?"Y[EM<%_\J.%8.R!X,V#JSV=O
MSKA';*4P33F$=_"B2,7".3'YG4DIWB.&_27[*.8$E(/0R:^CI%KS5G*$B7K=
M1/8S3!:DQ'&BF)926$+P?9"1%')"\WTPO;]6XK5TIFPQOT%5_K>NZ=[A)9^D
MI\U;H\1F)HQZDRX:GL9JYW,EIXR)F".3D1.&<&Q!'-05[Y@KG:E\W?@]22O=
M5^I-!=KOOWKTY/$YU@!_?#+766+=!EF50O<SI (FUZ&-5'5UC+Z#EUF_A?IP
M^-95>4'""1F3V6GL9A_U_'^<!$S05,H-G2@,QOOD&W.<F+?]:NG9(:93]ANS
MI?!')K.TC66=Y<A*H*2@<;]N/#'3C#D5[X+?EO/+[$I9DCQ1[$72T^E%NJNS
MOJ1.#VAU<7I^P!-*CULB:V'@OF[>%@G?0NS/'D_8Q=3)Q'TEDKG(MP7U!POB
MBLK7QVS$TQR>CU/S<"C;S>3A*1/&FO&"G87 )MY*VIQ-A2\FN0Y4G4'<G;$Y
MN=6V-<6*,T&%FL;)8_D.!L!5 J*_EJ1".P#J;G*E.@.-6GQ)JFB@9+%VY/-V
M#LEY8WPWGI&IE0]4E'W%P\:9;G5?)!5_D]RMZIH5*U((0:PX[VFZM/'">FY<
M;NL-"4<ENKOF(L^QZ)DD*&'PBIL\#DO\RAV&PN)4>US[][<YHJG'-?ZP0SWK
MZZ2XRM$>$6+ON)(E%8&Q/[NOVN+VM_)E\JQ:!Y V4[KEQ--Q6<;Y.^6#OL5G
M96.G%=T55Y?XIZCN>]4T''.98<^]RU,&8(<C'7Q&AJ3:G_\%[^Y7161_*2X9
MX>=(8B(I-=&]@VR&L"/-(V,\)D<\GLTL[4C8Y#LJ_3+JR G]ZJ#GB0$5T#?R
M/:7R*@ZG<%_L/*X9+UX9S%SCITAXT&8P7#/]=5FS%([41VH@Y3O&&_$%-D%Z
M0<^FFQ(&#5^6>%,)K.>BMKO</H["J=\0^%&,\<U'#+4BY(2DCQ@^+:'&@ZG@
M)NM?9*8FO]=08V!(M1Z!KZSI4C/Q'^_RJ"SFP[[AP4Y27BQ61/^U*:AO,-]A
MNMO"^EZZ/*V1YET+A0C"+CJ"XZWTH!'L@CEU: &@<8'85'"^7E'PJN$%:Y0X
M?AU%L\=J6H"]C?=RV47*)K1"UE5>[ERX>])BZ>N'FMQW9DFZ@4$:4:LP6ESE
M.AWKOF6G>.KT"'?,5FA7<8U$G\F7FSU2+F4T'0G <?!I[2/N%+6 %B"B8X$K
ML:_I9?4]F_ J]R0"W=%=6@."!2%[WV+K&/8C&V+\7E(U+<('5<5EV<G(5F-G
MM8!84/\G@V(XY$#)RC*\]BXH.'H;?- A.!.-ZTF&.'$_-W083Q+JL;:>]7#H
M66DE#KA.N"0Y]LRWWP90N>$*D2_"]A;X&W4>:@/(%G+0U,E9DSDQ(V+@DU<5
M[I-:%@9AHK5FWP?%!"8/%*(U**C 6^[V><F6-B1D\RMK<(1Y-<II/].-G,9S
MQ@C3W65IF<@A&R5]%1I'LF.Z8<T?3>B*[L;?]N_?X/QA>CT<5W8>53 0G,1#
M<7AJS!U;B9-R*VM^&]<ENZO*MP4K0!P)#6U_GVZ^G+P"&J0M]C,">C-,L3EZ
MCQ]B1^KSQTM':NE(/=2.%#FLNJD?^2A+@"WCJ*ODT7@__90$QQ.AYHA^DRO9
M4Q&H E6&7H20*2B:G(QN+\IFT*\*+O+040-L,A"\A(!/FX)%X]F8K?@\)=)S
MI9Q(H")IT./.[HU)>*) 5W"-KXEI^1"8V7'_(^IY=NLV/$*M-QZ/1OG$ .)I
M1+H3M=S?1S_RUS8[W(GKRG@2#LK$$S0(%#,+\.E\=\FU+AZ,<.9K@=!CL N#
M.)?TSJ^;BO1F],GHY=4-0>2F.J.J7A<;'/EJ7^X+92V?*11$4;7]H>T.CNES
M(+IZ<MW<B-;[.@V&<X=+HA80XG81;2OB&YW)3'0Z"(IZ<V7IR<=A>%4D!J>=
M,Z"/YER)$I)#UUECN>-^A)'N GT9?,?"C?L'G<^<3@GR8#([V$+4G(S*K1AH
M8W 992*4\X(]\M0&6P;4%ZN+5N=J-TD/V8V;=PKE#@>0'/-1T7XB);[H&I)Y
M)(M$RRSO(3-+D>9B>HOI1=*_4U;D6G@F]1!.31C4A4S[:0F1)(< B"TZS-I\
M]B5-614"$U?80#B.(5*%='+Q@HLIWM44@_UA"F[+@PLKDGREJ;E@(U>$(^A%
MMX?20DHH_)!]%O[U';52I&XNW753[J2)._&O F6(@_.0<%H=:BIN54>!M%@*
MS(T)#Z*;R,L05,Y-O"];8-D"=]\"&IA&T@;*8ZBZ(=@BJJ:K0J!IH%##Y+C;
MAU>\>-S%W 9L-.*11%9XWOZ\?%?7Q(ZFMDLVPP*#"BX.+L/ZAJ0?C.XF)>KT
MSA?#7 PS&N;MEBB.<)WOM2K/^$#^M&$]%9ORCP--VB, R!D S"<P?9>JJ\Q\
MTM.DPY?ACP_(&!\OMGC_3M*5_$-2<W63'^_@,(.GNPJ7XHKUOBK>(1+<E%1"
MHL8$01;RZ_(2DPR^P$W#GL&M-CN>B_G0^+^^=J,,=U#^&S3[$3J?K$U+O,T5
M-\>BX;^V%8HNE,0QFEH7*0(]> RET"IK&K!B'M_!4+T_U/Q\O<ZZABT8(9"#
MN2R=KW&%Q.0U0XAF72CZC\O1IQ^]OVI!IC9$3$BY_:'U>4AYDY@Z#JUI8R9E
M4VE1W#))FR#,\4:U4Q"\/^Z-&'OJR3)8"DXW\%MX)<!9Q[$@Q;+;R#-+,>?6
M.T0"6%XUS48HUW[K!3\-]?B;!F *R-TVZT.7-,UD<6A8;\UD0[Y"?=)586$<
MP!KH8QM52=3<6?TYV$-1,P-.>(DA+"33M8%U^P7!;Q<=SNM=43"8*B*(6)M5
M"8>FT#G3[_JZE*,[4D%I3LZJ%?I:IQ2=,Z8V$,("K&7P3@WCB*C_"KLLN867
M2$&["8AI:Q.HMF9>9G 5;&BO>KDH5:AE^8?0=R04.E59A[OLKE9 7V/T$H4S
M\257IWQ$)&]#BYO?F+2G1:RC.>858?K\T"8TZCN>4>#-$!;" <1XXD UM)J#
M3HOPH!&+U3;570!=_"A,RT4@33ALHH#D(2C>Z<I*P]+#?().8*YD"'6R96BC
M]-X5: S)S48>H8V3)&I?L6O_<JL,EA' ;ICX#W6 _O/S!:ZTP)4>*EQIRB_B
M^&%9ZK1P<2* R'X)EH3\OW<! \'F$!JP3Q2P+,W2[$*2D\YE1/!'+F%0//ET
M21]2S+;-U^E0M9%:4^6= -Q\<%R4C4/GP_6F<"RCPLKLR04'C$R P<$(CJFC
M7K0RG6AG/9, QS+GO<WV_70:;59VKHWP3VZ% 8'3%<G: 3 3 A@J2]0A]<&+
MQ\$W;/VZ9&%RDIC1SIC/,B"=P12DR:##)1B:['O4V;#D_),.ON]^G*$R%##]
MG8#/&$)1Q/W\VS5J1WKVQ"K<AW  (]*8NQ 6* 198%GN]2]44DS.?N*W*?N#
MQ(JOW-"4?PX$*0FWH@5:MODR1BP9T[/]$,?+D;"K(E?3SH<?X4>V6Z&H#/9=
M\MR'ZP$!\9X.##NB1)G>K:I'?AV9'2SXM74Q'(C8);FB?VR6_-:60%<4;U$-
M0P>6;*>721[ZQ1@*#B,_6K)UN3? /<60!:/=.5@LW70PW<=@1@<-LQ2V=K9Z
MLR,J.YAC6,7J&#P43<+%EV_3LQ8?7TR[(<RV1%=/_;AQL$M##/ZQ$+/C1:;F
M:K]_MOK&_?6LB=I=EO4UT;1=%?EUR2U!*B963$FA\)_CR%;"<C':KX^4X9VD
M4R'<T(QJXC-N(&67\^3G*<91\QN" 0E[I2 S%G@;097XZ/%XVM/^7!Q>Y-)2
M9"V-7W$J';--+L2NFYKBSS87#?K!/L7XN_E'IJ\2Q*NV>/.8#3)@$>42NVD7
M'A Y7KA/1[63H)B) D9<P(AFEK-*&6.G]ZJ"3KS%XH./W'6PII+OLY+1;9F2
M\Y9(QEJ#F-Q(4G@Y$KZ/M9))$EHGYFFT'QUFXB+OPGD#$KD&9S ]7Q3^C.<!
MWH>=G1D&@MM,_CI<9!CW; PE1*5P[*J\/C%LXR%*-,D1EJ<GUKPA37U7K#'_
M/G)"?IZO+AS%P6"_8.)M^"H3NDM":Q<\*+UZ6QP3%0X%=<8FO8S.GIXW\G.L
M)XCMXW2USEOW#?D MJT,R;O]AQ<>"9<-WC,3VJ(14?8]!3IO)$EF(J:;6V+!
M8, O7OW5$P +5:(Z2SU OP^+O#Z&&/S?_\?YL\=?OJS79]GJKU^]7/TU^$R*
MD9-_>-5L".^6_-V;/X?/OBN_*^KTH^%EO>6_^/=\M_^2__BB"?_T796_:][L
MPF;\$\#2^VJ-97Z]#0O3NJO0V3J<3B!+_/[U7\^?_4\9TNSB:HRBX?'S_JD,
M9\!K.$]BD?FNK(B13UB_,AJ^"L^2/O3+-\_E&^IN._[GK\[^>B:</JZ2PU[F
MQP(#F^$_!U_UCT</_579_(6VT.KY=Y$Y)CR0D2I.S"'.V3V3 R0N5+F_IL90
M#0:F#LK/5/(>Q-">CC[S=:3*8M-X(+P]-=N01DA^9BV^51=H)EQ+/, "&K$A
MCMV!QS.(5U"U2*O8?9,%Q]50N!3> Q442ZLRT5]>-!L.CXG MP!(;DT#W([F
MA1[ZL//E*;T: C$Z"CU5!&TW<"(EMGF_C"<#E'1)32YVW3X'WE<YC ZV<P=%
M$1ZB!A43)U1*91<WGYP6P<6&K^K5HF@(JJ-AFP2KYZEC)=_9%?U5LTE9W76R
M>G)P%XFIN[!<U6:A:))X_D"F<06KUU,.T5[/2@LXRATULG79K@^[#@\8S/RA
MU E>QMD3.^% %'X@PEDP<R$F#^?J94XY6W@NJ^:'/4757M>TTVOHIC#FX5B>
M9X_Q'A/!OVM;!D<#*,REBXB)DF9JE081+:)8&[O5X;&3/" (8_07$7QK9(M?
M9=\^.Y7>#9B$(RM+1P"><O:GU_F!FST@<J:Y^O*:WPW_2UG__= >]0-;JAA+
M&A<GVJF-)#6U#>?"PV<?$=7$1+IAA2R>GDLZ'W%UA6M!S S%#$H\+W7^?1L<
M/XLN@3LH^27W+YN"HAXZO;4_3'(+>0M[VU!>B6I);!F[=(Q.A<N*O#@Q>PO3
M<KQ#E"JI0![NG[1GD*?V3 ;&-^_&%\FS=J2Z7E!I9%,HZP%-=Q]V7!&RK-[U
M**1#G90YZ?&X#M<5F$'3K3FWBG?<L$P?]^OVZH?9.7FR=$Z6SLE#[9P@SG?3
MM=C^G;($&G3&)7>Q+R$E2\WKK*QS1CE'WFXJ28V9'J8M.<X!#<^!DH=#3X2K
MV;1?ML+1,F#Y!T73-2"=<FPZ=Z#06;#!BP5%"U)ZL8TG_9DO5@YF=1(^H,6P
M%L/R,M'[0Z\M3Z9K7 QD,1!'#E#V5YLVO^$:Z8#[CMN29;BE7IDXDE-.2,4&
M-%N+@2T&%@VL))BIY<O<CRRU?G%QC-7ZQ6X6NTGX([I>I+]1YY'B.%KO5*EA
M$UIL9K$9/V*W8;@5.YN8\DO;KH-6H,'WK ZP6-%B1=&*?&%XU]2, PD14KMA
M(<QQ: 2%<59?7DQI,27'?2#I>UL0"(4Z$!9NPVJ4FG'0%@I?VS6J7:3$R"%>
M6HQK,:YH7%7#56M1"5N,8S&.:!S%NZO\T'DQCJC7&F5N-1)2R&B,B.B?'I!!
M/5[LZ=Y#ZV(-Z*'@GKLK%L F7>\/;)C_VXB!B#(&.N<9V3#'. *W<:8(-S#^
MS0"&"$8832B/FHB,C]C#C8N@,9!B T2X0QUX*0"3(QI"MMM]TS*V0I&6@*@_
MKT@P\!+LM9AJ&-3\[!E9<2,^\KXAZ1;"61"2 U^]SEM08PN>&_2T3JLRE6[+
MYU; S:CK/=4-$_&%]&U.DS"173(-"DRQQ7O6BP#V-LV#JHI-<4RN8<V6L%<%
M-^]?NJ/W$9(54BT$R0K V_0+> 2R!9JN(,^[8VEYY!",_\OIK;>]"%@T5"%C
M#'V^ZHJ^%\PAVCMA<0E.SD!4?IQ$Z59E_91^W#$8)B\P>37T0;K-3. NZ6ID
M?AOHV2 /Q*A@?J*(OH6<R&5;^/D4>G29=9ZQQA5MC?"P,FI-NW=71YD:W4,4
MZ-@$T_!#_I7:"4>@)!59[:X8?U2KN4$9[,&,*#['+BIX=(-I//*N:]9L$3R<
M;V.&"0B5AO):G6>KE&V=V Y:GA&+<YP/1U_K;P6#9PG.6A1OWP^L?5IG+GR,
MYDZ"K=%!*9!_)F/01BGO 33DW<"@MTCX$(*W_OT07L9&$J_,6$^\0QL(S":Z
M1O;*P@6)BB&$ R)HG>*P%]#('S2@(LZDHAVP""4*#5.6LR1YBPU%&SK4[-Z@
M^4PH7O9?X3S9;FFRI0V'X.HB;X/E8,K4IK-"3,&LA]3#;9M*9]IE9GC2'A?3
M6TS/U1>$S"T<JOE;UE#S0HM;5:&A:F9#_3H>N>WZF$MY@@MU=')9FYN@HN@I
MR_O0(-9/%XCU K'^I1#KQ<W^X=PL6#9+5!^0"O;YNVQ5A+]KCG0H9S056EXJ
M'QJ(,"B7P>P:ZBK\V2+<6U5>2WLIQ 77K B67[1-OEE.]L7DHLGI41Q,+<E4
M88"D*"P3??O\2,*W_+G%A!83&IL0LQZNCZLM#36S0C754E#K'8IL1_W 6#P!
MV6I7J  OLV!+O].G+,U%99C"<!UPHP$[UM!57,4L?$>4,I!1'Q>[7>PVK<F
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M??GUH_,OS$RS\,Z[D0!'L5'LKL 9@48T_@5@$4](=O@CF5]:8:!OTIQ6N,6
MQX%8['YKIS2[JB_KU=?%NMA=A/?[Y/'Y%\15R+3QI#=2UL8MV82]D%^7;3 )
MD:3*;!G)@72JC%(RH/IOAZN\#A^Y*NO\;/43X</YVUU8AGPCVZ<ZBLFN7I$H
M A,./WG\Y#%^]&]-&_; ]^QF?G!J!QB*R*GH86\RMW=)OQ9?O/XM4[<31KL&
MQGL7'N'04IX9]@&J?I1D-D1MQMN?T?8;\@..W(Q?<[8B\$!8B%:S4M*#HO^
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M?Y3'2INL_CIUC2KW?OA'O!Q<52Z]]&Q[^2Q(]P4JU<'P=J.#.E=*N/9U\/J
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MN .32XB9(]F5$$?9+%"P(:OC6@!LL#58<&CC)X/XD#V!BX<X!5#Q+:?MPYL
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MO*PGV*_SC2([K&+&M-F?Z2N78=\+:6MF""C;?2 ^#,Y6X8^TKXOP38:MU?@
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M(_94SMW/PG802EH)=!:)L!:H<)P$2@$"X"[F^<P\!U#&\TJ*.U61#SS!X,;
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MZZ8Y""@G.AR61UE:O>G6CWQO&/BY4?(K1WEODM6DW#=H=AE')3QV&T#4G$*
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M)XI'N# )+1/"ADW!_=UFZR+#\F5SO&U<&ML278?PDOU@"39 3BBW==WL#I!
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MS\+$]M/QS]LV!([>D51GF%V^XQ#^MS%8/3Z&L29?^+CQ?_Q%3TV$3F3Q)$S
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M:#1-5 K]?2PS;(RZ4=R(M:&*"X +R,P4R,!G]/6"8(]+6.XR[0BF=B)"$8"
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MGUUC&J5FV='^V?$A(E_'(/IOX832NQA1>.4L($\*I1XY,&PV*>F--;%&&40
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MSPW6.Z1?75HB%ZN/FW4=8:)Y)R_I%KUN6"J(E8LH/4W3IWK>"FNW5SV%\XX
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M6>]X)%]%XB6IKU0QE$[9_[KFJN?S98N8E@BM;!R4"^;3^7@X&S5D!FQ)Q0(
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MIZZ*2Z5^E$J].%5Y",'"Y_$:'149NW7$9V936%<?[,4B<SVYGF7)8%@A9*B
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M0/)+#2R4%Z B_RWT6TPHHLC3,"0,:3FX34&]7FGVD=@]+BC]N#LR'9S%S<(
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M4@S:SDBB94'[!/N*T.36BT^IJ4%1W&.D@Z4H1A)O8#?V$GRFK6IB*-.$2WA
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MJ!L:0&020&UEAFC;(%^W:MC#<AJ4$.D0RKFAE.NIJ++,UC@OE#^QJ4:NDH8
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MR%[JFWH,O$I5#)[CUZG''VXGN4-1ECES/J=R9,FSPTM2F&R,E=*+$?++H_H
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MK$O,20#$8-:1FT0K9#.Y2;T[PQ--^1".:R4 &B0,B^(.>[X_>F&J=2JB(I8
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MD-KB;X4S8E$)%.,![_I^VZ7;A.ZU3SN+WX?7"ACE5*M'WAM9/W=L,T:6V(;
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M:^'U&.VUU:>1M5^QZL"N)8R_X5083C8N5Z@V:0>6AM3D(I7IM.!$6<3@%D6
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M)R-]DL$?A&4^/!S?=9EI9K^"40#OF> +0"K DJ;8$N:\YEP&FG$]##?#@T5
MI8T\(X<"!4>!.3EG39II!;K@QU(6!'\,C_WSKZ];D-9H9'/Q1K [AZ<X)5_B
M:;@A<96EJ6IMB^NG4"<T?*=#D92F(D8=1Z+NF4GP+WP,)-;N?=-KJ^"OMD[X
MVR+#C7Y[94"310KK(KNKY+73:9=>R4=O\%Y"/I&6\6"/-&TK=G%*R1J6.E6.
MO3,2D$UE?/-*GVC/'>,:FI>:J.>V&Y]QS8V@\ &T U95;.!=W:L;>E_W\.G8
M3$_.YG,PX\[&[PZ3V0SN87/Z;AX?GITN#@_CHZ/[M>WZO>6^X&3/W?OZ_,WO
M+,\O7U)*?_KLU>^__/1F]/*WGU^]^?7\]Y>O?O-F]S<L-GKMNM#>'1Q-CDX_
M\WRNMQPDA1B8#S3,D3?.+Y=K>-E* $\G<$"\!D_PW]8,46XO]M<Q!@Y'OQ4R
MAX/IY/1H?!AIV.RGUR.IMH"?RJ<U>WN% ")EG->.<N$/SEU+H282AES&J '^
MTF1.MX^YTK!2A%["F0''!T&@$D7 _\<22:"YG\V&U?"-F$!V>AGS V0]8#GB
M,LY0\8]>E/NC/^"BS^+16S!6\G^;3%BS0UXW/-.9K(S2GR$/)B*CH ?M\=BE
M-8*8<_7\FM<,)I" JIG+]*6RG(.,S$69QU27CZJ^QD+(3K%E12^W%>S4+G2A
MK+%4A*BJL:<#D(M'N8.W]QU^' :?3UVNB!%, ^AYXB\_[L'-0D.CO[*ZY@6G
M0"<%K49<I%,9W71_@S2!VA:P5WP=/_WI]:OO<<S6A!&QBYS,PGU7LW2L97%U
MN^#+MO3'>RE6LU?\=BR,Q1P]55E+&3#64:S!7.4<*DD-G"+.OV/E<[W43N4&
M8P=<C*!-7;BQ99SYW:\^,3@]J4H_$!XM,J;S\Q[BW3!=)"8^'H_?G1U,#]\=
M3N9G[V)SEKP[6LR/P%:=SPX.9H&/]BO,YRT!.[YP8;9W9V<GAP>3W2O=PT#I
MXEA'/-B1-]HO2/+T&T+DV\CW@Q* 1Y>S/!MRED/.\F-SEJ+N%@>')[/X^.#=
MX=%!#'_$I^_BP^/INX.#>)9,)@='QX='#\L4'KU\Z>EK)O&#&_<-HT1@T\-S
M"FZ_.SL\.3OX7#':3D[KQH#M4:B)79#>C?P__^/@#.YL'O_H)W#1$%#IC;2W
MO/4J47_%BBMIGWF)-WDY>BW>.7FE_%V*_5XW,"S.:IC:\)[CQ'>XK)Y+FNRE
MUP7SQB:\T'SX73(;6(P,]I6L#ZW';HH!7W5J+F&$%GR=*G(V*YBV9HU_>?7J
MKY:*/B?K6*@H_YP5,[";WE()D5)2<M@$V\*PNIBR'5B/A._ _#JFX3T'9G+J
MZ+G/]L&E2IE$B^Q=+''2K-$5V>N:/KDF373OJ>/;"<(O)-O5[K89D7OI];]B
M$%<,*&=R3^U"&FYF\.)1"US#I9L HAN5%!RMEG'I($K\958',2F,.%+";N?5
MG'-7Y]6R6.F#,.1#I;UP9$2\\@)YE8V5L-)6*]1@O-?Z<_0")11T5=QFL,\S
M!!D\#V7C/FU%6?K):<>ZN59MO<"^7),G7Y!=<QM7%&60F1-GPR3<B0Y.89<"
M1<&G%_]8V^"CX",CW#P1[U ? ;=J!L]3>O("TPR&X?^9JGPWY]5='J-S!_^"
M\HI7$E4+<5DGWT9XH%V=[NLLSJO=[-WO+2P56Z\PVXSXJJ;.&(P23,9[?_6K
M+W@B0<$Q!JBI<Q@V57%W0'V#BD B.0R(+N#O4CK%J5LJ37F-(8V7+VUUZ#EG
MP=]06GU'._K&H D&'J+4<F)6V?*Z^[;"+K;MOK.Z=_&GMYI8WJH(9ZG:8]1I
MI6T7B?UN>>^KQ[;S/YL*.^0_;D'%&9C,CHY/S/3XG3D^/7QW>'IP]BZ.C\V[
MP_G!>'(X.YV?C,=![..M5#[;+K(7<1UC5/WL=+S35/5Q8&SK,+UN-QSH%PD^
M(-Y\%F]^2/,,[NB]60:W0+!)+I9 VX7+1I[>&X,MU/>+PW9?0;+Y/$D.9R>G
M[R:+R>F[P[&9OYN=S,R[TVF<',/-='1X>!8&R6Q38N6:$>&$:"OBN^/C,<C8
M[N-E)RTO[9I>2LD^YPG_1:?"_RH6_'\K<?Q/VV1IO]S?:?E9:S?O>%6Z[KLD
M[".-O3[2L,#W%NQS8&HZO)@X$>:&?TJKOZ-N0#"#(J/(^S5=L0H!D5-')YCF
M)N9,+D?$,</?>\^BC68O^OW16ZS/D[+1$/0Q@&*CE,:6I2@I:[^@1+C)*L/I
M>?W:]I=O@\,44G&J6]3\"9L<W)TJN1!UX]J0QHQ5>@7VRUY6%.^E&Z3V.[.5
M)(U1,QBU7TI7ZW;+A^TN6RCF1)L>3G[AK8*8K>*2O$'@_Y_Y0^J85 *(<_,6
M"20DH[:K7''=>9(2/X7B+&4;OR>8/PBK,2_3&6TCI>X0"R,EPR]2TWK;4K5$
MX!;'8D>VRJM+1-XP5ZVJK./#@Y/3\<&7K,JR-=M:!@5J".MF9FFQ1LB+>&X:
M1G?7"E(IDZ*32^T)<_) $1D1@2>I=2E>T[>\Q)Y ?UK0_MZ4HI34^)A$-7;=
M<K0% 9.I(W,DJ?8Y];1C\A%?;()D'NPW<VF_:N<R$8RQR/?\GW4@[4U^@<ZZ
MU$<+@&%9P,$57/&&Z370';PP^1Z>?.RG&#U_<?I_@^'IF"R*SK+ +^2P/J62
MF>-3F#>^OZ8DQ"T">P#+NN&+BP9/4&84D!HY'1L0B<?9WC4=#ZF2(57R4-N[
M1,4(X-%"Z#>7FXSPU[2A2!4?EN%A=4HE&'4-LKAO5PYTAK/*1Z.@8--\B8J
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M&>4AXM59"4;MDB8I?)08Y^'7-W.=($D7AD[I_301>#239AR=[I^&I!D^XDW
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M\''81C*-=<?P*SV;]2FKCB-E*XW#C.S9/SG<'W=NO;_$H.K*C=5!4[I7S^'
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M21O)(!$46K&<Q0J4E.G1&-,4DYSD[20\1=_A-QM$4+*@I_72$PV6) QL&W4
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M .8U3N*PQ.WGMC,PE!>!(1$86F]@Z!5JH-I/EJG0]-20>.,F]'-*/2=0S8O
M"PLM@%LNER[<QL6??8I%45(%@-$"5@4S+9FK4?<GRG@X@$^Y$5JZ3<26WT4(
M7.4W9*PHVRA_(I&#)G4[TD?!W)X)N4JM;XZHXDJ&" $1<YL[T=E V(&-R#9B
MDY8@-O:0A*C.X<.S^BVL4>.0@NLSR$.&R;*7O.*T88-,0J?W!R(9+#8:<>&A
M^(1O-?:0I*-]7!N94Q5/.\9FQ'9/5DE$ZQ\[]>11P_'B6Z3>@-07V&M@OFTM
M]L),"=PDDLS94%F*YB(P1P#<-&27A'+,66 !#1)[-K'@!-B85,?4GT/R-5A0
M"\X/?XZ@ROCJ.C#+&,X,/PDC%8E"H87N%*(\#-7Z$:0D&).EAL2G$D/2.&V#
M0E\_-/#1^GB)T^T<?3+P%3D6,>##AO, , D_%I(\WJ:%+S @ET)>"MDFGZ1'
M]6HPL'A3[-XSFLJROA&V' ^RN'H7$3"DIT:3@T?X$=MME*XQM>FL&L[R28H3
M>" YV"-EY0,*U2['ZO)F^2_')"+SM &%\'K!I&^3/FO,HN*0,'++I<OU8H:G
MOX<]8R@)5,,/@"N%^ ,$D$:F,??ONK0TRDQ/5XZ_24C1(F<6^21'$<L0\X$(
MX0$K8**#M'F5B4D +H35X4,6EN28ZC'2A7>0)W-78G1OH!MYD1/)C8(-8RF#
MN=BCUD;\Y<EG6G[*09EZZM@1)T- <2Q_YFU9DT<[<4GQJ<5YFE%YWO1]6'YL
MPD ^'4'W=.@Y:-[TA[F7Q=?[B 4>#5K<!4_@?G!,EBYT=\#?)XNA:Q@C(%*>
M%"3-QO&J4T;=J?'QK&R8-UK(2$S.>LP708H0*4<@'^L&>KJ&K9/)T%AA].A;
M/>HM!S=*VXY8U9FD@DET,6.9;F2CS<8MM=CO1.:G)XTHX'?X&WLH4>W0%E(G
M,94^)IHX[7: *0Z1BNAQ'S#X;%UF47*S#!@+:#+YJ['+X/?*#&$JE>CP;9["
M$:\F^E8RRIJT3TEE$7P=#M[W)^06EU!M<%^-=U!)'FKF#0V*X*_X6\EZ[!?*
MF5^$FV?D6[PM"0EH8![LA_WQ8R0B*L9$@",):L!Z*VL#B5/\.$UVKB<>>YUT
MPNTG8%0-0.MZE.CU+,<@!=) .NPJ"#MB(H1K-G/2S"]&E,-J[F)4SK],N@-0
M<#K72YKT35+J)Z 8TXO'::_E.J%/)=/TGC@9"6&-X8X0Q-L<U+: SEGUL446
MZ<-ODO6U(6%X/]TX)S,&S5/\ 2K5<TA\VJ<6 #893)?4C7?T#A6"X+H$))<$
MUM-WF\;; <WM'HM^PIOBU":BHN*$-ZE*FQ6D14['=4T_91;A5;50;+LRP<)<
MK?"5D/??>?&&)DS-\?8/B2"V9:;,R21]42N1FB-TO? )$]F0((<H:NFB67;.
M>EBH:D.]!?@SLGSID_0^7O7=Q@3(FT)X+@  JE;(<ZC.,?38T4U$>P1@7\ST
M850YR;>\+00<8N@P6 <5XU&(&.X0G_6( YQ$^7I.:J2]&)A'IIB3-(6#1 2C
MWQ&<S?5>3+/PCHAL$S8.&(')Y<_<,"/9<3LXLB=C>762 &43R7F>U>D0^FJ-
M9L;KZ#W0HGZ*3L;.^.5;F6FW1V1/Y2'SS23UVYI4U@T1JWM$K-828G5M09<^
M5N*DP,*VT_7L":"2U 7ZD 15.AC[,1<'UP?T&Z;EC=>1$!FH6QX'^LY$?@IY
M&DM!XB&!5".V1%,U&KYGRX@(@&3E^%80B3)&$IDXOS?F!/@";TXQTZ%&WD
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M&0JHLH " @HL# 74E34">S,4J![-  )[NH_L- Y@^6R20H% :3H04)?14TP
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MK@]NFOGB<F7>A.":R0[\S,O1D<?+6H$TFWQ]LE &[&>&) %5LLF@I'A&4C3
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M9@ B#WV?&BH7V.9D9@]'8@MP=1*P#2W;CA0V>(*!YO#GV3>!,%VIC=4+_D^
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M,, $_$+D&##8_?.%&R!)T;X(Z"T2LK>CP&)F@;,@7$&XFUQ),)-PA<4C@*$
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MZHJQSIU@/)M/\(=-A+]^W<_R'.V4<-3:/MYR[?Y V^WZ/0)#&!4[O 0"^CT
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M;@_C6+->@9#>L!HX^_92CQ8996F>B;**FS-4<>2@T8-GV' >I=.<LC1/<=_
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M6+9-M>,V,:%A&T+,YC32]JI:942U:%\-4P\8]JNNMW^Y,5Z9YE\$ "YC)P
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MGS\"870$"16OA3B"L31L1=EVJMPH-%AGH9)%_ -!#S#REEX00(F?)7 O;2<
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MRM;S8\ZZVZE[<(T;0X%O4 E5;\5[<9%C#GW_A4;+3X[>='TL6\I^@^3WJ\/
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M2G-5=A,D@>2^"+FZM=C4^E!/9?.YEA5@JU;H2G.:KFQ!-V-8Z6$BU2Q&+0-
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M1FXH:YNN4*?,78#3Q1S*@4'0MVV[,9CW[21*6+JC[KH!?ABWI#<XV]A5[.K
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M4.D=E=^_!H88VI_4*U"=DP4+YTF]FHZ1((]W\K+\P^'=V_64 Y8'.FN#SMI
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MCRGNYT5"$D<YDS(I?TW%0%]3,6JOVUX::[<N$R-[TA 6VW" +E08S?Z[_X+
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MXRZ%.-:6\X7:6NBJ/ MN>QN82UD$Y"KK%A"-B8Y'P1T.3\0J.Y)1-I@EEV$
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MZ^-MCX6,3GS[GDZ10T?B"5VB/2NT)TI<:2N+LK8NUTW.>AFNT#Q1MT?V.,&
M9L13Z4'=_'?FYF^!N:=1&^/0R#!-8P7?3SWXU&EP$RTHKJ\*?^7MI0Q^=0:_
M.XUV=R+5QWDP.G7UXL,H/2X5C0+'1UIEMEHK\,-JJCF,X3M8H^%8E#8JIWB_
M3R_XI\/]TF[P-\ ]T^"[TJS;J//]A_ES;KE\5%/3%8)[^MO/5)RE/<1IC]8
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MO@=E?K5ZAV^3:77JH5R]UJY7R_E,A\^'"N5:II8K9ZJA=@=^\,C7.NW0&Z3
M/@N?XDP!G^!"M";8C@F,,3P11HX%Q9UE06W%,"<"U .(%L*FXM_(AI*SO.9H
MD CBA[@0]MWY9#+UL>NRA\>3JVB,AC5C-%/FW390^K67WJRG3RTY 74> %62
M.1S"-AWP89 YVL[SFQ?]3G:.3-T]6T,>*7&&M)^8%SI1#Q2"LPB8"A"W+@)T
M\7OH+W2^L,P_[@/XM^@_<,9X%>X?<T2K</_X=TB&RPJ)\&A$.CO2%B9PP;(Q
MQX.+P,&Z?,C51:!2N@2J,<?M,7#>A:@*D#"04+*F.5!-F<*]GN-O6:$1U#@A
MP:#&@K+,36-NRL 6S U29'1A*9L._!@R,=)MX10%&TU& BCW#7[/-D(F@-^"
MJHY&ML&0\+2CR7\L\CH0LC86U&X^$OSOV BDIKGD#*T$"W>--N>&B34P> ("
M0GB$"D2A$M30Y;D0RLI0FQ.G8=_.[1Y6A97E\5T;J6[HESR$^@II?[(>*H"1
MZ4 BDF]#"R(9$M 6CAU5W42,%2*=Y8PL69(1J8_?&\H4OX?*>N@!TF\[2"J,
MW^BMAH3;)+QQ>/ICT]!>6P#<K+-LB5 #)XY/<?0@&(^!:#MH;>B=;B*/N^:9
M8\J6)!/+"['5EJ;P@_U)"N+"D5$1KJ"JWM?=>MR3JPY#-7IU]'E1&Y6^;R</
M&7 *!&D!*8RZH^.)(]X9&*82#JUD>QKB'93Y!<]6^"(HI.$0:(%S:&UY(')!
M@DLNC*WP.QZX)P-=%\*AC&/9IBS@7<E D*C;;4D?;(MJ6.ZNP%?92+V?.R,5
M2F\#TM1$J/1D0+E1WT(<;P#\#@2Q9B"=P! 5A'140!.R30&I/R&W@+DF6)*P
M"!558P1';P,5;E7H43 58/NX%,);@3]:&PT*U)!/[+CO_"1 'F 0;A[D_!F:
M,1(>LJ40D>U H]=$L624#>91 3&B8$+($)%'!!SZNTP(,2+\H4,E=@*'UB6T
M29LP8DC5010+PW/!1I992)4U&9/2"._M_6B#AP6V;!LF9DHD,;>C8EZ1==U8
M$@9!7YX#M% 1H.U0P"8$N<<R=!VH821 X5<]7/C%Z6Z>8?Q"549F/N'6B;$$
MIHZG8X*)HWJO0DMT8^>8%!8RW65KNCT*(IATB%C 1(9D!'L+0G#'G#&T_AW,
M;7 6(CP8 :'SP9@6$-$AZA4=H5-$F,NH]1+\X]A!9^D6'-]##=.0'+AS(AP)
M&[%PIQP3'A2VNG$YST_;E0Q!;P(L 7"VM#R&L_;5. GJ/D#]7X82R#!MR[>9
M(<AD0+>@.K6'9$P"[Q<X)9Q@B#YT:6F@PVP.J;!$4#1E PNX'=%</>%[J(--
M=/>]I^>MD6HLN+?'% O#S^!WD,C<<H0K5\>F !G3$;'"@LN]MBO9\4($GJ3P
MS6CV<,1M9B1^7A,VF(L=U98U^ 9(;JA\XO-7@']$R,>K]I:YSQ;N"O&T$3N@
M/?P>XI< GOICO_#:GMR2Z4Q.[09V;UB.B!@*'F9P<[ ^L 4O&@^]>S4%^IY4
M=%D!S66?I"9\B>ZXAY<[MY %N=CZ//FT9X;]@9M@3UF_O.[>WI'1S62&/- P
MX%$#V:8#WY55X2&RU>?KPV57Y"4KJW"MI;04]&(QSS>)'U2&6R!E[%>>&Z+'
MHM?7_EE7^V\[FN;J3GL(W1(B-'<I@??FTGN1%2S9JH\/]F%#_CW>B\>)D&T^
M=5]T7NLZK>1ZL7BIBQ>UK8AC <DI67P/O?'"R&$&I:-N7]&FZIP05+]TJ(:F
M I2R(P#E$5S!7'#5.O@]9-&@4Q ?P7Z^@:>F*,^A! I-@ X//ZBSH[^#N4V^
MB^0:"C/ W[#VC\F3P9PE;'6[8B;3\)0[?+3L.XM_/6]R[!'U>UL&;(SWM6M7
M:5Q-#33)0\/B>RBCJN2^3G&KC[LC85W %'2+1 G\= )(5](%>TLI=Z;HD/Q4
M08?#)44#TBMGH!-&?QU4EM8I=,7:0E2T5*J7G46XHC.8' NXT\]=7L#]+@0Q
M!= J$ FN [VVC)15],_\R,;;8G'7BY,P$^(<V4)L!"$%QY95+*ZA<H2A!]=T
M5OE#>@TZ>M!+(;/NU'&H%H0.S0E;QER.Y^0?9#[%*6AP:/@#5I\P>^_4I<.A
MT6L1(M$K3,.93*%1+P)M!$QRYL2B8<_J8Z/[5A]Z U*77<O/9U%B\8)U<"!9
M1,W!Z@TBA=_8"_L_QIT3Y(,V5@=/^7I=O?H%$<H&8>1:YY@<D/^0]HD4QHD)
MB+P)AR90&KB" 3YM&BOX@.5J]4NX>X9C^9XGZX(;"5E8]RQ<1 $R++2/\%Z]
MQCB8:/!/#IZMB2P1;+!  QI:*W[%7X>&+?D4+?S?P4O&2KPC@[H&;')#2Q6N
MZ+B*E"/RK":8YG 1;Q>BI2&(*^Q8?N3U9;Q7V62^_4PFOA]72Q#6A*) Q82^
M-)5^(]'E0E1BGC.S8;,X+?':L%)KZM-5@]M,OOV,Q[\?YZ;M40DS^X4)]3NY
M!!<BU% RAT*VLW$8K?.@;YH/YF2LK2"A8M^/LW_V"35V'=0;**^M$,""[E7A
MB'@"DY=XR*"DGR/'")3.2"VQB,?TS<)50C%UJ+LX&K+H 3HLH,(OVY<0!QEK
M6!_[\3];S(NUS$SK,IMZ7.]DQV8]H31_>\-:@)1,\(*I(Q&;V2TK3U;U^BZN
MI=PXV5@537ZA/C;SK:S4FD%Q])-EV>_'/7/VMG'_[$3]8T3;(MX0HB*AGXG2
MBYS:NW)-(GO=,Q8)?0L ?/*,'>33\';T$1WF[B[&=]O)DNT<0Q,:#B:Y#G-[
M"@_OC*X[4.]M8=<'<J@5(!G)%Z-,I++/!]L)XS $<I:B9N#8UX%^0 Z;)207
M/LUL8P)0H(.<4]C%#P^1_7,8?;IURL+%^:>/9^TYS-"YACQ"(H ,[ \;M #6
MV"4X1?\AF_&.2?+VHHR<->$0"A6BV(EHRB/XG1'45%;AT,IP5/0+5-S':/M=
M_0<[WWRZ!/9_D;+D\-9)AS^19.Q7<AU6Y'0F"M7(#D'5;PF/>]1 B/S%=E4;
M2$*4A(_4/)='( ],?921+<O!&MANP]Z0P'+:0CCZ_=8R*CB:44$S*FA&Q8=E
M5/RU-<K__I#D"BA?W!&)!'[5Y^F9^N_P?++GW_&J.^':$6]D&L.S6O''*SPK
MS1_OA;((FN$RKM7:6=!GP@@X? <)?V"+[UY&SDOOI!D[)CZ)T?ED;W:7=^!@
M&CRB_!_L&:OP=\M&JL@$VI:"2L(D7D#$->+#Z(X0&QZH#IF;Z;=N31.%K<FY
MM#=5+YXR0L$P%:L]I'.%[VH10W>]?N0)8&IP/G!\>'#"N>R4@U?&Q*A!#CCC
M8&%H')R'<6*.^$TX5J/[B(6'%R34:!%%?P0<G\?OGT*L8E/=5=&Q1#]T%6Z=
M--@I@+X"!_H>*N_[$W$HYY @A%L.@MR>S@)U09'D@4@0C1NDZ$L."HV:.S=B
MR$+W="/*D1P &4?7SGA^W&02*[P-!B'-< QU#@-I.X)NN=M\S)?;B.%J*L.1
MR1R/2(;>ODT6@N_ =LEG!9M.8?6=?N$3_FP!:FK8GX85XZ.PVU:YQSDH$[\W
M<4<KR*D:RO-!7C#$1& _;$CJ.#V6A[_8Y(X>]$=?&Y>MQ)!MSXM-=&]\UJ(M
M@7N!ON/M &'Y7Z]:,C"VX$F/DQVP*UN:.9;[&G(4( H8[O1%%%/W MTD1 P7
M@<-$!XMR8>/%=D\_ZU\CIK*&4(80H ,4#$6A*/D5,+VR!SN-V7^Z7#YDU;5
M?<Q;)*"\2_MKVTY/S.J+&*/U6FW-67+I:3L31+]XE[ 2\)9P/0@3)&Z9Y4P\
MYRCHA&)$GMEFH:P-@1P$B&$T00&[I9&^KPCF<W)^8![T'0(D=P#) E^*P@ZT
M/O8E@GS_8BW">!-\Y)_\4LB5*WY3\.0J/0EQ:CYNJ!\[=M&)0!(AB$D;DDBR
MRNZ[.!0'-\>0L!MY%^(]3Q17.FRC=&\IN/#B;"13"*4W'&8+>?)DHLO>!GM)
M"R2[ RTF[,7I3.3.P(^<RVOQ5HS^X 88R4HD*,-EK/"@Q)"=L6\3#D/1U]!2
M4!V\ Z2 'I_UZ%=G5VQ/1+")/&X&4?2.=A^-LN56K!%$2!XHRF"4=KNX]YR;
MZ8/_B&]B<W]7#7@H>PV*]]4L-*B%3]S=IL'!IG"5AHGS== J31EE4X5#BFZL
MX+[!0=TI$ V)J'H1=$XC%MBI3E#H@R7B")3KA)*W7+\0<JS(D.+8LS7"9YEE
M$$F\\]R(LBDZ&N0#I%)^#]61+QC.C4CF$0IZA_V(!(041ZL1\'&)LGI,+TN2
M0-T_?!C/T-HR/%GP]]!U!%9]S]$5];E=&<(=?<.$BE,):@!01M5]J=1NWB]Q
M>-5[Y7PDFG8/-)**"#== IHL'G#!=CNF@&0^V5OMU!O%^Z8O=W@.:>9E/!YJ
ML9[Z@!W+CDKDBR_HABB]0[N(<( 7@").6'?"24I[RA'A%<F445K4"*GS2/TF
MG 59P;#PI(FZA#9[!#;&O@7@3TJP3<-%]2[7#OE-1<&ROX>R\+^.Y4E2"^QG
M/QZHVH*.))+'<E#=7T'((?L$&VXKQ/,N4;&@< E)5N=2<3\DN;<[ONCM-@/B
MO(1%1HB7"[Q$2(),B=B="!L+4W''&2YYW"]L;08TM"GCO$K7?[P3])FMX>(=
M-5LWY-N+Z,*'>A@B($G.=LVJK3!!@MS&YH0/L$20$+^LEP;H'Q$NTIGC^6TI
M%0[-'&E"3A0#B::E;+FIT]#"PZK]5G1CY76K>_J$,UP^RKE6MTR-R"W)R$/M
MN64-RZ\5()MJMSN?FYSAJ9$%$@+.X=- W'1\.2497<*_N@FMY_(V-B:;B60R
M([9;E)N3I_QFL1Y))_(V3C\7W+P-ES+NP2FZ9HCWB[VCS/445VC<BUX6JS<Q
M+]3GP\]QQI.$W!FF/T#RJW'^]U^Q]#\'J4I>^L N92E\,O<_[$T".*9Q)5,]
M<UHQ/E'%@&:,CPAOB[%""H7&*1)N5>MMMU0<>Y-UMP3#.P'A\8I%DS4%P':S
M5$C<%TIWH%G[VO3!V]U7",@DGIQ_E4\')P+Y.YRRF[0K^1DV-(%'E4L+$AH4
M3*(DFQ+V1Z!R)1+41*JL_YL[J]WS/<A;'7R;79?S2_CV3E>'Q&[MLEYROJR7
MQC;KI4VR7E[Y(YYWV^<'PZP9XHE[\B\W"/NWNPS(O8;NJBR^4*VK@Z(_FV#J
M)G,C8D A[G-,$#O-1(<!EN#[I/<41K3'_EP\R(^&+P5/V(&*O!6.2@@%Y:@?
M<J3\:$=+\O0)<RN,HZ&_IG9]7Z7*[:T6)1R$?"D\YT-_^XZ-FPO^)6GPCP;_
M:/#OCH)_[+N"?['S[WA5)[V&5Q=G2NLV&:HE6TH.2F;91C]M%>[N4V*QS$<R
M+%.?C::ULM!@%Y5 NGCW5D-R8_%R<.$@\1'MUW]8SGRNRO!,OXZ26-A:HU _
M@F3T*0%S XD7&5<3P&/8L(YL2O'5Q;K9U/NYU"CO*7R4_80)8TT-TXZ@8"+4
M'74%U2TB[* 25U4B_F?TN>5VZ@>D0IPD\JJHF!(YAR7B"85*3>%]"8!X"N?_
MSKR2D77HF/ RM/RA+W<Q1,O!!0[0*(Z,X-R(^PZN=UOI@)<J0VV0Z&0HSUF"
MYLSW]G>?\P!MEVP[.U7'%V833'?;R"">3J9!M7#C>B=QE)3X58X^#A.*P^_@
M=[IJ/S9I=GOI'QH_ACU8GGFTVTH<,#?@'DT\7\XO<RE_M16GD_G/IM;M%$P+
MGJ J"F'O7/SX8==4L;;KWM^*;6TV8;_]B.7V_6Z]];YMZ-\*; L>A/4E WB)
M_MCEN/4([U<=.[IC(3>+'UX^=YX7K/1+&LLR()^@#<)KV 6?\2I(+8/KYIC*
M\VN&DSU:F(@$5GBK]I_(](2/0*(BHXSL94AW$(^@C5P"U)+$(I$HKYH8>.*5
M0,045EM?GH7-_</\$2^8[]76>K_O?(&'X7F4%KE!\_')=(QOTYF3<]>+[.P7
M.;MICKMH[E*05<_WBL(Q_KE>S8/PQTCUIU&'W;Q2#U[$GX)7KPDSPW17OE<_
M1E)8L<KKHO3=DCW\JEA_=071]-NG?"@/W) ;9*6:X=G>4$1 P]:T#H;3#.RO
MA;(#6C;,_V"7ZPD"X$MIO%KC_>P@0Y?=@)(_S.D6+GG.:)R O)V"96R%C8AR
MU>>D^)_4:KNQ.(R_78P(CBZ;GIA901$_]5(B2!G2<;$,#@1L T@2<67[D.(Z
M8["(<EDEY.8>[;H2H'F?H,=UO,<Y>&!D= G]A]^=,><\Q>OB8-+-YN90XAH2
MFWPH",.%%,BRV=S!J7G]\P#KCQ)&"Y3T4[@(U$1 AE.4?-J1RSP:ZJVT=7#:
MT,C&B@W*#T<A"]QG:3\C8.Z8(JZW(W&T0ZWA _248TUD5V (1S[2NSXY'H*+
M5?.NH['NZJPYP_*X^1Q/QU>-3N)A/'UD<BW0>- ?!2%EKX+(T][B=C43(EI>
M %B;5$/ 82!/N(TH5# 12$.6,>16$IKPA3AWZ050ZII2!&F6F] 8@*W+%N7(
M0.F(.IL<:G^R'G&;JASGM"*'J'2:4"'T;A6USYCN?<$D(4W4T "^ B(%>05W
M'WG9:OK1R\+;@*AE'[C@97TOT],]1KT1L&<;9VIZHV,M89<B/!=D*8+2&-PZ
M$ZPCPC5'($($DAZQK1.2O.%0S-(;RUOY]U![BG4]7%%RGFXD:Q;UP=.!Y*8H
MG:$B#FR/M@DR$FHS!H]0<M(2G_T4L@W)83VJG?&<WGM!9&O/Z7V01W#"Q7^=
M0*L@FST40WX$ K+-T7Q?%RWL2S3?4XMEG>>2MLJ5&E.^W#H16#W]7( #JY 2
M;CA=V]'B2H(HYPJ<<XES)DD!D$D8;KR;.LE%0CF 4 ???8S;ZXWQ'8J"ES+C
MQHR@/KF?G("3F]RB-*3Y"NXTT"&-((S385%@"640"-MY;4)_(6FREFTRY-\>
M*-S6%PCP)DEYP57XJ/D6JO[V#E?/QO)>M1M7)FE4*'BA;OPQ+3A5>[6KOB>6
M/'H5QAQYNV\OW0!G;YM_ALOTH;("*>I8).'<?=Q/4@VJX_ -:UE#;8;0F&Z6
MC3%"!B)6^V5][KC[A/+M#I]T]*-GX?9L;8 SNWQZAW$4EJA#;D(QUMDE+_O2
M#=+INY1*J*CCNGM7Y5*1+;W-B/&-/)6AB((*%S+?O:0D8JR8D +VRMB>*DCE
M0S)TMR@O9J^BXC_9\C_E7_P/#"=2_. %NO#&1G IP]P"/[P?WMGB^61X9Z_A
MDB_4A-&()A%1A8WAV#_&\AI(_CB3%RLC$:']:Y/(8QC!WXZ:X/_1K \ZZ&.!
M >?[RD4 J?EAX_S__5>:2Z;_.9S707?]HZ#6!\C<UR)B5<1TH6@H$FHZAMN]
M0R0')^[P 5P,NRX?)"-)'[:3*4W;<-I1 _H[#!2G:*"8!HIIH/B. L6Q=P6*
MX^??\:J.3<_9+WO.LO"<K1]IIW_Y\KR\\WCA/XW_#A,_ C01%F\XI2VHY^)\
MS5-G=/AX".^[6U\(SJ FX^Z?^K\>?%NOX:YM.Z9/)T4)V"@B"'#EBC%R^W./
M-OZ'7-,!F@;"*VK%IR.)H4 * I!B$$C=8^-MQVXH=DEJTD;(\8TJ6'$,R/ 8
MR^U?MW$M).]KOO@*+G-&<7A9]Q)E?4:9YT8[#8-=-S,$,US1;4C0NL,%[%[X
M"KNXQ] &A-:M/34DKS$=3NAP8;8SA5]!P<>[0=CX]\1.Q_(.]5_VYSQ*33GG
M#PEO20M(?-"4? 6]IVQ?7RL=861 R?27!6WF&A1E1,6(_WVMTMH&RG P[4U#
M1;UY=0F%MN8[?]VQI^[!CKPLV';[B=>6B=7B9?/\I!O-(/K>O*61O )O79_6
MJOGTZPE0;2_7'?F)W2#57LLPU#5<WK5!%#149NIU_\Z_]F?/?8S\)?ZKC"U/
M#*"R342^"+J_R@6O6R(UW57LH&^ L:-"R3 FM<L"/L.1'PTUD,3N'^O'13L6
MXSA56YP"R5%!?7R65;MXIE4X46SY'/-LJJO4F@]@,>-9M9_8E!(#17R\5!;A
MIS3P?H?J0&:&)N+:M<C\$(EEZ&D#V) 6'-OP/B!6-/YDS]AF=@>M^\S.G9$B
M!K)M>O-RWQ=UM8=?7>E(? 7)[]'D:S<X^DPJW_B(?]%AY!'-^SV"M(0?Q#.Q
M@F3ZI4? IREM'Q5&EJ$Z-KBP)^#\G7#1MS.&SZ/SQQ>BQM)T(X*P$<SW.$MW
MXN-V JN?^\;,'XFDSUMUZAVKOBCX_WC)J=<\UIX)AU3CXW\_8GD$4N[!Z9V_
M\W4(!]I#GK/[NNO_[VCO)7ZE]]M/KQN.1&A"E#7R,]+8_ON?T>%MNN]F^%T,
MX,>_1!& \?AS,8"O&$99(:@W@ G%URYT_A',?>WEO9N9]SCW\R?_"V[%F?\D
M(WO/<C!QE[AM'Y@_9<K/Y4#2!@]=R[1O/P9<N'X L_VV,O(IS/8')J=EVL,6
MRE')K&4+__:(<BL<[1%G<PY=Q\CPK+69W70V<_)M[]GMW]PQA@/3;#QDQT]\
M1:[-5JUA4DG6,WN-MR,6$'](CHE2V=_LD]D9NKXFVYV*6$N],)L6PTF*,9U4
MY'C9:'[[R1Z&K4.1T,?2#66O?"C=:IOF2Z]=?\YU^_$GK=R8%H ]/$TWI+E:
M0/\STF52[$"NU?0QHZU-DUM'5&92A:2+,J3$X#CP?]LG:L$Q=7E[L]L8DA/^
M_(5/U%^IAX$[9 ,F][;\!)\KN-SD#A?/KHK/[?ZZPK=3K+.>/JPBF^RE1&#E
M93/M/^=?@%+AA\L-6$2G,^XV1. K)%QL;*6R5E(Y7DN.:EPCU4WU7BXH#1\W
M6O(Q6FPJ3#V5>"H/F03HYR\H#3]5-J!HCV.[K9UW+:,M8VRC;EM4JZ-:G0=-
M%'88>ORR?0 ^W':9Q1VSI?/]<KJ<9'C0&0TB3W)JJ:B7$G'EW!KT62V54>3*
MD_CTM$P/H_-)H$7<6^F8J3TU8C;?7O*1U&-I(@]S2LQI7D[.K28379$;3(('
M+3[19A]Z3-M"=PN]2<Q];-CZO-/O-V]R_?RB ESI,L9I,:0"Q\TJ0'DX&Y0_
MKPJBUU;,N^*%A-:]4BA</H!RN_'%PY [(Z3\9F+BP*CN"XBB_'!4U'IBT.\A
M?G?%#)D1ZG4LFUX;?E2<K>.26+<#JCDAZ?E>Q-3?("K4G^*^Y2=CN*A&'_FE
MO'RA%6J:)<G6'"?*&^.P6[=CV>[MSFYOL[,A7C@?WU66V_X2>U=@DDIY5+F$
M(KFHK1E.W$"=K>3CAL)OJQJZ3GE0%=WQ#;![[VS];'W(+'K1JEQF-E8JGBMI
MHLPG3A0$G7XNN 5!9-77+T04) -?$DN:FZRP<PYW)W#O(,/5@9!7'@3=$<R-
MVX'75Q]/JO&Q3\^MQ!50RP,9=;W8NOP.+FQR"W+WJ\6WG3"VV0JH1.^H6W3(
M>]NNAL?KU>!K.N+.!P/**[HC72/VLAY(6> VZ8&,BP:X5J?C#JXB)$E%1":L
MIN12,%0HM;MX([1P(,>-9=+/67!G+J.")PF0A!+4E@<UTO4NLOP>RKB/'7R7
M5#1ZJY=)M]>C\A[1E'$O"DQ3#65_V&Z%I#N^]Q4\S(_07_+?;I]I&;UD6].%
MY,Y*!R9J.K+W%<G=7S=]:MN*>4/R44CCI/U="L.WD-?L>@Y V%FXHHM,"HZV
MJ_,^>M6NU\JVX_9F6X^+3P34,L4"^$7NFW:O1]_#-6RD%02N$/,F:0)TT. R
M3K@5!FIO[&70'$X##;[\^W3/=)RHX^S<YKM+T0#:10PEU H)M2-";6<@:MUV
M,^[-):<3_O9?#\?XRYV +MAN@_TC8J'##O4@]GIKDFV:&[*^1TC2N(4\@*(U
MLN01WK)([J*@0N+II,\FAK5]?H?)?= D&=>':7_?3M^=?^X#Z) \:"NY)T>\
M"Z];]:YWW_5>E=R>=)'/%.#N=3?]K/XL4$+ 27N3-8''+R?;C^ EH]Y!^$IA
M4KRIXK[.9$.]HD@?0Y]>_NX]N"OWMI73]M*' ]9$S4/1:[;Z"_[[]Y!OZJ=?
MY&VMFZOF,@;N7 1)O:VRW&<3<@V ,S?TTQ ZF-Q)88^5O,,\6;^<V>LN3/C*
M<D6,102%C?F71+G('4*[,59H^/-RQKL"QQ59NVIQ(GRD_58OCN7VI9>UN8IO
M%,6-6?$[X.@2ZLVU/4*\ZDG'N]4 3I[4JZ(^4-Z=R;X1C@>6O5/YQ- 'M)=U
M8JMA79:T,U+!^6V4CVE^4@#N[R"AQBOK@!.^U[:N:5JM1ZOU:+7>'57KQ=]5
MK9=X[1VO&, 7 H"/\KY*"))B#DTM(.)^G ?BV5,[+$$#^Q<-$!7$\DI2O 8V
MKO;0.3H)MGT5MB_WJQCH)@KWJ/9,&]RL%-T"&?92[_%U0/@LV:J.R%?@=GX7
M50$?G-!65,B;3'*)Q1@==>K60-./#]Q#5<;:3<UK'G%>G41]\K>];<);1>%,
MGSG_?8R8F4@S(<$"VXN/R&_;QO 'S>/<*YW@X6Z12\'0DO<IC56YW4B[L[A^
MI'WCA?N<4 ?ZN;L]87SED'L?T^$CA]?S^>]N>NW9-^CI;F,,<':Z^]:P;[+X
MIBP@[=^&Y;7U<^^5.ICWMI_]1RX [=R.E] M$Z0-*RYRU)"CD_@F=;<D"7\9
M.V8RNV92[:U[)V=(VVL#B>3TS*-,.^>91VYO,XZY5GE2R[V;++]KU8EZ\+E!
M!2^0<,Z)V!LN:HOFJN0H0K'PN.AOY&5D$] F?#MGN+>JD&_1(>1FO[[7\%3[
M,F0U$(V<R,YM/  W0]4%-8(,42_0NO6PN[=%J(9#^E8YI-G9]CIZXEJP\'E"
M@@:>:^M[B(=: ;XNPVTG=MCR]G!0GZ#<%2-O9[2]8E5 '6-%MY^68^U\Z6?O
M! T?13).P0_A">,HP7@NR_T^:.YA<=91Z4X#GYSX8W2/RO93S[?_IH9@NTY-
M).:!-@KWDO.U2O*(^0H=PSM[VO/UXB_[GYBKSDF[%TI#L$*];4.94W5KV'2W
M+%)1_F]7PA1,MSF3H\M$OJ ;:H:>.!MVV_EA<KX81>LIOMMES<UF7>DQF[*Y
M^O:A\4\CNE)B()M0N[G'1T;M"$9NTX)22P*B#%G$^G_?(HF]R.4/W=$DPW;_
M?MQ3=,LYAS+-3YOHMQ!23N 7.5\<LRCKI:;,K?I=$%FN*@O+4 I/DV\_F>]1
MSP;VR.9F"D!9H6(;_0 P>]H%OOOH-0CMKJ;S\:[O0IZQC":+@ZF_[M'[/73A
M'6;V=I@9\KUL3,MW"U9W,>>>FZ7\3!;7JU=V$,>>X2Z>B3W_T18*MN:T4EPA
MSH,G7FWEB_'!,IZ!]HQQM(.GBSR#LY/,84USXN]];1.I*]:AMH*4:( D";[=
M#KNUSUU-"3^0D'0&.\?9]L(ZTM?=?Z_Y]EKE:[4++F\763?S.#0LJ/5QU= G
M5=0$C]S15?8J[<OP^-3QF4;^\'JWQ%0CPW06\8:I:)'A8Z8>,=J\&LA&K#LJ
M8+EN(#<0[@%(%.SK:#35PVGX6Q[LU/3=S9R>57#B#MOP]K8+U%GX9+K ]]#1
M"]U>>_C6 ==-2TQ'GTY_<#'XZTC9ZC#OA<Q^)P@?@,:.BMN![V 4*O@OK_5[
MQG<-F[%K5Y0Q)8E?V?":D>/X\(X=T+V3<',]2]W?NP)'+ Y:F*/7;1>)E0AU
M&XL@H2>B]H3W1M+!Q+W7#76BP"TJ1-1KUQ)EY!%P[^C=1NI\%_KZ1]G>?6:B
MO!,=^3KV>Z.'=C>DNI2\4M_^\O@,E2UO%]R,%_>.8!1!/N#-$'(DST]PX,%=
MK^B_;IX-OBK6(BTI3W4(V0\.NMUWMT$BQ_578+Y&=UV01)KM#=8X$G!ZDG T
MW-I^[]Y2J%;ND0!KO?XFI-Y!A[PEZ&]X)C[%&?.MKP^"?TWN);#O6!KIA^R?
M-<+Y3L/=6P !I1OI.+<$$GQQG4F[^W#VT+T71R$C'= .Z^_HY6?ZFFS?<G)'
M#RXSD:4+JW'1M/\0AK]-,U9*6$]+6468=KEN12C*S>+D]]4X?.SN3JL<S@ZS
M3BIM3.^9M;1H(J'TZ\G.<R$_ZN/\P1M79-]!@:A1;<P8MK/J:KTEMXQ+S8D0
M:5Z< F]5Q#Z! B6)>RP^##;+;D0 @WJDT5O4-I ']&/%_=<?V&Y> T[ .8 ]
MN7+S2''R:^EOO@UE>^T)SM^ZBE;<!OCFZ19 _:W@ E[7<S.RQ$^5QKJB@$Q\
M(F]60R8Y6!U'3DX_%]PD0)<*_KCY]7U[<&AAXF8+^-U(V 4'MPKUFW'G[?F*
MYHZ)4E[Q\8/XTL(1(+_F1C)OE7W%&N'3.G&].[97T1 .:AXV-D0'I[:B,XAX
M0O'H$)6:( *'-/6#*C>Z&\ B:4?DCG3W\FJ<EX ODX'CP%-L%^H1T=Q,]^U3
M&8Q#_!J(#M84ZV.H]:&CD?C)1/SGX[GC!!@S[.;WXAEC=1FI6]:Q,W\W@'=A
MNI=#LR4&Z@SFN+<?J^BV7+\"M$\C.(;AF*)W&=#9"XGPPYYAN4W!,<'VNC/W
MZK*[O0XWRM#$"9HX01,G[BAQ(O&NQ GN_#M>51JN$^O$]\85_C][W]6<.K(N
M^GZK[G^@YMQ=-5-E/ K$-?M,E0 13 XB^$4EA  AD$ !$+_^=K<"$@@<%AB,
M];*6C1NIN[^<@?68M4-=/5&?9NW!;:>4I 9&MKOZCFECY45\7:FOYLD&+$,[
MO*7@=?>K)-G7X5CL"'3(LG;B@';9@3O8[O8J%*(VIRR)0\/LK XB3J-&< 66
MV]X-<_X)!;8=>+<G#E+.']TD971.^Z\;F%MO)\>CT210IX'?&#GS\ZQ7"D>S
M]=YIG36LR9?L,DU.$QR+QS AVXBJ[+1C)B:32UMHI5K^/28::@69W=_G6J#V
M<8P:F@4*&T0*_%R4H5[HY W8A]D;<9C'B.-;Z=88QYL#QJ@.FX,*7BD9&#!C
M]4U ^&6Y?SB\5/3T_910KT_-'9\<67,\#\.UKI+J*,XZT"%T*TH*%5786)>;
MR HJ2E$=/=:C_DV%)3BT#OZ<B:Q%%>BS3K)&,=/=Y[+;XU*FQ@)Y 1>&K, !
M/=#9R9N'7RRY7SQ0P^WT(I\#=C_&UQX&Y$1^;=>3J'EPVO'IOA/A8#";;:VY
M89TM)DG,7);;PD R"UV>NB6V.5@%[F4(/6*-_7W4W>O(*RK-\=,#= O$-J/,
M5;<:6<X"*36/)8Q= W\M4G_\J\C",;;Q]DM/0 $A$NK(>HB*D3\!1B!,  #^
MRTH $*VJ1!OS]O4X,$$#C=LT+$/*BET@S1+@B<VK- NOK)(.VX"QWF@59NY3
M5)S!MG;*GOWUR$BQ\\B='&]@B@'!!'C2"0Q[B@P%'B;@P0W#G!/9#DF@* GD
M:HZ=](ZM-)Q,MH/R(@>+ Q&70XE;0#T%JY"2:2RC0/3 ,<'6XYX\&7+(47YB
M'W:?;M15V_W&0?(\!TW,M9O!X4S4 H)+ ()-=@8CBV,W@<)Q0BNRE2FH.;59
M!]L*GCO\Y!T)O7^+9<DJ)C>W9FG*#M>RQ\[>@72U&:SEHC@E7(]BW$M#U0R[
M);J;BI/ $A%'P4!*1=:O5#A*ESWBULTSM;!NKY# ><W>Q_C>C.)D8UB0!9_I
MI.OP@,[@]\!>(F ;_K"*31+:01'>&'HF-%U8:E:!G3748&PZC@:T]3\U6U/@
M7)WH'ZM0SK?\%%_?YR"BI_UCE[[YS^Z=DX9F,/QC%;'9'HL3B]RBL?>^&H(3
MEJ;M2T*=6T;!F3]A\9WF+P#4P+,TJ[CQQ'MNA,(,XC1>S/.#G+/GE'LCCC-C
M9-=[>A4+IR04U0P%2N1W$L63AQL[J;^HF%T6(LY4ZC<DD%W$>^RI"@2^C8#B
MN<<YVHN_#!;-C(/#^!Q&Y2TW0YK5T'$## 5+/%E3!F\$[?^* 5X,V_@!N+#T
MB1$@]R_IJ?@@7SV2<6AO47MO^W&-MK%Q*#F%R*&]XK2<=RHTW;&H#O&B!'F;
M4XS<.8OP48^A*AZH@8$:8[ IP@W;1*^;5$J2&6N8)8EKY5*U4Z;(D<YW@J:>
M(VV4Z[JPFT@<E28X<'%S.;T/@K/;%5=OM.U()(=L1<(>M0LT"5MU@<KF7+!F
M:**\57OH@ *+]?8!]9/:$F)=D2G,L@52!<Y$L<<3_+77=YVAO=Y3=JR=O[$-
M[],WG&^8)$HN$>! 3GM0IY7+8_4?$65[:B423XI;7?T6@W15;5?W=*0R,/<,
M5R:BY@41<#>"E3"]AM7=[CO=NW+"!FA\Q)13O0E_?JX/G0(R:APP"BCM!N@K
MV9S2S0BY2U;9$L3%$.9;NQ$G!^]NQS69DZSOJ%(88ID \% Q!<%3.@)0#YA<
M\']8.0RSXST)\S["\"OO>T/"*94]+()WWV$Y$-!,7>>SYTC&FS/BQXBCT-(2
M$H9;FG)2N?"K$UY@H0<KOBQWWZ:]X@":=B,TWMMI?.-L^LE)5?=DF4'ZTPY,
M/_=F4#ZY8?>X<:C;WJPK=((TT?'^:2>MIJ-<?0_+A&S2I5C?%_8D%O'ALP7O
M Q0XR9]=!?GP7?"SB:*,$- /=VH);Y19=>X]SQ%&1LCBAZ%7:/B 1SD]B:Q7
M[!-L[XY_G) R>Y/WZQB)K7$=*TQ.2P'+63_Q[6^OZ3H-I&"S*]B*PU*D/0Y)
M%-1V?@D^K%-Y$OCX??F]*G)688V7?'RS]>P>/W9RJ(VL'@/WV "PZ-A$3[#2
M2JUF7YQ5-NHRF(DA6F4S,#+MLY>\\G*?NOFP46L\C%J'4>LP:OU 4>O$AZ+6
MR=/O.!O%O7ZYOR';3FBWUME2QE8&2C"&GF51MS1VJ,M9 L^?+(S:W#B7 ;FZ
ME3EFMX&![ARKX &0B-<E!G4A58/&$6J]!1UGMHJ"I-,0R")4'2D)0+Y8Y16
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MV*=W6->JZ4"-L:+(1R+^3%3:JP$A#H(:[\.'[),QP*NLWB5P\5I! M(7IW0
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MVK=I\Q0*60YL3_:8M3/4K=?=V$:P,NNMQR -Q=).8(=R./7+_I;U,.="#_
M^?I5Q1I19*T\OF*W@/)D@,S&,>_-V5>,6NW*3A\[-!;)<1WL=?"@Z_+Z/5!.
ML7WG"SA:#_K67%^Y[>> ,LN?'6=G&P/HW\BI@SB.>_4(TMY>GH&)^_"^;%L#
M%?_!6X#?#KRC$YG\#G873H/%@],H^/K&BWR;\@0G)KX3>I$)D=09E\LA@:DC
M(7@JHK_#>I!7,*#7^TW[^QV:R"ZHYPHGGR%(.T6"LYMRPU1W3K>'&KC)?4-P
MAQM@@JB2H'L''EA?.(C3.EF@CM-,1*UO1XX7^W@6E&//\();^,%Y7^9]USZQ
MY/ /SM1.&*&RYR0 LO?ABM.3Q[+-W6]Z&UXC+Q^Z,7CT4[MXCM0MI!FY'33A
ME_:(Z$VT/<G $%.'%J:WFZ'O*=[<9#_6H]Y+3O\]MXH@L,<?>B;RX3B"R!V3
M^&3S>U'S!,7]Z9M!UVF3<V"?[R,4NTTWL:PGDF*[>)#;[V3?W%J3E#?%_IQI
M$ZU\<E=<I%CJ+N<!M$_$BV[/=NP2&<T7TN(V:*8$0AR[PZ@=UK+G]XH V5#O
M6%_S2N^ 0@^IN=S?KA\"GV?FP.R/MOFI E,YK(%I49AP!1<LE)$P1X3M3&:S
M:3R YR!R= 9#6NG)0)A;)36N;PV>YLF>B+DO3#P>IWC0:5M9+&"R$;P7IYX#
M*(RV/\OS-^NVGB->]#W@3[!ZPKY4OYKHDB/*N0/FF1MMLM48#[7O@Q4HUPUJ
M1:Z;*Z"N"[WOQ,PY  \@1:/.,ZRR+">C3AWM0S%VQU-KZRA"86_/QA3G"7N=
M] Y$J1N^TDX&:MW3B5;+UJQ7D6C[QBO7_3,8LKX9#!5%\\]S6,"&PNIAK(47
MES#-W<:L)6>JRMQ;O^$)N"EO?-E%#U^VA_O]VW%N]U(L4^F\@3S;5%*%:GNV
MD K+!E//4@6=X>XRC<(/;]C#\S8(?KR/?2*E+-A-A6U+#1Q,WL_D0DFM=GMM
M;C0#9J\=F,C;?/5]HQV>@L:/N,-9OWJRQX>;Q9Z?W%&'.E8 %N>MR\S:=]G9
MYP=3\JBSOUC*O=>:H-?''6[;L)1$2@<R8VCHT.KL* T.&AW!LR->TD:;U,DB
MQI73Q*!:*QD%:?/'O_@S^<;X#\"CSL(<S98_"?BW6\WNF\S>%@5^NV/R?:$
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M!9@$T)3B3^G48WF0\H8*0&^H FI>, ;7"7X._4??U3J\L-;SD[C7YU0<EW[
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MT<?V@?UD]#M/1H^&J!<G@/I957XR^L]"!!E^9<"OCPD_X_-G(8(,1?T<Z+M
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MP =#*D1?/'COX6LQJ-'W/7^ XD*?H#=N\!FA.)B@R=)P 1HMO8OAAP)5U=X
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M@ITXKZF&:)@XK5MXV^%.#O2&+CW'!2*H_(^WS*FF[]H&&88%WBIGC2FO V-
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M;7OAVQMD'EBX__V/.7H#V*>B"8+P 0(RLA"XG&/&0_&HCX@[0 05BM$^(NX
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M1T0HX;=-N[>V:3<W(J>:)GW:.0*IMGV.:I^S'W<4&^X4B'$D0XS98*MA"(S
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MS$K]5P! *IS#]YNZ!2YGB.[M72+T<A+L_IOHCV],B;6Q[GH5[ ZD@B;+_-P
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MNW)<1TISLQI:MYSYZ]?6_%C5H7$^7B]/:\O27+/FYJ;#5>/L _0>TK'$:6$
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M>.QG16 FV\OIM#=%?D :[XRPI[2=MV7#_6.CA=U"\Z#HCN!U']\/.;CV(JI
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M"<7"&0^B-SMCEXG0FTAT$900B+7'KD@(+KTBXJ]4#$RZ>@7ZK>=<;))C(KK
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M^\B#M*%TU;KQ[]DT[NL[K;%8Q/O10;RTS#SR%B]P/"X:GV B2?HL&>K7-/X
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M[B_H=NQL#LDGNLOU^=)=4F&Z2YCN$J:[!#/=Y4 )*2J6\/4"@3P/*"DI)DC
M)X24P,?3<8E/I>,IGDJ/F42:$44YD?CA3K7@,Y_%@=T%RZB8FE>-QF-W.A9:
MI2F'5K+G+6FIG"]I=FZ8%_BFUEGR#YLER_'T:4N3=KI3FK%Z^6+2MK19IRO/
ME0EL>?+V3)Y:+C>=:*\O2%JC4"L.A*JTABU3SUO6ME&SG@!6(=_=3.+3+E>?
MQRE4(HQ\WG*P5J:+$2@/R.AJ5IM)<KI)-=I\_+1E8R 6VG(E-^G3.<V6VA6E
MT*NAEB<CJHB-C:5:P^%<6VRX\LXJEX0DHM8^&5%ADH[:.Y#OY)>% E].-%)Q
M)HN8^T]&I%>CT_*,KE7)07XU7 \>YKV-P?'L:3^=B@5[9ID\&>VOMV4FT8OF
MYFL^>=J28<A-6;#G*;++EL<9)3,O#/L<GSIMF6'-- NZE2(9!=I [B<?I/YB
M ENFG[><IZW*0[,_G?8U9E=C="?5WQAK/GWZS$4JKK+EZDSK#Q+IA@T?1[.S
M-D]19T3?2>^8&I],].ED5<J+R0>9V9U5N[@"+:FFCK;SZHH;671M#?1$^YS:
M+3M,O#.DY_-^]<%<-;/3E,*F4,OX\Y9@^S#L,J"3Z3M:K]PO3', 8@=LR3YO
MV8F.Y/[.5*E^=TKQ*]MHE"F!.Z=V[6&GLU:6=BI?3'4+E<4<F(W)Y)S:)<?Q
MC+Q@4O%\ELK28";N'-,^JW9<)EF;C@IB/"\,P(CE)*' <5X9B..64K*>+><'
MB_1\P+#;5D;4\G,=T9SZ;[_V3E1>,%'Y7 L&8=VI<&ZKB6T/JNU$L[_K1YM2
MJ\QKFU$2W5>\^PW$1 P^V'9W41=H8Q+U_R;;=UUQ"B1'!4WYN?@R@J6(G"[E
M%-6QT=UAN&R?BC3Y.)OH#XG'&JF)Y=%H-AQG2Q)W@]V[\QMBLH%X67!H@-T,
MG,<.W7Q[ZNT+:PO'WI_3HX_0II+HYIVX \59?,<S00BV&^D(W@D'NH:!]M1L
M* K$,8 .-/[">_R&8\%GN3?I )Q@%&(</,?-(/G[YV>C@_"DZ;G?+G\L=+U5
M86&!G_X/ASU#'?&<!.10B*ZOYX<;V#46'-OP/W#]8OS)D?M\>.G:;?,4H:33
ML702>[VVZ7?-]TO<L;^QC@092](OU9PY\),.GH\XV&2H;+[<_-_Q=8Z?;KB!
M[N2_ZN9[TX%?[#<5QI:!M/'*[OUS!3EH^-[PTOOW#[F:4?WZ<"(",!'DB\4K
MPXFXU420L= B C$1(30%92)": K&1(30%)")"*$I*!,10E,P)@)"$Q7.Q.5F
MXKV5&5^+J&\WZM0[1GU5%+[MD$\V']\I ]%0T8?_[T?JQP?EP21C['TKN.[I
M^7YSJ/9:DM_PU<2"?;Y?:"0!,9)3 L:79MB=Q=-_C^?UT!SHCYH#1<7BS*<V
M!W2H<"*84 V^H1J0H1I<0 WBGUP-J/0EEK^[UJ=$F33H9!6Q>_R\F$+?>T@7
M+,--WKO ^G.?Y39>"M[9NL.X7ZB+^0R?0F4-E354UE!9/Z&R4I]&6X,>T._S
MYEG7E?'RECZ#9QX(97QEN_X*@[Q$6>_7SMUN82\7K\E]@8M?[RG1#4W%K5M7
M@_8"@S@X3/B$,U6Y"T:[$4TJ^<$\JVY7)6<A4&MES<=YYL>O9"+"LJ>$\'^'
M]A?:WV>WOP_<(+R*_;7B3-U>&UTK3YN3JIRPL\O5VDL_C\<C9.KTWF!H?U_?
M_EX\W/T*!O@1SLBK&."@IN5'S4R-GF>+CC!?FD)+9M"UHS0T0"9",LF7#/!S
M[@G>PQ2#$-[>"X*^X;COM6ES[W&'>OZ]QAWJ^3<;]_?5\_OL:UYFX$'?Z83/
MS '=P)6U+WE4^SEFYS-%>)<[(@G -LN]%HY0+4.U#-4R5,M/MBEV8_?CKM[6
M_NP5$9C!%PQP=AR0H@(JO#H!>XH(Q/M@(1IL5&+4*]'PG'(BC#C"B..S1-8O
M0 #!'/'XO94>UC41GI:*LV(T7E7FVLRBUB.JDR%+[4L?$Y-O+:SD&S3GVG/#
M0?<_FC*FQK&:3^;\C"8G ^#C0=;0,>'^06%9<K^E3G/Q9MJHS$&^NJ@.5APY
M<B;#"9]$9\IT.I*.)R+IQ"F-: @2(4B$(/$!D'C_678 0")>EMI%JLNM29!O
MI!^[P[XQ5C@($BP$B40DE60C3)(-02($B<^[=QDDE/C @7L 4()=Q=E%Y\&R
M\D6A0K=3C]7=JHU0(OWC%Y6,I!+0G6!.4]0^S\;OJV%6%SX /IM#<XM[CGCJ
M%B:0 2Y']J;P*X*^8 %<,0G5?I']A^V+$!_0_?W'<HX'B;N=Q#RXJJ*#/34N
MNN"/J)O1@)[)%'X,Q_(7]3>T8F<1;M"\#Z'O=VDN$$)P?;H["R%(T'W#*-!%
MF^P3U+1\I#D!\ZP/(66((%D,(%T;,Z>>H+C-MQ+3\631F'?[A<<*8ZEJ7D-$
MR"@@C*12R0C+7-'5^^H&$Z)&B!IW#0NO@QKYUGS*95=\EU32FITK] LMG4&H
M 2-$BJ4C2>8T-SK$C! SWAT8?A[0P%6RZ#^^P1>,@R7W4E_/L 65T''(B*LG
MNP&-X]5D]4O)@S.LY>%!T]?;'KIP'L,WW_2Y4N3@7[)XU[[/F15>'ICQHLEW
M6WUM4K:<3C8Z[RQ1V1,8%S P,&"82")]6J0Q-/+0R$,CO[:C?RDC3S-*(E';
MJ0_SK3U*Y&N]67J>0$:.#GK8",FD(Q29"HT\-/+P_.;VYS<76\HKHV4V4T^5
M\U6S0\6I\C*M#MO0RK_*04V8EOJ%TE+OM3_YU0<9JNM7&62HKE]FD-]$76]P
M.^#;7@;XYXE\+=Q^_<I!V]&XHQ80H\HFZ@[Z9PG_C]]H27JK+K?)_. Q)^<2
M'<U(S"?/O_M'77)_10]ZL=#Z_^RE_Y7SB?]YG8PGIZP4"6 J'B_ 3$_;5JNW
MVIKD4F_,[0:3F-'+B^\5T^\(,,]6WSTEYGF** 6IR9):QMZ06Z"(V593F&N-
M":ITC;)&8LSIOO#EB+$"988A_!S"C[)AJ*5"ZBLRRMB=QF.KT;6Y$'X^/_R\
M?Q?[JO##E#.Z,'Y(4'DM76RICYUTOQ['\(/23V)L.H2?[P@_;*]$5=;MV6B^
MC!K;\79;;O9-[NO 3^ VVF^%/Q_87[\J_G EBR\\YJ(YDC5%IU-K%9EVM(WP
M)XW<GSCU*BWA_^&:]D=U^SX^2;$G8_$SI0X^\:\!:/!G_WI C$H#[4PEP>/R
M@(=%!?=Z%Q4-U3!_^@E8^PJ&FS./PZ^.L< /E^E$C/1SNI!XP%Z7",&Q#8(D
M2/3>PPJ 5T&2BU^B\&Z"N,=JO[T.@G(I":A?Q$) #U,64$KZA(!8YIA0<G!$
M]E2PB:FP H3EC-&QCJT(JKJ%G\-/H,X2-C U"T?U,A!L!V5C"1;^<];0(-1L
M<19:\A_KZ-I([!W]4_#C3'S]AU!T474D?!,%OV3]_ ;,26[8P667#Z2(G;D!
M\VP@>4&<NE]'+WWM HX_HL,_XTLUES\2Y"R^*1^&:+/EHMC@9EJ?W#;C>B\C
MF\W$O'V(4>5&X1TH=3:%%PW0/0<L6Y8#I/["T']_::LAF"9/S>*/.U#?1?-=
MW:EK#U4EDQNWH=\4@?9\ ES[>96?3<0GDB!.BWZ#^! DOT& Y49E4E;%09-D
MEYT=)W#KL=Z9( &RZ>1K0GS-5#$^*%YG" ?VQE->U)TWJ_Q?%@!$P["!:_$4
M^7?,78#<CN&Z4XIX40]!T:$+9O]DV!<=M^-5BJ(7;Z[]>(NN=B'>@<,I(M8(
MD'1"\*#+6^&0RA$0F!&6*89D/5WA\S'M%.T\8'5A'#[51[PS+9\_W4-X#,:^
M&N"_PPG&*\0SOI>_W-Q]HNLJ%(37K"I82&<.__#W$5:O#4>5W*5G#  <,7QP
M%/<1+N0QHN6_"BY&_J>'"]=?6%/!!IBB8H&_W85L#9<10C?LDV7$'_O3D/UU
M H[.@AT0!<?"$['U.C8&QSURGPT%(QNJ:JPMEY7O2+LOLI]V#,%=<0HD1P5-
MF8.=\?O2W8LAOW''63 -#6F08^.7-N7G'F8/]BNCXJL5V*4<\_Q&3JKY82Y)
M#@9=QI2G95H<0*P#$( 6L NVZ8#+NO37-ECLX>[]1S>/'_J.JK"PP$__A\.>
MH8YXKI<F;*)X^O2]&ZL"V?Z)O$3_ QR,N)]X<8_;YB 0\MJ@3UP'-.4ZMK;I
M]^N@ />/MQ[Z)%(QE@T+?!^[SW<IM4['R' B@C 1%!5+AC7O@S 3H4D$9")"
MDPC*3(0F$9")"$WBPC/QSFRE5QW7VXTZ]8Y17]7X;SODP\,B7,O\G3+8%W]/
M?+3X.Y..T<E/7?Q]" 23 #K:3L@!$:#]9W>7BZ$B_KV6\<=3^D(CN=*<OWV&
M#POB'A?''5]BM-XR](E- &U974@8X=1_NJDGPZG_IE-/I2^QM-T[DZ>Y<+?Y
M%7QBB<\G#DXB+J;8]Q[FY>[8>IH;J-2?^]-E>(<R_!\>Q62VYQ_ ;11K_XZ\
MME"-+0#XX,S5WSKV//D49R[&?=+(DMOR))6M9(:=BC;Y^"G_'XZ&TZ""V&=2
MEI9@7%@J%75!%A-FSBJEQA93YGB&IW_\BD=HZ#M3R:M<] ^-\2L:X_.$X& 8
M8\+,[/CD0TTFB]G*+N6DA6ABN@Z>,4:=WB25M,4\J?#99KY'=]:-XAH:8_S'
M+R:22"10'8;0&$-C_!C[1#",<1)7V'1I.]_VF\:"*MK#AM%EN. 98WV]K+26
MV5Z)=*2VD:ZMV=(Z/8'&B#AP(NET.D*G7BJ(\@GVE_KZ"E@HX09JF&TJHKU/
M%$/*:'V&6#(0%R'N'D+^,2=E.,%?:X*_MJ?7V<,57E[0F*Q.M^\M,+VQ:E"2
MS%GYZ& Z!.UI(1KE ^CMU0O68L!D=T)>8$IUN97.[1H5CH\C;R_.1))G$H9#
M@_VJ!ONG+,$!V</#S,!A0/+V@.1811FHHI+AH 39 .IH$*EO@P'E*?! Z^,>
M0_:;(J4M%3&3Z5?6?"+<10OM)!CLL<&P$]T>.!*]F8GS;%.:&;EHJ;LL<-!.
MW TN&%.SX097:"=WY%\-AIWL!JM';M*.C^9LN\24^N0F;4?1>O*>O2?_+OEU
M+O==.H?QWC<0CWO]\>M-U[YKUD$YK$!J"::][9F";KF3;^442U0-RSEWB8R,
M=MM\L4-!M4_/JU2A--[9[-HU'45W@,39+[3C43/J2E?.3O(97IFA8T:->U\;
M?:'W&.A0CSRTH]@8X<V=>\\?6+>YO_J\(P5\,Q+?PY\" FP6BKGU;R##F;8<
M%0*ON"6$B0F !A](C(&]1G<_#R_ HNP,Q;:([%0!,M$5%70-5(8:WY3AO\",
M$#E!5X!*M!3=$J=@C3Z"&%\73'%*4.D(@1R7HT?BO!>_NJ5 Z'#PY_NS5NSI
MZ>/W3W=769IT7Q$A%HYI.0+\'GPL7%'AZ]%U6V"N7)*$@[YS$M0>PT0-<<?P
MV/(;".SX;JDWM!AQGXGK'<A*L; 2;5%7T1UC+%4T)VA<L).$8$)LF&!Y6:[
MT(C@PHJOC-MXQC."!=38N8E""R PU>T+TXM>-H7=L!8&NI.++NL"[\QG?Z']
MS.OP]Z"]3N$TKPQUY5[^79C&2I%\G?3&8$&' /HRZ"/K>$ QHB5LW:%Y4W7N
M31)<CN$33X:WOU^/2#.0!OQND.YE8A,L#-/CH# /#!C*_@!^B;%CPX^]7LF_
MM3'!)DP#LTUXIH#-P+L13:@&'**)U5Z1L#'\_HWG;^Z[MP .+C>(*E0.Y%!.
MGZ$E@[3J&K<;?IO+ALKE[BM)>6 4I=//[S#\]W^]B6'F8&#>I1 :^[03$'7O
M?@@R?/=/05T+6\L;:#(=VY=0^[GWA1EL:&2,2?R;./CYGQ]GQ(EN(!\([>B&
ML?>UXTO&_H>OW$$Y(.6AJ1@&@B=>GCAT]Q-7FJUG>,,\S<U_!&)J(L?E7[UF
M]JRWA'Y^D>^JA^]Z0\7/NI>VK?T2+%QU&7XIG?(YK)::S6JYQ1&M$M>I<^[B
M46YD8T'I7Z/9RW?=;O6:1+;9Z#9KY1S7R^>(0KG!-;)EKD9T>_"#>K[1ZQ)_
M[;VZOP\LZW>(<*S-YY04 HSW1.R]ONQ3>K[B'5;'LNN?;%^]!8)\[<B1XR$I
M$J:C,($(D>'_MW=M3:DK2_BO4*O.>0-/$N3BBU6 D9N2("#@"Y4;(9(;N1#A
MUY_IF80$""@JZEKEPZ[M(LE,,MW3W5]W3W<&?CHB=C.)F=Q7IZ*PP@/PN3TG
MF0L]^I\WHF"HE%:R%R+-E=G!@'%6JY?V([5J.L'[XG1-4[(,!0WO89UZ9TGX
ML=TX&[8LH/V[LE1TRX9;V1=;,5TEC+;%]Z;CDNHJ>04/#W5W)K'&YJ987X?C
MV4_E'G]U/VL,%+Z1KZ_UGE@VMUQ9N<()"/W :X7?X )$3[[M$%E*R4<VV+R8
M*/0SOQ5J3Q.G)P_J;EWKFPV+K7+JGVLDZ?<P.6$$Q/TZT!9XX<P$/YCU\U,)
M;HSTOCY^G(W87*[I7Y5<CFER/XO@"CNT-/^E4Z>8XGW35I>ZM:YUWT#P+!CG
MMB*!+-576;#ZMJQU.5YDL!+Q&^(R/Y$9/P5KVA8T^8BAFPU1#3)4HW)#KYJ-
M7^%>Z1^PRQ%H0&2U .]IGDY:AB)QJ #$DI4,LGLT ]WC6"M!QT6$+")PH2*2
MBVB#X07(4(0:9%_RB%6-GA %:$ *VPQ]-Y@;&0D9@K ,XBJUP-;)T"\J5"19
M"%-BPV9&JL@!2B4U^T+H$HU#9CQ1:= A.HY5QS?)C,_:XZHV90?KDM&;^T7%
MSU7&+;9A=8_L<2CD"OL<SF\CEMZJV';@I2)(>&LY#Q'KI.[F2<%]O&%F]YUY
MCAFOZC/OH=SI=/]<?Y,B_JPU'M<Z]!!A7F;.S8;+F;>HEV[[W[7&-*4U>D%N
MY<^%UMVZ.JP]T /V_&M\Z"S(9ZVQ_N!U'+%/M5@C<$;%.;-\'%>.Z:ISKO'E
MY?/]VF_Q];E06:/[*GZM.J_\N3:ME,C :S\DQ"UV1F"=D_2<@?0B54:Q'P.$
M>.R1B7T12:CP[5[\ ^[9G^C6[_FBJRQ\L+:60/U])WZQT*XU;R<UA65TZN8V
M7RBKRJ.Z[\1/O^^L3OQ3"?0Y)/EZ%W[I(A/3*:,LB4?C+.94BFLF\29'SX.2
M\HX6SKG')@1Z7S# 5"?<RD@0:<C40:\DD.V[.3WZY:B=,S.WBNCX@K,*2Y+&
M5A"3S1A8[!XLD*IL[#-/$8S(B)3?:BTA\:9,)OUFOEZV\DN6X8+<I3PHEPIV
MY8":8<@69V"+;_Z.E$P=UE?!",O?SE>-JH>#L,?"O1*+SHYE1G[S'8"U(Q+Z
M*UO9'G7[>OCT^J8J>D4ZUYT/'VRZY]^,EJQZ<@L&K*!XQ0'O%&(2*&R)A+I>
MM4S?Y9%JZ,\<RU=GN#JN*:'KX>'=C:+*,0E-55&-9DOTE#S++4;NP[RYGM,"
M LR%_0S7_X:TUAPP@6G$OS!O1H2)(^L;WAYC@)"ET9]3'RJ0AJ<9W,0&<+/H
MRT%O:2;@@!@A+ 7=QQ;\*WC\?87J2<WB/19Y'TE%8QYT>=Y5*2.OEY[NR]W@
MYO'=5>TQ,_)(BRFI58PI>J"U=.6IPVIC>6R7<_G[6B?X<YV_2"M@'%=J!4&#
M5B?$02&EM) _"+4\2 Y-E 8_8_['T8WZ3BJ4RI5I;S[1YKV'O%"YG+%V4/Q
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MOWZN=,BR.>6VX]]*5/E&B/+-.1OOT?7YA/S/AWE9"4$19<3C9JC<E)BWFU3
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M6IJ<#EXVZ.1_HB6OT/]FGJ%?_Q]02P,$%     @ "3QX5%V"0L'PG   D+H
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M6[ 9^;2.2,V=1G#(F/B7F9%_F?8WR_Y[AOG_'UGV;X;]PRX$  \5Y3%XJ(0
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MT0/"50F77W:U?+%OS[) L9I'6S>,Z>F,)%8.ZH =A;= H.X>6=BJ#<S1G \
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M=,G7=;_NHJT9_S)$0_"BZEWUQWHZ6R9;A-SI1U>2 ?<VPIE+(BAQ&T+\:VE
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M@<ZC9Q?\/-UIQPRSONX]!0PJ/2GJ6NU.% 1Q,H7=-HYP"%Y/#N*$L\\,\S\
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M;@)8\,B=E_638;L:&O_R*?4TXU>C[4(%X._#8LD.D;.#9/BL04M>FP5>)'_
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MCFSY<@C&_5;P!(O,-6!\:/'X@3K(H3:D4%4V\C0NO .'EQ*+NK: M34.@M[
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MOR&!V1K AM;H+Z:S7?3*4ZWU,PH? '\_E7DCTW</8W@ -'602^]MSL2Q%3P
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MY$T\<^:+)]A1=<3[CVL_9FOQ6=9X)1?WY.%;[[<3SRH;0IRBSX?Z"WOO!4;
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MY75BVT[4@3?]+BULS?3[BNG?KV;>$QJ[W_O%W.OLUTKDA*9J*TPPSDE.BCP
MNIN)VYN72:=@6Y22ZPJW+^H.[U!9;PMGG:"JE!(Y$04*-; BUP= E"_K=UCK
MR^('P#"W0V_$I9SKXC6&^I5>U=IU(B]4E?Y]Q*<'@/[N ^#%K?I_4)#U]D7B
MYMV3C<=J!)XM^Y^8?I,,.*L923Z=\<_K87+)BFBC&B\MBMHNYWW=S>!*NG?M
M)SE3;91ZIGI;(,Z0NN<MH7Z=KK)3VE@,NO^M=^YS&^+M*@:[)U1]M,W9]_T_
M%&RL9AT?>6R4[[3$^Q\ _["3Y-%.<L%UI<?](:?V 2!5V\Q^OI=Z2,4+:["]
MSO(.NNXRO2)?\8A_5/KP4>G;O$=3M/\RQ6@QUMM>_2*,4G*!'ZHEWG9G47(;
M@A33].%;0=-]/U9,:F3VF=:WHODH[#*DY]BWQ7G=1E349K*QD/6F,_11@$0A
MW?)]J=Z]W&4*\Z/PXOI'X3T/ ';)O[O>9#;F;E5>/3_S,7[_C^%[5.#1KQXC
M9XH7!&?AS<>OVI&O_AX.W:$@'WQ/=R^FB>>V7)G"[/.FB$;M1PUB2KP<6UM$
M$R96\-XMK43K[13SLF7Z,P4S85/AL8=_UM[*J%/'KM]I_>^]%EG"BWEL5]H3
M*;$)!ZBCQCF>@!X 88_YW 472'[V^9@]YL^<8R+ E>17/-H!!:WGMK05;LUO
MW"DFI!2N''_?,XU._?-JV9H/P\:H7WE93D;<\?Z:/.'B)--=I)>'ATVR\T]W
M G;%:ZKPK(CT-,P1N<<&Z9^0WC_VAQ+I$HG+[ < '<+]9E]_ZIY:7.S7W3F]
M9$\*6$'--K/YW8W>3^C5?'&ZO9FQRU9B*D*7_M4GBS67V=1LI^N-O,3*/6<%
MPG"A9?T?/#VKC:XA): FNQW36<'G9(M](C9Q;C'5%*==7DOZZ]]1 4FKHU5Y
MIV4V\7[9A[7*7 *5AQ?@V;HQS=ST$J_1YC6"QT[1B/A*SS_E/S3_AH_=_J_V
MU+;<G3X7'7&]]Y4C+O5A\E>]AH;%VQ1XD2(N!2>70:I5->7^!OI*GJA&,F]2
M-/4<)>8>=Q7K;-)>4#.ACWC!'% 6+=Z6>]&JH6Q61('1"X.1M+8(_$;D:=(%
M(C1'B-3_ML @A.XS2@\_BF_PVN**>B!C>?C:_*![_?-OAJ51.&=S-=VHXQ,Q
MJ\U/PW3QA4S)$C_]HK5@>6T:BU[W!,J&FID1G)^_XP9\DRIPG^X4=S["O>DN
M=-NH"C#,*./T4<^V$XR+BQOC4W4'G]=(R_"1.:8Z9.M/G(5PX:H+3AU3[+<5
MD.&FZ"\YGJ7AGNK*77QW:10Y5C%,2+ .'RFA0&.]D,U_ .SJOO#1.&I[R^19
MO*P;,:#^9F*JWU2G>^.S*#L'^VI[H@[\+#EI2KEL0<;FVP. ( Y#A7@89\B!
MWN.3;5\AUVJ/W0D_X<\,:Q"-*TYFS%G:T[C@3%#![ Y0Q [X"9QG*8,L""NZ
MGSN5! X=#=9#B[9CYG=$WB' ;_>>=$O/83H& Q8R2C%#7)PS@3NM[C>T_2L+
MK--.1DD6])J:L%9PVJKN T!%M"(:';$GK/Y)-!BPQ5;LH(F<_)(]QT0\\.F8
M7X4/ZP-(K,(^X+=0IC9R,^@T/_KE@544XCD/V1'_KV>GUEWS]$# -EL1OD*G
M%UT"Q$:L6OUU@SKO/%<&KUC(KM\@AX+2Q)[K@(CHG8BC0'TTZ@=_K!TL<7R
M248P&^"_H">-#X#;+_;-NS$P]A#%OQ95ZIT3*=<_3@Z4311!^/71XC6^,WXE
MIOQ$H!:+G\VE]E-&.].V</>:6F<SY3FRJC![MUI7=X6>_<63@W<IL6.V"URC
M9]&,X:;LCP"KCU)(,@CN61WZ %B#-#]N.3#VSD9U1R&^R=[72BM6ZL3X<4,3
M5/1'I97-*K";"X5;3HC#Z.+]W127 ^J\$1//JG,2?M>3(B-0&= NQ$J46R6
M,RP%NU@=K%U[JO[J3V[O=F$RP=]O&GD X%(;GE8_ )I=M5;;'+\S!>-^CI;?
MPW+#_T'?X=>=1]VF)8^9 /U8:]SF[R1N5UMPP:/O4WD7<$%E^C]I,.EQ-*9H
M'BQ:TW!,T1U*T(NR>UK@O#6$A_]B3NZY!D4:&FUN^D:02&&^9NOZJ)N&J6/M
M/Z2[P%H[)^\>/7DX;VZ\-8I0!5.K$$/3GN#4" V-%K5E31L9S1ERGG0><9!%
MC:TO>6L.Z8&_M%IM.WL+.,BJW).]J=YV> #X;CT  L+@UX8/@,6Z(76<>>%0
M: [ <ITO-0%J)WFIP/SAG5ZD,F!N&@UBM,KO/''PJM"JN;MI5?O?&.R"VYHD
MP?5#Y7:M0K=MW]8U/Q.D%S\Y'RB:Q_Q9EEF\YMJ-YBL C(9KO=)]?UQ$"X3(
M8YL6S%T3YW6O:9K EDR)YU1?@ 25CS]+NK)1LHL35'JA>Y%LY%)GKB!_*BW;
MU3D_ ((><;M.4OK_"I?H"*CQ_QJZ7EGLA8\^HU3^C4:');Z%VL]E,0(YA6)
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MS_!EV574T3:ELPW(#J&A2[#B!'C)A+9\Y)-BAC=BE3*N658=/CSBYDD_!EK
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M:_E2J. D@BJRMK:8F5C\+;DXM*Q]:TCBU3F3EX.D5.Z?8[,4#GR;F=(^1.Z
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M.YV<[6L6&71D%%B5W5$W4J9CDKY(J^QYL#94(^.1U0]FVT+?@#!RI[L^^/2
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MIKN48>9Q] ]85E_?D\!]?\*^EHKM4'NCJ['?^C75GCH3RI=G%6FGKQ!$,SZ
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M/VJN>!KW@+S6?"5@B3F BOAQJE2^[=+6N"/W<71V\TV&!7IOI7N;:L5,!K?
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MJTG09WBWTU@@*YP*MH(#C _JAU(*!X@^0/V6Y:#^.'*$]67S"P(4A<'Q&TS
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ME!B(!\4VYT=;<)^+'/=)MKP0)DN;[><,KF5#4:915(JG E6K<6# ).PE/MK
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M1PWE.+IY6C^U" _O7)X"3\_S@P/6PPN$<Q91(R$]@9))?W=+8PWY +E&@W_
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MJD]6%[=<VR'O6&1,JLFS&BJ8YU,G-24%,2S*&7X&M8O),\FTK<P2$-[E D@
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M>_!*05/^9*W:9)QZ\ ]:B?M#_P502P,$%     @ "3QX5,H#7?VN9P  *XH
M !@   !H;V]K+3(P,C$Q,C,Q>#$P:S P,BYJ<&?L? 58E&G;]M 2@L0@#1+2
MJ'2C("T@-71)2 A(-Z,H(%T" M(@##!TAT@C'4,X=)=TU_"/^[Z[R^ZQ^QW[
MO?^^7_S'/QXWQS-.\%S/?5[G=5[Q<#5^-0NXI2 C+P- 004 4)#_ %<3 "G
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MG$93(:,")-O\_HR"4#AV,3P*OJU_*Y.I*IS_3/U8>IMRYMI7E!..RHT,OF'
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M;V$U<BV8>I'">Z*G=4<"[SA#Y&VER-G_(R6SWI.Y!&_!)7FL7N5''9[395>
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M P$$#@%AS27\*S%G][:+>2==E;?GZ.CU1LC+M;A$F;='(-4;:>%WFP^_.ZI
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M.+P/$,<+_T(5.NJO.6ROI38\6_^8I;1P%@K3S&/V?>[33+H$&O^_G17Z7T#
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M1K_8V^6U5LBWHFJ^G#L$;B(9+?<G7=@G^^K0^-$^)S+_\$;NBZ>HM1JC.@S
M3F4KIQ(?.SF!I?RTD;MXG26C&G_VM_4"RNI$+]:Y)W;NWV1\Y'*H![)+YJ72
ML@O3W'%!'6?=1N??D5]'N_-Z?69_: QQ+C%GN#+*"GXP?VE8M)?TFVI"#9(A
M+:MT.;-V#7C-LUZVF/23%?K5ASY^GU<9H45PF\**FS+)R^O#$[<''8P>?6/D
MY! -C*<D@#1C%.T4CM+:Q@$X+N\]5A<ZS X [ PO,>D;$+89C7W+_V&.T%-A
MV)[O=B*22)&_Q*/;/B'_>HXSN:XUS13R-);#>=6\DFS\^V2*>$6?RIR2$Z@F
M[LRYRD]>CPF7AKT()U:@]VZ%09^^NLMM#O7ASL6-ZT$A/::98EZND^/XE4.-
MOO$HTNB+>[EK9Q\%QB1Y'Q;@V'7CC1E8ET\)6#%$A['F!:\EMP%[9F9.4D36
MHH>5 A1?CH=]JV'8AR9SZ7TK/YEYZF]2(S09[$ZU:_@$4MV1N+$MI@U3\ZXT
MA[/'5L.\M:NX"X3U;]YR) QQH:X;DS)G@B5ZJ[@0=3BJ<[U)$W^OG!3<,#9-
MF)NU:8'4$=?+ZJ"RK),(G8;SQW!'B.8X__TF\C,8>,=O'0&ZF%@AGZA?61MJ
ML-:\@V/-'2U:6[XB5"/#L;SP>Z7WOLB?;^2._^M.H?.%"YOA69N([XO/0W$C
M6(B2JTRS'1>RR1WWZI(%6;I$)SO+I!TEX(;W^R_\;*\ VT6(!N<Q L<X_!T9
MJ"-#5_JJ'C5[N,9'V[SSOFJ8VN>(+8[K*5U?B.JNC2)9C,+KI\634L[4YZ.-
M[S:9&P;L;#=CO L!FGT\O?HFW]=E-NTG@U12B$J?1ZGJS>P$;*0XWJE\2$EN
M?_]6HVZ*$9H-86O?Y\=O\?RUA"0^%!E-#"/,/ S;<_;*"JZ)S?ERIEVN!.J&
MJ&%3TF:5Y&\U@!2O,95\)1^,-^+)J+V.-YH?S(;N&RI9&F:6Z:9 R>&)M9ZW
M<PMM5!IW>:MVLK>2\$"M%UO03MIDJPV>==!1+MR@5.7!2W+]690-G5HE>9F-
M;<Y__'F$C-^%VZ'R_'Y"%6\&F/.)226;X[JCTT2#DVZ57P59-H]NE-.R"%$F
M;I7H\8;!!RT*-8<8W8\?LME*E%E7'7\S8--:MF,'=7 LF90Z<N]SND.WL ,<
MT+.BZ B :EOE [_'"$Z3V<(!9Z,GB9$?A8BU+ 0]G=[6P%UE39\D"BX%929H
M9IH$@*@(M1/%EAO%YI24VUGHQN7,A(0.-N3G7^<K6G,Z;V@F"D7%@3C]/G\H
MXE/S7A>035OGDF7GL2/+" "&DVB$R0 UC'&BR\HI/:"\(G)<) 6Y'XR57]K(
M9"@,65;7M?WAE.'O$]=TJ!13>Y@;'HNA[#M_U<D1V7G)N)Z:GYL1L5$&KK4!
M-&\M2C-'<K1'E"/ D8!SR!6@3;VQDOD*D":>CJ2OG"L 4);]-O<]0P#'<[2<
MN-_/"D(<\O05;3ELLHR6(E_OY3@@#@V'YMUYDP3-#4H960K$;J#QPLM=T+<.
M. =5I9PP6A2*^ZG"<$\=T5\J\*/ '09FWT1XQOW[IE.9?Z]_T!)9OOQ'12LZ
MNF@4*I=,JN57I->G:CK1"71U99ZV8,;]]=NN,@O61^$T,0ZY4]OWF]-B'\4]
MD\/)$XF60YL<N4>\+IR2E$V93#,J,M$YI?TM)C!%=,[/DQ_?J7.^6IZI<G1;
M2W.,24"7IL$LCK"7D/TR07Q6]^ZL*3=*(,.=]VCP5TSUL$,#B;:@W):TWISU
MJ@>D<:W*T1UYK6\X@/'^U8\Z^U6CHH4]E<(6/?W]&Q;OM*JWE[)$X=Q'?QXK
M^N:[3<KP!4\>M4+SAOYHC*H!;YDN>L6M$E>UI"61\&6<'D$<(68@;. ?%P2H
M"!HI*!?C-Y!5_?C(BG2&6Q(;-PX'N^-%U$-B0T51?L>OMO9'"2/RX=1S BDM
M#FN'!44W9V8F"]-M\KK19G0-2,!,"H7M3]=>>;13DHNY)J[P3>AQ*K;OP#><
M)J%AFQDWZ2VY4AAUFI[-DC <OR4Q9Q;">;B=? ^'\EU%LKKRR -QR+,HV:/=
MIMI*V_:[+P6G;[QT7^<6'L#2^V7+@-TG16T=+;?AS_@^QO/OGQ8Y#Z+VH[-@
MKKT4SHLCWW[3!E#;?1[D_&TA7K9BA/#>D#GHW6D058\0_[(Y&<CD=>A*Y(,^
MMH[7VT4YI?QCQ'RP6U(TW8$!<M_TMZ:([86>?5"M*Q+=UQ[JS5D-@FC;1''.
MO#V$,-;YG3[]2D&NO!(N6?.%0Y'A8(4<'6?UXB;3P@EHW%!>-)WF<57BG$(W
M+TIGT#B-H[K52LQ8 \#9^6<93C7DH<ISLZYD+^"%V1%Y'OPSQ#[#ZK9G\O05
MH S>.O2UV+SR=<SKR;&;\T+.2BHZ@RY0'6.8-[N']>AN+W/OS?J^+P6A(G;D
M2AU;4>'<EJ@(__ED90.UT9FG82F4:422MKIH5DY^TRJ]QV,X,_?77G\,(-O<
M>+>SY&=E^*!FB.N!UY$77ZIR76Q5+QY>SR=2TZ]-YU 8A$%4R_[7!B<P!NH>
MHC( NE=15QY=C$NBV+ ;B1OU349&>T>\&@C];3<4V*OK/J94,ZJG$D,ZE[S@
MIV/^D,G9)[3.*58D N75%+Q6]]HL2,**[(J'^#./.K<7DSP1^IY/T5:OSXID
M,;(P?D2!)>[;$[NGM.BE-'-RZ]@]8" DGI C-9\E3^M$=8W \/-S@CU'?27&
M%MRQ,S)R.)VX[6FH5,;=PAM)IFMYTD(B"/=@2.OC>9TX_FLF'N.X-1%51]YN
M'5Y4\,TR+L3!AX&M[MV"W((5C:P84/,1A\^K0G79E&:C6TU0JYC)F9!/T5V7
M2Z!]8^_ ,$-NE# M#(?7QZ^%OO*B3%VO1VAJP#A6&E+:V3LI]H W.=CI[I&)
M81MF\GW\S#)0Q)</1:4&$>9)WM^Q@\]&I<:+*0LM"!9Q#Q8L^+D,>>MP#-7?
MMK=Y7L@1()*O4Q8;MD0U-Q(;F8*OD.+W2MB'049XJ6%/WU#E^;PMU]KFA%J5
M"&.DSVH"S+L0J0O(")O:V;-V*HM<\K25\+.)I/.T>VP+!\777J+@-WXOC359
M^^B:1X$5< AE;SUV.TXL%Q@M@V<QA8KK]W6VYLM'O(\D#WA(OA#.GOY&N:H2
MQK6=J7:W]@;3RILR.BK/_8M<U*F?ME>=R57.($J@6$URA5S\/6!94,WAHVNA
M\#WB#0%=QXU$WV3JK>2:42_@*=>LV;-"+"9]OYRE4Y5TOD!D0GG;/:15B2L]
MQT/"*I2@PMWW^(8&JLR)!5JD',,RNAVZ@ZXAWHB >YG^<)O_9O0D>B/_\=/8
M^UV^\K?=V+Y$%N!$X^N^$KEY3Z-\U+G;1Z;9A+-\HX8*SQ?=E6Z1<#RX1CN1
M)HHK"F*]'IQOXO*2R^2I[T8I8L>TF /-1WMTZB]-<0##"DZB)V2K@V&ZTS.&
M"F%L$SI2RW(,5+=%7V'*4:6HH/&]9LIWKVM+7$[UR9W1TUV3(4NO+*NVQ+T=
M*O&QIYKS*SQ3D%(%/=$BJRKJ9.]!NJV/\IABJ+ZT]Z*TVPLSX^I(\SAI<]/H
M&R)A *=$,UW[H,.0QDWV:#ZOM2=G=ZNH+(08"%^)QJH?,X:^^<QS_)HYQ6%B
M59Q4SZ:D8)VP0+?^*R*>.FO[2,=\;?GT.9H#P%%&]C,/2)0OK?N3E(=#KD_R
M=I&]X9&FOWPXLSGV6^;4VDS.)L:8=@>]@U_@Z>_G)_^%*MHFH:%NJ%XU[R;J
M$WV]&R8PT<YL4+AQZ4X@>6=7:/CL?$V( ?Y-=:W1@BV[G))=[]M$^GK3Y&0)
MG-\BWDL25\SAOC5KY\9_*<>'&3)'27!K7=BUM%94U_B<J1=Z.FQA8TH-<\SS
M"^#&1B_XT.?>;HGF.]$,M1*=IJPI,9!MKL(QKR02Z#6>7>G:2*X1DA32)QP&
M#JZ>X:>FR[)]D[U[^H&WM)>GE_$MWLV^Q9(OLWB[6M TTLJ2AT6,?KPW:+2X
M-E_#2A93/?\9?5]$,SX0C1;.LL3E>? %X,(X_#Q1Q)TQ$31!96V01/X%[2Y$
MX@@<5"]&W\;=G[-.VN,GEQ08!@M]<\"+$G,[@C>D(NH%T=[61O=^>H6B$U7\
M@T7O08\DJ7"G2$\0E_\NFE*JUH@M7\VGTFJ];;91D7.0?QQ_.#>Q8+OB<S]'
M=]%0D 740=270ABSQL;],]WP*V&QP^RRZIHH3'IGMAL@42P9.D?PVS&/K-5-
M*[ /I)?!)^>I-H6[#+_,:I+R3-$!"6 *J^7KW')]P-!:7S)'BGE#@E$<[&.\
MAIAK3*?AFX\.>AK_)%69L5M9&VB*9+%-;/ZOGF'IXW]*_;B"6;^\(3O$M!N0
M_^DD>D2Z'4+?G[W^>#,20YI&P]%%5A(70'"GK)\7I<AGGAJWU;.A,2!ZO@\Q
MNL<:VDX9J6-X5ZK87VB%>0^BWN*T5GN0T<["/,#'O8QH?F$;((G-3<> +B&C
MHE[M5FC7W6(S/Y%_>V23]_S4V>L\B7TC+A3-U4\BJAUKNONNC/N=$L.0'*LC
MN.9;$,CRJ_VM9G81(;0B$&-JZP"&+64+7#9P/EJ,7<5OT)RN,:Z^4MCL\,MW
M89SA?[(\FU"V-ETTJ ^FUH'V$24QNCK,>K\5Y$L?8S ,F[;D/RK)&G4H=JWN
M%HJ6>R7A S"4>&?F@OJ*M7]>+V03AU/68(AS=@=19'?+<$)E6=Z&ZLTB#VHF
M8-$,<D?%2'?+>7PK8]AVH2&!N4:[^2L;'A;#2<F$F$U@Q= A^A!S8//FI_44
MBI%GKGZ4$!V,HH3DB9<YSAZ,WP7I%GU$#.B_K'GRA:<,DX=5U+],(-""ISW?
M;0,8_%-2HF#C8#,"A&/T<X(K1&)K!J"<+L2FIA!]LJS&M^RW7$G#-(K9!%)X
MWJP*C_95^ #K"75YIY7:SODJRD@X1)M#97R*L\8(;P<&^O.>@V^NR]_-F=-;
M4O1I);41ZL.R>_QBTD]\@5;R/F!#Z>Z:MQ%_1*%A&>5XG$9U\(U!%Y*@LHJ3
M4R;)R=BY]W[WI3VEG3RU_!E+8=#M>Q7Y4RK?+7>_03L?/L.[K\C]RJ#X0<R$
M6)]-UL_#.]A?>@'/;3QA%-3!DXHDPU\9\_'N2Z)XF)GZJT9CS<L!T Q=7.WX
M;"V.OX]6D=:6*L>SVS-5WXX4?)@+>GA.,1E+SD!G_IIJUTY,X;QUM$-Z;*2\
M[CPDB*M<9#;)S<.1Z!5DC?X5MM&\^F%^&U^OJ=Y XO:CZ [-83M<_9E,2*6[
M0N0\?]\RP=Y%EAF-RI-(_"U.A)I'G7=OINMTPG:PS\]:3A/F0JETM]EF8RV.
MTE++J09]816+,>8+6HPV5OM1%6%GK5UR[O249,LFJ<V-@'D2NKD>QUB.QJWE
M5W2CHD8W X.3'G^NN@($Z<?M!A6]%C&. YE+QPQJL[:XBGF.B8&KE'8F4XAV
MJ2LV?!(>#AY2*KI%?JVZ! V]^IX@2":(1=Z'G8^XM2L3/R^&0TVKSR,/F?(8
M4+DYE9237#%)F%RGC/64@&K,*-U*)6/-RGBLS*"#F!"W]WA48DX2'&*YP!SS
MD-BRU_.,*61=@?04NB" (R)?;G?II&7Y\U]Q'2JX7U_8I$E2PIR&6LJ72K+F
M2=VL-]70TF/*7>YZM,W#:#Q;AXYEO5)3:-3Z62AZYIQ[>:A;55@COI@X5T\F
MIL4)]^7#<45\.3(X-@,)"D9EC<>"+47?^NC4"U&E[%IK0IV^ES'M75TWF/.$
M>?"N -BB!Y#O%2PN]E1656<&89<I:8/UPCW$$Z(FIC@*V\_XR[#:A[(6B>$5
M/12RH6K#&H/;AM/[RDDOM%AQ&3J&O9^$8W7)8JB4K+/GM_T:+KML!&H+L^<=
MYJ;8+JPRV!^Y.;F6<$3?ZM$D1$/-C'TFCY6&5FA5&Q&:I%*C.%IY,UU6-"Y^
M#$W</"O]%7Y+>@3LD!PK^UXP[^KTMLI8^:7AA-+(K1#WNZG+ 6OZH9(+=,7,
MZ,:+--( )P3G#HS (2<N6DREU5"*_$[BG5NP^5"_%C: _.V7;%_\"$KX2N:*
ML/,J1C:G1D:V4B%Z4HC7>1.0..ZLJ.4'2^_ZQ$U2L)A1BZP\::#B5305\^Q)
M\ES0>4M;V^^Q;U4QVX^8:BP$T8K1-A+7<O^9+F:=5;SU+-=5G\R842)6I.*,
M--"8C1I?$!,>P."T;XT[XRC6A4*G+B^_< *3$[&BWKN81J/F=BY&"J%!7]9F
MSP0Y^[A*$$I##/6LA.-@_+5Y:,"/#:ARMS\,U@G'^,D\PJRE]M@2%9L_\588
M+3.PBOYV&?Y]HMTL>H*@Q@PN9+X8T,'P!IZAMUIO,Z^HGN-Q3(%..MSA/=3^
M%:/I)6H[\-6T##8S&35/+\!T39@K'>+N=]+@/^T/MN&>UIVR)6H[[[O[[CZ=
M/"5P*OP&AS(*<!V($?N1PB64U#57[<8M68HX3G\T@-D>F"+E+Z2O!8U$-@PM
MT]0-(V%EDY>)8@@U*M)%?!5CGF@O@!+ 6DNHZ"3<]I[>0/FXB;2!S$:7%Z1I
M+Q(@__#1%4![O/E-A]$3+7QO6>AZB7N,7&6U56&1Z+>#[NIE=NH>ZZ>\_!V6
MY)K3V67=WBU^#NHMNK[QT*DD$442;3Z.3]F?6JBB.CXU![?A$D<<I/(\[QU[
M$XXYC[):.^.OI0Y[-E+ AYO,#@J68#&8\+?G%ETQ>_<EO]"#?)$F(&>@7K3V
M<96 V^V8=8KDT4$'#\&G/?G)N7EI;+E?OZ!!&!='DV/K=+6;7AP339:KYI%_
MHJO_0#8Y#C [AJS^$P(KAYORTVOU(O:,H_'P,/^6;].L9#HD**\1 Y.4JS<!
MSL"5HRK=F3?WGG\>8]HO5Y+<TWH?P'F9J"NU%.W5VETE,66ZJOR@GF?A'B$C
M*$HOZ_/=1_:?CP#YU-,IZZZE(CO1U$W%.3:1//VZ!W7L'_@:[C![R4?C?NBT
M\>K$$2? ,* \?8KIFY\^X1[XU)_OIC!V07I(C]\FLUD"(S.&EMT-M6JAF_U/
M0!5A884)IC=CWV-CE+-7"@X8LT RP^X$,80!&1X"-6507P^@*/^#]O.-K/EU
MS=CY+A=)2WC>M?33/=0^(!?K?3(L4UJ@1(]-192K;?9Z#*W!XS@X\_.H^2ZF
M_\O(?@=[$N'*\"*R.WXO!Z,NC(0CG>"Z@"T7W,<CO/GY/#SM\??+#<T>VSW]
M$@I92['Y4#K(54^>K]>1H2>*H*TW#_?B;7^QV([^-756\'2LY#107=L0.'CX
MS7EQS/L!&#/VTS1&W)AT#:<3(/20Z77/"\]-Y=MD=!\7AN-%9+[;=0BFX8RZ
M6HQLZ106,N\O<[_F0:7O1+.>Q;M'WB&FI/N3=HA<7,"B*0>4NR"ENPV:"NR@
M05S;P!@VK>C@6%35%6-B3@M"*?9Y>%C$OS.%C 4'7X?E!K>Y^&PENZSH8"_X
MB)ZHLL54:E9+<'N\L<)Q<Q$#I.&'>U$[->NV0^;-8XL*N+9"XVN]=4RI[FB"
MM ./8:P<C:T$5*\-F$8:&H/2RGIT[=+3)A^;.[#=YE+&>Y%<,I;2\ !T8'.>
MK*BL%]+ O:"<ZJ!55<W62C@)9"1<]1I9E Y#I??7) /@H3R\]4T;;E7I -?1
MD[:W)VN6)L+0O,#0_OEV&_96S_XC_$"^L^:[43H,X=SG:"+5TMVNY"8QXQJ^
MK&.T+;5XM:&@3UOFT2P+E: 6A;[U=*V9%)8 'X;V% IO%*><:9G!KY1^!2+<
MQ>L%!%C5]*^$SJ$VK?E@^TQ#\=2LF;XV*%<<?TUEW1>FC,5,F<OS1;3P^7QO
MP=JQN2'C83O>#?(7T"TNSI1UW PHN;R^<7OWL"B>P!.+9/RPPO5:G_#$LX!D
MB-5] VE1BB_OD\*B!(WK'L+-NC:Y*#_)DQ=NX5IRJL;=4&-Z;D5&O\#1P:%2
MP\R+ @Q/?OZIC=$5M/LE6F%8N/T^;DDW+83/^I\%ND)VU21-V(656V8+M#>+
MC&.ANE0[0_8V>AQ^;S5UD]Q3#<+CLA3INT7S8L\E=S5'IGHS&_W3 LA6XKM/
MTUTYGG1W]))12GFZ?+=1:4UT":BB^: P[;%L.ZH;GH)B V)3OIQ\]1:/:I'J
ME33@9?R9SW0)HQ:FCUIW*RE%6[G; 'R2MSALQ3*%9<;1GZ7U@*P%;:A!0JZ\
ML:QTKX):Y5S2MC4H%)=P8OQ6_?.9B/]3W7>%-;EUZX8.4A2E-Q$B*%5Z[])%
M>B\B'4)"AP B1:F2 (F TI'0FT(@5.E=>@F$(KT'Z:"@:Z^S?M?>YYR+\_P7
M___L?2[>[^J[F<\<<XQWC/F.,0O-QDZY40-! 3YA"F<_YXP5N@?+DPMNY)L
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M+2;V$D)!LL>RZK]JY8WR:Z8@T>O>K[LT]B.TD5]]F,\'*G&_=Z]D$23KG%8
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M)-]6,$_,62,<F5G#1^=T#U5V --9;'LJR[4D'@*!A=WIG(Z#-]J#G2-8@T<
MU;;CXG*V-!2K:&HVOT%7-[4[;)!VR*Q2M/9 ^QIPC,3VSN.6^JF#.IC5+B5,
M9_/!LI)+7!^=SST'>A4@,LU!6_%5G=??UPW9):! %D@J3X% IZZ_'!GRJO/
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M:H=QV*M4:W.&<D#02;)S[5=P<![XYGPUV4X"("A>PE:CSS;FH1G3!R1,:'^
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MR>V)+[Y(TQ% A.F"6:*_O=G\E+/9JZ57>):7RON(JY[XD(-H_E._8Q^W BS
MCO+P"T-(6.'/G@H?&XV3NF3M(-90]V>^/8U/F0A>P97QDQ*A:H=?TJ3NV.VF
MISRS&X+4Y_5X<L9(TR%H'0?6@%O \VU^C\Y.[)-/"8.#Q%$X^GDVK4=E"B0
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M3M7BFD++I0#-K?P>#'<!V .EUQ7I$TZF")8BI%KT@\1EBY)<Q5I"[/+Y<4-
M47'?/A'6#_>FH@CXS'?55<!AI9=^-G439Z"BMDGAV3[7,*Y( :,UKH?> ,^(
MP'J"_HY]4';3^!G8O).D1;@<YJB;;69M(;S>?3[!3:J*Y- V(^+G[.^5NG%P
M1BU8U\K"']K)V?#%F"%I\WA=P_R[_B<Z@GPPF*2P205,Y=WYBI+-@]XDE,!H
M_#_5J'NBEDMS.VEOF*>$'\.\SF&=/ \(G 4:[\4!X3?5=BR#?O']&L^Q%5:1
MRO4X>1%94I0SB>OAE"^75%9XI+4<LMDXRK"'2\U!LC7]2C\7U'R2+2SH!1Y
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M[1$5N_(QWB?[D<?XU!PK--#?K/V%LW^.,=__$F?_-V/_DZ]9 !,9";%XR#B
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M^*L\]?Z>/+&=]!(TST>D[N  ]@?_YBD(Y"H*);0I:= 0ERB2-:31JI7(+F4
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MU8>(3-#<CJ\,)6#>6!9[]>!]V95YH609Y\9$4BC98+S9)3))YR/:C)^I7(\
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M'.\&P6B[$W/R4^Q-$M&70*DG2,#C4U@H'-";NGM:G4]>*N$ZT922ZK:R1(0
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M*"0B?$0]0RBD2N2'L$"6%AC2MDH,?J'RCZSDC&;<BR"M4^:%L)P@A*%I7WV
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M? _NKMVK)#I(.AWUX2M@P#[XO?^>QH4 =W[FX&OB<(AK(<QGEAOV)!L.K%L
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M2:(O]=^H=T4:.8P]8\E]\3>6O<RO4U4M(;G[0C<$$<?KM$);9B-#XP)XH'"
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M?1ND0O9]K(.QF[$O(V*\GN<XOA_O^^?[\7W']_VX_U[W==['<9_7>1[7==\
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M<E*R4@ $) ! _'D \#+P 8"'A86#A8&'@X-#0(!'1,9ZAXR$A(R/@8F*14Q
M2D),0$1$1L5,2T;!2$E$1,?SGI&5C9.3DY263XB779"9@Y/][T<@$! 0D)&0
M\=Z]PV,G)R)G_R\7<"> #@\1"-D*!4$!0*)#0*%#@'L!TC_]A('XMP+\>X&
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MV,9@&@[D@&C2%H)/EGK-&&KK!8R(A1.I@U/-BJ2FEI8+Z <8<9O*G)3A1 S
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M06S+>O:T+_\MG[*W)!-%!!V)?]+_F5OX%YW_Q7Q?:>=(I!88-7RJ&^QT,("
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MQ[4<X0S'"@\A)!CH3#Y/PAPQO!>4SY/19"ZU2HSI_2 #-\H?Y7&++7(WGII
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MJN':M.TFO '-2G0*Z5GT1 =V"%QPJZ1MB:Q@ XL](:<M>X_+9%T/O*&X0^/
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MLV282A9^O?MQ+,S#-!]MH@Y]H;<'0_5S=MF">747TO9PK*EASM:+[#W(>HU
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M(NKJ8B=Q(IX4P?6.S"(Y.LH&#G08L8(P/A&2^EB@=<'[.A1&:8ZFK-<#4!0
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M#YA/-=..\8Y#^>'#_G\*)O^_5I[G_R]02P,$%     @ "3QX5!1 ./S^Q@
M.<\  !@   !H;V]K+3(P,C$Q,C,Q>#$P:S P-BYJ<&>\NV507%'7[]E(@! @
MD #!(0$"P8*[$]Q=&G=)0P@. 0($@KLDN'OCW8T[-!(<NG&7((V[3MY;][Y3
M,_7,U,Q\F'5J?3BU]UEG_\^V]:M=YVGV:15 J"2G* = 0P< T/Y=@*<%@ P
M!PL+&^L9#C8V]O/G.+AXQ/AX+U[@D;]Z_9*8FH*6AIJ"BHJ.@8.)[AT;/145
ML\ '-DXN7EY>6B8A,4%N40X>7N[_"H+V_/ESO!=X9/CX9-QOJ=YR_[^VITX
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MZ67/1G^[ECT$,R4J!F.;%R1<'+!D@SV\K"H-C8SL!00\I^)IMJP[57)4/*_
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MBUE+IR"48GHCSI5VAKF6DAX7U+*D)$,H\'SNGX1E)L2DV=_BH.K=G#[/VB<
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M84WT#68'=RBY9:'UV V-AG!6E3FFKQ?B68ZHOEX*\2)B&G>46\ 6O=Z@K,7
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MFMG#3D077@)V3PH<:)38CZ^D1(EHUH6HQ2X?_8'*1*72827%%L.*_P'0YW\
M9*CKY=6DL.X!]KU3030TYH?2*J<]=V-P^DTT!O#; 9N<$ M, !LXCI<6XC)&
MFG%)20^\J<4<LT9K+GU36M,]XYQ-#44KHGYGE)H*BH6+M2 >VT"7;;CK//8N
M>AL8P]HPC.F<[JH%NJ84K_6!5IY_V1=XQU31"_MW!G,]+HCJ@";%Y)'> >E+
M-=\&KFQ7X?YA08=V>T%?4\Z_S%I[9P(+(^T:DG66V%@V7QBF NF)^27%%3G9
M9], G9 R]L'=4L'U%IDUNXWNN]?;20Z*#KFHXI8,?FB]F1F\4JI4X?,A>]A
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M9Q,(DBH*;4J(Z1TH5'=U>/Y%"I2GD_VE5;?E04:2]$J <&%^2:4LO%A$N87
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M8]^*<*(SB>9XLWH[^^LP4()_%=]R:K8;(U4XX,C #_3G"TK-3YE:QSVE.IR
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M*\P[9)TPB=+^)7')J0+.5'2MC[ 079!.6*<]^QJ]9PUT3 ?S1)[@C*.H^T<
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M"-96^AU0"1Z_L)>(X0@[,_U'28E;M8EGZ*)GO_XWI1MD-$7YL"F$5#P*V #
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M62-=TIMXD^_C/CX3NI,PIQH:+;53A"H-U5>!XJ;Q-#L?:XOQ^;#Y'AU5+--
M"SPBZ^M=V&FU" Y4:Y#HJ#*VNGZ95GKJ@T<\<JOQ8- $4C\>Z'20@NO)JGT<
MU.2+;TN@E0+7\,@K&935VD2F""VU58&CHU _X%6>WNNA:M0;EXE+&$.TCS?
MKFZ/IRU6*F%1<QX\RM7\#B7=1(O0?1)^8E_UAA3I* W< /[16AU_-!<6A8.
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M>[RP?^E80+SCLU7D,3VCB9@DOG&&:--8+\AC""EZD?^18#YNFFMD<+BX+7X
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MTD*MAL%!UHHE%>'TH-337M3Q9/$&2F\7KJ5L>!FGS7M[5I('9[H'NNZDA%$
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M0:C,&0$QCO>3+BD$_,%99X/->!/C3@H*W2'39)Y/T]-VZV 0R%6?Q^5>Z.D
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MQG(ZI RAU\X\T)P-;S0WVJ0^Z8EWI<C:>(81-ES53$9@;-4D.7/6^+5<N=R
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M&0/CSZ&D*WBM"!;KZ"]\XZ] W]PC'72P[6WE',LK@,(7!QF5?ZFQ#?AV]@H
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M$:/X$X3+ \EO>]:7168LAX6K6P5/?B7.M^D-D',0R_3IYV@6,QX.UO4K-/T
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MUTEDEWXV8U5DMDNK2;J\JS)Z!7KES*[P/[64VY-#L$)Y\![WLA:,="9^A-:
M6X?E;M^2O8&.KB 2H,</A4T*Y!MG-C^\@UNR+^1EXI'Q>S][D8><ID6KG$[B
M/Q;^EW1#N'0Y18N+X@\ _[:%)'$_15:J%5PI:)0G*\-,V[KA$D9F>!6Q^Z@1
ME!OTEEN2T1%0Y0 @'JT%_WD",RL]Q:C:$YNN*S#KU:/JXCLAZ3Y,L>1&%6>R
M(19\Q*G8_HY<DYSLRC0PMU['9*I\.71"' NTF='8U\&K9X;"H1G<(2@<DS?O
M3!*H/JWG1%[D$.ECU24?/]-FB+,8;LJ Y2(7*WLG=$ =,[Q-N][.7=\"A2&5
M\?ET>&>KS);SMW7)IQA"-H_$SC]/CUJ4 \KM<1P='T,)9/9(L!W(XZ/%!_?V
MH)1J[F=+FVVTWNJ8=JD+3WXE:[4N/_^#<2*_#WC] QB3',GY?>JE1>%DJ0B+
M4L"!+OV@8[AT0V[?3^K[FJ, BF2!8M1J@M5N/\2#5V"^.&34>O.$)G4C:^MC
M;V[%M4B*XQ'\^B.XR%F"8+''8N CL<_CDR9)0H&L!4'CD^TJCP4+F[#RJC^L
M)O:@:K&PCBS,;[446A6Y&8B>?_>N#3JF_O?(M5ZJ:R\IQ,>:>RV)$OT>5ROB
MU,NJ[[XU-=<@?K?+OQ8F0[S"?:JZD]1%ZWX-#RZD7;GMD#XM>ZK<3F>Y Y><
M&"(W7 MUPM\S[C)-C'Z'R'*=L@2'I8]Q$KK#-(C5GT?AB6>_)F5N"9,_2QHA
M+DL[6$:PE/*.O+6O+]OZ)!$7 7W\'N4(M\_TS,D[CN0>*0BM-\4N8"4O[5H&
M^D)8#"DQ?&Y3@L+6EE@O;2X7.@N354+S8(H@;<L$2F]FQ[W=D!/2T]MJPOY8
M":?R3R]81FLM"TT.R)\QWAP'*J. /*F5;R5VT,Z((?LK\'EC%^%JO?N<<+KB
MW5.7.Q$OMEX*);C2W#\:#.7_'XJ,C:^A0$3@8(8SN4C0RBM0/_>87_@*# GN
M07S'7X%"W?]N:@ -HA@[N;?.3R!;<82H9&#1/%MCPL=$=I+;IW/!,/;3Q?NH
MS20Y,$M H]N3EP.JINHP<2QN#]&<' @%318_#_V3;X?UJ6ESXA95CO)G9\[
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M*(G%.:; %Q:L%JV3R_."B%=7I'I64SD^;NF("7EMDZ27W[+M_MT]%O;6O17
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M":2/H'>$5O^ ?Z+NRW3+Z'V^/0Z(%/G\6#[T:-IH:T$4(T!<L\3=*B4AYWQ
MQD735*;[<WA Z<[<H/3JP$!#F@MS(I0ZQD#)E,&;<"GN1SO]HNV4$2EK^NX'
M,\?N\&IK+9ZR?0?@ZOB.HWPX3H3CJ1R2\C&C*JF9J/FH5S[VY^#45-%L8Q"H
M;+T@'O-(7A?+U9^B9<[1?+R1SC@$R>S++S;GFY-81@3160LGS)6-U77^HHH9
M21PF<<=).M># \-O4I+>@Q'4'><;WX]OV0@MP*'QVR_JW482"NQ</I*XA@,G
MK/;;.<+1?"3AK<^'_>2A__;G ,1!9*4\D"-V&XJGJ=Y-=;64LY,)8P FD=:A
M%VX"CJ^*UI1I)G4L#->-KG(30[5RB'KY/+^Z7#9>_#$;M1J8.XJ9/9$O>WU+
MZ<;C/#]1ZY%NC^0%P55AH<:ROCY2X+-?_:5[<V#MD*9]8I\G<OX/DKF/&45Z
M-LYUGX>=:3GU9<<2<UU?^)$EZ!Z67\['-.<?W:3S6YT^?O:MR"Z\XD;Q\I<=
M?/1O*->WJI!FC>]^0'_WN" Z4-FA#(]XGA9>Z$Q[RYV<B/Y@PR4N_0K\_$'3
M.GO>(C/K[MOEPFCBZ\K=EY1NKM+,-J:(Z6-NU7U@F'BB7#<N@+A]BLER/)FZ
MDC*(N[U.<ZY?9SC,7$^FQ4=V79-7<GZWD@UB+G[BZII8+<R]37N,M?LQ=QU5
MAE%]DZ\V>48Y.N!W9Q8W"-]@4QT6EZT8ZHD3C:KSZ*K6L_D4_M17X@ME6'N+
M ;^*J4VRE6?W"2$$YKQ\UV+_2[R7[XA2"D%<>1E+H[=@6/2WMCWNC72E8DGJ
MBB&VT4R67Y<1C97?B82-/O! 98&'"U:'[6<H2).M$+I\F%*A>)':;*:7.&,J
M21! ]%?(@W%CH1:_B,&W\6>H8_VBQ,;NPBG[25X4*$<#'@G;5O8G .F0EEK>
M5XZPM:U$-V>\L[0)?$OAR%SP]KXM",^^^_Q,1D% M#&A6J6F5'6D6&H+Z7"P
M3&7PLD:J.=0^7V '];1_)_ZB+:ZEU.28P8'QMXAYRZX:=C./V:Z3_5NU/ZRV
MYJJT5MPJD89<7:G.6O0/\-_P';"JZJ"RC122^DM,^:+[2 BRF:XOQ0^M)NJ5
MMH'"3DS#R%'9I"SB-[6<8,"9E<(9#G 5O^('9L=6Y%/V5F=VKI@U+]DXT2?I
M72X&7/0$AWX_JJ5N&G]O#)5H6]W;F&DR/[\)67!>&8A.Z.O(HL1 .M'*F[)G
M7N4-]T4+G3C,D=*MAIO:.ZX^Y8:SH0S'VU]T%^1\0CXHC)QX!$:"8_E-4A,M
MGIB/7>EZ92]%%NI*QVV/>):9:^L#L')B10::(NOY]FAI/;C$W.VEDVA_D-Z1
MECT29I[^9:K::76G-=VA.QR?HKNC!7PS:_E==:HD(664!&RZ;%9"F8J_-YR,
M0/2)VK,GZ^OCFOK>DVEI'WARE#97SBO5_UN&$3P&X;7@W?TN(&50@_S&''XD
M)IV(49*+4\5,=8DC>)#9\=?PT$ZTSJ%7%G1$KJ\=HBBWF1&4/*9UF!&[P[_Q
M>@5"<IVGGJ+O\BO#^BW.C_$?0"Q(M_;J+O<.<I#3OY!$H+?%NNS6^5B+\]3Y
M<M'(1F&W9$?E^0N6UH7N_"QW?U85CZ2JVIV^W\(K<#0_K"R%3E'K;H #9Q<E
MN5?9O]0UF%_^U_E>VNV.IT%>_S:MHE',K,UT*@=+ NS+[085[':@*R5;6:!;
M._PG<A<OTGI>9M$D84#LF3'Y K<Z-4QX8Z?H(UJ.QE2D<'"#L8^6D483"KX[
M$=()K?+T2*B,\'6?Y;V9BOP+C5"]=XXV('*7_#+[H+GF=1=T\Z,:N]]I,^+$
MDA$V4>H2\\[LL/IZ\JK&Y-]_FRH_C&M13,O"[M>ORC;5;\3;OH^]?40&2@H#
MA1A$Z22WBC0JR7!MS>5P;?6+[-H6Z6YH<4!<(#[5(A0=U_NHSTT(;OT7+_U#
M!SE=#$GWX:K=<%P.A%;#9$HNXE*\1Z?"8?7N%.W97WHT$[NJ.KK>;[EY#>H.
M+G#KZ>FI8!L,$HT<$?Q^'D%S<5[(XQ;W8U3-(-S6GBMHB:,Z#L1ZGQ5(4,LK
M<GREHNUEV'\JO,"DFI[V(B>W1_4*?(T=G/+-U75V];\T\EICXN+*.GT%VKLU
MI9VW!!":/O*[_UBCCV:HE-) 3@CJ(: $!^D;%A?9X:4GRA3']K6,+.VRY\#D
M*"GN7=1HR)BT*,3W)=3HT_6+N7.Q?UKW+<A'$.B(=GU4_9+<](/>E+YG.53D
MQQSD^\6P6UW+[B!,WD-W[KV64/G^'SPO7H0LDKE#S_4/3WIGT]O6*?5*.<X$
M!W?2ZWLB<KLW(N@;RU8G\PTT(G&.RB^(6PUN,_<J3M@:1YI&K$<W@E7[=R*.
M//!&:Z\ 5LZ<!\HGU*^];&MBH&]V"HDBJ5!J<^&4YQ6)>O3;%I9;*Q]C;+_$
MV;T9IG-43O.ZB7[7NECI8H_'C]WV.?AM,XZWY>SM8D]5E>8DK1"FI$D3;<P5
M)K)0PU+!+/!0=+>[Z#,CJA06[_>RR<+N5<NC6;U/1V0-4PX6>D',,5TS(Y</
M=>SFRE5L!<(/L-O[=J3ZX!6-+H-ZP=H^=N+$,C07>-?8SEBABF\K0ZLG-*!E
MFYF)'C/5P:>RXK@=!K8'-QOUV\2D)#VCTM(;LTQWIWQ=WI=*5_F9W=8,G$\3
M)R-]_ F'?@A=C@?"R!U66FT:S5'E:V'Q3\9?NO5SBSU2^1U V03RUM].G\:\
M+1\SK\&^Z89__4AE%#B@=8)7>8D640&1=J%*R2+)I['"0UN:'Q,_8WO?HW!&
M)P:$!,0X2!0M?PK$#V[Q\)<MMAQ5^#084Y25V]![Z=,B]@ V'57V>%+HKT@Q
M5.%YV7 ],Q O*-@4!3QP54_I68IE^+3]KT,\;PL3$)JL..G;,U OET9O/SW4
MLE_E!M@64Q]1V5.A?QC;@^6(U_#K1CYF459PABNX('P^1<C;%^$GCV&IL<A.
MD)-^:AQZ/N"W+M:IGAZ5N(VJKEU:Z0 ^?I/"\><N+[%^^AS'%?XD3K,YN*9R
M+,18B%C!5@'<5G@:][B_&WF9^=HF')[_?#" A.Q>S.T8?.(8'6V<;M^J6+D8
MIZ*8.4!@@16HJNS:]>85CQ0SYVC,7>3:B<,^V)J*EYM^ 89IJH:*R]N>^)=+
M'U=2+Y/->$G[_ .MKF\J$PKZ"0>"D?, H4H1I5= (?N&]C,\O,#7V[B%%6>"
M1RA=]?_Q,#B4[N,2B R> L]KXC[]UNE<"'T^BK&_,^:G&O%T=GW?FDKW[ZF[
M2FZYTV45NHY&E-L0(KFD((I7P"UWQQKZ!!>N>M73V>GS-[0%J:>AM9[R?8 [
MM'R1B8,H?99=!)NV]$F\Q89  AJ=[%R2!E3%=6RF.\F=2$\U;NU_A*8CTJ?9
MJ#8H:++U9<0W<L+.VVV7U;%$S\5E&JWR^A5 MO^BMYKD7#KY5\;_W.B0GK&Z
M9RGS)FB;%*TFXEE *#Q]6OYW/\6-Y@>&\_:NX(B3SG[(M73N2++=QVPJ#BD_
M$@[Z->3!#^<3>\?-G#8\/*S4QZY\*>:.GC##,%.O /\UX>;9=GWMA4))4^D@
M4>,,XFFD.W#1\>R?,B];OMR7%VXU*4:8"E&_/80;8>0Z!&T<5NV*G)G8A)TI
M)YWVX)B]E R7[THT<-L@P91#UQ,X;9RMV9,>LS 47>B69MQ&U9\0GKG;<*C[
M),AG?2V.L=VE\;4.B52\7!&[QAGR-T>8KP6=,EM^FSLV3C3B:R">SN_=?NJ[
MQC4<[(_7DV=NSH<#.Z(/D35F?HWSB_2^K0BIR<?2Y._7S="L3>J;&G%V*#[B
MY,F?W0F_2:8K7U"9+]W:$&=#/S/4SWNA9'WN5XZ9PS5\!31J9PJENMIDHL/M
M;>9VA",+$_U3LIBX1^L@*16#MN'W3 4/W6>EDY>5[?X1I3:S37UL3AW.X>T9
MT8DM=1[#@RU*MO#J34WM<^[6[GKW"IUX^3\'[3>\.-^52%\+R (>J'Y>*Y;Y
MF?F>>5"9;][Q3%DP7YH*V13>UHV-0%$)Y4B#T/W85OL&.AT!5@T3%$@1JA)(
MO_.-S1NAR9*E%.EI3.N0P<07!3U5_?G07B#YK).OT(C=YIAR/2"6P\QI7 ;D
MO_WK8W%$"]A1.<!#0POF$H TS66 KYT?P K\<=NDV7B?69PYO-#VL>LA""07
M*9"2RI:@FOJ &8> CV_;IQ*MQI>G9W0TI#O[!C=L,Z3 U (_H=;32A!*9YUK
MWAV=4L]/0+TU1DVA@;T3NQ;QC!<N#!TV]J6?15V@P5\$YC-?(@3W%B/UQ1.Y
MV^G/FC!E1FE;[DOBYOM7X , ,5]X9[6EX+BUK?/M]G!K[4];;4.'\0ZB&$L]
M?X"GQ_N$HQ,]K/4AXPOAN-)#)RMG5)5&3RW='TK$GY^ANGZ:4T$-*/) TR\A
M'Y]L-=3.4C"_ZU0.6F6EO3BT3?(^\<5]#HRC#_H$.;Q[MB/J21LX1342<X6;
MZ_K=PZ3%8V2-1 YL4E&EDF30DC0M)6L.,2 *25K0NS2H@V)VC/?QB;]QT,]%
MV'D*)1LJ)5O&^&^^&R))*;;S>[><RQ0_>I<0AEBAJF2J:YUKO=8!0YE?L:['
M_23WZ_A3[U/2?/6,!F*Y<<Q?P0E$;^TZA-ICAK\XRK#OOSS<UDNOQJ+GG\C;
M4<K;$=7^QMWQ!<^IWE[KAD1273D6\T:2;X!S)3\,WQ(G0@$6+^#(41O;@)EB
M8I*?NG>NUR>'MOW559H>P["4B#]+J9*&J>ZHKE26=%[2!1-Y,ES9WS'EE-:2
M!'K@VOY[DUD:X,!4EJ3'IE>FN$-;B+;O]WU[)7@9I"**H6M O=:: J4VG1"&
MG  FS&DXS<M<=O6U1F$?S 8.Z#X,%J(OY)]$>=QA&H@VB&\FM)/N^[T#Y&6D
M;*SS4!F?/C6V<IZ,-W;*=*\)=\NEOO^A2 ",6_N8I2I=X%;M@ZJJH%39Q,YT
M+/D:.],32IH@?_XF'1PR,%NY"61BZ/>[DMQGL=V65U([G#B)S#"57!:?U6Y?
MX9*EJ;1L;LF"/=6"'S3TF5P@/#..?WXV+EP/S94$)F=K_^' C/5K W7(MSX9
MICGPD:5%8\?INVJP<./O?9-AL3^%YD\Q:1 DK"X0^IEFGRK+5(V\-XKU20+-
M=3ZJCVGB6^1DDJK?BG%CJI(+FXAN])JMJM\B171 XU+QV+<Q\#BYA4JBZ..\
M6)1RO/_EF?$K8.*LW)5,8EK=/RK0O::5=.8'1[SV;:"H/:5(Q-\-898[V+M,
MPK5\EV(1$Q6+/<>6C_L="XHLB+F0!YI L 6C9'?M0+WI8U>FPY2N0RSO75&5
M3](S;_EMC) '*?-\V+49 ^)UU5,-YH&'"[["8#;O$2JRN6/KR4R=_7&->Y1&
M[)6F<]8N7?UWZ7Q*6(A[AUG!SUS2-!OJIO:[RY,P)?!>YLR,+U<,1>VY5O;.
M$_/[]5=@=%>3/ZRM#+0FHO1$2/+UJ<JJQN+Y<7;SO"@-K?ZPO7C\-TQVV0I"
M&0'QQ4DD6(]@Y<6RT/DZFN$5D%""#-;[.V+)Y]I%$ R^7"J*R!F.L&Y[0GY*
M11'Q,JI$QNW==70/53N@AS?.+SG@=GPNQ(_YNB1"4GI567+XN.GL8$NN]@HP
MLXC<)TP>,JRJ],.:\A;*3+FI*P/YN9%-HZ2AQ U9AP(36FRI>M8WG\*D?RAW
MHFKJL*>T"/"@EFVZ\'ON5:N0<#=<?CV*$ABU#HDC_B^57&585.&VWN0H(0(#
M@@B#=(<@TND0(M)=,G0,'0(.H$B#Q  B+0/,(*D,+2#2TMVA="O2,5P\Y_ZY
M<<YS[X_U:^]G[6]]:W]KK?=[UGKC^%[L3P+R<F8A,EO??<R5SZX X^9SC=9<
MD<JT8?A7ZDXRR5AW7ID:XS8+[BR/G.1JA:Y.I?DR\8!#AW.'*K>1L[KUVD4,
M3+987ZV1-FMNS_62_^SP""%EFF,6VHN-V-[(25=SU[3(\$KPV#H;ZW*Q>A/>
MDNJZ_]U/^"*8:>P=:I-:,,+[PNA[&<NTM3_Q-2YD.^P7.1G="0Q86ZF)EI7$
MUNVL@\H;K<AUW RL(\VJV$E\8W6=?4;6RI>]:7\1_9T34O=!D!%\9^U[']%#
MLM]WXLNT%MUBFC'^T[2O>*"':O%HU\M@1V![!V^*TD#.OWNVKUL:V;V<TU\\
M;R^IMU3L=YV]A37#L,6UQM>@A>W];,,#@6]UN-N&H%<=B$JSV2:R7RD[C6-C
MI7.C0J8B)7W@AM?@\]8U VE#RTNT2^NE \3DYP%FSZIB_. ]]C3!TLP,ZV?A
MPL'\F0";V!R,DU+AILI -HBXON3^H>Y@G75XGA]N:M"@[(X6PA VWQPA#/)A
M;PZ[X ZY F9JJ 2GPN;].HJ6<Y8X[34[*LN]X89:0TM8,7+"HP#"<9)R:97^
ME!0]^'0GP<KFY)9>Z05Y2>LERIIV!#8NS/_>'_3]FW[*!VED[&N1V.<C*XIU
M$X[C%F3O^O=I;!Q8J%4%8D,B^]W/+2&"H 1ATP!E5/Y"._-PNDQ%0EDQO6(=
M$/L:KX7P=N"$:&O;W=3B(D19QZK,75,"NLKZ;+(OO0'WX]G(Z^BM%_8S6NX&
M51;,S$T[4?@<W9B"1EM(2G?5KJC?9\9(DV4N^OY,IYQ ZN\*O*Q<47[4W[JB
M/3-[KI<[YOF[!=/1]VKM?KSL4@*/?54GJ$B'P9^OS/H+S.0QHG\>U>@;V3(H
M) %*-'J#+Z2LL)5N)"!0RDK90:4ZD6L=&O_D^T.I=/&C1]S"^BY[2PUD #?+
MY;)K7NEX/LWC6TEF3X3,.^[,X.<X@A)=(H-^T;N5:D(!&O)1"Q]LXC%OYWAA
M7@AKA%]"1@?$86"\R R),6-@DZM5)&\EF&@:Z&RN8=QP+<M/][*VF<R@3]7N
M>@.Y3#N"Q)E454?WSUF%N8=R(I/:,I,T/9^I<1:)XG'AR0//;P%@[/_.M@$N
M*YGM.2I^1&GV-O=R2@45'*]]IKLCJ+.,M37A'MEKNS1<F V,KM)WX[/^HJ4N
MK8,6[J-OO8]#3?YRP!^CR7Z'-*%DRKM]Z_4*,653\YR<A<R68@B9OMK!.F>P
M$,&]YH78Q2O@<',.C)=I/0K'+75Z9L?MUYQHN9'$+TQ];_KA1S&,=2BPFNVL
MJZ]*FG\<&[G"NOQ V9VAVBFMKI%R*KYZ:L_@"E"3-3Z-.)=-&4K1'5.XX);&
MXC9Q>B5W)*KK&FP:=(OD2]8N&9/PGUHOC([&L!6NWM18:8NY%VC!%D'*:KT7
M:*CP2:Y>CL<,#_K&"Z1!;9QA__ILA:S)U1;I.%"(D/GX?>.=ION?TH*2!UWX
MV%@_8:;PFG54LM^GMZ+&9C#U;Z!C:WDBG?I?+9%5?5EM<6(2*M*/K@"+>A,N
M;;4Y OAZOR(CS-1POVS)UJJ%O.7OK46R25]RSOXD]\'#2O8O(L&E49#+'^DE
MT\^R.SF&!<]7RY:-(BUG4KK>"Q\6O3R M'''Y3GVYB-2A)PR-MX97"@^'CHB
M<V^=?I4Z?UT:C_G5,;YZJ'TQ&;$'7[%T?\"=M\JTC[?] IT;95=W(VSN-6;/
MF/BGI<P7C&TJ+5NX-(ULYA%JYZ:_8+KYXR<>=]?*ZXIL_5GQ'[<RG_<L,.75
MK9FC'=([4L:F")&],;73??%'[HY#I!F):<]]C[KZS!7IE;@78T.U[*W#:O&,
M?E7>[PC"*C=LWDI:5W;Q8;T"!#QQL 1'$VQ$C'O.7FUQ5+'YU.+3*8)<CXG?
M95%L?U@-6QC"W9T=1ILZ7&EGEY\EEJPQ/0VV%"ON*=PB]7<M!'?/A:Z2[$1A
MLD7]=92.D>+HWO;O\4*#;OSH]/Y51GPIT>8DU>?U+_+P#724!+1CR'9<<^UI
MW#2;1\K?F0]OBZJ:GDLG>A!J,U.G#'")DX?K2'2RE!J]4#*M'C[8 M56Z(W8
MI:_>I,R*31+VS'BE'4+ZY[57='"X]$V_'UE*ZO4:,/5/-,4M+Y \0/O;RRY]
M D@.YQK;XF'>TB?:T+(-DY7>ZNKQ>>]XEZ39@14N10J2^'YU:^GG2Z!TI\TS
MIBP_L?=B"=XG;&J0EZF_\W5+7LRZWU)=JX\]*BUE^!93T((!AMAJ[GPV9VVK
M_>H:<C;.D?4CSF*A_=U9_^?Q&KOGL!J>'5P\A8T>;VQV_FI!]X?\]\[0IN'#
M'(J8+('!%CNDD%$LBZQ^Q;.A$?3$!,W09?KJ[0+PK**R7N@?O+TMH^Q[PVQ#
M!U.E=HEL#\PUQ'3%6^N>2YQ-:.;WLF$ID7_:?"DO/@J@43S][%Q+37KD#ZN]
M!G;[5<^B^9>^(+7?JN[T.KPA]A-G\Z/;,\W+TE#@=%^UQN2#JVS"P!,^<?1S
MK_-B4SD!DES[NE%P:>$Z_X!I.$2$X@@/9[^?"YI;>- %=QG4\ VD?A,_-^"&
MUCT;34U5=[%0]N+;1YP:>2(:(ZK4X,[D^19FW*\RD:.?=M5VG9S^:X_!WY8!
MV4!C./J1+P^I<._@&K[VI@S#Z7$I"1<^J7-MV9(@-=,M>B.KY+-_SH&W=0M.
MPVWV!3ID7]J:!?M$_!T$%U7 \)J1FKX1,DMX@O)VETR1N0*R '/4WU"V-@)?
M_6?440K5.C6):YY-E7ISX('%^11 >?&RCC9THTIL+7U:2="8V<N/0.H$M<G3
MDAM>MW:EHN?ROQZ C<B(LY5>[L><$A+SOQ;D1 4'/C2D9@A\D:/WQ1^&#%1-
M6.IEBIBNST(-:F,#2/B^KFI\[N%?HMM;,?T0KNS"$W^$X%$]Z,:K%M[X5&Q:
M-FF3^O0SR?IOJ(!VVM"&7]9J].UGJE&2(U= A96K7;8CQ?EDJ1/7BD)OO]V?
M5KM1T3-'J:B>CK[CQLX/'RN<XUU?-B0_5]%J)32TTF[\\N **(EBV!0QR,*R
M%Z<E;*7J!/>8HP?'JD;A1ACJ0J-%LL-BSJ>?9."P*Z#)B=O;^>9M3 U4YKWR
M#=F\F+"P1S?D8O4T?2!E3JC)^9E?X&>A*(+0DU%R[MB?1OFQY^7@ UHT8_D)
MLX69NDSZ8]C-2'CG;C1CJYS0INSOM;J2R L*F2^5#ULCH_N;E!I."Y"K_6!
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MZ X@\VZNH4F!^-]<?>3%Z/E=WOI!&OA0,^>A"^7#6)9P<1:C/.AC[9"/0D3
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M]V-F,SJE+E%)^SKBN?-N>.OZ'Z;'$GE=?G%G<PV]S][H))"<>B4P6[M<VT[
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M+VV^A._S+38P"5.:^^%T WPA]0?3]>STA7<)ZYM.$6.F0!"&R<T=Y3 (UL!
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M(J9%LT7E!J];7,.MU1U7$,[0=5V9["8\59?;$J.EC0;\X<-[6/C@F^Z@H#@
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MW/8'289;_&5+L BG&'G2%_!$9V--^L*3DLI7W=55(*FL:_$$Z@T]Z_46]7:
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M"<MKF6%NKN"1ACFBX^)*DM-PU;Z?B?)!IF<:R)SOPAT9+['? *-"*I)106%
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MK@/KAJ8?J?L==T4M/,.KR0;)X'Q9)O;!,%G*77R^-,BAZ/()% =W4[+5ZL.
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M@*^9_KT^G6U@GW38_52+NX'X+O'F8KA7 EE>:IB=3+2TZ/^Z5/-%:8L4 &"
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MPKHF^:<<3\(X,F(0S#Z:-23YAG&-RYLET *]M-B6PC%P8=G^BD@3HUVV^U3
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M"9=)Y8LHE!DK:D_/@Y0UK83IU55]QP]RT-O S"=?W 3UW'YS7<<-$.\064H
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MSV_^K;-EW5V:P/ECF?C)GHZW5@"V%_G.&$IAF -&(L;XJ^%5UIFH.LB*#;[
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M1%MQ"DVO/Z>RF3(@3.;(TLUGVN5.N2:[?F!@1#+WPD-A]^AD&NU+7@40Y(0
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MH%8]S433/NN06U\78K&5\+-4\V!$1,B:N+UIM1@] ;<!=GKS@Q 6K$Z\#4D
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M6E%L!>,N$^MR=Y/P^R^*!Q,00%6=^MOL%B%,&^MLT+_4(9'4@$ I\)&#,_A
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M::$G5#%MOGS_XRV^?W6B._ KOP!8/O4-]YAHZ.>*J2H\SW&493*\,\^9B*B
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MK'WV4/4=-YY.!@5;4@4AQ[I2]CG;E#$&)P/9'1JL')?B;Z^;<#7?[7H1[.J
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M'>EGW9"Q.ANJ*NR-9T$B(RWIJY&G:[Q[OF"4*/33:F8=61Y]/O8&DDJ<%&M
M-/X6X7*DO^F83JIX7.EF*^$=MJW@@_?ORG 5A&C/MWE56[QP?GR7VEQ4S^WM
MI_Q%>*2G5.;YV&%N5R#<EF\(+*"-&^8;:3+NSY\9Q+$B;TKZDE1]F^5<78KL
MMFZA%@$*WV"UF7I_<_Y7V'[CD=\--B:L#?">R8NV>%?T!(B2L9^.AR*R9I0
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M\@E[]G]3R?S'JD3<7XJ9\_^WBYE_FB0M' /M0+G:"*NUI-<,Q42.[<FI,UL
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MA)W7C&DTDZZ"DUE"Q8F$5/O89"N0Q"XD< 4L@F=?W;L :8$!<"=(,K 9(V,
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MV7R84.?N:D,#?_04_X4Y,5HXO,5*XW D(M.#W?#'FXI(J$+U-EIX#J+K_9G
M)-MXOK5!_W:\ELJX\6>40_LE#X36Q^.7;/2UPI;A?I[4P]ZXU1]*JZ_*]C/"
M7GUYE:BF(!ZLE WNQ[HGU^76]ZP;7[>5K2[N;7W-I.D/>V=&/^P5W(WF9CM/
MO5_L1I&V137VIZ\_/4E7;9S4<7G"--STKD(]W2QY9*(:)*"LN+U?ML]0H=&)
MCS,>Q=U2]Q'7R[2J%,%CKJG:/#5FJ/NFAXJJ/*$OF#%PHK::%G-+Y_EMF0&Z
M)[S>5>Z$TJ_T^**,@^/J&]&%PET"?SD9EV5:!!)(RKT7HJY1B+L=\"4E\^44
M^XHX*Q=CO4&$]$@<RO)>5%QDZHV.NHQ;BMR+OUPX?G]DX2]R8YF;;E*K<"<P
M3@ ,"!-K7ZC5_:Q*V+&Z75!JJ,7IHWVIS/[[H22"OE;RY*80":Q\2%_5XFYF
M9RJH^Z'4T.8YX3'(4??AEZ:DH#05#6L^7.=SX)>+1<]@=[0;OK6H/#;)2[UD
M.H^QC@*,Q!=$T%8#:L<>T&\;, OU=P#[,;NDW/0*I&1XN%FSUS\,;OV+MA\2
M;#FI,G3_,.?\\V38)[;*2<NQ_7(!'$$L)% AS3C>QV:_QBHY4<=&6<VK-_25
M+KSR.:X4O<?.RUTI&BQ&G5>42<-M(7212U#HC6^+WY)I=,KW@0\$.69++><$
M%)C]+_S57C*0PYO?;TYRU$3PJ;2-GT8]\8T_-VB-#38/(AD=);MR3/-:%2^&
MZF2LTDP!1!H=8>&1EQE9%6@%C"Z,&N/_HBXK?/3X$2,@&J=DR-S[2(#ECG)'
M[LT2(]TC;+"'7'JR'_LEW]O)S<M ^"RLM39F/8TWK#) %VV3IKY<NCR8GYP[
M\P@]<#OOI1>S*OO@S7R5B7.[80=YW,$>96LU"M.]2"0N=]CCGW=V]'8F;J;S
M,X\/*%-5L4VI/.(*I:DJ>'-=D]S#H\H9WH7G'QBEGWMD@]%PR!\MRWO@3."/
M!!Z4<TZYO #_+G:1<H>N%*I?-&Q4E&J$,RLH[RQO.PRGSGZ0K,YG-;QFU14-
MT7@<$RWG!6^EVQ6U0C#4N4DZU)':<NA]'J+LI595S76%2![CU2*!,B5$L*=5
M+Q[.>NG9C76EPA-#.]J+0;#JKZ:?XU^+OB5U<.)O0RA:TPL/2$A_&O[N/6#M
M,ML-:S*D[?06J#ZL+AK#W)>8V&7=E^\SR76/3]4M4.YQ0=L/"&,IZ?V7$@NV
M(:6>L!?"&G E=UN7>0ZPIPJ[0&FS ZJGVO)V7-^8$L>;TJB/PJ6E?UNC*WNV
MVBO:LCA4JZV3(#B#X\H6L5T_+TVVGF+5D(&;)RZI5CO)O3E5\ZPI=6_!3FN.
MXJ/7X^DJURC%.C=A+7\%B7E;YC?33! ?_-M,7K8!@>*$^;$4&KF*4@,Y^=,"
M&ND@7:*XO5H_L>L[)* P):;$E<_T^?PVL+VBFZX[9-'_A;]T_VBIBS%&97UU
M18M[56POQ#LA%C(AG1#Z7/A\8*"OQ;DQZAP<FL_K >Z\T!B-BU!Z-HQRAG/Q
MXY!XUD-'%<*_2/>R=(?=U[DY>L5W^G?#CN.NU"/:K_P#" TQ20?ZA,/7QP/5
M/A5[=._2C6TBEB,Y]\KV7\T:#IK9LH3 CW@J!2465?B&!8_G/O?@<)G[?4$"
M566H_86]2L]X?6V_)Z_^%L5M@85FI.PD)L92>D">/=6*\<>F)&L_&"7+P"U7
M/ZHFT1%20@\>7FR)#6FN_TQIBF9UU+X&3P6O"MOM)V-18D5(2=LG"N$]Y"'Z
MP-OB%2O2XU3L(B9@ 3>B.7^T='[)4_4V-'WOQ>IC@,XL<$:<U:7P<X#E-,>9
M]>:RNX7=N:7\_TEY$ NA%L<!O&2"3RGB@TAKRUL?C8D*%0C\^DL>0^F6J'WQ
M^Q5V2DKWR'EU^8?8@PWJH2.8Y\.FE[*<&MQ?](]W204O2,$6@=QH%J14JX%2
M-(%_<3S$79?PKM\)B<G=::RMDZ^Z?0JT+>0'_=N!2(4,[+8OT"E>CT"%<1JL
MPNPO->N=7?@^,/F7?3>R)3X21QPD2[3CU2\B)#7"]M1D>_9TGZ:DE6[K@A^5
M[+O.#T81+=J2NA-P<7:^"&R1VOQX.@!O :-.^)'\6S!G2\N#!NB)3#+X[]=#
MJRJP+N%!Z+_80Y3=>[E+E7*QJ!GV\+N?,0_YUC,3S\[6S.N]=HAE;&2_Z?D2
MFW%C6:3FN% H4SI@$?<K=(UMN)HPF/Q9@\@GNKDN#G6E7)M0QIP2&[L1W7L"
MGA10:#:&G7PB^<3CH"M1@FZ<*4H=G9,Y>L1-:.!X=1)2EN*9-L/V9\<P@W#-
MLL7*)4K-\%;6?Y8LDFC+5B B?%IRI3]I-.'*C7^WH<#EBID9\2J\AZ"^76*S
M].-HT6WYVVD:22:85JS\]UY>68]G3>#/HCCI7ZNQD@1(OWGJ &SM&P)BJ+$8
MFOK,++4I'^(;EWV]&2I=LE6H9D1;G+ONGD[9E978X2:B?QMZ#.>E!0+XHG+E
MBM*):C_[FOG:VC%5S8LY*1.:/=9!\_,MSAE'B-AF*3$FG"SVFP.T$FX?)9**
M*381?JYXUQ?@6[09 5"KG%7%\*.; ?T-KBAPB8%^>QV$1_H]3OWM15*LE+'P
M1?'U:SP.4M'4]NX9J7B,2\V?11-QA90XK'C[$**$M:C]E?=@0B.T,)+%=C(4
M3,"7/9GFIDWF*M)^D6-YS:G<&SW=[]M0T9TIV3B>&R,2X*I)73$R&*R/4XF_
MC-N,8KYL"MLZ?2'/A9"T9@YF?/P()<1QH*!9Z+V-'8U#5=\&TY"_@0,#3H^S
M;,JBHK-J9E4*$3-)8RH.L;06Y'01%RU=LSD,(F17-$'UP)>=X8Z$-*AM2]P*
M"?C2'I9K:?[0D8>Q>E1U/R*NV4L]#RUJ^6;&[6S_*D!TC6JC 8=4L7(:875.
M4@VQ*X$.*18*#%J)W"QZX1LA@0@F!<2CPD'"AQ%[7]EQ@_ [2E)I[^1VP3>H
M,D;\ZS;V4(=KS+<_/RM?1F3/=33WT"2RF/#4T;:*QFG[R/1%(M@PE">1P!91
M7?JQELOHS</[>)@9IHH/[K^"F5SD(X$Q-LWF^!O)*=S6,)8R]>#[.(7^CV:^
M6UM7)SA\#O(+DJ%+P/D1/J<!T*1 :C0@7,]JQAW*.&NOC@R:^NK#[1_+CUBC
M#HJ)B ^GC.OVE<U;3X0 T 50  'B&-5%,M7K<GM&8!7*M!PH</E!@); H\+U
MQ05TU\[Y^>L0U?TOO:*TI=Z8O>.1J06HDF]G^/?(H*6WO[IG-#F>%.[L>Z&\
M%3"AL-87S/C@P/5KJ*CTV13'4XQ,)XE]W]TA'S.),F@)14(Q[&:5S69,SE(Z
M,\(,K[-<9&$IKR:CI;*F[C(LN4D&?:$R2:SP.P8//YTL1KECGQ=P)N@:.Y=*
MQEMICC\6KD-]6'[W>O5>[\7]211(LG*&1W!W4!#I?XHBR92<C3;TG)%05_WF
M%0F2(*B.6@D&J3&&[)CVX[Y*W63@1UG4-(]@BLB.D6; YOW9_S15!O!T^"K&
MFFF=QG!8LY&49P =%2S*7!+HE9TTSC44ZJ:]PO*0ONL<1 (9R?O6?[35@Y;U
M^!8$C?*4$H<G3DV+C/-U;7#>2_& /A!%*->#GV=DVT8R[RX#=LBXJCO8@Y^M
MT'8V5*A_9N9/=!A:"LH=-A^>5@LCEB7"1ME67S#H<GX4Y@&1'T KQ@X,C+F>
M\@N<^"EF4FYT:2LCFMH2NYACCU9D6#8M9K^]&[8;;IBLOM 1WXR'!&B\RF^#
M-N]<IV9B/+!Z+]SUB[?50%\Z]W>4DAAYTQ>+J=(6X"T.7DC XY-KV5."H#,B
MH[$=UJ:9FZZ3['__UZ]/77FI;8DVE?+/GQD8_Q\>:4R76U5.['.5TBN%9KW:
MQ?]@W_=A4G&_W22K.6%FE7AO?4'PIS7+I"*<WT3L6*$OUZO;(HSU(^J*/6J&
M0*XB7[Z]"^/DK"N1NA[V/R^%?5W6W6G,<5\BJ9O"F0K66!E\+#;NIHT1B^[6
MB('X"@7??C19-_9TM\TS,-YQO/PLU=HZE9<$Q?HR5F\N^9$=]1CN)XZ>]*.+
M-Z'ZAOZ&_=,JW168=362;?TS(K 4O!L&IM=M?"M4>X>N6_.@=_W#K,1JK(2F
MGZIS&/0_4@Q84&EV>Z#VJ?!'_*FRNJ68P1:1>N8HYA@%--]+;:EE!S7]ALU<
MB8>D]K@)'Y*?PNL7/6EUC\RAH-;J28TE]&@%#LP#'HG@IL>3AS+SPU:^-GMV
MW+/[;Y["H<]#A8!-U/"3P--[RO2W%:U%YCO%Q"^2NQ/+US,6AFY_63RO^/LY
M@,1I";I+=]F6M(GK#>LU/[CTN3N;\*@:CS'I46*WHT>4?D5R+RAWTNSSVB+E
MT\_,:=EQX3HE/CI'(7%9'FX'\O71-;=G31R.= / 4?WU8QC=S'R?\\#:5J)H
M1&FP7UVMOQO,@CV0 ?5:#5W23ZD W*GE-79P@S%W)&246W5\)VZ[U;C2_,C9
M/5]7UWH49OOC207<-H"(_IUHBI.ST=X]K51(!C*+9Q=L2#XIUV:+!Q[@;+XB
MJA47(>OQ',F6J,E3+;MJ?3:5\U4Y4DCM*YG5XDR-X>5G3_A7!YSE_DX(ED",
MVR!:"1.J.S$\JM!DR/R$F]E9$.U'2NI=TED9E,A I_$%BX:=\2;8ZDB=4V!F
M:FUR,Z6F2,J]/S-4,[4/E7B!EF*G,5H)4TS$F^K"+00N&+;QO).O=T55.I:]
M:VU,X"TO^ZQ*GG#S#/JG'5KXM?9B?C>U,>0:LL8!S,_=ALH;^S0'II<3ERKR
M>/480EQ,S\+$'RKA?+2AL,BYWJC[X,"0E!.F-Y[DABN"2C437YN>WW_A<#X8
M\-[4\'N#V.I1*6'9J$N$[[/\0OZ$9;8J>5[4CX[&@3#T"?,Q%TM'NY-![F2+
M^2:R.^X^2'T1Y)N9QZ)>;N7!R=9@F$O\4MLDJP>S_,3&8<VW98M(YV>YZ_R5
MW:BB[II[QJ7O\W1!COS:)-'SLGW.'/)$A+L]GB%5MK@Q;K50MT)G?O NWHA@
M-DWP1]$9=Y@W_<,T+DV-IF:#8)R[:%@MS8H.HZVL:Y&,X@W8A"$=G[0_?_S'
M62!\3X:#7R0ND*F=Y^FM5_JO1)T?NA4!M@7[G.&*LE,\*2LIKF7N!A4M4^66
M0NX*=%75((-!0W3A?EI-75/;&@RR4H5,!1%6A2U[#Y&L'PJV?C?[U$<\XK+"
MJ-MA4ZW5;?7@4SLI@[XZ]#?T)Y?)F;!A'/Z"U^.&\IT>TTF4&<+##MK5=+=A
MX:=\Q4Q[5%FFV]>RF?DE/%P%-$M\0Y^DT*+>;%26UA@,<RLM6F4O[##MYV'3
ML0GZ+![;*AD?V<?#!C*_JGW/?I,;C3+U>),?C]::AZY*2"_!-H0]ZOQ'& /9
M9"'ELXDV\-.6[8ZZ:T(##^BNCN=3$XQEE9]*ZTKUO1V4;9J&33L49:$%'L5J
M=1,NA:6P9E4>RQ$=>JG'//M\ES.@%?#EY1'>;5#ZU>-U@>4K],N3N[85) !U
MW96.5^[AY$>,#]G;5E[&(!A*<"QG5$(6]*E#(+)FZ6_P)W(F)-=\ZY# 3WXM
M';A0N,LPGWSSV+[/>E-]S9 )\Z^YBW*60#A7/31Y@6T^-&WNP_&3P[1F]Z)<
M65<ZJ/9=M.'Y8*<DS ;TN>[<O.V:+._R2]2E"H+-&:%Y'QN)5S0-;?--##RX
M#_:YH@:PPW1?T&^N8Z2\O:X6/:5A"!DRM G0^<B),XC_C#(\2G'Z/<=,RYB.
M1!Z&.$O)*!ZH$D1!G/MM4H%_/..$,>8KB3T"DNIIQWC*<N^%I?YI]09]2[LB
M16Q)\?LLN<?50]&3/IHS<:<T]FE7HFG^5"REYXS0KR*Q>C-.)?(H[S"<G,,
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MO$BP]Q')D7N?VU+$H[ 1R3O?6/@P/7]Q><NMCB2Z Y6S&4;IG=KGN+(Z42V
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M/E9[Z"WZ4]GKI"JU3SEZ[W:77<KL0EMWC*'JHL;L0]R<Z-Q,_R!SPA=#PO;
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MPE:S8%;_:C.362L<R'+?O+.J?@5D%)5L@=QZT$G?4S> ^/7$'E?7CB($N11
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MVO&%XT/2U]Z2X6Q]O;O7TK 9V'S'7"\).8JF%W4<!K*C_HBLJMB][DUU3*<
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M>KM)HE-(>Z6)VJL#JNBUUG8T9#QW-"]_8(_O<#\7^4JM2:*TU+_G&>J*[09
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MOP&DON+G4K[ 5B:1M2FX]B&F1OAX" ML-=@SR>$2VGS2$1J>Y$AB?+RWB86
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MD_TOF!;;2#B]XK-0!_5&CQ\U85*!JVS.!%$8:$(Z=0_XKHK7]T%AKJ25@_*
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M"14%E0 -C8#U)<E+UG_W!6D',!&AS*#'8*!> ="84#"84)!N@/Q93CBHOUS
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MS1?R?BK6_1JX&2O^_/(>A^:PWGCG*^-N.[_S[3  <M?73^_V-)@BETGH7?E
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M"\:/0UESHC<U="R1</HL\L;^DPLY4]YLF0>G, =:8O&+PIS=YD'Z%E>[=36
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M.):EMQYR$F_K#38/Z 0/.^_0KC^Y<GF*I=Q4]$_TX40'(QY)&;&-Q<KY.%K
MA$VZ//JJ-H_UK.3?P#[]3+NY$L6QVR7(4R'E @A(4G/ND//7?5\<:K6%'AUQ
M:*:=2D\?F7T3<ZX%.W?&FT:R:N($]Y+$?LQJ826EEJ]-(*2HK O-_+38L]V+
M;_(^\ ?4N","V;2,_%EB2/7W"K?\O5K..J "JPLZ&S4<,V9Q,1=P(B(/<6;@
MZO[XIJEVW,8XH==]82D'&=5W[T!N<I$J?20I&S=2'G99EC;)]OB$,2\^DFN
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M\>R3!&W@Y,6LQ!EK",!W/^>8C?WT8A3%=ZPF^]E!4?4?9,G/@MVUGX)*R2$
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M<>A,A?7%94.^&<%F=Z%1B_>_H5_K\"1XSEFX7NSSMGH1V]&V/#M 3CV(.F.
M),WO"G=.76AC%5UJ0U=P@8#I8Y] Z92;HK31)?P6#U F+@8X19SC6$84"6RW
M;*_&%?89DV"*^T<W!OJ/#H\ZR>F'S113,O3Z%VOG<%F;NU&6F(*6/Z.D< VG
M1";U2#%U!2=[[/@HX']7#5&R$?'_JH!\?1K94CB[BMZZ"%^,?Y,P6G>@J+\[
M,#+\_:->\ZZ=%I"@']JHHG5I^1Q$&ZQ-&O'DO9$]K%F>2&R7P\_D6)(7S[D^
M3W9I.2ZWI-QJIU!HS+]@:N*++A(8*#/PIJ^)ZKXXL%_6_J)9]C1+Q:HA?G%Z
MH&K*'T2=8BP87.MMNK:YD9G?[%;\'$^>')% ,^Z+ 8(FMAAZ:( C[VSWLHQB
MU=DAV&A$H[?0?>:"_PMQ9?Q:!G%MK&=@BE')OB]V^<O:J9P9YZ2'[JG6+G,2
M<683;XSHV#E81REJDNEEH?7O&GEAI46_VN:3XU9M[[GUV=S.UDC0G28O"FHP
M@O(@P''_78G9V^?"H)IA0OMUM 0C<T<'MPMEN(,PWNI&4-2-2WPWD>ICS_#P
MH0:QY TAY3=H>[GC'!(7!%RGWK0WT^SDL((5YOG,S;_84'.U!P<Z1M#1!2)4
M*\"N]!OC?8N9E_1VPT?!Q.Q!5*^ECY&;:0@/!\H">YX#$U>(;75Y]7=C9H*O
M;YZ?%\DW!O]>4."S2-%COEQ#L _C,*,M)7U.:GMJ-@+A1M5I*^V"9G.FLZST
M.D5EV)UYB"%F]R8/CV'_%2Y>]MFJ2DOLC62S[(WKE,W$PCTH-IVY'"C3WMX\
M5-->[SV45<(X9@(_3:Q/7FX]#G^)>/08S04TJL#Q>8,+(8LV3%?7U=7:8[:8
M3O34?H-0_'%SEPI1H0GCVLL"3U\*-61P,UN"Z?R2TEXN2QI!W;#?1X6HW=:I
MR[MX'N/VQI$EJV+#N4:[!:8U.Q<Y>G,VMP5O':R\M!X*-)K!*V/ 8T$F*Q$6
M8B-!W_#C+871\[&6)/JZ !I)1Z&)97%4=WI)N!Q$#7.HT>C6K2W[;M/M1BX?
M/?F0LJN@6;B+0K[9G:I@;9,R>;^D^KIF''0UZ\MB5*>!8DSLI]!P4R8C"_;U
M,":8S#DG[4[&L:25,/A1A%6>1GIY"97&C0.E\J!8VS99'I2;VQ._.I?35&D=
M$?Y&[#3(.$J'D[8OF%^YR"KM54558RQG,(B4B83>@)PY&FDTOT9YXB-.61+(
M#6H*E*HW?6QH4;VWX8+6NVLXE.*P4.<L!.]K?,A9]QQ0+[TC>&Q</=Q'T-W,
MA7(!]=DG*LM&^%*.+_/+.E]4-!EW/F5HX$81HK97W !31/G=0R#!N[L54GS%
MELA!V/ID+_OO>)R$RY>8OUP*'D3.!M',NQT/SG07.VU5U=:I?T2N/;2,?S\A
M<5@I&UT3B[\^3ES$5JF6,253O\O()CP<W1=^L?H@4UGCT3J0<Z!^MKA0.MW]
MX]5QJ(:IR)!)>IZ#? 7X4W):!5ZJ:>;JR# (=RJV4+:",O(7S^B/,NKN!;+\
M;)T5#4OKTKJ%J[WC',Y&QV'<H8(%YE\_S6=?-0FANM/J"E U-#:8))Q^"!Z1
M5+0WHJVGXO2\%,;-!F?;.17H[D?OXUOZD#97B1 /8#)5E:V52).!;=0Y,A_$
MSFTJP!^MA[E'R0KYDQ9B\D_:^:F'%\MD01:^R";CY<<G0K64\0QKR<N8-@FL
MJAV_DOR'N 1D]>1#E+7W!<EJ:F9@G?9.MJ1G.CYE5L5$++E<9R!2@"O@NK0^
M/W"5\"X/4.&-%!-B#8;$DW,=V-/.@U/S:Z/,W=!3O5XO+TV\2] 4<S&Y_V74
M(4S6D%L!]KGAKL;AC?PC<VZP==HV_KF:QGL>/N,SVODY;Y)AG>@3@XN=&T>W
MG8-9E?C[D-=:G/R;L^Q0&1  V\:D=B+WQ\3I:<Y4\OM(Q'<($G)%\]P/3F%#
M#>#O'AXNZZ='$61.N-=;";.*LC\DPU-52.?Z#].E%R8?X!M]>H-H5[))F?M'
ML.:-L1))UM6A?+6R\;LL2V-[CEW2&3=&E1)^D98&OL5R><>VO^+'Z:U<KKL_
M>T?VW4B5T86N@M!-M\-8,6%SML;IXQMPHA-:-028:P3M)L)=N484\%N,)2S!
M,'*9G_> W/MD&^.TSD9*85GE:O'KDXQU4LOJEZ.$/6=T(4 7WY"_D[7U!G7=
M1'Z+]FHEL:H1N>L&URZ?5 ;*K!"6S5&S%/P7IWQ=2ED:?VHF E3PR#O;U;K'
M$J,2D7/X7B]M:FT9?P<7SQM?,^Z5\*0E^1\P0A%&OIV%[M<=OF25:5JK*&-1
M9GGBM@<3NPYD7U?1P2[E@C361.":UMK),4SHI5YC-#X'RJSTC!T_S@>AS3EO
M12^&EL@D'])67:RK7[;^B5%)JJ&B^_6HTZ=PAXE:.U\H]8_N037="9<X!$J#
M<_UW83T_P#X"46$;YW S/ZJ(?8[@6L)$Z-MOXB<?#<BEQ\ ^^;J:%HE<^-'\
MV'HK,D[;W!UB9IM"08!+]7_)$9W_F?"%S/]?4$L#!!0    (  D\>%3+ZF>%
M7U@  /1D   8    :&]O:RTR,#(Q,3(S,7@Q,&LP,3,N:G!G[+QU5!S=MB]:
M!+?@&AQ""!H\P25X"!;<$@C2:'"7"-:X!P@>G,;=@Q/<NJ%Q=W?MQ[?WV?K.
M.??8>_?=,5[UF'^M66O.WUQKVJJJ1DPA%@%\15D%60#I$0 @/?P Q P@#6"@
MH:&CH6*@HZ-C8F)@X1#CXF!CXU 0$N$14U/2TE!34E'1,7$^HV-@9Z2B8A%\
MSOZ"FX^/C_;9*]&7/"*<O'P\?TR"A(F)B8.-0XZ+2\Y#3T7/\Y^^$&T  092
M =(:,A(#\(@ "9D "=$)T#[HB8KTIPOXEPOI$3(**AHZ!B86]@-#-3[P" D9
M^1$*,BHJ"LK#J,_#.(!"@$I(SRV)1J3V 9W!@9CG<W0F!J-4^2\2]=%#)EX3
MQR^86*1DY!243YF?L3QGY>,7$'SY2DCZM8RLG+R"HL8[32UM'5T]TX]FYA:6
M("LG9Q=7-W</SZ_? @*#@D/ ,;%Q\0F)WY.2L[)_YN3FY1<45E165=?4UM4W
MM'=T=G7W]/;]'AN?F(3"IJ;A2\LKJVOK&YM;VT?')Z=GYQ>75]=_X$("D)'^
M<OVKN @><#U"04%&0?\#%](CMS\8"%!0Z;G1""75T#\X$#'P?,8@EHK.+/^%
MR<BK?DABXCB*1<K$M_3TZ ]H?T+V'P/VY;^$[*_ _H8+#N @(STL'C(!( Y<
M7+-D^6/] Y4*'PEV4V.W7]]>B\Y53R3B^^MTUU.%C:!GJ1G0!K1PN#MU"46-
M+X)L]U/VY816W,:JG5N?;,%K0^UO7Z$XAC;2)U$$_?:-0QH?E2$&U/Y*C@U!
MD:?Z>"33EVX#O$:S/TS$I'PLD0NSP.U'S\"[(CSLT .O08\7@>39%.;,_H*6
M)<)="X3.7.A\:L9-D2YTLW3!9OX7!=Z"1T221V*)+CX6PBS54B>=*SC^;EV
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MX;JQUCN435KW,%\?H+.7[F9-'0ZV,[DT*W47U'7DY^!NEVDMZL8C@5]VM#=
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M<R?/Q-:+C:U(X<Y*'!-9?&X$!:)3IR0?'1_F!?^[A!Q6\Y&6Q 5W3>)^./+
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MXE-AQ2,%B-Y_RW%LTK?3-ZU[6FC=!26/</0&A_),*@=JCUG,G^5:PWXFO(C
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M^#CR4O_8;T14_(\]PW$EODF3?C&:_<<L]&>_18>ULYJR[TEOTT_Q5&XV1Q$
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M)3V6?2\I1$%8](8Y[TIS69 CQG]J"J5VH"?C?^$QB327W);(ZGD?OU2&[5R
M3;Z.6;TB]NVBY-=K4WJI:RKU0@8+*]:-$9/4SD\U MT>')E*%<<'L]ME4;U>
M:T6U/QAFN%UP")QZAQ7=7ZLK%G[QC'KN"(F.\@'A#!S>FCF7,W)"D^!28KGE
M!ZL!I=6,93[95MU?[44N2LH -* M=U=JFK7^6A5=",JM;[A5,]+) S;S?66"
M3A+B\LEN]'L52*3"?X2=J>)DKE';Y_./10MH;/^;V')'SQ\:=124'\W.K.OK
M.ZW*.7U_0#DA3=9N7 Y.JTL2(48,2SVUS:X22"-(\KUADF;J<F_ $H[VQ%&;
M-5 U]AAC;IZ>;ASIB6MUPY2/H[LK'=%\&4,.)X1"ZPU[V:Z[.->3"L4?8L[9
M$FT\)/R;ZS/DA-D3]IY.0M,)Y GQ6!I*D,L?PK03MA+;)IFZU/N(Z=>O# H>
M&J!P%TE\SI%"LA$L"H(VG,*I,XJ,Q[+"]E5R.&BDX/GUQ=[RM%[Q>)D"*8ZS
M$+>!FO(L)"QRMR#JHP/#W-&H3R^WY'LC),TT(I*(]WDCCQ.&9MX:2@]8"[BZ
MSN8A-3X29=T'E\U:)5XDE'U?@1/PU/6=E83<5@;XY(DBY:%B7TC02LH_YO5)
MT1FVYVCL+U1<)6%U0TZKWWU^'#Q:VA$VUX/S*3(Q-OJ+DZ%OYURCU?Y9#Q^Q
ME*.:H]?R=ZK1\<SJAO&]O:49)H=$<^08AYVS8LM%CQ/,!N9M75_WIMCFMY[[
MIP_)!_E5VS"$[C5N'>L?]QO(DH3_<$N>G!O8:NW#QK*C^OA862:_W_IQ?:NZ
M^GN=5D>L-86#2Y@L0-&&#(TJE$>BUW%=X0MTC.7X03C=)]H4M358?_[B)>X,
M0U:\EB77S^J K.H&YT#N,#O1*:Q=<L8/.L^')4"N)0#\A1".<RXZ/T>8ZW68
M@ZYT^6*-:910\L_<[N6A^3$HNH_D3]2I@MD@D1CK\B>"A-QII^#RH*>:TFYM
MZY^I>J*)RZP:PD:OPF-"HG\ W#]\K)I[SCWU=+N97A!'>CM^/WD2.T&P8Q@Q
M^8N<?)];^3D1W>],M?'/G^7-G_Y(\1;DZYYXK4L>I];AM9ROIZLW;P J8T7_
MPO+FX+._SM&@RU>0T0NM*(9G,FHSGR6H8NMJ*IH26#1-TE8^_$[-SVYAK6Y$
M<O#@$1HD=NURC+9%%YO;J9W*4=PC%RV79Y1X02!QK8$LKASQLDK^OA?-N_@+
M&L]4B>%:>:+2#??G!=4$ X5XX;B-^M.252 ; )Z+5 WMA<8N$/NOED E<4_!
MD>4"4C/H].@&ZK_NTKU*IYC3D0C: N 2=>@SLS#]:H]%)QA8YK5Q0Z'8%W]N
M3MOEUB,,HMQ+R/(0Q@IS!9C)58$INF*JSUE/-6,1:?RPI >9:?'C:+GB'ES@
MVL3_Y4U03?0!YV[&C'F9A\W2IPJB3=$B$V/6\8YGNVW$W$".G,$%Y%,PF:7F
MS%8$2SM A!W1[O_*_31%S2T7[L&($:B 5W!1**@F.#7_>K"YN/9C/9:\JM!'
M3VT[J:\Q@"CO&_-OG.09&E,KQ)T.AY+">@L&\*&QSS1M6Z1=]AD';\;?X[G8
MK\Y1?*-KM/E6\G)3Q7,7*B\!#_M^BJ(13^!4_<YB1.T3C_?+*)_/.2$2;JY<
MW8^=QFJ>DVC*$B.=$E<%_EM__&.B5+B@(H( IL^+V%4%H.8O9WU0\8KF_J]B
MOO.=#0;\.FI7U-ZC2*S:LTJC:!-1(T;-&+6)+491I8K:LX)44VJO/+5G:E-[
M!Q&TM4K)4Q2/TO;7/^"]WO?#[\/[X?X'[G/=UWW.=9US1L/D#@]AGWG#Y9_M
MMHA]/9\9!UN=CPL5Y02  J8@.FHH.74XZ>AJ44&#5"E$]_=!R>:'A[/X^F6S
M&BIY:F6*QI3#GUK9F1_5P6BCRPTNIMMK9[\V0>6J;7/',D""-?IRN"_%;=]/
M!TVR[WY_;;,JD_0[6.N:=U*#1#U:_'*5U%N7S!L6=A>X&+HHS*QA/R)H #Z^
M^>$J&G7LG0,.W^AV4OYT59_9>:N(!/Q$(G3/_)MX3[:NN@/1+MQ,Y0-;=#+/
M"-Q__=FO/&L;,=<D=VJXC)<OSQ$5Q3C)<UJ08QXNS(5TJ'Z+F#.PW,H;Y[8<
MV;.$)8>U?N3>5PH"EG\)['Y\I@IL<*U::[EH^O <E(7_(17,4*TF!/.2%VMN
MCC=$B\@E:ER'&$N\K9AD'E]WG)+H"&J[I5@#H17__294?-_1A@RVH)%:71))
MT=$A#6V9)I4W_0$8>RXGL8S]53T/H41_/^*>0O$#+&_WT'(PKT7Y+,7(U$!H
M)T!,O'N$CQ[2L&>DR34X,[;$HTOQ<%]?OM![<:Y30>U,#&717#KD3A8,!QP*
M?'@<M%YCY[ &;^^$AG:T]P-&8F4\-HTC_A4M@%^#<HCAM;*)-<BO2U)R5]^2
MEGOK>%#9HU^]V!Q.5_\ ;GE_;K[OQW0H.SD.W$R93S7S#J5K8[@&%H-!^B U
M'*4?0ZKJXFL'GV_Y1E."43)O^$\IE++6+GAINZF #$;0->6^V-O!1 $X^1VC
M1#"(_*27@MI)KWVC/YG>'Y'-AC%Y].M6-XDF3@#19,B*I5FY7"#7:>?%&,U/
MILD1%K?1F%OM-Q, CR&#?P"K/.%+<&$9%U"Z64]JJ\Q#(?.?,E6;/:WPN<</
MN7RS#[Q-$B<KQYD0R>L!&G#Z^SAI'CBAD.2SVISCKM= 8W]KMX=8D&3A0(BY
M%=,D1FKN8N*8@D#AG9==CK1)SR@Z62?G)Q8.7H?:2:V,4OKV3_^K&"JYB"RS
MAIEMZ[/J"M]+)<;*[&M>G06_O[;!]KQ=Y1C1@E!O"%YB[?/QK_N7IV HX]HO
M5-$'_LX@61DT0\+&LYU,A:4*'ZM58T7RI&P&[UT7-4 (P)3.?:HI1CS^7)%4
MW6IJ'>1OL)=]:,=O%,ZZ8B=!E3;2L8P+]H%TWZM2:UM.^,FD>!EW>)$T%6CL
M/R X.]97>#<+ *7./BU34?_YR[GG5<% -)9:XN <4B,0[6IZF]MC9Q:4N!M[
M^^G >D7';'F[3^O)*X%$QS7.L%J.O6FUP^Y^*"/0MZ;]MY@2%C#2WMG9GOWL
M8THB,B>><MF'FD,9"[5,D@93)0NWXZ9C@]9Q6+F)>^Y*]C"@;MLV8@(19)2O
M\_J@=9QS]F*F2>F$1VKEE'-0F3G2,-7G-']\@P;Y8C"X^ZQ6[+[SY_:5OG I
M9<9]8^O4@?DZ:SW#I%2R,N96 >#&<KW6-[JN1 ;+_C)_OD;-YZ18%:0%P:"L
MN;$%9@,"3AWV;FI422P$!)3/ Z6J\,"<:]&:O[DJL/;5 9'OW$_D&0=<*1EY
M5+-X<YN)VVSQR "11$?TOA05YN?DUMFQ0S16M<T^0799+L7XGE,$?EW@K:27
M\>6F;X+P*828,N\==M;PL.9[%NQSGBM%NO-9JAKA1_YM\_NB(2N-JB1:P/W:
M_?105_Z]G-+FG*11^LK(%KI*R>PG4ZFI9FDO%C:QT3L%TY Z3*+4 V5_=YF!
M9P[[\5C:;W7?Y?;EFAL#1!0FHI.+&<'$ #NX<ULK+._+B4#09Q1XZ1\LKSSS
M.P9^A-P4Q>!4>#%:M0.$W;',"S=@S=#6_GH-JQIV+"NJ+#_N0=Z\^?1+%M<V
M4:%H$E+^KJ4.G.CARSUB;[%%E/?H2F&2"0T^8F12^ORLY>:9T%?K%N0BDCMX
M2._J/TB3=7US3]-TX.7P"J<8U>*CZZXJ"G>AD+K)X]6"V;B\#<R]AQT<+=-)
MR:,KG*#M<[7[O]EJF_AUEKA_ZVD\?MKSIF-:HK6NSHZTL^,9.*ER35&3BA0K
M3>CK6-AQ&42NX.&_3URJ5E?N!WT>"(\@9$Y+720-V:80;6'57I7C$<B7H#0V
M:WG5X5PH_U-SV@L]#*@M$C Q_\/G23.T4VOPD,UE:)JKH6SL+P*475GK7%.4
M*'%,BRG0* <0FQ$;KO:,1-O:FL'U-8561/S_85BE8@2X%;%$/L@&\^E;_10D
MZB?Y/PB$^EH7KOI_67T4;?R89"S>L$ B%S](8B'G/&*/G*&WCJX:<O=WOW<'
MR(/"!:,^YC'8-\9%<=BC!RH%"-HR!FDY'#MCX9X:?#LYAFK87@>5'I(\/HB#
M[K(44IUTD%:;2.I+.04L!)(91=GA- _^ )CX=_Q=# 6ZCGQM:!/,&C<B7O<0
MRY"\E'^+[%4*_$2N/[I-LTD0?<-Y+OQ(#+XT,0J@A: 0:M2T\B69OB?V]04!
M,D:Q*ISK\ZX0SI :BI_=E4-$W+9D?IH2^W"TTIZ1OE7^=X,(\<;W&[SC:(N+
MAEB#[$#-HB7![[JWR,URR11Y&EOZ/.IZ1!4T@'9L64R$K;+@4"6+]P_ 0D=(
M?/$'-V;]:8:Z)S5]O6RX^(YT$P.G^M61?31V"%U!@@8/N.7[6N.N9?37J3S;
M'H?/(A'H[:87LU! Z+B8AK@#7"C0FZ8!0Q(RC/3H4(_R,:"L&J.WY#K868/+
MIXVBYH?SN<JP<!@Z%$3G*8M.<YOC6TPTA].P:Z;XYNKS:KW1I=:0>)<@8B'[
MW;GP]Q']';$.@63?BO?='5V%Z2<J8O(4B_< 4WI+URK]*+<VC>/99.J@D?LI
M?U4'A:S^<S=EZUW*C+UX1:ED/BVALV"FB$ZR^EQU:$4B1P[W^5.&@4'LZ$S5
M :)<2<@MMZ;W6 ),TI3^IF=2(>[-H*<C;O,#_Y '-H];IU'J;F/B\'6Q)! K
MHVP"P(L*>%NL5$\X/^738]>+&95J;S8=V7TJBK&4NW_\S?*@UC\ SYBU_29%
MN#,S/T?:BXWUYF8=XF]A[!<Y"A)=L9F;L1"[<<+Q;/);U_S=N41Z#5!&2Y_=
M2) ,$BZ9@'</#*]EW\3%A]5'5.8PFQSWLS_]EE,>G7A'M7</V%!#D2^.S#4A
M%U.W/SZ?#+*>[=P8]3W6>X\LOIZK)$ 8J;=)8<3[-7?Q2;@(D<QU^Q@TK].$
MIHIIAS6V0IBAZ'"N^B8R?$,,6(2V/Z"$U#L<RK$FMJ<QC/34HXS..N4SM.?"
MGR_=I;C"76Q]7';V1+ D9-@K[M0GEU]:#*NF;(*6<'FIE7X]!.3H;O(6]->"
M4NO3]S'UIHO ]!J'Y>$)X!&=Y,R-9JH%BJ.V\S0("\T6S,+7Z=L++O&?\[!_
MW3GF=@?(,HS\IX\VK 1_=\QO>V(SPJ229/#X*NAM9!C;\D5RC\?IVAX.U;@!
M0BEX4)&3^%Z_QZNO2!9^RCUD?9T,GOHTV+Y;(E2S.)$O%XH.-)'%NJ=X.G7K
M;!Z_ZPVCL^E/5):B+Y&LUV"%Z7[$(ZP-844,.\:M#9L'QT5T0L$L]7[>QV)>
MAK(/]S_8/L8'0T5SU2NOC2OGQL=ZZ!] :C*OP#HWU0XJD19_ '))F]]22F1I
MGJ"D'^8S2V%\@^'3:IYF2[YE;3X"P>(8KR/^?^YC712<?!A1LV!%PF C\UA#
MQGKS\NDR.(Z1QA^8<V%467.;8)[S6XN*[HW 8%LJJU7VU+7K+\T3F9CYF1)>
MP;E#\[9N#GI1.U[:Q T?DQ;[O"5] 5IF,;4CKIH#V\T9L!VF*YE]G[<+KF[S
M%M8=%CN$?HV;:R;]>!KGLG74;>KSI?O76=P/I*C?I<_9$!]\'1"9WZ_ _>7+
MK"HL:JY\]B=6>T!%E2+T_S7DHZ_AT98E+9I2Q&83B,H9^+P=;+C&K201B9F2
MHBY^]Y[T,UJ,)(/F6#/B",FPN1%UC-(_HM&;([D]7\/?X**WGZ$K(WXG5XR6
MVO+,)GHWD)"#=0U]_+5 5IZJNNQ:6"XB*$BPH5F**_<.#2XV:J&U<WXT^+V#
M[:CO5'FI;##O=4 /5T*9I-+JX,L%*<X_@*:!>&'S+RIYO%]1F6?]?P^I?B-G
MV7.Y%H?0J)(/W4DYK2]ICL J,GV.!6F_( !0+<U FV:X(:N)OKGTTZ3$*UC/
MO?7->EUT%=3;1;X<2$7-E&$ J8F//$C W3DHBT/(=CMGK@\!4/7=4F/C_'&E
MUW6^2J<Z>^5>C ?PYE_VP7P*^%M.[COOZ"L4R@ZU2F^_BGE(1+ .RN[BOG G
M?(Z1'38Q4*4J:PW[N$UD&.#H$HWZ.0MYTS(N8WP-;EWB/B6C.>]HL [?CA_<
M3^@EWX B*O8#JK:)BYLO^6Z,U /LU*V&+)\FG56/I1.8I5MB^YV51--.S37P
MD>.#W-_7'%LF&HLF]*3,=<SV+"L6RO*-L9_(W4'VY /8U/6J'Q7TYABKV8&M
M,K8ZMUTO1^E#H&]?BOPVK]6(6(>74:"37;J6&6X?%BC$Y.] .+'COGWH[5/U
MJP*&#E"API4)ZY31M=37A65=!&4H&_R<1R*:(HS2_=C0BREIV#%VE%6GH;T4
MN[UA(6_'%Z4]LP_E097_N<N#@\]5 LM^8@&KV"G25C6684OF/%P^R%"NCF,8
MA.$,$>+,H$63#">6,AK633Q6"L4Z[/VU:P_M2(A5:*G A#_-)C%6KKR\&Y62
M]:Y&L(JZI/SRKC92?UM^^([[" V1&=<6M(, ?[\#*X*R3GJ340VKY$D.46TC
M;1_UF(> RBJO?)[<-VU*=32N/C!&LP,?.^**G%QIG-*Q2&^=UQ5\RH4>41 Q
M7D! 7MVR/+HN@%!<A4LJ\PY2YQ@#O(?<_8#ULH&PC#4;!=4_ #&0XNMQ)T6@
M_XA&77O+[+;]KXJ53UC:=5?7HDQ3U.TC)GW?7+57*6"1![R;X?^9TM41PY9N
M_*/*]G%\IG&72S)7^$@$NDY'-:)KV7RYU)V,-0Q__NI3+?IM2<W/#/R91400
MJ;E,?D<K+O8>/R 4_UILGR4J7!'KU,5+3<6-G_9C'O/%B6='?D[T439^ID1;
MEZUSK-9[81I:Y7XD G-'NDSR3I0^$;@W'*M6?^#G9]/,JB_ %F<99,XKIGR1
MJ*:0WM4P!;DE_B&Y^0^@%6^$O/W]SI '\MNQ_?!4JSR(9"NH*+*Y-!>K3MLM
MPY(CILOW6S#(.(ZXOO*P[SJ,Q;24KTY "(9,.L0<NMN"P[)88^(C+RU$VCO>
M^.9/^2W=OK'[]I,0+2"$;<5N2,90J-L'%/JX&QN^4G*,O2>MKC1J'^BCX-B%
M86D<80@^AFL_VM<ISW1,]I/$[$@^_ZQEI[ZUVRI%K8=D,E@Q:CWJ<*1RG[IE
ME6X'$@:8*SVWM;([)I-Y)6+[APPK)P1$HC4M0X@Y)"FCO\QP3<O/:"OM+]+$
MAF9UC,M:@28^: 3ENL?-,KU2:C5U.*:(/JW)_K9W9EN&7=O$W%[9#A7OHH+B
MV\!+>YYJ:5EC^\B=.[RGQ4QS>ZT6HSN&?AP=^Q,=:J+-;8H,0"D7(0Y!JV<E
M>/$WTROO4J<*F">Z8GM_SN$[F.P&T.\O3%:%FLY9" "O41H+Z/8H?V-,2,8M
MPF12!X[]X&[!U(/'H9":,NRQ>%';L_L%EOVPF-V2L[)4I&>.C4=+SMJ@^WS0
M97^LV@.E9*,2NF.E+L$O;^U/\?5RA"*V"W,'A\G\91;H--J*)4G,^ [>D9%K
MSHP#>J6;#O"=M0G^+VG0"N2UX04*Q]@#%?#>(X-*W6P"3X1]DAF%S7$PS:T9
MND6NA')'1)5/N+GF*&?@,.CX=;'_:=?_.?#D;//U9*C&0&U ^CEO\W4MC@7B
M(2?5Q#X_Y,=YFTG#D.;D.3\,-'XVA'P_Y]&&&9]@:EP7T_A]5-\I1?TV7[\S
MAW$+&/>)'%'%HD>OX_UEP/1#(5[A^H-1 ;!9R4>:<XDVK^(;_LPJ%EFV YJ#
MF+/#',ZM-H+X3F$U>>*C.7OXMKSN@-1T>4BS6:"*&I*14O>9M5U%KV^8DJ9?
M;YZ+6/@GK8U'V^XA2(83%4P%&<7'I0"&&N8I5F<"R;.<4+HA4_2+]5I$"1GQ
M>'70[Q[):(CWJ@["'!)B2G^;+C6P]5Q>))'/S2$I"?U\ [N:0??"A'60[C33
MZ\?4K4E.JOS*O4GO4EE@TOSA'7 ,6TV@5\[SRA'E4OT;NUEALC[%[V+%4D@,
MC$IZ28AS:ZY,^<R[I&]C$STN+F!WRI2FU=\](2SBD.G:<)%>3][=]S6DQ$(P
M*;H[D.O$[Z,;\TPVJ<6K&)@JH#6J)M'S@2&#8SQ#]4[OJ42+&VWI8P)<Q$*R
MW4;=W;9-?>.5)Y<< &U8L6_HAWH0Q/>XH,.!?)N@L:<9W^#4?<B'VYX!ACP2
M@@9,*R-[3^"!2<K&;OI?4B7=U[CZ08(!7A^=I@HX?L6959?U*N1Q:G'@3J$A
MM=_<VSI>CD<5K*26"C-HG[9P':@X0#K9'0"N>Y,V9?1:$KG1H9PG]IR7#PYJ
M'@FST:/:JDF.=]+]OB1Z73OT<ML\HFOY6@Q<XQZ+$E"0#Q_G!DO=88#0NCEY
MM9TX.&0+6C!FF!OP7KV8YUI80".XNHUEIZI2E T%3>DL$_-E>;CK11RR=-^[
M7JY]TW1B(4=7N"&?@&V= M^,DHLOK0U\T$+;G0@VB=M\YE$+"U2P+\20N2%"
MKA@\EO;CITNKNW8FQ781#X*0/&G_8-+ST/L^%>]B%7F,"0%OLKERE@=CA:G4
M(+A\, \1W_>T2NX,&//DM#Y%BOJF64M/]$.!6LMTC#C(!U>V:)A^8V=_3+\P
M&X_3%;U_;G(OL5-3BKJH91;/YN]Q>9<5/OOJ+R9]D-':L$C[+(<^$.T*D(KG
M%^6T 0H(/L?,V:Z6S1ORVT<7CW5]^!;%8?XUAXS2)$P>7#X<CE.5/H\^<J!Y
M/Z3IBU$+_>&,%4O1, 7#JTJ+S5( NRW,[.$+'CB9)YX<5!/Q<8GE^3"<H4;S
MMEO&*E]>?NU-7>0/4WJE**Z-_ KO3Y(XO-/-?KT?U5OS+0)]:D,CF";EB*#A
MR@2A*9\GPXDZV[J!BC?N<.X#^J.8+F7*<4.NN4H,*_:;O!1IL5D\#692I2Y^
MPO--#^F -L!,1W"G]-VT1+G<1-AW,N,CEG7VZ_P<<,*\1TH45\)RQ2CG=ZI3
MKME9';Y(N;S)LG!V1R[OG:PNKKU#NU?_NZ8.7E+>>,4_-*@#=BF<)^#T0,7V
M&FG;]S! ^ R-5NU]1[G0D:S06C(33^]N' 55V#TX7O[Y3SFSJW\_JROO2TJ4
M*5UX,CAT%BN^8U#H>M-^@=F]SF&UOGP>"?4% %U'7>C]?5!1-OY&'H_6MENW
MS]2D^7@/=031=H4E"PKI$PTUK1\QZB,FM#8?<(:9MY9"CN\JT;T"/Z<'5:O-
MQ'C:_7I]\-OFN,U_]5]B:<?L@?\VN_$-&Z";H%O4/-OS ,CBTDO7!/]6>P-0
MA/-&ODZDY\\%)U_,DG&A'/CME#>-;\Z'PY<KM:71_/V&C]J\Z//YQ@"!UE^]
MQ\M6Y%[;)>F_(F=%OAV.55+5C>"NWU8,S?1PL\Z/@62V.!V)MW1W^HQJR)HZ
M\]QUN[2\A&@2^^!M:?*1N++?:G)#S=9P=G=RR0M7LCGON-00X17K=_5BWEHN
MCE5]<,-8+R63<F(^\_^E]^5_,?1_5OX'4$L#!!0    (  D\>%2(-6'!V+,
M #O:   8    :&]O:RTR,#(Q,3(S,7@Q,&LP,30N:G!G[+L'4-O/LB8JC#$9
M3#;9!(-MDC')9# FFXS)P22#P)@,(N><#!BP"1(YYYQS-,9D1 8!)@>)*$"(
MY7_VGG/NVSJ[;^]N;=6^MSNJ+NDW,YKIGNG^NK\JZ6[N;@WP6$E.40Z \0
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MR=6G0FTV;6F>,JA9,[UV6O8ENRG^9N*-V?6'2%8%"R"KVSN-Q%^.V!M2='>
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M(6B2\?-['% 17P"IFI&]G^2TGI'>-9:KSC.P:U$9^.$3<]&(WR"K^U+A.@J
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M:]75L=](S_PZMY$LT0B5\58$_6;4SFX3EB4=2=1@I<R]3V'^A<>M?\-CO#O
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MMO<^"<0!.EM<3$L?B RMR8B6]\L&Q'QQA^;U.I0G^VI-_C"+$_G2F^V5CV6
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M]F\R9QY'(A/OF@J.:A$1AJIW^Q%QR_TXP';T"G3_9@4.T)@!.U9P YT2Z>,
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M*/AB1"DEF'/J'\FZ/T=O^TMI?@Y&;S&0[/.M37#]1:18P0'V*1$7FO*';6"
M6'^/QJ-M77_[7U8L_&G%@QH/L@.'^+W&&L8C3&/FA>%41['8ZR#D/O3TVOB%
MT;\87T/\\JF2GSXULO@=-(PRZ<$N^,[\"_B!D/AG_^^@!_^!'LZ(V,O@.GF_
M"ZN3]!WMY\3"05/ ;\A,[:'Z_@7+FA?W##^6UV\=0\[;GPIQ,4N6:FM$JSW@
MM,W)QP'N^&Z='D$7(:D/@8?3L1?RZ1U_RI\8:%QAMO\E/KI@W>2#VW[V+P
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MZGCX[:?/-M_3%\!LH^=;=HT@D(=\:=:R!6^NT0=.>K8K]W?CG1$K0B6WEG
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MP,K/O^A[U0W<#D7C /N$=3A HV4]#$LQ 3LYA&%/A:%-$&<<0*8?!YB1JVU
MF)SH3KOX&<#VA-I!_VEZ&%P7JWT4-'RQT@M)N6+)_:#8UT=I1^L7%Z\V-.(
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M.]:]J-_M_D7'C.]9VS9=-%MILN;HT^VT\%E\S?6I@V;C0SNQ8:Y.<  8]5D
M"N<(34]CY$E47-42BGAPLFO=$<*D<[0P&4D3(CVQ /K )<7/-]VIQ:8>9>SC
M8"#B:2N%+NT!NPE]YO[.-K%!R,J@KJ &%;WWZ='M!=I',+/-D[_Z=O[;QX,J
M?HT24Z=.3BXR5U9#F\UIR[^O![*'CO&(V.W-^J>2-+GV44R%([MI%A8F;.G%
MX76J\C#-D;1_"I&\ YO:IR<\'YBBH>;1FT\DJR(;NW(([IY[ZW6D,B[TE],D
M_F(?E<X4VC"HS(P!CNX^>7#JTJE!3VTKY# 9^0_+:\6G$=/1Y7OA&" [XG1
M-J.#R._KBM+0C07"93%)UH76XXR3+!3_Y&Y[_7T :@]4EL2.5;<NW))9>MT9
M-@C2F%YW(\HIR]:WR3:_(D/K/7LQ3+3,F$'7VNHP7^1O-4$8[\F.=8<G/[QS
MNB?Y?$.4^W.X..K&<(*NR@3JF//JF%)T_66F> TNWEX_R@:6O(O^DK<@?A)[
MW$OUQG%H9UYLACK;'),YDB/ @3II2#^R[WS?W?UY_^/K"TZI3,IA^*31-_3Y
MAQ??E<246!-_1XS/33S:M9):,1"P.U:5O!G_)JAU6@KI7+\8X:&$LW@<[;FY
M>2)\L"C_-AEEJRW.J*!U#@, :^=?\%]XS<J:3+7M10EE2E*[M_3U)'7,J#J_
M^&R_,&XG=6T7 F,ZR<+M&IDN2S%\P)-IL8YTGMI]7NA(]H;%74QPH+$? S2Z
M9H213QH,?-&7CGFN]SA3Y+WA_JIVQ-^]UST[;(TZ/)8C2  !VCR9=K;19<-]
MTC=R5,8>[CH&\^:_%,CA2_1Q#&_.;*58__+ $D^>NY^9I?Z.IOX[DEH7WK_=
M(/_3EBN@NPIV.U.)VNR:,HEOV2PG.H;!AXG2 QL,E65!2GZ\%?SL>]1YFW\3
M_QG$*:KIT[:!O0#K\J8X0C8]_9+IKB1/B0%N<40C1V;@F[O/;$O+XDQ2D'IQ
M>I\'WK?F*VK'_1-]/(D(L9\.=4^P/IJ;C 38/;:._2>_B%CS3*,R5I?!;_Z]
M#_ KY^U? -]"'0GK]Q&P>+S+/LU4J)\9QC$GP@!1 [;?7#Y@ !J@+];),I5#
MEK[%*UO?O^=)VH%!1IQ9_^6$-_7W258@Q.&7:,8-KFH6C\N.N&7>="<09GX&
M (#N94\Y O8'[S?8N._9,PU;W:R*.2<UEW7A;:\"-KSLCAA E/%@68M;)2/R
MVWC@@T-Q-@RP9%!W>O8DNMXFVEMZL[_<)&>>BAU+@;!Y\O1B]&0Z:"M0"P/T
MMKL?JZR3V_K\[V[RYG_@Y.(4?()6@C0^<,:Z@Q9[\<.<[).J%,FJ'G1CY(3^
M('&/??+LJ&RQ30(=TDET9/^@PNGT7EJ'?W4A[!^<*'%RFPJRQZ'C$5DM)M.)
M-*+Z^?DCY)<,.(:Z1=RCI&3CAF_C;P^'_'([LX._*HG1*\@?0:G^A[4H+*.I
M4'2%E)F"F7;.7/(E)HPM@("YWA?%%S'B#6+D/LD9DE9T)59TI9?(<7BF5\6G
M5^7ZA*_^BZM*S\O^M[Y%IRXR+R,=D\%QOAA:UGJ!^N8-8^HT]&3!?ASZI/Q0
M/BT"60M&UY.@/4NS(U:%J2$()%TQ9#(* Q +E:\)&&& >E8T!;9)\W0D0+=X
M2"R^3#5!(K: >P$V3F#EQ85CA_)H&K9&[4Q.2R!/?;Y,'LS7-V9K'+;T;&JB
MNR39R+GR\1POIG8Z7]V\N]ELJ:4#5FMAJ*H,)K^#DZ:+PX4C_0?U?/>\BY(>
M?72WY7H<23[2O1\D,T.R=_2>%E%^EFN?)[CNB\M/D@Z(G-:_6N4]/;+>2OV%
MH6!Z/)Z0G,FX9X?GY\D@*<P<\3;QN5M5[4>%;A)XBNG,TW7BB@>>'$Y)A+^-
M(X=8C[I@UPP/\,G][&WO:.Q,.JEJE%D0(V?F;'Q/37Y#__8V5'G0DF9-(R"K
MKE^)-[+"JK7?\_YOM;N_W*F2(0NE%BS!"7"< 3.[JC,&W8D2%I3\9F!MU71G
M<(1QJA-&LS("3Z.[_4[K"65$MQ<Q$;'3*(F%C5:T+Q&Z8Q4#L$YCIVZS6;GB
M?A*Q2I5A>LSD#==T_AB#HT^)FF>G@?[]W.']4O6<(1LF$4W8-U:%3?$MMDQW
MO:YRPIR<SB''AW@A;C3+.1<0S.[B'>9\%5%@YVCSU#?TV;YS@J!QDA(SES=!
M3FRZ.VE.>3I.<JNA2JAA2UB(?0"X^[E#:9DE3Y.2-)7<9,WK46I<!#?<I(YN
MH.1\W!K[0V=?#LGURCA:?/?SNLN3)&NIPZ6T$O(80-(\8+/TV]O@/D]@C"],
M6HZ3<7O_X(11?CG4/<K5U2^]7.HV;..[4EBX2_P^1;>I-OL0%T+KCLI0AFLY
MF&_YJ^I72ZCG-7?SONDM'B_\3-H3AXUB"3Y-<=[/6>L'OG1'"^&37V//E\1%
M]1:=C\2S^BY7Y#Y%D$ZI:TNTS:N(;AXT1MVPMK,JD+IN:2A.QD.\.Z;(+SJS
M2>H>(C?0U&#N;I@%?];_S9;N\6L;-#<\\UV)TD!FX<..K:XV6-W3UCE4DBMQ
M^$$C#3=*I[2YTJC.9$+O.L$;R.N0IW>+<3_[M%2E:3]$MPW>*B_V?7DKL#/T
MSC54VSB'.W/FMDHE=J!,>F]RZ]SI,3GW(>11)_M76)F,BN"%OECT]7:]*%5O
MD?LLX91RLZFZ!] X%+/E2VPT1E7,G:,M?,<)4^7X47+;R,(TL)E*N4I9OQE/
M(:+[NOADM7VD9\,>_6>;V76-]E)6P9G^\=)K#Y)*/D36.Z+Z0F4'8I<5OQZ3
MJ<F:(AWM*PQ,:<>B+7WN<RZQ*Y^(3'6Z/Q^0-V?TYT,LWPY7_41&]/)3J^BF
M>-(K$CIS(D?[="ES,WO0NMC ].O):FJM9C]TY,O%%L?H)QF?BIOGQT?'QQ%=
M]!$'MAP2%2 ;,/Q.TRK8DN>85BG +Y_MP[ ^@_,+?!S%$<']G(0+O;/^<*[2
MF^"28&AUE"G^M8BQ,/'DY';U$XDAW7<3BTI%GLUV:>U9WPK*;V;J[T,AEP]3
MU6JW63.BLT7-LNTR N9-P P&>]RY=[Q*"JV)$8VYK*41WQ$Q^/-*5DG!^V'3
M)+B:)D_:!S?9;CN3#6JTA!E?MXO?/=(+$M[ #G\]QK/%ZX8 3=J7^4ISW:QT
M5-.RPH\E*]NPR>:CO)A4X>+$[8$/!]\NW7E15%7EK<[IZK)ZK_%;S7G<,AE+
MIP&=NMY7_=Z)Y++<^RL:Z+VIN[>A%AEA1K%C55]%D=]O7>%</,3I$7K2L0WQ
M)O&G[Y_9?68#UV9M0K( 2P++$49V(;/C(A9YEFF48691(YLF35%DZ]0=.".3
M_44,V]Z5T.Y4K69Z,%ASF3="QBHS5R)44K N<ISW[1M<2SQFBY57,1GJRFVV
MW0=^5D?DDX<B7!2E)>72CL]*I&Z_SXW/$9K024Y2,2;0WWZRT=/2/W%!\;Z&
MQM<!(E[.+LVIJ;<M!(\%S(UV6X]K2]=/VDVMWJP*O+S.63$]*DFPT_TF]2N<
MN+:8L3@SU(^.HHWL_DYRX0B%0.O[DH#T:G5=!JUQQK&:_3 ;KV,Y2N,+EC,P
MLF5DU?[ S3K)?2^+=%6F<?81W*R\@\;CAI$WC_(US)TU"U5,B!"A[L<@LW<Z
M^,MDLHX<:7T"@RFF_-G/3V8//Y@L'7,'?]!EV3MTRRJGLK)5#V%(=,&/>+1N
MW.KR(7*CD!N:=BG39$#L4IO#MW"JEN<A%FAN[=56^#>J\@'6],J!+_N/+!!W
M%@TC;H1DF.?6;7D$9*WXR%66CG-2F)*S7[BG4Z7FV,PR0=;/=KM:ZB:C55[X
MAAR).E5R$DO/2QV0&8S?40X,OL2CI6OJ3UWO]/ UF)P$--E6J-UN>J4_WYJI
MP$\9 [@%)DV'C%!P88#+F57;C^K"9R;XN.NHDND5B%XA:#E7S%-E\4WD5ZP]
MHCZ%?4XCJEB3L*)^MX?7R\SIU<]O"FU.@2/41,D35"(84;5=[POAZY$PCTB/
MW1FV;('/\Q/1IE:W"P?H:^-?CK+TDU35-58AK/%-RL*.7B,*=(JX$R>P5[@O
MI&[O<_<X!4PWK=@R4)(A$-_=PRROW]PD)(%LNF(C89.AQ8T,,W28(DC B_1<
M4\-5R;G ;%A44%;R5%W73P_O@)A=L9_UO%K.OEXV]2"Q:&]_/YUW3,S93_W/
MVR22,I44]<_65-=5!WWD<AAV@'I7Q/AT[C?D]13LPXA-$V[5E%35D1T-Q^RH
M@ZX3;9ZM+ ?PLH"M-IT5M0CET@*.MNO5;^-!$(V&TFUT.B VE%KD.VXJ*E?^
M\?%H_*SYR*OLI43SK?2% +PO_"B'#P8?YP(/N",RW 3Z++FL"\?!IRGJK IP
M8Z,['];JO/A[":YG.VUJU_>6$D(GF,WC^%8E3_;QG,,Z)/0'3NXUM?+&\F1G
MFZ[PCL-R^+4-8MX$WC>8NNR\ES?M1I 4 .ZTPPN.-N)D-R4R,D!!$^6?NUU(
M+E%X$'$S7*J[-?Z&'V[8.Y$#<IRNS&^7C!6TN-^@KNE%+33.K,@+B@^0KJ]<
M4B[>#J[//O1N00^10M-Z)S;7@-,#@AL@3?_-JXW'2K;@ME *'F2^*:@[7AP#
M.'EPJ_-?3?[&4E-!*]B*"VY1;F/B;%?T!V!;0@%L;L]&2+4_W:X(HN@"*,+Y
M]R^26+L4S\A>F?R^&NOAERY&5%/M+]55'$^?<G%VQ0P=-NW.^:PZ=F.8USQ&
M3GS@^7R<R5+E7K9](HDI?.O]Q+<62:*=]"#_*J\&(+C%\Y%OW<U5FJ2!Z!?%
MY5)L+%9LC+O@#R9^>"1R-I*"M\UB/\1*9\#!MYO2,(#)F%\<$#]KAE;^+CJM
M13<!=GPW*(%T-2X-O#<E/NGD+F/W! ,T13A%E<&E$0AXL\GP^T=\R(BQX%2X
MY_WR;ZP:KA()/?T(RB<&&A^F(@OKG7H&3_B&KKE9N]*E9\EF/M7*M[\@2<H&
MFA=A<)YRR/OJ1/ LO*?EPB<-U;)R:2-[O3K;!\)-%;DR4Z<4>?#%-82!N>^&
MAZ(G+3[5#CE.9\/LN(;SJWXQ:,'0I%+4US;P@?#-,? V;6[*ULMZQQD!FH45
MY-W9V.OMEKZ!\Z\SH8HC-:2TXX7HCBO-KP]:D.+1C]G$+_<_40GQJN'%KJAE
M[RPN-JHS?%X,\YRUHQ-.NG1\]A5N0E+VTG_GL4I<3BD,$')VH2N$%(,^Z>J'
MS&ZJ8(!\V&F8^4M/XAENYEIIN6T%A+9)58"I2C&SL%X@>4SK=B%Z22"W/,63
M'R'=RWW-3?WB>J8L[8RV-'?S*N\&'=,2^1O8\]K9<;)=^2$N5(D_<J;E40*O
M=Y]R_&-^]DLM["WF9145_OUPL-\<:1-9M*, ^>6,8E8WY11M43LNFO<RM 7C
M]WH>\H%<@#F#K9[L<\L\#@4R2/-1LDM2<Z&<XJ3E]_0G;S,?#BLCW^:VS\BS
M:(AU<#EVH6:$;[-;W!>TRBRG92ZMW)[PNU2;MJWIEUI92?E=SO:+NYB&(//
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M"DPBJ/7?1FIR&?!V'SBMV&E4J4"-H>JG.2U:V_AWORL0%ZP0"EP"1$_3G3&
M<$ B:MD$W5^# 9+$8*=[I=$@/^N(YH?+C@[L8A3MKPC)C.0(MCF0BJJEUN3+
M-(QP^*0F^:>D"+UD_>)'XZUF0-POC_7]!C0+.@CDJG9((&23WZ /,GA,H*N
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MC7AA@-\@_P!=5U)-<%RIBG7#T4%*#>@?P.YB(4 K\SJ+$ICO_P=02P,$%
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MH -GC+*JHL?,SN_YPN^E))T U)N+D*C387#@%JG4JN]$%B'GAN_=$ HU@ZP
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MD;8'7AI@14=FO@#L'#A@ N F>3K+1%F0"B[[#A^/H'G=YL98%>=6MX=.?5Y
M_RK(Z4=0XV%*IVY79AG,^@5D$YS\]KV"8M"G;P4O/LE2(O%VM'FO8=B]<+*1
M576JJSN>2.3G>L%YI'-5T'MC_].$<ZS>^]FP"A7%M2EA64'[FGO.A[P$ KO*
MS-J/104 !6#?*)+F./99M#UDPXL%5)0?S'N$N^?A.R&3QKKIM[NFO<'"7,'<
M!JCY-4M06G4VE.Y!%6O&4)9WV'/D'49M*'KI-=!$/9YT 4X36@E[5(PGI.4M
M>EC78P=NY9:?1*(*-;X$W,CUT,8X3B_5GM\M6DB?--?X%EJ%%\T;S?8Y/AI[
M&=WWI+N?5.DGDBH)7K>,4!*PGU/O1VH2HI,M_]RDHICC82\I#0[T@97NBHB-
MJ:/S^M'#;[P*H6^&/V5(4]A4??T6>\:T)Z8&&4^S:A)*#+ZX9]$YP0ZLJ<'3
MT=>7M7QW:>:VH2V/-FC";QZ2WJ!%2OD!>72G9!G7*MO@>"NY&!T*KM&3%4],
M@2QDK%^4,O_M11B&+NI3)FOQBW5QV&=KW7_[(LR[5= -017H]C0(#D@0ENJ(
M$?]VEH582L",H',DW0F%M7>442K2A+1,5K?-$0%YBH566EAVENBH\N09?8!/
MCJ;15R])]]PERYHDYS#7RF5B=#(;_TW@XE;KZ4EQ1]JS$_Z@E>JQK:I0)=^F
M?;"0IF9T$": Z4;* -;W4#L/%]<=>WXLE@SNLV.]*%;&349.U))(9Z+[[!B!
M.Y:5;27D[F-AB(D7;^=M0,]@)U<[LM-:#35%)%)=M3 TW./L.Z-N\?,7>J"5
M3W  <V\GMQ<.?(=1;VA-%<*!X6\(?;8,C>X'65_WP )"[: XU*NREZUAH!WM
M&CCP<Q5&.#DJ2PNSN 9%>5NE0V\B88IPH(\B_V]5JA%5+A"]BE<WO4N! ^V<
MUG# =P!&R/\5VEH=67UT*M;'$!WVV]E!-R=4>_=ZTAW"]O',_D6L,EUY\<(K
M+G1J-DEQ0U0T9%?=(">(ZS4H>A;7G+'04V ?Q@Z3<_V7D4V$D4#/94+]O+XF
MI@\#]7HP\9]]:M'S$UK*^0;D\R1E9+1X'Z'Y,^NT,Q>$5N#HZA/Q#FB$5D@8
MO9TIP?1UZPUM+&SRQ ?QR/JB.XZ<<>=P<JMR7[S^*!;Q.&@N4U:[_,W /F-V
M-!S@AHKWII>.PX%T3@121,LXH=HP]+;CKD(T6'HBE"EF/XVMMM;=J(-O@,)*
MI\)+ + 8:]C++P;UDMW!FC<0NE81!V?Y":*7 A/+?GFAO_?R/;9K.E]Y1$]Y
MS"1I74/&^<M@^7-4C[4\(7#HC/&UX42DE%?KJK:0,A1A^7:='>9K&*^BG.11
M>Z]#*=!J&FC%F9=Z4[NUR\06[B3+= ]>I[XE8FT]%@ %4,_!$"8R3:;A '+0
MM9:6M-'OPQ7==U$$.ML2O^&' W0.%IHG_J9BQ-4"@J0M1HB0T.HF98#A>>JG
MY4,0PS6EQ5\JEC$W&#CO&?FCYY/O&R6.C6);UB$W"!S8RV6LJ@4%W9"-EBJ5
MU'O'$<,>(@ 1#A6O/Y!$=$CG)&YK*/[:" (B02"OL$&,?P>4*>S'#B*39V5;
MB]!/*\I3;+(H4Q)_\$M(2SN\A=<D5QZ B,I6,^;=MG9 0TI54X5Y7[.*GX!.
M95G_':[Y?^#2^ANNH/\D;L-NCT)+(1MI1H_FT==5#WP6< !2T6)/J8D(<.;L
M'BM)V,(KNAD<E^T:R[EAZ.<+W-M+1(1(\J:O@&_P$0O A?*FO('2=+V&@= W
MNP\961,Q8_?I+@,M_V/9M&]<8Q$0NDC\#**56<3I4CPRG8W<7688T9R]>K!D
M]V7MS79_]/3%\ 68.*)9;]5KOJIQAON*7@O:+7ZI.T!-/M+ZSMQALRMW4?SL
M'GO>[H;*KG6_7_P>?>K>6 _4>^:-6+40R]>.3.U^;VG#N5'TT=^.X[[C>C >
M29LX!2B^G9A &M+>2]I8XIMX8<NSJ4@E0,MW%J1Z=SK[@CN%#YWZ\&X"N3N2
M9QK#,L,J41YE$$L>DTFU_Y/G5"?U*:<1:+I*_)8@/G8E\OILLO6 R1[:9<%W
M&&/QGHQGDFDBQ;W4MM3.IPT.8#AOWV,V3-_?&OWVV=[^\"VA,_CNO'7=0)K
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M+966ELCF1E=!7#RWQ]H?B)+,O\S%CRVYQ9#/!_O;)K$NNU\A=7.F]F3R3N_
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MDN3#88 8.R$(HOZP 9U3YOX[815/TY=Y*PXRN?G&&!F9+B)'713]-DQ]^?P
M!^[_VEX?1X-K.5@2=/L]N:#;E#7<8V1 _W!*T/@Z57]^&>[!<@]X_>"K#PX
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M%F;3BI\%*MCGO11 82NVX\E0VH5==(D)XXFR6J;01).3 T(8>+Y!%35LB-<
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M&_"G?\KO PFW*(X3:+WW'HP6Y\WI\3W,((U!9)!%88O"?3Q_CA78FN3I58Y
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M]-@)P$ZOU3YO'L:NA>/H-J;-RTPQE^7Y?):$6 OOI#B30T("<(AAUEOJ\(%
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ML*YZ<^V?"GXB-L+"=,?E=&G3E_+0Y=!;[5R:JL4=]='09!/>&]E,7\P@],O
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M$9L"D#62>E>]?6]O6?2CXCC\</Y<^Q[PZV@FXZ;56;ZRF; >MZ_ZW:*J[[R
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M9TNL/D1F)]LY.9RYF$. 6H/,ZF<&H3N -4#69S(O#W6J;+6N>"':Y5H6(;+
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MF[B#E=*=)/:!GWZK_"SH)E]-!/$&&?,*%(\)_&PFVX(C+!X4?;(BIO,:TZ_
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MBHYPSTE8H#M=8)B%)S5\HGH\[](GT^9SX45-4((>; J:SGWALM/U#C(''D*
M7":$FYUT:@JGOBV<*<W\5:]NE&4YY0=>!CHY1K!1L:%3PBT>Y>5J?^H]IMQ;
M 3\*.FD[R8+^6G<JO/MO[;I]U9UGH\S32J$7R(K:"%#SM!IRT+ZCM6S<\?X*
M5_T/8HD*Y&7V+WWLZV3%^?E;FT;&S+ W90<LM+QQPR3NPEI#F8UJBQ$0XNHT
MA?>O#"]8,=Z^8N7G0;%-^H!DJU&JR]=ZQ%AS]JE"L9M"K_T.-@ZNUJM!P[W;
MO@JD YP.-$:/C-4\]$;<6[;R4M]6[E4]W?S<V'Z<+9DDW*#C6X*6Z-%!ZB;B
M)$R*(H(..</QQ'.3S+6^#,W%L>Z.S>P-D.>:V=2V!.P<34+N8XO?*7)Z19&!
M_-C,.X!5^@>%D,F;LW.)+\!JO(?%-,JLN:6MM2B=::8=X0WWBY]\5HA0I8C<
M-)/Z:Z:_R-,7E=OLEJ*YDTSM=;J<:NY&OPW_/BPW/:N1L'<*UP$TB\U:$;@O
MULS% 2"7R5/_5-P-M#WZ3+H+L#K/83%M+E=YH3"?3IJ-T/S,$RB9W%_^B11:
MX']B)#$L.R#>:2KKU$LQ)-Z\2H*[:6X6&7JZ;UIX&9,)[6MP18 \]  9:P<U
M7 <?/M9!@&8^0DZG0$HUH_.)%G:KFP4:6Y\,EC!:EU!NWR2=O=-JIM_(%2A;
M%MPZ^CQ*S>4VJM-HL ?9:76S+OY6Z2UVY>AQ$B;J%UD=G>0,:+:ES_3PQ<0S
M=$HWSI]$C22G"YNY9G9F3HI5N,8J*"1<$@> C/X3[$E7EL9.6RHO>U;P!O-C
M02_QT[CMC8^G[I:+3EQ=247$4)B3USF2]A.GC[$ZN<FQ.WH+G4^QVK]=W\_G
MGN8,- >8WGURZ2P.D(]LW++&Y.?A].-Z[/H6EB[)ARF%?$\!89^6KEOS\(9&
MJL!YG&PGZEO\9X(;I3T#T%M?"A2$2)--1R"KI$!!7H 2YI^ZI=%VB<Q4O\N(
M .T19HB"7KOGJ $KGF$Y'#49?C^TU Q\B VTXULQ,'54$@F08H_S#.!>T3.G
M1-#3 ,'A7&@?VP0"= -8)?&N8,6,QDM#S]$TH;. =CW_\$*E$)!AG98P+ A,
MU*0?J-QL&% _R*]JAUZ^ U]+:>>+Z)P&ISG9*IOS';>I.3MF,S3H]U($-=U3
MKF)M>[EJC)QRH5, E#<!E >,Q8?74@R8$'\7K.#G[-JBS(GZY2>W.Y$D4$0=
M7SU:N8L7/A;G?3*O$FSD,2)ED*O=\;6%_S*B)1VSB'FIAX]"'EWBN%87[E4V
M<TJ, (TI_)I0;C9?S45J @E1H\6@V!,@26VYU%\BF_]&+H)KI"I@F29D^G]-
MOFN\RTVT?+%G7E+E-' HI>D;X5Z<J@5+>9+!J&D\X1.JM9)NSR%_XY&^YU>D
MPG9T'DZI:W=9"JY+V2HH&7L.C->%_=MJ2L#YPH'/:O;#E#J>2\:'O]L/_]V'
MX=>]6#.-(C>%WK=7EEC\?W&LFV<ZQX'K3T58O+L=:V:=TQHI8D9@<R\8KH*)
M!'8<*8',&3J)P'T4H#-9D-.XRA?)[/WAI*V=+W)2*N5.U75N WT9TCU9EX/3
MAEY/9OR0*P8+N"9J$W9 &SMV_2[1 $.^7A&ZQ_&GI.NCXY>]5"NJHC;)NT4U
M]Q @X<SZG:%DF SX>I*JP_VC;5OE<+]6!HRQ  /:9\IR<42' -T1_U.R*/DU
MQ=ZVO9TJ8#9B,32"#\D"X9< T9O[_YS>S/CA]^\T47Z4&RB"[I<B1MJ.RP#*
M"I-#+N#U"Q*-4G:<#VMC6]Q$=J<#':%S&]\/ WGS+>QSC"UHG9!,J)MNY;J&
MH*,/5%B2FHSRR58ON&X133(E?DE&?7NLP#S$M=_862FT'41PR:XS=9GS!5B%
MGO;"$:",T_YKJ8%BROX%AR3\RCWN0 N46^GW)TS(+/8R37+L$YH]MG>J!Q-<
M753-Y\U=6\@>E'Z7X>H8E-7\R#1;IRXP2" ]IR$>2H(D/LN0#Q\>A*[> P8V
M=!!F?"U1C)4:M0L)8.9,E%(OK1LVMZB)3[WE'W*/7 K_X10SO[><POZNM7:C
M^YP2M-2N85"^B,+@TL8.MDY>C[<Z;E\\I6WJD(-I8*V.G"3+QRRQ(<ZP22S6
M\G^A,J=.AWNLP/\;QOT/CRWS?P;K\JDTV5^'H*KO",O)WG]:W3SMF0+Y?LMS
MY.W1WGYJ5%#6FO8I3T6&G?5\6F*N9F"IKD^",DE4[2T3]<8#&0I3G!6]E%J,
MI"<&J]!;#<>6MTP*J5*F;IZ')V]H?&@WN-U$(=5/\!"&*ECG(;M5O/:22BWS
M^/'U[<BC#BW3$3ZY8(O%NHK;:='AV1%IBXOGF-4(T,UDO_I5FN23+<#8K*(?
MR&+@::DEEJ,.\+T?Q)O*FW:6M.7(G9D+/I6&/0%(0@/0SA). &TTFMLYOTEW
M>0'=S:TK4#W3G>R&5_HA0,GA%_VUHH!>\,L'J? [$%QHGP1D!UA;WX%5<V %
MVR^/NB P6.AT\#H#^O7LW=A35[@WP$B/&=C#\UK=):@M;OY+!&AET>/04D$-
M<BT? 7K;VS1SB"]W 6CC<^+#ZP@0P\5'=UO<GZ'44ET"&O[T!8S6@PI8AB*@
M,^4($*;@SY8W;7R$GIV!:\F'5'"OYT/FV'=/+E$BX9?UIPI'+O4=\&6P5A,"
MU-M^N3J=\A7Z:_9U2H;F#,-53QZ?+X.O@HZ)M=@F,0Y:VC.$XG FT"J7#,]7
M)F.CM3=6,'U?R5S;> '\\'(.,'3^H!<NT(&_482JL6"_OM)O9!<!.MB'N @<
MM"8AC7(&OV@9SX^W4#Q7]N4GFD[=DB^AY5W@%< 1)FVC9Y"3.W4:]PM@L;3_
MN).7HLE/LC4]OMM,&2'P'$.D!X,2BKD)F7L,E/=+V_T YOW1^)>_D<7I)UE(
M=![N[KRG"UC6U#;=AH^8C=%$2LN'$Y:K=H6G>M^D<0D/>S2-,G@DPWRB1GQN
M\1G%,4:&J;"B4ET1RQXD#IZFH:I!:LLS_W>ZR*VZ@QE=.;< QO6&S+_ZK4W)
M_YR^T[_1]XC0YT_YU\>KN\[/"D8?_U[!7P[HU/4C:-1EE^#_A_%\7>SW7A^L
MRIQRQ,:J9**;K*88 Q+(*?FMBU%W<:*L/JO&NA9LO[:W=G*\^8"SW,[IB& K
M>$W476(7O9_@+\.R_NO/2,!#I#H-J#64_ONHY>)7;Y[<3P&::^4DX6T=-X**
M*1R00[,("]4<J<A]%(96:H=>18AX45:U,+0MM4U2IKV*C/#P]J2RG\#(W4R/
M(DVK\I<L%,8+]Y[%'P/-8A]EE]71E)MSLC";+QK&ICFUE!;7W5.YRZY'8<6N
MT#*WI=CQ$-7WLR7%>V,FTK2W9<.*DD4'HPD4Y\I2,VA:O>:4)8XJW?CC-,B]
MP?$=>AB,GH]):18CV(7(B76H!\S!9LXA*!+L'/+L[X*+?6EPT F)830.[Z&N
MV&7[_GD=-!9?BTD3?1WRT>E(!!Q6TA5]Q(;R:88,0HRWS)DI-"N<)"([GMW\
MP-O6?6"/GB_*=] 8J4WM?6R#4F4R%V(<&Y:E7:V%/ 1Z+)X.,N&J_X+%43'Q
MR"BL^2L&29>6C>IK]C#><V6U&A%R$[(OF>8GX^,=WS&>AZQ@HME IFE<]6/1
M??/M#HLC99(&&/QK&NZ:0:>^NAF9>F-0&R,G)9HVNV W-05^D; I8.A<UI(I
MIWK]:GK2H5<2Y-O9K++V)B?+BW*@]4'"@^+LQC1\;B.>M1"7!(,\-2KJ@7=Y
MW<TYC/<G'X73EK]RS[5*>T1Z-UF2KB\M:4(!;"Q:45FI^3;R]=/-"8!E8!:(
MAM\%VO'Z$O,15L6KA.X[?**D&-1!T9B5-(N%*)%K0O@9[TLR8O5_\-7'W=<[
M[JG3Y.+:;C^S#0\:TKD_ BW*9\R;CY<K,PM>2J]!UW^'W!<B<?\+&4WNMYI5
M1U.T?6GD Z03U=U&N-*4N,PPS<BH?&%TFW'YOH-6:W=H/$T0WM:9/(J*SEV_
M"S;^P-7^I6C5$#RC.Y#Q&P@0/@L=>(7S)4PTG48E/T5=8TVKA4)EL\<AX?$X
MFC#Z2([X)]T?),R,!4SP,8%^EL2;K,FL/I39.*HHV+9'67D<-]^D12A5X4N;
M:]"$CR:SCE57MNE+[CYYB!03=UGTPSV[LS.,G*M2R2E$,RRKU_+C GIR1U)<
ME=BH[_*$BPA; TFY5^+4,9H%FA-*<L=G.>SVS/#8!59ZC9;@C _^V\",O6$:
ML-%$_$($,Z^EQ*\G3CTUEJ1U:>+>UUPV)2OV-@W0:*CB8-I 3WJ4E"&ZK8 3
MO7 #B@%O+\E1[D8OOGK+EVYKU ]; A;^3(MEAFZ5C8D5/;@"%_H?G(S@CQX>
MJD2S[85=U-2'?Q2$$?9.T7FSRVLXJ6@^3W62"7IQF<V;IO:)@:JYA\ V87'[
M^Q-C9/WC\Y%6DB0IDS03CTVKB>+*!3I/GNS=]3 =W3%Q(PH;86OL2/XBO>PL
M$+8#[Y-+>DK7IQ7#^9\C>#^Q,AJ2D7]X+21Q,8M&:C$Y%$?[=OS%LUYZB27U
MMC?5JI0W&:'XXDM"V'$;\C5U%>4#YIO1#"HW:48EF_EG\;.)*9%(Z4;3&<RB
M1\(:67*7 C;;ZHQ?^G<N!H6I!X00^W0SK+FDURX-FI2/[&E.22Q7Q.'OD(<A
M/?)&ZD%JV%$_]_,)7CI)7)[H*A(+__Y@DE9"U;A5?A$[V3JH#S5GRR2U(HZ?
MYU,4$8] &35_DNJWM0GC;F[=D?IB>RQ-GGR.B1>,EM12;CB3-T#(*#8V4/I8
M 0&5(\,#:CRF<9FO++LTKGA0Y&XM,HWO.=K36LXV;1PW;XAU)F9S$_4.E:\)
MD;I _5.Y+!^LB[,[MSXDZR!^:7/#6Y*%QBOBYEJ;1B6=/T?%?+E54;L%\L>%
M #2C!X*[]&C"A/'V<X]62HO$HP>6ME#"[T\U]_ARW2T ^52 T%P'S0^UG_8J
MX*V%HCPR,[Z'+V.YS\]/Y""/L?C2";:*;*$M.7B!IJTR\RK,7T/I@74"SL>-
MT8"VBCV*KTXZ(R>;?5 3+;= ')R^N:\_=KPN14VD4J M$*)([)F'CY:?+\0@
M-7'+KB3W9"??>G["Q#!Y3[?TO;)#<O3=Y:>IDW5L[J!/6.$;+J[3>5\H*J$,
MW;>Y/[RBE!=D3<(EE(7B:WRW-C=_B1<AL1U-&#[[DCQ?=C^O_RM2=AG5+2EM
M(2F6'V0/?R32/,>(_=[#S4ICG?0)>U8YD?_ID%[E8-T/5TNF_*3<KVT4#]3K
MM+.[;)Q;7>11\UXOR)<^R/U<%#+],*AH4CNR/"0 M B&KBB]'MDQ\EKZ6EP6
MNCF28VO';-M@.+449,>S+B<=0M^:D[X^&I=FV\09.-Z,'F-I$](!OEB\@208
MNR;A_&E::U*[-2:\S<!-.3^F4] (DR"[S H9*42<H@]%P[<@L^%VG7=/_YNG
MS0V&=-T)=3A#;:"@A3 ;T\7SA/<%XR;A:G@4\4$Q^"!BS,K&D+3%@B>"I;H7
M=,ID.Q-DFC?-ASW?T01WBH"?WD%'\M\)'0P8,J-S-V&)$S((F6Q^'R)"A)+<
MCB1$!"N!S\.5WLAMAW8D_G9(>4_>Q1.*R<5R(KXD)8KT\N>+6 M\%99E_(F1
M]NHE<ZQ^"AS%1(#Z]N<+.?%%ZGYZBN?7^*N75'T$R,Y#J42>Z,YO;V]T@;*C
M VXT_GP)#KSL/U/L%U*3N7I1*(160>@U'F+=_/GROZ!24: &[__4$>Q_\8.+
M^/%_ %!+ P04    "  )/'A4%IW!A%M1  !\8   &    &AO;VLM,C R,3$R
M,S%X,3!K,#$V+FIP9\R[=UA47Y8N?,@2"R1G%! $R1F*J"21)$H.DD,)2"XR
MB@2) @*2D8PDD9QS$J'(H8A5@.2<2E)]=#\S=_K7/?/=[IGN^\RIY_WCU E[
MK[W76OM=:^V#GD$O Z1/E525  Q, ,"X_0'H.> Q< <7%P\7YPX>'AX^_AT"
M(@IB(D)"(MJ[Y" *1CIF)D8Z!@86-EX.EON/6!D8.,4>/N(7$!869N:0D!87
M!/,*"0O^Z248^/CX1(1$-,3$-(+W&.X)_L,'NAT@NX-1@2F.A7$?P"3#P"+#
M0'<#S+?]Q,'X\P'\VX&!B86-@XMW!Y^ \/:&&E( $P,+"Q,;"P<'&_OVJO_M
M=0";#.?N/0%Y7')M<[S[+A2";^.^W&%5J.R@?#YZP"9DX?H.GX"*FH:6COT!
M!^=#+F$143%Q"<G'3Q25E%54G^J\>*FKIV]@:&EE;6-K9^_@YN[AZ07U]@E^
M'Q(:%OXA(C[A4V)2\N>4U)S<O/R"PJ+BK]^KJFMJZ^H;&CN[NGMZ^_H'?HR-
M3TQ.3<_,PA'(E=6U7^L;FUN'1\<GIV?GJ-\7?Y(+ \#"^/?C/Y6+[%8N3&QL
M+&R\/\F%@>GUIQO(L''N">#>E=?&,W<AOR_X]@Z%0MR7R@Y\5J'G!Y06KJ,$
M5&S""/;#/XGV9\G^/L'>_;<D^S^"_8=<<( ("^-V\K#( %G@_((S)XB F]EH
MVFH,D[TUMMC!K1]??P>)#3K/"-?^O0YOJ#OTBOF9$H;(&P*=9QG6Z?9=-J,!
M26"?L]Q-Y5!Z=_>'D8,,[63U0%;0&)<:5>!2=(PL*7=N-F8$Y_\*@'@.D5MU
M@>17/.;67QUTJ8Z5^=+8T]\#2OPJ+,47I!![)"HAOW:&5YC1=9Z$SMU7%79]
MW !:Y>;N8^)% ^]MD;:A(7M?SWS 'S6<]#@L27'GWTXGZ,O0H"KR'N0CQ[^B
M/GUF>N,.$_*F%\UJZ&- !DE#GC1,\IY,).N/KWQK?O18G@'Y$JMRX:VA2)<?
M^V2%2!OF8U]_+YX)&#AX*/&#1<-*F9<PH*U(\;\!& .H3GJ^:OT!V8@'HTXF
MS6GNVN2E/U66\\+GVHCT.+Y"OYL1;O$4+D!S.\6.B[L>>[P^&WMX8A/5&'RJ
M;60J.AJP@!PBU!H7,1$$D1H^:K/^/J'GYT4@M] N]99F2U*/';% WS,2'= Y
M>$/:D&14S-X<KVJ5LCO[^UZK=MQ$T$P/X-,65F$]X6[G5%!;4R?H2C6VK$E.
M\K,<Z)=].E%NA-A+,<]%R4P-:DP@)[Y$IWETL[WFU;PGMXRQ::(.4&@K B\F
M9:M)TL3'HK^U<E\F>#0-XDD;.4L+C36/(Q8;*@([U5<&_;U>^JML.E+]Y.TV
M.\U[;X; L[LJF2Q)'[EBM,S>OCBKP#X>Y*VY/P!VW>5,\WI3SRCC-BV,\4L
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M(\-K6\+0<1"3?:!PF^*-N;WT\&,YE%O.1KY-JFR="8G?0.^+/WOKQ@. AH&
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M5C>8=9W!6?TX)LB?U;JQA'B$3PCL&8<.!CQH,>M:E\1)$AXM>$N*^5/RV_M
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M*^Q3)%#'L'B6PM*K2*5LHT"!3\]ZM+Y2RA'@ HPXOBAX_2/L1# ;G[;38FV
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M?Q;=T] 'I3$0G62#=+^WU$V\?M52G6A=EX$=U]]"J](OLA[(%+B::'JKO=#
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M"J(Y8Z/M!(BV:I+10!#)8C<@$)MO<HB;SQN+V+Y6HM&U=_QB3R7J^"6<<0B
M1D#.0=G,9,Q,4'6.HZBVF3"U,  -P,#Q[#"GQ%TFBK;D%P?E*8$BX97QR 4K
MR*MZLGA)#'BSV:Z;:AXS36O;\CT_R^.;?OAKQ7./V389F[W%FNT;RD/%BG!A
M"+Y5Y@\>)3LJU=?(>CV[80D:/&&,D=%_(]A_0]?_*;[=6S;V-.7J<7D'(OI1
MLC;+W<0-V UF$S,#*L5/XDN34M=NPKN/%84E 90A!X-=/)#7%[M'"1YN6=Q>
M+W4FKM5]:>XH$ZNN./!41^Q=7D6ME:PI6V;;C=C1@:E(,=XS2P5Z-Z6.YT0<
MV4IH:+AZO1[EOFWS^7^9//@? D\$6<;7;?BNXDRI#5)@&#YCS-X3/\S@LQKW
M-FHZ<A:50XRGYD\"0ZY]THW;>Z)?C<^@A,_V_M4=UH3YZ9&Z;<+-\X<N30,"
M_/XMGBOI>@D;<*K((I29FC,1"LY->[+R2/?\N5&OE7[ZU>@@>5Q"YI4G,DAR
M*23.J&M9[4EULUCMY7S^0*T=>$1S$3Y_"GM0>Z7G@1,;XB%54L+>^HZ3-G,V
M]$F0I\PD*+C:R!F$<B4DA*"!.JXJH7F7,%=7%<+.J#-&KK.F +AIB+]?;:SG
MB,(PB_S/SXR<6.NS-==T6^()3P]BWSU+.E,ZULJT&W@GJY*8C()I^!Z:]BP[
MLG:-VS5ZA;NC >*933TOSX[^"$I=N2XV*\#%U*#P2N$=H:.J(3.V$=O9NRUN
M:-FL5C_]M7&S=1;6>#GW7+-(\6 I"J(Y45@EZCK?_EVD =:OLMG/_"-(Q)[Q
M':L =I!0D& @ER&DV,I:EU.%A;]7N4T88RV5.:HF\/[894^R9&M$<MTN!=E@
M8>^W(EY/I=5B#S90\QOIR\G!6$H(O+4!B1(NJ7^=?7"BPJK[7J+^4[%E<V;D
M4=S;X"61+U^A'/J'#+JZ,BS3NWO5ET:5[GZ1S _LS]8=JIRY@(&!E]B'8]&/
MV_6"=:;W3M1-N2FF<_3W[T(L'RH!Y:A^CXX.,$-4^J46;FCPBC\O&NCPT0L7
M4=OF$>'3H:U/L=#DM^)_WNVE@](#'9;TR#!-!M M&F["SY*]7<<5GHB>Q_6O
MXM&*/U?W8<P*KN8.))ZQTY/T*+M.C'][=U$N/GI^[9L2AH2T- 0F(XS2ZVK4
MZS(:;)&2']O9T[632UT<%I_'7&'EPL@F:?IK_K\B\\<(X8]%IYR&^H@QN-J'
M>3;M8AO+&8*DYC:D7KAU<V-D%YT]WZ,H\'6&JC3U1>IVA[EU1&EQ66-K?XI:
MHO&/RHC \!MQW^(N8L&9DQU2)KR)Z<J<1W9%$90O7F',Z/*%@*6I0T_$2R>P
M!.A_N5QIWF#6<1OW4=)-4CS<O+/1!OO%J31HTAG!60'^]B]R]W]V^83]<,C#
M%?V5N R"]PE[=8R@&NAMK ,Z[6>)-T/)-9-<4M1.)KU.]['",!T,,#>169Y?
M[R>K3+#OF(MQ,9/M;\6NKQQ/'>QL/%WK+3CR3QK9<GT83['<KW$%>*_ @Z0M
M$=$_]0+NU*9R$]*36KUQ+*U['17\3F+?Z.(D];TD\4[JLP";[$IRI\\,;4[-
MNGI!3B=&,#RX3+#%E"B7 4[5]<8, S\'!X?TD7WFO6D_@X*M^XS4'5ES5$T8
M8LSP.*/E<WI]V\-L$DW-R6:M2D69_(,O#R8F0();W)&O3%J4O)DS?'23W=R\
M"SI<O"S.Q.ZR\+W>8^CUQV=@[JRO0*D%W$,#H_QHX,=U&TK//M_8U&0SZ7B+
MBOE5DSNND9FXVII8 :+C(@)H^+/?4CKNHHCK8RN*O=?)S8_3&MS"5J=[(/EH
MO(=>HA/O#2'SZ]-L?,B0#!@-#'"UH('R6XW:L&CA_4/MFQ/+\A]0OX?EVPRO
M]SI>*JE* ]E$FE2H4#[B#=>%6J+=([DP5#H:"#-<":"#^ABEK!V*YB>GZLK(
M!ZR>!FYPW]]2O6&#KCDB'@DW679YW@'QG#HMA?A2-I,9SO4Y8V)'B!!$2 +<
M<Q4W'2%GA*B$*5.U'"'3DXK1N]J*E$BZ_S2N^">"U'20@DKL[G#3%Y79#)?T
M( G*XZE$E_P:^%".'Z<]ZQ3/+ZH*WGK2@3MLXHJO%)B:L;(TN#=\4RQ"I^QM
M?[$IP'JA6)G</:R38 GD9T=AEV6J!(4,)]X=M@0MLB0K[&^*.I\[3N;QI#FQ
M1F7H%^5]EYL,>*KG_$4IO*)?+[LB&0OI#<)IG75>@MV68;@.I";0R&X?M866
M4EH;U35=KI8@7<SJ9BS?/#.4S+#ZW?89@P>65'T)] \[: <68'['AJEGN21Q
MV68.U*0BW:('5<U/!8TM\P$_- #)1_'^DAI(0ZR2*3-^;*G50>(]L#M_M;H/
M+Z05'Y NF;^BYDV1#78O=O<UX'$_K]-]AT]3I52_H<HA:YQZ=%Y]X)Y)R,1C
M=@?JOA1O Z&:(.5(A@4V-3'6GE88' R7.);]J:*QLSM4T_*3D.W-1]QV90WQ
M;&+#=Q='/#*=R*,WOSA9[1GN4UD  ^T,"3M</K?KT>"0^?X-.TJHV[!LO(]G
M\N?ZCC4-(2=F=O2=/E[7G]U>XALX3H2^)D;=2Q16T_<C#'@<<R)P4^3YN]:J
M_!HN<Z6,8JZF2Q<V+CRNKQ-/%])U3 RH(/;Z?J-4O2ZG[5=?6W,1_H1Z39>Z
M7_(-YXU?DZ6P1=WM)_&LO&&'B8.U\.XA_)U[1-$ 0;.4EWWV+<<=8)JU@$S4
M<=/PU S*N+6;2F]'H6J0(.HM)J"Q;@H,NDZPL0FOF3ZK%MJ]%XK;0RL!UFNZ
MSZ9=ZO(UAY/@:RZ ,8)AZO@/5T!$YJQ>K]K:/6B0XF-(J^=Q8AO=<T0TOU,M
MRU35"IM])P_$"V7*Y@,>$WK,H,C"2=9,;A?'@FJ7WV4>KC<62MG1W;')E>(#
MO?X.A":V9@U)A'PUC^E,%B6-S(;L+.WOZ0?'L_(,\'S$[_N!WZ<@)^5SG/5A
M\0'$UWWDD7Y:R4?P;L9+D.)%UMII6?6AP;>#D*G"XF9!8\-Y3?O/ 2\S55:M
ML(G2;9U4!OJD78R3NX;NKIA.[8%UOD:C/GZN(Z'3U-YIP4,#ABVO:Z-8,@6_
MGYO7I3>R2C1=%NTTDR$2#Q9#X_IS=Q,0Z\Z/9P-!ZZF;13G-6Y.%AKG%8B4\
MW-Q_BLCOA?S?3)(RPZO"WE.R)C/1#1JW9&HUUWE+9[9C!-0GFA_G;9S7ZGJ=
M%^/T;._4*6&GT(^\TL+-H!S8DB4'T^=MD>N;0;[)>V YQHLJ_\CJ@&@J'MJ\
M1=+;.PEG&$YMB2M9<Z(XI?492&6J,:H47<_:R)H9?8O+,QR1]+2\*;5<>(C8
M;*>P Q%;H\.V4#\)]Z3&UBJ(_9MV,O):?:R1CT)O3[.)+[BY]KOAC#%1J3W#
M)?9,&2PXO,^R<]<+QB1O*!8(>R2I/^3$JU._J&LA^\B@M"1H6R"_JH7;0JGV
M?$IX@4D\;\(YN\; BJSG5[T.:V9$;L,9)47J33)5&]7[\_#&O&^_-YV#&Q*R
MTL3[#C*OB[">_@.;8>^46\<0&MA\(J>[9P/8LI! *XC4^/!1B=-&WU!J7TWF
MAGM6,A^^5^60]L3'/(4YG!.B ?[-<TS&&^>D.5%+3Y=>H<76P)%F/G_;PCNG
MLGC05J/.G:,AQ^+PJ>>J4K6A-#(M =48NS=4UC+,=2HG8J.6L9Q)&A046->+
M$F5*J0MKHD-LCO>,/T=BJESXZ#*_<[P91!3E7.)^L0QSGG<@__T]ML1JFK!\
M<Y&U'C5E,V(;.H0&JN3$Q&X?4[[.%("MR%'QR3"R^FE5-P1WT1D<S :EP&:S
M^]+FWHD%/*;<XHRDX[H?HDA#D L0(-J^MSX('!GZ@@:6&]I07W>$^_=SQE^I
M:T +6UYB&IBKAP]MX3D =8H4[Q&J'>*,.  /99_:"L*RV%X77AM29#^Z5:<T
M-J6:*BIC\Z9I4C\1^X15!E7H8"KS;EQGLK3TI*GE\24399I6/)6B?C!1"'WX
MHSEY<0;?]0A@>_NOE]2F:VZ=FJGJ$I.G ^=SQKULT>$=':?GY5C_X#*+S2*8
MR,H21?;RWMAK%B/%B"EA(SG=>8R;4J;ZDD]:.":/U:LFRXCS3PC!.,$4KU=8
M5IG;@QP^'-2&3[79^,MP1/Z\&[1:J0<$_5#]D7Y74%K]M1[6(4?/H;VAFSV5
MUQT/PGPNA+Y3A,SJ!?E(@,AH2)<F^<OGH?L'QQ2I3W=63VV8^ \5LVX)X$JP
MRG=V5C)>4HSSU?:KL(H5TRYS2^<"?7EKAS26$$R6,S1 MW;#!#6Z(;NFWA43
M0-[LX":P?I[^'JBS?U+>VR3TZ G;%%-L!S%UVM; NZWS/V4(OG?^EUK+G7&H
MV/=AF0H-',08=+AJ^.T+%_45"'96YVO"U14V?9KXFM5G-HHJ6 XU*@X-B6D7
M&058:'^O5K^(EY,.LI&-X2H,%JF(F#9\'76&NT6ZQ%;77]EPVFN@RG1U#9DT
M>+1 ;03OG*[KN;XOG=-2"G/(:7 F,H&V^FXF=^M2G9UU@GM'!>/-6&-HSH8\
M1-:F\G<*^^$!,1O5>U TT-TO0I@5L4@<IM:BQMVKVMRP>(_S\=&ISE2EGVTA
M-+X/B?<NIJV\HSBTA4DKXJ=\55SZ<OITS99A4DI^N,V$T[W@GQ\5R54GTT]>
M[J<6NB!C2?J\_9UE<NW/HD7 <WF626^AOV.S5P,\/L*('"TON9%>D8'(K]]&
MZN;YKOQG_ M_+KN?E 3@-8^N'3)'6D\Z64RZ;^Z*F4)$1UM*Y0,;:N0Z9+)7
MIQO@QIN2^>\<="L@;A"N9(,)S%(\G:S.M+RM5*4ZJR-[+ZISW:]KM#FTZEU%
M)]D@O)II/W)D9#2?FE&D.J@+;MT.L3,QV-M+9Q*4DZ+(>JY:ACM1G45PI7R8
ME_F(Z^,65?OFODB3Y  3Z$<A7B5F2^[SQE%W(QVO8G5+6T#\F(,K6"9%>BLF
M98698/M<#5*X[>.QT"ZAG_22UV4>:^"*$ZN#6J-M#$RVG*&I6Y/A;F2B:[#'
M:O>!3&F8H(KO2X>T;(87$T%3S2&H]QIB<G# E\/SKH.]\\ES"?;?XL#;A(YU
MYN$6,<-#T1#$FN9NQO,QV-!P3Z8<80R*4:5HKD>&L79\]S9RJRE-&MZ3IVPN
M9N'<"WQ/UFN']5-&=E-7'116$YG_49GQR&A>I71&/T;_0.K FV'*?S@N=SN0
MYDK(O&#1))KV!+",7T2,KD8)SSM?SDA?QIEVE4&3Y4<6[XAD/!V;+'=;8]O#
MO2++^L5E=&VI/%916E;A5%:VMS?WHT89L<J*1?@[=C@(S,5=YO6X&A69@W+]
M=3W5@Q0MLK9GHN"Y[&Q89<P[DD 6^8$;VK)Z#!\UWLX+FXV.+[:7EVM+)QJ@
M.O& @TRA6%.MX6.G/$*Z,4;1@DC"$%6ZAX;W!<LE2[RP?>@:*Y6BGMXO=LHC
ML@D"2W5F,E4?\G5G4;<62E_%S1J'A=*4FU"(&2,T.2)6K_3*[>FZZ5I^9=:=
M2:Z5[I Q76P9'!0FP7'[IP_%*PIUQ4<CN;BJ/%@LA4-I/EA8*NB;QXS"IH)D
M/ \U"HG[(OPH1:N*E_K,15/+/$1*RVEB5C^M,^6]; -M?D2E=9NRC?CQ%"W.
M0W75P'EC _?TR^NY*],R&V U/@MHX)W[]>->.N</3-XK]=^B^A@>5BO)G]+
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MU48 ]X/>>K#0[+&S36H?WR'I-CB[U#Q^OU2D$[.+#].2X4G@O[H?_\KQJ9!
MA=S.92-S#!A4: \WB[,O7OQ<OG+YI.P7+RI4\*<*(JW@-O(9F?A?.TM_7[^.
M0;VQV%"O3L.LL"\C)VC@>Y^G]7%?%NM^AYS,,8/_REB+[__2&?K[QH;[9X#H
ME>Q!VWNP2.'"AJ'M+$?J\0^ORR??K3T%>AG#MW  ?T9%[X"W!V[M>JT,X[Q[
MPHS','N*>+$Y#OK/V6S+,I*I(_],T6JNI [6.S/))]*T1H4KOB\(*[%RP-G]
MOK#$A5I(OI5C5/^WNB -75)PM@,3Q_@I/1K@4G\*?WAW\2$;#=>\6+_/M7UJ
M!BS4/3*\K+S4 O+A1:.\8Z%(=XBR3JVP9:R?+D=L1\N$\/4#:5;5B8(,QBFI
MS[FI+G5XJ\JIO +IW_QBG\*^H=Y<E'\J^_I[BAK_WM%N@55+F+.%1?I/\HU8
MU B>JFT>RJQ;K-9P(8I[W?[HVV,&F[NQ\Y*D)/[AY07?A,VIPQS+JJ,5+M4,
MUEQY+&MJJ7+D-UCGE0*R$IW_*YK\?OFN6U_V$*#7UE8]MI/7TM80 Y]B(8K_
M,??2U67@(N[EZ[)JJ6@E?]-.8AFC=:87TQ_OT^J_\BM=R7P+Y?A6(3MY9?05
M.B9MJ7DPG%CHX&.2S6]F9*K&1JVS%F!.M_RZ[UG=&Q>#3/QODXX\>VPH;S<B
M2=\?S\^5IRT_2K]'T7*U6S>]T5Q):,>KTE97[Z#VQCD\IJ3!OM0I^N.6G*I]
MCR9B6>WJ;PWQ3S)W)"+)I'@IK"/Y:;1/[S> 2%$PK>2>.*BF0M*TYD0*G5FU
MP[>V9'YZSU)Q5F\)\!D<*HPQ.Y"W6>40YQ"_>19;I)!VO\GNQ8](& &JGUGH
M#<AM6X\[9*Q9!^E[";FF6G\2T]<C^FT_^I<J7>>R+<:4X@" !MS3;Y09FTUM
MXS/?R/..MIE+>7GU^FIA;?R!J!4Y^ PE?9R*A!X5-Z4;=:UU'ED/OR$9>2,.
MSN3$O-9I&G.?NTR#I W)3/U"3M;-#0IS[1):,7QAY7+%TY0W3HZ\<GZ05F(/
MQTUCHTJ&)X XM-JB6_LI2I@3WV)DW9.C9?;SV%2*10:2*Q:I(?9)[>^D-D3#
M?]S Q2#<Z21B9 FTFQ\#GT4%>0F_5.=?RA"<V7HW;[;#!*UEZVMKG3^.+3/Z
MJ]CYR]=M*I]'I$,^8USJ@G*9QGSW>-<)^+-7MHUAT7Y.[@^KKT4'OKS;?_[F
MX])BKG^\C/<@2=E& ].O($D3984QD;"04W6NWM\(V*=IT<V'SU:DO+!B@@OS
M[?3P\U!IW6>&WT;\U/*5IG6"SQ@U>L4@!L.2XAT"6<:'T^,<Y6,:!>[]&M]J
M2P)C%R,5>L'K*"^WL2#>T3\P+9U)#S5UZF=I6JVV1G9*)O&BKA)]BM@C.#_R
MB^TN;*H('G^UGTH>975ZT?C6^J53"L;;CG*OWE;QR"XZ83'^7E.U K+'X,JZ
M681E%.UGU]S,C(#$#$MD%OD&/+&EXL.C[ GWRS&<@K+<[KV@S'=/:%F8?HIG
MDYQQYKZC"*69$L_5*@KG_XH' )($_K:;A"5ES;D&\0/KQT:#HN$_<L!7#?.:
M0]OPZK_9.X:5?"@6= *CV-)-#9E<S(5XV$7%J5F[FK^BKV"QK;&^]4TEX[>!
MK-6AW@UQ9M,/3JR(\5::3<F &ONOM85EB\9P 3O%M</$%UD6W#7_6320?5(A
M%HGTA4RGAH552PDX(M7>("S:/(Y4=:)P=0?87/G%]^48G</]C')0AIQ+NDT"
MWBF<'\C[NTD*'=Z]D8;\ .L@_96?3UNE\A@]#W[<J'^[L)Q*2]I3P7D%?VG3
M/()EBHKBC:5\F=VB;JQO'J^1FM-D-&#EV4LI?6H5L27H/:.I>,+=OA)Q"B)!
M*74IMJ2]K*N^Q%G8>MA879<171^P4Q(DM!\!_/(30DP>2LU!0R_H+XF?_E@9
M#'[^>'6HJ#V;>*R@XZAR1T\<*_7D&[#Y5_1:UZFNPOZ&J9+:)ZHTKBI\U#(Z
MSYOFY.5+[(0>UT *#\ZQ+O51*K7/?#5JT4G) B9I5J&*JT+U>*S7Z0R7'N7,
MVK73;(</DO-1,;8UAR:->.,B<SCVK])=18=H&&Q_T;;OSQ7AEB[R3C5;YYHM
MRN?:ITZ'7DV_VU<QV0Z("^XZ<FF*;@= S]SZ:[*A#T6NN:14]V(*ES=S!6<B
M5Z'[.VQX(<J]3V.\9;KBIHM'P6QL$SQ@Y3(#(S@T3BN_:[/J_^ODNJ*:T+9M
MJ!8@2)50 DI5Z80.4I0FTA4P4O100ZA"(! 0I'>D7T,)2$>J]"8@A%"4%FIH
MH7>I 034ZWA?QS/>>./>][&^]M^:<^^Y]IY[K6:LR@L+CY;)*W(D.99)0TK3
M^DT8C.XC)#Z11P-F*[I"%EO#F10P)%#P!Z:-[5&$NOJ,1;OZ1MVD\]!-.$VG
METMK@TT7)$11=7OXAQ!%X7@=BHM>/^D7P!#3U_"87#V-+SF(/$B'+_.%&?HW
MH7PJD-5U]L.073$CO/"*S"E4FM#J4].M":J:I5T)RO?FK609@LOXC9FA-1.6
M=59DB=]&_-4*TE+RR-N%1XBNH.GD^.79R?<P,$.&87/UQ*4!',X=Z9Q9.@^K
M40ITC'57ZI#()!$\SQ-5.=O#_059*XMPP(SF0"JKFO*)F#(<#[I'+?,[_=C+
MMGV@MGREP<AQ,43O]HQ>?9(O3X->Y"1C;;Q6"S@PAQ-XE_0GVD\MM8QJ1B&;
M))KO$S3F-UJ39#4H-OO*N".A7PLCB /;,5,5?-&&/#.4/:P#G!1K](W*!AOP
M?E(+%W1 "P_!<.J(G*1#,FK;K!]GK375)+NJNK,\S@,<4KM?VQZF*$G&$=:C
M2);Z^,_>!-OJS8UP/<4G.K>;VDQ!+CE$GG5 XMC1F]B1_?8(ZG*.PD0*[&+3
MNB/"#0@W_"3"UV/>,=4KOP+P&$02@>F/]A'SU5P%0[&\=1E/\/;4 T^K$HEH
M1YPZ$6 FO^H9;Z#_8Q7@X.@G4A11&^DUP)HYHWXU5N^>=K^R) H89!KW=\5E
M25VR-%UXL#^15V*I!7G[O./+)MFMWLU.RAN^VS/E )@>Q'M?!S)8C65/\[$)
MRD$(M ZN+VGL12(.\I&2EM)VK.TPS?'%-)5ZVTSA!ZM\+QQ\5F?C[Z]Q08<Z
M#3$W>@CMP76"<8O/X<O*W[(' WWJ3BK?!:OBE Z&/0F.5L"F22]S9__'PTYH
MNX\XT832B@O4JM7U"#8J<X#\H#ZUFC) PDOY]I')F)OMB#!&LT4R;-)?N?3A
MD)W,MTH.@*9V']MV@OZGK,4%.MC\S6J4B(A]_'2^Y-5L>T2"<@K38<)+:'5.
MM'2<[HT<P+,8I@1C7Q4HXC]V$EC,C,9VO&+NB"$XBLM=\BY&^SM5*[R7EX")
M]%$.^\-,<8[BVB*K8>,._*_8Y"BI=LR/.RM81*7I.?N*'<$\8QCU \C-&,]"
M@@X[<]03=T.B;T[F>CG $3F /=@Z,9[=F.=CV*@W5%P0Q4A$'_<B5:]9O/<1
M3*ATZMT?S/!=MCY+W6;4J#"'4B&5-& JJ1[P6Z I;M#;^-"?B-$SMX[YVPT3
M(GN(#]O,#%+* \\&A).<@$AJ8R(@[V.0ZF[TL?G[^*O='IJ).1O%XE<654$$
M<)A;SN8FG 4[-R/JZ8&20#OT#0D'OEVJ^[LM=U<Q)M+%9:6Q,?5VN+3PH?SG
M8BX=Z>12)+JGZW,#^%:#6\,S[+5W>C741U>J-W\RD[GN/1\M$^.M;1US<?G&
M]^"V%B271FA+$ZZ(17OGE3D&TXD9)XWH1KPC@I+,(_AOA'2ZO@/7K30O1/FK
M+&<(K1^ ,9YR81&ION\U>'&VSW_Z/;IX\-:CP_C>:.L=V++NG;RZ\;W:#W,"
M?-VR.ASE7[K.?,2N-W+YK04IM72AE;^U^?[(L',^57ARI.BDH%_)O,;! [QI
M.Y1VI-WW70_%'7')]1YIMY*L5X= :UP?_:KX949+@ZJ/!W5]_A]N9,^DOTG^
M&6R7NEQQ!H<03$MFF^HI_XFWH3D;:]Z+A"P S6/:'MG'R[R(+([=XP7WEUX3
M:!WH]ML!BW^J::_5G4-]UHYCS2W<7!U%KBJS:X=S!1WGT.M.EKN1W.B'W-YO
MP>T\%=YP$>(NGI#N[<6'MVKB=<?$I&?:I+2C-U?2UOM:1Q'(HK3I1:,OAX^F
M"3N:FEW96@7>"T#(5RCN2<O/+_!MMZL4,7!E*.NSE&6,F,\7)I7Y2OT<(+PK
MFVJX55:NY>/'.SZKOJCL-9U0^%BIFZ#3.IYE=.3O?!ZV':<S@.)K T0#'IUO
M\M:&VJT,JEX6DW/Y=*/-PLMSF\:_O?Y*^?%J: %;L>!%-ZW0*>3'4S%I%?I!
MM$ N2]O7;NN-4Y0_UN(7X 9%)0CKBXM"E!M@H>#$#YT%6\9GICX>@3![XJP>
MJWOY(=<,:I>2&VH-F-YB?<V+5J%1WD(JW4T/,8M^*K0N?\.5HTIN$+G>E -\
MZO5#S]\(5>2X=KD PI:=ORYB/IJQ?D@FIC1XD4JF+),MAX/^3J&_\O[/$$^7
M0&IT]?SG4,W[>.'J#G/_><-7ZNN%JE=8)O[Y4W((_EJT!N\58'S8@2TQ*%S>
ME:G2S\5/WH_@7&K]Y"O-S;G9G-9";-,R1#JDB.;F6LT!1H5X,,+A L)O8CW>
M(G/HG9J9!NP4IONCW$>JHC4Y4JTY&16#4&8A3FGL/>^6FIQWW4@V2VR+40\K
M:?%='W1N<9R6?(%=#XF?6CG!(N[3CU , &N(\'?'*!/9U%+'YMA7$*>N/1?*
M50N_D(0!EJUCLFYDX&)]V MG$DW;;0+7(\&;U#3P**N).[\ [9S.WL&*'CBG
MW8W_M#N^S)IIRV2SV8L.5@RK]Y&RP-*Z%#O8OG,U4GV9SBL'NFP.HBM=]+=<
MGE927*+CT+_!WY:UL\4_+CHITRG?3VVZ>,:%7%?^@#XPB%PYR/=N#DC#^-GC
M]V2W?G)F==^4%0=*-LHA]H*TY<%CG\#[*>P1T6A+Q2Z?<ZTP5Q&0-)>*B5Z4
MQYV>N4161>T._K;&[=XKODMB5([@NV_0)X,2KV:@BMONC%Z\WU+?>O:\3@6'
M+3(5I:2;CZU.NBZ^</DF]C+!"T#K'TH;C,H\>JZ@G^R0N^D.:_9WX2JCJ8?
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M&,(1<PZ=:*S]%V>C+K_JUCCFQ0:6N\ 5KF-'Q=QCU> <T(B PG$,C8P9*YD
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M):<JK$P7'[3Q/3[G>\3PF5I=?=*.DY-5%'YU\FJH&7P#A$IV\A3D4 0#;&T
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MYJ]X-'E^7(+_$(]_GV(>FO^O0-A_T#$]Y6;'IPVUB6!3JFD-T,N5M>$<S*[
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M4-WF[=AKOKA5V-; :JF1ZJNJ,^R<'"'DF"T!YR6_KJ;W+7<ZX;A]Z28DYQU
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MF_FLWX>I[0<C*T*91$=F7$*)M_HAW\GK7HSE#R<9IW1?F0>C $J(Y@W.,W#
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M*W54G92HJ0NXB#VMR/)*EW]]J9+>7F.7E=Q."SF^>X";G7 L>-:2K6N,O86
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M9";=,4OR3ANI,R#YHT+^1SDWHQ?M;9P7*UVDQ5,&)'DSPEDXTDUC(5\F;H)
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M_..&$+K(YXLE'("M8'B_S8O@A7IAZ"8A&;VBV,SV//WVZTF'G-UF(Y%[P-
M]YBD\V:[@F$TAR]0UY5'3T=5MV[->$=*.X9CGQ]%3^FC7<96!K\@V)<Q525D
M:_%PGDG19>^V,#))11U( DMR&;]P6<C8;ZNP/#RA/]=&R9X:8D^HP7M>3SL8
M$#M\CH.+Z-N1!*D*?4JIVCHGY%^&9SNU&Z:BKX0N(SPJ&U)R8I+TK<]RW8PE
M]@CM:3" FV-[%9A1^#$<LZT><\"=0C6XC,YGR@E=1>"6^SGP>>OS'V^0YZ;^
ME][J(W1(+\8;R  ^#@A+WJ#V=VN#BMIKL<<QM/*R#V+G'?NZ^K4]XJ/I)Q*A
M/((&*;[B(;"W<?,K2L]R2-:EB<Y\]JJF;(YBX/*:(;,TQ8</S)FQK>O3+:??
MQ^4E16?IC,VT&6SS@V5=8),"<L;]^5I[_%!O";$W[7)*CN=5#?3UY4AF[O0\
M$PU;69V<[QT\]OEI"Z;Y0,6Q7W0\_/H%B'G83V]L*3(*AB<(FG!IXS[B^&7_
M;L97A'IH..[BX<BB3Z[,*7NPN[2CPST3BU\UBB2$2 [-^NJ7>4&$+S4C7FSS
MK#LH9BKJ0/(8O,+6F(-9>\G^L)%0_FV?>2Z%OKR8S]>W(W5Q8O-P&-,=)>J3
M_R*"I0/0\"9F.LYP5ZKJ7Z*$V?)I7UQ9GC (++&QAL[05W'2[>.(C#JT]Z)[
M.1\:!%SR]J:NT5Q\SLL__/5II4-7HA(B:NNP.&$'ZQS:V_%USEMW0]_J7BIF
MS*5I/^:.O46:K[QREN2RE=\##C?W$R'^EH7?@U3N)5'*LOS9#YST/;:?<N5!
MIK;_K%901$F>MWI3RQS;SWI;!#HZUU"TQ15)[T0FD^%P5*<TG)>C]OO>4U6M
M2_N8[$V-M5Z=Z@@DW>C-#E?UH]P=0$_M"W!#]IE>4O:'RH/?+R&ZB,>6TC4[
M2USF<#3 H$W4]?JT/\\GN*W/C5O$7XZ\S')"XI8.4R=L73WLNI9SXQ!+]&H)
MBV*+V%7VMV)J"]86I2L\!&QY93I:L>*EZ:<?-Q+]Q[!X'!0-P85V'K0]RVLQ
M:VS6P;K2]?(BEB>%GZNN_O#J!61^BW.PGC#<!$<SL+4+X,>B:&4\TPLSV+EB
M=:+K&0+ O^Q; 'R!$@Y<N9_?W@%;7QO? 0@=%9NVV#WKRYH<S&"RD;MJ=%L:
MG!1RQWM_@#D[C" V,%5Z^O9+?AWS4*F?V9$E79,U-8@HA^GX4(MIU2-D9#LT
MBH%/L$C72J%A?LM:NI(OY9NR@WH8D.06KIC=^@U5FNT=$$Q$%=N7JO''BJ>\
MYD@E[AW0&JA\7?IC'1;D=9_[>0O27V/P(MYVT5Z?WH;%$<D_MY28Y"9( PO^
M!<=]6_F[;6:C(ACR8+#?EYZ1QD[HY,R7P-1-U4GC1^:'=],"H/H= =CW=OK5
M1NR-GWLU] [HF&^3/Q-)Q."=P\X:7^=05)YNS]M"@.YZBA'FA@<0.NE;]Y@B
M+D>>-#$<8YU(93%W R\K3UCOB4NN'F<QJA'? 2-/U=<TI6'2(@-D(L'CW/N8
M*I:_J<D=\EA_P:YD^J.X"A92_]X#A0=V%9"OAI-1)DA25A6?RY$(4W^AY9 P
M%7(HY1^S6NJ&=SIOAA&FRUP!RAG'!1K#([#S74M_+I211A]R3A,A3@:<X'PN
M3!&"E\;[&D>6DX9-',([/4(C8X#4I_4+(<BGV>3\'3!?LCA][V[U.I:%+NO]
M.%U6#,<<I)]?ZZIWCRGS!"]8IT,=]W.+1.K#4[8U[>EU:>\=FWG$XML=D\(\
M[A&<LG[]\Y*5 'Y3R_3..DWN.E0OQ[EHMKPU]AB^&S=-B7)Q_EU*=G81>DLO
MF*0^_@5BL6.$V85KI@J!*\+9J]*Q1"A>@ZL5F0RX'C!%/.&7?#S7BK2_"U:Z
MJX&8$C-)\3#=G&N4DS;7-P?J&H].]-EB^;J^^-!BW,[>T A3=7X_>0= :VE+
MN)*GL-PET,*HG'$+GMUCIA9KB3=8VW(;ZQ8GC9'+]0OO)Z2]&=RZG;O.5=2=
MVGQ@?!J5'E![/3>1;V9=%6;?<<N%G$[\K$I17C%9P"E+C4_FEJ'G>&GKY)?N
M +/O1IFV,=/]@4UG<<N9J#?7%7:W=?\>)^4]X.3?^@'#RSPSHL"3?VRL39E,
MFG5@YR4RA3KJ[J9"GP8)--)D"@I2M1,%$T@B*W#!K14>CH@J:*O\</*R+@B2
M$+[+R)#%>>EEF$Y@TIH6GDM\[EV<H:_7_56AK2.SM?K'>X\.0SI; F3\IU[L
M[\>",+S)PA1_%I8O8"'@Y8B6"O<<;T5BN@2(5I-8YR<3XPX"%ACE;JQDW3RW
M^,+Y^/Q>1AJB;++HLPM.DF8VWR]1%$[?R(\@O$(2BY/*/=-?4@-[WU?.D9LD
M)7 Z=)%QZZ$Z#A+U?OS5<=&'K4B\%$DQQ$4.A=?8?'=?826:9D"UU;/%'UDO
M^2;Q,=6/K<^GT&D2?)^\>,4<9:I1JJW@:&])F3#.B9!<4]IY:M) BW[W<9K=
M_(][J ?48L#5SBUF@9D?';F](@<":IQP+_0,@2LFJMNTI+P%Y_G,4H:359G9
MG2V? 74\L8MIX61OTQ/Q>+'>8O\6%&TX25USB,KQ'G((\:N7_=(+!*,]*YPD
M\/N$ZX%?@=[,2_,)Q2H;V=Z6(#LY$.;;=JS.PM;4B:.VBM[%JNOUD;&PRR09
M)-^:?EFJ1PMQ-P[MY=.*RJJLO2,4G,,WA' %K^UXN::9RDI7[DK.H)0U0?:P
MX7# "?R!M0C0Q <5:\9['&EXY^(S=_=;<D+KY'%&8-W"^"I*D4NN1*PQBF'M
MOZY)7:'$M!3T9YTEFG]>36V8Z=N)BA]V>5,_T7$3K#EE<N)+ZKY]%/<P/,78
M95=$095ZG7V)+=7$T"]P\:&WH$EJ-HU%<Z7:541N(ZY@4W\^98,($PZO0&02
M7F=CE,;SYOP/U218QU0UOJ.FI[=05B/:G_8RJ['DTN61(\>(>Q%5VSICC@[&
MTDGYUSE+:3J#D+.#[BJ1).O2GS7K&OT#@,-,NKE@;H$535>G!2=]PON--9*E
M>M-!8T7QP>/#,1?E!^V=[XKWD[4ZE.^ S^;AFB=-YC[34KA)P49=O6@Q+\Z*
MEL2#"5#DA_@"TZJXRUZ)3[YU"08_2KC#=W4UE*85RD)@7%=CLK-O=(6+(/W,
M35_%6Z P,S=%H0>-%M:C7,KL_GX(%$_9V^O>*JK3&^5MK1J&R M1V.H4NOX'
M<V\9%5?0=0TV@0!! PGNT#@$=QH-[NXDN+O3.$%"T"9 \!#<@[N[.XT[-.Z-
MR^29]_UFWK\S:]:WYL?]4ZNJUKF[SMEU]KVU3@41N2(@_D6Y*B56RM\KF #>
M/PJ>VG"V9,89(AP]U2A;.P$;DS?T';X3RVYC_F2=*;0/G<[KF,6L?8>5*7#E
M+ Q%D^X'X@L\BPHF%3R2R+O^]&$\?05@BZJENS_ZD)\ND@J%L^VQ+V)AHVZ8
M7\W7[=7,5%8"Q8Z[/ZNPIB/HOCT@/#EZ.A)$:53A=7OS,U5>@4:6-]I+BVQH
M)U&Q+<LNG^F2>>4WMM/N9P#S\TSL'?RZ1%O!C(" -3,;O/[08' ]:_ MBMD;
M4)LP+=J$3V1.2?H!>EU:OV'\5_<D 9?["VLAD(43<3+ASIS\V;8YOS^?+]U3
MJ7HY)L^1ON&M2*%HIEKRVIY,,N'W2[)JR?8M$AH:+PEQ[INY<DP3I.,CCZNK
ML\H=PT8]PS$W-R #&IZI"?"4C!U;ZA\9[UU<7Y 7;4AZ43XO,6$(8<5B%U;X
M3H\27\I2<[T"2I"43QLMU"81KO?!>]4\<)^*I4M>F_*_5=\!_))Q38EK->G5
MS3PY,EGRG/>E[B=75YRGCA8MF06-"7E)L7J_9LJF=RL_'-N.<3[U6.\@S#XS
M8<%K-HN)US7 H83>O<K1A-NTX0 4J/ +WC<=;HA5J9 T)C.;44R+U4S?Z'1K
M39Z)=Q;#30W[42>IOPJ\0%<X9,F&1G::T6J-!B(&[!?\!$Y("WFF$])>X]@;
MO%L-*9]0=-_*!H-IVZ*]&I#Q&SV6B>G8L956?-VZSHQ(EWS)S6PUMU'S/6\/
M;QI25*A> 4M##L5_6#O.1C)$TXJ*"-UAL2A$-^5R)T9\K7$":&%)T^(U2/YS
M-,7VP5FR?3Z7*^QR&K9\J=$UGW2_PD*7FBLQ%5S=#::HE5BK&70E1#SEH(37
M(G/<AVY"G"ZZ*A9X_.TCT(=C&T<^7@R1\>&"!5D32\I=K!4\,J[GM^[:S:$J
M7HY0MP2J8$<D5(!N,#_B\W$@T^YUW)IB)0LG2TZR@%^U7R\A)6SRJQ7YG)UT
M.+-0'(<5'RZ1A Q&<>;B8P<O/^&.KVG]MZR(S*A<_+SF2N@E7"3DSB^Q,L*"
M:YB6U8>+"K,%U6"7(JB2Z3GWZN9?1)I(!IQN1V^W>ARN8^=?M3*2W%Y]H1%U
MA^7[5)Y@.S#+;1XE!+])-;-:#2GK0Q55QG11,LZMNF[4<]TX:/*4":XW1U!(
M^<K1(!P%01?G,PQ"EJ7+]L?0GADAQJ%ACO>\[7Q<O.9.GI(_;^KT7I1=49&4
M7TH:\S82PC&E,VW7(PO')KJ]Z0-GAYY\4#[7M -%) #_UC8HW9HSMJ#*@K $
M;OJ<R=_.7(,K"?*4&!JC9?8^IS!\; T6[P1<A69XC*.4@R5KITWD>I#1]( K
M,D2@)E*SBQ.C1GGPX'WK*P#_A)C1INWFI6,S:HJG=<K *,FU+_7WIP&A=,H-
MJP*NZ)D"+$?GR$T]<4PZ  K_DMOL[1/C-'I$0N@[SY;B+RQO+1X+G?QNAPZB
M8SG2=H0-MNT",25W#*3P^HM.R?Y )+;>O^O?PE87\J6P/4J2>NOI=T)*J_CY
M)V7%*Z"B_<L\3 [4E*7R26:9)(C3 M4+,:%V&YCA"A+2X%L>\_H(,23DN+R7
MDB_%1ZHX6?5&"N['])E/O]"7IH67<PI%4ZR"ZO%R;WJL"H5WB$^/>9Z%=,^/
M;(=K>-+Z]U2'T:4U(/G@K(WHV>Y:^O,:0VFC[]WY)R8%4"7'H:T&?T'4WPTF
MF+4(!NB$Y%XHS*&= F<'AE8Q3Q0>14K/I:9E5[*>([;3(5\ &P7@;6"%2IT7
M,[>&N UGJYNX*XTY[M]QU/%C\KS028UE/Z:2 IZ4$2S%_'J:-RC&H0('\;XN
MRL[1VY;2!!]TL/6T8I_]'M<?KH4I>A[*!R)XV$[0;0@F%)VB).O,XYH3U@5.
M!OOM @=$&$)[;[2[QPG$$<G6; QC.OU^>_#WRYW:%=PE;%I_JCWP4/#N55\6
M$LY2=\ JXW05^DN3>'9BF!U1>V Z8Z"OBAF7?+[:6P3T7-"L6!T(V0D"L:_:
MA:AEL*GDP*^935QL^2=J*]K]8S]13K\);>#.,JL0NU<I*JXPC27*1*QN4"\L
M>20^>@)M^-25<S@Z*E81J9S>4$/>8[>*TX0XOS4CE%>> K%(,R63DT^75EM]
M--KI3IXH>$MU'PNXKQEGGKM>#_/\:RQ%NWL-H4+ZN>D6FQN=.&&HG95[?B4?
M+^5AA[8T\L8D]_N+1FSTZM" _J()$X^GC^L6Z4>K$?SUS%KV=L+]1S:+CN2/
MN-]ZU?F$Q =%V4Q=H'\K%>/[:ZA6NJK9&Q&!C[=E1LBC-NR1;W\I#9*,6B+N
M#77Q3Z"(ACFPB-.81PJP,IC*T)#47)-Q'+[U_6@RA)1P*9!,<\2?JFP ^C8+
MV3J3IU%NLV9CE4WZ*:"JHEY^F&=N!=]J=YXO:&J"LE5\VKQTI,W<@8B>XKH%
M?Y&6A"T;C^V9J@&IO)@<*#\YD\R29OBZ&?-MB1>*QIQ8=#0DT"1_A;)_+G2)
MBW[O-B3*ASC=Y.+<K'C+[X4S(J A?PB]NCZKW#,_(&=MGW(OS13I1D5?&:Y^
MMZ@@&V&C3I#A^HZ,:ZAL^6BP@IA7%ZBCB38"# OY>Q2\8/7[1*=5K<3F(:N#
M=C[&@BPLP[84K3_+@*RC5PRD<J?M7Y#I4S3@PH(S1/E=DD.3%:+,KF+J4T'@
MWR!2P9065PO9=0J\HY_/1A'=2=P7A8^K/!/#5Z#8Y_ZI[1^M:8?H1^+=7@%&
MQBU1HX<&_YN.I1/=+.&GVI2M'M[<N P4&3.5]VX+Y:$! ,_L3""WGF:9[PYF
M=?/VU*TA DB1$!C"7VGO&[HZAM^H&R$D!MXG)UNR.3$20.M&+;5.@"<>[4=5
M!*F/JB@\_VR^Q_6@^,4VG)%].]^JC,G0-IPW0EM$T:9%P24+(CA:GVYK&8C;
MO>-]/E<6KKF$OP)TZ[;X=%(X<\L/9;$N1ZB$Y)_:I$%B%&&^A%+D2N L.I#Z
M0W>20@MMH73%M1/X9M*A#*+@3*-CB)VR:[A;E5DF&#Q=NJXXQ;E':1@T^@[%
M]''[7K-J5;H:OU&<6I 7[9S3EW3.C!BU@@X7-Z'@%I>L%5L13I_OT%PM3.P,
M@T3%=J1BI*B-$7WH8O\1[T7J<NRFUX#31\GRSO_W)J=S5!OVMOKJA L3I.IR
M&"UI7Y0IA+TKU=P9+:1P]^!.FW7EJ!!+RYV*4T);SBR9826$\(801M/FOD;B
M1U%7?:_:ZVIJS!?Z)#G=5'0JYT/C@7U9I-%X<?W$;"9OXA)@/V@A]WZC-+MM
MWU^T/Y//AFAK:U>IH&,SY@OA:FY;U=>JX!$LH>"UIM*1A7)\[A.76R+LAVK^
M<3N57NT4C&3/%+4JV5C$DY/8O=*!-S)Y]^K+EAK?OO\,0>%?'3-2:.)BX?S&
M*%DL=7I&_<V@R;3SC*'RDC,;IA.P2IYI3_Z1FFA\@AFI>+N8K(U+CK6ME0.5
M3D3S,2CDO&FY(0?)_6B .W[BQO#Y]YO T.$>1O(Z7NO%)?F#P*Z7]FO+<1Y,
M7J0Y$YL/*@*1#%_2.'U#P'&^Y46ZMN];"7CK^>0K<N;-!6Q2*I0%WS-[/@@M
M4L4;*.(3;3&"6@=0U\)DS++@TM,CJC_D]7):>:^6=\JJFM;*4- '*G?5&-P%
M&;6UU3W;U\]? 3,=1=D.?\% 7@T%M+_+M$U#ULN5F/O^0G.L<F>L%<>.>2%R
M&%7(EF8-WJMQ*:1QRG8ZRG..Y;W92S>'_0ZQD#+Y=TX!V=\K(."WD*=F*=C@
MS28ZVVC4,)@\5&3A0#-GO)8SR4,BX+(96GYV-7/!Y7Z!7V>=J#R]G.=T*3%-
M&M.Q!I*#BR0I8ZJ] C:I'03W7#B3D5EB\K!/0P]>\*I 2;,Z',*?/^\@"(?]
M##N:F$X/-+T4ZU:0U3T12!);:<^L]K=3UKGBS]7.YFJ?<&([NN 'F;[;O*#M
MS A?NU]1WNA9F(_&K[ZODD$OL^]!,]PP6RM9+#'D+)\;%"O<90T.8;I2L"(>
M;L QY/Y%I:<3!+::U!%67[EADM=6/8Q?H&MM: [>U4SC?:MH4(TE>'%F]+'^
MAHNG]&!! W\^ABL#ZTCW :AFBS_#E\&ZQ-]=%MW6T7)_I:^^I"=!DTFVETKH
MF##.Z=(/V-">5$E^QL*0-+Q9K%B?B_+:4Y(0"MWA!N]0 AV"Q+9IH(7R$6)S
M-,DN2#='2/;AW)'TPY7/9TY':OJV%0X5#OJ;- F:WTBQ?]^>J>H=!G*/!-H"
M(6+Y\FQKB&TR?*V98VW1;1F_M_?][;YR%.I'PV[EQCFRWGJKG)"\ J@HL .A
MC*^ -)WF@U[>5&L9232*)W>=7T]?:F8^L5T7>PA)-6I&B;]GZ41A:1P7(M[^
MYI-OMN_"DX0A6FO38F"V5^;5)T)(UQ@/Q)%CQ@7@%)ME*S-/[DU>IR?2#DYS
M,,5WH^J%.&ROHPA?E[^K0ZZISV1UV&SPSB5QF!(C-!M@ODP(AE>$19Q.$.O5
M'1?W?.%-ZN!*F:R=*@QXV5/#O$J.IK(G_.DQ" =Q+&CUD%)W"??A]EO9HR:2
MZ\=R'675+FJVS4Q\I,UB1R\S\]P;8 U]>+935A#NI.$=+.I:'0W6C9=!_>:U
M0=%?&^U>S7\XYRCOYELC0K4[6F4P2BV!QKT3/OYQF_\LRR998Y$ D[.Z_14@
M@ENAR4&3ZR]+ZHGWD6.L<(*8N^IGXH[W<M .!L3M29)?5#[MM/_ISA?\K3<B
M8.]M,*T@)QLI5K8^#V/1\=J-SL)8P^PNL='6ZO?"5)+=#5-J%=:6*K(.^:QY
MFXKK^]QJ-4(KA%Q1,)GR/(5WMDJYE1*1@749JSX=<?B\]8XI,0H*H9-*?[V#
MZ2/H%7#COHL/_,'R6'_R5<3J2\ <3HN@;9$T:Y\=^'G^X)"UYMTIKR2+^@05
M%8X8$L,+K@\@EM.6PXNUKK9JA%0%-$)N2AL[M]GL-2%?^G',O@8;GOP8C'GY
M5.)KCI7*OU6Q;*A RL;EH^YH6/QK,X\F&F?2M)A+H(^V[B40.EJ%UOO@GI-F
M!5G$PGNYF!#.5CLYT[.N7JY-7&[K&;LL929U0+KD> 9KT(<P),M:-D,(HB-B
M=(2D3UVRC05G3O%R-3\L3S1"MJ1-&LWN@LABZ%X!B+)+O+NO@(BCP#L3Q^TT
M],B=)G=/S84WS]MQ:M .#:5PO3-J T8ZRV!E;2+^2%Z!C0 >LHSYO9T^SY93
M<V=B&UIZ\E]P$%=:FI#UM%"QKFQOE0;W9_9^'\<5SUQP70.\:4K$^DJ>KV;Z
M^52:NXWO))3# *G3\-TRRG/.G?LMS]N=JM!FANEI42X.)IF0Q@&@[]S\(Y(7
MY[#>VJKA6POI;<0&80W%V+(L=Y</7#4E@P&&#TF'["#_8O[\G.PV(GTO!Y_G
M%\4ZG";M&+7%WQ!5],$--M*;DUE2*&C++M)R+@__B'B 8BBRGT!@J//ZY$Z[
MI&]7OZ;E_H=C=B-"^+SE/E:@,-C-L&WTCYZ<UE+H:8BKS+::NK[N#(H<6$9D
M';HC;A07FFE:T\'ETRV<&\=BYL9($WH'I8P:[](T3SO]HU:X;*"7=U+_$;,#
MJ610V>NKO^_5=!(F[:A3;/$('HE1??;**>^P;IG]"J=\33 SNVE7WFI(ZFTY
M,]A@B'4BP15/?U4<A/9/W(@_X(+NRS;MW%Q8O-K!"FCR9D(!%Q2]SJ#VNIRO
M%MFJY 83&-JYMN\,$('GI0NA0>S>%9'W6:Q>[CM9+35K <07&_LZQR=ORJJ9
M<DDOL@3.C-T>Q<,AMSU30\[G2R6&LL<$SAB\)X.WP@%T+2JA.E>'@=C3EYLU
M+ V)B?LB;D&@,+,G]RFH^OD. >+W$\Z+OS&_,N+1+CJ1?!\\*D2C''+W.T+#
MHJW:?[0WT_1 ND$2Z.""C#[3;Y:;#3@D'(#B"2T4X9L'G0(;$>S)@0@"E=8:
MA1S*1_G5Q88+/I*D7S#" <+.!VC:'4^9Z"9-"/,W/D;A\\ZJ$,^_K.&#2!^@
M<?G^@!+(^(L5UKA\N$#7J=N".>) N<=D2%;9_?',!V%0#LE]H-'I*V"#'&]K
M_1T%EATOY$"%=JRN![_>.<Q(E]P,=!L:@GH4+^753G+1%_V@.5)J=*_1C4>V
M:U2R@Y!QE4#5-4 :'Y!4N&5$MZXY>;:;.,:Y_%E1?7#1>O4#S!&PHH*FXC*X
M0WP!TER9\)Z6OY3CO@BE28P_.?0'N^FU3"=-0546MXN*QHX^Y,R_T-L1>+E]
MRC"KKAU2Q4.$</7@"\/(DP;E'&B,)(3[TO1,<47F5SHS8""? </Y'5][W.[Z
M/\]( 9^5U]1/-9@MG TH>F)=U/>SB&IB3RWFV9:&%ZIT3W.I&H*SWL!)JN('
M .X@6V A2.]0O7NF>]HOH:'@['1%6"AW/RWY=VGI:OXW:M[%-Q!BI5S*%!I
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M =8SVH0=X*0KD:_/0T,PTCG+D-U3,KI:27Z$$482W1NUN".MVO3''V]NJN2
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MX#?(SXJ;(^4+AC)>(+ V%O/=5#;1U9-5*1XS+/>YF2A^7F]1DF_IO4<(8P-
M-DQ "/WX$LO?K6!#=TE$8^.WC;H)?SV>WN^D#5J5-L<\@5'94<775HN>P6M?
M)J[]R,]%IWBFA/U].5&1;R7$S5'I'0 F0:/,T6O1"RR[%%XQ B>6_I(_6CST
M S #4HT!MQZ8[R^*X70[8FZ<'"VD<5-B<L$;GUF'3@2$PEDSMG:A/M.3^O+
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MC&XP?R0UK"*-NYL)7R&K[^4"?:2 < HZ._)Y(+ZFC6F;+DXDIQ\=WTXHH5+
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M]+$/$4.%6<3G?=?_]!WQ;7Q*JBOB%#EY.4'T_:TK/#<%?G&2<8S/7:YA!2Z
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MH#-_:'<R4YKQLIY+BHQV*X62FT"L_Y;#GKA)I<.7?M6^!G?1M5K<]F">B=2
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M\]'S"X#O<$ 18)FH]SJ] "8N@-FE"^"F=)7'YM$%4'4!?.XZ%]:2(=HOS;@
MI/<_'QP%8F+_POP+\R_,OS#_POS?P"3B6;PU:73>AIN6OSM]-,XJ>E*II0@$
M7HS_"U!+ P04    "  )/'A4*KDIG#]:  !D;   &    &AO;VLM,C R,3$R
M,S%X,3!K,#$Y+FIP9]R[!U046[,_.@H"$D00D R2,XKD*")9) ]A")+#D'.0
MI)*3@(" Y!P&!&88@H!(SGF0+#GGG&8>ZCG?/=]WO/>[[Z[U[O^]UZS=LU9W
M==6O:M>NL+M!?4-]!]Q5D)&7 =RX"0#<N/X#H"8!4@ L# Q,C%M8F)B8MV]C
M8>,2X>'BX."2$=[#)Z(BIZ&F(J>DI&7@8J:EXZ"GI&018.5X^(B7EY>&64A,
MD$>4ZS$OSP\F-V[?OHV+@TN*AT?*\X#R <__[0/U!4" =</[)@7:#3K 38(;
M: 0W4"T FFN<MV[\/ !_'#=NHJ'?PL#$NHV-<TT NPNX>0,-[28ZVJU;Z.C7
M=WVN[P/0"6X1/G@DB7%/U0B3SI&()R F$XO^:7D3L=K@+L-C8Z?7M[%)[I.2
MD3,R,;.PLO'R\0L("@E+/9.6D9635U#7T 1J:>OHFIB:F5M86ED[N[BZN7MX
M>KUY&Q@4'!(:%AOW/CXA\4-2<E9V3FY>?D%A444E%%8%KZZI_=K<TMK6WM'9
M-30\,HH8^S8^,3>_L+BTO+*ZMKZW?W!X='QR>G;^0Z\; +0;?QZ_U8O@6J^;
MZ.AHZ)@_]+IQT_T' 0'ZK0>/, @E53&-'._1\01@$3V-R2QONDW_6&V7V-AI
M$)N$@7>.<>^':C\U^^\I]OI_I-D_%/L/O28 N&@WKB</C0 @ 3B4H-G0C4IT
M-T_04L:N??2R_ER+!@6X[5N/ DB2@3-/4U$ &@3-ML !<=/8X/<U]7@L.-$K
MH$4(A%)O@8RW_E5DXZGBT<XY5K?L)>/YR16Z64%_,/?84^086Z/%1L3EMZ,"
M#JAWRI7X]C[=:W;5Q,Z578BGP[%==WG/2H02>]>6H7NY/9+PRAOYFF?P'W*M
M<[>CG8V,P)ZLRER+9@\]+\'B1;P%G?K2/BTO&ICN#,49\MNB %\-R_P&9'0E
MYKC'&E?I.8U5-3=9_=@N0LX1]&>S,[W_"JQ$@>68J#'>I^FH" 7H0Q[_CH/L
MI]S+XFU\B!;2_:3R[[C A&%B@=Q+A@X^UHT'C?4I?KN)&[.'! G1?XC2?J_Z
M$\*;#5<4(/5J<Q(%>-MH@ )D1$#]_I#5DA5MI'BF-44#*KO<V3&?_0-<]A^R
M$(Q$WMB&70W?SZ?]5OR\^5& /[#1_"&JG"7[FQI2\P03L8$"B%R,P_\!SO(?
MPF"ATM1?$_?+JL7AAO^U)6K_K27&_ITE[/[)$C#7G7M@$KC;!MYA",0FXLFV
MW.(8#<B "06(GC0\/XP^ SIE*Z>QQ[NNVN,JV9LQ]YV[^AK_1KSN3RLL_.?R
MN?I&=^SFJR(*/"DL.1S8<U" 0+^B+0XFV(3(SGQ%X9&UW;#\JZ@P;@H=@Y2X
MLTJ)OW.04!M>&N9.&S*7<5E76=14&%3+9G0E/B'M)@@-=WP_/9;R.^/G_YS?
MT//1W\].@>%:HJ[U%[LXHU2!C)VP?/E?/(DY9)BXAN*41W_C,>H_IZ+EZM]Y
ME.9_YE&9[KG3VA,@/3VFD>I;V4?TB,(AC9]KI561(/0--&>L][^0^G/V4H/R
MY_6-J;B?)XBL$2]%AL=,+5<T_J$9>?ME -3O?'&VKYQ=6,.J>H-X+#^I@?Z>
MCD9%RKBK3\Q_XG]6/U%'_.\[X/]X*5H8SO7? POX/JB IYW+ABXVLVX_,B@W
MH)^3."-W00'.-Z[8)XM;>^9(1Q38)FA48S12%7B<W<<*5*6)E]/FEM/O-2Z<
M-U^U(8VKBT4L/M<'C6/HRF*SP_X20+LLDY.MR&,-8-4?,T0T/KX\'QLRHM#6
M[*Z/#NXA,A!7L.M:1P$"UL!&;N=O)T"3Z9N5Y@^ '6V;KJU.M43XX+E90E#'
MP[U7P;LEI*X;WV"Y(Y_'R=XV&$743/@4RRRTA@L<EW83T!S[W_@TZQ(0@5#$
M![(G>D_N/%]+$,!7/=@<XSGCRY_7V1.X#*O%OW+FDVV:<&W(+0VLT=^3)GN7
M?Q)25)M0Y4K%U=;1]$FW='J\;]TO,"\-S^L^O#J,[.&3@X;K@%/A"X,S+#Q5
MM"CL6A\N#'\+-]A9C,I_-@*!U:6^$'+IMNQY]"@T1AA?2G.N.EAQE^%^L04Z
M' .H,L3E"+K;Y;)ZQ!Z>@B."9< _-=A!ENN\MJ7'<+Z6WEQN)2Z#[G3_X/'8
M;JFUPW'L"3!1_U74^9$F5JG[CJX^YZCV;)JEJ-C<A<BWS>]IVZ>)G@QZ@=3^
MFGG#)?DCEQ)%K38Q. L7WQ[MKU YZET%A[X5-EZ;"'RKA1C\V$;YO6Q!=>8T
M:W]''5;W3,X$VAYSTV>4./]3L5N]:\-5E!]D0%6IKLQ=T6:T=.?D?&IJ"/+2
MC\;Z(93%1.7TZ><[K.?@2>W3I\BSS:PT[>T/3$=]8A+8!6E"8>SC7/.#W^67
M]13F:NSS<T%#K@RP7;[-'5QUS%J1S'>[76"AMMRX6*1F33W;>[L1AO2V'=LR
M,&ZMDH3F+C(=,@V2M>MVHDOO)KU3LQ(V]AFJ6*?X)G_2"EYE+C'=3M--YSC&
MUV%-S>+]88MSRR:SJA)FNX$Y@^MS9?UM+^(1+YPD6>SS_0JFMB3MA5UBM4Q@
M5W=#XN3Y/A/I9[&)N-72K;JJJN%=RR5M8C>UAY)-U._?E_1L][5SM#,,:>5Y
M<+!DA:$3J4H#?C>(8?/VIU<P%*!,#@6(-T:,A38N'(\AZ^F1FN\;0VF2!O&_
M]R^=?X"J2EL[A]W&I'WG(^UZ3"CG2VU8[C;%1+F2O+"ABV?3-#<9R=R!_OSB
MLN?PDAU[UUEA>G#L;3&Y4US<--]!^6!X-;3_YK@ACAQ3K2<V9KSSAE;)IFT)
M+X@L_G Q=N.DDF]V#VT<'%6#Z.T/MG5)IV4).#E+VCC5K).X)Y-LPR\<E4)\
MZ$ SE2C(OG58*F^TTIWO?N(B1N[1I;<F %4S4%8\2VXT@0:W''3FZH(,I9;L
MEU  ]]M'3'F(%HG=*%WK&<T4_58G(BC:HNBA."S89-[1Q,>5;6T !Q0_<=S]
M=3Y1=8_'T#)?,5HY:H;QG:@!R&?*ZWSXF,]S(0^!N!(.W^ 5>[]YY#XT[052
M[EF'=3>+PS-UY7&9A.(9;,HDE',Y\$U<YSD5%6SYIT#/ O?O+S-XC_%QAR?X
M?5+D^ABT/FQ)&+2.::/!/\,*]G$[4+]@,7$*=+.[J"E!D.0S0BIV$,O]--(C
MRTZUMBYKME7;UL^/)QK?E&V3=V$QP#YPR/ UH8EMF%H="S\GX9\\; F<QY>8
MB-YAZ%=C#X&/X9+C;2<MWN0R]$M*K]/*WM-0FP"U%EJI&'3;U1G']]T1PX?H
M[1[Q@PP/'^=&9.;DVH$Y;9<O/+4GA[9XZZR.EL,$[2#&3_9.:)Z/BB1]'Q4E
M.4_1:2+NA7S!,M&[*89GHG,:O.FPKIK[T1I>#+>FQ$+&XPH/AC<[KR)?/*O
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M1'5G%JSQ;QY:\),"<[38C_[B]SRB;97/WOG\X@ IN^?7OE5VY25[623QIU)
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M0(X)[ZD-!.TSM7[E:!;EO4>D )];MIH/;A&I/O^Q$8ASW;ZWPQHO\HI'0U&
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MPN=#Q0G9>26;-QZ$7K_X;EF>HJ+$-^THR62A7L;^3M\72><"GWH;SKS]+H;
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M>+1 [?8:\?IB-!TKV!7K)LU7]]M%'9G/M@-,0AL;:":R1R[%;8Y6=W:@%_5
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M=8N]JTK9H8G.RR$1.U%L=R,3WS"6HKNJTD2 ZW'#V._T^+HD<AGU*O_'HF;
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MR]8%=M>\7L'C5DP]OD:5M/MG3PTZ<*KJ;6?.5U76Q,[@D1_OR]'KV'W^> -
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MXVS.#++M/ [S>P)-,O*2"/15:H/M:W/VP8%CHLJ%:VW')A"K=XIV+>WY##)
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MO':>?<[Z%1F#I"N>[U?&Y&DJ9%>F.KT*EJ_1N]-^:UX1)PR6Z_TY)K=WL9]
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M?+94#MQ/PBWXU+MP/JA(+E?>J./V;'6\2LOE7*VF5"/N/&?1KA_+K(_;?(H
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MCOL^+6G;CUQ>;'*M':YVS8%N'5Y#R2D;9_=<#/R:O7BGOL4_>Z=R"QQEA[?
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M(\JEO&M/?<Q+/SI39S83:$HQ\G8@ **9HI0B]5Y,<I+_F#)7^[?= K$;@0!
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MK;>LX^B6%K0%:34<O]T"[1>7-UTLV5Q@)><8@L-"KC1N_MC^'QO4C8&QLG'
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MA4F^0"I.&0$HB4 0  K>^8B=4Z60$UV<'KF63+K*;OO /,"EJ#VP+,C,DFQ
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M>WQ]QZX[V6*<YH\!]#)<=*Z3DW:TPH:\C6-UV$SI&C\05VG?]T;7GU/["PV
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M00%1TH"#@C3;1/<:9!4Y/#'TJ-U7:JWM(1W71"@CPLB964/7J*T];*3EUUO
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M?&9T"#_,!TO/ZG>96>8M=3E7[F1H>[ESC_2KLQ^X1>,9U6<7)_EH&DV>!R6
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M?*MUZN'M\[.R0*O4E_FFJ/1N"BKEG^/LZ2]>JW.EJ.<2U^FJ?2\I_!!&J.>
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MWL[MGP3'BW4);Q95WYQO3(OUP74[&Z7U=]@T?Z+?"S[)<3S_F2@="%76'<<
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MGWSJPP6*662[/0!3'6?A1EC")?IIX5:[EV;\J4]RS#YL<(N<$9N CW/;W#$
M.6\(\K8[FK,C/Z^*+K8.RL\^Q:@.$:S^!F+B*R>J^U2*!RZ0<$>0!K(; 1EM
M8AYHJO; =!\GO?<&'C.<[_+R&F:K!K2&&\D'S<DS!.M ?=3%&/<JJ:OL#(UX
M;U0(M<1G@0C]%0KPUKHJ!M#Y>^C5!25E"4[)1GIV+3IN!T#I'TA>1$:QDSAT
M[E*:.V=9D=UN4(UPIP'K$;XBL>/+38K& (Z2,8!>:.6D+L^PVXD?TXN\BN13
M!,(/_DPT7O#LV> !6_#2T!#ZCA^2;R46<GKY&0-8L49%!IU3E_49Q7[-NADS
M?8DP51\VF'8?8L%U/;Y<*RRJ=2[K\\LC+G\^PDBSB@M-^#3WZS 57H0>#E(_
M)P7T/*3R(""[W85FN.#EXQG3#Y[RL]>4]BBDOLW'MMD42HI\\EM%O</>"H."
MP8A,,)*7_.W*Z6D^MN/IWT.=$C6*HS!T*.C;=[Q0?8/P^P:D;A/R\_$JLG*(
M$1@D9O5=>B?M8\7WX@9-FY9=KLDT+S>-F\2[1(6E71UAP,H@#NI4U]:O4^JF
M+*2H6O@6^HTN>.4#&%$&:@B5Q0 F>(5N3LDQ &JK4V76'+'GH5)6"T0%&6IU
M4FPC34](SZ\4@94O_6M[.VEEZ8L&P&5.#"*1&Q1O2!030R.5@V:]<D2.7T'6
M707E0+KI:]SY[]1(2*AK$1&&C)9>+H1COR->"-:T&JP1=^K W2?P2R3Z)WB5
M%UJ" ?3((O31X'/W&R0$J0D\'I>GP@ @*',T!L"%U5K+8 1H(V-9L\!H^B5B
MNFRG 7IQG1C.VA2OEC6!&[%W,D?[%FD+M^V^_L/(^#KJW<MTD$AP25K4HR1%
MJZ/"G4E':<,&"*Z,LCM= O&G%,)*_\Y^]RO&?=#>=ZRO4/G2TV50DG?!6?'I
M^4:B/9H&TEM]A9X&'S.#N_,A:]#>.'\SXX[IAFH+\VJ$D9C^+&B#40*&[ LT
M%!;-IYD=XUXKDV(?MVU,6G\YVN95E)_KDJQ496"/9W]3/[3+(H\H+]HUGM.W
MW*FXT**T5Z,J8;?SBKT\8$,KS%F?=X'.**R82W;%YU;NR6K:>^>/-'TD6)\^
M/!/[I9\D6NF<?>IK_F.T!I$ %T>O*K(4%N3GY-CQ/KHV;$8ZPU^LZ-=\"1KE
M^]Z>.AS3RVOLUSQ G5'EX%XT<I'EDO7Z]>W=J*)IG\896458G&/7(]42W,Z;
M'D>4<UD5"U/.5'I)=[:CUVMMKT9G<,)@9&(A#(D#:0$A,M?W0^\'Z\T(M"'<
MSRJS/LH[&#!%1,QW1#=A'9@I>!$TW.%U/(!\TWG0UGE-GX\3'1F8^&A^@,4S
MOOR/W#*]Y0OHIA4VG(ZL=2(Q@!W@Y0ZXNV(GAP/17+8;4VR^RR"<O>ZH@I@A
MN86#!@::+1R#D$GI*^>_A-!_U"_%C6Q/Y6TQ+K%HF7]ZX4E7,E7J+'-V0N_=
MR<B_O]F<H3LAVV3KR'C[4=A#<%332T0YG&-"N&/ZBXKJM30&$!ERKQH#&&S%
M.F]H0><U3G5:+G;$6+RV1-T5\?E.Y:FW?!R%D<'4+VD@P@Q,V;EUHXD%GCX8
MP)V5X_$8>4%$I6"6UHSH<X%/;%<U^!OQ\$BQ+F@E\BX&H%L%AG:#MV_5]]DX
M3A6/4G(;?]IZ]=(_SA#1!TM@L,1R!=U)TC:7LF[N'G&35<^ZP+GG<$C?:QST
MQ!26QA1IH*FW.^E!&UG+V)$Y@,]$+!A0?==W*CJ)M.\6CD^<>E7T-Y#V_#0W
M/SKA(Z</-N8"SC.HHJZMC\O1C%!Y8?^BX:!VD,[D$X^Q"8DL.OWFP#/]/I5.
M_Q#G*H0 !O!@#.O[;-0[/Q1_>+XS$6\AG9KZRA">^LEI07FBNM@\V(XAK;1S
M1I2SEK(ZAT)E[>-5S<EY7^"[G5$JX_20?SJ1A"=AK&-J-N+C\U )[ZGIAE>D
MCDRJA2ZB$?;U*HK9;&U%UE*I>'"28I>1*=:O+\8FNJL$JI %:C1'%?JF$P@)
MT^"1J7TKT5\G?/,@7B4SJXR[N^SG4P!+CRO ET&^OMCY^K7UCI_GDEF'@K?<
M@(ZJ3DB"E1P9WQB:V2G3K7P-3+WD4"SM,JWXX 5G//T=F[';3"E\SOTM'94O
M46E%#BF*^!>E/A<^S1\E*GBI:ES;QPAOA<FV6-\V4_GJ% B-/'(_XJ\W52DR
M-5-I:DSU-$XBW+PC?BQMG!\L5*LA1**5/F_7$A*Q_/0B>:SUI4,,[!.+XO5%
MGXTR85S]$>6BO[4.7+2A9N>=0&_CO,MC>K=G?^P32MTA(/.<:P$#=@,C+S+
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M8N/7"&T4P%C%!BGT,?T>(NJH7_N*\[+S?!Z((C$FZ/0,#6\=CX><:!Z!]^I
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MV9SNC:+S;!V2KX!A-RL)JK:?_:.8R0['3OOT%JV?>I'NSJM$ 5W;(GY/RMC
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M^^+E[?$UU3AL]'\WT[EMVX !?,."[#ZHZRH03W/UAU!*B*(0RZYR<(&\B05
M)![R=+^D+-LIU2BU*?\IA5^L)/"O0?<_Y-/.3T**3U#:Z?];J%OY*B=-F<HX
M/"3L'S-BA*1P(]JFX\H*D6?'ZIR%3N4/2>KL!N5M#GD@Q^&(.'0L"]9=AK[
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MW#1W'Y6&F,JPC"&'<\+9'OU-E?Z_^W67$Y\WZ68M"WW)+?_"G)DDC"+N<P1
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M>G/I1373N^7E.=?BU*UXG8;='#VC0CJ]HFZ6M";JX56DUVW&1JV&V_#! 2?
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M '*[YU+3KY5'@=SK9V& \_MVTIZT3\*?6 <8Q]H\ [5+B6M:+ +E]3XKB<(
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MSR_BO#0K77@9J:K'3861^LV5L.3['']*N"U&,1@M1@QMZW9R3"LY]:(J-/<
M P8PL+?<HSKEV4X]:H$&&B#_)3[4,_X>'PQ"J+7$,@/>*A3=P^.#I#[TT]*)
MFJWI?28PBP'Y<VDB!VXHR4(*JV%>\G-.+NJ]!I1BM7]E\3Z(F\!_!4&H=-T,
MMV(,?O5)(*5Q_.B"7(QG?MC'B0(79]6]4RK;5M>] A>>.X6M:!5W]1*N-L9B
MGX#TMA+$CEI6JKOFQ]?GGM\[>3\-I(&.@>W=; 77[S1&8^@:A)2\#UCCPSMK
MB!.FP)?"KV+9,[,9G9?-0[)\I.G)IMXG*)]0!M'JOG"=HX\V0.B:C^1B.CX*
M/A3E7F7M.:"6&2ON_E*.GT@'.DQ9UURSC:^./Z[.H7=WD4/#%8GXYNT]<5!H
MO9=3=-(0OE\TIC!/!F@]P61W6,-"50-=7RGQ+$1=Z=3C'W3RD"O8MM<'75WZ
M!NP2:3DG3GA])V,0DQ&3LK9.6DQ=E:W"T,[02:_\+#W@J!&)T%-P4*#]Y+CL
M*?=]#M3+,EJ"HLU3%WKV<G*S^71<;0)E0UT(-_I*VK?)E@.(O'LECJD^043J
M%E7-/A_:L/&I!$'V5LL%I2I'?X'<RH'6*X1<4H6R)KO_[9NQ4X;:(0&4]915
M?R'U$?MBUWMECB"45#XP5-UR$/O0.SIZ1'5/6*!Z)[/P4=-@X:/W2;-"'2^:
MA;=JBY,X'UGSSA<U>AQ7%G8^"(;23/A:7Y&!O]JZ5U<L2E)T7Y/6I6'C2QX'
MEUG:/9C7ZR3G2+]ZHJG0JAPI=%%<TU9O/I20)8\\%A1=3/\)X-(JJM'?Y"-?
M^J73S1=3%4!2\%10#/IYK\A6L?QERNHIO8ZT<OQ=.QR1*=ZG/&I);4N(5Z4'
M63\]<L/C?5O\U.R!;Z=VV6CQVX)>I> B]@T!J&YF3 BO=[$/^JX]ORV&GM4A
M0_U'D]A#@:.F\XL"HBEE0XF*N;[RC@52Q6=I.()1+R8J]\0,EV>;4W/X8YDJ
MK2$C9A=&A^_4K.L-*U;9@;*1MWVL(O*>.$>:REW/I5$ .X8A;"K#^%(LK!F8
M/*4]M/&"8R1@P1%:IK;\"  3XOOJ4;>=UV-\>N&"Z>7P0"C=@(>XR6)IA3&!
MGZ0CRIU7$T3Y0SK%QT;>Z>/\&SR4X776QG1_>/)N= S-\RGD PM;U=2>J6=!
MB,EYFJY*O".-, QG=K76MT=LHA<^K6I]9B GH0EQ,@R5 CC-+N3&'+5[OV"*
M[B5L4^PE6<$35Q1#M=FW =+2"*7V&_$5CUUO42;F_?=BR3\53_+NU"D.2"\Z
M>9:@8NDP@".()<;_47I9K[)?>@2.G"[3 Q)V,"(-*H,,AX*"OX^*%'W,B-W\
M*QS%S[64GU5>20 0 29P]HPTBVHLC9JV&1\&>(4X@:[+E(8-TH8!HA->P "^
M,, YV39K*ABT;CX" RR![E'JT0&LJ6/$4!:[-S! 9>!Y<4#= 77JM>Q%2SZ(
MY146?C;39T$3OS?1NH0Q;J2O5ARYR*ML_R4H0NP6%YHSZDEZ4T;_T>)[X,$Z
MRD%2ZS6K72ZH3?=,.H8]J:W-Y!FZD@.XZ=*3MNY#-Y\M+65^.VVBK;F=.66_
M%5VH+ZZ3MO#3O&&7B6#S_O>>]D:)8E[V<5CO=8\^8&>(+30T[1&@?4*_G<I3
M5[!#++,(0A/K"YL_'>+9'!M7/E$*67_Y<;!26;YJ77_Y9(I_>$ZWU];.DG^P
M,D2A9C*;I[."FAG(W)W&OUN QR"0'N'Z8T?.]'F67/'XA(F_8,N#&U5;2OJ4
M692P6;T?IGUV6*>1$KE?7R7Y^G0ZS[6'YU%K!*N*'(AA>;!\"%Q7;GDF1_#@
M)2)C7AH.^_%%!%YQ+.84L;P/HGF&ML"GA=/%SW=2PI8?#L85U+PH$HJ:T0Y.
MZ$GOAJC&FOBDR.H<PT@NJ%UDXDB<5PBXH6PN$I1B655%4T'KX_L'^KN#A3V]
MU%'?\=:KCQ3J"'/>ENGI7@?W77;IN(DDAM: .)T<_790JUF;1UWE#;![YO0"
MV@>]/)[J-]@#ARI?60V0I,<_1B- V*J>E8W5F#"\'9$7WF&FO-(_J_G$2O/F
MO3=ED/M9OT.NE,G).SY*,_N&.E41LHNB@ACWB)1&-5V2F>>5-A+;#W<D*(V<
M.3;K1AQ*OONP&E40H$?;:W^==^\I[FZ-=]2UQO--TED/TTELC1-8$P\L+7Z7
M(6-0F*\U$J;\P!\ P&[S)_KO9(5_KY2)&L  M(-;=QDW87._/&#^_ <PP-HL
MYQ7J:1Z+R._/5[[<W[['R6X,)>FOS[TP#=,P=\/,?.03*('QU[RQ*XG>]R,M
MRCD;KP16S"*I>:361]V7-])T<;=:W*MB6JH*SE@\;5!R8J[$3_TD#I5<P-TN
M;U]O\" TZTEQ48XN+;-\_.N."Q+2U5)1L]'>IS-'YZ'V!RF<Y]8'$XET">-T
M.?96#[+ >:NVR;H7!PXF%?+D+W-\B-\9^7 ]^=RB,EZE/U)5@%A@0ZQ%S-5F
MC\>(?HBJ44B8JC+FP&G'L6]_Z.# MTVC@XLF_8D9E7VNR"ND0T^([:UR=1@Y
MU^R+$'OO=SJ3J?3V;LNE_?@Z:O93XB'"U2&U7,V52!3K+UD<#N[IH $"2U?'
M6CT-EM#]U.@,^)._$'O*/WB1,WW94FH, P"!B'LE?[93N6_)!(U(ST&AZ#?$
M?VW+9Y=Z5^XG'54DWGH?B'-S<TUE '+8H3K'K88!6@*B_I$*/E_K2YQ]$M#P
M\(_;O3O02S@5^EAS#R'X1;99:@YX90;Y2/Y7N3VE4M#K=JB?'^J4T=RMS#V2
M7<O1<L9/4<)3CAD8H(%QW>JO8E2ZOH%W*%1G9\?B]="E,> VG1T, $*F^E.V
M)-I]^'X&2"?]N]CM^#[5-!<,D)KZ[F+J$AH- SPC=[B[9OI%^&UX->BP]X;,
MN7!N:B.VY'L.?)R I<80&.#=Q22X(D='VM"G1PVM\<$RGIA-9_+\TTLG [U:
M3W/EOO;:DM1FZK?B)\!0\W$W=@9V<%Z.=-'=8 ZU2Z?W4;LOQYG,,5&"^=N.
M>7HC+K&*V7IP[DTOAPZ?FZN*%,_S_^F'Y7_XP<K?*]#F@THTA \.+30TW&J$
M_Y$6A8Q7-L@/H]N<RN+=]'LX]W.(F]/T(I$E"E0+9"GR*/1>0A0W+#YF6<5-
MU)_VX=!^F7+O=:X^$#6Q('VH%ZN?\]Z>\DB[H?93S*FNA';*%B%5V+[=FQ21
M3R67#04]'^K%:%H?WV$O?>3PY;"^<#L0^VIIJW"&/W!ZA74]-'\6YN94'5__
MGE*H.<FG15CG36\0=U $XH_LA0CK<34E@^@9=0O/YR*DC]@LL5W:[FWCQT1E
M?$L4G&SMR"3Y*Y$M+"CH(?[B@47&>L_XFX/<L@<=I[ X*HV3M':7JQ7D4TVM
M5@QF8RM&]MPNQMT>/[ -=9^7(HM7^ @Q0)6K2-?KSK)R=Q^Z<^].36RXX!^6
M,C.?N$BF[&!38?O47Y'^;HDJSN $F,QP;3>ZJ/TFRU7]L,,.\0(>Z:UR,++D
M;AVNK1QF=XD2LH(J=Y@-%<>_:02_SM?Y '"6+699TA+63&7CV@%9-%8%"!D*
M4/0^^F$BULGPW0>TZH"VI#\[?*DGP%[VXR:%"_@JZ>VM5\SQ\-?RYBUC_H.J
M1FOZ\:X/6^@Z94E;HC*9.D8VM]:G<P=JKX">A=*X7ORIR(6ZQ1G(16-H-#5C
MSS3L'0>7]K0:V1]W99BF[[Y:20^;61-I/GFS3-6CVB(0E._7O:1D=*:X%.VB
MO=:11 (#V/U&*GI/?/<ZBW5GYVW4K*O+G[\-'7]O7?'#5'?V9](S(4YGH)(3
M0W)^784EOHE(]7EZP-D[U1XD-[+*9;\V<53U4>6K1A+:F\+7<9I$]S-O\91J
M!0L316U7BH#:M0GZ-3R#;IBJ>=J!)]55^++@\]#B-W;[L]OST\]L:IXT:Y@C
MX2TE>UU%OB4O7+A.3A]WO;$,7EQD"D];H]9TTU.I%^$BV)DHSE"9\9[>;UDQ
M?PN$/_*H,, /8QD(6TD(#'"V# -<8[+VM:P87>= _:^HXJB.2R!J,("$3U1?
MG5B1XM*[HWM)9#@V4D&1O$M^%6*" 8+BCF$ Z%LJ&  AR$L+P@H#$,  (Y1K
MIQE00A@@#+2-XW2C<F#C#D'<)>&\N88!CNDF0?^J%5&V:C7+5,JMH.%N./10
M%L  &*PK, #D&@A%1 ?^VINA!@R #@-T L]1:R&Y</- JZFWB/-^ZCZZR2V
MVV ,J!\0\O#"Z%K'" <&V&J%VT.B\C?=G99<:T&9X;,FUKTA\ZL_LQ,'UZ@3
M7$9G)S# LDP^#-#6=PV" <3A_?BW1?W:H58<J*WE1.D>X1#( OS3'TIPCL,/
M\>\!<%.C8( '8EI0(JUV&.#F& 1!(0#]VEECP2]C]ZL_EU4B?@@7F,00".@:
M=S_\)+9-EN2CU(@$%R DPL]UY22US?^U;R'.[1H,,%5"^HOW/^WQFRTQ 55P
M40U?9\RTK+AZ:H&/H/>@BVUXX]$5([V6NXM_+"M69=@&'>B'.W B4P%JVSXN
M*5JZOX4!]J9>+ H>0X39XXN\<F6LK;V@63DW\EI#\+'X<PJ;\/6OK0L\*U:Z
M0_@Z/ \XWI2/%2Z4<X?-?I3MG7UY=D;!0!;$S\+3T.*3\G6E!=\:RE21M*>8
M:![&G,3>YXPM A[T&FZC0EJXYI5J#KA4&)=W]*3RL%K&O2B1+@[L_H\?$RD"
MN5S*H^4<AKV\O2S@#U]EB-&V*UQIC?'R;SVG2$H484T:"4B6(BZC(&MJW[9U
MH59Q+'^X3AG"+Y!:+.EDR=YQF(MG$>&SEF4F9QG@,V?K_STS1N@SIV(M/V%Y
MR^P;,'\$%.I'E7UT4N@U:YEY/+%!=+!U6C7T_4*>[[1"&'INS@UY'O]8<6CU
M>;1BQ _+$ILMUSU7L@CC 6<[V;Z#[9:GSU1PD8N3C;DC3/MCW1?1\B^C7!C?
MY_BI+\  \)7=,]<R9;<\SG%HMZY#B;10 \X*4:_!]1K79U+-=?3!8XUOD&T,
M!6N^3QB?+G3"M",E&2[2<XV4/RW,5^^WZW9H4#MXXB+S/O.[P][WL63% 3TT
MR,5I[UPJ2"Y^=I>\]D7I2TH>1Q(M?G3J$]R/DR\H73[E9!^D5T($RXJ3:3NC
MV%[=.8T769-6[[MHMK<]VM3:N9Z?_@<Y81$VG>&?2> J.W:67>:NL+KNVV"?
M\+SJEW[;6J9G?M(-/G_RV@3RI/&"GJ0J^"-)81#A04D)+D:=WDC"=R"PVA:.
MHQB_:"^PJ9X2EIFND7'=-OE:SO!,Z(JDN"M,/TE[?(_R-!DN2)L5-ZN?N"KQ
M8ZYW0\#GDS#XS;&^U*J70SSM:%&T2N3!M]5JFIJP)5!\[>+&W'Q2?/X4CYJ*
M_8*B2-NL?5;F;H587[R"K,) #M2K/R4UGIE^C%,A.'<'C9<C=TJYV.\:"?1J
MREQ*B;;J(R6#HC[XX)J$#+FI(V'J-FL !:7._.''":;'N_)?')I'\Q9TF>XD
M0E4!"V@4T*H:*7$#-LG\^;I"QX2RW=NJSL%3;3YL<'HO8920._G<-LMA0K;A
MM*>>\B@I:6=]N5X=E)^.MGZ7V=G612;47C3/&BI#SE\$37Q2M-'T57%,VS=)
M2JVO]JXER)4,.=#:FS#YZ]I;)__I"]'4"7 <P<2;GF1+P=.*5#!PW7P4^-?\
M>.LBZH;45>EJ"4X-\_A+\*0R]=D>@&T3D2RLD21%'KGQ2S-L:,GBS%&*.D6
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MLT1]C!]%&SV0O9+MKG[+SEPO(79Q^MPY1\=$JZR&/^4.%]2&L<IY<PR\&LF
M/C+"!0V_@S_=03IP& HI!OG^]A[=>"]U2:FOMDAFX+;XS7 E$*\&0MU,"T^>
M$.&$'1VX@GQ"#+FFNMO62+W6]MZZ&C^%8PEEW?TY)+>*BFMSX$[RA/6?51*N
M<H;]ORK^5\6_JT(_?!6[>IPVX141X.3(L)6<*)3D@@7+6C%.^*N XYH+FSM.
MPJRT\&7+30H\ACWD_-"R]0,>=IY'73][*P5/_E&AMX0'$YHM&B$N(?<F'3
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M[69)-AX>1.P@$SR]\,XC 7&_VE0,&\5Y= ;)BWH>4@G_/+VAPC)MM?'CRQ^
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M.SZ&Q=_<9>]_QUS?6%55:V]CV1^&D];VC%B*)L.UP-#$Q'A66J1Y8H#4&IC
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M_M.B2U(BPVTVD$_J8'MU^PV_1L8%$#KEN L73H0'@K2A8;Y*;4XNVG LS^&
MCF?:LO.WU]VEK[OU?\R[:3!:2=C%1_5M+EAFZQF!14HRH_CE(_^]$OXSFR.!
M3RL32A*Y*X2T3[28<*S94K<:M[T/$6W4P%2+)A_9>[0RF]4B?)8^[6]I0[)^
M--&@(17OG)@,DI^X/S[2/[JK_]/ZV?<A^90I=%S1\_D!J.FPV-3DX,K*R8[
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MTO,&LC<F@PH-W*BP$?GQTUHDUX#01<6B92L>U<@!F-G<72C%2B4LNHESS+,
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MCWS1M%<(5B.'1_J ,?O-IP(.&T/OI+O$S5X;UN%ZZNUZFA<R#C1/K]@0TNX
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ML:K9ABAMYX>WUN-+),O>>BSK/:I9!!.Q^Q#8: [N23KN5CT>B 7MJKN -QO
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M3S*KI8,R_][6W(NW1G^^4V]XG*;"RWO&7H(]D\<#_A1[D%4,3SN[Q5,SL'$
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M]DG.YOP8XB2@&['>O"/8O[?!E^9AL3<)/ONEO:J !V2L"-RJPT=I+5G)!9V
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M]:C<6YQM),\W'R),+<! 9'(FV87S+R*8A6":L"?/(SN6F8>[8EXBA&#9LE&
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M^,^.[ZUP"!\G+%);M+)^)OAZB&U991I[F>D]?T7A!TL&.7\ZVQLD%?5_^']
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M2=R$P=TE0F76'6C'\V(SVG#K:!E7H<VC;V]ZZT M64$24N@'7"!B+*G@7$3
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M5 +#C_DNUM//O^>/2A,<O<;X-OL;@'^DQ,>VC13H$E.ZG'CD]XBIN]/N)0Y
M17+B60BF4^PX7T3F8G,5+6@(MO.0.6DQ[_7Z-EXGOKH!2,9!EP3!<G8S*6Y)
ME<;X9U^DT+YSZ->P&@S)/YY:.B9+G]%G.-ZBO#Y6.-,+0UW*862->OO$CA]1
M[HE!4:?UJ&X&^]\O<&G;.H=458G4QAC?U3ILMYCXXB0*?9&%.,;7^&[Q1VT!
M^9C.FE9W _B8@^ZOP/1;Q;:#E#^*177^X)%B#!S_W05-H#^T_A5-PA5G)SJ
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M^92VC\7VL.#D("Q09 RB-[K;;(GMR1G]AC"#C?#S,3+E%$-V*#N,:9&@CJ9
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MB'=N6QA#;#Q40[HWVU7QA%Y'2H3E])$+;BW ESC"@W:/6;9A@IM'>UO%=5U
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M*WO^3Y]_K(\7T?_3PO]>+>3S%BZ?.);EYMFB6S'6(/;_#*&WC[[75T)G91)
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M2YW";U< W;B4(P'YD@GY\W-S<\/V9._GGC6S#W19!VXQ*-=),^-FYF8%/<U
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M(P6SR6+U?E^AG^:+0C2+ %@99).A HDYNIH'YQ^)U-S0](<OSNGIFQLFLVX
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M,#)Q\_#R/>$7D'@F*24M(RNGIJZAJ:6MHVMJ9O[2PM+*VMG%U<W=P]/K[;N
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MH:L(>ACG'$"E2'RI.1A*/EL;^GD-[+YFNT'!E/RLJFK>EJ U95#$M_1Z2+C
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M^F._=9Q@G\P ?W9[[T*ESA<!,)TH";G^]!;X&V^\M-[YB]PO10!?,K42]XQ
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M2J_MPKB#\:NWWY%H615- <QRFZ9Y)46GO1IHX*^3KZSF]PM9D#S(5X@ %M1
M8>Z.H *E]-P!].0M(XRBG>.:_ :HZTM&O,=HJU\\]O3WFHM1IFU>8P<>*JBI
M^"=)/Z#Z5+#ORSQVTG"!,@]"4I%4%26R,CA\J(?T3T?TF E0.M>(!QT_&$4
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M::#_M3TVRBL?K'D9M"F7(C,2P4T^L*46Q^_4J_/)O7G^_'04M U36C>(<VS
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M6:/(I7Y9J&1&0:NC7ZDLO3J0^0S5GR45D<_<U'5S,/(5JL,!L7&$W[EUQKK
M[^G41,^FSZ&8A<])KV7)OSEE(V+:D4"81ATB[P\V"WC":F+U^#M+40FH0U T
MT\=U$RLN:Z0/<+2RA+A0FD"5<E1WC\M),6&WV37P9T>*GL5(7A/FS]/<\GXZ
MR<YJ;5@38F3H"8G^I"[',^OFN%&TBXA<Q7U.HXJ)3JFU[H@!LN0@V<;5:B7'
M_1Z^$_$B,LT_90YD6/HEE GS-UKZ);S\R4G;-^*G/B>'Z4.^@J[-$XPCJCK2
M*M#1)3SMWDH*7WMYK;] B6T:OZ9/Y1<#G+CJ59$*[<2YEWE*#J'CVZVO(]S[
M\-R!P,E<R_QSYPNP.3\.]2&.4FLIZ_Y@0_'^+4 A59R3-08ELMO),1EO\!2H
MY$O#42'J75.HAX:0]::8S7I'\JK<MEVL4^/%^7?Z[$R?SPT[?IVZ@MD7$?O&
M#>4674ZH_9)4:1,;;&<XHTF8N,_K#2)>NS_I%&E:NE"7PL$ZL=!.J!T.[[@V
MR!4ILEOX ]!T78G< J(@ZC?-63=.,^I*??]#E8<_YI3J&>KI5R9W#N;B<(>Q
M7^XP-@C@G*QXY?>]>=O?AUJ=.>T/*>7?.:WICM-Z1>\P?[[ !LFG)^1NY52!
M#W,(0NPJ=L?TIA&6LT]T]<Z=X]H]]XX&(O^#-C$VN$WL\-&4S_;>A?H;[3^T
M4WZ/Q!!7>G>WXPCQV;[+XYEW6,(.?*["FX!WL@RXB\8J?]:#(@_24NR$)!T>
M$JDN^>Z\=A5Z50/JKHOG>XF"(K)=0X7KSRT#0 $ 1 K]5O==HVQ\HN%E1QH^
M;VT2*Y4D73ZA_LORQ']W_\2^2? .5;W2KSUSCTH*:FX!%'W]V'&/4/#@-+&;
MSX%6>ENQ&RP##9I+4>_<FXIM'7<LAMAX4S@E:0ZAFSV<I%'B"ME/\EE$0DB>
MU6=V&>R;=LI *$;%'DVC:1,8SXQ3MF6.-F =2$B4@=F$.@@?S3+1,<PMIC46
MPO(^TQ,882LH?#_"HGQQGOF@U)(]&T$F4!37FLS[BE!/(6YS\,Z(XZ/O3/<-
M;K?G'XR3;/_L1@2J=W$3^V/*^']H3DG7YR#E1G9^^-KY#A)?$&P0K-\"2)I7
M4N?NY&G6?$S]')CSJVGF_AI5^I+PY-_C8 U!"Z";8J.,6/3X1N(72%\5,KRM
M@YUO?:8%Z6 Z2T(C6"TS/[-QC$? %;F=YR"EC)P=4YG/"L#<D_U?QUE>*.1L
MG'3J;Y$HB)/@0[&RI#!DOAC&%"#Q\KH70A29LM)"_J.,BA/X[[+2O]]&).@\
M;[Z1TL.^>ZSU1A7V1S)YC6K^2SGJ_YP]VZ6);?]$@T-U4VW3J(N[6/KJ(](,
MQSREG);D9>8FZ+>G?N8OV5DV-=X?D?Y_LZV'-O%^9]]UX#5KJ7]-?Q?^J<8E
M_JEYO$:5_@^JB*ALOXY)_8J,O]_Z#P5<Y[A?;4(%"?9K=?B74*!$&G2WZ/+-
M+: $I./TWSJD\3>MQ\U,D2S?U'%<^] #G$%GTG=8XKUQH?Q;(5IFP?::Z2^I
M+.!/>?!_K.;ZCZSG?O\?BZWFOVH]?U/L$+7\3EKH5T':OW#5/^.[/.]_3HZ
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M@G:=/NW9-'LR9RG.ZM *!]X5K>&PXC=*#;BSTU+[-^>QN+ %E[%L)Y^9ZEN
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MK9$..^!).,58<>6,%2'-B-S3R^D8'U+__C8MU?#'+Z.%WG_HZI)F=;Y @85
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MNN^YHN[NO[ON^^NO>N].G:I;U6?Z]/?UZ1/ZXGOQ[X%#"K(790$( 0! P!^
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MQ()J,E8!M64:X]MM!XZ>%!QE6_D$[1=D?PZ8[]]"]BNP+[CZ 0I""+AYA%0
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M,G?=C?Y2OZ(47GQA*7B!J.=1'_::_V9U6=JS*,!@=I.#(BIU)[N12@]^&:4
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M-UK4]2C(ZC)Y><J!DS$0F4-TTDHA3XI:X9Z)!RW(^EK'7#?\>2@V39&\K.;
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M9MW'T-]YD$0 7C\ZP%MBMY7 !,IY#R*9D>?RRO^$.;[F ]1IX!_(,EY>4F<
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MS_!8MC@X6KJL1$&V7<+ &F- F?AI746VM4YEMP<!$->$WQ4%XLH8>UBL#UK
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MFHP]^_+Z[PLA .M6"("/?--3@PIW!T/O4T4V]5&C'?=H'#SV# $X#9"?KT
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MR:/6M)AH0-^?_Z:_PT@#(SU^00-G]%:S\.NJUN>;F)K$3<6RO!Q&A;]NW\Q
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M,#(W+FIP9^R[!U!43=<NNI$DD@3)68)D07(.(ED$0<E!"<(PDM-(&@3)24!
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MJGR& 2;8QI]^_?O0.OC92[:Y]_\_7MC__8Y5?E*&?-+( <WJ]X%W-0?NG;-
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M\(_M,G,7A,4^T@+5CO$E-O/8/XD*3%%2I+G\+)MR'ZK^[<(;,"+T4.K-Y6C
MM*6@M+MV/R+S4.LD]F+M6AEP@)B@E,UX44U6J.=E1DQ4:"#.0 ,-E!FB@43P
M\'^ZK8<+1N[9E-=J<NO2YT6%Y7CTZO?@Q)QLC"&A\"!%UECJK7>_V&X,X4N<
ME&GDL'&*8!UI!S;>0?!,=9T)=;G<3V>97Y\WNX'H0WJ568P<6X117914U>>'
M5UT64;X>(/),,^J6PIYI\&48QN/"4GYSUAGI$YENT'%[QBQ-/?4X^".+9::
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M9-P=ABXS5H'/&N*E0R?-3PD+LNY77W8_8&$TB&(N\4X7';'6+?WRX03'F@Y
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MMHLM]ST724+"K0[,LE)-W*E:G0._[RD^_E)/+]+<PH[V^S==]&W&2!FC;]]
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MM P=O1-\;L83@N+%CGKNOAVGM#ODIB1G#*)+K"S:#(8^QN#*^JWQY_/?6QE
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M08$6U_+*0]OB8A3%T[$;#6#0OG]ZR4Q'.M[$Y5>P)7SJ!,'M<+)T1_!*VSX
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MQV/AVMFKP?^;%QPMKI!T(*#8(I-=N$XIE9C&HJICW)_?S9M#\OV(=J:$FW-
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MR_1)'X=KE9]9+I?ETOYTBUT4W  I#]+AC;S[&P'6BN,5$5?G__!B>\]MDE!
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M'R3"1T/5$&7MJ"E>PGM)6RQUNBF(Z[)[?'[A_,YXZ8B]GLAGK?NN7TGBB6G
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MA4F68",:Q^>W^(B]_=J)R3R5U]\O2/=<&UR6:,;(>SC40]TD8W,^YTHH:<8
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M_H$O]#_T/_3_$8%I(_\+4$L#!!0    (  D\>%1T= [)69\  +^U   8
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MKL*L<_?&U^A)OC'3KD8[)L5ZTN<V\+:&KR$P9Q(;AM=FHWNAV 6<"(I$!8,
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M7TN)_$1=&FZ,3&<%_-SKQH3-LH".HL]AAK_]NXR+T@GAIOR<0FA*% /&W5"
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M^&O4B72Q0U;##XCCM4)U#-;"5[34W[EK5.;3CLIY-'-6+H_:A[>4 N6L2Q>
MB 'F<+$GI0!%VK1ICJ2R/0<*=GEEUV=GA^U4#Y[*6NW!<UG>Z2P;(Y=\1.X!
MC*.I]P"3P9O24AR4P%9C_.7+LUL\E7\WZW0@+8LHJO!?6[A+Y)9WO@?0'CX0
M&)\SP83"XKR_\P@CT]!;3CD"&O5S"0<1!I&MS7Z3A&;=MGQP!,.40T[3\=VE
MW-#MJ\T 09N__X-3R8FI(2*ODFL[A\LS;<O>RZH0X_GC;<\'K_)WORB5X_'>
M@LJNQB?O 3,0P,S?DF RE_$LIWH0YB0R 7EF+'!<=?4C#2Y..Z9&)J%MDOAB
MFURM&4'$S'>,6L+0R KW,$V9?("3">^,U32O8.A4Q7KT#%9]4^KP)X<3(XQW
M^Y%I[^&5/1.@$N-^$$TJ_/> 1>;(C[(*1>.(:">]A] S[%OA=MQO[FNE0Y]D
M:3"/4A0Y<4RE+!;[A0EVBYKZKC&O3O3DY+&IL =DVM+5 I9+FY*%A6P7[*B-
MXA&\!O/6^*9;G_#R8'Q:CES1J["MR$61?@R6]Z8">MP#ZLHQQ^/.WU%;9/VF
MNIZ'7<5T7T>4FZSN+ND2=+L2]O,/V]<H-9+_(;^=OV6W/)+.)PTI -5[_5*I
M3^J"OVF$&EA\1^_&E*):#!!:1E%/(B$F:>>HXM8ZSX7$"TS.:#0:1:$(F6A7
MUFMJ8<I/V@O&IAHVX<=FBLDW;V#=/Y.%7^YPY]GNV[F;4?5\C&.@CS7::#>9
M/STMW/'#C-=(?ANGIC1Z[NX\7\O_8<"2O+^>#9U7^S*9I2#;]2F!?IT;_H8Q
M#BO'P?+'+Q;4:X52X!*8CX;=QQ6=66V1.#$FA7#ID)3V[?/U&:FMP$.L4F^G
MO-WJ.83I\);1F_-2)L[84$N+"^?+$R"\,FS_S &?AA'$C("^'I(^KCEUJ+!!
MC_8GL#TWX0A%]I"66CLX%(PX=N&HY@:\VKE=T=ZA(XR:*033K+N![3R<\.<V
M>9FM*:CZ1.\!E"UD@8>5O%%];66W;92CJ@*$74Q45!TTETAMFSL\&)?]!]4V
M,QXN[N1/6BPE"@=\@9NBR,#3+.SMC!<S9YXKK<846%&.^O(ODR_"L1Q_M8>1
M)'40\#).Y$U7<M&'SBB/E&?QGS"G?AWVXJ48L=EI?]I1U=SP!1G7'@MB4G:P
MJ0XQ2[LI6^K)E6(?65;*/RKSDDRV5,,<; [:T/2)::Q:/E(4[07H3/AX"_WI
M@$(6X6"DM[,S>5VJRV<>IZ!^<OJUDP)0AF2KKR$0[_7D1-ZUP+P"5^&)QA#_
M^VO8_G+$]3ZK)A1VEG5B_(91H;Y!/^[E,^<Z5]9V#968MT<D^Q6E#D5&MA,I
M.8'+"+M/U1RAU 31]P"C<;25#AHCVV$G9W>2!+?8KBF"I]?YD<\<MSU'.0H2
M42^7;'7]/@D']9W+1Q,0]Q:H+;DTKYV<CAA7'Y%T3H<L5A8K>L3V,BLQU>NG
M3_?A_^@^=-*8:"4I ND)5]77U8"2+,G-@>\-])^%'[O2^ZL )F=;7WF#2X @
M2JDT=\/(B12EQ'-&^@,UIT66V;,H?XVIO?WRN$77:=+).R(QTQ_.=2^W0"1S
MR$6:Y@Z8W9D:I^8U5OXC\IZHY['&^)I#MHD-03Y?N567ZAI4BW"O4^:P#TTQ
M+-"S-@/$2SUN4FUR^X3IC:Q%?YX5__\]]'9B&FF8WKS=[!<H- F,,MPQ3U)P
MS#;'YE(^K52IL-8Y4D\OORR9 L+\)W5GL,(EE#4%/:6 &:=HFUZDA0^<[$EA
M;SMMZ#Z/GBHA,S^3/3[!AI+0D"$H*?X>T"62O[-((4[:X+RA05K./:?%$=,6
M[<DZV09!KB3%L]SE2Z5%69!F@\Y!Y<NR1+?+4K:^%BL'F64>%FH3BYLV>5,J
M5. Z]%\*)J=H&W#82.Z-X[3DF]$WALZ&$4$2N5FZ0KR!)MZ'47AEZCU1"CCY
M,3+S>%"GRR>GX,/0&?&$YKT&O7A)2&^KXUNWP(8/@)<7:T+6JD=XH8GE.\T)
M9(0'U377E JRW;S%%UFXTB(U,[PW4H*4ZEE)%'HB1)_F[_2UE31>>UDUF88^
MWXV_H9V,5VH)A2.]Z?@]+BJ67JY;P,)/4XLPI_-F]I0,M+['(IA(1D 9N)0B
MP>6M4H6[#9I<^$WV[_'6[><5"Z78T(N-0M"B@=2Q2%6E7-L =27RP4/5?QW>
M6:I*M[YP(HG*52#??V&.0].BVT8,:7*$1._(O"/;IV5\H/.X,M=W_ETI-.V5
M[J5S\R9 1"])^\EU$RZAOL5D@TW^\";X+,*.N/V!,3_,;M'6D[]G9,:WYI<Q
MW8X>T8ODUBFK!'P?-*TES6M+R=@$H^>;Z]C,S;2]>8\E&<//3"]U'GCZ/4#C
M'N 3+K.B^Q<!OY6Y/>8,VYV6H />M@3=65\(!$P)?:U#BBV#>84*9 1+V140
MM_/1TVJ5QI:,B%^A\_6'3+^X.F+*O4QO.!9D[OP?F'V[/-U1Z5])B[O,NS\D
M)EWE95:U/FW*0P>'@QG^SF7R+&DSY\T^N@7+P0),1"W4R^CC5GE5L[UII#LL
MD7J$0-)C2RLF&_M<]'+WS'_60^S?5?Y7=N/*_WI=:\]V<;UUEL=IPPZQM?/'
MQK':XXM";%/5MXI5.6IWS)@A_(;7GMD^"JB=.$.Y3\\'4LG_E W/BCWVP%YL
MJ?P'H-FO*;ONIH9-]2[3A"Z^T=Z].+%S%@@A%$L?2G/'27L*\PIMG6UVK%%U
M)O8.]ID2_"&SMY55<7%'8O]76N/!L"7&F+_73$-9QI2R40U-G8*M'9Y=>ZP$
M?EJ..I#NHP='IA4Q;9+O9'J5TGU[H::^>3A(Q6-!,$C89 ( F(71HXQG_^V!
M)!;748[^F)0/;CBV3ENTK352-\%*6GBR#Z\5()0:E(0=(T.!BF%[0Q7G2/3!
MUF.T =&*>\ _M,^DJ[CPO-[8LN+TV)J*+"(O?.3#-64<_;' 9I61!07.E/39
M*V@AB,79/NQ7B!F'<A^6V"WGN/\_#Q?;/2 $^%<6Y_0><#%0L#UCJ2@P;([0
MFQU,RP\+9[K^F* MMV[8+SZP=UP7Z"@3)N.BHX"B#X1+J#YXH[K((?+TO6ZJ
MVM-]XX9_@/8VT5S7+,GDPO];O^KJ#G-=''YU@*6\@K0S"7G_@DEPOM;=8H*1
MQLM $35!9PNI)]2!QO> ?Z JG>-7T::!I8O>=>;9^ GG=6);!V3#G !'OTD6
M4:5A8MOF5?D/UBXOOE9JO\3/7N:\NTU/O?\/4]ZX!_S=GJFKJ@/B22].D-=T
MD\MJ: -Z'<+RV837/?Z,FLF1J//E'5K_KM9/ICL6?R!5LY%+5Y2Z"^9&_@-(
MBX>05,!_&V2L.$;E2C)VX]TQF?__1IP):&,9!7$)#\$F0$N>^"]!&[B$>)?Z
MDUWZJ4K(0'\1.C*>/++\X!S__DQ)*+\1YJ/&1; 3A]@9P>#+"U)T&W7G0R>G
M"7$3T =J^#IX,GMFS+_\5GOA[GKW_KI%WZ&<!=JH=C348NPK#W!,OH#OYUU9
MQ=/<Y;IRP[ V#?8G940D?4K3 #("AN)ZWQS*7&IO:S_Z2Y9*O(DB9ECG$"=[
M[(CG8$OY++VX_]%\EW(#^;>)H1JGZ,>;A5,N".,7LWLS6IY:Z]7K<3UGS!D%
M :(2;=ZFL#-???U[ $B.-),WF1#([(T#?_9QT7G4VZWT]:'QC% *]ST :C6E
M(]C3:)/U_I.2<QI1!F=^^U%[?-&BU/SY'DL"&GOTZR!-<7O B>[JY">S9N\?
M63A,7?3,+K_%GP!6]URE/DMHX._.BK>,\E;H+H)-N76Y"R6CKQN+U LK%+-V
MQ>\!YR?5->T0P5JV%AK2U]G R"T:F2?[H6&%$4 ),^P#.V;"KJ;K,G&ZF6I!
M?XPYV9J1(EGF1N]!^Y<UA%')7'F5KV49 _CD3'X;>61JAVDW$Y(&)E+9DSG2
M+@3V@HQLO5J=V\,;(GDK*G*O!7]3*#V>[S_JI(MR(;KT5FMJ;FI,(N7]G&V%
M-H ?G4(+M=Q)LBOJ+2)_OR!/\8WYH,1;$SN#]ZN/LE^R5WK.+L.')H_<0%T&
M!RC0GCJ^A97& VF2C%OW79&)9\;RJ9Y8)U.^I<:*%.4#R2_F5O]C^BN6]#6A
MPMG'49SR+   +>#?91 E>E?UF?G[UZ[KI->=G)N-1FL5'/N.)D(0.*+/C[*Q
MN=I[(!<8RA%[R-YU@_ >QS81*N>K6]HG\+?_U+'5\4/8S^4[$F+<&YE<;4MZ
M"*9;2E 2KH3-IN#1_DDYBRU0NPV'_VZE=$\^(6]MRS_W[S@Q+S,!%>K9>6N%
MJ;9%J#9&D^CG:O HN(KQ8T@Y[2P&2'"_ZX,(9ZX@VZPX&^VSZW^:$0=LQ+PR
M1.T*3^ZH%I45V46:V!]Y("+/*GF QH8/,4<[4QU0KS4 D1WJR=5#I/1SO9CF
M"-MPOVQEFC=N<1=^+%I7^ 6_6AE<K]$2A+,_!@4HYWO,RL/J;(18VX(6Q5(2
M=96Q/N.KM,E\$P2"$^M3WT.CK?H(\@$GDXU2Z&K7;Q8I@GSYY:^?-CPRXQ+5
ML7?TO8.&K2*-#>^F>D@=09/= D,&]$'#[I"L2+&$ZV=! 5)6)SV&PID2KSR+
MX9T<RS62 009"<@1;^6IF1<M,+MLPL@^$UD1?"TC(TI>N*L#\?P\J$\A^2TT
MG"Q.\N!VRAY=ZB3\9[Q:4_VD(%5RF%9]6XR:_MN(3ZP*]X "^[#8LRS\=\VS
MIZG,"DTPNQP]M>T'9;Q%9R3:%SU\O9XY+(6)3@[%;R?^E/P!8%@-])LD=BFZ
MS;0SC5= 1\A<BO-%;<I7%M;3;VC2:V0XDA4GA:AT)E]<8U2_ONI=@ GW^!>%
MK-EEW0/<6?^,8_ME/ 3\'==/;-W*7=27V)1$K"<A=RP33"W7G+OU$=+W -YA
M_LB#TZO9.&A[J?OM TLF_+,,]I6WA,Q0<9<^7AH\P><^(VEQS:KUD.FM$.QR
ML.KP-)?6&_WMVOD0X2'T+W.Z[@$]5]$A1)7P3XFX/MV; X, ;Z?,<A"-R@"P
M=7.7@5 F::SQ@[!33/GG*RX[$ I=]Z2<^9VGG3U*;>.FT-8LT+Y?JJ1\])LW
M;V1?!H-9[N!+&+.CM/:RA?6JHPUZ3G"/\/<YH;Y"7[,G?\8H^=421:7XO:_"
M,_R?;Y_7]C^]2BS[/(#.6!= B"]G]"PV9X1[,[K!R[M.:_<BKBI.FOBY6_7Y
M:5GZNU?M$48H8I&8XJ*.1E[[^IEO'&H4FL3V,NXT4D7HTPZ2<KD[QS\JA3AM
MF &$E?08Z..3G94[(GJEUEBY=BS#>%U"WTF9X(T1^/B-LU +]P_'^Q/FH6(O
M9'NJWL5F;&9/N8C4C4L2FT]!.+_R=/[X>C20#Y2(,7+)>C:S9%(?\18\HG+<
M1TPD:;:6RM[]'$L#Y310CDNC,/:NX63/WKPQ0G2)"HNBDOU8"!>/3!VOH#FP
M9+'%2*@X)0MS=)*H?>^L(F(E/W$_%;ST*=3RI!*CNJ[Z\46Q2=8S3(#+8 7P
M%4T/)&HC@2^_,X1<M7]\*]=;9T3F?=6T&:B,9Z4I"@@6?$N.O@T>HU. ;&XP
M-59Y,D@S"9#8'#^Q^R0R)5H1T7W.:[V62<P/)+>S(AVAP('2!#WO\3X= >A-
M2S,8&A;4)450-U "^RK*+O$:C_V?;)_NN[^=)@G)/VN=5,C.TU_'*)QI1?9
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MPME&9) WD!1Z$FW;G:XE$X2#S_.$9ISFY&GD<OA(Q3:.4[$UU(_T2\CTZ91
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MAY=AEA_JC2EVOA=7UO5*KWP?)%,!8):%%%:+IJW7D!Y@; OPQ!7/<ZF'>=2
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M^T]TR1B2@O"BO,*"MM1H,V]^*9&]TIB%)$_GG'#F_[M7'Z0#^YJ!C9ME2M]
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M]8UB-Z-R9B4AWJ*ND6\C^YIMMG2$^XGF% ]B48K")[_7;-)VZP++*C7RI3Z
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M7,(_9A;;+L(:02XRW:M<&="O3U?CA(O5MNKY1'JYUAJE'Z^1)(!O0O5UUY'
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M^;Z7(5L_T6DVUJA+%"4MD-,0S2/0LH$PKAW#'/PI\/M/DE+9\U%3M\(9[?9
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MWR^I^ORB2Y<]M3A )7=U+/;L^L=8$)X&HTP 0U&?^-]-@G]T%#<ZEZ0+83W
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ME)3<>!=OY<<FTV+X&M"*FZYFI&\ZW1_OZ$HVX^GV?>/H[5!?07B2(L9A9P#
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M$W]C\"@ZWL3=*QF M%W<D9EC34-F$9)Z05G&+?A$]Z;KPJJDMLR2^Z0?: ^
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MS9CXR]["CY (&PBD<'VZH:%"A2WU3.007,[5[-#M/!@%=D,N@!+E4L-3PON
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MNW]^[&DP:CW_F\I W *^;9EL4*0I;+7H3@21S#(X;,!G)TD4);>9*& ;IG1
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M(UAMF'WZ!MABJF4L_JZDJYF$<RS,YG&6S'AC"W)Q5#ZIUSQF/N)/KW0.5T4
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M1&;$MA#D.Q0!!+DPU*;"46WZ[&+O@ ""ZKD4F5K(U-I2*Y1"6^ +GC@1<I[
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MHYXVK2:C"];H;9(6JU<FK6=SD[:RBW(R:TV:AFS6\/LIM7LVT6F6&UP1%IT
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MYR3)9$:\@N=A5QV].5XCO!M#'DI*B(8K$#I6&&A7<=2M4E8U6O$P=,::#IM
ME0L0IM)2U%NA4.B)F.GI3*7'8A$5F3CZ85T_<UAM5753Q^C-PWD!F6ZAXLP"
M#%;")Z&0XGQN@2SW[$@>PU(]+#[I &B>W]:)WUO8PP-0Y^'RV8^=N.56C-O
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M@'.9C?_]I>?^B;B&LS&U1!L+X=TV/<1P!ECZ!ZPBT5-<8;DH1G(;4WA2L<"
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MT<YS=^@LIVJ^W\+1=W?FLQ!37$R.W#P>_];S,>B]H**4@$J3 G&M0),!X=*
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M"U5.6,04?2%BN%.-^RLQN=#5JV0 4E&&*<(^,CF7F><><<L7R#Y:W!(Q=ZE
M4X8!,[#!S;]QJ G2#!>TOD%/1!E,!L^?""/!TQ\W*DH6-2R>GJ/ IK9)IS[O
M[D[9M_^[(D3*/,P8X<NB8+5!%HMI;G<>M:WUQ$Z[?I[)T_M':WHEME%(.^(M
MCSM7VJNP"JFH=4R[Z7"7/04N8A4\04I;VWJ^B;7X2>$^F-(/IG33Q1=[9$J_
M5Z/Y6YE+LI8_J"^ ;*7W.B[Q\(.Z=P?'QXIEKW-P/":V83C>\)SCWGE##V=8
M7J7[@L$:&9"Z1XF#]>* @_7MXF"=+^%@=>*H@B]PKB(53E4#S+H%1@KR'2IU
MW=C#RY<F\A"C&2,1PN4E%(J$:1+CMHXH\H16P*B),:P7O:,!_M.RDJ-R,RFB
M"=*,U!1>V@AD/!,_&0/0/$FYAM!^DT2G064[9RI8UA+/:\2T;4;REB?Q]YET
MNY.%P<\3IA(2 "^3O<:2KC)F]PZO%6XTG\K8%O:KE7L%%7J;[V'QU<P>1O4>
MOSD3GPHJRX,E$6UA.E-Z&:WA(HFCNQ*^#0ZS.1Q_%@2(,+[KLV:;+0);PZL=
M^Q$;LMLL\#W33=R_)SH-R!/^M<\XT75<,IW>_;;&3HH 6NA8(0_]MF+V1%VM
MY+0\3S5WV"!M,7W.3 KL>3(9!*RUV));7K&Y9:=K1V]2YKZ]8H]=3D&0GXF1
M^%FAY3\2J/J*6J<J =[@SV,C@XQ!%4.;<V5>+GEE[<$3OY!XD2JLN=;QBY-T
MTC"S48@H?H=08)2AA\,6EQ?;] A# I0-(H6'=%9*2$ +KH $D22-  270)SD
MU+,Y<"5A)%01P.J;G,,LQ[X6P-/$^[<9VN2R#$YI:"R]QM9FQMQVB,'',EW?
MQ S,B4A[T!/0')-;FJ7.^'GA4FD1J;X#T6G2*PIPH\0ZX@8EG.6]/K,N9B4:
MXX,MS,WM,"M0U#+VI&UQC-I4GK&>MMN4-<MO^WE!F\A'QPW3/+T8"D;)!_:,
MH ,IF;3UAC/Q!A0M?!Y/S8F8V>."/LXR,==D[!I1*ZW>GV',&0B?<1F$8T%Y
MVVJ)]755NT;4&T'8Q3T3'UM-J#PCBF1CU3C=)58P2';0W3E&['13KS#[1.-;
M*(3G$<&9#A10L!3HVHYEHOSL!@^;@U:!FD7%K5,5D&()7!'X)$U[%5W5Y?(@
M#Y.C$Q8H:*4HG#3VPB<5B.?B[:>?Q<7YZ(7H"5UZBTZ3+)@5^;\;\4O$?.F>
MRE,E<]JL[2TH,U,R"E.Y<'N8;$!1Q!:JIA$]9CJ(N22-''<5AV6\Q1KUV:!#
M4R>^*+7 I"B:+IL&I!"E(HG5V::CW.87+0<F+4QYD\(!E"D5),5'5)WC:'/%
M:NR Q^,,&F;_+P=ZM_<_[-X9]!9W!"W;7'[!:>YLIN;=7\2E9(":8A):Y3/'
MNFK&G6^^:+X.]L8BL7(4\>=,PSZSW(TR:1#F3U26(2H=EI<B!FV%;D<+XNS4
MO3+3=5&D"P),)S$FG\%^KU3:BI/*6Y"$NEP4=Q4\0"*6X:/5 2.F7&&Q-^3!
MI?,FRS0X^T+4?DZ$GM21%<S@$31E<:-M^J/\.O(Z\_F,^7Q_, ]7H1NY*'07
MG9EE1N5P(\NJ4G)RBR2)BZ[P-Y;LZ"QFO  WS.@6C4SQ=",O7V[U(>8.0T^,
M1M473<V,?NOHJ'U":>?U9%9CQ7?79F26G:%?J[_F6HFZ81]6(N:-AIL;L9WA
MH$UD&[L!C[$\9\Y5)_^DNB7[;/]M.I*WY!C#BBFX3,,=.3GH&FQ%WIM<U?+.
M.XA"G;2W9;=4*V6X)?$'(#Q4D8:UQ!1I$H-0FBCS^VWP$A9E0Y$[@]DW,,,F
MFZ)*;0 !"FWT9#*__W7QDX^X7<#20  9E\\>%B#C116HTH>0\;+RBMP_0$8)
M+W!U_O+-61]&1H>3<. %/C>Q#%Y:. #*\%CE.NH6)-Z"Q Y]RXKQ'] S[,/O
M9Y_.$, &C;6Y_.HWO_XO<,A6HM"\&.J073-0:.3Q5GOE37P'JBGJH'$GLZW<
MP@;X(;W#RQ--.QE%3,=3TMU6X$PLPR%E"#%J[A&ZE&'F;[0U%%E;X%S)V)HB
MFR>X+I@5JI/695X&P*MU);^E0/H7YZ^SA0KT!+$S+$(5=>QB]'H+^C"+1Q?'
M1S\<'^GCI;[$G4-..K:LJBB-5:PF.E_5/>,]R8PO.C*6M57)A8C^B(:UHL[N
M8<QN"<&#MZX.;4#Q1!&4596N0I<[*A6W&O3W!N= 8A?GJ,8'-+C*(HQ\!(/>
MJ6AN$\ZJ,W'-^>KJ_Y119(R^I7BQW;2;LE5VD@W3I6IK"K\DV0.M;O14.?_M
MIS"W,H2.PY3JJ+12*HM;9&)JE(2KQF1Q'+TY1K@5@\IBG4 Q-KG;B'>Y9DE.
M<%O J-:T"I7,9YY!F]XWZMN%"A@3[@69U7.*EIYJ.Y1S2AXZS)'-82KIL;',
M=&9.Y$2G6=Y9$YLZQA_+DKZ_>3C2.P78H,'LM%@X$6)AOMH9]$_()+4,@F%.
M&$<#X.4ZXU#RT,61H_HG4YT__Z3<2F4SC]!8*<?*2+SCHP=8&X,O,,2&5GCQ
MG-+%4SJCQD5>&>H[MR?)#15P0%V9="RCTHB/'QLL/*LAS$HVO]J-I['NJ09I
M%Z[^+)BIL(CN'Z=KC>B]39%E$Z\^E"5EH(X>XN"??/_R$ ?_<''PJ[7NR[U1
MN?<0]W6\I<9-\O'I%WA?J:-DM5YBD1L,T(&"2=&E0;4",B8Y>Z6Z6'/T\G5M
M+&;4/RHT8_M3K94VL'-(GS>WSBH,SSI)WJ^V\J:)W[QT:>D0U<HL0>T$=+,0
MT^&S/*4M'+DAO+*J<RP0#M.$+0U0=<BQ'A1K1(XEX5@T8O\U;0CWU?](W$N.
M#5%0EC64UB$;0"'PO@6<M0&6]0&O=^]#<86(9FT Q!_V/E]H-G,LP;QW$Y;+
MK\[%V3B#N0.IS3L1$YGNJMCRYFW?%X>EI@^R.@/4E7:OQ+Q_BV^EYP',@8Z5
MP)@BF1'7_1=S\']=5HCWZ]6?AIY#)JF515C0!6./N, 3V'#QR,F$_%=DZ^H0
MR9.6:F0-:=LH6V@8J[!V6I2/U-= +?(JQC;2$V6<H27JEYQ.,3P[MU50C<6N
MD?! 93%"-+A473GVO-B4^%I!B;6'2AIB9^)LX%3#.1CI/PL=5F768!)F,IZ6
M177,P&WS0TD;GF7CY5#!!!S31K"=:>-S)^A%KG6*ARH+4CVVV-5M*P;ZJW.=
M%ZZEY3BA,C9&($[BTS\+6"F,$W"[T%E>!.N&]T^IZ>>W80_>Y]1@IOFF\FF'
MNO*L*<2 !.^CV6.UB#,,"M+P+Q2Y%JQEK;MK\66NFZ_)+5OA+0UVB<X]ZZ0K
M%DF\)H#$1$15/L%.U=6X]?:L\?H5KD"*8=Q JHRM6AWH<N;,:I@R:Q4&5@VZ
M3 6GY#L<M%P;(#63, F!%2NK&2#TCS4)C9BU4LP7)M.U91;_G%)IL[M&7GH5
MT30Z0Q9R.CJ:'>K[[6MD)4<8"K<4AG##V'P_Q.<DCSR% K:D'0NG4/DOE%5R
MZOWGQ(9X14]A@[M1&>C"'N2^9L7HN-W70QA+.#3POO9M6?!?O-EYIGAFI=S5
M-S)()!M/?G+S*?&\HS88Z=LXBRXY&TPB]9V X>OSL9X624&P\GDB4$HC_ U=
MBR2;(^7K&I>5; -""MXM_N5:E#3]4W&+_N7H,R UQ /HLMD@JH8C8^%I9HX>
M<=902A7&/R5,MG8W9W"T<X.MXW]$SJ(>B\K!.,,D,91QQK.P]TXV[!=+I>Y;
M%YQ1B4SN4VWQ=9H$5H5JMTN#1<(:' 883#G5"(W@VT=LX6,RUQ".*\[ 2GN*
M?TJUP>;;,5E;B]/%T1CSZ/;4=<R9.6M'\7X+4]WS 9B]HRC&%/@<=1;.A%4L
MW?]XYG( \0@-<:8^Y0DJ7LB%DEB.HSN"#5%9;@*GE28C,V[+.Y-L P\C1B&T
MCQ6BR&#"-%7)0UC1)G#B.J7-O(4"GK'T:"@(YI.^;>(K-C'<"40IO3$@')5=
M7ZX,K*@D6>I%4K0R>H,DHUNZ.2S/INJ_(E+ "[QO]\Z<K;8W9Y=I!(C\@C$A
MH@GD94)!;F6:@LQG"E ;PP-!O\##.T@HB"MCJAM[Y@#K.N#H#&3HSFLI.UZO
M]S#HNHR]WQMQ'7U'H79WPJ[VT7N8<U,M^V&&;9#)'FKDVC$$8G?*KLO-B!9=
M.^55K>^'XB_>C1OK&9NK?+K[H <36]=NN=21J>Y.ND+.";>-@QG4/K,:HJ81
M>]H4H/UWQTCH_NF@"N"?"B((A(F)YL7ZMQ,WQL<SN,6(2&VB9B@ YZ0,O89M
M9500M"E9;)]/514_\^H#4-D]H@&^'$S]>+FM^C$Z]P@&^"/B31H#]'\7J<Y"
M;0UPFV$!GWSOWV0F8()E:1M0N8E[+E)3"=R"8C;UIS\:_1<(X$.1U;AJ&"<M
M)/P*O2A!3U?F:!^.TGT>I>$BT[8_2R./9^E]G*MI*O?D_*Q+&+#%&7*=*B&K
M!\8JOU4JMG8R$Y)'QKA4(3I@A7=72AESB5TCFUDRL8ARJ!RID"HO8 E&C9DN
M)8%L)85&*12ZVMIO/Q,_E5 ^-XD.2Y2>,"G&)EZW@<Q@^$"JL/I&"S30Q'48
M6]^)15U#>K,DTIAM:Y\U,< R"-("V\W2I)C.UD3V)O$TP5<TREI4\:^E_:=8
M-/#S%*5<$8 $9CF58$0#\9_''/*Z@K$,:2+<GJ]<>.0K_X+-!=LUI.SC!^8K
MB#=2V=$I$+R#G](M<M8#PQ*KP^[G7:O/]_%:O?2)5UU0R10T=2X59>^U0=QO
M#?C[& [:R7GCV,]AH,K_+:Q'PX2_!S+;M^2.=D?_8>;_%XZFPB&2W09!?V#!
M9!EAV#L=UWS-0;(<6?,%.@+5XZ.TORXF7*455-6\VJ6;0.DPU>:2%/YL0+#1
M9\0.A7]"_$J/03W#YT,%8HBRD0T1(2-074:?O.=]/(P1EX#'Q% FXZ55&L(X
M+['VIS/N%8L8"M7M[$[_T8"UUNN?EBND'RMP#@T53E0&N#U8L^4<(<V%2X!7
M. >#LI9_@.#6 8)'GE0E!KV/9@@&X"K4\:)9=\E?X;#KPG\*Z4S/O4_8#H@B
MW(C9VHSC@&-QV:EVY^%P\D@X'TT>&4==Z+);2K*/.<<YJ$-.D\9*]77+7F2.
MQIT), FY7,Y[MY'O0=9E;8)UP3-&OPRTK%-3]J $ MX)A\("*Z=Q56&!T?FA
MLL##51:X7Q>(\9FUO0:ARF#I*8E"Q\(69RY]-Z4KQ[APX<M9;WWDCM9JE."C
MJK5060[$L!Y>SXO:Z79M3])$ZH@R_:FLJBW09<8!,WCLIUKM-^<_&K#>Z?;^
MHRN/_J-WI?7.ID<\L)7?UI=;)&F9$%+#4"Q%!HBC*F+AI$I+JE%23S:^BLK8
MV5#0I3<?6Q\LADC <[M@M_"RQYQH< 0AV J1=(6.9 U&1Z:RNV\%TM4^Q:%1
MQ TK]P#[P!%>QW\>.V>K43RB_X&XPO>P85 'P6_ZHQ5GZD",97H;8NYL,*H;
MK">+DJFI.U,VTBTT-5@[5AFQN@">P;9<=5> "!CH-"CF6+@8"\];&.^91&))
MIBS"$F'@"P.VF26B9+3"\D%\:8N-G+0KRQKD<0JO4ZD:V[1@)1O=PB\V78=5
MW- -2#VV%%3#.6<%6$PI!HFSQ U=H(<DMWG)D;P]!!QQPNWV4%I\YC/83H*J
MD3ZXE/@KG#;J22G(U:?"QMQ61Z&.+BUBV/99A<]:JG44G0M+7E<TPU?C+^TT
M=C\CP4A^U-R*5%5C0;(&6/_/ N.0*298I7"0YV64+\42PL&E,@%CV+%RM1Q;
M<3L[7>.[!@G['C0( )-9T;;F3XO4N*9-[>=QAE@&\-%RE[GU6A,/7=4M1 H&
MA@@/ E?J+%WC=:8G!XQ;GLJZCSSHN4<>]&N2ZP"Q7!XZV!<V;VSZ<E*B>U!\
M"LQC:&N]DZ0 PN.\B*VLT8#4P&(7Q')67^)9,4%+,<%=3;H<*U01'B)CH3+!
M-7C,*%L)#[DP9A_*$$IA+J<Q]#RDQ)^8"G>@<(Y%ZDLP:].75$U+"&'X(D"#
M*U8T *:IHQ.00T $FA*,-=9'<Y/H6"5R4I47Z0#%GV&*E%X,4 *\0H$98/(<
MHRJX=::=B' .VFXP$AQ*0Q2!'V+&G*OQL;"NPC %@>K;F+'A]MC,L>H7:\HF
M.G(T\;'(-"ZEI1RO)#TQM7F4"&2F:J@J^AFTVYPPB2DE+<&;#J]1S&R+:U%6
M[>)J_2&1:>A5F-PD/3XGJ\].Z:I79WN3K;J7;I%KCT+F&P1Q,V&<>Y#WT! /
M+4B<!9E#*6V>A$9(HYHK)/SAH82#!.<OR]/"B)4M%;=V&Q+:&[8)"V@MBWR6
MI"0JM@.U.\?W3+R/*P"XD]:YMUIKA@8VD'1E9.3*+(F*YL$VIU/0Z+I(XS+*
M$K+/W94.F%IE-.8](E&JG>5H44%^C,IC;D+GR?7^MR?G3P1&.UA/>O79;AWZ
M7,88&&<];-U(+C+UJOQC\^'K8P_M<(-&M %ET..AHH@,./%)D;^:Z*\J7,52
M&EY\T\^27>8I_!>68S"/79T;GH.\+@^;O[/X2"= A'H%O5[%/BIV@Q5BRK"%
M,KSCQ5FW&^T'.OS&=5N9C_@BZ%4ZEY'YYM8$?MBOUG%K)Z[VL]'_;*;L@*-8
M(V?<Z^!6I< ]GJ7YN[Q=?=4,/81-%]J0>^0"#5NK.[C^XAQ^LC:F)0Y]IA[#
MA/6G6.X))]JO:3OL,M9TJ:]!5&0@-&ZHB7'89ROZ,B4188/QX#!K*_JR(6#G
M<#I7W $F)&2]8?^OOLE6FQA7]K 5LH%:RU/4L)Z2EG8(WWB,SM.77A$-"\QG
MP " A_>@ND-ZL.+/=L+TX%5[&R")U3%&F#5E!I/!T8/ &HUC,4'.JCBG%C-H
MQ,5\[%KD;=\RF(,&BS@196R0B6ZDBMA9(LH-THE%J&(7<OD%0S$3,E5C9((&
ME@OWFD  80H3:E*I@NVGR@9,E'B,(HF-B9K0%>5<B3 )B@,JX+=PSUWX1.ZM
M8-%P$U99S ]^W]5NDA*2TX3XF4"XLLM'91'Z$'X+'*MN<KB*__*4L!EH+&YA
M+YS!..9.<$@LBC28R4PY#H95M$JE4Y6Z$>*5#XTSPGQUSCM@#6N '4>Q=[<Z
MVZH\T2- /QL$+<ZU#"0/'6&,F12YQN!$_U%*@TR;.V+7-0_Q*8/+SS'FBD7)
M<2.P:,@L4XX@-KRQN G-+!J#+/\N0$DL0NHKQGYDCL>3-W%NK).[T4!G&(".
M(^ BCXASB=&]6Q>;U#+$Z70T-+&HU$%:CI,W!,/A 1E)QV/#HC)4=KUSV5QN
M$JH3D4%@N;B#N4V*: "H@ %P#ZRF/<!@!CC\NS!.'H:#_X1WQ[*-K&'$CDO"
M!'U#\\T0=>!G<HAM3";<120#Y=DL]E.=_]JIE9&,<TP/D/#_*,(M5B>Y8BH!
M9>Q;0*9641E4E^I4TW*):DNUQ'(Z*M48I[PF$?9@:F85H#G?PUR!"Y^5K=[^
MEYPO7G\0[^.L2#%#^ZS?TBS0%OQ1IKA]9]+4>HJ*D/*CC:4T26T.*>7&I%C7
MS;Y>+))(!W?BJ"1<_7)<9M4DMU@T$<M?*DHSQ2-AH>W+8U:E )R4R!6F!] 7
M?:,CHAVD&M&S(X%%-?%= 48'R:EZC&'VA\*)[2/ALRC3S\H@[K)*H#Q[MA/-
M5?'?]S&67U61IXACY<%[-#J[9ER4_T)PBQM'/S.'4)&Y"LH<*08&HV,WUP9'
M\G<$NF+)XVD2)X6;X#= M(1W+%[N?,UE%A1X^/R3FBIG[&^>^&\%2B=*K+(6
MZ*K3(<5;R*Q1LY&PG1164(F5,,,N,6]LL63D=(+05J,[@1[90.8EGA5ZRAZA
MH'OO8+#GK9OZ__GT_N=?WWS^_;=WK;[V[I6/;W[N;;%^R==E-/_TX>]___"O
M3__O@!.P1;^:8,2,E3L 26/!W0.0]&,'DNZ1_=O'Z?VOXE_O/__Z[M,G\:]?
MWOWV[L-/)ZV2OU2JNPJNZY@Y:BBSQ. J4+U<U-/N8-QBHM,L%W(,*EJ9$NT%
M]/E\:T;.PD"XUUY>M6Z;B\N7Y17[RX</__/^XYL>MM:)E_Q!)[D*9GV-^ S]
MY_GXES.?W'P_+]E][-79I9="]/?<2>SCL_H$-C;V#W>O1*W\NFN[3[.GXK\3
ME<;B313*3J*X^VOK=ZRT=Z!9:1(EM^5<+O/K=587^NH4 8^V3<)N&$;6" (M
M<PGEXYBKY.*B/+AVI46YXKT&G?(27I)4RKU2T'_B?9Z]VL0Z+I=TA6(]D[G8
MS:#RX[L/A^5O+/_H^MG9U;77]?_KL-OMI8@7^R=%O 7!J^^";Q]34XBC2-7&
MT[U4XN-R)-ZJ0&%RR0FK8<_#QI)P<7XQ>J![GE%QZ*_0*X[T<;T'UI'&6=AJ
M6[[[O]_]^/OG]_]\]U<3*[_M7C5T[](:0_9-T..?C<ZNGO]G0P^_ CY^M4H3
M+W&EK(PUNC:Q]_^FF_KKJ].7%Q>7E]= ^OGS\\L17,+/7W3T_O)R)4-098<J
M30@EDA4I:%N3!PIZ/A59&L#[D^3+*3++T<7EZ*OZ.CH/1\_.ST=G?RRF3X2,
M\K\]^3F5BYD.GJSLTO*KF[:>>^8DHYZ+=:5XLN0Q-.[$Y[:WRU?*RK<<6K%:
M=6R%1O?ZGT@6F?B  NNT]EMXN'&>7ZWFY]2!'J:^*3EFW17@?TC+>_WAK\D7
MY)#?2F+<E'&R;E(;8B5O6XY D;QL[LS1E?B'3(.9 #YW<3#0EP;ZBP<PT.]N
MC;])=+C1&/]TG(1W\,\LGT??__]02P,$%     @ "3QX5"<-*Q^N P  " X
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M0IC?PF0V'"U&^,#/Y6@\N0]'R]'P<,#[@\'\819.9F.XG2RG/^ZU[UBUGW+
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M%(N!FB ]P>.0ZT!(G4$_)"U*"A?HJ9(!"Z%9DSV(ZY !4+C@'=P'$4TFC/2
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M4T;O,?%Q11*;^MCRCGU>I[@Q_B0TR6O![C;=(_$%#6&B9O/PXK/(DQ>%8 K
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MC7!]ODWVW?=2V"^Z./T_4$L#!!0    (  D\>%3CI).JXP4  ),@   8
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MX,/B$F#J'!^$U5VTC;L5YGI!C@:G56^T-1H?.,W2L63E(;@K1VT>Y9I5UJ4
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M=[?_W^ ,MCU5TTB?C+/W05P$+0?O_' LIX@_G,#6P'G#7W$)YPQZ1 SZ6W#
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M#%VME^:]K7Y8EBV[SW<WAIL;NUJF3YZ\DC_?JL(3*$(1DU$Z$G<_W3G</7:
MXQ[]7P7*,?%UW-@P2.(IG SS=>T!S6-Q>5<S] Y$RI)-[G!]/DPCQL<1<) I
M\*DVQWI(]EOAN$R95.,4Y0,&0$#<P+77ILI3/<8YMIKG#+\3.^7XM]^./[.9
M\BXX^+1_>FKT-^>K']&".:V&?P$_0=:*U(L7@^]**'>)[H)[G83%S-5%."%
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M'=?G>HM\/5=D]4E"7&]V;;-CS(,:5I*2<6\2ZL5:3VON_=G!6C-^V!W_<__
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M2; F&7RABF5<2 ["4-@AJ4#QMPI).:<S[$(\HXY>L?/=$1M*2DM5@O:F 9<
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M/W*( #TVDB)K@?,\Z\ZF:[=G!W'NML4R%RXDMF?1$'FSB^N"HMI^L#^<DXK
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M=VOTK)8>UO.T7=.)<2Z!W(.1](,'M=ZL@UI/(*A%!_JR5_3H00-</Y1[?O0
MV!<6J*R7*WZ?8G+V-U)(T>)^JR6DZ6K&"%6@,A@)VK#[V> 9T#<:U2;MLZW1
M;9^VP:]Z]D*7'! 6=>)0)X^HX\KD+J%*!!FIO)Y?%/17K?O=ARNW?5;KP-?*
M-QG[[#5$$;UH'=)\ HW(;(@:3[<>%NK#1?\$=3EJ:0_!<25$B:-7U'Q-?E^%
M>8QO3B\;IPJ<3%#3@4HLX&;C;6=^)SBD&]!Q0C(4V?!^K()ACD6;U#1]ZC9)
M!]U;UT8:!=T.M;X"WT%C%_*/,8_K&\,W%>7M)#I&AR,V,K'1LPVO/LT+I)$/
M'>CJDO/9IYL:R+#NGSQ +R;8A^[GH85J6307JD]6&)5/<S27B6#)6+8Q/O%0
M@^U)Y77=OM*.N1S,G8LI]*(ASW.5:DPF2JSV"^_ZO)%\Z*;^[XJB&@P:B;[Y
M$6QQI/W.I@#03T20&(H$:R1[GMS%%+#AO_D5L+P/+E;/##D8PPZ8<$]C#?-0
M!%K:CRSCKFX_ G$NN-&K7 >V:CYE.S="\\1V%=>A$^C(;?'!@J '[0<'/9HK
M#Q?[UJ\P1]?$$WJ<.T4Q;A1(.%R"0B^SI.*:DDSJ+^1/N+_4HHA6IT&I9:^O
M)(A4S<S.3"8J;B4*C;#MXBIWR3VW$^,D1I>D*OE7V61"'E]&/1]=!PB>+[U"
M=/3?J;]=PO5$$'4Z7SN()UZ;9UWA@0&]B(M#W2(+FYC.>8E%&9>(P(\N\ESX
MT!;W)?? \YJK]7JW>:*^I* /=3A7XW%.?5W(C2NG.9MA6:CQU_(E'V;9U_;#
MZ!LXL# 7DFB!7G _NX&3SD6_T!B?H:.<E,I4J3#>=FHJ V70N)#UE^IKE+:=
MI)>@$7I2)71X>-C"(W5;5_=MA'Q@WQC:R2FG3X)U0R_/JOE5_ [7LSYG(<6B
ME9!K6!,*I[A$]UU1\^AYKJ]7(,_UM[@814FBTBBK'M\<W!MLOVK/XGF^O7<K
M;7COY8IHPP^0X[J$&DQY;!A>XT1/_)G-<4$LIRH5!:9P*ONDV<$P\D!2W7B+
M >19B+W3T0(WM (H9I@E:=GE"!*&:4<5AM!BP8RC8E$0OI>Q"K#[#"L[$4-;
M8JDD%XXSHGQVGA(,!L;Q4PJ38N>PF!20_)+@G$0>M79()4FS]V(G^$C- _8O
MHQ3Q$%[MPAP_)AGB^Y]6,?#=5[O/=T*BK']E^5?[KV"P,QB\#NV\M</N_WV^
M%PR"UV]V@I=[P<N=8._-FY"7P]S@!(02J%[C[7\JW&+U_UV ,(QG:@8?3M4V
M'%MHDCCX).NOD.&,O$7M$OZF+;8BN*["H,.3Q>"U+>8RGL_A=:WIKJ8%>V"M
MO2.MS^#NR=%#Y3$D>1O*N@T]^>14TX'$$>%3 FJ#^HC\'F^L%7'U'?VV6R%B
M'2'5( !SWL&#%HN'E/F"0I5B\D42 !OF&VSRXOSY\M'JK(;6$ZT=:,MQB2:J
M(\AC1UV3&</LDQA]]_!V+YU0=T,A6T@ ZL*Z+IS59Q2[Q(L\Q6Y>QXG1;EON
M(T]YERUTX.(I?=9> *NAOGB[MQ/,MJ?;P89A%P=4^P1":5-W9QQ+"6ICI6YB
M@@T\W^-&K,/6=QRV'NRLX]9/(&Z]2K'J-D.G5:UNZ(EWS.6&47F%:5F6R2$S
M'PS>OGBS!,_S"N\C["\=O-?"!]LVM?,]47.8Y8D@7UHM]')9.1N(L<HH16A6
M:O6#G''LL,.6'@Z'C?W&63HQZ?[-JRZ+]_;VU?;NBEA8#U I\2DK*%W@MZJ,
M.?F[,^_+*2KN&9=H *)VCNUBPSC57S*G,$A@FB$ZS))(U*NBS+-KF]):=T\*
MR+RK#;-?4_MXI7TENP'Q=XS=(QA;(]3K$]O-6=G)N',-I9Q;YZGR7\UAN^?O
MCP:*.!"5NQG-/@/="!=9SQW#_EB$=$%+U3<=AC9HN%KEA4&X4&]2FC$J4X%7
M1\4)==$;):.:_E*E;E3O8.P:=!KTOK>@WI"?UW=#CRI8S!3=W5R)+F.A[3..
MIFF,'O5X8M%[05%GQR@ZY?@4ZILK6CDMPVGKKI,L55+XA?:.'>J\/X_.3=(.
M3HUZN8XK/"[Z4R,S-WX(HB0?;S%K'7%S['93%3'C*'JTYJK?1_+7GRJ^[ ?(
M@\;D%3W=53#CM*+!N+^$6#IR%KJ!'YP::(P_:3=ZKHL%X&(;":[TE.0]4BAF
MWLWN$OMR\Z _/6E!N,PD:<%V/^PHXH)AY#>-,-$2UG1W#)&\TB(& <?Y_64>
M8PG.&/E1.C+8;>BD[S4WKI]"#Q-6)64CX$MTZ3T<L9$D6V- S&PCLDZPB"^E
M#H&OO!^#UTUL_&H'G*J4K"Y>#&._T6K<D7NN;QE:G (O]MU.!(R.3-*F]WD$
MJC7G.?LK8@#C=[G*)?1K1\#/.8CH-/\SX7"];T[-2J>@I$B_C,,B0&#O:/%C
MR:'W864[!]O0<4?]9A%W#@*N+JU!TG"2=9RI^MB]H&RHO[(<#8:L-[QX64,5
M,'V257 !&\2]0-%8Q]X&M;Y=^(H/OQQ\"FT!)>6%WF3R7,[3>&,CW6 MRKZ/
M;,M33 12;-KW5?N7%4TQ5DH2U#)08))$YRIA9$5I&,EM],B1JQ(+N]]'WN5H
MRQ/[81>K[7+GLR><@=_H'!^P%=2N?AC:D#XE&\+$B/[E7;5A,"7%*7EEI=!3
M-VG3S)"4(U2E N6)L\ J4LKC-NYFJ2$3-[+Y?EQ%#E.[C+.$X.IJ20*(0G7.
M/@',"\$\Z;"12" ;VC&TR4[),$N".S?#O)/LRN1%,%[O!298?(NGU;0YY R#
MX]00X1'Z>_X8_.$!H"@_P_>>NVJI-%VZA>IZ*D4+3-U./YVVV$E%01*%F3 N
M6JSR9B$MQ_78?LF$R.44IPZ/87<^O KN[]?D=P?D-[E_\OLUHH9$O4&C+^3Y
M%G4RCVQGEC1F/TB*<=-Q)KVV3=(89R?VD4(6ED;L YN$QDV#4*VVV "B71G!
MI#O9/ HY<K;*BZ>1K7+^8*B\)OMCGC=U"56J-[CM,'*R4#-R-8U\)=\+?;L(
MMEI9*JJI%%^9M3AM5M!QV-)F969F4QCX6TWSH!.DYP1MB=Y#NA9L82T'":DI
M+@4+W(_[+0Y2W8#2=IYN-':PCL:NH['W)TA>-J;9&^OAIW\<?0[^/#K[?'AZ
M&OSYZ^')X?''Q7 -;+H0DT;V@O+<[3&\T.F$WP\&Y06KD_CE**)LHMV=W9T'
M!3'H>6A(A'39__LGI&$8I.2.1G*'^2[ -4W4K(C>ZG^X\\!#DIN*Q"L9\_[5
MX,OG7@S+OMZ\V7Y#_*O,X?_&9@&XS6 ,"B^".RS/O]CYN[MN&5;OP8KLZ[-R
MW'LQLLG"W0:S;P$5N 2:+3[>8AOWXUGQ+/B?__R/W><OW^5IL)^,U7ECU<_H
M''_LLT2)L]('63O$,#BXP!K00^)T&%HXIKJ;O/UTGQ&3T")_18YIU::QUC+O
M2,L\/?KE\_[9[R>'P9?]7PZ#L^/@X/#D[.CCT<'^V6%P_#'X<,B/'!U_QC^_
MG!Q^!'G_^>#P-/QYF/_CY.B77\].@_W/'X)/1[\=G=&#I_CDZ>')T>$IF@WT
MDY/##\'IV?'!/]=:[5JKO7NMMHW<V\JKEM!Q]S]_/OS?8)\4VT>:[5PQ\_GX
M[.B [NC!\><_#D].X>8][.XNG.(&\)/WA\'A_QX>_'X&#.#]OX*S7P^#D\-?
MCD[/#I$E_'K\Z</A20#VQ/$)_..1J6/N8I WTD:?!:>_[I\<SN5RF_<I/9><
M=\WJDLP J9R.\SRZS$:4ZQ4ET8BKX'4[D"Y(GVZ 96X<CRZH*,FN0MM'DWU;
M12.)\'.V46Q*S>%J_N\CX2+.R>HLEH$VK37U&G%M;<%EVC.58^O<*@K^MK,-
M[QU@L$^J[!]IW6[Q[S+KA+7]>GS\SZ,O0)54E18<I:-M3-7\ )+P"E<T<K)D
M'FUU9@K++$Z9HBC**M>Y'G3)R/]L 0R<NF;=+UZB:$HPO*76K-[ VF$235\-
M]?ZF+I38_%O#.W"'3-WVP^^A@0RFS+:# XTV'HVE^1'FOAHW-49;QM'$#? X
M_1(I+AVIE&'(*+72%G[S:+&T2!Q)^YQYB6$385@8,RK"X,0V3/ID"D1]!B<!
M@AC7U\@H>B02ZEQ@?XH2)(B6[#'3J.HT&F&+*>X-BA$3D\9G_C 7"WYGW'&#
M07C_+KGE1."^?WMTFG.7=//@!X91"M0Y8M@2S)4VN]8B5#?*[)Q!U6T:<BVS
M?A^,_R3F9K Z,<Y#SK^ZR*B=LWZMDZ!=GYL!RS?]X\?V_&KOG=0@ SU8@,'>
MQG@3(U'^IR_UMAWJ9/S]46GP.SPX"YM9[6 [F%J_U,7\DQN#EMY,Z-%'B9#-
M)'"9*1,5737LW'*>4<K<(\ 4EQ9YZ8O*D=/VOVZ;[A[T(CL?\7J9)LC5\"_3
MPPBVL+W2'3FO16+L-2-!&<FCVMP,IE5SDIQG)3F.HX6AUHZ[YM8@ZWQ9[I?0
M<B9\J0RV5?0MRD?8P,IT$'#G5Z7Z^S&GL=DY C\T)27FACI"MB6C><,G<XTS
MLGD7RY(<,^I<9,Y7.; &08U*$,U?EF[:67/:KO,;FUH!<M.[^B\W1B;#N5O>
MA'A'WVR_>?/W&B2IYK"M7,S&P 5%M;U,OXU!W0$WXKZ*XW',"YBT3;N-0UU(
MR8?61HJH%)"_^M[=X5P?L<89555#3B[>[=L5= RO0*A-^W![1F<&K[?W7CUF
M@*9QW-A<6LI;,_[O(:4[H9O7DL+;MN@-[&<Q4[#YNS]U+)P=L2:8L[WW<I5B
M<ZQ-WB74]PUW9F^PO?NB>V?([@*3'0GSN]\=-Y:Y>)OLS7D^-ZYY\XU_^:+/
MN#W&VH6K_?PAK_9W=4"/N/B?_O&9E%SF;ME$&I^1NNM_QAHJ<KY]_L!HJO(]
MJJOR$]3GI(\J0JEH%AK<FF?:'17J_!$89O_[]>,PR95,"?C^5*Z]O553N>Z!
M'6G=;1C9W.96_M-'*.[-O6B+V<YR[]I]M;[4ZTN][*5^M3U7;UO9.\V^M3GW
M%Z_[$05P;GQ_!VYZRH^N-OQPMM5*<I@5F<9WEJ:WO[6N!GF*>7/?K5@VUNO>
M8NN5?KI"$GJ?X0)9SDZTQ2[88]>^E)Y=7!>X*#=EJ6C*XU97R7>W-;=V#GUW
M*_[I'UE'&OYWO[2;'N;"5;YY$"O:8TR8Z%%K8+6[W#&;:_[AS_T#^9=<^)MJ
MU\\'V\]7((JQW$8]K@;^9GLP9\<>4@-?B5U[ZM?N[BG(OW./4PFV$J2SU(7[
M(7;DJ5^FG_YA1==1:N!=6Y31'AMP:]G5]T4_' 6NI--E]>S'172SN_<@,?0;
MT W^'WIH%E[7]WGV53N"T^S&/ESR;W^G2F:/?7*]2SOW)@17Q.^[FMNXYEMK
MON6ZQT8CQ*Q\;,;U?=[PNP'$6-T;N49@N/O0SNXZM/,$0SLW,R16&Q+!U-?^
MNG_RVWYP]/E@^P'A$9:<[!) )BN[AG9XE=6=K^# K3XE:]R&K8$&=3AZ_^FP
MB57SH!L]5RW[\OO)Z>_[G\\0H^?T\(#H>/!B@+1\]NOA*@-G?#C\M/_G_LEA
M\,OAY\.3_4^PXR=?CD_X*L)7C]UR^PX8X-SU/Q$(@M9.NAX"<J.J>&=/U[29
M]?\2I5&N$J]P\I.Z>JR]P&8:2U3-CS.I$AQ>2T; -55FMNZ.[$41#)X/L)R2
M.@["C=5;0GT\N*Y9MPW,(S!9N/#S2A7!N$JN S7.9H*>H@B] Z$?3"W^^TSE
MU,KK0YQ'V*6KM305_O]O*A]=!%R;OWL/-7R+[YQ6?I>5@8>GQY_^./S0YZ+-
MJKRH5,K5L0R'7%X'T3?$H"FPFYE;M(F;M#^-4FS>C&=S$B&6,OQ1*W@]2MU+
MVU;XNQ(X$-XTE[G8.'LJZ99^'0J[3DJ-<[U"VX>&=@O149)V8V7,19H)VS8U
M-A?-P;76!;1CMP:Y7KD.[\+V%OA?%^R#; GX+_:[X&W#RQDZ]="%-*SCEDWT
M@?0(PMIN4S2L>XXXG*]!5W-)R-1R^PU(\'?U_<;C2))@E*BBD#9U?#B;-(#L
MT"3^AI@M>G?N% %E_KFZQS3##6'"8(YV'Z7"3T\A[*VGW$?+(%=:]T"ZYR?O
M#YC_ P(!T27KU2?BH_3<;!3P^U*5<8)JJ$+V:ZGHOS=J[7W B_GUPR*>:*2:
MWL*$MK)@YF@:,L':J:,RJ4ECTE(0!B,GK#CYJ[S(L^K\PFO;1^V'J*=\3K@>
MU&XN2Z@58ESH/P7%B#_C!C2"<"8/L"ZF&A,B3"T'1@K9:54(% 4V?C*M%GG4
MDPJXW^#Y<_E3$)(T',C^J-P._O3PKS+3A2^4YE"7(%FHR<T$NT;A.E6JSI%C
MLLN=!0.L0W_.W7/B H&8X(00BVFH"GA $(@*1/1RQN7?Y69E@BY"V%U>1Q.$
M#$HM%)%I%<D_N.<>)M_=17AO44R.#8J)%9?]KT<'L%DWE C"L*Q/HW8:7@NK
MY3D3M@^(OHTB6."I*BNPV( 7G,+[E72RQ <8[,@@U:A@$HW);N6>=Q<86%+7
M6MO['606:434Q4W ?*A-@>[2.%3I5SSJ.#4-IPO]:P.G9EK0DVYHM5[J$&/[
MPV!;.-."B_O#X>V'::F1UD]'"<C#->74#";4H@G3[P8(DT)!-3/%P*N-9.S>
M\)H/?3@+S@/(M(RVBID:16_!;-JZRM4,?O(89BV0+EZ54T7F1CQ:5O\(I4/\
MM<;KNA;X3+Z5I72HA ,KZ9Z0BIACN[D9OHU^S2V7],\)V &OU?.W.SO!;'NZ
M'=K+>D#:#1Q,J-O5P>/I*)[!A70 PTP_>QPII]YF(*_SK\#[KU!MK;T2A'P2
M%](?BF8W)HTECQ"9C!G!^R3+T/0]#X-/VU^VI4\Q=G2,@>B "A!^%P0\V&V/
M""2UCBP_4F3YYG61ZRCT.@K]H%58S-58%\XOD0E/J[(BO$2PC4!5L[U^&268
M6ZT[WDA@ATZGZV9C;NRZO>5TW7;]6W6?EO&C63F/^-(Y=B/V<$AUPTGTXUT[
M4L65)MJTLIR=A(1!#!))41,)31DTG_?C]$*<'S;RJT\A=G[:'+AM, (IQ';2
MYR;0,(S'/)P1I3+5J?J*NSY_QB(9/ZMBK/XO^"7)AK#F4P*<Q\@$C$,HUK3K
M#?D?C%0J33D=R$@2\O9M9"MCL\\8'\@9Z9?Z>AH:L.<&5C2Z%#I>USBR3+JE
MTYC&** A59SKC6!%#\,V$;H4-*[F>9:-\3DP[\1L[Q6S63']\-$:U7U_5H:!
M[[R);>'XE) -&?C0>P4%_>[W^\ZMN;Y6' =="A.K,5#!; ]F'C _=6(0SX+#
M7_"KJ;IVY-H0<6%IA'@2LPG 9$ MY+,U!=0IP #5?EC*77T#?YQ:^^.Z=W])
M:YVW'W<]^-LN7"PR<-7XKXKL7C>6#S=0G>=J=A&\>I@^V]_S*9S@$_=Z"8;K
M2]"]_:>4A+"TSPJ+5W"7+R-M2MRP,T"S2U.+B=.1S,6AL/4-:XU-*UAS\!'^
MM\HQ<0@C=C?1-V9Y-J[ [,&LDF_2I@"8WPLP>9,RGB4Q&W@;U_)=MY&BP>(-
M:8B5Y:25$#$&&NJ"Q./Z7&^1 NC*K#YYC>O-KFUV7)C>%DOPR*5EU(NUHM;<
M^[.#M6K\L#O^Y_Z!8;[KO7_0O7<;K]S2$>/U< &Y.WBS]YQM%<X>MIF7>95$
M.HO4]G4!B0^RG=MS44(IK6)]8/Z!?<04#$ED.,.27<YFN)=K$[Q:VS"- ^#X
MR4U2:BZDB]4\DV.]V_YN'^F,^^5<5KSI7,SQG(LYUCOK[^S_5&G,K0R%@:_U
MS ?=_[:.@VOEYV%[1RN*6S[9*["*6T[YY3>1GI@'?QF/*VR2F+L%HA1Y*B7A
M. S*O"JHTE _HKM6>I^HHLA&L?S^KRR&J5S"'E88JZ)2)W@&<\(HEHN!KAG,
M03\I[=GUAS:Y5.>6J?,H'5&Z?5$-<=H%%S21QW#3IJ5*TK^$Q+["$A^SE^'3
MS.]:XX:L,[;6,L\M9G.J<6YI\EM+?V]MZ=_]2:T5],?=_RXC_1X/8G=]$$L<
M1' 2G6/Z_Q+NF!N<R-H'UCB19KST7DW7\>9&O#Z$^B$P#,<?F')WPVRB$$9:
M;ZN_K6>28GZ3NDF_FK&1>! 74J-D2J]FL'_9N'=%5-R2S0"#8M:W#,SYW?/&
M":5>6G&Q^;Q94EXX6ZI>$B;E<<]?YD64!L/(U(S=AUV[4K 0NRL!"^' O7#F
M#:G>7U3.7.)=L%_@(^BJZ#'?^SVRK<'K_GQ!5[O%*5G=PP3HS!O-\32\[F K
M-YFTX2TTT-LTRZ<J\;B-?.1X)-#0A@ELC#;-!O)_YN[V&>:D&4"AF=%SBCJ@
M$%5'P!6; U]C:B^:.$1M:=P],6P>";_IYFIX1[&N@2G31FH=&2DH,G?GS&X.
M7H2O05X&P:'BJO<\6I _Z*@ZRLF/AQ\U"YV#,Q\FJCX6YKX/&8***V:<7FLD
M4*:,%A(,L^SK%MP)4,SH4^'Q5$7D)$ *B$5PQI!*< J1QM:@HN ^^9&X W9"
MM1=C6:V&4*)DR9AJ[H6"W$YQOFZ"Q?^1&O.O->*3,S9()"9S]C>AB,FD4H#F
MO.9;M^-;XZ7YEH>A!S18%G)_(ET'EHN=YI!5.9?<0\[;S9$OC L!8YFJ."T5
M58Q)C9C[Y@G!' 'Y"L[1ZC&LY<U5!I0D)H4@-M[5M;!KDSR;4FT]W1;X+S,3
M=W.0>R"P#3.]/!*FH,\%9OBKR4[H=_59GJ@A03'"U!#RQ<[(AYS2$0XG#5L_
MB?,A;1BHA%5-#5/57,0"VJ+4;$R)F? Z>K,QC3"R^."$+(L*ODMEN_"G+C<+
MHLL8[O:(C%K+EH2&]01S=),2<B4,E.6%I6DYB-*@=&4-4D?\(\2CXQ:= 4(I
M<0D4L]GMX/>9U'32!'B'[";J.2#D:@K\Q)F]._G>:?(@+YUE68$IHD$6H!^)
M(CKTA:_.([SO^!=5/3=2]]'J\=],I;T4DELPA1Q'U:A3</H1"O21*L XPB1_
MH@><Y\;>9N "Z0A-^F"NB[0Q)2A=A*#)1*"OQY @DTJ-7ZCO=>,^<_F<7E.4
MPN]'$66N(Z*@/N;'@:5Z .-J;Q6,JYBH<]P+<:^7Y-2G[9QK&9<)$PD(OBB^
MC,*V*GOYQ0R1F,9Z6@%_WDNX(O:)2H(-XA' R;?BR1:S9E EM\ILB\WY+7Z8
ML-3X8F15B<P$Z[+E1BT _=K4: 3"8@F*C97#^J= B"FQI,)9U :+!!#KJ?.I
M_(QU7K_N9Q/1G1@28:;B<7-7/$_%U464<N *)R/U[+=[.USVQ2_>#H[MR*H%
M&!7,E<LXJ_ ;Y!PC((0T$_EH9V(HI_G&>9K57)+"]]QJ!^;O>)4FR$N!YQ4Q
M5O*H-()E)IQBD>"4'<CLVAX\9FY$-^-XFED3>^NLB:>?-7%KHGZ"CMSG*Z!K
M_)&16X-1I]\Q^CKZ;'OI'H<,VHA8;LB[K^)"%-:QL0\(>]']WL5-+#W0_7[.
M+9 9ESQGA@_?!EWT*KH4<9YD\(4JEG,K.2!$88>T @/ JB5DC$XF<3ZEVX3S
M:=C+G9!'[MN6<%%L*"D^50G:GP9_ @PS-'.CA'>S!6>=P"H95/P<9IMJ=6K.
MII"-+*^A/)M%A@?,;RCS(RLHF%0YQW+ZG 'Y$D? 40N*/ &U\K]=C6#H6O2;
M-5^J@\S9]X4;(YDO22<& D&B4><Y8O("V5_5L8-;8(N>>JCIQ0IPJ!.5?GT'
M>CZPC;&@^Z[#2:L63EK(NW,XQ6 CWD0-6Z [R4O'H#RY$X\:J5F,%6<&PJ?.
MD2TJ#_()"INP4VI$ME@NP+[ ,=!QQ0 *?U7N6^?,=N-[JH[9? =;&@LC@YV9
M<9&!,6M<<R@,VL!V0[,7K9A[#WE$+?.?=TZ/XW"_>1D'GY4^+)\>'VJ+_;NW
M6K?@YBFHFW6_JB('^-@%-B MH2@BV KRJB=6G*!CJS!-GC($YV?EK)JU['N(
MCAQ22R[A)VD)]*![)[@?;"#/$Q>/.PW.4S&[C;C@#LH,SOQ[08"X[QRY)R]D
MEXM]GE;#OT01E?0M2NN"6U]18I?1\85D+QP[A.YZ[7:UDO9=7XW:Q;@.^99>
M+!?^F^^TAJMOC1W-VIIWWRKOP@:H8"J?)55!S3]:F[3)9CM[B7\VY#6=@S[%
M>-Z%93)!QAZ/X%!1WH'0 XOIYV?Q @*0KBFUQ;5,L2&B0O*\<XX6>^/A1Y04
MXN2$+'+DTD8IVW(+>QO4AN2Y:<?M&.$2R<X'B[E*C=O81BE#.%.TI#@[45V3
MV\&>]A3A<B5W4<[,K)QIP%ETXTP0O%8(V@2M;D'9+N$TZ<2& -.BFF",(M(H
M>=?UX^D=.*%7\A8;GXGM=#/#"\ ^!..V)_<"AZEU.+/'G-U-A>_4$%T)69WH
M>T];L@!]$NP7I:*KG.D(K%"V6.#H9^'=*"07]"JKDK'C6*+8Q#5%*N/4&.[^
M]"^B1#N>ICJ\7I/1%-=-$O,R/:8F$]\IX ;=KR(=D('W3ZHDZ;7HI^Y">+D"
M+@2WZGWM.[A?M6925VON\S@+3$\YGNF,#8V7TL-SO5Q:)>*<VW35,)#$19,O
MT<RBH$_(A)[H?"$/7R34N9*9F7U;0@[[)9MIHW4(2B.$F<W[R*/;@1__CR83
M9%\C9QN'TCQSK#-B7%%A['$=A75RJU*&EE!E"3LJ7G^<<N'?Z8=HCI>FT;=@
MOX\!@S/;4(]@:MT*B&-3DK@H?!V5TGPU^@92%O[PX_SN$=F^BDH?EPG23 BN
M $G.8]H(QA1DYL/@%95%Q9M>.\>VQ033JBC%$W&-))Y$V/N@G8+G*3^9<^?@
M4X^^,:S/8QFXSL'.CAYX@V2RO*^P9A-U0P6[":,7#&G,G?]L4TJ\C:,1Y=M)
MW]TTB!"JP<EZJQ>,O=I0>E<XR]M#"5UVU:C .3J*29S^HL^K*Z_>Y"(B' 1U
M+.3&"_&,TY9C#8Y)L> ,++,SQ*Y )H+ $H_A\%D&_' S^(ADM%^5(+NHL9M5
M+<_TTN%XSW,UG4><H(X+;1K^RUML-E*GKEMC%OYG#91QQRD?S]<I'T\_Y>.1
M6AL1F;WN6?/I #,W ,,=W0]8=%S:W%[='=93V@P+ 1D#"N PS[Y&8C "JPMT
M0UWTQ@L;IO:TXUQ=@6C;)[YM>XH$Q751@I'Z*&K*S5!2-SEC^?OI-D$=I/
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MOM42/Y\/*5X/..*P#/FB=R-W\--Q A3YU:7\P/1RI\Y:KKT:Z: .L#'^-T)
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M4"%%#UDPB\!2+*\WF[XNS?KD<G=!*S#231A$,6VR\8^CN:"*"\^9W*P<0:[
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MJXLM@#WMZ)#9;C*L?T/FPG\*<P$:Z1Q9JJ(A"2C][GH6!K7VN*!>U:9-OYL
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MYG.P#EB'R-"Q(WQK&XQSK2($" SBGAT^ZI[=P#M/I*]J)UQ_"G:R)'5(A+A
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M>9V-]3B02E"1&=4I.5DW/'Q%B\%RH=)S9Y-UC<^$F38P\3'"2 &H@.#9?6<
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MYN'+_P=02P$"% ,4    "  )/'A405WTG308  !&#P$ $0
M@ $     :&]O:RTR,#(Q,3(S,2YX<V102P$"% ,4    "  )/'A4<ERYZO83
M  #U- $ %0              @ %C&   :&]O:RTR,#(Q,3(S,5]C86PN>&UL
M4$L! A0#%     @ "3QX5 >""2B"/   U@$$ !4              ( !C"P
M &AO;VLM,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    (  D\>%1OF:@VMY(
M  ; "0 5              "  4%I  !H;V]K+3(P,C$Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    "  )/'A437@YB29?  !U* < %0              @ $K_
M:&]O:RTR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%     @ "3QX5$F4,^?HY00
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M:S P-2YJ<&=02P$"% ,4    "  )/'A4%$ X_/[&   YSP  &
M    @ %=&P@ :&]O:RTR,#(Q,3(S,7@Q,&LP,#8N:G!G4$L! A0#%     @
M"3QX5)#&1!_B5@  U%P  !@              ( !D>(( &AO;VLM,C R,3$R
M,S%X,3!K,# W+FIP9U!+ 0(4 Q0    (  D\>%1\7G)]$&H  ")R   8
M          "  :DY"0!H;V]K+3(P,C$Q,C,Q>#$P:S P."YJ<&=02P$"% ,4
M    "  )/'A418L[8-]8  "&90  &               @ 'OHPD :&]O:RTR
M,#(Q,3(S,7@Q,&LP,#DN:G!G4$L! A0#%     @ "3QX5)5T#$HR1   ]%,
M !@              ( !!/T) &AO;VLM,C R,3$R,S%X,3!K,#$P+FIP9U!+
M 0(4 Q0    (  D\>%16_V::;Y4  .&E   8              "  6Q!"@!H
M;V]K+3(P,C$Q,C,Q>#$P:S Q,2YJ<&=02P$"% ,4    "  )/'A4@_3R5,!
M   #4P  &               @ $1UPH :&]O:RTR,#(Q,3(S,7@Q,&LP,3(N
M:G!G4$L! A0#%     @ "3QX5,OJ9X5?6   ]&0  !@              ( !
M!Q@+ &AO;VLM,C R,3$R,S%X,3!K,#$S+FIP9U!+ 0(4 Q0    (  D\>%2(
M-6'!V+,  #O:   8              "  9QP"P!H;V]K+3(P,C$Q,C,Q>#$P
M:S Q-"YJ<&=02P$"% ,4    "  )/'A4D70#+;C!  !0X0  &
M    @ &J) P :&]O:RTR,#(Q,3(S,7@Q,&LP,34N:G!G4$L! A0#%     @
M"3QX5!:=P81;40  ?&   !@              ( !F.8, &AO;VLM,C R,3$R
M,S%X,3!K,#$V+FIP9U!+ 0(4 Q0    (  D\>%1KJ#<8]CT  (%%   8
M          "  2DX#0!H;V]K+3(P,C$Q,C,Q>#$P:S Q-RYJ<&=02P$"% ,4
M    "  )/'A47!7%!47<  #8\@  &               @ %5=@T :&]O:RTR
M,#(Q,3(S,7@Q,&LP,3@N:G!G4$L! A0#%     @ "3QX5"JY*9P_6@  9&P
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M:S R,RYJ<&=02P$"% ,4    "  )/'A4'ZC9>2MS  "$G   &
M    @ '1+A  :&]O:RTR,#(Q,3(S,7@Q,&LP,C0N:G!G4$L! A0#%     @
M"3QX5#'*S[L!&   \B<  !@              ( !,J(0 &AO;VLM,C R,3$R
M,S%X,3!K,#(U+FIP9U!+ 0(4 Q0    (  D\>%0T)#49;&,  '=M   8
M          "  6FZ$ !H;V]K+3(P,C$Q,C,Q>#$P:S R-BYJ<&=02P$"% ,4
M    "  )/'A4(+Z[@W2B  #.O   &               @ $+'A$ :&]O:RTR
M,#(Q,3(S,7@Q,&LP,C<N:G!G4$L! A0#%     @ "3QX5'1T#LE9GP  O[4
M !@              ( !M< 1 &AO;VLM,C R,3$R,S%X,3!K,#(X+FIP9U!+
M 0(4 Q0    (  D\>%2-&P%C!5T  "/; P 9              "  41@$@!H
M;V]K+3(P,C$Q,C,Q>&5X,3!D,34N:'1M4$L! A0#%     @ "3QX5"<-*Q^N
M P  " X  !@              ( !@+T2 &AO;VLM,C R,3$R,S%X97@R,V0Q
M+FAT;5!+ 0(4 Q0    (  D\>%3;=I<7! H  (I$   8              "
M 63!$@!H;V]K+3(P,C$Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    "  )/'A4
MS]59FKP)  "\0P  &               @ &>RQ( :&]O:RTR,#(Q,3(S,7AE
M>#,Q9#(N:'1M4$L! A0#%     @ "3QX5..DDZKC!0  DR   !@
M     ( !D-42 &AO;VLM,C R,3$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    (
M  D\>%0X>=GLNHH  /SS P 7              "  :G;$@!H;V]K+3(P,C$Q
M,C,Q>&5X,V0Q+FAT;5!+ 0(4 Q0    (  D\>%1Q89,'CQ\  *GX   7
M          "  9AF$P!H;V]K+3(P,C$Q,C,Q>&5X-&0S+FAT;5!+!08
..*  H -D*  !<AA,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
